WO2015153791A1 - Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2) - Google Patents

Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2) Download PDF

Info

Publication number
WO2015153791A1
WO2015153791A1 PCT/US2015/023921 US2015023921W WO2015153791A1 WO 2015153791 A1 WO2015153791 A1 WO 2015153791A1 US 2015023921 W US2015023921 W US 2015023921W WO 2015153791 A1 WO2015153791 A1 WO 2015153791A1
Authority
WO
WIPO (PCT)
Prior art keywords
domain
nucleotides
nucleic acid
molecule
grna
Prior art date
Application number
PCT/US2015/023921
Other languages
French (fr)
Inventor
Morgan L. MAEDER
Ari E. FRIEDLAND
Grant G. WELSTEAD
David A. Bumcrot
Original Assignee
Editas Medicine, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editas Medicine, Inc. filed Critical Editas Medicine, Inc.
Publication of WO2015153791A1 publication Critical patent/WO2015153791A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Definitions

  • the invention relates to CRISPR/CAS-related methods and components for editing of a target nucleic acid sequence, or modulating expression of a target nucleic acid sequence, and applications thereof in connection with herpes simplex virus type 2 (HSV-2).
  • HSV-2 herpes simplex virus type 2
  • Herpes simplex virus type 2 (HSV-2) is a sexually transmitted virus. It is most commonly known as genital herpes. Initial infection with HSV-2 generally causes painful blistering in the genital region. The disease causes lifelong, recurring bouts of viral reactivity. It is highly contagious and increases the risk of acquiring HIV infection, especially among patients with active lesions.
  • HSV keratitis is the most common cause of infectious blindness in the developed world (Dawson et. al., Suvey of Ophthalmology 1976; 21(2): 121-135). Worldwide, there are approximately 1.5 million cases of HSV-related ophthalmologic disease and 40,000 cases of HSV-related blindness or severe monocular visual impairment annually (Krawczyk et. al., Public Library of Science One 2015; 10(1): eOl 16800. Farooq and Shukla 2012; Survey of Ophthalmology 57(5): 448-462).
  • HSV-2 infection particularly the treatment and prevention of HSV-2 associated keratitis, encephalitis and meningitis.
  • a therapy that can cure, prevent, or treat HSV-2 infections would be superior to the current standard of care.
  • DNA is transported into the nucleus of the sensory nerve, and key viral RNAs associated with latency are transcribed (i.e., the LAT RNAs).
  • the methods and compositions discussed herein may be used to alter one or more of the UL19, UL30, UL48 and/or UL54 gene(s) to treat or prevent herpes simplex virus type 2 (HSV-2) by targeting the coding sequence of one or more of the UL19, UL30, UL48 and/or UL54 gene(s).
  • HSV-2 herpes simplex virus type 2
  • the methods and compositions discussed herein may be used to alter one or more of the UL19, UL30, UL48 and/or UL54 gene(s) to treat or prevent HSV-2 by targeting non-coding sequence of the UL19, UL30, UL48 and/or UL54 gene(s), e.g., promoter, an enhancer, an intron, 3'UTR, and/or polyadenylation signal.
  • non-coding sequence of the UL19, UL30, UL48 and/or UL54 gene(s) e.g., promoter, an enhancer, an intron, 3'UTR, and/or polyadenylation signal.
  • the first and second gRNA molecules are configured such, that when guiding a Cas9 molecule, e.g., a Cas9 nickase, a single strand break will be accompanied by an additional single strand break, positioned by a second gRNA, sufficiently close to one another to result in alteration of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene.
  • the first and second gRNA molecules are configured such that a single strand break positioned by said second gRNA is within 10, 20, 30, 40, or 50 nucleotides of the break positioned by said first gRNA molecule, e.g., when the Cas9 molecule is a nickase.
  • the two gRNA molecules are configured to position cuts at the same position, or within a few nucleotides of one another, on different strands, e.g., essentially mimicking a double strand break.
  • a double strand break can be accompanied by two additional single strand breaks, positioned by a second gRNA molecule and a third gRNA molecule.
  • the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position; and the targeting domains of a second and third gRNA molecule are configured such that two single strand breaks are positioned downstream of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position.
  • the targeting domain of the first gRNA molecule and the targeting domain of the second gRNA molecules are complementary to opposite strands of the target nucleic acid molecule.
  • the gRNA molecule and the second gRNA molecule are configured such that the PAMs are oriented outward.
  • the targeting domain of a gRNA molecule is configured to position a cleavage event sufficiently far from a preselected nucleotide, e.g., the nucleotide of a coding region, such that the nucleotide is not altered.
  • the targeting domain of a gRNA molecule is configured to position an intronic cleavage event sufficiently far from an intron/exon border, or naturally occurring splice signal, to avoid alteration of the exonic sequence or unwanted splicing events.
  • the gRNA molecule may be a first, second, third and/or fourth gRNA molecule, as described herein.
  • the targeting domain comprises a sequence that is the same as a targeting domain sequence described herein, e.g., from any of Tables 1A-1G, 2A-2F, 3A-3F, 4A-4G, 5A-5E, 6A-6G, 7A-7D, 8A-8E, 9A-9G, 10A-10D, 11A-11E, 12A-12G, 13A-13B, 14A-14E, 15A-15G, or 16A-16C.
  • a HSV-2 target position in the coding region e.g., the early coding region, of the UL19, UL30, UL48 or UL54 gene is targeted, e.g., for knockout.
  • the targeting domain comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, or Tables 4A-4G.
  • the targeting domain is independently selected from those in Tables 1A-1G.
  • the targeting domain is independently selected from Table 1A.
  • the targeting domain is independently selected from those in Tables 2A-2F.
  • the targeting domain is independently selected from Table 2A.
  • the targeting domain is independently selected from those in Tables 3A-3F. In an embodiment, the targeting domain is independently selected from Table 3A.
  • the targeting domain is independently selected from those in
  • the targeting domain is independently selected from those in Tables 12A-12G. In an embodiment, the targeting domain is independently selected from Table 12A. In an embodiment, the targeting domain is independently selected from those in
  • the targeting domain is independently selected from those in
  • the targeting domain is independently selected from those in
  • the targeting domain is independently selected from Table 16A.
  • the targeting domain comprises 24 nucleotides.
  • the eaCas9 molecule catalyzes a double strand break.
  • the nucleic acid encodes a gRNA molecule comprising a targeting domain is selected from those in Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A- 4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C.
  • the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 23 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 24 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 25 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 26 nucleotides in length.
  • the targeting domain comprises 16 nucleotides.
  • the targeting domain comprises 19 nucleotides.
  • the targeting domain comprises 25 nucleotides.
  • a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 35 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • a nucleic acid comprises (a) a sequence that encodes a gRNA molecule, e.g., the first gRNA molecule, comprising a targeting domain that is
  • the eaCas9 molecule catalyzes a double strand break.
  • the eaCas9 molecule comprises HNH-like domain cleavage activity but has no, or no significant, N-terminal RuvC-like domain cleavage activity.
  • the said eaCas9 molecule is an HNH-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at D10, e.g., D10A.
  • the eaCas9 molecule comprises N-terminal RuvC-like domain cleavage activity but has no, or no significant, HNH-like domain cleavage activity.
  • the eaCas9 molecule is an N-terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at H840, e.g., H840A.
  • the eaCas9 molecule is an N- terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at H863, e.g., H863A.
  • a nucleic acid disclosed herein may comprise (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the CCR5 gene as disclosed herein; (b) a sequence that encodes a Cas9 molecule.
  • a nucleic acid disclosed herein may comprise (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the UL19, UL30, UL48 or UL54 gene as disclosed herein; (b) a sequence that encodes a Cas9 molecule; and further may comprise (c)(i) a sequence that encodes a second gRNA molecule described herein having a targeting domain that is complementary to a second target domain of the UL19, UL30, UL48 or UL54 gene, and optionally, (c)(ii) a sequence that encodes a third gRNA molecule described herein having a targeting domain that is complementary to a third target domain of the UL19, UL30, UL48 or UL54 gene; and optionally, (c)(iii) a sequence that encodes a fourth gRNA molecule described herein having a targeting domain that is complementary to a fourth target domain of the UL19, UL30,
  • a nucleic acid encodes a second gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, to allow alteration, e.g., alteration associated with NHEJ, of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, either alone or in combination with the break positioned by said first gRNA molecule.
  • a cleavage event e.g., a double strand break or a single strand break
  • the third and fourth gRNA molecules may independently comprise a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from one of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A- 8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C.
  • the nucleic acid encodes a second gRNA which is a modular gRNA, e.g., wherein one or more nucleic acid molecules encode a modular gRNA.
  • the nucleic acid encoding a second gRNA is a chimeric gRNA.
  • the third and fourth gRNA may be a modular gRNA or a chimeric gRNA. When multiple gRNAs are used, any combination of modular or chimeric gRNAs may be used.
  • a nucleic acid may encode a second, a third, and/or a fourth gRNA, each independently, comprising a targeting domain comprising 16 nucleotides or more in length.
  • the nucleic acid encodes a second gRNA comprising a targeting domain that is 16 nucleotides in length.
  • the nucleic acid encodes a second gRNA comprising a targeting domain that is 17 nucleotides in length.
  • the nucleic acid encodes a second gRNA comprising a targeting domain that is 18 nucleotides in length.
  • the nucleic acid encodes a second gRNA comprising a targeting domain that is 19 nucleotides in length.
  • the nucleic acid encodes a second gRNA comprising a targeting domain that is 25 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 26 nucleotides in length.
  • the targeting domain comprises 19 nucleotides.
  • the targeting domain comprises 22 nucleotides.
  • the targeting domain comprises 23 nucleotides.
  • the targeting domain comprises 24 nucleotides.
  • the targeting domain comprises 25 nucleotides.
  • a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • one of (a), (b), and (c)(i) is encoded on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and a second and third of (a), (b), and (c)(i) is encoded on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector.
  • the first and second nucleic acid molecule may be AAV vectors.
  • each of (a), (b), (c)(i), (c)(ii) and (c)(iii) may be present on more than one nucleic acid molecule, but fewer than five nucleic acid molecules, e.g., AAV vectors.
  • nucleic acids described herein may further comprise a promoter operably linked to the sequence that encodes the Cas9 molecule of (b), e.g., a promoter described herein.
  • compositions comprising (a) a gRNA molecule comprising a targeting domain that is complementary with a target domain in the UL19, UL30, UL48 or UL54 gene, as described herein.
  • the composition of (a) may further comprise (b) a Cas9 molecule, e.g., a Cas9 molecule as described herein.
  • a composition of (a) and (b) may further comprise (c) a second, third and/or fourth gRNA molecule, e.g., a second, third and/or fourth gRNA molecule described herein.
  • the composition is a pharmaceutical composition.
  • compositions described herein can be used in the treatment or prevention of HSV-2 in a subject, e.g., in accordance with a method disclosed herein.
  • a method of altering a cell e.g., altering the structure, e.g., altering the sequence, of a target nucleic acid of a cell, comprising contacting said cell with: (a) a gRNA that targets the UL19, UL30, UL48 or UL54 gene, e.g., a gRNA as described herein; (b) a Cas9 molecule, e.g., a Cas9 molecule as described herein; and optionally, (c) a second, third and/or fourth gRNA that targets UL19, UL30, UL48 or UL54 gene, e.g., a second, third and/or fourth gRNA, as described herein.
  • the gRNA of (a) and optionally (c) may be selected from any of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A- 7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C, or a gRNA that differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables
  • the contacting step may be performed in vivo.
  • the method of altering a cell as described herein comprises acquiring knowledge of the sequence of a HSV-2 target position in said cell, prior to the contacting step.
  • Acquiring knowledge of the sequence of a HSV-2 target position in the cell may be by sequencing one or more of the UL19, UL30, UL48 or UL54 gene, or a portion of the UL19, UL30, UL48 and/or UL54 gene.
  • contacting comprises delivering to the cell a Cas9 molecule of (b), as a protein or an mRNA, and a nucleic acid which encodes a gRNA of (a) and optionally a second, third and/or fourth gRNA of (c).
  • a gRNA that targets the UL19, UL30, UL48 or UL54 gene e.g., a gRNA disclosed herein;
  • a Cas9 molecule e.g., a Cas9 molecule disclosed herein;
  • a second gRNA that targets the UL19, UL30, UL48 or UL54 gene e.g., a second gRNA disclosed herein, and
  • the method comprises acquiring knowledge of the sequence at a
  • the contacting step comprises delivering to said subject said Cas9 molecule of (b), as a protein or mRNA, and a nucleic acid which encodes (a), and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
  • the contacting step comprises delivering to the subject the gRNA of (a), as an RNA, optionally said second gRNA of (c)(i), further optionally (c)(ii), and still further optionally (c)(iii), as an RNA, a nucleic acid that encodes the Cas9 molecule of (b).
  • the method comprises (1) introducing a mutation at a HSV-2 target position by NHEJ or (2) knocking down expression of one or more of the UL19, UL30, UL48 and/or UL54 gene(s), e.g., by targeting the promoter region, a Cas9 molecule of (b) and at least one guide RNA, e.g., a guide RNA of (a) are included in the contacting step.
  • the contacting step comprises contacting the subject with a nucleic acid, e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
  • a nucleic acid e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
  • the contacting step comprises delivering to said subject said Cas9 molecule of (b), as a protein or mRNA, and a nucleic acid which encodes (a) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
  • the contacting step comprises delivering to the subject the Cas9 molecule of (b), as a protein or mRNA, the gRNA of (a), as an RNA, and optionally the second gRNA of (c)(i), further optionally (c)(ii), and still further optionally (c)(iii), as an RNA.
  • the contacting step comprises delivering to the subject the gRNA of (a), as an RNA, optionally said second gRNA of (c)(i), further optionally (c)(ii), and still further optionally (c)(iii), as an RNA, and a nucleic acid that encodes the Cas9 molecule of (b).
  • a reaction mixture comprising a gRNA molecule, a nucleic acid, or a composition described herein, and a cell, e.g., a cell from a subject having, or likely to develop HSV-2, or a subject which would benefit from a mutation at a HSV-2 target position.
  • a second gRNA molecule e.g., a second gRNA molecule described herein or a nucleic acid that encodes (c)(i);
  • the kit comprises nucleic acid, e.g., an AAV vector, that encodes one or more of (a), (b), (c)(i), (c)(ii), and (c)(iii).
  • nucleic acid e.g., an AAV vector
  • the gRNA molecule in used in combination with a Cas9 molecule, e.g., a Cas9 molecule described herein. Additionally or alternatively, in an embodiment, the gRNA molecule is used in combination with a second, third and/or fouth gRNA molecule, e.g., a second, third and/or fouth gRNA molecule described herein.
  • a gRNA molecule e.g., a gRNA molecule described herein, in the manufacture of a medicament for treating, or delaying the onset or progression of HSV-2 in a subject, e.g., in accordance with a method of treating, or delaying the onset or progression of HSV-2 as described herein.
  • the governing gRNA comprises a targeting domain that is complementary to a target domain in a sequence that encodes a Cas9 component, e.g., a Cas9 molecule or target gene gRNA molecule.
  • the target domain is designed with, or has, minimal homology to other nucleic acid sequences in the cell, e.g., to minimize off-target cleavage.
  • the targeting domain on the governing gRNA can be selected to reduce or minimize off-target effects.
  • a target domain for a governing gRNA can be disposed in the control or coding region of a Cas9 molecule or disposed between a control region and a transcribed region.
  • compositions, reaction mixtures and kits, as disclosed herein, can also include a governing gRNA molecule, e.g., a governing gRNA molecule disclosed herein.
  • a governing gRNA molecule e.g., a governing gRNA molecule disclosed herein.
  • Figs. 1A-1I are representations of several exemplary gRNAs.
  • Fig. 1A depicts a modular gRNA molecule derived in part (or modeled on a sequence in part) from Streptococcus pyogenes (S. pyogenes) as a duplexed structure (SEQ ID NOS: 42 and 43, respectively, in order of appearance);
  • Fig. IB depicts a unimolecular (or chimeric) gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 44);
  • Fig. IF depicts a modular gRNA molecule derived in part from Streptococcus thermophilus (S. thermophilus) as a duplexed structure (SEQ ID NOS: 48 and 49, respectively, in order of appearance);
  • Fig. 1G depicts an alignment of modular gRNA molecules of S. pyogenes and S. thermophilus (SEQ ID NOS: 50-53, respectively, in order of appearance).
  • Motif this is a motif based on the four sequences: residues conserved in all four sequences are indicated by single letter amino acid abbreviation; "*" indicates any amino acid found in the corresponding position of any of the four sequences; and "-” indicates any amino acid, e.g., any of the 20 naturally occurring amino acids, or absent.
  • Figs. 4A-4B show an alignment of the N-terminal RuvC-like domain from the Cas9 molecules disclosed in Chylinski et al. with sequence outliers removed (SEQ ID NOS: 104- 177, respectively, in order of appearance). The last line of Fig. 4B identifies 3 highly conserved residues.
  • Figs. 5A-5C show an alignment of the HNH-like domain from the Cas9 molecules disclosed in Chylinski et al (SEQ ID NOS: 178-252, respectively, in order of appearance). The last line of Fig. 5C identifies conserved residues.
  • Figs. 6A-6B show an alignment of the HNH-like domain from the Cas9 molecules disclosed in Chylinski et al. with sequence outliers removed (SEQ ID NOS: 253-302, respectively, in order of appearance).
  • SEQ ID NOS: 253-302 sequence outliers removed.
  • the last line of Fig. 6B identifies 3 highly conserved residues.
  • Figs. 7A-7B depict an alignment of Cas9 sequences from S. pyogenes and Neisseria meningitidis (TV. meningitidis).
  • the N-terminal RuvC-like domain is boxed and indicated with a "Y”.
  • the other two RuvC-like domains are boxed and indicated with a "B”.
  • HNH-like domain is boxed and indicated with a "G".
  • Sp S. pyogenes
  • Nm N. meningitidis.
  • Figs. 9A and 9B are schematic representations of the domain organization of S.
  • Fig. 9A shows the organization of the Cas9 domains, including amino acid positions, in reference to the two lobes of Cas9 (recognition (REC) and nuclease (NUC) lobes).
  • Fig. 9B shows the percent homology of each domain across 83 Cas9 orthologs.
  • Calculations of homology or sequence identity between two sequences are performed as follows.
  • the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
  • the optimal alignment is determined as the best score using the GAP program in the GCG software package with a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frame shift gap penalty of 5.
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
  • a governing gRNA molecule/Cas9 molecule complex binds to or promotes cleavage of a control region sequence, e.g., a promoter, operably linked to a sequence that encodes a Cas9 molecule, a sequence that encodes a transcribed region, an exon, or an intron, for the Cas9 molecule.
  • a governing gRNA molecule/Cas9 molecule complex binds to or promotes cleavage of a control region sequence, e.g., a promoter, operably linked to a gRNA molecule, or a sequence that encodes the gRNA molecule.
  • Modulator refers to an entity, e.g., a drug, that can alter the activity (e.g., enzymatic activity, transcriptional activity, or translational activity), amount, distribution, or structure of a subject molecule or genetic sequence.
  • modulation comprises cleavage, e.g., breaking of a covalent or non-covalent bond, or the forming of a covalent or non-covalent bond, e.g., the attachment of a moiety, to the subject molecule.
  • a modulator alters the, three dimensional, secondary, tertiary, or quaternary structure, of a subject molecule.
  • a modulator can increase, decrease, initiate, or eliminate a subject activity.
  • Displacement or “replaced”, as used herein with reference to a modification of a molecule does not require a process limitation but merely indicates that the replacement entity is present.
  • Prevent means the prevention of a disease in a mammal, e.g., in a human, including (a) avoiding or precluding the disease; (2) affecting the predisposition toward the disease, e.g., preventing at least one symptom of the disease or to delay onset of at least one symptom of the disease.
  • Herpes simplex virus type 2 Herpes simplex virus type 2
  • Herpes simplex virus type 2 (HSV-2) is a sexually transmitted virus. It is most commonly known as genital herpes. Initial infection with HSV-2 generally causes painful blistering in the genital region. The disease causes lifelong, recurring bouts of viral reactivity. It is highly contagious and increases the risk of acquiring HIV infection, especially among patients with active lesions. More than 500 million people are infected with HSV-2 worldwide. Up to 23 million individuals are infected for the first time each year. In the United States, approximately 16% of the population aged 14-49 is seropositive for HSV-2 infection.
  • HSV-2 infection persists for the lifetime of the host. Primary and re-activation infections can cause permanent neurologic sequelae and blindness. HSV-2 also increases a subject's risk of developing HIV. There is a considerable need for methods to treat and prevent HSV-2 infections.
  • HSV-2 infections most often occurs in the ano-genital region. Re-activation infections of the eye and central nervous system are the most severe and damaging HSV manifestations, as they can lead to blindness and permanent neurologic disability, respectively.
  • HSV-2 is contained within an icosahedral particle.
  • the virus enters the host via infection of epithelial cells within the skin and mucous membranes.
  • the virus produces immediate early genes within the epithelial cells, which encode enzymes and binding proteins necessary for viral synthesis.
  • the virus travels up sensory nerve axons via retrograde transport to the sensory dorsal root ganglion (DRG), most commonly a sacral DRG.
  • DRG sensory dorsal root ganglion
  • HSV-2 mainly travels to the sensory DRG located within the sacrum, but can travel to other sensory ganglia depending upon the site of primary infection. Within the DRG, it establishes a latent infection.
  • the latent infection persists for the lifetime of the host. This means that the virus uncoats, viral DNA is transported into the nucleus of the sensory nerve, and key viral RNAs associated with latency are transcribed (i.e., the LAT RNAs).
  • CD4+ T-cells and CD8+ cells are responsible for recognizing and clearing the pathogen.
  • Subjects with impaired T-cell responses- including those with HIV, those receiving immunosuppressants following organ transplants, and neonates with developing immune systems are subject to the most severe manifestations of HSV-2 infections.
  • Reactivations of latent infections are generally less severe and may be of shorter duration. Reactivation can affect the oral region, the ano-genital region, the eye, the central nervous system, the fingernails, and the pharynx. Reactivation generally affects the genital region but can also cause ophthalmologic disease, including keratitis (epithelial keratitis, stromal keratitis and disciform keratitis). Generally, ophthalmologic manifestations of HSV-2 are self-limiting. However, HSV-2 keratitis may rarely cause scarring, secondary infection with bacterial pathogens and rarely, blindness.
  • Re-activation may also occur in the eye via anterograde transport of the virus from the trigeminal ganglion, along the ophthalmic branch of the trigeminal nerve (the fifth cranial nerve) and into the eye. Re-activation of the virus may also occur from within the cornea. Latency within the trigeminal ganglion is established via one of two mechanisms. First, HSV-2 can travel via retrograde transport along the trigeminal nerve from the eye (after an eye infection) into the trigeminal ganglion. Alternatively, it can spread to the trigeminal ganglion via hematogenous spread following infection of the oral mucosa, genital region, or other extraocular site. After establishing latent infection of the trigeminal ganglion, at any time, particularly in the event of an immunocompromised host, the virus can re-establish infection by traveling anterograde along the trigeminal nerve and into the eye.
  • Ocular herpes can affect the anterior chamber of the eye, where it causes keratitis, or the posterior chamber, where it causes retinitis.
  • HSV-2 is responsible for the majority of cases of HSV-retinitis (Pepose et al., Ocular Infection and Immunity 1996; Mosby 1155-1168).
  • HSV-2 retinitis can lead to acute retinal necrosis (ARN), which will destroy the retina within 2 weeks without treatment (Banerjee and Rouse, Human Herpesviruses 2007; Cambridge University Press, Chapter 35). Even with treatment, the risk of permanent visual damage following ARN is higher than 50% (Roy et al., Ocular Immunology and Inflammation 2014; 22(3): 170-174).
  • stromal keratitis represents approximately 15% of keratitis cases and is associated with the highest risk of permanent visual damage. Stromal keratitis results in scarring and irregular astimagtism. Previous ocular HSV infection increases the risk for developing stromal infection, which means that subjects who have had a prior ocular HSV infection have an increased risk for permanent visual damage on reactivation. In children, stromal keratitis represents up to 60% of all keratitis cases so children are particularly at risk for permanent visual damage from HSV-associated keratitis.
  • HSV-associated keratitis may be increasing in the developed world (Farooq and Shukla 2012; Survey of Ophthalmology 57(5): 448-462).
  • Newborns are a population at particular risk for developing severe HSV-2 infections.
  • the disease is transmitted from the mother to the fetus during childbirth.
  • the chance of maternal-fetal transmission is highest in cases where the mother developed primary HSV infection during pregnancy.
  • the incidence of neonatal herpes is approximately 4-30 per 100,000 births.
  • Neonates may develop severe HSV-2 encephalitis and/or meningitis. In spite of prompt treatment with antiviral therapy, the rate of permanent neurologic sequelae in newborns infected with HSV-2 is significant.
  • HSV-2 infection is treated with antiviral therapy, including acyclovir, valacyclovir and famciclovir.
  • antiviral therapy including acyclovir, valacyclovir and famciclovir.
  • acyclovir acyclovir
  • valacyclovir acyclovir
  • famciclovir acyclovir
  • These therapies have been demonstrated to reduce viral shedding, decrease pain and improve healing time of lesions. Therapy is primarily given during acute infection and there is no curative treatment. Therapy may be given prophylactically in certain situations, including during childbirth in a mother with a recent HSV-2 infection or reactivation.
  • HIV-1 Human immunodeficiency virus-1 (HIV-1) acquisition rates are dramatically increased in subjects who are seropositive for HSV-2.
  • the risk of infection with HIV-1 is 3- fold higher in subjects with HSV-2.
  • Antivirals have no impact on reducing risk of HIV acquisition.
  • UL19 (also known as VP5) encodes the HSV-2 major capsid protein, VP5. Proper assembly of the viral capsid is known to be an essential part of viral replication, assembly, maturation and infection (Homa et al.. Reviews of Medical Virology 1997; 7(2):107-122). RNAi-mediated knockdown of VP5 along with another capsid capsid protein, VP23, in vitro, greatly diminished HSV proliferation (Jin et al., PLoS One 2014; 9(5): e96623). Knockout of UL19 can disable HSV-2 proliferation and therefore prevent and/or cure HSV-2 infection.
  • UL30 encodes the DNA polymerase catalytic subunit (HSV-2 pol). The 5' domain of HSV-2 pol is required for viral replication. Knockout of UL30 can disable HSV-2 replication and therefore prevent and/or cure HSV-2 infection.
  • UL48 encodes the viral protein known as VP16 in HSV-2.
  • VP-16 has been shown to be important in viral egress, the process by which the assembled viral capsid leaves the host nucleus and enters the cytoplasm (Mossman et al., Journal of Virology 2000; 74(14): 6287- 6289).
  • Mutation of UL48 in cell culture decreased the ability of HSV to assemble efficiently (Svobodova et al., Journal of Virology 2012; 86(1): 473-483). Knockout of UL48 can disable HSV-2 assembly and egress and therefore prevent and/or cure HSV-2 infection.
  • ICP27 a highly conserved, multi-functional protein. ICP27 is involved in transcription, RNA processing, RNA export and translation (Sandri-Goldin, Frontiers in Bioscience 2008; 13:5241-5256). ICP27 also shuts off host gene expression during HSV-2 infection. Knock out of UL54 can disable HSV-2 transcription, translation and RNA processing and therefore prevent and/or cure HSV-2 infection.
  • Knockout of the genes UL19, UL30, UL48 and UL54 can reduce HSV-2 infectivity, replication, or packaging and can therefore prevent or treat HSV-2 infection.
  • knock out of vital HSV-2 genes e.g., UL19, UL30, UL48 and UL54, individually or in combination can make HSV-2 more susceptible to antiviral therapy.
  • Knocking-out UL19, UL30, UL48 and UL54 individually or in combination may be combined with an antiviral therapy to prevent or treat cure HSV-2 infection.
  • compositions and methods described herein can be used in combination with another antiviral therapy, e.g., another anti-HSV-2 therapy described herein, to treat or prevent HSV-2 infection.
  • another antiviral therapy e.g., another anti-HSV-2 therapy described herein, to treat or prevent HSV-2 infection.
  • one or more of the UL19, UL30, UL48 and/or UL54 gene(s) is targeted as a targeted knockout, e.g., to inhibit essential viral functions, including, e.g. viral gene transcription, viral genome replication and viral capsid formation.
  • said approach comprises knocking out one HSV-2 gene (e.g., UL19, UL30, UL48 or UL54 gene).
  • said approach comprises knocking out two HSV-2 genes, e.g., two of UL19, UL30, UL48 or UL54 gene(s).
  • said approach comprises knocking out three HSV-2 genes, e.g., three or more of UL19, UL30, UL48 or UL54 gene(s). In another embodiment, said approach comprises knocking out four HSV-2 genes, e.g., each of UL19, UL30, UL48 and UL54 gene(s).
  • the method comprises initiating treatment of a subject after disease onset.
  • the method comprises initiating treatment of a subject prior to disease expression. In an embodiment, the method comprises initiating treatment of a subject in an early stage of disease, e.g., when a subject has been exposed to HSV-2 or is thought to have been exposed to HSV-2.
  • the method comprises initiating treatment of a subject prior to disease expression. In an embodiment, the method comprises initiating treatment of a subject in an early stage of disease, e.g., when a subject has tested positive for HSV-2 infections but has no signs or symptoms.
  • the method comprises initiating treatment of a subject at the appearance of painful blistering in or around the mouth, e.g., oral or oropharynx, e.g., in an infant, child, adult or young adult.
  • the method comprises initiating treatment of a subject at the appearance of painful blistering in the genital region, e.g., in an infant, child, adult or young adult.
  • the method comprises initiating treatment at the appearance of any of the following symptoms consistent or associated with HSV-2 meningitis and/or encephalitis: fever, headache, vomiting, photophobia, seizure, decline in level of
  • the method comprises initiating treatment at the appearance of any of the following signs consistent or associated with HSV meningitis and/or encephalitis: positive CSF culture for HSV-2, elevated WBC in CSF, neck stiffness/positive Brudzinski' s sign.
  • the method comprises initiating treatment in a patient with signs consistent with HSV-2 encephalitis and/or meningitis on EEG, CSF exam, MRI, PCR of CSF specimen, and/or PCR of brain biopsy specimen.
  • the method comprises initiating treatment at the appearance of any of the following symptoms consistent or associated with optic HSV-2: pain, photophobia, blurred vision, tearing, redness/injection, loss of vision, floaters, or flashes.
  • the method comprises initiating treatment at the appearance of any of the following findings on ophthalmologic exam consistent or associated with optic HSV-2, also known as HSV-2 keratitis: small, raised clear vesicles on corneal epithelium; irregular corneal surface, punctate epithelial erosions; dense stromal infiltrate; ulceration; necrosis; focal, multifocal, or diffuse cellular infiltrates; immune rings; neovascularization; or ghost vessels at any level of the cornea.
  • optic HSV-2 also known as HSV-2 keratitis: small, raised clear vesicles on corneal epithelium; irregular corneal surface, punctate epithelial erosions; dense stromal infiltrate; ulceration; necrosis; focal, multifocal, or diffuse cellular infiltrates; immune rings; neovascularization; or ghost vessels at any level of the cornea.
  • the method comprises initiating treatment at the appearance of symptoms and/or signs consistent or associated with either an HSV-1 or an HSV-2 infection of the eye, oropharynx, ano-genital region or central nervous system. While not wishing to be bound by theory, intiating treatment for HSV-2 infection in a case of suspected HS V- 1 or HSV-2 infection early in the disease course is beneficial.
  • the method comprises initiating treatment in utero in case of high risk of maternal-to-fetal transmission.
  • the method comprises initiating treatment during pregnancy in case of mother who has active HSV-2 infection or has recent primary HSV-2 infection.
  • the method comprises initiating treatment in case of suspected exposure to HSV-2.
  • the method comprises initiating treatment prophylactically, especially in case of suspected HSV-encephalitis or meningitis.
  • the method comprises initiating treatment of a subject who suffers from or is at risk of developing severe manifestations of HSV-2 infections, e.g., neonates, subjects with HIV, subjects who are on immunosuppressant therapy following organ transplantation, subjects who have cancer, subjects who are undergoing chemotherapy, subjects who will undergo chemotherapy, subjects who are undergoing radiation therapy, subjects who will undergo radiation therapy.
  • severe manifestations of HSV-2 infections e.g., neonates, subjects with HIV, subjects who are on immunosuppressant therapy following organ transplantation, subjects who have cancer, subjects who are undergoing chemotherapy, subjects who will undergo chemotherapy, subjects who are undergoing radiation therapy, subjects who will undergo radiation therapy.
  • HIV positive subjects and post-transplant subjects may experience severe HSV-2 activation or reactivation, including HSV-encephalitis and meningitis, due to immunodeficiency. Neonates are also at risk for severe HSV-encephalitis due to maternal-fetal transmission during childbirth.
  • Inhibiting essential viral functions may provide superior protection to said populations at risk for severe HSV-2 infections.
  • Subjects may experience lower rates of HSV-2 encephalitis and/or lower rates of severe neurologic sequelae following HSV-2 encephalitis, which will profoundly improve quality of life.
  • the method comprises initiating treatment of a subject who has tested positive for HSV-2. In an embodiment, the method comprises initiating treatment at the appearance of any one or more of the following findings consistent or associated with HSV-2: appearance of blistering in the ano-genital area, genital ulcers and/or flu-like illness.
  • the method comprises initiating treatment at the appearance of any of the following findings consistent or associated with HSV-2 infection: fever, headache, body aches, ano-genital blistering, oral ulceration, encephalitis, or keratitis.
  • the method comprises initiating treatment in a subject who has tested positive for HSV-2 infection via viral culture, direct fluorescent antibody study, skin biopsy, PCR, blood serologic test, CSF serologic test, CSF PCR, or brain biopsy. In an embodiment, the method comprises initiating treatment in a subject who has tested positive for HSV-2 infection via diagnostic vitrectomy, endoretinal biopsy, PCR of aqueous fluid, PCR of vitreous sample.
  • the method comprises initiating treatment in any patient exposed to HSV-2 and at high risk for severe sequelae from HSV infection.
  • a cell is manipulated by editing (e.g., introducing a mutation in) one or more target genes, e.g., UL19, UL30, UL48 or UL54 gene.
  • the expression of one or more target genes is modulated, e.g., in vivo.
  • a HSV-2 target position e.g., one or more of UL19, UL30, UL48 or UL54 gene(s)
  • Methods and compositions discussed herein provide for altering a HSV-2 target position in one or more of the UL19, UL30, UL48 and/or UL54 gene(s).
  • a HSV-2 target position can be altered by gene editing, e.g., using CRISPR-Cas9 mediated methods to alter one or more of the UL19, UL30, UL48 and/or UL54 gene(s).
  • An alteration of one or more of the UL19, UL30, UL48 and/or UL54 gene(s) can be mediated by any mechanism.
  • Exemplary mechanisms that can be associated with an alteration of one or more of the UL19, UL30, UL48 and/or UL54 gene(s) include, but are not limited to, non-homologous end joining (e.g., classical or alternative), microhomology- mediated end joining (MMEJ), homology-directed repair (e.g., endogenous donor template mediated), SDSA (synthesis dependent strand annealing), single strand annealing or single strand invasion.
  • a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a HSV-2 target position in the UL19, UL30, UL48 and/or UL54 gene.
  • a single gRNA molecule e.g., with a Cas9 nuclease other than a Cas9 nickase
  • the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream of (e.g., within 200 bp downstream) of a HSV-2 target position.
  • the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • two gRNA molecules are used to create two single strand breaks at or in close proximity to the HSV-2 target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 200 bp upstream) and a second single strand break is positioned downstream (e.g., within 200 bp downstream) of the HSV-2 target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • one double strand break and two single strand breaks are introduced (e.g., positioned by three gRNA molecules) at or in close proximity to a HSV-2 target position in the UL19, UL30, UL48 and/or UL54 gene.
  • four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a HSV-2 target position in the UL19, UL30, UL48 and/or UL54 gene.
  • four gRNA molecule e.g., with one or more
  • Cas9 nickases are used to create four single strand breaks to flank a HSV-2 target position in the UL19, UL30, UL48 and/or UL54 gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 200 bp upstream) of the HSV-2 target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 200 bp downstream) of the HSV-2 target position.
  • the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
  • gRNA structures with domains indicated thereon, are provided in Fig. 1. While not wishing to be bound by theory, in an embodiment, with regard to the three dimensional form, or intra- or inter-strand interactions of an active form of a gRNA, regions of high complementarity are sometimes shown as duplexes in Figs. 1A-1G and other depictions provided herein.
  • a tail domain optionally, a tail domain.
  • a modular gRNA comprises:
  • a first strand comprising, preferably from 5' to 3'
  • a targeting domain (which is complementary to a target nucleic acid in the UL19, UL30, UL48 or UL54 gene, e.g., a targeting domain from Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C); and
  • a second strand comprising, preferably from 5 ' to 3 ' :
  • a tail domain optionally, a tail domain.
  • Figs. 1A-1G provide examples of the placement of targeting domains.
  • the targeting domain comprises a nucleotide sequence that is complementary, e.g., at least 80, 85, 90, or 95% complementary, e.g., fully complementary, to the target sequence on the target nucleic acid.
  • the targeting domain is part of an RNA molecule and will therefore comprise the base uracil (U), while any DNA encoding the gRNA molecule will comprise the base thymine (T). While not wishing to be bound by theory, in an embodiment, it is believed that the complementarity of the targeting domain with the target sequence contributes to specificity of the interaction of the gRNA molecule/Cas9 molecule complex with a target nucleic acid.
  • the uracil bases in the targeting domain will pair with the adenine bases in the target sequence.
  • the target domain itself comprises in the 5' to 3' direction, an optional secondary domain, and a core domain.
  • the core domain is fully complementary with the target sequence.
  • the targeting domain is 5 to 50 nucleotides in length.
  • the strand of the target nucleic acid with which the targeting domain is complementary is referred to herein as the complementary strand.
  • Some or all of the nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
  • the targeting domain is 16 nucleotides in length.
  • the targeting domain is 17 nucleotides in length.
  • the targeting domain is 19 nucleotides in length.
  • the targeting domain is 21 nucleotides in length.
  • the targeting domain is 23 nucleotides in length.
  • the targeting domain is 24 nucleotides in length.
  • the targeting domain is 25 nucleotides in length.
  • the targeting domain comprises 16 nucleotides.
  • the targeting domain comprises 18 nucleotides.
  • the targeting domain comprises 19 nucleotides.
  • the targeting domain comprises 20 nucleotides.
  • the targeting domain comprises 21 nucleotides.
  • the targeting domain comprises 22 nucleotides.
  • the targeting domain comprises 23 nucleotides.
  • the targeting domain comprises 24 nucleotides.
  • the targeting domain comprises 25 nucleotides.
  • the targeting domain comprises 26 nucleotides.
  • Figs. 1A-1G provides examples of first complementarity domains.
  • the first complementarity domain is complementary with the second
  • the complementarity domain has sufficient complementarity to the second complementarity domain to form a duplexed region under at least some physiological conditions.
  • the first complementarity domain is 5 to 30 nucleotides in length. In an embodiment, the first complementarity domain is 5 to 25 nucleotides in length. In an embodiment, the first complementary domain is 7 to 25 nucleotides in length. In an embodiment, the first complementary domain is 7 to 22 nucleotides in length. In an embodiment, the first complementary domain is 7 to 18 nucleotides in length. In an embodiment, the first complementary domain is 7 to 15 nucleotides in length. In an embodiment, the first complementary domain is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length.
  • the first complementarity domain comprises 3 subdomains, which, in the 5' to 3' direction are: a 5' subdomain, a central subdomain, and a 3' subdomain.
  • the 5' subdomain is 4 to 9, e.g., 4, 5, 6, 7, 8 or 9 nucleotides in length.
  • the central subdomain is 1, 2, or 3, e.g., 1, nucleotide in length.
  • the 3' subdomain is 3 to 25, e.g., 4 to22, 4 to 18, or 4 to 10, or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length.
  • the first complementarity domain can share homology with, or be derived from, a naturally occurring first complementarity domain. In an embodiment, it has at least 50% homology with a first complementarity domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, first complementarity domain.
  • nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
  • Figs. 1A-1G provides example of linking domains.
  • linking domains are suitable for use in unimolecular gRNA molecules.
  • Linking domains can consist of a covalent bond, or be as short as one or a few nucleotides, e.g., 1, 2, 3, 4, or 5 nucleotides in length.
  • a linking domain is 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 or more nucleotides in length.
  • a linking domain is 2 to 50, 2 to 40, 2 to 30, 2 to 20, 2 to 10, or 2 to 5 nucleotides in length.
  • a linking domain shares homology with, or is derived from, a naturally occurring sequence, e.g., the sequence of a tracrRNA that is 5' to the second complementarity domain.
  • the linking domain has at least 50% homology with a linking domain disclosed herein.
  • nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
  • a modular gRNA can comprise additional sequence, 5' to the second complementarity domain, referred to herein as the 5' extension domain, see, e.g., Fig. 1A.
  • the 5' extension domain is, 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, or 2 to 4 nucleotides in length.
  • the 5' extension domain is 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides in length.
  • the second complementarity domain can include sequence that lacks complementarity with the first complementarity domain, e.g., sequence that loops out from the duplexed region.
  • complementarity domain are respectively, complementary, e.g., fully complementary, with the 3' subdomain and the 5' subdomain of the second complementarity domain.
  • nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
  • Figs. 1A-1G provide examples of proximal domains.
  • the proximal domain is 5 to 20 nucleotides in length.
  • the proximal domain can share homology with or be derived from a naturally occurring proximal domain. In an embodiment, it has at least 50% homology with a proximal domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, proximal domain.
  • nucleotides of the domain can have a modification, e.g., modification found in Section VIII herein.
  • Figs. 1A-1G provide examples of tail domains.
  • the tail domain is 0 (absent), 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length.
  • the tail domain nucleotides are from or share homology with sequence from the 5 ' end of a naturally occurring tail domain, see e.g., Fig. ID or Fig.lE.
  • the tail domain includes sequences that are complementary to each other and which, under at least some physiological conditions, form a duplexed region.
  • the tail domain is absent or is 1 to 50 nucleotides in length.
  • the tail domain can share homology with or be derived from a naturally occurring proximal tail domain. In an embodiment, it has at least 50% homology with a tail domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, tail domain.
  • the tail domain includes nucleotides at the 3' end that are related to the method of in vitro or in vivo transcription.
  • these nucleotides may be any nucleotides present before the 3 ' end of the DNA template.
  • U6 promoter is used for in vivo transcription
  • these nucleotides may be the sequence UUUUUU.
  • alternate pol-III promoters are used, these nucleotides may be various numbers or uracil bases or may include alternate bases.
  • the domains of gRNA molecules are described in more detail below.
  • the Targeting Domain is described in more detail below.
  • the targeting domain is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • the targeting domain is 16 nucleotides in length.
  • the targeting domain is 17 nucleotides in length.
  • the targeting domain is 18 nucleotides in length.
  • the targeting domain is 19 nucleotides in length.
  • the targeting domain is 21 nucleotides in length.
  • the targeting domain is 22 nucleotides in length.
  • the targeting domain is 23 nucleotides in length.
  • the targeting domain is 24 nucleotides in length.
  • the targeting domain is 25 nucleotides in length.
  • the targeting domain is 26 nucleotides in length. In an embodiment, the targeting domain comprises 16 nucleotides.
  • the targeting domain comprises 17 nucleotides.
  • the targeting domain comprises 18 nucleotides.
  • the targeting domain comprises 19 nucleotides.
  • the targeting domain comprises 20 nucleotides.
  • the targeting domain comprises 22 nucleotides.
  • the targeting domain comprises 23 nucleotides.
  • the targeting domain comprises 24 nucleotides.
  • the targeting domain comprises 25 nucleotides.
  • the targeting domain comprises 26 nucleotides.
  • the targeting domain is 10 +/-5, 20+/-5, 30+/-5,
  • the targeting domain is 20+/-5 nucleotides in length.
  • the targeting domain is 20+/- 10, 30+/- 10, 40+/- 10, 50+/- 10, 60+/-
  • the targeting domain is 10 to 100, 10 to 90, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 10 to 20 or 10 to 15 nucleotides in length. In another embodiment, the targeting domain is 20 to 100, 20 to 90, 20 to 80, 20 to 70, 20 to 60, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides in length.
  • the targeting domain has full complementarity with the target sequence.
  • the targeting domain has or includes 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain.
  • the target domain includes 1, 2, 3, 4 or 5 nucleotides that are complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 5' end. In an embodiment, the target domain includes 1, 2, 3, 4 or 5 nucleotides that are complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 3 ' end.
  • the target domain includes 1, 2, 3, or 4 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 5' end. In an embodiment, the target domain includes 1, 2, 3, or 4 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 3 ' end. In an embodiment, the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
  • the targeting domain comprises two consecutive nucleotides that are not complementary to the target domain ("non-complementary nucleotides”), e.g., two consecutive noncomplementary nucleotides that are within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3 ' end of the targeting domain, or more than 5 nucleotides away from one or both ends of the targeting domain.
  • non-complementary nucleotides two consecutive nucleotides that are within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3 ' end of the targeting domain, or more than 5 nucleotides away from one or both ends of the targeting domain.
  • no two consecutive nucleotides within 5 nucleotides of the 5 ' end of the targeting domain, within 5 nucleotides of the 3 ' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain, are not complementary to the targeting domain.
  • the targeting domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the targeting domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the targeting domain can be modified with a phosphorothioate, or other modification(s) from Section VIII.
  • a nucleotide of the targeting domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
  • the targeting domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or more than 5 nucleotides away from one or both ends of the targeting domain.
  • no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain.
  • no nucleotide is modified within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain.
  • Modifications in the targeting domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate targeting domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated in a system in Section IV.
  • the candidate targeting domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • all of the modified nucleotides are complementary to and capable of hybridizing to corresponding nucleotides present in the target domain. In another embodiment, 1, 2, 3, 4, 5, 6, 7 or 8 or more modified nucleotides are not complementary to or capable of hybridizing to corresponding nucleotides present in the target domain.
  • the targeting domain comprises, preferably in the 5' ⁇ 3' direction: a secondary domain and a core domain. These domains are discussed in more detail below.
  • the “core domain” of the targeting domain is complementary to the “core domain target” on the target nucleic acid.
  • the core domain comprises about 8 to about 13 nucleotides from the 3' end of the targeting domain (e.g., the most 3' 8 to 13 nucleotides of the targeting domain).
  • the core domain and targeting domain are independently, 6 +1-2, 7+/-2, 8+/-2, 9+/-2, 10+/-2, 11+/-2, 12+/-2, 13+/-2, 14+/-2, 15+/-2, or 16+-2, nucleotides in length.
  • the core domain and targeting domain are independently, 10+/-4 nucleotides in length.
  • the core domain and targeting domain are independently 3 to 20, 4 to 20, 5 to 20, 6 to 20, 7 to 20, 8 to 20, 9 to 20 10 to 20 or 15 to 20 nucleotides in length. In an embodiment, the core domain and targeting domain are independently 3 to 15, e.g., 6 to 15, 7 to 14, 7 to 13, 6 to 12, 7 to 12, 7 to 11, 7 to 10, 8 to 14, 8 to 13, 8 to 12, 8 to 11, 8 to 10 or 8 to 9 nucleotides in length.
  • the core domain is complementary with the core domain target.
  • the core domain has exact complementarity with the core domain target.
  • the core domain can have 1, 2, 3, 4 or 5 nucleotides that are not complementary with the corresponding nucleotide of the core domain.
  • complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
  • the "secondary domain" of the targeting domain of the gRNA is complementary to the "secondary domain target" of the target nucleic acid.
  • the secondary domain is positioned 5 ' to the core domain.
  • the secondary domain is absent or optional.
  • the targeting domain is 25 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 12 to 17 nucleotides in length.
  • the targeting domain is 24 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 11 to 16 nucleotides in length.
  • the targeting domain is 21 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 8 to 13 nucleotides in length.
  • the targeting domain is 20 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 7 to 12 nucleotides in length. In an embodiment, if the targeting domain is 19 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 6 to 11 nucleotides in length.
  • the targeting domain is 16 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length
  • the secondary domain is 3 to 8 nucleotides in length.
  • the secondary domain is complementary with the secondary domain target.
  • the core domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the core domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the core domain can be modified with a phosphorothioate, or other modification(s) from Section VIII.
  • a nucleotide of the core domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other
  • Modifications in the core domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate core domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated in the system described at Section IV.
  • the candidate core domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • the secondary domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the secondary domain comprises one or more modifications, e.g., modifications that render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the secondary domain can be modified with a phosphorothioate, or other modification(s) from Section VIII.
  • a nucleotide of the secondary domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
  • a secondary domain will contain no more than 1, 2, or 3 modifications.
  • Modifications in the secondary domain can be selected to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate secondary domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated in the system described at Section IV.
  • the candidate secondary domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • (1) the degree of complementarity between the core domain and its target, and (2) the degree of complementarity between the secondary domain and its target may differ. In an embodiment, (1) may be greater than (2). In an embodiment, (1) may be less than (2). In an embodiment, (1) and (2) are the same, e.g., each may be completely complementary with its target.
  • (1) the number of modifications (e.g., modifications from Section VIII) of the nucleotides of the core domain and (2) the number of modifications (e.g., modifications from Section VIII) of the nucleotides of the secondary domain may differ. In an embodiment, (1) may be less than (2). In an embodiment, (1) may be greater than (2). In an embodiment, (1) and (2) may be the same, e.g., each may be free of modifications.
  • the first complementarity domain is complementary with the second
  • the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
  • the first and second complementarity domains are:
  • the second complementarity domain is longer than the first complementarity domain, e.g., 2, 3, 4, 5, or 6, e.g., 6, nucleotides longer.
  • the first and second complementary domains independently, do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the first and second complementary domains independently, comprise one or more modifications, e.g., modifications that the render the domain less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the domain can be modified with a phosphorothioate, or other modification(s) from Section VIII.
  • a nucleotide of the domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other
  • the first and second complementary domains independently, include 1 , 2, 3, 4, 5, 6, 7 or 8 or more modifications. In an embodiment, the first and second complementary domains, independently, include 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end. In an embodiment, the first and second complementary domains, independently, include as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end.
  • the first and second complementary domains independently, include modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5 ' end of the domain, within 5 nucleotides of the 3 ' end of the domain, or more than 5 nucleotides away from one or both ends of the domain.
  • the first and second complementary domains independently, include no two consecutive nucleotides that are modified, within 5 nucleotides of the 5' end of the domain, within 5 nucleotides of the 3' end of the domain, or within a region that is more than 5 nucleotides away from one or both ends of the domain.
  • the first and second complementary domains independently, include no nucleotide that is modified within 5 nucleotides of the 5' end of the domain, within 5 nucleotides of the 3' end of the domain, or within a region that is more than 5 nucleotides away from one or both ends of the domain.
  • Modifications in a complementarity domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate complementarity domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated in the system described in Section IV.
  • the candidate complementarity domain can be placed, either alone, or with one or more other candidate changes in a gRNA
  • the first complementarity domain has at least 60, 70, 80, 85%, 90% or 95% homology with, or differs by no more than 1, 2, 3, 4, 5, or 6 nucleotides from, a reference first complementarity domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus, first complementarity domain, or a first complementarity domain described herein, e.g., from Figs. 1A-1G.
  • a reference first complementarity domain e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus
  • first complementarity domain e.g., from Figs. 1A-1G.
  • the duplexed region formed by first and second complementarity domains is typically 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 base pairs in length (excluding any looped out or unpaired nucleotides).
  • the first and second complementarity domains when duplexed, comprise 11 paired nucleotides, for example, in the gRNA sequence (one paired strand underlined, one bolded): NNNNNNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAA GGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 5).
  • the first and second complementarity domains when duplexed, comprise 15 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
  • the first and second complementarity domains when duplexed, comprise 16 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
  • the first and second complementarity domains when duplexed, comprise 21 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
  • nucleotides are exchanged to remove poly-U tracts, for example in the gRNA sequences (exchanged nucleotides underlined):
  • a modular gRNA can comprise additional sequence, 5' to the second complementarity domain.
  • the 5' extension domain is 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, or 2 to 4 nucleotides in length.
  • the 5' extension domain is 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides in length.
  • the 5 ' extension domain nucleotides do not comprise
  • the 5' extension domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the 5' extension domain can be modified with a phosphorothioate, or other modification(s) from Section VIII.
  • a nucleotide of the 5' extension domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
  • the 5' extension domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the 5' extension domain, within 5 nucleotides of the 3' end of the 5' extension domain, or more than 5 nucleotides away from one or both ends of the 5' extension domain.
  • no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the 5' extension domain, within 5 nucleotides of the 3' end of the 5' extension domain, or within a region that is more than 5 nucleotides away from one or both ends of the 5' extension domain.
  • no nucleotide is modified within 5 nucleotides of the 5 ' end of the 5 ' extension domain, within 5 nucleotides of the 3 ' end of the 5 ' extension domain, or within a region that is more than 5 nucleotides away from one or both ends of the 5' extension domain.
  • Modifications in the 5 ' extension domain can be selected so as to not interfere with gRNA molecule efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate 5 ' extension domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated in the system described at Section IV.
  • the candidate 5 ' extension domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • the 5' extension domain has at least 60, 70, 80, 85, 90 or 95% homology with, or differs by no more than 1, 2, 3, 4, 5, or 6 nucleotides from, a reference 5' extension domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S.
  • a reference 5' extension domain e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S.
  • thermophilus 5' extension domain, or a 5' extension domain described herein, e.g., from Figs. 1A-1G.
  • the linking domain is disposed between the first and second complementarity domains.
  • the two molecules are associated with one another by the complementarity domains.
  • the linking domain is 20+/-10, 30+/-10, 40+/-10, 50+/-10, 60+/-
  • the linking domain is 10 to 100, 10 to 90, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 10 to 20 or 10 to 15 nucleotides in length. In other embodiments, the linking domain is 20 to 100, 20 to 90, 20 to 80, 20 to 70, 20 to 60, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides in length.
  • the linking domain is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 17, 18, 19, or 20 nucleotides in length.
  • the linking domain is a covalent bond.
  • the linking domain comprises a duplexed region, typically adjacent to or within 1, 2, or 3 nucleotides of the 3' end of the first complementarity domain and/or the 5- end of the second complementarity domain.
  • the duplexed region can be 20+/- 10 base pairs in length.
  • the duplexed region can be 10+/-5, 15+/-5, 20+/-5, or 30+/-5 base pairs in length.
  • the duplexed region can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 base pairs in length.
  • sequences forming the duplexed region have exact complementarity with one another, though in some embodiments as many as 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides are not complementary with the corresponding nucleotides.
  • the linking domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the linking domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the linking domain can be modified with a phosphorothioate, or other modification(s) from Section VIII.
  • a nucleotide of the linking domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
  • the linking domain can comprise as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications.
  • Modifications in a linking domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate linking domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated a system described in Section IV.
  • a candidate linking domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • the linking domain has at least 60, 70, 80, 85, 90 or 95% homology with, or differs by no more than 1, 2, 3, 4, 5 , or 6 nucleotides from, a reference linking domain, e.g., a linking domain described herein, e.g., from Figs. 1A-1G.
  • the proximal domain is 6 +1-2, 1+1-2, 8+/-2, 9+/-2, 10+/-2, 11+/-2,
  • the proximal domain is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • the proximal domain is 5 to 20, 7, to 18, 9 to 16, or 10 to 14 nucleotides in length.
  • the proximal domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the proximal domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the proximal domain can be modified with a phosphorothioate, or other modification(s) from Section VIII.
  • a nucleotide of the proximal domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
  • the proximal domain can comprise as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications. In an embodiment, the proximal domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end, e.g., in a modular gRNA molecule. In an embodiment, the target domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end, e.g., in a modular gRNA molecule.
  • the proximal domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5 ' end of the proximal domain, within 5 nucleotides of the 3 ' end of the proximal domain, or more than 5 nucleotides away from one or both ends of the proximal domain.
  • no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the proximal domain, within 5 nucleotides of the 3 ' end of the proximal domain, or within a region that is more than 5 nucleotides away from one or both ends of the proximal domain.
  • the proximal domain has at least 60, 70, 80, 85 90 or 95% homology with, or differs by no more than 1, 2, 3, 4, 5 , or 6 nucleotides from, a reference proximal domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S.
  • a reference proximal domain e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S.
  • the tail domain is 10 +/-5, 20+/-5, 30+/-5, 40+/-5, 50+/-5, 60+/-5, 70+/-5, 80+/-5, 90+/-5, or 100+/-5 nucleotides, in length.
  • the tail domain is 20+/-5 nucleotides in length.
  • the tail domain is 10 to 100, 10 to 90, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 10 to 20 or 10 to 15 nucleotides in length.
  • the tail domain is 20 to 100, 20 to 90, 20 to 80, 20 to 70, 20 to 60, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides in length.
  • the tail domain is 1 to 20, 1 to 15, 1 to 10, or 1 to 5 nucleotides in length.
  • the tail domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII.
  • the tail domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic.
  • the backbone of the tail domain can be modified with a phosphorothioate, or other modification(s) from Section VIII.
  • a nucleotide of the tail domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other
  • the tail domain can have as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications.
  • the target domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end. In an embodiment, the target domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end.
  • the tail domain comprises a tail duplex domain, which can form a tail duplexed region.
  • the tail duplexed region can be 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 base pairs in length.
  • a further single stranded domain exists 3' to the tail duplexed domain.
  • this domain is 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In an embodiment it is 4 to 6 nucleotides in length.
  • AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC SEQ ID NO: 34
  • AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCGGAUC SEQ ID NO: 35
  • AAGGCUAGUCCGUUAUCA (SEQ ID NO: 37), or
  • the tail domain comprises the 3' sequence UUUUUU, e.g., if a U6 promoter is used for transcription.
  • the tail domain comprises the 3' sequence UUUU, e.g., if an HI promoter is used for transcription.
  • tail domain comprises variable numbers of 3' Us depending, e.g., on the termination signal of the pol-III promoter used.
  • the tail domain comprises variable 3 ' sequence derived from the DNA template if a T7 promoter is used.
  • the tail domain comprises variable 3' sequence derived from the
  • DNA template e.g., if in vitro transcription is used to generate the RNA molecule.
  • the tail domain comprises variable 3 ' sequence derived from the DNA template, e., if a pol-II promoter is used to drive transcription.
  • Modifications in the tail domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV.
  • gRNAs having a candidate tail domain having a selected length, sequence, degree of complementarity, or degree of modification can be evaluated in the system described in Section IV.
  • the candidate tail domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
  • the tail domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the tail domain, within 5 nucleotides of the 3' end of the tail domain, or more than 5 nucleotides away from one or both ends of the tail domain. In an embodiment, no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the tail domain, within 5 nucleotides of the 3' end of the tail domain, or within a region that is more than 5 nucleotides away from one or both ends of the tail domain.
  • no nucleotide is modified within 5 nucleotides of the 5 ' end of the tail domain, within 5 nucleotides of the 3' end of the tail domain, or within a region that is more than 5 nucleotides away from one or both ends of the tail domain.
  • the targeting domain comprises a core domain and optionally a secondary domain, and is 10 to 50 nucleotides in length;
  • the first complementarity domain is 5 to 25 nucleotides in length and, In an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference first complementarity domain disclosed herein;
  • the linking domain is 1 to 5 nucleotides in length
  • the second complementarity domain is 5 to 27 nucleotides in length and, in an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference second complementarity domain disclosed herein;
  • the proximal domain is 5 to 20 nucleotides in length and, in an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference proximal domain disclosed herein;
  • the tail domain is absent or a nucleotide sequence is 1 to 50 nucleotides in length and, in an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference tail domain disclosed herein.
  • a targeting domain (which is complementary to a target nucleic acid);
  • a first complementarity domain e.g., comprising 15, 16, 17, 18, 19, 20, 21, 22,
  • proximal and tail domain when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides;
  • the sequence from (a), (b), or (c) has at least 60, 75, 80, 85, 90, 95, or 99% homology with the corresponding sequence of a naturally occurring gRNA, or with a gRNA described herein.
  • proximal and tail domain when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 17 nucleotides
  • the targeting domain is 17 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 23 nucleotides
  • the targeting domain is 23 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
  • the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
  • the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
  • the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and the proximal and tail domain, when taken together, comprise at leastl5, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
  • the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
  • the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
  • the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
  • the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
  • the targeting domain comprises, has, or consists of, 22 nucleotides
  • the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
  • the targeting domain comprises, has, or consists of, 23 nucleotides
  • the targeting domain is 23 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
  • the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
  • the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
  • the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
  • the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
  • the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
  • the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
  • the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
  • the unimolecular, or chimeric, gRNA molecule (comprising a targeting domain, a first complementary domain, a linking domain, a second complementary domain, a proximal domain and, optionally, a tail domain) comprises the following sequence in which the targeting domain is depicted as 20 Ns but could be any sequence and range in length from 16 to 26 nucleotides and in which the gRNA sequence is followed by 6 Us, which serve as a termination signal for the U6 promoter, but which could be either absent or fewer in number:
  • the unimolecular, or chimeric, gRNA molecule is a S. pyogenes gRNA molecule.
  • the unimolecular, or chimeric, gRNA molecule (comprising a targeting domain, a first complementary domain, a linking domain, a second complementary domain, a proximal domain and, optionally, a tail domain) comprises the following sequence in which the targeting domain is depicted as 20 Ns but could be any sequence and range in length from 16 to 26 nucleotides and in which the gRNA sequence is followed by 6 Us, which serve as a termination signal for the U6 promoter, but which could be either absent or fewer in number:
  • the unimolecular, or chimeric, gRNA molecule is a S. aureus gRNA molecule.
  • a first strand comprising, preferably from 5' to 3' ;
  • a targeting domain e.g., comprising 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides;
  • a second strand comprising, preferably from 5 ' to 3 ' :
  • proximal and tail domain when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides;
  • the sequence from (a), (b), or (c) has at least 60, 75, 80, 85, 90, 95, or 99% homology with the corresponding sequence of a naturally occurring gRNA, or with a gRNA described herein.
  • proximal and tail domain when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • nucleotides 3 ' there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3 ' to the last nucleotide of the second complementarity domain. In an embodiment, there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3 ' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
  • the targeting domain comprises, has, or consists of, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 20 nucleotides
  • the targeting domain is 20 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length.
  • the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
  • the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
  • the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
  • the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
  • the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
  • 18 nucleotides e.g., 18 consecutive nucleotides having complementarity with the target domain
  • the targeting domain is 18 nucleotides in length
  • the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
  • the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
  • 19 nucleotides e.g., 19 consecutive nucleotides having complementarity with the target domain
  • the targeting domain is 19 nucleotides in length
  • the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
  • the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
  • the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
  • the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
  • the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
  • the targeting domain comprises, has, or consists of, 23 nucleotides
  • the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
  • the targeting domain comprises, has, or consists of, 24 nucleotides
  • the targeting domain is 24 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
  • the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
  • the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
  • Methods for designing gRNAs are described herein, including methods for selecting, designing and validating target domains. Exemplary targeting domains are also provided herein. Targeting Domains discussed herein can be incorporated into the gRNAs described herein.
  • BIOTECHNOL 31(9): 827-32; Fu et al., 2014 NAT BIOTECHNOL, doi: 10.1038/nbt.2808.
  • a software tool can be used to optimize the choice of gRNA within a user's target sequence, e.g., to minimize total off-target activity across the genome. Off target activity may be other than cleavage.
  • the tool can identify all off-target sequences (preceding either NAG or NGG PAMs) across the genome that contain up to certain number (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of mismatched base-pairs.
  • the cleavage efficiency at each off-target sequence can be predicted, e.g., using an experimentally-derived weighting scheme.
  • Each possible gRNA is then ranked according to its total predicted off-target cleavage; the top-ranked gRNAs represent those that are likely to have the greatest on-target and the least off-target cleavage.
  • Other functions e.g., automated reagent design for CRISPR construction, primer design for the on-target Surveyor assay, and primer design for high-throughput detection and quantification of off- target cleavage via next-gen sequencing, can also be included in the tool.
  • Candidate gRNA molecules can be evaluated by art-known methods or as described in Section IV herein.
  • Targeting Domains discussed herein can be incorporated into the gRNAs described herein.
  • gRNAs guide RNAs
  • Tables 1A- 1C guide RNAs
  • PubMed PMID 24463574, for the original references see Sander et al., 2007, NAR 35:W599-605; Sander et al., 2010, NAR 38: W462-8).
  • the software In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available Repeat-Masker program. RepeatMmasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence. Following identification, gRNAs for use with a S. pyogenes Cas9 were ranked into 3 tiers.
  • gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
  • gRNAs While it can be desirable to have gRNAs start with a 5 ' G, this requirement was relaxed for some gRNAs in tier 1 in order to identify guides in the correct orientation, within a reasonable distance to the target position (i.e., within the first 500 bp of the coding sequence) and with a high level of orthogonality against the human genome. In order to find a pair for the dual-nickase strategy it was necessary to either extend the distance from the target position or remove the requirement for the 5'G. Tier 2 gRNAs were selected based on loction within the first 500 bp of the coding sequence in the HSV gene. Tier 3 gRNAs were selected based on their location in the coding sequence, but downstream of the first 500 bp of the HSV gene. Note that tiers are non-inclusive (each gRNA is listed only once). In certain instances, no gRNA was identified based on the criteria of the particular tier.
  • gRNAs were identified for single-gRNA nuclease cleavage as well as for a dual-gRNA paired "nickase" strategy, as indicated.
  • gRNAs for use with the N. meningitidis (Tables 1F-1G) and S. aureus (Tables 1D- 1E) Cas9s were identified manually by scanning genomic DNA sequence for the presence of PAM sequences. These gRNAs were separated into two tiers for each species. The first tier includes gRNAs selected based on location in the first 500 bp of the coding sequence of the HSV gene. The second tier includes gRNAs selected based on location in the coding sequence, but downstream of the first 500 bp of the HSV gene.
  • gRNAs Guide RNAs
  • S. pyogenes, S. aureus and N. meningitidis Cas9s were identified using a DNA sequence searching algorithm.
  • Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas-offinder (reference:Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID: 24463181).
  • Said custom guide RNA design software scores guides after calculating their genomewide off-target propensity.
  • matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24.
  • an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface.
  • the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available
  • RepeatMasker program searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
  • gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of 5". aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM).
  • Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence.
  • a "high level of orthogonality" or "good orthogonality” may, for example, refer to
  • Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
  • S. pyogenes and N. meningitidis targets 17-mer, or 20-mer gRNAs were designed.
  • S. aureus targets 18-mer, 19-mer, 20-mer,
  • Targeting domains may comprise the 17-mer described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C.
  • Targeting domains, disclosed herein may comprises the 18-mer described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C.
  • Targeting domains may comprises the 19-mer described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C.
  • Targeting domains, disclosed herein may comprises the 20-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C.
  • Targeting domains may comprises the 21-mer described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C.
  • Targeting domains, disclosed herein may comprises the
  • the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 5A-5E, 6A-6G or
  • Targeting domains may comprises the 23-mer described in Tables 5A-5E, 6A-6G or 7A-7C,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C.
  • Targeting domains, disclosed herein may comprises the 24-mer described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C.
  • gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for the dual-gRNA paired "nickase” strategy is based on two considerations: 1. gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
  • the targeting domains discussed herein can be incorporated into the gRNAs described herein.
  • gRNAs were identified and ranked into 5 tiers for S. pyogenes (Tables 5A-5E), and
  • N. meningitidis (Tables 7A-7C); and 7 tiers for S. aureus (Tables 6A-6G).
  • the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality and (3) the presence of 5'G.
  • the targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) a high level of orthogonality.
  • the targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) the presence of 5'G.
  • the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT.
  • the targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, and (3) PAM is
  • the targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRT.
  • the targeting domain for tier 4 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRV.
  • the targeting domain for tier 5 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon), (2) the presence of 5'G and (3) PAM is NNGRRT.
  • the targeting domain for tier 6 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRT.
  • the targeting domain for tier 7 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRV.
  • tiers are non- inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier.
  • Cas9 were identified using the publically available web-based ZiFiT server (Fu et al., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014 Jan 26. doi: 10.1038/nbt.2808. PubMed PMID: 24463574, for the original references see Sander et al., 2007, NAR 35:W599-605; Sander et al., 2010, NAR 38: W462-8). In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites.
  • Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available Repeat-Masker program. RepeatMmasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence. Following identification, gRNAs for use with a S. pyogenes Cas9 were ranked into 3 tiers.
  • the gRNAs in tier 1 were selected based on their distance to the target site and their orthogonality in the genome (based on the ZiFiT identification of close matches in the human genome containing an NGG PAM). As an example, for all targets, both 17-mer and 20-mer gRNAs were designed. gRNAs were also selected both for single-gRNA nuclease cutting and for the dual gRNA nickase strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for which strategy is based on several considerations:
  • gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
  • gRNAs While it can be desirable to have gRNAs start with a 5 ' G, this requirement was relaxed for some gRNAs in tier 1 in order to identify guides in the correct orientation, within a reasonable distance to the target position (i.e., within the first 500 bp of the coding sequence) and with a high level of orthogonality against the human genome. In order to find a pair for the dual-nickase strategy it was necessary to either extend the distance from the target position or remove the requirement for the 5'G. Tier 2 gRNAs were selected based on loction within the first 500 bp of the coding sequence in the HSV gene. Tier 3 gRNAs were selected based on their location in the coding sequence, but downstream of the first 500 bp of the HSV gene. Note that tiers are non-inclusive (each gRNA is listed only once). In certain instances, no gRNA was identified based on the criteria of the particular tier.
  • Cas9s were identified manually by scanning genomic DNA sequence for the presence of PAM sequences. These gRNAs were separated into two tiers for each species. The first tier includes gRNAs selected based on location in the first 500 bp of the coding sequence of the HSV gene. The second tier includes gRNAs selected based on location in the coding sequence, but downstream of the first 500 bp of the HSV gene.
  • gRNAs Guide RNAs
  • S. pyogenes, S. aureus and N. meningitidis Cas9s were identified using a DNA sequence searching algorithm.
  • Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas-offinder (reference:Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID: 24463181).
  • Said custom guide RNA design software scores guides after calculating their genomewide off-target propensity.
  • matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24.
  • an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface.
  • the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available
  • RepeatMasker program searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
  • gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of 5". aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM).
  • Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence.
  • a "high level of orthogonality" or "good orthogonality” may, for example, refer to
  • S. pyogenes and N. meningitidis targets 17-mer, or 20-mer gRNAs were designed.
  • S. aureus targets 18-mer, 19-mer, 20-mer,
  • Targeting domains may comprise the 17-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D.
  • Targeting domains, disclosed herein may comprises the 18-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D.
  • Targeting domains may comprises the 19-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D.
  • Targeting domains, disclosed herein may comprises the 20-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D.
  • Targeting domains may comprises the 21-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D.
  • Targeting domains, disclosed herein may comprises the 22-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables
  • Targeting domains may comprises the 23-mer described in Tables 8A-8E, 9A-9G or 10A-10D,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A- 10D.
  • Targeting domains, disclosed herein may comprises the 24-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D.
  • gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for the dual-gRNA paired "nickase" strategy is based on two considerations:
  • gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
  • the targeting domains discussed herein can be incorporated into the gRNAs described herein.
  • gRNAs were identified and ranked into 5 tiers for S. pyogenes (Tables 8A-8E), and N. meningitidis (Tables 10A-10D); and 7 tiers for 5". aureus (Tables 9A-9G). For 5".
  • the targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) the presence of 5'G.
  • the targeting domain for tier 4 gRNA molecules were selected based on distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon).
  • the targeting domain for tier 5 gRNA molecules were selected based on distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon).
  • the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT.
  • the targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, and (3) PAM is
  • the targeting domain for tier 6 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRT.
  • the targeting domain for tier 7 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRV.
  • tiers are non- inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier. Strategies to identify gRNAs for S. pyogenes, S. aureus, and N. meningitidis to knock out the UL48 gene
  • Cas9 were identified using the publically available web-based ZiFiT server (Fu et al., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014 Jan 26. doi: 10.1038/nbt.2808. PubMed PMID: 24463574, for the original references see Sander et al., 2007, NAR 35:W599-605; Sander et al., 2010, NAR 38: W462-8). In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites.
  • Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available Repeat-Masker program. RepeatMmasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence. Following identification, gRNAs for use with a S. pyogenes Cas9 were ranked into 3 tiers.
  • the gRNAs in tier 1 were selected based on their distance to the target site and their orthogonality in the genome (based on the ZiFiT identification of close matches in the human genome containing an NGG PAM). As an example, for all targets, both 17-mer and 20-mer gRNAs were designed. gRNAs were also selected both for single-gRNA nuclease cutting and for the dual gRNA nickase strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for which strategy is based on several considerations:
  • gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
  • gRNAs were identified for single-gRNA nuclease cleavage as well as for a dual-gRNA paired "nickase" strategy, as indicated.
  • gRNAs for use with the N. meningitidis (Tables 3F) and S. aureus (Tables 3D-3E) Cas9s were identified manually by scanning genomic DNA sequence for the presence of PAM sequences. These gRNAs were separated into two tiers for each species. The first tier includes gRNAs selected based on location in the first 500 bp of the coding sequence of the HSV gene. The second tier includes gRNAs selected based on location in the coding sequence, but downstream of the first 500 bp of the HSV gene.
  • gRNAs Guide RNAs
  • S. pyogenes, S. aureus and N. meningitidis Cas9s were identified using a DNA sequence searching algorithm.
  • Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas-offinder (reference:Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID: 24463181).
  • Said custom guide RNA design software scores guides after calculating their genomewide off-target propensity.
  • matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24.
  • an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface.
  • the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available
  • RepeatMasker program RepeatMasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
  • gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of 5". aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM).
  • Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence.
  • a "high level of orthogonality" or "good orthogonality” may, for example, refer to
  • Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
  • S. pyogenes and N. meningitidis targets 17-mer, or 20-mer gRNAs were designed.
  • S. aureus targets 18-mer, 19-mer, 20-mer,
  • Targeting domains may comprise the 17-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B.
  • Targeting domains, disclosed herein may comprises the 18-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B.
  • Targeting domains may comprises the 19-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B.
  • Targeting domains, disclosed herein may comprises the 20-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B.
  • Targeting domains may comprises the 21-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B.
  • Targeting domains, disclosed herein may comprises the 22-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B.
  • Targeting domains may comprises the 23-mer described in Tables 11A-11E, 12A-12G or 13A-13B,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B.
  • Targeting domains may comprises the 24-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B.
  • gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria for selecting gRNAs and the
  • the targeting domains discussed herein can be incorporated into the gRNAs described herein.
  • gRNAs were identified and ranked into 5 tiers for S. pyogenes (Tables 11A-11E), and N. meningitidis (Tables 13A-13B); and 7 tiers for S. aureus (Tables 12A-12G). For S.
  • the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality and (3) the presence of 5'G.
  • the targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) a high level of orthogonality.
  • the targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) the presence of 5'G.
  • the targeting domain for tier 4 gRNA molecules were selected based on distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon).
  • the targeting domain for tier 5 gRNA molecules were selected based on distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon).
  • the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT.
  • the targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, and (3) PAM is NNGRRT.
  • the targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRT.
  • the targeting domain for tier 4 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRV.
  • the targeting domain for tier 5 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon), (2) the presence of 5'G and (3) PAM is NNGRRT.
  • the targeting domain for tier 6 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRT.
  • the targeting domain for tier 7 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRV.
  • tiers are non- inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier.
  • gRNAs were utilized for use with S. pyogenes, S. aureus and N. meningitidis Cas9 enzymes.
  • the gRNAs in tier 1 were selected based on their distance to the target site and their orthogonality in the genome (based on the ZiFiT identification of close matches in the human genome containing an NGG PAM). As an example, for all targets, both 17-mer and 20-mer gRNAs were designed. gRNAs were also selected both for single-gRNA nuclease cutting and for the dual gRNA nickase strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for which strategy is based on several considerations:
  • gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
  • gRNAs While it can be desirable to have gRNAs start with a 5 ' G, this requirement was relaxed for some gRNAs in tier 1 in order to identify guides in the correct orientation, within a reasonable distance to the target position (i.e., within the first 500 bp of the coding sequence) and with a high level of orthogonality against the human genome. In order to find a pair for the dual-nickase strategy it was necessary to either extend the distance from the target position or remove the requirement for the 5'G. Tier 2 gRNAs were selected based on loction within the first 500 bp of the coding sequence in the HSV gene. Tier 3 gRNAs were selected based on their location in the coding sequence, but downstream of the first 500 bp of the HSV gene. Note that tiers are non-inclusive (each gRNA is listed only once). In certain instances, no gRNA was identified based on the criteria of the particular tier.
  • gRNAs were identified for single-gRNA nuclease cleavage as well as for a dual-gRNA paired "nickase" strategy, as indicated.
  • gRNAs for use with the N. meningitidis (Tables 4F-4G) and S. aureus (Tables 4D- 4E) Cas9s were identified manually by scanning genomic DNA sequence for the presence of PAM sequences. These gRNAs were separated into two tiers for each species. The first tier includes gRNAs selected based on location in the first 500 bp of the coding sequence of the HSV gene. The second tier includes gRNAs selected based on location in the coding sequence, but downstream of the first 500 bp of the HSV gene.
  • gRNAs Guide RNAs
  • N. meningitidis Cas9s were identified using a DNA sequence searching algorithm.
  • Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas-offinder (reference:Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID: 24463181).
  • Said custom guide RNA design software scores guides after calculating their genomewide off-target propensity. Typically matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24.
  • an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface.
  • the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available
  • RepeatMasker program searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
  • gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of 5". aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM).
  • Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence.
  • a “high level of orthogonality” or “good orthogonality” may, for example, refer to 20-mer gRNAs that have no identical sequences in the human genome besides the intended target, nor any sequences that contain one or two mismatches in the target sequence.
  • Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
  • Targeting domains may comprise the 17-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C.
  • Targeting domains may comprises the 18-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C.
  • Targeting domains, disclosed herein may comprises the 19-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C.
  • Targeting domains may comprises the 20-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C.
  • Targeting domains may comprises the 21-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C.
  • Targeting domains may comprises the 22-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C.
  • Targeting domains, disclosed herein may comprises the 23-mer described in Tables 14A-14E, 15A-15G or 16A-16C,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C.
  • Targeting domains may comprises the 24-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C.
  • gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria for selecting gRNAs and the
  • gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
  • gRNAs were identified and ranked into 5 tiers for S. pyogenes (Tables 14A-14E), and
  • the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality and (3) the presence of 5'G.
  • the targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) a high level of orthogonality.
  • the targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) the presence of 5'G.
  • the targeting domain for tier 4 gRNA molecules were selected based on distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon).
  • the targeting domain for tier 5 gRNA molecules were selected based on distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon).
  • the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT.
  • the targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, and (3) PAM is
  • the targeting domain for tier 5 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon), (2) the presence of 5'G and (3) PAM is NNGRRT.
  • the targeting domain for tier 6 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRT.
  • the targeting domain for tier 7 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRV.
  • tiers are non- inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier.
  • Any of the targeting domains in the tables described herein can be used with a Cas9 nickase molecule to generate a single strand break.
  • any of the targeting domains in the tables described herein can be used with a Cas9 nuclease molecule to generate a double strand break.
  • one Cas9 can be one species
  • the second Cas9 can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
  • any upstream gRNA described herein may be paired with any downstream gRNA described herein.
  • an upstream gRNA designed for use with one species of Cas9 is paired with a downstream gRNA designed for use from a different species of Cas9, both Cas9 species are used to generate a single or double-strand break, as desired.
  • Table 1A provides exemplary targeting domains for knocking out the UL19 gene selected according to first tier parameters.
  • the targeting domains are selected based on location within the first 500bp of the coding sequence of the UL19 gene and orthogonality against the human genome. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing.
  • Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage.
  • Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single-stranded break nucleases (nickases).
  • dual targeting is used to create two nicks on opposite DNA strands by using S.
  • pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
  • Table IB provides exemplary targeting domains for knocking out the UL19 gene selected according to the second tier parameters.
  • the targeting domains are selected based on location within the first 500bp of the coding sequence of the UL19 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing.
  • Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage.
  • Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases).
  • dual targeting is used to create two nicks on opposite DNA strands by using S.
  • pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
  • Table IB Table IB

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CRISPR/CAS-related compositions and methods for treatment of HSV-2 are disclosed.

Description

CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING
HERPES SIMPLEX VIRUS TYPE 2 (HSV-2)
REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of U.S. Provisional Application No.
61/973,792, filed April 1, 2014, the contents of which are hereby incorporated by reference in their entirety.
FIELD OF THE INVENTION
The invention relates to CRISPR/CAS-related methods and components for editing of a target nucleic acid sequence, or modulating expression of a target nucleic acid sequence, and applications thereof in connection with herpes simplex virus type 2 (HSV-2).
BACKGROUND
Herpes simplex virus type 2 (HSV-2) is a sexually transmitted virus. It is most commonly known as genital herpes. Initial infection with HSV-2 generally causes painful blistering in the genital region. The disease causes lifelong, recurring bouts of viral reactivity. It is highly contagious and increases the risk of acquiring HIV infection, especially among patients with active lesions.
More than 500 million people are infected with HSV-2 worldwide. Up to 23 million individuals are infected for the first time each year. In the United States, approximately 1 in 5 adults is seropositive for HSV-2 infection (Xu et al., Abstract 739 in 42nd Annual Meeting of the Infectious Diseases Society of America; September 30, 2004). The incidence of HSV- 2 is increasing: since 1976, there has been a 30% increase in the presence of HSV-2 seropositivity in adults in the United States (Fleming et al., New England Journal of Medicine 1997; 337:1105-11).
Initial infection with HSV-2 generally causes painful blistering of the mucous membranes of the ano-genital region, or, less commonly, the oral region. After initial infection, HSV-2 establishes latent infection in all subjects.
Infection of HSV-2 is permanent. Latent infection that lasts for the lifetime of the host. Following establishment of latent infection, reactivation of HSV-2 can occur at any point during the lifetime of the subject. Reactivation of HSV-2 is more likely to occur in the elderly and in immunocompromised individuals, including in those who have cancer, those
l who have HIV/AIDs and in those who have undergone solid organ or hematopoietic stem cell transplant.
HSV-2 encephalitis and HSV-2 meningitis are among the most severe and debilitating types of HSV infections. HSV encephalitis is the most common form of non-epidemic encephalitis. The annual incidence of HSV encephalitis is 0.2-0.4 in 100,000 individuals (Saba et al., 2012; British Medical Journal 344: e3166). Subjects who develop HSV-2 encephalitis and/or meningitis commonly have permanent neurologic sequelae.
HSV keratitis is the most common cause of infectious blindness in the developed world (Dawson et. al., Suvey of Ophthalmology 1976; 21(2): 121-135). Worldwide, there are approximately 1.5 million cases of HSV-related ophthalmologic disease and 40,000 cases of HSV-related blindness or severe monocular visual impairment annually (Krawczyk et. al., Public Library of Science One 2015; 10(1): eOl 16800. Farooq and Shukla 2012; Survey of Ophthalmology 57(5): 448-462).
Newborns are a population at particular risk for developing severe HSV-2 infections. The disease is transmitted from the mother to the fetus during childbirth. The chance of maternal-fetal transmission is highest in cases where the mother developed primary HSV infection during pregnancy and in cases where the mother has active sores in the genital region as the fetus travels through the birth canal. The incidence of neonatal herpes is approximately 4-30 per 100,000 births (Brown ZA, et al., 2003; Journal of the American Medical Association; 289(2): 203-209. Dinh T-H, et al., 2008; Sexually Transmitted Disease; 35(1): 19-21.) Neonates can develop severe HSV-2 keratitis, retinitis, encephalitis and/or meningitis. Neonatal ocular herpes (keratitis or retinitis) can result in immediate, permanent vision loss. Ocular HSV-2 puts neonates at risk for later developing HSV-2 associated acute retinal necrosis, which can also lead to permanent vision loss. Untreated HSV-2 encephalitis leads to death in 50% of neonates. Even with prompt treatment with antiviral therapy, the majority of neonates who contract HSV-2 encephalitis or meningitis will suffer from permanent neurologic sequelae.
There are no curative or preventative treatments. Therapy is primarily given during acute infection. Primary HSV-2 infections can be is treated with antiviral therapy, including acyclovir, valacyclovir and famciclovir. These therapies may reduce viral shedding, decrease pain and improve healing time of lesions. Re-activated, latent infections may resolve without treatment (may be self-limiting) or may be treated with anti-viral therapy. Antiviral therapy may be given prophylactically in certain situations, including during childbirth in a mother with a recent HSV-2 infection or reactivation. Vaccines are in development for the prevention of HSV-2 infection. However, in controlled clinical trials, vaccination efficacy has been limited. A recent vaccine for both HS V- 1 and HSV-2 infections was found to be ineffective in the prevention of HSV-2 genital infections (Belshe et al., 2012; New England Journal of Medicine 366(1): 34-43).
Despite advances in antiretro viral therapies, there remains a need for the treatment and prevention of HSV-2 infection, particularly the treatment and prevention of HSV-2 associated keratitis, encephalitis and meningitis. A therapy that can cure, prevent, or treat HSV-2 infections would be superior to the current standard of care. SUMMARY OF THE INVENTION
Methods and compositions discussed herein, provide for the treatment or prevention of herpes simplex virus type 2 (HSV-2), commonly known as genital herpes. HSV-2 is contained within an icosahedral particle. The virus enters the host via infection of epithelial cells within the skin and mucous membranes. The virus produces immediate early genes within the epithelial cells, which encode enzymes and binding proteins necessary for viral synthesis. After primary infection, the virus travels up sensory nerve axons via retrograde transport to the sensory dorsal root ganglion (DRG). HSV-2 mainly travels to the sensory DRG located within the sacrum, but can travel to other sensory ganglia depending upon the site of primary infection. Within the DRG, it establishes a latent infection. The latent infection persists for the lifetime of the host. Within the DRG cell the virus uncoats, viral
DNA is transported into the nucleus of the sensory nerve, and key viral RNAs associated with latency are transcribed (i.e., the LAT RNAs).
Methods and compositions discussed herein can be used to provide for treatment or prevention of herpes simplex virus type 2 (HSV-2), or its symptoms, e.g., by knocking out one or more of the HSV-2 viral genes, e.g., by knocking out one or more of UL19, UL30, UL48 and/or UL54 gene(s). In one aspect, methods and compositions discussed herein may be used to alter one or more of the UL19, UL30, UL48 and/or UL54 gene(s) to treat or prevent HSV-2, by targeting, the gene, e.g., the non-coding or coding regions, e.g., the promoter region, or a transcribed sequence, e.g., intronic or exonic sequence. In an embodiment coding sequence, e.g., a coding region, e.g., an early coding region, of one or more the UL19, UL30, UL48 and/or UL54 gene(s), is targeted for alteration and knockout of expression.
In another aspect, the methods and compositions discussed herein may be used to alter one or more of the UL19, UL30, UL48 and/or UL54 gene(s) to treat or prevent herpes simplex virus type 2 (HSV-2) by targeting the coding sequence of one or more of the UL19, UL30, UL48 and/or UL54 gene(s). In one embodiment, the gene, e.g., the coding sequence of one or more of the UL19, UL30, UL48 and/or UL54 gene(s), are targeted to knockout one or more of UL19, UL30, UL48 and/or UL54 gene(s), e.g., to eliminate expression of one or more of UL19, UL30, UL48 and/or UL54 gene(s), e.g., to knockout one or more copies of one or more of UL19, UL30, UL48 and/or UL54 gene(s), e.g., by induction of an alteration comprising a deletion or mutation in one or more of UL19, UL30, UL48 and/or UL54 gene(s). In an embodiment, the method provides an alteration that comprises an insertion or deletion. As described herein, a targeted knockout approach is mediated by non-homologous end joining (NHEJ) using a CRISPR/Cas system comprising an enzymatically active Cas9 (eaCas9) molecule.
In one embodiment, an early coding sequence of one or more of the UL19, UL30, UL48 and/or UL54 gene(s) is targeted to knockout one or more of UL19, UL30, UL48 and/or UL54 gene(s). In an embodiment, targeting affects one or more copies of the UL19, UL30, UL48 and/or UL54 gene(s). In an embodiment, a targeted knockout approach reduces or eliminates expression of one or more functional UL19, UL30, UL48 and/or UL54 gene product(s). In an embodiment, the method provides an alteration that comprises an insertion or deletion.
In another aspect, the methods and compositions discussed herein may be used to alter one or more of the UL19, UL30, UL48 and/or UL54 gene(s) to treat or prevent HSV-2 by targeting non-coding sequence of the UL19, UL30, UL48 and/or UL54 gene(s), e.g., promoter, an enhancer, an intron, 3'UTR, and/or polyadenylation signal. In one embodiment, the gene, e.g., the non-coding sequence of the UL19, UL30, UL48 and/or UL54 gene(s), is targeted to knockout the gene, e.g., to eliminate expression of the gene, e.g., to knockout one or more copies of the UL19, UL30, UL48 and/or UL54 gene(s), e.g., by induction of an alteration comprising a deletion or mutation in the UL19, UL30, UL48 and/or UL54 gene(s). In an embodiment, the method provides an alteration that comprises an insertion or deletion.
"HSV-2 target UL19 position", as used herein, refers to a position in the UL19 gene, which if altered by NHEJ-mediated alteration, results in reduction or elimination of expression of functional UL19 gene product. In an embodiment, the position is in the UL19 gene coding region, e.g., an early coding region.
"HSV-2 target UL30 position", as used herein, refers to a position in the UL30 gene, which if altered by NHEJ-mediated alteration, results in reduction or elimination of expression of functional UL30 gene product. In an embodiment, the position is in the UL30 gene coding region, e.g., an early coding region.
"HSV-2 target UL48 position", as used herein, refers to a position in the UL48 gene, which if altered by NHEJ-mediated alteration, results in reduction or elimination of expression of functional UL48 gene product. In an embodiment, the position is in the UL48 gene coding region, e.g., an early coding region.
"HSV-2 target UL54 position", as used herein, refers to a position in the UL54 gene, which if altered by NHEJ-mediated alteration, results in reduction or elimination of expression of functional UL54 gene product. In an embodiment, the position is in the UL54 gene coding region, e.g., an early coding region.
"HSV-2 target position", as used herein, refers to any of a HSV-2 target UL19 target position, a HSV-2 target UL30 target position, a HSV-2 target UL48 target position or a HSV-2 target UL54 target position.
In one aspect, disclosed herein is a gRNA molecule, e.g., an isolated or non- naturally occurring gRNA molecule, comprising a targeting domain which is complementary with a target domain from the UL19, UL30, UL48 or UL54 gene.
In an embodiment, the targeting domain of the gRNA molecule is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene to allow alteration, e.g., alteration associated with NHEJ, of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene. In an embodiment, the targeting domain is configured such that a cleavage event, e.g., a double strand or single strand break, is positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of a HSV-2 target position. The break, e.g., a double strand or single strand break, can be positioned upstream or downstream of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene. In an embodiment, the targeting domain of the gRNA molecule is configured to provide a cleavage event selected from a double strand break and a single strand break, within 500 (e.g., within 500, 400, 300, 250, 200, 150, 100, 80, 60, 40, 20, or 10) nucleotides of a HSV-2 target position.
In an embodiment, a second gRNA molecule comprising a second targeting domain is configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to the HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, to allow alteration, e.g., alteration associated with NHEJ, of the HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, either alone or in combination with the break positioned by said first gRNA molecule. In an embodiment, the targeting domains of the first and second gRNA molecules are configured such that a cleavage event, e.g., a double strand or single strand break, is positioned, independently for each of the gRNA molecules, within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position. In an embodiment, the breaks, e.g., double strand or single strand breaks, are positioned on both sides of a nucleotide of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene. In an embodiment, the breaks, e.g., double strand or single strand breaks, are positioned on one side, e.g., upstream or downstream, of a nucleotide of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene. In an embodiment, the targeting domain of the first and/or second gRNA molecule is configured to provide a cleavage event selected from a double strand break and a single strand break, within 500 (e.g., within 500, 400, 300, 250, 200, 150, 100, 80, 60, 40, 20, or 10) nucleotides of a HSV-2 target position.
In an embodiment, a single strand break is accompanied by an additional single strand break, positioned by a second gRNA molecule, as discussed below. For example, the targeting domains are configured such that a cleavage event, e.g., the two single strand breaks, are positioned within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of a HSV-2 target position. In an embodiment, the first and second gRNA molecules are configured such, that when guiding a Cas9 molecule, e.g., a Cas9 nickase, a single strand break will be accompanied by an additional single strand break, positioned by a second gRNA, sufficiently close to one another to result in alteration of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene. In an embodiment, the first and second gRNA molecules are configured such that a single strand break positioned by said second gRNA is within 10, 20, 30, 40, or 50 nucleotides of the break positioned by said first gRNA molecule, e.g., when the Cas9 molecule is a nickase. In an embodiment, the two gRNA molecules are configured to position cuts at the same position, or within a few nucleotides of one another, on different strands, e.g., essentially mimicking a double strand break.
In an embodiment, a double strand break can be accompanied by an additional double strand break, positioned by a second gRNA molecule, as is discussed below. For example, the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position; and the targeting domain of a second gRNA molecule is configured such that a double strand break is positioned downstream of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position.
In an embodiment, a double strand break can be accompanied by two additional single strand breaks, positioned by a second gRNA molecule and a third gRNA molecule. For example, the targeting domain of a first gRNA molecule is configured such that a double strand break is positioned upstream of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position; and the targeting domains of a second and third gRNA molecule are configured such that two single strand breaks are positioned downstream of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position. In an embodiment, the targeting domain of the first, second and third gRNA molecules are configured such that a cleavage event, e.g., a double strand or single strand break, is positioned, independently for each of the gRNA molecules.
In an embodiment, a first and second single strand breaks can be accompanied by two additional single strand breaks positioned by a third gRNA molecule and a fourth gRNA molecule. For example, the targeting domain of a first and second gRNA molecule are configured such that two single strand breaks are positioned upstream of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position; and the targeting domains of a third and fourth gRNA molecule are configured such that two single strand breaks are positioned downstream of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides of the target position. In an embodiment, the targeting domain of the first, second, third, and/or fourth gRNA molecule is configured to provide a cleavage event selected from a double strand break and a single strand break, within 500 (e.g., within 500, 400, 300, 250, 200, 150, 100, 80, 60, 40, 20, or 10) nucleotides of a HSV-2 target position.
It is contemplated herein that, in an embodiment, when multiple gRNAs are used to generate (1) two single stranded breaks in close proximity, (2) two double stranded breaks, e.g., flanking a HSV-2 target position (e.g., to remove a piece of DNA, e.g., to create a deletion mutation) or to create more than one indel in the gene, e.g., in a coding region, e.g., an early coding region, (3) one double stranded break and two paired nicks flanking a HSV-2 target position (e.g., to remove a piece of DNA, e.g., to insert a deletion) or (4) four single stranded breaks, two on each side of a position, that they are targeting the same HSV-2 target position. It is further contemplated herein that multiple gRNAs may be used to target more than one HSV-2 target position in the same gene, e.g., one or more of UL19, UL30, UL48 and/or UL54 gene(s).
In an embodiment, the targeting domain of the first gRNA molecule and the targeting domain of the second gRNA molecules are complementary to opposite strands of the target nucleic acid molecule. In an embodiment, the gRNA molecule and the second gRNA molecule are configured such that the PAMs are oriented outward.
In an embodiment, the targeting domain of a gRNA molecule is configured to avoid unwanted target chromosome elements, such as repeat elements, e.g., Alu repeats, in the target domain. The gRNA molecule may be a first, second, third and/or fourth gRNA molecule, as described herein.
In an embodiment, the targeting domain of a gRNA molecule is configured to position a cleavage event sufficiently far from a preselected nucleotide, e.g., the nucleotide of a coding region, such that the nucleotide is not altered. In an embodiment, the targeting domain of a gRNA molecule is configured to position an intronic cleavage event sufficiently far from an intron/exon border, or naturally occurring splice signal, to avoid alteration of the exonic sequence or unwanted splicing events. The gRNA molecule may be a first, second, third and/or fourth gRNA molecule, as described herein.
In an embodiment, the targeting domain comprises a sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence described herein, e.g., from any of Tables 1A-1G, 2A-2F, 3A-3F, 4A-4G, 5A-5E, 6A-6G, 7A-7D, 8A-8E, 9A- 9G, 10A-10D, 11A-11E, 12A-12G, 13A-13B, 14A-14E, 15A-15G, or 16A-16C. In an embodiment, the targeting domain comprises a sequence that is the same as a targeting domain sequence described herein, e.g., from any of Tables 1A-1G, 2A-2F, 3A-3F, 4A-4G, 5A-5E, 6A-6G, 7A-7D, 8A-8E, 9A-9G, 10A-10D, 11A-11E, 12A-12G, 13A-13B, 14A-14E, 15A-15G, or 16A-16C.
In another embodiment, a HSV-2 target position in the coding region, e.g., the early coding region, of the UL19, UL30, UL48 or UL54 gene is targeted, e.g., for knockout. In an embodiment, the targeting domain comprises a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, or Tables 4A-4G. In an embodiment, the targeting domain is independently selected from those in Tables 1A-1G. In another embodiment, the targeting domain is independently selected from Table 1A. In an embodiment, the targeting domain is independently selected from those in Tables 2A-2F. In an embodiment, the targeting domain is independently selected from Table 2A.
In an embodiment, the targeting domain is independently selected from those in Tables 3A-3F. In an embodiment, the targeting domain is independently selected from Table 3A.
In an embodiment, the targeting domain is independently selected from those in Tables 4A-4G. In an embodiment, the targeting domain is independently selected from Table 4A.
In an embodiment, the targeting domain is independently selected from those in
Tables 5A-5E. In an embodiment, the targeting domain is independently selected from Table 5A.
In an embodiment, the targeting domain is independently selected from those in Tables 6A-6G. In an embodiment, the targeting domain is independently selected from Table 6A.
In an embodiment, the targeting domain is independently selected from those in Tables 7A-7D. In an embodiment, the targeting domain is independently selected from Table 7A.
In an embodiment, the targeting domain is independently selected from those in Tables 8A-8E. In an embodiment, the targeting domain is independently selected from Table 8A.
In an embodiment, the targeting domain is independently selected from those in Tables 9A-9G. In an embodiment, the targeting domain is independently selected from Table 9A.
In an embodiment, the targeting domain is independently selected from those in
Tables 10A-10D. In an embodiment, the targeting domain is independently selected from Table 10A.
In an embodiment, the targeting domain is independently selected from those in Tables 11A-11E. In an embodiment, the targeting domain is independently selected from Table 11A.
In an embodiment, the targeting domain is independently selected from those in Tables 12A-12G. In an embodiment, the targeting domain is independently selected from Table 12A. In an embodiment, the targeting domain is independently selected from those in
Tables 13A-13B. In an embodiment, the targeting domain is independently selected from Table 13A.
In an embodiment, the targeting domain is independently selected from those in
Tables 14A-14E. In an embodiment, the targeting domain is independently selected from Table 14A.
In an embodiment, the targeting domain is independently selected from those in
Tables 15A-15G. In an embodiment, the targeting domain is independently selected from Table 15A.
In an embodiment, the targeting domain is independently selected from those in
Tables 16A-16C. In an embodiment, the targeting domain is independently selected from Table 16A.
In an embodiment, when the HSV-2 target position is the UL19, UL30, UL48 or UL54 gene coding region, e.g., an early coding region, and more than one gRNA is used to position breaks, e.g., two single stranded breaks or two double stranded breaks, or a combination of single strand and double strand breaks, e.g., to create one or more indels, in the target nucleic acid sequence, the targeting domain of each guide RNA is independently selected from one of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F or Tables 4A-4G.
In an embodiment, when the HSV-2 target position is the UL19 gene coding region, e.g., an early coding region, and more than one gRNA is used to position breaks, e.g., two single stranded breaks or two double stranded breaks, or a combination of single strand and double strand breaks, e.g., to create one or more indels, in the target nucleic acid sequence, the targeting domain of each guide RNA is independently selected from any one of Tables 1A-1G, 5A-5E, 6A-6G, or 7A-7D.
In an embodiment, when the HSV-2 target position is the UL30 gene coding region, e.g., an early coding region, and more than one gRNA is used to position breaks, e.g., two single stranded breaks or two double stranded breaks, or a combination of single strand and double strand breaks, e.g., to create one or more indels, in the target nucleic acid sequence, the targeting domain of each guide RNA is independently selected from one of Tables 2A- 2F, 8A-8E, 9A-9G, or 10A-10D.
In an embodiment, when the HSV-2 target position is the UL48 gene coding region, e.g., an early coding region, and more than one gRNA is used to position breaks, e.g., two single stranded breaks or two double stranded breaks, or a combination of single strand and double strand breaks, e.g., to create one or more indels, in the target nucleic acid sequence, the targeting domain of each guide RNA is independently selected from one of Tables 3A- 3F, 11A-11E, 12A-12G, or 13A-13B.
In an embodiment, when the HSV-2 target position is the UL54 gene coding region, e.g., an early coding region, and more than one gRNA is used to position breaks, e.g., two single stranded breaks or two double stranded breaks, or a combination of single strand and double strand breaks, e.g., to create one or more indels, in the target nucleic acid sequence, the targeting domain of each guide RNA is independently selected from one of Tables 4A- 4G, 14A-14E, 15A-15G, or 16A-16C.
In an embodiment, the gRNA, e.g., a gRNA comprising a targeting domain, which is complementary with the UL19, UL30, UL48 or UL54 gene, is a modular gRNA. In other embodiments, the gRNA is a unimolecular or chimeric gRNA.
In an embodiment, the targeting domain which is complementary with a target domain from the HSV-2 target position in the UL19, UL30, UL48 or UL54 gene is 16 nucleotides or more in length. In an embodiment, the targeting domain is 16 nucleotides in length. In an embodiment, the targeting domain is 17 nucleotides in length. In another embodiment, the targeting domain is 18 nucleotides in length. In still another embodiment, the targeting domain is 19 nucleotides in length. In still another embodiments, the targeting domain is 20 nucleotides in length. In still another embodiment, the targeting domain is 21 nucleotides in length. In still another embodiment, the targeting domain is 22 nucleotides in length. In still another embodiment, the targeting domain is 23 nucleotides in length. In still another embodiment, the targeting domain is 24 nucleotides in length. In still another embodiment, the targeting domain is 25 nucleotides in length. In still another embodiment, the targeting domain is 26 nucleotides in length.
In an embodiment, the targeting domain comprises 16 nucleotides.
In an embodiment, the targeting domain comprises 17 nucleotides.
In an embodiment, the targeting domain comprises 18 nucleotides.
In an embodiment, the targeting domain comprises 19 nucleotides.
In an embodiment, the targeting domain comprises 20 nucleotides.
In an embodiment, the targeting domain comprises 21 nucleotides.
In an embodiment, the targeting domain comprises 22 nucleotides.
In an embodiment, the targeting domain comprises 23 nucleotides.
In an embodiment, the targeting domain comprises 24 nucleotides.
In an embodiment, the targeting domain comprises 25 nucleotides.
In an embodiment, the targeting domain comprises 26 nucleotides. A gRNA as described herein may comprise from 5' to 3': a targeting domain (comprising a "core domain", and optionally a "secondary domain"); a first complementarity domain; a linking domain; a second complementarity domain; a proximal domain; and a tail domain. In some embodiments, the proximal domain and tail domain are taken together as a single domain.
In an embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
In another embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
In another embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 35 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
In another embodiment, a gRNA comprises a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain equal to or greather than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26nucleotides in length.
A cleavage event, e.g., a double strand or single strand break, is generated by a Cas9 molecule. The Cas9 molecule may be an enzymatically active Cas9 (eaCas9) molecule, e.g., an eaCas9 molecule that forms a double strand break in a target nucleic acid or an eaCas9 molecule forms a single strand break in a target nucleic acid (e.g., a nickase molecule).
In an embodiment, the eaCas9 molecule catalyzes a double strand break.
In some embodiments, the eaCas9 molecule comprises HNH-like domain cleavage activity but has no, or no significant, N-terminal RuvC-like domain cleavage activity. In this case, the eaCas9 molecule is an HNH-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at D10, e.g., D10A. In other embodiments, the eaCas9 molecule comprises N-terminal RuvC-like domain cleavage activity but has no, or no significant, HNH-like domain cleavage activity. In an embodiment, the eaCas9 molecule is an N- terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at H840, e.g., H840A. In an embodiment, the eaCas9 molecule is an N-terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at H863, e.g., H863A.
In an embodiment, a single strand break is formed in the strand of the target nucleic acid to which the targeting domain of said gRNA is complementary. In another embodiment, a single strand break is formed in the strand of the target nucleic acid other than the strand to which the targeting domain of said gRNA is complementary.
In another aspect, disclosed herein is a nucleic acid, e.g., an isolated or non-naturally occurring nucleic acid, e.g., DNA, that comprises (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain, e.g., with a HSV-2 target position in UL19, UL30, UL48 or UL54 gene as disclosed herein.
In an embodiment, the nucleic acid encodes a gRNA molecule, e.g., a first gRNA molecule, comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene to allow alteration, e.g., alteration associated with NHEJ, of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene.
In an embodiment, the nucleic acid encodes a gRNA molecule, e.g., the first gRNA molecule, comprising a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any one of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A- 6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A- 16C. In an embodiment, the nucleic acid encodes a gRNA molecule comprising a targeting domain is selected from those in Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A- 4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C.
In an embodiment, the nucleic acid encodes a modular gRNA, e.g., one or more nucleic acids encode a modular gRNA. In other embodiments, the nucleic acid encodes a chimeric gRNA. The nucleic acid may encode a gRNA, e.g., the first gRNA molecule, comprising a targeting domain comprising 16 nucleotides or more in length. In an embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 16 nucleotides in length. In another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 17 nucleotides in length. In another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 18 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 19 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 20 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 21 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 22 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 23 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 24 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 25 nucleotides in length. In still another embodiment, the nucleic acid encodes a gRNA, e.g., the first gRNA molecule, comprising a targeting domain that is 26 nucleotides in length.
In an embodiment, the targeting domain comprises 16 nucleotides.
In an embodiment, the targeting domain comprises 17 nucleotides.
In an embodiment, the targeting domain comprises 18 nucleotides.
In an embodiment, the targeting domain comprises 19 nucleotides.
In an embodiment, the targeting domain comprises 20 nucleotides.
In an embodiment, the targeting domain comprises 21 nucleotides.
In an embodiment, the targeting domain comprises 22 nucleotides.
In an embodiment, the targeting domain comprises 23 nucleotides.
In an embodiment, the targeting domain comprises 24 nucleotides.
In an embodiment, the targeting domain comprises 25 nucleotides.
In an embodiment, the targeting domain comprises 26 nucleotides.
In an embodiment, a nucleic acid encodes a gRNA comprising from 5' to 3': a targeting domain (comprising a "core domain", and optionally a "secondary domain"); a first complementarity domain; a linking domain; a second complementarity domain; a proximal domain; and a tail domain. In some embodiments, the proximal domain and tail domain are taken together as a single domain.
In an embodiment, a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, a nucleic acid encodes a gRNA e.g., the first gRNA molecule, comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 35 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, a nucleic acid encodes a gRNA comprising e.g., the first gRNA molecule, a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain equal to or greater than 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, a nucleic acid comprises (a) a sequence that encodes a gRNA molecule, e.g., the first gRNA molecule, comprising a targeting domain that is
complementary with a target domain in the UL19, UL30, UL48 or UL54 gene as disclosed herein, and further comprising (b) a sequence that encodes a Cas9 molecule.
The Cas9 molecule may be a nickase molecule, an enzymatically activating Cas9 (eaCas9) molecule, e.g., an eaCas9 molecule that forms a double strand break in a target nucleic acid and/or an eaCas9 molecule that forms a single strand break in a target nucleic acid. In an embodiment, a single strand break is formed in the strand of the target nucleic acid to which the targeting domain of said gRNA is complementary. In another embodiment, a single strand break is formed in the strand of the target nucleic acid other than the strand to which to which the targeting domain of said gRNA is complementary.
In an embodiment, the eaCas9 molecule catalyzes a double strand break.
In an embodiment, the eaCas9 molecule comprises HNH-like domain cleavage activity but has no, or no significant, N-terminal RuvC-like domain cleavage activity. In another embodiment, the said eaCas9 molecule is an HNH-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at D10, e.g., D10A. In another embodiment, the eaCas9 molecule comprises N-terminal RuvC-like domain cleavage activity but has no, or no significant, HNH-like domain cleavage activity. In another embodiment, the eaCas9 molecule is an N-terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at H840, e.g., H840A. In another embodiment, the eaCas9 molecule is an N- terminal RuvC-like domain nickase, e.g., the eaCas9 molecule comprises a mutation at H863, e.g., H863A.
A nucleic acid disclosed herein may comprise (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the CCR5 gene as disclosed herein; (b) a sequence that encodes a Cas9 molecule.
A nucleic acid disclosed herein may comprise (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the UL19, UL30, UL48 or UL54 gene as disclosed herein; (b) a sequence that encodes a Cas9 molecule; and further may comprise (c)(i) a sequence that encodes a second gRNA molecule described herein having a targeting domain that is complementary to a second target domain of the UL19, UL30, UL48 or UL54 gene, and optionally, (c)(ii) a sequence that encodes a third gRNA molecule described herein having a targeting domain that is complementary to a third target domain of the UL19, UL30, UL48 or UL54 gene; and optionally, (c)(iii) a sequence that encodes a fourth gRNA molecule described herein having a targeting domain that is complementary to a fourth target domain of the UL19, UL30, UL48 or UL54 gene.
In an embodiment, a nucleic acid encodes a second gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, to allow alteration, e.g., alteration associated with NHEJ, of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, either alone or in combination with the break positioned by said first gRNA molecule.
In an embodiment, a nucleic acid encodes a third gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene to allow alteration, e.g., alteration associated with NHEJ, of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, either alone or in combination with the break positioned by the first and/or second gRNA molecule.
In an embodiment, a nucleic acid encodes a fourth gRNA molecule comprising a targeting domain configured to provide a cleavage event, e.g., a double strand break or a single strand break, sufficiently close to a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene to allow alteration, e.g., alteration associated with NHEJ, of a HSV-2 target position in the UL19, UL30, UL48 or UL54 gene, either alone or in combination with the break positioned by the first gRNA molecule, the second gRNA molecule and/or the third gRNA molecule. In an embodiment, the nucleic acid encodes a second gRNA molecule. The second gRNA is selected to target the same HSV-2 target position as the first gRNA molecule. Optionally, the nucleic acid may encode a third gRNA, and further optionally, the nucleic acid may encode a fourth gRNA molecule. The third gRNA molecule and the fourth gRNA molecule are selected to target the same HSV-2 target position as the first and second gRNA molecules.
In an embodiment, the nucleic acid encodes a second gRNA molecule comprising a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from one of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C. In an embodiment, the nucleic acid encodes a second gRNA molecule comprising a targeting domain selected from those in Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A- 10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A- 15G, or Tables 16A-16C. In an embodiment, when a third or fourth gRNA molecule are present, the third and fourth gRNA molecules may independently comprise a targeting domain comprising a sequence that is the same as, or differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from one of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A- 8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C. In a further embodiment, when a third or fourth gRNA molecule are present, the third and fourth gRNA molecules may independently comprise a targeting domain selected from those in Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C.
In an embodiment, the nucleic acid encodes a second gRNA which is a modular gRNA, e.g., wherein one or more nucleic acid molecules encode a modular gRNA. In another embodiment, the nucleic acid encoding a second gRNA is a chimeric gRNA. In another embodimentls, when a nucleic acid encodes a third or fourth gRNA, the third and fourth gRNA may be a modular gRNA or a chimeric gRNA. When multiple gRNAs are used, any combination of modular or chimeric gRNAs may be used. A nucleic acid may encode a second, a third, and/or a fourth gRNA, each independently, comprising a targeting domain comprising 16 nucleotides or more in length. In an embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 16 nucleotides in length. In another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 17 nucleotides in length. In another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 18 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 19 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 20 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 21 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 22 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 23 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 24 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 25 nucleotides in length. In still another embodiment, the nucleic acid encodes a second gRNA comprising a targeting domain that is 26 nucleotides in length.
In an embodiment, the targeting domain comprises 16 nucleotides.
In an embodiment, the targeting domain comprises 17 nucleotides.
In an embodiment, the targeting domain comprises 18 nucleotides.
In an embodiment, the targeting domain comprises 19 nucleotides.
In an embodiment, the targeting domain comprises 20 nucleotides.
In an embodiment, the targeting domain comprises 21 nucleotides.
In an embodiment, the targeting domain comprises 22 nucleotides.
In an embodiment, the targeting domain comprises 23 nucleotides.
In an embodiment, the targeting domain comprises 24 nucleotides.
In an embodiment, the targeting domain comprises 25 nucleotides.
In an embodiment, the targeting domain comprises 26 nucleotides.
In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA, each independently, comprising from 5 ' to 3 ' : a targeting domain (comprising a "core domain", and optionally a "secondary domain"); a first complementarity domain; a linking domain; a second complementarity domain; a proximal domain; and a tail domain. In some embodiments, the proximal domain and tail domain are taken together as a single domain.
In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 35 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, a nucleic acid encodes a second, a third, and/or a fourth gRNA comprising a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and a targeting domain equal to or greater thanl6, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, a nucleic acid encodes (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the UL19, UL30, UL48 or UL54 gene, as disclosed herein, and (b) a sequence that encodes a Cas9 molecule, e.g., a Cas9 molecule described herein. In an embodiment, (a) and (b) are present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., the same adeno- associated virus (AAV) vector. In an embodiment, the nucleic acid molecule is an AAV vector. Exemplary AAV vectors that may be used in any of the described compositions and methods include an AAV2 vector, a modified AAV2 vector, an AAV3 vector, a modified AAV3 vector, an AAV6 vector, a modified AAV6 vector, an AAV8 vector and an AAV9 vector.
In another embodiment, (a) is present on a first nucleic acid molecule, e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (b) is present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecules may be AAV vectors.
In another embodiment, a nucleic acid encodes (a) a sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target domain in the UL19, UL30, UL48 or UL54 gene as disclosed herein, and (b) a sequence that encodes a Cas9 molecule, e.g., a Cas9 molecule described herein; and further comprises (c)(i) a sequence that encodes a second gRNA molecule as described herein, and optionally, (c)(ii) a sequence that encodes a third gRNA molecule described herein having a targeting domain that is complementary to a third target domain of the UL19, UL30, UL48 or UL54 gene; and optionally, (c)(iii) a sequence that encodes a fourth gRNA molecule described herein having a targeting domain that is complementary to a fourth target domain of the UL19, UL30, UL48 or UL54 gene. In an embodiment, the nucleic acid comprises (a), (b) and (c)(i). In an embodiment, the nucleic acid comprises (a), (b), (c)(i) and (c)(ii). In an embodiment, the nucleic acid comprises (a), (b), (c)(i), (c)(ii) and (c)(iii). Each of (a) and (c)(i) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., the same adeno-associated virus (AAV) vector. In an embodiment, the nucleic acid molecule is an AAV vector.
In another embodiment, (a) and (c)(i) are on different vectors. For example, (a) may be present on a first nucleic acid molecule, e.g. a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (c)(i) may be present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. In an embodiment, the first and second nucleic acid molecules are AAV vectors.
In another embodiment, each of (a), (b), and (c)(i) are present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, one of (a), (b), and (c)(i) is encoded on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and a second and third of (a), (b), and (c)(i) is encoded on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.
In an embodiment, (a) is present on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, a first AAV vector; and (b) and (c)(i) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.
In another embodiment, (b) is present on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (a) and (c)(i) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors. In another embodiment, (c)(i) is present on a first nucleic acid molecule, e.g., a first vector, e.g., a first viral vector, e.g., a first AAV vector; and (b) and (a) are present on a second nucleic acid molecule, e.g., a second vector, e.g., a second vector, e.g., a second AAV vector. The first and second nucleic acid molecule may be AAV vectors.
In another embodiment, each of (a), (b) and (c)(i) are present on different nucleic acid molecules, e.g., different vectors, e.g., different viral vectors, e.g., different AAV vector. For example, (a) may be on a first nucleic acid molecule, (b) on a second nucleic acid molecule, and (c)(i) on a third nucleic acid molecule. The first, second and third nucleic acid molecule may be AAV vectors.
In another embodiment, when a third and/or fourth gRNA molecule are present, each of (a), (b), (c)(i), (c)(ii) and (c)(iii) may be present on the same nucleic acid molecule, e.g., the same vector, e.g., the same viral vector, e.g., an AAV vector. In an embodiment, the nucleic acid molecule is an AAV vector. In an alternate embodiment, each of (a), (b), (c)(i), (c)(ii) and (c)(iii) may be present on the different nucleic acid molecules, e.g., different vectors, e.g., the different viral vectors, e.g., different AAV vectors. In a further
embodiment, each of (a), (b), (c)(i), (c)(ii) and (c)(iii) may be present on more than one nucleic acid molecule, but fewer than five nucleic acid molecules, e.g., AAV vectors.
The nucleic acids described herein may comprise a promoter operably linked to the sequence that encodes the gRNA molecule of (a), e.g., a promoter described herein. The nucleic acid may further comprise a second promoter operably linked to the sequence that encodes the second, third and/or fourth gRNA molecule of (c), e.g., a promoter described herein. The promoter and second promoter differ from one another. In some embodiments, the promoter and second promoter are the same.
The nucleic acids described herein may further comprise a promoter operably linked to the sequence that encodes the Cas9 molecule of (b), e.g., a promoter described herein.
In another aspect, disclosed herein is a composition comprising (a) a gRNA molecule comprising a targeting domain that is complementary with a target domain in the UL19, UL30, UL48 or UL54 gene, as described herein. The composition of (a) may further comprise (b) a Cas9 molecule, e.g., a Cas9 molecule as described herein. A composition of (a) and (b) may further comprise (c) a second, third and/or fourth gRNA molecule, e.g., a second, third and/or fourth gRNA molecule described herein. In an embodiment, the composition is a pharmaceutical composition. The compositions described herein, e.g., pharmaceutical compositions described herein, can be used in the treatment or prevention of HSV-2 in a subject, e.g., in accordance with a method disclosed herein. In another aspect, disclosed herein is a method of altering a cell, e.g., altering the structure, e.g., altering the sequence, of a target nucleic acid of a cell, comprising contacting said cell with: (a) a gRNA that targets the UL19, UL30, UL48 or UL54 gene, e.g., a gRNA as described herein; (b) a Cas9 molecule, e.g., a Cas9 molecule as described herein; and optionally, (c) a second, third and/or fourth gRNA that targets UL19, UL30, UL48 or UL54 gene, e.g., a second, third and/or fourth gRNA, as described herein.
In an embodiment, the method comprises contacting said cell with (a) and (b).
In an embodiment, the method comprises contacting said cell with (a), (b), and (c).
The gRNA of (a) and optionally (c) may be selected from any of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A- 7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C, or a gRNA that differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A- 16C.
In an embodiment, the method comprises contacting a cell from a subject suffering from or likely to develop HSV-2. The cell may be from a subject that would benefit from having a mutation at a HSV-2 target position.
In an embodiment, the contacting step may be performed in vivo.
In an embodiment, the method of altering a cell as described herein comprises acquiring knowledge of the sequence of a HSV-2 target position in said cell, prior to the contacting step. Acquiring knowledge of the sequence of a HSV-2 target position in the cell may be by sequencing one or more of the UL19, UL30, UL48 or UL54 gene, or a portion of the UL19, UL30, UL48 and/or UL54 gene.
In an embodiment, the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses at least one of (a), (b), and (c). In some embodiments, the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses each of (a), (b), and (c). In another embodiment, the contacting step of the method comprises delivering to the cell a Cas9 molecule of (b) and a nucleic acid which encodes a gRNA of (a) and optionally, a second gRNA (c)(i), and further optionally, a third gRNA (c)(ii) and/or fourth gRNA (c)(iii). In an embodiment, the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses at least one of (a), (b), (c) and (d). In some embodiments, the contacting step of the method comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, that expresses each of (a), (b), and (c). In another embodiment, the contacting step of the method comprises delivering to the cell a Cas9 molecule of (b), a nucleic acid which encodes a gRNA of (a) and a template nucleic acid of (d), and optionally, a second gRNA (c)(i), and further optionally, a third gRNA (c)(iv) and/or fourth gRNA (c)(iii).
In an embodiment, contacting comprises contacting the cell with a nucleic acid, e.g., a vector, e.g., an AAV vector, e.g., an AAV2 vector, a modified AAV2 vector, an AAV3 vector, a modified AAV3 vector, an AAV6 vector, a modified AAV6 vector, an AAV8 vector or an AAV9 vector, as described herein.
In an embodiment, contacting comprises delivering to the cell a Cas9 molecule of (b), as a protein or an mRNA, and a nucleic acid which encodes a gRNA of (a) and optionally a second, third and/or fourth gRNA of (c).
In an embodiment, contacting comprises delivering to the cell a Cas9 molecule of (b), as a protein or an mRNA, said gRNA of (a), as an RNA, and optionally said second, third and/or fourth gRNA of (c), as an RNA.
In an embodiment, contacting comprises delivering to the cell a gRNA of (a) as an RNA, optionally the second, third and/or fourth gRNA of (c) as an RNA, and a nucleic acid that encodes the Cas9 molecule of (b).
In another aspect, disclosed herein is a method of treating a subject suffering from or likely to develop HSV-2, e.g., altering the structure, e.g., sequence, of a target nucleic acid of the subject, comprising contacting the subject (or a cell from the subject) with:
(a) a gRNA that targets the UL19, UL30, UL48 or UL54 gene, e.g., a gRNA disclosed herein;
(b) a Cas9 molecule, e.g., a Cas9 molecule disclosed herein; and
optionally, (c)(i) a second gRNA that targets the UL19, UL30, UL48 or UL54 gene, e.g., a second gRNA disclosed herein, and
further optionally, (c)(ii) a third gRNA, and still further optionally, (c)(iii) a fourth gRNA that target the UL19, UL30, UL48 or UL54 gene, e.g., a third and fourth gRNA disclosed herein.
In some embodiments, contacting comprises contacting with (a) and (b).
In some embodiments, contacting comprises contacting with (a), (b), and (c)(i). In some embodiments, contacting comprises contacting with (a), (b), (c)(i) and (c)(ii). In some embodiments, contacting comprises contacting with (a), (b), (c)(i), (c)(ii) and
(c)(iii).
The targeting domain of the gRNA of (a) or (c) (e.g., (c)(i), (c)(ii), or (c)(iii) may be selected from any of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C, or a targeting domain of a gRNA that differs by no more than 1, 2, 3, 4, or 5 nucleotides from, a targeting domain sequence from any of Tables 1A-1G, Tables 2A- 2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A- 13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C.
In an embodiment, the method comprises acquiring knowledge of the sequence at a HSV-2 target position in said subject.
In an embodiment, the method comprises acquiring knowledge of the sequence at a
HSV-2 target position in said subject by sequencing one or more of the UL19, UL30, UL48 and/or UL54 gene(s) or a portion of the UL19, UL30, UL48md/ or UL54 gene(s).
In an embodiment, the method comprises introducing a mutation at a HSV-2 target position.
In an embodiment, the method comprises introducing a mutation at a HSV-2 target position by NHEJ.
In an embodiment, a cell of the subject is contacted is in vivo with (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
In an embodiment, the cell of the subject is contacted in vivo by intravenous delivery of (a), (b), and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
In an embodiment, the contacting step comprises contacting the subject with a nucleic acid, e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
In an embodiment, the contacting step comprises delivering to said subject said Cas9 molecule of (b), as a protein or mRNA, and a nucleic acid which encodes (a), and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
In an embodiment, the contacting step comprises delivering to the subject the Cas9 molecule of (b), as a protein or mRNA, the gRNA of (a), as an RNA, and optionally the second gRNA of (c)(i), further optionally (c)(ii), and still further optionally (c)(iii), as an RNA.
In an embodiment, the contacting step comprises delivering to the subject the gRNA of (a), as an RNA, optionally said second gRNA of (c)(i), further optionally (c)(ii), and still further optionally (c)(iii), as an RNA, a nucleic acid that encodes the Cas9 molecule of (b).
When the method comprises (1) introducing a mutation at a HSV-2 target position by NHEJ or (2) knocking down expression of one or more of the UL19, UL30, UL48 and/or UL54 gene(s), e.g., by targeting the promoter region, a Cas9 molecule of (b) and at least one guide RNA, e.g., a guide RNA of (a) are included in the contacting step.
In an embodiment, a cell of the subject is contacted is in vivo with (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii). In an embodiment, the cell of the subject is contacted in vivo by intravenous delivery of (a), (b) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
In an embodiment, the contacting step comprises contacting the subject with a nucleic acid, e.g., a vector, e.g., an AAV vector, described herein, e.g., a nucleic acid that encodes at least one of (a), (b), and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
In an embodiment, the contacting step comprises delivering to said subject said Cas9 molecule of (b), as a protein or mRNA, and a nucleic acid which encodes (a) and optionally (c)(i), further optionally (c)(ii), and still further optionally (c)(iii).
In an embodiment, the contacting step comprises delivering to the subject the Cas9 molecule of (b), as a protein or mRNA, the gRNA of (a), as an RNA, and optionally the second gRNA of (c)(i), further optionally (c)(ii), and still further optionally (c)(iii), as an RNA.
In an embodiment, the contacting step comprises delivering to the subject the gRNA of (a), as an RNA, optionally said second gRNA of (c)(i), further optionally (c)(ii), and still further optionally (c)(iii), as an RNA, and a nucleic acid that encodes the Cas9 molecule of (b).
In another aspect, disclosed herein is a reaction mixture comprising a gRNA molecule, a nucleic acid, or a composition described herein, and a cell, e.g., a cell from a subject having, or likely to develop HSV-2, or a subject which would benefit from a mutation at a HSV-2 target position.
In another aspect, disclosed herein is a kit comprising, (a) a gRNA molecule described herein, or nucleic acid that encodes the gRNA, and one or more of the following: (b) a Cas9 molecule, e.g., a Cas9 molecule described herein, or a nucleic acid or mRNA that encodes the Cas9;
(c) (i) a second gRNA molecule, e.g., a second gRNA molecule described herein or a nucleic acid that encodes (c)(i);
(c)(ii) a third gRNA molecule, e.g., a second gRNA molecule described herein or a nucleic acid that encodes (c)(ii);
(c)(iii) a fourth gRNA molecule, e.g., a second gRNA molecule described herein or a nucleic acid that encodes (c)(iii).
In an embodiment, the kit comprises nucleic acid, e.g., an AAV vector, that encodes one or more of (a), (b), (c)(i), (c)(ii), and (c)(iii).
In yet another aspect, disclosed herein is a gRNA molecule, e.g., a gRNA molecule described herein, for use in treating, or delaying the onset or progression of HSV-2 infection in a subject, e.g., in accordance with a method of treating, or delaying the onset or progression of HSV-2 infection as described herein.
In an embodiment, the gRNA molecule in used in combination with a Cas9 molecule, e.g., a Cas9 molecule described herein. Additionally or alternatively, in an embodiment, the gRNA molecule is used in combination with a second, third and/or fouth gRNA molecule, e.g., a second, third and/or fouth gRNA molecule described herein.
In still another aspect, disclosed herein is use of a gRNA molecule, e.g., a gRNA molecule described herein, in the manufacture of a medicament for treating, or delaying the onset or progression of HSV-2 in a subject, e.g., in accordance with a method of treating, or delaying the onset or progression of HSV-2 as described herein.
In an embodiment, the medicament comprises a Cas9 molecule, e.g., a Cas9 molecule described herein. Additionaly or alternatively, in an embodiment, the medicament comprises a second, third and/or fouth gRNA molecule, e.g., a second, third and/or fouth gRNA molecule described herein.
The gRNA molecules and methods, as disclosed herein, can be used in combination with a governing gRNA molecule. As used herein, a governing gRNA molecule refers to a gRNA molecule comprising a targeting domain which is complementary to a target domain on a nucleic acid that encodes a component of the CRISPR/Cas system introduced into a cell or subject. For example, the methods described herein can further include contacting a cell or subject with a governing gRNA molecule or a nucleic acid encoding a governing molecule. In an embodiment, the governing gRNA molecule targets a nucleic acid that encodes a Cas9 molecule or a nucleic acid that encodes a target gene gRNA molecule. In an embodiment, the governing gRNA comprises a targeting domain that is complementary to a target domain in a sequence that encodes a Cas9 component, e.g., a Cas9 molecule or target gene gRNA molecule. In an embodiment, the target domain is designed with, or has, minimal homology to other nucleic acid sequences in the cell, e.g., to minimize off-target cleavage. For example, the targeting domain on the governing gRNA can be selected to reduce or minimize off-target effects. In an embodiment, a target domain for a governing gRNA can be disposed in the control or coding region of a Cas9 molecule or disposed between a control region and a transcribed region. In an embodiment, a target domain for a governing gRNA can be disposed in the control or coding region of a target gene gRNA molecule or disposed between a control region and a transcribed region for a target gene gRNA. While not wishing to be bound by theory, in an embodiment, it is believed that altering, e.g., inactivating, a nucleic acid that encodes a Cas9 molecule or a nucleic acid that encodes a target gene gRNA molecule can be effected by cleavage of the targeted nucleic acid sequence or by binding of a Cas9 molecule/governing gRNA molecule complex to the targeted nucleic acid sequence.
The compositions, reaction mixtures and kits, as disclosed herein, can also include a governing gRNA molecule, e.g., a governing gRNA molecule disclosed herein.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Headings, including numeric and alphabetical headings and subheadings, are for organization and presentation and are not intended to be limiting.
Other features and advantages of the invention will be apparent from the detailed description, drawings, and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
Figs. 1A-1I are representations of several exemplary gRNAs.
Fig. 1A depicts a modular gRNA molecule derived in part (or modeled on a sequence in part) from Streptococcus pyogenes (S. pyogenes) as a duplexed structure (SEQ ID NOS: 42 and 43, respectively, in order of appearance); Fig. IB depicts a unimolecular (or chimeric) gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 44);
Fig. 1C depicts a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 45);
Fig. ID depicts a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 46);
Fig. IE depicts a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 47);
Fig. IF depicts a modular gRNA molecule derived in part from Streptococcus thermophilus (S. thermophilus) as a duplexed structure (SEQ ID NOS: 48 and 49, respectively, in order of appearance);
Fig. 1G depicts an alignment of modular gRNA molecules of S. pyogenes and S. thermophilus (SEQ ID NOS: 50-53, respectively, in order of appearance).
Figs. 1H-1I depicts additional exemplary structures of unimolecular gRNA molecules. Fig. 1H shows an exemplary structure of a unimolecular gRNA molecule derived in part from S. pyogenes as a duplexed structure (SEQ ID NO: 45). Fig. II shows an exemplary structure of a unimolecular gRNA molecule derived in part from S. aureus as a duplexed structure (SEQ ID NO: 40).
Figs. 2A-2G depict an alignment of Cas9 sequences from Chylinski et al. (RNA Biol. 2013; 10(5): 726-737). The N-terminal RuvC-like domain is boxed and indicated with a "Y". The other two RuvC-like domains are boxed and indicated with a "B". The HNH-like domain is boxed and indicated by a "G". Sm: S. mutans (SEQ ID NO: 1); Sp: S. pyogenes (SEQ ID NO: 2); St: 5". thermophilus (SEQ ID NO: 3); Li: L. innocua (SEQ ID NO: 4).
Motif: this is a motif based on the four sequences: residues conserved in all four sequences are indicated by single letter amino acid abbreviation; "*" indicates any amino acid found in the corresponding position of any of the four sequences; and "-" indicates any amino acid, e.g., any of the 20 naturally occurring amino acids, or absent.
Figs. 3A-3B show an alignment of the N-terminal RuvC-like domain from the Cas9 molecules disclosed in Chylinski et al (SEQ ID NOS: 54-103, respectively, in order of appearance). The last line of Fig. 3B identifies 4 highly conserved residues.
Figs. 4A-4B show an alignment of the N-terminal RuvC-like domain from the Cas9 molecules disclosed in Chylinski et al. with sequence outliers removed (SEQ ID NOS: 104- 177, respectively, in order of appearance). The last line of Fig. 4B identifies 3 highly conserved residues. Figs. 5A-5C show an alignment of the HNH-like domain from the Cas9 molecules disclosed in Chylinski et al (SEQ ID NOS: 178-252, respectively, in order of appearance). The last line of Fig. 5C identifies conserved residues.
Figs. 6A-6B show an alignment of the HNH-like domain from the Cas9 molecules disclosed in Chylinski et al. with sequence outliers removed (SEQ ID NOS: 253-302, respectively, in order of appearance). The last line of Fig. 6B identifies 3 highly conserved residues.
Figs. 7A-7B depict an alignment of Cas9 sequences from S. pyogenes and Neisseria meningitidis (TV. meningitidis). The N-terminal RuvC-like domain is boxed and indicated with a "Y". The other two RuvC-like domains are boxed and indicated with a "B". The
HNH-like domain is boxed and indicated with a "G". Sp: S. pyogenes; Nm: N. meningitidis. Motif: this is a motif based on the two sequences: residues conserved in both sequences are indicated by a single amino acid designation; "*" indicates any amino acid found in the corresponding position of any of the two sequences; "-" indicates any amino acid, e.g., any of the 20 naturally occurring amino acids, and "-" indicates any amino acid, e.g., any of the 20 naturally occurring amino acids, or absent.
Fig. 8 shows a nucleic acid sequence encoding Cas9 of N. meningitidis (SEQ ID NO: 303). Sequence indicated by an "R" is an SV40 NLS; sequence indicated as "G" is an HA tag; and sequence indicated by an "O" is a synthetic NLS sequence; the remaining
(unmarked) sequence is the open reading frame (ORF).
Figs. 9A and 9B are schematic representations of the domain organization of S.
pyogenes Cas 9. Fig. 9A shows the organization of the Cas9 domains, including amino acid positions, in reference to the two lobes of Cas9 (recognition (REC) and nuclease (NUC) lobes). Fig. 9B shows the percent homology of each domain across 83 Cas9 orthologs.
Definitions
"Domain", as used herein, is used to describe segments of a protein or nucleic acid. Unless otherwise indicated, a domain is not required to have any specific functional property.
Calculations of homology or sequence identity between two sequences (the terms are used interchangeably herein) are performed as follows. The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The optimal alignment is determined as the best score using the GAP program in the GCG software package with a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frame shift gap penalty of 5. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences.
"Governing gRNA molecule", as used herein, refers to a gRNA molecule that comprises a targeting domain that is complementary to a target domain on a nucleic acid that comprises a sequence that encodes a component of the CRISPR/Cas system that is introduced into a cell or subject. A governing gRNA does not target an endogenous cell or subject sequence. In an embodiment, a governing gRNA molecule comprises a targeting domain that is complementary with a target sequence on: (a) a nucleic acid that encodes a Cas9 molecule; (b) a nucleic acid that encodes a gRNA which comprises a targeting domain that targets the UL19, UL30, UL48 or UL54 gene (a target gene gRNA); or on more than one nucleic acid that encodes a CRISPR/Cas component, e.g., both (a) and (b). In an embodiment, a nucleic acid molecule that encodes a CRISPR/Cas component, e.g., that encodes a Cas9 molecule or a target gene gRNA, comprises more than one target domain that is complementary with a governing gRNA targeting domain. While not wishing to be bound by theory, in an embodiment, it is believed that a governing gRNA molecule complexes with a Cas9 molecule and results in Cas9 mediated inactivation of the targeted nucleic acid, e.g., by cleavage or by binding to the nucleic acid, and results in cessation or reduction of the production of a CRISPR/Cas system component. In an embodiment, the Cas9 molecule forms two complexes: a complex comprising a Cas9 molecule with a target gene gRNA, which complex will alter the UL19, UL30, UL48 or UL54 gene; and a complex comprising a Cas9 molecule with a governing gRNA molecule, which complex will act to prevent further production of a CRISPR/Cas system component, e.g., a Cas9 molecule or a target gene gRNA molecule. In an embodiment, a governing gRNA molecule/Cas9 molecule complex binds to or promotes cleavage of a control region sequence, e.g., a promoter, operably linked to a sequence that encodes a Cas9 molecule, a sequence that encodes a transcribed region, an exon, or an intron, for the Cas9 molecule. In an embodiment, a governing gRNA molecule/Cas9 molecule complex binds to or promotes cleavage of a control region sequence, e.g., a promoter, operably linked to a gRNA molecule, or a sequence that encodes the gRNA molecule. In an embodiment, the governing gRNA, e.g., a Cas9-targeting governing gRNA molecule, or a target gene gRNA-targeting governing gRNA molecule, limits the effect of the Cas9 molecule/target gene gRNA molecule complex-mediated gene targeting. In an embodiment, a governing gRNA places temporal, level of expression, or other limits, on activity of the Cas9 molecule/target gene gRNA molecule complex. In an embodiment, a governing gRNA reduces off-target or other unwanted activity. In an embodiment, a governing gRNA molecule inhibits, e.g., entirely or substantially entirely inhibits, the production of a component of the Cas9 system and thereby limits, or governs, its activity.
"Modulator", as used herein, refers to an entity, e.g., a drug, that can alter the activity (e.g., enzymatic activity, transcriptional activity, or translational activity), amount, distribution, or structure of a subject molecule or genetic sequence. In an embodiment, modulation comprises cleavage, e.g., breaking of a covalent or non-covalent bond, or the forming of a covalent or non-covalent bond, e.g., the attachment of a moiety, to the subject molecule. In an embodiment, a modulator alters the, three dimensional, secondary, tertiary, or quaternary structure, of a subject molecule. A modulator can increase, decrease, initiate, or eliminate a subject activity.
"Large molecule", as used herein, refers to a molecule having a molecular weight of at least 2, 3, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 kD. Large molecules include proteins, polypeptides, nucleic acids, biologies, and carbohydrates.
"Polypeptide", as used herein, refers to a polymer of amino acids having less than 100 amino acid residues. In an embodiment, it has less than 50, 20, or 10 amino acid residues.
"Reference molecule", e.g., a reference Cas9 molecule or reference gRNA, as used herein, refers to a molecule to which a subject molecule, e.g., a subject Cas9 molecule of subject gRNA molecule, e.g., a modified or candidate Cas9 molecule is compared. For example, a Cas9 molecule can be characterized as having no more than 10% of the nuclease activity of a reference Cas9 molecule. Examples of reference Cas9 molecules include naturally occurring unmodified Cas9 molecules, e.g., a naturally occurring Cas9 molecule such as a Cas9 molecule of S. pyogenes, S. aureus or S. thermophilus. In an embodiment, the reference Cas9 molecule is the naturally occurring Cas9 molecule having the closest sequence identity or homology with the Cas9 molecule to which it is being compared. In an embodiment, the reference Cas9 molecule is a sequence, e.g., a naturally occurring or known sequence, which is the parental form on which a change, e.g., a mutation has been made.
"Replacement", or "replaced", as used herein with reference to a modification of a molecule does not require a process limitation but merely indicates that the replacement entity is present. "Small molecule", as used herein, refers to a compound having a molecular weight less than about 2 kD, e.g., less than about 2 kD, less than about 1.5 kD, less than about 1 kD, or less than about 0.75 kD.
"Subject", as used herein, may mean either a human or non-human animal. The term includes, but is not limited to, mammals (e.g., humans, other primates, pigs, rodents (e.g., mice and rats or hamsters), rabbits, guinea pigs, cows, horses, cats, dogs, sheep, and goats). In an embodiment, the subject is a human. In other embodiments, the subject is poultry.
"Treat", "treating" and "treatment", as used herein, mean the treatment of a disease in a mammal, e.g., in a human, including (a) inhibiting the disease, i.e., arresting or preventing its development; (b) relieving the disease, i.e., causing regression of the disease state; and (c) curing the disease.
"Prevent", "preventing" and "prevention", as used herein, means the prevention of a disease in a mammal, e.g., in a human, including (a) avoiding or precluding the disease; (2) affecting the predisposition toward the disease, e.g., preventing at least one symptom of the disease or to delay onset of at least one symptom of the disease.
"X" as used herein in the context of an amino acid sequence, refers to any amino acid (e.g., any of the twenty natural amino acids) unless otherwise specified.
Herpes simplex virus type 2
Herpes simplex virus type 2 (HSV-2) is a sexually transmitted virus. It is most commonly known as genital herpes. Initial infection with HSV-2 generally causes painful blistering in the genital region. The disease causes lifelong, recurring bouts of viral reactivity. It is highly contagious and increases the risk of acquiring HIV infection, especially among patients with active lesions. More than 500 million people are infected with HSV-2 worldwide. Up to 23 million individuals are infected for the first time each year. In the United States, approximately 16% of the population aged 14-49 is seropositive for HSV-2 infection.
HSV-2 infection persists for the lifetime of the host. Primary and re-activation infections can cause permanent neurologic sequelae and blindness. HSV-2 also increases a subject's risk of developing HIV. There is a considerable need for methods to treat and prevent HSV-2 infections.
During primary infection, the virus most often infects cells of the ano-genital region, causing painful vesicles in the affected region. Re-activation of HSV-2 infections most often occurs in the ano-genital region. Re-activation infections of the eye and central nervous system are the most severe and damaging HSV manifestations, as they can lead to blindness and permanent neurologic disability, respectively.
HSV-2 is contained within an icosahedral particle. The virus enters the host via infection of epithelial cells within the skin and mucous membranes. The virus produces immediate early genes within the epithelial cells, which encode enzymes and binding proteins necessary for viral synthesis. After primary infection, the virus travels up sensory nerve axons via retrograde transport to the sensory dorsal root ganglion (DRG), most commonly a sacral DRG. HSV-2 mainly travels to the sensory DRG located within the sacrum, but can travel to other sensory ganglia depending upon the site of primary infection. Within the DRG, it establishes a latent infection. The latent infection persists for the lifetime of the host. This means that the virus uncoats, viral DNA is transported into the nucleus of the sensory nerve, and key viral RNAs associated with latency are transcribed (i.e., the LAT RNAs).
Host immune defense is very important to combating HSV infection. CD4+ T-cells and CD8+ cells are responsible for recognizing and clearing the pathogen. Subjects with impaired T-cell responses- including those with HIV, those receiving immunosuppressants following organ transplants, and neonates with developing immune systems are subject to the most severe manifestations of HSV-2 infections.
During a primary infection, subjects experience painful blistering in the genital region that may last 4-15 days. The blisters may break, releasing clear fluid that is highly infectious. The sores most commonly involve the vagina, labia, cervix, penis, scrotum, anus and skin around the thighs. HSV-2 primary infections may also involve the oral region, including the lips, gums and nasal mucous membranes. Less commonly, HSV-2 primary infection may involve the eyes, central nervous system, fingers and fingernail beds (herpetic whitlow). HSV-2 infection is transmitted primarily through sexual activity. The blisters may break, releasing clear fluid that is highly infectious. Primary infection is often accompanied by a flu-like illness, including fever, chills and muscle aches.
Reactivations of latent infections are generally less severe and may be of shorter duration. Reactivation can affect the oral region, the ano-genital region, the eye, the central nervous system, the fingernails, and the pharynx. Reactivation generally affects the genital region but can also cause ophthalmologic disease, including keratitis (epithelial keratitis, stromal keratitis and disciform keratitis). Generally, ophthalmologic manifestations of HSV-2 are self-limiting. However, HSV-2 keratitis may rarely cause scarring, secondary infection with bacterial pathogens and rarely, blindness. In some cases, reactivation can occur in the central nervous system (CNS) via retrograde transport of the virus into the CNS. Generally, patients who are immune compromised develop HSV-2 induced encephalitis or meningitis. HSV-2 encephalitis and meningitis are both extremely severe. Subjects generally experience permanent neurologic damage in spite of treatment with antiviral therapy.
Primary infections and reactivation infections in the central nervous system (CNS), called encephalitis and meningitis, are particularly damaging. In a study of infants with HSV-encephalitis or meningitis treated with high dose antiviral therapy, there was found to be a 4% mortality rate and 69% of survivors had permanent neurologic sequelae (Kimberlin et al., Pediatrics. 2001; 108: 230-238). The majority of infants and adults who develop HSV- 2 encephalitis or meningitis will experience permanent neurologic damage in spite of treatment with antiviral therapy. Reactivation infections in the CNS occur via anterograde transport of the virus into the CNS. Most commonly, patients who are immune compromised or infants develop HSV-2 induced encephalitis and/or meningitis. Healthy adults more rarely develop HSV-2 disease of the CNS.
In subjects with HSV-2 infections, the virus generally establishes latency in the sacral ganglia, leading to re-activation infection of the genital region.
Re-activation may also occur in the eye via anterograde transport of the virus from the trigeminal ganglion, along the ophthalmic branch of the trigeminal nerve (the fifth cranial nerve) and into the eye. Re-activation of the virus may also occur from within the cornea. Latency within the trigeminal ganglion is established via one of two mechanisms. First, HSV-2 can travel via retrograde transport along the trigeminal nerve from the eye (after an eye infection) into the trigeminal ganglion. Alternatively, it can spread to the trigeminal ganglion via hematogenous spread following infection of the oral mucosa, genital region, or other extraocular site. After establishing latent infection of the trigeminal ganglion, at any time, particularly in the event of an immunocompromised host, the virus can re-establish infection by traveling anterograde along the trigeminal nerve and into the eye.
Ocular herpes can affect the anterior chamber of the eye, where it causes keratitis, or the posterior chamber, where it causes retinitis. In neonates and children, HSV-2 is responsible for the majority of cases of HSV-retinitis (Pepose et al., Ocular Infection and Immunity 1996; Mosby 1155-1168). HSV-2 retinitis can lead to acute retinal necrosis (ARN), which will destroy the retina within 2 weeks without treatment (Banerjee and Rouse, Human Herpesviruses 2007; Cambridge University Press, Chapter 35). Even with treatment, the risk of permanent visual damage following ARN is higher than 50% (Roy et al., Ocular Immunology and Inflammation 2014; 22(3): 170-174).
Keratitis is the most common form of ocular herpes. HSV-2 keratitis can manifest as dentritic keratitis, stromal keratitis, blepharatis and conjunctivitis. In the United States, there are approximately 48,000 cases of recurrent or primary HSV-related keratitis infections annually (Liesegang et. al., 1989; 107(8): 1155-1 159). Of all cases of HSV-related keratitis, approximately 1.5-3% of subjects experience severe, permanent visual impairment
(Wiihelmus et. al., Archives of Ophthalmology 1981; 99(9): 1578-82).
Overall, stromal keratitis represents approximately 15% of keratitis cases and is associated with the highest risk of permanent visual damage. Stromal keratitis results in scarring and irregular astimagtism. Previous ocular HSV infection increases the risk for developing stromal infection, which means that subjects who have had a prior ocular HSV infection have an increased risk for permanent visual damage on reactivation. In children, stromal keratitis represents up to 60% of all keratitis cases so children are particularly at risk for permanent visual damage from HSV-associated keratitis. A retrospective study in the United States from 1950-1982 found that there are approximately 2.6 new or recurrent stromal keratitis cases per 100,000 person years, or approximately 8,000 cases of stromal keratitis annually (Liesegang et. al., 1989: 107(8): 1 155-1159). A more recent study in France in 2002 estimated the incidence of new or recurrent stromal keratitis cases to be 9.6 per 100,000 (Labetoulle et al., Ophthalmology 2005; 11.2(5):888-895). The incidence of
HSV-associated keratitis may be increasing in the developed world (Farooq and Shukla 2012; Survey of Ophthalmology 57(5): 448-462).
The compositions and methods described herein can be used for the treatment and prevention of HSV-2 infections, including but not limited to HSV-2 stromal keratitis, HSV-2 retinitis, HSV-2 encephalitis and HSV-2 meningitis.
Newborns are a population at particular risk for developing severe HSV-2 infections. The disease is transmitted from the mother to the fetus during childbirth. The chance of maternal-fetal transmission is highest in cases where the mother developed primary HSV infection during pregnancy. The incidence of neonatal herpes is approximately 4-30 per 100,000 births. Neonates may develop severe HSV-2 encephalitis and/or meningitis. In spite of prompt treatment with antiviral therapy, the rate of permanent neurologic sequelae in newborns infected with HSV-2 is significant.
HSV-2 infection is treated with antiviral therapy, including acyclovir, valacyclovir and famciclovir. These therapies have been demonstrated to reduce viral shedding, decrease pain and improve healing time of lesions. Therapy is primarily given during acute infection and there is no curative treatment. Therapy may be given prophylactically in certain situations, including during childbirth in a mother with a recent HSV-2 infection or reactivation.
There is no effective therapy that prevents HSV-2 infection. The use of antiviral therapy during active infection and the use of condoms decrease transmission rates by approximately 50%.
Human immunodeficiency virus-1 (HIV-1) acquisition rates are dramatically increased in subjects who are seropositive for HSV-2. The risk of infection with HIV-1 is 3- fold higher in subjects with HSV-2. Antivirals have no impact on reducing risk of HIV acquisition.
Methods to Treat, Prevent or Reduce HSV-2 Infection
Disclosed herein are the approaches to treat, prevent, or reduce HSV-2 infection, using the compositions and methods described herein.
HSV-2 relies on the genes UL19, UL30, UL48 and UL54 for infection, proliferation and assembly. Knockout of any of these genes singly or in combination can prevent and/or cure HSV-2 infections. As the HSV-2 virus establishes latency in discrete, localized regions within the body, it is highly amenable to local delivery that delivers a disabling treatment in the region of latency. Targeting knock-out to a discrete region or regions, (e.g., the trigeminal dorsal root ganglion, e.g., the cervical dorsal root ganglia, e.g., the sacral dorsal root ganglia) can eliminate latent infection by disabling the HSV-2 virus.
Described herein are the approaches to treat or prevent HSV-2 by knocking out viral genes. Methods described herein include the knockout of the following HSV-2 encoded genes: UL19, UL30, UL48 and UL54, or any combination thereof (e.g., any two, three or all of the UL19, UL30, UL48 or UL54 gene).
UL19 (also known as VP5) encodes the HSV-2 major capsid protein, VP5. Proper assembly of the viral capsid is known to be an essential part of viral replication, assembly, maturation and infection (Homa et al.. Reviews of Medical Virology 1997; 7(2):107-122). RNAi-mediated knockdown of VP5 along with another capsid capsid protein, VP23, in vitro, greatly diminished HSV proliferation (Jin et al., PLoS One 2014; 9(5): e96623). Knockout of UL19 can disable HSV-2 proliferation and therefore prevent and/or cure HSV-2 infection. UL30 encodes the DNA polymerase catalytic subunit (HSV-2 pol). The 5' domain of HSV-2 pol is required for viral replication. Knockout of UL30 can disable HSV-2 replication and therefore prevent and/or cure HSV-2 infection.
UL48 encodes the viral protein known as VP16 in HSV-2. VP-16 has been shown to be important in viral egress, the process by which the assembled viral capsid leaves the host nucleus and enters the cytoplasm (Mossman et al., Journal of Virology 2000; 74(14): 6287- 6289). Mutation of UL48 in cell culture decreased the ability of HSV to assemble efficiently (Svobodova et al., Journal of Virology 2012; 86(1): 473-483). Knockout of UL48 can disable HSV-2 assembly and egress and therefore prevent and/or cure HSV-2 infection.
UL54 encodes ICP27, a highly conserved, multi-functional protein. ICP27 is involved in transcription, RNA processing, RNA export and translation (Sandri-Goldin, Frontiers in Bioscience 2008; 13:5241-5256). ICP27 also shuts off host gene expression during HSV-2 infection. Knock out of UL54 can disable HSV-2 transcription, translation and RNA processing and therefore prevent and/or cure HSV-2 infection.
Knockout of the genes UL19, UL30, UL48 and UL54, individually or in combination, can reduce HSV-2 infectivity, replication, or packaging and can therefore prevent or treat HSV-2 infection.
In addition, knock out of vital HSV-2 genes, e.g., UL19, UL30, UL48 and UL54, individually or in combination can make HSV-2 more susceptible to antiviral therapy.
Mutations in important genes can render HSV-2 and other viruses more susceptible to treatment with antivirals (Zhou et al., Journal of Virology 2014; 88(19): 11121-11129).
Knocking-out UL19, UL30, UL48 and UL54, individually or in combination may be combined with an antiviral therapy to prevent or treat cure HSV-2 infection. The
compositions and methods described herein can be used in combination with another antiviral therapy, e.g., another anti-HSV-2 therapy described herein, to treat or prevent HSV-2 infection.
In one approach, one or more of the UL19, UL30, UL48 and/or UL54 gene(s) is targeted as a targeted knockout, e.g., to inhibit essential viral functions, including, e.g. viral gene transcription, viral genome replication and viral capsid formation. In an embodiment, said approach comprises knocking out one HSV-2 gene (e.g., UL19, UL30, UL48 or UL54 gene). In another embodiment, said approach comprises knocking out two HSV-2 genes, e.g., two of UL19, UL30, UL48 or UL54 gene(s). In another embodiment, said approach comprises knocking out three HSV-2 genes, e.g., three or more of UL19, UL30, UL48 or UL54 gene(s). In another embodiment, said approach comprises knocking out four HSV-2 genes, e.g., each of UL19, UL30, UL48 and UL54 gene(s).
While not wishing to be bound by theory, it is considered that inhibiting essential viral functions, e.g., viral gene transcription, viral genome replication and viral capsid formation, decreases the duration of primary or recurrent infection and/or decrease shedding of viral particles. Subjects also experience shorter duration(s) of illness, decreased risk of transmission to sexual partners, decreased risk of transmission to the fetus in the case of pregnancy and/or the potential for full clearance of HSV-2 (cure).
Knockout of one or more copies (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more copies) of one or more target gene (e.g., UL19, UL30, UL48 or UL54 gene) may be performed prior to disease onset or after disease onset, but preferably early in the disease course.
In an embodiment, the method comprises initiating treatment of a subject prior to disease onset.
In an embodiment, the method comprises initiating treatment of a subject after disease onset.
In an embodiment, the method comprises initiating treatment of a subject well after disease onset, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 36, 48 or more months after onset of HSV-2 infection. In an embodiment, the method comprises initiating treatment of a subject well after disease onset, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 40, 50 or 60 years after onset of HSV-2 infection. While not wishing to be bound by theory it is believed that this may be effective if subjects present well into the course of illness.
In an embodiment, the method comprises initiating treatment of a subject in an advanced stage of disease, e.g., during acute or latent periods. In an embodiment, the method comprises initiating treatment of a subject in severe, acute stages of the disease affecting the central nervous system, eyes, oropharynx, genital region, and/or other regions.
Overall, initiation of treatment for subjects at all stages of disease is expected to improve healing, decrease duration of disease and be of benefit to subjects.
In an embodiment, the method comprises initiating treatment of a subject prior to disease expression. In an embodiment, the method comprises initiating treatment of a subject in an early stage of disease, e.g., when a subject has been exposed to HSV-2 or is thought to have been exposed to HSV-2.
In an embodiment, the method comprises initiating treatment of a subject prior to disease expression. In an embodiment, the method comprises initiating treatment of a subject in an early stage of disease, e.g., when a subject has tested positive for HSV-2 infections but has no signs or symptoms.
In an embodiment, the method comprises initiating treatment of a subject at the appearance of painful blistering in or around the mouth, e.g., oral or oropharynx, e.g., in an infant, child, adult or young adult.
In an embodiment, the method comprises initiating treatment of a subject at the appearance of painful blistering in the genital region, e.g., in an infant, child, adult or young adult.
In an embodiment, the method comprises initiating treatment of a subject suspected of having HSV-2 meningitis and/or HSV-2 encephalitis.
In an embodiment, the method comprises initiating treatment at the appearance of any of the following symptoms consistent or associated with HSV-2 meningitis and/or encephalitis: fever, headache, vomiting, photophobia, seizure, decline in level of
consciousness, lethargy, or drowsiness.
In an embodiment, the method comprises initiating treatment at the appearance of any of the following signs consistent or associated with HSV meningitis and/or encephalitis: positive CSF culture for HSV-2, elevated WBC in CSF, neck stiffness/positive Brudzinski' s sign. In an embodiment, the method comprises initiating treatment in a patient with signs consistent with HSV-2 encephalitis and/or meningitis on EEG, CSF exam, MRI, PCR of CSF specimen, and/or PCR of brain biopsy specimen.
In an embodiment, the method comprises initiating treatment at the appearance of any of the following symptoms consistent or associated with optic HSV-2: pain, photophobia, blurred vision, tearing, redness/injection, loss of vision, floaters, or flashes.
In an embodiment, the method comprises initiating treatment at the appearance of any of the following findings on ophthalmologic exam consistent or associated with optic HSV-2, also known as HSV-2 keratitis: small, raised clear vesicles on corneal epithelium; irregular corneal surface, punctate epithelial erosions; dense stromal infiltrate; ulceration; necrosis; focal, multifocal, or diffuse cellular infiltrates; immune rings; neovascularization; or ghost vessels at any level of the cornea.
In an embodiment, the method comprises initiating treatment at the appearance of any of the following findings on ophthalmologic exam consistent or associated with HSV-2 retinitis or acute retinal necrosis: reduced visual acuity; uveitis; vitritis; scleral injection; inflammation of the anterior and/or vitreous chamber/s; vitreous haze; optic nerve edema; peripheral retinal whitening; retinal tear; retinal detachment; retinal necrosis; evidence of occlusive vasculopathy with arterial involvement, including arterioloar sheathing and arteriolar attenuation.
In an embodiment, the method comprises initiating treatment at the appearance of symptoms and/or signs consistent or associated with either an HSV-1 or an HSV-2 infection of the eye, oropharynx, ano-genital region or central nervous system. While not wishing to be bound by theory, intiating treatment for HSV-2 infection in a case of suspected HS V- 1 or HSV-2 infection early in the disease course is beneficial.
In an embodiment, the method comprises initiating treatment in utero in case of high risk of maternal-to-fetal transmission.
In an embodiment, the method comprises initiating treatment during pregnancy in case of mother who has active HSV-2 infection or has recent primary HSV-2 infection.
In an embodiment, the method comprises initiating treatment prior to organ transplantation or immediately following organ transplantation.
In an embodiment, the method comprises initiating treatment in case of suspected exposure to HSV-2.
In an embodiment, the method comprises initiating treatment prophylactically, especially in case of suspected HSV-encephalitis or meningitis.
In an embodiment, the method comprises initiating treatment of a subject who suffers from or is at risk of developing severe manifestations of HSV-2 infections, e.g., neonates, subjects with HIV, subjects who are on immunosuppressant therapy following organ transplantation, subjects who have cancer, subjects who are undergoing chemotherapy, subjects who will undergo chemotherapy, subjects who are undergoing radiation therapy, subjects who will undergo radiation therapy.
While not wishing to be bound by theory, it is considered that both HIV positive subjects and post-transplant subjects may experience severe HSV-2 activation or reactivation, including HSV-encephalitis and meningitis, due to immunodeficiency. Neonates are also at risk for severe HSV-encephalitis due to maternal-fetal transmission during childbirth.
Inhibiting essential viral functions, e.g., viral gene transcription, viral genome replication and viral capsid formation, may provide superior protection to said populations at risk for severe HSV-2 infections. Subjects may experience lower rates of HSV-2 encephalitis and/or lower rates of severe neurologic sequelae following HSV-2 encephalitis, which will profoundly improve quality of life.
In an embodiment, the method comprises initiating treatment of a subject who has tested positive for HSV-2. In an embodiment, the method comprises initiating treatment at the appearance of any one or more of the following findings consistent or associated with HSV-2: appearance of blistering in the ano-genital area, genital ulcers and/or flu-like illness.
In an embodiment, the method comprises initiating treatment at the appearance of any of the following findings consistent or associated with HSV-2 infection: fever, headache, body aches, ano-genital blistering, oral ulceration, encephalitis, or keratitis.
In an embodiment, the method comprises initiating treatment in a subject who has tested positive for HSV-2 infection via viral culture, direct fluorescent antibody study, skin biopsy, PCR, blood serologic test, CSF serologic test, CSF PCR, or brain biopsy. In an embodiment, the method comprises initiating treatment in a subject who has tested positive for HSV-2 infection via diagnostic vitrectomy, endoretinal biopsy, PCR of aqueous fluid, PCR of vitreous sample.
In an embodiment, the method comprises initiating treatment in any patient exposed to HSV-2 and at high risk for severe sequelae from HSV infection.
In some embodiments, a cell is manipulated by editing (e.g., introducing a mutation in) one or more target genes, e.g., UL19, UL30, UL48 or UL54 gene. In some embodiments, the expression of one or more target genes (e.g., one or more UL19, UL30, UL48 or UL54 gene described herein) is modulated, e.g., in vivo.
In an embodiment, the method comprises delivery of gRNA by an AAV. In an embodiment, the method comprises delivery of gRNA by a lentivirus. In an embodiment, the method comprises delivery of gRNA by a nanoparticle. In an embodiment, the method comprises delivery of gRNA by a gel-based AAV for topical therapy.
In an embodiment, the method further comprising treating the subject a second antiviral therapy, e.g., an anti-HSV-2 therapy described herein. The compositions described herein can be administered concurrently with, prior to, or subsequent to, one or more additional therapies or therapeutic agents. The composition and the other therapy or therapeutic agent can be administered in any order. In an embodiment, the effect of the two treatments is synergistic. Exemplary anti-HSV-2 therapies include, but are not limited to, acyclovir, valacyclovir, famciclovir, penciclovir, or a vaccine.
Methods of Altering UL19, UL30, UL48 and/or UL54 gene(s)
As disclosed herein, a HSV-2 target position, e.g., one or more of UL19, UL30, UL48 or UL54 gene(s), can be altered by gene editing, e.g., using CRISPR-Cas9 mediated methods as described herein. Methods and compositions discussed herein, provide for altering a HSV-2 target position in one or more of the UL19, UL30, UL48 and/or UL54 gene(s). A HSV-2 target position can be altered by gene editing, e.g., using CRISPR-Cas9 mediated methods to alter one or more of the UL19, UL30, UL48 and/or UL54 gene(s).
An alteration of one or more of the UL19, UL30, UL48 and/or UL54 gene(s) can be mediated by any mechanism. Exemplary mechanisms that can be associated with an alteration of one or more of the UL19, UL30, UL48 and/or UL54 gene(s) include, but are not limited to, non-homologous end joining (e.g., classical or alternative), microhomology- mediated end joining (MMEJ), homology-directed repair (e.g., endogenous donor template mediated), SDSA (synthesis dependent strand annealing), single strand annealing or single strand invasion.
In an embodiment, a single strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a HSV-2 target position in the UL19, UL30, UL48 and/or UL54 gene. In an embodiment, a single gRNA molecule (e.g., with a Cas9 nickase) is used to create a single strand break at or in close proximity to the HSV-2 target position, e.g., the gRNA is configured such that the single strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the HSV-2 target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, a double strand break is introduced (e.g., positioned by one gRNA molecule) at or in close proximity to a HSV-2 target position in the UL19, UL30, UL48 and/or UL54 gene. In an embodiment, a single gRNA molecule (e.g., with a Cas9 nuclease other than a Cas9 nickase) is used to create a double strand break at or in close proximity to the HSV-2 target position, e.g., the gRNA molecule is configured such that the double strand break is positioned either upstream (e.g., within 200 bp upstream) or downstream of (e.g., within 200 bp downstream) of a HSV-2 target position. In an embodiment, the break is positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two single strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a HSV-2 target position in the UL19, UL30, UL48 and/or UL54 gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the HSV-2 target position, e.g., the gRNAs molecules are configured such that both of the single strand breaks are positioned upstream (e.g., within 200 bp upstream) or downstream (e.g., within 200 bp downstream) of the HSV-2 target position. In another embodiment, two gRNA molecules (e.g., with two Cas9 nickcases) are used to create two single strand breaks at or in close proximity to the HSV-2 target position, e.g., the gRNAs molecules are configured such that one single strand break is positioned upstream (e.g., within 200 bp upstream) and a second single strand break is positioned downstream (e.g., within 200 bp downstream) of the HSV-2 target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two double strand breaks are introduced (e.g., positioned by two gRNA molecules) at or in close proximity to a HSV-2 target position in the UL19, UL30, UL48 and/or UL54 gene. In an embodiment, two gRNA molecules (e.g., with one or two Cas9 nucleases that are not Cas9 nickases) are used to create two double strand breaks to flank a HSV-2 target position, e.g., the gRNA molecules are configured such that one double strand break is positioned upstream (e.g., within 200 bp upstream) and a second double strand break is positioned downstream (e.g., within 200 bp downstream) of the HSV-2 target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, one double strand break and two single strand breaks are introduced (e.g., positioned by three gRNA molecules) at or in close proximity to a HSV-2 target position in the UL19, UL30, UL48 and/or UL54 gene. In an embodiment, three gRNA molecules (e.g., with a Cas9 nuclease other than a Cas9 nickase and one or two Cas9 nickases) to create one double strand break and two single strand breaks to flank a HSV-2 target position, e.g., the gRNA molecules are configured such that the double strand break is positioned upstream or downstream of (e.g., within 200 bp upstream or downstream) of the HSV-2 target position, and the two single strand breaks are positioned at the opposite site, e.g., downstream or upstream (within 200 bp downstream or upstream), of the HSV-2 target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, four single strand breaks are introduced (e.g., positioned by four gRNA molecules) at or in close proximity to a HSV-2 target position in the UL19, UL30, UL48 and/or UL54 gene. In an embodiment, four gRNA molecule (e.g., with one or more
Cas9 nickases are used to create four single strand breaks to flank a HSV-2 target position in the UL19, UL30, UL48 and/or UL54 gene, e.g., the gRNA molecules are configured such that a first and second single strand breaks are positioned upstream (e.g., within 200 bp upstream) of the HSV-2 target position, and a third and a fourth single stranded breaks are positioned downstream (e.g., within 200 bp downstream) of the HSV-2 target position. In an embodiment, the breaks are positioned to avoid unwanted target chromosome elements, such as repeat elements, e.g., an Alu repeat.
In an embodiment, two or more (e.g., three or four) gRNA molecules are used with one Cas9 molecule. In another embodiment, when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
I. gRNA Molecules
A gRNA molecule, as that term is used herein, refers to a nucleic acid that promotes the specific targeting or homing of a gRNA molecule/Cas9 molecule complex to a target nucleic acid. gRNA molecules can be unimolecular (having a single RNA molecule), sometimes referred to herein as "chimeric" gRNAs, or modular (comprising more than one, and typically two, separate RNA molecules). A gRNA molecule comprises a number of domains. The gRNA molecule domains are described in more detail below.
Several exemplary gRNA structures, with domains indicated thereon, are provided in Fig. 1. While not wishing to be bound by theory, in an embodiment, with regard to the three dimensional form, or intra- or inter-strand interactions of an active form of a gRNA, regions of high complementarity are sometimes shown as duplexes in Figs. 1A-1G and other depictions provided herein.
In an embodiment, a unimolecular, or chimeric, gRNA comprises, preferably from 5' to 3':
a targeting domain (which is complementary to a target nucleic acid in the UL19, UL30, UL48 or UL54 gene, e.g., a targeting domain from any of Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E,
Tables 15A-15G, or Tables 16A-16C;
a first complementarity domain;
a linking domain;
a second complementarity domain (which is complementary to the first complementarity domain);
a proximal domain; and
optionally, a tail domain.
embodiment, a modular gRNA comprises:
a first strand comprising, preferably from 5' to 3'
a targeting domain (which is complementary to a target nucleic acid in the UL19, UL30, UL48 or UL54 gene, e.g., a targeting domain from Tables 1A-1G, Tables 2A-2F, Tables 3A-3F, Tables 4A-4G, Tables 5A-5E, Tables 6A-6G, Tables 7A-7D, Tables 8A-8E, Tables 9A-9G, Tables 10A-10D, Tables 11A-11E, Tables 12A-12G, Tables 13A-13B, Tables 14A-14E, Tables 15A-15G, or Tables 16A-16C); and
a first complementarity domain; and
a second strand, comprising, preferably from 5 ' to 3 ' :
optionally, a 5' extension domain;
a second complementarity domain;
a proximal domain; and
optionally, a tail domain.
The domains are discussed briefly below.
The Targeting Domain
Figs. 1A-1G provide examples of the placement of targeting domains.
The targeting domain comprises a nucleotide sequence that is complementary, e.g., at least 80, 85, 90, or 95% complementary, e.g., fully complementary, to the target sequence on the target nucleic acid. The targeting domain is part of an RNA molecule and will therefore comprise the base uracil (U), while any DNA encoding the gRNA molecule will comprise the base thymine (T). While not wishing to be bound by theory, in an embodiment, it is believed that the complementarity of the targeting domain with the target sequence contributes to specificity of the interaction of the gRNA molecule/Cas9 molecule complex with a target nucleic acid. It is understood that in a targeting domain and target sequence pair, the uracil bases in the targeting domain will pair with the adenine bases in the target sequence. In an embodiment, the target domain itself comprises in the 5' to 3' direction, an optional secondary domain, and a core domain. In an embodiment, the core domain is fully complementary with the target sequence. In an embodiment, the targeting domain is 5 to 50 nucleotides in length. The strand of the target nucleic acid with which the targeting domain is complementary is referred to herein as the complementary strand. Some or all of the nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
In an embodiment, the targeting domain is 16 nucleotides in length.
In an embodiment, the targeting domain is 17 nucleotides in length.
In an embodiment, the targeting domain is 18 nucleotides in length.
In an embodiment, the targeting domain is 19 nucleotides in length.
In an embodiment, the targeting domain is 20 nucleotides in length.
In an embodiment, the targeting domain is 21 nucleotides in length.
In an embodiment, the targeting domain is 22 nucleotides in length.
In an embodiment, the targeting domain is 23 nucleotides in length.
In an embodiment, the targeting domain is 24 nucleotides in length.
In an embodiment, the targeting domain is 25 nucleotides in length.
In an embodiment, the targeting domain is 26 nucleotides in length.
In an embodiment, the targeting domain comprises 16 nucleotides.
In an embodiment, the targeting domain comprises 17 nucleotides.
In an embodiment, the targeting domain comprises 18 nucleotides.
In an embodiment, the targeting domain comprises 19 nucleotides.
In an embodiment, the targeting domain comprises 20 nucleotides.
In an embodiment, the targeting domain comprises 21 nucleotides.
In an embodiment, the targeting domain comprises 22 nucleotides.
In an embodiment, the targeting domain comprises 23 nucleotides.
In an embodiment, the targeting domain comprises 24 nucleotides.
In an embodiment, the targeting domain comprises 25 nucleotides.
In an embodiment, the targeting domain comprises 26 nucleotides.
Targeting domains are discussed in more detail below.
The First Complementarity Domain
Figs. 1A-1G provides examples of first complementarity domains.
The first complementarity domain is complementary with the second
complementarity domain, and in an embodiment, has sufficient complementarity to the second complementarity domain to form a duplexed region under at least some physiological conditions. In an embodiment, the first complementarity domain is 5 to 30 nucleotides in length. In an embodiment, the first complementarity domain is 5 to 25 nucleotides in length. In an embodiment, the first complementary domain is 7 to 25 nucleotides in length. In an embodiment, the first complementary domain is 7 to 22 nucleotides in length. In an embodiment, the first complementary domain is 7 to 18 nucleotides in length. In an embodiment, the first complementary domain is 7 to 15 nucleotides in length. In an embodiment, the first complementary domain is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length.
In an embodiment, the first complementarity domain comprises 3 subdomains, which, in the 5' to 3' direction are: a 5' subdomain, a central subdomain, and a 3' subdomain. In an embodiment, the 5' subdomain is 4 to 9, e.g., 4, 5, 6, 7, 8 or 9 nucleotides in length. In an embodiment, the central subdomain is 1, 2, or 3, e.g., 1, nucleotide in length. In an embodiment, the 3' subdomain is 3 to 25, e.g., 4 to22, 4 to 18, or 4 to 10, or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length.
The first complementarity domain can share homology with, or be derived from, a naturally occurring first complementarity domain. In an embodiment, it has at least 50% homology with a first complementarity domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, first complementarity domain.
Some or all of the nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
First complementarity domains are discussed in more detail below.
The Linking Domain
Figs. 1A-1G provides example of linking domains.
A linking domain serves to link the first complementarity domain with the second complementarity domain of a unimolecular gRNA. The linking domain can link the first and second complementarity domains covalently or non-covalently. In an embodiment, the linkage is covalent. In an embodiment, the linking domain covalently couples the first and second complementarity domains, see, e.g., Figs. IB-IE. In an embodiment, the linking domain is, or comprises, a covalent bond interposed between the first complementarity domain and the second complementarity domain. Typically the linking domain comprises one or more, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.
In modular gRNA molecules the two molecules are associated by virtue of the hybridization of the complementarity domains see e.g., Figs. 1A.
A wide variety of linking domains are suitable for use in unimolecular gRNA molecules. Linking domains can consist of a covalent bond, or be as short as one or a few nucleotides, e.g., 1, 2, 3, 4, or 5 nucleotides in length. In an embodiment, a linking domain is 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 or more nucleotides in length. In an embodiment, a linking domain is 2 to 50, 2 to 40, 2 to 30, 2 to 20, 2 to 10, or 2 to 5 nucleotides in length. In an embodiment, a linking domain shares homology with, or is derived from, a naturally occurring sequence, e.g., the sequence of a tracrRNA that is 5' to the second complementarity domain. In an embodiment, the linking domain has at least 50% homology with a linking domain disclosed herein.
Some or all of the nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
Linking domains are discussed in more detail below.
The 5 ' Extension Domain
In an embodiment, a modular gRNA can comprise additional sequence, 5' to the second complementarity domain, referred to herein as the 5' extension domain, see, e.g., Fig. 1A. In an embodiment, the 5' extension domain is, 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, or 2 to 4 nucleotides in length. In an embodiment, the 5' extension domain is 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides in length.
The Second Complementarity Domain
Figs. 1A-1G provide examples of second complementarity domains.
The second complementarity domain is complementary with the first
complementarity domain, and in an embodiment, has sufficient complementarity to the second complementarity domain to form a duplexed region under at least some physiological conditions. In an embodiment, e.g., as shown in Figs. 1A-1B, the second complementarity domain can include sequence that lacks complementarity with the first complementarity domain, e.g., sequence that loops out from the duplexed region.
In an embodiment, the second complementarity domain is 5 to 27 nucleotides in length. In an embodiment, it is longer than the first complementarity region. In an embodiment the second complementary domain is 7 to 27 nucleotides in length. In an embodiment, the second complementary domain is 7 to 25 nucleotides in length. In an embodiment, the second complementary domain is 7 to 20 nucleotides in length. In an embodiment, the second complementary domain is 7 to 17 nucleotides in length. In an embodiment, the complementary domain is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length. In an embodiment, the second complementarity domain comprises 3 subdomains, which, in the 5' to 3' direction are: a 5' subdomain, a central subdomain, and a 3' subdomain. In an embodiment, the 5' subdomain is 3 to 25, e.g., 4 to 22, 4 tol8, or 4 to 10, or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. In an embodiment, the central subdomain is 1, 2, 3, 4 or 5, e.g., 3, nucleotides in length. In an embodiment, the 3' subdomain is 4 to 9, e.g., 4, 5, 6, 7, 8 or 9 nucleotides in length.
In an embodiment, the 5 ' subdomain and the 3 ' subdomain of the first
complementarity domain, are respectively, complementary, e.g., fully complementary, with the 3' subdomain and the 5' subdomain of the second complementarity domain.
The second complementarity domain can share homology with or be derived from a naturally occurring second complementarity domain. In an embodiment, it has at least 50% homology with a second complementarity domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, first complementarity domain.
Some or all of the nucleotides of the domain can have a modification, e.g., a modification found in Section VIII herein.
A Proximal domain
Figs. 1A-1G provide examples of proximal domains.
In an embodiment, the proximal domain is 5 to 20 nucleotides in length. In an embodiment, the proximal domain can share homology with or be derived from a naturally occurring proximal domain. In an embodiment, it has at least 50% homology with a proximal domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, proximal domain.
Some or all of the nucleotides of the domain can have a modification, e.g., modification found in Section VIII herein.
A Tail Domain
Figs. 1A-1G provide examples of tail domains.
As can be seen by inspection of the tail domains in Figs. 1A-1E, a broad spectrum of tail domains are suitable for use in gRNA molecules. In an embodiment, the tail domain is 0 (absent), 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In embodiment, the tail domain nucleotides are from or share homology with sequence from the 5 ' end of a naturally occurring tail domain, see e.g., Fig. ID or Fig.lE. In an embodiment, the tail domain includes sequences that are complementary to each other and which, under at least some physiological conditions, form a duplexed region.
In an embodiment, the tail domain is absent or is 1 to 50 nucleotides in length. In an embodiment, the tail domain can share homology with or be derived from a naturally occurring proximal tail domain. In an embodiment, it has at least 50% homology with a tail domain disclosed herein, e.g., an S. pyogenes, S. aureus or S. thermophilus, tail domain.
In an embodiment, the tail domain includes nucleotides at the 3' end that are related to the method of in vitro or in vivo transcription. When a T7 promoter is used for in vitro transcription of the gRNA, these nucleotides may be any nucleotides present before the 3 ' end of the DNA template. When a U6 promoter is used for in vivo transcription, these nucleotides may be the sequence UUUUUU. When alternate pol-III promoters are used, these nucleotides may be various numbers or uracil bases or may include alternate bases.
The domains of gRNA molecules are described in more detail below. The Targeting Domain
The "targeting domain" of the gRNA is complementary to the "target domain" on the target nucleic acid. The strand of the target nucleic acid comprising the nucleotide sequence complementary to the core domain of the gRNA is referred to herein as the "complementary strand" of the target nucleic acid. Guidance on the selection of targeting domains can be found, e.g., in Fu Y et al., Nat Biotechnol 2014 (doi: 10.1038/nbt.2808) and Sternberg SH et al., Nature 2014 (doi: 10.1038/naturel3011).
In an embodiment, the targeting domain is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, the targeting domain is 16 nucleotides in length.
In an embodiment, the targeting domain is 17 nucleotides in length.
In an embodiment, the targeting domain is 18 nucleotides in length.
In an embodiment, the targeting domain is 19 nucleotides in length.
In an embodiment, the targeting domain is 20 nucleotides in length.
In an embodiment, the targeting domain is 21 nucleotides in length.
In an embodiment, the targeting domain is 22 nucleotides in length.
In an embodiment, the targeting domain is 23 nucleotides in length.
In an embodiment, the targeting domain is 24 nucleotides in length.
In an embodiment, the targeting domain is 25 nucleotides in length.
In an embodiment, the targeting domain is 26 nucleotides in length. In an embodiment, the targeting domain comprises 16 nucleotides.
In an embodiment, the targeting domain comprises 17 nucleotides.
In an embodiment, the targeting domain comprises 18 nucleotides.
In an embodiment, the targeting domain comprises 19 nucleotides.
In an embodiment, the targeting domain comprises 20 nucleotides.
In an embodiment, the targeting domain comprises 21 nucleotides.
In an embodiment, the targeting domain comprises 22 nucleotides.
In an embodiment, the targeting domain comprises 23 nucleotides.
In an embodiment, the targeting domain comprises 24 nucleotides.
In an embodiment, the targeting domain comprises 25 nucleotides.
In an embodiment, the targeting domain comprises 26 nucleotides.
In an embodiment, the targeting domain is 10 +/-5, 20+/-5, 30+/-5,
60+/-5, 70+/-5, 80+/-5, 90+/-5, or 100+/-5 nucleotides, in length.
In an embodiment, the targeting domain is 20+/-5 nucleotides in length.
In an embodiment, the targeting domain is 20+/- 10, 30+/- 10, 40+/- 10, 50+/- 10, 60+/-
10, 70+/-10, 80+/-10, 90+/-10, or 100+/- 10 nucleotides, in length.
In an embodiment, the targeting domain is 30+/- 10 nucleotides in length.
In an embodiment, the targeting domain is 10 to 100, 10 to 90, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 10 to 20 or 10 to 15 nucleotides in length. In another embodiment, the targeting domain is 20 to 100, 20 to 90, 20 to 80, 20 to 70, 20 to 60, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides in length.
Typically the targeting domain has full complementarity with the target sequence. In an embodiment the targeting domain has or includes 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain.
In an embodiment, the target domain includes 1, 2, 3, 4 or 5 nucleotides that are complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 5' end. In an embodiment, the target domain includes 1, 2, 3, 4 or 5 nucleotides that are complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 3 ' end.
In an embodiment, the target domain includes 1, 2, 3, or 4 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 5' end. In an embodiment, the target domain includes 1, 2, 3, or 4 nucleotides that are not complementary with the corresponding nucleotide of the targeting domain within 5 nucleotides of its 3 ' end. In an embodiment, the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
In some embodiments, the targeting domain comprises two consecutive nucleotides that are not complementary to the target domain ("non-complementary nucleotides"), e.g., two consecutive noncomplementary nucleotides that are within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3 ' end of the targeting domain, or more than 5 nucleotides away from one or both ends of the targeting domain.
In an embodiment, no two consecutive nucleotides within 5 nucleotides of the 5 ' end of the targeting domain, within 5 nucleotides of the 3 ' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain, are not complementary to the targeting domain.
In an embodiment, there are no noncomplementary nucleotides within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain.
In an embodiment, the targeting domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the targeting domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the targeting domain can be modified with a phosphorothioate, or other modification(s) from Section VIII. In an embodiment, a nucleotide of the targeting domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
In some embodiments, the targeting domain includes 1, 2, 3, 4, 5, 6, 7 or 8 or more modifications. In an embodiment, the targeting domain includes 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end. In an embodiment, the targeting domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end.
In some embodiments, the targeting domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or more than 5 nucleotides away from one or both ends of the targeting domain.
In an embodiment, no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain. In an embodiment, no nucleotide is modified within 5 nucleotides of the 5' end of the targeting domain, within 5 nucleotides of the 3' end of the targeting domain, or within a region that is more than 5 nucleotides away from one or both ends of the targeting domain.
Modifications in the targeting domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate targeting domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in a system in Section IV. The candidate targeting domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, all of the modified nucleotides are complementary to and capable of hybridizing to corresponding nucleotides present in the target domain. In another embodiment, 1, 2, 3, 4, 5, 6, 7 or 8 or more modified nucleotides are not complementary to or capable of hybridizing to corresponding nucleotides present in the target domain.
In an embodiment, the targeting domain comprises, preferably in the 5'→3' direction: a secondary domain and a core domain. These domains are discussed in more detail below.
The Core Domain and Secondary Domain of the Targeting Domain
The "core domain" of the targeting domain is complementary to the "core domain target" on the target nucleic acid. In an embodiment, the core domain comprises about 8 to about 13 nucleotides from the 3' end of the targeting domain (e.g., the most 3' 8 to 13 nucleotides of the targeting domain).
In an embodiment, the core domain and targeting domain, are independently, 6 +1-2, 7+/-2, 8+/-2, 9+/-2, 10+/-2, 11+/-2, 12+/-2, 13+/-2, 14+/-2, 15+/-2, or 16+-2, nucleotides in length.
In an embodiment, the core domain and targeting domain, are independently, 10+/-2 nucleotides in length.
In an embodiment, the core domain and targeting domain, are independently, 10+/-4 nucleotides in length.
In an embodiment, the core domain and targeting domain are independently 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotides in length.
In an embodiment, the core domain and targeting domain are independently 3 to 20, 4 to 20, 5 to 20, 6 to 20, 7 to 20, 8 to 20, 9 to 20 10 to 20 or 15 to 20 nucleotides in length. In an embodiment, the core domain and targeting domain are independently 3 to 15, e.g., 6 to 15, 7 to 14, 7 to 13, 6 to 12, 7 to 12, 7 to 11, 7 to 10, 8 to 14, 8 to 13, 8 to 12, 8 to 11, 8 to 10 or 8 to 9 nucleotides in length.
The core domain is complementary with the core domain target. Typically the core domain has exact complementarity with the core domain target. In some embodiments, the core domain can have 1, 2, 3, 4 or 5 nucleotides that are not complementary with the corresponding nucleotide of the core domain. In an embodiment, the degree of
complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
The "secondary domain" of the targeting domain of the gRNA is complementary to the "secondary domain target" of the target nucleic acid.
In an embodiment, the secondary domain is positioned 5 ' to the core domain.
In an embodiment, the secondary domain is absent or optional.
In an embodiment, if the targeting domain is 26 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 12 to 17 nucleotides in length.
In an embodiment, if the targeting domain is 25 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 12 to 17 nucleotides in length.
In an embodiment, if the targeting domain is 24 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 11 to 16 nucleotides in length.
In an embodiment, if the targeting domain is 23 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 10 to 15 nucleotides in length.
In an embodiment, if the targeting domain is 22 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 9 to 14 nucleotides in length.
In an embodiment, if the targeting domain is 21 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 8 to 13 nucleotides in length.
In an embodiment, if the targeting domain is 20 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 7 to 12 nucleotides in length. In an embodiment, if the targeting domain is 19 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 6 to 11 nucleotides in length.
In an embodiment, if the targeting domain is 18 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 5 to 10 nucleotides in length.
In an embodiment, if the targeting domain is 17 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 4 to 9 nucleotides in length.
In an embodiment, if the targeting domain is 16 nucleotides in length and the core domain (counted from the 3' end of the targeting domain) is 8 to 13 nucleotides in length, the secondary domain is 3 to 8 nucleotides in length.
In an embodiment, the secondary domain is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 nucleotides in length.
The secondary domain is complementary with the secondary domain target.
Typically the secondary domain has exact complementarity with the secondary domain target. In some embodiments the secondary domain can have 1, 2, 3, 4 or 5 nucleotides that are not complementary with the corresponding nucleotide of the secondary domain. In an embodiment, the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
In an embodiment, the core domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the core domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the core domain can be modified with a phosphorothioate, or other modification(s) from Section VIII. In an embodiment a nucleotide of the core domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other
modification(s) from Section VIII. Typically, a core domain will contain no more than 1, 2, or 3 modifications.
Modifications in the core domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate core domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described at Section IV. The candidate core domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, the secondary domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the secondary domain comprises one or more modifications, e.g., modifications that render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the secondary domain can be modified with a phosphorothioate, or other modification(s) from Section VIII. In an embodiment a nucleotide of the secondary domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII. Typically, a secondary domain will contain no more than 1, 2, or 3 modifications.
Modifications in the secondary domain can be selected to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate secondary domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described at Section IV. The candidate secondary domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, (1) the degree of complementarity between the core domain and its target, and (2) the degree of complementarity between the secondary domain and its target, may differ. In an embodiment, (1) may be greater than (2). In an embodiment, (1) may be less than (2). In an embodiment, (1) and (2) are the same, e.g., each may be completely complementary with its target.
In an embodiment, (1) the number of modifications (e.g., modifications from Section VIII) of the nucleotides of the core domain and (2) the number of modifications (e.g., modifications from Section VIII) of the nucleotides of the secondary domain may differ. In an embodiment, (1) may be less than (2). In an embodiment, (1) may be greater than (2). In an embodiment, (1) and (2) may be the same, e.g., each may be free of modifications.
The First and Second Complementarity Domains
The first complementarity domain is complementary with the second
complementarity domain.
Typically the first domain does not have exact complementarity with the second complementarity domain target. In some embodiments, the first complementarity domain can have 1, 2, 3, 4 or 5 nucleotides that are not complementary with the corresponding nucleotide of the second complementarity domain. In an embodiment, 1, 2, 3, 4, 5 or 6, e.g., 3 nucleotides, will not pair in the duplex, and, e.g., form a non-duplexed or looped-out region. In an embodiment, an unpaired, or loop-out, region, e.g., a loop-out of 3 nucleotides, is present on the second complementarity domain. In an embodiment, the unpaired region begins 1 , 2, 3, 4, 5, or 6, e.g., 4, nucleotides from the 5 ' end of the second complementarity domain.
In an embodiment, the degree of complementarity, together with other properties of the gRNA, is sufficient to allow targeting of a Cas9 molecule to the target nucleic acid.
In an embodiment, the first and second complementarity domains are:
independently, 6 +1-2, Ί+Ι-2, 8+/-2, 9+/-2, 10+/-2, 11+/-2, 12+/-2, 13+/-2, 14+/-2, 15+/-2, 16+/-2, 17+/-2, 18+/-2, 19+/-2, or 20+/-2, 21+/-2, 22+/-2, 23+/-2, or 24+/-2 nucleotides in length;
independently, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, or 26 nucleotides in length; or
independently, 5 to 24, 5 to 23, 5 to 22, 5 to 21, 5 to 20, 7 to 18, 9 to 16, or 10 to 14 nucleotides in length.
In an embodiment, the second complementarity domain is longer than the first complementarity domain, e.g., 2, 3, 4, 5, or 6, e.g., 6, nucleotides longer.
In an embodiment, the first and second complementary domains, independently, do not comprise modifications, e.g., modifications of the type provided in Section VIII.
In an embodiment, the first and second complementary domains, independently, comprise one or more modifications, e.g., modifications that the render the domain less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the domain can be modified with a phosphorothioate, or other modification(s) from Section VIII. In an embodiment a nucleotide of the domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other
modification(s) from Section VIII.
In an embodiment, the first and second complementary domains, independently, include 1 , 2, 3, 4, 5, 6, 7 or 8 or more modifications. In an embodiment, the first and second complementary domains, independently, include 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end. In an embodiment, the first and second complementary domains, independently, include as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end. In an embodiment, the first and second complementary domains, independently, include modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5 ' end of the domain, within 5 nucleotides of the 3 ' end of the domain, or more than 5 nucleotides away from one or both ends of the domain. In an embodiment, the first and second complementary domains, independently, include no two consecutive nucleotides that are modified, within 5 nucleotides of the 5' end of the domain, within 5 nucleotides of the 3' end of the domain, or within a region that is more than 5 nucleotides away from one or both ends of the domain. In an embodiment, the first and second complementary domains, independently, include no nucleotide that is modified within 5 nucleotides of the 5' end of the domain, within 5 nucleotides of the 3' end of the domain, or within a region that is more than 5 nucleotides away from one or both ends of the domain.
Modifications in a complementarity domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate complementarity domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described in Section IV. The candidate complementarity domain can be placed, either alone, or with one or more other candidate changes in a gRNA
molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, the first complementarity domain has at least 60, 70, 80, 85%, 90% or 95% homology with, or differs by no more than 1, 2, 3, 4, 5, or 6 nucleotides from, a reference first complementarity domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus, first complementarity domain, or a first complementarity domain described herein, e.g., from Figs. 1A-1G.
In an embodiment, the second complementarity domain has at least 60, 70, 80, 85%, 90%, or 95% homology with, or differs by no more than 1, 2, 3, 4, 5, or 6 nucleotides from, a reference second complementarity domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus, second complementarity domain, or a second complementarity domain described herein, e.g., from Figs. 1A-1G.
The duplexed region formed by first and second complementarity domains is typically 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 base pairs in length (excluding any looped out or unpaired nucleotides).
In some embodiments, the first and second complementarity domains, when duplexed, comprise 11 paired nucleotides, for example, in the gRNA sequence (one paired strand underlined, one bolded): NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAA GGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 5).
In some embodiments, the first and second complementarity domains, when duplexed, comprise 15 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAUGCUGAAAAGCAUAGCAAGU UAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC
(SEQ ID NO: 27).
In some embodiments the first and second complementarity domains, when duplexed, comprise 16 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAUGCUGGAAACAGCAUAGCAA GUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGU GC (SEQ ID NO: 28).
In some embodiments the first and second complementarity domains, when duplexed, comprise 21 paired nucleotides, for example in the gRNA sequence (one paired strand underlined, one bolded):
NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAUGCUGUUUUGGAAACAAAAC AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGC (SEQ ID NO: 29).
In some embodiments, nucleotides are exchanged to remove poly-U tracts, for example in the gRNA sequences (exchanged nucleotides underlined):
NNNNNNNNNNNNNNNNNNNNGUAUUAGAGCUAGAAAUAGCAAGUUAAUAUAA GGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 30);
NNNNNNNNNNNNNNNNNNNNGUUUAAGAGCUAGAAAUAGCAAGUUUAAAUAA GGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 31); or
NNNNNNNNNNNNNNNNNNNNGUAUUAGAGCUAUGCUGUAUUGGAAACAAUAC AGCAUAGCAAGUUAAUAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGC (SEQ ID NO: 32). The 5 ' Extension Domain
In an embodiment, a modular gRNA can comprise additional sequence, 5' to the second complementarity domain. In an embodiment, the 5' extension domain is 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, or 2 to 4 nucleotides in length. In an embodiment, the 5' extension domain is 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides in length.
In an embodiment, the 5 ' extension domain nucleotides do not comprise
modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the 5' extension domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the 5' extension domain can be modified with a phosphorothioate, or other modification(s) from Section VIII. In an embodiment, a nucleotide of the 5' extension domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII.
In some embodiments, the 5' extension domain can comprise as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications. In an embodiment, the 5' extension domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end, e.g., in a modular gRNA molecule. In an embodiment, the 5' extension domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end, e.g., in a modular gRNA molecule.
In some embodiments, the 5' extension domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the 5' extension domain, within 5 nucleotides of the 3' end of the 5' extension domain, or more than 5 nucleotides away from one or both ends of the 5' extension domain. In an embodiment, no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the 5' extension domain, within 5 nucleotides of the 3' end of the 5' extension domain, or within a region that is more than 5 nucleotides away from one or both ends of the 5' extension domain. In an embodiment, no nucleotide is modified within 5 nucleotides of the 5 ' end of the 5 ' extension domain, within 5 nucleotides of the 3 ' end of the 5 ' extension domain, or within a region that is more than 5 nucleotides away from one or both ends of the 5' extension domain.
Modifications in the 5 ' extension domain can be selected so as to not interfere with gRNA molecule efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate 5 ' extension domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described at Section IV. The candidate 5 ' extension domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, the 5' extension domain has at least 60, 70, 80, 85, 90 or 95% homology with, or differs by no more than 1, 2, 3, 4, 5, or 6 nucleotides from, a reference 5' extension domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S.
thermophilus, 5' extension domain, or a 5' extension domain described herein, e.g., from Figs. 1A-1G.
The Linking Domain
In a unimolecular gRNA molecule the linking domain is disposed between the first and second complementarity domains. In a modular gRNA molecule, the two molecules are associated with one another by the complementarity domains.
In an embodiment, the linking domain is 10 +/-5, 20+/-5, 30+/-5, 40+/-5, 50+/-5, 60+/-5, 70+/-5, 80+/-5, 90+/-5, or 100+/-5 nucleotides, in length.
In an embodiment, the linking domain is 20+/-10, 30+/-10, 40+/-10, 50+/-10, 60+/-
10, 70+/-10, 80+/-10, 90+/-10, or 100+/- 10 nucleotides, in length.
In an embodiment, the linking domain is 10 to 100, 10 to 90, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 10 to 20 or 10 to 15 nucleotides in length. In other embodiments, the linking domain is 20 to 100, 20 to 90, 20 to 80, 20 to 70, 20 to 60, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides in length.
In an embodiment, the linking domain is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 17, 18, 19, or 20 nucleotides in length.
In and embodiment, the linking domain is a covalent bond.
In an embodiment, the linking domain comprises a duplexed region, typically adjacent to or within 1, 2, or 3 nucleotides of the 3' end of the first complementarity domain and/or the 5- end of the second complementarity domain. In an embodiment, the duplexed region can be 20+/- 10 base pairs in length. In an embodiment, the duplexed region can be 10+/-5, 15+/-5, 20+/-5, or 30+/-5 base pairs in length. In an embodiment, the duplexed region can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 base pairs in length.
Typically the sequences forming the duplexed region have exact complementarity with one another, though in some embodiments as many as 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides are not complementary with the corresponding nucleotides.
In an embodiment, the linking domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the linking domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the linking domain can be modified with a phosphorothioate, or other modification(s) from Section VIII. In an embodiment a nucleotide of the linking domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII. In an embodiment, the linking domain can comprise as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications.
Modifications in a linking domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate linking domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated a system described in Section IV. A candidate linking domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, the linking domain has at least 60, 70, 80, 85, 90 or 95% homology with, or differs by no more than 1, 2, 3, 4, 5 , or 6 nucleotides from, a reference linking domain, e.g., a linking domain described herein, e.g., from Figs. 1A-1G.
The Proximal Domain
In an embodiment, the proximal domain is 6 +1-2, 1+1-2, 8+/-2, 9+/-2, 10+/-2, 11+/-2,
12+/-2, 13+/-2, 14+/-2, 14+/-2, 16+/-2, 17+/-2, 18+/-2, 19+/-2, or 20+/-2 nucleotides in length.
In an embodiment, the proximal domain is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, the proximal domain is 5 to 20, 7, to 18, 9 to 16, or 10 to 14 nucleotides in length.
In an embodiment, the proximal domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the proximal domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the proximal domain can be modified with a phosphorothioate, or other modification(s) from Section VIII. In an embodiment a nucleotide of the proximal domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other modification(s) from Section VIII. In some embodiments, the proximal domain can comprise as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications. In an embodiment, the proximal domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end, e.g., in a modular gRNA molecule. In an embodiment, the target domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end, e.g., in a modular gRNA molecule.
In some embodiments, the proximal domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5 ' end of the proximal domain, within 5 nucleotides of the 3 ' end of the proximal domain, or more than 5 nucleotides away from one or both ends of the proximal domain. In an embodiment, no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the proximal domain, within 5 nucleotides of the 3 ' end of the proximal domain, or within a region that is more than 5 nucleotides away from one or both ends of the proximal domain. In an embodiment, no nucleotide is modified within 5 nucleotides of the 5 ' end of the proximal domain, within 5 nucleotides of the 3' end of the proximal domain, or within a region that is more than 5 nucleotides away from one or both ends of the proximal domain.
Modifications in the proximal domain can be selected to not interfere with gRNA molecule efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate proximal domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described at Section IV. The candidate proximal domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, the proximal domain has at least 60, 70, 80, 85 90 or 95% homology with, or differs by no more than 1, 2, 3, 4, 5 , or 6 nucleotides from, a reference proximal domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S.
thermophilus, proximal domain, or a proximal domain described herein, e.g., from Figs. 1A- 1G.
The Tail Domain
In an embodiment, the tail domain is 10 +/-5, 20+/-5, 30+/-5, 40+/-5, 50+/-5, 60+/-5, 70+/-5, 80+/-5, 90+/-5, or 100+/-5 nucleotides, in length.
In an embodiment, the tail domain is 20+/-5 nucleotides in length.
In an embodiment, the tail domain is 20+/-10, 30+/-10, 40+/-10, 50+/-10, 60+/-10, 70+/- 10, 80+/- 10, 90+/- 10, or 100+/- 10 nucleotides, in length. In an embodiment, the tail domain is 25+/- 10 nucleotides in length.
In an embodiment, the tail domain is 10 to 100, 10 to 90, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 10 to 20 or 10 to 15 nucleotides in length.
In other embodiments, the tail domain is 20 to 100, 20 to 90, 20 to 80, 20 to 70, 20 to 60, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides in length.
In an embodiment, the tail domain is 1 to 20, 1 to 15, 1 to 10, or 1 to 5 nucleotides in length.
In an embodiment, the tail domain nucleotides do not comprise modifications, e.g., modifications of the type provided in Section VIII. However, in an embodiment, the tail domain comprises one or more modifications, e.g., modifications that it render it less susceptible to degradation or more bio-compatible, e.g., less immunogenic. By way of example, the backbone of the tail domain can be modified with a phosphorothioate, or other modification(s) from Section VIII. In an embodiment a nucleotide of the tail domain can comprise a 2' modification, e.g., a 2-acetylation, e.g., a 2' methylation, or other
modification(s) from Section VIII.
In some embodiments, the tail domain can have as many as 1, 2, 3, 4, 5, 6, 7 or 8 modifications. In an embodiment, the target domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 5' end. In an embodiment, the target domain comprises as many as 1, 2, 3, or 4 modifications within 5 nucleotides of its 3' end.
In an embodiment, the tail domain comprises a tail duplex domain, which can form a tail duplexed region. In an embodiment, the tail duplexed region can be 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 base pairs in length. In an embodiment, a further single stranded domain, exists 3' to the tail duplexed domain. In an embodiment, this domain is 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In an embodiment it is 4 to 6 nucleotides in length.
In an embodiment, the tail domain has at least 60, 70, 80, or 90% homology with, or differs by no more than 1, 2, 3, 4, 5 ,or 6 nucleotides from, a reference tail domain, e.g., a naturally occurring, e.g., an S. pyogenes, S. aureus or S. thermophilus, tail domain, or a tail domain described herein, e.g., from Figs. 1A-1G.
In an embodiment, the proximal and tail domain, taken together comprise the following sequences:
AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU (SEQ ID NO: 33), or
AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC (SEQ ID NO: 34), or AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCGGAUC (SEQ ID NO: 35), or
AAGGCUAGUCCGUUAUCAACUUGAAAAAGUG (SEQ ID NO: 36), or
AAGGCUAGUCCGUUAUCA (SEQ ID NO: 37), or
AAGGCUAGUCCG (SEQ ID NO: 38).
In an embodiment, the tail domain comprises the 3' sequence UUUUUU, e.g., if a U6 promoter is used for transcription.
In an embodiment, the tail domain comprises the 3' sequence UUUU, e.g., if an HI promoter is used for transcription.
In an embodiment, tail domain comprises variable numbers of 3' Us depending, e.g., on the termination signal of the pol-III promoter used.
In an embodiment, the tail domain comprises variable 3 ' sequence derived from the DNA template if a T7 promoter is used.
In an embodiment, the tail domain comprises variable 3' sequence derived from the
DNA template, e.g., if in vitro transcription is used to generate the RNA molecule.
In an embodiment, the tail domain comprises variable 3 ' sequence derived from the DNA template, e., if a pol-II promoter is used to drive transcription.
Modifications in the tail domain can be selected so as to not interfere with targeting efficacy, which can be evaluated by testing a candidate modification in the system described in Section IV. gRNAs having a candidate tail domain having a selected length, sequence, degree of complementarity, or degree of modification, can be evaluated in the system described in Section IV. The candidate tail domain can be placed, either alone, or with one or more other candidate changes in a gRNA molecule/Cas9 molecule system known to be functional with a selected target and evaluated.
In an embodiment, the tail domain comprises modifications at two consecutive nucleotides, e.g., two consecutive nucleotides that are within 5 nucleotides of the 5' end of the tail domain, within 5 nucleotides of the 3' end of the tail domain, or more than 5 nucleotides away from one or both ends of the tail domain. In an embodiment, no two consecutive nucleotides are modified within 5 nucleotides of the 5' end of the tail domain, within 5 nucleotides of the 3' end of the tail domain, or within a region that is more than 5 nucleotides away from one or both ends of the tail domain. In an embodiment, no nucleotide is modified within 5 nucleotides of the 5 ' end of the tail domain, within 5 nucleotides of the 3' end of the tail domain, or within a region that is more than 5 nucleotides away from one or both ends of the tail domain.
In an embodiment a gRNA has the following structure:
5' [targeting domain] -[first complementarity domain] -[linking domain] -[second complementarity domain] -[proximal domain]-[tail domain]-3'
wherein, the targeting domain comprises a core domain and optionally a secondary domain, and is 10 to 50 nucleotides in length;
the first complementarity domain is 5 to 25 nucleotides in length and, In an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference first complementarity domain disclosed herein;
the linking domain is 1 to 5 nucleotides in length;
the second complementarity domain is 5 to 27 nucleotides in length and, in an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference second complementarity domain disclosed herein;
the proximal domain is 5 to 20 nucleotides in length and, in an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference proximal domain disclosed herein; and
the tail domain is absent or a nucleotide sequence is 1 to 50 nucleotides in length and, in an embodiment has at least 50, 60, 70, 80, 85, 90 or 95% homology with a reference tail domain disclosed herein.
Exemplary Chimeric gRNAs
In an embodiment, a unimolecular, or chimeric, gRNA comprises, preferably from 5' to 3':
a targeting domain (which is complementary to a target nucleic acid);
a first complementarity domain, e.g., comprising 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, or 26 nucleotides;
a linking domain;
a second complementarity domain (which is complementary to the first complementarity domain);
a proximal domain; and
a tail domain,
wherein,
(a) the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides;
(b) there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain; or
(c) there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the sequence from (a), (b), or (c), has at least 60, 75, 80, 85, 90, 95, or 99% homology with the corresponding sequence of a naturally occurring gRNA, or with a gRNA described herein.
In an embodiment, the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3 ' to the last nucleotide of the second complementarity domain.
In an embodiment, there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3 ' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides
(e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length. In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides
(e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and the proximal and tail domain, when taken together, comprise at leastl5, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides
(e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides
(e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain. In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the unimolecular, or chimeric, gRNA molecule (comprising a targeting domain, a first complementary domain, a linking domain, a second complementary domain, a proximal domain and, optionally, a tail domain) comprises the following sequence in which the targeting domain is depicted as 20 Ns but could be any sequence and range in length from 16 to 26 nucleotides and in which the gRNA sequence is followed by 6 Us, which serve as a termination signal for the U6 promoter, but which could be either absent or fewer in number:
NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAA AUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU UU (SEQ ID NO: 45). In an embodiment, the unimolecular, or chimeric, gRNA molecule is a S. pyogenes gRNA molecule.
In some embodiments, the unimolecular, or chimeric, gRNA molecule (comprising a targeting domain, a first complementary domain, a linking domain, a second complementary domain, a proximal domain and, optionally, a tail domain) comprises the following sequence in which the targeting domain is depicted as 20 Ns but could be any sequence and range in length from 16 to 26 nucleotides and in which the gRNA sequence is followed by 6 Us, which serve as a termination signal for the U6 promoter, but which could be either absent or fewer in number:
NNNNNNNNNNNNNNNNNNNNGUUUUAGUACUCUGGAAACAGAAUCUAC UAAAACAAGGCAAAAUGCCGUGUUUAUCUCGUCAACUUGUUGGCGAGAUUUU UU (SEQ ID NO: 40). In an embodiment, the unimolecular, or chimeric, gRNA molecule is a S. aureus gRNA molecule.
Exemplary Modular gRNAs
In an embodiment, a modular gRNA comprises:
a first strand comprising, preferably from 5' to 3' ;
a targeting domain, e.g., comprising 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides;
a first complementarity domain; and
a second strand, comprising, preferably from 5 ' to 3 ' :
optionally a 5' extension domain;
a second complementarity domain;
a proximal domain; and
a tail domain,
wherein:
(a) the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides;
(b) there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain; or
(c) there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the sequence from (a), (b), or (c), has at least 60, 75, 80, 85, 90, 95, or 99% homology with the corresponding sequence of a naturally occurring gRNA, or with a gRNA described herein.
In an embodiment, the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3 ' to the last nucleotide of the second complementarity domain. In an embodiment, there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3 ' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides
(e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length. In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 16 nucleotides (e.g., 16 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 16 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 17 nucleotides (e.g., 17 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 17 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 18 nucleotides (e.g., 18 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 18 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 19 nucleotides (e.g., 19 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 19 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 20 nucleotides (e.g., 20 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 20 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 21 nucleotides (e.g., 21 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 21 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 22 nucleotides (e.g., 22 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 22 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides
(e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 23 nucleotides (e.g., 23 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 23 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides
(e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain. In an embodiment, the targeting domain comprises, has, or consists of, 24 nucleotides (e.g., 24 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 24 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 25 nucleotides (e.g., 25 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 25 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and there are at least 15, 18, 20, 25, 30, 31, 35,
40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain.
In an embodiment, the targeting domain comprises, has, or consists of, 26 nucleotides (e.g., 26 consecutive nucleotides) having complementarity with the target domain, e.g., the targeting domain is 26 nucleotides in length; and there are at least 16, 19, 21, 26, 31, 32, 36,
41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain.
II. Methods for Designing gRNAs
Methods for designing gRNAs are described herein, including methods for selecting, designing and validating target domains. Exemplary targeting domains are also provided herein. Targeting Domains discussed herein can be incorporated into the gRNAs described herein.
Methods for selection and validation of target sequences as well as off-target analyses are described, e.g., in Mali et al., 2013 SCIENCE 339(6121): 823-826; Hsu et al. NAT
BIOTECHNOL, 31(9): 827-32; Fu et al., 2014 NAT BIOTECHNOL, doi: 10.1038/nbt.2808.
PubMed PMID: 24463574; Heigwer et al., 2014 NAT METHODS 11(2): 122-3. doi:
10.1038/nmeth.2812. PubMed PMID: 24481216; Bae et al., 2014 BIOTNFORMATICS PubMed PMID: 24463181; Xiao A et al., 2014 BIOINFORMATICS PubMed PMID: 24389662.
For example, a software tool can be used to optimize the choice of gRNA within a user's target sequence, e.g., to minimize total off-target activity across the genome. Off target activity may be other than cleavage. For each possible gRNA choice using S. pyogenes Cas9, the tool can identify all off-target sequences (preceding either NAG or NGG PAMs) across the genome that contain up to certain number (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of mismatched base-pairs. The cleavage efficiency at each off-target sequence can be predicted, e.g., using an experimentally-derived weighting scheme. Each possible gRNA is then ranked according to its total predicted off-target cleavage; the top-ranked gRNAs represent those that are likely to have the greatest on-target and the least off-target cleavage. Other functions, e.g., automated reagent design for CRISPR construction, primer design for the on-target Surveyor assay, and primer design for high-throughput detection and quantification of off- target cleavage via next-gen sequencing, can also be included in the tool. Candidate gRNA molecules can be evaluated by art-known methods or as described in Section IV herein.
The Targeting Domains discussed herein can be incorporated into the gRNAs described herein.
Strategies to identify gRNAs for S. pyogenes, S. aureus, and N. meningitidis to knock out the UL19 gene
As an example, three strategies were utilized to identify gRNAs for use with S.
pyogenes, S. aureus and N. meningitidis Cas9 enzymes. In the first strategy, guide RNAs (gRNAs) for use with the S. pyogenes (Tables 1A- 1C) Cas9 were identified using the publically available web-based ZiFiT server (Fu et al., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014 Jan 26. doi: 10.1038/nbt.2808. PubMed PMID: 24463574, for the original references see Sander et al., 2007, NAR 35:W599-605; Sander et al., 2010, NAR 38: W462-8). In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available Repeat-Masker program. RepeatMmasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence. Following identification, gRNAs for use with a S. pyogenes Cas9 were ranked into 3 tiers.
The gRNAs in tier 1 were selected based on their distance to the target site and their orthogonality in the genome (based on the ZiFiT identification of close matches in the human genome containing an NGG PAM). As an example, for all targets, both 17-mer and 20-mer gRNAs were designed. gRNAs were also selected both for single-gRNA nuclease cutting and for the dual gRNA nickase strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for which strategy is based on several considerations:
1. For the dual nickase strategy, gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, it will also often result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus just causing indel mutations at the site of one gRNA.
While it can be desirable to have gRNAs start with a 5 ' G, this requirement was relaxed for some gRNAs in tier 1 in order to identify guides in the correct orientation, within a reasonable distance to the target position (i.e., within the first 500 bp of the coding sequence) and with a high level of orthogonality against the human genome. In order to find a pair for the dual-nickase strategy it was necessary to either extend the distance from the target position or remove the requirement for the 5'G. Tier 2 gRNAs were selected based on loction within the first 500 bp of the coding sequence in the HSV gene. Tier 3 gRNAs were selected based on their location in the coding sequence, but downstream of the first 500 bp of the HSV gene. Note that tiers are non-inclusive (each gRNA is listed only once). In certain instances, no gRNA was identified based on the criteria of the particular tier.
As discussed above, gRNAs were identified for single-gRNA nuclease cleavage as well as for a dual-gRNA paired "nickase" strategy, as indicated.
gRNAs for use with the N. meningitidis (Tables 1F-1G) and S. aureus (Tables 1D- 1E) Cas9s were identified manually by scanning genomic DNA sequence for the presence of PAM sequences. These gRNAs were separated into two tiers for each species. The first tier includes gRNAs selected based on location in the first 500 bp of the coding sequence of the HSV gene. The second tier includes gRNAs selected based on location in the coding sequence, but downstream of the first 500 bp of the HSV gene.
In a second strategy, Guide RNAs (gRNAs) for use with S. pyogenes, S. aureus and N. meningitidis Cas9s were identified using a DNA sequence searching algorithm. Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas-offinder (reference:Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID: 24463181). Said custom guide RNA design software scores guides after calculating their genomewide off-target propensity. Typically matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24. Once the off-target sites are computationally determined, an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface. In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available
RepeatMasker program. RepeatMasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
Following identification, gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of 5". aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM). Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence. A "high level of orthogonality" or "good orthogonality" may, for example, refer to
20- mer gRNAs that have no identical sequences in the human genome besides the intended target, nor any sequences that contain one or two mismatches in the target sequence.
Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
As an example, for S. pyogenes and N. meningitidis targets, 17-mer, or 20-mer gRNAs were designed. As another example, for S. aureus targets, 18-mer, 19-mer, 20-mer,
21- mer, 22-mer, 23-mer and 24-mer gRNAs were designed. Targeting domains, disclosed herein, may comprise the 17-mer described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C. Targeting domains, disclosed herein, may comprises the 18-mer described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C. Targeting domains, disclosed herein, may comprises the 19-mer described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C. Targeting domains, disclosed herein, may comprises the 20-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C. Targeting domains, disclosed herein, may comprises the 21-mer described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C. Targeting domains, disclosed herein, may comprises the
22- mer described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 5A-5E, 6A-6G or
7A-7C. Targeting domains, disclosed herein, may comprises the 23-mer described in Tables 5A-5E, 6A-6G or 7A-7C,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C. Targeting domains, disclosed herein, may comprises the 24-mer described in Tables 5A-5E, 6A-6G or 7A-7C, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 5A-5E, 6A-6G or 7A-7C. gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for the dual-gRNA paired "nickase" strategy is based on two considerations: 1. gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, cleaving with dual nickase pairs can also result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus causing indel mutations at the site of one gRNA.
The targeting domains discussed herein can be incorporated into the gRNAs described herein.
gRNAs were identified and ranked into 5 tiers for S. pyogenes (Tables 5A-5E), and
N. meningitidis (Tables 7A-7C); and 7 tiers for S. aureus (Tables 6A-6G). For S. pyogenes, and N. meningitidis, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality and (3) the presence of 5'G. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) a high level of orthogonality. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) the presence of 5'G. The targeting domain for tier 4 gRNA molecules were selected based on distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon). The targeting domain for tier 5 gRNA molecules were selected based on distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon). For S. aureus, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, and (3) PAM is
NNGRRT. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRT. The targeting domain for tier 4 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRV. The targeting domain for tier 5 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon), (2) the presence of 5'G and (3) PAM is NNGRRT. The targeting domain for tier 6 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRT. The targeting domain for tier 7 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRV. Note that tiers are non- inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier.
Strategies to identify gRNAs for S. pyogenes, S. Aureus, and N. meningitidis to knock out the UL30 gene
As an example, three strategies were utilized to identify gRNAs for use with S.
pyogenes, S. aureus and N. meningitidis Cas9 enzymes.
In the first strategy, guide RNAs (gRNAs) for use with the S. pyogenes (Tables 2A-
2C) Cas9 were identified using the publically available web-based ZiFiT server (Fu et al., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014 Jan 26. doi: 10.1038/nbt.2808. PubMed PMID: 24463574, for the original references see Sander et al., 2007, NAR 35:W599-605; Sander et al., 2010, NAR 38: W462-8). In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available Repeat-Masker program. RepeatMmasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence. Following identification, gRNAs for use with a S. pyogenes Cas9 were ranked into 3 tiers.
The gRNAs in tier 1 were selected based on their distance to the target site and their orthogonality in the genome (based on the ZiFiT identification of close matches in the human genome containing an NGG PAM). As an example, for all targets, both 17-mer and 20-mer gRNAs were designed. gRNAs were also selected both for single-gRNA nuclease cutting and for the dual gRNA nickase strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for which strategy is based on several considerations:
1. For the dual nickase strategy, gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, it will also often result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus just causing indel mutations at the site of one gRNA.
While it can be desirable to have gRNAs start with a 5 ' G, this requirement was relaxed for some gRNAs in tier 1 in order to identify guides in the correct orientation, within a reasonable distance to the target position (i.e., within the first 500 bp of the coding sequence) and with a high level of orthogonality against the human genome. In order to find a pair for the dual-nickase strategy it was necessary to either extend the distance from the target position or remove the requirement for the 5'G. Tier 2 gRNAs were selected based on loction within the first 500 bp of the coding sequence in the HSV gene. Tier 3 gRNAs were selected based on their location in the coding sequence, but downstream of the first 500 bp of the HSV gene. Note that tiers are non-inclusive (each gRNA is listed only once). In certain instances, no gRNA was identified based on the criteria of the particular tier.
As discussed above, gRNAs were identified for single-gRNA nuclease cleavage as well as for a dual-gRNA paired "nickase" strategy, as indicated.
gRNAs for use with the N. meningitidis (Tables 2F) and S. aureus (Tables 2D-2E)
Cas9s were identified manually by scanning genomic DNA sequence for the presence of PAM sequences. These gRNAs were separated into two tiers for each species. The first tier includes gRNAs selected based on location in the first 500 bp of the coding sequence of the HSV gene. The second tier includes gRNAs selected based on location in the coding sequence, but downstream of the first 500 bp of the HSV gene.
In a second strategy, Guide RNAs (gRNAs) for use with S. pyogenes, S. aureus and N. meningitidis Cas9s were identified using a DNA sequence searching algorithm. Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas-offinder (reference:Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID: 24463181). Said custom guide RNA design software scores guides after calculating their genomewide off-target propensity. Typically matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24. Once the off-target sites are computationally determined, an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface. In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available
RepeatMasker program. RepeatMasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
Following identification, gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of 5". aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM). Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence. A "high level of orthogonality" or "good orthogonality" may, for example, refer to
20- mer gRNAs that have no identical sequences in the human genome besides the intended target, nor any sequences that contain one or two mismatches in the target sequence.
Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
As an example, for S. pyogenes and N. meningitidis targets, 17-mer, or 20-mer gRNAs were designed. As another example, for S. aureus targets, 18-mer, 19-mer, 20-mer,
21- mer, 22-mer, 23-mer and 24-mer gRNAs were designed. Targeting domains, disclosed herein, may comprise the 17-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D. Targeting domains, disclosed herein, may comprises the 18-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D. Targeting domains, disclosed herein, may comprises the 19-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D. Targeting domains, disclosed herein, may comprises the 20-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D. Targeting domains, disclosed herein, may comprises the 21-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D. Targeting domains, disclosed herein, may comprises the 22-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables
8A-8E, 9A-9G or 10A-10D. Targeting domains, disclosed herein, may comprises the 23-mer described in Tables 8A-8E, 9A-9G or 10A-10D,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A- 10D. Targeting domains, disclosed herein, may comprises the 24-mer described in Tables 8A-8E, 9A-9G or 10A-10D, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 8A-8E, 9A-9G or 10A-10D. gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for the dual-gRNA paired "nickase" strategy is based on two considerations:
1. gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, cleaving with dual nickase pairs can also result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus causing indel mutations at the site of one gRNA.
The targeting domains discussed herein can be incorporated into the gRNAs described herein.
gRNAs were identified and ranked into 5 tiers for S. pyogenes (Tables 8A-8E), and N. meningitidis (Tables 10A-10D); and 7 tiers for 5". aureus (Tables 9A-9G). For 5".
pyogenes, and N. meningitidis, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality and (3) the presence of 5'G. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) a high level of orthogonality. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) the presence of 5'G. The targeting domain for tier 4 gRNA molecules were selected based on distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon). The targeting domain for tier 5 gRNA molecules were selected based on distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon). For S. aureus, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, and (3) PAM is
NNGRRT. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRT. The targeting domain for tier 4 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRV. The targeting domain for tier 5 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon), (2) the presence of 5'G and (3) PAM is NNGRRT. The targeting domain for tier 6 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRT. The targeting domain for tier 7 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRV. Note that tiers are non- inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier. Strategies to identify gRNAs for S. pyogenes, S. aureus, and N. meningitidis to knock out the UL48 gene
As an example, three strategies were utilized to identify gRNAs for use with S.
pyogenes, S. aureus and N. meningitidis Cas9 enzymes.
In the first strategy, guide RNAs (gRNAs) for use with the S. pyogenes (Tables 3A-
3C) Cas9 were identified using the publically available web-based ZiFiT server (Fu et al., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014 Jan 26. doi: 10.1038/nbt.2808. PubMed PMID: 24463574, for the original references see Sander et al., 2007, NAR 35:W599-605; Sander et al., 2010, NAR 38: W462-8). In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available Repeat-Masker program. RepeatMmasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence. Following identification, gRNAs for use with a S. pyogenes Cas9 were ranked into 3 tiers.
The gRNAs in tier 1 were selected based on their distance to the target site and their orthogonality in the genome (based on the ZiFiT identification of close matches in the human genome containing an NGG PAM). As an example, for all targets, both 17-mer and 20-mer gRNAs were designed. gRNAs were also selected both for single-gRNA nuclease cutting and for the dual gRNA nickase strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for which strategy is based on several considerations:
1. For the dual nickase strategy, gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, it will also often result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus just causing indel mutations at the site of one gRNA.
While it can be desirable to have gRNAs start with a 5 ' G, this requirement was relaxed for some gRNAs in tier 1 in order to identify guides in the correct orientation, within a reasonable distance to the target position (i.e., within the first 500 bp of the coding sequence) and with a high level of orthogonality against the human genome. In order to find a pair for the dual-nickase strategy it was necessary to either extend the distance from the target position or remove the requirement for the 5'G. Tier 2 gRNAs were selected based on loction within the first 500 bp of the coding sequence in the HSV gene. Tier 3 gRNAs were selected based on their location in the coding sequence, but downstream of the first 500 bp of the HSV gene. Note that tiers are non-inclusive (each gRNA is listed only once). In certain instances, no gRNA was identified based on the criteria of the particular tier.
As discussed above, gRNAs were identified for single-gRNA nuclease cleavage as well as for a dual-gRNA paired "nickase" strategy, as indicated.
gRNAs for use with the N. meningitidis (Tables 3F) and S. aureus (Tables 3D-3E) Cas9s were identified manually by scanning genomic DNA sequence for the presence of PAM sequences. These gRNAs were separated into two tiers for each species. The first tier includes gRNAs selected based on location in the first 500 bp of the coding sequence of the HSV gene. The second tier includes gRNAs selected based on location in the coding sequence, but downstream of the first 500 bp of the HSV gene.
In a second strategy, Guide RNAs (gRNAs) for use with S. pyogenes, S. aureus and N. meningitidis Cas9s were identified using a DNA sequence searching algorithm. Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas-offinder (reference:Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID: 24463181). Said custom guide RNA design software scores guides after calculating their genomewide off-target propensity. Typically matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24. Once the off-target sites are computationally determined, an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface. In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available
RepeatMasker program. RepeatMasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence. Following identification, gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of 5". aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM). Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence. A "high level of orthogonality" or "good orthogonality" may, for example, refer to
20- mer gRNAs that have no identical sequences in the human genome besides the intended target, nor any sequences that contain one or two mismatches in the target sequence.
Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
As an example, for S. pyogenes and N. meningitidis targets, 17-mer, or 20-mer gRNAs were designed. As another example, for S. aureus targets, 18-mer, 19-mer, 20-mer,
21- mer, 22-mer, 23-mer and 24-mer gRNAs were designed. Targeting domains, disclosed herein, may comprise the 17-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B. Targeting domains, disclosed herein, may comprises the 18-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B. Targeting domains, disclosed herein, may comprises the 19-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B. Targeting domains, disclosed herein, may comprises the 20-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B. Targeting domains, disclosed herein, may comprises the 21-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B. Targeting domains, disclosed herein, may comprises the 22-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B. Targeting domains, disclosed herein, may comprises the 23-mer described in Tables 11A-11E, 12A-12G or 13A-13B,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B. Targeting domains, disclosed herein, may comprises the 24-mer described in Tables 11A-11E, 12A-12G or 13A-13B, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 11A-11E, 12A-12G or 13A-13B. gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria for selecting gRNAs and the
determination for which gRNAs can be used for the dual-gRNA paired "nickase" strategy is based on two considerations:
1. gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, cleaving with dual nickase pairs can also result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus causing indel mutations at the site of one gRNA.
The targeting domains discussed herein can be incorporated into the gRNAs described herein. gRNAs were identified and ranked into 5 tiers for S. pyogenes (Tables 11A-11E), and N. meningitidis (Tables 13A-13B); and 7 tiers for S. aureus (Tables 12A-12G). For S.
pyogenes, and N. meningitidis, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality and (3) the presence of 5'G. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) a high level of orthogonality. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) the presence of 5'G. The targeting domain for tier 4 gRNA molecules were selected based on distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon). The targeting domain for tier 5 gRNA molecules were selected based on distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon). For S. aureus, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, and (3) PAM is NNGRRT. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRT. The targeting domain for tier 4 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRV. The targeting domain for tier 5 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon), (2) the presence of 5'G and (3) PAM is NNGRRT. The targeting domain for tier 6 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRT. The targeting domain for tier 7 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRV. Note that tiers are non- inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier.
Strategies to identify gRNAs for S. pyogenes, S. aureus, and N. meningitidis to knock out the UL54 gene
As an example, three strategies were utilized to identify gRNAs for use with S. pyogenes, S. aureus and N. meningitidis Cas9 enzymes.
In the first strategy, guide RNAs (gRNAs) for use with the S. pyogenes (Tables 4A- 4C) Cas9 were identified using the publically available web-based ZiFiT server (Fu et al., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014 Jan 26. doi: 10.1038/nbt.2808. PubMed PMID: 24463574, for the original references see Sander et al., 2007, NAR 35:W599-605; Sander et al., 2010, NAR 38: W462-8). In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available Repeat-Masker program. RepeatMmasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence. Following identification, gRNAs for use with a S. pyogenes Cas9 were ranked into 3 tiers.
The gRNAs in tier 1 were selected based on their distance to the target site and their orthogonality in the genome (based on the ZiFiT identification of close matches in the human genome containing an NGG PAM). As an example, for all targets, both 17-mer and 20-mer gRNAs were designed. gRNAs were also selected both for single-gRNA nuclease cutting and for the dual gRNA nickase strategy. Criteria for selecting gRNAs and the determination for which gRNAs can be used for which strategy is based on several considerations:
1. For the dual nickase strategy, gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, it will also often result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus just causing indel mutations at the site of one gRNA.
While it can be desirable to have gRNAs start with a 5 ' G, this requirement was relaxed for some gRNAs in tier 1 in order to identify guides in the correct orientation, within a reasonable distance to the target position (i.e., within the first 500 bp of the coding sequence) and with a high level of orthogonality against the human genome. In order to find a pair for the dual-nickase strategy it was necessary to either extend the distance from the target position or remove the requirement for the 5'G. Tier 2 gRNAs were selected based on loction within the first 500 bp of the coding sequence in the HSV gene. Tier 3 gRNAs were selected based on their location in the coding sequence, but downstream of the first 500 bp of the HSV gene. Note that tiers are non-inclusive (each gRNA is listed only once). In certain instances, no gRNA was identified based on the criteria of the particular tier.
As discussed above, gRNAs were identified for single-gRNA nuclease cleavage as well as for a dual-gRNA paired "nickase" strategy, as indicated.
gRNAs for use with the N. meningitidis (Tables 4F-4G) and S. aureus (Tables 4D- 4E) Cas9s were identified manually by scanning genomic DNA sequence for the presence of PAM sequences. These gRNAs were separated into two tiers for each species. The first tier includes gRNAs selected based on location in the first 500 bp of the coding sequence of the HSV gene. The second tier includes gRNAs selected based on location in the coding sequence, but downstream of the first 500 bp of the HSV gene.
In a second strategy, Guide RNAs (gRNAs) for use with S. pyogenes, S. aureus and
N. meningitidis Cas9s were identified using a DNA sequence searching algorithm. Guide RNA design was carried out using a custom guide RNA design software based on the public tool cas-offinder (reference:Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases., Bioinformatics. 2014 Feb 17. Bae S, Park J, Kim JS. PMID: 24463181). Said custom guide RNA design software scores guides after calculating their genomewide off-target propensity. Typically matches ranging from perfect matches to 7 mismatches are considered for guides ranging in length from 17 to 24. Once the off-target sites are computationally determined, an aggregate score is calculated for each guide and summarized in a tabular output using a web-interface. In addition to identifying potential gRNA sites adjacent to PAM sequences, the software also identifies all PAM adjacent sequences that differ by 1, 2, 3 or more nucleotides from the selected gRNA sites. Genomic DNA sequence for each gene was obtained from the UCSC Genome browser and sequences were screened for repeat elements using the publically available
RepeatMasker program. RepeatMasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
Following identification, gRNAs were ranked into tiers based on their distance to the target site, their orthogonality and presence of a 5' G (based on identification of close matches in the human genome containing a relavant PAM (e.g., in the case of S. pyogenes, a NGG PAM, in the case of 5". aureus, a NNGRRT or NNGRRV PAM, and in the case of N. meningitidis, a NNNNGATT or NNNNGCTT PAM). Orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence. A "high level of orthogonality" or "good orthogonality" may, for example, refer to 20-mer gRNAs that have no identical sequences in the human genome besides the intended target, nor any sequences that contain one or two mismatches in the target sequence.
Targeting domains with good orthogonality are selected to minimize off-target DNA cleavage.
As an example, for S. pyogenes and N. meningitidis targets, 17-mer, or 20-mer gRNAs were designed. As another example, for S. aureus targets, 18-mer, 19-mer, 20-mer, 21-mer, 22-mer, 23-mer and 24-mer gRNAs were designed. Targeting domains, disclosed herein, may comprise the 17-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 18 or more nucleotides may comprise the 17-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C. Targeting domains, disclosed herein, may comprises the 18-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 19 or more nucleotides may comprise the 18-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C. Targeting domains, disclosed herein, may comprises the 19-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 20 or more nucleotides may comprise the 19-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C. Targeting domains, disclosed herein, may comprises the 20-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 21 or more nucleotides may comprise the 20-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C. Targeting domains, disclosed herein, may comprises the 21-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 22 or more nucleotides may comprise the 21-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C. Targeting domains, disclosed herein, may comprises the 22-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 23 or more nucleotides may comprise the 22-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C. Targeting domains, disclosed herein, may comprises the 23-mer described in Tables 14A-14E, 15A-15G or 16A-16C,e.g., the targeting domains of 24 or more nucleotides may comprise the 23-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C. Targeting domains, disclosed herein, may comprises the 24-mer described in Tables 14A-14E, 15A-15G or 16A-16C, e.g., the targeting domains of 25 or more nucleotides may comprise the 24-mer gRNAs described in Tables 14A-14E, 15A-15G or 16A-16C. gRNAs were identified for both single-gRNA nuclease cleavage and for a dual-gRNA paired "nickase" strategy. Criteria for selecting gRNAs and the
determination for which gRNAs can be used for the dual-gRNA paired "nickase" strategy is based on two considerations:
1. gRNA pairs should be oriented on the DNA such that PAMs are facing out and cutting with the D10A Cas9 nickase will result in 5' overhangs.
2. An assumption that cleaving with dual nickase pairs will result in deletion of the entire intervening sequence at a reasonable frequency. However, cleaving with dual nickase pairs can also result in indel mutations at the site of only one of the gRNAs. Candidate pair members can be tested for how efficiently they remove the entire sequence versus causing indel mutations at the site of one gRNA.
The targeting domains discussed herein can be incorporated into the gRNAs described herein.
gRNAs were identified and ranked into 5 tiers for S. pyogenes (Tables 14A-14E), and
N. meningitidis (Tables 16A-16C); and 7 tiers for S. aureus (Tables 15A-15G). For S.
pyogenes, and N. meningitidis, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality and (3) the presence of 5'G. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) a high level of orthogonality. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) the presence of 5'G. The targeting domain for tier 4 gRNA molecules were selected based on distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon). The targeting domain for tier 5 gRNA molecules were selected based on distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon). For S. aureus, the targeting domain for tier 1 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, (3) the presence of 5'G and (4) PAM is NNGRRT. The targeting domain for tier 2 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon), (2) a high level of orthogonality, and (3) PAM is
NNGRRT. The targeting domain for tier 3 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRT. The targeting domain for tier 4 gRNA molecules were selected based on (1) distance to a target site (e.g., start codon), e.g., within 500bp (e.g., downstream) of the target site (e.g., start codon) and (2) PAM is NNGRRV. The targeting domain for tier 5 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon), (2) the presence of 5'G and (3) PAM is NNGRRT. The targeting domain for tier 6 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRT. The targeting domain for tier 7 gRNA molecules were selected based on (1) distance to the target site (e.g., start codon), e.g., within reminder of the coding sequence, e.g., downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon) and (2) PAM is NNGRRV. Note that tiers are non- inclusive (each gRNA is listed only once for the strategy). In certain instances, no gRNA was identified based on the criteria of the particular tier.
In an embodiment, two or more (e.g., three or four) gRNA molecules are used with one Cas9 molecule. In another embodiment, when two or more (e.g., three or four) gRNAs are used with two or more Cas9 molecules, at least one Cas9 molecule is from a different species than the other Cas9 molecule(s). For example, when two gRNA molecules are used with two Cas9 molecules, one Cas9 molecule can be from one species and the other Cas9 molecule can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
Any of the targeting domains in the tables described herein can be used with a Cas9 nickase molecule to generate a single strand break.
Any of the targeting domains in the tables described herein can be used with a Cas9 nuclease molecule to generate a double strand break.
When two gRNAs designed for use to target two Cas9 molecules, one Cas9 can be one species, the second Cas9 can be from a different species. Both Cas9 species are used to generate a single or double-strand break, as desired.
It is contemplated herein that any upstream gRNA described herein may be paired with any downstream gRNA described herein. When an upstream gRNA designed for use with one species of Cas9 is paired with a downstream gRNA designed for use from a different species of Cas9, both Cas9 species are used to generate a single or double-strand break, as desired. Exemplary Targeting Domains
Table 1A provides exemplary targeting domains for knocking out the UL19 gene selected according to first tier parameters. The targeting domains are selected based on location within the first 500bp of the coding sequence of the UL19 gene and orthogonality against the human genome. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 1A
Figure imgf000102_0001
HSV2-UL19-106 - CCUGAGUACGAUCGAGG 17 415
HSV2-UL19-107 - AGAGUUUGACGCCCUGC 17 416
HSV2-UL19-108 - GAGUUUGACGCCCUGCU 17 417
HSV2-UL19-110 - GUCGCUCGUGCGCUUUC 17 418
HSV2-UL19-111 - GUGCGCUUUCUGGAGCU 17 419
HSV2-UL19-113 - CG U G U G CACCAAG U U CC 17 420
HSV2-UL19-114 - CACCAAGUUCCCGGAGC 17 421
HSV2-UL19-116 - UGGCUUACAUGAACGAA 17 422
HSV2-UL19-119 - GCAUAAUUACAUGACGA 17 423
HSV2-UL19-120 - CGAAGGUCAUCGACCGC 17 424
HSV2-UL19-121 - GAAGGUCAUCGACCGCC 17 425
HSV2-UL19-136 + UAAUGCCCGUCCCGUCC 17 426
HSV2-UL19-150 + CGUCAUGUAAUUAUGCA 17 427
HSV2-UL19-152 + AUGCACGGGCUGCUCGA 17 428
HSV2-UL19-154 + GCACGGGCUGCUCGACG 17 429
HSV2-UL19-155 + GGCUGCUCGACGGGGUG 17 430
HSV2-UL19-160 + GCCGUCGCGGGCGAUGA 17 431
HSV2-UL19-164 + UUCAUGUAAGCCAGCUC 17 432
HSV2-UL19-165 + UCAUGUAAGCCAGCUCC 17 433
HSV2-UL19-169 + GAAAGCGCACGAGCGAC 17 434
HSV2-UL19-174 + CAAACUCUACGUCAUAC 17 435
HSV2-UL19-182 + CUCGAUCGUACUCAGGA 17 436
HSV2-UL19-183 + CGUACUCAGGAUGGAGC 17 437
HSV2-UL19-184 + ACUCAGGAUGGAGCCGG 17 438
HSV2-UL19-195 + GGUAACCCGGGGGGUCG 17 439
HSV2-UL19-197 + CCCGGGGGGUCGCGGGC 17 440
Table IB provides exemplary targeting domains for knocking out the UL19 gene selected according to the second tier parameters. The targeting domains are selected based on location within the first 500bp of the coding sequence of the UL19 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp. Table IB
Figure imgf000104_0001
HSV2-UL19-59 + GACGGGGUGCGGGCCGUCGC 20 482
HSV2-UL19-60 + GCGGGCCGUCGCGGGCGAUG 20 483
HSV2-UL19-62 + GGGCCGUCGCGGGCGAUGAG 20 484
HSV2-UL19-63 + CGUCGCGGGCGAUGAGGGGC 20 485
HSV2-UL19-64 + CGCGGGCGAUGAGGGGCUGG 20 486
HSV2-UL19-67 + GUAAGCCAGCUCCGGGAACU 20 487
HSV2-UL19-68 + CU UGGUGCACACGCACGCCA 20 488
HSV2-UL19-69 + UGCACACGCACGCCACGGAC 20 489
HSV2-UL19-71 + CAGAAAGCGCACGAGCGACA 20 490
HSV2-UL19-72 + GAGCGACAGGGUGUUGCAGU 20 491
HSV2-UL19-73 + UGUUGCAGUAGGACCCCAGC 20 492
HSV2-UL19-74 + GUUGCAGUAGGACCCCAGCA 20 493
HSV2-UL19-76 + GUCAUACAGGCUGUUUUCGU 20 494
HSV2-UL19-77 + GCUGUUUUCGUCGGAGCGCA 20 495
HSV2-UL19-78 + GUUUUCGUCGGAGCGCACGG 20 496
HSV2-UL19-79 + CGAAAAAAUCAAAGAGUCUG 20 497
HSV2-UL19-80 + AAAAAUCAAAGAGUCUGCGG 20 498
HSV2-UL19-81 + AAAAUCAAAGAGUCUGCGGU 20 499
HSV2-UL19-82 + ACGCCACCUCGAUCGUACUC 20 500
HSV2-UL19-86 + GUACUCAGGAUGGAGCCGGU 20 501
HSV2-UL19-87 + UCAGGAUGGAGCCGGUGGGC 20 502
HSV2-UL19-88 + GAUGGAGCCGGUGGGCAGGA 20 503
HSV2-UL19-89 + GCCGGUGGGCAGGAUGGCCG 20 504
HSV2-UL19-90 + GCAGGAUGGCCGCGGCGUAC 20 505
HSV2-UL19-91 + GCCGCGGCGUACCGGUAACC 20 506
HSV2-UL19-92 + CCGCGGCGUACCGGUAACCC 20 507
HSV2-UL19-93 + CGCGGCGUACCGGUAACCCG 20 508
HSV2-UL19-94 + GCGGCGUACCGGUAACCCGG 20 509
HSV2-UL19-95 + CGGCGUACCGGUAACCCGGG 20 510
HSV2-UL19-97 + CCGGUAACCCGGGGGGUCGC 20 511
HSV2-UL19-99 + CGGGGGGUCGCGGGCAGGAG 20 512
HSV2-UL19-100 - UCCUGCCCGCGACCCCC 17 513
HSV2-UL19-101 - CCUGCCCGCGACCCCCC 17 514
HSV2-UL19-102 - GCGACCCCCCGGGUUAC 17 515
HSV2-UL19-103 - GGGUUACCGGUACGCCG 17 516
HSV2-UL19-104 - GCGGCCAUCCUGCCCAC 17 517
HSV2-UL19-109 - AGUUUGACGCCCUGCUG 17 518
HSV2-UL19-112 - GGAGCUCGGCCUGUCCG 17 519
HSV2-UL19-115 - CUGGCUUACAUGAACGA 17 520
HSV2-UL19-117 - AGGGCGUGUGCAGUUCG 17 521
HSV2-UL19-118 - CCCCUCAUCGCCCGCGA 17 522
HSV2-UL19-122 - GAACGCCGCCU UCAGCC 17 523
HSV2-UL19-123 - CUUCAGCCUGGCCACCG 17 524
HSV2-UL19-124 - GGCCAUUGCCCUGCUCA 17 525
HSV2-UL19-125 - GCCAUUGCCCUGCUCAC 17 526
HSV2-UL19-126 - CCAU UGCCCUGCUCACG 17 527 HSV2-UL19-127 - CAUUGCCCUGCUCACGG 17 528
HSV2-UL19-128 - UGCCCUGCUCACGGGGG 17 529
HSV2-UL19-129 - GCUCACGGGGGAGGCCC 17 530
HSV2-UL19-130 - ACGGGGGAGGCCCUGGA 17 531
HSV2-UL19-131 - CGGGGGAGGCCCUGGAC 17 532
HSV2-UL19-132 - GGAGGCCCUGGACGGGA 17 533
HSV2-UL19-133 - GAGGCCCUGGACGGGAC 17 534
HSV2-UL19-134 + GCUGGAUGGCGCGCAGC 17 535
HSV2-UL19-135 + CGCGCAGCUGGCGAUGC 17 536
HSV2-UL19-137 + AAUGCCCGUCCCGUCCA 17 537
HSV2-UL19-138 + GGGCCUCCCCCGUGAGC 17 538
HSV2-UL19-139 + GGCCUCCCCCGUGAGCA 17 539
HSV2-UL19-140 + CCCCGUGAGCAGGGCAA 17 540
HSV2-UL19-141 + GAGCAGGGCAAUGGCCU 17 541
HSV2-UL19-142 + CAGGGCAAUGGCCUCGG 17 542
HSV2-UL19-143 + CAAUGGCCUCGGUGGCC 17 543
HSV2-UL19-144 + CUCGGUGGCCAGGCUGA 17 544
HSV2-UL19-145 + GGUGGCCAGGCUGAAGG 17 545
HSV2-UL19-146 + GGCUGAAGGCGGCGUUC 17 546
HSV2-UL19-147 + GCUGAAGGCGGCGUUCA 17 547
HSV2-UL19-148 + AGGCGGCGUUCAGGGCC 17 548
HSV2-UL19-149 + CGGCGUUCAGGGCCCGG 17 549
HSV2-UL19-151 + GUCAUGUAAUUAUGCAC 17 550
HSV2-UL19-153 + UGCACGGGCUGCUCGAC 17 551
HSV2-UL19-156 + GCUGCUCGACGGGGUGC 17 552
HSV2-UL19-157 + CGGGGUGCGGGCCGUCG 17 553
HSV2-UL19-158 + GGGGUGCGGGCCGUCGC 17 554
HSV2-UL19-159 + GGCCGUCGCGGGCGAUG 17 555
HSV2-UL19-161 + CCGUCGCGGGCGAUGAG 17 556
HSV2-UL19-162 + CGCGGGCGAUGAGGGGC 17 557
HSV2-UL19-163 + GGGCGAUGAGGGGCUGG 17 558
HSV2-UL19-166 + AGCCAGCUCCGGGAACU 17 559
HSV2-UL19-167 + GGUGCACACGCACGCCA 17 560
HSV2-UL19-168 + ACACGCACGCCACGGAC 17 561
HSV2-UL19-170 + AAAGCGCACGAGCGACA 17 562
HSV2-UL19-171 + CGACAGGGUGUUGCAGU 17 563
HSV2-UL19-172 + UGCAGUAGGACCCCAGC 17 564
HSV2-UL19-173 + GCAGUAGGACCCCAGCA 17 565
HSV2-UL19-175 + AUACAGGCUGUUUUCGU 17 566
HSV2-UL19-176 + GUUUUCGUCGGAGCGCA 17 567
HSV2-UL19-177 + UUCGUCGGAGCGCACGG 17 568
HSV2-UL19-178 + AAAAAU CAAAG AG UCU G 17 569
HSV2-UL19-179 + AAU CAAAG AG U CU GCG G 17 570
HSV2-UL19-180 + AUCAAAGAGUCUGCGGU 17 571
HSV2-UL19-181 + CCACCUCGAUCGUACUC 17 572
HSV2-UL19-185 + CUCAGGAUGGAGCCGGU 17 573 HSV2-UL19-186 + GGAUGGAGCCGGUGGGC 17 574
HSV2-UL19-187 + GGAGCCGGUGGGCAGGA 17 575
HSV2-UL19-188 + GGUGGGCAGGAUGGCCG 17 576
HSV2-UL19-189 + GGAUGGCCGCGGCGUAC 17 577
HSV2-UL19-190 + GCGGCGUACCGGUAACC 17 578
HSV2-UL19-191 + CGGCGUACCGGUAACCC 17 579
HSV2-UL19-192 + GGCGUACCGGUAACCCG 17 580
HSV2-UL19-193 + GCG U ACCGG UAACCCGG 17 581
HSV2-UL19-194 + CGUACCGGUAACCCGGG 17 582
HSV2-UL19-196 + GUAACCCGGGGGGUCGC 17 583
HSV2-UL19-198 + GGGGUCGCGGGCAGGAG 17 584
Table 1C provides exemplary targeting domains for knocking out the UL19 gene selected according to the third tier parameters. The targeting domains are selected based on location within the coding sequence (but downstream of the first 500bp) of the UL19 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 1C
Figure imgf000107_0001
HSV2-UL19-356 - GCCUGGCGACCAGGGUUGCC 20 596
HSV2-UL19-357 - CCUGGCGACCAGGGUUGCCC 20 597
HSV2-UL19-358 - CAGGGUUGCCCGGGCGACCC 20 598
HSV2-UL19-359 - CCCUGGUCGCCGAGCUGAAG 20 599
HSV2-UL19-360 - UUGCGACACGAGCUUCUUCC 20 600
HSV2-UL19-361 - UGCGACACGAGCUUCUUCCU 20 601
HSV2-UL19-362 - CACGAGCUUCUUCCUGGGCA 20 602
HSV2-UL19-363 - GAGCUUCUUCCUGGGCAAGG 20 603
HSV2-UL19-364 - AGCUUCUUCCUGGGCAAGGC 20 604
HSV2-UL19-365 - CAAGGCGGGCCAUCGCCGCG 20 605
HSV2-UL19-366 - CCAUCGCCGCGAGGCCAUCG 20 606
HSV2-UL19-367 - GCCGCGAGGCCAUCGAGGCC 20 607
HSV2-UL19-368 - GGCCAUCGAGGCCUGGCUCG 20 608
HSV2-UL19-369 - CUGGCUCGUGGACCUGACCA 20 609
HSV2-UL19-370 - CACGGCGACGCAGCCGUCCG 20 610
HSV2-UL19-371 - CUGACGCACGCCGACACGCG 20 611
HSV2-UL19-372 - UGACGCACGCCGACACGCGC 20 612
HSV2-UL19-373 - CGCACGCCGACACGCGCGGG 20 613
HSV2-UL19-374 - CGCCGACACGCGCGGGCGGC 20 614
HSV2-UL19-375 - ACGCGCGGGCGGCCGGUCGA 20 615
HSV2-UL19-376 - CGCGCGGGCGGCCGGUCGAC 20 616
HSV2-UL19-377 - GCGCGGGCGGCCGGUCGACG 20 617
HSV2-UL19-378 - GCGGCCGGUCGACGGGGUGC 20 618
HSV2-UL19-379 - CCUCCUGCAGUCCUUCCUGA 20 619
HSV2-UL19-380 - CCUGCAGUCCUUCCUGAAGG 20 620
HSV2-UL19-381 - GCAGUCCUUCCUGAAGGUGG 20 621
HSV2-UL19-382 - CCUGAAGGUGGAGGACACCG 20 622
HSV2-UL19-383 - GGACACCGAGGCCGACGUGC 20 623
HSV2-UL19-384 - GCCGACGUGCCGGUGACCUA 20 624
HSV2-UL19-385 - GCCGGUGACCUACGGCGAGA 20 625
HSV2-UL19-386 - UACGGCGAGAUGGUCUUGAA 20 626
HSV2-UL19-387 - ACGGCGAGAUGGUCUUGAAC 20 627
HSV2-UL19-388 - CGGCGAGAUGGUCUUGAACG 20 628
HSV2-UL19-389 - GAACGGGGCCAACCUCGUCA 20 629
HSV2-UL19-390 - GGCCAACCUCGUCACGGCGC 20 630
HSV2-UL19-391 - CCUCGUCACGGCGCUGGUGA 20 631
HSV2-UL19-392 - CUCGUCACGGCGCUGGUGAU 20 632
HSV2-UL19-393 - CACGGCGCUGGUGAUGGGCA 20 633
HSV2-UL19-394 - UGGUGAUGGGCAAGGCCGUG 20 634
HSV2-UL19-395 - GGGCAAGGCCGUGCGGAGCC 20 635
HSV2-UL19-396 - CGUGCGGAGCCUGGACGACG 20 636
HSV2-UL19-397 - GUGCGGAGCCUGGACGACGU 20 637
HSV2-UL19-398 - CGACGUGGGCCGCCACCUGC 20 638
HSV2-UL19-399 - CCGCCACCUGCUGGAUAUGC 20 639
HSV2-UL19-400 - CCACCUGCUGGAUAUGCAGG 20 640
HSV2-UL19-401 - UAUGCAGGAGGAGCAACUCG 20 641 HSV2-UL19-402 - AGGAGCAACUCGAGGCGAAC 20 642
HSV2-UL19-403 - GGAGCAACUCGAGGCGAACC 20 643
HSV2-UL19-404 - CGAGGCGAACCGGGAGACGC 20 644
HSV2-UL19-405 - CCAGACAACGCGCGUGCGCG 20 645
HSV2-UL19-406 - AACGCGCGUGCGCGCGGAUC 20 646
HSV2-UL19-407 - GCGCGUGCGCGCGGAUCUGG 20 647
HSV2-UL19-408 - CGCGCGGAUCUGGUGGCCAU 20 648
HSV2-UL19-409 - AUCUGGUGGCCAUAGGCGAC 20 649
HSV2-UL19-410 - GGUGGCCAUAGGCGACAGGC 20 650
HSV2-UL19-411 - AGGCGACAGGCUGGUCUUCC 20 651
HSV2-UL19-412 - CGACAGGCUGGUCUUCCUGG 20 652
HSV2-UL19-413 - GCUGGUCUUCCUGGAGGCCC 20 653
HSV2-UL19-414 - CACCAACGUGCCCUACCCCC 20 654
HSV2-UL19-415 - CAACGUGCCCUACCCCCUGG 20 655
HSV2-UL19-416 - AACGUGCCCUACCCCCUGGU 20 656
HSV2-UL19-417 - CUACCCCCUGGUGGGCGCCA 20 657
HSV2-UL19-418 - CCUGACGUUCGUCCUGCCCC 20 658
HSV2-UL19-419 - CUGACGUUCGUCCUGCCCCU 20 659
HSV2-UL19-420 - UGACGUUCGUCCUGCCCCUG 20 660
HSV2-UL19-421 - GCCCCUGGGGCUGUUCAACC 20 661
HSV2-UL19-422 - GGGGCUGUUCAACCCGGCCA 20 662
HSV2-UL19-423 - GAGCGCUUCGCCGCGCACGC 20 663
HSV2-UL19-424 - AGCGCUUCGCCGCGCACGCC 20 664
HSV2-UL19-425 - GCGCU UCGCCGCGCACGCCG 20 665
HSV2-UL19-426 - CGCCGCGCACGCCGGGGACC 20 666
HSV2-UL19-427 - GGGGACCUGGUGCCCGCCCC 20 667
HSV2-UL19-428 - GGUGCCCGCCCCCGGCCACC 20 668
HSV2-UL19-429 - AGCCCCGCGCGUUCCCUCCC 20 669
HSV2-UL19-430 - CUCCCCGGCAGCUGUUUUUU 20 670
HSV2-UL19-431 - UCCCCGGCAGCUGUUUUUUU 20 671
HSV2-UL19-432 - CCCCGGCAGCUGUUUUUUUG 20 672
HSV2-UL19-433 - GCAGCUGUUUUUUUGGGGAA 20 673
HSV2-UL19-434 - UUUUUGGGGAAAGGACCACC 20 674
HSV2-UL19-435 - GAAAGGACCACCAGGUUCUG 20 675
HSV2-UL19-436 - CCAGGUUCUGCGGCUGUCCA 20 676
HSV2-UL19-437 - GCGGCUGUCCAUGGAGAACG 20 677
HSV2-UL19-438 - CUGUCCAUGGAGAACGCGGU 20 678
HSV2-UL19-439 - UGUCCAUGGAGAACGCGGUC 20 679
HSV2-UL19-440 - UUCGCUCAUGAACAUCGACG 20 680
HSV2-UL19-441 - AUGAACAUCGACGCGGCCGU 20 681
HSV2-UL19-442 - UGAACAUCGACGCGGCCGUC 20 682
HSV2-UL19-443 - GAACAUCGACGCGGCCGUCG 20 683
HSV2-UL19-444 - AACAUCGACGCGGCCGUCGG 20 684
HSV2-UL19-445 - CG U G AACCACG ACCCCG U CG 20 685
HSV2-UL19-446 - GUCGAGGCCGCGAAUCCGUA 20 686
HSV2-UL19-447 - UCGAGGCCGCGAAUCCGUAC 20 687 HSV2-UL19-448 - CGAGGCCGCGAAUCCGUACG 20 688
HSV2-UL19-449 - UCCGUACGGGGCGUACGUCG 20 689
HSV2-UL19-450 - CGGGGCGUACGUCGCGGCCC 20 690
HSV2-UL19-451 - GCGUACGUCGCGGCCCCGGC 20 691
HSV2-UL19-452 - GUCGCGGCCCCGGCCGGCCC 20 692
HSV2-UL19-453 - GGCCCCGGCCGGCCCCGGCG 20 693
HSV2-UL19-454 - AGCAGCGUUUUCUGAACGCC 20 694
HSV2-UL19-455 - AGCGUUUUCUGAACGCCUGG 20 695
HSV2-UL19-456 - UGGCGGCAGCGCCUCGCCCA 20 696
HSV2-UL19-457 - GGCAGCGCCUCGCCCACGGC 20 697
HSV2-UL19-458 - GCAGCGCCUCGCCCACGGCC 20 698
HSV2-UL19-459 - GCCUCGCCCACGGCCGGGUC 20 699
HSV2-UL19-460 - UCGCCCACGGCCGGGUCCGG 20 700
HSV2-UL19-461 - CGCCCACGGCCGGGUCCGGU 20 701
HSV2-UL19-462 - CGCCGAGUGCCAGAUGACCG 20 702
HSV2-UL19-463 - GCAGCCCGACAACGCCAACC 20 703
HSV2-UL19-464 - CGACAACGCCAACCUGGCUC 20 704
HSV2-UL19-465 - CCCCGCGUUCGACUUCUUCG 20 705
HSV2-UL19-466 - CCCGCGUUCGACUUCUUCGC 20 706
HSV2-UL19-467 - GUUCGACUUCUUCGCGGGCG 20 707
HSV2-UL19-468 - GUGGCCGACGUCGAGCUUCC 20 708
HSV2-UL19-469 - GCCGACGUCGAGCUUCCCGG 20 709
HSV2-UL19-470 - UCCCGGCGGCGAAGUCCCCC 20 710
HSV2-UL19-471 - GGCGGCGAAGUCCCCCCGGC 20 711
HSV2-UL19-472 - CGAAGUCCCCCCGGCCGGUC 20 712
HSV2-UL19-473 - GAAGUCCCCCCGGCCGGUCC 20 713
HSV2-UL19-474 - AAGUCCCCCCGGCCGGUCCG 20 714
HSV2-UL19-475 - AGUCCCCCCGGCCGGUCCGG 20 715
HSV2-UL19-476 - GGCCGGUCCGGGGGCGAUCC 20 716
HSV2-UL19-477 - CGGGGGCGAUCCAGGCCACC 20 717
HSV2-UL19-478 - GAUCCAGGCCACCUGGCGCG 20 718
HSV2-UL19-479 - GCCACCUGGCGCGUGGUCAA 20 719
HSV2-UL19-480 - GGUCAACGGCAACCUGCCCC 20 720
HSV2-UL19-481 - CCUGCCCCUGGCGCUGUGUC 20 721
HSV2-UL19-482 - GCCCCUGGCGCUGUGUCCGG 20 722
HSV2-UL19-483 - CGGUGGCGUUUCGUGACGCC 20 723
HSV2-UL19-484 - GGUGGCGUUUCGUGACGCCC 20 724
HSV2-UL19-485 - GUGGCGUUUCGUGACGCCCG 20 725
HSV2-UL19-486 - GUUUCGUGACGCCCGGGGCC 20 726
HSV2-UL19-487 - GACGCCCGGGGCCUGGAGCU 20 727
HSV2-UL19-488 - CGGGGCCUGGAGCUCGGCGU 20 728
HSV2-UL19-489 - CGGCGUUGGCCGCCACGCCA 20 729
HSV2-UL19-490 - UGGCCGCCACGCCAUGGCGC 20 730
HSV2-UL19-491 - GCUACCAUAGCCGCCGUCCG 20 731
HSV2-UL19-492 - CUACCAUAGCCGCCGUCCGC 20 732
HSV2-UL19-493 - UACCAUAGCCGCCGUCCGCG 20 733 HSV2-UL19-494 - CGCCGUCCGCGGGGCGUUCG 20 734
HSV2-UL19-495 - GUUCGAGGACCGCAGCUACC 20 735
HSV2-UL19-496 - CGAGGACCGCAGCUACCCGG 20 736
HSV2-UL19-497 - CUGCUGCAAGCCGCGAUUCA 20 737
HSV2-UL19-498 - CGAGCACGUGUUCUGCGCCC 20 738
HSV2-UL19-499 - ACGUGUUCUGCGCCCUGGCG 20 739
HSV2-UL19-500 - CUCAGUGCAUCACCAGCUAC 20 740
HSV2-UL19-501 - CUGGAACAACACGCGAUGCG 20 741
HSV2-UL19-502 - GUUCGUGAACGACUACUCGC 20 742
HSV2-UL19-503 - UCGUACAUCGUGACCUACCU 20 743
HSV2-UL19-504 - CGUACAUCGUGACCUACCUC 20 744
HSV2-UL19-505 - GUACAUCGUGACCUACCUCG 20 745
HSV2-UL19-506 - UACAUCGUGACCUACCUCGG 20 746
HSV2-UL19-507 - CCUCGGGGGCGACCUCCCCG 20 747
HSV2-UL19-508 - CGACCUCCCCGAGGAGUGCA 20 748
HSV2-UL19-509 - AGGAGUGCAUGGCCGUGUAU 20 749
HSV2-UL19-510 - GGAGUGCAUGGCCGUGUAUC 20 750
HSV2-UL19-511 - CAUGGCCGUGUAUCGGGACC 20 751
HSV2-UL19-512 - GGCCGUGUAUCGGGACCUGG 20 752
HSV2-UL19-513 - GGACCUGGUGGCCCACGUCG 20 753
HSV2-UL19-514 - GGUGGCCCACGUCGAGGCCC 20 754
HSV2-UL19-515 - CGUCGAGGCCCUGGCCCAGC 20 755
HSV2-UL19-516 - CGAGGCCCUGGCCCAGCUGG 20 756
HSV2-UL19-517 - GGUGGACGACUUUACCCUGC 20 757
HSV2-UL19-518 - GUGGACGACUUUACCCUGCC 20 758
HSV2-UL19-519 - CGACUUUACCCUGCCGGGCC 20 759
HSV2-UL19-520 - UACCCUGCCGGGCCCGGAGC 20 760
HSV2-UL19-521 - ACCCUGCCGGGCCCGGAGCU 20 761
HSV2-UL19-522 - CUGCCGGGCCCGGAGCUGGG 20 762
HSV2-UL19-523 - UGCCGGGCCCGGAGCUGGGC 20 763
HSV2-UL19-524 - GGGCCCGGAGCUGGGCGGGC 20 764
HSV2-UL19-525 - GGAGCUGGGCGGGCAGGCUC 20 765
HSV2-UL19-526 - GAAUCACCUGAUGCGCGACC 20 766
HSV2-UL19-527 - CGCUGCUGCCGCCCCUCGUG 20 767
HSV2-UL19-528 - GCUGCUGCCGCCCCUCGUGU 20 768
HSV2-UL19-529 - CCCCUCGUGUGGGACUGCGA 20 769
HSV2-UL19-530 - CGACGGCCU UAUGCGACACG 20 770
HSV2-UL19-531 - CCUUAUGCGACACGCGGCCC 20 771
HSV2-UL19-532 - UGGACCGCCACCGAGACUGC 20 772
HSV2-UL19-533 - CCGAGACUGCCGGAUUGACG 20 773
HSV2-UL19-534 - CGAGACUGCCGGAUUGACGC 20 774
HSV2-UL19-535 - GAGACUGCCGGAUUGACGCG 20 775
HSV2-UL19-536 - AGACUGCCGGAUUGACGCGG 20 776
HSV2-UL19-537 - GACUGCCGGAUUGACGCGGG 20 777
HSV2-UL19-538 - ACUGCCGGAUUGACGCGGGG 20 778
HSV2-UL19-539 - GGGGCACGAGCCCGUCUACG 20 779 HSV2-UL19-540 - GCACGAGCCCGUCUACGCGG 20 780
HSV2-UL19-541 - CUACGCGGCGGCGUGCAACG 20 781
HSV2-UL19-542 - GGCGGCGUGCAACGUGGCGA 20 782
HSV2-UL19-543 - GCCGACU UUAACCGCAACGA 20 783
HSV2-UL19-544 - ACU U UAACCGCAACGACGGC 20 784
HSV2-UL19-545 - CCGGCUGCUGCACAACACCC 20 785
HSV2-UL19-546 - GCACAACACCCAGGCCCGCG 20 786
HSV2-UL19-547 - CGGCCGACGCCGCCGACGAC 20 787
HSV2-UL19-548 - CCGCCGACGACCGGCCGCAC 20 788
HSV2-UL19-549 - CGACGACCGGCCGCACCGGC 20 789
HSV2-UL19-550 - GGCCGCACCGGCCGGCCGAC 20 790
HSV2-UL19-551 - CAAAAUCUACUAUUACGUGC 20 791
HSV2-UL19-552 - CUACUAUUACGUGCUGGUGC 20 792
HSV2-UL19-553 - UGCUGGUGCCGGCCUUCUCG 20 793
HSV2-UL19-554 - GCUGGUGCCGGCCUUCUCGC 20 794
HSV2-UL19-555 - CUGGUGCCGGCCUUCUCGCG 20 795
HSV2-UL19-556 - UGGUGCCGGCCUUCUCGCGG 20 796
HSV2-UL19-557 - GCGGGGGCGCUGCUGCACCG 20 797
HSV2-UL19-558 - CGGGGGCGCUGCUGCACCGC 20 798
HSV2-UL19-559 - GGGGGCGCUGCUGCACCGCG 20 799
HSV2-UL19-560 - GGGGCGCUGCUGCACCGCGG 20 800
HSV2-UL19-561 - GUACGCCACGCUGCAGAACA 20 801
HSV2-UL19-562 - CGCCACGCUGCAGAACAUGG 20 802
HSV2-UL19-563 - GCUGCAGAACAUGGUGGUCC 20 803
HSV2-UL19-564 - GUGGUCCCGGAGAUCGCCCC 20 804
HSV2-UL19-565 - CCCGGAGAUCGCCCCCGGUG 20 805
HSV2-UL19-566 - CCCGCUGCAUCCCGCCAAUC 20 806
HSV2-UL19-567 - GCUGCAUCCCGCCAAUCUGG 20 807
HSV2-UL19-568 - CGCCAAUCUGGUGGCCAACA 20 808
HSV2-UL19-569 - GUCAAGCGCAUGUUCCACAA 20 809
HSV2-UL19-570 - UCAAGCGCAUGUUCCACAAC 20 810
HSV2-UL19-571 - AACGGGCGCGUCGUCGUCGA 20 811
HSV2-UL19-572 - ACGGGCGCGUCGUCGUCGAC 20 812
HSV2-UL19-573 - GCCCGCCAUGCUCACGCUGC 20 813
HSV2-UL19-574 - CAUGCUCACGCUGCAGGUGC 20 814
HSV2-UL19-575 - GCAGGUGCUGGCGCACAACA 20 815
HSV2-UL19-576 - CAACAUGGCCGAGCGCACGA 20 816
HSV2-UL19-577 - GACGGCGCUGCUGUGCUCCG 20 817
HSV2-UL19-578 - GUGCUCCGCGGCGCCCGACG 20 818
HSV2-UL19-579 - UGCUCCGCGGCGCCCGACGC 20 819
HSV2-UL19-580 - GGGCGCCAACACCGCGUCGA 20 820
HSV2-UL19-581 - GCCAACAUGCGCAUCUUCGA 20 821
HSV2-UL19-582 - CCAACAUGCGCAUCUUCGAC 20 822
HSV2-UL19-583 - CAACAUGCGCAUCUUCGACG 20 823
HSV2-UL19-584 - UUCGACGGGGCGCUGCACGC 20 824
HSV2-UL19-585 - GCACGCCGGCGUGCUGCUCA 20 825 HSV2-UL19-586 - G CU CAU G G CCCCCCAG CACC 20 826
HSV2-UL19-587 - CUGGACCACACCAUCCAAAA 20 827
HSV2-UL19-588 - GCCCGUCCACGCGCUGUUUG 20 828
HSV2-UL19-589 - CCCGUCCACGCGCUGUUUGC 20 829
HSV2-UL19-590 - GUUUGCGGGCGCCGACCACG 20 830
HSV2-UL19-591 - CAACGCGCCCAACUUCCCCC 20 831
HSV2-UL19-592 - CCCCCCGGCCCUGCGCGACC 20 832
HSV2-UL19-593 - CCUGGCGCGCGACGUCCCCC 20 833
HSV2-UL19-594 - CGACGUCCCCCUGGUCCCCC 20 834
HSV2-UL19-595 - CCCCCUGGUCCCCCCGGCCC 20 835
HSV2-UL19-596 - CCCCUGGUCCCCCCGGCCCU 20 836
HSV2-UL19-597 - CCCUGGUCCCCCCGGCCCUG 20 837
HSV2-UL19-598 - CCUGGUCCCCCCGGCCCUGG 20 838
HSV2-UL19-599 - CU CCU CCAU CCGCCAG CCCG 20 839
HSV2-UL19-600 - GCAGCACGCCCGCGAGAGCG 20 840
HSV2-UL19-601 - GCACGCCCGCGAGAGCGCGG 20 841
HSV2-UL19-602 - CACGCCCGCGAGAGCGCGGC 20 842
HSV2-UL19-603 - ACGCCCGCGAGAGCGCGGCG 20 843
HSV2-UL19-604 - CGCCCGCGAGAGCGCGGCGG 20 844
HSV2-UL19-605 - CGCGCUGACCUACGCGCUCA 20 845
HSV2-UL19-606 - GCUGACCUACGCGCUCAUGG 20 846
HSV2-UL19-607 - CUGACCUACGCGCUCAUGGC 20 847
HSV2-UL19-608 - UGACCUACGCGCUCAUGGCG 20 848
HSV2-UL19-609 - GUACUUCAAGAUGAGCCCCG 20 849
HSV2-UL19-610 - CCUGUAUCACCAGCUCAAGA 20 850
HSV2-UL19-611 - CUGUAUCACCAGCUCAAGAC 20 851
HSV2-UL19-612 - CUCAAGACGGGCCUCCACCC 20 852
HSV2-UL19-613 - UCAAGACGGGCCUCCACCCC 20 853
HSV2-UL19-614 - ACGGGCCUCCACCCCGGGUU 20 854
HSV2-UL19-615 - CGGGCCUCCACCCCGGGUUC 20 855
HSV2-UL19-616 - GGUUCGGGUUCACCGUCGUG 20 856
HSV2-UL19-617 - CGGGUUCACCGUCGUGCGGC 20 857
HSV2-UL19-618 - GCUGUUUUCCGAGCGCGCGU 20 858
HSV2-UL19-619 - GUUUUCCGAGCGCGCGUCGG 20 859
HSV2-UL19-620 - CGCGUCGGAGGCGUACUUUC 20 860
HSV2-UL19-621 - GCGUCGGAGGCGUACUUUCU 20 861
HSV2-UL19-622 - GUACUUUCUGGGCCAGCUCC 20 862
HSV2-UL19-623 - CU UUCUGGGCCAGCUCCAGG 20 863
HSV2-UL19-624 - CCAG G U G G CCCG CCACG AAA 20 864
HSV2-UL19-625 - CAGGUGGCCCGCCACGAAAC 20 865
HSV2-UL19-626 - GUGGCCCGCCACGAAACGGG 20 866
HSV2-UL19-627 - UGGCCCGCCACGAAACGGGC 20 867
HSV2-UL19-628 - GGCCCGCCACGAAACGGGCG 20 868
HSV2-UL19-629 - GCCCGCCACGAAACGGGCGG 20 869
HSV2-UL19-630 - CCCGCCACGAAACGGGCGGG 20 870
HSV2-UL19-631 - CCGCCACGAAACGGGCGGGG 20 871 HSV2-UL19-632 - UUCACGCUCACCCAGCCGCG 20 872
HSV2-UL19-633 - CACCCAGCCGCGCGGAAACG 20 873
HSV2-UL19-634 - GCCGCGCGGAAACGUGGACC 20 874
HSV2-UL19-635 - CCGCGCGGAAACGUGGACCU 20 875
HSV2-UL19-636 - CGGAAACGUGGACCUGGGUG 20 876
HSV2-UL19-637 - GGAAACGUGGACCUGGGUGU 20 877
HSV2-UL19-638 - UGUGGGCUACACCGCCGUCG 20 878
HSV2-UL19-639 - CUACACCGCCGUCGCGGCCA 20 879
HSV2-UL19-640 - UACACCGCCGUCGCGGCCAC 20 880
HSV2-UL19-641 - CACCG U CCG CAACCCCG U U A 20 881
HSV2-UL19-642 - CCGCAACCCCGUUACGGACA 20 882
HSV2-UL19-643 - CGCAACCCCGUUACGGACAU 20 883
HSV2-UL19-644 - CUCCCCCAAAACUUUUACCU 20 884
HSV2-UL19-645 - CAAAACUUUUACCUCGGCCG 20 885
HSV2-UL19-646 - AAAACUUUUACCUCGGCCGC 20 886
HSV2-UL19-647 - AAACU U U UACCUCGGCCGCG 20 887
HSV2-UL19-648 - CCCCCCGCUGCUAGACAACG 20 888
HSV2-UL19-649 - CGCCGUGUACCUGCGCAACG 20 889
HSV2-UL19-650 - GUACCUGCGCAACGCGGUCG 20 890
HSV2-UL19-651 - CCUGCGCAACGCGGUCGUGG 20 891
HSV2-UL19-652 - CUGCGCAACGCGGUCGUGGC 20 892
HSV2-UL19-653 - ACGCGGUCGUGGCGGGAAAC 20 893
HSV2-UL19-654 - GGUCGUGGCGGGAAACCGGC 20 894
HSV2-UL19-655 - GUCGUGGCGGGAAACCGGCU 20 895
HSV2-UL19-656 - UCGUGGCGGGAAACCGGCUG 20 896
HSV2-UL19-657 - GGCGGGAAACCGGCUGGGGC 20 897
HSV2-UL19-658 - GGGGCCGGCCCAGCCCCUCC 20 898
HSV2-UL19-659 - G CCCAG CCCCU CCCGG U CU U 20 899
HSV2-UL19-660 - CCCGGUCU UUGGCUGCGCCC 20 900
HSV2-UL19-661 - UUGGCUGCGCCCAGGUGCCG 20 901
HSV2-UL19-662 - GCCCAGGUGCCGCGGCGCGC 20 902
HSV2-UL19-663 - GGUGCCGCGGCGCGCCGGCA 20 903
HSV2-UL19-664 - CGGCGCGCCGGCAUGGACCA 20 904
HSV2-UL19-665 - GGCGCGCCGGCAUGGACCAC 20 905
HSV2-UL19-666 - CGCCGGCAUGGACCACGGGC 20 906
HSV2-UL19-667 - UGAGUUCAUCGCCACCCCCG 20 907
HSV2-UL19-668 - CAUCGCCACCCCCGUGGCCA 20 908
HSV2-UL19-669 - CG G ACAU CAACU ACU U U CG C 20 909
HSV2-UL19-670 - UUCGCCGGCCCUGCAACCCG 20 910
HSV2-UL19-671 - UCGCCGGCCCUGCAACCCGC 20 911
HSV2-UL19-672 - CGCCGGCCCUGCAACCCGCG 20 912
HSV2-UL19-673 - CUGCAACCCGCGGGGACGCG 20 913
HSV2-UL19-674 - AACCCGCGGGGACGCGCGGC 20 914
HSV2-UL19-675 - CCGCGGGGACGCGCGGCCGG 20 915
HSV2-UL19-676 - CGCGGCCGGCGGCGUGUACG 20 916
HSV2-UL19-677 - GCGGCCGGCGGCGUGUACGC 20 917 HSV2-UL19-678 - CGGCCGGCGGCGUGUACGCG 20 918
HSV2-UL19-679 - GGCCGGCGGCGUGUACGCGG 20 919
HSV2-UL19-680 - CGGCGUGUACGCGGGGGACA 20 920
HSV2-UL19-681 - CGUGUACGCGGGGGACAAGG 20 921
HSV2-UL19-682 - GUGUACGCGGGGGACAAGGA 20 922
HSV2-UL19-683 - UGUACGCGGGGGACAAGGAG 20 923
HSV2-UL19-684 - GUACGCGGGGGACAAGGAGG 20 924
HSV2-UL19-685 - AUAGCCCUCAUGUACGACCA 20 925
HSV2-UL19-686 - CGACCACGGCCAGAGCGACC 20 926
HSV2-UL19-687 - ACGGCCAGAGCGACCCGGCG 20 927
HSV2-UL19-688 - CGACCCGGCGCGGCCCUUCG 20 928
HSV2-UL19-689 - GGCGCGGCCCUUCGCGGCCA 20 929
HSV2-UL19-690 - UCGCGGCCACGGCCAACCCG 20 930
HSV2-UL19-691 - CGCGGCCACGGCCAACCCGU 20 931
HSV2-UL19-692 - CCAACCCGUGGGCGUCGCAG 20 932
HSV2-UL19-693 - GCGUCGCAGCGGUUCUCGUA 20 933
HSV2-UL19-694 - CGUCGCAGCGGUUCUCGUAC 20 934
HSV2-UL19-695 - GUCGCAGCGGUUCUCGUACG 20 935
HSV2-UL19-696 - UACGGGGACCUGCUGUACAA 20 936
HSV2-UL19-697 - ACGGGGACCUGCUGUACAAC 20 937
HSV2-UL19-698 - CGGGGACCUGCUGUACAACG 20 938
HSV2-UL19-699 - AACGGGGCCUAUCACCUCAA 20 939
HSV2-UL19-700 - ACGGGGCCUAUCACCUCAAC 20 940
HSV2-UL19-701 - CGGGGCCUAUCACCUCAACG 20 941
HSV2-UL19-702 - CU GCU U CAAG U U CU U CACCG 20 942
HSV2-UL19-703 - CUUCACCGCGGCCGACAUCA 20 943
HSV2-UL19-704 - CACGGCCAAACAUCGCUGCC 20 944
HSV2-UL19-705 - CUGCCUGGAGCGUCUCAUCG 20 945
HSV2-UL19-706 - GGAGCGUCUCAUCGUGGAAA 20 946
HSV2-UL19-707 - GAGCGUCUCAUCGUGGAAAC 20 947
HSV2-UL19-708 - UCUCAUCGUGGAAACGGGAU 20 948
HSV2-UL19-709 - CAUCGUGGAAACGGGAUCGG 20 949
HSV2-UL19-710 - AACGGGAUCGGCGGUAUCCA 20 950
HSV2-UL19-711 - CGUGCAGUUUAAGCGCCCGC 20 951
HSV2-UL19-712 - GUGCAGUUUAAGCGCCCGCC 20 952
HSV2-UL19-713 - UGCAGUUUAAGCGCCCGCCG 20 953
HSV2-UL19-714 - GCCGGGGUGCCGCGAGCUCG 20 954
HSV2-UL19-715 - GAGCUCGUGGAAGACCCGUG 20 955
HSV2-UL19-716 - AGACCCGUGCGGCCUGUUUC 20 956
HSV2-UL19-717 - CUGCUACGCAGCGCCCGCGA 20 957
HSV2-UL19-718 - UGCUACGCAGCGCCCGCGAU 20 958
HSV2-UL19-719 - GCUACGCAGCGCCCGCGAUG 20 959
HSV2-UL19-720 - ACGCAGCGCCCGCGAUGGGG 20 960
HSV2-UL19-721 - CUACGACGCCUCCCCGCUAA 20 961
HSV2-UL19-722 - UACGACGCCUCCCCGCUAAA 20 962
HSV2-UL19-723 - CGUCCAGGCCGUCCUGG 17 963 HSV2-UL19-724 - CUGGGGGCGUUUGAGCG 17 964
HSV2-UL19-725 - GGCGUUUGAGCGCGGCA 17 965
HSV2-UL19-726 - GAUGCUGCACGUGCUGU 17 966
HSV2-UL19-727 - GCACGUGCUGUUGGAGA 17 967
HSV2-UL19-728 - GGAGAAGGCGCCUCCCC 17 968
HSV2-UL19-729 - CAACGAUAUCUCGACAA 17 969
HSV2-UL19-730 - AACGAUAUCUCGACAAC 17 970
HSV2-UL19-731 - UCUCGACAACGGGCGCC 17 971
HSV2-UL19-732 - ACGGGCGCCUGGCGACC 17 972
HSV2-UL19-733 - CGGGCGCCUGGCGACCA 17 973
HSV2-UL19-734 - UGGCGACCAGGGUUGCC 17 974
HSV2-UL19-735 - GGCGACCAGGGUUGCCC 17 975
HSV2-UL19-736 - GGUUGCCCGGGCGACCC 17 976
HSV2-UL19-737 - UGGUCGCCGAGCUGAAG 17 977
HSV2-UL19-738 - CGACACGAGCUUCUUCC 17 978
HSV2-UL19-739 - GACACGAGCUUCUUCCU 17 979
HSV2-UL19-740 - GAGCUUCUUCCUGGGCA 17 980
HSV2-UL19-741 - CUUCUUCCUGGGCAAGG 17 981
HSV2-UL19-742 - UUCUUCCUGGGCAAGGC 17 982
HSV2-UL19-743 - GGCGGGCCAUCGCCGCG 17 983
HSV2-UL19-744 - UCGCCGCGAGGCCAUCG 17 984
HSV2-UL19-745 - GCGAGGCCAUCGAGGCC 17 985
HSV2-UL19-746 - CAUCGAGGCCUGGCUCG 17 986
HSV2-UL19-747 - GCUCGUGGACCUGACCA 17 987
HSV2-UL19-748 - GGCGACGCAGCCGUCCG 17 988
HSV2-UL19-749 - ACGCACGCCGACACGCG 17 989
HSV2-UL19-750 - CGCACGCCGACACGCGC 17 990
HSV2-UL19-751 - ACGCCGACACGCGCGGG 17 991
HSV2-UL19-752 - CGACACGCGCGGGCGGC 17 992
HSV2-UL19-753 - CGCGGGCGGCCGGUCGA 17 993
HSV2-UL19-754 - GCGGGCGGCCGGUCGAC 17 994
HSV2-UL19-755 - CGGGCGGCCGGUCGACG 17 995
HSV2-UL19-756 - GCCGGUCGACGGGGUGC 17 996
HSV2-UL19-757 - CCUGCAGUCCUUCCUGA 17 997
HSV2-UL19-758 - GCAGUCCUUCCUGAAGG 17 998
HSV2-UL19-759 - GUCCUUCCUGAAGGUGG 17 999
HSV2-UL19-760 - GAAGGUGGAGGACACCG 17 1000
HSV2-UL19-761 - CACCGAGGCCGACGUGC 17 1001
HSV2-UL19-762 - GACGUGCCGGUGACCUA 17 1002
HSV2-UL19-763 - GGUGACCUACGGCGAGA 17 1003
HSV2-UL19-764 - GGCGAGAUGGUCUUGAA 17 1004
HSV2-UL19-765 - GCGAGAUGGUCUUGAAC 17 1005
HSV2-UL19-766 - CGAGAUGGUCUUGAACG 17 1006
HSV2-UL19-767 - CGGGGCCAACCUCGUCA 17 1007
HSV2-UL19-768 - CAACCU CG U CACGGCG C 17 1008
HSV2-UL19-769 - CGUCACGGCGCUGGUGA 17 1009 HSV2-UL19-770 - GUCACGGCGCUGGUGAU 17 1010
HSV2-UL19-771 - GGCGCUGGUGAUGGGCA 17 1011
HSV2-UL19-772 - UGAUGGGCAAGGCCGUG 17 1012
HSV2-UL19-773 - CAAGGCCGUGCGGAGCC 17 1013
HSV2-UL19-774 - GCGGAGCCUGGACGACG 17 1014
HSV2-UL19-775 - CGGAGCCUGGACGACGU 17 1015
HSV2-UL19-776 - CGUGGGCCGCCACCUGC 17 1016
HSV2-UL19-777 - CCACCUGCUGGAUAUGC 17 1017
HSV2-UL19-778 - CCUGCUGGAUAUGCAGG 17 1018
HSV2-UL19-779 - GCAGGAGGAGCAACUCG 17 1019
HSV2-UL19-780 - AGCAACUCGAGGCGAAC 17 1020
HSV2-UL19-781 - GCAACUCGAGGCGAACC 17 1021
HSV2-UL19-782 - GGCGAACCGGGAGACGC 17 1022
HSV2-UL19-783 - GACAACGCGCGUGCGCG 17 1023
HSV2-UL19-784 - GCGCGUGCGCGCGGAUC 17 1024
HSV2-UL19-785 - CGUGCGCGCGGAUCUGG 17 1025
HSV2-UL19-786 - GCGGAUCUGGUGGCCAU 17 1026
HSV2-UL19-787 - UGGUGGCCAUAGGCGAC 17 1027
HSV2-UL19-788 - GGCCAUAGGCGACAGGC 17 1028
HSV2-UL19-789 - CGACAGGCUGGUCUUCC 17 1029
HSV2-UL19-790 - CAGGCUGGUCUUCCUGG 17 1030
HSV2-UL19-791 - GGUCUUCCUGGAGGCCC 17 1031
HSV2-UL19-792 - CAACGUGCCCUACCCCC 17 1032
HSV2-UL19-793 - CGUGCCCUACCCCCUGG 17 1033
HSV2-UL19-794 - GUGCCCUACCCCCUGGU 17 1034
HSV2-UL19-795 - CCCCCUGGUGGGCGCCA 17 1035
HSV2-UL19-796 - GACGUUCGUCCUGCCCC 17 1036
HSV2-UL19-797 - ACGUUCGUCCUGCCCCU 17 1037
HSV2-UL19-798 - CGUUCGUCCUGCCCCUG 17 1038
HSV2-UL19-799 - CCUGGGGCUGUUCAACC 17 1039
HSV2-UL19-800 - GCUGUUCAACCCGGCCA 17 1040
HSV2-UL19-801 - CGCUUCGCCGCGCACGC 17 1041
HSV2-UL19-802 - GCUUCGCCGCGCACGCC 17 1042
HSV2-UL19-803 - CUUCGCCGCGCACGCCG 17 1043
HSV2-UL19-804 - CGCGCACGCCGGGGACC 17 1044
HSV2-UL19-805 - GACCUGGUGCCCGCCCC 17 1045
HSV2-UL19-806 - GCCCGCCCCCGGCCACC 17 1046
HSV2-UL19-807 - CCCGCGCGUUCCCUCCC 17 1047
HSV2-UL19-808 - CCCGGCAGCUGUUUUUU 17 1048
HSV2-UL19-809 - CCGGCAGCUGUUUUUUU 17 1049
HSV2-UL19-810 - CGGCAGCUGUUUUUUUG 17 1050
HSV2-UL19-811 - GCUGUUUUUUUGGGGAA 17 1051
HSV2-UL19-812 - UUGGGGAAAGGACCACC 17 1052
HSV2-UL19-813 - AG G ACCACCAG G U UCU G 17 1053
HSV2-UL19-814 - GGUUCUGCGGCUGUCCA 17 1054
HSV2-UL19-815 - GCUGUCCAUGGAGAACG 17 1055 HSV2-UL19-816 - UCCAUGGAGAACGCGGU 17 1056
HSV2-UL19-817 - CCAUGGAGAACGCGGUC 17 1057
HSV2-UL19-818 - GCUCAUGAACAUCGACG 17 1058
HSV2-UL19-819 - AACAUCGACGCGGCCGU 17 1059
HSV2-UL19-820 - ACAUCGACGCGGCCGUC 17 1060
HSV2-UL19-821 - CAUCGACGCGGCCGUCG 17 1061
HSV2-UL19-822 - AUCGACGCGGCCGUCGG 17 1062
HSV2-UL19-823 - G AACCACG ACCCCG U CG 17 1063
HSV2-UL19-824 - GAGGCCGCGAAUCCGUA 17 1064
HSV2-UL19-825 - AGGCCGCGAAUCCGUAC 17 1065
HSV2-UL19-826 - GGCCGCGAAUCCGUACG 17 1066
HSV2-UL19-827 - GUACGGGGCGUACGUCG 17 1067
HSV2-UL19-828 - GGCGUACGUCGCGGCCC 17 1068
HSV2-UL19-829 - UACGUCGCGGCCCCGGC 17 1069
HSV2-UL19-830 - GCGGCCCCGGCCGGCCC 17 1070
HSV2-UL19-831 - CCCGGCCGGCCCCGGCG 17 1071
HSV2-UL19-832 - AGCGUUUUCUGAACGCC 17 1072
HSV2-UL19-833 - GUUUUCUGAACGCCUGG 17 1073
HSV2-UL19-834 - CGGCAGCGCCUCGCCCA 17 1074
HSV2-UL19-835 - AGCGCCUCGCCCACGGC 17 1075
HSV2-UL19-836 - GCGCCUCGCCCACGGCC 17 1076
HSV2-UL19-837 - UCGCCCACGGCCGGGUC 17 1077
HSV2-UL19-838 - CCCACGGCCGGGUCCGG 17 1078
HSV2-UL19-839 - CCACGGCCGGGUCCGGU 17 1079
HSV2-UL19-840 - CGAGUGCCAGAUGACCG 17 1080
HSV2-UL19-841 - GCCCGACAACGCCAACC 17 1081
HSV2-UL19-842 - CAACGCCAACCUGGCUC 17 1082
HSV2-UL19-843 - CGCGUUCGACUUCUUCG 17 1083
HSV2-UL19-844 - GCGUUCGACUUCUUCGC 17 1084
HSV2-UL19-845 - CGACUUCUUCGCGGGCG 17 1085
HSV2-UL19-846 - GCCGACGUCGAGCUUCC 17 1086
HSV2-UL19-847 - GACGUCGAGCUUCCCGG 17 1087
HSV2-UL19-848 - CGGCGGCGAAGUCCCCC 17 1088
HSV2-UL19-849 - GGCGAAGUCCCCCCGGC 17 1089
HSV2-UL19-850 - AGUCCCCCCGGCCGGUC 17 1090
HSV2-UL19-851 - GUCCCCCCGGCCGGUCC 17 1091
HSV2-UL19-852 - UCCCCCCGGCCGGUCCG 17 1092
HSV2-UL19-853 - CCCCCCGGCCGGUCCGG 17 1093
HSV2-UL19-854 - CGGUCCGGGGGCGAUCC 17 1094
HSV2-UL19-855 - GGGCGAUCCAGGCCACC 17 1095
HSV2-UL19-856 - CCAGGCCACCUGGCGCG 17 1096
HSV2-UL19-857 - ACCUGGCGCGUGGUCAA 17 1097
HSV2-UL19-858 - CAACGGCAACCUGCCCC 17 1098
HSV2-UL19-859 - GCCCCUGGCGCUGUGUC 17 1099
HSV2-UL19-860 - CCUGGCGCUGUGUCCGG 17 1100
HSV2-UL19-861 - UGGCGUUUCGUGACGCC 17 1101 HSV2-UL19-862 - GGCGUUUCGUGACGCCC 17 1102
HSV2-UL19-863 - GCGUUUCGUGACGCCCG 17 1103
HSV2-UL19-864 - UCGUGACGCCCGGGGCC 17 1104
HSV2-UL19-865 - GCCCGGGGCCUGGAGCU 17 1105
HSV2-UL19-866 - GGCCUGGAGCUCGGCGU 17 1106
HSV2-UL19-867 - CGUUGGCCGCCACGCCA 17 1107
HSV2-UL19-868 - CCGCCACGCCAUGGCGC 17 1108
HSV2-UL19-869 - ACCAUAGCCGCCGUCCG 17 1109
HSV2-UL19-870 - CCAUAGCCGCCGUCCGC 17 1110
HSV2-UL19-871 - CAUAGCCGCCGUCCGCG 17 1111
HSV2-UL19-872 - CGUCCGCGGGGCGUUCG 17 1112
HSV2-UL19-873 - CGAGGACCGCAGCUACC 17 1113
HSV2-UL19-874 - GGACCGCAGCUACCCGG 17 1114
HSV2-UL19-875 - CUGCAAGCCGCGAUUCA 17 1115
HSV2-UL19-876 - GCACGUGUUCUGCGCCC 17 1116
HSV2-UL19-877 - UGUUCUGCGCCCUGGCG 17 1117
HSV2-UL19-878 - AGUGCAUCACCAGCUAC 17 1118
HSV2-UL19-879 - GAACAACACGCGAUGCG 17 1119
HSV2-UL19-880 - CGUGAACGACUACUCGC 17 1120
HSV2-UL19-881 - UACAUCGUGACCUACCU 17 1121
HSV2-UL19-882 - ACAUCGUGACCUACCUC 17 1122
HSV2-UL19-883 - CAUCGUGACCUACCUCG 17 1123
HSV2-UL19-884 - AUCGUGACCUACCUCGG 17 1124
HSV2-UL19-885 - CGGGGGCGACCUCCCCG 17 1125
HSV2-UL19-886 - CCUCCCCGAGGAGUGCA 17 1126
HSV2-UL19-887 - AGUGCAUGGCCGUGUAU 17 1127
HSV2-UL19-888 - GUGCAUGGCCGUGUAUC 17 1128
HSV2-UL19-889 - GGCCGUGUAUCGGGACC 17 1129
HSV2-UL19-890 - CGUGUAUCGGGACCUGG 17 1130
HSV2-UL19-891 - CCUGGUGGCCCACGUCG 17 1131
HSV2-UL19-892 - GGCCCACGUCGAGGCCC 17 1132
HSV2-UL19-893 - CGAGGCCCUGGCCCAGC 17 1133
HSV2-UL19-894 - GGCCCUGGCCCAGCUGG 17 1134
HSV2-UL19-895 - GGACGACUUUACCCUGC 17 1135
HSV2-UL19-896 - GACGACU U UACCCUGCC 17 1136
HSV2-UL19-897 - CUUUACCCUGCCGGGCC 17 1137
HSV2-UL19-898 - CCUGCCGGGCCCGGAGC 17 1138
HSV2-UL19-899 - CUGCCGGGCCCGGAGCU 17 1139
HSV2-UL19-900 - CCGGGCCCGGAGCUGGG 17 1140
HSV2-UL19-901 - CGGGCCCGGAGCUGGGC 17 1141
HSV2-UL19-902 - CCCGGAGCUGGGCGGGC 17 1142
HSV2-UL19-903 - GCUGGGCGGGCAGGCUC 17 1143
HSV2-UL19-904 - UCACCUGAUGCGCGACC 17 1144
HSV2-UL19-905 - UGCUGCCGCCCCUCGUG 17 1145
HSV2-UL19-906 - GCUGCCGCCCCUCGUGU 17 1146
HSV2-UL19-907 - CUCGUGUGGGACUGCGA 17 1147 HSV2-UL19-908 - CGGCCUUAUGCGACACG 17 1148
HSV2-UL19-909 - UAUGCGACACGCGGCCC 17 1149
HSV2-UL19-910 - ACCGCCACCGAGACUGC 17 1150
HSV2-UL19-911 - AGACUGCCGGAUUGACG 17 1151
HSV2-UL19-912 - GACUGCCGGAUUGACGC 17 1152
HSV2-UL19-913 - ACUGCCGGAUUGACGCG 17 1153
HSV2-UL19-914 - CUGCCGGAUUGACGCGG 17 1154
HSV2-UL19-915 - UGCCGGAUUGACGCGGG 17 1155
HSV2-UL19-916 - GCCGGAUUGACGCGGGG 17 1156
HSV2-UL19-917 - GCACGAGCCCGUCUACG 17 1157
HSV2-UL19-918 - CGAGCCCGUCUACGCGG 17 1158
HSV2-UL19-919 - CGCGGCGGCGUGCAACG 17 1159
HSV2-UL19-920 - GGCGUGCAACGUGGCGA 17 1160
HSV2-UL19-921 - GACU U UAACCGCAACGA 17 1161
HSV2-UL19-922 - UUAACCGCAACGACGGC 17 1162
HSV2-UL19-923 - GCUGCUGCACAACACCC 17 1163
HSV2-UL19-924 - CA ACACCCAG G CCCG CG 17 1164
HSV2-UL19-925 - CCGACGCCGCCGACGAC 17 1165
HSV2-UL19-926 - CCGACGACCGGCCGCAC 17 1166
HSV2-UL19-927 - CGACCGGCCGCACCGGC 17 1167
HSV2-UL19-928 - CGCACCGGCCGGCCGAC 17 1168
HSV2-UL19-929 - AAUCUACUAUUACGUGC 17 1169
HSV2-UL19-930 - CUAUUACGUGCUGGUGC 17 1170
HSV2-UL19-931 - UGGUGCCGGCCUUCUCG 17 1171
HSV2-UL19-932 - GGUGCCGGCCUUCUCGC 17 1172
HSV2-UL19-933 - GUGCCGGCCUUCUCGCG 17 1173
HSV2-UL19-934 - UGCCGGCCUUCUCGCGG 17 1174
HSV2-UL19-935 - GGGGCGCUGCUGCACCG 17 1175
HSV2-UL19-936 - GGGCGCUGCUGCACCGC 17 1176
HSV2-UL19-937 - GGCGCUGCUGCACCGCG 17 1177
HSV2-UL19-938 - GCGCUGCUGCACCGCGG 17 1178
HSV2-UL19-939 - CGCCACGCUGCAGAACA 17 1179
HSV2-UL19-940 - CACGCUGCAGAACAUGG 17 1180
HSV2-UL19-941 - GCAGAACAUGGUGGUCC 17 1181
HSV2-UL19-942 - GUCCCGGAGAUCGCCCC 17 1182
HSV2-UL19-943 - GGAGAUCGCCCCCGGUG 17 1183
HSV2-UL19-944 - GCUGCAUCCCGCCAAUC 17 1184
HSV2-UL19-945 - GCAUCCCGCCAAUCUGG 17 1185
HSV2-UL19-946 - CAAUCUGGUGGCCAACA 17 1186
HSV2-UL19-947 - AAGCGCAUGUU CCACAA 17 1187
HSV2-UL19-948 - AGCGCAUGUUCCACAAC 17 1188
HSV2-UL19-949 - GGGCGCGUCGUCGUCGA 17 1189
HSV2-UL19-950 - GGCGCGUCGUCGUCGAC 17 1190
HSV2-UL19-951 - CGCCAUGCUCACGCUGC 17 1191
HSV2-UL19-952 - GCUCACGCUGCAGGUGC 17 1192
HSV2-UL19-953 - GGUGCUGGCG CACAACA 17 1193 HSV2-UL19-954 - CAUGGCCGAGCGCACGA 17 1194
HSV2-UL19-955 - GGCGCUGCUGUGCUCCG 17 1195
HSV2-UL19-956 - CUCCGCGGCGCCCGACG 17 1196
HSV2-UL19-957 - UCCGCGGCGCCCGACGC 17 1197
HSV2-UL19-958 - CGCCAACACCGCGUCGA 17 1198
HSV2-UL19-959 - AACAUGCGCAUCUUCGA 17 1199
HSV2-UL19-960 - ACAUGCGCAUCUUCGAC 17 1200
HSV2-UL19-961 - CAUGCGCAUCUUCGACG 17 1201
HSV2-UL19-962 - GACGGGGCGCUGCACGC 17 1202
HSV2-UL19-963 - CGCCGGCGUGCUGCUCA 17 1203
HSV2-UL19-964 - CAU GG CCCCCCAGCACC 17 1204
HSV2-UL19-965 - G ACCACACCAU CCAAAA 17 1205
HSV2-UL19-966 - CGUCCACGCGCUGUUUG 17 1206
HSV2-UL19-967 - GUCCACGCGCUGUUUGC 17 1207
HSV2-UL19-968 - UGCGGGCGCCGACCACG 17 1208
HSV2-UL19-969 - CG CG CCCAACU U CCCCC 17 1209
HSV2-UL19-970 - CCCGGCCCUGCGCGACC 17 1210
HSV2-UL19-971 - GGCGCGCGACGUCCCCC 17 1211
HSV2-UL19-972 - CGUCCCCCUGGUCCCCC 17 1212
HSV2-UL19-973 - CCUGGUCCCCCCGGCCC 17 1213
HSV2-UL19-974 - CUGGUCCCCCCGGCCCU 17 1214
HSV2-UL19-975 - UGGUCCCCCCGGCCCUG 17 1215
HSV2-UL19-976 - GGUCCCCCCGGCCCUGG 17 1216
HSV2-UL19-977 - CUCCAUCCGCCAGCCCG 17 1217
HSV2-UL19-978 - GCACGCCCGCGAGAGCG 17 1218
HSV2-UL19-979 - CGCCCGCGAGAGCGCGG 17 1219
HSV2-UL19-980 - GCCCGCGAGAGCGCGGC 17 1220
HSV2-UL19-981 - CCCGCGAGAGCGCGGCG 17 1221
HSV2-UL19-982 - CCGCGAGAGCGCGGCGG 17 1222
HSV2-UL19-983 - GCUGACCUACGCGCUCA 17 1223
HSV2-UL19-984 - GACCUACGCGCUCAUGG 17 1224
HSV2-UL19-985 - ACCUACGCGCUCAUGGC 17 1225
HSV2-UL19-986 - CCUACGCGCUCAUGGCG 17 1226
HSV2-UL19-987 - CU UCAAG AUG AGCCCCG 17 1227
HSV2-UL19-988 - GUAUCACCAGCUCAAGA 17 1228
HSV2-UL19-989 - UAUCACCAGCUCAAGAC 17 1229
HSV2-UL19-990 - AAGACGGGCCUCCACCC 17 1230
HSV2-UL19-991 - AGACGGGCCUCCACCCC 17 1231
HSV2-UL19-992 - GGCCUCCACCCCGGGUU 17 1232
HSV2-UL19-993 - GCCUCCACCCCGGGUUC 17 1233
HSV2-UL19-994 - UCGGGUUCACCGUCGUG 17 1234
HSV2-UL19-995 - GUUCACCGUCGUGCGGC 17 1235
HSV2-UL19-996 - GUUUUCCGAGCGCGCGU 17 1236
HSV2-UL19-997 - UUCCGAGCGCGCGUCGG 17 1237
HSV2-UL19-998 - GUCGGAGGCGUACUUUC 17 1238
HSV2-UL19-999 - UCGGAGGCGUACUUUCU 17 1239 HSV2-UL19-1000 - CUUUCUGGGCCAGCUCC 17 1240
HSV2-UL19-1001 - UCUGGGCCAGCUCCAGG 17 1241
HSV2-UL19-1002 - G G U G G CCCG CCACG AAA 17 1242
HSV2-UL19-1003 - GUGGCCCGCCACGAAAC 17 1243
HSV2-UL19-1004 - GCCCGCCACGAAACGGG 17 1244
HSV2-UL19-1005 - CCCGCCACGAAACGGGC 17 1245
HSV2-UL19-1006 - CCGCCACGAAACGGGCG 17 1246
HSV2-UL19-1007 - CGCCACGAAACGGGCGG 17 1247
HSV2-UL19-1008 - G CCACG AAACG G G CG G G 17 1248
HSV2-UL19-1009 - CCACGAAACGGGCGGGG 17 1249
HSV2-UL19-1010 - ACGCUCACCCAGCCGCG 17 1250
HSV2-UL19-1011 - CCAGCCGCGCGG AAACG 17 1251
HSV2-UL19-1012 - GCGCGGAAACGUGGACC 17 1252
HSV2-UL19-1013 - CGCGGAAACGUGGACCU 17 1253
HSV2-UL19-1014 - AAACGUGGACCUGGGUG 17 1254
HSV2-UL19-1015 - AACGUGGACCUGGGUGU 17 1255
HSV2-UL19-1016 - GGGCUACACCGCCGUCG 17 1256
HSV2-UL19-1017 - CACCGCCGUCGCGGCCA 17 1257
HSV2-UL19-1018 - ACCGCCGUCGCGGCCAC 17 1258
HSV2-UL19-1019 - CG U CCG CAACCCCG U U A 17 1259
HSV2-UL19-1020 - CAACCCCG U U ACG G ACA 17 1260
HSV2-UL19-1021 - AACCCCG U U ACGGACAU 17 1261
HSV2-UL19-1022 - CCCCAAAACU U U U ACCU 17 1262
HSV2-UL19-1023 - AACUUUUACCUCGGCCG 17 1263
HSV2-UL19-1024 - ACUUUUACCUCGGCCGC 17 1264
HSV2-UL19-1025 - CUUUUACCUCGGCCGCG 17 1265
HSV2-UL19-1026 - CCCGCUGCUAGACAACG 17 1266
HSV2-UL19-1027 - CGUGUACCUGCGCAACG 17 1267
HSV2-UL19-1028 - CCUGCGCAACGCGGUCG 17 1268
HSV2-UL19-1029 - GCGCAACGCGGUCGUGG 17 1269
HSV2-UL19-1030 - CGCAACGCGGUCGUGGC 17 1270
HSV2-UL19-1031 - CGGUCGUGGCGGGAAAC 17 1271
HSV2-UL19-1032 - CGUGGCGGGAAACCGGC 17 1272
HSV2-UL19-1033 - GUGGCGGGAAACCGGCU 17 1273
HSV2-UL19-1034 - UGGCGGGAAACCGGCUG 17 1274
HSV2-UL19-1035 - GGGAAACCGGCUGGGGC 17 1275
HSV2-UL19-1036 - GCCGGCCCAGCCCCUCC 17 1276
HSV2-UL19-1037 - CAG CCCCU CCCGG U CU U 17 1277
HSV2-UL19-1038 - GGUCUUUGGCUGCGCCC 17 1278
HSV2-UL19-1039 - GCUGCGCCCAGGUGCCG 17 1279
HSV2-UL19-1040 - CAGGUGCCGCGGCGCGC 17 1280
HSV2-UL19-1041 - GCCGCGGCGCGCCGGCA 17 1281
HSV2-UL19-1042 - CGCGCCGGCAUGGACCA 17 1282
HSV2-UL19-1043 - GCGCCGGCAUGGACCAC 17 1283
HSV2-UL19-1044 - CGGCAUGGACCACGGGC 17 1284
HSV2-UL19-1045 - GUUCAUCGCCACCCCCG 17 1285 HSV2-UL19-1046 - CGCCACCCCCGUGGCCA 17 1286
HSV2-UL19-1047 - ACAUCAACUACUUUCGC 17 1287
HSV2-UL19-1048 - GCCGGCCCUGCAACCCG 17 1288
HSV2-UL19-1049 - CCGGCCCUGCAACCCGC 17 1289
HSV2-UL19-1050 - CGGCCCUGCAACCCGCG 17 1290
HSV2-UL19-1051 - CAACCCGCGGGGACGCG 17 1291
HSV2-UL19-1052 - CCGCGGGGACGCGCGGC 17 1292
HSV2-UL19-1053 - CGGGGACGCGCGGCCGG 17 1293
HSV2-UL19-1054 - GGCCGGCGGCGUGUACG 17 1294
HSV2-UL19-1055 - GCCGGCGGCGUGUACGC 17 1295
HSV2-UL19-1056 - CCGGCGGCGUGUACGCG 17 1296
HSV2-UL19-1057 - CGGCGGCGUGUACGCGG 17 1297
HSV2-UL19-1058 - CGUGUACGCGGGGGACA 17 1298
HSV2-UL19-1059 - GUACGCGGGGGACAAGG 17 1299
HSV2-UL19-1060 - UACGCGGGGGACAAGGA 17 1300
HSV2-UL19-1061 - ACGCGGGGGACAAGGAG 17 1301
HSV2-UL19-1062 - CGCGGGGGACAAGGAGG 17 1302
HSV2-UL19-1063 - GCCCUCAUGUACGACCA 17 1303
HSV2-UL19-1064 - CCACGGCCAGAGCGACC 17 1304
HSV2-UL19-1065 - GCCAGAGCGACCCGGCG 17 1305
HSV2-UL19-1066 - CCCGGCGCGGCCCUUCG 17 1306
HSV2-UL19-1067 - GCGGCCCUUCGCGGCCA 17 1307
HSV2-UL19-1068 - CGGCCACGGCCAACCCG 17 1308
HSV2-UL19-1069 - GGCCACG G CCAACCCG U 17 1309
HSV2-UL19-1070 - ACCCGUGGGCGUCGCAG 17 1310
HSV2-UL19-1071 - UCGCAGCGGUUCUCGUA 17 1311
HSV2-UL19-1072 - CGCAGCGGUUCUCGUAC 17 1312
HSV2-UL19-1073 - GCAGCGGUUCUCGUACG 17 1313
HSV2-UL19-1074 - GGGGACCUGCUGUACAA 17 1314
HSV2-UL19-1075 - GGGACCUGCUGUACAAC 17 1315
HSV2-UL19-1076 - GGACCUGCUGUACAACG 17 1316
HSV2-UL19-1077 - GGGGCCUAUCACCUCAA 17 1317
HSV2-UL19-1078 - GGGCCUAUCACCUCAAC 17 1318
HSV2-UL19-1079 - GGCCUAUCACCUCAACG 17 1319
HSV2-UL19-1080 - CU U CAAG U UCU U CACCG 17 1320
HSV2-UL19-1081 - CACCGCGGCCGACAUCA 17 1321
HSV2-UL19-1082 - GGCCAAACAUCGCUGCC 17 1322
HSV2-UL19-1083 - CCUGGAGCGUCUCAUCG 17 1323
HSV2-UL19-1084 - GCGUCUCAUCGUGGAAA 17 1324
HSV2-UL19-1085 - CGUCUCAUCGUGGAAAC 17 1325
HSV2-UL19-1086 - CAUCGUGGAAACGGGAU 17 1326
HSV2-UL19-1087 - CGUGGAAACGGGAUCGG 17 1327
HSV2-UL19-1088 - GGGAUCGGCGGUAUCCA 17 1328
HSV2-UL19-1089 - GCAGUUUAAGCGCCCGC 17 1329
HSV2-UL19-1090 - CAGUUUAAGCGCCCGCC 17 1330
HSV2-UL19-1091 - AGUUUAAGCGCCCGCCG 17 1331 HSV2-UL19-1092 - GGGGUGCCGCGAGCUCG 17 1332
HSV2-UL19-1093 - CUCGUGGAAGACCCGUG 17 1333
HSV2-UL19-1094 - CCCGUGCGGCCUGUUUC 17 1334
HSV2-UL19-1095 - CUACGCAGCGCCCGCGA 17 1335
HSV2-UL19-1096 - UACGCAGCGCCCGCGAU 17 1336
HSV2-UL19-1097 - ACGCAGCGCCCGCGAUG 17 1337
HSV2-UL19-1098 - CAGCGCCCGCGAUGGGG 17 1338
HSV2-UL19-1099 - CGACGCCUCCCCGCUAA 17 1339
HSV2-UL19-1100 - GACGCCUCCCCGCUAAA 17 1340
HSV2-UL19-1101 + UACAGAGACAGGCCCUUUAG 20 1341
HSV2-UL19-1102 + ACAGAGACAGGCCCUUUAGC 20 1342
HSV2-UL19-1103 + CAGAGACAGGCCCUUUAGCG 20 1343
HSV2-UL19-1104 + AGACAGGCCCUUUAGCGGGG 20 1344
HSV2-UL19-1105 + AGAUGAGAUACUGCGUAAAG 20 1345
HSV2-UL19-1106 + GAUGAGAUACUGCGUAAAGU 20 1346
HSV2-UL19-1107 + UAAAGUGGGUCUCUCGCGCG 20 1347
HSV2-UL19-1108 + AAAGUGGGUCUCUCGCGCGU 20 1348
HSV2-UL19-1109 + GCGCGUGGGCCUCCCCAUCG 20 1349
HSV2-UL19-1110 + CGCGUGGGCCUCCCCAUCGC 20 1350
HSV2-UL19-1111 + CAUCGCGGGCGCUGCGUAGC 20 1351
HSV2-UL19-1112 + AUCGCGGGCGCUGCGUAGCA 20 1352
HSV2-UL19-1113 + GCGGGCGCUGCGUAGCAGGG 20 1353
HSV2-UL19-1114 + CGGGCGCUGCGUAGCAGGGC 20 1354
HSV2-UL19-1115 + GGGCGCUGCGUAGCAGGGCG 20 1355
HSV2-UL19-1116 + GCGUAGCAGGGCGGGGUCGC 20 1356
HSV2-UL19-1117 + CAGGGCGGGGUCGCUGGCGC 20 1357
HSV2-UL19-1118 + GGGUCGCUGGCGCAGGUGAU 20 1358
HSV2-UL19-1119 + GGUCGCUGGCGCAGGUGAUC 20 1359
HSV2-UL19-1120 + GCUGGCGCAGGUGAUCGGGU 20 1360
HSV2-UL19-1121 + UCGGGUAGGCUUCCUGAAAC 20 1361
HSV2-UL19-1122 + GCUUCCUGAAACAGGCCGCA 20 1362
HSV2-UL19-1123 + CUUCCUGAAACAGGCCGCAC 20 1363
HSV2-UL19-1124 + ACGGGUCUUCCACGAGCUCG 20 1364
HSV2-UL19-1125 + UCCACGAGCUCGCGGCACCC 20 1365
HSV2-UL19-1126 + ACGAGCUCGCGGCACCCCGG 20 1366
HSV2-UL19-1127 + CGAGCUCGCGGCACCCCGGC 20 1367
HSV2-UL19-1128 + GCGCUUAAACUGCACGUCGC 20 1368
HSV2-UL19-1129 + AAACUGCACGUCGCUGGCAG 20 1369
HSV2-UL19-1130 + CUGCACGUCGCUGGCAGCGG 20 1370
HSV2-UL19-1131 + GUCGCUGGCAGCGGUGGCCG 20 1371
HSV2-UL19-1132 + UUUCCACGAUGAGACGCUCC 20 1372
HSV2-UL19-1133 + ACGCUCCAGGCAGCGAUGUU 20 1373
HSV2-UL19-1134 + GCGAUGUUUGGCCGUGAUGU 20 1374
HSV2-UL19-1135 + UUUGGCCGUGAUGUCGGCCG 20 1375
HSV2-UL19-1136 + CGCGGUGAAGAACUUGAAGC 20 1376
HSV2-UL19-1137 + GCGGUGAAGAACUUGAAGCA 20 1377 HSV2-UL19-1138 + CGGUGAAGAACU UGAAG CAG 20 1378
HSV2-UL19-1139 + AGAACUUGAAGCAGGGGCUG 20 1379
HSV2-UL19-1140 + CUUGAAGCAGGGGCUGAGGA 20 1380
HSV2-UL19-1141 + UUGAAGCAGGGGCUGAGGAC 20 1381
HSV2-UL19-1142 + GCAGGGGCUGAGGACGGGCG 20 1382
HSV2-UL19-1143 + GGACGGGCGAGGCCCCGUUG 20 1383
HSV2-UL19-1144 + CGAGGCCCCGUUGAGGUGAU 20 1384
HSV2-UL19-1145 + GAUAGGCCCCGUUGUACAGC 20 1385
HSV2-UL19-1146 + GAGAACCGCUGCGACGCCCA 20 1386
HSV2-UL19-1147 + AGAACCGCUGCGACGCCCAC 20 1387
HSV2-UL19-1148 + CCGCUGCGACGCCCACGGGU 20 1388
HSV2-UL19-1149 + CGACGCCCACGGGUUGGCCG 20 1389
HSV2-UL19-1150 + CGGGUUGGCCGUGGCCGCGA 20 1390
HSV2-UL19-1151 + GGGUUGGCCGUGGCCGCGAA 20 1391
HSV2-UL19-1152 + GUGGCCGCGAAGGGCCGCGC 20 1392
HSV2-UL19-1153 + UGGCCGCGAAGGGCCGCGCC 20 1393
HSV2-UL19-1154 + AGGGCCGCGCCGGGUCGCUC 20 1394
HSV2-UL19-1155 + GCGCCGGGUCGCUCUGGCCG 20 1395
HSV2-UL19-1156 + UCUGGCCGUGGUCGUACAUG 20 1396
HSV2-UL19-1157 + CUGGCCGUGGUCGUACAUGA 20 1397
HSV2-UL19-1158 + GUCCCCCGCGUACACGCCGC 20 1398
HSV2-UL19-1159 + CCGCCGGCCGCGCGUCCCCG 20 1399
HSV2-UL19-1160 + CGCCGGCCGCGCGUCCCCGC 20 1400
HSV2-UL19-1161 + CGCGCGUCCCCGCGGGUUGC 20 1401
HSV2-UL19-1162 + GCGCGUCCCCGCGGGUUGCA 20 1402
HSV2-UL19-1163 + GUCCCCGCGGGUUGCAGGGC 20 1403
HSV2-UL19-1164 + GCGAAAGUAGUUGAUGUCCG 20 1404
HSV2-UL19-1165 + GUAGUUGAUGUCCGUGGCCA 20 1405
HSV2-UL19-1166 + UAGUUGAUGUCCGUGGCCAC 20 1406
HSV2-UL19-1167 + AGUUGAUGUCCGUGGCCACG 20 1407
HSV2-UL19-1168 + GUUGAUGUCCGUGGCCACGG 20 1408
HSV2-UL19-1169 + GAUGUCCGUGGCCACGGGGG 20 1409
HSV2-UL19-1170 + GGUGGCGAUGAACUCACACA 20 1410
HSV2-UL19-1171 + CACACACGGCAUCCUGCCCG 20 1411
HSV2-UL19-1172 + AUCCUGCCCGUGGUCCAUGC 20 1412
HSV2-UL19-1173 + UGGUCCAUGCCGGCGCGCCG 20 1413
HSV2-UL19-1174 + UGCCGGCGCGCCGCGGCACC 20 1414
HSV2-UL19-1175 + GCCGGCGCGCCGCGGCACCU 20 1415
HSV2-UL19-1176 + ACCUGGGCGCAGCCAAAGAC 20 1416
HSV2-UL19-1177 + CCUGGGCGCAGCCAAAGACC 20 1417
HSV2-UL19-1178 + GGGCGCAGCCAAAGACCGGG 20 1418
HSV2-UL19-1179 + GGCGCAGCCAAAGACCGGGA 20 1419
HSV2-UL19-1180 + GCGCAGCCAAAGACCGGGAG 20 1420
HSV2-UL19-1181 + AGCCAAAGACCGGGAGGGGC 20 1421
HSV2-UL19-1182 + GCCAAAGACCGGGAGGGGCU 20 1422
HSV2-UL19-1183 + AAGACCGGGAGGGGCUGGGC 20 1423 HSV2-UL19-1184 + GGGGCUGGGCCGGCCCCAGC 20 1424
HSV2-UL19-1185 + CCGCCACGACCGCG U UGCGC 20 1425
HSV2-UL19-1186 + GACCGCGUUGCGCAGGUACA 20 1426
HSV2-UL19-1187 + CGCGUUGCGCAGGUACACGG 20 1427
HSV2-UL19-1188 + GCGGCCGCGUUGUCUAGCAG 20 1428
HSV2-UL19-1189 + CGGCCGCGUUGUCUAGCAGC 20 1429
HSV2-UL19-1190 + GGCCGCGUUGUCUAGCAGCG 20 1430
HSV2-UL19-1191 + GCCGCGUUGUCUAGCAGCGG 20 1431
HSV2-UL19-1192 + CCGCGUUGUCUAGCAGCGGG 20 1432
HSV2-UL19-1193 + CGCGU UGUCUAGCAGCGGGG 20 1433
HSV2-UL19-1194 + CUAGCAGCGGGGGGGCCCCG 20 1434
HSV2-UL19-1195 + GCGGGGGGGCCCCGCGGCCG 20 1435
HSV2-UL19-1196 + CGCGGCCGAGGUAAAAGUUU 20 1436
HSV2-UL19-1197 + GCGGCCGAGGUAAAAGUUUU 20 1437
HSV2-UL19-1198 + CGGCCGAGGUAAAAGUUUUG 20 1438
HSV2-UL19-1199 + GGCCGAGGUAAAAGUUUUGG 20 1439
HSV2-UL19-1200 + CGAGGUAAAAGUUUUGGGGG 20 1440
HSV2-UL19-1201 + GAGGUUGCCCAUGUCCGUAA 20 1441
HSV2-UL19-1202 + AGGUUGCCCAUGUCCGUAAC 20 1442
HSV2-UL19-1203 + GGUUGCCCAUGUCCGUAACG 20 1443
HSV2-UL19-1204 + CCAUGUCCGUAACGGGGUUG 20 1444
HSV2-UL19-1205 + GUCCGUAACGGGGUUGCGGA 20 1445
HSV2-UL19-1206 + GGGGUUGCGGACGGUGCCCG 20 1446
HSV2-UL19-1207 + GACGGUGCCCGUGGCCGCGA 20 1447
HSV2-UL19-1208 + GGUGCCCGUGGCCGCGACGG 20 1448
HSV2-UL19-1209 + CGGCGGUGUAGCCCACACCC 20 1449
HSV2-UL19-1210 + CCCAGGUCCACGUUUCCGCG 20 1450
HSV2-UL19-1211 + GGUCCACGUUUCCGCGCGGC 20 1451
HSV2-UL19-1212 + GUCCACGUUUCCGCGCGGCU 20 1452
HSV2-UL19-1213 + U G ACCCCCCCG CCCG U U U CG 20 1453
HSV2-UL19-1214 + CCCCCCCGCCCGUUUCGUGG 20 1454
HSV2-UL19-1215 + CCCCCCGCCCGUUUCGUGGC 20 1455
HSV2-UL19-1216 + CCGU UUCGUGGCGGGCCACC 20 1456
HSV2-UL19-1217 + CGUGGCGGGCCACCUGGAGC 20 1457
HSV2-UL19-1218 + GUACGCCUCCGACGCGCGCU 20 1458
HSV2-UL19-1219 + CU CG G AAAACAGCACG U U CU 20 1459
HSV2-UL19-1220 + GCACGUUCUCGGUCACGAAG 20 1460
HSV2-UL19-1221 + GAAGCGGUCCUGCCGCACGA 20 1461
HSV2-UL19-1222 + CACGACG G U G AACCCG AACC 20 1462
HSV2-UL19-1223 + ACGACGGUGAACCCGAACCC 20 1463
HSV2-UL19-1224 + CGACGGUGAACCCGAACCCG 20 1464
HSV2-UL19-1225 + CGGUGAACCCGAACCCGGGG 20 1465
HSV2-UL19-1226 + UGAACCCGAACCCGGGGUGG 20 1466
HSV2-UL19-1227 + GGUGGAGGCCCGUCUUGAGC 20 1467
HSV2-UL19-1228 + CCGUCU UGAGCUGGUGAUAC 20 1468
HSV2-UL19-1229 + CGUCUUGAGCUGGUGAUACA 20 1469 HSV2-UL19-1230 + GAGCUGGUGAUACAGGGCCA 20 1470
HSV2-UL19-1231 + AGCUGGUGAUACAGGGCCAC 20 1471
HSV2-UL19-1232 + GCUGGUGAUACAGGGCCACG 20 1472
HSV2-UL19-1233 + GUACCCCGCCAUGAGCGCGU 20 1473
HSV2-UL19-1234 + UCUCCCCCGCCGCGCUCUCG 20 1474
HSV2-UL19-1235 + CUCCCCCGCCGCGCUCUCGC 20 1475
HSV2-UL19-1236 + CUCGCGGGCGUGCUGCACCA 20 1476
HSV2-UL19-1237 + UCGCGGGCGUGCUGCACCAC 20 1477
HSV2-UL19-1238 + GGGCGUGCUGCACCACGGGC 20 1478
HSV2-UL19-1239 + CGUGCUGCACCACGGGCUGG 20 1479
HSV2-UL19-1240 + CUGCACCACGGGCUGGCGGA 20 1480
HSV2-UL19-1241 + CACCACGGGCUGGCGGAUGG 20 1481
HSV2-UL19-1242 + GCGGAUGGAGGAGAAGUAGU 20 1482
HSV2-UL19-1243 + AGGAGAAGUAGUUGGCCCCC 20 1483
HSV2-UL19-1244 + GGAGAAGUAGUUGGCCCCCA 20 1484
HSV2-UL19-1245 + AAGUAGUUGGCCCCCAGGGC 20 1485
HSV2-UL19-1246 + AGUAGUUGGCCCCCAGGGCC 20 1486
HSV2-UL19-1247 + GUAGUUGGCCCCCAGGGCCG 20 1487
HSV2-UL19-1248 + UAGUUGGCCCCCAGGGCCGG 20 1488
HSV2-UL19-1249 + AGUUGGCCCCCAGGGCCGGG 20 1489
HSV2-UL19-1250 + CCCCCAGGGCCGGGGGGACC 20 1490
HSV2-UL19-1251 + CCCCAGGGCCGGGGGGACCA 20 1491
HSV2-UL19-1252 + CCCAGGGCCGGGGGGACCAG 20 1492
HSV2-UL19-1253 + CCAGGGCCGGGGGGACCAGG 20 1493
HSV2-UL19-1254 + CCAGGGGGACGUCGCGCGCC 20 1494
HSV2-UL19-1255 + CGUCGCGCGCCAGGUCGCGC 20 1495
HSV2-UL19-1256 + GUCGCGCGCCAGGUCGCGCA 20 1496
HSV2-UL19-1257 + CGCGCCAGGUCGCGCAGGGC 20 1497
HSV2-UL19-1258 + GCGCCAGGUCGCGCAGGGCC 20 1498
HSV2-UL19-1259 + CGCCAGGUCGCGCAGGGCCG 20 1499
HSV2-UL19-1260 + GCCAGGUCGCGCAGGGCCGG 20 1500
HSV2-UL19-1261 + CCAGGUCGCGCAGGGCCGGG 20 1501
HSV2-UL19-1262 + GCGCAGGGCCGGGGGGAAGU 20 1502
HSV2-UL19-1263 + CGCAGGGCCGGGGGGAAGUU 20 1503
HSV2-UL19-1264 + CGGGGGGAAGUUGGGCGCGU 20 1504
HSV2-UL19-1265 + AGUUGGGCGCGUUGGCCACG 20 1505
HSV2-UL19-1266 + GGGCGCGUUGGCCACGUGGU 20 1506
HSV2-UL19-1267 + CG G CG CCCG CAAACAG CG CG 20 1507
HSV2-UL19-1268 + GCCCGCAAACAGCGCGUGGA 20 1508
HSV2-UL19-1269 + CCCG CAAACAG CGCGUGGAC 20 1509
HSV2-UL19-1270 + CAAACAG CGCGUGGACGGGC 20 1510
HSV2-UL19-1271 + CGUAGAAGUAUUCGCCAUUU 20 1511
HSV2-UL19-1272 + GAAGUAUUCGCCAUUUUGGA 20 1512
HSV2-UL19-1273 + AUUCGCCAUUUUGGAUGGUG 20 1513
HSV2-UL19-1274 + CAUUUUGGAUGGUGUGGUCC 20 1514
HSV2-UL19-1275 + GGAUGGUGUGGUCCAGGUGC 20 1515 HSV2-UL19-1276 + GAUGGUGUGGUCCAGGUGCU 20 1516
HSV2-UL19-1277 + AUGGUGUGGUCCAGGUGCUG 20 1517
HSV2-UL19-1278 + UGGUGUGGUCCAGGUGCUGG 20 1518
HSV2-UL19-1279 + GGUGUGGUCCAGGUGCUGGG 20 1519
HSV2-UL19-1280 + GGGGGCCAUGAGCAGCACGC 20 1520
HSV2-UL19-1281 + CCCGUCGAAGAUGCGCAUGU 20 1521
HSV2-UL19-1282 + GCGCAUGUUGGCCGUCGACG 20 1522
HSV2-UL19-1283 + GUUGGCCGUCGACGCGGUGU 20 1523
HSV2-UL19-1284 + CGCGGUGUUGGCGCCCGCGU 20 1524
HSV2-UL19-1285 + GCGGUGUUGGCGCCCGCGUC 20 1525
HSV2-UL19-1286 + GGCGCCCGCGUCGGGCGCCG 20 1526
HSV2-UL19-1287 + CAGCAGCGCCGUCGUGCGCU 20 1527
HSV2-UL19-1288 + CAGCACCUGCAGCGUGAGCA 20 1528
HSV2-UL19-1289 + CACCUGCAGCGUGAGCAUGG 20 1529
HSV2-UL19-1290 + ACCUGCAGCGUGAGCAUGGC 20 1530
HSV2-UL19-1291 + CGACGACGACGCGCCCGU UG 20 1531
HSV2-UL19-1292 + GAACAUGCGCUUGACCGUGU 20 1532
HSV2-UL19-1293 + GACCGUGUUGGCCACCAGAU 20 1533
HSV2-UL19-1294 + CGUGUUGGCCACCAGAUUGG 20 1534
HSV2-UL19-1295 + GUGUUGGCCACCAGAUUGGC 20 1535
HSV2-UL19-1296 + ACCAGAUUGGCGGGAUGCAG 20 1536
HSV2-UL19-1297 + CCAGAUUGGCGGGAUGCAGC 20 1537
HSV2-UL19-1298 + GAUUGGCGGGAUGCAGCGGG 20 1538
HSV2-UL19-1299 + AUUGGCGGGAUGCAGCGGGU 20 1539
HSV2-UL19-1300 + GGCGGGAUGCAGCGGGUGGG 20 1540
HSV2-UL19-1301 + GCGGGAUGCAGCGGGUGGGC 20 1541
HSV2-UL19-1302 + CGGGAUGCAGCGGGUGGGCG 20 1542
HSV2-UL19-1303 + AUGCAGCGGGUGGGCGGGGU 20 1543
HSV2-UL19-1304 + CGGGUGGGCGGGGUCGGUCA 20 1544
HSV2-UL19-1305 + GGGUGGGCGGGGUCGGUCAC 20 1545
HSV2-UL19-1306 + GGGUCGGUCACGGGAUCGCU 20 1546
HSV2-UL19-1307 + GGUCGGUCACGGGAUCGCUC 20 1547
HSV2-UL19-1308 + AUCGCUCGGGCACUCCUCAC 20 1548
HSV2-UL19-1309 + UCGCUCGGGCACUCCUCACC 20 1549
HSV2-UL19-1310 + CGCUCGGGCACUCCUCACCG 20 1550
HSV2-UL19-1311 + GCUCGGGCACUCCUCACCGG 20 1551
HSV2-UL19-1312 + UCCUCACCGGGGGCGAUCUC 20 1552
HSV2-UL19-1313 + CCUCACCGGGGGCGAUCUCC 20 1553
HSV2-UL19-1314 + G ACCACCAU G U U CU G CAGCG 20 1554
HSV2-UL19-1315 + UCUGCAGCGUGGCGUACACG 20 1555
HSV2-UL19-1316 + UGGCGUACACGCGGUCGAAG 20 1556
HSV2-UL19-1317 + GCGGUCGAAGCGGACCCCCG 20 1557
HSV2-UL19-1318 + GCAGCAGCGCCCCCGCGAGA 20 1558
HSV2-UL19-1319 + CAGCGCCCCCGCGAGAAGGC 20 1559
HSV2-UL19-1320 + GCACGUAAUAGUAGAUUUUG 20 1560
HSV2-UL19-1321 + CGUAAUAGUAGAUUUUGUGG 20 1561 HSV2-UL19-1322 + AUAGUAGAUUUUGUGGUGGA 20 1562
HSV2-UL19-1323 + UUUGUGGUGGACGGUCCAGU 20 1563
HSV2-UL19-1324 + UGGUGGACGGUCCAGUCGGC 20 1564
HSV2-UL19-1325 + GGACGGUCCAGUCGGCCGGC 20 1565
HSV2-UL19-1326 + GUCCAGUCGGCCGGCCGGUG 20 1566
HSV2-UL19-1327 + AGUCGGCCGGCCGGUGCGGC 20 1567
HSV2-UL19-1328 + CGGCCGGUGCGGCCGGUCGU 20 1568
HSV2-UL19-1329 + CCGGUGCGGCCGGUCGUCGG 20 1569
HSV2-UL19-1330 + CGGCCGGUCGUCGGCGGCGU 20 1570
HSV2-UL19-1331 + CGUCGGCGGCGUCGGCCGCG 20 1571
HSV2-UL19-1332 + GUCGGCGGCGUCGGCCGCGC 20 1572
HSV2-UL19-1333 + CGGCGUCGGCCGCGCGGGCC 20 1573
HSV2-UL19-1334 + GGCGUCGGCCGCGCGGGCCU 20 1574
HSV2-UL19-1335 + CCUGGGUGUUGUGCAGCAGC 20 1575
HSV2-UL19-1336 + GCAGCAGCCGGCCGUCGUUG 20 1576
HSV2-UL19-1337 + GCCGUCGUUGCGGUUAAAGU 20 1577
HSV2-UL19-1338 + GUUGCACGCCGCCGCGUAGA 20 1578
HSV2-UL19-1339 + UUGCACGCCGCCGCGUAGAC 20 1579
HSV2-UL19-1340 + CGUGCCCCCCCGCGUCAAUC 20 1580
HSV2-UL19-1341 + CCGCGUCAAUCCGGCAGUCU 20 1581
HSV2-UL19-1342 + CGUCAAUCCGGCAGUCUCGG 20 1582
HSV2-UL19-1343 + CAAUCCGGCAGUCUCGGUGG 20 1583
HSV2-UL19-1344 + GGCAGUCUCGGUGGCGGUCC 20 1584
HSV2-UL19-1345 + GCAGUCUCGGUGGCGGUCCA 20 1585
HSV2-UL19-1346 + CCAGGGCCGCGUGUCGCAUA 20 1586
HSV2-UL19-1347 + GGCCGUCGCAGUCCCACACG 20 1587
HSV2-UL19-1348 + GCCGUCGCAGUCCCACACGA 20 1588
HSV2-UL19-1349 + CCG U CG CAG U CCCACACG AG 20 1589
HSV2-UL19-1350 + UCGCAGUCCCACACGAGGGG 20 1590
HSV2-UL19-1351 + ACGAGGGGCGGCAGCAGCGC 20 1591
HSV2-UL19-1352 + CGAGGGGCGGCAGCAGCGCC 20 1592
HSV2-UL19-1353 + GCAGCGCCGGGUCGCGCAUC 20 1593
HSV2-UL19-1354 + GCGCAUCAGGUGAUUCAGCU 20 1594
HSV2-UL19-1355 + UGAGCCUGCCCGCCCAGCUC 20 1595
HSV2-UL19-1356 + GAGCCUGCCCGCCCAGCUCC 20 1596
HSV2-UL19-1357 + UGCCCGCCCAGCUCCGGGCC 20 1597
HSV2-UL19-1358 + CGCCCAGCUCCGGGCCCGGC 20 1598
HSV2-UL19-1359 + GCCCAGCUCCGGGCCCGGCA 20 1599
HSV2-UL19-1360 + G G G U AAAG U CG U CCACCAG C 20 1600
HSV2-UL19-1361 + GGUAAAGUCGUCCACCAGCU 20 1601
HSV2-UL19-1362 + AGUCGUCCACCAGCUGGGCC 20 1602
HSV2-UL19-1363 + GUCGUCCACCAGCUGGGCCA 20 1603
HSV2-UL19-1364 + GCUGGGCCAGGGCCUCGACG 20 1604
HSV2-UL19-1365 + CUGGGCCAGGGCCUCGACGU 20 1605
HSV2-UL19-1366 + GGGCCUCGACGUGGGCCACC 20 1606
HSV2-UL19-1367 + GGCCACCAGGUCCCGAUACA 20 1607 HSV2-UL19-1368 + AUACACGGCCAUGCACUCCU 20 1608
HSV2-UL19-1369 + UACACGGCCAUGCACUCCUC 20 1609
HSV2-UL19-1370 + ACACGGCCAUGCACUCCUCG 20 1610
HSV2-UL19-1371 + CGGCCAUGCACUCCUCGGGG 20 1611
HSV2-UL19-1372 + CCUCGGGGAGGUCGCCCCCG 20 1612
HSV2-UL19-1373 + GGGGAGGUCGCCCCCGAGGU 20 1613
HSV2-UL19-1374 + UCGCGUGUUGUUCCAGUAGC 20 1614
HSV2-UL19-1375 + ACUGAGUCACGAGCCGCGCC 20 1615
HSV2-UL19-1376 + CUGAGUCACGAGCCGCGCCA 20 1616
HSV2-UL19-1377 + GUGCUCGUUGCCGUGAAUCG 20 1617
HSV2-UL19-1378 + CGUGAAUCGCGGCUUGCAGC 20 1618
HSV2-UL19-1379 + U G CAG CAG G U AAAACACCG C 20 1619
HSV2-UL19-1380 + GCAGCAGGUAAAACACCGCC 20 1620
HSV2-UL19-1381 + AAAACACCGCCGGGUAGCUG 20 1621
HSV2-UL19-1382 + UGCGGUCCUCGAACGCCCCG 20 1622
HSV2-UL19-1383 + G U CCU CG AACG CCCCG CG G A 20 1623
HSV2-UL19-1384 + CUCGAACGCCCCGCGGACGG 20 1624
HSV2-UL19-1385 + CGCCCCGCGGACGGCGGCUA 20 1625
HSV2-UL19-1386 + CGGACGGCGGCUAUGGUAGC 20 1626
HSV2-UL19-1387 + GGCUAUGGUAGCCGGCGCCA 20 1627
HSV2-UL19-1388 + UGGUAGCCGGCGCCAUGGCG 20 1628
HSV2-UL19-1389 + UAGCCGGCGCCAUGGCGUGG 20 1629
HSV2-UL19-1390 + GGCGGCCAACGCCGAGCUCC 20 1630
HSV2-UL19-1391 + CAACGCCGAGCUCCAGGCCC 20 1631
HSV2-UL19-1392 + AACGCCGAGCUCCAGGCCCC 20 1632
HSV2-UL19-1393 + CG G G CG U CACG AAACG CCAC 20 1633
HSV2-UL19-1394 + ACG CCACCG G ACACAG CG CC 20 1634
HSV2-UL19-1395 + CG CCACCG G ACACAG CG CCA 20 1635
HSV2-UL19-1396 + GCCACCGGACACAGCGCCAG 20 1636
HSV2-UL19-1397 + CCGGACACAGCGCCAGGGGC 20 1637
HSV2-UL19-1398 + GUUGCCGUUGACCACGCGCC 20 1638
HSV2-UL19-1399 + GCCGU UGACCACGCGCCAGG 20 1639
HSV2-UL19-1400 + UGACCACGCGCCAGGUGGCC 20 1640
HSV2-UL19-1401 + CAGGUGGCCUGGAUCGCCCC 20 1641
HSV2-UL19-1402 + GGCCUGGAUCGCCCCCGGAC 20 1642
HSV2-UL19-1403 + UGGAUCGCCCCCGGACCGGC 20 1643
HSV2-UL19-1404 + GGAUCGCCCCCGGACCGGCC 20 1644
HSV2-UL19-1405 + GAUCGCCCCCGGACCGGCCG 20 1645
HSV2-UL19-1406 + AUCGCCCCCGGACCGGCCGG 20 1646
HSV2-UL19-1407 + UCGCCCCCGGACCGGCCGGG 20 1647
HSV2-UL19-1408 + GGCCGGGGGGACUUCGCCGC 20 1648
HSV2-UL19-1409 + GCCGGGGGGACUUCGCCGCC 20 1649
HSV2-UL19-1410 + GCCGCCGGGAAGCUCGACGU 20 1650
HSV2-UL19-1411 + GCCCGCGAAGAAGUCGAACG 20 1651
HSV2-UL19-1412 + CCCG CG AAG AAG U CG AACGC 20 1652
HSV2-UL19-1413 + CCGCGAAGAAGUCGAACGCG 20 1653 HSV2-UL19-1414 + CGGGGUGCAGCUCCAGAGCC 20 1654
HSV2-UL19-1415 + GUGCAGCUCCAGAGCCAGGU 20 1655
HSV2-UL19-1416 + CAGAGCCAGGUUGGCGUUGU 20 1656
HSV2-UL19-1417 + AGAGCCAGGUUGGCGUUGUC 20 1657
HSV2-UL19-1418 + GGGCUGCAUGAACUGCUCCG 20 1658
HSV2-UL19-1419 + UGAACUGCUCCGCGGUCAUC 20 1659
HSV2-UL19-1420 + CUCCGCGGUCAUCUGGCACU 20 1660
HSV2-UL19-1421 + UCUGGCACUCGGCGACCCAC 20 1661
HSV2-UL19-1422 + ACUCGGCGACCCACCGGACC 20 1662
HSV2-UL19-1423 + CGACCCACCGGACCCGGCCG 20 1663
HSV2-UL19-1424 + GACCCACCGGACCCGGCCGU 20 1664
HSV2-UL19-1425 + ACCGGACCCGGCCGUGGGCG 20 1665
HSV2-UL19-1426 + GUGGGCGAGGCGCUGCCGCC 20 1666
HSV2-UL19-1427 + ACGCUGCUGCAUGUCCGCGC 20 1667
HSV2-UL19-1428 + CGCUGCUGCAUGUCCGCGCC 20 1668
HSV2-UL19-1429 + GCUGCUGCAUGUCCGCGCCG 20 1669
HSV2-UL19-1430 + CUGCAUGUCCGCGCCGGGGC 20 1670
HSV2-UL19-1431 + AUGUCCGCGCCGGGGCCGGC 20 1671
HSV2-UL19-1432 + UGUCCGCGCCGGGGCCGGCC 20 1672
HSV2-UL19-1433 + GUCCGCGCCGGGGCCGGCCG 20 1673
HSV2-UL19-1434 + GCCGCGACGUACGCCCCGUA 20 1674
HSV2-UL19-1435 + GUACGCCCCGUACGGAUUCG 20 1675
HSV2-UL19-1436 + GUACGGAUUCGCGGCCUCGA 20 1676
HSV2-UL19-1437 + UACGGAUUCGCGGCCUCGAC 20 1677
HSV2-UL19-1438 + ACGGAUUCGCGGCCUCGACG 20 1678
HSV2-UL19-1439 + UCGCGGCCUCGACGGGGUCG 20 1679
HSV2-UL19-1440 + GUCGUGGUUCACGCCCCCGA 20 1680
HSV2-UL19-1441 + GCGUCGAUGUUCAUGAGCGA 20 1681
HSV2-UL19-1442 + CAUGAGCGAAGGAUGACACA 20 1682
HSV2-UL19-1443 + GGUCCCGACCGCGU UCUCCA 20 1683
HSV2-UL19-1444 + CCAUGGACAGCCGCAGAACC 20 1684
HSV2-UL19-1445 + UGGACAGCCGCAGAACCUGG 20 1685
HSV2-UL19-1446 + UUCCCCAAAAAAACAGCUGC 20 1686
HSV2-UL19-1447 + UCCCCAAAAAAACAGCUGCC 20 1687
HSV2-UL19-1448 + CCCCAAAAAAACAGCUGCCG 20 1688
HSV2-UL19-1449 + CA AAAAAACAG CU G CCG G G G 20 1689
HSV2-UL19-1450 + AAAAAAACAGCUGCCGGGGA 20 1690
HSV2-UL19-1451 + GCUGCCGGGGAGGGAACGCG 20 1691
HSV2-UL19-1452 + CUGCCGGGGAGGGAACGCGC 20 1692
HSV2-UL19-1453 + UGCCGGGGAGGGAACGCGCG 20 1693
HSV2-UL19-1454 + GGAGGGAACGCGCGGGGCUC 20 1694
HSV2-UL19-1455 + GAGGGAACGCGCGGGGCUCC 20 1695
HSV2-UL19-1456 + GGAACGCGCGGGGCUCCGGG 20 1696
HSV2-UL19-1457 + CGCGCGGGGCUCCGGGUGGC 20 1697
HSV2-UL19-1458 + GCGCGGGGCUCCGGGUGGCC 20 1698
HSV2-UL19-1459 + CGCGGGGCUCCGGGUGGCCG 20 1699 HSV2-UL19-1460 + GCGGGGCUCCGGGUGGCCGG 20 1700
HSV2-UL19-1461 + GGGCUCCGGGUGGCCGGGGG 20 1701
HSV2-UL19-1462 + GGCUCCGGGUGGCCGGGGGC 20 1702
HSV2-UL19-1463 + GGUGGCCGGGGGCGGGCACC 20 1703
HSV2-UL19-1464 + GGGGGCGGGCACCAGGUCCC 20 1704
HSV2-UL19-1465 + CACCAGGUCCCCGGCGUGCG 20 1705
HSV2-UL19-1466 + GUGCGCGGCGAAGCGCUCCA 20 1706
HSV2-UL19-1467 + GCGGCGAAGCGCUCCAUGGC 20 1707
HSV2-UL19-1468 + CGGCGAAGCGCUCCAUGGCC 20 1708
HSV2-UL19-1469 + UGGCCGGGUUGAACAGCCCC 20 1709
HSV2-UL19-1470 + GGCCGGGUUGAACAG CCCCA 20 1710
HSV2-UL19-1471 + GCCGGGUUGAACAGCCCCAG 20 1711
HSV2-UL19-1472 + GGUUGAACAGCCCCAGGGGC 20 1712
HSV2-UL19-1473 + CCAGGGGCAGGACGAACGUC 20 1713
HSV2-UL19-1474 + CAGGACGAACG U CAG GU CCA 20 1714
HSV2-UL19-1475 + UCAGGUCCAUGGCGCCCACC 20 1715
HSV2-UL19-1476 + CAGGUCCAUGGCGCCCACCA 20 1716
HSV2-UL19-1477 + AGGUCCAUGGCGCCCACCAG 20 1717
HSV2-UL19-1478 + GGUCCAUGGCGCCCACCAGG 20 1718
HSV2-UL19-1479 + CAUGGCGCCCACCAGGGGGU 20 1719
HSV2-UL19-1480 + AUGGCGCCCACCAGGGGGUA 20 1720
HSV2-UL19-1481 + CACCAGGGGGUAGGGCACGU 20 1721
HSV2-UL19-1482 + CAGGGGGUAGGGCACGUUGG 20 1722
HSV2-UL19-1483 + GGGGUAGGGCACGUUGGUGG 20 1723
HSV2-UL19-1484 + CGGCGUAGAUGCGUCUCUCC 20 1724
HSV2-UL19-1485 + GGCGUAGAUGCGUCUCUCCA 20 1725
HSV2-UL19-1486 + UGCGUCUCUCCAGGGCCUCC 20 1726
HSV2-UL19-1487 + GAAGACCAGCCUGUCGCCUA 20 1727
HSV2-UL19-1488 + CCGCGCGCACGCGCGUUGUC 20 1728
HSV2-UL19-1489 + CGCGCGCACGCGCGUUGUCU 20 1729
HSV2-UL19-1490 + GCGCGCACGCGCGUUGUCUG 20 1730
HSV2-UL19-1491 + CGCGCACGCGCGUUGUCUGG 20 1731
HSV2-UL19-1492 + GCGCACGCGCGUUGUCUGGG 20 1732
HSV2-UL19-1493 + CGAGUUCAUCCAGCGUCUCC 20 1733
HSV2-UL19-1494 + GCU CCU CCU GCAU AUCCAGC 20 1734
HSV2-UL19-1495 + CCUCCUGCAUAUCCAGCAGG 20 1735
HSV2-UL19-1496 + CCUGCAUAUCCAGCAGGUGG 20 1736
HSV2-UL19-1497 + GGUGGCGGCCCACGUCGUCC 20 1737
HSV2-UL19-1498 + CACGUCGUCCAGGCUCCGCA 20 1738
HSV2-UL19-1499 + CCAU CACCAG CGCCG UGACG 20 1739
HSV2-UL19-1500 + CACCAGCGCCGUGACGAGGU 20 1740
HSV2-UL19-1501 + G U U CAAGACCAU CU CGCCG U 20 1741
HSV2-UL19-1502 + ACCAUCUCGCCGUAGGUCAC 20 1742
HSV2-UL19-1503 + GCCGUAGGUCACCGGCACGU 20 1743
HSV2-UL19-1504 + GGUCACCGGCACGUCGGCCU 20 1744
HSV2-UL19-1505 + CCUCGGUGUCCUCCACCUUC 20 1745 HSV2-UL19-1506 + G G U G U CCU CCACCU U CAGG A 20 1746
HSV2-UL19-1507 + CCACCUUCAGGAAGGACUGC 20 1747
HSV2-UL19-1508 + CCUUCAGGAAGGACUGCAGG 20 1748
HSV2-UL19-1509 + CUGCAGGAGGCGCUGUUUGA 20 1749
HSV2-UL19-1510 + CAGGAGGCGCUGUUUGAUGG 20 1750
HSV2-UL19-1511 + GAGGCGCUGUUUGAUGGCGG 20 1751
HSV2-UL19-1512 + GCGCUGUUUGAUGGCGGCGG 20 1752
HSV2-UL19-1513 + GUGACCAGCACCCCGUCGAC 20 1753
HSV2-UL19-1514 + GACCGGCCGCCCGCGCGUGU 20 1754
HSV2-UL19-1515 + CGCGCGUGUCGGCGUGCGUC 20 1755
HSV2-UL19-1516 + GCGUGUCGGCGUGCGUCAGG 20 1756
HSV2-UL19-1517 + CGUGUCGGCGUGCGUCAGGC 20 1757
HSV2-UL19-1518 + GUGUCGGCGUGCGUCAGGCG 20 1758
HSV2-UL19-1519 + GGCGUGCGUCAGGCGGGGCA 20 1759
HSV2-UL19-1520 + CGUCAGGCGGGGCACGGCCA 20 1760
HSV2-UL19-1521 + AGGCGGGGCACGGCCACGGA 20 1761
HSV2-UL19-1522 + CACGGACGGCUGCGUCGCCG 20 1762
HSV2-UL19-1523 + ACGGCUGCGUCGCCGUGGUC 20 1763
HSV2-UL19-1524 + CGUGGUCAGGUCCACGAGCC 20 1764
HSV2-UL19-1525 + GUCCACGAGCCAGGCCUCGA 20 1765
HSV2-UL19-1526 + GCCAGGCCUCGAUGGCCUCG 20 1766
HSV2-UL19-1527 + CCUCGAUGGCCUCGCGGCGA 20 1767
HSV2-UL19-1528 + GGCGAUGGCCCGCCUUGCCC 20 1768
HSV2-UL19-1529 + GCAAAAGCUCCGCUUCAGCU 20 1769
HSV2-UL19-1530 + UCCGCU UCAGCUCGGCGACC 20 1770
HSV2-UL19-1531 + CCGCUUCAGCUCGGCGACCA 20 1771
HSV2-UL19-1532 + GCUCGGCGACCAGGGUCGCC 20 1772
HSV2-UL19-1533 + CUCGGCGACCAGGGUCGCCC 20 1773
HSV2-UL19-1534 + CAGGGUCGCCCGGGCAACCC 20 1774
HSV2-UL19-1535 + CCCGGGCAACCCUGGUCGCC 20 1775
HSV2-UL19-1536 + GUUGUCGAGAUAUCGUUGCA 20 1776
HSV2-UL19-1537 + UUGUCGAGAUAUCGUUGCAU 20 1777
HSV2-UL19-1538 + AUCGUUGCAUGGGCAACAGC 20 1778
HSV2-UL19-1539 + UCGUUGCAUGGGCAACAGCA 20 1779
HSV2-UL19-1540 + GCAUGGGCAACAGCAGGGCC 20 1780
HSV2-UL19-1541 + CA U G G G CAACAG CAG G G CCA 20 1781
HSV2-UL19-1542 + AUGGGCAACAGCAGGGCCAG 20 1782
HSV2-UL19-1543 + G G CAACAG CAGGGCCAGGGG 20 1783
HSV2-UL19-1544 + CCAACAGCACGUGCAGCAUC 20 1784
HSV2-UL19-1545 + CAGCACGUGCAGCAUCUGGU 20 1785
HSV2-UL19-1546 + UGCCGCGCUCAAACGCCCCC 20 1786
HSV2-UL19-1547 + G CG CU CAAACG CCCCCAG G A 20 1787
HSV2-UL19-1548 + CAAACG CCCCCAG GACG G CC 20 1788
HSV2-UL19-1549 + AGAGACAGGCCCUUUAG 17 1789
HSV2-UL19-1550 + GAGACAGGCCCUUUAGC 17 1790
HSV2-UL19-1551 + AGACAGGCCCUUUAGCG 17 1791 HSV2-UL19-1552 + CAGGCCCUUUAGCGGGG 17 1792
HSV2-UL19-1553 + UGAGAUACUGCGUAAAG 17 1793
HSV2-UL19-1554 + GAGAUACUGCGUAAAGU 17 1794
HSV2-UL19-1555 + AGUGGGUCUCUCGCGCG 17 1795
HSV2-UL19-1556 + GUGGGUCUCUCGCGCGU 17 1796
HSV2-UL19-1557 + CGUGGGCCUCCCCAUCG 17 1797
HSV2-UL19-1558 + GUGGGCCUCCCCAUCGC 17 1798
HSV2-UL19-1559 + CGCGGGCGCUGCGUAGC 17 1799
HSV2-UL19-1560 + GCGGGCGCUGCGUAGCA 17 1800
HSV2-UL19-1561 + GGCGCUGCGUAGCAGGG 17 1801
HSV2-UL19-1562 + GCGCUGCGUAGCAGGGC 17 1802
HSV2-UL19-1563 + CGCUGCGUAGCAGGGCG 17 1803
HSV2-UL19-1564 + UAGCAGGGCGGGGUCGC 17 1804
HSV2-UL19-1565 + GGCGGGGUCGCUGGCGC 17 1805
HSV2-UL19-1566 + UCGCUGGCGCAGGUGAU 17 1806
HSV2-UL19-1567 + CGCUGGCGCAGGUGAUC 17 1807
HSV2-UL19-1568 + GGCGCAGGUGAUCGGGU 17 1808
HSV2-UL19-1569 + GGUAGGCUUCCUGAAAC 17 1809
HSV2-UL19-1570 + UCCUGAAACAGGCCGCA 17 1810
HSV2-UL19-1571 + CCUGAAACAGGCCGCAC 17 1811
HSV2-UL19-1572 + GGUCUUCCACGAGCUCG 17 1812
HSV2-UL19-1573 + ACGAGCUCGCGGCACCC 17 1813
HSV2-UL19-1574 + AGCUCGCGGCACCCCGG 17 1814
HSV2-UL19-1575 + GCUCGCGGCACCCCGGC 17 1815
HSV2-UL19-1576 + CUUAAACUGCACGUCGC 17 1816
HSV2-UL19-1577 + CUGCACGUCGCUGGCAG 17 1817
HSV2-UL19-1578 + CACGUCGCUGGCAGCGG 17 1818
HSV2-UL19-1579 + GCUGGCAGCGGUGGCCG 17 1819
HSV2-UL19-1580 + CCACGAUGAGACGCUCC 17 1820
HSV2-UL19-1581 + CUCCAGGCAGCGAUGUU 17 1821
HSV2-UL19-1582 + AUGUUUGGCCGUGAUGU 17 1822
HSV2-UL19-1583 + GGCCGUGAUGUCGGCCG 17 1823
HSV2-UL19-1584 + GGUGAAGAACUUGAAGC 17 1824
HSV2-UL19-1585 + G UGAAGAACU UGAAGCA 17 1825
HSV2-UL19-1586 + UGAAGAACUUGAAGCAG 17 1826
HSV2-UL19-1587 + ACUUGAAGCAGGGGCUG 17 1827
HSV2-UL19-1588 + GAAGCAGGGGCUGAGGA 17 1828
HSV2-UL19-1589 + AAGCAGGGGCUGAGGAC 17 1829
HSV2-UL19-1590 + GGGGCUGAGGACGGGCG 17 1830
HSV2-UL19-1591 + CGGGCGAGGCCCCGUUG 17 1831
HSV2-UL19-1592 + GGCCCCGUUGAGGUGAU 17 1832
HSV2-UL19-1593 + AGGCCCCGUUGUACAGC 17 1833
HSV2-UL19-1594 + AACCGCUGCGACGCCCA 17 1834
HSV2-UL19-1595 + ACCG CUGCGACG CCCAC 17 1835
HSV2-UL19-1596 + CUGCGACGCCCACGGGU 17 1836
HSV2-UL19-1597 + CGCCCACGGGUUGGCCG 17 1837 HSV2-UL19-1598 + GUUGGCCGUGGCCGCGA 17 1838
HSV2-UL19-1599 + UUGGCCGUGGCCGCGAA 17 1839
HSV2-UL19-1600 + GCCGCGAAGGGCCGCGC 17 1840
HSV2-UL19-1601 + CCGCGAAGGGCCGCGCC 17 1841
HSV2-UL19-1602 + GCCGCGCCGGGUCGCUC 17 1842
HSV2-UL19-1603 + CCGGGUCGCUCUGGCCG 17 1843
HSV2-UL19-1604 + GGCCGUGGUCGUACAUG 17 1844
HSV2-UL19-1605 + GCCGUGGUCGUACAUGA 17 1845
HSV2-UL19-1606 + CCCCGCGUACACGCCGC 17 1846
HSV2-UL19-1607 + CCGGCCGCGCGUCCCCG 17 1847
HSV2-UL19-1608 + CGGCCGCGCGUCCCCGC 17 1848
HSV2-UL19-1609 + GCGUCCCCGCGGGUUGC 17 1849
HSV2-UL19-1610 + CGUCCCCGCGGGUUGCA 17 1850
HSV2-UL19-1611 + CCCGCGGGUUGCAGGGC 17 1851
HSV2-UL19-1612 + AAAG U AG U U G AU G U CCG 17 1852
HSV2-UL19-1613 + GUUGAUGUCCGUGGCCA 17 1853
HSV2-UL19-1614 + UUGAUGUCCGUGGCCAC 17 1854
HSV2-UL19-1615 + UGAUGUCCGUGGCCACG 17 1855
HSV2-UL19-1616 + GAUGUCCGUGGCCACGG 17 1856
HSV2-UL19-1617 + GUCCGUGGCCACGGGGG 17 1857
HSV2-UL19-1618 + GGCGAUGAACUCACACA 17 1858
HSV2-UL19-1619 + ACACGGCAUCCUGCCCG 17 1859
HSV2-UL19-1620 + CUGCCCGUGGUCCAUGC 17 1860
HSV2-UL19-1621 + UCCAUGCCGGCGCGCCG 17 1861
HSV2-UL19-1622 + CGGCGCGCCGCGGCACC 17 1862
HSV2-UL19-1623 + GGCGCGCCGCGGCACCU 17 1863
HSV2-UL19-1624 + UGGGCGCAGCCAAAGAC 17 1864
HSV2-UL19-1625 + GGGCGCAGCCAAAGACC 17 1865
HSV2-UL19-1626 + CGCAGCCAAAGACCGGG 17 1866
HSV2-UL19-1627 + GCAGCCAAAGACCGGGA 17 1867
HSV2-UL19-1628 + CAG CCAAAG ACCGG G AG 17 1868
HSV2-UL19-1629 + CAAAGACCGGGAGGGGC 17 1869
HSV2-UL19-1630 + AAAGACCGGGAGGGGCU 17 1870
HSV2-UL19-1631 + ACCGGGAGGGGCUGGGC 17 1871
HSV2-UL19-1632 + GCUGGGCCGGCCCCAGC 17 1872
HSV2-UL19-1633 + CCACGACCGCGUUGCGC 17 1873
HSV2-UL19-1634 + CGCGUUGCGCAGGUACA 17 1874
HSV2-UL19-1635 + GUUGCGCAGGUACACGG 17 1875
HSV2-UL19-1636 + GCCGCGUUGUCUAGCAG 17 1876
HSV2-UL19-1637 + CCGCGUUGUCUAGCAGC 17 1877
HSV2-UL19-1638 + CGCGUUGUCUAGCAGCG 17 1878
HSV2-UL19-1639 + GCGUUGUCUAGCAGCGG 17 1879
HSV2-UL19-1640 + CGUUGUCUAGCAGCGGG 17 1880
HSV2-UL19-1641 + GUUGUCUAGCAGCGGGG 17 1881
HSV2-UL19-1642 + GCAGCGGGGGGGCCCCG 17 1882
HSV2-UL19-1643 + GGGGGGCCCCGCGGCCG 17 1883 HSV2-UL19-1644 + GGCCGAGGUAAAAGUUU 17 1884
HSV2-UL19-1645 + GCCGAGGUAAAAGUUUU 17 1885
HSV2-UL19-1646 + CCGAGGUAAAAGUUUUG 17 1886
HSV2-UL19-1647 + CGAGGUAAAAGUUUUGG 17 1887
HSV2-UL19-1648 + GGUAAAAGUUUUGGGGG 17 1888
HSV2-UL19-1649 + GUUGCCCAUGUCCGUAA 17 1889
HSV2-UL19-1650 + UUGCCCAUGUCCGUAAC 17 1890
HSV2-UL19-1651 + UGCCCAUGUCCGUAACG 17 1891
HSV2-UL19-1652 + UGUCCGUAACGGGGUUG 17 1892
HSV2-UL19-1653 + CGUAACGGGGUUGCGGA 17 1893
HSV2-UL19-1654 + GUUGCGGACGGUGCCCG 17 1894
HSV2-UL19-1655 + GGUGCCCGUGGCCGCGA 17 1895
HSV2-UL19-1656 + GCCCGUGGCCGCGACGG 17 1896
HSV2-UL19-1657 + CGGUGUAGCCCACACCC 17 1897
HSV2-UL19-1658 + AGGUCCACGUUUCCGCG 17 1898
HSV2-UL19-1659 + CCACGUUUCCGCGCGGC 17 1899
HSV2-UL19-1660 + CACGUUUCCGCGCGGCU 17 1900
HSV2-UL19-1661 + CCCCCCCGCCCGUUUCG 17 1901
HSV2-UL19-1662 + CCCCGCCCGUUUCGUGG 17 1902
HSV2-UL19-1663 + CCCGCCCGUUUCGUGGC 17 1903
HSV2-UL19-1664 + UUUCGUGGCGGGCCACC 17 1904
HSV2-UL19-1665 + GGCGGGCCACCUGGAGC 17 1905
HSV2-UL19-1666 + CGCCUCCGACGCGCGCU 17 1906
HSV2-UL19-1667 + G G AAAACAGCACG U U CU 17 1907
HSV2-UL19-1668 + CG U U CU CGG U CACGAAG 17 1908
HSV2-UL19-1669 + GCGGUCCUGCCGCACGA 17 1909
HSV2-UL19-1670 + GACGGUGAACCCGAACC 17 1910
HSV2-UL19-1671 + ACGGUGAACCCGAACCC 17 1911
HSV2-UL19-1672 + CGGUGAACCCGAACCCG 17 1912
HSV2-UL19-1673 + UGAACCCGAACCCGGGG 17 1913
HSV2-UL19-1674 + ACCCGAACCCGGGGUGG 17 1914
HSV2-UL19-1675 + GGAGGCCCGUCUUGAGC 17 1915
HSV2-UL19-1676 + UCUUGAGCUGGUGAUAC 17 1916
HSV2-UL19-1677 + CUUGAGCUGGUGAUACA 17 1917
HSV2-UL19-1678 + CUGGUGAUACAGGGCCA 17 1918
HSV2-UL19-1679 + UGGUGAUACAGGGCCAC 17 1919
HSV2-UL19-1680 + GGUGAUACAGGGCCACG 17 1920
HSV2-UL19-1681 + CCCCG CCAU G AG CGCG U 17 1921
HSV2-UL19-1682 + CCCCCGCCGCGCUCUCG 17 1922
HSV2-UL19-1683 + CCCCGCCGCGCUCUCGC 17 1923
HSV2-UL19-1684 + GCGGGCGUGCUGCACCA 17 1924
HSV2-UL19-1685 + CGGGCGUGCUGCACCAC 17 1925
HSV2-UL19-1686 + CGUGCUGCACCACGGGC 17 1926
HSV2-UL19-1687 + GCUGCACCACGGGCUGG 17 1927
HSV2-UL19-1688 + CACCACGGGCUGGCGGA 17 1928
HSV2-UL19-1689 + CACGGGCUGGCGGAUGG 17 1929 HSV2-UL19-1690 + GAUGGAGGAGAAGUAGU 17 1930
HSV2-UL19-1691 + AGAAGUAGUUGGCCCCC 17 1931
HSV2-UL19-1692 + GAAGUAGUUGGCCCCCA 17 1932
HSV2-UL19-1693 + UAGUUGGCCCCCAGGGC 17 1933
HSV2-UL19-1694 + AGUUGGCCCCCAGGGCC 17 1934
HSV2-UL19-1695 + GUUGGCCCCCAGGGCCG 17 1935
HSV2-UL19-1696 + UUGGCCCCCAGGGCCGG 17 1936
HSV2-UL19-1697 + UGGCCCCCAGGGCCGGG 17 1937
HSV2-UL19-1698 + CCAGGGCCGGGGGGACC 17 1938
HSV2-UL19-1699 + CAGGGCCGGGGGGACCA 17 1939
HSV2-UL19-1700 + AGGGCCGGGGGGACCAG 17 1940
HSV2-UL19-1701 + GGGCCGGGGGGACCAGG 17 1941
HSV2-UL19-1702 + GGGGGACGUCGCGCGCC 17 1942
HSV2-UL19-1703 + CGCGCGCCAGGUCGCGC 17 1943
HSV2-UL19-1704 + GCGCGCCAGGUCGCGCA 17 1944
HSV2-UL19-1705 + GCCAGGUCGCGCAGGGC 17 1945
HSV2-UL19-1706 + CCAGGUCGCGCAGGGCC 17 1946
HSV2-UL19-1707 + CAGGUCGCGCAGGGCCG 17 1947
HSV2-UL19-1708 + AGGUCGCGCAGGGCCGG 17 1948
HSV2-UL19-1709 + GGUCGCGCAGGGCCGGG 17 1949
HSV2-UL19-1710 + CAGGGCCGGGGGGAAGU 17 1950
HSV2-UL19-1711 + AGGGCCGGGGGGAAGUU 17 1951
HSV2-UL19-1712 + GGGGAAGUUGGGCGCGU 17 1952
HSV2-UL19-1713 + UGGGCGCGUUGGCCACG 17 1953
HSV2-UL19-1714 + CGCGUUGGCCACGUGGU 17 1954
HSV2-UL19-1715 + CG CCCG CAAACAG CG CG 17 1955
HSV2-UL19-1716 + CGCAAACAGCGCGUGGA 17 1956
HSV2-UL19-1717 + GCAAACAGCGCGUGGAC 17 1957
HSV2-UL19-1718 + ACAGCGCGUGGACGGGC 17 1958
HSV2-UL19-1719 + AGAAGUAUUCGCCAUUU 17 1959
HSV2-UL19-1720 + GUAUUCGCCAUUUUGGA 17 1960
HSV2-UL19-1721 + CGCCAUUUUGGAUGGUG 17 1961
HSV2-UL19-1722 + UUUGGAUGGUGUGGUCC 17 1962
HSV2-UL19-1723 + UGGUGUGGUCCAGGUGC 17 1963
HSV2-UL19-1724 + GGUGUGGUCCAGGUGCU 17 1964
HSV2-UL19-1725 + GUGUGGUCCAGGUGCUG 17 1965
HSV2-UL19-1726 + UGUGGUCCAGGUGCUGG 17 1966
HSV2-UL19-1727 + GUGGUCCAGGUGCUGGG 17 1967
HSV2-UL19-1728 + GGCCAUGAGCAGCACGC 17 1968
HSV2-UL19-1729 + GUCGAAGAUGCGCAUGU 17 1969
HSV2-UL19-1730 + CAUGUUGGCCGUCGACG 17 1970
HSV2-UL19-1731 + GGCCGUCGACGCGGUGU 17 1971
HSV2-UL19-1732 + GGUGUUGGCGCCCGCGU 17 1972
HSV2-UL19-1733 + GUGUUGGCGCCCGCGUC 17 1973
HSV2-UL19-1734 + GCCCGCGUCGGGCGCCG 17 1974
HSV2-UL19-1735 + CAGCGCCGUCGUGCGCU 17 1975 HSV2-UL19-1736 + CACCUGCAGCGUGAGCA 17 1976
HSV2-UL19-1737 + CUGCAGCGUGAGCAUGG 17 1977
HSV2-UL19-1738 + UGCAGCGUGAGCAUGGC 17 1978
HSV2-UL19-1739 + CGACGACGCGCCCGUUG 17 1979
HSV2-UL19-1740 + CAUGCGCUUGACCGUGU 17 1980
HSV2-UL19-1741 + CGUGUUGGCCACCAGAU 17 1981
HSV2-UL19-1742 + G U U GG CCACCAG AU U G G 17 1982
HSV2-UL19-1743 + UUGGCCACCAGAUUGGC 17 1983
HSV2-UL19-1744 + AGAUUGGCGGGAUGCAG 17 1984
HSV2-UL19-1745 + GAUUGGCGGGAUGCAGC 17 1985
HSV2-UL19-1746 + UGGCGGGAUGCAGCGGG 17 1986
HSV2-UL19-1747 + GGCGGGAUGCAGCGGGU 17 1987
HSV2-UL19-1748 + GGGAUGCAGCGGGUGGG 17 1988
HSV2-UL19-1749 + GGAUGCAGCGGGUGGGC 17 1989
HSV2-UL19-1750 + GAUGCAGCGGGUGGGCG 17 1990
HSV2-UL19-1751 + CAGCGGGUGGGCGGGGU 17 1991
HSV2-UL19-1752 + GUGGGCGGGGUCGGUCA 17 1992
HSV2-UL19-1753 + UGGGCGGGGUCGGUCAC 17 1993
HSV2-UL19-1754 + UCGGUCACGGGAUCGCU 17 1994
HSV2-UL19-1755 + CGGUCACGGGAUCGCUC 17 1995
HSV2-UL19-1756 + GCUCGGGCACUCCUCAC 17 1996
HSV2-UL19-1757 + CUCGGGCACUCCUCACC 17 1997
HSV2-UL19-1758 + UCGGGCACUCCUCACCG 17 1998
HSV2-UL19-1759 + CGGGCACUCCUCACCGG 17 1999
HSV2-UL19-1760 + UCACCGGGGGCGAUCUC 17 2000
HSV2-UL19-1761 + CACCGGGGGCGAUCUCC 17 2001
HSV2-UL19-1762 + CACCAUGUUCUGCAGCG 17 2002
HSV2-UL19-1763 + GCAGCGUGGCGUACACG 17 2003
HSV2-UL19-1764 + CGUACACGCGGUCGAAG 17 2004
HSV2-UL19-1765 + GUCGAAGCGGACCCCCG 17 2005
HSV2-UL19-1766 + GCAGCGCCCCCGCGAGA 17 2006
HSV2-UL19-1767 + CGCCCCCGCGAGAAGGC 17 2007
HSV2-UL19-1768 + CGUAAUAGUAGAUUUUG 17 2008
HSV2-UL19-1769 + AAUAGUAGAUUUUGUGG 17 2009
HSV2-UL19-1770 + GUAGAUUUUGUGGUGGA 17 2010
HSV2-UL19-1771 + GUGGUGGACGGUCCAGU 17 2011
HSV2-UL19-1772 + UGGACGGUCCAGUCGGC 17 2012
HSV2-UL19-1773 + CGGUCCAGUCGGCCGGC 17 2013
HSV2-UL19-1774 + CAGUCGGCCGGCCGGUG 17 2014
HSV2-UL19-1775 + CGGCCGGCCGGUGCGGC 17 2015
HSV2-UL19-1776 + CCGGUGCGGCCGGUCGU 17 2016
HSV2-UL19-1777 + GUGCGGCCGGUCGUCGG 17 2017
HSV2-UL19-1778 + CCGGUCGUCGGCGGCGU 17 2018
HSV2-UL19-1779 + CGGCGGCGUCGGCCGCG 17 2019
HSV2-UL19-1780 + GGCGGCGUCGGCCGCGC 17 2020
HSV2-UL19-1781 + CGUCGGCCGCGCGGGCC 17 2021 HSV2-UL19-1782 + GUCGGCCGCGCGGGCCU 17 2022
HSV2-UL19-1783 + GGGUGUUGUGCAGCAGC 17 2023
HSV2-UL19-1784 + GCAGCCGGCCGUCGUUG 17 2024
HSV2-UL19-1785 + GUCGUUGCGGUUAAAGU 17 2025
HSV2-UL19-1786 + GCACGCCGCCGCGUAGA 17 2026
HSV2-UL19-1787 + CACGCCGCCGCGUAGAC 17 2027
HSV2-UL19-1788 + GCCCCCCCGCGUCAAUC 17 2028
HSV2-UL19-1789 + CGUCAAUCCGGCAGUCU 17 2029
HSV2-UL19-1790 + CAAUCCGGCAGUCUCGG 17 2030
HSV2-UL19-1791 + UCCGGCAGUCUCGGUGG 17 2031
HSV2-UL19-1792 + AGUCUCGGUGGCGGUCC 17 2032
HSV2-UL19-1793 + GUCUCGGUGGCGGUCCA 17 2033
HSV2-UL19-1794 + GGGCCGCGUGUCGCAUA 17 2034
HSV2-UL19-1795 + CG U CG CAG U CCCACACG 17 2035
HSV2-UL19-1796 + G U CG CAG U CCCACACG A 17 2036
HSV2-UL19-1797 + UCGCAGUCCCACACGAG 17 2037
HSV2-UL19-1798 + CAGUCCCACACGAGGGG 17 2038
HSV2-UL19-1799 + AGGGGCGGCAGCAGCGC 17 2039
HSV2-UL19-1800 + GGGGCGGCAGCAGCGCC 17 2040
HSV2-UL19-1801 + GCGCCGGGUCGCGCAUC 17 2041
HSV2-UL19-1802 + CAUCAGGUGAUUCAGCU 17 2042
HSV2-UL19-1803 + GCCUGCCCGCCCAGCUC 17 2043
HSV2-UL19-1804 + CCUGCCCGCCCAGCUCC 17 2044
HSV2-UL19-1805 + CCGCCCAGCUCCGGGCC 17 2045
HSV2-UL19-1806 + CCAGCUCCGGGCCCGGC 17 2046
HSV2-UL19-1807 + CAGCUCCGGGCCCGGCA 17 2047
HSV2-UL19-1808 + UAAAGUCGUCCACCAGC 17 2048
HSV2-UL19-1809 + AAAG UCGUCCACCAGCU 17 2049
HSV2-UL19-1810 + CGUCCACCAGCUGGGCC 17 2050
HSV2-UL19-1811 + GUCCACCAGCUGGGCCA 17 2051
HSV2-UL19-1812 + GGGCCAGGGCCUCGACG 17 2052
HSV2-UL19-1813 + GGCCAGGGCCUCGACGU 17 2053
HSV2-UL19-1814 + CCUCGACGUGGGCCACC 17 2054
HSV2-UL19-1815 + CACCAGGUCCCGAUACA 17 2055
HSV2-UL19-1816 + CACGGCCAUGCACUCCU 17 2056
HSV2-UL19-1817 + ACGGCCAUGCACUCCUC 17 2057
HSV2-UL19-1818 + CGGCCAUGCACUCCUCG 17 2058
HSV2-UL19-1819 + CCAUGCACUCCUCGGGG 17 2059
HSV2-UL19-1820 + CGGGGAGGUCGCCCCCG 17 2060
HSV2-UL19-1821 + GAGGUCGCCCCCGAGGU 17 2061
HSV2-UL19-1822 + CGUGUUGUUCCAGUAGC 17 2062
HSV2-UL19-1823 + GAGUCACGAGCCGCGCC 17 2063
HSV2-UL19-1824 + AGUCACGAGCCGCGCCA 17 2064
HSV2-UL19-1825 + CUCGUUGCCGUGAAUCG 17 2065
HSV2-UL19-1826 + GAAUCGCGGCUUGCAGC 17 2066
HSV2-UL19-1827 + AGCAGGUAAAACACCGC 17 2067 HSV2-UL19-1828 + G CAG G U AAAACACCG CC 17 2068
HSV2-UL19-1829 + ACACCGCCGGGUAGCUG 17 2069
HSV2-UL19-1830 + GGUCCUCGAACGCCCCG 17 2070
HSV2-UL19-1831 + CUCGAACGCCCCGCGGA 17 2071
HSV2-UL19-1832 + GAACGCCCCGCGGACGG 17 2072
HSV2-UL19-1833 + CCCGCGGACGGCGGCUA 17 2073
HSV2-UL19-1834 + ACGGCGGCUAUGGUAGC 17 2074
HSV2-UL19-1835 + UAUGGUAGCCGGCGCCA 17 2075
HSV2-UL19-1836 + UAGCCGGCGCCAUGGCG 17 2076
HSV2-UL19-1837 + CCGGCGCCAUGGCGUGG 17 2077
HSV2-UL19-1838 + GGCCAACGCCGAGCUCC 17 2078
HSV2-UL19-1839 + CGCCGAGCUCCAGGCCC 17 2079
HSV2-UL19-1840 + GCCGAGCUCCAGGCCCC 17 2080
HSV2-UL19-1841 + GCGUCACGAAACGCCAC 17 2081
HSV2-UL19-1842 + CCACCGGACACAGCGCC 17 2082
HSV2-UL19-1843 + CACCGGACACAGCGCCA 17 2083
HSV2-UL19-1844 + ACCG G ACACAG CG CCAG 17 2084
HSV2-UL19-1845 + GACACAGCGCCAGGGGC 17 2085
HSV2-UL19-1846 + GCCGUUGACCACGCGCC 17 2086
HSV2-UL19-1847 + GUUGACCACGCGCCAGG 17 2087
HSV2-UL19-1848 + CCACGCGCCAGGUGGCC 17 2088
HSV2-UL19-1849 + GUGGCCUGGAUCGCCCC 17 2089
HSV2-UL19-1850 + CUGGAUCGCCCCCGGAC 17 2090
HSV2-UL19-1851 + AUCGCCCCCGGACCGGC 17 2091
HSV2-UL19-1852 + UCGCCCCCGGACCGGCC 17 2092
HSV2-UL19-1853 + CGCCCCCGGACCGGCCG 17 2093
HSV2-UL19-1854 + GCCCCCGGACCGGCCGG 17 2094
HSV2-UL19-1855 + CCCCCGGACCGGCCGGG 17 2095
HSV2-UL19-1856 + CGGGGGGACUUCGCCGC 17 2096
HSV2-UL19-1857 + GGGGGGACUUCGCCGCC 17 2097
HSV2-UL19-1858 + GCCGGGAAGCUCGACGU 17 2098
HSV2-UL19-1859 + CGCGAAGAAGUCGAACG 17 2099
HSV2-UL19-1860 + GCGAAGAAGUCGAACGC 17 2100
HSV2-UL19-1861 + CGAAGAAGUCGAACGCG 17 2101
HSV2-UL19-1862 + GGUGCAGCUCCAGAGCC 17 2102
HSV2-UL19-1863 + CAGCUCCAGAGCCAGGU 17 2103
HSV2-UL19-1864 + AGCCAGGUUGGCGUUGU 17 2104
HSV2-UL19-1865 + GCCAGGUUGGCGUUGUC 17 2105
HSV2-UL19-1866 + CUGCAUGAACUGCUCCG 17 2106
HSV2-UL19-1867 + ACUGCUCCGCGGUCAUC 17 2107
HSV2-UL19-1868 + CGCGGUCAUCUGGCACU 17 2108
HSV2-UL19-1869 + GGCACUCGGCGACCCAC 17 2109
HSV2-UL19-1870 + CGGCGACCCACCGGACC 17 2110
HSV2-UL19-1871 + CCCACCGGACCCGGCCG 17 2111
HSV2-UL19-1872 + CCACCGGACCCGGCCGU 17 2112
HSV2-UL19-1873 + GGACCCGGCCGUGGGCG 17 2113 HSV2-UL19-1874 + GGCGAGGCGCUGCCGCC 17 2114
HSV2-UL19-1875 + CUGCUGCAUGUCCGCGC 17 2115
HSV2-UL19-1876 + UGCUGCAUGUCCGCGCC 17 2116
HSV2-UL19-1877 + GCUGCAUGUCCGCGCCG 17 2117
HSV2-UL19-1878 + CAUGUCCGCGCCGGGGC 17 2118
HSV2-UL19-1879 + UCCGCGCCGGGGCCGGC 17 2119
HSV2-UL19-1880 + CCGCGCCGGGGCCGGCC 17 2120
HSV2-UL19-1881 + CGCGCCGGGGCCGGCCG 17 2121
HSV2-UL19-1882 + GCGACGUACGCCCCGUA 17 2122
HSV2-UL19-1883 + CGCCCCGUACGGAUUCG 17 2123
HSV2-UL19-1884 + CGGAUUCGCGGCCUCGA 17 2124
HSV2-UL19-1885 + GGAUUCGCGGCCUCGAC 17 2125
HSV2-UL19-1886 + GAUUCGCGGCCUCGACG 17 2126
HSV2-UL19-1887 + CGGCCUCGACGGGGUCG 17 2127
HSV2-UL19-1888 + GUGGUUCACGCCCCCGA 17 2128
HSV2-UL19-1889 + UCGAUGUUCAUGAGCGA 17 2129
HSV2-UL19-1890 + GAGCGAAGGAUGACACA 17 2130
HSV2-UL19-1891 + CCCGACCGCGUUCUCCA 17 2131
HSV2-UL19-1892 + UGGACAGCCGCAGAACC 17 2132
HSV2-UL19-1893 + ACAGCCGCAGAACCUGG 17 2133
HSV2-UL19-1894 + CCCAAA AAAAC AG CU G C 17 2134
HSV2-UL19-1895 + CCAA AAAAACAG CU G CC 17 2135
HSV2-UL19-1896 + CA AAAAAACAG CU G CCG 17 2136
HSV2-UL19-1897 + AAAAACAG CU G CCG G G G 17 2137
HSV2-UL19-1898 + AAAACAG CU G CCG G G G A 17 2138
HSV2-UL19-1899 + GCCGGGGAGGGAACGCG 17 2139
HSV2-UL19-1900 + CCGGGGAGGGAACGCGC 17 2140
HSV2-UL19-1901 + CGGGGAGGGAACGCGCG 17 2141
HSV2-UL19-1902 + GGGAACGCGCGGGGCUC 17 2142
HSV2-UL19-1903 + GGAACGCGCGGGGCUCC 17 2143
HSV2-UL19-1904 + ACGCGCGGGGCUCCGGG 17 2144
HSV2-UL19-1905 + GCGGGGCUCCGGGUGGC 17 2145
HSV2-UL19-1906 + CGGGGCUCCGGGUGGCC 17 2146
HSV2-UL19-1907 + GGGGCUCCGGGUGGCCG 17 2147
HSV2-UL19-1908 + GGGCUCCGGGUGGCCGG 17 2148
HSV2-UL19-1909 + CUCCGGGUGGCCGGGGG 17 2149
HSV2-UL19-1910 + UCCGGGUGGCCGGGGGC 17 2150
HSV2-UL19-1911 + GGCCGGGGGCGGGCACC 17 2151
HSV2-UL19-1912 + GGCGGGCACCAGGUCCC 17 2152
HSV2-UL19-1913 + CAGGUCCCCGGCGUGCG 17 2153
HSV2-UL19-1914 + CGCGGCGAAGCGCUCCA 17 2154
HSV2-UL19-1915 + GCGAAGCGCUCCAUGGC 17 2155
HSV2-UL19-1916 + CGAAGCGCUCCAUGGCC 17 2156
HSV2-UL19-1917 + CCGGGUUGAACAGCCCC 17 2157
HSV2-UL19-1918 + CGGGUUGAACAGCCCCA 17 2158
HSV2-UL19-1919 + GGGUUGAACAGCCCCAG 17 2159 HSV2-UL19-1920 + UGAACAGCCCCAGGGGC 17 2160
HSV2-UL19-1921 + GGGGCAGGACGAACGUC 17 2161
HSV2-UL19-1922 + GACGAACGUCAGGUCCA 17 2162
HSV2-UL19-1923 + GGUCCAUGGCGCCCACC 17 2163
HSV2-UL19-1924 + GUCCAUGGCGCCCACCA 17 2164
HSV2-UL19-1925 + UCCAUGGCGCCCACCAG 17 2165
HSV2-UL19-1926 + CCAUGGCGCCCACCAGG 17 2166
HSV2-UL19-1927 + GGCGCCCACCAGGGGGU 17 2167
HSV2-UL19-1928 + GCGCCCACCAGGGGGUA 17 2168
HSV2-UL19-1929 + CAGGGGGUAGGGCACGU 17 2169
HSV2-UL19-1930 + GGGGUAGGGCACGUUGG 17 2170
HSV2-UL19-1931 + GUAGGGCACGUUGGUGG 17 2171
HSV2-UL19-1932 + CGUAGAUGCGUCUCUCC 17 2172
HSV2-UL19-1933 + GUAGAUGCGUCUCUCCA 17 2173
HSV2-UL19-1934 + GUCUCUCCAGGGCCUCC 17 2174
HSV2-UL19-1935 + GACCAGCCUGUCGCCUA 17 2175
HSV2-UL19-1936 + CGCGCACGCGCGUUGUC 17 2176
HSV2-UL19-1937 + GCGCACGCGCGUUGUCU 17 2177
HSV2-UL19-1938 + CGCACGCGCGUUGUCUG 17 2178
HSV2-UL19-1939 + GCACGCGCGUUGUCUGG 17 2179
HSV2-UL19-1940 + CACGCGCGUUGUCUGGG 17 2180
HSV2-UL19-1941 + G U U CAU CCAGCG U CU CC 17 2181
HSV2-UL19-1942 + CCUCCUGCAUAUCCAGC 17 2182
HSV2-UL19-1943 + CCUGCAUAUCCAGCAGG 17 2183
HSV2-UL19-1944 + GCAUAUCCAGCAGGUGG 17 2184
HSV2-UL19-1945 + GGCGGCCCACGUCGUCC 17 2185
HSV2-UL19-1946 + GUCGUCCAGGCUCCGCA 17 2186
HSV2-UL19-1947 + UCACCAGCGCCGUGACG 17 2187
HSV2-UL19-1948 + CAGCGCCGUGACGAGGU 17 2188
HSV2-UL19-1949 + CAAGACCAUCUCGCCGU 17 2189
HSV2-UL19-1950 + AUCUCGCCGUAGGUCAC 17 2190
HSV2-UL19-1951 + GUAGGUCACCGGCACGU 17 2191
HSV2-UL19-1952 + CACCGGCACGUCGGCCU 17 2192
HSV2-UL19-1953 + CGGUGUCCUCCACCUUC 17 2193
HSV2-UL19-1954 + GUCCUCCACCUUCAGGA 17 2194
HSV2-UL19-1955 + CCUUCAGGAAGGACUGC 17 2195
HSV2-UL19-1956 + UCAGGAAGGACUGCAGG 17 2196
HSV2-UL19-1957 + CAGGAGGCGCUGUUUGA 17 2197
HSV2-UL19-1958 + GAGGCGCUGUUUGAUGG 17 2198
HSV2-UL19-1959 + GCGCUGUUUGAUGGCGG 17 2199
HSV2-UL19-1960 + CUGUUUGAUGGCGGCGG 17 2200
HSV2-UL19-1961 + ACCAG CACCCCG U CG AC 17 2201
HSV2-UL19-1962 + CGGCCGCCCGCGCGUGU 17 2202
HSV2-UL19-1963 + GCGUGUCGGCGUGCGUC 17 2203
HSV2-UL19-1964 + UGUCGGCGUGCGUCAGG 17 2204
HSV2-UL19-1965 + GUCGGCGUGCGUCAGGC 17 2205 HSV2-UL19-1966 + UCGGCGUGCGUCAGGCG 17 2206
HSV2-UL19-1967 + GUGCGUCAGGCGGGGCA 17 2207
HSV2-UL19-1968 + CAGGCGGGGCACGGCCA 17 2208
HSV2-UL19-1969 + CGGGGCACGGCCACGGA 17 2209
HSV2-UL19-1970 + GGACGGCUGCGUCGCCG 17 2210
HSV2-UL19-1971 + GCUGCGUCGCCGUGGUC 17 2211
HSV2-UL19-1972 + GGUCAGGUCCACGAGCC 17 2212
HSV2-UL19-1973 + CACGAGCCAGGCCUCGA 17 2213
HSV2-UL19-1974 + AGGCCUCGAUGGCCUCG 17 2214
HSV2-UL19-1975 + CGAUGGCCUCGCGGCGA 17 2215
HSV2-UL19-1976 + GAUGGCCCGCCUUGCCC 17 2216
HSV2-UL19-1977 + AAAGCUCCGCUUCAGCU 17 2217
HSV2-UL19-1978 + GCU UCAGCUCGGCGACC 17 2218
HSV2-UL19-1979 + CU UCAGCUCGGCGACCA 17 2219
HSV2-UL19-1980 + CGGCGACCAGGGUCGCC 17 2220
HSV2-UL19-1981 + GGCGACCAGGGUCGCCC 17 2221
HSV2-UL19-1982 + GGUCGCCCGGGCAACCC 17 2222
HSV2-UL19-1983 + GGGCAACCCUGGUCGCC 17 2223
HSV2-UL19-1984 + GUCGAGAUAUCGUUGCA 17 2224
HSV2-UL19-1985 + UCGAGAUAUCGUUGCAU 17 2225
HSV2-UL19-1986 + GUUGCAUGGGCAACAGC 17 2226
HSV2-UL19-1987 + UUGCAUGGGCAACAGCA 17 2227
HSV2-UL19-1988 + UGGGCAACAGCAGGGCC 17 2228
HSV2-UL19-1989 + G G G CAACAG CAG G G CCA 17 2229
HSV2-UL19-1990 + G G CAACAG CAG G G CCAG 17 2230
HSV2-UL19-1991 + AACAGCAGGGCCAGGGG 17 2231
HSV2-UL19-1992 + ACAGCACGUGCAGCAUC 17 2232
HSV2-UL19-1993 + CACGUGCAGCAUCUGGU 17 2233
HSV2-UL19-1994 + CGCGCUCAAACGCCCCC 17 2234
HSV2-UL19-1995 + CUCAAACG CCCCC AG G A 17 2235
HSV2-UL19-1996 + ACGCCCCCAGGACGGCC 17 2236
Table ID provides exemplary targeting domains for knocking out the UL19 gene selected according to the first tier parameters. The targeting domains are selected based on location within first 500bp of the coding sequence of the UL19 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. aureus Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. aureus Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a strand targeting domain provided that the two gRNAs are oriented on the DNA such that
PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp
Table ID
Figure imgf000144_0001
HSV2-UL19-237 - GCGUGUGCACCAAGUUC 17 2265
HSV2-UL19-113 - CGUGUGCACCAAGUUCC 17 420
HSV2-UL19-239 - UCCCGGAGCUGGCUUAC 17 2266
HSV2-UL19-240 - GGAGCUGGCUUACAUGA 17 2267
HSV2-UL19-241 - GCUGGCUUACAUGAACG 17 2268
HSV2-UL19-242 - CGAAGGGCGUGUGCAGU 17 2269
HSV2-UL19-243 - CGACGGCCCGCACCCCG 17 2270
HSV2-UL19-244 - CCGUGCAUAAUUACAUG 17 2271
HSV2-UL19-245 - ACGAAGGUCAUCGACCG 17 2272
HSV2-UL19-246 - UCAUCGACCGCCGGGCC 17 2273
HSV2-UL19-247 - CGCCUUCAGCCUGGCCA 17 2274
HSV2-UL19-248 - AGGCCAUUGCCCUGCUC 17 2275
HSV2-UL19-124 - GGCCAUUGCCCUGCUCA 17 525
HSV2-UL19-125 - GCCAUUGCCCUGCUCAC 17 526
HSV2-UL19-126 - CCAUUGCCCUGCUCACG 17 527
HSV2-UL19-127 - CAUUGCCCUGCUCACGG 17 528
HSV2-UL19-253 - UGCUCACGGGGGAGGCC 17 2276
HSV2-UL19-254 - CACGGGGGAGGCCCUGG 17 2277
HSV2-UL19-130 - ACGGGGGAGGCCCUGGA 17 531
HSV2-UL19-256 - GGGAGGCCCUGGACGGG 17 2278
HSV2-UL19-257 + AGGCUAAUGCCCGUCCCGUC 20 2279
HSV2-UL19-258 + UCCCGUCCAGGGCCUCCCCC 20 2280
HSV2-UL19-259 + UCCAGGGCCUCCCCCGUGAG 20 2281
HSV2-UL19-260 + CAAUGGCCUCGGUGGCCAGG 20 2282
HSV2-UL19-261 + GCCAGGCUGAAGGCGGCGUU 20 2283
HSV2-UL19-262 + CCUUCGUCAUGUAAUUAUGC 20 2284
HSV2-UL19-263 + AAUUAUGCACGGGCUGCUCG 20 2285
HSV2-UL19-53 + AUUAUGCACGGGCUGCUCGA 20 401
HSV2-UL19-265 + CACGGGCUGCUCGACGGGGU 20 2286
HSV2-UL19-266 + UCGACGGGGUGCGGGCCGUC 20 2287
HSV2-UL19-267 + GGUGCGGGCCGUCGCGGGCG 20 2288
HSV2-UL19-268 + UGCGGGCCGUCGCGGGCGAU 20 2289
HSV2-UL19-60 + GCGGGCCGUCGCGGGCGAUG 20 483
HSV2-UL19-270 + UCGCGGGCGAUGAGGGGCUG 20 2290
HSV2-UL19-271 + CGAUGAGGGGCUGGUGGACC 20 2291
HSV2-UL19-272 + U U CG U U CAU G U AAG CCAGCU 20 2292
HSV2-UL19-65 + UCGUUCAUGUAAGCCAGCUC 20 405
HSV2-UL19-66 + CGUUCAUGUAAGCCAGCUCC 20 406
HSV2-UL19-275 + ACUUGGUGCACACGCACGCC 20 2293
HSV2-UL19-276 + ACACGCACGCCACGGACAGG 20 2294
HSV2-UL19-277 + GCCACGGACAGGCCGAGCUC 20 2295
HSV2-UL19-278 + GGCCGAGCUCCAGAAAGCGC 20 2296
HSV2-UL19-279 + UCCAGAAAGCGCACGAGCGA 20 2297
HSV2-UL19-280 + CGAGCGACAGGGUGUUGCAG 20 2298
HSV2-UL19-281 + GUGUUGCAGUAGGACCCCAG 20 2299
HSV2-UL19-282 + CGUCAUACAGGCUGUUUUCG 20 2300 HSV2-UL19-76 + GUCAUACAGGCUGUUUUCGU 20 494
HSV2-UL19-284 + UUUCGUCGGAGCGCACGGCG 20 2301
HSV2-UL19-285 + GCACGGCGGCG AAAAAAU CA 20 2302
HSV2-UL19-286 + AAAAAAU CAAAG AG U CU GCG 20 2303
HSV2-UL19-80 + AAAAAUCAAAGAGUCUGCGG 20 498
HSV2-UL19-288 + GACGCCACCUCGAUCGUACU 20 2304
HSV2-UL19-289 + CCACCUCGAUCGUACUCAGG 20 2305
HSV2-UL19-83 + CACCUCGAUCGUACUCAGGA 20 409
HSV2-UL19-291 + UCGUACUCAGGAUGGAGCCG 20 2306
HSV2-UL19-292 + CUCAGGAUGGAGCCGGUGGG 20 2307
HSV2-UL19-293 + GGCCGCGGCGUACCGGUAAC 20 2308
HSV2-UL19-91 + GCCGCGGCGUACCGGUAACC 20 506
HSV2-UL19-92 + CCGCGGCGUACCGGUAACCC 20 507
HSV2-UL19-93 + CGCGGCGUACCGGUAACCCG 20 508
HSV2-UL19-297 + UACCGGUAACCCGGGGGGUC 20 2309
HSV2-UL19-298 + GUAACCCGGGGGGUCGCGGG 20 2310
HSV2-UL19-98 + UAACCCGGGGGGUCGCGGGC 20 413
HSV2-UL19-300 + CUAAUGCCCGUCCCGUC 17 2311
HSV2-UL19-301 + CGUCCAGGGCCUCCCCC 17 2312
HSV2-UL19-302 + AGGGCCUCCCCCGUGAG 17 2313
HSV2-UL19-303 + UGGCCUCGGUGGCCAGG 17 2314
HSV2-UL19-304 + AGGCUGAAGGCGGCGUU 17 2315
HSV2-UL19-305 + UCGUCAUGUAAUUAUGC 17 2316
HSV2-UL19-306 + UAUGCACGGGCUGCUCG 17 2317
HSV2-UL19-152 + AUGCACGGGCUGCUCGA 17 428
HSV2-UL19-308 + GGGCUGCUCGACGGGGU 17 2318
HSV2-UL19-309 + ACGGGGUGCGGGCCGUC 17 2319
HSV2-UL19-310 + GCGGGCCGUCGCGGGCG 17 2320
HSV2-UL19-311 + GGGCCGUCGCGGGCGAU 17 2321
HSV2-UL19-159 + GGCCGUCGCGGGCGAUG 17 555
HSV2-UL19-313 + CGGGCGAUGAGGGGCUG 17 2322
HSV2-UL19-314 + UGAGGGGCUGGUGGACC 17 2323
HSV2-UL19-315 + GUUCAUGUAAGCCAGCU 17 2324
HSV2-UL19-164 + UUCAUGUAAGCCAGCUC 17 432
HSV2-UL19-165 + UCAUGUAAGCCAGCUCC 17 433
HSV2-UL19-318 + UGGUGCACACGCACGCC 17 2325
HSV2-UL19-319 + CGCACGCCACGGACAGG 17 2326
HSV2-UL19-320 + ACGGACAGGCCGAGCUC 17 2327
HSV2-UL19-321 + CGAGCUCCAGAAAGCGC 17 2328
HSV2-UL19-322 + AGAAAGCGCACGAGCGA 17 2329
HSV2-UL19-323 + GCGACAGGGUGUUGCAG 17 2330
HSV2-UL19-324 + U UGCAG U AG G ACCCCAG 17 2331
HSV2-UL19-325 + CAUACAGGCUGUUUUCG 17 2332
HSV2-UL19-175 + AUACAGGCUGUUUUCGU 17 566
HSV2-UL19-327 + CGUCGGAGCGCACGGCG 17 2333
HSV2-UL19-328 + CG G CG G CG AAAAAAU CA 17 2334 HSV2-UL19-329 + AAAUCAAAGAGUCUGCG 17 2335
HSV2-UL19-179 + AAU CAAAG AGUCUGCGG 17 570
HSV2-UL19-331 + GCCACCUCGAUCGUACU 17 2336
HSV2-UL19-332 + CCUCGAUCGUACUCAGG 17 2337
HSV2-UL19-182 + CUCGAUCGUACUCAGGA 17 436
HSV2-UL19-334 + UACUCAGGAUGGAGCCG 17 2338
HSV2-UL19-335 + AGGAUGGAGCCGGUGGG 17 2339
HSV2-UL19-336 + CGCGGCGUACCGGUAAC 17 2340
HSV2-UL19-190 + GCGGCGUACCGGUAACC 17 578
HSV2-UL19-191 + CGGCGUACCGGUAACCC 17 579
HSV2-UL19-192 + GGCGUACCGGUAACCCG 17 580
HSV2-UL19-340 + CGGUAACCCGGGGGGUC 17 2341
HSV2-UL19-341 + ACCCGGGGGGUCGCGGG 17 2342
HSV2-UL19-197 + CCCGGGGGGUCGCGGGC 17 440
Table IE provides exemplary targeting domains for knocking out the UL19 gene selected according to the second tier parameters. The targeting domains are selected based on location within the coding sequence (but downstream of the first 500bp) of the UL19 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. aureus Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. aureus Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table IE
Figure imgf000147_0001
HSV2-UL19-2005 - GGGCGACCCUGGUCGCCGAG 20 2350
HSV2-UL19-2006 - ACCCUGGUCGCCGAGCUGAA 20 2351
HSV2-UL19-359 - CCCUGGUCGCCGAGCUGAAG 20 599
HSV2-UL19-2008 - UGAAGCGGAGCUUUUGCGAC 20 2352
HSV2-UL19-2009 - UUUGCGACACGAGCUUCUUC 20 2353
HSV2-UL19-2010 - CGAGCUUCUUCCUGGGCAAG 20 2354
HSV2-UL19-2011 - GGGCAAGGCGGGCCAUCGCC 20 2355
HSV2-UL19-2012 - GGGCCAUCGCCGCGAGGCCA 20 2356
HSV2-UL19-2013 - AGGCCAUCGAGGCCUGGCUC 20 2357
HSV2-UL19-2014 - CCUGACGCACGCCGACACGC 20 2358
HSV2-UL19-2015 - CACGCGCGGGCGGCCGGUCG 20 2359
HSV2-UL19-375 - ACGCGCGGGCGGCCGGUCGA 20 615
HSV2-UL19-2017 - AGCGCCUCCUGCAGUCCUUC 20 2360
HSV2-UL19-2018 - UCCUGCAGUCCUUCCUGAAG 20 2361
HSV2-UL19-380 - CCUGCAGUCCUUCCUGAAGG 20 620
HSV2-UL19-2020 - UGCAGUCCUUCCUGAAGGUG 20 2362
HSV2-UL19-2021 - CUUCCUGAAGGUGGAGGACA 20 2363
HSV2-UL19-2022 - CGACGUGCCGGUGACCUACG 20 2364
HSV2-UL19-2023 - UGACCUACGGCGAGAUGGUC 20 2365
HSV2-UL19-2024 - CUACGGCGAGAUGGUCUUGA 20 2366
HSV2-UL19-386 - UACGGCGAGAUGGUCUUGAA 20 626
HSV2-UL19-2026 - ACCUCGUCACGGCGCUGGUG 20 2367
HSV2-UL19-2027 - CUGGUGAUGGGCAAGGCCGU 20 2368
HSV2-UL19-394 - UGGUGAUGGGCAAGGCCGUG 20 634
HSV2-UL19-2029 - UGGGCAAGGCCGUGCGGAGC 20 2369
HSV2-UL19-2030 - CCGUGCGGAGCCUGGACGAC 20 2370
HSV2-UL19-2031 - ACGACGUGGGCCGCCACCUG 20 2371
HSV2-UL19-2032 - GCCGCCACCUGCUGGAUAUG 20 2372
HSV2-UL19-399 - CCGCCACCUGCUGGAUAUGC 20 639
HSV2-UL19-2034 - GCCACCUGCUGGAUAUGCAG 20 2373
HSV2-UL19-400 - CCACCUGCUGGAUAUGCAGG 20 640
HSV2-UL19-2036 - GGAUAUGCAGGAGGAGCAAC 20 2374
HSV2-UL19-2037 - UGCAGGAGGAGCAACUCGAG 20 2375
HSV2-UL19-2038 - GAGGAGCAACUCGAGGCGAA 20 2376
HSV2-UL19-402 - AGGAGCAACUCGAGGCGAAC 20 642
HSV2-UL19-403 - GGAGCAACUCGAGGCGAACC 20 643
HSV2-UL19-2041 - UCGAGGCGAACCGGGAGACG 20 2377
HSV2-UL19-2042 - GGCGAACCGGGAGACGCUGG 20 2378
HSV2-UL19-2043 - CCGGGAGACGCUGGAUGAAC 20 2379
HSV2-UL19-2044 - CCCAGACAACGCGCGUGCGC 20 2380
HSV2-UL19-2045 - UAGGCGACAGGCUGGUCUUC 20 2381
HSV2-UL19-411 - AGGCGACAGGCUGGUCUUCC 20 651
HSV2-UL19-2047 - GGCUGGUCUUCCUGGAGGCC 20 2382
HSV2-UL19-413 - GCUGGUCUUCCUGGAGGCCC 20 653
HSV2-UL19-2049 - UGGUCUUCCUGGAGGCCCUG 20 2383
HSV2-UL19-2050 - CCAACGUGCCCUACCCCCUG 20 2384 HSV2-UL19-2051 - CCUACCCCCUGGUGGGCGCC 20 2385
HSV2-UL19-2052 - ACCUGACGUUCGUCCUGCCC 20 2386
HSV2-UL19-418 - CCUGACGUUCGUCCUGCCCC 20 658
HSV2-UL19-2054 - UGGGGCUGUUCAACCCGGCC 20 2387
HSV2-UL19-422 - GGGGCUGUUCAACCCGGCCA 20 662
HSV2-UL19-2056 - GGAGCGCUUCGCCGCGCACG 20 2388
HSV2-UL19-423 - GAGCGCUUCGCCGCGCACGC 20 663
HSV2-UL19-424 - AGCGCUUCGCCGCGCACGCC 20 664
HSV2-UL19-2059 - UGGUGCCCGCCCCCGGCCAC 20 2389
HSV2-UL19-428 - GGUGCCCGCCCCCGGCCACC 20 668
HSV2-UL19-2061 - CCUCCCCGGCAGCUGUUUUU 20 2390
HSV2-UL19-430 - CUCCCCGGCAGCUGUUUUUU 20 670
HSV2-UL19-431 - UCCCCGGCAGCUGUUUUUUU 20 671
HSV2-UL19-432 - CCCCGGCAGCUGU UUUUUUG 20 672
HSV2-UL19-2065 - GGCAGCUGUUUUUUUGGGGA 20 2391
HSV2-UL19-2066 - ACCAGGUUCUGCGGCUGUCC 20 2392
HSV2-UL19-436 - CCAGGUUCUGCGGCUGUCCA 20 676
HSV2-UL19-2068 - AGGUUCUGCGGCUGUCCAUG 20 2393
HSV2-UL19-2069 - GCUGUCCAUGGAGAACGCGG 20 2394
HSV2-UL19-438 - CUGUCCAUGGAGAACGCGGU 20 678
HSV2-UL19-2071 - CCGUGUGUCAUCCUUCGCUC 20 2395
HSV2-UL19-2072 - CAUGAACAUCGACGCGGCCG 20 2396
HSV2-UL19-441 - AUGAACAUCGACGCGGCCGU 20 681
HSV2-UL19-442 - UGAACAUCGACGCGGCCGUC 20 682
HSV2-UL19-2075 - UCGACGCGGCCGUCGGGGGC 20 2397
HSV2-UL19-2076 - GGGCGUGAACCACGACCCCG 20 2398
HSV2-UL19-2077 - ACCACGACCCCGUCGAGGCC 20 2399
HSV2-UL19-2078 - CGUCGAGGCCGCGAAUCCGU 20 2400
HSV2-UL19-446 - GUCGAGGCCGCGAAUCCGUA 20 686
HSV2-UL19-2080 - CGGCCCCGGCCGGCCCCGGC 20 2401
HSV2-UL19-2081 - CGGACAUGCAGCAGCGUUUU 20 2402
HSV2-UL19-2082 - CGGCAGCGCCUCGCCCACGG 20 2403
HSV2-UL19-2083 - CUCGCCCACGGCCGGGUCCG 20 2404
HSV2-UL19-2084 - CGGCCGGGUCCGGUGGGUCG 20 2405
HSV2-UL19-2085 - UCGCCGAGUGCCAGAUGACC 20 2406
HSV2-UL19-462 - CGCCGAGUGCCAGAUGACCG 20 702
HSV2-UL19-2087 - CCGACAACGCCAACCUGGCU 20 2407
HSV2-UL19-464 - CGACAACGCCAACCUGGCUC 20 704
HSV2-UL19-2089 - ACCCCGCGUUCGACUUCUUC 20 2408
HSV2-UL19-2090 - CUUCGCGGGCGUGGCCGACG 20 2409
HSV2-UL19-2091 - CGACGUCGAGCUUCCCGGCG 20 2410
HSV2-UL19-2092 - GCGAAGUCCCCCCGGCCGGU 20 2411
HSV2-UL19-472 - CGAAGUCCCCCCGGCCGGUC 20 712
HSV2-UL19-473 - GAAG U CCCCCCG GCCG G U CC 20 713
HSV2-UL19-2095 - CCGGUGGCGUUUCGUGACGC 20 2412
HSV2-UL19-483 - CGGUGGCGUUUCGUGACGCC 20 723 HSV2-UL19-2097 - CGUUUCGUGACGCCCGGGGC 20 2413
HSV2-UL19-486 - GUUUCGUGACGCCCGGGGCC 20 726
HSV2-UL19-2099 - GGCUACCAUAGCCGCCGUCC 20 2414
HSV2-UL19-491 - GCUACCAUAGCCGCCGUCCG 20 731
HSV2-UL19-2101 - AGCCGCCGUCCGCGGGGCGU 20 2415
HSV2-UL19-2102 - CCGCCGUCCGCGGGGCGUUC 20 2416
HSV2-UL19-2103 - GCAAGCCGCGAUUCACGGCA 20 2417
HSV2-UL19-2104 - ACUCAGUGCAUCACCAGCUA 20 2418
HSV2-UL19-500 - CUCAGUGCAUCACCAGCUAC 20 740
HSV2-UL19-2106 - ACACGCGAUGCGCGGCGUUC 20 2419
HSV2-UL19-2107 - CUCGUACAUCGUGACCUACC 20 2420
HSV2-UL19-503 - UCGUACAUCGUGACCUACCU 20 743
HSV2-UL19-504 - CGUACAUCGUGACCUACCUC 20 744
HSV2-UL19-2110 - CUACCUCGGGGGCGACCUCC 20 2421
HSV2-UL19-2111 - ACCUCGGGGGCGACCUCCCC 20 2422
HSV2-UL19-507 - CCUCGGGGGCGACCUCCCCG 20 747
HSV2-UL19-2113 - GAGGAGUGCAUGGCCGUGUA 20 2423
HSV2-UL19-509 - AGGAGUGCAUGGCCGUGUAU 20 749
HSV2-UL19-2115 - UCGGGACCUGGUGGCCCACG 20 2424
HSV2-UL19-2116 - UCGAGGCCCUGGCCCAGCUG 20 2425
HSV2-UL19-2117 - UGGUGGACGACUUUACCCUG 20 2426
HSV2-UL19-2118 - ACGACUUUACCCUGCCGGGC 20 2427
HSV2-UL19-519 - CGACUUUACCCUGCCGGGCC 20 759
HSV2-UL19-2120 - UUACCCUGCCGGGCCCGGAG 20 2428
HSV2-UL19-2121 - CCUGCCGGGCCCGGAGCUGG 20 2429
HSV2-UL19-2122 - GCUGGGCGGGCAGGCUCAGG 20 2430
HSV2-UL19-2123 - GCGGGCAGGCUCAGGCCGAG 20 2431
HSV2-UL19-2124 - GCGCUGCUGCCGCCCCUCGU 20 2432
HSV2-UL19-527 - CGCUGCUGCCGCCCCUCGUG 20 767
HSV2-UL19-2126 - GCCUUAUGCGACACGCGGCC 20 2433
HSV2-UL19-2127 - CACGCGGCCCUGGACCGCCA 20 2434
HSV2-UL19-2128 - CUGGACCGCCACCGAGACUG 20 2435
HSV2-UL19-2129 - ACCGAGACUGCCGGAUUGAC 20 2436
HSV2-UL19-533 - CCGAGACUGCCGGAUUGACG 20 773
HSV2-UL19-534 - CGAGACUGCCGGAUUGACGC 20 774
HSV2-UL19-535 - GAGACUGCCGGAUUGACGCG 20 775
HSV2-UL19-536 - AGACUGCCGGAUUGACGCGG 20 776
HSV2-UL19-2134 - CCGGAUUGACGCGGGGGGGC 20 2437
HSV2-UL19-2135 - CGGCCGCACCGGCCGGCCGA 20 2438
HSV2-UL19-2136 - GUGCUGGUGCCGGCCUUCUC 20 2439
HSV2-UL19-553 - UGCUGGUGCCGGCCUUCUCG 20 793
HSV2-UL19-554 - GCUGGUGCCGGCCUUCUCGC 20 794
HSV2-UL19-2139 - CGCGGGGGCGCUGCUGCACC 20 2440
HSV2-UL19-557 - GCGGGGGCGCUGCUGCACCG 20 797
HSV2-UL19-558 - CGGGGGCGCUGCUGCACCGC 20 798
HSV2-UL19-2142 - ACCGCGUGUACGCCACGCUG 20 2441 HSV2-UL19-2143 - CGCUGCAGAACAUGGUGGUC 20 2442
HSV2-UL19-563 - GCUGCAGAACAUGGUGGUCC 20 803
HSV2-UL19-2145 - GGUCCCGGAGAUCGCCCCCG 20 2443
HSV2-UL19-2146 - UCCCGGAGAUCGCCCCCGGU 20 2444
HSV2-UL19-565 - CCCGGAGAUCGCCCCCGGUG 20 805
HSV2-UL19-2148 - UCGCCCCCGGUGAGGAGUGC 20 2445
HSV2-UL19-2149 - GGUCAAGCGCAUGUUCCACA 20 2446
HSV2-UL19-2150 - CAACGGGCGCGUCGUCGUCG 20 2447
HSV2-UL19-2151 - GGUGCUGGCGCACAACAUGG 20 2448
HSV2-UL19-2152 - UGUGCUCCGCGGCGCCCGAC 20 2449
HSV2-UL19-2153 - GGCCAACAUGCGCAUCUUCG 20 2450
HSV2-UL19-581 - GCCAACAUGCGCAUCUUCGA 20 821
HSV2-UL19-2155 - UGCUCAUGGCCCCCCAGCAC 20 2451
HSV2-UL19-2156 - G G ACCACACCAU CCAAAAUG 20 2452
HSV2-UL19-2157 - UGCCCGUCCACGCGCUGUUU 20 2453
HSV2-UL19-2158 - UCCCCCUGGUCCCCCCGGCC 20 2454
HSV2-UL19-595 - CCCCCUGGUCCCCCCGGCCC 20 835
HSV2-UL19-596 - CCCCUGGUCCCCCCGGCCCU 20 836
HSV2-UL19-2161 - GCCCGUGGUGCAGCACGCCC 20 2455
HSV2-UL19-2162 - CCGUGGUGCAGCACGCCCGC 20 2456
HSV2-UL19-2163 - AGCACGCCCGCGAGAGCGCG 20 2457
HSV2-UL19-601 - GCACGCCCGCGAGAGCGCGG 20 841
HSV2-UL19-602 - CACGCCCGCGAGAGCGCGGC 20 842
HSV2-UL19-603 - ACGCCCGCGAGAGCGCGGCG 20 843
HSV2-UL19-604 - CGCCCGCGAGAGCGCGGCGG 20 844
HSV2-UL19-2168 - CCCGCGAGAGCGCGGCGGGG 20 2458
HSV2-UL19-2169 - CGCUGACCUACGCGCUCAUG 20 2459
HSV2-UL19-606 - GCUGACCUACGCGCUCAUGG 20 846
HSV2-UL19-2171 - UCAUGGCGGGGUACUUCAAG 20 2460
HSV2-UL19-2172 - CCCUGUAUCACCAGCUCAAG 20 2461
HSV2-UL19-2173 - GCUCAAGACGGGCCUCCACC 20 2462
HSV2-UL19-2174 - GACGGGCCUCCACCCCGGGU 20 2463
HSV2-UL19-2175 - UCGGGUUCACCGUCGUGCGG 20 2464
HSV2-UL19-2176 - GCGGCAGGACCGCUUCGUGA 20 2465
HSV2-UL19-2177 - GGCAGGACCGCUUCGUGACC 20 2466
HSV2-UL19-2178 - GACCGAGAACGUGCUGUUUU 20 2467
HSV2-UL19-2179 - UGCUGUUUUCCGAGCGCGCG 20 2468
HSV2-UL19-618 - GCUGUUUUCCGAGCGCGCGU 20 858
HSV2-UL19-2181 - GCGCGUCGGAGGCGUACUUU 20 2469
HSV2-UL19-2182 - CCAGCUCCAGGUGGCCCGCC 20 2470
HSV2-UL19-2183 - UCCAGGUGGCCCGCCACGAA 20 2471
HSV2-UL19-2184 - GGUGGCCCGCCACGAAACGG 20 2472
HSV2-UL19-626 - GUGGCCCGCCACGAAACGGG 20 866
HSV2-UL19-627 - UGGCCCGCCACGAAACGGGC 20 867
HSV2-UL19-628 - GGCCCGCCACGAAACGGGCG 20 868
HSV2-UL19-629 - GCCCGCCACGAAACGGGCGG 20 869 HSV2-UL19-2189 - CUUCACGCUCACCCAGCCGC 20 2473
HSV2-UL19-632 - UUCACGCUCACCCAGCCGCG 20 872
HSV2-UL19-2191 - UCACCCAGCCGCGCGGAAAC 20 2474
HSV2-UL19-2192 - AGCCGCGCGGAAACGUGGAC 20 2475
HSV2-UL19-2193 - GCGGAAACGUGGACCUGGGU 20 2476
HSV2-UL19-2194 - GCUACACCGCCGUCGCGGCC 20 2477
HSV2-UL19-2195 - GCACCGUCCGCAACCCCGUU 20 2478
HSV2-UL19-2196 - UCCGCAACCCCGUUACGGAC 20 2479
HSV2-UL19-2197 - CCAAAACUUUUACCUCGGCC 20 2480
HSV2-UL19-645 - CAAAACUUUUACCUCGGCCG 20 885
HSV2-UL19-2199 - ACCUGCGCAACGCGGUCGUG 20 2481
HSV2-UL19-651 - CCUGCGCAACGCGGUCGUGG 20 891
HSV2-UL19-652 - CUGCGCAACGCGGUCGUGGC 20 892
HSV2-UL19-2202 - CGGUCGUGGCGGGAAACCGG 20 2482
HSV2-UL19-654 - GGUCGUGGCGGGAAACCGGC 20 894
HSV2-UL19-2204 - AGGUGCCGCGGCGCGCCGGC 20 2483
HSV2-UL19-2205 - GCGGCGCGCCGGCAUGGACC 20 2484
HSV2-UL19-2206 - GCGCCGGCAUGGACCACGGG 20 2485
HSV2-UL19-2207 - CCACGGGCAGGAUGCCGUGU 20 2486
HSV2-UL19-2208 - UCAUCGCCACCCCCGUGGCC 20 2487
HSV2-UL19-2209 - UUUCGCCGGCCCUGCAACCC 20 2488
HSV2-UL19-670 - UUCGCCGGCCCUGCAACCCG 20 910
HSV2-UL19-671 - UCGCCGGCCCUGCAACCCGC 20 911
HSV2-UL19-2212 - GCGCGGCCGGCGGCGUGUAC 20 2489
HSV2-UL19-676 - CGCGGCCGGCGGCGUGUACG 20 916
HSV2-UL19-677 - GCGGCCGGCGGCGUGUACGC 20 917
HSV2-UL19-678 - CGGCCGGCGGCGUGUACGCG 20 918
HSV2-UL19-2216 - GCGGCGUGUACGCGGGGGAC 20 2490
HSV2-UL19-680 - CGGCGUGUACGCGGGGGACA 20 920
HSV2-UL19-2218 - GCGUGUACGCGGGGGACAAG 20 2491
HSV2-UL19-681 - CGUGUACGCGGGGGACAAGG 20 921
HSV2-UL19-682 - GUGUACGCGGGGGACAAGGA 20 922
HSV2-UL19-683 - UGUACGCGGGGGACAAGGAG 20 923
HSV2-UL19-2222 - CCCUCAUGUACGACCACGGC 20 2492
HSV2-UL19-2223 - UUCGCGGCCACGGCCAACCC 20 2493
HSV2-UL19-2224 - GGCGUCGCAGCGGUUCUCGU 20 2494
HSV2-UL19-693 - GCGUCGCAGCGGUUCUCGUA 20 933
HSV2-UL19-694 - CGUCGCAGCGGUUCUCGUAC 20 934
HSV2-UL19-2227 - GUACGGGGACCUGCUGUACA 20 2495
HSV2-UL19-696 - UACGGGGACCUGCUGUACAA 20 936
HSV2-UL19-2229 - CAACGGGGCCUAUCACCUCA 20 2496
HSV2-UL19-699 - AACGGGGCCUAUCACCUCAA 20 939
HSV2-UL19-2231 - UCACGGCCAAACAUCGCUGC 20 2497
HSV2-UL19-704 - CACGGCCAAACAUCGCUGCC 20 944
HSV2-UL19-2233 - GCUGCCUGGAGCGUCUCAUC 20 2498
HSV2-UL19-705 - CUGCCUGGAGCGUCUCAUCG 20 945 HSV2-UL19-2235 - UGGAGCGUCUCAUCGUGGAA 20 2499
HSV2-UL19-706 - GGAGCGUCUCAUCGUGGAAA 20 946
HSV2-UL19-2237 - ACGUGCAGUUUAAGCGCCCG 20 2500
HSV2-UL19-711 - CGUGCAGUUUAAGCGCCCGC 20 951
HSV2-UL19-2239 - UAAGCGCCCGCCGGGGUGCC 20 2501
HSV2-UL19-2240 - CGCCGGGGUGCCGCGAGCUC 20 2502
HSV2-UL19-714 - GCCGGGGUGCCGCGAGCUCG 20 954
HSV2-UL19-2242 - AAGACCCGUGCGGCCUGUUU 20 2503
HSV2-UL19-716 - AGACCCGUGCGGCCUGUUUC 20 956
HSV2-UL19-2244 - CCUGCUACGCAGCGCCCGCG 20 2504
HSV2-UL19-717 - CUGCUACGCAGCGCCCGCGA 20 957
HSV2-UL19-718 - UGCUACGCAGCGCCCGCGAU 20 958
HSV2-UL19-719 - GCUACGCAGCGCCCGCGAUG 20 959
HSV2-UL19-2248 - CGCGAUGGGGAGGCCCACGC 20 2505
HSV2-UL19-2249 - CGAUGGGGAGGCCCACGCGC 20 2506
HSV2-UL19-2250 - UCUACGACGCCUCCCCGCUA 20 2507
HSV2-UL19-2251 - GGCCGUCCUGGGGGCGU 17 2508
HSV2-UL19-2252 - AGAUGCUGCACGUGCUG 17 2509
HSV2-UL19-726 - GAUGCUGCACGUGCUGU 17 966
HSV2-UL19-2254 - UGCUGCACGUGCUGUUG 17 2510
HSV2-UL19-2255 - GCAACGAUAUCUCGACA 17 2511
HSV2-UL19-2256 - AACGGGCGCCUGGCGAC 17 2512
HSV2-UL19-2257 - CUGGCGACCAGGGUUGC 17 2513
HSV2-UL19-2258 - CCGGGCGACCCUGGUCG 17 2514
HSV2-UL19-2259 - CGACCCUGGUCGCCGAG 17 2515
HSV2-UL19-2260 - CUGGUCGCCGAGCUGAA 17 2516
HSV2-UL19-737 - UGGUCGCCGAGCUGAAG 17 977
HSV2-UL19-2262 - AGCGGAGCUUUUGCGAC 17 2517
HSV2-UL19-2263 - GCGACACGAGCUUCUUC 17 2518
HSV2-UL19-2264 - GCU UCUUCCUGGGCAAG 17 2519
HSV2-UL19-2265 - CAAG GCGGGCCAUCGCC 17 2520
HSV2-UL19-2266 - CCAUCGCCGCGAGGCCA 17 2521
HSV2-UL19-2267 - CCAUCGAGGCCUGGCUC 17 2522
HSV2-UL19-2268 - GACGCACGCCGACACGC 17 2523
HSV2-UL19-2269 - GCGCGGGCGGCCGGUCG 17 2524
HSV2-UL19-753 - CGCGGGCGGCCGGUCGA 17 993
HSV2-UL19-2271 - GCCUCCUGCAGUCCUUC 17 2525
HSV2-UL19-2272 - UGCAGUCCUUCCUGAAG 17 2526
HSV2-UL19-758 - GCAGUCCUUCCUGAAGG 17 998
HSV2-UL19-2274 - AGUCCUUCCUGAAGGUG 17 2527
HSV2-UL19-2275 - CCUGAAGGUGGAGGACA 17 2528
HSV2-UL19-2276 - CGUGCCGGUGACCUACG 17 2529
HSV2-UL19-2277 - CCUACGGCGAGAUGGUC 17 2530
HSV2-UL19-2278 - CGGCGAGAUGGUCUUGA 17 2531
HSV2-UL19-764 - GGCGAGAUGGUCUUGAA 17 1004
HSV2-UL19-2280 - UCGUCACGGCGCUGGUG 17 2532 HSV2-UL19-2281 - GUGAUGGGCAAGGCCGU 17 2533
HSV2-UL19-772 - UGAUGGGCAAGGCCGUG 17 1012
HSV2-UL19-2283 - GCAAGGCCGUGCGGAGC 17 2534
HSV2-UL19-2284 - UGCGGAGCCUGGACGAC 17 2535
HSV2-UL19-2285 - ACGUGGGCCGCCACCUG 17 2536
HSV2-UL19-2286 - GCCACCUGCUGGAUAUG 17 2537
HSV2-UL19-777 - CCACCUGCUGGAUAUGC 17 1017
HSV2-UL19-2288 - ACCUGCUGGAUAUGCAG 17 2538
HSV2-UL19-778 - CCUGCUGGAUAUGCAGG 17 1018
HSV2-UL19-2290 - UAUGCAGGAGGAGCAAC 17 2539
HSV2-UL19-2291 - AGGAGGAGCAACUCGAG 17 2540
HSV2-UL19-2292 - GAGCAACUCGAGGCGAA 17 2541
HSV2-UL19-780 - AGCAACUCGAGGCGAAC 17 1020
HSV2-UL19-781 - GCAACUCGAGGCGAACC 17 1021
HSV2-UL19-2295 - AGGCGAACCGGGAGACG 17 2542
HSV2-UL19-2296 - GAACCGGGAGACGCUGG 17 2543
HSV2-UL19-2297 - GGAGACGCUGGAUGAAC 17 2544
HSV2-UL19-2298 - AGACAACGCGCGUGCGC 17 2545
HSV2-UL19-2299 - GCGACAGGCUGGUCUUC 17 2546
HSV2-UL19-789 - CGACAGGCUGGUCUUCC 17 1029
HSV2-UL19-2301 - UGGUCUUCCUGGAGGCC 17 2547
HSV2-UL19-791 - GGUCUUCCUGGAGGCCC 17 1031
HSV2-UL19-2303 - UCUUCCUGGAGGCCCUG 17 2548
HSV2-UL19-2304 - ACGUGCCCUACCCCCUG 17 2549
HSV2-UL19-2305 - ACCCCCUGGUGGGCGCC 17 2550
HSV2-UL19-2306 - UGACGUUCGUCCUGCCC 17 2551
HSV2-UL19-796 - GACGUUCGUCCUGCCCC 17 1036
HSV2-UL19-2308 - GGCUGUUCAACCCGGCC 17 2552
HSV2-UL19-800 - GCUGUUCAACCCGGCCA 17 1040
HSV2-UL19-2310 - GCGCUUCGCCGCGCACG 17 2553
HSV2-UL19-801 - CGCU UCGCCGCGCACGC 17 1041
HSV2-UL19-802 - GCU UCGCCGCGCACGCC 17 1042
HSV2-UL19-2313 - UGCCCGCCCCCGGCCAC 17 2554
HSV2-UL19-806 - GCCCGCCCCCGGCCACC 17 1046
HSV2-UL19-2315 - CCCCGGCAGCUGUUUUU 17 2555
HSV2-UL19-808 - CCCGGCAGCUGUUUUUU 17 1048
HSV2-UL19-809 - CCGGCAGCUGUUUUUUU 17 1049
HSV2-UL19-810 - CGGCAGCUGUUUUUUUG 17 1050
HSV2-UL19-2319 - AGCUGUUUUUUUGGGGA 17 2556
HSV2-UL19-2320 - AGGUUCUGCGGCUGUCC 17 2557
HSV2-UL19-814 - GGUUCUGCGGCUGUCCA 17 1054
HSV2-UL19-2322 - UUCUGCGGCUGUCCAUG 17 2558
HSV2-UL19-2323 - G U CCAUG G AG AACG CG G 17 2559
HSV2-UL19-816 - UCCAUGGAGAACGCGGU 17 1056
HSV2-UL19-2325 - UGUGUCAUCCUUCGCUC 17 2560
HSV2-UL19-2326 - GAACAUCGACGCGGCCG 17 2561 HSV2-UL19-819 - AACAUCGACGCGGCCGU 17 1059
HSV2-UL19-820 - ACAUCGACGCGGCCGUC 17 1060
HSV2-UL19-2329 - ACGCGGCCGUCGGGGGC 17 2562
HSV2-UL19-2330 - CG U G AACCACG ACCCCG 17 2563
HSV2-UL19-2331 - ACGACCCCGUCGAGGCC 17 2564
HSV2-UL19-2332 - CGAGGCCGCGAAUCCGU 17 2565
HSV2-UL19-824 - GAGGCCGCGAAUCCGUA 17 1064
HSV2-UL19-2334 - CCCCGGCCGGCCCCGGC 17 2566
HSV2-UL19-2335 - ACAUGCAGCAGCGUUUU 17 2567
HSV2-UL19-2336 - CAGCGCCUCGCCCACGG 17 2568
HSV2-UL19-2337 - GCCCACGGCCGGGUCCG 17 2569
HSV2-UL19-2338 - CCGGGUCCGGUGGGUCG 17 2570
HSV2-UL19-2339 - CCGAGUGCCAGAUGACC 17 2571
HSV2-UL19-840 - CGAGUGCCAGAUGACCG 17 1080
HSV2-UL19-2341 - ACAACGCCAACCUGGCU 17 2572
HSV2-UL19-842 - CAACGCCAACCUGGCUC 17 1082
HSV2-UL19-2343 - CCGCGUUCGACUUCUUC 17 2573
HSV2-UL19-2344 - CGCGGGCGUGGCCGACG 17 2574
HSV2-UL19-2345 - CGUCGAGCUUCCCGGCG 17 2575
HSV2-UL19-2346 - AAGUCCCCCCGGCCGGU 17 2576
HSV2-UL19-850 - AGUCCCCCCGGCCGGUC 17 1090
HSV2-UL19-851 - GUCCCCCCGGCCGGUCC 17 1091
HSV2-UL19-2349 - GUGGCGUUUCGUGACGC 17 2577
HSV2-UL19-861 - UGGCGUUUCGUGACGCC 17 1101
HSV2-UL19-2351 - UUCGUGACGCCCGGGGC 17 2578
HSV2-UL19-864 - UCGUGACGCCCGGGGCC 17 1104
HSV2-UL19-2353 - UACCAUAGCCGCCGUCC 17 2579
HSV2-UL19-869 - ACCAUAGCCGCCGUCCG 17 1109
HSV2-UL19-2355 - CGCCGUCCGCGGGGCGU 17 2580
HSV2-UL19-2356 - CCGUCCGCGGGGCGUUC 17 2581
HSV2-UL19-2357 - AGCCGCGAUUCACGGCA 17 2582
HSV2-UL19-2358 - CAGUGCAUCACCAGCUA 17 2583
HSV2-UL19-878 - AGUGCAUCACCAGCUAC 17 1118
HSV2-UL19-2360 - CGCGAUGCGCGGCGUUC 17 2584
HSV2-UL19-2361 - GUACAUCGUGACCUACC 17 2585
HSV2-UL19-881 - UACAUCGUGACCUACCU 17 1121
HSV2-UL19-882 - ACAUCGUGACCUACCUC 17 1122
HSV2-UL19-2364 - CCUCGGGGGCGACCUCC 17 2586
HSV2-UL19-2365 - UCGGGGGCGACCUCCCC 17 2587
HSV2-UL19-885 - CGGGGGCGACCUCCCCG 17 1125
HSV2-UL19-2367 - GAGUGCAUGGCCGUGUA 17 2588
HSV2-UL19-887 - AGUGCAUGGCCGUGUAU 17 1127
HSV2-UL19-2369 - GGACCUGGUGGCCCACG 17 2589
HSV2-UL19-2370 - AGGCCCUGGCCCAGCUG 17 2590
HSV2-UL19-2371 - UGGACGACUUUACCCUG 17 2591
HSV2-UL19-2372 - ACUUUACCCUGCCGGGC 17 2592 HSV2-UL19-897 - CUUUACCCUGCCGGGCC 17 1137
HSV2-UL19-2374 - CCCUGCCGGGCCCGGAG 17 2593
HSV2-UL19-2375 - GCCGGGCCCGGAGCUGG 17 2594
HSV2-UL19-2376 - GGGCGGGCAGGCUCAGG 17 2595
HSV2-UL19-2377 - GGCAGGCUCAGGCCGAG 17 2596
HSV2-UL19-2378 - CUGCUGCCGCCCCUCGU 17 2597
HSV2-UL19-905 - UGCUGCCGCCCCUCGUG 17 1145
HSV2-UL19-2380 - UUAUGCGACACGCGGCC 17 2598
HSV2-UL19-2381 - GCGGCCCUGGACCGCCA 17 2599
HSV2-UL19-2382 - GACCGCCACCGAGACUG 17 2600
HSV2-UL19-2383 - GAGACUGCCGGAUUGAC 17 2601
HSV2-UL19-911 - AGACUGCCGGAUUGACG 17 1151
HSV2-UL19-912 - GACUGCCGGAUUGACGC 17 1152
HSV2-UL19-913 - ACUGCCGGAUUGACGCG 17 1153
HSV2-UL19-914 - CUGCCGGAUUGACGCGG 17 1154
HSV2-UL19-2388 - GAUUGACGCGGGGGGGC 17 2602
HSV2-UL19-2389 - CCGCACCGGCCGGCCGA 17 2603
HSV2-UL19-2390 - CUGGUGCCGGCCUUCUC 17 2604
HSV2-UL19-931 - UGGUGCCGGCCUUCUCG 17 1171
HSV2-UL19-932 - GGUGCCGGCCUUCUCGC 17 1172
HSV2-UL19-2393 - GGGGGCGCUGCUGCACC 17 2605
HSV2-UL19-935 - GGGGCGCUGCUGCACCG 17 1175
HSV2-UL19-936 - GGGCGCUGCUGCACCGC 17 1176
HSV2-UL19-2396 - GCGUGUACGCCACGCUG 17 2606
HSV2-UL19-2397 - UGCAGAACAUGGUGGUC 17 2607
HSV2-UL19-941 - GCAGAACAUGGUGGUCC 17 1181
HSV2-UL19-2399 - CCCGGAGAUCGCCCCCG 17 2608
HSV2-UL19-2400 - CGGAGAUCGCCCCCGGU 17 2609
HSV2-UL19-943 - GGAGAUCGCCCCCGGUG 17 1183
HSV2-UL19-2402 - CCCCCGGUGAGGAGUGC 17 2610
HSV2-UL19-2403 - CAAGCGCAUGUUCCACA 17 2611
HSV2-UL19-2404 - CGGGCGCGUCGUCGUCG 17 2612
HSV2-UL19-2405 - GCUGGCGCACAACAUGG 17 2613
HSV2-UL19-2406 - GCUCCGCGGCGCCCGAC 17 2614
HSV2-UL19-2407 - CAACAU GCG CAU CU U CG 17 2615
HSV2-UL19-959 - AACAUGCGCAUCUUCGA 17 1199
HSV2-UL19-2409 - UCAUGGCCCCCCAGCAC 17 2616
HSV2-UL19-2410 - CCACACCAU CCAAAAU G 17 2617
HSV2-UL19-2411 - CCGUCCACGCGCUGUUU 17 2618
HSV2-UL19-2412 - CCCUGGUCCCCCCGGCC 17 2619
HSV2-UL19-973 - CCUGGUCCCCCCGGCCC 17 1213
HSV2-UL19-974 - CUGGUCCCCCCGGCCCU 17 1214
HSV2-UL19-2415 - CGUGGUGCAGCACGCCC 17 2620
HSV2-UL19-2416 - UGGUGCAGCACGCCCGC 17 2621
HSV2-UL19-2417 - ACGCCCGCGAGAGCGCG 17 2622
HSV2-UL19-979 - CGCCCGCGAGAGCGCGG 17 1219 HSV2-UL19-980 - GCCCGCGAGAGCGCGGC 17 1220
HSV2-UL19-981 - CCCGCGAGAGCGCGGCG 17 1221
HSV2-UL19-982 - CCGCGAGAGCGCGGCGG 17 1222
HSV2-UL19-2422 - GCGAGAGCGCGGCGGGG 17 2623
HSV2-UL19-2423 - UGACCUACGCGCUCAUG 17 2624
HSV2-UL19-984 - GACCUACGCGCUCAUGG 17 1224
HSV2-UL19-2425 - UGGCGGGGUACUUCAAG 17 2625
HSV2-UL19-2426 - UGUAUCACCAGCUCAAG 17 2626
HSV2-UL19-2427 - CAAGACGGGCCUCCACC 17 2627
HSV2-UL19-2428 - GGGCCUCCACCCCGGGU 17 2628
HSV2-UL19-2429 - GGUUCACCGUCGUGCGG 17 2629
HSV2-UL19-2430 - GCAGGACCGCUUCGUGA 17 2630
HSV2-UL19-2431 - AGGACCGCUUCGUGACC 17 2631
HSV2-UL19-2432 - CGAGAACGUGCUGUUUU 17 2632
HSV2-UL19-2433 - UGUUUUCCGAGCGCGCG 17 2633
HSV2-UL19-996 - GUUUUCCGAGCGCGCGU 17 1236
HSV2-UL19-2435 - CGUCGGAGGCGUACUUU 17 2634
HSV2-UL19-2436 - GCUCCAGGUGGCCCGCC 17 2635
HSV2-UL19-2437 - AGGUGGCCCGCCACGAA 17 2636
HSV2-UL19-2438 - GGCCCGCCACGAAACGG 17 2637
HSV2-UL19-1004 - GCCCGCCACGAAACGGG 17 1244
HSV2-UL19-1005 - CCCGCCACGAAACGGGC 17 1245
HSV2-UL19-1006 - CCGCCACGAAACGGGCG 17 1246
HSV2-UL19-1007 - CGCCACGAAACGGGCGG 17 1247
HSV2-UL19-2443 - CACGCUCACCCAGCCGC 17 2638
HSV2-UL19-1010 - ACG CU CACCCAGCCG CG 17 1250
HSV2-UL19-2445 - CCCAGCCGCGCGGAAAC 17 2639
HSV2-UL19-2446 - CGCGCGGAAACGUGGAC 17 2640
HSV2-UL19-2447 - GAAACGUGGACCUGGGU 17 2641
HSV2-UL19-2448 - ACACCGCCGUCGCGGCC 17 2642
HSV2-UL19-2449 - CCG U CCG CAACCCCG U U 17 2643
HSV2-UL19-2450 - GCAACCCCGU UACGGAC 17 2644
HSV2-UL19-2451 - AAACU U U UACCUCGGCC 17 2645
HSV2-UL19-1023 - AACUUUUACCUCGGCCG 17 1263
HSV2-UL19-2453 - UGCGCAACGCGGUCGUG 17 2646
HSV2-UL19-1029 - GCGCAACGCGGUCGUGG 17 1269
HSV2-UL19-1030 - CGCAACGCGGUCGUGGC 17 1270
HSV2-UL19-2456 - UCGUGGCGGGAAACCGG 17 2647
HSV2-UL19-1032 - CGUGGCGGGAAACCGGC 17 1272
HSV2-UL19-2458 - UGCCGCGGCGCGCCGGC 17 2648
HSV2-UL19-2459 - GCGCGCCGGCAUGGACC 17 2649
HSV2-UL19-2460 - CCGGCAUGGACCACGGG 17 2650
HSV2-UL19-2461 - CGGGCAGGAUGCCGUGU 17 2651
HSV2-UL19-2462 - UCGCCACCCCCGUGGCC 17 2652
HSV2-UL19-2463 - CGCCGGCCCUGCAACCC 17 2653
HSV2-UL19-1048 - GCCGGCCCUGCAACCCG 17 1288 HSV2-UL19-1049 - CCGGCCCUGCAACCCGC 17 1289
HSV2-UL19-2466 - CGGCCGGCGGCGUGUAC 17 2654
HSV2-UL19-1054 - GGCCGGCGGCGUGUACG 17 1294
HSV2-UL19-1055 - GCCGGCGGCGUGUACGC 17 1295
HSV2-UL19-1056 - CCGGCGGCGUGUACGCG 17 1296
HSV2-UL19-2470 - GCGUGUACGCGGGGGAC 17 2655
HSV2-UL19-1058 - CGUGUACGCGGGGGACA 17 1298
HSV2-UL19-2472 - UGUACGCGGGGGACAAG 17 2656
HSV2-UL19-1059 - GUACGCGGGGGACAAGG 17 1299
HSV2-UL19-1060 - UACGCGGGGGACAAGGA 17 1300
HSV2-UL19-1061 - ACGCGGGGGACAAGGAG 17 1301
HSV2-UL19-2476 - UCAUGUACGACCACGGC 17 2657
HSV2-UL19-2477 - GCGGCCACGGCCAACCC 17 2658
HSV2-UL19-2478 - GUCGCAGCGGUUCUCGU 17 2659
HSV2-UL19-1071 - UCGCAGCGGUUCUCGUA 17 1311
HSV2-UL19-1072 - CG CAG CG G U U CU CG U AC 17 1312
HSV2-UL19-2481 - CGGGGACCUGCUGUACA 17 2660
HSV2-UL19-1074 - GGGGACCUGCUGUACAA 17 1314
HSV2-UL19-2483 - CGGGGCCUAUCACCUCA 17 2661
HSV2-UL19-1077 - GGGGCCUAUCACCUCAA 17 1317
HSV2-UL19-2485 - CGGCCAAACAUCGCUGC 17 2662
HSV2-UL19-1082 - GGCCAAACAUCGCUGCC 17 1322
HSV2-UL19-2487 - GCCUGGAGCGUCUCAUC 17 2663
HSV2-UL19-1083 - CCUGGAGCGUCUCAUCG 17 1323
HSV2-UL19-2489 - AGCGUCUCAUCGUGGAA 17 2664
HSV2-UL19-1084 - GCGUCUCAUCGUGGAAA 17 1324
HSV2-UL19-2491 - UGCAGUUUAAGCGCCCG 17 2665
HSV2-UL19-1089 - GCAGUUUAAGCGCCCGC 17 1329
HSV2-UL19-2493 - GCGCCCGCCGGGGUGCC 17 2666
HSV2-UL19-2494 - CGGGGUGCCGCGAGCUC 17 2667
HSV2-UL19-1092 - GGGGUGCCGCGAGCUCG 17 1332
HSV2-UL19-2496 - ACCCGUGCGGCCUGUUU 17 2668
HSV2-UL19-1094 - CCCGUGCGGCCUGU UUC 17 1334
HSV2-UL19-2498 - GCUACGCAGCGCCCGCG 17 2669
HSV2-UL19-1095 - CUACGCAGCGCCCGCGA 17 1335
HSV2-UL19-1096 - UACGCAGCGCCCGCGAU 17 1336
HSV2-UL19-1097 - ACGCAGCGCCCGCGAUG 17 1337
HSV2-UL19-2502 - GAUGGGGAGGCCCACGC 17 2670
HSV2-UL19-2503 - UGGGGAGGCCCACGCGC 17 2671
HSV2-UL19-2504 - ACGACGCCUCCCCGCUA 17 2672
HSV2-UL19-2505 + UUACAGAGACAGGCCCUUUA 20 2673
HSV2-UL19-1101 + UACAGAGACAGGCCCUUUAG 20 1341
HSV2-UL19-1102 + ACAGAGACAGGCCCUUUAGC 20 1342
HSV2-UL19-1103 + CAGAGACAGGCCCUUUAGCG 20 1343
HSV2-UL19-2509 + UUAGCGGGGAGGCGUCGUAG 20 2674
HSV2-UL19-2510 + UAGAUGAGAUACUGCGUAAA 20 2675 HSV2-UL19-2511 + GUAAAGUGGGUCUCUCGCGC 20 2676
HSV2-UL19-2512 + CGCGCGUGGGCCUCCCCAUC 20 2677
HSV2-UL19-2513 + CCAUCGCGGGCGCUGCGUAG 20 2678
HSV2-UL19-2514 + CGCGGGCGCUGCGUAGCAGG 20 2679
HSV2-UL19-1113 + GCGGGCGCUGCGUAGCAGGG 20 1353
HSV2-UL19-2516 + GGGGUCGCUGGCGCAGGUGA 20 2680
HSV2-UL19-2517 + CAGGUGAUCGGGUAGGCUUC 20 2681
HSV2-UL19-2518 + GGCUUCCUGAAACAGGCCGC 20 2682
HSV2-UL19-2519 + ACAGGCCGCACGGGUCUUCC 20 2683
HSV2-UL19-2520 + CACGAGCUCGCGGCACCCCG 20 2684
HSV2-UL19-2521 + CGUCGCUGGCAGCGGUGGCC 20 2685
HSV2-UL19-2522 + CCGCCGAUCCCGUU UCCACG 20 2686
HSV2-UL19-2523 + UGGCCGUGAUGUCGGCCGCG 20 2687
HSV2-UL19-2524 + CCGUGAUGUCGGCCGCGGUG 20 2688
HSV2-UL19-2525 + UGUCGGCCGCGGUGAAGAAC 20 2689
HSV2-UL19-2526 + CCGCGGUGAAGAACUUGAAG 20 2690
HSV2-UL19-1136 + CGCGGUGAAGAACUUGAAGC 20 1376
HSV2-UL19-2528 + UGAAGAACUUGAAGCAGGGG 20 2691
HSV2-UL19-2529 + AAGAACUUGAAGCAGGGGCU 20 2692
HSV2-UL19-2530 + ACUUGAAGCAGGGGCUGAGG 20 2693
HSV2-UL19-2531 + GAAGCAGGGGCUGAGGACGG 20 2694
HSV2-UL19-2532 + UGAGGACGGGCGAGGCCCCG 20 2695
HSV2-UL19-2533 + GUUGUACAGCAGGUCCCCGU 20 2696
HSV2-UL19-2534 + UGUACAGCAGGUCCCCGUAC 20 2697
HSV2-UL19-2535 + CGAGAACCGCUGCGACGCCC 20 2698
HSV2-UL19-2536 + CCCACGGGU UGGCCGUGGCC 20 2699
HSV2-UL19-2537 + ACGGGUUGGCCGUGGCCGCG 20 2700
HSV2-UL19-2538 + CGUGGCCGCGAAGGGCCGCG 20 2701
HSV2-UL19-2539 + CGCUCUGGCCGUGGUCGUAC 20 2702
HSV2-UL19-2540 + CUCUGGCCGUGGUCGUACAU 20 2703
HSV2-UL19-2541 + GCCGCCGGCCGCGCGUCCCC 20 2704
HSV2-UL19-2542 + CCGCGCGUCCCCGCGGGUUG 20 2705
HSV2-UL19-2543 + CCCCGCGGGUUGCAGGGCCG 20 2706
HSV2-UL19-2544 + AGUAGUUGAUGUCCGUGGCC 20 2707
HSV2-UL19-1165 + GUAGUUGAUGUCCGUGGCCA 20 1405
HSV2-UL19-1166 + UAGUUGAUGUCCGUGGCCAC 20 1406
HSV2-UL19-2547 + CCGUGGCCACGGGGGUGGCG 20 2708
HSV2-UL19-2548 + AUGCCGGCGCGCCGCGGCAC 20 2709
HSV2-UL19-2549 + CACCUGGGCG CAG CCAAAG A 20 2710
HSV2-UL19-1176 + ACCUGGGCGCAGCCAAAGAC 20 1416
HSV2-UL19-1177 + CCUGGGCGCAGCCAAAGACC 20 1417
HSV2-UL19-2552 + UGGGCGCAGCCAAAGACCGG 20 2711
HSV2-UL19-1178 + GGGCGCAGCCAAAGACCGGG 20 1418
HSV2-UL19-2554 + CAGCCAAAGACCGGGAGGGG 20 2712
HSV2-UL19-2555 + GGCGGCCGCGUUGUCUAGCA 20 2713
HSV2-UL19-1188 + GCGGCCGCGUUGUCUAGCAG 20 1428 HSV2-UL19-1189 + CGGCCGCGUUGUCUAGCAGC 20 1429
HSV2-UL19-1190 + GGCCGCGUUGUCUAGCAGCG 20 1430
HSV2-UL19-1191 + GCCGCGUUGUCUAGCAGCGG 20 1431
HSV2-UL19-2560 + GCAGCGGGGGGGCCCCGCGG 20 2714
HSV2-UL19-2561 + CCGCGGCCGAGGUAAAAGUU 20 2715
HSV2-UL19-1196 + CGCGGCCGAGGUAAAAGUUU 20 1436
HSV2-UL19-1197 + GCGGCCGAGGUAAAAGUUUU 20 1437
HSV2-UL19-1198 + CGGCCGAGGUAAAAGUUUUG 20 1438
HSV2-UL19-1199 + GGCCGAGGUAAAAGUUUUGG 20 1439
HSV2-UL19-2566 + GGAGGUUGCCCAUGUCCGUA 20 2716
HSV2-UL19-1201 + GAGGUUGCCCAUGUCCGUAA 20 1441
HSV2-UL19-2568 + CCCAUGUCCGUAACGGGGUU 20 2717
HSV2-UL19-2569 + AGGUCCACGUUUCCGCGCGG 20 2718
HSV2-UL19-2570 + CCACGUUUCCGCGCGGCUGG 20 2719
HSV2-UL19-2571 + UUCCGCGCGGCUGGGUGAGC 20 2720
HSV2-UL19-2572 + ACCCCCCCGCCCGUUUCGUG 20 2721
HSV2-UL19-2573 + CCCGUUUCGUGGCGGGCCAC 20 2722
HSV2-UL19-1216 + CCGUUUCGUGGCGGGCCACC 20 1456
HSV2-UL19-2575 + CGGGCCACCUGGAGCUGGCC 20 2723
HSV2-UL19-2576 + AGUACGCCUCCGACGCGCGC 20 2724
HSV2-UL19-1218 + GUACGCCUCCGACGCGCGCU 20 1458
HSV2-UL19-2578 + AAAACAGCACGUUCUCGGUC 20 2725
HSV2-UL19-2579 + AGCGGUCCUGCCGCACGACG 20 2726
HSV2-UL19-2580 + CCUGCCGCACGACGGUGAAC 20 2727
HSV2-UL19-2581 + GCACGACGGUGAACCCGAAC 20 2728
HSV2-UL19-1222 + CACGACG G U G AACCCG AACC 20 1462
HSV2-UL19-2583 + ACGGUGAACCCGAACCCGGG 20 2729
HSV2-UL19-1225 + CGGUGAACCCGAACCCGGGG 20 1465
HSV2-UL19-2585 + ACCCGGGGUGGAGGCCCGUC 20 2730
HSV2-UL19-2586 + CCCGUCUUGAGCUGGUGAUA 20 2731
HSV2-UL19-2587 + UGAGCUGGUGAUACAGGGCC 20 2732
HSV2-UL19-1230 + GAGCUGGUGAUACAGGGCCA 20 1470
HSV2-UL19-2589 + ACAGGGCCACGGGGCUCAUC 20 2733
HSV2-UL19-2590 + UCAUCUUGAAGUACCCCGCC 20 2734
HSV2-UL19-2591 + UUCUCCCCCGCCGCGCUCUC 20 2735
HSV2-UL19-2592 + UCUCGCGGGCGUGCUGCACC 20 2736
HSV2-UL19-2593 + GCGUGCUGCACCACGGGCUG 20 2737
HSV2-UL19-2594 + GCUGCACCACGGGCUGGCGG 20 2738
HSV2-UL19-1240 + CUGCACCACGGGCUGGCGGA 20 1480
HSV2-UL19-2596 + GCACCACGGGCUGGCGGAUG 20 2739
HSV2-UL19-1241 + CACCACGGGCUGGCGGAUGG 20 1481
HSV2-UL19-2598 + CCACGGGCUGGCGGAUGGAG 20 2740
HSV2-UL19-2599 + GAGGAGAAGUAGUUGGCCCC 20 2741
HSV2-UL19-2600 + GAAGUAGUUGGCCCCCAGGG 20 2742
HSV2-UL19-1245 + AAGUAGUUGGCCCCCAGGGC 20 1485
HSV2-UL19-1246 + AGUAGUUGGCCCCCAGGGCC 20 1486 HSV2-UL19-1247 + GUAGUUGGCCCCCAGGGCCG 20 1487
HSV2-UL19-1248 + UAGUUGGCCCCCAGGGCCGG 20 1488
HSV2-UL19-2605 + GCCCCCAGGGCCGGGGGGAC 20 2743
HSV2-UL19-1250 + CCCCCAGGGCCGGGGGGACC 20 1490
HSV2-UL19-1251 + CCCCAGGGCCGGGGGGACCA 20 1491
HSV2-UL19-1252 + CCCAGGGCCGGGGGGACCAG 20 1492
HSV2-UL19-2609 + ACGUCGCGCGCCAGGUCGCG 20 2744
HSV2-UL19-2610 + GCGCGCCAGGUCGCGCAGGG 20 2745
HSV2-UL19-1257 + CGCGCCAGGUCGCGCAGGGC 20 1497
HSV2-UL19-1258 + GCGCCAGGUCGCGCAGGGCC 20 1498
HSV2-UL19-1259 + CGCCAGGUCGCGCAGGGCCG 20 1499
HSV2-UL19-1260 + GCCAGGUCGCGCAGGGCCGG 20 1500
HSV2-UL19-1261 + CCAGGUCGCGCAGGGCCGGG 20 1501
HSV2-UL19-2616 + CGCGCAGGGCCGGGGGGAAG 20 2746
HSV2-UL19-2617 + UCGGCGCCCGCAAACAGCGC 20 2747
HSV2-UL19-2618 + CGCCCGCAAACAGCGCGUGG 20 2748
HSV2-UL19-2619 + GCAAACAGCGCGUGGACGGG 20 2749
HSV2-UL19-2620 + GCGCGUGGACGGGCAGGACG 20 2750
HSV2-UL19-2621 + ACGUAGAAGUAUUCGCCAUU 20 2751
HSV2-UL19-2622 + UGGAUGGUGUGGUCCAGGUG 20 2752
HSV2-UL19-1275 + GGAUGGUGUGGUCCAGGUGC 20 1515
HSV2-UL19-1276 + GAUGGUGUGGUCCAGGUGCU 20 1516
HSV2-UL19-1277 + AUGGUGUGGUCCAGGUGCUG 20 1517
HSV2-UL19-2626 + GGUCCAGGUGCUGGGGGGCC 20 2753
HSV2-UL19-2627 + CGCCGGCGUGCAGCGCCCCG 20 2754
HSV2-UL19-2628 + ACGCGGUGUUGGCGCCCGCG 20 2755
HSV2-UL19-2629 + UGGCGCCCGCGUCGGGCGCC 20 2756
HSV2-UL19-1286 + GGCGCCCGCGUCGGGCGCCG 20 1526
HSV2-UL19-2631 + UGUGCGCCAGCACCUGCAGC 20 2757
HSV2-UL19-2632 + GCACCUGCAGCGUGAGCAUG 20 2758
HSV2-UL19-2633 + UCGACGACGACGCGCCCGUU 20 2759
HSV2-UL19-1291 + CGACGACGACGCGCCCGU UG 20 1531
HSV2-UL19-2635 + CCGUGUUGGCCACCAGAUUG 20 2760
HSV2-UL19-1294 + CGUGUUGGCCACCAGAUUGG 20 1534
HSV2-UL19-2637 + CACCAGAUUGGCGGGAUGCA 20 2761
HSV2-UL19-2638 + AGAUUGGCGGGAUGCAGCGG 20 2762
HSV2-UL19-2639 + UGGCGGGAUGCAGCGGGUGG 20 2763
HSV2-UL19-1300 + GGCGGGAUGCAGCGGGUGGG 20 1540
HSV2-UL19-2641 + GCGGGUGGGCGGGGUCGGUC 20 2764
HSV2-UL19-1304 + CGGGUGGGCGGGGUCGGUCA 20 1544
HSV2-UL19-2643 + GGGGUCGGUCACGGGAUCGC 20 2765
HSV2-UL19-2644 + GAUCGCUCGGGCACUCCUCA 20 2766
HSV2-UL19-1308 + AUCGCUCGGGCACUCCUCAC 20 1548
HSV2-UL19-1309 + UCGCUCGGGCACUCCUCACC 20 1549
HSV2-UL19-2647 + CUCCUCACCGGGGGCGAUCU 20 2767
HSV2-UL19-1312 + UCCUCACCGGGGGCGAUCUC 20 1552 HSV2-UL19-2649 + GCAGCGUGGCGUACACGCGG 20 2768
HSV2-UL19-2650 + GUGGCGUACACGCGGUCGAA 20 2769
HSV2-UL19-2651 + CGCGGUGCAGCAGCGCCCCC 20 2770
HSV2-UL19-2652 + CGGUGCAGCAGCGCCCCCGC 20 2771
HSV2-UL19-2653 + ACGUAAUAGUAGAUUUUGUG 20 2772
HSV2-UL19-2654 + UCGUCGGCGGCGUCGGCCGC 20 2773
HSV2-UL19-2655 + GCGGCGUCGGCCGCGCGGGC 20 2774
HSV2-UL19-2656 + CGUUGCACGCCGCCGCGUAG 20 2775
HSV2-UL19-2657 + CGGCAGUCUCGGUGGCGGUC 20 2776
HSV2-UL19-2658 + UAAGGCCGUCGCAGUCCCAC 20 2777
HSV2-UL19-2659 + AGGCCGUCGCAGUCCCACAC 20 2778
HSV2-UL19-1347 + GGCCGUCGCAGUCCCACACG 20 1587
HSV2-UL19-2661 + CACGAGGGGCGGCAGCAGCG 20 2779
HSV2-UL19-2662 + AUCAGGUGAUUCAGCUCGGC 20 2780
HSV2-UL19-2663 + CUGAGCCUG CCCG CCCAG CU 20 2781
HSV2-UL19-2664 + CCGCCCAGCUCCGGGCCCGG 20 2782
HSV2-UL19-2665 + AGGGUAAAGUCGUCCACCAG 20 2783
HSV2-UL19-2666 + AAGUCGUCCACCAGCUGGGC 20 2784
HSV2-UL19-2667 + AGCUGGGCCAGGGCCUCGAC 20 2785
HSV2-UL19-2668 + GAUACACGGCCAUGCACUCC 20 2786
HSV2-UL19-1368 + AUACACGGCCAUGCACUCCU 20 1608
HSV2-UL19-1369 + UACACGGCCAUGCACUCCUC 20 1609
HSV2-UL19-1370 + ACACGGCCAUGCACUCCUCG 20 1610
HSV2-UL19-2672 + ACUCCUCGGGGAGGUCGCCC 20 2787
HSV2-UL19-2673 + CCCGAGGUAGGUCACGAUGU 20 2788
HSV2-UL19-2674 + GGUCACGAUGUACGAGACCA 20 2789
HSV2-UL19-2675 + AGACCAGCGAGUAGUCGUUC 20 2790
HSV2-UL19-2676 + UUCCAGUAGCUGGUGAUGCA 20 2791
HSV2-UL19-2677 + AGCUGGUGAUGCACUGAGUC 20 2792
HSV2-UL19-2678 + CACUGAGUCACGAGCCGCGC 20 2793
HSV2-UL19-2679 + UCACGAGCCGCGCCAGGGCG 20 2794
HSV2-UL19-2680 + CAGAACACGUGCUCGUUGCC 20 2795
HSV2-UL19-2681 + UUGCAGCAGGU AAAACACCG 20 2796
HSV2-UL19-2682 + CCGCCGGGUAGCUGCGGUCC 20 2797
HSV2-UL19-2683 + CUGCGGUCCUCGAACGCCCC 20 2798
HSV2-UL19-2684 + CCAUGGCGUGGCGGCCAACG 20 2799
HSV2-UL19-2685 + CCAACGCCGAGCUCCAGGCC 20 2800
HSV2-UL19-2686 + AGCUCCAGGCCCCGGGCGUC 20 2801
HSV2-UL19-2687 + CCGGGCGUCACG AAACG CCA 20 2802
HSV2-UL19-2688 + AACGCCACCGGACACAGCGC 20 2803
HSV2-UL19-1394 + ACGCCACCGGACACAGCGCC 20 1634
HSV2-UL19-2690 + UUGACCACGCGCCAGGUGGC 20 2804
HSV2-UL19-2691 + CCAGGUGGCCUGGAUCGCCC 20 2805
HSV2-UL19-2692 + CUGGAUCGCCCCCGGACCGG 20 2806
HSV2-UL19-1403 + UGGAUCGCCCCCGGACCGGC 20 1643
HSV2-UL19-1404 + GGAUCGCCCCCGGACCGGCC 20 1644 HSV2-UL19-1405 + GAUCGCCCCCGGACCGGCCG 20 1645
HSV2-UL19-1406 + AUCGCCCCCGGACCGGCCGG 20 1646
HSV2-UL19-2697 + CGGCCGGGGGGACUUCGCCG 20 2807
HSV2-UL19-1408 + GGCCGGGGGGACUUCGCCGC 20 1648
HSV2-UL19-1409 + GCCGGGGGGACUUCGCCGCC 20 1649
HSV2-UL19-2700 + GCUCGACGUCGGCCACGCCC 20 2808
HSV2-UL19-2701 + CG ACG U CGGCCACG CCCG CG 20 2809
HSV2-UL19-2702 + CG G CCACG CCCGCG AAG AAG 20 2810
HSV2-UL19-2703 + CGCCCGCGAAGAAGUCGAAC 20 2811
HSV2-UL19-1411 + GCCCGCGAAGAAGUCGAACG 20 1651
HSV2-UL19-2705 + UCGAACGCGGGGUGCAGCUC 20 2812
HSV2-UL19-2706 + CCAGAGCCAGGUUGGCGUUG 20 2813
HSV2-UL19-2707 + GGUUGGCGUUGUCGGGCUGC 20 2814
HSV2-UL19-2708 + AUCUGGCACUCGGCGACCCA 20 2815
HSV2-UL19-2709 + GCGACCCACCGGACCCGGCC 20 2816
HSV2-UL19-2710 + CCCACCGGACCCGGCCGUGG 20 2817
HSV2-UL19-2711 + AGGCGCUGCCGCCAGGCGUU 20 2818
HSV2-UL19-2712 + AACGCUGCUGCAUGUCCGCG 20 2819
HSV2-UL19-1427 + ACGCUGCUGCAUGUCCGCGC 20 1667
HSV2-UL19-2714 + CAUGUCCGCGCCGGGGCCGG 20 2820
HSV2-UL19-1431 + AUGUCCGCGCCGGGGCCGGC 20 1671
HSV2-UL19-2716 + GGCCGCGACGUACGCCCCGU 20 2821
HSV2-UL19-2717 + CGUACGGAUUCGCGGCCUCG 20 2822
HSV2-UL19-1436 + GUACGGAUUCGCGGCCUCGA 20 1676
HSV2-UL19-2719 + CGACGGCCGCGUCGAUGUUC 20 2823
HSV2-UL19-2720 + GGCCGCGUCGAUGUUCAUGA 20 2824
HSV2-UL19-2721 + CGCGUCGAUGUUCAUGAGCG 20 2825
HSV2-UL19-2722 + CGGUCCCGACCGCGU UCUCC 20 2826
HSV2-UL19-2723 + GCGUUCUCCAUGGACAGCCG 20 2827
HSV2-UL19-2724 + U U UCCCCAAAAAAACAGCUG 20 2828
HSV2-UL19-1446 + UUCCCCAAAAAAACAGCUGC 20 1686
HSV2-UL19-1447 + UCCCCAAAAAAACAGCUGCC 20 1687
HSV2-UL19-1448 + CCCCAAA AAAACAG CU G CCG 20 1688
HSV2-UL19-2728 + CCAA AAAAACAG CU G CCG G G 20 2829
HSV2-UL19-1449 + CAAAAAAACAGCUGCCGGGG 20 1689
HSV2-UL19-1450 + AAAAAAACAGCUGCCGGGGA 20 1690
HSV2-UL19-2731 + AGCUGCCGGGGAGGGAACGC 20 2830
HSV2-UL19-1451 + GCUGCCGGGGAGGGAACGCG 20 1691
HSV2-UL19-2733 + GGGAGGGAACGCGCGGGGCU 20 2831
HSV2-UL19-2734 + ACGCGCGGGGCUCCGGGUGG 20 2832
HSV2-UL19-1457 + CGCGCGGGGCUCCGGGUGGC 20 1697
HSV2-UL19-1458 + GCGCGGGGCUCCGGGUGGCC 20 1698
HSV2-UL19-2737 + GGGGCUCCGGGUGGCCGGGG 20 2833
HSV2-UL19-2738 + CCAGGUCCCCGGCGUGCGCG 20 2834
HSV2-UL19-2739 + CGCGGCGAAGCGCUCCAUGG 20 2835
HSV2-UL19-2740 + CGAAGCGCUCCAUGGCCGGG 20 2836 HSV2-UL19-2741 + AUGGCCGGGUUGAACAGCCC 20 2837
HSV2-UL19-1469 + UGGCCGGGUUGAACAGCCCC 20 1709
HSV2-UL19-2743 + GGGUUGAACAGCCCCAGGGG 20 2838
HSV2-UL19-2744 + UGAACAGCCCCAGGGGCAGG 20 2839
HSV2-UL19-2745 + GUCAGGUCCAUGGCGCCCAC 20 2840
HSV2-UL19-1475 + UCAGGUCCAUGGCGCCCACC 20 1715
HSV2-UL19-1476 + CAGGUCCAUGGCGCCCACCA 20 1716
HSV2-UL19-2748 + CCAUGGCGCCCACCAGGGGG 20 2841
HSV2-UL19-2749 + GCGGCGUAGAUGCGUCUCUC 20 2842
HSV2-UL19-2750 + AUGCGUCUCUCCAGGGCCUC 20 2843
HSV2-UL19-1486 + UGCGUCUCUCCAGGGCCUCC 20 1726
HSV2-UL19-2752 + UCCGCGCGCACGCGCGUUGU 20 2844
HSV2-UL19-1488 + CCGCGCGCACGCGCGUUGUC 20 1728
HSV2-UL19-1489 + CGCGCGCACGCGCGUUGUCU 20 1729
HSV2-UL19-1490 + GCGCGCACGCGCGUUGUCUG 20 1730
HSV2-UL19-2756 + GCGUUGUCUGGGGGGCGCUU 20 2845
HSV2-UL19-2757 + CCAGCGUCUCCCGGUUCGCC 20 2846
HSV2-UL19-2758 + UGCCCAUCACCAGCGCCGUG 20 2847
HSV2-UL19-2759 + GCCUCGGUGUCCUCCACCUU 20 2848
HSV2-UL19-1505 + CCUCGGUGUCCUCCACCUUC 20 1745
HSV2-UL19-2761 + CGGUGUCCUCCACCUUCAGG 20 2849
HSV2-UL19-2762 + UCCACCUUCAGGAAGGACUG 20 2850
HSV2-UL19-1507 + CCACCUUCAGGAAGGACUGC 20 1747
HSV2-UL19-2764 + CGCGUGUCGGCGUGCGUCAG 20 2851
HSV2-UL19-1516 + GCGUGUCGGCGUGCGUCAGG 20 1756
HSV2-UL19-2766 + GCGUCAGGCGGGGCACGGCC 20 2852
HSV2-UL19-2767 + GCGUCGCCGUGGUCAGGUCC 20 2853
HSV2-UL19-2768 + CGGCGAUGGCCCGCCUUGCC 20 2854
HSV2-UL19-1528 + GGCGAUGGCCCGCCUUGCCC 20 1768
HSV2-UL19-2770 + GAUGGCCCGCCUUGCCCAGG 20 2855
HSV2-UL19-2771 + CUCCGCUUCAGCUCGGCGAC 20 2856
HSV2-UL19-2772 + AGCUCGGCGACCAGGGUCGC 20 2857
HSV2-UL19-2773 + UGGUCGCCAGGCGCCCGUUG 20 2858
HSV2-UL19-2774 + CGUUGUCGAGAUAUCGUUGC 20 2859
HSV2-UL19-2775 + UAUCGUUGCAUGGGCAACAG 20 2860
HSV2-UL19-2776 + UGCAUGGGCAACAGCAGGGC 20 2861
HSV2-UL19-1540 + G CA U G G G CAACAG CAGG G CC 20 1780
HSV2-UL19-1541 + CA U G G G CAACAG CAG G G CCA 20 1781
HSV2-UL19-1542 + AUGGGCAACAGCAGGGCCAG 20 1782
HSV2-UL19-2780 + GUGCCGCGCUCAAACGCCCC 20 2862
HSV2-UL19-2781 + UCAAACGCCCCCAGGACGGC 20 2863
HSV2-UL19-2782 + CAGAGACAGGCCCUUUA 17 2864
HSV2-UL19-1549 + AGAGACAGGCCCUUUAG 17 1789
HSV2-UL19-1550 + GAGACAGGCCCUUUAGC 17 1790
HSV2-UL19-1551 + AGACAGGCCCUUUAGCG 17 1791
HSV2-UL19-2786 + GCGGGGAGGCGUCGUAG 17 2865 HSV2-UL19-2787 + AUGAGAUACUGCGUAAA 17 2866
HSV2-UL19-2788 + AAGUGGGUCUCUCGCGC 17 2867
HSV2-UL19-2789 + GCGUGGGCCUCCCCAUC 17 2868
HSV2-UL19-2790 + UCGCGGGCGCUGCGUAG 17 2869
HSV2-UL19-2791 + GGGCGCUGCGUAGCAGG 17 2870
HSV2-UL19-1561 + GGCGCUGCGUAGCAGGG 17 1801
HSV2-UL19-2793 + GUCGCUGGCGCAGGUGA 17 2871
HSV2-UL19-2794 + GUGAUCGGGUAGGCUUC 17 2872
HSV2-UL19-2795 + UUCCUGAAACAGGCCGC 17 2873
HSV2-UL19-2796 + GGCCGCACGGGUCUUCC 17 2874
HSV2-UL19-2797 + GAGCUCGCGGCACCCCG 17 2875
HSV2-UL19-2798 + CGCUGGCAGCGGUGGCC 17 2876
HSV2-UL19-2799 + CCGAUCCCGU UUCCACG 17 2877
HSV2-UL19-2800 + CCGUGAUGUCGGCCGCG 17 2878
HSV2-UL19-2801 + UGAUGUCGGCCGCGGUG 17 2879
HSV2-UL19-2802 + CGGCCGCGGUGAAGAAC 17 2880
HSV2-UL19-2803 + CGGUGAAGAACUUGAAG 17 2881
HSV2-UL19-1584 + GGUGAAGAACUUGAAGC 17 1824
HSV2-UL19-2805 + AGAACUUGAAGCAGGGG 17 2882
HSV2-UL19-2806 + AACUUGAAGCAGGGGCU 17 2883
HSV2-UL19-2807 + UGAAGCAGGGGCUGAGG 17 2884
HSV2-UL19-2808 + GCAGGGGCUGAGGACGG 17 2885
HSV2-UL19-2809 + GGACGGGCGAGGCCCCG 17 2886
HSV2-UL19-2810 + GUACAGCAGGUCCCCGU 17 2887
HSV2-UL19-2811 + ACAGCAGGUCCCCGUAC 17 2888
HSV2-UL19-2812 + GAACCGCUGCGACGCCC 17 2889
HSV2-UL19-2813 + ACGGGUUGGCCGUGGCC 17 2890
HSV2-UL19-2814 + GGUUGGCCGUGGCCGCG 17 2891
HSV2-UL19-2815 + GGCCGCGAAGGGCCGCG 17 2892
HSV2-UL19-2816 + UCUGGCCGUGGUCGUAC 17 2893
HSV2-UL19-2817 + UGGCCGUGGUCGUACAU 17 2894
HSV2-UL19-2818 + GCCGGCCGCGCGUCCCC 17 2895
HSV2-UL19-2819 + CGCGUCCCCGCGGGUUG 17 2896
HSV2-UL19-2820 + CGCGGGUUGCAGGGCCG 17 2897
HSV2-UL19-2821 + AGUUGAUGUCCGUGGCC 17 2898
HSV2-UL19-1613 + GUUGAUGUCCGUGGCCA 17 1853
HSV2-UL19-1614 + UUGAUGUCCGUGGCCAC 17 1854
HSV2-UL19-2824 + UGGCCACGGGGGUGGCG 17 2899
HSV2-UL19-2825 + CCGGCGCGCCGCGGCAC 17 2900
HSV2-UL19-2826 + CUGGGCGCAG CCAAAG A 17 2901
HSV2-UL19-1624 + UGGGCGCAG CCAAAG AC 17 1864
HSV2-UL19-1625 + GGGCGCAGCCAAAGACC 17 1865
HSV2-UL19-2829 + GCGCAGCCAAAGACCGG 17 2902
HSV2-UL19-1626 + CGCAGCCAAAGACCGGG 17 1866
HSV2-UL19-2831 + CCAAAG ACCGGGAGGGG 17 2903
HSV2-UL19-2832 + GGCCGCGUUGUCUAGCA 17 2904 HSV2-UL19-1636 + GCCGCGUUGUCUAGCAG 17 1876
HSV2-UL19-1637 + CCGCGUUGUCUAGCAGC 17 1877
HSV2-UL19-1638 + CGCGU UGUCUAGCAGCG 17 1878
HSV2-UL19-1639 + GCGUUGUCUAGCAGCGG 17 1879
HSV2-UL19-2837 + GCGGGGGGGCCCCGCGG 17 2905
HSV2-UL19-2838 + CGGCCGAGGUAAAAGUU 17 2906
HSV2-UL19-1644 + GGCCGAGGUAAAAGUUU 17 1884
HSV2-UL19-1645 + GCCGAGGUAAAAGUUUU 17 1885
HSV2-UL19-1646 + CCGAGGUAAAAGUUUUG 17 1886
HSV2-UL19-1647 + CGAGGUAAAAGUUUUGG 17 1887
HSV2-UL19-2843 + GGUUGCCCAUGUCCGUA 17 2907
HSV2-UL19-1649 + GUUGCCCAUGUCCGUAA 17 1889
HSV2-UL19-2845 + AUGUCCGUAACGGGGUU 17 2908
HSV2-UL19-2846 + UCCACGUUUCCGCGCGG 17 2909
HSV2-UL19-2847 + CGUUUCCGCGCGGCUGG 17 2910
HSV2-UL19-2848 + CGCGCGGCUGGGUGAGC 17 2911
HSV2-UL19-2849 + CCCCCGCCCGUUUCGUG 17 2912
HSV2-UL19-2850 + GUUUCGUGGCGGGCCAC 17 2913
HSV2-UL19-1664 + UUUCGUGGCGGGCCACC 17 1904
HSV2-UL19-2852 + GCCACCUGGAGCUGGCC 17 2914
HSV2-UL19-2853 + ACGCCUCCGACGCGCGC 17 2915
HSV2-UL19-1666 + CGCCUCCGACGCGCGCU 17 1906
HSV2-UL19-2855 + ACAGCACGUUCUCGGUC 17 2916
HSV2-UL19-2856 + GGUCCUGCCGCACGACG 17 2917
HSV2-UL19-2857 + GCCGCACGACGGUGAAC 17 2918
HSV2-UL19-2858 + CGACGGUGAACCCGAAC 17 2919
HSV2-UL19-1670 + GACG G U G AACCCG AACC 17 1910
HSV2-UL19-2860 + GUGAACCCGAACCCGGG 17 2920
HSV2-UL19-1673 + UGAACCCGAACCCGGGG 17 1913
HSV2-UL19-2862 + CGGGGUGGAGGCCCGUC 17 2921
HSV2-UL19-2863 + GUCUUGAGCUGGUGAUA 17 2922
HSV2-UL19-2864 + GCUGGUGAUACAGGGCC 17 2923
HSV2-UL19-1678 + CUGGUGAUACAGGGCCA 17 1918
HSV2-UL19-2866 + GGGCCACGGGGCUCAUC 17 2924
HSV2-UL19-2867 + UCUUGAAGUACCCCGCC 17 2925
HSV2-UL19-2868 + UCCCCCGCCGCGCUCUC 17 2926
HSV2-UL19-2869 + CGCGGGCGUGCUGCACC 17 2927
HSV2-UL19-2870 + UGCUGCACCACGGGCUG 17 2928
HSV2-UL19-2871 + GCACCACGGGCUGGCGG 17 2929
HSV2-UL19-1688 + CACCACGGGCUGGCGGA 17 1928
HSV2-UL19-2873 + CCACGGGCUGGCGGAUG 17 2930
HSV2-UL19-1689 + CACGGGCUGGCGGAUGG 17 1929
HSV2-UL19-2875 + CGGGCUGGCGGAUGGAG 17 2931
HSV2-UL19-2876 + GAGAAGUAGUUGGCCCC 17 2932
HSV2-UL19-2877 + GUAGUUGGCCCCCAGGG 17 2933
HSV2-UL19-1693 + UAGUUGGCCCCCAGGGC 17 1933 HSV2-UL19-1694 + AGUUGGCCCCCAGGGCC 17 1934
HSV2-UL19-1695 + GUUGGCCCCCAGGGCCG 17 1935
HSV2-UL19-1696 + UUGGCCCCCAGGGCCGG 17 1936
HSV2-UL19-2882 + CCCAGGGCCGGGGGGAC 17 2934
HSV2-UL19-1698 + CCAGGGCCGGGGGGACC 17 1938
HSV2-UL19-1699 + CAGGGCCGGGGGGACCA 17 1939
HSV2-UL19-1700 + AGGGCCGGGGGGACCAG 17 1940
HSV2-UL19-2886 + UCGCGCGCCAGGUCGCG 17 2935
HSV2-UL19-2887 + CGCCAGGUCGCGCAGGG 17 2936
HSV2-UL19-1705 + GCCAGGUCGCGCAGGGC 17 1945
HSV2-UL19-1706 + CCAGGUCGCGCAGGGCC 17 1946
HSV2-UL19-1707 + CAGGUCGCGCAGGGCCG 17 1947
HSV2-UL19-1708 + AGGUCGCGCAGGGCCGG 17 1948
HSV2-UL19-1709 + GGUCGCGCAGGGCCGGG 17 1949
HSV2-UL19-2893 + GCAGGGCCGGGGGGAAG 17 2937
HSV2-UL19-2894 + GCGCCCGCAAACAGCGC 17 2938
HSV2-UL19-2895 + CCGCAAACAGCGCGUGG 17 2939
HSV2-UL19-2896 + AACAGCGCGUGGACGGG 17 2940
HSV2-UL19-2897 + CGUGGACGGGCAGGACG 17 2941
HSV2-UL19-2898 + UAGAAGUAUUCGCCAUU 17 2942
HSV2-UL19-2899 + AUGGUGUGGUCCAGGUG 17 2943
HSV2-UL19-1723 + UGGUGUGGUCCAGGUGC 17 1963
HSV2-UL19-1724 + GGUGUGGUCCAGGUGCU 17 1964
HSV2-UL19-1725 + GUGUGGUCCAGGUGCUG 17 1965
HSV2-UL19-2903 + CCAGGUGCUGGGGGGCC 17 2944
HSV2-UL19-2904 + CGGCGUGCAGCGCCCCG 17 2945
HSV2-UL19-2905 + CGGUGUUGGCGCCCGCG 17 2946
HSV2-UL19-2906 + CGCCCGCGUCGGGCGCC 17 2947
HSV2-UL19-1734 + GCCCGCGUCGGGCGCCG 17 1974
HSV2-UL19-2908 + GCGCCAGCACCUGCAGC 17 2948
HSV2-UL19-2909 + CCUGCAGCGUGAGCAUG 17 2949
HSV2-UL19-2910 + ACGACGACG CGCCCG U U 17 2950
HSV2-UL19-1739 + CGACGACGCGCCCGUUG 17 1979
HSV2-UL19-2912 + UGUUGGCCACCAGAUUG 17 2951
HSV2-UL19-1742 + GUUGGCCACCAGAUUGG 17 1982
HSV2-UL19-2914 + CAGAUUGGCGGGAUGCA 17 2952
HSV2-UL19-2915 + UUGGCGGGAUGCAGCGG 17 2953
HSV2-UL19-2916 + CGGGAUGCAGCGGGUGG 17 2954
HSV2-UL19-1748 + GGGAUGCAGCGGGUGGG 17 1988
HSV2-UL19-2918 + GGUGGGCGGGGUCGGUC 17 2955
HSV2-UL19-1752 + GUGGGCGGGGUCGGUCA 17 1992
HSV2-UL19-2920 + GUCGGUCACGGGAUCGC 17 2956
HSV2-UL19-2921 + CGCUCGGGCACUCCUCA 17 2957
HSV2-UL19-1756 + GCUCGGGCACUCCUCAC 17 1996
HSV2-UL19-1757 + CUCGGGCACUCCUCACC 17 1997
HSV2-UL19-2924 + CUCACCGGGGGCGAUCU 17 2958 HSV2-UL19-1760 + UCACCGGGGGCGAUCUC 17 2000
HSV2-UL19-2926 + GCGUGGCGUACACGCGG 17 2959
HSV2-UL19-2927 + GCGUACACGCGGUCGAA 17 2960
HSV2-UL19-2928 + GGUGCAGCAGCGCCCCC 17 2961
HSV2-UL19-2929 + UGCAGCAGCGCCCCCGC 17 2962
HSV2-UL19-2930 + UAAUAGUAGAUUUUGUG 17 2963
HSV2-UL19-2931 + UCGGCGGCGUCGGCCGC 17 2964
HSV2-UL19-2932 + GCGUCGGCCGCGCGGGC 17 2965
HSV2-UL19-2933 + UGCACGCCGCCGCGUAG 17 2966
HSV2-UL19-2934 + CAGUCUCGGUGGCGGUC 17 2967
HSV2-UL19-2935 + GGCCGUCGCAGUCCCAC 17 2968
HSV2-UL19-2936 + CCGUCGCAGU CCCACAC 17 2969
HSV2-UL19-1795 + CG U CG CAG U CCCACACG 17 2035
HSV2-UL19-2938 + GAGGGGCGGCAGCAGCG 17 2970
HSV2-UL19-2939 + AGGUGAUUCAGCUCGGC 17 2971
HSV2-UL19-2940 + AGCCUGCCCGCCCAGCU 17 2972
HSV2-UL19-2941 + CCCAGCUCCGGGCCCGG 17 2973
HSV2-UL19-2942 + G U AAAG UCGUCCACCAG 17 2974
HSV2-UL19-2943 + UCGUCCACCAGCUGGGC 17 2975
HSV2-UL19-2944 + UGGGCCAGGGCCUCGAC 17 2976
HSV2-UL19-2945 + ACACGGCCAUGCACUCC 17 2977
HSV2-UL19-1816 + CACGGCCAUGCACUCCU 17 2056
HSV2-UL19-1817 + ACGGCCAUGCACUCCUC 17 2057
HSV2-UL19-1818 + CGGCCAUGCACUCCUCG 17 2058
HSV2-UL19-2949 + CCUCGGGGAGGUCGCCC 17 2978
HSV2-UL19-2950 + GAGGUAGGUCACGAUGU 17 2979
HSV2-UL19-2951 + CACGAUGUACGAGACCA 17 2980
HSV2-UL19-2952 + CCAGCGAGUAGUCGUUC 17 2981
HSV2-UL19-2953 + CAGUAGCUGGUGAUGCA 17 2982
HSV2-UL19-2954 + UGGUGAUGCACUGAGUC 17 2983
HSV2-UL19-2955 + U G AG U CACG AG CCG CGC 17 2984
HSV2-UL19-2956 + CGAGCCGCGCCAGGGCG 17 2985
HSV2-UL19-2957 + AACACGUGCUCGUUGCC 17 2986
HSV2-UL19-2958 + CAG CAG G U AAAACACCG 17 2987
HSV2-UL19-2959 + CCGGGUAGCUGCGGUCC 17 2988
HSV2-UL19-2960 + CGGUCCUCGAACGCCCC 17 2989
HSV2-UL19-2961 + UGGCGUGGCGGCCAACG 17 2990
HSV2-UL19-2962 + ACGCCGAGCUCCAGGCC 17 2991
HSV2-UL19-2963 + UCCAGGCCCCGGGCGUC 17 2992
HSV2-UL19-2964 + G G CG U CACG AAACG CCA 17 2993
HSV2-UL19-2965 + GCCACCGGACACAGCGC 17 2994
HSV2-UL19-1842 + CCACCGGACACAGCGCC 17 2082
HSV2-UL19-2967 + ACCACGCGCCAGGUGGC 17 2995
HSV2-UL19-2968 + GGUGGCCUGGAUCGCCC 17 2996
HSV2-UL19-2969 + GAUCGCCCCCGGACCGG 17 2997
HSV2-UL19-1851 + AUCGCCCCCGGACCGGC 17 2091 HSV2-UL19-1852 + UCGCCCCCGGACCGGCC 17 2092
HSV2-UL19-1853 + CGCCCCCGGACCGGCCG 17 2093
HSV2-UL19-1854 + GCCCCCGGACCGGCCGG 17 2094
HSV2-UL19-2974 + CCGGGGGGACUUCGCCG 17 2998
HSV2-UL19-1856 + CGGGGGGACUUCGCCGC 17 2096
HSV2-UL19-1857 + GGGGGGACUUCGCCGCC 17 2097
HSV2-UL19-2977 + CGACGUCGGCCACGCCC 17 2999
HSV2-UL19-2978 + CGUCGGCCACGCCCGCG 17 3000
HSV2-UL19-2979 + CCACGCCCGCGAAGAAG 17 3001
HSV2-UL19-2980 + CCGCGAAGAAGUCGAAC 17 3002
HSV2-UL19-1859 + CG CGAAGAAG U CGAACG 17 2099
HSV2-UL19-2982 + AACGCGGGGUGCAGCUC 17 3003
HSV2-UL19-2983 + GAGCCAGGUUGGCGUUG 17 3004
HSV2-UL19-2984 + UGGCGUUGUCGGGCUGC 17 3005
HSV2-UL19-2985 + UGGCACUCGGCGACCCA 17 3006
HSV2-UL19-2986 + ACCCACCGGACCCGGCC 17 3007
HSV2-UL19-2987 + ACCGGACCCGGCCGUGG 17 3008
HSV2-UL19-2988 + CGCUGCCGCCAGGCGU U 17 3009
HSV2-UL19-2989 + GCUGCUGCAUGUCCGCG 17 3010
HSV2-UL19-1875 + CUGCUGCAUGUCCGCGC 17 2115
HSV2-UL19-2991 + GUCCGCGCCGGGGCCGG 17 3011
HSV2-UL19-1879 + UCCGCGCCGGGGCCGGC 17 2119
HSV2-UL19-2993 + CGCGACGUACGCCCCGU 17 3012
HSV2-UL19-2994 + ACGGAUUCGCGGCCUCG 17 3013
HSV2-UL19-1884 + CGGAUUCGCGGCCUCGA 17 2124
HSV2-UL19-2996 + CGGCCGCGUCGAUGUUC 17 3014
HSV2-UL19-2997 + CGCGUCGAUGUUCAUGA 17 3015
HSV2-UL19-2998 + GUCGAUGUUCAUGAGCG 17 3016
HSV2-UL19-2999 + UCCCGACCGCGUUCUCC 17 3017
HSV2-UL19-3000 + UUCUCCAUGGACAGCCG 17 3018
HSV2-UL19-3001 + CCCCAAAAAAACAG CU G 17 3019
HSV2-UL19-1894 + CCCAAAAAAACAG CU G C 17 2134
HSV2-UL19-1895 + CCAAAAAAACAG CU G CC 17 2135
HSV2-UL19-1896 + CA AAAAAACAG CU G CCG 17 2136
HSV2-UL19-3005 + AAAAAACAGCUGCCGGG 17 3020
HSV2-UL19-1897 + AAAAACAG CU G CCG G G G 17 2137
HSV2-UL19-1898 + AAAACAG CU G CCG G G G A 17 2138
HSV2-UL19-3008 + UGCCGGGGAGGGAACGC 17 3021
HSV2-UL19-1899 + GCCGGGGAGGGAACGCG 17 2139
HSV2-UL19-3010 + AGGGAACGCGCGGGGCU 17 3022
HSV2-UL19-3011 + CGCGGGGCUCCGGGUGG 17 3023
HSV2-UL19-1905 + GCGGGGCUCCGGGUGGC 17 2145
HSV2-UL19-1906 + CGGGGCUCCGGGUGGCC 17 2146
HSV2-UL19-3014 + GCUCCGGGUGGCCGGGG 17 3024
HSV2-UL19-3015 + GGUCCCCGGCGUGCGCG 17 3025
HSV2-UL19-3016 + GGCGAAGCGCUCCAUGG 17 3026 HSV2-UL19-3017 + AGCGCUCCAUGGCCGGG 17 3027
HSV2-UL19-3018 + GCCGGGUUGAACAGCCC 17 3028
HSV2-UL19-1917 + CCGGGU UGAACAGCCCC 17 2157
HSV2-UL19-3020 + UUGAACAGCCCCAGGGG 17 3029
HSV2-UL19-3021 + ACAG CCCCAG G G G CAG G 17 3030
HSV2-UL19-3022 + AGGUCCAUGGCGCCCAC 17 3031
HSV2-UL19-1923 + GGUCCAUGGCGCCCACC 17 2163
HSV2-UL19-1924 + GUCCAUGGCGCCCACCA 17 2164
HSV2-UL19-3025 + UGGCGCCCACCAGGGGG 17 3032
HSV2-UL19-3026 + GCGUAGAUGCGUCUCUC 17 3033
HSV2-UL19-3027 + CGUCUCUCCAGGGCCUC 17 3034
HSV2-UL19-1934 + GUCUCUCCAGGGCCUCC 17 2174
HSV2-UL19-3029 + GCGCGCACGCGCGUUGU 17 3035
HSV2-UL19-1936 + CGCGCACGCGCGUUGUC 17 2176
HSV2-UL19-1937 + GCGCACGCGCGUUGUCU 17 2177
HSV2-UL19-1938 + CGCACGCGCGUUGUCUG 17 2178
HSV2-UL19-3033 + UUGUCUGGGGGGCGCUU 17 3036
HSV2-UL19-3034 + GCGUCUCCCGGUUCGCC 17 3037
HSV2-UL19-3035 + CCAU CACCAG CG CCG U G 17 3038
HSV2-UL19-3036 + U CG G U G U CCU CCACCU U 17 3039
HSV2-UL19-1953 + CG G U G U CCU CCACCU U C 17 2193
HSV2-UL19-3038 + UGUCCUCCACCUUCAGG 17 3040
HSV2-UL19-3039 + ACCUUCAGGAAGGACUG 17 3041
HSV2-UL19-1955 + CCUUCAGGAAGGACUGC 17 2195
HSV2-UL19-3041 + GUGUCGGCGUGCGUCAG 17 3042
HSV2-UL19-1964 + UGUCGGCGUGCGUCAGG 17 2204
HSV2-UL19-3043 + UCAGGCGGGGCACGGCC 17 3043
HSV2-UL19-3044 + UCGCCGUGGUCAGGUCC 17 3044
HSV2-UL19-3045 + CGAUGGCCCGCCUUGCC 17 3045
HSV2-UL19-1976 + GAUGGCCCGCCUUGCCC 17 2216
HSV2-UL19-3047 + GGCCCGCCUUGCCCAGG 17 3046
HSV2-UL19-3048 + CGCUUCAGCUCGGCGAC 17 3047
HSV2-UL19-3049 + UCGGCGACCAGGGUCGC 17 3048
HSV2-UL19-3050 + UCGCCAGGCGCCCGUUG 17 3049
HSV2-UL19-3051 + UGUCGAGAUAUCGUUGC 17 3050
HSV2-UL19-3052 + CGU UGCAUGGG CAACAG 17 3051
HSV2-UL19-3053 + AUGGGCAACAGCAGGGC 17 3052
HSV2-UL19-1988 + U G G G CAACAG CAG G G CC 17 2228
HSV2-UL19-1989 + G G G CAACAG C AG G G CCA 17 2229
HSV2-UL19-1990 + G G CAACAG CAG G G CCAG 17 2230
HSV2-UL19-3057 + CCGCGCUCAAACGCCCC 17 3053
HSV2-UL19-3058 + AACGCCCCCAGGACGGC 17 3054
Table IF provides exemplary targeting domains for knocking out the UL19 gene selected according to the first tier parameters. The targeting domains are selected based on location within first 500bp of the coding sequence of the UL19 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using N. meningitidis Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table IF
Figure imgf000171_0001
Table 1G provides exemplary targeting domains for knocking out the UL19 gene selected according to the second tier parameters. The targeting domains are selected based on location within the coding sequence, but downstream of the first 500bp of the HSV gene UL19 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using N. meningitidis Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 1G
Figure imgf000171_0002
Length
HSV2-UL19-3059 - GGUGUUUUACCUGCUGCAAG 20 3057
HSV2-UL19-3060 - CCUGGACCGCCACCGAGACU 20 3058
HSV2-UL19-3061 - GUUUUACCUGCUGCAAG 17 3059
HSV2-UL19-3062 - GGACCGCCACCGAGACU 17 3060
HSV2-UL19-3063 + UGCGCUUGACCGUGUUGGCC 20 3061
HSV2-UL19-3064 + G G CCG G CACCAG CACG U AAU 20 3062
HSV2-UL19-1353 + GCAGCGCCGGGUCGCGCAUC 20 1593
HSV2-UL19-3066 + GGGCCGCGACGUACGCCCCG 20 3063
HSV2-UL19-3067 + GCUUGACCGUGUUGGCC 17 3064
HSV2-UL19-3068 + CGGCACCAGCACGUAAU 17 3065
HSV2-UL19-1801 + GCGCCGGGUCGCGCAUC 17 2041
HSV2-UL19-3070 + CCGCGACGUACGCCCCG 17 3066
Table 2A provides exemplary targeting domains for knocking out the UL30 gene selected according to first tier parameters. The targeting domains are selected based on location within the first 500bp of the coding sequence of the UL30 gene and orthogonality against the human genome. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 2 A
Figure imgf000172_0001
HSV2-UL30-37 - CCCCUAAGGUGUACUGCGGG 20 3074
HSV2-UL30-38 - CCCUAAGGUGUACUGCGGGG 20 3075
HSV2-UL30-39 - CGAGCGCGACGUCCUCCGCG 20 3076
HSV2-UL30-40 - GAGCGCGACGUCCUCCGCGU 20 3077
HSV2-UL30-43 - GUCCUCCGCGUGGGCCCGGA 20 3078
HSV2-UL30-46 - GCCGCGUCGCUUGCGCCUGU 20 3079
HSV2-UL30-47 - CCGCGUCGCUUGCGCCUGUG 20 3080
HSV2-UL30-48 - CGUCGCU UGCGCCUGUGGGG 20 3081
HSV2-UL30-50 - CGGUGCGGACCAUGCCCCCG 20 3082
HSV2-UL30-51 - GGUGCGGACCAUGCCCCCGA 20 3083
HSV2-UL30-53 - CUUCCACGUGUACGACAUCC 20 3084
HSV2-UL30-60 + ACGUGGAAGACGGUGACGGU 20 3085
HSV2-UL30-62 + GACGGUGGGGUCGAACCCCU 20 3086
HSV2-UL30-63 + ACGGUGGGGUCGAACCCCUC 20 3087
HSV2-UL30-64 + CGGUGGGGUCGAACCCCUCG 20 3088
HSV2-UL30-65 + GGUGGGGUCGAACCCCUCGG 20 3089
HSV2-UL30-66 + GGUCGAACCCCUCGGGGGCA 20 3090
HSV2-UL30-68 + CCCCACAGGCGCAAGCGACG 20 3091
HSV2-UL30-69 + CGACGCGGCCAGAAGCCCUC 20 3092
HSV2-UL30-74 + CCCCCCCGCAG UACACCU UA 20 3093
HSV2-UL30-75 + CCCCCCGCAG UACACCU U AG 20 3094
HSV2-UL30-76 + AGUACACCUUAGGGGCGCGC 20 3095
HSV2-UL30-77 + ACACCUUAGGGGCGCGCCGG 20 3096
HSV2-UL30-84 + CCCGGUGCGCUGCUCCGCGG 20 3097
HSV2-UL30-85 + GCGUCCUCGUCCAGCGAACG 20 3098
HSV2-UL30-86 + CGUCCUCGUCCAGCGAACGC 20 3099
HSV2-UL30-89 + UAGUACGUAUGGCGCUGAGC 20 3100
HSV2-UL30-91 + AUGGCGCUGAGCCGGCCCGA 20 3101
HSV2-UL30-93 + GAGGGCCUUUGGCUGCGUUC 20 3102
HSV2-UL30-94 + GCUGCGUUCCGGUCUGAGCG 20 3103
HSV2-UL30-95 + GCGUUCCGGUCUGAGCGAGG 20 3104
HSV2-UL30-97 + GUUCCGGUCUGAGCGAGGUG 20 3105
HSV2-UL30-100 + GGUUGUAGAAGUUCUGCCGG 20 3106
HSV2-UL30-101 + UAGAAGUUCUGCCGGCGGCA 20 3107
HSV2-UL30-102 + AAGUUCUGCCGGCGGCAAGG 20 3108
HSV2-UL30-104 + GGCAAGGCGGCGGUGCCGUC 20 3109
HSV2-UL30-105 + GCAAGGCGGCGGUGCCGUCU 20 3110
HSV2-UL30-110 + CCGUCUGGGUGGCUCCCCGG 20 3111
HSV2-UL30-141 - CACCGCCGCCUUGCCGC 17 3112
HSV2-UL30-143 - GACCGGAACGCAGCCAA 17 3113
HSV2-UL30-148 - CCCGCGUUCGCUGGACG 17 3114
HSV2-UL30-154 - UCCACGACGGCCGCCUC 17 3115
HSV2-UL30-156 - GCCCCUAAGGUGUACUG 17 3116
HSV2-UL30-157 - CCCCUAAGGUGUACUGC 17 3117
HSV2-UL30-159 - CCUAAGGUGUACUGCGG 17 3118
HSV2-UL30-160 - CUAAGGUGUACUGCGGG 17 3119 HSV2-UL30-161 - UAAGGUGUACUGCGGGG 17 3120
HSV2-UL30-162 - GCGCGACGUCCUCCGCG 17 3121
HSV2-UL30-163 - CGCGACGUCCUCCGCGU 17 3122
HSV2-UL30-166 - CUCCGCGUGGGCCCGGA 17 3123
HSV2-UL30-169 - GCGUCGCUUGCGCCUGU 17 3124
HSV2-UL30-170 - CGUCGCU UGCGCCUGUG 17 3125
HSV2-UL30-171 - CGCU UGCGCCUGUGGGG 17 3126
HSV2-UL30-173 - UGCGGACCAUGCCCCCG 17 3127
HSV2-UL30-174 - GCGGACCAUGCCCCCGA 17 3128
HSV2-UL30-176 - CCACGUGUACGACAUCC 17 3129
HSV2-UL30-183 + UGGAAGACGGUGACGGU 17 3130
HSV2-UL30-185 + GGUGGGGUCGAACCCCU 17 3131
HSV2-UL30-186 + GUGGGGUCGAACCCCUC 17 3132
HSV2-UL30-187 + UGGGGUCGAACCCCUCG 17 3133
HSV2-UL30-188 + GGGGUCGAACCCCUCGG 17 3134
HSV2-UL30-189 + CGAACCCCUCGGGGGCA 17 3135
HSV2-UL30-191 + CACAGGCGCAAGCGACG 17 3136
HSV2-UL30-192 + CGCGGCCAGAAGCCCUC 17 3137
HSV2-UL30-197 + CCCCGCAGUACACCUUA 17 3138
HSV2-UL30-198 + CCCGCAGUACACCUUAG 17 3139
HSV2-UL30-199 + ACACCUUAGGGGCGCGC 17 3140
HSV2-UL30-200 + CCUUAGGGGCGCGCCGG 17 3141
HSV2-UL30-207 + GGUGCGCUGCUCCGCGG 17 3142
HSV2-UL30-208 + UCCUCGUCCAGCGAACG 17 3143
HSV2-UL30-209 + CCUCGUCCAGCGAACGC 17 3144
HSV2-UL30-212 + UACGUAUGGCGCUGAGC 17 3145
HSV2-UL30-214 + GCGCUGAGCCGGCCCGA 17 3146
HSV2-UL30-216 + GGCCU UUGGCUGCGUUC 17 3147
HSV2-UL30-217 + GCGUUCCGGUCUGAGCG 17 3148
HSV2-UL30-218 + UUCCGGUCUGAGCGAGG 17 3149
HSV2-UL30-220 + CCGGUCUGAGCGAGGUG 17 3150
HSV2-UL30-223 + UGUAGAAGUUCUGCCGG 17 3151
HSV2-UL30-224 + AAGUUCUGCCGGCGGCA 17 3152
HSV2-UL30-225 + UUCUGCCGGCGGCAAGG 17 3153
HSV2-UL30-227 + AAGGCGGCGGUGCCGUC 17 3154
HSV2-UL30-228 + AGGCGGCGGUGCCGUCU 17 3155
HSV2-UL30-233 + UCUGGGUGGCUCCCCGG 17 3156
Table 2B provides exemplary targeting domains for knocking out the UL30 gene selected according to the second tier parameters. The targeting domains are selected based on location within the first 500bp of the coding sequence of the UL30 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 2B
Figure imgf000175_0001
HSV2-UL30-44 - GCGUGGGCCCGGAGGGCUUC 20 3188
HSV2-UL30-45 - GGCCGCGUCGCUUGCGCCUG 20 3189
HSV2-UL30-49 - CUUGCGCCUGUGGGGCGGUG 20 3190
HSV2-UL30-52 - GUGCGGACCAUGCCCCCGAG 20 3191
HSV2-UL30-54 - GUACGACAUCCUGGAGCACG 20 3192
HSV2-UL30-55 + ACGCGUGUUCCACGUGCUCC 20 3193
HSV2-UL30-56 + GCUCCAGGAUGUCGUACACG 20 3194
HSV2-UL30-57 + GAUGUCGUACACGUGGAAGA 20 3195
HSV2-UL30-58 + GUACACGUGGAAGACGGUGA 20 3196
HSV2-UL30-59 + CACGUGGAAGACGGUGACGG 20 3197
HSV2-UL30-61 + CGUGGAAGACGGUGACGGUG 20 3198
HSV2-UL30-67 + CAU G G U CCG CACCG CCCCAC 20 3199
HSV2-UL30-70 + GACGCGGCCAGAAGCCCUCC 20 3200
HSV2-UL30-71 + AGAAGCCCUCCGGGCCCACG 20 3201
HSV2-UL30-72 + AGCCCUCCGGGCCCACGCGG 20 3202
HSV2-UL30-73 + UCCCCCCCGCAGUACACCUU 20 3203
HSV2-UL30-78 + CCUUAGGGGCGCGCCGGAGG 20 3204
HSV2-UL30-79 + CGCGCCGGAGGCGGCCGUCG 20 3205
HSV2-UL30-80 + GAGGCGGCCGUCGUGGACCC 20 3206
HSV2-UL30-81 + GACCCCGGUGCGCUGCUCCG 20 3207
HSV2-UL30-82 + ACCCCGGUGCGCUGCUCCGC 20 3208
HSV2-UL30-83 + CCCCGGUGCGCUGCUCCGCG 20 3209
HSV2-UL30-87 + GUCCUCGUCCAGCGAACGCG 20 3210
HSV2-UL30-88 + CGCACUCGCUGUAGUACGUA 20 3211
HSV2-UL30-90 + UAUGGCGCUGAGCCGGCCCG 20 3212
HSV2-UL30-92 + UGAGCCGGCCCGAGGGCCUU 20 3213
HSV2-UL30-96 + CGU UCCGGUCUGAGCGAGGU 20 3214
HSV2-UL30-98 + UUCCGGUCUGAGCGAGGUGG 20 3215
HSV2-UL30-99 + GGGGGUUGUAGAAGUUCUGC 20 3216
HSV2-UL30-103 + UUCUGCCGGCGGCAAGGCGG 20 3217
HSV2-UL30-106 + AGGCGGCGGUGCCGUCUGGG 20 3218
HSV2-UL30-107 + GUGCCGUCUGGGUGGCUCCC 20 3219
HSV2-UL30-108 + UGCCGUCUGGGUGGCUCCCC 20 3220
HSV2-UL30-109 + GCCGUCUGGGUGGCUCCCCG 20 3221
HSV2-UL30-111 + GGGUGGCUCCCCGGGGGUUG 20 3222
HSV2-UL30-112 + GGUGGCUCCCCGGGGGUUGU 20 3223
HSV2-UL30-113 + GUGGCUCCCCGGGGGUUGUG 20 3224
HSV2-UL30-114 + UGGCUCCCCGGGGGUUGUGG 20 3225
HSV2-UL30-115 + GGCUCCCCGGGGGUUGUGGG 20 3226
HSV2-UL30-116 + CCAGACGCCGCCCGAGCCGC 20 3227
HSV2-UL30-117 + CCGAGCCGCCGGCUUCCCCC 20 3228
HSV2-UL30-118 + CGAGCCGCCGGCUUCCCCCC 20 3229
HSV2-UL30-119 + GAGCCGCCGGCU UCCCCCCG 20 3230
HSV2-UL30-120 + AGCCGCCGGCUUCCCCCCGG 20 3231
HSV2-UL30-121 + GGCUUCCCCCCGGGGGAAGC 20 3232
HSV2-UL30-122 + GCUUCCCCCCGGGGGAAGCC 20 3233 HSV2-UL30-123 + GGGGGAAGCCGGGCCGCCCG 20 3234
HSV2-UL30-124 - UUGUGCCGCGGGCGGCC 17 3235
HSV2-UL30-125 - GGCGGCCCGGCUUCCCC 17 3236
HSV2-UL30-126 - GCGGCCCGGCUUCCCCC 17 3237
HSV2-UL30-127 - CGGCCCGGCUUCCCCCG 17 3238
HSV2-UL30-128 - GGCCCGGCUUCCCCCGG 17 3239
HSV2-UL30-129 - GCCCGGCUUCCCCCGGG 17 3240
HSV2-UL30-130 - UUCCCCCGGGGGGAAGC 17 3241
HSV2-UL30-131 - CCCCGGGGGGAAGCCGG 17 3242
HSV2-UL30-132 - GGGGGAAGCCGGCGGCU 17 3243
HSV2-UL30-133 - GGGGAAGCCGGCGGCUC 17 3244
HSV2-UL30-134 - GAAGCCGGCGGCUCGGG 17 3245
HSV2-UL30-135 - GCGGCUCGGGCGGCGUC 17 3246
HSV2-UL30-136 - CGGCUCGGGCGGCGUCU 17 3247
HSV2-UL30-137 - UUGCCCCCCACAACCCC 17 3248
HSV2-UL30-138 - UGCCCCCCACAACCCCC 17 3249
HSV2-UL30-139 - GCCCCCCACAACCCCCG 17 3250
HSV2-UL30-140 - CCGGGGAGCCACCCAGA 17 3251
HSV2-UL30-142 - CCCCACCUCGCUCAGAC 17 3252
HSV2-UL30-144 - ACGCAGCCAAAGGCCCU 17 3253
HSV2-UL30-145 - CGCAGCCAAAGGCCCUC 17 3254
HSV2-UL30-146 - GCCAAAGGCCCUCGGGC 17 3255
HSV2-UL30-147 - UAUCGCCCCGCGUUCGC 17 3256
HSV2-UL30-149 - GGACGAGGACGCCCCCG 17 3257
HSV2-UL30-150 - CCCGCGGAGCAGCGCAC 17 3258
HSV2-UL30-151 - CCGCGGAGCAGCGCACC 17 3259
HSV2-UL30-152 - CGCGGAGCAGCGCACCG 17 3260
HSV2-UL30-153 - CGCACCGGGGUCCACGA 17 3261
HSV2-UL30-155 - CCUCCGGCGCGCCCCUA 17 3262
HSV2-UL30-158 - CCCUAAGGUGUACUGCG 17 3263
HSV2-UL30-164 - CGUCCUCCGCGUGGGCC 17 3264
HSV2-UL30-165 - CCUCCGCGUGGGCCCGG 17 3265
HSV2-UL30-167 - UGGGCCCGGAGGGCUUC 17 3266
HSV2-UL30-168 - CGCGUCGCUUGCGCCUG 17 3267
HSV2-UL30-172 - GCGCCUGUGGGGCGGUG 17 3268
HSV2-UL30-175 - CGGACCAUGCCCCCGAG 17 3269
HSV2-UL30-177 - CGACAUCCUGGAGCACG 17 3270
HSV2-UL30-178 + CGUGUUCCACGUGCUCC 17 3271
HSV2-UL30-179 + CCAG G AU G U CGUACACG 17 3272
HSV2-UL30-180 + GUCGUACACGUGGAAGA 17 3273
HSV2-UL30-181 + CACGUGGAAGACGGUGA 17 3274
HSV2-UL30-182 + GUGGAAGACGGUGACGG 17 3275
HSV2-UL30-184 + GGAAGACGGUGACGGUG 17 3276
HSV2-UL30-190 + GGUCCGCACCGCCCCAC 17 3277
HSV2-UL30-193 + GCGGCCAGAAGCCCUCC 17 3278
HSV2-UL30-194 + AGCCCUCCGGGCCCACG 17 3279 HSV2-UL30-195 + CCUCCGGGCCCACGCGG 17 3280
HSV2-UL30-196 + CCCCCGCAGUACACCUU 17 3281
HSV2-UL30-201 + UAGGGGCGCGCCGGAGG 17 3282
HSV2-UL30-202 + GCCGGAGGCGGCCGUCG 17 3283
HSV2-UL30-203 + GCGGCCGUCGUGGACCC 17 3284
HSV2-UL30-204 + CCCGGUGCGCUGCUCCG 17 3285
HSV2-UL30-205 + CCGGUGCGCUGCUCCGC 17 3286
HSV2-UL30-206 + CGGUGCGCUGCUCCGCG 17 3287
HSV2-UL30-210 + CUCGUCCAGCGAACGCG 17 3288
HSV2-UL30-211 + ACUCGCUGUAGUACGUA 17 3289
HSV2-UL30-213 + GGCGCUGAGCCGGCCCG 17 3290
HSV2-UL30-215 + GCCGGCCCGAGGGCCUU 17 3291
HSV2-UL30-219 + UCCGGUCUGAGCGAGGU 17 3292
HSV2-UL30-221 + CGGUCUGAGCGAGGUGG 17 3293
HSV2-UL30-222 + GGUUGUAGAAGUUCUGC 17 3294
HSV2-UL30-226 + UGCCGGCGGCAAGGCGG 17 3295
HSV2-UL30-229 + CGGCGGUGCCGUCUGGG 17 3296
HSV2-UL30-230 + CCGUCUGGGUGGCUCCC 17 3297
HSV2-UL30-231 + CGUCUGGGUGGCUCCCC 17 3298
HSV2-UL30-232 + GUCUGGGUGGCUCCCCG 17 3299
HSV2-UL30-234 + UGGCUCCCCGGGGGUUG 17 3300
HSV2-UL30-235 + GGCUCCCCGGGGGUUGU 17 3301
HSV2-UL30-236 + GCUCCCCGGGGGU UGUG 17 3302
HSV2-UL30-237 + CUCCCCGGGGGUUGUGG 17 3303
HSV2-UL30-238 + UCCCCGGGGGUUGUGGG 17 3304
HSV2-UL30-239 + GACGCCGCCCGAGCCGC 17 3305
HSV2-UL30-240 + AGCCGCCGGCUUCCCCC 17 3306
HSV2-UL30-241 + GCCGCCGGCUUCCCCCC 17 3307
HSV2-UL30-242 + CCGCCGGCUUCCCCCCG 17 3308
HSV2-UL30-243 + CGCCGGCUUCCCCCCGG 17 3309
HSV2-UL30-244 + UUCCCCCCGGGGGAAGC 17 3310
HSV2-UL30-245 + UCCCCCCGGGGGAAGCC 17 3311
HSV2-UL30-246 + GGAAGCCGGGCCGCCCG 17 3312
Table 2C provides exemplary targeting domains for knocking out the UL30 gene selected according to the third tier parameters. The targeting domains are selected based on location within the coding sequence (but downstream of the first 500bp) of the UL30 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 2C
Figure imgf000179_0001
HSV2-UL30-478 - GGGGCGUCGACGCCACCACC 20 3348
HSV2-UL30-479 - CGCCACCACCCGGUUUAUCC 20 3349
HSV2-UL30-480 - CCGGUUUAUCCUGGACAACC 20 3350
HSV2-UL30-481 - CGGUUUAUCCUGGACAACCC 20 3351
HSV2-UL30-482 - GGUUUAUCCUGGACAACCCG 20 3352
HSV2-UL30-483 - AACCCGGGGUUUGUCACCUU 20 3353
HSV2-UL30-484 - CGGGGUUUGUCACCUUCGGC 20 3354
HSV2-UL30-485 - GGCUGGUACCGCCUCAAGCC 20 3355
HSV2-UL30-486 - UACCGCCUCAAGCCCGGCCG 20 3356
HSV2-UL30-487 - ACCGCCUCAAGCCCGGCCGC 20 3357
HSV2-UL30-488 - GCCCGGCCGCGGGAACGCGC 20 3358
HSV2-UL30-489 - GGCCCAACCGCGCCCCCCGA 20 3359
HSV2-UL30-490 - CCGCGCCCCCCGACGGCGUU 20 3360
HSV2-UL30-491 - CGACGUCGAGUUUAACUGCA 20 3361
HSV2-UL30-492 - CGUCGAGUUUAACUGCACGG 20 3362
HSV2-UL30-493 - UAACUGCACGGCGGACAACC 20 3363
HSV2-UL30-494 - GGCGGACAACCUGGCCGUCG 20 3364
HSV2-UL30-495 - GCGGACAACCUGGCCGUCGA 20 3365
HSV2-UL30-496 - CGGACAACCUGGCCGUCGAG 20 3366
HSV2-UL30-497 - GGACAACCUGGCCGUCGAGG 20 3367
HSV2-UL30-498 - GGGGGCCAUGUGUGACCUGC 20 3368
HSV2-UL30-499 - GUGCUUCGAUAUCGAAUGCA 20 3369
HSV2-UL30-500 - UUCGAUAUCGAAUGCAAGGC 20 3370
HSV2-UL30-501 - UCGAUAUCGAAUGCAAGGCC 20 3371
HSV2-UL30-502 - CGAUAUCGAAUGCAAGGCCG 20 3372
HSV2-UL30-503 - GAUAUCGAAUGCAAGGCCGG 20 3373
HSV2-UL30-504 - AUAUCGAAUGCAAGGCCGGG 20 3374
HSV2-UL30-505 - UAUCGAAUGCAAGGCCGGGG 20 3375
HSV2-UL30-506 - CGAAUGCAAGGCCGGGGGGG 20 3376
HSV2-UL30-507 - GGCCGGGGGGGAGGACGAGC 20 3377
HSV2-UL30-508 - GGAGGACGAGCUGGCCUUUC 20 3378
HSV2-UL30-509 - CGAGCUGGCCUUUCCGGUCG 20 3379
HSV2-UL30-510 - CUUUCCGGUCGCGGAACGCC 20 3380
HSV2-UL30-511 - CACAUCCUCCUGUUUUCGCU 20 3381
HSV2-UL30-512 - ACCUCAGCGAUCUCGCCUCC 20 3382
HSV2-UL30-513 - CCUCAGCGAUCUCGCCUCCA 20 3383
HSV2-UL30-514 - CU CAG CG AU CU CG CCU CCAG 20 3384
HSV2-UL30-515 - UCUCGCCUCCAGGGGCCUGC 20 3385
HSV2-UL30-516 - CCUGCCGGCCCCCGUCGUCC 20 3386
HSV2-UL30-517 - CAGCGAAUUCGAGAUGCUGC 20 3387
HSV2-UL30-518 - AUGACCUUCGUCAAGCAGUA 20 3388
HSV2-UL30-519 - UACGGCCCCGAGUUCGUGAC 20 3389
HSV2-UL30-520 - ACGGCCCCGAGUUCGUGACC 20 3390
HSV2-UL30-521 - ACAACAU CAU CAACU U CG AC 20 3391
HSV2-UL30-522 - CUUCGUCCUGACCAAGCUGA 20 3392
HSV2-UL30-523 - CAAGCUGACGGAGAUCUACA 20 3393 HSV2-UL30-524 - AUCUACAAGGUCCCGCUCGA 20 3394
HSV2-UL30-525 - UCUACAAGGUCCCGCUCGAC 20 3395
HSV2-UL30-526 - AAGGUCCCGCUCGACGGGUA 20 3396
HSV2-UL30-527 - AGGUCCCGCUCGACGGGUAC 20 3397
HSV2-UL30-528 - GACGGGUACGGGCGCAUGAA 20 3398
HSV2-UL30-529 - GGUACGGGCGCAUGAACGGC 20 3399
HSV2-UL30-530 - GUACGGGCGCAUGAACGGCC 20 3400
HSV2-UL30-531 - UACGGGCGCAUGAACGGCCG 20 3401
HSV2-UL30-532 - GCCGGGGUGUGUUCCGCGUG 20 3402
HSV2-UL30-533 - CCGGGGUGUGUUCCGCGUGU 20 3403
HSV2-UL30-534 - GUGUUCCGCGUGUGGGACAU 20 3404
HSV2-UL30-535 - UCAGAAGCGCAGCAAGAUCA 20 3405
HSV2-UL30-536 - CGCAGCAAGAUCAAGGUGAA 20 3406
HSV2-UL30-537 - GCAGCAAGAUCAAGGUGAAC 20 3407
HSV2-UL30-538 - CAAGAUCAAGGUGAACGGGA 20 3408
HSV2-UL30-539 - AUGGUGAACAUCGACAUGUA 20 3409
HSV2-UL30-540 - GUACGGCAUCAUCACCGACA 20 3410
HSV2-UL30-541 - CAAGCUGAACGCCGUCGCCG 20 3411
HSV2-UL30-542 - CGUCGCCGAGGCCGUCUUGA 20 3412
HSV2-UL30-543 - CGUCUUGAAGGACAAGAAGA 20 3413
HSV2-UL30-544 - AUCCCCGCCUACUACGCCUC 20 3414
HSV2-UL30-545 - UCCCCGCCUACUACGCCUCC 20 3415
HSV2-UL30-546 - GCCUCCGGGCCCGCGCAGCG 20 3416
HSV2-UL30-547 - CCUCCGGGCCCGCGCAGCGC 20 3417
HSV2-UL30-548 - CUCCGGGCCCGCGCAGCGCG 20 3418
HSV2-UL30-549 - CCCGCGCAGCGCGGGGUGAU 20 3419
HSV2-UL30-550 - GAUCGGCGAGUAUUGUGUGC 20 3420
HSV2-UL30-551 - UUGUGUGCAGGACUCGCUGC 20 3421
HSV2-UL30-552 - GUGCAGGACUCGCUGCUGGU 20 3422
HSV2-UL30-553 - UGCAGGACUCGCUGCUGGUC 20 3423
HSV2-UL30-554 - CUUCAAGUUUCUGCCGCACC 20 3424
HSV2-UL30-555 - GCUUUCCGCCGUCGCGCGCC 20 3425
HSV2-UL30-556 - UUCCGCCGUCGCGCGCCUGG 20 3426
HSV2-UL30-557 - UCCGCCGUCGCGCGCCUGGC 20 3427
HSV2-UL30-558 - AUCACCCGCACCAUCUACGA 20 3428
HSV2-UL30-559 - CACGUGCCUCCUGCGCCUUG 20 3429
HSV2-UL30-560 - ACGUGCCUCCUGCGCCUUGC 20 3430
HSV2-UL30-561 - CCUGCGCCUUGCGGGCCAGA 20 3431
HSV2-UL30-562 - CUGCGCCUUGCGGGCCAGAA 20 3432
HSV2-UL30-563 - CCAGAAGGGCUUCAUCCUGC 20 3433
HSV2-UL30-564 - CU UCAUCCUG CCG G ACACCC 20 3434
HSV2-UL30-565 - UUCAUCCUG CCG G ACACCCA 20 3435
HSV2-UL30-566 - UCAUCCUGCCGGACACCCAG 20 3436
HSV2-UL30-567 - UCCUGCCGGACACCCAGGGG 20 3437
HSV2-UL30-568 - CGGACACCCAGGGGCGGUUU 20 3438
HSV2-UL30-569 - GGACACCCAGGGGCGGUUUC 20 3439 HSV2-UL30-570 - GACACCCAGGGGCGGUUUCG 20 3440
HSV2-UL30-571 - GCGGUUUCGGGGCCUCGACA 20 3441
HSV2-UL30-572 - GUUUCGGGGCCUCGACAAGG 20 3442
HSV2-UL30-573 - CAAGGAGGCGCCCAAGCGCC 20 3443
HSV2-UL30-574 - CCAAGCGCCCGGCCGUGCCU 20 3444
HSV2-UL30-575 - CAAGCGCCCGGCCGUGCCUC 20 3445
HSV2-UL30-576 - AAGCGCCCGGCCGUGCCUCG 20 3446
HSV2-UL30-577 - AGCGCCCGGCCGUGCCUCGG 20 3447
HSV2-UL30-578 - GCGCCCGGCCGUGCCUCGGG 20 3448
HSV2-UL30-579 - CCGGCCGUGCCUCGGGGGGA 20 3449
HSV2-UL30-580 - CGGCCGUGCCUCGGGGGGAA 20 3450
HSV2-UL30-581 - GGCCGUGCCUCGGGGGGAAG 20 3451
HSV2-UL30-582 - UGCCUCGGGGGGAAGGGGAG 20 3452
HSV2-UL30-583 - UCGGGGGGAAGGGGAGCGGC 20 3453
HSV2-UL30-584 - CGGGGGGAAGGGGAGCGGCC 20 3454
HSV2-UL30-585 - GGGGGGAAGGGGAGCGGCCG 20 3455
HSV2-UL30-586 - GGGGGAAGGGGAGCGGCCGG 20 3456
HSV2-UL30-587 - GAAGGGGAGCGGCCGGGGGA 20 3457
HSV2-UL30-588 - AAGGGGAGCGGCCGGGGGAC 20 3458
HSV2-UL30-589 - GAGCGGCCGGGGGACGGGAA 20 3459
HSV2-UL30-590 - AGCGGCCGGGGGACGGGAAC 20 3460
HSV2-UL30-591 - GCGGCCGGGGGACGGGAACG 20 3461
HSV2-UL30-592 - GGGGGACGGGAACGGGGACG 20 3462
HSV2-UL30-593 - CGGGAACGGGGACGAGGAUA 20 3463
HSV2-UL30-594 - CGAGGAUAAGGACGACGACG 20 3464
HSV2-UL30-595 - GAUAAGGACGACGACGAGGA 20 3465
HSV2-UL30-596 - AUAAGGACGACGACGAGGAC 20 3466
HSV2-UL30-597 - UAAGGACGACGACGAGGACG 20 3467
HSV2-UL30-598 - CGACGACGAGGACGGGGACG 20 3468
HSV2-UL30-599 - GACGAGGACGGGGACGAGGA 20 3469
HSV2-UL30-600 - ACGAGGACGGGGACGAGGAC 20 3470
HSV2-UL30-601 - CGAGGACGGGGACGAGGACG 20 3471
HSV2-UL30-602 - CGAGGACGGGGACGAGCGCG 20 3472
HSV2-UL30-603 - GGACGGGGACGAGCGCGAGG 20 3473
HSV2-UL30-604 - GAGGAGGUCGCGCGCGAGAC 20 3474
HSV2-UL30-605 - AGGAGGUCGCGCGCGAGACC 20 3475
HSV2-UL30-606 - GGAGGUCGCGCGCGAGACCG 20 3476
HSV2-UL30-607 - GAGGUCGCGCGCGAGACCGG 20 3477
HSV2-UL30-608 - UCGCGCGCGAGACCGGGGGC 20 3478
HSV2-UL30-609 - GAGACCGGGGGCCGGCACGU 20 3479
HSV2-UL30-610 - AGACCGGGGGCCGGCACGUU 20 3480
HSV2-UL30-611 - GGGCCGGCACGUUGGGUACC 20 3481
HSV2-UL30-612 - GGCCGGCACGUUGGGUACCA 20 3482
HSV2-UL30-613 - GCCGGCACGU UGGGUACCAG 20 3483
HSV2-UL30-614 - CCGGCACGUUGGGUACCAGG 20 3484
HSV2-UL30-615 - ACGUUGGGUACCAGGGGGCC 20 3485 HSV2-UL30-616 - CGU UGGGUACCAGGGGGCCC 20 3486
HSV2-UL30-617 - CG G G U CCU CG ACCCCACCU C 20 3487
HSV2-UL30-618 - GGGUCCUCGACCCCACCUCC 20 3488
HSV2-UL30-619 - CGGGUUUCACGUCGACCCCG 20 3489
HSV2-UL30-620 - GUUUCACGUCGACCCCGUGG 20 3490
HSV2-UL30-621 - CCUGUACCCCAGCAUCAUCC 20 3491
HSV2-UL30-622 - GCUUCAGUACGCUCUCCCUG 20 3492
HSV2-UL30-623 - UACGCUCUCCCUGCGGCCCG 20 3493
HSV2-UL30-624 - GCCCGAGGCCGUCGCGCACC 20 3494
HSV2-UL30-625 - CGAGGCCGUCGCGCACCUGG 20 3495
HSV2-UL30-626 - GGCCGUCGCGCACCUGGAGG 20 3496
HSV2-UL30-627 - UCGCGCACCUGGAGGCGGAC 20 3497
HSV2-UL30-628 - CGCGCACCUGGAGGCGGACC 20 3498
HSV2-UL30-629 - GGAGGCGGACCGGGACUACC 20 3499
HSV2-UL30-630 - CCGGGACUACCUGGAGAUCG 20 3500
HSV2-UL30-631 - GGACUACCUGGAGAUCGAGG 20 3501
HSV2-UL30-632 - GACUACCUGGAGAUCGAGGU 20 3502
HSV2-UL30-633 - ACUACCUGGAGAUCGAGGUG 20 3503
HSV2-UL30-634 - CUACCUGGAGAUCGAGGUGG 20 3504
HSV2-UL30-635 - UACCUGGAGAUCGAGGUGGG 20 3505
HSV2-UL30-636 - AGAUCGAGGUGGGGGGCCGA 20 3506
HSV2-UL30-637 - CCGACGGCUGUUCUUCGUGA 20 3507
HSV2-UL30-638 - UGAGCAUCCUGCUGCGCGAC 20 3508
HSV2-UL30-639 - CAUCCUGCUGCGCGACUGGC 20 3509
HSV2-UL30-640 - UGCGAAAGCAGAUCCGCUCG 20 3510
HSV2-UL30-641 - G AU CCCCCAG AG CACCCCCG 20 3511
HSV2-UL30-642 - CCCCCAGAGCACCCCCGAGG 20 3512
HSV2-UL30-643 - CGUCCUCCUCG ACAAG CAAC 20 3513
HSV2-UL30-644 - CA AG CAACAG G CCG CCAU CA 20 3514
HSV2-UL30-645 - GCAACAGGCCGCCAUCAAGG 20 3515
HSV2-UL30-646 - CAUCAAGGUGGUGUGCAACU 20 3516
HSV2-UL30-647 - GUGGUGUGCAACUCGGUGUA 20 3517
HSV2-UL30-648 - UGGUGUGCAACUCGGUGUAC 20 3518
HSV2-UL30-649 - AACUCGGUGUACGGGUUCAC 20 3519
HSV2-UL30-650 - ACUCGGUGUACGGGUUCACC 20 3520
HSV2-UL30-651 - CUCGGUGUACGGGUUCACCG 20 3521
HSV2-UL30-652 - GGGUUCACCGGGGUGCAGCA 20 3522
HSV2-UL30-653 - UCUUCUGCCCUGCCUGCACG 20 3523
HSV2-UL30-654 - G CCG CCACCG U G ACG ACCAU 20 3524
HSV2-UL30-655 - GCGCGUACGUGCACGCGCGC 20 3525
HSV2-UL30-656 - CGCGUACGUGCACGCGCGCU 20 3526
HSV2-UL30-657 - GUACGUGCACGCGCGCUGGG 20 3527
HSV2-UL30-658 - GGCGGAGUUCGAUCAGCUGC 20 3528
HSV2-UL30-659 - UCAGCUGCUGGCCGACUUUC 20 3529
HSV2-UL30-660 - GCUGCUGGCCGACUUUCCGG 20 3530
HSV2-UL30-661 - GCUGGCCGACUUUCCGGAGG 20 3531 HSV2-UL30-662 - GCCGACUUUCCGGAGGCGGC 20 3532
HSV2-UL30-663 - GCGGCCGGCAUGCGCGCCCC 20 3533
HSV2-UL30-664 - UACUCCAUGCGCAUCAUCUA 20 3534
HSV2-UL30-665 - ACUCCAUGCGCAUCAUCUAC 20 3535
HSV2-UL30-666 - CUCCAUGCGCAUCAUCUACG 20 3536
HSV2-UL30-667 - GCGCAUCAUCUACGGGGACA 20 3537
HSV2-UL30-668 - UCCAUUUUCGUUUUGUGCCG 20 3538
HSV2-UL30-669 - CGUUUUGUGCCGCGGCCUCA 20 3539
HSV2-UL30-670 - GUGCCGCGGCCUCACGGCCG 20 3540
HSV2-UL30-671 - UGCCGCGGCCUCACGGCCGC 20 3541
HSV2-UL30-672 - CGGCCUCACGGCCGCGGGCC 20 3542
HSV2-UL30-673 - CCUCACGGCCGCGGGCCUGG 20 3543
HSV2-UL30-674 - GGCCGCGGGCCUGGUGGCCA 20 3544
HSV2-UL30-675 - GCCGCGGGCCUGGUGGCCAU 20 3545
HSV2-UL30-676 - GGUGGCCAUGGGCGACAAGA 20 3546
HSV2-UL30-677 - AU CG CCAAG AAAAAG U AC AU 20 3547
HSV2-UL30-678 - AAGUACAUCGGCGUCAUCUG 20 3548
HSV2-UL30-679 - AGUACAUCGGCGUCAUCUGC 20 3549
HSV2-UL30-680 - GUACAUCGGCGUCAUCUGCG 20 3550
HSV2-UL30-681 - UACAUCGGCGUCAUCUGCGG 20 3551
HSV2-UL30-682 - CGGGGGCAAGAUGCUCAUCA 20 3552
HSV2-UL30-683 - GGGGGCAAGAUGCUCAUCAA 20 3553
HSV2-UL30-684 - CAAGAUGCUCAUCAAGGGCG 20 3554
HSV2-UL30-685 - GCUCAUCAAGGGCGUGGAUC 20 3555
HSV2-UL30-686 - CGU UUAUCAACCGCACCUCC 20 3556
HSV2-UL30-687 - GUUUAUCAACCGCACCUCCA 20 3557
HSV2-UL30-688 - CAACCGCACCUCCAGGGCCC 20 3558
HSV2-UL30-689 - UUUUACGACGAUACCGUAUC 20 3559
HSV2-UL30-690 - CGACGAUACCGUAUCCGGAG 20 3560
HSV2-UL30-691 - GUUAGCCGAGCGCCCCGCAG 20 3561
HSV2-UL30-692 - CCGAGCGCCCCGCAGAGGAG 20 3562
HSV2-UL30-693 - GCGCCCCGCAGAGGAGUGGC 20 3563
HSV2-UL30-694 - GCUGGCGCGACCCCUGCCCG 20 3564
HSV2-UL30-695 - CUGGCGCGACCCCUGCCCGA 20 3565
HSV2-UL30-696 - ACCCCUGCCCGAGGGACUGC 20 3566
HSV2-UL30-697 - CCCGAGGGACUGCAGGCGUU 20 3567
HSV2-UL30-698 - CCGAGGGACUGCAGGCGUUC 20 3568
HSV2-UL30-699 - CGAGGGACUGCAGGCGUUCG 20 3569
HSV2-UL30-700 - CCGUCCUCGUAGACGCCCAU 20 3570
HSV2-UL30-701 - CCAUCGGCGCAUCACCGACC 20 3571
HSV2-UL30-702 - GGCGCAUCACCGACCCGGAG 20 3572
HSV2-UL30-703 - GCGCAUCACCGACCCGGAGA 20 3573
HSV2-UL30-704 - CGACCCGGAGAGGGACAUCC 20 3574
HSV2-UL30-705 - CG CG U ACACCAACAAG CG CC 20 3575
HSV2-UL30-706 - CAAGCGCCUGGCCCACCUGA 20 3576
HSV2-UL30-707 - GACGGUGUAUUACAAGCUCA 20 3577 HSV2-UL30-708 - GCUCAUGGCCCGCCGCGCGC 20 3578
HSV2-UL30-709 - CGCGCAGGUCCCGUCCAUCA 20 3579
HSV2-UL30-710 - AGGUCCCGUCCAU CAAG G AC 20 3580
HSV2-UL30-711 - CCGGAUCCCGUACGUGAUCG 20 3581
HSV2-UL30-712 - GAUCGUGGCCCAGACCCGCG 20 3582
HSV2-UL30-713 - GGCCCAGACCCGCGAGGUAG 20 3583
HSV2-UL30-714 - GACCCGCGAGGUAGAGGAGA 20 3584
HSV2-UL30-715 - AGGUAGAGGAGACGGUCGCG 20 3585
HSV2-UL30-716 - AGAGGAGACGGUCGCGCGGC 20 3586
HSV2-UL30-717 - GAGCUAGACGCCGCCGCCCC 20 3587
HSV2-UL30-718 - AGCUAGACGCCGCCGCCCCA 20 3588
HSV2-UL30-719 - GCUAGACGCCGCCGCCCCAG 20 3589
HSV2-UL30-720 - GGACGAGCCCGCCCCCCCAG 20 3590
HSV2-UL30-721 - CCCAGCGGCCCUGCCCUCCC 20 3591
HSV2-UL30-722 - CCUCCCCGGCCAAGCGCCCC 20 3592
HSV2-UL30-723 - CUCCCCGGCCAAGCGCCCCC 20 3593
HSV2-UL30-724 - G CCG U CG CAU GCCG ACCCCC 20 3594
HSV2-UL30-725 - CCGUCGCAUGCCGACCCCCC 20 3595
HSV2-UL30-726 - UCGCAUGCCGACCCCCCGGG 20 3596
HSV2-UL30-727 - GUCCAAGCCCCGCAAGCUGC 20 3597
HSV2-UL30-728 - CAAGCUGCUGGUGUCCGAGC 20 3598
HSV2-UL30-729 - GCUGCUGGUGUCCGAGCUGG 20 3599
HSV2-UL30-730 - GCUGGUGUCCGAGCUGGCGG 20 3600
HSV2-UL30-731 - UCCGAGCUGGCGGAGGAUCC 20 3601
HSV2-UL30-732 - CCGAGCUGGCGGAGGAUCCC 20 3602
HSV2-UL30-733 - AUCCCGGGUACGCCAUCGCC 20 3603
HSV2-UL30-734 - UCCCGGGUACGCCAUCGCCC 20 3604
HSV2-UL30-735 - CCCGGGUACGCCAUCGCCCG 20 3605
HSV2-UL30-736 - CCGGGGCGUUCCGCUCAACA 20 3606
HSV2-UL30-737 - CUAUUACUUCUCGCACCUGC 20 3607
HSV2-UL30-738 - UAUUACUUCUCGCACCUGCU 20 3608
HSV2-UL30-739 - AUUACUUCUCGCACCUGCUG 20 3609
HSV2-UL30-740 - UUACUUCUCGCACCUGCUGG 20 3610
HSV2-UL30-741 - CUUCUCGCACCUGCUGGGGG 20 3611
HSV2-UL30-742 - GGCGGCCUGCGUGACGUUCA 20 3612
HSV2-UL30-743 - GUGACGUUCAAGGCCCUGUU 20 3613
HSV2-UL30-744 - UCACCGAGAGUCUGUUAAAG 20 3614
HSV2-UL30-745 - AGAGGUUUAUUCCCGAGACG 20 3615
HSV2-UL30-746 - UCCCGAGACGUGGCACCCCC 20 3616
HSV2-UL30-747 - GUGGCACCCCCCGGACGACG 20 3617
HSV2-UL30-748 - CCCCGGACGACGUGGCCGCG 20 3618
HSV2-UL30-749 - ACGACGUGGCCGCGCGGCUC 20 3619
HSV2-UL30-750 - CGACGUGGCCGCGCGGCUCA 20 3620
HSV2-UL30-751 - GGCCGCGCGGCUCAGGGCCG 20 3621
HSV2-UL30-752 - GCCGCGCGGCUCAGGGCCGC 20 3622
HSV2-UL30-753 - CCGCGCGGCUCAGGGCCGCG 20 3623 HSV2-UL30-754 - CGGCUCAGGGCCGCGGGGUU 20 3624
HSV2-UL30-755 - GGCUCAGGGCCGCGGGGUUC 20 3625
HSV2-UL30-756 - CAGGGCCGCGGGGUUCGGGC 20 3626
HSV2-UL30-757 - GGCCGCGGGGUUCGGGCCGG 20 3627
HSV2-UL30-758 - GCCGCGGGGUUCGGGCCGGC 20 3628
HSV2-UL30-759 - CCGCGGGGUUCGGGCCGGCG 20 3629
HSV2-UL30-760 - CGCGGGGUUCGGGCCGGCGG 20 3630
HSV2-UL30-761 - GGGUUCGGGCCGGCGGGGGC 20 3631
HSV2-UL30-762 - GCCGGCGGGGGCCGGCGCUA 20 3632
HSV2-UL30-763 - GGCGGGGGCCGGCGCUACGG 20 3633
HSV2-UL30-764 - GGGGGCCGGCGCUACGGCGG 20 3634
HSV2-UL30-765 - GACGCCAUCACGCCCGC 17 3635
HSV2-UL30-766 - ACGCCAUCACGCCCGCC 17 3636
HSV2-UL30-767 - GACCGUCAUCACGCUUC 17 3637
HSV2-UL30-768 - ACCGUCAUCACGCUUCU 17 3638
HSV2-UL30-769 - CUGGGUCUGACCCCCGA 17 3639
HSV2-UL30-770 - GUCGCCGUUCACGUCUA 17 3640
HSV2-UL30-771 - UUCACGUCUACGGCACG 17 3641
HSV2-UL30-772 - GUACUUUUACAUGAACA 17 3642
HSV2-UL30-773 - CU U U U ACAU G AACAAGG 17 3643
HSV2-UL30-774 - UUACAUGAACAAGGCGG 17 3644
HSV2-UL30-775 - CAUGAACAAGGCGGAGG 17 3645
HSV2-UL30-776 - ACAAGGCGGAGGUGGAU 17 3646
HSV2-UL30-777 - CGAUCUCUGCGAGCGCC 17 3647
HSV2-UL30-778 - UCUCUGCGAGCGCCUGG 17 3648
HSV2-UL30-779 - CUGCGAGCGCCUGGCGG 17 3649
HSV2-UL30-780 - GGCCCUGCGCGAGUCGC 17 3650
HSV2-UL30-781 - GCCCUGCGCGAGUCGCC 17 3651
HSV2-UL30-782 - CCCUGCGCGAGUCGCCG 17 3652
HSV2-UL30-783 - CCUGCGCGAGUCGCCGG 17 3653
HSV2-UL30-784 - CCGGGGGCGUCGUUCCG 17 3654
HSV2-UL30-785 - GUUCCGCGGCAUCUCCG 17 3655
HSV2-UL30-786 - CU CCG CGG ACCACU U CG 17 3656
HSV2-UL30-787 - CGCGGACCACUUCGAGG 17 3657
HSV2-UL30-788 - GGACCACUUCGAGGCGG 17 3658
HSV2-UL30-789 - CCACUUCGAGGCGGAGG 17 3659
HSV2-UL30-790 - CU UCGAGGCGGAGGUGG 17 3660
HSV2-UL30-791 - CGCGUCUUCGUGCGAAG 17 3661
HSV2-UL30-792 - GCGUCUUCGUGCGAAGC 17 3662
HSV2-UL30-793 - GCGAAGCGGGCGCGCGC 17 3663
HSV2-UL30-794 - ACUUUUGCCCCGCGAUC 17 3664
HSV2-UL30-795 - CGCGAUCAGGAAGUACG 17 3665
HSV2-UL30-796 - GCGAUCAGGAAGUACGA 17 3666
HSV2-UL30-797 - CGAUCAGGAAGUACGAG 17 3667
HSV2-UL30-798 - GAUCAGGAAGUACGAGG 17 3668
HSV2-UL30-799 - AUCAGGAAGUACGAGGG 17 3669 HSV2-UL30-800 - G CG U CGACG CCACCACC 17 3670
HSV2-UL30-801 - CACCACCCG G U U U AU CC 17 3671
HSV2-UL30-802 - GUUUAUCCUGGACAACC 17 3672
HSV2-UL30-803 - UUUAUCCUGGACAACCC 17 3673
HSV2-UL30-804 - UUAUCCUGGACAACCCG 17 3674
HSV2-UL30-805 - CCGGGGUUUGUCACCUU 17 3675
HSV2-UL30-806 - GGUUUGUCACCUUCGGC 17 3676
HSV2-UL30-807 - UGGUACCGCCUCAAGCC 17 3677
HSV2-UL30-808 - CGCCUCAAGCCCGGCCG 17 3678
HSV2-UL30-809 - GCCUCAAGCCCGGCCGC 17 3679
HSV2-UL30-810 - CGGCCGCGGGAACGCGC 17 3680
HSV2-UL30-811 - CCAACCGCGCCCCCCGA 17 3681
HSV2-UL30-812 - CGCCCCCCGACGGCGUU 17 3682
HSV2-UL30-813 - CGUCGAGUUUAACUGCA 17 3683
HSV2-UL30-814 - CGAGUUUAACUGCACGG 17 3684
HSV2-UL30-815 - CUGCACGGCGGACAACC 17 3685
HSV2-UL30-816 - GGACAACCUGGCCGUCG 17 3686
HSV2-UL30-817 - GACAACCUGGCCGUCGA 17 3687
HSV2-UL30-818 - ACAACCUGGCCGUCGAG 17 3688
HSV2-UL30-819 - CAACCUGGCCGUCGAGG 17 3689
HSV2-UL30-820 - GGCCAUGUGUGACCUGC 17 3690
HSV2-UL30-821 - CUUCGAUAUCGAAUGCA 17 3691
HSV2-UL30-822 - GAUAUCGAAUGCAAGGC 17 3692
HSV2-UL30-823 - AUAUCGAAUGCAAGGCC 17 3693
HSV2-UL30-824 - UAUCGAAUGCAAGGCCG 17 3694
HSV2-UL30-825 - AUCGAAUGCAAGGCCGG 17 3695
HSV2-UL30-826 - UCGAAUGCAAGGCCGGG 17 3696
HSV2-UL30-827 - CGAAUGCAAGGCCGGGG 17 3697
HSV2-UL30-828 - AUGCAAGGCCGGGGGGG 17 3698
HSV2-UL30-829 - CGGGGGGGAGGACGAGC 17 3699
HSV2-UL30-830 - GGACGAGCUGGCCUUUC 17 3700
HSV2-UL30-831 - GCUGGCCUUUCCGGUCG 17 3701
HSV2-UL30-832 - UCCGGUCGCGGAACGCC 17 3702
HSV2-UL30-833 - AUCCUCCUGUUUUCGCU 17 3703
HSV2-UL30-834 - UCAGCGAUCUCGCCUCC 17 3704
HSV2-UL30-835 - CAGCGAUCUCGCCUCCA 17 3705
HSV2-UL30-836 - AGCGAUCUCGCCUCCAG 17 3706
HSV2-UL30-837 - CGCCUCCAGGGGCCUGC 17 3707
HSV2-UL30-838 - GCCGGCCCCCGUCGUCC 17 3708
HSV2-UL30-839 - CGAAUUCGAGAUGCUGC 17 3709
HSV2-UL30-840 - ACCUUCGUCAAGCAGUA 17 3710
HSV2-UL30-841 - GGCCCCGAGU UCGUGAC 17 3711
HSV2-UL30-842 - GCCCCGAGUUCGUGACC 17 3712
HSV2-UL30-843 - ACAUCAU CAACU U CG AC 17 3713
HSV2-UL30-844 - CG U CCU G ACCAAG CU G A 17 3714
HSV2-UL30-845 - GCUGACGGAGAUCUACA 17 3715 HSV2-UL30-846 - UACAAGGUCCCGCUCGA 17 3716
HSV2-UL30-847 - ACAAGGUCCCGCUCGAC 17 3717
HSV2-UL30-848 - GUCCCGCUCGACGGGUA 17 3718
HSV2-UL30-849 - UCCCGCUCGACGGGUAC 17 3719
HSV2-UL30-850 - GGGUACGGGCGCAUGAA 17 3720
HSV2-UL30-851 - ACGGGCGCAUGAACGGC 17 3721
HSV2-UL30-852 - CGGGCGCAUGAACGGCC 17 3722
HSV2-UL30-853 - GGGCGCAUGAACGGCCG 17 3723
HSV2-UL30-854 - GGGGUGUGUUCCGCGUG 17 3724
HSV2-UL30-855 - GGGUGUGUUCCGCGUGU 17 3725
HSV2-UL30-856 - UUCCGCGUGUGGGACAU 17 3726
HSV2-UL30-857 - GAAGCGCAGCAAGAUCA 17 3727
HSV2-UL30-858 - AGCAAGAUCAAGGUGAA 17 3728
HSV2-UL30-859 - GCAAGAUCAAGGUGAAC 17 3729
HSV2-UL30-860 - GAUCAAGGUGAACGGGA 17 3730
HSV2-UL30-861 - GUGAACAUCGACAUGUA 17 3731
HSV2-UL30-862 - CGGCAUCAUCACCGACA 17 3732
HSV2-UL30-863 - GCUGAACGCCGUCGCCG 17 3733
HSV2-UL30-864 - CGCCGAGGCCGUCUUGA 17 3734
HSV2-UL30-865 - CUUGAAGGACAAGAAGA 17 3735
HSV2-UL30-866 - CCCGCCUACUACGCCUC 17 3736
HSV2-UL30-867 - CCGCCUACUACGCCUCC 17 3737
HSV2-UL30-868 - UCCGGGCCCGCGCAGCG 17 3738
HSV2-UL30-869 - CCGGGCCCGCGCAGCGC 17 3739
HSV2-UL30-870 - CGGGCCCGCGCAGCGCG 17 3740
HSV2-UL30-871 - GCGCAGCGCGGGGUGAU 17 3741
HSV2-UL30-872 - CGGCGAGUAUUGUGUGC 17 3742
HSV2-UL30-873 - UGUGCAGGACUCGCUGC 17 3743
HSV2-UL30-874 - CAGGACUCGCUGCUGGU 17 3744
HSV2-UL30-875 - AGGACUCGCUGCUGGUC 17 3745
HSV2-UL30-876 - CAAGUUUCUGCCGCACC 17 3746
HSV2-UL30-877 - UUCCGCCGUCGCGCGCC 17 3747
HSV2-UL30-878 - CGCCGUCGCGCGCCUGG 17 3748
HSV2-UL30-879 - GCCGUCGCGCGCCUGGC 17 3749
HSV2-UL30-880 - ACCCGCACCAUCUACGA 17 3750
HSV2-UL30-881 - GUGCCUCCUGCGCCUUG 17 3751
HSV2-UL30-882 - UGCCUCCUGCGCCUUGC 17 3752
HSV2-UL30-883 - GCGCCUUGCGGGCCAGA 17 3753
HSV2-UL30-884 - CGCCUUGCGGGCCAGAA 17 3754
HSV2-UL30-885 - GAAGGGCUUCAUCCUGC 17 3755
HSV2-UL30-886 - CAUCCUGCCGGACACCC 17 3756
HSV2-UL30-887 - AUCCUGCCGGACACCCA 17 3757
HSV2-UL30-888 - UCCUGCCGGACACCCAG 17 3758
HSV2-UL30-889 - UGCCGGACACCCAGGGG 17 3759
HSV2-UL30-890 - ACACCCAGGGGCGGUUU 17 3760
HSV2-UL30-891 - CACCCAGGGGCGGUUUC 17 3761 HSV2-UL30-892 - ACCCAGGGGCGGUUUCG 17 3762
HSV2-UL30-893 - GUUUCGGGGCCUCGACA 17 3763
HSV2-UL30-894 - UCGGGGCCUCGACAAGG 17 3764
HSV2-UL30-895 - GGAGGCGCCCAAGCGCC 17 3765
HSV2-UL30-896 - AGCGCCCGGCCGUGCCU 17 3766
HSV2-UL30-897 - GCGCCCGGCCGUGCCUC 17 3767
HSV2-UL30-898 - CGCCCGGCCGUGCCUCG 17 3768
HSV2-UL30-899 - GCCCGGCCGUGCCUCGG 17 3769
HSV2-UL30-900 - CCCGGCCGUGCCUCGGG 17 3770
HSV2-UL30-901 - GCCGUGCCUCGGGGGGA 17 3771
HSV2-UL30-902 - CCGUGCCUCGGGGGGAA 17 3772
HSV2-UL30-903 - CGUGCCUCGGGGGGAAG 17 3773
HSV2-UL30-904 - CUCGGGGGGAAGGGGAG 17 3774
HSV2-UL30-905 - GGGGGAAGGGGAGCGGC 17 3775
HSV2-UL30-906 - GGGGAAGGGGAGCGGCC 17 3776
HSV2-UL30-907 - GGGAAGGGGAGCGGCCG 17 3777
HSV2-UL30-908 - GGAAGGGGAGCGGCCGG 17 3778
HSV2-UL30-909 - GGGGAGCGGCCGGGGGA 17 3779
HSV2-UL30-910 - GGGAGCGGCCGGGGGAC 17 3780
HSV2-UL30-911 - CGGCCGGGGGACGGGAA 17 3781
HSV2-UL30-912 - GGCCGGGGGACGGGAAC 17 3782
HSV2-UL30-913 - GCCGGGGGACGGGAACG 17 3783
HSV2-UL30-914 - GGACGGGAACGGGGACG 17 3784
HSV2-UL30-915 - GAACGGGGACGAGGAUA 17 3785
HSV2-UL30-916 - GGAUAAGGACGACGACG 17 3786
HSV2-UL30-917 - AAGGACGACGACGAGGA 17 3787
HSV2-UL30-918 - AGGACGACGACGAGGAC 17 3788
HSV2-UL30-919 - GGACGACGACGAGGACG 17 3789
HSV2-UL30-920 - CGACGAGGACGGGGACG 17 3790
HSV2-UL30-921 - GAGGACGGGGACGAGGA 17 3791
HSV2-UL30-922 - AGGACGGGGACGAGGAC 17 3792
HSV2-UL30-923 - GGACGGGGACGAGGACG 17 3793
HSV2-UL30-924 - GGACGGGGACGAGCGCG 17 3794
HSV2-UL30-925 - CGGGGACGAGCGCGAGG 17 3795
HSV2-UL30-926 - GAGGUCGCGCGCGAGAC 17 3796
HSV2-UL30-927 - AGGUCGCGCGCGAGACC 17 3797
HSV2-UL30-928 - GGUCGCGCGCGAGACCG 17 3798
HSV2-UL30-929 - GUCGCGCGCGAGACCGG 17 3799
HSV2-UL30-930 - CGCGCGAGACCGGGGGC 17 3800
HSV2-UL30-931 - ACCGGGGGCCGGCACGU 17 3801
HSV2-UL30-932 - CCGGGGGCCGGCACGU U 17 3802
HSV2-UL30-933 - CCGGCACGUUGGGUACC 17 3803
HSV2-UL30-934 - CGGCACGUUGGGUACCA 17 3804
HSV2-UL30-935 - GGCACGUUGGGUACCAG 17 3805
HSV2-UL30-936 - GCACGUUGGGUACCAGG 17 3806
HSV2-UL30-937 - UUGGGUACCAGGGGGCC 17 3807 HSV2-UL30-938 - UGGGUACCAGGGGGCCC 17 3808
HSV2-UL30-939 - GUCCUCGACCCCACCUC 17 3809
HSV2-UL30-940 - U CCU CG ACCCCACCU CC 17 3810
HSV2-UL30-941 - G U U U CACG U CG ACCCCG 17 3811
HSV2-UL30-942 - UCACGUCGACCCCGUGG 17 3812
HSV2-UL30-943 - GUACCCCAGCAUCAUCC 17 3813
HSV2-UL30-944 - UCAGUACGCUCUCCCUG 17 3814
HSV2-UL30-945 - GCUCUCCCUGCGGCCCG 17 3815
HSV2-UL30-946 - CGAGGCCGUCGCGCACC 17 3816
HSV2-UL30-947 - GGCCGUCGCGCACCUGG 17 3817
HSV2-UL30-948 - CGUCGCGCACCUGGAGG 17 3818
HSV2-UL30-949 - CGCACCUGGAGGCGGAC 17 3819
HSV2-UL30-950 - GCACCUGGAGGCGGACC 17 3820
HSV2-UL30-951 - GGCGGACCGGGACUACC 17 3821
HSV2-UL30-952 - GGACUACCUGGAGAUCG 17 3822
HSV2-UL30-953 - CUACCUGGAGAUCGAGG 17 3823
HSV2-UL30-954 - UACCUGGAGAUCGAGGU 17 3824
HSV2-UL30-955 - ACCUGGAGAUCGAGGUG 17 3825
HSV2-UL30-956 - CCUGGAGAUCGAGGUGG 17 3826
HSV2-UL30-957 - CUGGAGAUCGAGGUGGG 17 3827
HSV2-UL30-958 - UCGAGGUGGGGGGCCGA 17 3828
HSV2-UL30-959 - ACGGCUGUUCUUCGUGA 17 3829
HSV2-UL30-960 - GCAUCCUGCUGCGCGAC 17 3830
HSV2-UL30-961 - CCUGCUGCGCGACUGGC 17 3831
HSV2-UL30-962 - GAAAGCAGAUCCGCUCG 17 3832
HSV2-UL30-963 - CCCCCAGAGCACCCCCG 17 3833
HSV2-UL30-964 - CCAGAGCACCCCCGAGG 17 3834
HSV2-UL30-965 - CCUCCUCGACAAGCAAC 17 3835
HSV2-UL30-966 - GCAACAGGCCGCCAUCA 17 3836
HSV2-UL30-967 - ACAGGCCGCCAUCAAGG 17 3837
HSV2-UL30-968 - CAAGGUGGUGUGCAACU 17 3838
HSV2-UL30-969 - GUGUGCAACUCGGUGUA 17 3839
HSV2-UL30-970 - UGUGCAACUCGGUGUAC 17 3840
HSV2-UL30-971 - UCGGUGUACGGGUUCAC 17 3841
HSV2-UL30-972 - CGGUGUACGGGUUCACC 17 3842
HSV2-UL30-973 - GGUGUACGGGUUCACCG 17 3843
HSV2-UL30-974 - UUCACCGGGGUGCAGCA 17 3844
HSV2-UL30-975 - UCUGCCCUGCCUGCACG 17 3845
HSV2-UL30-976 - GCCACCGUGACGACCAU 17 3846
HSV2-UL30-977 - CGUACGUGCACGCGCGC 17 3847
HSV2-UL30-978 - GUACGUGCACGCGCGCU 17 3848
HSV2-UL30-979 - CGUGCACGCGCGCUGGG 17 3849
HSV2-UL30-980 - GGAGUUCGAUCAGCUGC 17 3850
HSV2-UL30-981 - GCUGCUGGCCGACUUUC 17 3851
HSV2-UL30-982 - GCUGGCCGACUUUCCGG 17 3852
HSV2-UL30-983 - GGCCGACUUUCCGGAGG 17 3853 HSV2-UL30-984 - GACUUUCCGGAGGCGGC 17 3854
HSV2-UL30-985 - GCCGGCAUGCGCGCCCC 17 3855
HSV2-UL30-986 - UCCAUGCGCAUCAUCUA 17 3856
HSV2-UL30-987 - CCAUGCGCAUCAUCUAC 17 3857
HSV2-UL30-988 - CAUGCGCAUCAUCUACG 17 3858
HSV2-UL30-989 - CAUCAUCUACGGGGACA 17 3859
HSV2-UL30-990 - AUUUUCGUUUUGUGCCG 17 3860
HSV2-UL30-991 - UUUGUGCCGCGGCCUCA 17 3861
HSV2-UL30-992 - CCGCGGCCUCACGGCCG 17 3862
HSV2-UL30-993 - CGCGGCCUCACGGCCGC 17 3863
HSV2-UL30-994 - CCUCACGGCCGCGGGCC 17 3864
HSV2-UL30-995 - CACGGCCGCGGGCCUGG 17 3865
HSV2-UL30-996 - CGCGGGCCUGGUGGCCA 17 3866
HSV2-UL30-997 - GCGGGCCUGGUGGCCAU 17 3867
HSV2-UL30-998 - GGCCAUGGGCGACAAGA 17 3868
HSV2-UL30-999 - G CCAAG AAAAAG U ACAU 17 3869
HSV2-UL30-1000 - UACAUCGGCGUCAUCUG 17 3870
HSV2-UL30-1001 - ACAUCGGCGUCAUCUGC 17 3871
HSV2-UL30-1002 - CAUCGGCGUCAUCUGCG 17 3872
HSV2-UL30-1003 - AUCGGCGUCAUCUGCGG 17 3873
HSV2-UL30-1004 - GGGCAAGAUGCUCAUCA 17 3874
HSV2-UL30-1005 - GGCAAGAUGCUCAUCAA 17 3875
HSV2-UL30-1006 - GAUGCUCAUCAAGGGCG 17 3876
HSV2-UL30-1007 - CAUCAAGGGCGUGGAUC 17 3877
HSV2-UL30-1008 - UUAUCAACCGCACCUCC 17 3878
HSV2-UL30-1009 - UAUCAACCGCACCUCCA 17 3879
HSV2-UL30-1010 - CCGCACCUCCAGGGCCC 17 3880
HSV2-UL30-1011 - UACGACGAUACCGUAUC 17 3881
HSV2-UL30-1012 - CGAUACCGUAUCCGGAG 17 3882
HSV2-UL30-1013 - AGCCGAGCGCCCCGCAG 17 3883
HSV2-UL30-1014 - AGCGCCCCGCAGAGGAG 17 3884
HSV2-UL30-1015 - CCCCGCAGAGGAGUGGC 17 3885
HSV2-UL30-1016 - GGCGCGACCCCUGCCCG 17 3886
HSV2-UL30-1017 - GCGCGACCCCUGCCCGA 17 3887
HSV2-UL30-1018 - CCUGCCCGAGGGACUGC 17 3888
HSV2-UL30-1019 - GAGGGACUGCAGGCGUU 17 3889
HSV2-UL30-1020 - AGGGACUGCAGGCGUUC 17 3890
HSV2-UL30-1021 - GGGACUGCAGGCGUUCG 17 3891
HSV2-UL30-1022 - UCCUCGUAGACGCCCAU 17 3892
HSV2-UL30-1023 - UCGGCGCAUCACCGACC 17 3893
HSV2-UL30-1024 - GCAUCACCGACCCGGAG 17 3894
HSV2-UL30-1025 - CAUCACCGACCCGGAGA 17 3895
HSV2-UL30-1026 - CCCGGAGAGGGACAUCC 17 3896
HSV2-UL30-1027 - GUACACCAACAAGCGCC 17 3897
HSV2-UL30-1028 - GCGCCUGGCCCACCUGA 17 3898
HSV2-UL30-1029 - GGUGUAUUACAAGCUCA 17 3899 HSV2-UL30-1030 - CAUGGCCCGCCGCGCGC 17 3900
HSV2-UL30-1031 - GCAGGUCCCGUCCAUCA 17 3901
HSV2-UL30-1032 - UCCCGUCCAUCAAGGAC 17 3902
HSV2-UL30-1033 - GAUCCCGUACGUGAUCG 17 3903
HSV2-UL30-1034 - CGUGGCCCAGACCCGCG 17 3904
HSV2-UL30-1035 - CCAG ACCCG CG AG G U AG 17 3905
HSV2-UL30-1036 - CCGCGAGGUAGAGGAGA 17 3906
HSV2-UL30-1037 - UAGAGGAGACGGUCGCG 17 3907
HSV2-UL30-1038 - GGAGACGGUCGCGCGGC 17 3908
HSV2-UL30-1039 - CUAGACGCCGCCGCCCC 17 3909
HSV2-UL30-1040 - UAGACGCCGCCGCCCCA 17 3910
HSV2-UL30-1041 - AGACGCCGCCGCCCCAG 17 3911
HSV2-UL30-1042 - CGAGCCCGCCCCCCCAG 17 3912
HSV2-UL30-1043 - AGCGGCCCUGCCCUCCC 17 3913
HSV2-UL30-1044 - CCCCGGCCAAGCGCCCC 17 3914
HSV2-UL30-1045 - CCCGGCCAAGCGCCCCC 17 3915
HSV2-UL30-1046 - GUCGCAUGCCGACCCCC 17 3916
HSV2-UL30-1047 - UCGCAUGCCGACCCCCC 17 3917
HSV2-UL30-1048 - CAUGCCGACCCCCCGGG 17 3918
HSV2-UL30-1049 - CAAGCCCCGCAAGCUGC 17 3919
HSV2-UL30-1050 - GCUGCUGGUGUCCGAGC 17 3920
HSV2-UL30-1051 - GCUGGUGUCCGAGCUGG 17 3921
HSV2-UL30-1052 - GGUGUCCGAGCUGGCGG 17 3922
HSV2-UL30-1053 - GAGCUGGCGGAGGAUCC 17 3923
HSV2-UL30-1054 - AGCUGGCGGAGGAUCCC 17 3924
HSV2-UL30-1055 - CCGGGUACGCCAUCGCC 17 3925
HSV2-UL30-1056 - CGGGUACGCCAUCGCCC 17 3926
HSV2-UL30-1057 - GGGUACGCCAUCGCCCG 17 3927
HSV2-UL30-1058 - GGGCGUUCCGCUCAACA 17 3928
HSV2-UL30-1059 - UUACUUCUCGCACCUGC 17 3929
HSV2-UL30-1060 - UACUUCUCGCACCUGCU 17 3930
HSV2-UL30-1061 - ACUUCUCGCACCUGCUG 17 3931
HSV2-UL30-1062 - CUUCUCGCACCUGCUGG 17 3932
HSV2-UL30-1063 - CUCGCACCUGCUGGGGG 17 3933
HSV2-UL30-1064 - GGCCUGCGUGACGUUCA 17 3934
HSV2-UL30-1065 - ACGUU CAAG GCCCUGUU 17 3935
HSV2-UL30-1066 - CCGAGAGUCUGUUAAAG 17 3936
HSV2-UL30-1067 - GGUUUAUUCCCGAGACG 17 3937
HSV2-UL30-1068 - CGAGACGUGGCACCCCC 17 3938
HSV2-UL30-1069 - GCACCCCCCGGACGACG 17 3939
HSV2-UL30-1070 - CGGACGACGUGGCCGCG 17 3940
HSV2-UL30-1071 - ACGUGGCCGCGCGGCUC 17 3941
HSV2-UL30-1072 - CGUGGCCGCGCGGCUCA 17 3942
HSV2-UL30-1073 - CGCGCGGCUCAGGGCCG 17 3943
HSV2-UL30-1074 - GCGCGGCUCAGGGCCGC 17 3944
HSV2-UL30-1075 - CGCGGCUCAGGGCCGCG 17 3945 HSV2-UL30-1076 - CUCAGGGCCGCGGGGUU 17 3946
HSV2-UL30-1077 - UCAGGGCCGCGGGGUUC 17 3947
HSV2-UL30-1078 - GGCCGCGGGGUUCGGGC 17 3948
HSV2-UL30-1079 - CGCGGGGUUCGGGCCGG 17 3949
HSV2-UL30-1080 - GCGGGGUUCGGGCCGGC 17 3950
HSV2-UL30-1081 - CGGGGUUCGGGCCGGCG 17 3951
HSV2-UL30-1082 - GGGGUUCGGGCCGGCGG 17 3952
HSV2-UL30-1083 - UUCGGGCCGGCGGGGGC 17 3953
HSV2-UL30-1084 - GGCGGGGGCCGGCGCUA 17 3954
HSV2-UL30-1085 - GGGGGCCGGCGCUACGG 17 3955
HSV2-UL30-1086 - GGCCGGCGCUACGGCGG 17 3956
HSV2-UL30-1087 + AGUUUCCUCCGCCGUAGCGC 20 3957
HSV2-UL30-1088 + GCCGUAGCGCCGGCCCCCGC 20 3958
HSV2-UL30-1089 + CCCCGCCGGCCCGAACCCCG 20 3959
HSV2-UL30-1090 + CCCCGCGGCCCUGAGCCGCG 20 3960
HSV2-UL30-1091 + AGCCGCGCGGCCACGUCGUC 20 3961
HSV2-UL30-1092 + GCCGCGCGGCCACGUCGUCC 20 3962
HSV2-UL30-1093 + CCGCGCGGCCACGUCGUCCG 20 3963
HSV2-UL30-1094 + CGCGCGGCCACGUCGUCCGG 20 3964
HSV2-UL30-1095 + GCGCGGCCACGUCGUCCGGG 20 3965
HSV2-UL30-1096 + GUCCGGGGGGUGCCACGUCU 20 3966
HSV2-UL30-1097 + UCCGGGGGGUGCCACGUCUC 20 3967
HSV2-UL30-1098 + AAACCUCU U UAACAG ACUCU 20 3968
HSV2-UL30-1099 + UAACAGACUCUCGGUGAUCU 20 3969
HSV2-UL30-1100 + UCUUGGCGUUAUUUCCAAAC 20 3970
HSV2-UL30-1101 + CUUGGCGUUAUUUCCAAACA 20 3971
HSV2-UL30-1102 + CAGGGCCUUGAACGUCACGC 20 3972
HSV2-UL30-1103 + UCACGCAGGCCGCCCCCAGC 20 3973
HSV2-UL30-1104 + AAGUAAUAGUCCGUGUUGAG 20 3974
HSV2-UL30-1105 + CCGUGUUGAGCGGAACGCCC 20 3975
HSV2-UL30-1106 + CGUGUUGAGCGGAACGCCCC 20 3976
HSV2-UL30-1107 + GAGCGGAACGCCCCGGGCGA 20 3977
HSV2-UL30-1108 + GCCCCGGGCGAUGGCGUACC 20 3978
HSV2-UL30-1109 + CCCCGGGCGAUGGCGUACCC 20 3979
HSV2-UL30-1110 + CCCGGGAUCCUCCGCCAGCU 20 3980
HSV2-UL30-1111 + GCUCGGACACCAGCAGCUUG 20 3981
HSV2-UL30-1112 + CUCGGACACCAGCAGCUUGC 20 3982
HSV2-UL30-1113 + UCGGACACCAGCAGCUUGCG 20 3983
HSV2-UL30-1114 + CACCAGCAGCUUGCGGGGCU 20 3984
HSV2-UL30-1115 + CGGGGCUUGGACGCGCCUCC 20 3985
HSV2-UL30-1116 + GGGGCUUGGACGCGCCUCCC 20 3986
HSV2-UL30-1117 + GGGCUUGGACGCGCCUCCCG 20 3987
HSV2-UL30-1118 + GGCUUGGACGCGCCUCCCGG 20 3988
HSV2-UL30-1119 + GCUUGGACGCGCCUCCCGGG 20 3989
HSV2-UL30-1120 + GGACGCGCCUCCCGGGGGGU 20 3990
HSV2-UL30-1121 + CCCGGGGGGUCGGCAUGCGA 20 3991 HSV2-UL30-1122 + CGGCAUGCGACGGCGUCUCC 20 3992
HSV2-UL30-1123 + GGCAUGCGACGGCGUCUCCC 20 3993
HSV2-UL30-1124 + GCAUGCGACGGCGUCUCCCG 20 3994
HSV2-UL30-1125 + CAUGCGACGGCGUCUCCCGG 20 3995
HSV2-UL30-1126 + CGGCGUCUCCCGGGGGCGCU 20 3996
HSV2-UL30-1127 + GUCUCCCGGGGGCGCUUGGC 20 3997
HSV2-UL30-1128 + UCUCCCGGGGGCGCUUGGCC 20 3998
HSV2-UL30-1129 + CUCCCGGGGGCGCU UGGCCG 20 3999
HSV2-UL30-1130 + CCGGGGGCGCUUGGCCGGGG 20 4000
HSV2-UL30-1131 + CGGGGGCGCUUGGCCGGGGA 20 4001
HSV2-UL30-1132 + GGCGCU UGGCCGGGGAGGGC 20 4002
HSV2-UL30-1133 + GCGCUUGGCCGGGGAGGGCA 20 4003
HSV2-UL30-1134 + GCCGGGGAGGGCAGGGCCGC 20 4004
HSV2-UL30-1135 + CCGGGGAGGGCAGGGCCGCU 20 4005
HSV2-UL30-1136 + CGGGGAGGGCAGGGCCGCUG 20 4006
HSV2-UL30-1137 + GGGGAGGGCAGGGCCGCUGG 20 4007
HSV2-UL30-1138 + GGGAGGGCAGGGCCGCUGGG 20 4008
HSV2-UL30-1139 + GGAGGGCAGGGCCGCUGGGG 20 4009
HSV2-UL30-1140 + GGGCAGGGCCGCUGGGGGGG 20 4010
HSV2-UL30-1141 + GGCAGGGCCGCUGGGGGGGC 20 4011
HSV2-UL30-1142 + GGGGGGGCGGGCUCGUCCCC 20 4012
HSV2-UL30-1143 + GGGGGGCGGGCUCGUCCCCU 20 4013
HSV2-UL30-1144 + GGGGGCGGGCUCGUCCCCUG 20 4014
HSV2-UL30-1145 + GGCGGGCUCGUCCCCUGGGG 20 4015
HSV2-UL30-1146 + GGGCUCGUCCCCUGGGGCGG 20 4016
HSV2-UL30-1147 + GGGCGGCGGCGUCUAGCUCG 20 4017
HSV2-UL30-1148 + CGGCGGCGUCUAGCUCGCGG 20 4018
HSV2-UL30-1149 + GGCGGCGUCUAGCUCGCGGA 20 4019
HSV2-UL30-1150 + GGCGUCUAGCUCGCGGAGGG 20 4020
HSV2-UL30-1151 + CGACCGUCUCCUCUACCUCG 20 4021
HSV2-UL30-1152 + GACCGUCUCCUCUACCUCGC 20 4022
HSV2-UL30-1153 + UCUCCUCUACCUCGCGGGUC 20 4023
HSV2-UL30-1154 + CUCCUCUACCUCGCGGGUCU 20 4024
HSV2-UL30-1155 + GUCUGGGCCACGAUCACGUA 20 4025
HSV2-UL30-1156 + UCUGGGCCACGAUCACGUAC 20 4026
HSV2-UL30-1157 + CCACGAUCACGUACGGGAUC 20 4027
HSV2-UL30-1158 + GUACGGGAUCCGGUCCUUGA 20 4028
HSV2-UL30-1159 + GGGAUCCGGUCCUUGAUGGA 20 4029
HSV2-UL30-1160 + GGAUCCGGUCCUUGAUGGAC 20 4030
HSV2-UL30-1161 + UGAUGGACGGGACCUGCGCG 20 4031
HSV2-UL30-1162 + UGGACGGGACCUGCGCGCGG 20 4032
HSV2-UL30-1163 + GGACGGGACCUGCGCGCGGC 20 4033
HSV2-UL30-1164 + UGAGCUUGUAAUACACCGUC 20 4034
HSV2-UL30-1165 + GCU UGUAAUACACCGUCAGG 20 4035
HSV2-UL30-1166 + CUUGUAAUACACCGUCAGGU 20 4036
HSV2-UL30-1167 + AAUACACCGUCAGGUGGGCC 20 4037 HSV2-UL30-1168 + CAGGUGGGCCAGGCGCUUGU 20 4038
HSV2-UL30-1169 + CGCUUGUUGGUGUACGCGCG 20 4039
HSV2-UL30-1170 + GCUUGUUGGUGUACGCGCGC 20 4040
HSV2-UL30-1171 + GCGCGGGUGUCUGCUCAGUU 20 4041
HSV2-UL30-1172 + CGGGUGUCUGCUCAGUUCGG 20 4042
HSV2-UL30-1173 + GUCUGCUCAGUUCGGCGGUG 20 4043
HSV2-UL30-1174 + CGGCGGUGAGGACAAAGUCC 20 4044
HSV2-UL30-1175 + AAGUCCUGGAUGUCCCUCUC 20 4045
HSV2-UL30-1176 + AGUCCUGGAUGUCCCUCUCC 20 4046
HSV2-UL30-1177 + CUGGAUGUCCCUCUCCGGGU 20 4047
HSV2-UL30-1178 + CCGGGUCGGUGAUGCGCCGA 20 4048
HSV2-UL30-1179 + CGGGUCGGUGAUGCGCCGAU 20 4049
HSV2-UL30-1180 + UGCGCCGAUGGGCGUCUACG 20 4050
HSV2-UL30-1181 + CCGAUGGGCGUCUACGAGGA 20 4051
HSV2-UL30-1182 + CCCG AACGCCU G CAG U CCCU 20 4052
HSV2-UL30-1183 + CCGAACGCCUGCAGUCCCUC 20 4053
HSV2-UL30-1184 + ACGCCUGCAGUCCCUCGGGC 20 4054
HSV2-UL30-1185 + CGCCUGCAGUCCCUCGGGCA 20 4055
HSV2-UL30-1186 + GCCUGCAGUCCCUCGGGCAG 20 4056
HSV2-UL30-1187 + UCGCGCCAGCCACUCCUCUG 20 4057
HSV2-UL30-1188 + CGCGCCAGCCACUCCUCUGC 20 4058
HSV2-UL30-1189 + GCG CCAG CCACU CCU CU G CG 20 4059
HSV2-UL30-1190 + CCACUCCUCUGCGGGGCGCU 20 4060
HSV2-UL30-1191 + UGCGGGGCGCUCGGCUAACG 20 4061
HSV2-UL30-1192 + GGGGCGCUCGGCUAACGCGG 20 4062
HSV2-UL30-1193 + GGCUAACGCGGCGGCCGCUC 20 4063
HSV2-UL30-1194 + CGCGGCGGCCGCUCCGGAUA 20 4064
HSV2-UL30-1195 + CG G U AU CG U CG U AAAACAG C 20 4065
HSV2-UL30-1196 + CGUAAAACAGCAGGUCGACC 20 4066
HSV2-UL30-1197 + G U AAAACAGCAG G U CG ACCA 20 4067
HSV2-UL30-1198 + CAGCAGGUCGACCAGGGCCC 20 4068
HSV2-UL30-1199 + CAGGUCGACCAGGGCCCUGG 20 4069
HSV2-UL30-1200 + CGACCAGGGCCCUGGAGGUG 20 4070
HSV2-UL30-1201 + GACGCCGAUGUACUUUUUCU 20 4071
HSV2-UL30-1202 + CUUGGCGAUGAGCAGCAGCU 20 4072
HSV2-UL30-1203 + UUUUCGCACUCGAGCUUGAU 20 4073
HSV2-UL30-1204 + UUUCGCACUCGAGCUUGAUC 20 4074
HSV2-UL30-1205 + UUCGCACUCGAGCUUGAUCG 20 4075
HSV2-UL30-1206 + UCGCACUCGAGCUUGAUCGG 20 4076
HSV2-UL30-1207 + CGCACUCGAGCUUGAUCGGG 20 4077
HSV2-UL30-1208 + ACUCGAGCUUGAUCGGGGGG 20 4078
HSV2-UL30-1209 + GGAACAGCGCGCGCGAGAUG 20 4079
HSV2-UL30-1210 + GCUCGCCAUCUUGUCGCCCA 20 4080
HSV2-UL30-1211 + UCUUGUCGCCCAUGGCCACC 20 4081
HSV2-UL30-1212 + GCCCAUGGCCACCAGGCCCG 20 4082
HSV2-UL30-1213 + CCACCAGGCCCGCGGCCGUG 20 4083 HSV2-UL30-1214 + GGCCCGCGGCCGUGAGGCCG 20 4084
HSV2-UL30-1215 + G CCG CG G CACAAAACG AAAA 20 4085
HSV2-UL30-1216 + GUCCCCGUAGAUGAUGCGCA 20 4086
HSV2-UL30-1217 + UAGAUGAUGCGCAUGGAGUA 20 4087
HSV2-UL30-1218 + GAUGCGCAUGGAGUACGGAC 20 4088
HSV2-UL30-1219 + AUGCGCAUGGAGUACGGACC 20 4089
HSV2-UL30-1220 + UGCGCAUGGAGUACGGACCG 20 4090
HSV2-UL30-1221 + GCGCAUGGAGUACGGACCGG 20 4091
HSV2-UL30-1222 + CGGACCGGGGGCGCGCAUGC 20 4092
HSV2-UL30-1223 + GCGCGCAUGCCGGCCGCCUC 20 4093
HSV2-UL30-1224 + GCCGGCCGCCUCCGGAAAGU 20 4094
HSV2-UL30-1225 + GCACGUACGCGCGCGUCGCG 20 4095
HSV2-UL30-1226 + GCGUCGCGAGGAGCAUCUCG 20 4096
HSV2-UL30-1227 + GAGGAGCAUCUCGCGGCCGA 20 4097
HSV2-UL30-1228 + CUCGCGGCCGAUGGUCGUCA 20 4098
HSV2-UL30-1229 + GCGGCCGAUGGUCGUCACGG 20 4099
HSV2-UL30-1230 + GCCGAUGGUCGUCACGGUGG 20 4100
HSV2-UL30-1231 + UCACGGUGGCGGCCACGUGC 20 4101
HSV2-UL30-1232 + GGUGGCGGCCACGUGCAGGC 20 4102
HSV2-UL30-1233 + GUGGCGGCCACGUGCAGGCA 20 4103
HSV2-UL30-1234 + CAGAAGACCGUGCUGCACCC 20 4104
HSV2-UL30-1235 + CGAGUUGCACACCACCUUGA 20 4105
HSV2-UL30-1236 + G U U G CACACCACCU U G AU GG 20 4106
HSV2-UL30-1237 + UGGCGGCCUGUUGCUUGUCG 20 4107
HSV2-UL30-1238 + CGGCCUGUUGCUUGUCGAGG 20 4108
HSV2-UL30-1239 + CUGUUGCUUGUCGAGGAGGA 20 4109
HSV2-UL30-1240 + GUCGAGGAGGACGGCCUCCU 20 4110
HSV2-UL30-1241 + UCGAGGAGGACGGCCUCCUC 20 4111
HSV2-UL30-1242 + CGAGGAGGACGGCCUCCUCG 20 4112
HSV2-UL30-1243 + GAGGAGGACGGCCUCCUCGG 20 4113
HSV2-UL30-1244 + CGGCCUCCUCGGGGGUGCUC 20 4114
HSV2-UL30-1245 + GGCCUCCUCGGGGGUGCUCU 20 4115
HSV2-UL30-1246 + GCCUCCUCGGGGGUGCUCUG 20 4116
HSV2-UL30-1247 + CCUCCUCGGGGGUGCUCUGG 20 4117
HSV2-UL30-1248 + UGCUCUGGGGGAUCCGCGAG 20 4118
HSV2-UL30-1249 + CGAGCGGAUCUGCUUUCGCA 20 4119
HSV2-UL30-1250 + UGGCCAGCCAGUCGCGCAGC 20 4120
HSV2-UL30-1251 + CGCGCAGCAGGAUGCUCAGC 20 4121
HSV2-UL30-1252 + UCAGCAGGCUCUCGCGUACG 20 4122
HSV2-UL30-1253 + CAGCAGGCUCUCGCGUACGU 20 4123
HSV2-UL30-1254 + CCU U CACG AAG AACAG CCG U 20 4124
HSV2-UL30-1255 + GGCCCCCCACCUCGAUCUCC 20 4125
HSV2-UL30-1256 + CCUCGAUCUCCAGGUAGUCC 20 4126
HSV2-UL30-1257 + GGUAGUCCCGGUCCGCCUCC 20 4127
HSV2-UL30-1258 + GUCCGCCUCCAGGUGCGCGA 20 4128
HSV2-UL30-1259 + CUCCAGGUGCGCGACGGCCU 20 4129 HSV2-UL30-1260 + UCCAGGUGCGCGACGGCCUC 20 4130
HSV2-UL30-1261 + GCGCGACGGCCUCGGGCCGC 20 4131
HSV2-UL30-1262 + CGCGACGGCCUCGGGCCGCA 20 4132
HSV2-UL30-1263 + GGGAGAGCGUACUGAAGCAC 20 4133
HSV2-UL30-1264 + GCGUACUGAAGCACAGGUUG 20 4134
HSV2-UL30-1265 + CGUACUGAAGCACAGGUUGU 20 4135
HSV2-UL30-1266 + UGAAGCACAGGUUGUGGGCC 20 4136
HSV2-UL30-1267 + GUUGUGGGCCUGGAUGAUGC 20 4137
HSV2-UL30-1268 + UUGUGGGCCUGGAUGAUGCU 20 4138
HSV2-UL30-1269 + UGUGGGCCUGGAUGAUGCUG 20 4139
HSV2-UL30-1270 + CCUGGAUGAUGCUGGGGUAC 20 4140
HSV2-UL30-1271 + GAUGAUGCUGGGGUACAGGC 20 4141
HSV2-UL30-1272 + G G C AAAG U C AAAC ACCACCA 20 4142
HSV2-UL30-1273 + G CAAAG U CAAAC ACCACCAC 20 4143
HSV2-UL30-1274 + CAAAG U CAAACACCACCACG 20 4144
HSV2-UL30-1275 + CACGGGGUCGACGUG AAACC 20 4145
HSV2-UL30-1276 + GGGGUCGACGUGAAACCCGG 20 4146
HSV2-UL30-1277 + G U CGACG U G AAACCCG G AGG 20 4147
HSV2-UL30-1278 + UCGACGUGAAACCCGGAGGU 20 4148
HSV2-UL30-1279 + CGACG UGAAACCCGGAGGUG 20 4149
HSV2-UL30-1280 + GAAACCCGGAGGUGGGGUCG 20 4150
HSV2-UL30-1281 + CGGAGGUGGGGUCGAGGACC 20 4151
HSV2-UL30-1282 + GGAGGUGGGGUCGAGGACCC 20 4152
HSV2-UL30-1283 + GGUCGAGGACCCGGGCCCCC 20 4153
HSV2-UL30-1284 + CCCCCUGGUACCCAACGUGC 20 4154
HSV2-UL30-1285 + GUACCCAACGUGCCGGCCCC 20 4155
HSV2-UL30-1286 + UCGUCCCCGUUCCCGUCCCC 20 4156
HSV2-UL30-1287 + G GCCG CU CCCCU U CCCCCCG 20 4157
HSV2-UL30-1288 + CUCCCCUUCCCCCCGAGGCA 20 4158
HSV2-UL30-1289 + CCUUCCCCCCGAGGCACGGC 20 4159
HSV2-UL30-1290 + CUUCCCCCCGAGGCACGGCC 20 4160
HSV2-UL30-1291 + CCGAGGCACGGCCGGGCGCU 20 4161
HSV2-UL30-1292 + CGAGGCACGGCCGGGCGCUU 20 4162
HSV2-UL30-1293 + GCU UGGGCGCCUCCUUGUCG 20 4163
HSV2-UL30-1294 + CGAGGCCCCGAAACCGCCCC 20 4164
HSV2-UL30-1295 + GAGGCCCCGAAACCGCCCCU 20 4165
HSV2-UL30-1296 + CGAAACCGCCCCUGGGUGUC 20 4166
HSV2-UL30-1297 + ACCGCCCCUGGGUGUCCGGC 20 4167
HSV2-UL30-1298 + CCGGCAGGAUGAAGCCCUUC 20 4168
HSV2-UL30-1299 + UGAAGCCCUUCUGGCCCGCA 20 4169
HSV2-UL30-1300 + CCUUCUGGCCCGCAAGGCGC 20 4170
HSV2-UL30-1301 + UCUGGCCCGCAAGGCGCAGG 20 4171
HSV2-UL30-1302 + GCAGGAGGCACGUGAAGACG 20 4172
HSV2-UL30-1303 + ACGUGAAGACGCGGAUCUGC 20 4173
HSV2-UL30-1304 + GAUCUGCUGGCCGUCGUAGA 20 4174
HSV2-UL30-1305 + GCUGGCCGUCGUAGAUGGUG 20 4175 HSV2-UL30-1306 + CUGGCCGUCGUAGAUGGUGC 20 4176
HSV2-UL30-1307 + GGGUGAUGUUGAUGCCCGCC 20 4177
HSV2-UL30-1308 + GAUGCCCGCCAGGCGCGCGA 20 4178
HSV2-UL30-1309 + GCCCGCCAGGCGCGCGACGG 20 4179
HSV2-UL30-1310 + GCGCGACGGCGGAAAGCUCC 20 4180
HSV2-UL30-1311 + ACGGCGGAAAGCUCCAGGUG 20 4181
HSV2-UL30-1312 + GCCGAUCACCCCGCGCUGCG 20 4182
HSV2-UL30-1313 + CCGAUCACCCCGCGCUGCGC 20 4183
HSV2-UL30-1314 + CACCCCGCGCUGCGCGGGCC 20 4184
HSV2-UL30-1315 + CCCGCGCUGCGCGGGCCCGG 20 4185
HSV2-UL30-1316 + CGCGGGCCCGGAGGCGUAGU 20 4186
HSV2-UL30-1317 + GGGCCCGGAGGCGUAGUAGG 20 4187
HSV2-UL30-1318 + GGCCCGGAGGCGUAGUAGGC 20 4188
HSV2-UL30-1319 + GCCCGGAGGCGUAGUAGGCG 20 4189
HSV2-UL30-1320 + CGUAGUAGGCGGGGAUGUCG 20 4190
HSV2-UL30-1321 + CUUCUUCUUGUCCUUCAAGA 20 4191
HSV2-UL30-1322 + CU UGUCCUUCAAGACGGCCU 20 4192
HSV2-UL30-1323 + CU UCAAGACGGCCUCGGCGA 20 4193
HSV2-UL30-1324 + GACGGCGUUCAGCUUGUAGC 20 4194
HSV2-UL30-1325 + GCUGGAGAGUUUGACCUUGU 20 4195
HSV2-UL30-1326 + UCUUGCUGCGCUUCUGAAAG 20 4196
HSV2-UL30-1327 + UGCGCUUCUGAAAGUGGCUC 20 4197
HSV2-UL30-1328 + UCUGGCCGAUGUCCCACACG 20 4198
HSV2-UL30-1329 + CCCACACGCGGAACACACCC 20 4199
HSV2-UL30-1330 + AUGCGCCCGUACCCGUCGAG 20 4200
HSV2-UL30-1331 + UGCGCCCGUACCCGUCGAGC 20 4201
HSV2-UL30-1332 + CUUGUAGAUCUCCGUCAGCU 20 4202
HSV2-UL30-1333 + AGAUCUCCGUCAGCUUGGUC 20 4203
HSV2-UL30-1334 + CGUCAGCUUGGUCAGGACGA 20 4204
HSV2-UL30-1335 + GUCAGCUUGGUCAGGACGAA 20 4205
HSV2-UL30-1336 + GAAGUUGAUGAUGUUGUACC 20 4206
HSV2-UL30-1337 + GUUGUACCCGGUCACGAACU 20 4207
HSV2-UL30-1338 + UUGUACCCGGUCACGAACUC 20 4208
HSV2-UL30-1339 + UGUACCCGGUCACGAACUCG 20 4209
HSV2-UL30-1340 + GGGGCCGUACUGCUUGACGA 20 4210
HSV2-UL30-1341 + CUGCUUGACGAAGGUCAUGA 20 4211
HSV2-UL30-1342 + CGAAUUCGCUGUCAAACUCC 20 4212
HSV2-UL30-1343 + GCUGUCAAACUCCAGGACGA 20 4213
HSV2-UL30-1344 + CUGUCAAACUCCAGGACGAC 20 4214
HSV2-UL30-1345 + UGUCAAACUCCAGGACGACG 20 4215
HSV2-UL30-1346 + GUCAAACUCCAGGACGACGG 20 4216
HSV2-UL30-1347 + AACUCCAGGACGACGGGGGC 20 4217
HSV2-UL30-1348 + CCAGGACGACGGGGGCCGGC 20 4218
HSV2-UL30-1349 + GACGGGGGCCGGCAGGCCCC 20 4219
HSV2-UL30-1350 + GGGGGCCGGCAGGCCCCUGG 20 4220
HSV2-UL30-1351 + CCCUGGAGGCGAGAUCGCUG 20 4221 HSV2-UL30-1352 + UGGAGGCGAGAUCGCUGAGG 20 4222
HSV2-UL30-1353 + GGAGGCGAGAUCGCUGAGGU 20 4223
HSV2-UL30-1354 + GAGAUCGCUGAGGUGGGACU 20 4224
HSV2-UL30-1355 + AGAUCGCUGAGGUGGGACUC 20 4225
HSV2-UL30-1356 + GAUCGCUGAGGUGGGACUCG 20 4226
HSV2-UL30-1357 + CGCUGAGGUGGGACUCGGGG 20 4227
HSV2-UL30-1358 + GUGGGACUCGGGGAGGUCGC 20 4228
HSV2-UL30-1359 + CGCAGGAUCCGAGCGAAAAC 20 4229
HSV2-UL30-1360 + AGGAUCCGAGCGAAAACAGG 20 4230
HSV2-UL30-1361 + AAAACAGGAGGAUGUGCUCG 20 4231
HSV2-UL30-1362 + AAACAGGAGGAUGUGCUCGA 20 4232
HSV2-UL30-1363 + CAGGAGGAUGUGCUCGAGGG 20 4233
HSV2-UL30-1364 + GAGGAUGUGCUCGAGGGCGG 20 4234
HSV2-UL30-1365 + GAUGUGCUCGAGGGCGGUGG 20 4235
HSV2-UL30-1366 + GCUCGAGGGCGGUGGUGGAC 20 4236
HSV2-UL30-1367 + GGACAGGUCGUAGAGCAGAC 20 4237
HSV2-UL30-1368 + CGUAGAGCAGACAGGAGAUC 20 4238
HSV2-UL30-1369 + GACAGGAGAUCUGGAUGACG 20 4239
HSV2-UL30-1370 + AUCUGGAUGACGAGGUCUUC 20 4240
HSV2-UL30-1371 + UCUGGAUGACGAGGUCUUCC 20 4241
HSV2-UL30-1372 + UCUUCCGGGCGUUCCGCGAC 20 4242
HSV2-UL30-1373 + CGGGCGUUCCGCGACCGGAA 20 4243
HSV2-UL30-1374 + GGCCAGCUCGUCCUCCCCCC 20 4244
HSV2-UL30-1375 + AUCGAAGCACAUGAGCUUGU 20 4245
HSV2-UL30-1376 + AAGCACAUGAGCUUGUAGGC 20 4246
HSV2-UL30-1377 + ACAUGAGCUUGUAGGCCGGC 20 4247
HSV2-UL30-1378 + GUAGGCCGGCAGGU CACACA 20 4248
HSV2-UL30-1379 + G U CACACAU GG CCCCCU CG A 20 4249
HSV2-UL30-1380 + ACAUGGCCCCCUCGACGGCC 20 4250
HSV2-UL30-1381 + GUUAAACUCGACGUCGCUCG 20 4251
HSV2-UL30-1382 + CUCGAGGUUCCGAACGCCGU 20 4252
HSV2-UL30-1383 + UCGAGGUUCCGAACGCCGUC 20 4253
HSV2-UL30-1384 + CGAGGUUCCGAACGCCGUCG 20 4254
HSV2-UL30-1385 + GAGGUUCCGAACGCCGUCGG 20 4255
HSV2-UL30-1386 + AGGUUCCGAACGCCGUCGGG 20 4256
HSV2-UL30-1387 + CCGAACGCCGUCGGGGGGCG 20 4257
HSV2-UL30-1388 + ACGCCGUCGGGGGGCGCGGU 20 4258
HSV2-UL30-1389 + CGCCGUCGGGGGGCGCGGUU 20 4259
HSV2-UL30-1390 + GUCGGGGGGCGCGGUUGGGC 20 4260
HSV2-UL30-1391 + GUUGGGCCGGCGCGUUCCCG 20 4261
HSV2-UL30-1392 + GGCCGGCGCGUUCCCGCGGC 20 4262
HSV2-UL30-1393 + GCCGGCGCGUUCCCGCGGCC 20 4263
HSV2-UL30-1394 + CGU UCCCGCGGCCGGGCUUG 20 4264
HSV2-UL30-1395 + UCCCGCGGCCGGGCUUGAGG 20 4265
HSV2-UL30-1396 + CU UGAGGCGGUACCAGCCGA 20 4266
HSV2-UL30-1397 + CAGCCGAAGGUGACAAACCC 20 4267 HSV2-UL30-1398 + AG CCG AAGG U G ACAAACCCC 20 4268
HSV2-UL30-1399 + U G ACAAACCCCG GGUUGUCC 20 4269
HSV2-UL30-1400 + CCGGGUUGUCCAGGAUAAAC 20 4270
HSV2-UL30-1401 + CGGGUUGUCCAGGAUAAACC 20 4271
HSV2-UL30-1402 + GUUGUCCAGGAUAAACCGGG 20 4272
HSV2-UL30-1403 + GUCCAGGAUAAACCGGGUGG 20 4273
HSV2-UL30-1404 + CCCCUCGUACUUCCUGAUCG 20 4274
HSV2-UL30-1405 + CCCUCGUACUUCCUGAUCGC 20 4275
HSV2-UL30-1406 + CCUCGUACUUCCUGAUCGCG 20 4276
HSV2-UL30-1407 + CG G G G CAAAAG UUGUCGCAC 20 4277
HSV2-UL30-1408 + GCAAAAGUUGUCGCACAGGU 20 4278
HSV2-UL30-1409 + GCCCGCUUCGCACGAAGACG 20 4279
HSV2-UL30-1410 + GCACGAAGACGCGGUAGUAC 20 4280
HSV2-UL30-1411 + CACGAAGACGCGGUAGUACA 20 4281
HSV2-UL30-1412 + AAGACGCGGUAGUACAGGGU 20 4282
HSV2-UL30-1413 + AGACGCGGUAGUACAGGGUC 20 4283
HSV2-UL30-1414 + CGU UUCGUAAUAGUACACGU 20 4284
HSV2-UL30-1415 + CCACCACCUCCGCCUCGAAG 20 4285
HSV2-UL30-1416 + CUCCGCCUCGAAGUGGUCCG 20 4286
HSV2-UL30-1417 + AGUGGUCCGCGGAGAUGCCG 20 4287
HSV2-UL30-1418 + AUGCCGCGGAACGACGCCCC 20 4288
HSV2-UL30-1419 + ACGCCCCCGGCGACUCGCGC 20 4289
HSV2-UL30-1420 + CGCCCCCGGCGACUCGCGCA 20 4290
HSV2-UL30-1421 + ACUCGCGCAGGGCCGCCGCC 20 4291
HSV2-UL30-1422 + AGGCGCUCGCAGAGAUCGCG 20 4292
HSV2-UL30-1423 + GGCGCUCGCAGAGAUCGCGC 20 4293
HSV2-UL30-1424 + GCGCUCGCAGAGAUCGCGCG 20 4294
HSV2-UL30-1425 + CGCAGAGAUCGCGCGGGGCA 20 4295
HSV2-UL30-1426 + CGCGCGGGGCACGGCACUGC 20 4296
HSV2-UL30-1427 + CCGCGUGCCGUAGACGUGAA 20 4297
HSV2-UL30-1428 + AGACGUGAACGGCGACGCGA 20 4298
HSV2-UL30-1429 + AACGGCGACGCGAUGGCCUU 20 4299
HSV2-UL30-1430 + ACGGCGACGCGAUGGCCUUC 20 4300
HSV2-UL30-1431 + CGGCGACGCGAUGGCCUUCG 20 4301
HSV2-UL30-1432 + GGCGACGCGAUGGCCUUCGG 20 4302
HSV2-UL30-1433 + CAGACCCAGAAGCGUGAUGA 20 4303
HSV2-UL30-1434 + CAGAAGCGUGAUGACGGUCC 20 4304
HSV2-UL30-1435 + AAGCGUGAUGACGGUCCCGG 20 4305
HSV2-UL30-1436 + AGCGUGAUGACGGUCCCGGC 20 4306
HSV2-UL30-1437 + GACGGUCCCGGCGGGCGUGA 20 4307
HSV2-UL30-1438 + UGGCGUCCAUAAAUCGCUCG 20 4308
HSV2-UL30-1439 + UUCCUCCGCCGUAGCGC 17 4309
HSV2-UL30-1440 + GUAGCGCCGGCCCCCGC 17 4310
HSV2-UL30-1441 + CGCCGGCCCGAACCCCG 17 4311
HSV2-UL30-1442 + CGCGGCCCUGAGCCGCG 17 4312
HSV2-UL30-1443 + CGCGCGGCCACGUCGUC 17 4313 HSV2-UL30-1444 + GCGCGGCCACGUCGUCC 17 4314
HSV2-UL30-1445 + CGCGGCCACGUCGUCCG 17 4315
HSV2-UL30-1446 + GCGGCCACGUCGUCCGG 17 4316
HSV2-UL30-1447 + CGGCCACGUCGUCCGGG 17 4317
HSV2-UL30-1448 + CGGGGGGUGCCACGUCU 17 4318
HSV2-UL30-1449 + GGGGGGUGCCACGUCUC 17 4319
HSV2-UL30-1450 + CCUCU UUAACAGACUCU 17 4320
HSV2-UL30-1451 + CAGACUCUCGGUGAUCU 17 4321
HSV2-UL30-1452 + UGGCGUUAUUUCCAAAC 17 4322
HSV2-UL30-1453 + GGCGUUAUUUCCAAACA 17 4323
HSV2-UL30-1454 + GGCCUUGAACGUCACGC 17 4324
HSV2-UL30-1455 + CGCAGGCCGCCCCCAGC 17 4325
HSV2-UL30-1456 + UAAUAGUCCGUGUUGAG 17 4326
HSV2-UL30-1457 + UGUUGAGCGGAACGCCC 17 4327
HSV2-UL30-1458 + GUUGAGCGGAACGCCCC 17 4328
HSV2-UL30-1459 + CGGAACGCCCCGGGCGA 17 4329
HSV2-UL30-1460 + CCGGGCGAUGGCGUACC 17 4330
HSV2-UL30-1461 + CGGGCGAUGGCGUACCC 17 4331
HSV2-UL30-1462 + GGGAUCCUCCGCCAGCU 17 4332
HSV2-UL30-1463 + CGGACACCAGCAGCUUG 17 4333
HSV2-UL30-1464 + GGACACCAGCAGCUUGC 17 4334
HSV2-UL30-1465 + GACACCAGCAGCUUGCG 17 4335
HSV2-UL30-1466 + CAGCAGCUUGCGGGGCU 17 4336
HSV2-UL30-1467 + GGCUUGGACGCGCCUCC 17 4337
HSV2-UL30-1468 + GCUUGGACGCGCCUCCC 17 4338
HSV2-UL30-1469 + CUUGGACGCGCCUCCCG 17 4339
HSV2-UL30-1470 + UUGGACGCGCCUCCCGG 17 4340
HSV2-UL30-1471 + UGGACGCGCCUCCCGGG 17 4341
HSV2-UL30-1472 + CGCGCCUCCCGGGGGGU 17 4342
HSV2-UL30-1473 + GGGGGGUCGGCAUGCGA 17 4343
HSV2-UL30-1474 + CAUGCGACGGCGUCUCC 17 4344
HSV2-UL30-1475 + AUGCGACGGCGUCUCCC 17 4345
HSV2-UL30-1476 + UGCGACGGCGUCUCCCG 17 4346
HSV2-UL30-1477 + GCGACGGCGUCUCCCGG 17 4347
HSV2-UL30-1478 + CGUCUCCCGGGGGCGCU 17 4348
HSV2-UL30-1479 + UCCCGGGGGCGCUUGGC 17 4349
HSV2-UL30-1480 + CCCGGGGGCGCUUGGCC 17 4350
HSV2-UL30-1481 + CCGGGGGCGCUUGGCCG 17 4351
HSV2-UL30-1482 + GGGGCGCUUGGCCGGGG 17 4352
HSV2-UL30-1483 + GGGCGCUUGGCCGGGGA 17 4353
HSV2-UL30-1484 + GCUUGGCCGGGGAGGGC 17 4354
HSV2-UL30-1485 + CUUGGCCGGGGAGGGCA 17 4355
HSV2-UL30-1486 + GGGGAGGGCAGGGCCGC 17 4356
HSV2-UL30-1487 + GGGAGGGCAGGGCCGCU 17 4357
HSV2-UL30-1488 + GGAGGGCAGGGCCGCUG 17 4358
HSV2-UL30-1489 + GAGGGCAGGGCCGCUGG 17 4359 HSV2-UL30-1490 + AGGGCAGGGCCGCUGGG 17 4360
HSV2-UL30-1491 + GGGCAGGGCCGCUGGGG 17 4361
HSV2-UL30-1492 + CAGGGCCGCUGGGGGGG 17 4362
HSV2-UL30-1493 + AGGGCCGCUGGGGGGGC 17 4363
HSV2-UL30-1494 + GGGGCGGGCUCGUCCCC 17 4364
HSV2-UL30-1495 + GGGCGGGCUCGUCCCCU 17 4365
HSV2-UL30-1496 + GGCGGGCUCGUCCCCUG 17 4366
HSV2-UL30-1497 + GGGCUCGUCCCCUGGGG 17 4367
HSV2-UL30-1498 + CUCGUCCCCUGGGGCGG 17 4368
HSV2-UL30-1499 + CGGCGGCGUCUAGCUCG 17 4369
HSV2-UL30-1500 + CGGCGUCUAGCUCGCGG 17 4370
HSV2-UL30-1501 + GGCGUCUAGCUCGCGGA 17 4371
HSV2-UL30-1502 + GUCUAGCUCGCGGAGGG 17 4372
HSV2-UL30-1503 + CCGUCUCCUCUACCUCG 17 4373
HSV2-UL30-1504 + CGUCUCCUCUACCUCGC 17 4374
HSV2-UL30-1505 + CCUCUACCUCGCGGGUC 17 4375
HSV2-UL30-1506 + CUCUACCUCGCGGGUCU 17 4376
HSV2-UL30-1507 + UGGGCCACGAUCACGUA 17 4377
HSV2-UL30-1508 + GGGCCACGAUCACGUAC 17 4378
HSV2-UL30-1509 + CGAUCACGUACGGGAUC 17 4379
HSV2-UL30-1510 + CGGGAUCCGGUCCUUGA 17 4380
HSV2-UL30-1511 + AUCCGGUCCUUGAUGGA 17 4381
HSV2-UL30-1512 + UCCGGUCCUUGAUGGAC 17 4382
HSV2-UL30-1513 + UGGACGGGACCUGCGCG 17 4383
HSV2-UL30-1514 + ACGGGACCUGCGCGCGG 17 4384
HSV2-UL30-1515 + CGGGACCUGCGCGCGGC 17 4385
HSV2-UL30-1516 + GCUUGUAAUACACCGUC 17 4386
HSV2-UL30-1517 + UGUAAUACACCGUCAGG 17 4387
HSV2-UL30-1518 + GUAAUACACCGUCAGGU 17 4388
HSV2-UL30-1519 + ACACCGUCAGGUGGGCC 17 4389
HSV2-UL30-1520 + GUGGGCCAGGCGCUUGU 17 4390
HSV2-UL30-1521 + UUGUUGGUGUACGCGCG 17 4391
HSV2-UL30-1522 + UGUUGGUGUACGCGCGC 17 4392
HSV2-UL30-1523 + CGGGUGUCUGCUCAGUU 17 4393
HSV2-UL30-1524 + GUGUCUGCUCAGUUCGG 17 4394
HSV2-UL30-1525 + UGCUCAGUUCGGCGGUG 17 4395
HSV2-UL30-1526 + CGGUGAGGACAAAGUCC 17 4396
HSV2-UL30-1527 + UCCUGGAUGUCCCUCUC 17 4397
HSV2-UL30-1528 + CCUGGAUGUCCCUCUCC 17 4398
HSV2-UL30-1529 + GAUGUCCCUCUCCGGGU 17 4399
HSV2-UL30-1530 + GGUCGGUGAUGCGCCGA 17 4400
HSV2-UL30-1531 + GUCGGUGAUGCGCCGAU 17 4401
HSV2-UL30-1532 + GCCGAUGGGCGUCUACG 17 4402
HSV2-UL30-1533 + AUGGGCGUCUACGAGGA 17 4403
HSV2-UL30-1534 + GAACGCCUGCAGUCCCU 17 4404
HSV2-UL30-1535 + AACGCCUGCAGUCCCUC 17 4405 HSV2-UL30-1536 + CCUGCAGUCCCUCGGGC 17 4406
HSV2-UL30-1537 + CUGCAGUCCCUCGGGCA 17 4407
HSV2-UL30-1538 + UGCAGUCCCUCGGGCAG 17 4408
HSV2-UL30-1539 + CGCCAGCCACUCCUCUG 17 4409
HSV2-UL30-1540 + GCCAGCCACUCCUCUGC 17 4410
HSV2-UL30-1541 + CCAGCCACUCCUCUGCG 17 4411
HSV2-UL30-1542 + CUCCUCUGCGGGGCGCU 17 4412
HSV2-UL30-1543 + GGGGCGCUCGGCUAACG 17 4413
HSV2-UL30-1544 + GCGCUCGGCUAACGCGG 17 4414
HSV2-UL30-1545 + UAACGCGGCGGCCGCUC 17 4415
HSV2-UL30-1546 + GGCGGCCGCUCCGGAUA 17 4416
HSV2-UL30-1547 + UAUCGUCGUAAAACAGC 17 4417
HSV2-UL30-1548 + AAAACAG CAGGUCGACC 17 4418
HSV2-UL30-1549 + AAACAG CAGGUCGACCA 17 4419
HSV2-UL30-1550 + CAGGUCGACCAGGGCCC 17 4420
HSV2-UL30-1551 + GUCGACCAGGGCCCUGG 17 4421
HSV2-UL30-1552 + CCAGGGCCCUGGAGGUG 17 4422
HSV2-UL30-1553 + GCCGAUGUACUUUUUCU 17 4423
HSV2-UL30-1554 + GGCGAUGAGCAGCAGCU 17 4424
HSV2-UL30-1555 + UCGCACUCGAGCUUGAU 17 4425
HSV2-UL30-1556 + CGCACUCGAGCUUGAUC 17 4426
HSV2-UL30-1557 + GCACUCGAGCUUGAUCG 17 4427
HSV2-UL30-1558 + CACUCGAGCUUGAUCGG 17 4428
HSV2-UL30-1559 + ACUCGAGCUUGAUCGGG 17 4429
HSV2-UL30-1560 + CGAGCUUGAUCGGGGGG 17 4430
HSV2-UL30-1561 + ACAGCGCGCGCGAGAUG 17 4431
HSV2-UL30-1562 + CGCCAUCUUGUCGCCCA 17 4432
HSV2-UL30-1563 + UGUCGCCCAUGGCCACC 17 4433
HSV2-UL30-1564 + CAUGGCCACCAGGCCCG 17 4434
HSV2-UL30-1565 + CCAGGCCCGCGGCCGUG 17 4435
HSV2-UL30-1566 + CCGCGGCCGUGAGGCCG 17 4436
HSV2-UL30-1567 + GCGGCACAAAACGAAAA 17 4437
HSV2-UL30-1568 + CCCGUAGAUGAUGCGCA 17 4438
HSV2-UL30-1569 + AUGAUGCGCAUGGAGUA 17 4439
HSV2-UL30-1570 + GCGCAUGGAGUACGGAC 17 4440
HSV2-UL30-1571 + CGCAUGGAGUACGGACC 17 4441
HSV2-UL30-1572 + GCAUGGAGUACGGACCG 17 4442
HSV2-UL30-1573 + CAUGGAGUACGGACCGG 17 4443
HSV2-UL30-1574 + ACCGGGGGCGCGCAUGC 17 4444
HSV2-UL30-1575 + CGCAUGCCGGCCGCCUC 17 4445
HSV2-UL30-1576 + GGCCGCCUCCGGAAAGU 17 4446
HSV2-UL30-1577 + CGUACGCGCGCGUCGCG 17 4447
HSV2-UL30-1578 + UCGCGAGGAGCAUCUCG 17 4448
HSV2-UL30-1579 + GAGCAUCUCGCGGCCGA 17 4449
HSV2-UL30-1580 + GCGGCCGAUGGUCGUCA 17 4450
HSV2-UL30-1581 + GCCGAUGGUCGUCACGG 17 4451 HSV2-UL30-1582 + GAUGGUCGUCACGGUGG 17 4452
HSV2-UL30-1583 + CGGUGGCGGCCACGUGC 17 4453
HSV2-UL30-1584 + GGCGGCCACGUGCAGGC 17 4454
HSV2-UL30-1585 + GCGGCCACGUGCAGGCA 17 4455
HSV2-UL30-1586 + AAGACCGUGCUGCACCC 17 4456
HSV2-UL30-1587 + G U U G CACACCACCU U G A 17 4457
HSV2-UL30-1588 + GCACACCACCUUGAUGG 17 4458
HSV2-UL30-1589 + CGGCCUGUUGCUUGUCG 17 4459
HSV2-UL30-1590 + CCUGUUGCUUGUCGAGG 17 4460
HSV2-UL30-1591 + UUGCUUGUCGAGGAGGA 17 4461
HSV2-UL30-1592 + GAGGAGGACGGCCUCCU 17 4462
HSV2-UL30-1593 + AGGAGGACGGCCUCCUC 17 4463
HSV2-UL30-1594 + GGAGGACGGCCUCCUCG 17 4464
HSV2-UL30-1595 + GAGGACGGCCUCCUCGG 17 4465
HSV2-UL30-1596 + CCUCCUCGGGGGUGCUC 17 4466
HSV2-UL30-1597 + CUCCUCGGGGGUGCUCU 17 4467
HSV2-UL30-1598 + UCCUCGGGGGUGCUCUG 17 4468
HSV2-UL30-1599 + CCUCGGGGGUGCUCUGG 17 4469
HSV2-UL30-1600 + UCUGGGGGAUCCGCGAG 17 4470
HSV2-UL30-1601 + GCGGAUCUGCUUUCGCA 17 4471
HSV2-UL30-1602 + CCAGCCAGUCGCGCAGC 17 4472
HSV2-UL30-1603 + GCAGCAGGAUGCUCAGC 17 4473
HSV2-UL30-1604 + GCAGGCUCUCGCGUACG 17 4474
HSV2-UL30-1605 + CAGGCUCUCGCGUACGU 17 4475
HSV2-UL30-1606 + U CACG AAG AACAGCCG U 17 4476
HSV2-UL30-1607 + CCCCCACCUCGAUCUCC 17 4477
HSV2-UL30-1608 + CGAUCUCCAGGUAGUCC 17 4478
HSV2-UL30-1609 + AGUCCCGGUCCGCCUCC 17 4479
HSV2-UL30-1610 + CGCCUCCAGGUGCGCGA 17 4480
HSV2-UL30-1611 + CAGGUGCGCGACGGCCU 17 4481
HSV2-UL30-1612 + AGGUGCGCGACGGCCUC 17 4482
HSV2-UL30-1613 + CGACGGCCUCGGGCCGC 17 4483
HSV2-UL30-1614 + GACGGCCUCGGGCCGCA 17 4484
HSV2-UL30-1615 + AGAGCGUACUGAAGCAC 17 4485
HSV2-UL30-1616 + UACUGAAGCACAGGUUG 17 4486
HSV2-UL30-1617 + ACUGAAGCACAGGUUGU 17 4487
HSV2-UL30-1618 + AGCACAGGUUGUGGGCC 17 4488
HSV2-UL30-1619 + GUGGGCCUGGAUGAUGC 17 4489
HSV2-UL30-1620 + UGGGCCUGGAUGAUGCU 17 4490
HSV2-UL30-1621 + GGGCCUGGAUGAUGCUG 17 4491
HSV2-UL30-1622 + GGAUGAUGCUGGGGUAC 17 4492
HSV2-UL30-1623 + GAUGCUGGGGUACAGGC 17 4493
HSV2-UL30-1624 + AAAG U CAAACACCACCA 17 4494
HSV2-UL30-1625 + AAG U CAAACACCACCAC 17 4495
HSV2-UL30-1626 + AG U CAAACACCACCACG 17 4496
HSV2-UL30-1627 + GGGGUCGACGUGAAACC 17 4497 HSV2-UL30-1628 + G U CGACG U G AAACCCG G 17 4498
HSV2-UL30-1629 + GACGUGAAACCCGGAGG 17 4499
HSV2-UL30-1630 + ACG U G AAACCCG GAGG U 17 4500
HSV2-UL30-1631 + CGUGAAACCCGGAGGUG 17 4501
HSV2-UL30-1632 + ACCCGGAGGUGGGGUCG 17 4502
HSV2-UL30-1633 + AGGUGGGGUCGAGGACC 17 4503
HSV2-UL30-1634 + GGUGGGGUCGAGGACCC 17 4504
HSV2-UL30-1635 + CGAGGACCCGGGCCCCC 17 4505
HSV2-UL30-1636 + CCUGGUACCCAACGUGC 17 4506
HSV2-UL30-1637 + CCCAACGUGCCGGCCCC 17 4507
HSV2-UL30-1638 + UCCCCGUUCCCGUCCCC 17 4508
HSV2-UL30-1639 + CGCUCCCCUUCCCCCCG 17 4509
HSV2-UL30-1640 + CCCU U CCCCCCG AG GCA 17 4510
HSV2-UL30-1641 + UCCCCCCGAGGCACGGC 17 4511
HSV2-UL30-1642 + CCCCCCGAGGCACGGCC 17 4512
HSV2-UL30-1643 + AGGCACGGCCGGGCGCU 17 4513
HSV2-UL30-1644 + GGCACGGCCGGGCGCU U 17 4514
HSV2-UL30-1645 + UGGGCGCCUCCUUGUCG 17 4515
HSV2-UL30-1646 + GGCCCCGAAACCGCCCC 17 4516
HSV2-UL30-1647 + GCCCCGAAACCGCCCCU 17 4517
HSV2-UL30-1648 + AACCGCCCCUGGGUGUC 17 4518
HSV2-UL30-1649 + GCCCCUGGGUGUCCGGC 17 4519
HSV2-UL30-1650 + GCAGGAUGAAGCCCUUC 17 4520
HSV2-UL30-1651 + AGCCCUUCUGGCCCGCA 17 4521
HSV2-UL30-1652 + UCUGGCCCGCAAGGCGC 17 4522
HSV2-UL30-1653 + GGCCCGCAAGGCGCAGG 17 4523
HSV2-UL30-1654 + GGAGGCACGUGAAGACG 17 4524
HSV2-UL30-1655 + UGAAGACGCGGAUCUGC 17 4525
HSV2-UL30-1656 + CUGCUGGCCGUCGUAGA 17 4526
HSV2-UL30-1657 + GGCCGUCGUAGAUGGUG 17 4527
HSV2-UL30-1658 + GCCGUCGUAGAUGGUGC 17 4528
HSV2-UL30-1659 + UGAUGUUGAUGCCCGCC 17 4529
HSV2-UL30-1660 + GCCCGCCAGGCGCGCGA 17 4530
HSV2-UL30-1661 + CGCCAGGCGCGCGACGG 17 4531
HSV2-UL30-1662 + CGACGGCGGAAAGCUCC 17 4532
HSV2-UL30-1663 + GCGGAAAGCUCCAGGUG 17 4533
HSV2-UL30-1664 + GAUCACCCCGCGCUGCG 17 4534
HSV2-UL30-1665 + AUCACCCCGCGCUGCGC 17 4535
HSV2-UL30-1666 + CCCGCGCUGCGCGGGCC 17 4536
HSV2-UL30-1667 + GCGCUGCGCGGGCCCGG 17 4537
HSV2-UL30-1668 + GGGCCCGGAGGCGUAGU 17 4538
HSV2-UL30-1669 + CCCGGAGGCGUAGUAGG 17 4539
HSV2-UL30-1670 + CCGGAGGCGUAGUAGGC 17 4540
HSV2-UL30-1671 + CGGAGGCGUAGUAGGCG 17 4541
HSV2-UL30-1672 + AGUAGGCGGGGAUGUCG 17 4542
HSV2-UL30-1673 + CUUCUUGUCCUUCAAGA 17 4543 HSV2-UL30-1674 + GUCCUUCAAGACGGCCU 17 4544
HSV2-UL30-1675 + CAAGACGGCCUCGGCGA 17 4545
HSV2-UL30-1676 + GGCGUUCAGCUUGUAGC 17 4546
HSV2-UL30-1677 + GGAGAGUUUGACCUUGU 17 4547
HSV2-UL30-1678 + UGCUGCGCUUCUGAAAG 17 4548
HSV2-UL30-1679 + GCUUCUGAAAGUGGCUC 17 4549
HSV2-UL30-1680 + GGCCGAUGUCCCACACG 17 4550
HSV2-UL30-1681 + ACACGCGGAACACACCC 17 4551
HSV2-UL30-1682 + CGCCCGUACCCGUCGAG 17 4552
HSV2-UL30-1683 + GCCCGUACCCGUCGAGC 17 4553
HSV2-UL30-1684 + GUAGAUCUCCGUCAGCU 17 4554
HSV2-UL30-1685 + UCUCCGUCAGCUUGGUC 17 4555
HSV2-UL30-1686 + CAGCUUGGUCAGGACGA 17 4556
HSV2-UL30-1687 + AGCUUGGUCAGGACGAA 17 4557
HSV2-UL30-1688 + GUUGAUGAUGUUGUACC 17 4558
HSV2-UL30-1689 + GUACCCGGUCACGAACU 17 4559
HSV2-UL30-1690 + UACCCGGUCACGAACUC 17 4560
HSV2-UL30-1691 + ACCCGGUCACGAACUCG 17 4561
HSV2-UL30-1692 + GCCGUACUGCUUGACGA 17 4562
HSV2-UL30-1693 + CUUGACGAAGGUCAUGA 17 4563
HSV2-UL30-1694 + AUUCGCUGU CAAACU CC 17 4564
HSV2-UL30-1695 + GUCAAACUCCAGGACGA 17 4565
HSV2-UL30-1696 + UCAAACUCCAGGACGAC 17 4566
HSV2-UL30-1697 + CAAACUCCAGGACGACG 17 4567
HSV2-UL30-1698 + AAACUCCAGGACGACGG 17 4568
HSV2-UL30-1699 + UCCAGGACGACGGGGGC 17 4569
HSV2-UL30-1700 + GGACGACGGGGGCCGGC 17 4570
HSV2-UL30-1701 + GGGGGCCGGCAGGCCCC 17 4571
HSV2-UL30-1702 + GGCCGGCAGGCCCCUGG 17 4572
HSV2-UL30-1703 + UGGAGGCGAGAUCGCUG 17 4573
HSV2-UL30-1704 + AGGCGAGAUCGCUGAGG 17 4574
HSV2-UL30-1705 + GGCGAGAUCGCUGAGGU 17 4575
HSV2-UL30-1706 + AUCGCUGAGGUGGGACU 17 4576
HSV2-UL30-1707 + UCGCUGAGGUGGGACUC 17 4577
HSV2-UL30-1708 + CGCUGAGGUGGGACUCG 17 4578
HSV2-UL30-1709 + UGAGGUGGGACUCGGGG 17 4579
HSV2-UL30-1710 + GGACUCGGGGAGGUCGC 17 4580
HSV2-UL30-1711 + AGGAUCCGAGCGAAAAC 17 4581
HSV2-UL30-1712 + AUCCGAGCGAAAACAGG 17 4582
HSV2-UL30-1713 + ACAGGAGGAUGUGCUCG 17 4583
HSV2-UL30-1714 + CAGGAGGAUGUGCUCGA 17 4584
HSV2-UL30-1715 + GAGGAUGUGCUCGAGGG 17 4585
HSV2-UL30-1716 + GAUGUGCUCGAGGGCGG 17 4586
HSV2-UL30-1717 + GUGCUCGAGGGCGGUGG 17 4587
HSV2-UL30-1718 + CGAGGGCGGUGGUGGAC 17 4588
HSV2-UL30-1719 + CAGGUCGUAGAGCAGAC 17 4589 HSV2-UL30-1720 + AGAGCAGACAGGAGAUC 17 4590
HSV2-UL30-1721 + AGGAGAUCUGGAUGACG 17 4591
HSV2-UL30-1722 + UGGAUGACGAGGUCUUC 17 4592
HSV2-UL30-1723 + GGAUGACGAGGUCUUCC 17 4593
HSV2-UL30-1724 + UCCGGGCGUUCCGCGAC 17 4594
HSV2-UL30-1725 + GCGUUCCGCGACCGGAA 17 4595
HSV2-UL30-1726 + CAGCUCGUCCUCCCCCC 17 4596
HSV2-UL30-1727 + GAAGCACAUGAGCUUGU 17 4597
HSV2-UL30-1728 + CACAUGAGCUUGUAGGC 17 4598
HSV2-UL30-1729 + UGAGCUUGUAGGCCGGC 17 4599
HSV2-UL30-1730 + GGCCGGCAGGUCACACA 17 4600
HSV2-UL30-1731 + ACACAUGGCCCCCUCGA 17 4601
HSV2-UL30-1732 + UGGCCCCCUCGACGGCC 17 4602
HSV2-UL30-1733 + AAACUCGACGUCGCUCG 17 4603
HSV2-UL30-1734 + GAGGUUCCGAACGCCGU 17 4604
HSV2-UL30-1735 + AGGUUCCGAACGCCGUC 17 4605
HSV2-UL30-1736 + GGUUCCGAACGCCGUCG 17 4606
HSV2-UL30-1737 + GUUCCGAACGCCGUCGG 17 4607
HSV2-UL30-1738 + UUCCGAACGCCGUCGGG 17 4608
HSV2-UL30-1739 + AACGCCGUCGGGGGGCG 17 4609
HSV2-UL30-1740 + CCGUCGGGGGGCGCGGU 17 4610
HSV2-UL30-1741 + CGUCGGGGGGCGCGGUU 17 4611
HSV2-UL30-1742 + GGGGGGCGCGGUUGGGC 17 4612
HSV2-UL30-1743 + GGGCCGGCGCGUUCCCG 17 4613
HSV2-UL30-1744 + CGGCGCGU UCCCGCGGC 17 4614
HSV2-UL30-1745 + GGCGCGUUCCCGCGGCC 17 4615
HSV2-UL30-1746 + UCCCGCGGCCGGGCUUG 17 4616
HSV2-UL30-1747 + CGCGGCCGGGCUUGAGG 17 4617
HSV2-UL30-1748 + GAGGCGGUACCAGCCGA 17 4618
HSV2-UL30-1749 + CCG AAGG U G ACAAACCC 17 4619
HSV2-UL30-1750 + CGAAG G U G ACAAACCCC 17 4620
HSV2-UL30-1751 + CAAACCCCGGGUUGUCC 17 4621
HSV2-UL30-1752 + GGUUGUCCAGGAUAAAC 17 4622
HSV2-UL30-1753 + GUUGUCCAGGAUAAACC 17 4623
HSV2-UL30-1754 + GUCCAGGAUAAACCGGG 17 4624
HSV2-UL30-1755 + CAGGAUAAACCGGGUGG 17 4625
HSV2-UL30-1756 + CUCGUACUUCCUGAUCG 17 4626
HSV2-UL30-1757 + UCGUACUUCCUGAUCGC 17 4627
HSV2-UL30-1758 + CGUACUUCCUGAUCGCG 17 4628
HSV2-UL30-1759 + G G CAAAAG UUGUCGCAC 17 4629
HSV2-UL30-1760 + AAAG UUGUCGCACAGGU 17 4630
HSV2-UL30-1761 + CGCUUCGCACGAAGACG 17 4631
HSV2-UL30-1762 + CGAAG ACGCGGUAGU AC 17 4632
HSV2-UL30-1763 + GAAGACGCGGUAGUACA 17 4633
HSV2-UL30-1764 + ACGCGGUAGUACAGGGU 17 4634
HSV2-UL30-1765 + CGCGGUAGUACAGGGUC 17 4635 HSV2-UL30-1766 + UUCGUAAUAGUACACGU 17 4636
HSV2-UL30-1767 + CCACCUCCGCCUCGAAG 17 4637
HSV2-UL30-1768 + CGCCUCGAAGUGGUCCG 17 4638
HSV2-UL30-1769 + GGUCCGCGGAGAUGCCG 17 4639
HSV2-UL30-1770 + CCGCGGAACGACGCCCC 17 4640
HSV2-UL30-1771 + CCCCCGGCGACUCGCGC 17 4641
HSV2-UL30-1772 + CCCCGGCGACUCGCGCA 17 4642
HSV2-UL30-1773 + CGCGCAGGGCCGCCGCC 17 4643
HSV2-UL30-1774 + CGCUCGCAGAGAUCGCG 17 4644
HSV2-UL30-1775 + GCUCGCAGAGAUCGCGC 17 4645
HSV2-UL30-1776 + CUCGCAGAGAUCGCGCG 17 4646
HSV2-UL30-1777 + AGAGAUCGCGCGGGGCA 17 4647
HSV2-UL30-1778 + GCGGGGCACGGCACUGC 17 4648
HSV2-UL30-1779 + CGUGCCGUAGACGUGAA 17 4649
HSV2-UL30-1780 + CGUGAACGGCGACGCGA 17 4650
HSV2-UL30-1781 + GGCGACGCGAUGGCCUU 17 4651
HSV2-UL30-1782 + GCGACGCGAUGGCCUUC 17 4652
HSV2-UL30-1783 + CGACGCGAUGGCCUUCG 17 4653
HSV2-UL30-1784 + GACGCGAUGGCCUUCGG 17 4654
HSV2-UL30-1785 + ACCCAGAAGCGUGAUGA 17 4655
HSV2-UL30-1786 + AAGCGUGAUGACGGUCC 17 4656
HSV2-UL30-1787 + CGUGAUGACGGUCCCGG 17 4657
HSV2-UL30-1788 + GUGAUGACGGUCCCGGC 17 4658
HSV2-UL30-1789 + GGUCCCGGCGGGCGUGA 17 4659
HSV2-UL30-1790 + CGUCCAUAAAUCGCUCG 17 4660
Table 2D provides exemplary targeting domains for knocking out the UL30 gene selected according to the first tier parameters. The targeting domains are selected based on location within first 500bp of the coding sequence of the UL30 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. aureus Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. aureus Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 2D
1st Tier Target
DNA
g NA Name Targeting Domain Site
Strand
Length Seq ID
HSV2-UL30-247 - CGCGGGCGGCCCGGCUUCCC 20 4661
HSV2-UL30-2 - GCGGGCGGCCCGGCUUCCCC 20 3158
HSV2-UL30-3 - CGGGCGGCCCGGCUUCCCCC 20 3159
HSV2-UL30-4 - GGGCGGCCCGGCUUCCCCCG 20 3160
HSV2-UL30-5 - GGCGGCCCGGCUUCCCCCGG 20 3161
HSV2-UL30-6 - GCGGCCCGGCUUCCCCCGGG 20 3162
HSV2-UL30-253 - CCCGGGGGGAAGCCGGCGGC 20 4662
HSV2-UL30-254 - GCCGGCGGCUCGGGCGGCGU 20 4663
HSV2-UL30-255 - U U U U U U G CCCCCCACAACCC 20 4664
HSV2-UL30-14 - U U U U U G CCCCCCACAACCCC 20 3170
HSV2-UL30-15 - U U U U G CCCCCCACAACCCCC 20 3171
HSV2-UL30-16 - U U U G CCCCCCACAACCCCCG 20 3172
HSV2-UL30-259 - CACCGCCGCCUUGCCGCCGG 20 4665
HSV2-UL30-260 - CAACCCCCACCU CGCU CAG A 20 4666
HSV2-UL30-19 - AACCCCCACCU CGCU CAG AC 20 3174
HSV2-UL30-262 - CGGAACGCAGCCAAAGGCCC 20 4667
HSV2-UL30-263 - UCAGCGCCAUACGUACUACA 20 4668
HSV2-UL30-264 - UACGUACUACAGCGAGUGCG 20 4669
HSV2-UL30-265 - GAUUUAUCGCCCCGCGUUCG 20 4670
HSV2-UL30-266 - UAUCGCCCCGCGUUCGCUGG 20 4671
HSV2-UL30-267 - UCGCCCCGCGUUCGCUGGAC 20 4672
HSV2-UL30-268 - CGCUGGACGAGGACGCCCCC 20 4673
HSV2-UL30-26 - GCUGGACGAGGACGCCCCCG 20 3179
HSV2-UL30-270 - CGCCCCCGCGGAGCAGCGCA 20 4674
HSV2-UL30-27 - GCCCCCGCGGAGCAGCGCAC 20 3180
HSV2-UL30-272 - GCGCGCCCCUAAGGUGUACU 20 4675
HSV2-UL30-33 - CGCGCCCCUAAGGUGUACUG 20 3071
HSV2-UL30-34 - GCGCCCCUAAGGUGUACUGC 20 3072
HSV2-UL30-35 - CGCCCCUAAGGUGUACUGCG 20 3185
HSV2-UL30-36 - GCCCCUAAGGUGUACUGCGG 20 3073
HSV2-UL30-37 - CCCCUAAGGUGUACUGCGGG 20 3074
HSV2-UL30-278 - UAAGGUGUACUGCGGGGGGG 20 4676
HSV2-UL30-279 - ACGAGCGCGACGUCCUCCGC 20 4677
HSV2-UL30-280 - GCGACGUCCUCCGCGUGGGC 20 4678
HSV2-UL30-41 - CGACGUCCUCCGCGUGGGCC 20 3186
HSV2-UL30-282 - ACGUCCUCCGCGUGGGCCCG 20 4679
HSV2-UL30-283 - UGGCCGCGUCGCUUGCGCCU 20 4680
HSV2-UL30-45 - GGCCGCGUCGCUUGCGCCUG 20 3189
HSV2-UL30-285 - GCU UGCGCCUGUGGGGCGGU 20 4681
HSV2-UL30-286 - GGGCGGUGCGGACCAUGCCC 20 4682
HSV2-UL30-287 - GCGGUGCGGACCAUGCCCCC 20 4683
HSV2-UL30-50 - CGGUGCGGACCAUGCCCCCG 20 3082
HSV2-UL30-289 - UCUUCCACGUGUACGACAUC 20 4684 HSV2-UL30-53 - CU U CCACG U G U ACG ACAU CC 20 3084
HSV2-UL30-291 - UGUACGACAUCCUGGAGCAC 20 4685
HSV2-UL30-54 - GUACGACAUCCUGGAGCACG 20 3192
HSV2-UL30-293 - GGGCGGCCCGGCU UCCC 17 4686
HSV2-UL30-125 - GGCGGCCCGGCUUCCCC 17 3236
HSV2-UL30-126 - GCGGCCCGGCUUCCCCC 17 3237
HSV2-UL30-127 - CGGCCCGGCUUCCCCCG 17 3238
HSV2-UL30-128 - GGCCCGGCUUCCCCCGG 17 3239
HSV2-UL30-129 - GCCCGGCUUCCCCCGGG 17 3240
HSV2-UL30-299 - GGGGGGAAGCCGGCGGC 17 4687
HSV2-UL30-300 - GGCGGCUCGGGCGGCGU 17 4688
HSV2-UL30-301 - U U U GCCCCCCACAACCC 17 4689
HSV2-UL30-137 - UUGCCCCCCACAACCCC 17 3248
HSV2-UL30-138 - UGCCCCCCACAACCCCC 17 3249
HSV2-UL30-139 - GCCCCCCACAACCCCCG 17 3250
HSV2-UL30-305 - CGCCGCCUUGCCGCCGG 17 4690
HSV2-UL30-306 - CCCCCACCUCGCUCAGA 17 4691
HSV2-UL30-142 - CCCCACCUCGCUCAGAC 17 3252
HSV2-UL30-308 - AACGCAGCCAAAGGCCC 17 4692
HSV2-UL30-309 - GCGCCAUACGUACUACA 17 4693
HSV2-UL30-310 - GUACUACAGCGAGUGCG 17 4694
HSV2-UL30-311 - UUAUCGCCCCGCGUUCG 17 4695
HSV2-UL30-312 - CGCCCCGCGUUCGCUGG 17 4696
HSV2-UL30-313 - CCCCGCGUUCGCUGGAC 17 4697
HSV2-UL30-314 - UGGACGAGGACGCCCCC 17 4698
HSV2-UL30-149 - GGACGAGGACGCCCCCG 17 3257
HSV2-UL30-316 - CCCCGCGGAGCAGCGCA 17 4699
HSV2-UL30-150 - CCCGCGGAGCAGCGCAC 17 3258
HSV2-UL30-318 - CGCCCCUAAGGUGUACU 17 4700
HSV2-UL30-156 - GCCCCUAAGGUGUACUG 17 3116
HSV2-UL30-157 - CCCCUAAGGUGUACUGC 17 3117
HSV2-UL30-158 - CCCUAAGGUGUACUGCG 17 3263
HSV2-UL30-159 - CCUAAGGUGUACUGCGG 17 3118
HSV2-UL30-160 - CUAAGGUGUACUGCGGG 17 3119
HSV2-UL30-324 - GGUGUACUGCGGGGGGG 17 4701
HSV2-UL30-325 - AGCGCGACGUCCUCCGC 17 4702
HSV2-UL30-326 - ACGUCCUCCGCGUGGGC 17 4703
HSV2-UL30-164 - CGUCCUCCGCGUGGGCC 17 3264
HSV2-UL30-328 - UCCUCCGCGUGGGCCCG 17 4704
HSV2-UL30-329 - CCGCGUCGCUUGCGCCU 17 4705
HSV2-UL30-168 - CGCGUCGCUUGCGCCUG 17 3267
HSV2-UL30-331 - UGCGCCUGUGGGGCGGU 17 4706
HSV2-UL30-332 - CGGUGCGGACCAUGCCC 17 4707
HSV2-UL30-333 - GUGCGGACCAUGCCCCC 17 4708
HSV2-UL30-173 - UGCGGACCAUGCCCCCG 17 3127
HSV2-UL30-335 - UCCACGUGUACGACAUC 17 4709 HSV2-UL30-176 - CCACGUGUACGACAUCC 17 3129
HSV2-UL30-337 - ACGACAUCCUGGAGCAC 17 4710
HSV2-UL30-177 - CGACAUCCUGGAGCACG 17 3270
HSV2-UL30-339 + UACGCGUGUUCCACGUGCUC 20 4711
HSV2-UL30-340 + UGCUCCAGGAUGUCGUACAC 20 4712
HSV2-UL30-56 + GCUCCAGGAUGUCGUACACG 20 3194
HSV2-UL30-342 + ACACGUGGAAGACGGUGACG 20 4713
HSV2-UL30-59 + CACGUGGAAGACGGUGACGG 20 3197
HSV2-UL30-344 + GGAAGACGGUGACGGUGGGG 20 4714
HSV2-UL30-345 + UGACGGUGGGGUCGAACCCC 20 4715
HSV2-UL30-62 + GACGGUGGGGUCGAACCCCU 20 3086
HSV2-UL30-63 + ACGGUGGGGUCGAACCCCUC 20 3087
HSV2-UL30-348 + ACAGGCGCAAGCGACGCGGC 20 4716
HSV2-UL30-349 + GCGACGCGGCCAGAAGCCCU 20 4717
HSV2-UL30-350 + CAGAAGCCCUCCGGGCCCAC 20 4718
HSV2-UL30-71 + AGAAGCCCUCCGGGCCCACG 20 3201
HSV2-UL30-352 + AAGCCCUCCGGGCCCACGCG 20 4719
HSV2-UL30-353 + GUCCCCCCCGCAGUACACCU 20 4720
HSV2-UL30-73 + UCCCCCCCGCAGUACACCUU 20 3203
HSV2-UL30-355 + CAGUACACCUUAGGGGCGCG 20 4721
HSV2-UL30-76 + AGUACACCUUAGGGGCGCGC 20 3095
HSV2-UL30-357 + GCGCGCCGGAGGCGGCCGUC 20 4722
HSV2-UL30-358 + GGACCCCGGUGCGCUGCUCC 20 4723
HSV2-UL30-81 + GACCCCGGUGCGCUGCUCCG 20 3207
HSV2-UL30-82 + ACCCCGGUGCGCUGCUCCGC 20 3208
HSV2-UL30-361 + CGCGGGGGCGUCCUCGUCCA 20 4724
HSV2-UL30-362 + GGCGUCCUCGUCCAGCGAAC 20 4725
HSV2-UL30-85 + GCGUCCUCGUCCAGCGAACG 20 3098
HSV2-UL30-364 + AGCGAACGCGGGGCGAUAAA 20 4726
HSV2-UL30-365 + UCGCUGUAGUACGUAUGGCG 20 4727
HSV2-UL30-366 + ACGUAUGGCGCUGAGCCGGC 20 4728
HSV2-UL30-367 + GUAUGGCGCUGAGCCGGCCC 20 4729
HSV2-UL30-368 + GCCUUUGGCUGCGUUCCGGU 20 4730
HSV2-UL30-369 + UUGGCUGCGUUCCGGUCUGA 20 4731
HSV2-UL30-370 + UGCGUUCCGGUCUGAGCGAG 20 4732
HSV2-UL30-95 + GCGUUCCGGUCUGAGCGAGG 20 3104
HSV2-UL30-96 + CGUUCCGGUCUGAGCGAGGU 20 3214
HSV2-UL30-373 + UCUGAGCGAGGUGGGGGUUG 20 4733
HSV2-UL30-374 + CGGCAAGGCGGCGGUGCCGU 20 4734
HSV2-UL30-375 + GGUGCCGUCUGGGUGGCUCC 20 4735
HSV2-UL30-107 + GUGCCGUCUGGGUGGCUCCC 20 3219
HSV2-UL30-108 + UGCCGUCUGGGUGGCUCCCC 20 3220
HSV2-UL30-378 + UGGGUGGCUCCCCGGGGGUU 20 4736
HSV2-UL30-111 + GGGUGGCUCCCCGGGGGUUG 20 3222
HSV2-UL30-112 + GGUGGCUCCCCGGGGGUUGU 20 3223
HSV2-UL30-113 + GUGGCUCCCCGGGGGUUGUG 20 3224 HSV2-UL30-382 + GCAAAAAACCCAGACGCCGC 20 4737
HSV2-UL30-383 + CCCGAGCCGCCGGCUUCCCC 20 4738
HSV2-UL30-117 + CCGAGCCGCCGGCUUCCCCC 20 3228
HSV2-UL30-118 + CGAGCCGCCGGCUUCCCCCC 20 3229
HSV2-UL30-119 + GAGCCGCCGGCU UCCCCCCG 20 3230
HSV2-UL30-120 + AGCCGCCGGCUUCCCCCCGG 20 3231
HSV2-UL30-388 + CGGCUUCCCCCCGGGGGAAG 20 4739
HSV2-UL30-389 + GCGUGUUCCACGUGCUC 17 4740
HSV2-UL30-390 + UCCAGGAUGUCGUACAC 17 4741
HSV2-UL30-179 + CCAGGAUGUCGUACACG 17 3272
HSV2-UL30-392 + CGUGGAAGACGGUGACG 17 4742
HSV2-UL30-182 + GUGGAAGACGGUGACGG 17 3275
HSV2-UL30-394 + AGACGGUGACGGUGGGG 17 4743
HSV2-UL30-395 + CGGUGGGGUCGAACCCC 17 4744
HSV2-UL30-185 + GGUGGGGUCGAACCCCU 17 3131
HSV2-UL30-186 + GUGGGGUCGAACCCCUC 17 3132
HSV2-UL30-398 + GGCGCAAGCGACGCGGC 17 4745
HSV2-UL30-399 + ACGCGGCCAGAAGCCCU 17 4746
HSV2-UL30-400 + AAGCCCUCCGGGCCCAC 17 4747
HSV2-UL30-194 + AGCCCUCCGGGCCCACG 17 3279
HSV2-UL30-402 + CCCUCCGGGCCCACGCG 17 4748
HSV2-UL30-403 + CCCCCCGCAGUACACCU 17 4749
HSV2-UL30-196 + CCCCCGCAGUACACCUU 17 3281
HSV2-UL30-405 + UACACCUUAGGGGCGCG 17 4750
HSV2-UL30-199 + ACACCUUAGGGGCGCGC 17 3140
HSV2-UL30-407 + CGCCGGAGGCGGCCGUC 17 4751
HSV2-UL30-408 + CCCCGGUGCGCUGCUCC 17 4752
HSV2-UL30-204 + CCCGGUGCGCUGCUCCG 17 3285
HSV2-UL30-205 + CCGGUGCGCUGCUCCGC 17 3286
HSV2-UL30-411 + GGGGGCGUCCUCGUCCA 17 4753
HSV2-UL30-412 + GUCCUCGUCCAGCGAAC 17 4754
HSV2-UL30-208 + U CCU CG U CCAGCG AACG 17 3143
HSV2-UL30-414 + GAACGCGGGGCGAUAAA 17 4755
HSV2-UL30-415 + CUGUAGUACGUAUGGCG 17 4756
HSV2-UL30-416 + UAUGGCGCUGAGCCGGC 17 4757
HSV2-UL30-417 + UGGCGCUGAGCCGGCCC 17 4758
HSV2-UL30-418 + UUUGGCUGCGUUCCGGU 17 4759
HSV2-UL30-419 + GCUGCGUUCCGGUCUGA 17 4760
HSV2-UL30-420 + GUUCCGGUCUGAGCGAG 17 4761
HSV2-UL30-218 + UUCCGGUCUGAGCGAGG 17 3149
HSV2-UL30-219 + UCCGGUCUGAGCGAGGU 17 3292
HSV2-UL30-423 + GAGCGAGGUGGGGGUUG 17 4762
HSV2-UL30-424 + CAAGGCGGCGGUGCCGU 17 4763
HSV2-UL30-425 + GCCGUCUGGGUGGCUCC 17 4764
HSV2-UL30-230 + CCGUCUGGGUGGCUCCC 17 3297
HSV2-UL30-231 + CGUCUGGGUGGCUCCCC 17 3298 HSV2-UL30-428 + GUGGCUCCCCGGGGGUU 17 4765
HSV2-UL30-234 + UGGCUCCCCGGGGGUUG 17 3300
HSV2-UL30-235 + GGCUCCCCGGGGGUUGU 17 3301
HSV2-UL30-236 + GCUCCCCGGGGGU UGUG 17 3302
HSV2-UL30-432 + AAAAACCCAGACGCCGC 17 4766
HSV2-UL30-433 + GAGCCGCCGGCUUCCCC 17 4767
HSV2-UL30-240 + AGCCGCCGGCUUCCCCC 17 3306
HSV2-UL30-241 + GCCGCCGGCUUCCCCCC 17 3307
HSV2-UL30-242 + CCGCCGGCUUCCCCCCG 17 3308
HSV2-UL30-243 + CGCCGGCUUCCCCCCGG 17 3309
HSV2-UL30-438 + CUUCCCCCCGGGGGAAG 17 4768
Table 2E provides exemplary targeting domains for knocking out the UL30 gene selected according to the second tier parameters. The targeting domains are selected based on location within the coding sequence (but downstream of the first 500bp) of the UL30 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. aureus Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. aureus Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 2E
Figure imgf000213_0001
HSV2-UL30-458 - GGCGGCCCUGCGCGAGUCGC 20 3328
HSV2-UL30-459 - GCGGCCCUGCGCGAGUCGCC 20 3329
HSV2-UL30-1804 - CGUCGUUCCGCGGCAUCUCC 20 4778
HSV2-UL30-1805 - CGGCAUCUCCGCGGACCACU 20 4779
HSV2-UL30-1806 - UCUCCGCGGACCACUUCGAG 20 4780
HSV2-UL30-465 - CUCCGCGGACCACUUCGAGG 20 3335
HSV2-UL30-1808 - ACCACUUCGAGGCGGAGGUG 20 4781
HSV2-UL30-468 - CCACUUCGAGGCGGAGGUGG 20 3338
HSV2-UL30-1810 - GCGCGCCGACGUGUACUAUU 20 4782
HSV2-UL30-1811 - CUGUACUACCGCGUCUUCGU 20 4783
HSV2-UL30-1812 - CUACCGCGUCUUCGUGCGAA 20 4784
HSV2-UL30-1813 - GACAACU U U UGCCCCGCGAU 20 4785
HSV2-UL30-472 - ACAACUUUUGCCCCGCGAUC 20 3342
HSV2-UL30-1815 - UUGCCCCGCGAUCAGGAAGU 20 4786
HSV2-UL30-1816 - GCCCCGCGAUCAGGAAGUAC 20 4787
HSV2-UL30-473 - CCCCGCGAUCAGGAAGUACG 20 3343
HSV2-UL30-474 - CCCGCGAUCAGGAAGUACGA 20 3344
HSV2-UL30-475 - CCGCGAUCAGGAAGUACGAG 20 3345
HSV2-UL30-1820 - ACGCCACCACCCGGU U U AUC 20 4788
HSV2-UL30-1821 - CCCGGUU UAUCCUGGACAAC 20 4789
HSV2-UL30-480 - CCGGU UUAUCCUGGACAACC 20 3350
HSV2-UL30-1823 - GUACCGCCUCAAGCCCGGCC 20 4790
HSV2-UL30-486 - UACCGCCUCAAGCCCGGCCG 20 3356
HSV2-UL30-487 - ACCGCCUCAAGCCCGGCCGC 20 3357
HSV2-UL30-1826 - ACCGCGCCCCCCGACGGCGU 20 4791
HSV2-UL30-490 - CCGCGCCCCCCGACGGCGUU 20 3360
HSV2-UL30-1828 - CCCCG ACGG CG U U CGGAACC 20 4792
HSV2-UL30-1829 - GUUCGGAACCUCGAGCGACG 20 4793
HSV2-UL30-1830 - ACGUCGAGUUUAACUGCACG 20 4794
HSV2-UL30-1831 - CACGGCGGACAACCUGGCCG 20 4795
HSV2-UL30-1832 - CGGCGGACAACCUGGCCGUC 20 4796
HSV2-UL30-494 - GGCGGACAACCUGGCCGUCG 20 3364
HSV2-UL30-495 - GCGGACAACCUGGCCGUCGA 20 3365
HSV2-UL30-1835 - CAAGCUCAUGUGCUUCGAUA 20 4797
HSV2-UL30-1836 - CUUCGAUAUCGAAUGCAAGG 20 4798
HSV2-UL30-500 - UUCGAUAUCGAAUGCAAGGC 20 3370
HSV2-UL30-501 - UCGAUAUCGAAUGCAAGGCC 20 3371
HSV2-UL30-502 - CGAUAUCGAAUGCAAGGCCG 20 3372
HSV2-UL30-503 - GAUAUCGAAUGCAAGGCCGG 20 3373
HSV2-UL30-504 - AUAUCGAAUGCAAGGCCGGG 20 3374
HSV2-UL30-505 - UAUCGAAUGCAAGGCCGGGG 20 3375
HSV2-UL30-1843 - UCGAAUGCAAGGCCGGGGGG 20 4799
HSV2-UL30-1844 - AUGCAAGGCCGGGGGGGAGG 20 4800
HSV2-UL30-1845 - ACGAGCUGGCCUUUCCGGUC 20 4801
HSV2-UL30-509 - CGAGCUGGCCUUUCCGGUCG 20 3379
HSV2-UL30-1847 - CCUUUCCGGUCGCGGAACGC 20 4802 HSV2-UL30-510 - CUUUCCGGUCGCGGAACGCC 20 3380
HSV2-UL30-1849 - CG ACCU G U CCACCACCG CCC 20 4803
HSV2-UL30-1850 - GCACAUCCUCCUGUUUUCGC 20 4804
HSV2-UL30-1851 - GCUCGGAUCCUGCGACCUCC 20 4805
HSV2-UL30-1852 - CACCUCAGCGAUCUCGCCUC 20 4806
HSV2-UL30-512 - ACCUCAGCGAUCUCGCCUCC 20 3382
HSV2-UL30-1854 - GCCUGCCGGCCCCCGUCGUC 20 4807
HSV2-UL30-516 - CCUGCCGGCCCCCGUCGUCC 20 3386
HSV2-UL30-1856 - CGUCGUCCUGGAGUUUGACA 20 4808
HSV2-UL30-1857 - CCUGGAGUUUGACAGCGAAU 20 4809
HSV2-UL30-1858 - CUUCGUCAAGCAGUACGGCC 20 4810
HSV2-UL30-1859 - GUACGGCCCCGAGUUCGUGA 20 4811
HSV2-UL30-1860 - CCUUCGUCCUGACCAAGCUG 20 4812
HSV2-UL30-522 - CUUCGUCCUGACCAAGCUGA 20 3392
HSV2-UL30-1862 - GAUCUACAAGGUCCCGCUCG 20 4813
HSV2-UL30-1863 - CAAGGUCCCGCUCGACGGGU 20 4814
HSV2-UL30-1864 - CGCUCGACGGGUACGGGCGC 20 4815
HSV2-UL30-1865 - GGGUACGGGCGCAUGAACGG 20 4816
HSV2-UL30-529 - GGUACGGGCGCAUGAACGGC 20 3399
HSV2-UL30-1867 - GGCCGGGGUGUGUUCCGCGU 20 4817
HSV2-UL30-532 - GCCGGGGUGUGUUCCGCGUG 20 3402
HSV2-UL30-1869 - UCCGCGUGUGGGACAUCGGC 20 4818
HSV2-UL30-1870 - ACAUCGGCCAGAGCCACUUU 20 4819
HSV2-UL30-1871 - AGAAGCGCAGCAAGAUCAAG 20 4820
HSV2-UL30-1872 - GCGCAGCAAGAUCAAGGUGA 20 4821
HSV2-UL30-536 - CGCAGCAAGAUCAAGGUGAA 20 3406
HSV2-UL30-1874 - AGAUCAAGGUGAACGGGAUG 20 4822
HSV2-UL30-1875 - UCAAACUCUCCAGCUACAAG 20 4823
HSV2-UL30-1876 - CUACAAGCUGAACGCCGUCG 20 4824
HSV2-UL30-1877 - ACGCCGUCGCCGAGGCCGUC 20 4825
HSV2-UL30-1878 - CCGUCGCCGAGGCCGUCUUG 20 4826
HSV2-UL30-1879 - CCGAGGCCGUCUUGAAGGAC 20 4827
HSV2-UL30-1880 - AGGCCGUCUUGAAGGACAAG 20 4828
HSV2-UL30-1881 - CCG U CU U G AAGG ACAAG AAG 20 4829
HSV2-UL30-1882 - UGAAGGACAAGAAGAAGGAU 20 4830
HSV2-UL30-1883 - CAUCCCCGCCUACUACGCCU 20 4831
HSV2-UL30-1884 - CGCCUCCGGGCCCGCGCAGC 20 4832
HSV2-UL30-546 - GCCUCCGGGCCCGCGCAGCG 20 3416
HSV2-UL30-1886 - CGCGCAGCGCGGGGUGAUCG 20 4833
HSV2-UL30-1887 - UGAUCGGCGAGUAUUGUGUG 20 4834
HSV2-UL30-1888 - UGUGCAGGACUCGCUGCUGG 20 4835
HSV2-UL30-1889 - UCUUCAAGUUUCUGCCGCAC 20 4836
HSV2-UL30-554 - CUUCAAGUUUCUGCCGCACC 20 3424
HSV2-UL30-1891 - UUUCCGCCGUCGCGCGCCUG 20 4837
HSV2-UL30-1892 - UCACGUGCCUCCUGCGCCUU 20 4838
HSV2-UL30-1893 - GCCUCCUGCGCCUUGCGGGC 20 4839 HSV2-UL30-1894 - UCCUGCGCCUUGCGGGCCAG 20 4840
HSV2-UL30-1895 - GCCAGAAGGGCUUCAUCCUG 20 4841
HSV2-UL30-1896 - GCU UCAUCCUGCCGGACACC 20 4842
HSV2-UL30-564 - CU UCAUCCUGCCGGACACCC 20 3434
HSV2-UL30-1898 - CCGGACACCCAGGGGCGGUU 20 4843
HSV2-UL30-568 - CGGACACCCAGGGGCGGUUU 20 3438
HSV2-UL30-1900 - GGCGGUUUCGGGGCCUCGAC 20 4844
HSV2-UL30-571 - GCGGUUUCGGGGCCUCGACA 20 3441
HSV2-UL30-1902 - CCCAAGCGCCCGGCCGUGCC 20 4845
HSV2-UL30-574 - CCAAGCGCCCGGCCGUGCCU 20 3444
HSV2-UL30-575 - CAAGCGCCCGGCCGUGCCUC 20 3445
HSV2-UL30-576 - AAGCGCCCGGCCGUGCCUCG 20 3446
HSV2-UL30-577 - AGCGCCCGGCCGUGCCUCGG 20 3447
HSV2-UL30-578 - GCGCCCGGCCGUGCCUCGGG 20 3448
HSV2-UL30-1908 - CCCGGCCGUGCCUCGGGGGG 20 4846
HSV2-UL30-579 - CCGGCCGUGCCUCGGGGGGA 20 3449
HSV2-UL30-580 - CGGCCGUGCCUCGGGGGGAA 20 3450
HSV2-UL30-581 - GGCCGUGCCUCGGGGGGAAG 20 3451
HSV2-UL30-1912 - CUCGGGGGGAAGGGGAGCGG 20 4847
HSV2-UL30-583 - UCGGGGGGAAGGGGAGCGGC 20 3453
HSV2-UL30-584 - CGGGGGGAAGGGGAGCGGCC 20 3454
HSV2-UL30-585 - GGGGGGAAGGGGAGCGGCCG 20 3455
HSV2-UL30-1916 - GGAAGGGGAGCGGCCGGGGG 20 4848
HSV2-UL30-587 - GAAGGGGAGCGGCCGGGGGA 20 3457
HSV2-UL30-588 - AAGGGGAGCGGCCGGGGGAC 20 3458
HSV2-UL30-1919 - GGAGCGGCCGGGGGACGGGA 20 4849
HSV2-UL30-589 - GAGCGGCCGGGGGACGGGAA 20 3459
HSV2-UL30-590 - AGCGGCCGGGGGACGGGAAC 20 3460
HSV2-UL30-1922 - GCCGGGGGACGGGAACGGGG 20 4850
HSV2-UL30-1923 - CGGGGGACGGGAACGGGGAC 20 4851
HSV2-UL30-1924 - ACGGGAACGGGGACGAGGAU 20 4852
HSV2-UL30-1925 - GGACGAGGAUAAGGACGACG 20 4853
HSV2-UL30-1926 - ACGAGGAUAAGGACGACGAC 20 4854
HSV2-UL30-1927 - GGAUAAGGACGACGACGAGG 20 4855
HSV2-UL30-595 - GAUAAGGACGACGACGAGGA 20 3465
HSV2-UL30-596 - AUAAGGACGACGACGAGGAC 20 3466
HSV2-UL30-1930 - GGACGACGACGAGGACGGGG 20 4856
HSV2-UL30-1931 - ACGACGACGAGGACGGGGAC 20 4857
HSV2-UL30-1932 - CGACGAGGACGGGGACGAGG 20 4858
HSV2-UL30-599 - GACGAGGACGGGGACGAGGA 20 3469
HSV2-UL30-600 - ACGAGGACGGGGACGAGGAC 20 3470
HSV2-UL30-1935 - GGACGGGGACGAGGACGGGG 20 4859
HSV2-UL30-1936 - GGACGAGGACGGGGACGAGC 20 4860
HSV2-UL30-1937 - ACGAGGACGGGGACGAGCGC 20 4861
HSV2-UL30-602 - CGAGGACGGGGACGAGCGCG 20 3472
HSV2-UL30-1939 - CGAGCGCGAGGAGGUCGCGC 20 4862 HSV2-UL30-1940 - CGAGGAGGUCGCGCGCGAGA 20 4863
HSV2-UL30-604 - GAGGAGGUCGCGCGCGAGAC 20 3474
HSV2-UL30-605 - AGGAGGUCGCGCGCGAGACC 20 3475
HSV2-UL30-1943 - CGAGACCGGGGGCCGGCACG 20 4864
HSV2-UL30-1944 - GGGGCCGGCACGUUGGGUAC 20 4865
HSV2-UL30-611 - GGGCCGGCACGUUGGGUACC 20 3481
HSV2-UL30-612 - GGCCGGCACGUUGGGUACCA 20 3482
HSV2-UL30-1947 - CACGUUGGGUACCAGGGGGC 20 4866
HSV2-UL30-1948 - CCG GG U CCU CG ACCCCACCU 20 4867
HSV2-UL30-1949 - CAGUACGCUCUCCCUGCGGC 20 4868
HSV2-UL30-1950 - GGCCCGAGGCCGUCGCGCAC 20 4869
HSV2-UL30-624 - GCCCGAGGCCGUCGCGCACC 20 3494
HSV2-UL30-1952 - AGGCCGUCGCGCACCUGGAG 20 4870
HSV2-UL30-1953 - GUCGCGCACCUGGAGGCGGA 20 4871
HSV2-UL30-627 - UCGCGCACCUGGAGGCGGAC 20 3497
HSV2-UL30-1955 - UGGAGGCGGACCGGGACUAC 20 4872
HSV2-UL30-629 - GGAGGCGGACCGGGACUACC 20 3499
HSV2-UL30-1957 - GGACCGGGACUACCUGGAGA 20 4873
HSV2-UL30-1958 - GGGACUACCUGGAGAUCGAG 20 4874
HSV2-UL30-631 - GGACUACCUGGAGAUCGAGG 20 3501
HSV2-UL30-632 - GACUACCUGGAGAUCGAGGU 20 3502
HSV2-UL30-633 - ACUACCUGGAGAUCGAGGUG 20 3503
HSV2-UL30-1962 - GGGGCCGACGGCUGUUCUUC 20 4875
HSV2-UL30-1963 - CUUCGUGAAGGCCCACGUAC 20 4876
HSV2-UL30-1964 - UCGUGAAGGCCCACGUACGC 20 4877
HSV2-UL30-1965 - CCCACGUACGCGAGAGCCUG 20 4878
HSV2-UL30-1966 - CUGCGCGACUGGCUGGCCAU 20 4879
HSV2-UL30-1967 - AUGCGAAAGCAGAUCCGCUC 20 4880
HSV2-UL30-1968 - AGAUCCGCUCGCGGAUCCCC 20 4881
HSV2-UL30-1969 - GCGGAUCCCCCAGAGCACCC 20 4882
HSV2-UL30-1970 - GGAUCCCCCAGAGCACCCCC 20 4883
HSV2-UL30-641 - GAUCCCCCAGAGCACCCCCG 20 3511
HSV2-UL30-1972 - GGUGGUGUGCAACUCGGUGU 20 4884
HSV2-UL30-1973 - CAACUCGGUGUACGGGUUCA 20 4885
HSV2-UL30-649 - AACUCGGUGUACGGGUUCAC 20 3519
HSV2-UL30-1975 - CACCGUGACGACCAUCGGCC 20 4886
HSV2-UL30-1976 - CGCGCGUACGUGCACGCGCG 20 4887
HSV2-UL30-1977 - CGUACGUGCACGCGCGCUGG 20 4888
HSV2-UL30-657 - GUACGUGCACGCGCGCUGGG 20 3527
HSV2-UL30-1979 - AUCAGCUGCUGGCCGACUUU 20 4889
HSV2-UL30-659 - UCAGCUGCUGGCCGACUUUC 20 3529
HSV2-UL30-1981 - GUACUCCAUGCGCAUCAUCU 20 4890
HSV2-UL30-664 - UACUCCAUGCGCAUCAUCUA 20 3534
HSV2-UL30-665 - ACUCCAUGCGCAUCAUCUAC 20 3535
HSV2-UL30-1984 - UGCGCAUCAUCUACGGGGAC 20 4891
HSV2-UL30-1985 - UGUGCCGCGGCCUCACGGCC 20 4892 HSV2-UL30-1986 - CGGCCGCGGGCCUGGUGGCC 20 4893
HSV2-UL30-1987 - UGGCCAUGGGCGACAAGAUG 20 4894
HSV2-UL30-1988 - GUUCCUCCCCCCGAUCAAGC 20 4895
HSV2-UL30-1989 - CCCCCCGAUCAAGCUCGAGU 20 4896
HSV2-UL30-1990 - CCAAGCUGCUGCUCAUCGCC 20 4897
HSV2-UL30-1991 - AAAGUACAUCGGCGUCAUCU 20 4898
HSV2-UL30-678 - AAGUACAUCGGCGUCAUCUG 20 3548
HSV2-UL30-679 - AGUACAUCGGCGUCAUCUGC 20 3549
HSV2-UL30-1994 - GCGGGGGCAAGAUGCUCAUC 20 4899
HSV2-UL30-1995 - GCAAGAUGCUCAUCAAGGGC 20 4900
HSV2-UL30-1996 - GCGUUUAUCAACCGCACCUC 20 4901
HSV2-UL30-1997 - GUUUUACGACGAUACCGUAU 20 4902
HSV2-UL30-689 - UUUUACGACGAUACCGUAUC 20 3559
HSV2-UL30-1999 - CGGAGCGGCCGCCGCGUUAG 20 4903
HSV2-UL30-2000 - CGCGU UAGCCGAGCGCCCCG 20 4904
HSV2-UL30-2001 - CGUUAGCCGAGCGCCCCGCA 20 4905
HSV2-UL30-691 - GUUAGCCGAGCGCCCCGCAG 20 3561
HSV2-UL30-2003 - GUGGCUGGCGCGACCCCUGC 20 4906
HSV2-UL30-2004 - GGCUGGCGCGACCCCUGCCC 20 4907
HSV2-UL30-694 - GCUGGCGCGACCCCUGCCCG 20 3564
HSV2-UL30-2006 - GCCCGAGGGACUGCAGGCGU 20 4908
HSV2-UL30-697 - CCCGAGGGACUGCAGGCGUU 20 3567
HSV2-UL30-2008 - CCCAUCGGCG CAU CACCG AC 20 4909
HSV2-UL30-701 - CCAUCGGCGCAUCACCGACC 20 3571
HSV2-UL30-2010 - AUCGGCGCAUCACCGACCCG 20 4910
HSV2-UL30-2011 - CGGCGCAUCACCGACCCGGA 20 4911
HSV2-UL30-702 - GGCGCAUCACCGACCCGGAG 20 3572
HSV2-UL30-2013 - CCGACCCGGAGAGGGACAUC 20 4912
HSV2-UL30-2014 - CCAG G ACU U U G U CCU CACCG 20 4913
HSV2-UL30-2015 - ACUUUGUCCUCACCGCCGAA 20 4914
HSV2-UL30-2016 - GCGCGCAGGUCCCGUCCAUC 20 4915
HSV2-UL30-2017 - CAGGUCCCGUCCAUCAAGGA 20 4916
HSV2-UL30-2018 - CGUGAUCGUGGCCCAGACCC 20 4917
HSV2-UL30-2019 - CGUGGCCCAGACCCGCGAGG 20 4918
HSV2-UL30-2020 - UGGCCCAGACCCGCGAGGUA 20 4919
HSV2-UL30-713 - GGCCCAGACCCGCGAGGUAG 20 3583
HSV2-UL30-2022 - CGCGCGGCUGGCCGCCCUCC 20 4920
HSV2-UL30-2023 - CGAGCUAGACGCCGCCGCCC 20 4921
HSV2-UL30-717 - GAGCUAGACGCCGCCGCCCC 20 3587
HSV2-UL30-718 - AGCUAGACGCCGCCGCCCCA 20 3588
HSV2-UL30-2026 - AGACGCCGCCGCCCCAGGGG 20 4922
HSV2-UL30-2027 - CCCUCCCCGGCCAAGCGCCC 20 4923
HSV2-UL30-722 - CCUCCCCGGCCAAGCGCCCC 20 3592
HSV2-UL30-723 - CUCCCCGGCCAAGCGCCCCC 20 3593
HSV2-UL30-2030 - CGCCGUCGCAUGCCGACCCC 20 4924
HSV2-UL30-724 - G CCG U CG CAU GCCG ACCCCC 20 3594 HSV2-UL30-725 - CCGUCGCAUGCCGACCCCCC 20 3595
HSV2-UL30-2033 - GCCCCGCAAGCUGCUGGUGU 20 4925
HSV2-UL30-2034 - AGCUGCUGGUGUCCGAGCUG 20 4926
HSV2-UL30-729 - GCUGCUGGUGUCCGAGCUGG 20 3599
HSV2-UL30-2036 - UGCUGGUGUCCGAGCUGGCG 20 4927
HSV2-UL30-2037 - GUCCGAGCUGGCGGAGGAUC 20 4928
HSV2-UL30-2038 - GAUCCCGGGUACGCCAUCGC 20 4929
HSV2-UL30-733 - AUCCCGGGUACGCCAUCGCC 20 3603
HSV2-UL30-2040 - CCCGGGGCGUUCCGCUCAAC 20 4930
HSV2-UL30-2041 - ACUAUUACUUCUCGCACCUG 20 4931
HSV2-UL30-737 - CUAUUACUUCUCGCACCUGC 20 3607
HSV2-UL30-738 - UAUUACUUCUCGCACCUGCU 20 3608
HSV2-UL30-2044 - CGUGACGUUCAAGGCCCUGU 20 4932
HSV2-UL30-743 - GUGACGUUCAAGGCCCUGUU 20 3613
HSV2-UL30-2046 - UGGAAAUAACGCCAAGAUCA 20 4933
HSV2-UL30-2047 - GAAAUAACG CCAAG AU CACC 20 4934
HSV2-UL30-2048 - AGAUCACCGAGAGUCUGUUA 20 4935
HSV2-UL30-2049 - UCUGUUAAAGAGGUUUAUUC 20 4936
HSV2-UL30-2050 - U UCCCGAGACG UGGCACCCC 20 4937
HSV2-UL30-2051 - GACGACGUGGCCGCGCGGCU 20 4938
HSV2-UL30-2052 - UGGCCGCGCGGCUCAGGGCC 20 4939
HSV2-UL30-751 - GGCCGCGCGGCUCAGGGCCG 20 3621
HSV2-UL30-2054 - GCGGCUCAGGGCCGCGGGGU 20 4940
HSV2-UL30-2055 - GGGCCGCGGGGUUCGGGCCG 20 4941
HSV2-UL30-757 - GGCCGCGGGGUUCGGGCCGG 20 3627
HSV2-UL30-758 - GCCGCGGGGUUCGGGCCGGC 20 3628
HSV2-UL30-2058 - CGGCGGGGGCCGGCGCUACG 20 4942
HSV2-UL30-763 - GGCGGGGGCCGGCGCUACGG 20 3633
HSV2-UL30-2060 - CGGGGGCCGGCGCUACGGCG 20 4943
HSV2-UL30-764 - GGGGGCCGGCGCUACGGCGG 20 3634
HSV2-UL30-2062 - GCUACGGCGGAGGAAACUCG 20 4944
HSV2-UL30-2063 - GAAACUCGUCGAAUGUUGCA 20 4945
HSV2-UL30-2064 - GGACGCCAUCACGCCCG 17 4946
HSV2-UL30-765 - GACGCCAUCACGCCCGC 17 3635
HSV2-UL30-2066 - GGACCGUCAUCACGCUU 17 4947
HSV2-UL30-2067 - GCU UCUGGGUCUGACCC 17 4948
HSV2-UL30-2068 - CGCGGCAGUACUUUUAC 17 4949
HSV2-UL30-2069 - ACU U U U ACAU G AACAAG 17 4950
HSV2-UL30-773 - CUUUUACAUGAACAAGG 17 3643
HSV2-UL30-2071 - ACAUGAACAAGGCGGAG 17 4951
HSV2-UL30-2072 - UGCCCCGCGCGAUCUCU 17 4952
HSV2-UL30-2073 - CCUGGCGGCGGCCCUGC 17 4953
HSV2-UL30-2074 - CGGCCCUGCGCGAGUCG 17 4954
HSV2-UL30-780 - GGCCCUGCGCGAGUCGC 17 3650
HSV2-UL30-781 - GCCCUGCGCGAGUCGCC 17 3651
HSV2-UL30-2077 - CGUUCCGCGGCAUCUCC 17 4955 HSV2-UL30-2078 - CAUCUCCGCGGACCACU 17 4956
HSV2-UL30-2079 - CCGCGGACCACU UCGAG 17 4957
HSV2-UL30-787 - CGCGGACCACU UCGAGG 17 3657
HSV2-UL30-2081 - ACUUCGAGGCGGAGGUG 17 4958
HSV2-UL30-790 - CU UCGAGGCGGAGGUGG 17 3660
HSV2-UL30-2083 - CGCCGACGUGUACUAUU 17 4959
HSV2-UL30-2084 - UACUACCGCGUCUUCGU 17 4960
HSV2-UL30-2085 - CCGCGUCUUCGUGCGAA 17 4961
HSV2-UL30-2086 - AACUUUUGCCCCGCGAU 17 4962
HSV2-UL30-794 - ACUUUUGCCCCGCGAUC 17 3664
HSV2-UL30-2088 - CCCCG CG AU CAG G AAG U 17 4963
HSV2-UL30-2089 - CCG CG AU CAG G AAG U AC 17 4964
HSV2-UL30-795 - CGCGAUCAGGAAGUACG 17 3665
HSV2-UL30-796 - GCGAUCAGGAAGUACGA 17 3666
HSV2-UL30-797 - CGAUCAGGAAGUACGAG 17 3667
HSV2-UL30-2093 - CCACCACCCG G U U U AU C 17 4965
HSV2-UL30-2094 - GGUUUAUCCUGGACAAC 17 4966
HSV2-UL30-802 - GUUUAUCCUGGACAACC 17 3672
HSV2-UL30-2096 - CCGCCUCAAGCCCGGCC 17 4967
HSV2-UL30-808 - CGCCUCAAGCCCGGCCG 17 3678
HSV2-UL30-809 - GCCUCAAGCCCGGCCGC 17 3679
HSV2-UL30-2099 - GCGCCCCCCGACGGCGU 17 4968
HSV2-UL30-812 - CGCCCCCCGACGGCGUU 17 3682
HSV2-UL30-2101 - CGACGGCGUUCGGAACC 17 4969
HSV2-UL30-2102 - CGGAACCUCGAGCGACG 17 4970
HSV2-UL30-2103 - UCGAGUUUAACUGCACG 17 4971
HSV2-UL30-2104 - GGCGGACAACCUGGCCG 17 4972
HSV2-UL30-2105 - CG G ACAACCU G GCCG U C 17 4973
HSV2-UL30-816 - GGACAACCUGGCCGUCG 17 3686
HSV2-UL30-817 - GACAACCUGGCCGUCGA 17 3687
HSV2-UL30-2108 - GCUCAUGUGCUUCGAUA 17 4974
HSV2-UL30-2109 - CGAUAUCGAAUGCAAGG 17 4975
HSV2-UL30-822 - GAUAUCGAAUGCAAGGC 17 3692
HSV2-UL30-823 - AUAUCGAAUGCAAGGCC 17 3693
HSV2-UL30-824 - UAUCGAAUGCAAGGCCG 17 3694
HSV2-UL30-825 - AUCGAAUGCAAGGCCGG 17 3695
HSV2-UL30-826 - UCGAAUGCAAGGCCGGG 17 3696
HSV2-UL30-827 - CGAAUGCAAGGCCGGGG 17 3697
HSV2-UL30-2116 - AAUGCAAGGCCGGGGGG 17 4976
HSV2-UL30-2117 - CAAGGCCGGGGGGGAGG 17 4977
HSV2-UL30-2118 - AGCUGGCCUUUCCGGUC 17 4978
HSV2-UL30-831 - GCUGGCCUUUCCGGUCG 17 3701
HSV2-UL30-2120 - UUCCGGUCGCGGAACGC 17 4979
HSV2-UL30-832 - UCCGGUCGCGGAACGCC 17 3702
HSV2-UL30-2122 - CCUGUCCACCACCGCCC 17 4980
HSV2-UL30-2123 - CAUCCUCCUGUUUUCGC 17 4981 HSV2-UL30-2124 - CGGAUCCUGCGACCUCC 17 4982
HSV2-UL30-2125 - CUCAGCGAUCUCGCCUC 17 4983
HSV2-UL30-834 - UCAGCGAUCUCGCCUCC 17 3704
HSV2-UL30-2127 - UGCCGGCCCCCGUCGUC 17 4984
HSV2-UL30-838 - GCCGGCCCCCGUCGUCC 17 3708
HSV2-UL30-2129 - CGUCCUGGAGUUUGACA 17 4985
HSV2-UL30-2130 - GGAGUUUGACAGCGAAU 17 4986
HSV2-UL30-2131 - CGUCAAGCAGUACGGCC 17 4987
HSV2-UL30-2132 - CGGCCCCGAGUUCGUGA 17 4988
HSV2-UL30-2133 - UCGUCCUGACCAAGCUG 17 4989
HSV2-UL30-844 - CGUCCUGACCAAGCUGA 17 3714
HSV2-UL30-2135 - CU AC AAG GUCCCGCUCG 17 4990
HSV2-UL30-2136 - GGUCCCGCUCGACGGGU 17 4991
HSV2-UL30-2137 - UCGACGGGUACGGGCGC 17 4992
HSV2-UL30-2138 - UACGGGCGCAUGAACGG 17 4993
HSV2-UL30-851 - ACGGGCGCAUGAACGGC 17 3721
HSV2-UL30-2140 - CGGGGUGUGUUCCGCGU 17 4994
HSV2-UL30-854 - GGGGUGUGUUCCGCGUG 17 3724
HSV2-UL30-2142 - GCGUGUGGGACAUCGGC 17 4995
HSV2-UL30-2143 - UCGGCCAGAGCCACUUU 17 4996
HSV2-UL30-2144 - AGCGCAGCAAGAUCAAG 17 4997
HSV2-UL30-2145 - CAGCAAGAUCAAGGUGA 17 4998
HSV2-UL30-858 - AG CAAG AU CAAG G U G AA 17 3728
HSV2-UL30-2147 - UCAAGGUGAACGGGAUG 17 4999
HSV2-UL30-2148 - AACUCU CCAG CU ACAAG 17 5000
HSV2-UL30-2149 - CAAGCUGAACGCCGUCG 17 5001
HSV2-UL30-2150 - CCGUCGCCGAGGCCGUC 17 5002
HSV2-UL30-2151 - UCGCCGAGGCCGUCUUG 17 5003
HSV2-UL30-2152 - AGGCCGUCUUGAAGGAC 17 5004
HSV2-UL30-2153 - CCGUCU UGAAGGACAAG 17 5005
HSV2-UL30-2154 - UCUUGAAGGACAAGAAG 17 5006
HSV2-UL30-2155 - AGGACAAGAAGAAGGAU 17 5007
HSV2-UL30-2156 - CCCCGCCUACUACGCCU 17 5008
HSV2-UL30-2157 - CUCCGGGCCCGCGCAGC 17 5009
HSV2-UL30-868 - UCCGGGCCCGCGCAGCG 17 3738
HSV2-UL30-2159 - GCAGCGCGGGGUGAUCG 17 5010
HSV2-UL30-2160 - UCGGCGAGUAUUGUGUG 17 5011
HSV2-UL30-2161 - GCAGGACUCGCUGCUGG 17 5012
HSV2-UL30-2162 - UCAAGUUUCUGCCGCAC 17 5013
HSV2-UL30-876 - CAAGUUUCUGCCGCACC 17 3746
HSV2-UL30-2164 - CCGCCGUCGCGCGCCUG 17 5014
HSV2-UL30-2165 - CGUGCCUCCUGCGCCUU 17 5015
HSV2-UL30-2166 - UCCUGCGCCUUGCGGGC 17 5016
HSV2-UL30-2167 - UGCGCCUUGCGGGCCAG 17 5017
HSV2-UL30-2168 - AGAAGGGCUUCAUCCUG 17 5018
HSV2-UL30-2169 - UCAUCCUGCCGGACACC 17 5019 HSV2-UL30-886 - CAUCCUGCCGGACACCC 17 3756
HSV2-UL30-2171 - GACACCCAGGGGCGGUU 17 5020
HSV2-UL30-890 - ACACCCAGGGGCGGUUU 17 3760
HSV2-UL30-2173 - GGUUUCGGGGCCUCGAC 17 5021
HSV2-UL30-893 - GUUUCGGGGCCUCGACA 17 3763
HSV2-UL30-2175 - AAGCGCCCGGCCGUGCC 17 5022
HSV2-UL30-896 - AGCGCCCGGCCGUGCCU 17 3766
HSV2-UL30-897 - GCGCCCGGCCGUGCCUC 17 3767
HSV2-UL30-898 - CGCCCGGCCGUGCCUCG 17 3768
HSV2-UL30-899 - GCCCGGCCGUGCCUCGG 17 3769
HSV2-UL30-900 - CCCGGCCGUGCCUCGGG 17 3770
HSV2-UL30-2181 - GGCCGUGCCUCGGGGGG 17 5023
HSV2-UL30-901 - GCCGUGCCUCGGGGGGA 17 3771
HSV2-UL30-902 - CCGUGCCUCGGGGGGAA 17 3772
HSV2-UL30-903 - CGUGCCUCGGGGGGAAG 17 3773
HSV2-UL30-2185 - GGGGGGAAGGGGAGCGG 17 5024
HSV2-UL30-905 - GGGGGAAGGGGAGCGGC 17 3775
HSV2-UL30-906 - GGGGAAGGGGAGCGGCC 17 3776
HSV2-UL30-907 - GGGAAGGGGAGCGGCCG 17 3777
HSV2-UL30-2189 - AGGGGAGCGGCCGGGGG 17 5025
HSV2-UL30-909 - GGGGAGCGGCCGGGGGA 17 3779
HSV2-UL30-910 - GGGAGCGGCCGGGGGAC 17 3780
HSV2-UL30-2192 - GCGGCCGGGGGACGGGA 17 5026
HSV2-UL30-911 - CGGCCGGGGGACGGGAA 17 3781
HSV2-UL30-912 - GGCCGGGGGACGGGAAC 17 3782
HSV2-UL30-2195 - GGGGGACGGGAACGGGG 17 5027
HSV2-UL30-2196 - GGGACGGGAACGGGGAC 17 5028
HSV2-UL30-2197 - GGAACGGGGACGAGGAU 17 5029
HSV2-UL30-2198 - CGAGGAUAAGGACGACG 17 5030
HSV2-UL30-2199 - AGGAUAAGGACGACGAC 17 5031
HSV2-UL30-2200 - UAAGGACGACGACGAGG 17 5032
HSV2-UL30-917 - AAGGACGACGACGAGGA 17 3787
HSV2-UL30-918 - AGGACGACGACGAGGAC 17 3788
HSV2-UL30-2203 - CGACGACGAGGACGGGG 17 5033
HSV2-UL30-2204 - ACGACGAGGACGGGGAC 17 5034
HSV2-UL30-2205 - CGAGGACGGGGACGAGG 17 5035
HSV2-UL30-921 - GAGGACGGGGACGAGGA 17 3791
HSV2-UL30-922 - AGGACGGGGACGAGGAC 17 3792
HSV2-UL30-2208 - CGGGGACGAGGACGGGG 17 5036
HSV2-UL30-2209 - CGAGGACGGGGACGAGC 17 5037
HSV2-UL30-2210 - AGGACGGGGACGAGCGC 17 5038
HSV2-UL30-924 - GGACGGGGACGAGCGCG 17 3794
HSV2-UL30-2212 - GCGCGAGGAGGUCGCGC 17 5039
HSV2-UL30-2213 - GGAGGUCGCGCGCGAGA 17 5040
HSV2-UL30-926 - GAGGUCGCGCGCGAGAC 17 3796
HSV2-UL30-927 - AGGUCGCGCGCGAGACC 17 3797 HSV2-UL30-2216 - GACCGGGGGCCGGCACG 17 5041
HSV2-UL30-2217 - GCCGGCACGUUGGGUAC 17 5042
HSV2-UL30-933 - CCGGCACGUUGGGUACC 17 3803
HSV2-UL30-934 - CGGCACGUUGGGUACCA 17 3804
HSV2-UL30-2220 - GUUGGGUACCAGGGGGC 17 5043
HSV2-UL30-2221 - GGUCCUCGACCCCACCU 17 5044
HSV2-UL30-2222 - UACGCUCUCCCUGCGGC 17 5045
HSV2-UL30-2223 - CCGAGGCCGUCGCGCAC 17 5046
HSV2-UL30-946 - CGAGGCCGUCGCGCACC 17 3816
HSV2-UL30-2225 - CCGUCGCGCACCUGGAG 17 5047
HSV2-UL30-2226 - GCGCACCUGGAGGCGGA 17 5048
HSV2-UL30-949 - CGCACCUGGAGGCGGAC 17 3819
HSV2-UL30-2228 - AGGCGGACCGGGACUAC 17 5049
HSV2-UL30-951 - GGCGGACCGGGACUACC 17 3821
HSV2-UL30-2230 - CCGGGACUACCUGGAGA 17 5050
HSV2-UL30-2231 - ACUACCUGGAGAUCGAG 17 5051
HSV2-UL30-953 - CUACCUGGAGAUCGAGG 17 3823
HSV2-UL30-954 - UACCUGGAGAUCGAGGU 17 3824
HSV2-UL30-955 - ACCUGGAGAUCGAGGUG 17 3825
HSV2-UL30-2235 - GCCGACGGCUGUUCUUC 17 5052
HSV2-UL30-2236 - CGUGAAGGCCCACGUAC 17 5053
HSV2-UL30-2237 - UGAAGGCCCACGUACGC 17 5054
HSV2-UL30-2238 - ACGUACGCGAGAGCCUG 17 5055
HSV2-UL30-2239 - CGCGACUGGCUGGCCAU 17 5056
HSV2-UL30-2240 - CGAAAGCAGAUCCGCUC 17 5057
HSV2-UL30-2241 - UCCGCUCGCGGAUCCCC 17 5058
HSV2-UL30-2242 - GAUCCCCCAGAGCACCC 17 5059
HSV2-UL30-2243 - UCCCCCAGAGCACCCCC 17 5060
HSV2-UL30-963 - CCCCCAGAGCACCCCCG 17 3833
HSV2-UL30-2245 - GGUGUGCAACUCGGUGU 17 5061
HSV2-UL30-2246 - CUCGGUGUACGGGUUCA 17 5062
HSV2-UL30-971 - UCGGUGUACGGGUUCAC 17 3841
HSV2-UL30-2248 - CGUGACGACCAUCGGCC 17 5063
HSV2-UL30-2249 - GCGUACGUGCACGCGCG 17 5064
HSV2-UL30-2250 - ACGUGCACGCGCGCUGG 17 5065
HSV2-UL30-979 - CGUGCACGCGCGCUGGG 17 3849
HSV2-UL30-2252 - AGCUGCUGGCCGACUUU 17 5066
HSV2-UL30-981 - GCUGCUGGCCGACUUUC 17 3851
HSV2-UL30-2254 - CUCCAUGCGCAUCAUCU 17 5067
HSV2-UL30-986 - UCCAUGCGCAUCAUCUA 17 3856
HSV2-UL30-987 - CCAUGCGCAUCAUCUAC 17 3857
HSV2-UL30-2257 - GCAUCAUCUACGGGGAC 17 5068
HSV2-UL30-2258 - GCCGCGGCCUCACGGCC 17 5069
HSV2-UL30-2259 - CCGCGGGCCUGGUGGCC 17 5070
HSV2-UL30-2260 - CCAUGGGCGACAAGAUG 17 5071
HSV2-UL30-2261 - CCUCCCCCCGAUCAAGC 17 5072 HSV2-UL30-2262 - CCCGAUCAAGCUCGAGU 17 5073
HSV2-UL30-2263 - AGCUGCUGCUCAUCGCC 17 5074
HSV2-UL30-2264 - GUACAUCGGCGUCAUCU 17 5075
HSV2-UL30-1000 - UACAUCGGCGUCAUCUG 17 3870
HSV2-UL30-1001 - ACAUCGGCGUCAUCUGC 17 3871
HSV2-UL30-2267 - GGGGCAAGAUGCUCAUC 17 5076
HSV2-UL30-2268 - AGAUGCUCAUCAAGGGC 17 5077
HSV2-UL30-2269 - U U U AU CAACCG CACCU C 17 5078
HSV2-UL30-2270 - UUACGACGAUACCGUAU 17 5079
HSV2-UL30-1011 - UACGACGAUACCGUAUC 17 3881
HSV2-UL30-2272 - AGCGGCCGCCGCGUUAG 17 5080
HSV2-UL30-2273 - GUUAGCCGAGCGCCCCG 17 5081
HSV2-UL30-2274 - UAGCCGAGCGCCCCGCA 17 5082
HSV2-UL30-1013 - AGCCGAGCGCCCCGCAG 17 3883
HSV2-UL30-2276 - GCUGGCGCGACCCCUGC 17 5083
HSV2-UL30-2277 - UGGCGCGACCCCUGCCC 17 5084
HSV2-UL30-1016 - GGCGCGACCCCUGCCCG 17 3886
HSV2-UL30-2279 - CGAGGGACUGCAGGCGU 17 5085
HSV2-UL30-1019 - GAGGGACUGCAGGCGUU 17 3889
HSV2-UL30-2281 - AUCGGCGCAUCACCGAC 17 5086
HSV2-UL30-1023 - UCGGCGCAUCACCGACC 17 3893
HSV2-UL30-2283 - GGCGCAUCACCGACCCG 17 5087
HSV2-UL30-2284 - CGCAUCACCGACCCGGA 17 5088
HSV2-UL30-1024 - GCAUCACCGACCCGGAG 17 3894
HSV2-UL30-2286 - ACCCGGAGAGGGACAUC 17 5089
HSV2-UL30-2287 - GGACUUUGUCCUCACCG 17 5090
HSV2-UL30-2288 - U U G U CCU CACCG CCGAA 17 5091
HSV2-UL30-2289 - CGCAGGUCCCGUCCAUC 17 5092
HSV2-UL30-2290 - G U CCCG U CCAUCAAG G A 17 5093
HSV2-UL30-2291 - GAUCGUGGCCCAGACCC 17 5094
HSV2-UL30-2292 - GGCCCAGACCCGCGAGG 17 5095
HSV2-UL30-2293 - CCCAGACCCGCGAGGUA 17 5096
HSV2-UL30-1035 - CCAG ACCCG CG AG G U AG 17 3905
HSV2-UL30-2295 - GCGGCUGGCCGCCCUCC 17 5097
HSV2-UL30-2296 - GCUAGACGCCGCCGCCC 17 5098
HSV2-UL30-1039 - CUAGACGCCGCCGCCCC 17 3909
HSV2-UL30-1040 - UAGACGCCGCCGCCCCA 17 3910
HSV2-UL30-2299 - CGCCGCCGCCCCAGGGG 17 5099
HSV2-UL30-2300 - UCCCCGGCCAAGCGCCC 17 5100
HSV2-UL30-1044 - CCCCGGCCAAGCGCCCC 17 3914
HSV2-UL30-1045 - CCCGGCCAAGCGCCCCC 17 3915
HSV2-UL30-2303 - CGUCGCAUGCCGACCCC 17 5101
HSV2-UL30-1046 - GUCGCAUGCCGACCCCC 17 3916
HSV2-UL30-1047 - UCGCAUGCCGACCCCCC 17 3917
HSV2-UL30-2306 - CCGCAAGCUGCUGGUGU 17 5102
HSV2-UL30-2307 - UGCUGGUGUCCGAGCUG 17 5103 HSV2-UL30-1051 - GCUGGUGUCCGAGCUGG 17 3921
HSV2-UL30-2309 - UGGUGUCCGAGCUGGCG 17 5104
HSV2-UL30-2310 - CGAGCUGGCGGAGGAUC 17 5105
HSV2-UL30-2311 - CCCGGGUACGCCAUCGC 17 5106
HSV2-UL30-1055 - CCGGGUACGCCAUCGCC 17 3925
HSV2-UL30-2313 - GGGGCGUUCCGCUCAAC 17 5107
HSV2-UL30-2314 - AUUACUUCUCGCACCUG 17 5108
HSV2-UL30-1059 - UUACUUCUCGCACCUGC 17 3929
HSV2-UL30-1060 - UACUUCUCGCACCUGCU 17 3930
HSV2-UL30-2317 - G ACG U U CAAG GCCCUGU 17 5109
HSV2-UL30-1065 - ACGUUCAAGGCCCUGUU 17 3935
HSV2-UL30-2319 - AAAUAACGCCAAGAUCA 17 5110
HSV2-UL30-2320 - AUAACGCCAAGAUCACC 17 5111
HSV2-UL30-2321 - UCACCGAGAGUCUGUUA 17 5112
HSV2-UL30-2322 - GUUAAAGAGGUUUAUUC 17 5113
HSV2-UL30-2323 - CCGAGACGUGGCACCCC 17 5114
HSV2-UL30-2324 - GACGUGGCCGCGCGGCU 17 5115
HSV2-UL30-2325 - CCGCGCGGCUCAGGGCC 17 5116
HSV2-UL30-1073 - CGCGCGGCUCAGGGCCG 17 3943
HSV2-UL30-2327 - GCUCAGGGCCGCGGGGU 17 5117
HSV2-UL30-2328 - CCGCGGGGUUCGGGCCG 17 5118
HSV2-UL30-1079 - CGCGGGGUUCGGGCCGG 17 3949
HSV2-UL30-1080 - GCGGGGUUCGGGCCGGC 17 3950
HSV2-UL30-2331 - CGGGGGCCGGCGCUACG 17 5119
HSV2-UL30-1085 - GGGGGCCGGCGCUACGG 17 3955
HSV2-UL30-2333 - GGGCCGGCGCUACGGCG 17 5120
HSV2-UL30-1086 - GGCCGGCGCUACGGCGG 17 3956
HSV2-UL30-2335 - ACGGCGGAGGAAACUCG 17 5121
HSV2-UL30-2336 - ACUCGUCGAAUGUUGCA 17 5122
HSV2-UL30-2337 + AAGGCUCUAUGCAACAUUCG 20 5123
HSV2-UL30-2338 + UAGCGCCGGCCCCCGCCGGC 20 5124
HSV2-UL30-2339 + CCGGCCCGAACCCCGCGGCC 20 5125
HSV2-UL30-2340 + GAGCCGCGCGGCCACGUCGU 20 5126
HSV2-UL30-1091 + AGCCGCGCGGCCACGUCGUC 20 3961
HSV2-UL30-1092 + GCCGCGCGGCCACGUCGUCC 20 3962
HSV2-UL30-1093 + CCGCGCGGCCACGUCGUCCG 20 3963
HSV2-UL30-2344 + CGUCCGGGGGGUGCCACGUC 20 5127
HSV2-UL30-1096 + GUCCGGGGGGUGCCACGUCU 20 3966
HSV2-UL30-1097 + UCCGGGGGGUGCCACGUCUC 20 3967
HSV2-UL30-2347 + AUCUUGGCGUUAUUUCCAAA 20 5128
HSV2-UL30-2348 + CGUUAUUUCCAAACAGGGCC 20 5129
HSV2-UL30-2349 + GCAGGCCGCCCCCAGCAGGU 20 5130
HSV2-UL30-2350 + AGGCCGCCCCCAGCAGGUGC 20 5131
HSV2-UL30-2351 + GCGAGAAGUAAUAGUCCGUG 20 5132
HSV2-UL30-2352 + GAAGUAAUAGUCCGUGUUGA 20 5133
HSV2-UL30-1104 + AAGUAAUAGUCCGUGUUGAG 20 3974 HSV2-UL30-2354 + UCCGUGUUGAGCGGAACGCC 20 5134
HSV2-UL30-2355 + CGCCCCGGGCGAUGGCGUAC 20 5135
HSV2-UL30-1108 + GCCCCGGGCGAUGGCGUACC 20 3978
HSV2-UL30-2357 + ACCCGGGAUCCUCCGCCAGC 20 5136
HSV2-UL30-2358 + AGCUCGGACACCAGCAGCUU 20 5137
HSV2-UL30-1111 + GCUCGGACACCAGCAGCUUG 20 3981
HSV2-UL30-2360 + ACACCAGCAGCUUGCGGGGC 20 5138
HSV2-UL30-2361 + GCGGGGCUUGGACGCGCCUC 20 5139
HSV2-UL30-1115 + CGGGGCUUGGACGCGCCUCC 20 3985
HSV2-UL30-1116 + GGGGCUUGGACGCGCCUCCC 20 3986
HSV2-UL30-1117 + GGGCUUGGACGCGCCUCCCG 20 3987
HSV2-UL30-2365 + UCGGCAUGCGACGGCGUCUC 20 5140
HSV2-UL30-1122 + CGGCAUGCGACGGCGUCUCC 20 3992
HSV2-UL30-1123 + GGCAUGCGACGGCGUCUCCC 20 3993
HSV2-UL30-2368 + CGUCUCCCGGGGGCGCUUGG 20 5141
HSV2-UL30-1127 + GUCUCCCGGGGGCGCUUGGC 20 3997
HSV2-UL30-1128 + UCUCCCGGGGGCGCUUGGCC 20 3998
HSV2-UL30-1129 + CUCCCGGGGGCGCU UGGCCG 20 3999
HSV2-UL30-2372 + CCCGGGGGCGCUUGGCCGGG 20 5142
HSV2-UL30-2373 + GGGCGCUUGGCCGGGGAGGG 20 5143
HSV2-UL30-2374 + GGCCGGGGAGGGCAGGGCCG 20 5144
HSV2-UL30-1134 + GCCGGGGAGGGCAGGGCCGC 20 4004
HSV2-UL30-1135 + CCGGGGAGGGCAGGGCCGCU 20 4005
HSV2-UL30-1136 + CGGGGAGGGCAGGGCCGCUG 20 4006
HSV2-UL30-1137 + GGGGAGGGCAGGGCCGCUGG 20 4007
HSV2-UL30-2379 + AGGGCAGGGCCGCUGGGGGG 20 5145
HSV2-UL30-2380 + UGGGGGGGCGGGCUCGUCCC 20 5146
HSV2-UL30-1142 + GGGGGGGCGGGCUCGUCCCC 20 4012
HSV2-UL30-2382 + GGGGCGGCGGCGUCUAGCUC 20 5147
HSV2-UL30-1147 + GGGCGGCGGCGUCUAGCUCG 20 4017
HSV2-UL30-2384 + GCGGCGGCGUCUAGCUCGCG 20 5148
HSV2-UL30-2385 + GCGACCGUCUCCUCUACCUC 20 5149
HSV2-UL30-2386 + GUCUCCUCUACCUCGCGGGU 20 5150
HSV2-UL30-2387 + GGUCUGGGCCACGAUCACGU 20 5151
HSV2-UL30-1155 + GUCUGGGCCACGAUCACGUA 20 4025
HSV2-UL30-2389 + CGUACGGGAUCCGGUCCUUG 20 5152
HSV2-UL30-2390 + CGGGAUCCGGUCCUUGAUGG 20 5153
HSV2-UL30-1159 + GGGAUCCGGUCCUUGAUGGA 20 4029
HSV2-UL30-2392 + AUGGACGGGACCUGCGCGCG 20 5154
HSV2-UL30-2393 + GGACCUGCGCGCGGCGGGCC 20 5155
HSV2-UL30-2394 + AGCUUGUAAUACACCGUCAG 20 5156
HSV2-UL30-2395 + GCGCUUGUUGGUGUACGCGC 20 5157
HSV2-UL30-2396 + GGUGUCUGCUCAGUUCGGCG 20 5158
HSV2-UL30-2397 + UGUCUGCUCAGUUCGGCGGU 20 5159
HSV2-UL30-2398 + UCGGCGGUGAGGACAAAGUC 20 5160
HSV2-UL30-2399 + AAAGUCCUGGAUGUCCCUCU 20 5161 HSV2-UL30-2400 + UCCGGGUCGGUGAUGCGCCG 20 5162
HSV2-UL30-2401 + UGAUGCGCCGAUGGGCGUCU 20 5163
HSV2-UL30-2402 + AUGCGCCGAUGGGCGUCUAC 20 5164
HSV2-UL30-2403 + GGGCGUCUACGAGGACGGCC 20 5165
HSV2-UL30-2404 + CCCCGAACGCCUGCAGUCCC 20 5166
HSV2-UL30-2405 + AACGCCUGCAGUCCCUCGGG 20 5167
HSV2-UL30-1184 + ACGCCUGCAGUCCCUCGGGC 20 4054
HSV2-UL30-2407 + GUCGCGCCAGCCACUCCUCU 20 5168
HSV2-UL30-1187 + UCGCGCCAGCCACUCCUCUG 20 4057
HSV2-UL30-2409 + CGGCUAACGCGGCGGCCGCU 20 5169
HSV2-UL30-2410 + U CG U AAAACAG CAG G U CG AC 20 5170
HSV2-UL30-2411 + ACAGCAGGUCGACCAGGGCC 20 5171
HSV2-UL30-1198 + CAGCAGGUCGACCAGGGCCC 20 4068
HSV2-UL30-2413 + GCACCAGAUCCACGCCCUUG 20 5172
HSV2-UL30-2414 + CGAUGUACUUUUUCUUGGCG 20 5173
HSV2-UL30-2415 + UGGCGAUGAGCAGCAGCUUG 20 5174
HSV2-UL30-2416 + UGGUGAACGUUUUUUCGCAC 20 5175
HSV2-UL30-2417 + UUUUUCGCACUCGAGCUUGA 20 5176
HSV2-UL30-1203 + UUUUCGCACUCGAGCUUGAU 20 4073
HSV2-UL30-1204 + UUUCGCACUCGAGCUUGAUC 20 4074
HSV2-UL30-1205 + UUCGCACUCGAGCUUGAUCG 20 4075
HSV2-UL30-1206 + UCGCACUCGAGCUUGAUCGG 20 4076
HSV2-UL30-1207 + CGCACUCGAGCUUGAUCGGG 20 4077
HSV2-UL30-2423 + CACUCGAGCUUGAUCGGGGG 20 5177
HSV2-UL30-1208 + ACUCGAGCUUGAUCGGGGGG 20 4078
HSV2-UL30-2425 + CGGGGGGAGGAACAGCGCGC 20 5178
HSV2-UL30-2426 + UGGCCACCAGGCCCGCGGCC 20 5179
HSV2-UL30-2427 + CCGUGAGGCCGCGGCACAAA 20 5180
HSV2-UL30-2428 + GGCCGCGGCACAAAACGAAA 20 5181
HSV2-UL30-1215 + G CCG CG G CACAAAACG AAAA 20 4085
HSV2-UL30-2430 + UGUCCCCGUAGAUGAUGCGC 20 5182
HSV2-UL30-1216 + GUCCCCGUAGAUGAUGCGCA 20 4086
HSV2-UL30-2432 + GUAGAUGAUGCGCAUGGAGU 20 5183
HSV2-UL30-2433 + UGAUGCGCAUGGAGUACGGA 20 5184
HSV2-UL30-1218 + GAUGCGCAUGGAGUACGGAC 20 4088
HSV2-UL30-1219 + AUGCGCAUGGAGUACGGACC 20 4089
HSV2-UL30-2436 + GGCGCGCAUGCCGGCCGCCU 20 5185
HSV2-UL30-1223 + GCGCGCAUGCCGGCCGCCUC 20 4093
HSV2-UL30-2438 + GAAAGUCGGCCAGCAGCUGA 20 5186
HSV2-UL30-2439 + CGUGCACGUACGCGCGCGUC 20 5187
HSV2-UL30-2440 + UGCACGUACGCGCGCGUCGC 20 5188
HSV2-UL30-1225 + GCACGUACGCGCGCGUCGCG 20 4095
HSV2-UL30-2442 + CGGUGGCGGCCACGUGCAGG 20 5189
HSV2-UL30-2443 + GCGGCCACGUGCAGGCAGGG 20 5190
HSV2-UL30-2444 + GAAGACCGUGCUGCACCCCG 20 5191
HSV2-UL30-2445 + CACCCCGG UGAACCCG U ACA 20 5192 HSV2-UL30-2446 + UGAUGGCGGCCUGUUGCUUG 20 5193
HSV2-UL30-2447 + AUGGCGGCCUGUUGCUUGUC 20 5194
HSV2-UL30-1237 + UGGCGGCCUGUUGCUUGUCG 20 4107
HSV2-UL30-2449 + GCGGCCUGUUGCUUGUCGAG 20 5195
HSV2-UL30-2450 + UGUCGAGGAGGACGGCCUCC 20 5196
HSV2-UL30-1240 + GUCGAGGAGGACGGCCUCCU 20 4110
HSV2-UL30-1241 + UCGAGGAGGACGGCCUCCUC 20 4111
HSV2-UL30-2453 + ACGGCCUCCUCGGGGGUGCU 20 5197
HSV2-UL30-1244 + CGGCCUCCUCGGGGGUGCUC 20 4114
HSV2-UL30-1245 + GGCCUCCUCGGGGGUGCUCU 20 4115
HSV2-UL30-1246 + GCCUCCUCGGGGGUGCUCUG 20 4116
HSV2-UL30-2457 + GGGGGUGCUCUGGGGGAUCC 20 5198
HSV2-UL30-2458 + GUGCUCUGGGGGAUCCGCGA 20 5199
HSV2-UL30-2459 + AUGGCCAGCCAGUCGCGCAG 20 5200
HSV2-UL30-2460 + CUCAGCAGGCUCUCGCGUAC 20 5201
HSV2-UL30-2461 + UCUCGCGUACGUGGGCCUUC 20 5202
HSV2-UL30-2462 + CGCGUACGUGGGCCUUCACG 20 5203
HSV2-UL30-2463 + CCUCCAGGUGCGCGACGGCC 20 5204
HSV2-UL30-2464 + UGCGCGACGGCCUCGGGCCG 20 5205
HSV2-UL30-1261 + GCGCGACGGCCUCGGGCCGC 20 4131
HSV2-UL30-1262 + CGCGACGGCCUCGGGCCGCA 20 4132
HSV2-UL30-2467 + CGACGGCCUCGGGCCGCAGG 20 5206
HSV2-UL30-2468 + CGGGCCGCAGGGAGAGCGUA 20 5207
HSV2-UL30-2469 + AGCGUACUGAAGCACAGGUU 20 5208
HSV2-UL30-2470 + CUGAAGCACAGGUUGUGGGC 20 5209
HSV2-UL30-2471 + GGUUGUGGGCCUGGAUGAUG 20 5210
HSV2-UL30-1267 + GUUGUGGGCCUGGAUGAUGC 20 4137
HSV2-UL30-2473 + U G G CAAAG U CAAACACCACC 20 5211
HSV2-UL30-1272 + G G CAAAG U CAAACACC ACCA 20 4142
HSV2-UL30-2475 + AACACCACCACGGGGUCGAC 20 5212
HSV2-UL30-2476 + CCACGGGGUCGACGUG AAAC 20 5213
HSV2-UL30-1275 + CACGGGGUCGACGUG AAACC 20 4145
HSV2-UL30-2478 + GGUCGACGUGAAACCCGGAG 20 5214
HSV2-UL30-1277 + GUCGACGUGAAACCCGGAGG 20 4147
HSV2-UL30-2480 + CGUGAAACCCGGAGGUGGGG 20 5215
HSV2-UL30-2481 + UGAAACCCGGAGGUGGGGUC 20 5216
HSV2-UL30-2482 + CCGGAGGUGGGGUCGAGGAC 20 5217
HSV2-UL30-2483 + CCCGGCCGCUCCCCUUCCCC 20 5218
HSV2-UL30-2484 + CCCUUCCCCCCGAGGCACGG 20 5219
HSV2-UL30-2485 + CCCGAGGCACGGCCGGGCGC 20 5220
HSV2-UL30-2486 + GGCGCU UGGGCGCCUCCUUG 20 5221
HSV2-UL30-2487 + GGCGCCUCCUUGUCGAGGCC 20 5222
HSV2-UL30-2488 + UCGAGGCCCCGAAACCGCCC 20 5223
HSV2-UL30-2489 + AACCGCCCCUGGGUGUCCGG 20 5224
HSV2-UL30-2490 + GCCCCUGGGUGUCCGGCAGG 20 5225
HSV2-UL30-2491 + CCCUUCUGGCCCGCAAGGCG 20 5226 HSV2-UL30-1300 + CCUUCUGGCCCGCAAGGCGC 20 4170
HSV2-UL30-2493 + CCG C AAG G CG CAG G AG G CAC 20 5227
HSV2-UL30-2494 + CGCAGGAGGCACGUGAAGAC 20 5228
HSV2-UL30-2495 + UGCUGGCCGUCGUAGAUGGU 20 5229
HSV2-UL30-2496 + UGCCCGCCAGGCGCGCGACG 20 5230
HSV2-UL30-1309 + GCCCGCCAGGCGCGCGACGG 20 4179
HSV2-UL30-2498 + GCGGAAAGCUCCAGGUGCGG 20 5231
HSV2-UL30-2499 + GCUCCAGGUGCGGCAGAAAC 20 5232
HSV2-UL30-2500 + CCAGGUGCGGCAGAAACUUG 20 5233
HSV2-UL30-2501 + GAACAGCUGCCCGACCAGCA 20 5234
HSV2-UL30-2502 + CGCCGAUCACCCCGCGCUGC 20 5235
HSV2-UL30-2503 + UCACCCCGCGCUGCGCGGGC 20 5236
HSV2-UL30-1314 + CACCCCGCGCUGCGCGGGCC 20 4184
HSV2-UL30-2505 + CGGGCCCGGAGGCGUAGUAG 20 5237
HSV2-UL30-1317 + GGGCCCGGAGGCGUAGUAGG 20 4187
HSV2-UL30-1318 + GGCCCGGAGGCGUAGUAGGC 20 4188
HSV2-UL30-2508 + CGACGGCGUUCAGCUUGUAG 20 5238
HSV2-UL30-1324 + GACGGCGUUCAGCUUGUAGC 20 4194
HSV2-UL30-2510 + CGGCGUUCAGCUUGUAGCUG 20 5239
HSV2-UL30-2511 + ACCUUGAUCUUGCUGCGCUU 20 5240
HSV2-UL30-2512 + CUCUGGCCGAUGUCCCACAC 20 5241
HSV2-UL30-1328 + UCUGGCCGAUGUCCCACACG 20 4198
HSV2-UL30-2514 + CGU UCAUGCGCCCGUACCCG 20 5242
HSV2-UL30-2515 + CAUGCGCCCGUACCCGUCGA 20 5243
HSV2-UL30-1330 + AUGCGCCCGUACCCGUCGAG 20 4200
HSV2-UL30-2517 + UAGAUCUCCGUCAGCUUGGU 20 5244
HSV2-UL30-2518 + UCUCCGUCAGCUUGGUCAGG 20 5245
HSV2-UL30-2519 + CCGUCAGCUUGGUCAGGACG 20 5246
HSV2-UL30-2520 + UGGUCAGGACGAAGGGCCAG 20 5247
HSV2-UL30-2521 + UGAUGAUGUUGUACCCGGUC 20 5248
HSV2-UL30-2522 + UGUUGUACCCGGUCACGAAC 20 5249
HSV2-UL30-1337 + GUUGUACCCGGUCACGAACU 20 4207
HSV2-UL30-2524 + ACUCGGGGCCGUACUGCUUG 20 5250
HSV2-UL30-2525 + CGUACUGCUUGACGAAGGUC 20 5251
HSV2-UL30-2526 + UCAUGAAGGCCAGCAGCAUC 20 5252
HSV2-UL30-2527 + U CG AAU U CGCU G U CAAACU C 20 5253
HSV2-UL30-2528 + CGCUGUCAAACUCCAGGACG 20 5254
HSV2-UL30-1343 + GCUGUCAAACUCCAGGACGA 20 4213
HSV2-UL30-1344 + CU G U CAAACU CCAGGACG AC 20 4214
HSV2-UL30-2531 + CGACGGGGGCCGGCAGGCCC 20 5255
HSV2-UL30-1349 + GACGGGGGCCGGCAGGCCCC 20 4219
HSV2-UL30-2533 + GGGCCGGCAGGCCCCUGGAG 20 5256
HSV2-UL30-2534 + GGCCCCUGGAGGCGAGAUCG 20 5257
HSV2-UL30-2535 + CUGGAGGCGAGAUCGCUGAG 20 5258
HSV2-UL30-1352 + UGGAGGCGAGAUCGCUGAGG 20 4222
HSV2-UL30-2537 + CGAGAUCGCUGAGGUGGGAC 20 5259 HSV2-UL30-1354 + GAGAUCGCUGAGGUGGGACU 20 4224
HSV2-UL30-1355 + AGAUCGCUGAGGUGGGACUC 20 4225
HSV2-UL30-1356 + GAUCGCUGAGGUGGGACUCG 20 4226
HSV2-UL30-2541 + GGUGGGACUCGGGGAGGUCG 20 5260
HSV2-UL30-2542 + ACUCGGGGAGGUCGCAGGAU 20 5261
HSV2-UL30-2543 + GGGGAGGUCGCAGGAUCCGA 20 5262
HSV2-UL30-2544 + UCGCAGGAUCCGAGCGAAAA 20 5263
HSV2-UL30-1359 + CGCAGGAUCCGAGCGAAAAC 20 4229
HSV2-UL30-2546 + CAGG AU CCG AG CG AAAACAG 20 5264
HSV2-UL30-2547 + GCGAAAACAGGAGGAUGUGC 20 5265
HSV2-UL30-2548 + GAAAACAGGAGGAUGUGCUC 20 5266
HSV2-UL30-2549 + GGAUGUGCUCGAGGGCGGUG 20 5267
HSV2-UL30-2550 + GGGCGGUGGUGGACAGGUCG 20 5268
HSV2-UL30-2551 + UGGACAGGUCGUAGAGCAGA 20 5269
HSV2-UL30-1367 + GGACAGGUCGUAGAGCAGAC 20 4237
HSV2-UL30-2553 + UCGUAGAGCAGACAGGAGAU 20 5270
HSV2-UL30-2554 + GCAGACAGGAGAUCUGGAUG 20 5271
HSV2-UL30-2555 + GAUCUGGAUGACGAGGUCUU 20 5272
HSV2-UL30-2556 + GUCUUCCGGGCGUUCCGCGA 20 5273
HSV2-UL30-1372 + UCUUCCGGGCGUUCCGCGAC 20 4242
HSV2-UL30-2558 + CCCCGGCCUUGCAUUCGAUA 20 5274
HSV2-UL30-2559 + UGCAUUCGAUAUCGAAGCAC 20 5275
HSV2-UL30-2560 + GCAGUUAAACUCGACGUCGC 20 5276
HSV2-UL30-2561 + ACUCGACGUCGCUCGAGGUU 20 5277
HSV2-UL30-2562 + GCUCGAGGUUCCGAACGCCG 20 5278
HSV2-UL30-1382 + CUCGAGGUUCCGAACGCCGU 20 4252
HSV2-UL30-1383 + UCGAGGUUCCGAACGCCGUC 20 4253
HSV2-UL30-1384 + CGAGGUUCCGAACGCCGUCG 20 4254
HSV2-UL30-2566 + AACGCCGUCGGGGGGCGCGG 20 5279
HSV2-UL30-2567 + GGGCCGGCGCGU UCCCGCGG 20 5280
HSV2-UL30-2568 + GCGCGUUCCCGCGGCCGGGC 20 5281
HSV2-UL30-2569 + CGGGCUUGAGGCGGUACCAG 20 5282
HSV2-UL30-2570 + CCAG CCG AAG G U G ACAAACC 20 5283
HSV2-UL30-2571 + GUGACAAACCCCGGGUUGUC 20 5284
HSV2-UL30-2572 + CCCGGGUUGUCCAGGAUAAA 20 5285
HSV2-UL30-2573 + CCCCCUCGUACUUCCUGAUC 20 5286
HSV2-UL30-1404 + CCCCUCGUACUUCCUGAUCG 20 4274
HSV2-UL30-2575 + CCAGCGCGCGCCCGCUUCGC 20 5287
HSV2-UL30-2576 + CGCACGAAGACGCGGUAGUA 20 5288
HSV2-UL30-2577 + GAAGACGCGGUAGUACAGGG 20 5289
HSV2-UL30-2578 + CGCG CU CCACCACCU CCG CC 20 5290
HSV2-UL30-2579 + CCUCCGCCUCGAAGUGGUCC 20 5291
HSV2-UL30-1416 + CUCCGCCUCGAAGUGGUCCG 20 4286
HSV2-UL30-2581 + AAGUGGUCCGCGGAGAUGCC 20 5292
HSV2-UL30-1417 + AGUGGUCCGCGGAGAUGCCG 20 4287
HSV2-UL30-2583 + GACGCCCCCGGCGACUCGCG 20 5293 HSV2-UL30-2584 + GGGCCGCCGCCAGGCGCUCG 20 5294
HSV2-UL30-2585 + CAGGCGCUCGCAGAGAUCGC 20 5295
HSV2-UL30-1422 + AGGCGCUCGCAGAGAUCGCG 20 4292
HSV2-UL30-2587 + UACUGCCGCGUGCCGUAGAC 20 5296
HSV2-UL30-2588 + GAACGGCGACGCGAUGGCCU 20 5297
HSV2-UL30-1429 + AACGGCGACGCGAUGGCCUU 20 4299
HSV2-UL30-1430 + ACGGCGACGCGAUGGCCUUC 20 4300
HSV2-UL30-2591 + UGGCCUUCGGGGGUCAGACC 20 5298
HSV2-UL30-2592 + GAAGCGUGAUGACGGUCCCG 20 5299
HSV2-UL30-2593 + AUGGCGUCCAUAAAUCGCUC 20 5300
HSV2-UL30-1438 + UGGCGUCCAUAAAUCGCUCG 20 4308
HSV2-UL30-2595 + GCUCUAUGCAACAUUCG 17 5301
HSV2-UL30-2596 + CGCCGGCCCCCGCCGGC 17 5302
HSV2-UL30-2597 + GCCCGAACCCCGCGGCC 17 5303
HSV2-UL30-2598 + CCGCGCGGCCACGUCGU 17 5304
HSV2-UL30-1443 + CGCGCGGCCACGUCGUC 17 4313
HSV2-UL30-1444 + GCGCGGCCACGUCGUCC 17 4314
HSV2-UL30-1445 + CGCGGCCACGUCGUCCG 17 4315
HSV2-UL30-2602 + CCGGGGGGUGCCACGUC 17 5305
HSV2-UL30-1448 + CGGGGGGUGCCACGUCU 17 4318
HSV2-UL30-1449 + GGGGGGUGCCACGUCUC 17 4319
HSV2-UL30-2605 + UUGGCGUUAUUUCCAAA 17 5306
HSV2-UL30-2606 + UAUUUCCAAACAGGGCC 17 5307
HSV2-UL30-2607 + GGCCGCCCCCAGCAGGU 17 5308
HSV2-UL30-2608 + CCGCCCCCAGCAGGUGC 17 5309
HSV2-UL30-2609 + AGAAGUAAUAGUCCGUG 17 5310
HSV2-UL30-2610 + GUAAUAGUCCGUGUUGA 17 5311
HSV2-UL30-1456 + UAAUAGUCCGUGUUGAG 17 4326
HSV2-UL30-2612 + GUGUUGAGCGGAACGCC 17 5312
HSV2-UL30-2613 + CCCGGGCGAUGGCGUAC 17 5313
HSV2-UL30-1460 + CCGGGCGAUGGCGUACC 17 4330
HSV2-UL30-2615 + CGGGAUCCUCCGCCAGC 17 5314
HSV2-UL30-2616 + UCGGACACCAGCAGCUU 17 5315
HSV2-UL30-1463 + CG G ACACCAG CAGCU U G 17 4333
HSV2-UL30-2618 + CCAGCAGCUUGCGGGGC 17 5316
HSV2-UL30-2619 + GGGCUUGGACGCGCCUC 17 5317
HSV2-UL30-1467 + GGCUUGGACGCGCCUCC 17 4337
HSV2-UL30-1468 + GCUUGGACGCGCCUCCC 17 4338
HSV2-UL30-1469 + CUUGGACGCGCCUCCCG 17 4339
HSV2-UL30-2623 + GCAUGCGACGGCGUCUC 17 5318
HSV2-UL30-1474 + CAUGCGACGGCGUCUCC 17 4344
HSV2-UL30-1475 + AUGCGACGGCGUCUCCC 17 4345
HSV2-UL30-2626 + CUCCCGGGGGCGCUUGG 17 5319
HSV2-UL30-1479 + UCCCGGGGGCGCUUGGC 17 4349
HSV2-UL30-1480 + CCCGGGGGCGCUUGGCC 17 4350
HSV2-UL30-1481 + CCGGGGGCGCUUGGCCG 17 4351 HSV2-UL30-2630 + GGGGGCGCUUGGCCGGG 17 5320
HSV2-UL30-2631 + CGCUUGGCCGGGGAGGG 17 5321
HSV2-UL30-2632 + CGGGGAGGGCAGGGCCG 17 5322
HSV2-UL30-1486 + GGGGAGGGCAGGGCCGC 17 4356
HSV2-UL30-1487 + GGGAGGGCAGGGCCGCU 17 4357
HSV2-UL30-1488 + GGAGGGCAGGGCCGCUG 17 4358
HSV2-UL30-1489 + GAGGGCAGGGCCGCUGG 17 4359
HSV2-UL30-2637 + GCAGGGCCGCUGGGGGG 17 5323
HSV2-UL30-2638 + GGGGGCGGGCUCGUCCC 17 5324
HSV2-UL30-1494 + GGGGCGGGCUCGUCCCC 17 4364
HSV2-UL30-2640 + GCGGCGGCGUCUAGCUC 17 5325
HSV2-UL30-1499 + CGGCGGCGUCUAGCUCG 17 4369
HSV2-UL30-2642 + GCGGCGUCUAGCUCGCG 17 5326
HSV2-UL30-2643 + ACCGUCUCCUCUACCUC 17 5327
HSV2-UL30-2644 + UCCUCUACCUCGCGGGU 17 5328
HSV2-UL30-2645 + CUGGGCCACGAUCACGU 17 5329
HSV2-UL30-1507 + UGGGCCACGAUCACGUA 17 4377
HSV2-UL30-2647 + ACGGGAUCCGGUCCUUG 17 5330
HSV2-UL30-2648 + GAUCCGGUCCUUGAUGG 17 5331
HSV2-UL30-1511 + AUCCGGUCCUUGAUGGA 17 4381
HSV2-UL30-2650 + GACGGGACCUGCGCGCG 17 5332
HSV2-UL30-2651 + CCUGCGCGCGGCGGGCC 17 5333
HSV2-UL30-2652 + UUGUAAUACACCGUCAG 17 5334
HSV2-UL30-2653 + CUUGUUGGUGUACGCGC 17 5335
HSV2-UL30-2654 + GUCUGCUCAGUUCGGCG 17 5336
HSV2-UL30-2655 + CUGCUCAGUUCGGCGGU 17 5337
HSV2-UL30-2656 + G CG G U G AG G ACAAAG U C 17 5338
HSV2-UL30-2657 + GUCCUGGAUGUCCCUCU 17 5339
HSV2-UL30-2658 + GGGUCGGUGAUGCGCCG 17 5340
HSV2-UL30-2659 + UGCGCCGAUGGGCGUCU 17 5341
HSV2-UL30-2660 + CGCCGAUGGGCGUCUAC 17 5342
HSV2-UL30-2661 + CGUCUACGAGGACGGCC 17 5343
HSV2-UL30-2662 + CGAACGCCUGCAGUCCC 17 5344
HSV2-UL30-2663 + GCCUGCAGUCCCUCGGG 17 5345
HSV2-UL30-1536 + CCUGCAGUCCCUCGGGC 17 4406
HSV2-UL30-2665 + GCGCCAGCCACUCCUCU 17 5346
HSV2-UL30-1539 + CGCCAG CCACU CCU CU G 17 4409
HSV2-UL30-2667 + CUAACGCGGCGGCCGCU 17 5347
HSV2-UL30-2668 + UAAAACAGCAGGUCGAC 17 5348
HSV2-UL30-2669 + GCAGGUCGACCAGGGCC 17 5349
HSV2-UL30-1550 + CAGGUCGACCAGGGCCC 17 4420
HSV2-UL30-2671 + CCAGAUCCACGCCCU UG 17 5350
HSV2-UL30-2672 + UGUACUUUUUCUUGGCG 17 5351
HSV2-UL30-2673 + CGAUGAGCAGCAGCUUG 17 5352
HSV2-UL30-2674 + UGAACGUUUUUUCGCAC 17 5353
HSV2-UL30-2675 + UUCGCACUCGAGCUUGA 17 5354 HSV2-UL30-1555 + UCGCACUCGAGCUUGAU 17 4425
HSV2-UL30-1556 + CGCACUCGAGCUUGAUC 17 4426
HSV2-UL30-1557 + GCACUCGAGCUUGAUCG 17 4427
HSV2-UL30-1558 + CACUCGAGCUUGAUCGG 17 4428
HSV2-UL30-1559 + ACUCGAGCUUGAUCGGG 17 4429
HSV2-UL30-2681 + UCGAGCUUGAUCGGGGG 17 5355
HSV2-UL30-1560 + CGAGCUUGAUCGGGGGG 17 4430
HSV2-UL30-2683 + GGGGAGGAACAGCGCGC 17 5356
HSV2-UL30-2684 + CCACCAGGCCCGCGGCC 17 5357
HSV2-UL30-2685 + UGAGGCCGCGGCACAAA 17 5358
HSV2-UL30-2686 + CGCGGCACAAAACGAAA 17 5359
HSV2-UL30-1567 + GCGG CACAAAACG AAAA 17 4437
HSV2-UL30-2688 + CCCCGUAGAUGAUGCGC 17 5360
HSV2-UL30-1568 + CCCGUAGAUGAUGCGCA 17 4438
HSV2-UL30-2690 + GAUGAUGCGCAUGGAGU 17 5361
HSV2-UL30-2691 + UGCGCAUGGAGUACGGA 17 5362
HSV2-UL30-1570 + GCGCAUGGAGUACGGAC 17 4440
HSV2-UL30-1571 + CGCAUGGAGUACGGACC 17 4441
HSV2-UL30-2694 + GCGCAUGCCGGCCGCCU 17 5363
HSV2-UL30-1575 + CGCAUGCCGGCCGCCUC 17 4445
HSV2-UL30-2696 + AGUCGGCCAGCAGCUGA 17 5364
HSV2-UL30-2697 + GCACGUACGCGCGCGUC 17 5365
HSV2-UL30-2698 + ACGUACGCGCGCGUCGC 17 5366
HSV2-UL30-1577 + CGUACGCGCGCGUCGCG 17 4447
HSV2-UL30-2700 + UGGCGGCCACGUGCAGG 17 5367
HSV2-UL30-2701 + GCCACGUGCAGGCAGGG 17 5368
HSV2-UL30-2702 + GACCG UGCUG CACCCCG 17 5369
HSV2-UL30-2703 + CCCGGUGAACCCGUACA 17 5370
HSV2-UL30-2704 + UGGCGGCCUGUUGCUUG 17 5371
HSV2-UL30-2705 + GCGGCCUGUUGCUUGUC 17 5372
HSV2-UL30-1589 + CGGCCUGUUGCUUGUCG 17 4459
HSV2-UL30-2707 + GCCUGUUGCUUGUCGAG 17 5373
HSV2-UL30-2708 + CGAGGAGGACGGCCUCC 17 5374
HSV2-UL30-1592 + GAGGAGGACGGCCUCCU 17 4462
HSV2-UL30-1593 + AGGAGGACGGCCUCCUC 17 4463
HSV2-UL30-2711 + GCCUCCUCGGGGGUGCU 17 5375
HSV2-UL30-1596 + CCUCCUCGGGGGUGCUC 17 4466
HSV2-UL30-1597 + CUCCUCGGGGGUGCUCU 17 4467
HSV2-UL30-1598 + UCCUCGGGGGUGCUCUG 17 4468
HSV2-UL30-2715 + GGUGCUCUGGGGGAUCC 17 5376
HSV2-UL30-2716 + CUCUGGGGGAUCCGCGA 17 5377
HSV2-UL30-2717 + GCCAGCCAGUCGCGCAG 17 5378
HSV2-UL30-2718 + AGCAGGCUCUCGCGUAC 17 5379
HSV2-UL30-2719 + CGCGUACGUGGGCCUUC 17 5380
HSV2-UL30-2720 + GUACGUGGGCCUUCACG 17 5381
HSV2-UL30-2721 + CCAGGUGCGCGACGGCC 17 5382 HSV2-UL30-2722 + GCGACGGCCUCGGGCCG 17 5383
HSV2-UL30-1613 + CGACGGCCUCGGGCCGC 17 4483
HSV2-UL30-1614 + GACGGCCUCGGGCCGCA 17 4484
HSV2-UL30-2725 + CGGCCUCGGGCCGCAGG 17 5384
HSV2-UL30-2726 + GCCGCAGGGAGAGCGUA 17 5385
HSV2-UL30-2727 + GUACUGAAGCACAGGUU 17 5386
HSV2-UL30-2728 + AAGCACAGGUUGUGGGC 17 5387
HSV2-UL30-2729 + UGUGGGCCUGGAUGAUG 17 5388
HSV2-UL30-1619 + GUGGGCCUGGAUGAUGC 17 4489
HSV2-UL30-2731 + CA AAG U CAAACACCACC 17 5389
HSV2-UL30-1624 + AAAG U CAAACACCACCA 17 4494
HSV2-UL30-2733 + ACCACCACGGGGUCGAC 17 5390
HSV2-UL30-2734 + CGGGGUCGACGUGAAAC 17 5391
HSV2-UL30-1627 + GGGGUCGACGUGAAACC 17 4497
HSV2-UL30-2736 + CGACGUGAAACCCGGAG 17 5392
HSV2-UL30-1629 + GACGUGAAACCCGGAGG 17 4499
HSV2-UL30-2738 + GAAACCCGGAGGUGGGG 17 5393
HSV2-UL30-2739 + AACCCGGAGGUGGGGUC 17 5394
HSV2-UL30-2740 + GAGGUGGGGUCGAGGAC 17 5395
HSV2-UL30-2741 + GGCCGCUCCCCUUCCCC 17 5396
HSV2-UL30-2742 + UUCCCCCCGAGGCACGG 17 5397
HSV2-UL30-2743 + GAGGCACGGCCGGGCGC 17 5398
HSV2-UL30-2744 + GCU UGGGCGCCUCCUUG 17 5399
HSV2-UL30-2745 + GCCUCCUUGUCGAGGCC 17 5400
HSV2-UL30-2746 + AGGCCCCGAAACCGCCC 17 5401
HSV2-UL30-2747 + CGCCCCUGGGUGUCCGG 17 5402
HSV2-UL30-2748 + CCUGGGUGUCCGGCAGG 17 5403
HSV2-UL30-2749 + UUCUGGCCCGCAAGGCG 17 5404
HSV2-UL30-1652 + UCUGGCCCGCAAGGCGC 17 4522
HSV2-UL30-2751 + CAAGGCGCAGGAGGCAC 17 5405
HSV2-UL30-2752 + AGGAGGCACGUG AAG AC 17 5406
HSV2-UL30-2753 + UGGCCGUCGUAGAUGGU 17 5407
HSV2-UL30-2754 + CCGCCAGGCGCGCGACG 17 5408
HSV2-UL30-1661 + CGCCAGGCGCGCGACGG 17 4531
HSV2-UL30-2756 + GAAAGCUCCAGGUGCGG 17 5409
HSV2-UL30-2757 + CCAGGUGCGG CAG AAAC 17 5410
HSV2-UL30-2758 + GGUGCGGCAGAAACUUG 17 5411
HSV2-UL30-2759 + CAGCUGCCCGACCAGCA 17 5412
HSV2-UL30-2760 + CGAUCACCCCGCGCUGC 17 5413
HSV2-UL30-2761 + CCCCGCGCUGCGCGGGC 17 5414
HSV2-UL30-1666 + CCCGCGCUGCGCGGGCC 17 4536
HSV2-UL30-2763 + GCCCGGAGGCGUAGUAG 17 5415
HSV2-UL30-1669 + CCCGGAGGCGUAGUAGG 17 4539
HSV2-UL30-1670 + CCGGAGGCGUAGUAGGC 17 4540
HSV2-UL30-2766 + CGGCGUUCAGCUUGUAG 17 5416
HSV2-UL30-1676 + GGCGUUCAGCUUGUAGC 17 4546 HSV2-UL30-2768 + CGUUCAGCUUGUAGCUG 17 5417
HSV2-UL30-2769 + UUGAUCUUGCUGCGCUU 17 5418
HSV2-UL30-2770 + UGGCCGAUGUCCCACAC 17 5419
HSV2-UL30-1680 + GGCCGAUGUCCCACACG 17 4550
HSV2-UL30-2772 + UCAUGCGCCCGUACCCG 17 5420
HSV2-UL30-2773 + GCGCCCGUACCCGUCGA 17 5421
HSV2-UL30-1682 + CGCCCGUACCCGUCGAG 17 4552
HSV2-UL30-2775 + AUCUCCGUCAGCUUGGU 17 5422
HSV2-UL30-2776 + CCGUCAGCUUGGUCAGG 17 5423
HSV2-UL30-2777 + UCAGCUUGGUCAGGACG 17 5424
HSV2-UL30-2778 + UCAGGACGAAGGGCCAG 17 5425
HSV2-UL30-2779 + UGAUGUUGUACCCGGUC 17 5426
HSV2-UL30-2780 + UGUACCCGGUCACGAAC 17 5427
HSV2-UL30-1689 + GUACCCGGUCACGAACU 17 4559
HSV2-UL30-2782 + CGGGGCCGUACUGCUUG 17 5428
HSV2-UL30-2783 + ACUGCUUGACGAAGGUC 17 5429
HSV2-UL30-2784 + UGAAGGCCAGCAGCAUC 17 5430
HSV2-UL30-2785 + AAUUCGCUGUCAAACUC 17 5431
HSV2-UL30-2786 + UGUCAAACUCCAGGACG 17 5432
HSV2-UL30-1695 + GUCAAACUCCAGGACGA 17 4565
HSV2-UL30-1696 + UCAAACUCCAGGACGAC 17 4566
HSV2-UL30-2789 + CGGGGGCCGGCAGGCCC 17 5433
HSV2-UL30-1701 + GGGGGCCGGCAGGCCCC 17 4571
HSV2-UL30-2791 + CCGGCAGGCCCCUGGAG 17 5434
HSV2-UL30-2792 + CCCUGGAGGCGAGAUCG 17 5435
HSV2-UL30-2793 + GAGGCGAGAUCGCUGAG 17 5436
HSV2-UL30-1704 + AGGCGAGAUCGCUGAGG 17 4574
HSV2-UL30-2795 + GAUCGCUGAGGUGGGAC 17 5437
HSV2-UL30-1706 + AUCGCUGAGGUGGGACU 17 4576
HSV2-UL30-1707 + UCGCUGAGGUGGGACUC 17 4577
HSV2-UL30-1708 + CGCUGAGGUGGGACUCG 17 4578
HSV2-UL30-2799 + GGGACUCGGGGAGGUCG 17 5438
HSV2-UL30-2800 + CGGGGAGGUCGCAGGAU 17 5439
HSV2-UL30-2801 + GAGGUCGCAGGAUCCGA 17 5440
HSV2-UL30-2802 + CAGGAUCCGAGCGAAAA 17 5441
HSV2-UL30-1711 + AGGAUCCGAGCGAAAAC 17 4581
HSV2-UL30-2804 + GAUCCGAGCGAAAACAG 17 5442
HSV2-UL30-2805 + AAAACAGGAGGAUGUGC 17 5443
HSV2-UL30-2806 + AACAGGAGGAUGUGCUC 17 5444
HSV2-UL30-2807 + UGUGCUCGAGGGCGGUG 17 5445
HSV2-UL30-2808 + CGGUGGUGGACAGGUCG 17 5446
HSV2-UL30-2809 + ACAG G U CG U AG AG CAG A 17 5447
HSV2-UL30-1719 + CAGGUCGUAGAGCAGAC 17 4589
HSV2-UL30-2811 + UAGAGCAGACAGGAGAU 17 5448
HSV2-UL30-2812 + GACAGGAGAUCUGGAUG 17 5449
HSV2-UL30-2813 + CUGGAUGACGAGGUCUU 17 5450 HSV2-UL30-2814 + UUCCGGGCGUUCCGCGA 17 5451
HSV2-UL30-1724 + UCCGGGCGUUCCGCGAC 17 4594
HSV2-UL30-2816 + CGGCCUUGCAUUCGAUA 17 5452
HSV2-UL30-2817 + AUUCGAUAUCGAAGCAC 17 5453
HSV2-UL30-2818 + GUUAAACUCGACGUCGC 17 5454
HSV2-UL30-2819 + CGACGUCGCUCGAGGUU 17 5455
HSV2-UL30-2820 + CGAGGUUCCGAACGCCG 17 5456
HSV2-UL30-1734 + GAGGUUCCGAACGCCGU 17 4604
HSV2-UL30-1735 + AGGUUCCGAACGCCGUC 17 4605
HSV2-UL30-1736 + GGUUCCGAACGCCGUCG 17 4606
HSV2-UL30-2824 + GCCGUCGGGGGGCGCGG 17 5457
HSV2-UL30-2825 + CCGGCGCGUUCCCGCGG 17 5458
HSV2-UL30-2826 + CGUUCCCGCGGCCGGGC 17 5459
HSV2-UL30-2827 + GCUUGAGGCGGUACCAG 17 5460
HSV2-UL30-2828 + GCCGAAGGUGACAAACC 17 5461
HSV2-UL30-2829 + ACAAACCCCGGGUUGUC 17 5462
HSV2-UL30-2830 + GGGUUGUCCAGGAUAAA 17 5463
HSV2-UL30-2831 + CCUCGUACUUCCUGAUC 17 5464
HSV2-UL30-1756 + CUCGUACUUCCUGAUCG 17 4626
HSV2-UL30-2833 + GCGCGCGCCCGCUUCGC 17 5465
HSV2-UL30-2834 + ACGAAGACGCGGUAGUA 17 5466
HSV2-UL30-2835 + GACGCGGUAGUACAGGG 17 5467
HSV2-UL30-2836 + G CU CCACCACCU CCGCC 17 5468
HSV2-UL30-2837 + CCGCCUCGAAGUGGUCC 17 5469
HSV2-UL30-1768 + CGCCUCGAAGUGGUCCG 17 4638
HSV2-UL30-2839 + UGGUCCGCGGAGAUGCC 17 5470
HSV2-UL30-1769 + GGUCCGCGGAGAUGCCG 17 4639
HSV2-UL30-2841 + GCCCCCGGCGACUCGCG 17 5471
HSV2-UL30-2842 + CCGCCGCCAGGCGCUCG 17 5472
HSV2-UL30-2843 + GCGCUCGCAGAGAUCGC 17 5473
HSV2-UL30-1774 + CGCUCGCAGAGAUCGCG 17 4644
HSV2-UL30-2845 + UGCCGCGUGCCGUAGAC 17 5474
HSV2-UL30-2846 + CGGCGACGCGAUGGCCU 17 5475
HSV2-UL30-1781 + GGCGACGCGAUGGCCUU 17 4651
HSV2-UL30-1782 + GCGACGCGAUGGCCUUC 17 4652
HSV2-UL30-2849 + CCUUCGGGGGUCAGACC 17 5476
HSV2-UL30-2850 + GCGUGAUGACGGUCCCG 17 5477
HSV2-UL30-2851 + GCGUCCAUAAAUCGCUC 17 5478
HSV2-UL30-1790 + CGUCCAUAAAUCGCUCG 17 4660
Table 2F provides exemplary targeting domains for knocking out the UL30 gene selected according to the first tier parameters. The targeting domains are selected based on location within first 500bp of the coding sequence of the UL30 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using N. meningitidis Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 2F
Figure imgf000237_0001
Table 3A provides exemplary targeting domains for knocking out the UL48 gene selected according to first tier parameters. The targeting domains are selected based on location within the first 500bp of the coding sequence of the UL48 gene and orthogonality against the human genome. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 3A
Figure imgf000237_0002
HSV2-UL48-3 GAUCUGUUUGCGGACGCGGA 20 5484
HSV2-UL48-116 CGAUCUGUUUGCGGACG 17 5485
HSV2-UL48-117 CUGUUUGCGGACGCGGA 17 5486
HSV2-UL48-5 UCUGUUUGCGGACGCGGACG 20 5487
HSV2-UL48-119 GUUUGCGGACGCGGACG 17 5488
HSV2-UL48-11 GCCCCUCCGCUGUACGCCAC 20 5489
HSV2-UL48-12 CUCCGCUGUACGCCACCGGU 20 5490
HSV2-UL48-13 CGCCACCGGUCGGCUGAGUC 20 5491
HSV2-UL48-125 CCUCCGCUGUACGCCAC 17 5492
HSV2-UL48-126 CGCUGUACGCCACCGGU 17 5493
HSV2-UL48-17 CGACGAUCUGGGCUUCAGCG 20 5494
HSV2-UL48-18 GACGAUCUGGGCUUCAGCGC 20 5495
HSV2-UL48-131 CGAUCUGGGCUUCAGCG 17 5496
HSV2-UL48-132 GAUCUGGGCUUCAGCGC 17 5497
HSV2-UL48-20 CAUGCUAGAUACCUGGAACG 20 5498
HSV2-UL48-134 GCUAGAUACCUGGAACG 17 5499
HSV2-UL48-24 GACCAACGCCGACAUGUACC 20 5500
HSV2-UL48-25 UGCCCAGCGACGUGAUCGAC 20 5501
HSV2-UL48-138 CAACGCCGACAUGUACC 17 5502
HSV2-UL48-139 CCAGCGACGUGAUCGAC 17 5503
HSV2-UL48-29 CAGCGACGUGAUCGACUGGG 20 5504
HSV2-UL48-30 CCGAUCGACAUUCGCGCCCA 20 5505
HSV2-UL48-31 CAUUCGCGCCCACGGCGACG 20 5506
HSV2-UL48-32 CGAGCUGCCUUCGUACUACG 20 5507
HSV2-UL48-33 GCCUUCGUACUACGAGGCCA 20 5508
HSV2-UL48-34 GCCAUGGCGCAGUUUUUCCG 20 5509
HSV2-UL48-35 AGUUUUUCCGCGGUGAGCUG 20 5510
HSV2-UL48-36 GUUUUUCCGCGGUGAGCUGC 20 5511
HSV2-UL48-143 CGACGUGAUCGACUGGG 17 5512
HSV2-UL48-144 AUCGACAUUCGCGCCCA 17 5513
HSV2-UL48-145 UCGCGCCCACGGCGACG 17 5514
HSV2-UL48-146 GCUGCCUUCGUACUACG 17 5515
HSV2-UL48-147 UUCGUACUACGAGGCCA 17 5516
HSV2-UL48-148 AUGGCGCAGUUUUUCCG 17 5517
HSV2-UL48-149 UUUUCCGCGGUGAGCUG 17 5518
HSV2-UL48-150 UUUCCGCGGUGAGCUGC 17 5519
HSV2-UL48-42 + ACCGCGGAAAAACUGCGCCA 20 5520
HSV2-UL48-43 + GCCAUGGCCUCGUAGUACGA 20 5521
HSV2-UL48-44 + AGUACGAAGGCAGCUCGUCG 20 5522
HSV2-UL48-45 + GUACGAAGGCAGCUCGUCGC 20 5523
HSV2-UL48-46 + CGAAGGCAGCUCGUCGCGGG 20 5524
HSV2-UL48-47 + AGGCAGCUCGUCGCGGGUGG 20 5525
HSV2-UL48-48 + GGCAGCUCGUCGCGGGUGGC 20 5526
HSV2-UL48-156 + GCGGAAAAACUGCGCCA 17 5527
HSV2-UL48-157 + AUGGCCUCGUAGUACGA 17 5528
HSV2-UL48-158 + ACGAAGGCAGCUCGUCG 17 5529 HSV2-UL48-159 + CGAAGGCAGCUCGUCGC 17 5530
HSV2-UL48-160 + AGGCAGCUCGUCGCGGG 17 5531
HSV2-UL48-161 + CAGCUCGUCGCGGGUGG 17 5532
HSV2-UL48-162 + AGCUCGUCGCGGGUGGC 17 5533
HSV2-UL48-50 + CUCGUCGCGGGUGGCGGGCA 20 5534
HSV2-UL48-164 + GUCGCGGGUGGCGGGCA 17 5535
HSV2-UL48-55 + GGGGAACGCCACGUCGCCGU 20 5536
HSV2-UL48-56 + CCGUGGGCGCGAAUGUCGAU 20 5537
HSV2-UL48-57 + CGUGGGCGCGAAUGUCGAUC 20 5538
HSV2-UL48-58 + GUGGGCGCGAAUGUCGAUCG 20 5539
HSV2-UL48-59 + AAUGUCGAUCGGGGAGCGCU 20 5540
HSV2-UL48-60 + AUGUCGAUCGGGGAGCGCUC 20 5541
HSV2-UL48-61 + UGUCGAUCGGGGAGCGCUCG 20 5542
HSV2-UL48-62 + CCCCCAGUCGAUCACGUCGC 20 5543
HSV2-UL48-63 + CCCCAGUCGAUCACGUCGCU 20 5544
HSV2-UL48-169 + GAACGCCACGUCGCCGU 17 5545
HSV2-UL48-170 + UGGGCGCGAAUGUCGAU 17 5546
HSV2-UL48-171 + GGGCGCGAAUGUCGAUC 17 5547
HSV2-UL48-172 + GGCGCGAAUGUCGAUCG 17 5548
HSV2-UL48-173 + GUCGAUCGGGGAGCGCU 17 5549
HSV2-UL48-174 + UCGAUCGGGGAGCGCUC 17 5550
HSV2-UL48-175 + CGAUCGGGGAGCGCUCG 17 5551
HSV2-UL48-176 + CCAGUCGAUCACGUCGC 17 5552
HSV2-UL48-177 + CAGUCGAUCACGUCGCU 17 5553
HSV2-UL48-65 + CUUGCACUCCCGGUACAUGU 20 5554
HSV2-UL48-66 + CUCCCGGUACAUGUCGGCGU 20 5555
HSV2-UL48-67 + CGGUACAUGUCGGCGUUGGU 20 5556
HSV2-UL48-68 + GGUACAUGUCGGCGUUGGUC 20 5557
HSV2-UL48-179 + GCACUCCCGGUACAUGU 17 5558
HSV2-UL48-180 + CCGGUACAUGUCGGCGU 17 5559
HSV2-UL48-181 + UACAUGUCGGCGUUGGU 17 5560
HSV2-UL48-182 + ACAUGUCGGCGUUGGUC 17 5561
HSV2-UL48-71 + CUCGUUCCAGGUAUCUAGCA 20 5562
HSV2-UL48-185 + GUUCCAGGUAUCUAGCA 17 5563
HSV2-UL48-73 + UCUAGCAUGGUACACAGCGC 20 5564
HSV2-UL48-187 + AGCAUGGUACACAGCGC 17 5565
HSV2-UL48-76 + CGUCGAGGAGACGGUUAAAC 20 5566
HSV2-UL48-77 + GUCGAGGAGACGGUUAAACA 20 5567
HSV2-UL48-78 + GAGACGGUUAAACAGGGCCG 20 5568
HSV2-UL48-79 + AGACGGUUAAACAGGGCCGC 20 5569
HSV2-UL48-80 + GACGGUUAAACAGGGCCGCG 20 5570
HSV2-UL48-81 + ACGGUUAAACAGGGCCGCGG 20 5571
HSV2-UL48-82 + CGGUUAAACAGGGCCGCGGG 20 5572
HSV2-UL48-190 + CGAGGAGACGGUUAAAC 17 5573
HSV2-UL48-191 + GAGGAGACGGUUAAACA 17 5574
HSV2-UL48-192 + ACGGUUAAACAGGGCCG 17 5575 HSV2-UL48-193 + CGGUUAAACAGGGCCGC 17 5576
HSV2-UL48-194 + GGUUAAACAGGGCCGCG 17 5577
HSV2-UL48-195 + GUUAAACAGGGCCGCGG 17 5578
HSV2-UL48-196 + UUAAACAGGGCCGCGGG 17 5579
HSV2-UL48-94 + GGCCUGACUCAGCCGACCGG 20 5580
HSV2-UL48-95 + AGCCGACCGGUGGCGUACAG 20 5581
HSV2-UL48-97 + GACCGGUGGCGUACAGCGGA 20 5582
HSV2-UL48-98 + ACCGGUGGCGUACAGCGGAG 20 5583
HSV2-UL48-208 + CUGACUCAGCCGACCGG 17 5584
HSV2-UL48-209 + CGACCGGUGGCGUACAG 17 5585
HSV2-UL48-211 + CGGUGGCGUACAGCGGA 17 5586
HSV2-UL48-212 + GGUGGCGUACAGCGGAG 17 5587
HSV2-UL48-101 + CGUACAGCGGAGGGGCGGCU 20 5588
HSV2-UL48-215 + ACAGCGGAGGGGCGGCU 17 5589
HSV2-UL48-106 + GUGUUCUUGGGACCCCCGGC 20 5590
HSV2-UL48-114 + CAAACAGAUCGUCGACCAAC 20 5591
HSV2-UL48-220 + UUCUUGGGACCCCCGGC 17 5592
HSV2-UL48-228 + ACAGAUCGUCGACCAAC 17 5593
Table 3B provides exemplary targeting domains for knocking out the UL48 gene selected according to the second tier parameters. The targeting domains are selected based on location within the first 500bp of the coding sequence of the UL48 gene. It is
contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 3B
Figure imgf000240_0001
HSV2-UL48-8 CACCGCCCCCCAGGCCAGCC 20 5598
HSV2-UL48-9 ACCGCCCCCCAGGCCAGCCG 20 5599
HSV2-UL48-10 CCGCCCCCCAGGCCAGCCGG 20 5600
HSV2-UL48-14 GCCCAUGCCCGUCCCCCCCG 20 5601
HSV2-UL48-15 UAACCGUCUCCUCGACGAUC 20 5602
HSV2-UL48-16 AACCGUCUCCUCGACGAUCU 20 5603
HSV2-UL48-19 UGUGUACCAUGCUAGAUACC 20 5604
HSV2-UL48-21 UGGAACGAGGACCUGUUCUC 20 5605
HSV2-UL48-22 GGAACGAGGACCUGUUCUCU 20 5606
HSV2-UL48-23 CGACCAACGCCGACAUGUAC 20 5607
HSV2-UL48-26 GCCCAGCGACGUGAUCGACU 20 5608
HSV2-UL48-27 CCCAGCGACGUGAUCGACUG 20 5609
HSV2-UL48-28 CCAGCGACGUGAUCGACUGG 20 5610
HSV2-UL48-37 UCCGCGGUGAGCUGCGGGCG 20 5611
HSV2-UL48-38 CCGCGGUGAGCUGCGGGCGC 20 5612
HSV2-UL48-39 CGGUGAGCUGCGGGCGCGGG 20 5613
HSV2-UL48-40 GGGCGCGGGAGGAGAGCUAC 20 5614
HSV2-UL48-41 + CCCGCGCCCGCAGCUCACCG 20 5615
HSV2-UL48-49 + GCUCGUCGCGGGUGGCGGGC 20 5616
HSV2-UL48-51 + GUCGCGGGUGGCGGGCAGGG 20 5617
HSV2-UL48-52 + UCGCGGGUGGCGGGCAGGGU 20 5618
HSV2-UL48-53 + CGCGGGUGGCGGGCAGGGUG 20 5619
HSV2-UL48-54 + UGGGGAACGCCACGUCGCCG 20 5620
HSV2-UL48-64 + UCGACAGAAACUUGCACUCC 20 5621
HSV2-UL48-69 + UGGUCGGGAACCCAGAGAAC 20 5622
HSV2-UL48-70 + AGAGAACAGGUCCUCGUUCC 20 5623
HSV2-UL48-72 + AUCUAGCAUGGUACACAGCG 20 5624
HSV2-UL48-74 + CGCUGAAGCCCAGAUCGUCG 20 5625
HSV2-UL48-75 + AGCCCAGAUCGUCGAGGAGA 20 5626
HSV2-UL48-83 + GGUUAAACAGGGCCGCGGGG 20 5627
HSV2-UL48-84 + AAACAGGGCCGCGGGGGGGA 20 5628
HSV2-UL48-85 + AACAGGGCCGCGGGGGGGAC 20 5629
HSV2-UL48-86 + GGCCGCGGGGGGGACGGGCA 20 5630
HSV2-UL48-87 + GCCGCGGGGGGGACGGGCAU 20 5631
HSV2-UL48-88 + GCGGGGGGGACGGGCAUGGG 20 5632
HSV2-UL48-89 + GGGGACGGGCAUGGGCGGCG 20 5633
HSV2-UL48-90 + GGGACGGGCAUGGGCGGCGA 20 5634
HSV2-UL48-91 + UGGGCGGCGAGGGCAUCAGC 20 5635
HSV2-UL48-92 + GGGCGGCGAGGGCAUCAGCU 20 5636
HSV2-UL48-93 + CUGGGCCUGACUCAGCCGAC 20 5637
HSV2-UL48-96 + CGACCGGUGGCGUACAGCGG 20 5638
HSV2-UL48-99 + GGUGGCGUACAGCGGAGGGG 20 5639
HSV2-UL48-100 + GCGUACAGCGGAGGGGCGGC 20 5640
HSV2-UL48-102 + GUACAGCGGAGGGGCGGCUG 20 5641
HSV2-UL48-103 + AGGGGCGGCUGGGGUGUUCU 20 5642
HSV2-UL48-104 + GGGGCGGCUGGGGUGUUCUU 20 5643 HSV2-UL48-105 + UGGGGUGUUCUUGGGACCCC 20 5644
HSV2-UL48-107 + CUUGGGACCCCCGGCUGGCC 20 5645
HSV2-UL48-108 + UUGGGACCCCCGGCUGGCCU 20 5646
HSV2-UL48-109 + UGGGACCCCCGGCUGGCCUG 20 5647
HSV2-UL48-110 + GGGACCCCCGGCUGGCCUGG 20 5648
HSV2-UL48-111 + GGACCCCCGGCUGGCCUGGG 20 5649
HSV2-UL48-112 + CCCCCGGCUGGCCUGGGGGG 20 5650
HSV2-UL48-113 + CCGGCUGGCCUGGGGGGCGG 20 5651
HSV2-UL48-115 GGUCGACGAUCUGUUUG 17 5652
HSV2-UL48-118 UGUUUGCGGACGCGGAC 17 5653
HSV2-UL48-120 UUUCGCCACCGCCCCCC 17 5654
HSV2-UL48-121 CCGCCCCCCAGGCCAGC 17 5655
HSV2-UL48-122 CGCCCCCCAGGCCAGCC 17 5656
HSV2-UL48-123 GCCCCCCAGGCCAGCCG 17 5657
HSV2-UL48-124 CCCCCCAGGCCAGCCGG 17 5658
HSV2-UL48-128 CAUGCCCGUCCCCCCCG 17 5659
HSV2-UL48-129 CCGUCUCCUCGACGAUC 17 5660
HSV2-UL48-130 CGUCUCCUCGACGAUCU 17 5661
HSV2-UL48-133 GUACCAUGCUAGAUACC 17 5662
HSV2-UL48-135 AACGAGGACCUGUUCUC 17 5663
HSV2-UL48-136 ACGAGGACCUGUUCUCU 17 5664
HSV2-UL48-137 CCAACGCCGACAUGUAC 17 5665
HSV2-UL48-140 CAGCGACGUGAUCGACU 17 5666
HSV2-UL48-141 AGCGACGUGAUCGACUG 17 5667
HSV2-UL48-142 GCGACGUGAUCGACUGG 17 5668
HSV2-UL48-151 GCGGUGAGCUGCGGGCG 17 5669
HSV2-UL48-152 CGGUGAGCUGCGGGCGC 17 5670
HSV2-UL48-153 UGAGCUGCGGGCGCGGG 17 5671
HSV2-UL48-154 CGCGGGAGGAGAGCUAC 17 5672
HSV2-UL48-155 + GCGCCCGCAGCUCACCG 17 5673
HSV2-UL48-163 + CGUCGCGGGUGGCGGGC 17 5674
HSV2-UL48-165 + GCGGGUGGCGGGCAGGG 17 5675
HSV2-UL48-166 + CGGGUGGCGGGCAGGGU 17 5676
HSV2-UL48-167 + GGGUGGCGGGCAGGGUG 17 5677
HSV2-UL48-168 + GGAACGCCACGUCGCCG 17 5678
HSV2-UL48-178 + ACAGAAACUUGCACUCC 17 5679
HSV2-UL48-183 + UCGGGAACCCAGAGAAC 17 5680
HSV2-UL48-184 + GAACAGGUCCUCGUUCC 17 5681
HSV2-UL48-186 + UAGCAUGGUACACAGCG 17 5682
HSV2-UL48-188 + UGAAGCCCAGAUCGUCG 17 5683
HSV2-UL48-189 + CCAGAUCGUCGAGGAGA 17 5684
HSV2-UL48-197 + UAAACAGGGCCGCGGGG 17 5685
HSV2-UL48-198 + CAGGGCCGCGGGGGGGA 17 5686
HSV2-UL48-199 + AGGGCCGCGGGGGGGAC 17 5687
HSV2-UL48-200 + CGCGGGGGGGACGGGCA 17 5688
HSV2-UL48-201 + GCGGGGGGGACGGGCAU 17 5689 HSV2-UL48-202 + GGGGGGACGGGCAUGGG 17 5690
HSV2-UL48-203 + GACGGGCAUGGGCGGCG 17 5691
HSV2-UL48-204 + ACGGGCAUGGGCGGCGA 17 5692
HSV2-UL48-205 + GCGGCGAGGGCAUCAGC 17 5693
HSV2-UL48-206 + CGGCGAGGGCAUCAGCU 17 5694
HSV2-UL48-207 + GGCCUGACUCAGCCGAC 17 5695
HSV2-UL48-210 + CCGGUGGCGUACAGCGG 17 5696
HSV2-UL48-213 + GGCGUACAGCGGAGGGG 17 5697
HSV2-UL48-214 + UACAGCGGAGGGGCGGC 17 5698
HSV2-UL48-216 + CAGCGGAGGGGCGGCUG 17 5699
HSV2-UL48-217 + GGCGGCUGGGGUGUUCU 17 5700
HSV2-UL48-218 + GCGGCUGGGGUGUUCUU 17 5701
HSV2-UL48-219 + GGUGUUCUUGGGACCCC 17 5702
HSV2-UL48-221 + GGGACCCCCGGCUGGCC 17 5703
HSV2-UL48-222 + GGACCCCCGGCUGGCCU 17 5704
HSV2-UL48-223 + GACCCCCGGCUGGCCUG 17 5705
HSV2-UL48-224 + ACCCCCGGCUGGCCUGG 17 5706
HSV2-UL48-225 + CCCCCGGCUGGCCUGGG 17 5707
HSV2-UL48-226 + CCGGCUGGCCUGGGGGG 17 5708
HSV2-UL48-227 + GCUGGCCUGGGGGGCGG 17 5709
HSV2-UL48-175 CGAUCGGGGAGCGCUCG 17 5551
Table 3C provides exemplary targeting domains for knocking out the UL48 gene selected according to the third tier parameters. The targeting domains are selected based on location within the coding sequence, but downstream of the first 500bp of the UL48 gene. In an embodiment, the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands and that are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 3C
Figure imgf000243_0001
HSV2-UL48-231 CGUUCGGCAGCUACACCGCC 20 5713
HSV2-UL48-232 UACACCGCCAGGCACACAUG 20 5714
HSV2-UL48-233 ACACCGCCAGGCACACAUGC 20 5715
HSV2-UL48-234 CACCGCCAGGCACACAUGCG 20 5716
HSV2-UL48-235 GGGGCCGCAACCGCGACCUG 20 5717
HSV2-UL48-236 GGGCCGCAACCGCGACCUGC 20 5718
HSV2-UL48-237 GAUGCUGCGCACCACGAUCG 20 5719
HSV2-UL48-238 UGCGCACCACGAUCGCGGAC 20 5720
HSV2-UL48-239 CUACCGCGAGACCGCGCGCC 20 5721
HSV2-UL48-240 UUCUGAGCCGCGAGAUCCUA 20 5722
HSV2-UL48-241 UCUGAGCCGCGAGAUCCUAU 20 5723
HSV2-UL48-242 CGUACGCCGAGCAGAUGAUG 20 5724
HSV2-UL48-243 AUGCGGCCCGAUCUGUUCGA 20 5725
HSV2-UL48-244 CGACGGCCUCUGCUGCGACC 20 5726
HSV2-UL48-245 UCUGCUGCGACCUGGAGAGC 20 5727
HSV2-UL48-246 CCUGGAGAGCUGGCGCCAGU 20 5728
HSV2-UL48-247 CAGCCCCUGAUGUUUAUCAA 20 5729
HSV2-UL48-248 UCAACGGAUCGCUCACCGUG 20 5730
HSV2-UL48-249 CAACGGAUCGCUCACCGUGC 20 5731
HSV2-UL48-250 AACGGAUCGCUCACCGUGCG 20 5732
HSV2-UL48-251 CACCGUGCGGGGAGUUCCCG 20 5733
HSV2-UL48-252 CGUGCGGGGAGUUCCCGUGG 20 5734
HSV2-UL48-253 GGGGAGUUCCCGUGGAGGCC 20 5735
HSV2-UL48-254 CCGUGGAGGCCCGGCGACUG 20 5736
HSV2-UL48-255 CGUGGAGGCCCGGCGACUGC 20 5737
HSV2-UL48-256 CGAGCACCUGAACCUCCCGC 20 5738
HSV2-UL48-257 CCUCCCGCUGGUGCGAAGUG 20 5739
HSV2-UL48-258 CCCGCUGGUGCGAAGUGCGG 20 5740
HSV2-UL48-259 GCUGGUGCGAAGUGCGGCGG 20 5741
HSV2-UL48-260 GGUGCGAAGUGCGGCGGCGG 20 5742
HSV2-UL48-261 AGUGCGGCGGCGGAGGAACC 20 5743
HSV2-UL48-262 GUGCGGCGGCGGAGGAACCC 20 5744
HSV2-UL48-263 UGCGGCGGCGGAGGAACCCG 20 5745
HSV2-UL48-264 CACGACCCCGCCCGUCCUGC 20 5746
HSV2-UL48-265 ACGACCCCGCCCGUCCUGCA 20 5747
HSV2-UL48-266 GCCCGUCCUGCAGGGCAACC 20 5748
HSV2-UL48-267 GGCAACCAGGCCCGCUCCUC 20 5749
HSV2-UL48-268 GCAACCAGGCCCGCUCCUCU 20 5750
HSV2-UL48-269 GGUACUUUAUGCUGCUGAUC 20 5751
HSV2-UL48-270 GUACUUUAUGCUGCUGAUCC 20 5752
HSV2-UL48-271 GCUGCUGAUCCGGGCCAAGU 20 5753
HSV2-UL48-272 GUACUCCAGCGUCGCGACCU 20 5754
HSV2-UL48-273 CUCCAGCGUCGCGACCUCGG 20 5755
HSV2-UL48-274 UCCAGCGUCGCGACCUCGGA 20 5756
HSV2-UL48-275 CGGAGGGCGAGUCCGUCAUG 20 5757
HSV2-UL48-276 GGAGGGCGAGUCCGUCAUGC 20 5758 HSV2-UL48-277 CGGGAGCACGCGUAUAGCCG 20 5759
HSV2-UL48-278 GGGAGCACGCGUAUAGCCGC 20 5760
HSV2-UL48-279 AGCACGCGUAUAGCCGCGGG 20 5761
HSV2-UL48-280 GGGCGGACCAGAAACAAUUA 20 5762
HSV2-UL48-281 CAAUUACGGAUCGACAAUCG 20 5763
HSV2-UL48-282 AAUUACGGAUCGACAAUCGA 20 5764
HSV2-UL48-283 CGAGGGCCUGCUCGACCUCC 20 5765
HSV2-UL48-284 GGACGACGAUGACGCUCCUG 20 5766
HSV2-UL48-285 CGACGAUGACGCUCCUGCGG 20 5767
HSV2-UL48-286 GAUGACGCUCCUGCGGAGGC 20 5768
HSV2-UL48-287 AUGACGCUCCUGCGGAGGCC 20 5769
HSV2-UL48-288 CGCUCCUGCGGAGGCCGGGC 20 5770
HSV2-UL48-289 UCCUGCGGAGGCCGGGCUGG 20 5771
HSV2-UL48-290 GCGCAUGUCGUUUCUCUCCG 20 5772
HSV2-UL48-291 CGCAUGUCGUUUCUCUCCGC 20 5773
HSV2-UL48-292 CCCCAUUACCGACGUCAGCC 20 5774
HSV2-UL48-293 CCCAUUACCGACGUCAGCCU 20 5775
HSV2-UL48-294 CCUGGGAGACGAACUCCGCC 20 5776
HSV2-UL48-295 GGAGACGAACUCCGCCUGGA 20 5777
HSV2-UL48-296 CGAACUCCGCCUGGACGGCG 20 5778
HSV2-UL48-297 ACUCCGCCUGGACGGCGAGG 20 5779
HSV2-UL48-298 CCGCCUGGACGGCGAGGAGG 20 5780
HSV2-UL48-299 UAUGACGCCCGCCGACGCCC 20 5781
HSV2-UL48-300 CGCCCUGGACGACUUCGACU 20 5782
HSV2-UL48-301 CGACUUCGACUUGGAGAUGC 20 5783
HSV2-UL48-302 GACUUCGACUUGGAGAUGCU 20 5784
HSV2-UL48-303 ACUUCGACUUGGAGAUGCUG 20 5785
HSV2-UL48-304 CUUCGACUUGGAGAUGCUGG 20 5786
HSV2-UL48-305 CUUGGAGAUGCUGGGGGACG 20 5787
HSV2-UL48-306 GGACGUGGAGUCCCCCUCCC 20 5788
HSV2-UL48-307 GACGUGGAGUCCCCCUCCCC 20 5789
HSV2-UL48-308 ACCCACGACCCCGUCUCGUA 20 5790
HSV2-UL48-309 CCCACGACCCCGUCUCGUAU 20 5791
HSV2-UL48-310 CCACGACCCCGUCUCGUAUG 20 5792
HSV2-UL48-311 CCCCGUCUCGUAUGGGGCUU 20 5793
HSV2-UL48-312 CUCGUAUGGGGCUUUGGACG 20 5794
HSV2-UL48-313 ACAGAUGUUUACCGAUGCCA 20 5795
HSV2-UL48-314 CAGAUGUUUACCGAUGCCAU 20 5796
HSV2-UL48-315 GCCAUGGGCAUUGACGACUU 20 5797
HSV2-UL48-316 CCAUGGGCAUUGACGACUUU 20 5798
HSV2-UL48-317 CAUGGGCAUUGACGACUUUG 20 5799
HSV2-UL48-318 AUGGGCAUUGACGACUUUGG 20 5800
HSV2-UL48-319 UGGGCAUUGACGACUUUGGG 20 5801
HSV2-UL48-320 + CCCAAAGUCGUCAAUGCCCA 20 5802
HSV2-UL48-321 + GUCGUCAAUGCCCAUGGCAU 20 5803
HSV2-UL48-322 + GUCCAAAGCCCCAUACGAGA 20 5804 HSV2-UL48-323 + UCCAAAGCCCCAUACGAGAC 20 5805
HSV2-UL48-324 + CCAAAGCCCCAUACGAGACG 20 5806
HSV2-UL48-325 + CCCCAUACGAGACGGGGUCG 20 5807
HSV2-UL48-326 + CCCAUACGAGACGGGGUCGU 20 5808
HSV2-UL48-327 + ACGGGGUCGUGGGUCAUUCC 20 5809
HSV2-UL48-328 + CGGGGUCGUGGGUCAUUCCC 20 5810
HSV2-UL48-329 + GGGGUCGUGGGUCAUUCCCG 20 5811
HSV2-UL48-330 + GUCGUGGGUCAUUCCCGGGG 20 5812
HSV2-UL48-331 + UCGUGGGUCAUUCCCGGGGA 20 5813
HSV2-UL48-332 + CGUGGGUCAUUCCCGGGGAG 20 5814
HSV2-UL48-333 + GUGGGUCAUUCCCGGGGAGG 20 5815
HSV2-UL48-334 + UCUCCAAGUCGAAGUCGUCC 20 5816
HSV2-UL48-335 + CUCCAAGUCGAAGUCGUCCA 20 5817
HSV2-UL48-336 + GUCGAAGUCGUCCAGGGCGU 20 5818
HSV2-UL48-337 + GAAGUCGUCCAGGGCGUCGG 20 5819
HSV2-UL48-338 + AAGUCGUCCAGGGCGUCGGC 20 5820
HSV2-UL48-339 + UAUCCACCUCCUCGCCGUCC 20 5821
HSV2-UL48-340 + CCACCUCCUCGCCGUCCAGG 20 5822
HSV2-UL48-341 + CCAGGCGGAGUUCGUCUCCC 20 5823
HSV2-UL48-342 + UUCGUCUCCCAGGCUGACGU 20 5824
HSV2-UL48-343 + UCCCAGGCUGACGUCGGUAA 20 5825
HSV2-UL48-344 + CCCAGGCUGACGUCGGUAAU 20 5826
HSV2-UL48-345 + CCAGGCUGACGUCGGUAAUG 20 5827
HSV2-UL48-346 + CAGGCUGACGUCGGUAAUGG 20 5828
HSV2-UL48-347 + GCUGACGUCGGUAAUGGGGG 20 5829
HSV2-UL48-348 + GACGUCGGUAAUGGGGGCGG 20 5830
HSV2-UL48-349 + GUCGGUAAUGGGGGCGGUGG 20 5831
HSV2-UL48-350 + GGGCGGUGGUGGACAGUCUG 20 5832
HSV2-UL48-351 + GGCGGUGGUGGACAGUCUGC 20 5833
HSV2-UL48-352 + GCGGUGGUGGACAGUCUGCG 20 5834
HSV2-UL48-353 + CGGUGGUGGACAGUCUGCGG 20 5835
HSV2-UL48-354 + UCUGCGGGGGCGUUGUCCCG 20 5836
HSV2-UL48-355 + GCGGAGAGAAACGACAUGCG 20 5837
HSV2-UL48-356 + CAUGCGCGGCGCCACCAGCC 20 5838
HSV2-UL48-357 + GCCACCAGCCCGGCCUCCGC 20 5839
HSV2-UL48-358 + GCAGGAGCGUCAUCGUCGUC 20 5840
HSV2-UL48-359 + CAGGAGCGUCAUCGUCGUCC 20 5841
HSV2-UL48-360 + GAGCGUCAUCGUCGUCCGGG 20 5842
HSV2-UL48-361 + CGUCGUCCGGGAGGUCGAGC 20 5843
HSV2-UL48-362 + UGUCGAUCCGUAAUUGUUUC 20 5844
HSV2-UL48-363 + AAUUGUUUCUGGUCCGCCCG 20 5845
HSV2-UL48-364 + AUACGCGUGCUCCCGCAUGA 20 5846
HSV2-UL48-365 + CAUGACGGACUCGCCCUCCG 20 5847
HSV2-UL48-366 + GCCCUCCGAGGUCGCGACGC 20 5848
HSV2-UL48-367 + GCUGGAGUACGAGUCCAACU 20 5849
HSV2-UL48-368 + AGUACGAGUCCAACUUGGCC 20 5850 HSV2-UL48-369 + CAGCAGCAUAAAGUACCCAG 20 5851
HSV2-UL48-370 + GCAUAAAGUACCCAGAGGAG 20 5852
HSV2-UL48-371 + CAUAAAGUACCCAGAGGAGC 20 5853
HSV2-UL48-372 + AGUACCCAGAGGAGCGGGCC 20 5854
HSV2-UL48-373 + AGCGGGCCUGGUUGCCCUGC 20 5855
HSV2-UL48-374 + GGCCUGGUUGCCCUGCAGGA 20 5856
HSV2-UL48-375 + GCCUGGUUGCCCUGCAGGAC 20 5857
HSV2-UL48-376 + UGGUUGCCCUGCAGGACGGG 20 5858
HSV2-UL48-377 + GGUUGCCCUGCAGGACGGGC 20 5859
HSV2-UL48-378 + GUUGCCCUGCAGGACGGGCG 20 5860
HSV2-UL48-379 + GCAGGACGGGCGGGGUCGUG 20 5861
HSV2-UL48-380 + CAGGACGGGCGGGGUCGUGA 20 5862
HSV2-UL48-381 + AGGACGGGCGGGGUCGUGAG 20 5863
HSV2-UL48-382 + CGGGGUCGUGAGGGGCGCCC 20 5864
HSV2-UL48-383 + GGGGUCGUGAGGGGCGCCCC 20 5865
HSV2-UL48-384 + GCCGCCGCACUUCGCACCAG 20 5866
HSV2-UL48-385 + CCGCCGCACUUCGCACCAGC 20 5867
HSV2-UL48-386 + CCGCACUUCGCACCAGCGGG 20 5868
HSV2-UL48-387 + UUCGCACCAGCGGGAGGUUC 20 5869
HSV2-UL48-388 + GGUUCAGGUGCUCGCGAAUG 20 5870
HSV2-UL48-389 + GGUUUAGCUCCCGCAGUCGC 20 5871
HSV2-UL48-390 + GUUUAGCUCCCGCAGUCGCC 20 5872
HSV2-UL48-391 + CCGCAGUCGCCGGGCCUCCA 20 5873
HSV2-UL48-392 + CGCAGUCGCCGGGCCUCCAC 20 5874
HSV2-UL48-393 + CUCCACGGGAACUCCCCGCA 20 5875
HSV2-UL48-394 + GCGAUCCGUUGAUAAACAUC 20 5876
HSV2-UL48-395 + CGAUCCGUUGAUAAACAUCA 20 5877
HSV2-UL48-396 + GAUCCGUUGAUAAACAUCAG 20 5878
HSV2-UL48-397 + GCUGAAACAGACACGCCAAC 20 5879
HSV2-UL48-398 + CCAACUGGCGCCAGCUCUCC 20 5880
HSV2-UL48-399 + AGCUCUCCAGGUCGCAGCAG 20 5881
HSV2-UL48-400 + GCAGAGGCCGUCGAACAGAU 20 5882
HSV2-UL48-401 + CAGAGGCCGUCGAACAGAUC 20 5883
HSV2-UL48-402 + AUCGGGCCGCAUCAUCUGCU 20 5884
HSV2-UL48-403 + CAUCAUCUGCUCGGCGUACG 20 5885
HSV2-UL48-404 + GCUCGGCGUACGCGGCCCAU 20 5886
HSV2-UL48-405 + ACGCGGCCCAUAGGAUCUCG 20 5887
HSV2-UL48-406 + GGAUCUCGCGGCUCAGAAAG 20 5888
HSV2-UL48-407 + AGAGGUAUAGAUGCAGAAAC 20 5889
HSV2-UL48-408 + GCAGAAACAGGACGCGCGCC 20 5890
HSV2-UL48-409 + CAGGACGCGCGCCAGGCGCG 20 5891
HSV2-UL48-410 + GCGCCAGGCGCGCGGUCUCG 20 5892
HSV2-UL48-411 + GUAGUACCUGUCCGCGAUCG 20 5893
HSV2-UL48-412 + UGGUGCGCAGCAUCUCCCGC 20 5894
HSV2-UL48-413 + GCAGCAUCUCCCGCAGGUCG 20 5895
HSV2-UL48-414 + UCUCCCGCAGGUCGCGGUUG 20 5896 HSV2-UL48-415 + UGCGGCCCCGCAUGUGUGCC 20 5897
HSV2-UL48-416 + GGCCCCGCAUGUGUGCCUGG 20 5898
HSV2-UL48-417 + GCGGUGUAGCUGCCGAACGC 20 5899
HSV2-UL48-418 + GCUGCCGAACGCUGGCGCGC 20 5900
HSV2-UL48-419 + GAACGCUGGCGCGCAGGUAC 20 5901
HSV2-UL48-420 + UGGCGCGCAGGUACCGGUAC 20 5902
HSV2-UL48-421 + GGCGCGCAGGUACCGGUACA 20 5903
HSV2-UL48-422 GUUGGCAAAUUUUUGCU 17 5904
HSV2-UL48-423 UUUGCUCGGCCCUGUAC 17 5905
HSV2-UL48-424 ACCUGCGCGCCAGCGUU 17 5906
HSV2-UL48-425 UCGGCAGCUACACCGCC 17 5907
HSV2-UL48-426 ACCGCCAGGCACACAUG 17 5908
HSV2-UL48-427 CCGCCAGGCACACAUGC 17 5909
HSV2-UL48-428 CGCCAGGCACACAUGCG 17 5910
HSV2-UL48-429 GCCGCAACCGCGACCUG 17 5911
HSV2-UL48-430 CCGCAACCGCGACCUGC 17 5912
HSV2-UL48-431 GCUGCGCACCACGAUCG 17 5913
HSV2-UL48-432 GCACCACGAUCGCGGAC 17 5914
HSV2-UL48-433 CCGCGAGACCGCGCGCC 17 5915
HSV2-UL48-434 UGAGCCGCGAGAUCCUA 17 5916
HSV2-UL48-435 GAGCCGCGAGAUCCUAU 17 5917
HSV2-UL48-436 ACGCCGAGCAGAUGAUG 17 5918
HSV2-UL48-437 CGGCCCGAUCUGUUCGA 17 5919
HSV2-UL48-438 CGGCCUCUGCUGCGACC 17 5920
HSV2-UL48-439 GCUGCGACCUGGAGAGC 17 5921
HSV2-UL48-440 GGAGAGCUGGCGCCAGU 17 5922
HSV2-UL48-441 CCCCUGAUGUUUAUCAA 17 5923
HSV2-UL48-442 ACGGAUCGCUCACCGUG 17 5924
HSV2-UL48-443 CGGAUCGCUCACCGUGC 17 5925
HSV2-UL48-444 GGAUCGCUCACCGUGCG 17 5926
HSV2-UL48-445 CGUGCGGGGAGUUCCCG 17 5927
HSV2-UL48-446 GCGGGGAGUUCCCGUGG 17 5928
HSV2-UL48-447 GAGUUCCCGUGGAGGCC 17 5929
HSV2-UL48-448 UGGAGGCCCGGCGACUG 17 5930
HSV2-UL48-449 GGAGGCCCGGCGACUGC 17 5931
HSV2-UL48-450 GCACCUGAACCUCCCGC 17 5932
HSV2-UL48-451 CCCGCUGGUGCGAAGUG 17 5933
HSV2-UL48-452 GCUGGUGCGAAGUGCGG 17 5934
HSV2-UL48-453 GGUGCGAAGUGCGGCGG 17 5935
HSV2-UL48-454 GCGAAGUGCGGCGGCGG 17 5936
HSV2-UL48-455 GCGGCGGCGGAGGAACC 17 5937
HSV2-UL48-456 CGGCGGCGGAGGAACCC 17 5938
HSV2-UL48-457 GGCGGCGGAGGAACCCG 17 5939
HSV2-UL48-458 GACCCCGCCCGUCCUGC 17 5940
HSV2-UL48-459 ACCCCGCCCGUCCUGCA 17 5941
HSV2-UL48-460 CGUCCUGCAGGGCAACC 17 5942 HSV2-UL48-461 AACCAGGCCCGCUCCUC 17 5943
HSV2-UL48-462 ACCAGGCCCGCUCCUCU 17 5944
HSV2-UL48-463 ACUUUAUGCUGCUGAUC 17 5945
HSV2-UL48-464 CUUUAUGCUGCU GAUCC 17 5946
HSV2-UL48-465 GCUGAUCCGGGCCAAGU 17 5947
HSV2-UL48-466 CUCCAGCGUCGCGACCU 17 5948
HSV2-UL48-467 CAGCGUCGCGACCUCGG 17 5949
HSV2-UL48-468 AGCGUCGCGACCUCGGA 17 5950
HSV2-UL48-469 AGGGCGAGUCCGUCAUG 17 5951
HSV2-11L48-470 GGGCGAGUCCGUCAUGC 17 5952
HSV2-UL48-471 GAGCACGCGUAUAGCCG 17 5953
HSV2-UL48-472 AGCACGCGUAUAGCCGC 17 5954
HSV2-UL48-473 ACGCGUAUAGCCGCGGG 17 5955
HSV2-UL48-474 CGGACCAGAAACAAUUA 17 5956
HSV2-UL48-475 UUACGGAUCGACAAUCG 17 5957
HSV2-UL48-476 UACGGAUCGACAAUCGA 17 5958
HSV2-UL48-477 GGGCCUGCUCGACCUCC 17 5959
HSV2-UL48-478 CGACGAUGACGCUCCUG 17 5960
HSV2-IIL48-479 CGAUGACGCUCCUGCGG 17 5961
HSV2-UL48-480 GACGCUCCUGCGGAGGC 17 5962
HSV2-UL48-481 ACGCUCCUGCGGAGGCC 17 5963
HSV2-UL48-482 UCCUGCGGAGGCCGGGC 17 5964
HSV2-UL48-483 UGCGGAGGCCGGGCUGG 17 5965
HSV2-UL48-484 CAUGUCGUUUCUCUCCG 17 5966
HSV2-UL48-485 AUGUCGUUUCUCUCCGC 17 5967
HSV2-UL48-486 CAUUACCGACGUCAGCC 17 5968
HSV2-UL48-487 AUUACCGACGUCAGCCU 17 5969
HSV2-UL48-488 GGGAGACGAACUCCGCC 17 5970
HSV2-UL48-489 GACGAACUCCGCCUGGA 17 5971
HSV2-UL48-490 ACUCCGCCUGGACGGCG 17 5972
HSV2-UL48-491 CCGCCUGG AC GGC G AGG 17 5973
HSV2-UL48-492 CCUGGACGGCGAGGAGG 17 5974
HSV2-UL48-493 GACGCCCGCCGACGCCC 17 5975
HSV2-UL48-494 CCUGGACGACUUCGACU 17 5976
HSV2-UL48-495 CUUCGACUUGGAGAUGC 17 5977
HSV2-UL48-496 UUCGACUUGGAGAUGCU 17 5978
HSV2-UL48-497 UCGACUUGGAGAUGCUG 17 5979
HSV2-UL48-498 CGACUUGG AG AU GCUGG 17 5980
HSV2-UL48-499 GGAGAUGCUGGGGGACG 17 5981
HSV2-UL48-500 CGUGGAGUCCCCCUCCC 17 5982
HSV2-UL48-501 GUGGAGUCCCCCUCCCC 17 5983
HSV2-UL48-502 CACGACCCCGUCUCGUA 17 5984
HSV2-UL48-503 ACGACCCCGUCUCGUAU 17 5985
HSV2-UL48-504 CGACCCCGUCUCGUAUG 17 5986
HSV2-UL48-505 CGUCUCGUAUGGGGCUU 17 5987
HSV2-UL48-506 GUAUGGGGCUUUGGACG 17 5988 HSV2-UL48-507 GAUGUUUACCGAUGCCA 17 5989
HSV2-UL48-508 AUGUUUACCGAUGCCAU 17 5990
HSV2-UL48-509 AUGGGCAUUGACGACUU 17 5991
HSV2-UL48-510 UGGGCAUUGACGACUUU 17 5992
HSV2-UL48-511 GGGCAUUGACGACUUUG 17 5993
HSV2-UL48-512 GGCAUUGACGACUUUGG 17 5994
HSV2-UL48-513 GC AUUG AC GACUUUGGG 17 5995
HSV2-UL48-514 + A AAGUCGUC A AU GCCCA 17 5996
HSV2-UL48-515 + GUCAAUGCCCAUGGCAU 17 5997
HSV2-UL48-516 + CAAAGCCCCAUACGAGA 17 5998
HSV2-UL48-517 + AAAGCCCCAUACGAGAC 17 5999
HSV2-UL48-518 + AAGCCCCAUACGAGACG 17 6000
HSV2-UL48-519 + CAUACGAGACGGGGUCG 17 6001
HSV2-UL48-520 + AUACGAGACGGGGUCGU 17 6002
HSV2-UL48-521 + GGGUCGUGGGUCAUUCC 17 6003
HSV2-UL48-522 + GGUCGUGGGUCAUUCCC 17 6004
HSV2-UL48-523 + GUCGUGGGUCAUUCCCG 17 6005
HSV2-UL48-524 + GUGGGUCAUUCCCGGGG 17 6006
HSV2-UL48-525 + UGGGUCAUUCCCGGGGA 17 6007
HSV2-UL48-526 + GGGUCAUUCCCGGGGAG 17 6008
HSV2-UL48-527 + GGUCAUUCCCGGGGAGG 17 6009
HSV2-UL48-528 + CCAAGUCGAAGUCGUCC 17 6010
HSV2-UL48-529 + CAAGUCGAAGUCGUCCA 17 6011
HSV2-UL48-530 + GAAGUCGUCCAGGGCGU 17 6012
HSV2-UL48-531 + GUCGUCCAGGGCGUCGG 17 6013
HSV2-UL48-532 + UCGUCCAGGGCGUCGGC 17 6014
HSV2-UL48-533 + CCACCUCCUCGCCGUCC 17 6015
HSV2-UL48-534 + CCUCCUCGCCGUCCAGG 17 6016
HSV2-UL48-535 + GGCGGAGUUCGUCUCCC 17 6017
HSV2-UL48-536 + GUCUCCCAGGCUGACGU 17 6018
HSV2-UL48-537 + CAGGCUGACGUCGGUAA 17 6019
HSV2-UL48-538 + AGGCUGACGUCGGUAAU 17 6020
HSV2-UL48-539 + GGCUGACGUCGGUAAUG 17 6021
HSV2-UL48-540 + GCUGACGUCGGUAAUGG 17 6022
HSV2-UL48-541 + GACGUCGGUAAUGGGGG 17 6023
HSV2-UL48-542 + GUCGGUAAUGGGGGCGG 17 6024
HSV2-UL48-543 + GGUAAUGGGGGCGGUGG 17 6025
HSV2-UL48-544 + CGGUGGUGGACAGUCUG 17 6026
HSV2-UL48-545 + GGUGGUGGACAGUCUGC 17 6027
HSV2-UL48-546 + GUGGUGGACAGUCUGCG 17 6028
HSV2-UL48-547 + UGGUGG AC AGUC UGCGG 17 6029
HSV2-UL48-548 + GCGGGGGCGUUGUCCCG 17 6030
HSV2-UL48-549 + GAGAGAAACGACAUGCG 17 6031
HSV2-UL48-550 + GCGCGGCGCCACCAGCC 17 6032
HSV2-UL48-551 + ACCAGCCCGGCCUCCGC 17 6033
HSV2-UL48-552 + GGAGCGUCAUCGUCGUC 17 6034 HSV2-UL48-553 + GAGCGUC AUCGU CGUCC 17 6035
HSV2-UL48-554 + CGUCAUCGUCGUCCGGG 17 6036
HSV2-UL48-555 + CGUCCGGGAGGUCGAGC 17 6037
HSV2-UL48-556 + CGAUCCGUAAUUGUUUC 17 6038
HSV2-UL48-557 + UGUUUCUGGUCCGCCCG 17 6039
HSV2-UL48-558 + CGCGUGCUCCCGCAUGA 17 6040
HSV2-UL48-559 + GACGGACUCGCCCUCCG 17 6041
HSV2-UL48-560 + CUCCGAGGUCGCGACGC 17 6042
HSV2-UL48-561 + GGAGUACGAGUCCAACU 17 6043
HSV2-UL48-562 + ACGAGUCCAACUUGGCC 17 6044
HSV2-UL48-563 + CAGCAUAAAGUACCCAG 17 6045
HSV2-UL48-564 + UAAAGUACCCAGAGGAG 17 6046
HSV2-UL48-565 + AAAGUACCCAGAGGAGC 17 6047
HSV2-UL48-566 + ACCCAGAGGAGCGGGCC 17 6048
HSV2-UL48-567 + GGGCCUGGUUGCCCUGC 17 6049
HSV2-UL48-568 + CUGGUUGCCCUGCAGGA 17 6050
HSV2-UL48-569 + UGGUUGCCCUGCAGGAC 17 6051
HSV2-UL48-570 + UUGCCCUGCAGGACGGG 17 6052
HSV2-UL48-571 + UGCCCUGCAGGACGGGC 17 6053
HSV2-UL48-572 + GCCCUGCAGGACGGGCG 17 6054
HSV2-UL48-573 + GGACGGGCGGGGUCGUG 17 6055
HSV2-UL48-574 + GACGGGCGGGGUCGUGA 17 6056
HSV2-UL48-575 + ACGGGCGGGGUCGUGAG 17 6057
HSV2-UL48-576 + GGUCGUGAGGGGCGCCC 17 6058
HSV2-UL48-577 + GUCGUGAGGGGCGCCCC 17 6059
HSV2-UL48-578 + GCCGCACUUCGCACCAG 17 6060
HSV2-UL48-579 + CCGCACUUCGCACCAGC 17 6061
HSV2-UL48-580 + CACUUCGCACCAGCGGG 17 6062
HSV2-UL48-581 + GCACCAGCGGGAGGUUC 17 6063
HSV2-UL48-582 + UCAGGUGCUCGCGAAUG 17 6064
HSV2-UL48-583 + UUAGCUCCCGCAGUCGC 17 6065
HSV2-UL48-584 + UAGCUCCCGCAGUCGCC 17 6066
HSV2-UL48-585 + CAGUCGCCGGGCCUCCA 17 6067
HSV2-UL48-586 + AGUCGCCGGGCCUCCAC 17 6068
HSV2-UL48-587 + CACGGGAACUCCCCGCA 17 6069
HSV2-UL48-588 + AUCCGUUGAUAAACAUC 17 6070
HSV2-UL48-589 + UCCGUUGAUAAACAUCA 17 6071
HSV2-UL48-590 + CCGUUGAUAAACAUCAG 17 6072
HSV2-UL48-591 + GAAACAGACACGCCAAC 17 6073
HSV2-UL48-592 + ACUGGCGCCAGCUCUCC 17 6074
HSV2-UL48-593 + UCUCCAGGUCGCAGCAG 17 6075
HSV2-UL48-594 + GAGGCCGUCGAACAGAU 17 6076
HSV2-UL48-595 + AGGCCGUCGAACAGAUC 17 6077
HSV2-UL48-596 + GGGCCGCAUCAUCUGCU 17 6078
HSV2-UL48-597 + CAUCUGCUCGGCGUACG 17 6079
HSV2-UL48-598 + CGGCGUACGCGGCCCAU 17 6080 HSV2-UL48-599 + CGGCCCAUAGGAUCUCG 17 6081
HSV2-UL48-600 + UCUCGCGGCUCAGAAAG 17 6082
HSV2-UL48-601 + GGUAUAGAUGCAGAAAC 17 6083
HSV2-UL48-602 + GAAACAGGACGCGCGCC 17 6084
HSV2-UL48-603 + GACGCGCGCCAGGCGCG 17 6085
HSV2-UL48-604 + CCAGGCGCGCGGUCUCG 17 6086
HSV2-UL48-605 + GUACCUGUCCGCGAUCG 17 6087
HSV2-UL48-606 + UGCGCAGCAUCUCCCGC 17 6088
HSV2-UL48-607 + GCAUCUCCCGCAGGUCG 17 6089
HSV2-UL48-608 + CCCGCAGGUCGCGGUUG 17 6090
HSV2-UL48-609 + GGCCCCGCAUGUGUGCC 17 6091
HSV2-UL48-610 + CCCGCAUGUGUGCCUGG 17 6092
HSV2-UL48-611 + GUGUAGCUGCCGAACGC 17 6093
HSV2-UL48-612 + GCCGAACGCUGGCGCGC 17 6094
HSV2-UL48-613 + CGCUGGCGCGCAGGUAC 17 6095
HSV2-UL48-614 + CGCGCAGGUACCGGUAC 17 6096
HSV2-UL48-615 + GCGCAGGUACCGGUACA 17 6097
Table 3D provides exemplary targeting domains for knocking out the UL48 gene selected according to the first tier parameters. The targeting domains are selected based on location within first 500bp of the coding sequence of the UL48 gene. In an embodiment, the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. aureus Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks. In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. aureus Cas9 nickases with two targeting domains that are complementary to opposite DNA strands and that are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 3D
Figure imgf000252_0001
HSV2-UL48-624 CGCUGUACGCCACCGGUCGG 20 6103
HSV2-UL48-625 UUAACCGUCUCCUCGACGAU 20 6104
HSV2-UL48-626 UCGACGAUCUGGGCUUCAGC 20 6105
HSV2-UL48-627 CUGUGUACCAUGCUAGAUAC 20 6106
HSV2-UL48-19 UGUGUACCAUGCUAGAUACC 20 5604
HSV2-UL48-629 UACCAUGCUAGAUACCUGGA 20 6107
HSV2-UL48-630 CCAUGCUAGAUACCUGGAAC 20 6108
HSV2-UL48-631 CUGGAACGAGGACCUGUUCU 20 6109
HSV2-UL48-632 CCGACCAACGCCGACAUGUA 20 6110
HSV2-UL48-23 CGACCAACGCCGACAUGUAC 20 5607
HSV2-UL48-24 GACCAACGCCGACAUGUACC 20 5500
HSV2-UL48-635 CUGCCCAGCGACGUGAUCGA 20 6111
HSV2-UL48-25 UGCCCAGCGACGUGAUCGAC 20 5501
HSV2-UL48-26 GCCCAGCGACGUGAUCGACU 20 5608
HSV2-UL48-27 CCCAGCGACGUGAUCGACUG 20 5609
HSV2-UL48-28 CCAGCGACGUGAUCGACUGG 20 5610
HSV2-UL48-640 CUGGGGGGAUGCGCACGUCC 20 6112
HSV2-UL48-641 CACCCUGCCCGCCACCCGCG 20 6113
HSV2-UL48-642 CGACGAGCUGCCUUCGUACU 20 6114
HSV2-UL48-643 CAUGGCGCAGUUUUUCCGCG 20 6115
HSV2-UL48-644 CAGUUUUUCCGCGGUGAGCU 20 6116
HSV2-UL48-645 UUCCGCGGUGAGCUGCGGGC 20 6117
HSV2-UL48-37 UCCGCGGUGAGCUGCGGGCG 20 5611
HSV2-UL48-38 CCGCGGUGAGCUGCGGGCGC 20 5612
HSV2-UL48-648 GCGGUGAGCUGCGGGCGCGG 20 6118
HSV2-UL48-39 CGGUGAGCUGCGGGCGCGGG 20 5613
HSV2-UL48-650 GUGAGCUGCGGGCGCGGGAG 20 6119
HSV2-UL48-651 CGGGCGCGGGAGGAGAGCUA 20 6120
HSV2-UL48-652 UGGUCGACGAUCUGUUU 17 6121
HSV2-UL48-653 ACGAUCUGUUUGCGGAC 17 6122
HSV2-UL48-654 UCUGUUUGCGGACGCGG 17 6123
HSV2-UL48-117 CUGUUUGCGGACGCGGA 17 5486
HSV2-UL48-656 ACCGCCCCCCAGGCCAG 17 6124
HSV2-UL48-121 CCGCCCCCCAGGCCAGC 17 5655
HSV2-UL48-122 CGCCCCCCAGGCCAGCC 17 5656
HSV2-UL48-659 GGCCAGCCGGGGGUCCC 17 6125
HSV2-UL48-660 UGUACGCCACCGGUCGG 17 6126
HSV2-UL48-661 ACCGUCUCCUCGACGAU 17 6127
HSV2-UL48-662 ACGAUCUGGGCUUCAGC 17 6128
HSV2-UL48-663 UGUACCAUGCUAGAUAC 17 6129
HSV2-UL48-133 GUACCAUGCUAGAUACC 17 5662
HSV2-UL48-665 CAUGCUAGAUACCUGGA 17 6130
HSV2-UL48-666 UGCUAGAUACCUGGAAC 17 6131
HSV2-UL48-667 GAACGAGGACCUGUUCU 17 6132
HSV2-UL48-668 ACCAACGCCGACAUGUA 17 6133
HSV2-UL48-137 CCAACGCCGACAUGUAC 17 5665 HSV2-UL48-138 CAACGCCGACAUGUACC 17 5502
HSV2-UL48-671 CCCAGCGACGUGAUCGA 17 6134
HSV2-UL48-139 CCAGCGACGUGAUCGAC 17 5503
HSV2-UL48-140 CAGCGACGUGAUCGACU 17 5666
HSV2-UL48-141 AGCGACGUGAUCGACUG 17 5667
HSV2-UL48-142 GCGACGUGAUCGACUGG 17 5668
HSV2-UL48-676 GGGGGAUGCGCACGUCC 17 6135
HSV2-UL48-677 CCUGCCCGCCACCCGCG 17 6136
HSV2-UL48-678 CGAGCUGCCUUCGUACU 17 6137
HSV2-UL48-679 GGCGCAGUUUUUCCGCG 17 6138
HSV2-UL48-680 UUUUUCCGCGGUGAGCU 17 6139
HSV2-UL48-681 CGCGGUGAGCUGCGGGC 17 6140
HSV2-UL48-151 GCGGUGAGCUGCGGGCG 17 5669
HSV2-UL48-152 CGGUGAGCUGCGGGCGC 17 5670
HSV2-UL48-684 GUGAGCUGCGGGCGCGG 17 6141
HSV2-UL48-153 UGAGCUGCGGGCGCGGG 17 5671
HSV2-UL48-686 AGCUGCGGGCGCGGGAG 17 6142
HSV2-UL48-687 GCGCGGGAGGAGAGCUA 17 6143
HSV2-UL48-688 + GGCUGGCCUGGGGGGCGGUG 20 6144
HSV2-UL48-109 + UGGGACCCCCGGCUGGCCUG 20 5647
HSV2-UL48-108 + UUGGGACCCCCGGCUGGCCU 20 5646
HSV2-UL48-107 + CUUGGGACCCCCGGCUGGCC 20 5645
HSV2-UL48-692 + UCUUGGGACCCCCGGCUGGC 20 6145
HSV2-UL48-103 + AGGGGCGGCUGGGGUGUUCU 20 5642
HSV2-UL48-694 + GAGGGGCGGCUGGGGUGUUC 20 6146
HSV2-UL48-100 + GCGUACAGCGGAGGGGCGGC 20 5640
HSV2-UL48-696 + GGCGUACAGCGGAGGGGCGG 20 6147
HSV2-UL48-96 + CGACCGGUGGCGUACAGCGG 20 5638
HSV2-UL48-698 + CCGACCGGUGGCGUACAGCG 20 6148
HSV2-UL48-95 + AGCCGACCGGUGGCGUACAG 20 5581
HSV2-UL48-700 + CAGCCGACCGGUGGCGUACA 20 6149
HSV2-UL48-701 + AUGGGCGGCGAGGGCAUCAG 20 6150
HSV2-UL48-702 + GGGGGACGGGCAUGGGCGGC 20 6151
HSV2-UL48-703 + GGGGGGGACGGGCAUGGGCG 20 6152
HSV2-UL48-704 + GGGCCGCGGGGGGGACGGGC 20 6153
HSV2-UL48-705 + UAAACAGGGCCGCGGGGGGG 20 6154
HSV2-UL48-82 + CGGUUAAACAGGGCCGCGGG 20 5572
HSV2-UL48-81 + ACGGUUAAACAGGGCCGCGG 20 5571
HSV2-UL48-80 + GACGGUUAAACAGGGCCGCG 20 5570
HSV2-UL48-79 + AGACGGUUAAACAGGGCCGC 20 5569
HSV2-UL48-78 + GAGACGGUUAAACAGGGCCG 20 5568
HSV2-UL48-711 + GGAGACGGUUAAACAGGGCC 20 6155
HSV2-UL48-712 + UCGUCGAGGAGACGGUUAAA 20 6156
HSV2-UL48-74 + CGCUGAAGCCCAGAUCGUCG 20 5625
HSV2-UL48-714 + GCGCUGAAGCCCAGAUCGUC 20 6157
HSV2-UL48-715 + CCGCGCUGAAGCCCAGAUCG 20 6158 HSV2-UL48-716 + UACACAGCGCGGGACCCGCG 20 6159
HSV2-UL48-72 + AUCUAGCAUGGUACACAGCG 20 5624
HSV2-UL48-718 + UAUCUAGCAUGGUACACAGC 20 6160
HSV2-UL48-719 + CGGCGUUGGUCGGGAACCCA 20 6161
HSV2-UL48-720 + GUCGGCGUUGGUCGGGAACC 20 6162
HSV2-UL48-68 + GGUACAUGUCGGCGUUGGUC 20 5557
HSV2-UL48-67 + CGGUACAUGUCGGCGUUGGU 20 5556
HSV2-UL48-723 + CCGGUACAUGUCGGCGUUGG 20 6163
HSV2-UL48-724 + ACGUCGCUGGGCAGCGUCGA 20 6164
HSV2-UL48-725 + CCCCCCAGUCGAUCACGUCG 20 6165
HSV2-UL48-60 + AUGUCGAUCGGGGAGCGCUC 20 5541
HSV2-UL48-59 + AAUGUCGAUCGGGGAGCGCU 20 5540
HSV2-UL48-728 + GAAUGUCGAUCGGGGAGCGC 20 6166
HSV2-UL48-58 + GUGGGCGCGAAUGUCGAUCG 20 5539
HSV2-UL48-57 + CGUGGGCGCGAAUGUCGAUC 20 5538
HSV2-UL48-56 + CCGUGGGCGCGAAUGUCGAU 20 5537
HSV2-UL48-732 + GCCGUGGGCGCGAAUGUCGA 20 6167
HSV2-UL48-733 + AACGCCACGUCGCCGUGGGC 20 6168
HSV2-UL48-734 + GUGGGGAACGCCACGUCGCC 20 6169
HSV2-UL48-53 + CGCGGGUGGCGGGCAGGGUG 20 5619
HSV2-UL48-52 + UCGCGGGUGGCGGGCAGGGU 20 5618
HSV2-UL48-51 + GUCGCGGGUGGCGGGCAGGG 20 5617
HSV2-UL48-738 + CGUCGCGGGUGGCGGGCAGG 20 6170
HSV2-UL48-739 + AGCUCGUCGCGGGUGGCGGG 20 6171
HSV2-UL48-740 + AAGGCAGCUCGUCGCGGGUG 20 6172
HSV2-UL48-741 + UAGUACGAAGGCAGCUCGUC 20 6173
HSV2-UL48-742 + CUGCGCCAUGGCCUCGUAGU 20 6174
HSV2-UL48-41 + CCCGCGCCCGCAGCUCACCG 20 5615
HSV2-UL48-744 + UCCCGCGCCCGCAGCUCACC 20 6175
HSV2-UL48-745 + UGGCCUGGGGGGCGGUG 17 6176
HSV2-UL48-223 + GACCCCCGGCUGGCCUG 17 5705
HSV2-UL48-222 + GGACCCCCGGCUGGCCU 17 5704
HSV2-UL48-221 + GGGACCCCCGGCUGGCC 17 5703
HSV2-UL48-749 + UGGGACCCCCGGCUGGC 17 6177
HSV2-UL48-217 + GGCGGCUGGGGUGUUCU 17 5700
HSV2-UL48-751 + GGGCGGCUGGGGUGUUC 17 6178
HSV2-UL48-214 + UACAGCGGAGGGGCGGC 17 5698
HSV2-UL48-753 + GUACAGCGGAGGGGCGG 17 6179
HSV2-UL48-210 + CCGGUGGCGUACAGCGG 17 5696
HSV2-UL48-755 + ACCGGUGGCGUACAGCG 17 6180
HSV2-UL48-209 + CGACCGGUGGCGUACAG 17 5585
HSV2-UL48-757 + CCGACCGGUGGCGUACA 17 6181
HSV2-UL48-758 + GGCGGCGAGGGCAUCAG 17 6182
HSV2-UL48-759 + GGACGGGCAUGGGCGGC 17 6183
HSV2-UL48-760 + GGGGACGGGCAUGGGCG 17 6184
HSV2-UL48-761 + CCGCGGGGGGGACGGGC 17 6185 HSV2-UL48-762 + ACAGGGCCGCGGGGGGG 17 6186
HSV2-UL48-196 + UUAAACAGGGCCGCGGG 17 5579
HSV2-UL48-195 + GUUAAACAGGGCCGCGG 17 5578
HSV2-UL48-194 + GGUUAAACAGGGCCGCG 17 5577
HSV2-UL48-193 + CGGUUAAACAGGGCCGC 17 5576
HSV2-UL48-192 + ACGGUUAAACAGGGCCG 17 5575
HSV2-UL48-768 + GACGGUUAAACAGGGCC 17 6187
HSV2-UL48-769 + UCGAGGAGACGGUUAAA 17 6188
HSV2-UL48-188 + UGAAGCCCAGAUCGUCG 17 5683
HSV2-UL48-771 + CUGAAGCCCAGAUCGUC 17 6189
HSV2-UL48-772 + CGCUGAAGCCCAGAUCG 17 6190
HSV2-UL48-773 + ACAGCGCGGGACCCGCG 17 6191
HSV2-UL48-186 + UAGCAUGGUACACAGCG 17 5682
HSV2-UL48-775 + CUAGCAUGGUACACAGC 17 6192
HSV2-UL48-776 + CGUUGGUCGGGAACCCA 17 6193
HSV2-UL48-777 + GGCGUUGGUCGGGAACC 17 6194
HSV2-UL48-182 + ACAUGUCGGCGUUGGUC 17 5561
HSV2-UL48-181 + UACAUGUCGGCGUUGGU 17 5560
HSV2-UL48-780 + GUACAUGUCGGCGUUGG 17 6195
HSV2-UL48-781 + UCGCUGGGCAGCGUCGA 17 6196
HSV2-UL48-782 + CCCAGUCGAUCACGUCG 17 6197
HSV2-UL48-174 + UCGAUCGGGGAGCGCUC 17 5550
HSV2-UL48-173 + GUCGAUCGGGGAGCGCU 17 5549
HSV2-UL48-785 + UGUCGAUCGGGGAGCGC 17 6198
HSV2-UL48-172 + GGCGCGAAUGUCGAUCG 17 5548
HSV2-UL48-171 + GGGCGCGAAUGUCGAUC 17 5547
HSV2-UL48-170 + UGGGCGCGAAUGUCGAU 17 5546
HSV2-UL48-789 + GUGGGCGCGAAUGUCGA 17 6199
HSV2-UL48-790 + GCCACGUCGCCGUGGGC 17 6200
HSV2-UL48-791 + GGGAACGCCACGUCGCC 17 6201
HSV2-UL48-167 + GGGUGGCGGGCAGGGUG 17 5677
HSV2-UL48-166 + CGGGUGGCGGGCAGGGU 17 5676
HSV2-UL48-165 + GCGGGUGGCGGGCAGGG 17 5675
HSV2-UL48-795 + CGCGGGUGGCGGGCAGG 17 6202
HSV2-UL48-796 + UCGUCGCGGGUGGCGGG 17 6203
HSV2-UL48-797 + GCAGCUCGUCGCGGGUG 17 6204
HSV2-UL48-798 + UACGAAGGCAGCUCGUC 17 6205
HSV2-UL48-799 + CGCCAUGGCCUCGUAGU 17 6206
HSV2-UL48-155 + GCGCCCGCAGCUCACCG 17 5673
HSV2-UL48-801 + CGCGCCCGCAGCUCACC 17 6207
Table 3E provides exemplary targeting domains for knocking out the UL48 gene selected according to the second tier parameters. The targeting domains are selected based on location within the coding sequence, but downstream of the first 500bp of the UL48 gene. In an embodiment, the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. aureus Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks. In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. aureus Cas9 nickases with two targeting domains that are complementary to opposite DNA strands and that are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 3E
Figure imgf000257_0001
HSV2-UL48-261 AGUGCGGCGGCGGAGGAACC 20 5743
HSV2-UL48-835 UCACGACCCCGCCCGUCCUG 20 6228
HSV2-UL48-836 GGGCAACCAGGCCCGCUCCU 20 6229
HSV2-UL48-837 GGGUACUUUAUGCUGCUGAU 20 6230
HSV2-UL48-838 UGCUGCUGAUCCGGGCCAAG 20 6231
HSV2-UL48-839 CGUACUCCAGCGUCGCGACC 20 6232
HSV2-UL48-272 GUACUCCAGCGUCGCGACCU 20 5754
HSV2-UL48-841 ACUCCAGCGUCGCGACCUCG 20 6233
HSV2-UL48-842 CAGCGUCGCGACCUCGGAGG 20 6234
HSV2-UL48-843 UCGGAGGGCGAGUCCGUCAU 20 6235
HSV2-UL48-275 CGGAGGGCGAGUCCGUCAUG 20 5757
HSV2-UL48-276 GGAGGGCGAGUCCGUCAUGC 20 5758
HSV2-UL48-846 GCGGGAGCACGCGUAUAGCC 20 6236
HSV2-UL48-847 GAGCACGCGUAUAGCCGCGG 20 6237
HSV2-UL48-848 GCGUAUAGCCGCGGGCGGAC 20 6238
HSV2-UL48-849 CGGGCGGACCAGAAACAAUU 20 6239
HSV2-UL48-850 AAACAAUUACGGAUCGACAA 20 6240
HSV2-UL48-851 ACAAUUACGGAUCGACAAUC 20 6241
HSV2-UL48-852 UCGAGGGCCUGCUCGACCUC 20 6242
HSV2-UL48-853 CGGACGACGAUGACGCUCCU 20 6243
HSV2-UL48-284 GGACGACGAUGACGCUCCUG 20 5766
HSV2-UL48-855 CGAUGACGCUCCUGCGGAGG 20 6244
HSV2-UL48-856 CGCGCAUGUCGUUUCUCUCC 20 6245
HSV2-UL48-290 GCGCAUGUCGUUUCUCUCCG 20 5772
HSV2-UL48-858 CCCCCAUUACCGACGUCAGC 20 6246
HSV2-UL48-292 CCCCAUUACCGACGUCAGCC 20 5774
HSV2-UL48-293 CCCAUUACCGACGUCAGCCU 20 5775
HSV2-UL48-861 UACCGACGUCAGCCUGGGAG 20 6247
HSV2-UL48-862 GCCUGGGAGACGAACUCCGC 20 6248
HSV2-UL48-863 AGACGAACUCCGCCUGGACG 20 6249
HSV2-UL48-864 ACGAACUCCGCCUGGACGGC 20 6250
HSV2-UL48-296 CGAACUCCGCCUGGACGGCG 20 5778
HSV2-UL48-866 UCCGCCUGGACGGCGAGGAG 20 6251
HSV2-UL48-867 AUAUGACGCCCGCCGACGCC 20 6252
HSV2-UL48-868 ACGCCCUGGACGACUUCGAC 20 6253
HSV2-UL48-300 CGCCCUGGACGACUUCGACU 20 5782
HSV2-UL48-870 ACGACUUCGACUUGGAGAUG 20 6254
HSV2-UL48-301 CGACUUCGACUUGGAGAUGC 20 5783
HSV2-UL48-302 GACUUCGACUUGGAGAUGCU 20 5784
HSV2-UL48-303 ACUUCGACUUGGAGAUGCUG 20 5785
HSV2-UL48-874 ACUUGGAGAUGCUGGGGGAC 20 6255
HSV2-UL48-305 CUUGGAGAUGCUGGGGGACG 20 5787
HSV2-UL48-876 GGGACGUGGAGUCCCCCUCC 20 6256
HSV2-UL48-306 GGACGUGGAGUCCCCCUCCC 20 5788
HSV2-UL48-307 GACGUGGAGUCCCCCUCCCC 20 5789
HSV2-UL48-879 GACCCACGACCCCGUCUCGU 20 6257 HSV2-UL48-308 ACCCACGACCCCGUCUCGUA 20 5790
HSV2-UL48-881 ACCCCGUCUCGUAUGGGGCU 20 6258
HSV2-UL48-882 UCUCGUAUGGGGCUUUGGAC 20 6259
HSV2-UL48-883 GGCUUUGGACGUGGACGAUU 20 6260
HSV2-UL48-884 GGACGUGGACGAUUUUGAGU 20 6261
HSV2-UL48-885 AACAGAUGUUUACCGAUGCC 20 6262
HSV2-UL48-886 UGCCAUGGGCAUUGACGACU 20 6263
HSV2-UL48-315 GCCAUGGGCAUUGACGACUU 20 5797
HSV2-UL48-316 CCAUGGGCAUUGACGACUUU 20 5798
HSV2-UL48-317 CAUGGGCAUUGACGACUUUG 20 5799
HSV2-UL48-890 CACCGCCAGGCACACAU 17 6264
HSV2-UL48-426 ACCGCCAGGCACACAUG 17 5908
HSV2-UL48-892 GGCCGCAACCGCGACCU 17 6265
HSV2-UL48-429 GCCGCAACCGCGACCUG 17 5911
HSV2-UL48-430 CCGCAACCGCGACCUGC 17 5912
HSV2-UL48-895 UGCUGCGCACCACGAUC 17 6266
HSV2-UL48-896 CGCGGACAGGUACUACC 17 6267
HSV2-UL48-897 UGCAUCUAUACCUCUUU 17 6268
HSV2-UL48-898 AUACCUCUUUCUGAGCC 17 6269
HSV2-UL48-899 CUGAGCCGCGAGAUCCU 17 6270
HSV2-UL48-900 CCUAUGGGCCGCGUACG 17 6271
HSV2-UL48-901 ACGGCCUCUGCUGCGAC 17 6272
HSV2-UL48-438 CGGCCUCUGCUGCGACC 17 5920
HSV2-UL48-903 GCCUCUGCUGCGACCUG 17 6273
HSV2-UL48-904 GCCCCUGAUGUUUAUCA 17 6274
HSV2-UL48-905 AACGGAUCGCUCACCGU 17 6275
HSV2-UL48-442 ACGGAUCGCUCACCGUG 17 5924
HSV2-UL48-443 CGGAUCGCUCACCGUGC 17 5925
HSV2-UL48-444 GGAUCGCUCACCGUGCG 17 5926
HSV2-UL48-909 CCGUGCGGGGAGUUCCC 17 6276
HSV2-UL48-445 CGUGCGGGGAGUUCCCG 17 5927
HSV2-UL48-911 GUGGAGGCCCGGCGACU 17 6277
HSV2-UL48-448 UGGAGGCCCGGCGACUG 17 5930
HSV2-UL48-449 GGAGGCCCGGCGACUGC 17 5931
HSV2-UL48-914 GGAGCUAAACCACAUUC 17 6278
HSV2-UL48-915 ACCACAUUCGCGAGCAC 17 6279
HSV2-UL48-916 CUGAACCUCCCGCUGGU 17 6280
HSV2-UL48-917 UGGUGCGAAGUGCGGCG 17 6281
HSV2-UL48-453 GGUGCGAAGUGCGGCGG 17 5935
HSV2-UL48-919 UGCGAAGUGCGGCGGCG 17 6282
HSV2-UL48-454 GCGAAGUGCGGCGGCGG 17 5936
HSV2-UL48-921 UGCGGCGGCGGAGGAAC 17 6283
HSV2-UL48-455 GCGGCGGCGGAGGAACC 17 5937
HSV2-UL48-923 CGACCCCGCCCGUCCUG 17 6284
HSV2-UL48-924 CAACCAGGCCCGCUCCU 17 6285
HSV2-UL48-925 UACUUUAUGCUGCUGAU 17 6286 HSV2-UL48-926 UGCUGAUCCGGGCCAAG 17 6287
HSV2-UL48-927 ACUCCAGCGUCGCGACC 17 6288
HSV2-UL48-466 CUCCAGCGUCGCGACCU 17 5948
HSV2-UL48-929 CCAGCGUCGCGACCUCG 17 6289
HSV2-UL48-930 CGUCGCGACCUCGGAGG 17 6290
HSV2-UL48-931 GAGGGCGAGUCCGUCAU 17 6291
HSV2-UL48-469 AGGGCGAGUCCGUCAUG 17 5951
HSV2-UL48-470 GGGCGAGUCCGUCAUGC 17 5952
HSV2-UL48-934 GGAGCACGCGUAUAGCC 17 6292
HSV2-UL48-935 CACGCGUAUAGCCGCGG 17 6293
HSV2-UL48-936 UAUAGCCGCGGGCGGAC 17 6294
HSV2-UL48-937 GCGGACCAGAAACAAUU 17 6295
HSV2-UL48-938 CAAUUACGGAUCGACAA 17 6296
HSV2-UL48-939 AUUACGGAUCGACAAUC 17 6297
HSV2-UL48-940 AGGGCCUGCUCGACCUC 17 6298
HSV2-UL48-941 ACGACGAUGACGCUCCU 17 6299
HSV2-UL48-478 CGACGAUGACGCUCCUG 17 5960
HSV2-UL48-943 UGACGCUCCUGCGGAGG 17 6300
HSV2-UL48-944 GCAUGUCGUUUCUCUCC 17 6301
HSV2-UL48-484 CAUGUCGUUUCUCUCCG 17 5966
HSV2-UL48-946 CCAUUACCGACGUCAGC 17 6302
HSV2-UL48-486 CAUUACCGACGUCAGCC 17 5968
HSV2-UL48-487 AUUACCGACGUCAGCCU 17 5969
HSV2-UL48-949 CGACGUCAGCCUGGGAG 17 6303
HSV2-UL48-950 UGGGAGACGAACUCCGC 17 6304
HSV2-UL48-951 CGAACUCCGCCUGGACG 17 6305
HSV2-UL48-952 AACUCCGCCUGGACGGC 17 6306
HSV2-UL48-490 ACUCCGCCUGGACGGCG 17 5972
HSV2-UL48-954 GCCUGGACGGCGAGGAG 17 6307
HSV2-UL48-955 UGACGCCCGCCGACGCC 17 6308
HSV2-UL48-956 CCCUGGACGACUUCGAC 17 6309
HSV2-UL48-494 CCUGGACGACUUCGACU 17 5976
HSV2-UL48-958 ACUUCGACUUGGAGAUG 17 6310
HSV2-UL48-495 CUUCGACUUGGAGAUGC 17 5977
HSV2-UL48-496 UUCGACUUGGAGAUGCU 17 5978
HSV2-UL48-497 UCGACUUGGAGAUGCUG 17 5979
HSV2-UL48-962 UGGAGAUGCUGGGGGAC 17 6311
HSV2-UL48-499 GGAGAUGCUGGGGGACG 17 5981
HSV2-UL48-964 ACGUGGAGUCCCCCUCC 17 6312
HSV2-UL48-500 CGUGGAGUCCCCCUCCC 17 5982
HSV2-UL48-501 GUGGAGUCCCCCUCCCC 17 5983
HSV2-UL48-967 CCACGACCCCGUCUCGU 17 6313
HSV2-UL48-502 CACGACCCCGUCUCGUA 17 5984
HSV2-UL48-969 CCGUCUCGUAUGGGGCU 17 6314
HSV2-UL48-970 CGUAUGGGGCUUUGGAC 17 6315
HSV2-UL48-971 UUUGGACGUGGACGAUU 17 6316 HSV2-UL48-972 CGUGGACGAUUUUGAGU 17 6317
HSV2-UL48-973 AGAUGUUUACCGAUGCC 17 6318
HSV2-UL48-974 CAUGGGCAUUGACGACU 17 6319
HSV2-UL48-509 AUGGGCAUUGACGACUU 17 5991
HSV2-UL48-510 UGGGCAUUGACGACUUU 17 5992
HSV2-UL48-511 GGGCAUUGACGACUUUG 17 5993
HSV2-UL48-978 + GCGCAGGUACCGGUACAGGG 20 6320
HSV2-UL48-979 + CUGGCGCGCAGGUACCGGUA 20 6321
HSV2-UL48-980 + UGUGCCUGGCGGUGUAGCUG 20 6322
HSV2-UL48-981 + AAGAGGUAUAGAUGCAGAAA 20 6323
HSV2-UL48-982 + CUCAGAAAGAGGUAUAGAUG 20 6324
HSV2-UL48-983 + AUAGGAUCUCGCGGCUCAGA 20 6325
HSV2-UL48-984 + GCCCAUAGGAUCUCGCGGCU 20 6326
HSV2-UL48-985 + UGCUCGGCGUACGCGGCCCA 20 6327
HSV2-UL48-986 + AGCAGAGGCCGUCGAACAGA 20 6328
HSV2-UL48-987 + CCAGGUCGCAGCAGAGGCCG 20 6329
HSV2-UL48-988 + GCCAGCUCUCCAGGUCGCAG 20 6330
HSV2-UL48-989 + CCGUUGAUAAACAUCAGGGG 20 6331
HSV2-UL48-394 + GCGAUCCGUUGAUAAACAUC 20 5876
HSV2-UL48-991 + AGCGAUCCGUUGAUAAACAU 20 6332
HSV2-UL48-992 + CCACGGGAACUCCCCGCACG 20 6333
HSV2-UL48-392 + CGCAGUCGCCGGGCCUCCAC 20 5874
HSV2-UL48-391 + CCGCAGUCGCCGGGCCUCCA 20 5873
HSV2-UL48-995 + CCCGCAGUCGCCGGGCCUCC 20 6334
HSV2-UL48-996 + UGGUUUAGCUCCCGCAGUCG 20 6335
HSV2-UL48-997 + AGCGGGAGGUUCAGGUGCUC 20 6336
HSV2-UL48-385 + CCGCCGCACUUCGCACCAGC 20 5867
HSV2-UL48-384 + GCCGCCGCACUUCGCACCAG 20 5866
HSV2-UL48-1000 + CGCCGCCGCACUUCGCACCA 20 6337
HSV2-UL48-1001 + GCGGGGUCGUGAGGGGCGCC 20 6338
HSV2-UL48-379 + GCAGGACGGGCGGGGUCGUG 20 5861
HSV2-UL48-1003 + UGCAGGACGGGCGGGGUCGU 20 6339
HSV2-UL48-1004 + CCUGCAGGACGGGCGGGGUC 20 6340
HSV2-UL48-376 + UGGUUGCCCUGCAGGACGGG 20 5858
HSV2-UL48-1006 + CUGGUUGCCCUGCAGGACGG 20 6341
HSV2-UL48-1007 + GGGCCUGGUUGCCCUGCAGG 20 6342
HSV2-UL48-1008 + GAGCGGGCCUGGUUGCCCUG 20 6343
HSV2-UL48-1009 + AGCAUAAAGUACCCAGAGGA 20 6344
HSV2-UL48-369 + CAGCAGCAUAAAGUACCCAG 20 5851
HSV2-UL48-1011 + UCAGCAGCAUAAAGUACCCA 20 6345
HSV2-UL48-1012 + GAUCAGCAGCAUAAAGUACC 20 6346
HSV2-UL48-1013 + GAGUACGAGUCCAACUUGGC 20 6347
HSV2-UL48-1014 + CGAGGUCGCGACGCUGGAGU 20 6348
HSV2-UL48-366 + GCCCUCCGAGGUCGCGACGC 20 5848
HSV2-UL48-1016 + CGCCCUCCGAGGUCGCGACG 20 6349
HSV2-UL48-1017 + CCGCAUGACGGACUCGCCCU 20 6350 HSV2-UL48-1018 + UAUACGCGUGCUCCCGCAUG 20 6351
HSV2-UL48-1019 + CGUCAUCGUCGUCCGGGAGG 20 6352
HSV2-UL48-359 + CAGGAGCGUCAUCGUCGUCC 20 5841
HSV2-UL48-358 + GCAGGAGCGUCAUCGUCGUC 20 5840
HSV2-UL48-1022 + CGCAGGAGCGUCAUCGUCGU 20 6353
HSV2-UL48-357 + GCCACCAGCCCGGCCUCCGC 20 5839
HSV2-UL48-1024 + CGCCACCAGCCCGGCCUCCG 20 6354
HSV2-UL48-1025 + CGGGGGCGUUGUCCCGCGGA 20 6355
HSV2-UL48-1026 + UGCGGGGGCGUUGUCCCGCG 20 6356
HSV2-UL48-354 + UCUGCGGGGGCGUUGUCCCG 20 5836
HSV2-UL48-1028 + GUCUGCGGGGGCGUUGUCCC 20 6357
HSV2-UL48-351 + GGCGGUGGUGGACAGUCUGC 20 5833
HSV2-UL48-350 + GGGCGGUGGUGGACAGUCUG 20 5832
HSV2-UL48-1031 + GGGGCGGUGGUGGACAGUCU 20 6358
HSV2-UL48-1032 + CGUCGGUAAUGGGGGCGGUG 20 6359
HSV2-UL48-344 + CCCAGGCUGACGUCGGUAAU 20 5826
HSV2-UL48-343 + UCCCAGGCUGACGUCGGUAA 20 5825
HSV2-UL48-1035 + CUCCCAGGCUGACGUCGGUA 20 6360
HSV2-UL48-340 + CCACCUCCUCGCCGUCCAGG 20 5822
HSV2-UL48-1037 + UCCACCUCCUCGCCGUCCAG 20 6361
HSV2-UL48-1038 + CGAAGUCGUCCAGGGCGUCG 20 6362
HSV2-UL48-1039 + AUCUCCAAGUCGAAGUCGUC 20 6363
HSV2-UL48-1040 + CGUCCCCCAGCAUCUCCAAG 20 6364
HSV2-UL48-332 + CGUGGGUCAUUCCCGGGGAG 20 5814
HSV2-UL48-331 + UCGUGGGUCAUUCCCGGGGA 20 5813
HSV2-UL48-330 + GUCGUGGGUCAUUCCCGGGG 20 5812
HSV2-UL48-1044 + GGUCGUGGGUCAUUCCCGGG 20 6365
HSV2-UL48-329 + GGGGUCGUGGGUCAUUCCCG 20 5811
HSV2-UL48-328 + CGGGGUCGUGGGUCAUUCCC 20 5810
HSV2-UL48-327 + ACGGGGUCGUGGGUCAUUCC 20 5809
HSV2-UL48-1048 + GACGGGGUCGUGGGUCAUUC 20 6366
HSV2-UL48-1049 + GCCCCAUACGAGACGGGGUC 20 6367
HSV2-UL48-322 + GUCCAAAGCCCCAUACGAGA 20 5804
HSV2-UL48-1051 + CGUCCAAAGCCCCAUACGAG 20 6368
HSV2-UL48-1052 + GUCCACGUCCAAAGCCCCAU 20 6369
HSV2-UL48-1053 + CAGGUACCGGUACAGGG 17 6370
HSV2-UL48-1054 + GCGCGCAGGUACCGGUA 17 6371
HSV2-UL48-1055 + GCCUGGCGGUGUAGCUG 17 6372
HSV2-UL48-1056 + AGGUAUAGAUGCAGAAA 17 6373
HSV2-UL48-1057 + AGAAAGAGGUAUAGAUG 17 6374
HSV2-UL48-1058 + GGAUCUCGCGGCUCAGA 17 6375
HSV2-UL48-1059 + CAUAGGAUCUCGCGGCU 17 6376
HSV2-UL48-1060 + UCGGCGUACGCGGCCCA 17 6377
HSV2-UL48-1061 + AGAGGCCGUCGAACAGA 17 6378
HSV2-UL48-1062 + GGUCGCAGCAGAGGCCG 17 6379
HSV2-UL48-1063 + AGCUCUCCAGGUCGCAG 17 6380 HSV2-UL48-1064 + UUGAUAAACAUCAGGGG 17 6381
HSV2-UL48-588 + AUCCGUUGAUAAACAUC 17 6070
HSV2-UL48-1066 + GAUCCGUUGAUAAACAU 17 6382
HSV2-UL48-1067 + CGGGAACUCCCCGCACG 17 6383
HSV2-UL48-586 + AGUCGCCGGGCCUCCAC 17 6068
HSV2-UL48-585 + CAGUCGCCGGGCCUCCA 17 6067
HSV2-UL48-1070 + GCAGUCGCCGGGCCUCC 17 6384
HSV2-UL48-1071 + UUUAGCUCCCGCAGUCG 17 6385
HSV2-UL48-1072 + GGGAGGUUCAGGUGCUC 17 6386
HSV2-UL48-579 + CCGCACUUCGCACCAGC 17 6061
HSV2-UL48-578 + GCCGCACUUCGCACCAG 17 6060
HSV2-UL48-1075 + CGCCGCACUUCGCACCA 17 6387
HSV2-UL48-1076 + GGGUCGUGAGGGGCGCC 17 6388
HSV2-UL48-573 + GGACGGGCGGGGUCGUG 17 6055
HSV2-UL48-1078 + AGGACGGGCGGGGUCGU 17 6389
HSV2-UL48-1079 + GCAGGACGGGCGGGGUC 17 6390
HSV2-UL48-570 + UUGCCCUGCAGGACGGG 17 6052
HSV2-UL48-1081 + GUUGCCCUGCAGGACGG 17 6391
HSV2-UL48-1082 + CCUGGUUGCCCUGCAGG 17 6392
HSV2-UL48-1083 + CGGGCCUGGUUGCCCUG 17 6393
HSV2-UL48-1084 + AUAAAGUACCCAGAGGA 17 6394
HSV2-UL48-563 + CAGCAUAAAGUACCCAG 17 6045
HSV2-UL48-1086 + GCAGCAUAAAGUACCCA 17 6395
HSV2-UL48-1087 + CAGCAGCAUAAAGUACC 17 6396
HSV2-UL48-1088 + UACGAGUCCAACUUGGC 17 6397
HSV2-UL48-1089 + GGUCGCGACGCUGGAGU 17 6398
HSV2-UL48-560 + CUCCGAGGUCGCGACGC 17 6042
HSV2-UL48-1091 + CCUCCGAGGUCGCGACG 17 6399
HSV2-UL48-1092 + CAUGACGGACUCGCCCU 17 6400
HSV2-UL48-1093 + ACGCGUGCUCCCGCAUG 17 6401
HSV2-UL48-1094 + CAUCGUCGUCCGGGAGG 17 6402
HSV2-UL48-553 + GAGCGUCAUCGUCGUCC 17 6035
HSV2-UL48-552 + GGAGCGUCAUCGUCGUC 17 6034
HSV2-UL48-1097 + AGGAGCGUCAUCGUCGU 17 6403
HSV2-UL48-551 + ACCAGCCCGGCCUCCGC 17 6033
HSV2-UL48-1099 + CACCAGCCCGGCCUCCG 17 6404
HSV2-UL48-1100 + GGGCGUUGUCCCGCGGA 17 6405
HSV2-UL48-1101 + GGGGGCGUUGUCCCGCG 17 6406
HSV2-UL48-548 + GCGGGGGCGUUGUCCCG 17 6030
HSV2-UL48-1103 + UGCGGGGGCGUUGUCCC 17 6407
HSV2-UL48-545 + GGUGGUGGACAGUCUGC 17 6027
HSV2-UL48-544 + CGGUGGUGGACAGUCUG 17 6026
HSV2-UL48-1106 + GCGGUGGUGGACAGUCU 17 6408
HSV2-UL48-1107 + CGGUAAUGGGGGCGGUG 17 6409
HSV2-UL48-538 + AGGCUGACGUCGGUAAU 17 6020
HSV2-UL48-537 + CAGGCUGACGUCGGUAA 17 6019 HSV2-UL48-1110 + CCAGGCUGACGUCGGUA 17 6410
HSV2-UL48-534 + CCUCCUCGCCGUCCAGG 17 6016
HSV2-UL48-1112 + ACCUCCUCGCCGUCCAG 17 6411
HSV2-UL48-1113 + AGUCGUCCAGGGCGUCG 17 6412
HSV2-UL48-1114 + UCCAAGUCGAAGUCGUC 17 6413
HSV2-UL48-1115 + CCCCCAGCAUCUCCAAG 17 6414
HSV2-UL48-526 + GGGUCAUUCCCGGGGAG 17 6008
HSV2-UL48-525 + UGGGUCAUUCCCGGGGA 17 6007
HSV2-UL48-524 + GUGGGUCAUUCCCGGGG 17 6006
HSV2-UL48-1119 + CGUGGGUCAUUCCCGGG 17 6415
HSV2-UL48-523 + GUCGUGGGUCAUUCCCG 17 6005
HSV2-UL48-522 + GGUCGUGGGUCAUUCCC 17 6004
HSV2-UL48-521 + GGGUCGUGGGUCAUUCC 17 6003
HSV2-UL48-1123 + GGGGUCGUGGGUCAUUC 17 6416
HSV2-UL48-1124 + CCAUACGAGACGGGGUC 17 6417
HSV2-UL48-516 + CAAAGCCCCAUACGAGA 17 5998
HSV2-UL48-1126 + CCAAAGCCCCAUACGAG 17 6418
HSV2-UL48-1127 + CACGUCCAAAGCCCCAU 17 6419
Table 3F provides exemplary targeting domains for knocking out the UL48 gene selected according to the second tier parameters. The targeting domains are selected based on location within the coding sequence, but downstream of the first 500bp of the UL48 gene. In an embodiment, the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks. In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using N. meningitidis Cas9 nickases with two targeting domains that are complementary to opposite DNA strands and that are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 3F
Figure imgf000264_0001
Table 4A provides exemplary targeting domains for knocking out the UL54 gene selected according to first tier parameters. The targeting domains are selected based on location within the first 500bp of the coding sequence of the UL54 gene and orthogonality against the human genome. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 4A
Figure imgf000265_0001
HSV-UL54-24 + CGCCGGGGCCGUAUCGACCC 20 6447
HSV-UL54-25 + GGCCGUAUCGACCCCGGCCC 20 6448
HSV-UL54-26 + CGUAUCGACCCCGGCCCCGG 20 6449
HSV-UL54-27 + GGAUGCGGUGCCUUGGUCGA 20 6450
HSV-UL54-28 + GAUGCGGUGCCUUGGUCGAC 20 6451
HSV-UL54-29 + AUGCGGUGCCUUGGUCGACG 20 6452
HSV-UL54-30 + UGCGGUGCCUUGGUCGACGG 20 6453
HSV-UL54-31 + GUGCCUUGGUCGACGGGGGU 20 6454
HSV-UL54-32 + GGUCGACGGGGGUUGGAUGC 20 6455
HSV-UL54-33 + CGGGCCACCUUCCCCCCGUG 20 6456
HSV-UL54-34 + UCCCCCCGUGCGGUUCCCGG 20 6457
HSV-UL54-35 + CCCCCCGUGCGGUUCCCGGG 20 6458
HSV-UL54-36 + AAGCCG ACCG CCU GG U CCCG 20 6459
HSV-UL54-37 + CCCGAGGCGCGACCACACGC 20 6460
HSV-UL54-38 + GAGGCGCGACCACACGCCGG 20 6461
HSV-UL54-39 + CGACCACACGCCGGUGGUCG 20 6462
HSV-UL54-40 + GACCACACGCCGGUGGUCGC 20 6463
HSV-UL54-41 + CGGGCGAGGCGUCGAGGCUU 20 6464
HSV-UL54-42 + GGCGAGGCGUCGAGGCUUCG 20 6465
HSV-UL54-43 + GCGAGGCGUCGAGGCUUCGG 20 6466
HSV-UL54-44 + UCGGGGGUGCCGGCGUCCUC 20 6467
HSV-UL54-45 + GGGCGGGCCGGGGGACCUUU 20 6468
HSV-UL54-46 + UUUGGGAAUCGCCGCGUCGA 20 6469
HSV-UL54-47 + UUCCAUGUCCUCGUCCGACG 20 6470
HSV-UL54-48 + CUCCCCGCUGCUGUCGGACU 20 6471
HSV-UL54-49 + CCCCGCUGCUGUCGGACUCG 20 6472
HSV-UL54-50 + GUCCUCCUCGAGCUCGCUGU 20 6473
HSV-UL54-51 + CCUCGAGCUCGCUGUCGGAC 20 6474
HSV-UL54-52 + UGUCGGACAGGUCCAAUCCU 20 6475
HSV-UL54-53 - GAUAUGCUAAUCGACCU 17 6476
HSV-UL54-54 - GCUAAUCGACCUAGGAU 17 6477
HSV-UL54-55 - GUCCGACAGCGAGCUCG 17 6478
HSV-UL54-56 - CGACAGCGAGCUCGAGG 17 6479
HSV-UL54-57 - GCUCGAGGAGGACGCUC 17 6480
HSV-UL54-58 - CUCGUCGGACGAGGACA 17 6481
HSV-UL54-59 - ACCCCUGCGGAGACGGA 17 6482
HSV-UL54-60 - GGCGGAGGCCAUCGACG 17 6483
HSV-UL54-61 - GACGCGGCGAUUCCCAA 17 6484
HSV-UL54-62 - AGCCUCGACGCCUCGCC 17 6485
HSV-UL54-63 - CCGCCACCCGCGACCAC 17 6486
HSV-UL54-64 - CCGCGACCACCGGCGUG 17 6487
HSV-UL54-65 - GCGUGUGGUCGCGCCUC 17 6488
HSV-UL54-66 - GGUCGCGCCUCGGGACC 17 6489
HSV-UL54-67 - CGCGCCUCGGGACCAGG 17 6490
HSV-UL54-68 - UCCCCCCGGGAACCGCA 17 6491
HSV-UL54-69 - CCCCCGGGAACCGCACG 17 6492 HSV-UL54-70 - CCCCGGGAACCGCACGG 17 6493
HSV-UL54-71 - CCCGGGAACCGCACGGG 17 6494
HSV-UL54-72 - CGCAUCCCCGAGGCGGG 17 6495
HSV-UL54-73 - CGGGGCCGGGGUCGAUA 17 6496
HSV-UL54-74 - CGGGGUCGAUACGGCCC 17 6497
HSV-UL54-75 + CCGGCGGGGUUUUGGUG 17 6498
HSV-UL54-76 + CGGGGCCGUAUCGACCC 17 6499
HSV-UL54-77 + CGUAUCGACCCCGGCCC 17 6500
HSV-UL54-78 + AUCGACCCCGGCCCCGG 17 6501
HSV-UL54-79 + UGCGGUGCCUUGGUCGA 17 6502
HSV-UL54-80 + GCGGUGCCUUGGUCGAC 17 6503
HSV-UL54-81 + CGGUGCCUUGGUCGACG 17 6504
HSV-UL54-82 + GGUGCCUUGGUCGACGG 17 6505
HSV-UL54-83 + CCUUGGUCGACGGGGGU 17 6506
HSV-UL54-84 + CGACGGGGGUUGGAUGC 17 6507
HSV-UL54-85 + GCCACCU U CCCCCCG U G 17 6508
HSV-UL54-86 + CCCCGUGCGGU UCCCGG 17 6509
HSV-UL54-87 + CCCGUGCGGU UCCCGGG 17 6510
HSV-UL54-88 + CCGACCGCCUGGUCCCG 17 6511
HSV-UL54-89 + GAGGCGCGACCACACGC 17 6512
HSV-UL54-90 + GCGCGACCACACGCCGG 17 6513
HSV-UL54-91 + CCACACGCCGGUGGUCG 17 6514
HSV-UL54-92 + CACACGCCGGUGGUCGC 17 6515
HSV-UL54-93 + GCGAGGCGUCGAGGCUU 17 6516
HSV-UL54-94 + GAGGCGUCGAGGCUUCG 17 6517
HSV-UL54-95 + AGGCGUCGAGGCUUCGG 17 6518
HSV-UL54-96 + GGGGUGCCGGCGUCCUC 17 6519
HSV-UL54-97 + CGGGCCGGGGGACCUUU 17 6520
HSV-UL54-98 + GGGAAUCGCCGCGUCGA 17 6521
HSV-UL54-99 + CAUGUCCUCGUCCGACG 17 6522
HSV-UL54-100 + CCCGCUGCUGUCGGACU 17 6523
HSV-UL54-101 + CGCUGCUGUCGGACUCG 17 6524
HSV-UL54-102 + CUCCUCGAGCUCGCUGU 17 6525
HSV-UL54-103 + CGAGCUCGCUGUCGGAC 17 6526
HSV-UL54-104 + CGGACAGGUCCAAUCCU 17 6527
Table 4B provides exemplary targeting domains for knocking out the UL54 gene selected according to the second tier parameters. The targeting domains are selected based on location within the first 500bp of the coding sequence of the UL54 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 4B
Figure imgf000268_0001
HSV-UL54-138 - AGGCACCGCAUCCCCGAGGC 20 6561
HSV-UL54-139 - CAUCCCCGAGGCGGGCGGCG 20 6562
HSV-UL54-140 - GCGGGCGGCGAGGUCGCCGC 20 6563
HSV-UL54-141 - CGGGCGGCGAGGUCGCCGCC 20 6564
HSV-UL54-142 - GGGCGGCGAGGUCGCCGCCG 20 6565
HSV-UL54-143 - GGCGAGGUCGCCGCCGGGGC 20 6566
HSV-UL54-144 - GCGAGGUCGCCGCCGGGGCC 20 6567
HSV-UL54-145 - CGAGGUCGCCGCCGGGGCCG 20 6568
HSV-UL54-146 - CGGGGUCGAUACGGCCCCGG 20 6569
HSV-UL54-147 - ACUCCACACCAAAACCCCGC 20 6570
HSV-UL54-148 + GCGGGGUUUUGGUGUGGAGU 20 6571
HSV-UL54-149 + UGGUGUGGAGUCGGCGCCGC 20 6572
HSV-UL54-150 + GGUGUGGAGUCGGCGCCGCC 20 6573
HSV-UL54-151 + GUGUGGAGUCGGCGCCGCCG 20 6574
HSV-UL54-152 + GGCGACCUCGCCGCCCGCCU 20 6575
HSV-UL54-153 + GCGACCUCGCCGCCCGCCUC 20 6576
HSV-UL54-154 + CGACCUCGCCGCCCGCCUCG 20 6577
HSV-UL54-155 + CGCCGCCCGCCUCGGGGAUG 20 6578
HSV-UL54-156 + GCCUCGGGGAUGCGGUGCCU 20 6579
HSV-UL54-157 + UGGUCGACGGGGGUUGGAUG 20 6580
HSV-UL54-158 + CCUUCCCCCCGUGCGGUUCC 20 6581
HSV-UL54-159 + CUUCCCCCCGUGCGGUUCCC 20 6582
HSV-UL54-160 + UUCCCCCCGUGCGGUUCCCG 20 6583
HSV-UL54-161 + CCGGGGGGAAGCCGACCGCC 20 6584
HSV-UL54-162 + CACACGCCGGUGGUCGCGGG 20 6585
HSV-UL54-163 + ACGCCGGUGGUCGCGGGUGG 20 6586
HSV-UL54-164 + GGUCGCGGGUGGCGGAUCGU 20 6587
HSV-UL54-165 + UCGGCUCCCCGCCGCGCUGC 20 6588
HSV-UL54-166 + CGGCUCCCCGCCGCGCUGCC 20 6589
HSV-UL54-167 + CCCCGCCGCGCUGCCGGGCG 20 6590
HSV-UL54-168 + CGCUGCCGGGCGAGGCGUCG 20 6591
HSV-UL54-169 + GGGCGAGGCGUCGAGGCUUC 20 6592
HSV-UL54-170 + CGUCGAGGCUUCGGGGGUGC 20 6593
HSV-UL54-171 + UUCGGGGGUGCCGGCGUCCU 20 6594
HSV-UL54-172 + CGGGGGUGCCGGCGUCCUCG 20 6595
HSV-UL54-173 + GGGUGCCGGCGUCCUCGGGG 20 6596
HSV-UL54-174 + GGUGCCGGCGUCCUCGGGGC 20 6597
HSV-UL54-175 + CCGGCGUCCUCGGGGCGGGC 20 6598
HSV-UL54-176 + CGGCGUCCUCGGGGCGGGCC 20 6599
HSV-UL54-177 + GGCGUCCUCGGGGCGGGCCG 20 6600
HSV-UL54-178 + GCGUCCUCGGGGCGGGCCGG 20 6601
HSV-UL54-179 + GGGGCGGGCCGGGGGACCUU 20 6602
HSV-UL54-180 + CUCCGCCCCUCCGUCUCCGC 20 6603
HSV-UL54-181 + U CCG CCCCU CCG U CU CCG CA 20 6604
HSV-UL54-182 + CCGCCCCUCCGUCUCCGCAG 20 6605
HSV-UL54-183 + GGAACACUCCCCGCUGCUGU 20 6606 HSV-UL54-184 + UCCCCGCUGCUGUCGGACUC 20 6607
HSV-UL54-185 + UGUCGGACUCGGGGUCGUCG 20 6608
HSV-UL54-186 + CGGACUCGGGGUCGUCGCGG 20 6609
HSV-UL54-187 + GUCGAUUAGCAUAUCAAUGU 20 6610
HSV-UL54-188 - AGGAGGACGCUCUGGAG 17 6611
HSV-UL54-189 - GGAGGACGCUCUGGAGC 17 6612
HSV-UL54-190 - CGCUCUGGAGCGGGACG 17 6613
HSV-UL54-191 - UCUGGAGCGGGACGAGG 17 6614
HSV-UL54-192 - CUGGAGCGGGACGAGGA 17 6615
HSV-UL54-193 - CCCGAGUCCGACAGCAG 17 6616
HSV-UL54-194 - CCGAGUCCGACAGCAGC 17 6617
HSV-UL54-195 - CGAGUCCGACAGCAGCG 17 6618
HSV-UL54-196 - CGGGGAGUGUUCCUCGU 17 6619
HSV-UL54-197 - GUGUUCCUCGUCGGACG 17 6620
HSV-UL54-198 - GACAUGGAAGACCCCUG 17 6621
HSV-UL54-199 - GAAGACCCCUGCGGAGA 17 6622
HSV-UL54-200 - GACCCCUGCGGAGACGG 17 6623
HSV-UL54-201 - CCCCUGCGGAGACGGAG 17 6624
HSV-UL54-202 - CUGCGGAGACGGAGGGG 17 6625
HSV-UL54-203 - CGGAGACGGAGGGGCGG 17 6626
HSV-UL54-204 - GAUUCCCAAAGGUCCCC 17 6627
HSV-UL54-205 - UCCCCCGGCCCGCCCCG 17 6628
HSV-UL54-206 - GCCCGCCCCGAGGACGC 17 6629
HSV-UL54-207 - CGCCUCGCCCGGCAGCG 17 6630
HSV-UL54-208 - CUCGCCCGGCAGCGCGG 17 6631
HSV-UL54-209 - UCGCCCGGCAGCGCGGC 17 6632
HSV-UL54-210 - CGCCCGGCAGCGCGGCG 17 6633
HSV-UL54-211 - GGCGUGUGGUCGCGCCU 17 6634
HSV-UL54-212 - CCUCGGGACCAGGCGGU 17 6635
HSV-UL54-213 - GGCGGUCGGCUUCCCCC 17 6636
HSV-UL54-214 - GCGGUCGGCUUCCCCCC 17 6637
HSV-UL54-215 - CCCCCCGGGAACCGCAC 17 6638
HSV-UL54-216 - GGAACCGCACGGGGGGA 17 6639
HSV-UL54-217 - ACCGCACGGGGGGAAGG 17 6640
HSV-UL54-218 - CCAACCCCCG UCG ACCA 17 6641
HSV-UL54-219 - AAGGCACCGCAUCCCCG 17 6642
HSV-UL54-220 - GCACCGCAUCCCCGAGG 17 6643
HSV-UL54-221 - CACCGCAUCCCCGAGGC 17 6644
HSV-UL54-222 - CCCCGAGGCGGGCGGCG 17 6645
HSV-UL54-223 - GGCGGCGAGGUCGCCGC 17 6646
HSV-UL54-224 - GCGGCGAGGUCGCCGCC 17 6647
HSV-UL54-225 - CGGCGAGGUCGCCGCCG 17 6648
HSV-UL54-226 - GAGGUCGCCGCCGGGGC 17 6649
HSV-UL54-227 - AGGUCGCCGCCGGGGCC 17 6650
HSV-UL54-228 - GGUCGCCGCCGGGGCCG 17 6651
HSV-UL54-229 - GGUCGAUACGGCCCCGG 17 6652 HSV-UL54-230 - CCACACCAAAACCCCGC 17 6653
HSV-UL54-231 + GGGUUUUGGUGUGGAGU 17 6654
HSV-UL54-232 + UGUGGAGUCGGCGCCGC 17 6655
HSV-UL54-233 + GUGGAGUCGGCGCCGCC 17 6656
HSV-UL54-234 + UGGAGUCGGCGCCGCCG 17 6657
HSV-UL54-235 + GACCUCGCCGCCCGCCU 17 6658
HSV-UL54-236 + ACCUCGCCGCCCGCCUC 17 6659
HSV-UL54-237 + CCUCGCCGCCCGCCUCG 17 6660
HSV-UL54-238 + CGCCCGCCUCGGGGAUG 17 6661
HSV-UL54-239 + UCGGGGAUGCGGUGCCU 17 6662
HSV-UL54-240 + UCGACGGGGGUUGGAUG 17 6663
HSV-UL54-241 + UCCCCCCGUGCGGUUCC 17 6664
HSV-UL54-242 + CCCCCCGUGCGGUUCCC 17 6665
HSV-UL54-243 + CCCCCGUGCGGUUCCCG 17 6666
HSV-UL54-244 + GGGGGAAGCCGACCGCC 17 6667
HSV-UL54-245 + ACGCCGGUGGUCGCGGG 17 6668
HSV-UL54-246 + CCGGUGGUCGCGGGUGG 17 6669
HSV-UL54-247 + CGCGGGUGGCGGAUCGU 17 6670
HSV-UL54-248 + GCUCCCCGCCGCGCUGC 17 6671
HSV-UL54-249 + CUCCCCGCCGCGCUGCC 17 6672
HSV-UL54-250 + CGCCGCGCUGCCGGGCG 17 6673
HSV-UL54-251 + UGCCGGGCGAGGCGUCG 17 6674
HSV-UL54-252 + CGAGGCGUCGAGGCUUC 17 6675
HSV-UL54-253 + CGAGGCUUCGGGGGUGC 17 6676
HSV-UL54-254 + GGGGGUGCCGGCGUCCU 17 6677
HSV-UL54-255 + GGGUGCCGGCGUCCUCG 17 6678
HSV-UL54-256 + UGCCGGCGUCCUCGGGG 17 6679
HSV-UL54-257 + GCCGGCGUCCUCGGGGC 17 6680
HSV-UL54-258 + GCGUCCUCGGGGCGGGC 17 6681
HSV-UL54-259 + CGUCCUCGGGGCGGGCC 17 6682
HSV-UL54-260 + GUCCUCGGGGCGGGCCG 17 6683
HSV-UL54-261 + UCCUCGGGGCGGGCCGG 17 6684
HSV-UL54-262 + GCGGGCCGGGGGACCUU 17 6685
HSV-UL54-263 + CGCCCCUCCGUCUCCGC 17 6686
HSV-UL54-264 + GCCCCUCCGUCUCCGCA 17 6687
HSV-UL54-265 + CCCCUCCGUCUCCGCAG 17 6688
HSV-UL54-266 + ACACU CCCCG CU GCU G U 17 6689
HSV-UL54-267 + CCGCUGCUGUCGGACUC 17 6690
HSV-UL54-268 + CGGACUCGGGGUCGUCG 17 6691
HSV-UL54-269 + ACUCGGGGUCGUCGCGG 17 6692
HSV-UL54-270 + GAUUAGCAUAUCAAUGU 17 6693
Table 4C provides exemplary targeting domains for knocking out the UL54 gene selected according to the third tier parameters. The targeting domains are selected based on location within the coding sequence (but downstream of the first 500bp) of the UL54 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. pyogenes Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 4C
Figure imgf000272_0001
HSV-UL54-298 - ACACCAU CG ACCCCG CCG U U 20 6721
HSV-UL54-299 - CACCAUCGACCCCGCCGUUC 20 6722
HSV-UL54-300 - CAUCGACCCCGCCGUUCGGG 20 6723
HSV-UL54-301 - GCGAUCCAUAUCCGAGCGCG 20 6724
HSV-UL54-302 - AUCCAUAUCCGAGCGCGCGG 20 6725
HSV-UL54-303 - GAGCGCAUCAGCGAAAGCUU 20 6726
HSV-UL54-304 - AAGCUUUGGACGCAGUGCCC 20 6727
HSV-UL54-305 - CUGGUCAUGCAAGACCCCUU 20 6728
HSV-UL54-306 - GUCAUGCAAGACCCCUUUGG 20 6729
HSV-UL54-307 - UCAUGCAAGACCCCUUUGGC 20 6730
HSV-UL54-308 - UUCCCGCCGCGAACAGCCCC 20 6731
HSV-UL54-309 - U CCCG CCGCG AACAG CCCCU 20 6732
HSV-UL54-310 - CAGCCCCUGGGCUCCCGUGC 20 6733
HSV-UL54-311 - UCCCGUGCUGGCCACCCAAG 20 6734
HSV-UL54-312 - CCCGUGCUGGCCACCCAAGC 20 6735
HSV-UL54-313 - CCGUGCUGGCCACCCAAGCG 20 6736
HSV-UL54-314 - CGUGCUGGCCACCCAAGCGG 20 6737
HSV-UL54-315 - GUGCUGGCCACCCAAGCGGG 20 6738
HSV-UL54-316 - UGCUGGCCACCCAAGCGGGG 20 6739
HSV-UL54-317 - GGUUUGACGCCGAGACCCGU 20 6740
HSV-UL54-318 - GUUUGACGCCGAGACCCGUC 20 6741
HSV-UL54-319 - CCGAGACCCGUCGGGUUUCC 20 6742
HSV-UL54-320 - CGAGACCCGUCGGGUUUCCU 20 6743
HSV-UL54-321 - UCGGGUUUCCUGGGAAACCC 20 6744
HSV-UL54-322 - UGGGAAACCCUGGUCGCUCA 20 6745
HSV-UL54-323 - GCACAUUCGCAGCCAACCCG 20 6746
HSV-UL54-324 - CACAUUCGCAGCCAACCCGC 20 6747
HSV-UL54-325 - GCGGGCCGCGUCGACAGCCA 20 6748
HSV-UL54-326 - GCGCGACUGCGUGCUGCGCC 20 6749
HSV-UL54-327 - GCGCCAGGAAAAUCUCAUCG 20 6750
HSV-UL54-328 - GGAAAAUCUCAUCGAGGCCC 20 6751
HSV-UL54-329 - CAUCGAGGCCCUGGCGUCCG 20 6752
HSV-UL54-330 - GGCGUCCGCGGAUGAGACGC 20 6753
HSV-UL54-331 - CCGCGGAUGAGACGCUGGCG 20 6754
HSV-UL54-332 - CAAUCUGCCGCUCCGCCCCC 20 6755
HSV-UL54-333 - CGCCCCCAGGACCCUAUCAU 20 6756
HSV-UL54-334 - CCAGGACCCUAUCAUCGGAA 20 6757
HSV-UL54-335 - GGACCCUAUCAUCGGAACGG 20 6758
HSV-UL54-336 - CGGAACGGCGGCCGCCGUGC 20 6759
HSV-UL54-337 - CUUUCUGCAGUGCUACCUGA 20 6760
HSV-UL54-338 - CAGUGCUACCUGAAGGCCCG 20 6761
HSV-UL54-339 - CUGAAGGCCCGAGGCCUGUG 20 6762
HSV-UL54-340 - UGAAGGCCCGAGGCCUGUGC 20 6763
HSV-UL54-341 - GGCCCGAGGCCUGUGCGGGC 20 6764
HSV-UL54-342 - GGCUGGACGACCUGUGCUCG 20 6765
HSV-UL54-343 - GUGCUCGCGGCGACGCCUGU 20 6766 HSV-UL54-344 - GCGACGCCUGUCGGACAUUA 20 6767
HSV-UL54-345 - GGAUAUUGCCUCCUUUGUGU 20 6768
HSV-UL54-346 - CUCCUUUGUGUUGGUCAUCC 20 6769
HSV-UL54-347 - CU CG CCAACCGCG U CG AG CG 20 6770
HSV-UL54-348 - CCGCGUCGAGCGCGGCGUGU 20 6771
HSV-UL54-349 - GGAGAUCGACUACACGACCG 20 6772
HSV-UL54-350 - GAGAUCGACUACACGACCGU 20 6773
HSV-UL54-351 - AGAUCGACUACACGACCGUG 20 6774
HSV-UL54-352 - GAUCGACUACACGACCGUGG 20 6775
HSV-UL54-353 - GACUACACGACCGUGGGGGU 20 6776
HSV-UL54-354 - ACUACACGACCGUGGGGGUU 20 6777
HSV-UL54-355 - CUACACGACCGUGGGGGUUG 20 6778
HSV-UL54-356 - ACGACCGUGGGGGUUGGGGC 20 6779
HSV-UL54-357 - GACGAUGCACUUUUACAUCC 20 6780
HSV-UL54-358 - ACGAUGCACUUUUACAUCCC 20 6781
HSV-UL54-359 - CGAUGCACUUUUACAUCCCG 20 6782
HSV-UL54-360 - GAUGCACUUUUACAUCCCGG 20 6783
HSV-UL54-361 - UUACAUCCCGGGGGCCUGCA 20 6784
HSV-UL54-362 - CAUCCCGGGGGCCUGCAUGG 20 6785
HSV-UL54-363 - AUCCCGGGGGCCUGCAUGGC 20 6786
HSV-UL54-364 - GGCGGGUCUCAUUGAAAUAC 20 6787
HSV-UL54-365 - AAUACUGGACACGCACCGCC 20 6788
HSV-UL54-366 - CAGUCGCGUGUGCGAGCUGA 20 6789
HSV-UL54-367 - AUCGCCCCCUUAUAUGUGCA 20 6790
HSV-UL54-368 + UGCACAUAUAAGGGGGCGAU 20 6791
HSV-UL54-369 + UCAGCUCGCACACGCGACUG 20 6792
HSV-UL54-370 + GGCGGUGCGUGUCCAGUAUU 20 6793
HSV-UL54-371 + GUAUUUCAAUGAGACCCGCC 20 6794
HSV-UL54-372 + GCCAUGCAGGCCCCCGGGAU 20 6795
HSV-UL54-373 + CCAUGCAGGCCCCCGGGAUG 20 6796
HSV-UL54-374 + UGCAGGCCCCCGGGAUGUAA 20 6797
HSV-UL54-375 + CCGGGAUGUAAAAGUGCAUC 20 6798
HSV-UL54-376 + CGGGAUGUAAAAGUGCAUCG 20 6799
HSV-UL54-377 + GGGAUGUAAAAGUGCAUCGU 20 6800
HSV-UL54-378 + GGAUGUAAAAGUGCAUCGUC 20 6801
HSV-UL54-379 + G CCCCAACCCCCACG G U CG U 20 6802
HSV-UL54-380 + CAACCCCCACGGUCGUGUAG 20 6803
HSV-UL54-381 + AACCCCCACGGUCGUGUAGU 20 6804
HSV-UL54-382 + ACCCCCACGGUCGUGUAGUC 20 6805
HSV-UL54-383 + CCACGGUCGUGUAGUCGAUC 20 6806
HSV-UL54-384 + CACGGUCGUGUAGUCGAUCU 20 6807
HSV-UL54-385 + ACGGUCGUGUAGUCGAUCUC 20 6808
HSV-UL54-386 + CGGUCGUGUAGUCGAUCUCC 20 6809
HSV-UL54-387 + ACACGCCGCGCUCGACGCGG 20 6810
HSV-UL54-388 + CGCUCGACGCGGUUGGCGAG 20 6811
HSV-UL54-389 + GGAUGACCAACACAAAGGAG 20 6812 HSV-UL54-390 + ACACAAAGGAGGCAAUAUCC 20 6813
HSV-UL54-391 + UAAUGUCCGACAGGCGUCGC 20 6814
HSV-UL54-392 + ACAGGCGUCGCCGCGAGCAC 20 6815
HSV-UL54-393 + CGAGCACAGGUCGUCCAGCC 20 6816
HSV-UL54-394 + GCCCGCACAGGCCUCGGGCC 20 6817
HSV-UL54-395 + GCACAGGCCUCGGGCCUUCA 20 6818
HSV-UL54-396 + CACAGGCCUCGGGCCUUCAG 20 6819
HSV-UL54-397 + CGGGCCUUCAGGUAGCACUG 20 6820
HSV-UL54-398 + UCAGGUAGCACUGCAGAAAG 20 6821
HSV-UL54-399 + GCACGGCGGCCGCCGUUCCG 20 6822
HSV-UL54-400 + CCGU UCCGAUGAUAGGGUCC 20 6823
HSV-UL54-401 + UUCCGAUGAUAGGGUCCUGG 20 6824
HSV-UL54-402 + AUGAUAGGGUCCUGGGGGCG 20 6825
HSV-UL54-403 + GGGGGCGGAGCGGCAGAUUG 20 6826
HSV-UL54-404 + CGCCAGCGUCUCAUCCGCGG 20 6827
HSV-UL54-405 + GCGUCUCAUCCGCGGACGCC 20 6828
HSV-UL54-406 + CGGACGCCAGGGCCUCGAUG 20 6829
HSV-UL54-407 + GGGCCUCGAUGAGAUUUUCC 20 6830
HSV-UL54-408 + CGAUGAGAUUUUCCUGGCGC 20 6831
HSV-UL54-409 + GGCGCAGCACGCAGUCGCGC 20 6832
HSV-UL54-410 + UGGCUGUCGACGCGGCCCGC 20 6833
HSV-UL54-411 + GCGGGUUGGCUGCGAAUGUG 20 6834
HSV-UL54-412 + CGGGUUGGCUGCGAAUGUGC 20 6835
HSV-UL54-413 + UGAGCGACCAGGGUUUCCCA 20 6836
HSV-UL54-414 + G GG U U U CCCAG G AAACCCG A 20 6837
HSV-UL54-415 + AGGAAACCCGACGGGUCUCG 20 6838
HSV-UL54-416 + GGAAACCCGACGGGUCUCGG 20 6839
HSV-UL54-417 + GACGGGUCUCGGCGUCAAAC 20 6840
HSV-UL54-418 + ACGGGUCUCGGCGUCAAACC 20 6841
HSV-UL54-419 + CCCCGCUUGGGUGGCCAGCA 20 6842
HSV-UL54-420 + CCCGCUUGGGUGGCCAGCAC 20 6843
HSV-UL54-421 + CCGCUUGGGUGGCCAGCACG 20 6844
HSV-UL54-422 + CGCUUGGGUGGCCAGCACGG 20 6845
HSV-UL54-423 + GCUUGGGUGGCCAGCACGGG 20 6846
HSV-UL54-424 + CUUGGGUGGCCAGCACGGGA 20 6847
HSV-UL54-425 + GCACGGGAGCCCAGGGGCUG 20 6848
HSV-UL54-426 + AGGGGCUGUUCGCGGCGGGA 20 6849
HSV-UL54-427 + GGGGCUGUUCGCGGCGGGAA 20 6850
HSV-UL54-428 + GCCAAAGGGGUCUUGCAUGA 20 6851
HSV-UL54-429 + CCAAAGGGGUCUUGCAUGAC 20 6852
HSV-UL54-430 + AAGGGGUCUUGCAUGACCAG 20 6853
HSV-UL54-431 + GGGCACUGCGUCCAAAGCUU 20 6854
HSV-UL54-432 + AAGCUUUCGCUGAUGCGCUC 20 6855
HSV-UL54-433 + CCGCGCGCUCGGAUAUGGAU 20 6856
HSV-UL54-434 + CGCGCUCGGAUAUGGAUCGC 20 6857
HSV-UL54-435 + CCCGAACGGCGGGGUCGAUG 20 6858 HSV-UL54-436 + GAACGGCGGGGUCGAUGGUG 20 6859
HSV-UL54-437 + AACGGCGGGGUCGAUGGUGU 20 6860
HSV-UL54-438 + UUCGCUCCGGGACCGGGGCG 20 6861
HSV-UL54-439 + GGACCGGGGCGCGGCCGUCC 20 6862
HSV-UL54-440 + GGGCGCGGCCGUCCGCGUGC 20 6863
HSV-UL54-441 + UCCGCGUGCGGGGGGGUCAG 20 6864
HSV-UL54-442 + CGUGCGGGGGGGUCAGGGAC 20 6865
HSV-UL54-443 + UCAGCGGAGGGGGGGCCUGG 20 6866
HSV-UL54-444 + GGCGCGUGCCUCGUGGCCGC 20 6867
HSV-UL54-445 + CGUGGCCGCGGGCCCCCGGA 20 6868
HSV-UL54-446 + CGGGCCCCCGGAGACGUCGA 20 6869
HSV-UL54-447 + CCGGAGACGUCGAGCUGCUC 20 6870
HSV-UL54-448 + CGGAGACGUCGAGCUGCUCC 20 6871
HSV-UL54-449 + GGAGACGUCGAGCUGCUCCC 20 6872
HSV-UL54-450 + GAGACGUCGAGCUGCUCCCC 20 6873
HSV-UL54-451 + CUCCGCGCCGCGCCUCGCCG 20 6874
HSV-UL54-452 + UCCGCGCCGCGCCUCGCCGU 20 6875
HSV-UL54-453 + CCGCGCCGCGCCUCGCCGUG 20 6876
HSV-UL54-454 + CGCCGCGCCUCGCCGUGGGU 20 6877
HSV-UL54-455 + CGCCUCGCCGUGGGUGGCGC 20 6878
HSV-UL54-456 + CGCCGUGGGUGGCGCCGGGG 20 6879
HSV-UL54-457 + UGGGUGGCGCCGGGGCCGUC 20 6880
HSV-UL54-458 + GGGCCGUCCGUCCGCGCCGA 20 6881
HSV-UL54-459 + UCCGUCCGCGCCGACGCGGG 20 6882
HSV-UL54-460 + UCCGCGCCGACGCGGGGUGG 20 6883
HSV-UL54-461 + CGCCGACGCGGGGUGGCGAC 20 6884
HSV-UL54-462 + ACGCGGGGUGGCGACCCCCU 20 6885
HSV-UL54-463 + CCUUGGUUGUGGGCGUUUCU 20 6886
HSV-UL54-464 + CUUGGUUGUGGGCGUUUCUG 20 6887
HSV-UL54-464 + CUUGGUUGUGGGCGUUUCUG 20 6887
HSV-UL54-464 + CUUGGUUGUGGGCGUUUCUG 20 6887
HSV-UL54-467 - AAACG CCCACAACCAAG 17 6888
HSV-UL54-468 - AACG CCCACAACCAAG G 17 6889
HSV-UL54-469 - GGGUCGCCACCCCGCGU 17 6890
HSV-UL54-470 - GCCACCCCGCGUCGGCG 17 6891
HSV-UL54-471 - CCCCGCGUCGGCGCGGA 17 6892
HSV-UL54-472 - GCGUCGGCGCGGACGGA 17 6893
HSV-UL54-473 - GCGCGGACGGACGGCCC 17 6894
HSV-UL54-474 - GGCCCCGGCGCCACCCA 17 6895
HSV-UL54-475 - CGGCGCCACCCACGGCG 17 6896
HSV-UL54-476 - CCACCCACGGCGAGGCG 17 6897
HSV-UL54-477 - CACGGCGAGGCGCGGCG 17 6898
HSV-UL54-478 - GGCGAGGCGCGGCGCGG 17 6899
HSV-UL54-479 - GCGAGGCGCGGCGCGGA 17 6900
HSV-UL54-480 - CGAGGCGCGGCGCGGAG 17 6901
HSV-UL54-481 - GAGCAGCUCGACGUCUC 17 6902 HSV-UL54-482 - AGCAGCUCGACGUCUCC 17 6903
HSV-UL54-483 - GCAGCUCGACGUCUCCG 17 6904
HSV-UL54-484 - CAGCUCGACGUCUCCGG 17 6905
HSV-UL54-485 - ACGUCUCCGGGGGCCCG 17 6906
HSV-UL54-486 - GGGGGCCCGCGGCCACG 17 6907
HSV-UL54-487 - GCCACGAGGCACGCGCC 17 6908
HSV-UL54-488 - GGCCCCCCCUCCGCUGA 17 6909
HSV-UL54-489 - CCUGACCCCCCCGCACG 17 6910
HSV-UL54-490 - ACCCCCCCGCACGCGGA 17 6911
HSV-UL54-491 - CGCGGACGGCCGCGCCC 17 6912
HSV-UL54-492 - CGGCCGCGCCCCGGUCC 17 6913
HSV-UL54-493 - CCCGGUCCCGGAGCGAA 17 6914
HSV-UL54-494 - CCAUCGACCCCGCCGUU 17 6915
HSV-UL54-495 - CAUCGACCCCGCCGUUC 17 6916
HSV-UL54-496 - CGACCCCGCCGUUCGGG 17 6917
HSV-UL54-497 - AUCCAUAUCCGAGCGCG 17 6918
HSV-UL54-498 - CAUAUCCGAGCGCGCGG 17 6919
HSV-UL54-499 - CGCAUCAGCGAAAGCUU 17 6920
HSV-UL54-500 - CUUUGGACGCAGUGCCC 17 6921
HSV-UL54-501 - G U CAU GCAAG ACCCCU U 17 6922
HSV-UL54-502 - AUGCAAGACCCCUUUGG 17 6923
HSV-UL54-503 - UGCAAGACCCCUUUGGC 17 6924
HSV-UL54-504 - CCGCCGCGAACAGCCCC 17 6925
HSV-UL54-505 - CGCCGCGAACAGCCCCU 17 6926
HSV-UL54-506 - CCCCUGGGCUCCCGUGC 17 6927
HSV-UL54-507 - CGUGCUGGCCACCCAAG 17 6928
HSV-UL54-508 - GUGCUGGCCACCCAAGC 17 6929
HSV-UL54-509 - UGCUGGCCACCCAAGCG 17 6930
HSV-UL54-510 - GCUGGCCACCCAAGCGG 17 6931
HSV-UL54-511 - CUGGCCACCCAAGCGGG 17 6932
HSV-UL54-512 - UGGCCACCCAAGCGGGG 17 6933
HSV-UL54-513 - UUGACGCCGAGACCCGU 17 6934
HSV-UL54-514 - UGACGCCGAGACCCGUC 17 6935
HSV-UL54-515 - AGACCCGUCGGGUUUCC 17 6936
HSV-UL54-516 - GACCCGUCGGGUUUCCU 17 6937
HSV-UL54-517 - GGUUUCCUGGGAAACCC 17 6938
HSV-UL54-518 - GAAACCCUGGUCGCUCA 17 6939
HSV-UL54-519 - CAUUCGCAGCCAACCCG 17 6940
HSV-UL54-520 - AUUCGCAGCCAACCCGC 17 6941
HSV-UL54-521 - GGCCGCGUCGACAGCCA 17 6942
HSV-UL54-522 - CGACUGCGUGCUGCGCC 17 6943
HSV-UL54-523 - CCAG G AAAAU CU CAUCG 17 6944
HSV-UL54-524 - AAAU CU CAU CG AGG CCC 17 6945
HSV-UL54-525 - CGAGGCCCUGGCGUCCG 17 6946
HSV-UL54-526 - GUCCGCGGAUGAGACGC 17 6947
HSV-UL54-527 - CGGAUGAGACGCUGGCG 17 6948 HSV-UL54-528 - UCUGCCGCUCCGCCCCC 17 6949
HSV-UL54-529 - CCCCAGGACCCUAUCAU 17 6950
HSV-UL54-530 - GGACCCUAUCAUCGGAA 17 6951
HSV-UL54-531 - CCCUAUCAUCGGAACGG 17 6952
HSV-UL54-532 - AACGGCGGCCGCCGUGC 17 6953
HSV-UL54-533 - UCUGCAGUGCUACCUGA 17 6954
HSV-UL54-534 - UGCUACCUGAAGGCCCG 17 6955
HSV-UL54-535 - AAGGCCCGAGGCCUGUG 17 6956
HSV-UL54-536 - AGGCCCGAGGCCUGUGC 17 6957
HSV-UL54-537 - CCGAGGCCUGUGCGGGC 17 6958
HSV-UL54-538 - UGGACGACCUGUGCUCG 17 6959
HSV-UL54-539 - CUCGCGGCGACGCCUGU 17 6960
HSV-UL54-540 - ACGCCUGUCGGACAUUA 17 6961
HSV-UL54-541 - UAUUGCCUCCUUUGUGU 17 6962
HSV-UL54-542 - CUUUGUGUUGGUCAUCC 17 6963
HSV-UL54-543 - GCCAACCGCGUCGAGCG 17 6964
HSV-UL54-544 - CGUCGAGCGCGGCGUGU 17 6965
HSV-UL54-545 - GAUCGACUACACGACCG 17 6966
HSV-UL54-546 - AUCGACUACACGACCGU 17 6967
HSV-UL54-547 - UCGACUACACGACCGUG 17 6968
HSV-UL54-548 - CGACUACACGACCGUGG 17 6969
HSV-UL54-549 - UACACGACCGUGGGGGU 17 6970
HSV-UL54-550 - ACACGACCGUGGGGGUU 17 6971
HSV-UL54-551 - CACGACCGUGGGGGUUG 17 6972
HSV-UL54-552 - ACCGUGGGGGUUGGGGC 17 6973
HSV-UL54-553 - GAUGCACUUUUACAUCC 17 6974
HSV-UL54-554 - AUGCACUUUUACAUCCC 17 6975
HSV-UL54-555 - UGCACUUUUACAUCCCG 17 6976
HSV-UL54-556 - GCACUUUUACAUCCCGG 17 6977
HSV-UL54-557 - CAUCCCGGGGGCCUGCA 17 6978
HSV-UL54-558 - CCCGGGGGCCUGCAUGG 17 6979
HSV-UL54-559 - CCGGGGGCCUGCAUGGC 17 6980
HSV-UL54-560 - GGGUCUCAUUGAAAUAC 17 6981
HSV-UL54-561 - ACUGGACACGCACCGCC 17 6982
HSV-UL54-562 - UCGCGUGUGCGAGCUGA 17 6983
HSV-UL54-563 - GCCCCCUUAUAUGUGCA 17 6984
HSV-UL54-564 + UGCACAUAUAAGGGGGC 17 6985
HSV-UL54-565 + UCAGCUCGCACACGCGA 17 6986
HSV-UL54-566 + GGCGGUGCGUGUCCAGU 17 6987
HSV-UL54-567 + GUAUUUCAAUGAGACCC 17 6988
HSV-UL54-568 + GCCAUGCAGGCCCCCGG 17 6989
HSV-UL54-569 + CCAUGCAGGCCCCCGGG 17 6990
HSV-UL54-570 + UGCAGGCCCCCGGGAUG 17 6991
HSV-UL54-571 + CCGGGAUGUAAAAGUGC 17 6992
HSV-UL54-572 + CGGGAUGUAAAAGUGCA 17 6993
HSV-UL54-573 + GGGAUGUAAAAGUGCAU 17 6994 HSV-UL54-574 + GGAUGUAAAAGUGCAUC 17 6995
HSV-UL54-575 + GCCCCAACCCCCACGGU 17 6996
HSV-UL54-576 + CAACCCCCACGGUCGUG 17 6997
HSV-UL54-577 + AACCCCCACGGUCGUGU 17 6998
HSV-UL54-578 + ACCCCCACGGUCGUGUA 17 6999
HSV-UL54-579 + CCACGGUCGUGUAGUCG 17 7000
HSV-UL54-580 + CACGGUCGUGUAGUCGA 17 7001
HSV-UL54-581 + ACGGUCGUGUAGUCGAU 17 7002
HSV-UL54-582 + CGGUCGUGUAGUCGAUC 17 7003
HSV-UL54-583 + ACACGCCGCGCUCGACG 17 7004
HSV-UL54-584 + CGCUCGACGCGGUUGGC 17 7005
HSV-UL54-585 + GGAUGACCAACACAAAG 17 7006
HSV-UL54-586 + ACACAAAGGAGGCAAUA 17 7007
HSV-UL54-587 + UAAUGUCCGACAGGCGU 17 7008
HSV-UL54-588 + ACAGGCGUCGCCGCGAG 17 7009
HSV-UL54-589 + CGAGCACAGGUCGUCCA 17 7010
HSV-UL54-590 + GCCCGCACAGGCCUCGG 17 7011
HSV-UL54-591 + GCACAGGCCUCGGGCCU 17 7012
HSV-UL54-592 + CACAGGCCUCGGGCCUU 17 7013
HSV-UL54-593 + CGGGCCUUCAGGUAGCA 17 7014
HSV-UL54-594 + UCAGGUAGCACUGCAGA 17 7015
HSV-UL54-595 + GCACGGCGGCCGCCGUU 17 7016
HSV-UL54-596 + CCGUUCCGAUGAUAGGG 17 7017
HSV-UL54-597 + UUCCGAUGAUAGGGUCC 17 7018
HSV-UL54-598 + AUGAUAGGGUCCUGGGG 17 7019
HSV-UL54-599 + GGGGGCGGAGCGGCAGA 17 7020
HSV-UL54-600 + CGCCAGCGUCUCAUCCG 17 7021
HSV-UL54-601 + GCGUCUCAUCCGCGGAC 17 7022
HSV-UL54-602 + CGGACGCCAGGGCCUCG 17 7023
HSV-UL54-603 + GGGCCUCGAUGAGAUUU 17 7024
HSV-UL54-604 + CGAUGAGAUUUUCCUGG 17 7025
HSV-UL54-605 + GGCGCAGCACGCAGUCG 17 7026
HSV-UL54-606 + UGGCUGUCGACGCGGCC 17 7027
HSV-UL54-607 + GCGGGUUGGCUGCGAAU 17 7028
HSV-UL54-608 + CGGGUUGGCUGCGAAUG 17 7029
HSV-UL54-609 + UGAGCGACCAGGGUUUC 17 7030
HSV-UL54-610 + GGGUUUCCCAGG AAACC 17 7031
HSV-UL54-611 + AGGAAACCCGACGGGUC 17 7032
HSV-UL54-612 + GGAAACCCGACGGGUCU 17 7033
HSV-UL54-613 + GACGGGUCUCGGCGUCA 17 7034
HSV-UL54-614 + ACGGGUCUCGGCGUCAA 17 7035
HSV-UL54-615 + CCCCGCUUGGGUGGCCA 17 7036
HSV-UL54-616 + CCCGCUUGGGUGGCCAG 17 7037
HSV-UL54-617 + CCGCUUGGGUGGCCAGC 17 7038
HSV-UL54-618 + CGCUUGGGUGGCCAGCA 17 7039
HSV-UL54-619 + GCUUGGGUGGCCAGCAC 17 7040 HSV-UL54-620 + CU UGGGUGGCCAGCACG 17 7041
HSV-UL54-621 + GCACGGGAGCCCAGGGG 17 7042
HSV-UL54-622 + AGGGGCUGUUCGCGGCG 17 7043
HSV-UL54-623 + GGGGCUGUUCGCGGCGG 17 7044
HSV-UL54-624 + GCCAAAGGGGUCUUGCA 17 7045
HSV-UL54-625 + CCAAAGGGGUCUUGCAU 17 7046
HSV-UL54-626 + AAGGGGUCUUGCAUGAC 17 7047
HSV-UL54-627 + GGGCACUGCGU CCAAAG 17 7048
HSV-UL54-628 + AAGCUUUCGCUGAUGCG 17 7049
HSV-UL54-629 + CCGCGCGCUCGGAUAUG 17 7050
HSV-UL54-630 + CGCGCUCGGAUAUGGAU 17 7051
HSV-UL54-631 + CCCGAACGGCGGGGUCG 17 7052
HSV-UL54-632 + GAACGGCGGGGUCGAUG 17 7053
HSV-UL54-633 + AACGGCGGGGUCGAUGG 17 7054
HSV-UL54-634 + UUCGCUCCGGGACCGGG 17 7055
HSV-UL54-635 + GGACCGGGGCGCGGCCG 17 7056
HSV-UL54-636 + GGGCGCGGCCGUCCGCG 17 7057
HSV-UL54-637 + UCCGCGUGCGGGGGGGU 17 7058
HSV-UL54-638 + CGUGCGGGGGGGUCAGG 17 7059
HSV-UL54-639 + UCAGCGGAGGGGGGGCC 17 7060
HSV-UL54-640 + GGCGCGUGCCUCGUGGC 17 7061
HSV-UL54-641 + CGUGGCCGCGGGCCCCC 17 7062
HSV-UL54-642 + CGGGCCCCCGGAGACGU 17 7063
HSV-UL54-643 + CCGGAGACGUCGAGCUG 17 7064
HSV-UL54-644 + CGGAGACGUCGAGCUGC 17 7065
HSV-UL54-645 + GGAGACGUCGAGCUGCU 17 7066
HSV-UL54-646 + GAGACGUCGAGCUGCUC 17 7067
HSV-UL54-647 + CUCCGCGCCGCGCCUCG 17 7068
HSV-UL54-648 + UCCGCGCCGCGCCUCGC 17 7069
HSV-UL54-649 + CCGCGCCGCGCCUCGCC 17 7070
HSV-UL54-650 + CGCCGCGCCUCGCCGUG 17 7071
HSV-UL54-651 + CGCCUCGCCGUGGGUGG 17 7072
HSV-UL54-652 + CGCCGUGGGUGGCGCCG 17 7073
HSV-UL54-653 + UGGGUGGCGCCGGGGCC 17 7074
HSV-UL54-654 + GGGCCGUCCGUCCGCGC 17 7075
HSV-UL54-655 + UCCGUCCGCGCCGACGC 17 7076
HSV-UL54-656 + UCCGCGCCGACGCGGGG 17 7077
HSV-UL54-657 + CGCCGACGCGGGGUGGC 17 7078
HSV-UL54-658 + ACGCGGGGUGGCGACCC 17 7079
HSV-UL54-659 + CCUUGGUUGUGGGCGUU 17 7080
HSV-UL54-660 + CUUGGUUGUGGGCGUUU 17 7081
HSV-UL54-661 + UUGGUUGUGGGCGUUUC 17 7082
HSV-UL54-662 + UGGUUGUGGGCGUUUCU 17 7083 Table 4D provides exemplary targeting domains for knocking out the UL54 gene selected according to the first tier parameters. The targeting domains are selected based on location within first 500bp of the coding sequence of the UL54 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. aureus Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. aureus Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 4D
Figure imgf000281_0001
HSV-UL54-699 - GGGAGUGUUCCUCGUCGGAC 20 7109
HSV-UL54-700 - GUUCCUCGUCGGACGAGGAC 20 7110
HSV-UL54-6 - UUCCUCGUCGGACGAGGACA 20 6429
HSV-UL54-115 - GAGGACAUGGAAGACCCCUG 20 6538
HSV-UL54-116 - AUGGAAGACCCCUGCGGAGA 20 6539
HSV-UL54-704 - GGAAGACCCCUGCGGAGACG 20 7111
HSV-UL54-117 - GAAGACCCCUGCGGAGACGG 20 6540
HSV-UL54-706 - ACCCCUGCGGAGACGGAGGG 20 7112
HSV-UL54-119 - CCCCUGCGGAGACGGAGGGG 20 6542
HSV-UL54-708 - CAAAGGUCCCCCGGCCCGCC 20 7113
HSV-UL54-709 - AAGGUCCCCCGGCCCGCCCC 20 7114
HSV-UL54-710 - CCCCGAGGACGCCGGCACCC 20 7115
HSV-UL54-711 - ACGCCUCGCCCGGCAGCGCG 20 7116
HSV-UL54-125 - CGCCUCGCCCGGCAGCGCGG 20 6548
HSV-UL54-126 - GCCUCGCCCGGCAGCGCGGC 20 6549
HSV-UL54-127 - CCUCGCCCGGCAGCGCGGCG 20 6550
HSV-UL54-715 - CACCGGCGUGUGGUCGCGCC 20 7117
HSV-UL54-128 - ACCGGCGUGUGGUCGCGCCU 20 6551
HSV-UL54-717 - ACCAGGCGGUCGGCUUCCCC 20 7118
HSV-UL54-130 - CCAGGCGGUCGGCUUCCCCC 20 6553
HSV-UL54-131 - CAGGCGGUCGGCUUCCCCCC 20 6554
HSV-UL54-720 - GGCUUCCCCCCGGGAACCGC 20 7119
HSV-UL54-16 - GCUUCCCCCCGGGAACCGCA 20 6439
HSV-UL54-132 - CU UCCCCCCGGGAACCGCAC 20 6555
HSV-UL54-17 - U U CCCCCCG GG AACCG CACG 20 6440
HSV-UL54-18 - UCCCCCCGGGAACCGCACGG 20 6441
HSV-UL54-19 - CCCCCCGGGAACCGCACGGG 20 6442
HSV-UL54-726 - UCGACCAAGGCACCGCAUCC 20 7120
HSV-UL54-727 - CAAGGCACCGCAUCCCCGAG 20 7121
HSV-UL54-728 - CCGCAUCCCCGAGGCGGGCG 20 7122
HSV-UL54-729 - GGCGGGCGGCGAGGUCGCCG 20 7123
HSV-UL54-140 - GCGGGCGGCGAGGUCGCCGC 20 6563
HSV-UL54-731 - CGGCGAGGUCGCCGCCGGGG 20 7124
HSV-UL54-143 - GGCGAGGUCGCCGCCGGGGC 20 6566
HSV-UL54-733 + GCGGCGACCUCGCCGCCCGC 20 7125
HSV-UL54-27 + GGAUGCGGUGCCUUGGUCGA 20 6450
HSV-UL54-735 + UGCGGUUCCCGGGGGGAAGC 20 7126
HSV-UL54-736 + GGCGCGACCACACGCCGGUG 20 7127
HSV-UL54-737 + GCCCCGGCGGCGACCUCGCC 20 7128
HSV-UL54-738 + CCCCGGCGGCGACCUCGCCG 20 7129
HSV-UL54-739 + CG G CG ACCU CG CCG CCCGCC 20 7130
HSV-UL54-740 + CGCCCGCCUCGGGGAUGCGG 20 7131
HSV-UL54-741 + CUCGGGGAUGCGGUGCCUUG 20 7132
HSV-UL54-742 + CCCGUGCGGU UCCCGGGGGG 20 7133
HSV-UL54-743 + CCGUGCGGUUCCCGGGGGGA 20 7134
HSV-UL54-744 + CGUGCGGUUCCCGGGGGGAA 20 7135 HSV-UL54-745 + GUGCGGUUCCCGGGGGGAAG 20 7136
HSV-UL54-746 + GCGGUUCCCGGGGGGAAGCC 20 7137
HSV-UL54-747 + GGGGGGAAGCCGACCGCCUG 20 7138
HSV-UL54-748 + GGGGGAAGCCGACCGCCUGG 20 7139
HSV-UL54-749 + GGGGAAGCCGACCGCCUGGU 20 7140
HSV-UL54-750 + AGGCGCGACCACACGCCGGU 20 7141
HSV-UL54-751 + CGCCGCGCUGCCGGGCGAGG 20 7142
HSV-UL54-752 + GCCGCGCUGCCGGGCGAGGC 20 7143
HSV-UL54-753 + CCGCGCUGCCGGGCGAGGCG 20 7144
HSV-UL54-754 + CGCGCUGCCGGGCGAGGCGU 20 7145
HSV-UL54-173 + GGGUGCCGGCGUCCUCGGGG 20 6596
HSV-UL54-179 + GGGGCGGGCCGGGGGACCUU 20 6602
HSV-UL54-757 + GGCGGGCCGGGGGACCUUUG 20 7146
HSV-UL54-758 + CCCCUCCGUCUCCGCAGGGG 20 7147
HSV-UL54-759 + CCCUCCGUCUCCGCAGGGGU 20 7148
HSV-UL54-760 + CCGUCUCCGCAGGGGUCUUC 20 7149
HSV-UL54-761 + CGUCUCCGCAGGGGUCUUCC 20 7150
HSV-UL54-762 + UCUCCGCAGGGGUCUUCCAU 20 7151
HSV-UL54-763 + CUCCGCAGGGGUCUUCCAUG 20 7152
HSV-UL54-764 + CAGGGGUCUUCCAUGUCCUC 20 7153
HSV-UL54-765 + AGGGGUCUUCCAUGUCCUCG 20 7154
HSV-UL54-766 + UGUCCUCGUCCGACGAGGAA 20 7155
HSV-UL54-767 + GUCCUCGUCCGACGAGGAAC 20 7156
HSV-UL54-768 + GUCCGACGAGGAACACUCCC 20 7157
HSV-UL54-769 + CCGACGAGGAACACUCCCCG 20 7158
HSV-UL54-770 + CGAGGAACACUCCCCGCUGC 20 7159
HSV-UL54-771 + CGCUGCUGUCGGACUCGGGG 20 7160
HSV-UL54-772 + GCUGCUGUCGGACUCGGGGU 20 7161
HSV-UL54-773 + CUGCUGUCGGACUCGGGGUC 20 7162
HSV-UL54-774 + UGCUGUCGGACUCGGGGUCG 20 7163
HSV-UL54-775 + GGUCGUCGCGGCGGCCCUCC 20 7164
HSV-UL54-776 + CUCGUCCCGCUCCAGAGCGU 20 7165
HSV-UL54-777 + CGUCCCGCUCCAGAGCGUCC 20 7166
HSV-UL54-778 + GUCCCGCUCCAGAGCGUCCU 20 7167
HSV-UL54-779 + CCCGCUCCAGAGCGUCCUCC 20 7168
HSV-UL54-780 + CUCCAGAGCGUCCUCCUCGA 20 7169
HSV-UL54-781 + UCCAGAGCGUCCUCCUCGAG 20 7170
HSV-UL54-782 + GAGCGUCCUCCUCGAGCUCG 20 7171
HSV-UL54-783 + AGCGUCCUCCUCGAGCUCGC 20 7172
HSV-UL54-784 + CUCGAGCUCGCUGUCGGACA 20 7173
HSV-UL54-785 + CGAGCUCGCUGUCGGACAGG 20 7174
HSV-UL54-786 + GAGCUCGCUGUCGGACAGGU 20 7175
HSV-UL54-787 + GCUCGCUGUCGGACAGGUCC 20 7176
HSV-UL54-52 + UGUCGGACAGGUCCAAUCCU 20 6475
HSV-UL54-789 + UCCUAGGUCGAUUAGCAUAU 20 7177
HSV-UL54-790 + GGUCGAUUAGCAUAUCAAUG 20 7178 HSV-UL54-188 - AGGAGGACGCUCUGGAG 17 6611
HSV-UL54-190 - CGCUCUGGAGCGGGACG 17 6613
HSV-UL54-793 - UGAUAUGCUAAUCGACC 17 7179
HSV-UL54-794 - CCUGUCCGACAGCGAGC 17 7180
HSV-UL54-795 - UGUCCGACAGCGAGCUC 17 7181
HSV-UL54-55 - GUCCGACAGCGAGCUCG 17 6478
HSV-UL54-797 - GGACAUGGAAGACCCCU 17 7182
HSV-UL54-798 - GGAAGACCCCUGCGGAG 17 7183
HSV-UL54-799 - ACGCUCUGGAGCGGGAC 17 7184
HSV-UL54-194 - CCGAGUCCGACAGCAGC 17 6617
HSV-UL54-801 - UGCUAAUCGACCUAGGA 17 7185
HSV-UL54-802 - AUUGGACCUGUCCGACA 17 7186
HSV-UL54-803 - CCGACAGCGAGCUCGAG 17 7187
HSV-UL54-804 - AGCUCGAGGAGGACGCU 17 7188
HSV-UL54-57 - GCUCGAGGAGGACGCUC 17 6480
HSV-UL54-806 - GAGGAGGACGCUCUGGA 17 7189
HSV-UL54-807 - GGACGCUCUGGAGCGGG 17 7190
HSV-UL54-808 - CUCUGGAGCGGGACGAG 17 7191
HSV-UL54-809 - GGGCCGCCGCGACGACC 17 7192
HSV-UL54-810 - CCCCGAGUCCGACAGCA 17 7193
HSV-UL54-193 - CCCGAGUCCGACAGCAG 17 6616
HSV-UL54-195 - CGAGUCCGACAGCAGCG 17 6618
HSV-UL54-813 - GCGGGGAGUGUUCCUCG 17 7194
HSV-UL54-814 - GGAGUGUUCCUCGUCGG 17 7195
HSV-UL54-815 - AGUGUUCCUCGUCGGAC 17 7196
HSV-UL54-816 - CCUCGUCGGACGAGGAC 17 7197
HSV-UL54-58 - CUCGUCGGACGAGGACA 17 6481
HSV-UL54-198 - GACAUGGAAGACCCCUG 17 6621
HSV-UL54-199 - GAAGACCCCUGCGGAGA 17 6622
HSV-UL54-820 - AGACCCCUGCGGAGACG 17 7198
HSV-UL54-200 - GACCCCUGCGGAGACGG 17 6623
HSV-UL54-822 - CCUGCGGAGACGGAGGG 17 7199
HSV-UL54-202 - CUGCGGAGACGGAGGGG 17 6625
HSV-UL54-824 - AGGUCCCCCGGCCCGCC 17 7200
HSV-UL54-825 - GUCCCCCGGCCCGCCCC 17 7201
HSV-UL54-826 - CGAGGACGCCGGCACCC 17 7202
HSV-UL54-827 - CCUCGCCCGGCAGCGCG 17 7203
HSV-UL54-208 - CUCGCCCGGCAGCGCGG 17 6631
HSV-UL54-209 - UCGCCCGGCAGCGCGGC 17 6632
HSV-UL54-210 - CGCCCGGCAGCGCGGCG 17 6633
HSV-UL54-831 - CGGCGUGUGGUCGCGCC 17 7204
HSV-UL54-211 - GGCGUGUGGUCGCGCCU 17 6634
HSV-UL54-833 - AGGCGGUCGGCUUCCCC 17 7205
HSV-UL54-213 - GGCGGUCGGCUUCCCCC 17 6636
HSV-UL54-214 - GCGGUCGGCUUCCCCCC 17 6637
HSV-UL54-836 - UUCCCCCCGGGAACCGC 17 7206 HSV-UL54-68 - UCCCCCCGGGAACCGCA 17 6491
HSV-UL54-215 - CCCCCCGGGAACCGCAC 17 6638
HSV-UL54-69 - CCCCCGGGAACCGCACG 17 6492
HSV-UL54-70 - CCCCGGGAACCGCACGG 17 6493
HSV-UL54-71 - CCCGGGAACCGCACGGG 17 6494
HSV-UL54-842 - ACCAAGGCACCGCAUCC 17 7207
HSV-UL54-843 - GGCACCGCAUCCCCGAG 17 7208
HSV-UL54-844 - CAUCCCCGAGGCGGGCG 17 7209
HSV-UL54-845 - GGGCGGCGAGGUCGCCG 17 7210
HSV-UL54-223 - GGCGGCGAGGUCGCCGC 17 6646
HSV-UL54-847 - CGAGGUCGCCGCCGGGG 17 7211
HSV-UL54-226 - GAGGUCGCCGCCGGGGC 17 6649
HSV-UL54-849 + GCGGCGACCUCGCCGCC 17 7212
HSV-UL54-850 + GGAUGCGGUGCCUUGGU 17 7213
HSV-UL54-851 + UGCGGUUCCCGGGGGGA 17 7214
HSV-UL54-852 + GGCGCGACCACACGCCG 17 7215
HSV-UL54-853 + GCCCCGGCGGCGACCUC 17 7216
HSV-UL54-854 + CCCCGGCGGCGACCUCG 17 7217
HSV-UL54-855 + CGGCGACCUCGCCGCCC 17 7218
HSV-UL54-238 + CGCCCGCCUCGGGGAUG 17 6661
HSV-UL54-857 + CUCGGGGAUGCGGUGCC 17 7219
HSV-UL54-87 + CCCGUGCGGU UCCCGGG 17 6510
HSV-UL54-859 + CCGUGCGGUUCCCGGGG 17 7220
HSV-UL54-860 + CGUGCGGUUCCCGGGGG 17 7221
HSV-UL54-861 + GUGCGGUUCCCGGGGGG 17 7222
HSV-UL54-862 + GCGGUUCCCGGGGGGAA 17 7223
HSV-UL54-863 + GGGGGGAAGCCGACCGC 17 7224
HSV-UL54-244 + GGGGGAAGCCGACCGCC 17 6667
HSV-UL54-865 + GGGGAAGCCGACCGCCU 17 7225
HSV-UL54-866 + AGGCGCGACCACACGCC 17 7226
HSV-UL54-250 + CGCCGCGCUGCCGGGCG 17 6673
HSV-UL54-868 + GCCGCGCUGCCGGGCGA 17 7227
HSV-UL54-869 + CCGCGCUGCCGGGCGAG 17 7228
HSV-UL54-870 + CGCGCUGCCGGGCGAGG 17 7229
HSV-UL54-255 + GGGUGCCGGCGUCCUCG 17 6678
HSV-UL54-872 + GGGGCGGGCCGGGGGAC 17 7230
HSV-UL54-873 + GGCGGGCCGGGGGACCU 17 7231
HSV-UL54-265 + CCCCUCCGUCUCCGCAG 17 6688
HSV-UL54-875 + CCCUCCGUCUCCGCAGG 17 7232
HSV-UL54-876 + CCGUCUCCGCAGGGGUC 17 7233
HSV-UL54-877 + CGUCUCCGCAGGGGUCU 17 7234
HSV-UL54-878 + UCUCCGCAGGGGUCUUC 17 7235
HSV-UL54-879 + CUCCGCAGGGGUCUUCC 17 7236
HSV-UL54-880 + CAGGGGUCUUCCAUGUC 17 7237
HSV-UL54-881 + AGGGGUCUUCCAUGUCC 17 7238
HSV-UL54-882 + UGUCCUCGUCCGACGAG 17 7239 HSV-UL54-883 + GUCCUCGUCCGACGAGG 17 7240
HSV-UL54-884 + GUCCGACGAGGAACACU 17 7241
HSV-UL54-885 + CCG ACG AG G AACACU CC 17 7242
HSV-UL54-886 + CGAGGAACACUCCCCGC 17 7243
HSV-UL54-101 + CGCUGCUGUCGGACUCG 17 6524
HSV-UL54-888 + GCUGCUGUCGGACUCGG 17 7244
HSV-UL54-889 + CUGCUGUCGGACUCGGG 17 7245
HSV-UL54-890 + UGCUGUCGGACUCGGGG 17 7246
HSV-UL54-891 + GGUCGUCGCGGCGGCCC 17 7247
HSV-UL54-892 + CUCGUCCCGCUCCAGAG 17 7248
HSV-UL54-893 + CGUCCCGCUCCAGAGCG 17 7249
HSV-UL54-894 + GUCCCGCUCCAGAGCGU 17 7250
HSV-UL54-895 + CCCG CUCCAG AG CG U CC 17 7251
HSV-UL54-896 + CU CCAGAGCG UCCUCCU 17 7252
HSV-UL54-897 + UCCAGAGCGUCCUCCUC 17 7253
HSV-UL54-898 + GAGCGUCCUCCUCGAGC 17 7254
HSV-UL54-899 + AGCGUCCUCCUCGAGCU 17 7255
HSV-UL54-900 + CUCGAGCUCGCUGUCGG 17 7256
HSV-UL54-103 + CGAGCUCGCUGUCGGAC 17 6526
HSV-UL54-902 + GAGCUCGCUGUCGGACA 17 7257
HSV-UL54-903 + GCUCGCUGUCGGACAGG 17 7258
HSV-UL54-904 + UGUCGGACAGGUCCAAU 17 7259
HSV-UL54-905 + UCCUAGGUCGAUUAGCA 17 7260
HSV-UL54-906 + GGUCGAUUAGCAUAUCA 17 7261
Table 4E provides exemplary targeting domains for knocking out the UL54 gene selected according to the second tier parameters. The targeting domains are selected based on location within the coding sequence, but downstream of the first 500bp of the UL54 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a S. aureus Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using S. aureus Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 4E
2nd Tier Target
DNA
g NA Name Targeting Domain Site Seq
Strand
Length ID
HSV-UL54-907 - CCACGGCGAGGCGCGGCGCG 20 7262
HSV-UL54-908 - CACCCACGGCGAGGCGCGGC 20 7263
HSV-UL54-281 - ACCCACGGCGAGGCGCGGCG 20 6704
HSV-UL54-910 - GUCUCCGGGGGCCCGCGGCC 20 7264
HSV-UL54-911 - GGUCGCCACCCCGCGUCGGC 20 7265
HSV-UL54-912 - GCCACCCCGCGUCGGCGCGG 20 7266
HSV-UL54-913 - CGGCCCCGGCGCCACCCACG 20 7267
HSV-UL54-282 - CACGGCGAGGCGCGGCGCGG 20 6705
HSV-UL54-283 - ACGGCGAGGCGCGGCGCGGA 20 6706
HSV-UL54-284 - CGGCGAGGCGCGGCGCGGAG 20 6707
HSV-UL54-917 - AGGGGAGCAGCUCGACGUCU 20 7268
HSV-UL54-285 - GGGGAGCAGCUCGACGUCUC 20 6708
HSV-UL54-286 - GGGAGCAGCUCGACGUCUCC 20 6709
HSV-UL54-920 - U G U CCCU G ACCCCCCCG CAC 20 7269
HSV-UL54-921 - CGGACGGCCGCGCCCCGGUC 20 7270
HSV-UL54-296 - GGACGGCCGCGCCCCGGUCC 20 6719
HSV-UL54-923 - GGCCGCGCCCCGGUCCCGGA 20 7271
HSV-UL54-924 - GACACCAUCGACCCCGCCGU 20 7272
HSV-UL54-925 - GGCGGUUCUGCGAUCCAUAU 20 7273
HSV-UL54-926 - CAUAUCCGAGCGCGCGGCGG 20 7274
HSV-UL54-927 - CGCGGCGGUCGAGCGCAUCA 20 7275
HSV-UL54-928 - CGAGCGCAUCAGCGAAAGCU 20 7276
HSV-UL54-929 - GGUCAUGCAAGACCCCUUUG 20 7277
HSV-UL54-306 - GUCAUGCAAGACCCCUUUGG 20 6729
HSV-UL54-931 - GCGGGAUGCCGUUUCCCGCC 20 7278
HSV-UL54-932 - U U UCCCGCCGCG AACAGCCC 20 7279
HSV-UL54-933 - CUCCCGUGCUGGCCACCCAA 20 7280
HSV-UL54-311 - UCCCGUGCUGGCCACCCAAG 20 6734
HSV-UL54-312 - CCCGUGCUGGCCACCCAAGC 20 6735
HSV-UL54-313 - CCGUGCUGGCCACCCAAGCG 20 6736
HSV-UL54-314 - CGUGCUGGCCACCCAAGCGG 20 6737
HSV-UL54-938 - CCAAGCGGGGGGGUUUGACG 20 7281
HSV-UL54-939 - GGGUUUGACGCCGAGACCCG 20 7282
HSV-UL54-940 - GCCGAGACCCGUCGGGUUUC 20 7283
HSV-UL54-319 - CCGAGACCCGUCGGGUUUCC 20 6742
HSV-UL54-320 - CGAGACCCGUCGGGUUUCCU 20 6743
HSV-UL54-943 - AAACCCUGGUCGCUCACGGC 20 7284
HSV-UL54-944 - CGCACAUUCGCAGCCAACCC 20 7285
HSV-UL54-945 - UGCGCGACUGCGUGCUGCGC 20 7286
HSV-UL54-326 - GCGCGACUGCGUGCUGCGCC 20 6749
HSV-UL54-947 - GCUGCGCCAGGAAAAUCUCA 20 7287
HSV-UL54-948 - UCAUCGAGGCCCUGGCGUCC 20 7288
HSV-UL54-671 - CGAGGCCCUGGCGUCCGCGG 20 7089 HSV-UL54-950 - ACAAUCUGCCGCUCCGCCCC 20 7289
HSV-UL54-951 - CCGCCCCCAGGACCCUAUCA 20 7290
HSV-UL54-333 - CGCCCCCAGGACCCUAUCAU 20 6756
HSV-UL54-953 - UCGGAACGGCGGCCGCCGUG 20 7291
HSV-UL54-336 - CGGAACGGCGGCCGCCGUGC 20 6759
HSV-UL54-955 - GCCCCUUUCUGCAGUGCUAC 20 7292
HSV-UL54-956 - CUGCAGUGCUACCUGAAGGC 20 7293
HSV-UL54-957 - CCUGAAGGCCCGAGGCCUGU 20 7294
HSV-UL54-958 - AGGCCCGAGGCCUGUGCGGG 20 7295
HSV-UL54-959 - UGUGCUCGCGGCGACGCCUG 20 7296
HSV-UL54-960 - GGCGACGCCUGUCGGACAUU 20 7297
HSV-UL54-961 - GGCCCGCCUCGCCAACCGCG 20 7298
HSV-UL54-962 - ACCGCGUCGAGCGCGGCGUG 20 7299
HSV-UL54-348 - CCGCGUCGAGCGCGGCGUGU 20 6771
HSV-UL54-964 - CGGAGAUCGACUACACGACC 20 7300
HSV-UL54-349 - GGAGAUCGACUACACGACCG 20 6772
HSV-UL54-350 - GAGAUCGACUACACGACCGU 20 6773
HSV-UL54-967 - CGACUACACGACCGUGGGGG 20 7301
HSV-UL54-353 - GACUACACGACCGUGGGGGU 20 6776
HSV-UL54-969 - GACCGUGGGGGUUGGGGCCG 20 7302
HSV-UL54-970 - AGACGAUGCACUUUUACAUC 20 7303
HSV-UL54-357 - GACGAUGCACUUUUACAUCC 20 6780
HSV-UL54-358 - ACGAUGCACUUUUACAUCCC 20 6781
HSV-UL54-973 - ACAUCCCGGGGGCCUGCAUG 20 7304
HSV-UL54-974 - GGCCUGCAUGGCGGGUCUCA 20 7305
HSV-UL54-975 - UGGCGGGUCUCAUUGAAAUA 20 7306
HSV-UL54-976 - AAAUACUGGACACGCACCGC 20 7307
HSV-UL54-365 - AAUACUGGACACGCACCGCC 20 6788
HSV-UL54-978 - GGAGUGUUCCAGUCGCGUGU 20 7308
HSV-UL54-377 + GGGAUGUAAAAGUGCAUCGU 20 6800
HSV-UL54-382 + ACCCCCACGGUCGUGUAGUC 20 6805
HSV-UL54-981 + ACACGCGACUGGAACACUCC 20 7309
HSV-UL54-370 + GGCGGUGCGUGUCCAGUAUU 20 6793
HSV-UL54-983 + GCGGUGCGUGUCCAGUAUUU 20 7310
HSV-UL54-984 + UAUUUCAAUGAGACCCGCCA 20 7311
HSV-UL54-985 + UGAGACCCGCCAUGCAGGCC 20 7312
HSV-UL54-986 + CAUGCAGGCCCCCGGGAUGU 20 7313
HSV-UL54-378 + GGAUGUAAAAGUGCAUCGUC 20 6801
HSV-UL54-988 + GAUGUAAAAGUGCAUCGUCU 20 7314
HSV-UL54-989 + CGGCCCCAACCCCCACGGUC 20 7315
HSV-UL54-990 + CCCCCACGGUCGUGUAGUCG 20 7316
HSV-UL54-385 + ACGGUCGUGUAGUCGAUCUC 20 6808
HSV-UL54-386 + CGGUCGUGUAGUCGAUCUCC 20 6809
HSV-UL54-993 + GGUCGUGUAGUCGAUCUCCG 20 7317
HSV-UL54-387 + ACACGCCGCGCUCGACGCGG 20 6810
HSV-UL54-995 + CACGCCGCGCUCGACGCGGU 20 7318 HSV-UL54-996 + CGCGGUUGGCGAGGCGGGCC 20 7319
HSV-UL54-997 + AAUGUCCGACAGGCGUCGCC 20 7320
HSV-UL54-998 + CAGGCGUCGCCGCGAGCACA 20 7321
HSV-UL54-999 + CCCGCACAGGCCUCGGGCCU 20 7322
HSV-UL54-1000 + ACAGGCCUCGGGCCUUCAGG 20 7323
HSV-UL54-1001 + GCCUUCAGGUAGCACUGCAG 20 7324
HSV-UL54-1002 + GUAGCACUGCAGAAAGGGGC 20 7325
HSV-UL54-399 + GCACGGCGGCCGCCGUUCCG 20 6822
HSV-UL54-1004 + CACGGCGGCCGCCGUUCCGA 20 7326
HSV-UL54-402 + AUGAUAGGGUCCUGGGGGCG 20 6825
HSV-UL54-1006 + UGAUAGGGUCCUGGGGGCGG 20 7327
HSV-UL54-1007 + GGGGCGGAGCGGCAGAUUGU 20 7328
HSV-UL54-1008 + CCGCGGACGCCAGGGCCUCG 20 7329
HSV-UL54-1009 + GGACGCCAGGGCCUCGAUGA 20 7330
HSV-UL54-1010 + UGAGAUUUUCCUGGCGCAGC 20 7331
HSV-UL54-409 + GGCGCAGCACGCAGUCGCGC 20 6832
HSV-UL54-1012 + GCGCAGCACGCAGUCGCGCA 20 7332
HSV-UL54-1013 + GGGUUGGCUGCGAAUGUGCG 20 7333
HSV-UL54-1014 + GCCGUGAGCGACCAGGGUUU 20 7334
HSV-UL54-415 + AGGAAACCCGACGGGUCUCG 20 6838
HSV-UL54-416 + GGAAACCCGACGGGUCUCGG 20 6839
HSV-UL54-1017 + GAAACCCGACGGGUCUCGGC 20 7335
HSV-UL54-1018 + CGGGUCUCGGCGUCAAACCC 20 7336
HSV-UL54-1019 + CG U CAAACCCCCCCGCU U GG 20 7337
HSV-UL54-421 + CCGCUUGGGUGGCCAGCACG 20 6844
HSV-UL54-422 + CGCUUGGGUGGCCAGCACGG 20 6845
HSV-UL54-423 + GCUUGGGUGGCCAGCACGGG 20 6846
HSV-UL54-424 + CUUGGGUGGCCAGCACGGGA 20 6847
HSV-UL54-1024 + UUGGGUGGCCAGCACGGGAG 20 7338
HSV-UL54-1025 + GGGCUGUUCGCGGCGGGAAA 20 7339
HSV-UL54-1026 + GGCGGGAAACGGCAUCCCGC 20 7340
HSV-UL54-429 + CCAAAGGGGUCUUGCAUGAC 20 6852
HSV-UL54-1028 + CAAAGGGGUCUUGCAUGACC 20 7341
HSV-UL54-1029 + AGCUUUCGCUGAUGCGCUCG 20 7342
HSV-UL54-1030 + UGAUGCGCUCGACCGCCGCG 20 7343
HSV-UL54-1031 + CCGCCGCGCGCUCGGAUAUG 20 7344
HSV-UL54-1032 + AUAUGGAUCGCAGAACCGCC 20 7345
HSV-UL54-1033 + ACGGCGGGGUCGAUGGUGUC 20 7346
HSV-UL54-1034 + UCCGGGACCGGGGCGCGGCC 20 7347
HSV-UL54-439 + GGACCGGGGCGCGGCCGUCC 20 6862
HSV-UL54-1036 + GACCGGGGCGCGGCCGUCCG 20 7348
HSV-UL54-1037 + GUGCGGGGGGGUCAGGGACA 20 7349
HSV-UL54-1038 + GGCCGCGGGCCCCCGGAGAC 20 7350
HSV-UL54-449 + GGAGACGUCGAGCUGCUCCC 20 6872
HSV-UL54-450 + GAGACGUCGAGCUGCUCCCC 20 6873
HSV-UL54-1041 + AGACGUCGAGCUGCUCCCCU 20 7351 HSV-UL54-451 + CUCCGCGCCGCGCCUCGCCG 20 6874
HSV-UL54-452 + UCCGCGCCGCGCCUCGCCGU 20 6875
HSV-UL54-453 + CCGCGCCGCGCCUCGCCGUG 20 6876
HSV-UL54-1045 + CGCGCCGCGCCUCGCCGUGG 20 7352
HSV-UL54-454 + CGCCGCGCCUCGCCGUGGGU 20 6877
HSV-UL54-1047 + GCCGCGCCUCGCCGUGGGUG 20 7353
HSV-UL54-1048 + CGUGGGUGGCGCCGGGGCCG 20 7354
HSV-UL54-1049 + CCGCGCCGACGCGGGGUGGC 20 7355
HSV-UL54-1050 + GCCGACGCGGGGUGGCGACC 20 7356
HSV-UL54-464 + CUUGGUUGUGGGCGUUUCUG 20 6887
HSV-UL54-464 + CUUGGUUGUGGGCGUUUCUG 20 6887
HSV-UL54-464 + CUUGGUUGUGGGCGUUUCUG 20 6887
HSV-UL54-1054 - CGGCGAGGCGCGGCGCG 17 7357
HSV-UL54-1055 - CCACGGCGAGGCGCGGC 17 7358
HSV-UL54-477 - CACGGCGAGGCGCGGCG 17 6898
HSV-UL54-1057 - UCCGGGGGCCCGCGGCC 17 7359
HSV-UL54-1058 - CGCCACCCCGCGUCGGC 17 7360
HSV-UL54-1059 - ACCCCGCGUCGGCGCGG 17 7361
HSV-UL54-1060 - CCCCGGCGCCACCCACG 17 7362
HSV-UL54-478 - GGCGAGGCGCGGCGCGG 17 6899
HSV-UL54-479 - GCGAGGCGCGGCGCGGA 17 6900
HSV-UL54-480 - CGAGGCGCGGCGCGGAG 17 6901
HSV-UL54-1064 - GGAGCAGCUCGACGUCU 17 7363
HSV-UL54-481 - GAGCAGCUCGACGUCUC 17 6902
HSV-UL54-482 - AGCAGCUCGACGUCUCC 17 6903
HSV-UL54-1067 - CCCUGACCCCCCCGCAC 17 7364
HSV-UL54-1068 - ACGGCCGCGCCCCGGUC 17 7365
HSV-UL54-492 - CGGCCGCGCCCCGGUCC 17 6913
HSV-UL54-1070 - CGCGCCCCGGUCCCGGA 17 7366
HSV-UL54-1071 - ACCAUCGACCCCGCCGU 17 7367
HSV-UL54-1072 - GGUUCUGCGAUCCAUAU 17 7368
HSV-UL54-1073 - AUCCGAGCGCGCGGCGG 17 7369
HSV-UL54-1074 - GGCGGUCGAGCGCAUCA 17 7370
HSV-UL54-1075 - GCGCAUCAGCGAAAGCU 17 7371
HSV-UL54-1076 - CAUGCAAGACCCCUUUG 17 7372
HSV-UL54-502 - AUGCAAGACCCCUUUGG 17 6923
HSV-UL54-1078 - GGAUGCCGUUUCCCGCC 17 7373
HSV-UL54-1079 - CCCGCCGCGAACAGCCC 17 7374
HSV-UL54-1080 - CCGUGCUGGCCACCCAA 17 7375
HSV-UL54-507 - CGUGCUGGCCACCCAAG 17 6928
HSV-UL54-508 - GUGCUGGCCACCCAAGC 17 6929
HSV-UL54-509 - UGCUGGCCACCCAAGCG 17 6930
HSV-UL54-510 - GCUGGCCACCCAAGCGG 17 6931
HSV-UL54-1085 - AGCGGGGGGGUUUGACG 17 7376
HSV-UL54-1086 - UUUGACGCCGAGACCCG 17 7377
HSV-UL54-1087 - GAGACCCGUCGGGUUUC 17 7378 HSV-UL54-515 - AGACCCGUCGGGUUUCC 17 6936
HSV-UL54-516 - GACCCGUCGGGUUUCCU 17 6937
HSV-UL54-1090 - CCCUGGUCGCUCACGGC 17 7379
HSV-UL54-1091 - ACAUUCGCAGCCAACCC 17 7380
HSV-UL54-1092 - GCGACUGCGUGCUGCGC 17 7381
HSV-UL54-522 - CGACUGCGUGCUGCGCC 17 6943
HSV-UL54-1094 - GCGCCAGGAAAAUCUCA 17 7382
HSV-UL54-1095 - UCGAGGCCCUGGCGUCC 17 7383
HSV-UL54-1096 - GGCCCUGGCGUCCGCGG 17 7384
HSV-UL54-1097 - AUCUGCCGCUCCGCCCC 17 7385
HSV-UL54-1098 - CCCCCAGGACCCUAUCA 17 7386
HSV-UL54-529 - CCCCAGGACCCUAUCAU 17 6950
HSV-UL54-1100 - GAACGGCGGCCGCCGUG 17 7387
HSV-UL54-532 - AACGGCGGCCGCCGUGC 17 6953
HSV-UL54-1102 - CCUU UCUGCAGUGCUAC 17 7388
HSV-UL54-1103 - CAGUGCUACCUGAAGGC 17 7389
HSV-UL54-1104 - GAAGGCCCGAGGCCUGU 17 7390
HSV-UL54-1105 - CCCGAGGCCUGUGCGGG 17 7391
HSV-UL54-1106 - GCUCGCGGCGACGCCUG 17 7392
HSV-UL54-1107 - GACGCCUGUCGGACAUU 17 7393
HSV-UL54-1108 - CCGCCUCGCCAACCGCG 17 7394
HSV-UL54-1109 - GCGUCGAGCGCGGCGUG 17 7395
HSV-UL54-544 - CGUCGAGCGCGGCGUGU 17 6965
HSV-UL54-1111 - AGAUCGACUACACGACC 17 7396
HSV-UL54-545 - GAUCGACUACACGACCG 17 6966
HSV-UL54-546 - AUCGACUACACGACCGU 17 6967
HSV-UL54-1114 - CUACACGACCGUGGGGG 17 7397
HSV-UL54-549 - UACACGACCGUGGGGGU 17 6970
HSV-UL54-1116 - CGUGGGGGUUGGGGCCG 17 7398
HSV-UL54-1117 - CGAUGCACUUUUACAUC 17 7399
HSV-UL54-553 - GAUGCACUUUUACAUCC 17 6974
HSV-UL54-554 - AUGCACUUUUACAUCCC 17 6975
HSV-UL54-1120 - UCCCGGGGGCCUGCAUG 17 7400
HSV-UL54-1121 - CUGCAUGGCGGGUCUCA 17 7401
HSV-UL54-1122 - CGGGUCUCAUUGAAAUA 17 7402
HSV-UL54-1123 - UACUGGACACGCACCGC 17 7403
HSV-UL54-561 - ACUGGACACGCACCGCC 17 6982
HSV-UL54-1125 - GUGUUCCAGUCGCGUGU 17 7404
HSV-UL54-573 + GGGAUGUAAAAGUGCAU 17 6994
HSV-UL54-578 + ACCCCCACGGUCGUGUA 17 6999
HSV-UL54-1128 + ACACGCG ACU G G AACAC 17 7405
HSV-UL54-566 + GGCGGUGCGUGUCCAGU 17 6987
HSV-UL54-1130 + GCGGUGCGUGUCCAGUA 17 7406
HSV-UL54-1131 + UAU U UCAAUG AGACCCG 17 7407
HSV-UL54-1132 + UGAGACCCGCCAUGCAG 17 7408
HSV-UL54-1133 + CAUGCAGGCCCCCGGGA 17 7409 HSV-UL54-574 + GGAUGUAAAAGUGCAUC 17 6995
HSV-UL54-1135 + GAUGUAAAAGUGCAUCG 17 7410
HSV-UL54-1136 + CGGCCCCAACCCCCACG 17 7411
HSV-UL54-1137 + CCCCCACGGUCGUGUAG 17 7412
HSV-UL54-581 + ACGGUCGUGUAGUCGAU 17 7002
HSV-UL54-582 + CGGUCGUGUAGUCGAUC 17 7003
HSV-UL54-1140 + GGUCGUGUAGUCGAUCU 17 7413
HSV-UL54-583 + ACACGCCGCGCUCGACG 17 7004
HSV-UL54-1142 + CACGCCGCGCUCGACGC 17 7414
HSV-UL54-1143 + CGCGGU UGGCGAGGCGG 17 7415
HSV-UL54-1144 + AAUGU CCGACAGGCG U C 17 7416
HSV-UL54-1145 + CAGGCGUCGCCGCGAGC 17 7417
HSV-UL54-1146 + CCCGCACAGGCCUCGGG 17 7418
HSV-UL54-1147 + ACAGGCCUCGGGCCUUC 17 7419
HSV-UL54-1148 + GCCUUCAGGUAGCACUG 17 7420
HSV-UL54-1149 + GUAGCACUGCAGAAAGG 17 7421
HSV-UL54-595 + GCACGGCGGCCGCCGUU 17 7016
HSV-UL54-1151 + CACGGCGGCCGCCGUUC 17 7422
HSV-UL54-598 + AUGAUAGGGUCCUGGGG 17 7019
HSV-UL54-1153 + UGAUAGGGUCCUGGGGG 17 7423
HSV-UL54-1154 + GGGGCGGAGCGGCAGAU 17 7424
HSV-UL54-1155 + CCGCGGACGCCAGGGCC 17 7425
HSV-UL54-1156 + GGACGCCAGGGCCUCGA 17 7426
HSV-UL54-1157 + UGAGAUUUUCCUGGCGC 17 7427
HSV-UL54-605 + GGCGCAGCACGCAGUCG 17 7026
HSV-UL54-1159 + GCGCAGCACGCAGUCGC 17 7428
HSV-UL54-1160 + GGGUUGGCUGCGAAUGU 17 7429
HSV-UL54-1161 + GCCGUGAGCGACCAGGG 17 7430
HSV-UL54-611 + AGGAAACCCGACGGGUC 17 7032
HSV-UL54-612 + GGAAACCCGACGGGUCU 17 7033
HSV-UL54-1164 + GAAACCCGACGGGUCUC 17 7431
HSV-UL54-1165 + CGGGUCUCGGCGUCAAA 17 7432
HSV-UL54-1166 + CGUCAAACCCCCCCGCU 17 7433
HSV-UL54-617 + CCGCUUGGGUGGCCAGC 17 7038
HSV-UL54-618 + CGCUUGGGUGGCCAGCA 17 7039
HSV-UL54-619 + GCUUGGGUGGCCAGCAC 17 7040
HSV-UL54-620 + CU UGGGUGGCCAGCACG 17 7041
HSV-UL54-1171 + UUGGGUGGCCAGCACGG 17 7434
HSV-UL54-1172 + GGGCUGUUCGCGGCGGG 17 7435
HSV-UL54-1173 + GGCGGGAAACGGCAUCC 17 7436
HSV-UL54-625 + CCAAAGGGGUCUUGCAU 17 7046
HSV-UL54-1175 + CAAAGGGGUCUUGCAUG 17 7437
HSV-UL54-1176 + AGCUUUCGCUGAUGCGC 17 7438
HSV-UL54-1177 + UGAUGCGCUCGACCGCC 17 7439
HSV-UL54-1178 + CCGCCGCGCGCUCGGAU 17 7440
HSV-UL54-1179 + AUAUGGAUCGCAGAACC 17 7441 HSV-UL54-1180 + ACGGCGGGGUCGAUGGU 17 7442
HSV-UL54-1181 + UCCGGGACCGGGGCGCG 17 7443
HSV-UL54-635 + GGACCGGGGCGCGGCCG 17 7056
HSV-UL54-1183 + GACCGGGGCGCGGCCGU 17 7444
HSV-UL54-1184 + GUGCGGGGGGGUCAGGG 17 7445
HSV-UL54-1185 + GGCCGCGGGCCCCCGGA 17 7446
HSV-UL54-645 + GGAGACGUCGAGCUGCU 17 7066
HSV-UL54-646 + GAGACGUCGAGCUGCUC 17 7067
HSV-UL54-1188 + AGACGUCGAGCUGCUCC 17 7447
HSV-UL54-647 + CUCCGCGCCGCGCCUCG 17 7068
HSV-UL54-648 + UCCGCGCCGCGCCUCGC 17 7069
HSV-UL54-649 + CCGCGCCGCGCCUCGCC 17 7070
HSV-UL54-1192 + CGCGCCGCGCCUCGCCG 17 7448
HSV-UL54-650 + CGCCGCGCCUCGCCGUG 17 7071
HSV-UL54-1194 + GCCGCGCCUCGCCGUGG 17 7449
HSV-UL54-1195 + CGUGGGUGGCGCCGGGG 17 7450
HSV-UL54-1196 + CCGCGCCGACGCGGGGU 17 7451
HSV-UL54-1197 + GCCGACGCGGGGUGGCG 17 7452
HSV-UL54-661 + UUGGUUGUGGGCGUUUC 17 7082
HSV-UL54-662 + UGGUUGUGGGCGUUUCU 17 7083
HSV-UL54-1200 + GGUUGUGGGCGUUUCUG 17 7453
Table 4F provides exemplary targeting domains for knocking out the UL54 gene selected according to the first tier parameters. The targeting domains are selected based on location within first 500bp of the coding sequence of the UL54 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 single-stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using N. meningitidis Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 4F
Figure imgf000293_0001
HSV-UL54-8 - AGGGGCGGAGGCCAUCGACG 20 6431
HSV-UL54-665 + CGUCGAUGGCCUCCGCCCCU 20 7085
HSV-UL54-187 + GUCGAUUAGCAUAUCAAUGU 20 6610
HSV-UL54-667 - UUGAUAUGCUAAUCGAC 17 7086
HSV-UL54-60 - GGCGGAGGCCAUCGACG 17 6483
HSV-UL54-669 + CGUCGAUGGCCUCCGCC 17 7087
HSV-UL54-670 + GUCGAUUAGCAUAUCAA 17 7088
Table 4G provides exemplary targeting domains for knocking out the UL54 gene selected according to the second tier parameters. The targeting domains are selected based on location within the coding sequence (but downstream of the first 500bp) of UL54 gene. It is contemplated herein that the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that gives double stranded cleavage. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 single- stranded break nucleases (nickases). In an embodiment, dual targeting is used to create two nicks on opposite DNA strands by using N. meningitidis Cas9 nickases with two targeting domains that are complementary to opposite DNA strands, e.g., a gRNA comprising any minus strand targeting domain may be paired any gRNA comprising a plus strand targeting domain provided that the two gRNAs are oriented on the DNA such that PAMs face outward and the distance between the 5' ends of the gRNAs is 0-50bp.
Table 4G
Figure imgf000294_0001
Table 5 A provides exemplary targeting domains for knocking out the UL19 gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase). Table 5A
Figure imgf000295_0001
Table 5B provides exemplary targeting domains for knocking out the UL19 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 5B
Figure imgf000296_0001
HSV2-UL19-75 + CGUCAAACUCUACGUCAUAC 20 408
HSV2-UL19-92 + CCGCGGCGUACCGGUAACCC 20 507
HSV2-UL19-1548 + CAAACGCCCCCAGGACGGCC 20 1788
HSV2-UL19-49 + UGAAGGCGGCGU UCAGGGCC 20 476
HSV2-UL19-66 + CGUUCAUGUAAGCCAGCUCC 20 406
HSV2-UL19-21 - UGACGAAGGUCAUCGACCGC 20 397
HSV2-UL19-97 + CCGGUAACCCGGGGGGUCGC 20 511
HSV2-UL19-98 + UAACCCGGGGGGUCGCGGGC 20 413
HSV2-UL19-36 + UGGCGCGCAGCUGGCGAUGC 20 464
HSV2-UL19-8 - CGUAGAGU UUGACGCCCUGC 20 389
HSV2-UL19-82 + ACGCCACCUCGAUCGUACUC 20 500
HSV2-UL19-65 + UCGUUCAUGUAAGCCAGCUC 20 405
HSV2-UL19-47 + CCAGGCUGAAGGCGGCGUUC 20 474
HSV2-UL19-11 - CCUGUCGCUCGUGCGCU UUC 20 391
HSV2-UL19-27 - AGGCCAUUGCCCUGCUCACG 20 455
HSV2-UL19-93 + CGCGGCGUACCGGUAACCCG 20 508
HSV2-UL19-4 - CCCGGGU UACCGGUACGCCG 20 444
HSV2-UL19-6 - CUCCAUCCUGAGUACGAUCG 20 387
HSV2-UL19-58 + CGACGGGGUGCGGGCCGUCG 20 481
HSV2-UL19-96 + ACCGGUAACCCGGGGGGUCG 20 412
HSV2-UL19-7 - CAUCCUGAGUACGAUCGAGG 20 388
HSV2-UL19-50 + AGGCGGCGUUCAGGGCCCGG 20 477
HSV2-UL19-85 + CGUACUCAGGAUGGAGCCGG 20 411
HSV2-UL19-95 + CGGCGUACCGGUAACCCGGG 20 510
HSV2-UL19-56 + ACGGGCUGCUCGACGGGGUG 20 403
HSV2-UL19-3083 + AGCGGCCAUUGGGUUCCUUG 20 7466
HSV2-UL19-3084 + UCGCGGGCAGGAGCGGCCAU 20 7467
HSV2-UL19-3085 - CGCAACGUCCAGGCCGUCCU 20 7468
HSV2-UL19-12 - CUCGUGCGCUUUCUGGAGCU 20 392
HSV2-UL19-3086 + CGCGGGCAGGAGCGGCCAUU 20 7469
Table 5C provides exemplary targeting domains for knocking out the UL19 gene selected according to the third tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 5C
Figure imgf000297_0001
HSV2-UL19-167 + G G U G CACACG CACG CCA 17 560
HSV2-UL19-173 + GCAGUAGGACCCCAGCA 17 565
HSV2-UL19-139 + GGCCUCCCCCGUGAGCA 17 539
HSV2-UL19-124 - GGCCAUUGCCCUGCUCA 17 525
HSV2-UL19-147 + GCUGAAGGCGGCGUUCA 17 547
HSV2-UL19-119 - GCAUAAUUACAUGACGA 17 423
HSV2-UL19-187 + GGAGCCGGUGGGCAGGA 17 575
HSV2-UL19-132 - GGAGGCCCUGGACGGGA 17 533
HSV2-UL19-3087 + GCGCGCGAGCUGCUGGA 17 7470
HSV2-UL19-104 - GCGGCCAUCCUGCCCAC 17 517
HSV2-UL19-151 + GUCAUGUAAUUAUGCAC 17 550
HSV2-UL19-125 - GCCAUUGCCCUGCUCAC 17 526
HSV2-UL19-133 - GAGGCCCUGGACGGGAC 17 534
HSV2-UL19-129 - GCUCACGGGGGAGGCCC 17 530
HSV2-UL19-134 + GCUGGAUGGCGCGCAGC 17 535
HSV2-UL19-138 + GGGCCUCCCCCGUGAGC 17 538
HSV2-UL19-158 + GGGGUGCGGGCCGUCGC 17 554
HSV2-UL19-186 + GGAUGGAGCCGGUGGGC 17 574
HSV2-UL19-156 + GCUGCUCGACGGGGUGC 17 552
HSV2-UL19-146 + GGCUGAAGGCGGCGUUC 17 546
HSV2-UL19-198 + GGGGUCGCGGGCAGGAG 17 584
HSV2-UL19-154 + GCACGGGCUGCUCGACG 17 429
HSV2-UL19-188 + GGUGGGCAGGAUGGCCG 17 576
HSV2-UL19-112 - GGAGCUCGGCCUGUCCG 17 519
HSV2-UL19-145 + GGUGGCCAGGCUGAAGG 17 545
HSV2-UL19-163 + GGGCGAUGAGGGGCUGG 17 558
HSV2-UL19-3088 + GCCAUUGGGUUCCUUGG 17 7471
HSV2-UL19-155 + GGCUGCUCGACGGGGUG 17 430
HSV2-UL19-3089 + GGCCAUUGGGUUCCUUG 17 7472
HSV2-UL19-141 + GAGCAGGGCAAUGGCCU 17 541
HSV2-UL19-3090 + GCGGCCAUUGGGUUCCU 17 7473
HSV2-UL19-111 - GUGCGCUUUCUGGAGCU 17 419
HSV2-UL19-108 - GAGUUUGACGCCCUGCU 17 417
HSV2-UL19-3091 + GGGCAGGAGCGGCCAUU 17 7474
HSV2-UL19-74 + GUUGCAGUAGGACCCCAGCA 20 493
HSV2-UL19-88 + GAUGGAGCCGGUGGGCAGGA 20 503
HSV2-UL19-33 - GGGGGAGGCCCUGGACGGGA 20 461
HSV2-UL19-45 + GGCCUCGGUGGCCAGGCUGA 20 472
HSV2-UL19-5 - GCCGCGGCCAUCCUGCCCAC 20 445
HSV2-UL19-26 - GAGGCCAUUGCCCUGCUCAC 20 454
HSV2-UL19-34 - GGGGAGGCCCUGGACGGGAC 20 462
HSV2-UL19-2 - GCUCCUGCCCGCGACCCCCC 20 442
HSV2-UL19-3092 - GCGCAACGUCCAGGCCGUCC 20 7475
HSV2-UL19-35 + GCUGCUGGAUGGCGCGCAGC 20 463
HSV2-UL19-84 + GAUCGUACUCAGGAUGGAGC 20 410
HSV2-UL19-59 + GACGGGGUGCGGGCCGUCGC 20 482 HSV2-UL19-89 + GCCGGUGGGCAGGAUGGCCG 20 504
HSV2-UL19-43 + GAGCAGGGCAAUGGCCUCGG 20 470
HSV2-UL19-3093 + GCGGCCAUUGGGUUCCUUGG 20 7476
HSV2-UL19-3094 + GGAGCGGCCAUUGGGUUCCU 20 7477
HSV2-UL19-72 + GAGCGACAGGGUGUUGCAGU 20 491
HSV2-UL19-86 + GUACUCAGGAUGGAGCCGGU 20 501
HSV2-UL19-3095 + GAGCGGCCAUUGGGUUCCUU 20 7478
Table 5D provides exemplary targeting domains for knocking out the UL19 gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 5D
Figure imgf000299_0001
HSV2-UL19-172 + UGCAGUAGGACCCCAGC 17 564
HSV2-UL19-114 - CACCAAG U U CCCGGAGC 17 421
HSV2-UL19-183 + CGUACUCAGGAUGGAGC 17 437
HSV2-UL19-
+ U UCCUUGGGGGAUUCGC 17
3098 7481
HSV2-UL19-197 + CCCGGGGGGUCGCGGGC 17 440
HSV2-UL19-162 + CGCGGGCGAUGAGGGGC 17 557
HSV2-UL19-135 + CGCGCAGCUGGCGAUGC 17 536
HSV2-UL19-107 - AGAGUU UGACGCCCUGC 17 416
HSV2-UL19-164 + UUCAUGUAAGCCAGCUC 17 432
HSV2-UL19-161 + CCGUCGCGGGCGAUGAG 17 556
HSV2-UL19-126 - CCAUUGCCCUGCUCACG 17 527
HSV2-UL19-123 - CUUCAGCCUGGCCACCG 17 524
HSV2-UL19-157 + CGGGGUGCGGGCCGUCG 17 553
HSV2-UL19-117 - AGGGCGUGUGCAGUUCG 17 521
HSV2-UL19-127 - CAU UGCCCUGCUCACGG 17 528
HSV2-UL19-149 + CGGCGUUCAGGGCCCGG 17 549
HSV2-UL19-184 + ACUCAGGAUGGAGCCGG 17 438
HSV2-UL19-179 + AAUCAAAGAGUCUGCGG 17 570
HSV2-UL19-142 + CAGGGCAAUGGCCUCGG 17 542
HSV2-UL19-128 - UGCCCUGCUCACGGGGG 17 529
HSV2-UL19-723 - CGUCCAGGCCGUCCUGG 17 963
HSV2-UL19-109 - AGUUUGACGCCCUGCUG 17 518
HSV2-UL19-178 + AAAAAUCAAAGAGUCUG 17 569
HSV2-UL19-
+ CGGGCAGGAGCGGCCAU 17
3099 7482
HSV2-UL19-166 + AGCCAGCUCCGGGAACU 17 559
HSV2-UL19-171 + CGACAGGGUGUUGCAGU 17 563
HSV2-UL19-175 + AUACAGGCUGUUU UCGU 17 566
HSV2-UL19-185 + CUCAGGAUGGAGCCGGU 17 573
HSV2-UL19-180 + AUCAAAGAGUCUGCGGU 17 571
HSV2-UL19-41 + CU CCCCCG U G AG CAG G G CAA 20 468
HSV2-UL19-
- UGGAGCCUGCGAAUCCCCCA 20
3100 7483
HSV2-UL19-40 + CAGGGCCUCCCCCGUGAGCA 20 467
HSV2-UL19-25 - CGAGGCCAUUGCCCUGCUCA 20 453
HSV2-UL19-19 - CAGCCCCUCAUCGCCCGCGA 20 450
HSV2-UL19-83 + CACCUCGAUCGUACUCAGGA 20 409
HSV2-UL19-31 - CUCACGGGGGAGGCCCUGGA 20 459
HSV2-UL19-69 + U G CACACG CACG CCACG G AC 20 489
HSV2-UL19-32 - UCACGGGGGAGGCCCUGGAC 20 460
HSV2-UL19-3 - CCCGCG ACCCCCCGG G U U AC 20 443
HSV2-UL19-1 - CGCUCCUGCCCGCGACCCCC 20 441
HSV2-UL19-30 - CCUGCUCACGGGGGAGGCCC 20 458
HSV2-UL19-23 - CCUGAACGCCGCCUUCAGCC 20 451
HSV2-UL19-73 + UGUUGCAGUAGGACCCCAGC 20 492 HSV2-UL19-39 + CCAGGGCCUCCCCCGUGAGC 20 466
HSV2-UL19-63 + CGUCGCGGGCGAUGAGGGGC 20 485
HSV2-UL19-87 + UCAGGAUGGAGCCGGUGGGC 20 502
HSV2-UL19-57 + CGGGCUGCUCGACGGGGUGC 20 480
HSV2-UL19-99 + CGGGGGGUCGCGGGCAGGAG 20 512
HSV2-UL19-55 + UAUGCACGGGCUGCUCGACG 20 402
HSV2-UL19-24 - CGCCUUCAGCCUGGCCACCG 20 452
HSV2-UL19-13 - UCUGGAGCUCGGCCUGUCCG 20 447
HSV2-UL19-18 - CGAAGGGCGUGUGCAGUUCG 20 449
HSV2-UL19-46 + CUCGGUGGCCAGGCUGAAGG 20 473
HSV2-UL19-80 + A A A A A U C A A AG AGUCUGCGG 20 498
HSV2-UL19-29 - CAU UGCCCUGCUCACGGGGG 20 457
HSV2-UL19-345 - CAACGUCCAGGCCGUCCUGG 20 585
HSV2-UL19-64 + CGCGGGCGAUGAGGGGCUGG 20 486
HSV2-UL19-10 - UAGAGUU UGACGCCCUGCUG 20 446
HSV2-UL19-79 + CG AAAAAAUCAAAG AG U CU G 20 497
HSV2-UL19-42 + CGUGAGCAGGGCAAUGGCCU 20 469
HSV2-UL19-81 + AAAAUCAAAGAGUCUGCGGU 20 499
Table 5E provides exemplary targeting domains for knocking out the UL19 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 5E
Figure imgf000301_0001
HSV2-UL19-764 - GGCGAGAUGGUCUUGAA 17 1004
HSV2-UL19-1099 - CGACGCCUCCCCGCUAA 17 1339
HSV2-UL19-1649 + G U U G CCCAU GU CCG U AA 17 1889
HSV2-UL19-953 - GGUGCUGGCGCACAACA 17 1193
HSV2-UL19-946 - CAAUCUGGUGGCCAACA 17 1186
HSV2-UL19-939 - CGCCACGCUGCAGAACA 17 1179
HSV2-UL19-1618 + GGCGAUGAACUCACACA 17 1858
HSV2-UL19-1890 + GAGCGAAGGAUGACACA 17 2130
HSV2-UL19-1020 - CAACCCCGUUACGGACA 17 1260
HSV2-UL19-1058 - CGUGUACGCGGGGGACA 17 1298
HSV2-UL19-1815 + CACCAGGUCCCGAUACA 17 2055
HSV2-UL19-1677 + CUUGAGCUGGUGAUACA 17 1917
HSV2-UL19-1634 + CGCGUUGCGCAGGUACA 17 1874
HSV2-UL19-1924 + GUCCAUGGCGCCCACCA 17 2164
HSV2-UL19-1684 + GCGGGCGUGCUGCACCA 17 1924
HSV2-UL19-1063 - GCCCUCAUGUACGACCA 17 1303
HSV2-UL19-1979 + CUUCAGCUCGGCGACCA 17 2219
HSV2-UL19-733 - CGGGCGCCUGGCGACCA 17 973
HSV2-UL19-1699 + CAGGGCCGGGGGGACCA 17 1939
HSV2-UL19-1042 - CGCGCCGGCAUGGACCA 17 1282
HSV2-UL19-747 - GCUCGUGGACCUGACCA 17 987
HSV2-UL19-1692 + GAAGUAGUUGGCCCCCA 17 1932
HSV2-UL19-1918 + CGGGUUGAACAGCCCCA 17 2158
HSV2-UL19-1594 + AACCG CU GCG ACG CCCA 17 1834
HSV2-UL19-834 - CGGCAGCGCCUCGCCCA 17 1074
HSV2-UL19-867 - CGUUGGCCGCCACGCCA 17 1107
HSV2-UL19-1843 + CACCG G ACACAG CG CCA 17 2083
HSV2-UL19-1824 + AGUCACGAGCCGCGCCA 17 2064
HSV2-UL19-1835 + UAUGGUAGCCGGCGCCA 17 2075
HSV2-UL19-795 - CCCCCUGGUGGGCGCCA 17 1035
HSV2-UL19-1968 + CAGGCGGGGCACGGCCA 17 2208
HSV2-UL19-800 - GCUGUUCAACCCGGCCA 17 1040
HSV2-UL19-1017 - CACCGCCGUCGCGGCCA 17 1257
HSV2-UL19-1067 - GCGGCCCUUCGCGGCCA 17 1307
HSV2-UL19-1678 + CUGGUGAUACAGGGCCA 17 1918
HSV2-UL19-1989 + GGGCAACAGCAGGGCCA 17 2229
HSV2-UL19-1811 + GUCCACCAGCUGGGCCA 17 2051
HSV2-UL19-1046 - CGCCACCCCCGUGGCCA 17 1286
HSV2-UL19-1613 + GUUGAUGUCCGUGGCCA 17 1853
HSV2-UL19-1088 - GGGAUCGGCGGUAUCCA 17 1328
HSV2-UL19-1914 + CGCGGCGAAGCGCUCCA 17 2154
HSV2-UL19-1933 + GUAGAUGCGUCUCUCCA 17 2173
HSV2-UL19-1891 + CCCGACCGCGUUCUCCA 17 2131
HSV2-UL19-1922 + GACGAACGUCAGGUCCA 17 2162
HSV2-UL19-1793 + GUCUCGGUGGCGGUCCA 17 2033
HSV2-UL19-814 - GGUUCUGCGGCUGUCCA 17 1054 HSV2-UL19-1585 + G UGAAGAACUUGAAG CA 17 1825
HSV2-UL19-1987 + UUGCAUGGG C AAC AG CA 17 2227
HSV2-UL19-1736 + CACCUGCAGCGUGAGCA 17 1976
HSV2-UL19-1560 + GCGGGCGCUGCGUAGCA 17 1800
HSV2-UL19-1570 + UCCUGAAACAGGCCGCA 17 1810
HSV2-UL19-1946 + GUCGUCCAGGCUCCGCA 17 2186
HSV2-UL19-1704 + GCGCGCCAGGUCGCGCA 17 1944
HSV2-UL19-1807 + CAGCUCCGGGCCCGGCA 17 2047
HSV2-UL19-1041 - GCCGCGGCGCGCCGGCA 17 1281
HSV2-UL19-725 - GGCGUUUGAGCGCGGCA 17 965
HSV2-UL19-1967 + GUGCGUCAGGCGGGGCA 17 2207
HSV2-UL19-771 - GGCGCUGGUGAUGGGCA 17 1011
HSV2-UL19-740 - GAGCUUCUUCCUGGGCA 17 980
HSV2-UL19-886 - CCUCCCCGAGGAGUGCA 17 1126
HSV2-UL19-1984 + GUCGAGAUAUCGUUGCA 17 2224
HSV2-UL19-1610 + CGUCCCCGCGGGUUGCA 17 1850
HSV2-UL19-1081 - CACCGCGGCCGACAUCA 17 1321
HSV2-UL19-983 - GCUGACCUACGCGCUCA 17 1223
HSV2-UL19-963 - CGCCGGCGUGCUGCUCA 17 1203
HSV2-UL19-767 - CGGGGCCAACCUCGUCA 17 1007
HSV2-UL19-1752 + GUGGGCGGGGUCGGUCA 17 1992
HSV2-UL19-875 - CUGCAAGCCGCGAUUCA 17 1115
HSV2-UL19-988 - GUAUCACCAGCUCAAGA 17 1228
HSV2-UL19-1766 + GCAGCGCCCCCGCGAGA 17 2006
HSV2-UL19-763 - GGUGACCUACGGCGAGA 17 1003
HSV2-UL19-727 - GCACGUGCUGUUGGAGA 17 967
HSV2-UL19-1786 + GCACGCCGCCGCGUAGA 17 2026
HSV2-UL19-921 - GACUUUAACCGCAACGA 17 1161
HSV2-UL19-1796 + GUCGCAGUCCCACACGA 17 2036
HSV2-UL19-1669 + GCGGUCCUGCCGCACGA 17 1909
HSV2-UL19-954 - CAUGGCCGAGCGCACGA 17 1194
HSV2-UL19-1888 + GUGGUUCACGCCCCCGA 17 2128
HSV2-UL19-1889 + UCGAUGUUCAUGAGCGA 17 2129
HSV2-UL19-1095 - CUACGCAGCGCCCGCGA 17 1335
HSV2-UL19-1655 + GGUGCCCGUGGCCGCGA 17 1895
HSV2-UL19-1598 + GUUGGCCGUGGCCGCGA 17 1838
HSV2-UL19-1975 + CGAUGGCCUCGCGGCGA 17 2215
HSV2-UL19-920 - GGCGUGCAACGUGGCGA 17 1160
HSV2-UL19-907 - CUCGUGUGGGACUGCGA 17 1147
HSV2-UL19-1973 + CACGAGCCAGGCCUCGA 17 2213
HSV2-UL19-1884 + CGGAUUCGCGGCCUCGA 17 2124
HSV2-UL19-958 - CGCCAACACCGCGUCGA 17 1198
HSV2-UL19-949 - GGGCGCGUCGUCGUCGA 17 1189
HSV2-UL19-753 - CGCGGGCGGCCGGUCGA 17 993
HSV2-UL19-959 - AACAUGCGCAUCUUCGA 17 1199
HSV2-UL19-1060 - UACGCGGGGGACAAGGA 17 1300 HSV2-UL19-1995 + CUCAAACGCCCCCAGGA 17 2235
HSV2-UL19-1954 + GUCCUCCACCUUCAGGA 17 2194
HSV2-UL19-1588 + GAAGCAGGGGCUGAGGA 17 1828
HSV2-UL19-1969 + CGGGGCACGGCCACGGA 17 2209
HSV2-UL19-1831 + CUCGAACGCCCCGCGGA 17 2071
HSV2-UL19-1688 + CACCACGGGCUGGCGGA 17 1928
HSV2-UL19-1653 + CGUAACGGGGUUGCGGA 17 1893
HSV2-UL19-1627 + GCAGCCAAAGACCGGGA 17 1867
HSV2-UL19-1898 + AAAACAG CUGCCGGGGA 17 2138
HSV2-UL19-3087 + GCGCGCGAGCUGCUGGA 17 7470
HSV2-UL19-1716 + CG CAAACAG CG CG U G G A 17 1956
HSV2-UL19-1770 + GUAGAUUUUGUGGUGGA 17 2010
HSV2-UL19-1720 + GUAUUCGCCAUUUUGGA 17 1960
HSV2-UL19-1605 + GCCGUGGUCGUACAUGA 17 1845
HSV2-UL19-757 - CCUGCAGUCCUUCCUGA 17 997
HSV2-UL19-769 - CGUCACGGCGCUGGUGA 17 1009
HSV2-UL19-1957 + CAGGAGGCGCUGUUUGA 17 2197
HSV2-UL19-1794 + GGGCCGCGUGUCGCAUA 17 2034
HSV2-UL19-762 - GACGUGCCGGUGACCUA 17 1002
HSV2-UL19-1935 + GACCAGCCUGUCGCCUA 17 2175
HSV2-UL19-1833 + CCCGCGGACGGCGGCUA 17 2073
HSV2-UL19-1882 + GCGACGUACGCCCCGUA 17 2122
HSV2-UL19-824 - GAGGCCGCGAAUCCGUA 17 1064
HSV2-UL19-1071 - UCGCAGCGGUUCUCGUA 17 1311
HSV2-UL19-1928 + GCGCCCACCAGGGGGUA 17 2168
HSV2-UL19-1019 - CGUCCGCAACCCCGUUA 17 1259
HSV2-UL19-1003 - GUGGCCCGCCACGAAAC 17 1243
HSV2-UL19-1031 - CGGUCGUGGCGGGAAAC 17 1271
HSV2-UL19-1085 - CGUCUCAUCGUGGAAAC 17 1325
HSV2-UL19-1569 + GGUAGGCUUCCUGAAAC 17 1809
HSV2-UL19-948 - AGCGCAUGUUCCACAAC 17 1188
HSV2-UL19-730 - AACGAUAUCUCGACAAC 17 970
HSV2-UL19-1075 - GGGACCUGCUGUACAAC 17 1315
HSV2-UL19-1078 - GGGCCUAUCACCUCAAC 17 1318
HSV2-UL19-780 - AGCAACUCGAGGCGAAC 17 1020
HSV2-UL19-765 - GCGAGAUGGUCUUGAAC 17 1005
HSV2-UL19-1650 + UUGCCCAUGUCCGUAAC 17 1890
HSV2-UL19-1685 + CGGGCGUGCUGCACCAC 17 1925
HSV2-UL19-1043 - GCGCCGGCAUGGACCAC 17 1283
HSV2-UL19-1869 + GGCACUCGGCGACCCAC 17 2109
HSV2-UL19-1595 + ACCGCUGCGACG CCCAC 17 1835
HSV2-UL19-1841 + GCGUCACGAAACGCCAC 17 2081
HSV2-UL19-1018 - ACCGCCGUCGCGGCCAC 17 1258
HSV2-UL19-1679 + UGGUGAUACAGGGCCAC 17 1919
HSV2-UL19-1614 + UUGAUGUCCGUGGCCAC 17 1854
HSV2-UL19-1571 + CCUGAAACAGGCCGCAC 17 1811 HSV2-UL19-926 - CCGACGACCGGCCGCAC 17 1166
HSV2-UL19-1756 + GCUCGGGCACUCCUCAC 17 1996
HSV2-UL19-1950 + AUCUCGCCGUAGGUCAC 17 2190
HSV2-UL19-1753 + UGGGCGGGGUCGGUCAC 17 1993
HSV2-UL19-1624 + UGGGCGCAGCCAAAGAC 17 1864
HSV2-UL19-989 - UAUCACCAGCUCAAGAC 17 1229
HSV2-UL19-3101 + G CCAAU U U U ACAG AG AC 17 7484
HSV2-UL19-1787 + CACGCCGCCGCGUAGAC 17 2027
HSV2-UL19-925 - CCGACGCCGCCGACGAC 17 1165
HSV2-UL19-928 - CGCACCGGCCGGCCGAC 17 1168
HSV2-UL19-787 - UGGUGGCCAUAGGCGAC 17 1027
HSV2-UL19-1885 + GGAUUCGCGGCCUCGAC 17 2125
HSV2-UL19-1961 + ACCAG CACCCCG U CG AC 17 2201
HSV2-UL19-950 - GGCGCGUCGUCGUCGAC 17 1190
HSV2-UL19-754 - GCGGGCGGCCGGUCGAC 17 994
HSV2-UL19-960 - ACAUGCGCAUCUUCGAC 17 1200
HSV2-UL19-1589 + AAGCAGGGGCUGAGGAC 17 1829
HSV2-UL19-1850 + CUGGAUCGCCCCCGGAC 17 2090
HSV2-UL19-1717 + GCAAACAGCGCGUGGAC 17 1957
HSV2-UL19-1676 + UCUUGAGCUGGUGAUAC 17 1916
HSV2-UL19-878 - AGUGCAUCACCAGCUAC 17 1118
HSV2-UL19-825 - AGGCCGCGAAUCCGUAC 17 1065
HSV2-UL19-1072 - CGCAGCGGUUCUCGUAC 17 1312
HSV2-UL19-841 - GCCCGACAACGCCAACC 17 1081
HSV2-UL19-799 - CCUGGGGCUGUUCAACC 17 1039
HSV2-UL19-1892 + UGGACAGCCGCAGAACC 17 2132
HSV2-UL19-1670 + GACG G U G AACCCG AACC 17 1910
HSV2-UL19-781 - GCAACUCGAGGCGAACC 17 1021
HSV2-UL19-812 - U U G G G G AAAG G ACCACC 17 1052
HSV2-UL19-1923 + GGUCCAUGGCGCCCACC 17 2163
HSV2-UL19-855 - GGGCGAUCCAGGCCACC 17 1095
HSV2-UL19-806 - GCCCGCCCCCGGCCACC 17 1046
HSV2-UL19-1664 + UUUCGUGGCGGGCCACC 17 1904
HSV2-UL19-1814 + CCUCGACGUGGGCCACC 17 2054
HSV2-UL19-964 - CAUGGCCCCCCAGCACC 17 1204
HSV2-UL19-1622 + CGGCGCGCCGCGGCACC 17 1862
HSV2-UL19-1911 + GGCCGGGGGCGGGCACC 17 2151
HSV2-UL19-1757 + CUCGGGCACUCCUCACC 17 1997
HSV2-UL19-1625 + G G G CG CAG CCAAAG ACC 17 1865
HSV2-UL19-1064 - CCACGGCCAGAGCGACC 17 1304
HSV2-UL19-904 - UCACCUGAUGCGCGACC 17 1144
HSV2-UL19-970 - CCCGGCCCUGCGCGACC 17 1210
HSV2-UL19-1978 + GCUUCAGCUCGGCGACC 17 2218
HSV2-UL19-732 - ACGGGCGCCUGGCGACC 17 972
HSV2-UL19-1870 + CGGCGACCCACCGGACC 17 2110
HSV2-UL19-889 - GGCCGUGUAUCGGGACC 17 1129 HSV2-UL19-804 - CGCGCACGCCGGGGACC 17 1044
HSV2-UL19-1698 + CCAGGGCCGGGGGGACC 17 1938
HSV2-UL19-1012 - GCGCGGAAACGUGGACC 17 1252
HSV2-UL19-873 - CGAGGACCGCAGCUACC 17 1113
HSV2-UL19-1982 + GGUCGCCCGGGCAACCC 17 2222
HSV2-UL19-1671 + ACGGUGAACCCGAACCC 17 1911
HSV2-UL19-923 - GCUGCUGCACAACACCC 17 1163
HSV2-UL19-1657 + CGG UG U AGCCCACACCC 17 1897
HSV2-UL19-990 - AAGACGGGCCUCCACCC 17 1230
HSV2-UL19-1573 + ACGAGCUCGCGGCACCC 17 1813
HSV2-UL19-736 - GGUUGCCCGGGCGACCC 17 976
HSV2-UL19-991 - AGACGGGCCUCCACCCC 17 1231
HSV2-UL19-792 - CAACGUGCCCUACCCCC 17 1032
HSV2-UL19-1994 + CGCGCUCAAACGCCCCC 17 2234
HSV2-UL19-1691 + AGAAGUAGUUGGCCCCC 17 1931
HSV2-UL19-848 - CGGCGGCGAAGUCCCCC 17 1088
HSV2-UL19-971 - GGCGCGCGACGUCCCCC 17 1211
HSV2-UL19-972 - CGUCCCCCUGGUCCCCC 17 1212
HSV2-UL19-969 - CG CG CCCAACU U CCCCC 17 1209
HSV2-UL19-1917 + CCGGG UU GAACAGCCCC 17 2157
HSV2-UL19-805 - GACCUGGUGCCCGCCCC 17 1045
HSV2-UL19-942 - GUCCCGGAGAUCGCCCC 17 1182
HSV2-UL19-1849 + GUGGCCUGGAUCGCCCC 17 2089
HSV2-UL19-1840 + GCCGAGCUCCAGGCCCC 17 2080
HSV2-UL19-858 - CAACG G CAACCUG CCCC 17 1098
HSV2-UL19-796 - GACGUUCGUCCUGCCCC 17 1036
HSV2-UL19-728 - GGAGAAGGCGCCUCCCC 17 968
HSV2-UL19-862 - GGCGUUUCGUGACGCCC 17 1102
HSV2-UL19-1038 - GGUCUUUGGCUGCGCCC 17 1278
HSV2-UL19-876 - GCACGUGUUCUGCGCCC 17 1116
HSV2-UL19-1981 + GGCGACCAGGGUCGCCC 17 2221
HSV2-UL19-1839 + CGCCGAGCUCCAGGCCC 17 2079
HSV2-UL19-892 - GGCCCACGUCGAGGCCC 17 1132
HSV2-UL19-791 - GGUCUUCCUGGAGGCCC 17 1031
HSV2-UL19-973 - CCUGGUCCCCCCGGCCC 17 1213
HSV2-UL19-830 - GCGGCCCCGGCCGGCCC 17 1070
HSV2-UL19-909 - UAUGCGACACGCGGCCC 17 1149
HSV2-UL19-828 - GGCGUACGUCGCGGCCC 17 1068
HSV2-UL19-1976 + GAUGGCCCGCCUUGCCC 17 2216
HSV2-UL19-735 - GGCGACCAGGGUUGCCC 17 975
HSV2-UL19-807 - CCCGCGCGUUCCCUCCC 17 1047
HSV2-UL19-1912 + GGCGGGCACCAGGUCCC 17 2152
HSV2-UL19-1862 + GGUGCAGCUCCAGAGCC 17 2102
HSV2-UL19-1972 + GGUCAGGUCCACGAGCC 17 2212
HSV2-UL19-773 - CAAGGCCGUGCGGAGCC 17 1013
HSV2-UL19-832 - AGCGUU UUCUGAACGCC 17 1072 HSV2-UL19-802 - GCUUCGCCGCGCACGCC 17 1042
HSV2-UL19-861 - UGGCGU UUCGUGACGCC 17 1101
HSV2-UL19-1828 + GCAGGUAAAACACCGCC 17 2068
HSV2-UL19-1090 - CAGUUUAAGCGCCCGCC 17 1330
HSV2-UL19-1857 + GGGGGGACUUCGCCGCC 17 2097
HSV2-UL19-1874 + GGCGAGGCGCUGCCGCC 17 2114
HSV2-UL19-1842 + CCACCGGACACAGCGCC 17 2082
HSV2-UL19-1800 + GGGGCGGCAGCAGCGCC 17 2040
HSV2-UL19-1846 + GCCGUUGACCACGCGCC 17 2086
HSV2-UL19-1823 + GAGUCACGAGCCGCGCC 17 2063
HSV2-UL19-1601 + CCGCGAAGGGCCGCGCC 17 1841
HSV2-UL19-1876 + UGCUGCAUGUCCGCGCC 17 2116
HSV2-UL19-1702 + GGGGGACGUCGCGCGCC 17 1942
HSV2-UL19-731 - UCUCGACAACGGGCGCC 17 971
HSV2-UL19-1980 + CGGCGACCAGGGUCGCC 17 2220
HSV2-UL19-1983 + GGGCAACCCUGGUCGCC 17 2223
HSV2-UL19-745 - GCGAGGCCAUCGAGGCC 17 985
HSV2-UL19-836 - GCGCCUCGCCCACGGCC 17 1076
HSV2-UL19-1996 + ACGCCCCCAGGACGGCC 17 2236
HSV2-UL19-1852 + UCGCCCCCGGACCGGCC 17 2092
HSV2-UL19-1880 + CCGCGCCGGGGCCGGCC 17 2120
HSV2-UL19-1694 + AGUUGGCCCCCAGGGCC 17 1934
HSV2-UL19-1988 + UGGGCAACAGCAGGGCC 17 2228
HSV2-UL19-1706 + CCAGGUCGCG CAG G G CC 17 1946
HSV2-UL19-897 - CUUUACCCUGCCGGGCC 17 1137
HSV2-UL19-1805 + CCGCCCAGCUCCGGGCC 17 2045
HSV2-UL19-1781 + CGUCGGCCGCGCGGGCC 17 2021
HSV2-UL19-864 - UCGUGACGCCCGGGGCC 17 1104
HSV2-UL19-1810 + CGUCCACCAGCUGGGCC 17 2050
HSV2-UL19-1916 + CGAAGCGCUCCAUGGCC 17 2156
HSV2-UL19-1848 + CCACGCGCCAGGUGGCC 17 2088
HSV2-UL19-1906 + CGGGGCUCCGGGUGGCC 17 2146
HSV2-UL19-896 - GACGACU U U ACCCUGCC 17 1136
HSV2-UL19-1895 + CCAAAAAAACAGCUGCC 17 2135
HSV2-UL19-1082 - GGCCAAACAUCGCUGCC 17 1322
HSV2-UL19-734 - UGGCGACCAGGGUUGCC 17 974
HSV2-UL19-854 - CGGUCCGGGGGCGAUCC 17 1094
HSV2-UL19-1036 - GCCGGCCCAGCCCCUCC 17 1276
HSV2-UL19-1934 + GUCUCUCCAGGGCCUCC 17 2174
HSV2-UL19-1804 + CCUGCCCGCCCAGCUCC 17 2044
HSV2-UL19-1000 - CUUUCUGGGCCAGCUCC 17 1240
HSV2-UL19-1838 + GGCCAACGCCGAGCUCC 17 2078
HSV2-UL19-1580 + CCACGAUGAGACGCUCC 17 1820
HSV2-UL19-1903 + GGAACGCGCGGGGCUCC 17 2143
HSV2-UL19-1761 + CACCGGGGGCGAUCUCC 17 2001
HSV2-UL19-1932 + CGUAGAUGCGUCUCUCC 17 2172 HSV2-UL19-1941 + G U U CAU CCAGCG U CU CC 17 2181
HSV2-UL19-3071 - GCUCGCGCGCAACGUCC 17 7454
HSV2-UL19-3078 - CAACG UCCAGGCCGUCC 17 7461
HSV2-UL19-1945 + GGCGGCCCACGUCGUCC 17 2185
HSV2-UL19-851 - GUCCCCCCGGCCGGUCC 17 1091
HSV2-UL19-1792 + AGUCUCGGUGGCGGUCC 17 2032
HSV2-UL19-941 - GCAGAACAUGGUGGUCC 17 1181
HSV2-UL19-1722 + UUUGGAUGGUGUGGUCC 17 1962
HSV2-UL19-846 - GCCGACGUCGAGCUUCC 17 1086
HSV2-UL19-789 - CGACAGGCUGGUCUUCC 17 1029
HSV2-UL19-738 - CGACACGAGCUUCUUCC 17 978
HSV2-UL19-1584 + GGUGAAGAACUUGAAGC 17 1824
HSV2-UL19-1986 + GUUGCAUGGGCAACAGC 17 2226
HSV2-UL19-1593 + AGGCCCCGUUGUACAGC 17 1833
HSV2-UL19-1808 + UAAAGUCGUCCACCAGC 17 2048
HSV2-UL19-1632 + GCUGGGCCGGCCCCAGC 17 1872
HSV2-UL19-893 - CGAGGCCCUGGCCCAGC 17 1133
HSV2-UL19-1942 + CCUCCUGCAUAUCCAGC 17 2182
HSV2-UL19-1783 + GGGUGUUGUGCAGCAGC 17 2023
HSV2-UL19-1637 + CCGCGUUGUCUAGCAGC 17 1877
HSV2-UL19-134 + GCUGGAUGGCGCGCAGC 17 535
HSV2-UL19-1745 + GAUUGGCGGGAUGCAGC 17 1985
HSV2-UL19-1826 + GAAUCGCGGCUUGCAGC 17 2066
HSV2-UL19-898 - CCUGCCGGGCCCGGAGC 17 1138
HSV2-UL19-1665 + GGCGGGCCACCUGGAGC 17 1905
HSV2-UL19-1675 + GGAGGCCCGUCUUGAGC 17 1915
HSV2-UL19-1822 + CGUGUUGUUCCAGUAGC 17 2062
HSV2-UL19-1559 + CGCGGGCGCUGCGUAGC 17 1799
HSV2-UL19-1834 + ACGGCGGCUAUGGUAGC 17 2074
HSV2-UL19-1550 + GAGACAGGCCCUUUAGC 17 1790
HSV2-UL19-1860 + GCGAAGAAGUCGAACGC 17 2100
HSV2-UL19-1728 + GGCCAUGAGCAGCACGC 17 1968
HSV2-UL19-801 - CGCUUCGCCGCGCACGC 17 1041
HSV2-UL19-962 - GACGGGGCGCUGCACGC 17 1202
HSV2-UL19-782 - GGCGAACCGGGAGACGC 17 1022
HSV2-UL19-957 - UCCGCGGCGCCCGACGC 17 1197
HSV2-UL19-912 - GACUGCCGGAUUGACGC 17 1152
HSV2-UL19-1055 - GCCGGCGGCGUGUACGC 17 1295
HSV2-UL19-1827 + AGCAGGUAAAACACCGC 17 2067
HSV2-UL19-936 - GGGCGCUGCUGCACCGC 17 1176
HSV2-UL19-1049 - CCGGCCCUGCAACCCGC 17 1289
HSV2-UL19-1608 + CGGCCGCGCGUCCCCGC 17 1848
HSV2-UL19-1089 - GCAGUUUAAGCGCCCGC 17 1329
HSV2-UL19-1606 + CCCCGCGUACACGCCGC 17 1846
HSV2-UL19-1856 + CGGGGGGACUUCGCCGC 17 2096
HSV2-UL19-1024 - ACUUUUACCUCGGCCGC 17 1264 HSV2-UL19-870 - CCAUAGCCGCCGUCCGC 17 1110
HSV2-UL19-1799 + AGGGGCGGCAGCAGCGC 17 2039
HSV2-UL19-1900 + CCGGGGAGGGAACGCGC 17 2140
HSV2-UL19-750 - CGCACGCCGACACGCGC 17 990
HSV2-UL19-1780 + GGCGGCGUCGGCCGCGC 17 2020
HSV2-UL19-1600 + GCCGCGAAGGGCCGCGC 17 1840
HSV2-UL19-1875 + CUGCUGCAUGUCCGCGC 17 2115
HSV2-UL19-1040 - CAGGUGCCGCGGCGCGC 17 1280
HSV2-UL19-1703 + CGCGCGCCAGGUCGCGC 17 1943
HSV2-UL19-768 - CAACCUCGUCACGGCGC 17 1008
HSV2-UL19-868 - CCGCCACGCCAUGGCGC 17 1108
HSV2-UL19-1565 + GGCGGGGUCGCUGGCGC 17 1805
HSV2-UL19-1633 + CCACGACCGCG U UGCGC 17 1873
HSV2-UL19-1558 + GUGGGCCUCCCCAUCGC 17 1798
HSV2-UL19-880 - CGUGAACGACUACUCGC 17 1120
HSV2-UL19-1683 + CCCCGCCGCGCUCUCGC 17 1923
HSV2-UL19-932 - GGUGCCGGCCUUCUCGC 17 1172
HSV2-UL19-1576 + CUUAAACUGCACGUCGC 17 1816
HSV2-UL19-1564 + UAGCAGGGCGGGGUCGC 17 1804
HSV2-UL19-844 - GCGUUCGACUUCUUCGC 17 1084
HSV2-UL19-1047 - ACAUCAACUACUUUCGC 17 1287
HSV2-UL19-742 - UUCUUCCUGGGCAAGGC 17 982
HSV2-UL19-1767 + CGCCCCCGCGAGAAGGC 17 2007
HSV2-UL19-788 - GGCCAUAGGCGACAGGC 17 1028
HSV2-UL19-1965 + GUCGGCGUGCGUCAGGC 17 2205
HSV2-UL19-835 - AGCGCCUCGCCCACGGC 17 1075
HSV2-UL19-922 - UUAACCGCAACGACGGC 17 1162
HSV2-UL19-1032 - CGUGGCGGGAAACCGGC 17 1272
HSV2-UL19-927 - CGACCGGCCGCACCGGC 17 1167
HSV2-UL19-1851 + AUCGCCCCCGGACCGGC 17 2091
HSV2-UL19-1575 + GCUCGCGGCACCCCGGC 17 1815
HSV2-UL19-849 - GGCGAAGUCCCCCCGGC 17 1089
HSV2-UL19-829 - UACGUCGCGGCCCCGGC 17 1069
HSV2-UL19-1806 + CCAGCUCCGGGCCCGGC 17 2046
HSV2-UL19-1773 + CGGUCCAGUCGGCCGGC 17 2013
HSV2-UL19-1879 + UCCGCGCCGGGGCCGGC 17 2119
HSV2-UL19-980 - GCCCGCGAGAGCGCGGC 17 1220
HSV2-UL19-1052 - CCGCGGGGACGCGCGGC 17 1292
HSV2-UL19-1659 + CCACGUUUCCGCGCGGC 17 1899
HSV2-UL19-752 - CGACACGCGCGGGCGGC 17 992
HSV2-UL19-995 - GUUCACCGUCGUGCGGC 17 1235
HSV2-UL19-1775 + CGGCCGGCCGGUGCGGC 17 2015
HSV2-UL19-1772 + UGGACGGUCCAGUCGGC 17 2012
HSV2-UL19-1693 + UAGUUGGCCCCCAGGGC 17 1933
HSV2-UL19-1562 + GCGCUGCGUAGCAGGGC 17 1802
HSV2-UL19-1705 + GCCAGGUCGCGCAGGGC 17 1945 HSV2-UL19-1611 + CCCGCGGGUUGCAGGGC 17 1851
HSV2-UL19-1005 - CCCGCCACGAAACGGGC 17 1245
HSV2-UL19-1686 + CGUGCUGCACCACGGGC 17 1926
HSV2-UL19-1044 - CGGCAUGGACCACGGGC 17 1284
HSV2-UL19-1718 + ACAGCGCGUGGACGGGC 17 1958
HSV2-UL19-902 - CCCGGAGCUGGGCGGGC 17 1142
HSV2-UL19-1920 + UGAACAGCCCCAGGGGC 17 2160
HSV2-UL19-1845 + GACACAGCGCCAGGGGC 17 2085
HSV2-UL19-1629 + CAAAGACCGGGAGGGGC 17 1869
HSV2-UL19-1878 + CAUGUCCGCGCCGGGGC 17 2118
HSV2-UL19-1910 + UCCGGGUGGCCGGGGGC 17 2150
HSV2-UL19-1035 - GGGAAACCGGCUGGGGC 17 1275
HSV2-UL19-901 - CGGGCCCGGAGCUGGGC 17 1141
HSV2-UL19-1631 + ACCGGGAGGGGCUGGGC 17 1871
HSV2-UL19-1749 + GGAUGCAGCGGGUGGGC 17 1989
HSV2-UL19-1915 + GCGAAGCGCUCCAUGGC 17 2155
HSV2-UL19-1738 + UGCAGCGUGAGCAUGGC 17 1978
HSV2-UL19-985 - ACCUACGCGCUCAUGGC 17 1225
HSV2-UL19-1030 - CGCAACGCGGUCGUGGC 17 1270
HSV2-UL19-1663 + CCCGCCCGUUUCGUGGC 17 1903
HSV2-UL19-1905 + GCGGGGCUCCGGGUGGC 17 2145
HSV2-UL19-1743 + UUGGCCACCAGAUUGGC 17 1983
HSV2-UL19-1620 + CUGCCCGUGGUCCAUGC 17 1860
HSV2-UL19-777 - CCACCUGCUGGAUAUGC 17 1017
HSV2-UL19-910 - ACCGCCACCGAGACUGC 17 1150
HSV2-UL19-1955 + CCUUCAGGAAGGACUGC 17 2195
HSV2-UL19-776 - CGUGGGCCGCCACCUGC 17 1016
HSV2-UL19-895 - GGACGACUUUACCCUGC 17 1135
HSV2-UL19-1894 + CCCAAAAAAACAGCUGC 17 2134
HSV2-UL19-3079 + CGUUGCGCGCGAGCUGC 17 7462
HSV2-UL19-951 - CGCCAUGCUCACGCUGC 17 1191
HSV2-UL19-761 - CACCGAGGCCGACGUGC 17 1001
HSV2-UL19-929 - AAUCUACUAUUACGUGC 17 1169
HSV2-UL19-1723 + UGGUGUGGUCCAGGUGC 17 1963
HSV2-UL19-952 - GCUCACGCUGCAGGUGC 17 1192
HSV2-UL19-756 - GCCGGUCGACGGGGUGC 17 996
HSV2-UL19-930 - CUAUUACGUGCUGGUGC 17 1170
HSV2-UL19-1609 + GCGUCCCCGCGGGUUGC 17 1849
HSV2-UL19-967 - GUCCACGCGCUGUUUGC 17 1207
HSV2-UL19-944 - GCUGCAUCCCGCCAAUC 17 1184
HSV2-UL19-1788 + GCCCCCCCGCGUCAAUC 17 2028
HSV2-UL19-1992 + ACAGCACGUGCAGCAUC 17 2232
HSV2-UL19-1801 + GCGCCGGGUCGCGCAUC 17 2041
HSV2-UL19-1867 + ACUGCUCCGCGGUCAUC 17 2107
HSV2-UL19-784 - GCGCGUGCGCGCGGAUC 17 1024
HSV2-UL19-1567 + CGCUGGCGCAGGUGAUC 17 1807 HSV2-UL19-888 - GUGCAUGGCCGUGUAUC 17 1128
HSV2-UL19-882 - ACAUCGUGACCUACCUC 17 1122
HSV2-UL19-1817 + ACGGCCAUGCACUCCUC 17 2057
HSV2-UL19-1803 + GCCUGCCCGCCCAGCUC 17 2043
HSV2-UL19-1755 + CGGUCACGGGAUCGCUC 17 1995
HSV2-UL19-1602 + GCCGCGCCGGGUCGCUC 17 1842
HSV2-UL19-903 - GCUGGGCGGGCAGGCUC 17 1143
HSV2-UL19-1902 + GGGAACGCGCGGGGCUC 17 2142
HSV2-UL19-842 - CAACGCCAACCUGGCUC 17 1082
HSV2-UL19-1760 + UCACCGGGGGCGAUCUC 17 2000
HSV2-UL19-1921 + GGGGCAGGACGAACGUC 17 2161
HSV2-UL19-820 - ACAUCGACGCGGCCGUC 17 1060
HSV2-UL19-1733 + GUGUUGGCGCCCGCGUC 17 1973
HSV2-UL19-1963 + GCGUGUCGGCGUGCGUC 17 2203
HSV2-UL19-850 - AGUCCCCCCGGCCGGUC 17 1090
HSV2-UL19-817 - CCAUGGAGAACGCGGUC 17 1057
HSV2-UL19-837 - UCGCCCACGGCCGGGUC 17 1077
HSV2-UL19-1971 + GCUGCGUCGCCGUGGUC 17 2211
HSV2-UL19-859 - GCCCCUGGCGCUGUGUC 17 1099
HSV2-UL19-1936 + CGCGCACGCGCGUUGUC 17 2176
HSV2-UL19-1865 + GCCAGGUUGGCGUUGUC 17 2105
HSV2-UL19-1953 + CGGUGUCCUCCACCUUC 17 2193
HSV2-UL19-993 - GCCUCCACCCCGGGUUC 17 1233
HSV2-UL19-998 - GUCGGAGGCGUACUUUC 17 1238
HSV2-UL19-1094 - CCCGUGCGGCCUGUUUC 17 1334
HSV2-UL19-1553 + UGAGAUACUGCGUAAAG 17 1793
HSV2-UL19-1668 + CGUUCUCGGUCACGAAG 17 1908
HSV2-UL19-1764 + CGUACACGCGGUCGAAG 17 2004
HSV2-UL19-737 - UGGUCGCCGAGCUGAAG 17 977
HSV2-UL19-1925 + U CCAU G G CG CCCACCAG 17 2165
HSV2-UL19-1700 + AGGGCCGGGGGGACCAG 17 1940
HSV2-UL19-1919 + GGGUUGAACAGCCCCAG 17 2159
HSV2-UL19-1844 + ACCGGACACAGCGCCAG 17 2084
HSV2-UL19-1990 + G G CAACAG CAG G G CCAG 17 2230
HSV2-UL19-1586 + UGAAGAACUUGAAGCAG 17 1826
HSV2-UL19-1636 + GCCGCGUUGUCUAGCAG 17 1876
HSV2-UL19-1070 - ACCCGUGGGCGUCGCAG 17 1310
HSV2-UL19-1577 + CUGCACGUCGCUGGCAG 17 1817
HSV2-UL19-1744 + AGAUUGGCGGGAUGCAG 17 1984
HSV2-UL19-1797 + U CGCAG U CCCACACG AG 17 2037
HSV2-UL19-1061 - ACGCGGGGGACAAGGAG 17 1301
HSV2-UL19-1628 + CAGCCAAAGACCGGGAG 17 1868
HSV2-UL19-1549 + AGAGACAGGCCCUUUAG 17 1789
HSV2-UL19-1011 - CCAGCCGCGCGGAAACG 17 1251
HSV2-UL19-1026 - CCCGCUGCUAGACAACG 17 1266
HSV2-UL19-1076 - GGACCUGCUGUACAACG 17 1316 HSV2-UL19-1027 - CGUGUACCUGCGCAACG 17 1267
HSV2-UL19-919 - CGCGGCGGCGUGCAACG 17 1159
HSV2-UL19-1079 - GGCCUAUCACCUCAACG 17 1319
HSV2-UL19-815 - GCUGUCCAUGGAGAACG 17 1055
HSV2-UL19-1859 + CGCGAAGAAGUCGAACG 17 2099
HSV2-UL19-766 - CGAGAUGGUCUUGAACG 17 1006
HSV2-UL19-1651 + UGCCCAUGUCCGUAACG 17 1891
HSV2-UL19-1795 + CG U CG CAG U CCCACACG 17 2035
HSV2-UL19-908 - CGGCCUUAUGCGACACG 17 1148
HSV2-UL19-1763 + GCAGCGUGGCGUACACG 17 2003
HSV2-UL19-968 - UGCGGGCGCCGACCACG 17 1208
HSV2-UL19-1680 + GGUGAUACAGGGCCACG 17 1920
HSV2-UL19-1615 + UGAUGUCCGUGGCCACG 17 1855
HSV2-UL19-1713 + UGGGCGCGUUGGCCACG 17 1953
HSV2-UL19-774 - GCGGAGCCUGGACGACG 17 1014
HSV2-UL19-956 - CUCCGCGGCGCCCGACG 17 1196
HSV2-UL19-818 - GCUCAUGAACAUCGACG 17 1058
HSV2-UL19-1886 + GAUUCGCGGCCUCGACG 17 2126
HSV2-UL19-1812 + GGGCCAGGGCCUCGACG 17 2052
HSV2-UL19-1730 + CAUGUUGGCCGUCGACG 17 1970
HSV2-UL19-755 - CGGGCGGCCGGUCGACG 17 995
HSV2-UL19-961 - CAUGCGCAUCUUCGACG 17 1201
HSV2-UL19-1947 + UCACCAGCGCCGUGACG 17 2187
HSV2-UL19-911 - AGACUGCCGGAUUGACG 17 1151
HSV2-UL19-917 - GCACGAGCCCGUCUACG 17 1157
HSV2-UL19-826 - GGCCGCGAAUCCGUACG 17 1066
HSV2-UL19-1073 - GCAGCGGUUCUCGUACG 17 1313
HSV2-UL19-1054 - GGCCGGCGGCGUGUACG 17 1294
HSV2-UL19-760 - GAAGGUGGAGGACACCG 17 1000
HSV2-UL19-935 - GGGGCGCUGCUGCACCG 17 1175
HSV2-UL19-1758 + UCGGGCACUCCUCACCG 17 1998
HSV2-UL19-1080 - CUUCAAGU U CU U CACCG 17 1320
HSV2-UL19-840 - CGAGUGCCAGAUGACCG 17 1080
HSV2-UL19-1068 - CGGCCACGGCCAACCCG 17 1308
HSV2-UL19-1048 - GCCGGCCCUGCAACCCG 17 1288
HSV2-UL19-1672 + CGG UG AACCCGAACCCG 17 1912
HSV2-UL19-1045 - GUUCAUCGCCACCCCCG 17 1285
HSV2-UL19-1765 + GUCGAAGCGGACCCCCG 17 2005
HSV2-UL19-1820 + CGGGGAGGUCGCCCCCG 17 2060
HSV2-UL19-987 - CUUCAAGAUGAGCCCCG 17 1227
HSV2-UL19-1830 + GGUCCUCGAACGCCCCG 17 2070
HSV2-UL19-1642 + GCAGCGGGGGGGCCCCG 17 1882
HSV2-UL19-885 - CGGGGGCGACCUCCCCG 17 1125
HSV2-UL19-1607 + CCGGCCGCGCGUCCCCG 17 1847
HSV2-UL19-977 - CUCCAUCCGCCAGCCCG 17 1217
HSV2-UL19-863 - GCGUUUCGUGACGCCCG 17 1103 HSV2-UL19-1619 + ACACGGCAUCCUGCCCG 17 1859
HSV2-UL19-1654 + GUUGCGGACGGUGCCCG 17 1894
HSV2-UL19-803 - CUUCGCCGCGCACGCCG 17 1043
HSV2-UL19-1091 - AG U U UAAGCGCCCGCCG 17 1331
HSV2-UL19-1877 + GCUGCAUGUCCGCGCCG 17 2117
HSV2-UL19-1621 + UCCAUGCCGGCGCGCCG 17 1861
HSV2-UL19-1734 + GCCCGCGUCGGGCGCCG 17 1974
HSV2-UL19-1970 + GGACGGCUGCGUCGCCG 17 2210
HSV2-UL19-1853 + CGCCCCCGGACCGGCCG 17 2093
HSV2-UL19-1871 + CCCACCGGACCCGGCCG 17 2111
HSV2-UL19-1881 + CGCGCCGGGGCCGGCCG 17 2121
HSV2-UL19-1643 + GGGGGGCCCCGCGGCCG 17 1883
HSV2-UL19-1023 - AACUUUUACCUCGGCCG 17 1263
HSV2-UL19-1583 + GGCCGUGAUGUCGGCCG 17 1823
HSV2-UL19-1695 + GUUGGCCCCCAGGGCCG 17 1935
HSV2-UL19-1707 + CAGGUCGCGCAGGGCCG 17 1947
HSV2-UL19-1603 + CCGGGUCGCUCUGGCCG 17 1843
HSV2-UL19-1579 + GCUGGCAGCGGUGGCCG 17 1819
HSV2-UL19-1907 + GGGGCUCCGGGUGGCCG 17 2147
HSV2-UL19-1597 + CGCCCACGGGUUGGCCG 17 1837
HSV2-UL19-1896 + CAAAAAAACAGCUGCCG 17 2136
HSV2-UL19-1039 - GCUGCGCCCAGGUGCCG 17 1279
HSV2-UL19-1866 + CUGCAUGAACUGCUCCG 17 2106
HSV2-UL19-955 - GGCGCUGCUGUGCUCCG 17 1195
HSV2-UL19-748 - GGCGACGCAGCCGUCCG 17 988
HSV2-UL19-869 - ACCAUAGCCGCCGUCCG 17 1109
HSV2-UL19-852 - UCCCCCCGGCCGGUCCG 17 1092
HSV2-UL19-1612 + AAAG U AG U U G AU G U CCG 17 1852
HSV2-UL19-1638 + CGCGUUGUCUAGCAGCG 17 1878
HSV2-UL19-1762 + CACCAUGUUCUGCAGCG 17 2002
HSV2-UL19-978 - GCACGCCCGCGAGAGCG 17 1218
HSV2-UL19-724 - CUGGGGGCGUUUGAGCG 17 964
HSV2-UL19-1551 + AGACAGGCCCUUUAGCG 17 1791
HSV2-UL19-1861 + CGAAGAAG U CGAACG CG 17 2101
HSV2-UL19-1899 + GCCGGGGAGGGAACGCG 17 2139
HSV2-UL19-749 - ACGCACGCCGACACGCG 17 989
HSV2-UL19-1051 - CAACCCGCGGGGACGCG 17 1291
HSV2-UL19-913 - ACUGCCGGAUUGACGCG 17 1153
HSV2-UL19-1056 - CCGGCGGCGUGUACGCG 17 1296
HSV2-UL19-937 - GGCGCUGCUGCACCGCG 17 1177
HSV2-UL19-1050 - CGGCCCUGCAACCCGCG 17 1290
HSV2-UL19-924 - CAACACCCAGGCCCGCG 17 1164
HSV2-UL19-1010 - ACGCUCACCCAGCCGCG 17 1250
HSV2-UL19-743 - GGCGGGCCAUCGCCGCG 17 983
HSV2-UL19-1025 - CUUUUACCUCGGCCGCG 17 1265
HSV2-UL19-1779 + CGGCGGCGUCGGCCGCG 17 2019 HSV2-UL19-871 - CAUAGCCGCCGUCCGCG 17 1111
HSV2-UL19-1658 + AGGUCCACGUUUCCGCG 17 1898
HSV2-UL19-1715 + CGCCCGCAAACAGCGCG 17 1955
HSV2-UL19-1901 + CGGGGAGGGAACGCGCG 17 2141
HSV2-UL19-1555 + AGUGGGUCUCUCGCGCG 17 1795
HSV2-UL19-856 - CCAGGCCACCUGGCGCG 17 1096
HSV2-UL19-783 - GACAACG CG CG U G CG CG 17 1023
HSV2-UL19-933 - GUGCCGGCCUUCUCGCG 17 1173
HSV2-UL19-1966 + UCGGCGUGCGUCAGGCG 17 2206
HSV2-UL19-1065 - GCCAGAGCGACCCGGCG 17 1305
HSV2-UL19-831 - CCCGGCCGGCCCCGGCG 17 1071
HSV2-UL19-981 - CCCGCGAGAGCGCGGCG 17 1221
HSV2-UL19-1563 + CGCUGCGUAGCAGGGCG 17 1803
HSV2-UL19-1006 - CCGCCACGAAACGGGCG 17 1246
HSV2-UL19-1590 + GGGGCUGAGGACGGGCG 17 1830
HSV2-UL19-845 - CGACUUCUUCGCGGGCG 17 1085
HSV2-UL19-1873 + GGACCCGGCCGUGGGCG 17 2113
HSV2-UL19-1750 + GAUGCAGCGGGUGGGCG 17 1990
HSV2-UL19-1836 + UAGCCGGCGCCAUGGCG 17 2076
HSV2-UL19-986 - CCUACGCGCUCAUGGCG 17 1226
HSV2-UL19-877 - UGUUCUGCGCCCUGGCG 17 1117
HSV2-UL19-879 - GAACAACACGCGAUGCG 17 1119
HSV2-UL19-1913 + CAGGUCCCCGGCGUGCG 17 2153
HSV2-UL19-1825 + CUCGUUGCCGUGAAUCG 17 2065
HSV2-UL19-1557 + CGUGGGCCUCCCCAUCG 17 1797
HSV2-UL19-744 - UCGCCGCGAGGCCAUCG 17 984
HSV2-UL19-1083 - CCUGGAGCGUCUCAUCG 17 1323
HSV2-UL19-779 - GCAGGAGGAGCAACUCG 17 1019
HSV2-UL19-883 - CAUCGUGACCUACCUCG 17 1123
HSV2-UL19-1974 + AGGCCUCGAUGGCCUCG 17 2214
HSV2-UL19-1818 + CGGCCAUGCACUCCUCG 17 2058
HSV2-UL19-1572 + GGUCUUCCACGAGCUCG 17 1812
HSV2-UL19-1092 - GGGGUGCCGCGAGCUCG 17 1332
HSV2-UL19-746 - CAUCGAGGCCUGGCUCG 17 986
HSV2-UL19-1682 + CCCCCGCCGCGCUCUCG 17 1922
HSV2-UL19-931 - UGGUGCCGGCCUUCUCG 17 1171
HSV2-UL19-891 - CCUGGUGGCCCACGUCG 17 1131
HSV2-UL19-827 - GUACGGGGCGUACGUCG 17 1067
HSV2-UL19-823 - G AACCACGACCCCG UCG 17 1063
HSV2-UL19-1016 - GGGCUACACCGCCGUCG 17 1256
HSV2-UL19-821 - CAUCGACGCGGCCGUCG 17 1061
HSV2-UL19-1028 - CCUGCGCAACGCGGUCG 17 1268
HSV2-UL19-1887 + CGGCCUCGACGGGGUCG 17 2127
HSV2-UL19-1883 + CGCCCCGUACGGAUUCG 17 2123
HSV2-UL19-1066 - CCCGGCGCGGCCCUUCG 17 1306
HSV2-UL19-843 - CGCGUUCGACUUCUUCG 17 1083 HSV2-UL19-872 - CGUCCGCGGGGCGUUCG 17 1112
HSV2-UL19-1661 + CCCCCCCGCCCGUUUCG 17 1901
HSV2-UL19-1059 - GUACGCGGGGGACAAGG 17 1299
HSV2-UL19-741 - CUUCUUCCUGGGCAAGG 17 981
HSV2-UL19-758 - GCAGUCCUUCCUGAAGG 17 998
HSV2-UL19-1926 + CCAUGGCGCCCACCAGG 17 2166
HSV2-UL19-1701 + GGGCCGGGGGGACCAGG 17 1941
HSV2-UL19-1847 + GUUGACCACGCGCCAGG 17 2087
HSV2-UL19-1001 - UCUGGGCCAGCUCCAGG 17 1241
HSV2-UL19-1943 + CCUGCAUAUCCAGCAGG 17 2183
HSV2-UL19-778 - CCUGCUGGAUAUGCAGG 17 1018
HSV2-UL19-1956 + UCAGGAAGGACUGCAGG 17 2196
HSV2-UL19-1964 + UGUCGGCGUGCGUCAGG 17 2204
HSV2-UL19-1062 - CGCGGGGGACAAGGAGG 17 1302
HSV2-UL19-1635 + GUUGCGCAGGUACACGG 17 1875
HSV2-UL19-1616 + GAUGUCCGUGGCCACGG 17 1856
HSV2-UL19-1656 + GCCCGUGGCCGCGACGG 17 1896
HSV2-UL19-1832 + GAACGCCCCGCGGACGG 17 2072
HSV2-UL19-1759 + CGGGCACUCCUCACCGG 17 1999
HSV2-UL19-874 - GGACCGCAGCUACCCGG 17 1114
HSV2-UL19-1574 + AGCUCGCGGCACCCCGG 17 1814
HSV2-UL19-847 - GACGUCGAGCUUCCCGG 17 1087
HSV2-UL19-1854 + GCCCCCGGACCGGCCGG 17 2094
HSV2-UL19-1053 - CGGGGACGCGCGGCCGG 17 1293
HSV2-UL19-1696 + UUGGCCCCCAGGGCCGG 17 1936
HSV2-UL19-1708 + AGGUCGCGCAGGGCCGG 17 1948
HSV2-UL19-1908 + GGGCUCCGGGUGGCCGG 17 2148
HSV2-UL19-853 - CCCCCCGGCCGGUCCGG 17 1093
HSV2-UL19-838 - CCCACGGCCGGGUCCGG 17 1078
HSV2-UL19-860 - CCUGGCGCUGUGUCCGG 17 1100
HSV2-UL19-1639 + GCGUUGUCUAGCAGCGG 17 1879
HSV2-UL19-1578 + CACGUCGCUGGCAGCGG 17 1818
HSV2-UL19-914 - CUGCCGGAUUGACGCGG 17 1154
HSV2-UL19-918 - CGAGCCCGUCUACGCGG 17 1158
HSV2-UL19-1057 - CGGCGGCGUGUACGCGG 17 1297
HSV2-UL19-938 - GCGCUGCUGCACCGCGG 17 1178
HSV2-UL19-979 - CGCCCGCGAGAGCGCGG 17 1219
HSV2-UL19-934 - UGCCGGCCUUCUCGCGG 17 1174
HSV2-UL19-982 - CCGCGAGAGCGCGGCGG 17 1222
HSV2-UL19-1960 + CUGUUUGAUGGCGGCGG 17 2200
HSV2-UL19-1007 - CGCCACGAAACGGGCGG 17 1247
HSV2-UL19-1959 + GCGCUGUUUGAUGGCGG 17 2199
HSV2-UL19-1087 - CGUGGAAACGGGAUCGG 17 1327
HSV2-UL19-884 - AUCGUGACCUACCUCGG 17 1124
HSV2-UL19-1790 + CAAUCCGGCAGUCUCGG 17 2030
HSV2-UL19-822 - AUCGACGCGGCCGUCGG 17 1062 HSV2-UL19-997 - UUCCGAGCGCGCGUCGG 17 1237
HSV2-UL19-1777 + GUGCGGCCGGUCGUCGG 17 2017
HSV2-UL19-1561 + GGCGCUGCGUAGCAGGG 17 1801
HSV2-UL19-1004 - GCCCGCCACGAAACGGG 17 1244
HSV2-UL19-1626 + CGCAGCCAAAGACCGGG 17 1866
HSV2-UL19-1855 + CCCCCGGACCGGCCGGG 17 2095
HSV2-UL19-1697 + UGGCCCCCAGGGCCGGG 17 1937
HSV2-UL19-1709 + GGUCGCGCAGGGCCGGG 17 1949
HSV2-UL19-1904 + ACGCGCGGGGCUCCGGG 17 2144
HSV2-UL19-1640 + CGUUGUCUAGCAGCGGG 17 1880
HSV2-UL19-1746 + UGGCGGGAUGCAGCGGG 17 1986
HSV2-UL19-915 - UGCCGGAUUGACGCGGG 17 1155
HSV2-UL19-751 - ACGCCGACACGCGCGGG 17 991
HSV2-UL19-1008 - GCCACGAAACGGGCGGG 17 1248
HSV2-UL19-1991 + AACAGCAGGGCCAGGGG 17 2231
HSV2-UL19-1798 + CAG U CCCACACG AG GG G 17 2038
HSV2-UL19-1673 + U G AACCCG AACCCG GG G 17 1913
HSV2-UL19-1897 + AAAAACAG CU G CCG G G G 17 2137
HSV2-UL19-1641 + GUUGUCUAGCAGCGGGG 17 1881
HSV2-UL19-1552 + CAGGCCCUUUAGCGGGG 17 1792
HSV2-UL19-916 - GCCGGAUUGACGCGGGG 17 1156
HSV2-UL19-1009 - CCACGAAACGGGCGGGG 17 1249
HSV2-UL19-1819 + CCAUGCACUCCUCGGGG 17 2059
HSV2-UL19-1617 + GUCCGUGGCCACGGGGG 17 1857
HSV2-UL19-1909 + CUCCGGGUGGCCGGGGG 17 2149
HSV2-UL19-1648 + GGUAAAAGUUUUGGGGG 17 1888
HSV2-UL19-1098 - CAGCGCCCGCGAUGGGG 17 1338
HSV2-UL19-900 - CCGGGCCCGGAGCUGGG 17 1140
HSV2-UL19-1727 + GUGGUCCAGGUGCUGGG 17 1967
HSV2-UL19-1940 + CACGCGCGUUGUCUGGG 17 2180
HSV2-UL19-1748 + GGGAUGCAGCGGGUGGG 17 1988
HSV2-UL19-940 - CACGCUGCAGAACAUGG 17 1180
HSV2-UL19-1737 + CUGCAGCGUGAGCAUGG 17 1977
HSV2-UL19-984 - GACCUACGCGCUCAUGG 17 1224
HSV2-UL19-1689 + CACGGGCUGGCGGAUGG 17 1929
HSV2-UL19-1958 + GAGGCGCUGUUUGAUGG 17 2198
HSV2-UL19-1893 + ACAGCCGCAGAACCUGG 17 2133
HSV2-UL19-890 - CGUGUAUCGGGACCUGG 17 1130
HSV2-UL19-793 - CGUGCCCUACCCCCUGG 17 1033
HSV2-UL19-976 - GGUCCCCCCGGCCCUGG 17 1216
HSV2-UL19-833 - GUUUUCUGAACGCCUGG 17 1073
HSV2-UL19-723 - CGUCCAGGCCGUCCUGG 17 963
HSV2-UL19-790 - CAGGCUGGUCUUCCUGG 17 1030
HSV2-UL19-894 - GGCCCUGGCCCAGCUGG 17 1134
HSV2-UL19-1687 + GCUGCACCACGGGCUGG 17 1927
HSV2-UL19-1726 + UGUGGUCCAGGUGCUGG 17 1966 HSV2-UL19-945 - GCAUCCCGCCAAUCUGG 17 1185
HSV2-UL19-785 - CGUGCGCGCGGAUCUGG 17 1025
HSV2-UL19-1939 + GCACGCGCGUUGUCUGG 17 2179
HSV2-UL19-1837 + CCGGCGCCAUGGCGUGG 17 2077
HSV2-UL19-1029 - GCGCAACGCGGUCGUGG 17 1269
HSV2-UL19-1662 + CCCCGCCCGUUUCGUGG 17 1902
HSV2-UL19-759 - GUCCUUCCUGAAGGUGG 17 999
HSV2-UL19-1944 + GCAUAUCCAGCAGGUGG 17 2184
HSV2-UL19-1791 + UCCGGCAGUCUCGGUGG 17 2031
HSV2-UL19-1674 + ACCCGAACCCGGGGUGG 17 1914
HSV2-UL19-1931 + GUAGGGCACGUUGGUGG 17 2171
HSV2-UL19-1769 + AAUAGUAGAUUUUGUGG 17 2009
HSV2-UL19-1742 + GUUGGCCACCAGAUUGG 17 1982
HSV2-UL19-1930 + GGGGUAGGGCACGUUGG 17 2170
HSV2-UL19-1647 + CGAGGUAAAAGUUUUGG 17 1887
HSV2-UL19-1604 + GGCCGUGGUCGUACAUG 17 1844
HSV2-UL19-1097 - ACGCAGCGCCCGCGAUG 17 1337
HSV2-UL19-798 - CGUUCGUCCUGCCCCUG 17 1038
HSV2-UL19-975 - UGGUCCCCCCGGCCCUG 17 1215
HSV2-UL19-3080 - ACGUCCAGGCCGUCCUG 17 7463
HSV2-UL19-1829 + ACACCGCCGGGUAGCUG 17 2069
HSV2-UL19-1034 - UGGCGGGAAACCGGCUG 17 1274
HSV2-UL19-1587 + ACUUGAAGCAGGGGCUG 17 1827
HSV2-UL19-1725 + GUGUGGUCCAGGUGCUG 17 1965
HSV2-UL19-1938 + CGCACGCGCGUUGUCUG 17 2178
HSV2-UL19-813 - AGGACCACCAGGUUCUG 17 1053
HSV2-UL19-1093 - CUCGUGGAAGACCCGUG 17 1333
HSV2-UL19-772 - UGAUGGGCAAGGCCGUG 17 1012
HSV2-UL19-905 - UGCUGCCGCCCCUCGUG 17 1145
HSV2-UL19-994 - UCGGGUUCACCGUCGUG 17 1234
HSV2-UL19-943 - GGAGAUCGCCCCCGGUG 17 1183
HSV2-UL19-1774 + CAGUCGGCCGGCCGGUG 17 2014
HSV2-UL19-1014 - AAACGUGGACCUGGGUG 17 1254
HSV2-UL19-1721 + CGCCAUUUUGGAUGGUG 17 1961
HSV2-UL19-1591 + CGGGCGAGGCCCCGUUG 17 1831
HSV2-UL19-1739 + CGACGACGCGCCCGUUG 17 1979
HSV2-UL19-1784 + GCAGCCGGCCGUCGUUG 17 2024
HSV2-UL19-1652 + UGUCCGUAACGGGGUUG 17 1892
HSV2-UL19-966 - CGUCCACGCGCUGUUUG 17 1206
HSV2-UL19-1768 + CGUAAUAGUAGAUUUUG 17 2008
HSV2-UL19-1646 + CCGAGG UAAAAG U U U U G 17 1886
HSV2-UL19-810 - CGGCAGCUGUUUUUUUG 17 1050
HSV2-UL19-3102 - GCCUGUCUCUGUAAAAU 17 7485
HSV2-UL19-1021 - AACCCCGUUACGGACAU 17 1261
HSV2-UL19-786 - GCGGAUCUGGUGGCCAU 17 1026
HSV2-UL19-1985 + UCGAGAUAUCGUUGCAU 17 2225 HSV2-UL19-1741 + CGUGUUGGCCACCAGAU 17 1981
HSV2-UL19-1096 - UACGCAGCGCCCGCGAU 17 1336
HSV2-UL19-1086 - CAUCGUGGAAACGGGAU 17 1326
HSV2-UL19-1566 + UCGCUGGCGCAGGUGAU 17 1806
HSV2-UL19-1592 + GGCCCCGUUGAGGUGAU 17 1832
HSV2-UL19-770 - GUCACGGCGCUGGUGAU 17 1010
HSV2-UL19-887 - AGUGCAUGGCCGUGUAU 17 1127
HSV2-UL19-1868 + CGCGGUCAUCUGGCACU 17 2108
HSV2-UL19-1623 + GGCGCGCCGCGGCACCU 17 1863
HSV2-UL19-1013 - CGCGGAAACGUGGACCU 17 1253
HSV2-UL19-881 - UACAUCGUGACCUACCU 17 1121
HSV2-UL19-1022 - CCCCAAAACU U U U ACCU 17 1262
HSV2-UL19-797 - ACGUUCGUCCUGCCCCU 17 1037
HSV2-UL19-974 - CUGGUCCCCCCGGCCCU 17 1214
HSV2-UL19-1952 + CACCGGCACGUCGGCCU 17 2192
HSV2-UL19-1782 + GUCGGCCGCGCGGGCCU 17 2022
HSV2-UL19-1816 + CACGGCCAUGCACUCCU 17 2056
HSV2-UL19-3081 - AACGUCCAGGCCGUCCU 17 7464
HSV2-UL19-739 - GACACGAGCUUCUUCCU 17 979
HSV2-UL19-1809 + AAAG UCGUCCACCAGCU 17 2049
HSV2-UL19-1802 + CAUCAGGUGAUUCAGCU 17 2042
HSV2-UL19-1977 + AAAGCUCCGCUUCAGCU 17 2217
HSV2-UL19-899 - CUGCCGGGCCCGGAGCU 17 1139
HSV2-UL19-865 - GCCCGGGGCCUGGAGCU 17 1105
HSV2-UL19-1666 + CGCCUCCGACGCGCGCU 17 1906
HSV2-UL19-1735 + CAGCGCCGUCGUGCGCU 17 1975
HSV2-UL19-1754 + UCGGUCACGGGAUCGCU 17 1994
HSV2-UL19-1033 - GUGGCGGGAAACCGGCU 17 1273
HSV2-UL19-1660 + CACGUUUCCGCGCGGCU 17 1900
HSV2-UL19-1630 + AAAGACCGGGAGGGGCU 17 1870
HSV2-UL19-1724 + GGUGUGGUCCAGGUGCU 17 1964
HSV2-UL19-1789 + CGUCAAUCCGGCAGUCU 17 2029
HSV2-UL19-1937 + GCGCACGCGCGUUGUCU 17 2177
HSV2-UL19-1667 + G G AAAACAG CACG U U CU 17 1907
HSV2-UL19-999 - UCGGAGGCGUACUUUCU 17 1239
HSV2-UL19-1554 + GAGAUACUGCGUAAAGU 17 1794
HSV2-UL19-1785 + GUCGUUGCGGUUAAAGU 17 2025
HSV2-UL19-1710 + CAGGGCCGGGGGGAAGU 17 1950
HSV2-UL19-1771 + GUGGUGGACGGUCCAGU 17 2011
HSV2-UL19-1690 + GAUGGAGGAGAAGUAGU 17 1930
HSV2-UL19-1951 + GUAGGUCACCGGCACGU 17 2191
HSV2-UL19-1929 + CAGGGGGUAGGGCACGU 17 2169
HSV2-UL19-775 - CGGAGCCUGGACGACGU 17 1015
HSV2-UL19-1813 + GGCCAGGGCCUCGACGU 17 2053
HSV2-UL19-1858 + GCCGGGAAGCUCGACGU 17 2098
HSV2-UL19-1069 - GGCCACGGCCAACCCGU 17 1309 HSV2-UL19-1949 + CAAG ACCAU CU CGCCG U 17 2189
HSV2-UL19-1872 + CCACCGGACCCGGCCGU 17 2112
HSV2-UL19-819 - AACAUCGACGCGGCCGU 17 1059
HSV2-UL19-1732 + GGUGUUGGCGCCCGCGU 17 1972
HSV2-UL19-1681 + CCCCGCCAUGAGCGCGU 17 1921
HSV2-UL19-996 - GUUUUCCGAGCGCGCGU 17 1236
HSV2-UL19-1556 + GUGGGUCUCUCGCGCGU 17 1796
HSV2-UL19-1712 + GGGGAAGUUGGGCGCGU 17 1952
HSV2-UL19-1778 + CCGGUCGUCGGCGGCGU 17 2018
HSV2-UL19-866 - GGCCUGGAGCUCGGCGU 17 1106
HSV2-UL19-1776 + CCGGUGCGGCCGGUCGU 17 2016
HSV2-UL19-1863 + CAGCUCCAGAGCCAGGU 17 2103
HSV2-UL19-1948 + CAGCGCCGUGACGAGGU 17 2188
HSV2-UL19-1821 + GAGGUCGCCCCCGAGGU 17 2061
HSV2-UL19-839 - CCACGGCCGGGUCCGGU 17 1079
HSV2-UL19-816 - UCCAUGGAGAACGCGGU 17 1056
HSV2-UL19-1596 + CUGCGACGCCCACGGGU 17 1836
HSV2-UL19-1747 + GGCGGGAUGCAGCGGGU 17 1987
HSV2-UL19-1568 + GGCGCAGGUGAUCGGGU 17 1808
HSV2-UL19-1751 + CAGCGGGUGGGCGGGGU 17 1991
HSV2-UL19-1927 + GGCGCCCACCAGGGGGU 17 2167
HSV2-UL19-794 - GUGCCCUACCCCCUGGU 17 1034
HSV2-UL19-1993 + CACGUGCAGCAUCUGGU 17 2233
HSV2-UL19-1714 + CGCGUUGGCCACGUGGU 17 1954
HSV2-UL19-1729 + GUCGAAGAUGCGCAUGU 17 1969
HSV2-UL19-1582 + AUGUUUGGCCGUGAUGU 17 1822
HSV2-UL19-726 - GAUGCUGCACGUGCUGU 17 966
HSV2-UL19-1740 + CAUGCGCUUGACCGUGU 17 1980
HSV2-UL19-1962 + CGGCCGCCCGCGCGUGU 17 2202
HSV2-UL19-906 - GCUGCCGCCCCUCGUGU 17 1146
HSV2-UL19-1731 + GGCCGUCGACGCGGUGU 17 1971
HSV2-UL19-1015 - AACGUGGACCUGGGUGU 17 1255
HSV2-UL19-1864 + AGCCAGGUUGGCGUUGU 17 2104
HSV2-UL19-1037 - CAGCCCCUCCCGGUCUU 17 1277
HSV2-UL19-1711 + AGGGCCGGGGGGAAGUU 17 1951
HSV2-UL19-992 - GGCCUCCACCCCGGGUU 17 1232
HSV2-UL19-1581 + CUCCAGGCAGCGAUGUU 17 1821
HSV2-UL19-1719 + AGAAGUAUUCGCCAUUU 17 1959
HSV2-UL19-1644 + GGCCGAGGUAAAAGUUU 17 1884
HSV2-UL19-1645 + GCCGAGGUAAAAGUUUU 17 1885
HSV2-UL19-808 - CCCGGCAGCUGUUUUUU 17 1048
HSV2-UL19-809 - CCGGCAGCUGUUUUUUU 17 1049
HSV2-UL19-587 - CUGGACCACACCAUCCAAAA 20 827
HSV2-UL19-624 - CCAGGUGGCCCGCCACGAAA 20 864
HSV2-UL19-706 - GGAGCGUCUCAUCGUGGAAA 20 946
HSV2-UL19-722 - UACGACGCCUCCCCGCUAAA 20 962 HSV2-UL19-569 - GUCAAGCGCAUGUUCCACAA 20 809
HSV2-UL19-351 - AUGCAACGAUAUCUCGACAA 20 591
HSV2-UL19-696 - UACGGGGACCUGCUGUACAA 20 936
HSV2-UL19-699 - AACGGGGCCUAUCACCUCAA 20 939
HSV2-UL19-479 - GCCACCUGGCGCGUGGUCAA 20 719
HSV2-UL19-1151 + GGGU UGGCCGUGGCCGCGAA 20 1391
HSV2-UL19-433 - GCAGCUGUUUUUUUGGGGAA 20 673
HSV2-UL19-386 - UACGGCGAGAUGGUCUUGAA 20 626
HSV2-UL19-721 - CUACGACGCCUCCCCGCUAA 20 961
HSV2-UL19-1201 + GAGGUUGCCCAUGUCCGUAA 20 1441
HSV2-UL19-575 - GCAGGUGCUGGCG CACAACA 20 815
HSV2-UL19-568 - CGCCAAUCUGGUGGCCAACA 20 808
HSV2-UL19-561 - GUACGCCACGCUGCAGAACA 20 801
HSV2-UL19-1170 + GGUGGCGAUGAACUCACACA 20 1410
HSV2-UL19-1442 + CAUGAGCGAAGGAUGACACA 20 1682
HSV2-UL19-642 - CCG CAACCCCG U U ACG G ACA 20 882
HSV2-UL19-680 - CGGCGUGUACGCGGGGGACA 20 920
HSV2-UL19-1367 + GGCCACCAGGUCCCGAUACA 20 1607
HSV2-UL19-1229 + CGUCUUGAGCUGGUGAUACA 20 1469
HSV2-UL19-1186 + GACCGCGUUGCGCAGGUACA 20 1426
HSV2-UL19-1476 + CAG G U CCAU GG CG CCCACCA 20 1716
HSV2-UL19-1236 + CUCGCGGGCGUGCUGCACCA 20 1476
HSV2-UL19-685 - AUAGCCCUCAUGUACGACCA 20 925
HSV2-UL19-1531 + CCGCUUCAGCUCGGCGACCA 20 1771
HSV2-UL19-355 - CAACGGGCGCCUGGCGACCA 20 595
HSV2-UL19-1251 + CCCCAGGGCCGGGGGGACCA 20 1491
HSV2-UL19-664 - CGGCGCGCCGGCAUGGACCA 20 904
HSV2-UL19-369 - CUGGCUCGUGGACCUGACCA 20 609
HSV2-UL19-1244 + GGAGAAGUAGUUGGCCCCCA 20 1484
HSV2-UL19-1470 + GGCCGGGUUGAACAGCCCCA 20 1710
HSV2-UL19-1146 + GAGAACCGCUGCGACGCCCA 20 1386
HSV2-UL19-456 - UGGCGGCAGCGCCUCGCCCA 20 696
HSV2-UL19-489 - CGGCGUUGGCCGCCACGCCA 20 729
HSV2-UL19-1395 + CGCCACCGGACACAGCGCCA 20 1635
HSV2-UL19-1376 + CUGAGUCACGAGCCGCGCCA 20 1616
HSV2-UL19-1387 + GGCUAUGGUAGCCGGCGCCA 20 1627
HSV2-UL19-417 - CUACCCCCUGGUGGGCGCCA 20 657
HSV2-UL19-1520 + CGUCAGGCGGGGCACGGCCA 20 1760
HSV2-UL19-422 - GGGGCUGUUCAACCCGGCCA 20 662
HSV2-UL19-639 - CUACACCGCCGUCGCGGCCA 20 879
HSV2-UL19-689 - GGCGCGGCCCUUCGCGGCCA 20 929
HSV2-UL19-1230 + GAGCUGGUGAUACAGGGCCA 20 1470
HSV2-UL19-1541 + CAU G G G CA ACAG CAG G G CCA 20 1781
HSV2-UL19-1363 + GUCGUCCACCAGCUGGGCCA 20 1603
HSV2-UL19-668 - CAUCGCCACCCCCGUGGCCA 20 908
HSV2-UL19-1165 + GUAGUUGAUGUCCGUGGCCA 20 1405 HSV2-UL19-710 - AACGGGAUCGGCGGUAUCCA 20 950
HSV2-UL19-1466 + GUGCGCGGCGAAGCGCUCCA 20 1706
HSV2-UL19-1485 + GGCGUAGAUGCGUCUCUCCA 20 1725
HSV2-UL19-1443 + GGUCCCGACCGCGUUCUCCA 20 1683
HSV2-UL19-1474 + CAGGACGAACGUCAGGUCCA 20 1714
HSV2-UL19-1345 + GCAGUCUCGGUGGCGGUCCA 20 1585
HSV2-UL19-436 - CCAGGUUCUGCGGCUGUCCA 20 676
HSV2-UL19-1137 + GCGGUGAAGAACUUGAAGCA 20 1377
HSV2-UL19-1539 + UCGU UGCAUGGGCAACAGCA 20 1779
HSV2-UL19-1288 + CAGCACCUGCAGCGUGAGCA 20 1528
HSV2-UL19-1112 + AUCGCGGGCGCUGCGUAGCA 20 1352
HSV2-UL19-1122 + GCUUCCUGAAACAGGCCGCA 20 1362
HSV2-UL19-1498 + CACGUCGUCCAGGCUCCGCA 20 1738
HSV2-UL19-1256 + GUCGCGCGCCAGGUCGCGCA 20 1496
HSV2-UL19-1359 + GCCCAGCUCCGGGCCCGGCA 20 1599
HSV2-UL19-663 - GGUGCCGCGGCGCGCCGGCA 20 903
HSV2-UL19-347 - GGGGGCGUUUGAGCGCGGCA 20 587
HSV2-UL19-1519 + GGCGUGCGUCAGGCGGGGCA 20 1759
HSV2-UL19-393 - CACGGCGCUGGUGAUGGGCA 20 633
HSV2-UL19-362 - CACGAGCUUCUUCCUGGGCA 20 602
HSV2-UL19-508 - CGACCUCCCCGAGGAGUGCA 20 748
HSV2-UL19-1536 + GUUGUCGAGAUAUCGUUGCA 20 1776
HSV2-UL19-1162 + GCGCGUCCCCGCGGGUUGCA 20 1402
HSV2-UL19-703 - CUUCACCGCGGCCGACAUCA 20 943
HSV2-UL19-605 - CGCGCUGACCUACGCGCUCA 20 845
HSV2-UL19-585 - GCACGCCGGCGUGCUGCUCA 20 825
HSV2-UL19-389 - GAACGGGGCCAACCUCGUCA 20 629
HSV2-UL19-1304 + CGGGUGGGCGGGGUCGGUCA 20 1544
HSV2-UL19-497 - CUGCUGCAAGCCGCGAUUCA 20 737
HSV2-UL19-610 - CCU G U AU CACCAG CU CAAGA 20 850
HSV2-UL19-1318 + GCAGCAGCGCCCCCGCGAGA 20 1558
HSV2-UL19-385 - GCCGGUGACCUACGGCGAGA 20 625
HSV2-UL19-349 - GCUGCACGUGCUGUUGGAGA 20 589
HSV2-UL19-1338 + GUUGCACGCCGCCGCGUAGA 20 1578
HSV2-UL19-543 - GCCGACUUUAACCGCAACGA 20 783
HSV2-UL19-1348 + GCCGUCGCAGUCCCACACGA 20 1588
HSV2-UL19-1221 + GAAGCGGUCCUGCCGCACGA 20 1461
HSV2-UL19-576 - CAACAUGGCCGAGCGCACGA 20 816
HSV2-UL19-1440 + GUCGUGGUUCACGCCCCCGA 20 1680
HSV2-UL19-1441 + GCGUCGAUGUUCAUGAGCGA 20 1681
HSV2-UL19-717 - CUGCUACGCAGCGCCCGCGA 20 957
HSV2-UL19-1207 + GACGGUGCCCGUGGCCGCGA 20 1447
HSV2-UL19-1150 + CGGGUUGGCCGUGGCCGCGA 20 1390
HSV2-UL19-1527 + CCUCGAUGGCCUCGCGGCGA 20 1767
HSV2-UL19-542 - GGCGGCGUGCAACGUGGCGA 20 782
HSV2-UL19-529 - CCCCUCGUGUGGGACUGCGA 20 769 HSV2-UL19-1525 + GUCCACGAGCCAGGCCUCGA 20 1765
HSV2-UL19-1436 + GUACGGAUUCGCGGCCUCGA 20 1676
HSV2-UL19-580 - GGGCGCCAACACCGCGUCGA 20 820
HSV2-UL19-571 - AACGGGCGCGUCGUCGUCGA 20 811
HSV2-UL19-375 - ACGCGCGGGCGGCCGGUCGA 20 615
HSV2-UL19-581 - GCCAACAUGCGCAUCUUCGA 20 821
HSV2-UL19-682 - GUGUACGCGGGGGACAAGGA 20 922
HSV2-UL19-1547 + GCGCUCAAACGCCCCCAGGA 20 1787
HSV2-UL19-1506 + GGUGUCCUCCACCU UCAGGA 20 1746
HSV2-UL19-1140 + CUUGAAGCAGGGGCUGAGGA 20 1380
HSV2-UL19-1521 + AGGCGGGGCACGGCCACGGA 20 1761
HSV2-UL19-1383 + GUCCUCGAACGCCCCGCGGA 20 1623
HSV2-UL19-1240 + CUGCACCACGGGCUGGCGGA 20 1480
HSV2-UL19-1205 + GUCCGUAACGGGGUUGCGGA 20 1445
HSV2-UL19-1179 + GGCGCAGCCAAAGACCGGGA 20 1419
HSV2-UL19-1450 + AAAAAAACAGCUGCCGGGGA 20 1690
HSV2-UL19-3073 + GUUGCGCGCGAGCUGCUGGA 20 7456
HSV2-UL19-1268 + GCCCGCAAACAGCGCGUGGA 20 1508
HSV2-UL19-1322 + AUAGUAGAUUUUGUGGUGGA 20 1562
HSV2-UL19-1272 + GAAGUAUUCGCCAUUUUGGA 20 1512
HSV2-UL19-1157 + CUGGCCGUGGUCGUACAUGA 20 1397
HSV2-UL19-379 - CCUCCUGCAGUCCUUCCUGA 20 619
HSV2-UL19-391 - CCUCGUCACGGCGCUGGUGA 20 631
HSV2-UL19-1509 + CUGCAGGAGGCGCUGUUUGA 20 1749
HSV2-UL19-1346 + CCAGGGCCGCGUGUCGCAUA 20 1586
HSV2-UL19-384 - GCCGACGUGCCGGUGACCUA 20 624
HSV2-UL19-1487 + GAAGACCAGCCUGUCGCCUA 20 1727
HSV2-UL19-1385 + CGCCCCGCGGACGGCGGCUA 20 1625
HSV2-UL19-1434 + GCCGCGACGUACGCCCCGUA 20 1674
HSV2-UL19-446 - GUCGAGGCCGCGAAUCCGUA 20 686
HSV2-UL19-693 - GCGUCGCAGCGGU UCUCGUA 20 933
HSV2-UL19-1480 + AUGGCGCCCACCAGGGGGUA 20 1720
HSV2-UL19-641 - CACCG UCCGCAACCCCGU UA 20 881
HSV2-UL19-625 - CAG G U G GCCCGCCACG AAAC 20 865
HSV2-UL19-653 - ACGCGGUCGUGGCGGGAAAC 20 893
HSV2-UL19-707 - GAGCGUCUCAUCGUGGAAAC 20 947
HSV2-UL19-1121 + UCGGGUAGGCUUCCUGAAAC 20 1361
HSV2-UL19-570 - UCAAGCGCAUGUUCCACAAC 20 810
HSV2-UL19-352 - UGCAACGAUAUCUCGACAAC 20 592
HSV2-UL19-697 - ACGGGGACCUGCUGUACAAC 20 937
HSV2-UL19-700 - ACGGGGCCUAUCACCUCAAC 20 940
HSV2-UL19-402 - AGGAGCAACUCGAGGCGAAC 20 642
HSV2-UL19-387 - ACGGCGAGAUGGUCUUGAAC 20 627
HSV2-UL19-1202 + AGGUUGCCCAUGUCCGUAAC 20 1442
HSV2-UL19-1237 + UCGCGGGCGUGCUGCACCAC 20 1477
HSV2-UL19-665 - GGCGCGCCGGCAUGGACCAC 20 905 HSV2-UL19-1421 + UCUGGCACUCGGCGACCCAC 20 1661
HSV2-UL19-1147 + AGAACCGCU GCGACGCCCAC 20 1387
HSV2-UL19-1393 + CGGGCGUCACGAAACGCCAC 20 1633
HSV2-UL19-640 - UACACCGCCGUCGCGGCCAC 20 880
HSV2-UL19-1231 + AGCUGGUGAUACAGGGCCAC 20 1471
HSV2-UL19-1166 + UAGUUGAUGUCCGUGGCCAC 20 1406
HSV2-UL19-1123 + CUUCCUGAAACAGGCCGCAC 20 1363
HSV2-UL19-548 - CCGCCGACGACCGGCCGCAC 20 788
HSV2-UL19-1308 + AUCGCUCGGGCACUCCUCAC 20 1548
HSV2-UL19-1502 + ACCAUCUCGCCGUAGGUCAC 20 1742
HSV2-UL19-1305 + GGGUGGGCGGGGUCGGUCAC 20 1545
HSV2-UL19-1176 + ACCUGGGCGCAGCCAAAGAC 20 1416
HSV2-UL19-611 - CU G U AU CACCAG CU CAAG AC 20 851
HSV2-UL19-3103 + GAAGCCAAUUUUACAGAGAC 20 7486
HSV2-UL19-1339 + UUGCACGCCGCCGCGUAGAC 20 1579
HSV2-UL19-547 - CGGCCGACGCCGCCGACGAC 20 787
HSV2-UL19-550 - GGCCGCACCGGCCGGCCGAC 20 790
HSV2-UL19-409 - AUCUGGUGGCCAUAGGCGAC 20 649
HSV2-UL19-1437 + UACGGAUUCGCGGCCUCGAC 20 1677
HSV2-UL19-1513 + GUGACCAGCACCCCGUCGAC 20 1753
HSV2-UL19-572 - ACGGGCGCGUCGUCGUCGAC 20 812
HSV2-UL19-376 - CGCGCGGGCGGCCGGUCGAC 20 616
HSV2-UL19-582 - CCAACAUGCGCAUCUUCGAC 20 822
HSV2-UL19-1141 + UUGAAGCAGGGGCUGAGGAC 20 1381
HSV2-UL19-1402 + GGCCUGGAUCGCCCCCGGAC 20 1642
HSV2-UL19-1269 + CCCGCAAACAGCGCGUGGAC 20 1509
HSV2-UL19-1228 + CCGUCUUGAGCUGGUGAUAC 20 1468
HSV2-UL19-500 - CUCAGUGCAUCACCAGCUAC 20 740
HSV2-UL19-447 - UCGAGGCCGCGAAUCCGUAC 20 687
HSV2-UL19-694 - CGUCGCAGCGGUUCUCGUAC 20 934
HSV2-UL19-463 - GCAGCCCGACAACGCCAACC 20 703
HSV2-UL19-421 - GCCCCUGGGGCUGUUCAACC 20 661
HSV2-UL19-1444 + CCAUGGACAGCCGCAGAACC 20 1684
HSV2-UL19-1222 + CACGACG G U G AACCCG AACC 20 1462
HSV2-UL19-403 - GGAGCAACUCGAGGCGAACC 20 643
HSV2-UL19-434 - UUUUUGGGGAAAGGACCACC 20 674
HSV2-UL19-1475 + UCAGGUCCAUGGCGCCCACC 20 1715
HSV2-UL19-477 - CGGGGGCGAUCCAGGCCACC 20 717
HSV2-UL19-428 - GGUGCCCGCCCCCGGCCACC 20 668
HSV2-UL19-1216 + CCGUUUCGUGGCGGGCCACC 20 1456
HSV2-UL19-1366 + GGGCCUCGACGUGGGCCACC 20 1606
HSV2-UL19-586 - GCUCAUGGCCCCCCAGCACC 20 826
HSV2-UL19-1174 + UGCCGGCGCGCCGCGGCACC 20 1414
HSV2-UL19-1463 + GGUGGCCGGGGGCGGGCACC 20 1703
HSV2-UL19-1309 + UCGCUCGGGCACUCCUCACC 20 1549
HSV2-UL19-1177 + CCUGGGCGCAGCCAAAGACC 20 1417 HSV2-UL19-686 - CGACCACGGCCAGAGCGACC 20 926
HSV2-UL19-526 - GAAUCACCUGAUGCGCGACC 20 766
HSV2-UL19-592 - CCCCCCGGCCCUGCGCGACC 20 832
HSV2-UL19-1530 + UCCGCUUCAGCUCGGCGACC 20 1770
HSV2-UL19-354 - ACAACGGGCG CCU GG CG ACC 20 594
HSV2-UL19-1422 + ACUCGGCGACCCACCGGACC 20 1662
HSV2-UL19-511 - CAUGGCCGUGUAUCGGGACC 20 751
HSV2-UL19-426 - CGCCGCGCACGCCGGGGACC 20 666
HSV2-UL19-1250 + CCCCCAGGGCCGGGGGGACC 20 1490
HSV2-UL19-634 - GCCGCGCGGAAACGUGGACC 20 874
HSV2-UL19-495 - GUUCGAGGACCGCAGCUACC 20 735
HSV2-UL19-1534 + CAGGGUCGCCCGGGCAACCC 20 1774
HSV2-UL19-1223 + ACGACGGUGAACCCGAACCC 20 1463
HSV2-UL19-545 - CCGGCUGCUGCACAACACCC 20 785
HSV2-UL19-1209 + CGGCGGUGUAGCCCACACCC 20 1449
HSV2-UL19-612 - CU CAAG ACG GG CCU CCACCC 20 852
HSV2-UL19-1125 + UCCACGAGCUCGCGGCACCC 20 1365
HSV2-UL19-358 - CAGGGUUGCCCGGGCGACCC 20 598
HSV2-UL19-613 - UCAAGACGGGCCUCCACCCC 20 853
HSV2-UL19-414 - CACCAACGUGCCCUACCCCC 20 654
HSV2-UL19-1546 + UGCCGCGCUCAAACGCCCCC 20 1786
HSV2-UL19-1243 + AGGAGAAGUAGUUGGCCCCC 20 1483
HSV2-UL19-470 - UCCCGGCGGCGAAGUCCCCC 20 710
HSV2-UL19-593 - CCUGGCGCGCGACGUCCCCC 20 833
HSV2-UL19-594 - CGACGUCCCCCUGGUCCCCC 20 834
HSV2-UL19-591 - CAACG CG CCCAACU U CCCCC 20 831
HSV2-UL19-1469 + UGGCCGGGUUGAACAGCCCC 20 1709
HSV2-UL19-427 - GGGGACCUGGUGCCCGCCCC 20 667
HSV2-UL19-564 - GUGGUCCCGGAGAUCGCCCC 20 804
HSV2-UL19-1401 + CAGGUGGCCUGGAUCGCCCC 20 1641
HSV2-UL19-1392 + AACGCCGAGCUCCAGGCCCC 20 1632
HSV2-UL19-480 - GGUCAACGGCAACCUGCCCC 20 720
HSV2-UL19-418 - CCUGACGUUCGUCCUGCCCC 20 658
HSV2-UL19-350 - GUUGGAGAAGGCGCCUCCCC 20 590
HSV2-UL19-484 - GGUGGCGU UUCGUGACGCCC 20 724
HSV2-UL19-660 - CCCGGUCUUUGGCUGCGCCC 20 900
HSV2-UL19-498 - CGAGCACGUGU UCUGCGCCC 20 738
HSV2-UL19-1533 + CUCGGCGACCAGGGUCGCCC 20 1773
HSV2-UL19-1391 + CAACGCCGAGCUCCAGGCCC 20 1631
HSV2-UL19-514 - GGUGGCCCACGUCGAGGCCC 20 754
HSV2-UL19-413 - GCUGGUCU UCCUGGAGGCCC 20 653
HSV2-UL19-595 - CCCCCUGGUCCCCCCGGCCC 20 835
HSV2-UL19-452 - GUCGCGGCCCCGGCCGGCCC 20 692
HSV2-UL19-531 - CCUUAUGCGACACGCGGCCC 20 771
HSV2-UL19-450 - CGGGGCGUACGUCGCGGCCC 20 690
HSV2-UL19-1528 + GGCGAUGGCCCGCCUUGCCC 20 1768 HSV2-UL19-357 - CCUGGCGACCAGGGUUGCCC 20 597
HSV2-UL19-429 - AGCCCCGCGCGUUCCCUCCC 20 669
HSV2-UL19-1464 + GGGGGCGGGCACCAGGUCCC 20 1704
HSV2-UL19-1414 + CGGGGUGCAGCUCCAGAGCC 20 1654
HSV2-UL19-1524 + CGUGGUCAGGUCCACGAGCC 20 1764
HSV2-UL19-395 - GGGCAAGGCCGUGCGGAGCC 20 635
HSV2-UL19-454 - AGCAGCGUUUUCUGAACGCC 20 694
HSV2-UL19-424 - AGCGCUUCGCCGCGCACGCC 20 664
HSV2-UL19-483 - CGGUGGCGUUUCGUGACGCC 20 723
HSV2-UL19-1380 + GCAGCAGGUAAAACACCGCC 20 1620
HSV2-UL19-712 - GUGCAGUUUAAGCGCCCGCC 20 952
HSV2-UL19-1409 + GCCGGGGGGACU UCGCCGCC 20 1649
HSV2-UL19-1426 + GUGGGCGAGGCGCUGCCGCC 20 1666
HSV2-UL19-1394 + ACGCCACCGGACACAGCGCC 20 1634
HSV2-UL19-1352 + CGAGGGGCGGCAGCAGCGCC 20 1592
HSV2-UL19-1398 + GUUGCCGUUGACCACGCGCC 20 1638
HSV2-UL19-1375 + ACUGAGUCACGAGCCGCGCC 20 1615
HSV2-UL19-1153 + UGGCCGCGAAGGGCCGCGCC 20 1393
HSV2-UL19-1428 + CGCUGCUGCAUGUCCGCGCC 20 1668
HSV2-UL19-1254 + CCAGGGGGACGUCGCGCGCC 20 1494
HSV2-UL19-353 - AUAUCUCGACAACGGGCGCC 20 593
HSV2-UL19-1532 + GCUCGGCGACCAGGGUCGCC 20 1772
HSV2-UL19-1535 + CCCGGGCAACCCUGGUCGCC 20 1775
HSV2-UL19-367 - GCCGCGAGGCCAUCGAGGCC 20 607
HSV2-UL19-458 - GCAGCGCCUCGCCCACGGCC 20 698
HSV2-UL19-1548 + CAAACGCCCCCAGGACGGCC 20 1788
HSV2-UL19-1404 + GGAUCGCCCCCGGACCGGCC 20 1644
HSV2-UL19-1432 + UGUCCGCGCCGGGGCCGGCC 20 1672
HSV2-UL19-1246 + AGUAGUUGGCCCCCAGGGCC 20 1486
HSV2-UL19-1540 + G CAU G G G CAACAG CAG G G CC 20 1780
HSV2-UL19-1258 + GCGCCAGGUCGCGCAGGGCC 20 1498
HSV2-UL19-519 - CGACUUUACCCUGCCGGGCC 20 759
HSV2-UL19-1357 + UGCCCGCCCAGCUCCGGGCC 20 1597
HSV2-UL19-1333 + CGGCGUCGGCCGCGCGGGCC 20 1573
HSV2-UL19-486 - GUU UCGUGACGCCCGGGGCC 20 726
HSV2-UL19-1362 + AGUCGUCCACCAGCUGGGCC 20 1602
HSV2-UL19-1468 + CGGCGAAGCGCUCCAUGGCC 20 1708
HSV2-UL19-1400 + UGACCACGCGCCAGGUGGCC 20 1640
HSV2-UL19-1458 + GCGCGGGGCUCCGGGUGGCC 20 1698
HSV2-UL19-518 - GUGGACGACUUUACCCUGCC 20 758
HSV2-UL19-1447 + UCCCCAAAAAAACAGCUGCC 20 1687
HSV2-UL19-704 - CACGGCCAAACAUCGCUGCC 20 944
HSV2-UL19-356 - GCCUGGCGACCAGGGUUGCC 20 596
HSV2-UL19-476 - GGCCGGUCCGGGGGCGAUCC 20 716
HSV2-UL19-658 - GGGGCCGGCCCAGCCCCUCC 20 898
HSV2-UL19-1486 + UGCGUCUCUCCAGGGCCUCC 20 1726 HSV2-UL19-1356 + GAGCCUGCCCGCCCAGCUCC 20 1596
HSV2-UL19-622 - GUACUUUCUGGGCCAGCUCC 20 862
HSV2-UL19-1390 + GGCGGCCAACGCCGAGCUCC 20 1630
HSV2-UL19-1132 + UUUCCACGAUGAGACGCUCC 20 1372
HSV2-UL19-1455 + GAGGGAACGCGCGGGGCUCC 20 1695
HSV2-UL19-1313 + CCUCACCGGGGGCGAUCUCC 20 1553
HSV2-UL19-1484 + CGGCGUAGAUGCGUCUCUCC 20 1724
HSV2-UL19-1493 + CGAGUUCAUCCAGCGUCUCC 20 1733
HSV2-UL19-3074 - GCAGCUCGCGCGCAACGUCC 20 7457
HSV2-UL19-3092 - GCGCAACGUCCAGGCCGUCC 20 7475
HSV2-UL19-1497 + GGUGGCGGCCCACGUCGUCC 20 1737
HSV2-UL19-473 - GAAGUCCCCCCGGCCGGUCC 20 713
HSV2-UL19-1344 + GGCAGUCUCGGUGGCGGUCC 20 1584
HSV2-UL19-563 - GCUGCAGAACAUGGUGGUCC 20 803
HSV2-UL19-1274 + CAUUUUGGAUGGUGUGGUCC 20 1514
HSV2-UL19-468 - GUGGCCGACGUCGAGCUUCC 20 708
HSV2-UL19-411 - AGGCGACAGGCUGGUCUUCC 20 651
HSV2-UL19-360 - UUGCGACACGAGCUUCUUCC 20 600
HSV2-UL19-1136 + CGCGGUGAAGAACUUGAAGC 20 1376
HSV2-UL19-1538 + AUCGU UGCAUGGGCAACAGC 20 1778
HSV2-UL19-1145 + GAUAGGCCCCGUUGUACAGC 20 1385
HSV2-UL19-1360 + G G G U AAAG U CG U CCACCAG C 20 1600
HSV2-UL19-1184 + GGGGCUGGGCCGGCCCCAGC 20 1424
HSV2-UL19-515 - CGUCGAGGCCCUGGCCCAGC 20 755
HSV2-UL19-1494 + GCUCCUCCUGCAUAUCCAGC 20 1734
HSV2-UL19-1335 + CCUGGGUGUUGUGCAGCAGC 20 1575
HSV2-UL19-1189 + CGGCCGCGUUGUCUAGCAGC 20 1429
HSV2-UL19-35 + GCUGCUGGAUGGCGCGCAGC 20 463
HSV2-UL19-1297 + CCAGAUUGGCGGGAUGCAGC 20 1537
HSV2-UL19-1378 + CGUGAAUCGCGGCUUGCAGC 20 1618
HSV2-UL19-520 - UACCCUGCCGGGCCCGGAGC 20 760
HSV2-UL19-1217 + CGUGGCGGGCCACCUGGAGC 20 1457
HSV2-UL19-1227 + GGUGGAGGCCCGUCUUGAGC 20 1467
HSV2-UL19-1374 + UCGCGUGUUGUUCCAGUAGC 20 1614
HSV2-UL19-1111 + CAUCGCGGGCGCUGCGUAGC 20 1351
HSV2-UL19-1386 + CGGACGGCGGCUAUGGUAGC 20 1626
HSV2-UL19-1102 + ACAGAGACAGGCCCUUUAGC 20 1342
HSV2-UL19-1412 + CCCGCGAAGAAGUCGAACGC 20 1652
HSV2-UL19-1280 + GGGGGCCAUGAGCAGCACGC 20 1520
HSV2-UL19-423 - GAGCGCUUCGCCGCGCACGC 20 663
HSV2-UL19-584 - UUCGACGGGGCGCUGCACGC 20 824
HSV2-UL19-404 - CGAGGCGAACCGGGAGACGC 20 644
HSV2-UL19-579 - UGCUCCGCGGCGCCCGACGC 20 819
HSV2-UL19-534 - CGAGACUGCCGGAUUGACGC 20 774
HSV2-UL19-677 - GCGGCCGGCGGCGUGUACGC 20 917
HSV2-UL19-1379 + U G CAG CAG G U AAAACACCG C 20 1619 HSV2-UL19-558 - CGGGGGCGCUGCUGCACCGC 20 798
HSV2-UL19-671 - UCGCCGGCCCUGCAACCCGC 20 911
HSV2-UL19-1160 + CGCCGGCCGCGCGUCCCCGC 20 1400
HSV2-UL19-711 - CGUGCAGUUUAAGCGCCCGC 20 951
HSV2-UL19-1158 + GUCCCCCGCGUACACGCCGC 20 1398
HSV2-UL19-1408 + GGCCGGGGGGACUUCGCCGC 20 1648
HSV2-UL19-646 - AAAACUUUUACCUCGGCCGC 20 886
HSV2-UL19-492 - CUACCAUAGCCGCCGUCCGC 20 732
HSV2-UL19-1351 + ACGAGGGGCGGCAGCAGCGC 20 1591
HSV2-UL19-1452 + CUGCCGGGGAGGGAACGCGC 20 1692
HSV2-UL19-372 - UGACGCACGCCGACACGCGC 20 612
HSV2-UL19-1332 + GUCGGCGGCGUCGGCCGCGC 20 1572
HSV2-UL19-1152 + GUGGCCGCGAAGGGCCGCGC 20 1392
HSV2-UL19-1427 + ACGCUGCUGCAUGUCCGCGC 20 1667
HSV2-UL19-662 - GCCCAGGUGCCGCGGCGCGC 20 902
HSV2-UL19-1255 + CGUCGCGCGCCAGGUCGCGC 20 1495
HSV2-UL19-390 - GGCCAACCUCGUCACGGCGC 20 630
HSV2-UL19-490 - UGGCCGCCACGCCAUGGCGC 20 730
HSV2-UL19-1117 + CAGGGCGGGGUCGCUGGCGC 20 1357
HSV2-UL19-1185 + CCGCCACGACCGCGUUGCGC 20 1425
HSV2-UL19-1110 + CGCGUGGGCCUCCCCAUCGC 20 1350
HSV2-UL19-502 - GUUCGUGAACGACUACUCGC 20 742
HSV2-UL19-1235 + CUCCCCCGCCGCGCUCUCGC 20 1475
HSV2-UL19-554 - GCUGGUGCCGGCCUUCUCGC 20 794
HSV2-UL19-1128 + GCGCUUAAACUGCACGUCGC 20 1368
HSV2-UL19-1116 + GCGUAGCAGGGCGGGGUCGC 20 1356
HSV2-UL19-466 - CCCGCGUUCGACUUCUUCGC 20 706
HSV2-UL19-669 - CGGACAUCAACUACUUUCGC 20 909
HSV2-UL19-364 - AGCUUCUUCCUGGGCAAGGC 20 604
HSV2-UL19-1319 + CAGCGCCCCCGCGAGAAGGC 20 1559
HSV2-UL19-410 - GGUGGCCAUAGGCGACAGGC 20 650
HSV2-UL19-1517 + CGUGUCGGCGUGCGUCAGGC 20 1757
HSV2-UL19-457 - GGCAGCGCCUCGCCCACGGC 20 697
HSV2-UL19-544 - ACUUUAACCGCAACGACGGC 20 784
HSV2-UL19-654 - GGUCGUGGCGGGAAACCGGC 20 894
HSV2-UL19-549 - CGACGACCGGCCGCACCGGC 20 789
HSV2-UL19-1403 + UGGAUCGCCCCCGGACCGGC 20 1643
HSV2-UL19-1127 + CGAGCUCGCGGCACCCCGGC 20 1367
HSV2-UL19-471 - GGCGGCGAAGUCCCCCCGGC 20 711
HSV2-UL19-451 - GCGUACGUCGCGGCCCCGGC 20 691
HSV2-UL19-1358 + CGCCCAGCUCCGGGCCCGGC 20 1598
HSV2-UL19-1325 + GGACGGUCCAGUCGGCCGGC 20 1565
HSV2-UL19-1431 + AUGUCCGCGCCGGGGCCGGC 20 1671
HSV2-UL19-602 - CACGCCCGCGAGAGCGCGGC 20 842
HSV2-UL19-674 - AACCCGCGGGGACGCGCGGC 20 914
HSV2-UL19-1211 + GGUCCACGUUUCCGCGCGGC 20 1451 HSV2-UL19-374 - CGCCGACACGCGCGGGCGGC 20 614
HSV2-UL19-617 - CGGGUUCACCGUCGUGCGGC 20 857
HSV2-UL19-1327 + AGUCGGCCGGCCGGUGCGGC 20 1567
HSV2-UL19-1324 + UGGUGGACGGUCCAGUCGGC 20 1564
HSV2-UL19-1245 + AAGUAGUUGGCCCCCAGGGC 20 1485
HSV2-UL19-1114 + CGGGCGCUGCGUAGCAGGGC 20 1354
HSV2-UL19-1257 + CGCGCCAGGUCGCGCAGGGC 20 1497
HSV2-UL19-1163 + GUCCCCGCGGGUUGCAGGGC 20 1403
HSV2-UL19-627 - UGGCCCGCCACGAAACGGGC 20 867
HSV2-UL19-1238 + GGGCGUGCUGCACCACGGGC 20 1478
HSV2-UL19-666 - CGCCGGCAUGGACCACGGGC 20 906
HSV2-UL19-1270 + CAAACAGCGCGUGGACGGGC 20 1510
HSV2-UL19-524 - GGGCCCGGAGCUGGGCGGGC 20 764
HSV2-UL19-1472 + GGUUGAACAGCCCCAGGGGC 20 1712
HSV2-UL19-1397 + CCGGACACAGCGCCAGGGGC 20 1637
HSV2-UL19-1181 + AGCCAAAGACCGGGAGGGGC 20 1421
HSV2-UL19-1430 + CUGCAUGUCCGCGCCGGGGC 20 1670
HSV2-UL19-1462 + GGCUCCGGGUGGCCGGGGGC 20 1702
HSV2-UL19-657 - GGCGGGAAACCGGCUGGGGC 20 897
HSV2-UL19-523 - UGCCGGGCCCGGAGCUGGGC 20 763
HSV2-UL19-1183 + AAGACCGGGAGGGGCUGGGC 20 1423
HSV2-UL19-1301 + GCGGGAUGCAGCGGGUGGGC 20 1541
HSV2-UL19-1467 + GCGGCGAAGCGCUCCAUGGC 20 1707
HSV2-UL19-1290 + ACCUGCAGCGUGAGCAUGGC 20 1530
HSV2-UL19-607 - CUGACCUACGCGCUCAUGGC 20 847
HSV2-UL19-652 - CUGCGCAACGCGGUCGUGGC 20 892
HSV2-UL19-1215 + CCCCCCGCCCGUUUCGUGGC 20 1455
HSV2-UL19-1457 + CGCGCGGGGCUCCGGGUGGC 20 1697
HSV2-UL19-1295 + GUGU UGGCCACCAGAUUGGC 20 1535
HSV2-UL19-1172 + AUCCUGCCCGUGGUCCAUGC 20 1412
HSV2-UL19-399 - CCGCCACCUGCUGGAUAUGC 20 639
HSV2-UL19-532 - UGGACCGCCACCGAGACUGC 20 772
HSV2-UL19-1507 + CCACCUUCAGGAAGGACUGC 20 1747
HSV2-UL19-398 - CGACGUGGGCCGCCACCUGC 20 638
HSV2-UL19-517 - GGUGGACGACUUUACCCUGC 20 757
HSV2-UL19-1446 + U U CCCCAAAAAAACAG CU GC 20 1686
HSV2-UL19-3076 + GGACGU UGCGCGCGAGCUGC 20 7459
HSV2-UL19-573 - GCCCGCCAUGCUCACGCUGC 20 813
HSV2-UL19-383 - GGACACCGAGGCCGACGUGC 20 623
HSV2-UL19-551 - CAAAAUCUACUAUUACGUGC 20 791
HSV2-UL19-1275 + GGAUGGUGUGGUCCAGGUGC 20 1515
HSV2-UL19-574 - CAUGCUCACGCUGCAGGUGC 20 814
HSV2-UL19-378 - GCGGCCGGUCGACGGGGUGC 20 618
HSV2-UL19-552 - CUACUAUUACGUGCUGGUGC 20 792
HSV2-UL19-1161 + CGCGCGUCCCCGCGGGUUGC 20 1401
HSV2-UL19-589 - CCCGUCCACGCGCUGUUUGC 20 829 HSV2-UL19-566 - CCCGCUGCAUCCCGCCAAUC 20 806
HSV2-UL19-1340 + CGUGCCCCCCCGCGUCAAUC 20 1580
HSV2-UL19-1544 + CCAACAGCACGUGCAGCAUC 20 1784
HSV2-UL19-1353 + GCAGCGCCGGGUCGCGCAUC 20 1593
HSV2-UL19-1419 + UGAACUGCUCCGCGGUCAUC 20 1659
HSV2-UL19-406 - AACGCGCGUGCGCGCGGAUC 20 646
HSV2-UL19-1119 + GGUCGCUGGCGCAGGUGAUC 20 1359
HSV2-UL19-510 - GGAGUGCAUGGCCGUGUAUC 20 750
HSV2-UL19-504 - CGUACAUCGUGACCUACCUC 20 744
HSV2-UL19-1369 + UACACGGCCAUGCACUCCUC 20 1609
HSV2-UL19-1355 + UGAGCCUGCCCGCCCAGCUC 20 1595
HSV2-UL19-1307 + GGUCGGUCACGGGAUCGCUC 20 1547
HSV2-UL19-1154 + AGGGCCGCGCCGGGUCGCUC 20 1394
HSV2-UL19-525 - GGAGCUGGGCGGGCAGGCUC 20 765
HSV2-UL19-1454 + GGAGGGAACGCGCGGGGCUC 20 1694
HSV2-UL19-464 - CGACAACGCCAACCUGGCUC 20 704
HSV2-UL19-1312 + UCCUCACCGGGGGCGAUCUC 20 1552
HSV2-UL19-1473 + CCAGGGGCAGGACGAACGUC 20 1713
HSV2-UL19-442 - UGAACAUCGACGCGGCCGUC 20 682
HSV2-UL19-1285 + GCGGUGUUGGCGCCCGCGUC 20 1525
HSV2-UL19-1515 + CGCGCGUGUCGGCGUGCGUC 20 1755
HSV2-UL19-472 - CGAAGUCCCCCCGGCCGGUC 20 712
HSV2-UL19-439 - UGUCCAUGGAGAACGCGGUC 20 679
HSV2-UL19-459 - GCCUCGCCCACGGCCGGGUC 20 699
HSV2-UL19-1523 + ACGGCUGCGUCGCCGUGGUC 20 1763
HSV2-UL19-481 - CCUGCCCCUGGCGCUGUGUC 20 721
HSV2-UL19-1488 + CCGCGCGCACGCGCGUUGUC 20 1728
HSV2-UL19-1417 + AGAGCCAGGUUGGCGUUGUC 20 1657
HSV2-UL19-1505 + CCUCGGUGUCCUCCACCUUC 20 1745
HSV2-UL19-615 - CGGGCCUCCACCCCGGGUUC 20 855
HSV2-UL19-620 - CGCGUCGGAGGCGUACUUUC 20 860
HSV2-UL19-716 - AGACCCGUGCGGCCUGUUUC 20 956
HSV2-UL19-1105 + AGAUGAGAUACUGCGUAAAG 20 1345
HSV2-UL19-1220 + G CACG U U CU CGG U CACGAAG 20 1460
HSV2-UL19-1316 + UGGCGUACACGCGGUCGAAG 20 1556
HSV2-UL19-359 - CCCUGGUCGCCGAGCUGAAG 20 599
HSV2-UL19-1477 + AGGUCCAUGGCGCCCACCAG 20 1717
HSV2-UL19-1252 + CCCAGGGCCGGGGGGACCAG 20 1492
HSV2-UL19-1471 + GCCGGGUUGAACAGCCCCAG 20 1711
HSV2-UL19-1396 + GCCACCGGACACAGCGCCAG 20 1636
HSV2-UL19-1542 + AU G G G CAACAG CAG G G CCAG 20 1782
HSV2-UL19-1138 + CGGUGAAGAACUUGAAGCAG 20 1378
HSV2-UL19-1188 + GCGGCCGCGUUGUCUAGCAG 20 1428
HSV2-UL19-692 - CCAACCCGUGGGCGUCGCAG 20 932
HSV2-UL19-1129 + AAACUGCACGUCGCUGGCAG 20 1369
HSV2-UL19-1296 + ACCAGAUUGGCGGGAUGCAG 20 1536 HSV2-UL19-1349 + CCGUCGCAGUCCCACACGAG 20 1589
HSV2-UL19-683 - UGUACGCGGGGGACAAGGAG 20 923
HSV2-UL19-1180 + GCGCAGCCAAAGACCGGGAG 20 1420
HSV2-UL19-1101 + UACAGAGACAGGCCCUUUAG 20 1341
HSV2-UL19-633 - CACCCAGCCGCGCGGAAACG 20 873
HSV2-UL19-648 - CCCCCCGCUGCUAGACAACG 20 888
HSV2-UL19-698 - CGGGGACCUGCUGUACAACG 20 938
HSV2-UL19-649 - CGCCGUGUACCUGCGCAACG 20 889
HSV2-UL19-541 - CUACGCGGCGGCGUGCAACG 20 781
HSV2-UL19-701 - CGGGGCCUAUCACCUCAACG 20 941
HSV2-UL19-437 - GCGGCUGUCCAUGGAGAACG 20 677
HSV2-UL19-1411 + GCCCGCGAAGAAGUCGAACG 20 1651
HSV2-UL19-388 - CGGCGAGAUGGUCUUGAACG 20 628
HSV2-UL19-1203 + GGUUGCCCAUGUCCGUAACG 20 1443
HSV2-UL19-1347 + GGCCGUCGCAGUCCCACACG 20 1587
HSV2-UL19-530 - CGACGGCCUUAUGCGACACG 20 770
HSV2-UL19-1315 + UCUGCAGCGUGGCGUACACG 20 1555
HSV2-UL19-590 - GUU UGCGGGCGCCGACCACG 20 830
HSV2-UL19-1232 + GCUGGUGAUACAGGGCCACG 20 1472
HSV2-UL19-1167 + AGUUGAUGUCCGUGGCCACG 20 1407
HSV2-UL19-1265 + AGU UGGGCGCGUUGGCCACG 20 1505
HSV2-UL19-396 - CGUGCGGAGCCUGGACGACG 20 636
HSV2-UL19-578 - GUGCUCCGCGGCGCCCGACG 20 818
HSV2-UL19-440 - UUCGCUCAUGAACAUCGACG 20 680
HSV2-UL19-1438 + ACGGAUUCGCGGCCUCGACG 20 1678
HSV2-UL19-1364 + GCUGGGCCAGGGCCUCGACG 20 1604
HSV2-UL19-1282 + GCGCAUGUUGGCCGUCGACG 20 1522
HSV2-UL19-377 - GCGCGGGCGGCCGGUCGACG 20 617
HSV2-UL19-583 - CAACAUGCGCAUCUUCGACG 20 823
HSV2-UL19-1499 + CCAU CACCAG CGCCG UGACG 20 1739
HSV2-UL19-533 - CCGAGACUGCCGGAUUGACG 20 773
HSV2-UL19-539 - GGGGCACGAGCCCGUCUACG 20 779
HSV2-UL19-448 - CGAGGCCGCGAAUCCGUACG 20 688
HSV2-UL19-695 - GUCGCAGCGGUUCUCGUACG 20 935
HSV2-UL19-676 - CGCGGCCGGCGGCGUGUACG 20 916
HSV2-UL19-382 - CCUGAAGGUGGAGGACACCG 20 622
HSV2-UL19-557 - GCGGGGGCGCUGCUGCACCG 20 797
HSV2-UL19-1310 + CGCUCGGGCACUCCUCACCG 20 1550
HSV2-UL19-702 - CUGCUUCAAGUUCUUCACCG 20 942
HSV2-UL19-462 - CGCCGAGUGCCAGAUGACCG 20 702
HSV2-UL19-690 - UCGCGGCCACGGCCAACCCG 20 930
HSV2-UL19-670 - UUCGCCGGCCCUGCAACCCG 20 910
HSV2-UL19-1224 + CGACGGUGAACCCGAACCCG 20 1464
HSV2-UL19-667 - UGAGUUCAUCGCCACCCCCG 20 907
HSV2-UL19-1317 + GCGGUCGAAGCGGACCCCCG 20 1557
HSV2-UL19-1372 + CCUCGGGGAGGUCGCCCCCG 20 1612 HSV2-UL19-609 - GUACUUCAAGAUGAGCCCCG 20 849
HSV2-UL19-1382 + UGCGGUCCUCGAACGCCCCG 20 1622
HSV2-UL19-1194 + CUAGCAGCGGGGGGGCCCCG 20 1434
HSV2-UL19-507 - CCUCGGGGGCGACCUCCCCG 20 747
HSV2-UL19-1159 + CCGCCGGCCGCGCGUCCCCG 20 1399
HSV2-UL19-599 - CU CCU CCAU CCG CCAGCCCG 20 839
HSV2-UL19-485 - GUGGCGUUUCGUGACGCCCG 20 725
HSV2-UL19-1171 + CACACACGGCAUCCUGCCCG 20 1411
HSV2-UL19-1206 + GGGGU UGCGGACGGUGCCCG 20 1446
HSV2-UL19-425 - GCGCUUCGCCGCGCACGCCG 20 665
HSV2-UL19-713 - UGCAGUUUAAGCGCCCGCCG 20 953
HSV2-UL19-1429 + GCUGCUGCAUGUCCGCGCCG 20 1669
HSV2-UL19-1173 + UGGUCCAUGCCGGCGCGCCG 20 1413
HSV2-UL19-1286 + GGCGCCCGCGUCGGGCGCCG 20 1526
HSV2-UL19-1522 + CACGGACGGCUGCGUCGCCG 20 1762
HSV2-UL19-1405 + GAUCGCCCCCGGACCGGCCG 20 1645
HSV2-UL19-1423 + CGACCCACCGGACCCGGCCG 20 1663
HSV2-UL19-1433 + GUCCGCGCCGGGGCCGGCCG 20 1673
HSV2-UL19-1195 + GCGGGGGGGCCCCGCGGCCG 20 1435
HSV2-UL19-645 - CAAAACUUUUACCUCGGCCG 20 885
HSV2-UL19-1135 + UU UGGCCGUGAUGUCGGCCG 20 1375
HSV2-UL19-1247 + GUAGUUGGCCCCCAGGGCCG 20 1487
HSV2-UL19-1259 + CGCCAGGUCGCGCAGGGCCG 20 1499
HSV2-UL19-1155 + GCGCCGGGUCGCUCUGGCCG 20 1395
HSV2-UL19-1131 + GUCGCUGGCAGCGGUGGCCG 20 1371
HSV2-UL19-1459 + CGCGGGGCUCCGGGUGGCCG 20 1699
HSV2-UL19-1149 + CGACGCCCACGGGUUGGCCG 20 1389
HSV2-UL19-1448 + CCCCAAAAAAACAG C U G CCG 20 1688
HSV2-UL19-661 - UUGGCUGCGCCCAGGUGCCG 20 901
HSV2-UL19-1418 + GGGCUGCAUGAACUGCUCCG 20 1658
HSV2-UL19-577 - GACGGCGCUGCUGUGCUCCG 20 817
HSV2-UL19-370 - CACGGCGACGCAGCCGUCCG 20 610
HSV2-UL19-491 - GCUACCAUAGCCGCCGUCCG 20 731
HSV2-UL19-474 - AAGUCCCCCCGGCCGGUCCG 20 714
HSV2-UL19-1164 + GCGAAAGUAGUUGAUGUCCG 20 1404
HSV2-UL19-1190 + GGCCGCGUUGUCUAGCAGCG 20 1430
HSV2-UL19-1314 + GACCACCAUGUUCUGCAGCG 20 1554
HSV2-UL19-600 - GCAGCACGCCCGCGAGAGCG 20 840
HSV2-UL19-346 - GUCCUGGGGGCGUUUGAGCG 20 586
HSV2-UL19-1103 + CAGAGACAGGCCCUUUAGCG 20 1343
HSV2-UL19-1413 + CCGCGAAGAAGUCGAACGCG 20 1653
HSV2-UL19-1451 + GCUGCCGGGGAGGGAACGCG 20 1691
HSV2-UL19-371 - CUGACGCACGCCGACACGCG 20 611
HSV2-UL19-673 - CUGCAACCCGCGGGGACGCG 20 913
HSV2-UL19-535 - GAGACUGCCGGAUUGACGCG 20 775
HSV2-UL19-678 - CGGCCGGCGGCGUGUACGCG 20 918 HSV2-UL19-559 - GGGGGCGCUGCUGCACCGCG 20 799
HSV2-UL19-672 - CGCCGGCCCUGCAACCCGCG 20 912
HSV2-UL19-546 - GCACAACACCCAGGCCCGCG 20 786
HSV2-UL19-632 - UUCACGCUCACCCAGCCGCG 20 872
HSV2-UL19-365 - CAAGGCGGGCCAUCGCCGCG 20 605
HSV2-UL19-647 - AAACUUUUACCUCGGCCGCG 20 887
HSV2-UL19-1331 + CGUCGGCGGCGUCGGCCGCG 20 1571
HSV2-UL19-493 - UACCAUAGCCGCCGUCCGCG 20 733
HSV2-UL19-1210 + CCCAGGUCCACGUUUCCGCG 20 1450
HSV2-UL19-1267 + CGGCGCCCGCAAACAGCGCG 20 1507
HSV2-UL19-1453 + UGCCGGGGAGGGAACGCGCG 20 1693
HSV2-UL19-1107 + UAAAGUGGGUCUCUCGCGCG 20 1347
HSV2-UL19-478 - GAUCCAGGCCACCUGGCGCG 20 718
HSV2-UL19-405 - CCAGACAACGCGCGUGCGCG 20 645
HSV2-UL19-555 - CUGGUGCCGGCCUUCUCGCG 20 795
HSV2-UL19-1518 + GUGUCGGCGUGCGUCAGGCG 20 1758
HSV2-UL19-687 - ACGGCCAGAGCGACCCGGCG 20 927
HSV2-UL19-453 - GGCCCCGGCCGGCCCCGGCG 20 693
HSV2-UL19-603 - ACGCCCGCGAGAGCGCGGCG 20 843
HSV2-UL19-1115 + GGGCGCUGCGUAGCAGGGCG 20 1355
HSV2-UL19-628 - GGCCCGCCACGAAACGGGCG 20 868
HSV2-UL19-1142 + GCAGGGGCUGAGGACGGGCG 20 1382
HSV2-UL19-467 - GUUCGACUUCUUCGCGGGCG 20 707
HSV2-UL19-1425 + ACCGGACCCGGCCGUGGGCG 20 1665
HSV2-UL19-1302 + CGGGAUGCAGCGGGUGGGCG 20 1542
HSV2-UL19-1388 + UGGUAGCCGGCGCCAUGGCG 20 1628
HSV2-UL19-608 - UGACCUACGCGCUCAUGGCG 20 848
HSV2-UL19-499 - ACGUGU UCUGCGCCCUGGCG 20 739
HSV2-UL19-501 - CUGGAACAACACGCGAUGCG 20 741
HSV2-UL19-1465 + CACCAGGUCCCCGGCGUGCG 20 1705
HSV2-UL19-1377 + GUGCUCGUUGCCGUGAAUCG 20 1617
HSV2-UL19-1109 + GCGCGUGGGCCUCCCCAUCG 20 1349
HSV2-UL19-366 - CCAUCGCCGCGAGGCCAUCG 20 606
HSV2-UL19-705 - CUGCCUGGAGCGUCUCAUCG 20 945
HSV2-UL19-401 - UAUGCAGGAGGAGCAACUCG 20 641
HSV2-UL19-505 - GUACAUCGUGACCUACCUCG 20 745
HSV2-UL19-1526 + GCCAGGCCUCGAUGGCCUCG 20 1766
HSV2-UL19-1370 + ACACGGCCAUGCACUCCUCG 20 1610
HSV2-UL19-1124 + ACGGGUCUUCCACGAGCUCG 20 1364
HSV2-UL19-714 - GCCGGGGUGCCGCGAGCUCG 20 954
HSV2-UL19-368 - GGCCAUCGAGGCCUGGCUCG 20 608
HSV2-UL19-1234 + UCUCCCCCGCCGCGCUCUCG 20 1474
HSV2-UL19-553 - UGCUGGUGCCGGCCUUCUCG 20 793
HSV2-UL19-513 - GGACCUGGUGGCCCACGUCG 20 753
HSV2-UL19-449 - UCCGUACGGGGCGUACGUCG 20 689
HSV2-UL19-445 - CGUGAACCACGACCCCGUCG 20 685 HSV2-UL19-638 - UGUGGGCUACACCGCCGUCG 20 878
HSV2-UL19-443 - GAACAUCGACGCGGCCGUCG 20 683
HSV2-UL19-650 - GUACCUGCGCAACGCGGUCG 20 890
HSV2-UL19-1439 + UCGCGGCCUCGACGGGGUCG 20 1679
HSV2-UL19-1435 + GUACGCCCCGUACGGAUUCG 20 1675
HSV2-UL19-688 - CGACCCGGCGCGGCCCUUCG 20 928
HSV2-UL19-465 - CCCCGCGUUCGACUUCUUCG 20 705
HSV2-UL19-494 - CGCCGUCCGCGGGGCGUUCG 20 734
HSV2-UL19-1213 + UGACCCCCCCGCCCGUUUCG 20 1453
HSV2-UL19-681 - CGUGUACGCGGGGGACAAGG 20 921
HSV2-UL19-363 - GAGCUUCUUCCUGGGCAAGG 20 603
HSV2-UL19-380 - CCUGCAGUCCUUCCUGAAGG 20 620
HSV2-UL19-1478 + GGUCCAUGGCGCCCACCAGG 20 1718
HSV2-UL19-1253 + CCAGGGCCGGGGGGACCAGG 20 1493
HSV2-UL19-1399 + GCCGUUGACCACGCGCCAGG 20 1639
HSV2-UL19-623 - CUUUCUGGGCCAGCUCCAGG 20 863
HSV2-UL19-1495 + CCUCCUGCAUAUCCAGCAGG 20 1735
HSV2-UL19-400 - CCACCUGCUGGAUAUGCAGG 20 640
HSV2-UL19-1508 + CCUUCAGGAAGGACUGCAGG 20 1748
HSV2-UL19-1516 + GCGUGUCGGCGUGCGUCAGG 20 1756
HSV2-UL19-684 - GUACGCGGGGGACAAGGAGG 20 924
HSV2-UL19-1187 + CGCGUUGCGCAGGUACACGG 20 1427
HSV2-UL19-1168 + GUUGAUGUCCGUGGCCACGG 20 1408
HSV2-UL19-1208 + GGUGCCCGUGGCCGCGACGG 20 1448
HSV2-UL19-1384 + CUCGAACGCCCCGCGGACGG 20 1624
HSV2-UL19-1311 + GCUCGGGCACUCCUCACCGG 20 1551
HSV2-UL19-496 - CGAGGACCGCAGCUACCCGG 20 736
HSV2-UL19-1126 + ACGAGCUCGCGGCACCCCGG 20 1366
HSV2-UL19-469 - GCCGACGUCGAGCUUCCCGG 20 709
HSV2-UL19-1406 + AUCGCCCCCGGACCGGCCGG 20 1646
HSV2-UL19-675 - CCGCGGGGACGCGCGGCCGG 20 915
HSV2-UL19-1248 + UAGUUGGCCCCCAGGGCCGG 20 1488
HSV2-UL19-1260 + GCCAGGUCGCGCAGGGCCGG 20 1500
HSV2-UL19-1460 + GCGGGGCUCCGGGUGGCCGG 20 1700
HSV2-UL19-475 - AGUCCCCCCGGCCGGUCCGG 20 715
HSV2-UL19-460 - UCGCCCACGGCCGGGUCCGG 20 700
HSV2-UL19-482 - GCCCCUGGCGCUGUGUCCGG 20 722
HSV2-UL19-1191 + GCCGCGUUGUCUAGCAGCGG 20 1431
HSV2-UL19-1130 + CUGCACGUCGCUGGCAGCGG 20 1370
HSV2-UL19-536 - AGACUGCCGGAUUGACGCGG 20 776
HSV2-UL19-540 - GCACGAGCCCGUCUACGCGG 20 780
HSV2-UL19-679 - GGCCGGCGGCGUGUACGCGG 20 919
HSV2-UL19-560 - GGGGCGCUGCUGCACCGCGG 20 800
HSV2-UL19-601 - GCACGCCCGCGAGAGCGCGG 20 841
HSV2-UL19-556 - UGGUGCCGGCCUUCUCGCGG 20 796
HSV2-UL19-604 - CGCCCGCGAGAGCGCGGCGG 20 844 HSV2-UL19-1512 + GCGCUGUUUGAUGGCGGCGG 20 1752
HSV2-UL19-629 - GCCCGCCACGAAACGGGCGG 20 869
HSV2-UL19-1511 + GAGGCGCUGUUUGAUGGCGG 20 1751
HSV2-UL19-709 - CAUCGUGGAAACGGGAUCGG 20 949
HSV2-UL19-506 - UACAUCGUGACCUACCUCGG 20 746
HSV2-UL19-1342 + CGUCAAUCCGGCAGUCUCGG 20 1582
HSV2-UL19-444 - AACAUCGACGCGGCCGUCGG 20 684
HSV2-UL19-619 - GUUUUCCGAGCGCGCGUCGG 20 859
HSV2-UL19-1329 + CCGGUGCGGCCGGUCGUCGG 20 1569
HSV2-UL19-1113 + GCGGGCGCUGCGUAGCAGGG 20 1353
HSV2-UL19-626 - GUGGCCCGCCACGAAACGGG 20 866
HSV2-UL19-1178 + GGGCGCAGCCAAAGACCGGG 20 1418
HSV2-UL19-1407 + UCGCCCCCGGACCGGCCGGG 20 1647
HSV2-UL19-1249 + AGUUGGCCCCCAGGGCCGGG 20 1489
HSV2-UL19-1261 + CCAGGUCGCGCAGGGCCGGG 20 1501
HSV2-UL19-1456 + GGAACGCGCGGGGCUCCGGG 20 1696
HSV2-UL19-1192 + CCGCGUUGUCUAGCAGCGGG 20 1432
HSV2-UL19-1298 + GAU UGGCGGGAUGCAGCGGG 20 1538
HSV2-UL19-537 - GACUGCCGGAUUGACGCGGG 20 777
HSV2-UL19-373 - CGCACGCCGACACGCGCGGG 20 613
HSV2-UL19-630 - CCCGCCACGAAACGGGCGGG 20 870
HSV2-UL19-1543 + G G CAACAG CAG G G CCAG GG G 20 1783
HSV2-UL19-1350 + UCGCAGUCCCACACGAGGGG 20 1590
HSV2-UL19-1225 + CGGUGAACCCGAACCCGGGG 20 1465
HSV2-UL19-1449 + CAAAAAAACAG CU G CCG G G G 20 1689
HSV2-UL19-1193 + CGCGUUGUCUAGCAGCGGGG 20 1433
HSV2-UL19-1104 + AGACAGGCCCU UUAGCGGGG 20 1344
HSV2-UL19-538 - ACUGCCGGAU UGACGCGGGG 20 778
HSV2-UL19-631 - CCGCCACGAAACGGGCGGGG 20 871
HSV2-UL19-1371 + CGGCCAUGCACUCCUCGGGG 20 1611
HSV2-UL19-1169 + GAUGUCCGUGGCCACGGGGG 20 1409
HSV2-UL19-1461 + GGGCUCCGGGUGGCCGGGGG 20 1701
HSV2-UL19-1200 + CGAGGUAAAAGUUUUGGGGG 20 1440
HSV2-UL19-720 - ACGCAGCGCCCGCGAUGGGG 20 960
HSV2-UL19-522 - CUGCCGGGCCCGGAGCUGGG 20 762
HSV2-UL19-1279 + GGUGUGGUCCAGGUGCUGGG 20 1519
HSV2-UL19-1492 + GCGCACGCGCGUUGUCUGGG 20 1732
HSV2-UL19-1300 + GGCGGGAUGCAGCGGGUGGG 20 1540
HSV2-UL19-562 - CGCCACGCUGCAGAACAUGG 20 802
HSV2-UL19-1289 + CACCUGCAGCGUGAGCAUGG 20 1529
HSV2-UL19-606 - GCUGACCUACGCGCUCAUGG 20 846
HSV2-UL19-1241 + CACCACGGGCUGGCGGAUGG 20 1481
HSV2-UL19-1510 + CAGGAGGCGCUGUUUGAUGG 20 1750
HSV2-UL19-1445 + UGGACAGCCGCAGAACCUGG 20 1685
HSV2-UL19-512 - GGCCGUGUAUCGGGACCUGG 20 752
HSV2-UL19-415 - CAACGUGCCCUACCCCCUGG 20 655 HSV2-UL19-598 - CCUGGUCCCCCCGGCCCUGG 20 838
HSV2-UL19-455 - AGCGUUUUCUGAACGCCUGG 20 695
HSV2-UL19-345 - CAACGUCCAGGCCGUCCUGG 20 585
HSV2-UL19-412 - CGACAGGCUGGUCUUCCUGG 20 652
HSV2-UL19-516 - CGAGGCCCUGGCCCAGCUGG 20 756
HSV2-UL19-1239 + CGUGCUGCACCACGGGCUGG 20 1479
HSV2-UL19-1278 + UGGUGUGGUCCAGGUGCUGG 20 1518
HSV2-UL19-567 - GCUGCAUCCCGCCAAUCUGG 20 807
HSV2-UL19-407 - GCGCGUGCGCGCGGAUCUGG 20 647
HSV2-UL19-1491 + CGCGCACGCGCGUUGUCUGG 20 1731
HSV2-UL19-1389 + UAGCCGGCGCCAUGGCGUGG 20 1629
HSV2-UL19-651 - CCUGCGCAACGCGGUCGUGG 20 891
HSV2-UL19-1214 + CCCCCCCGCCCGUUUCGUGG 20 1454
HSV2-UL19-381 - GCAGUCCUUCCUGAAGGUGG 20 621
HSV2-UL19-1496 + CCUGCAUAUCCAGCAGGUGG 20 1736
HSV2-UL19-1343 + CAAUCCGGCAGUCUCGGUGG 20 1583
HSV2-UL19-1226 + UGAACCCGAACCCGGGGUGG 20 1466
HSV2-UL19-1483 + GGGGUAGGGCACGUUGGUGG 20 1723
HSV2-UL19-1321 + CGUAAUAGUAGAUUUUGUGG 20 1561
HSV2-UL19-1294 + CGUGU UGGCCACCAGAUUGG 20 1534
HSV2-UL19-1482 + CAGGGGGUAGGGCACGUUGG 20 1722
HSV2-UL19-1199 + GGCCGAGGUAAAAGUUUUGG 20 1439
HSV2-UL19-1156 + UCUGGCCGUGGUCGUACAUG 20 1396
HSV2-UL19-719 - GCUACGCAGCGCCCGCGAUG 20 959
HSV2-UL19-420 - UGACGUUCGUCCUGCCCCUG 20 660
HSV2-UL19-597 - CCCUGGUCCCCCCGGCCCUG 20 837
HSV2-UL19-3077 - GCAACGUCCAGGCCGUCCUG 20 7460
HSV2-UL19-1381 + AAAACACCGCCGGGUAGCUG 20 1621
HSV2-UL19-656 - UCGUGGCGGGAAACCGGCUG 20 896
HSV2-UL19-1139 + AGAACUUGAAGCAGGGGCUG 20 1379
HSV2-UL19-1277 + AUGGUGUGGUCCAGGUGCUG 20 1517
HSV2-UL19-1490 + GCGCGCACGCGCGUUGUCUG 20 1730
HSV2-UL19-435 - GAAAGGACCACCAGGUUCUG 20 675
HSV2-UL19-715 - GAGCUCGUGGAAGACCCGUG 20 955
HSV2-UL19-394 - UGGUGAUGGGCAAGGCCGUG 20 634
HSV2-UL19-527 - CGCUGCUGCCGCCCCUCGUG 20 767
HSV2-UL19-616 - GGUUCGGGUUCACCGUCGUG 20 856
HSV2-UL19-565 - CCCGGAGAUCGCCCCCGGUG 20 805
HSV2-UL19-1326 + GUCCAGUCGGCCGGCCGGUG 20 1566
HSV2-UL19-636 - CGGAAACGUGGACCUGGGUG 20 876
HSV2-UL19-1273 + AUUCGCCAUUUUGGAUGGUG 20 1513
HSV2-UL19-1143 + GGACGGGCGAGGCCCCGUUG 20 1383
HSV2-UL19-1291 + CGACGACGACGCGCCCGUUG 20 1531
HSV2-UL19-1336 + GCAGCAGCCGGCCGUCGUUG 20 1576
HSV2-UL19-1204 + CCAUGUCCGUAACGGGGUUG 20 1444
HSV2-UL19-588 - GCCCGUCCACGCGCUGUUUG 20 828 HSV2-UL19-1320 + GCACGUAAUAGUAGAUUUUG 20 1560
HSV2-UL19-1198 + CGGCCGAGGUAAAAGUUUUG 20 1438
HSV2-UL19-432 - CCCCGGCAGCUGUUU UUUUG 20 672
HSV2-UL19-3104 - AGGGCCUGUCUCUGUAAAAU 20 7487
HSV2-UL19-643 - CGCAACCCCGUUACGGACAU 20 883
HSV2-UL19-408 - CGCGCGGAUCUGGUGGCCAU 20 648
HSV2-UL19-1537 + UUGUCGAGAUAUCGUUGCAU 20 1777
HSV2-UL19-1293 + GACCGUGUUGGCCACCAGAU 20 1533
HSV2-UL19-718 - UGCUACGCAGCGCCCGCGAU 20 958
HSV2-UL19-708 - UCUCAUCGUGGAAACGGGAU 20 948
HSV2-UL19-1118 + GGGUCGCUGGCGCAGGUGAU 20 1358
HSV2-UL19-1144 + CGAGGCCCCGUUGAGGUGAU 20 1384
HSV2-UL19-392 - CUCGUCACGGCGCUGGUGAU 20 632
HSV2-UL19-509 - AGGAGUGCAUGGCCGUGUAU 20 749
HSV2-UL19-1420 + CUCCGCGGUCAUCUGGCACU 20 1660
HSV2-UL19-1175 + GCCGGCGCGCCGCGGCACCU 20 1415
HSV2-UL19-635 - CCGCGCGGAAACGUGGACCU 20 875
HSV2-UL19-503 - UCGUACAUCGUGACCUACCU 20 743
HSV2-UL19-644 - CU CCCCCAAAACU U U U ACCU 20 884
HSV2-UL19-419 - CUGACGUUCGUCCUGCCCCU 20 659
HSV2-UL19-596 - CCCCUGGUCCCCCCGGCCCU 20 836
HSV2-UL19-1504 + GGUCACCGGCACGUCGGCCU 20 1744
HSV2-UL19-1334 + GGCGUCGGCCGCGCGGGCCU 20 1574
HSV2-UL19-1368 + AUACACGGCCAUGCACUCCU 20 1608
HSV2-UL19-3085 - CGCAACGUCCAGGCCGUCCU 20 7468
HSV2-UL19-361 - UGCGACACGAGCUUCUUCCU 20 601
HSV2-UL19-1361 + GGUAAAGUCGUCCACCAGCU 20 1601
HSV2-UL19-1354 + GCGCAUCAGGUGAUUCAGCU 20 1594
HSV2-UL19-1529 + GCAAAAGCUCCGCUUCAGCU 20 1769
HSV2-UL19-521 - ACCCUGCCGGGCCCGGAGCU 20 761
HSV2-UL19-487 - GACGCCCGGGGCCUGGAGCU 20 727
HSV2-UL19-1218 + GUACGCCUCCGACGCGCGCU 20 1458
HSV2-UL19-1287 + CAGCAGCGCCGUCGUGCGCU 20 1527
HSV2-UL19-1306 + GGGUCGGUCACGGGAUCGCU 20 1546
HSV2-UL19-655 - GUCGUGGCGGGAAACCGGCU 20 895
HSV2-UL19-1212 + GUCCACGUUUCCGCGCGGCU 20 1452
HSV2-UL19-1182 + GCCAAAGACCGGGAGGGGCU 20 1422
HSV2-UL19-1276 + GAUGGUGUGGUCCAGGUGCU 20 1516
HSV2-UL19-1341 + CCGCGUCAAUCCGGCAGUCU 20 1581
HSV2-UL19-1489 + CGCGCGCACGCGCGUUGUCU 20 1729
HSV2-UL19-1219 + CUCGGAAAACAGCACGUUCU 20 1459
HSV2-UL19-621 - GCGUCGGAGGCGUACUUUCU 20 861
HSV2-UL19-1106 + GAUGAGAUACUGCGUAAAGU 20 1346
HSV2-UL19-1337 + GCCGUCGUUGCGGUUAAAGU 20 1577
HSV2-UL19-1262 + GCGCAGGGCCGGGGGGAAGU 20 1502
HSV2-UL19-1323 + UUUGUGGUGGACGGUCCAGU 20 1563 HSV2-UL19-1242 + GCGGAUGGAGGAGAAGUAGU 20 1482
HSV2-UL19-1503 + GCCGUAGGUCACCGGCACGU 20 1743
HSV2-UL19-1481 + CACCAGGGGGUAGGGCACGU 20 1721
HSV2-UL19-397 - GUGCGGAGCCUGGACGACGU 20 637
HSV2-UL19-1365 + CUGGGCCAGGGCCUCGACGU 20 1605
HSV2-UL19-1410 + GCCGCCGGGAAGCUCGACGU 20 1650
HSV2-UL19-691 - CGCGGCCACGGCCAACCCGU 20 931
HSV2-UL19-1501 + GUUCAAGACCAUCUCGCCGU 20 1741
HSV2-UL19-1424 + GACCCACCGGACCCGGCCGU 20 1664
HSV2-UL19-441 - AUGAACAUCGACGCGGCCGU 20 681
HSV2-UL19-1284 + CGCGGUGUUGGCGCCCGCGU 20 1524
HSV2-UL19-1233 + GUACCCCGCCAUGAGCGCGU 20 1473
HSV2-UL19-618 - GCUGUUUUCCGAGCGCGCGU 20 858
HSV2-UL19-1108 + AAAGUGGGUCUCUCGCGCGU 20 1348
HSV2-UL19-1264 + CGGGGGGAAGUUGGGCGCGU 20 1504
HSV2-UL19-1330 + CGGCCGGUCGUCGGCGGCGU 20 1570
HSV2-UL19-488 - CGGGGCCUGGAGCUCGGCGU 20 728
HSV2-UL19-1328 + CGGCCGGUGCGGCCGGUCGU 20 1568
HSV2-UL19-1415 + GUGCAGCUCCAGAGCCAGGU 20 1655
HSV2-UL19-1500 + CACCAGCGCCGUGACGAGGU 20 1740
HSV2-UL19-1373 + GGGGAGGUCGCCCCCGAGGU 20 1613
HSV2-UL19-461 - CGCCCACGGCCGGGUCCGGU 20 701
HSV2-UL19-438 - CUGUCCAUGGAGAACGCGGU 20 678
HSV2-UL19-1148 + CCGCUGCGACGCCCACGGGU 20 1388
HSV2-UL19-1299 + AUUGGCGGGAUGCAGCGGGU 20 1539
HSV2-UL19-1120 + GCUGGCGCAGGUGAUCGGGU 20 1360
HSV2-UL19-1303 + AUGCAGCGGGUGGGCGGGGU 20 1543
HSV2-UL19-1479 + CAUGGCGCCCACCAGGGGGU 20 1719
HSV2-UL19-416 - AACGUGCCCUACCCCCUGGU 20 656
HSV2-UL19-1545 + CAGCACGUGCAGCAUCUGGU 20 1785
HSV2-UL19-1266 + GGGCGCGUUGGCCACGUGGU 20 1506
HSV2-UL19-1281 + CCCGUCGAAGAUGCGCAUGU 20 1521
HSV2-UL19-1134 + GCGAUGUUUGGCCGUGAUGU 20 1374
HSV2-UL19-348 - CCAGAUGCUGCACGUGCUGU 20 588
HSV2-UL19-1292 + GAACAUGCGCUUGACCGUGU 20 1532
HSV2-UL19-1514 + GACCGGCCGCCCGCGCGUGU 20 1754
HSV2-UL19-528 - GCUGCUGCCGCCCCUCGUGU 20 768
HSV2-UL19-1283 + GUUGGCCGUCGACGCGGUGU 20 1523
HSV2-UL19-637 - GGAAACGUGGACCUGGGUGU 20 877
HSV2-UL19-1416 + CAGAGCCAGGUUGGCGUUGU 20 1656
HSV2-UL19-659 - GCCCAGCCCCUCCCGGUCUU 20 899
HSV2-UL19-1263 + CGCAGGGCCGGGGGGAAGUU 20 1503
HSV2-UL19-614 - ACGGGCCUCCACCCCGGGUU 20 854
HSV2-UL19-1133 + ACGCUCCAGGCAGCGAUGUU 20 1373
HSV2-UL19-1271 + CGUAGAAGUAUUCGCCAUUU 20 1511
HSV2-UL19-1196 + CGCGGCCGAGGUAAAAGUUU 20 1436 HSV2-UL19-1197 + GCGGCCGAGGUAAAAGUUUU 20 1437
HSV2-UL19-430 - CUCCCCGGCAGCUGUUUUUU 20 670
HSV2-UL19-431 - UCCCCGGCAGCUGUUUUUUU 20 671
Table 6 A provides exemplary targeting domains for knocking out the UL19 gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), have a high level of orthogonality, and start with a 5'G. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 6A
Figure imgf000338_0001
HSV2-UL19-3129 - GCCGCUCCUGCCCGCGACCCC 21 7512
HSV2-UL19-3130 - GGCCGCUCCUGCCCGCGACCCC 22 7513
HSV2-UL19-3131 - GUAGAGU UUGACGCCCUGC 19 7514
HSV2-UL19-3132 - GACGUAGAGUU UGACGCCCUGC 22 7515
HSV2-U L19-3133 - GCCAUCCUGCCCACCGGCUCCAUC 24 7516
HSV2-U L19-3134 - GAAAACAGCCUGUAUGACG 19 7517
HSV2-UL19-3135 - GACGAAAACAGCCUGUAUGACG 22 7518
Table 6B provides exemplary targeting domains for knocking out the UL19 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), and have a high level of orthogonality. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 6B
Figure imgf000339_0001
HSV2-UL19-3154 + CGUACUCAGGAUGGAGCCGGUGGG 24 7537
HSV2-UL19-3155 + UGGACGUUGCGCGCGAGCUG 20 7538
HSV2-UL19-3156 + CUGGACGUUGCGCGCGAGCUG 21 7539
HSV2-UL19-3157 + CCUGGACGU UGCGCGCGAGCUG 22 7540
HSV2-UL19-3158 + CGGCCAUUGGGUUCCU UG 18 7541
HSV2-UL19-3083 + AGCGGCCAUUGGGUUCCUUG 20 7466
HSV2-UL19-3159 + AGGAGCGGCCAUUGGGUUCCUUG 23 7542
HSV2-UL19-3160 + CAGGAGCGGCCAUUGGG UUCCUUG 24 7543
HSV2-UL19-3161 + CGCCACCUCGAUCGUACU 18 7544
HSV2-UL19-3162 + ACGCCACCUCGAUCGUACU 19 7545
HSV2-UL19-3163 + UGGGACGCCACCUCGAUCGUACU 23 7546
HSV2-UL19-3164 - CGCUCCUGCCCGCGACCCC 19 7547
HSV2-UL19-199 - CCGCUCCUGCCCGCGACCCC 20 2237
HSV2-UL19-3165 - UGGCCGCUCCUGCCCGCGACCCC 23 7548
HSV2-UL19-3166 - AUGGCCGCUCCUGCCCGCGACCCC 24 7549
HSV2-UL19-3167 - UAGAGUU UGACGCCCUGC 18 7550
HSV2-UL19-8 - CGUAGAGUUUGACGCCCUGC 20 389
HSV2-UL19-3168 - ACGUAGAGU UUGACGCCCUGC 21 7551
HSV2-UL19-3169 - UGACGUAGAGUUUGACGCCCUGC 23 7552
HSV2-UL19-3170 - AUGACGUAGAGUUUGACGCCCUGC 24 7553
HSV2-UL19-3171 - AUCCUGCCCACCGGCUCCAUC 21 7554
HSV2-UL19-3172 - CAUCCUGCCCACCGGCUCCAUC 22 7555
HSV2-UL19-3173 - CCAUCCUGCCCACCGGCUCCAUC 23 7556
HSV2-UL19-3174 - AAAACAGCCUGUAUGACG 18 7557
HSV2-UL19-203 - CGAAAACAGCCUGUAUGACG 20 2241
HSV2-UL19-3175 - ACG AAAACAGCCUGUAUGACG 21 7558
HSV2-UL19-3176 - CGACG AAAACAGCCUGUAUGACG 23 7559
HSV2-UL19-3177 - CCG ACG AAAACAGCCUG U AUG ACG 24 7560
Table 6C provides exemplary targeting domains for knocking out the UL19 gene selected according to the third tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), and have a high level of orthogonality. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 6C
Figure imgf000340_0001
HSV2-U L19-3178 + CGCGGGCAGGAGCGGCCA 18 7561
HSV2-U L19-3179 + UCGCGGGCAGGAGCGGCCA 19 7562
HSV2-U L19-3180 + G UCGCGGGCAGGAGCGGCCA 20 7563
HSV2-U L19-3181 + CAGGAUGGAGCCGG UGGG 18 7564
HSV2-U L19-3182 + UCAGGAUGGAGCCGGUGGG 19 7565
HSV2-U L19-292 + CUCAGGAUGGAGCCGG UGGG 20 2307
HSV2-U L19-3183 - CUGCCCACCGGCUCCAUC 18 7566
HSV2-U L19-3184 - CCUGCCCACCGGCUCCAUC 19 7567
HSV2-U L19-200 - UCCUGCCCACCGGCUCCAUC 20 2238
Table 6D provides exemplary targeting domains for knocking out the UL19 gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), and have a high level of orthogonality. The PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 6D
Figure imgf000341_0001
HSV2-UL19-3201 + AUGGCCGCGGCGUACCGGUAACC 23 7584
HSV2-UL19-3202 + GAUGGCCGCGGCGUACCGGUAACC 24 7585
HSV2-UL19-3203 + AUGAGGGGCUGGUGGACC 18 7586
HSV2-UL19-3204 + GAUGAGGGGCUGGUGGACC 19 7587
HSV2-UL19-271 + CGAUGAGGGGCUGGUGGACC 20 2291
HSV2-UL19-3205 + GCGAUGAGGGGCUGGUGGACC 21 7588
HSV2-UL19-3206 + GGCG AUGAGGGGCUGGUGGACC 22 7589
HSV2-UL19-3207 + GGGCGAUGAGGGGCUGGUGGACC 23 7590
HSV2-UL19-3208 + CGGGCGAUGAGGGGCUGGUGGACC 24 7591
HSV2-UL19-3209 + GCGGCGUACCGGUAACCC 18 7592
HSV2-UL19-3210 + CGCGGCGUACCGGUAACCC 19 7593
HSV2-UL19-92 + CCGCGGCGUACCGGUAACCC 20 507
HSV2-UL19-3211 + GCCGCGGCGUACCGGUAACCC 21 7594
HSV2-UL19-3212 + GGCCGCGGCGUACCGGUAACCC 22 7595
HSV2-UL19-3213 + UGGCCGCGGCGUACCGGUAACCC 23 7596
HSV2-UL19-3214 + AUGGCCGCGGCGUACCGGUAACCC 24 7597
HSV2-UL19-3215 + CCGUCCAGGGCCUCCCCC 18 7598
HSV2-UL19-3216 + CCCGUCCAGGGCCUCCCCC 19 7599
HSV2-UL19-258 + UCCCGUCCAGGGCCUCCCCC 20 2280
HSV2-UL19-3217 + GUCCCGUCCAGGGCCUCCCCC 21 7600
HSV2-UL19-3218 + CGUCCCGUCCAGGGCCUCCCCC 22 7601
HSV2-UL19-3219 + CCGUCCCGUCCAGGGCCUCCCCC 23 7602
HSV2-UL19-3220 + CCCGUCCCGUCCAGGGCCUCCCCC 24 7603
HSV2-UL19-3221 + UUGGUGCACACGCACGCC 18 7604
HSV2-UL19-3222 + CUUGGUGCACACGCACGCC 19 7605
HSV2-UL19-275 + ACUUGGUGCACACGCACGCC 20 2293
HSV2-UL19-3223 + AACUUGGUGCACACGCACGCC 21 7606
HSV2-UL19-3224 + GAACUUGGUG CACACG CACG CC 22 7607
HSV2-UL19-3225 + GGAACUUGGUGCACACGCACGCC 23 7608
HSV2-UL19-3226 + GGGAACUUGGUGCACACGCACGCC 24 7609
HSV2-UL19-3227 + UUCAUGUAAGCCAGCUCC 18 7610
HSV2-UL19-3228 + GUUCAUGUAAGCCAGCUCC 19 7611
HSV2-UL19-66 + CGUUCAUGUAAGCCAGCUCC 20 406
HSV2-UL19-3229 + UCGUUCAUGUAAGCCAGCUCC 21 7612
HSV2-UL19-3230 + UUCGUUCAUGUAAGCCAGCUCC 22 7613
HSV2-UL19-3231 + CUUCGUUCAUGUAAGCCAGCUCC 23 7614
HSV2-UL19-3232 + CCUUCGUUCAUGUAAGCCAGCUCC 24 7615
HSV2-UL19-3233 + GAGCGGCCAU UGGGUUCC 18 7616
HSV2-UL19-3234 + GGAGCGGCCAUUGGGUUCC 19 7617
HSV2-UL19-3235 + AGGAGCGGCCAUUGGGUUCC 20 7618
HSV2-UL19-3236 + CAGGAGCGGCCAUUGGGUUCC 21 7619
HSV2-UL19-3237 + GCAGGAGCGGCCAUUGGGUUCC 22 7620
HSV2-UL19-3238 + GGCAGGAGCGGCCAUUGGGUUCC 23 7621
HSV2-UL19-3239 + GGGCAGGAGCGGCCAUUGGGUUCC 24 7622
HSV2-UL19-3240 + CCGAGCUCCAGAAAGCGC 18 7623
HSV2-UL19-3241 + GCCGAGCUCCAGAAAGCGC 19 7624 HSV2-UL19-278 + GGCCGAGCUCCAGAAAGCGC 20 2296
HSV2-UL19-3242 + AGGCCGAGCUCCAGAAAGCGC 21 7625
HSV2-UL19-3243 + CAGGCCGAGCUCCAGAAAGCGC 22 7626
HSV2-UL19-3244 + ACAGGCCGAGCUCCAGAAAGCGC 23 7627
HSV2-UL19-3245 + GACAGGCCGAGCUCCAGAAAGCGC 24 7628
HSV2-UL19-3246 + ACGGCCUGGACGUUGCGC 18 7629
HSV2-UL19-3247 + GACGGCCUGGACGUUGCGC 19 7630
HSV2-UL19-3248 + GG ACGGCCUGGACGUUGCGC 20 7631
HSV2-UL19-3249 + AGG ACGGCCUGGACGUUGCGC 21 7632
HSV2-UL19-3250 + CAGG ACGGCCUGGACGUUGCGC 22 7633
HSV2-UL19-3251 + CCAGGACGGCCUGGACGUUGCGC 23 7634
HSV2-UL19-3252 + CCCAGGACGGCCUGGACGUUGCGC 24 7635
HSV2-UL19-3253 + AAACGCCCCCAGGACGGC 18 7636
HSV2-UL19-3254 + CAAACGCCCCCAGGACGGC 19 7637
HSV2-UL19-2781 + UCAAACGCCCCCAGGACGGC 20 2863
HSV2-UL19-3255 + ACCCGGGGGGUCGCGGGC 18 7638
HSV2-UL19-3256 + AACCCGGGGGGUCGCGGGC 19 7639
HSV2-UL19-98 + UAACCCGGGGGGUCGCGGGC 20 413
HSV2-UL19-3257 + GUAACCCGGGGGGUCGCGGGC 21 7640
HSV2-UL19-3258 + GG UAACCCGGGGGGUCGCGGGC 22 7641
HSV2-UL19-3259 + CGGU AACCCGGGGGGUCGCGGGC 23 7642
HSV2-UL19-3260 + CCGGUAACCCGGGGGGUCGCGGGC 24 7643
HSV2-UL19-3261 + UUCGUCAUGUAAUUAUGC 18 7644
HSV2-UL19-3262 + CUUCGUCAUGUAAUUAUGC 19 7645
HSV2-UL19-262 + CCUUCGUCAUGUAAUUAUGC 20 2284
HSV2-UL19-3263 + ACCUUCGUCAUGUAAUUAUGC 21 7646
HSV2-UL19-3264 + GACCUUCGUCAUGUAAUUAUGC 22 7647
HSV2-UL19-3265 + UGACCUUCGUCAUGUAAUUAUGC 23 7648
HSV2-UL19-3266 + AUGACCUUCGUCAUGUAAUUAUGC 24 7649
HSV2-UL19-3267 + GUUCAUGUAAGCCAGCUC 18 7650
HSV2-UL19-3268 + CGUUCAUGUAAGCCAGCUC 19 7651
HSV2-UL19-65 + UCGUUCAUGUAAGCCAGCUC 20 405
HSV2-UL19-3269 + UUCGUUCAUGUAAGCCAGCUC 21 7652
HSV2-UL19-3270 + CUUCGU UCAUGUAAGCCAGCUC 22 7653
HSV2-UL19-3271 + CCUUCGUUCAUGUAAGCCAGCUC 23 7654
HSV2-UL19-3272 + CCCUUCGUUCAUGUAAGCCAGCUC 24 7655
HSV2-UL19-3273 + CACGGACAGGCCGAGCUC 18 7656
HSV2-UL19-3274 + CCACGGACAGGCCGAGCUC 19 7657
HSV2-UL19-277 + GCCACGGACAGGCCGAGCUC 20 2295
HSV2-UL19-3275 + CGCCACGGACAGGCCGAGCUC 21 7658
HSV2-UL19-3276 + ACGCCACGGACAGGCCGAGCUC 22 7659
HSV2-UL19-3277 + CACGCCACGGACAGGCCGAGCUC 23 7660
HSV2-UL19-3278 + GCACGCCACGGACAGGCCGAGCUC 24 7661
HSV2-UL19-3279 + GCUAAUGCCCGUCCCGUC 18 7662
HSV2-UL19-3280 + GGCUAAUGCCCGUCCCGUC 19 7663
HSV2-UL19-257 + AGGCUAAUGCCCGUCCCGUC 20 2279 HSV2-UL19-3281 + CAGGCUAAUGCCCGUCCCGUC 21 7664
HSV2-UL19-3282 + GCAGGCUAAUGCCCGUCCCGUC 22 7665
HSV2-UL19-3283 + UGCAGGCUAAUGCCCGUCCCGUC 23 7666
HSV2-UL19-3284 + AUGCAGGCUAAUGCCCGUCCCGUC 24 7667
HSV2-UL19-3285 + GACGGGGUGCGGGCCGUC 18 7668
HSV2-UL19-3286 + CGACGGGGUGCGGGCCGUC 19 7669
HSV2-UL19-266 + UCGACGGGGUGCGGGCCGUC 20 2287
HSV2-UL19-3287 + CUCGACGGGGUGCGGGCCGUC 21 7670
HSV2-UL19-3288 + GCUCGACGGGGUGCGGGCCGUC 22 7671
HSV2-UL19-3289 + UGCUCGACGGGGUGCGGGCCGUC 23 7672
HSV2-UL19-3290 + CUGCUCGACGGGGUGCGGGCCGUC 24 7673
HSV2-UL19-3291 + CCGGUAACCCGGGGGGUC 18 7674
HSV2-UL19-3292 + ACCGGUAACCCGGGGGGUC 19 7675
HSV2-UL19-297 + UACCGGUAACCCGGGGGGUC 20 2309
HSV2-UL19-3293 + GUACCGGUAACCCGGGGGGUC 21 7676
HSV2-UL19-3294 + CGU ACCGGUAACCCGGGGGGUC 22 7677
HSV2-UL19-3295 + GCGU ACCGGUAACCCGGGGGGUC 23 7678
HSV2-UL19-3296 + GGCGUACCGGUAACCCGGGGGGUC 24 7679
HSV2-UL19-3297 + GUUGCAGUAGGACCCCAG 18 7680
HSV2-UL19-3298 + UGUUGCAGUAGGACCCCAG 19 7681
HSV2-UL19-281 + GUGU UGCAGUAGGACCCCAG 20 2299
HSV2-UL19-3299 + GGUGUUGCAGUAGGACCCCAG 21 7682
HSV2-UL19-3300 + GGG UGUUGCAGUAGGACCCCAG 22 7683
HSV2-UL19-3301 + AGGG UGUUGCAGUAGGACCCCAG 23 7684
HSV2-UL19-3302 + CAGGGUGUUGCAGUAGGACCCCAG 24 7685
HSV2-UL19-3303 + AGCGACAGGGUGUUGCAG 18 7686
HSV2-UL19-3304 + GAGCGACAGGGUGUUGCAG 19 7687
HSV2-UL19-280 + CGAGCGACAGGGUGUUGCAG 20 2298
HSV2-UL19-3305 + ACGAGCGACAGGGUGUUGCAG 21 7688
HSV2-UL19-3306 + CACGAGCGACAGGGUGUUGCAG 22 7689
HSV2-UL19-3307 + GCACGAGCGACAGGGUGUUGCAG 23 7690
HSV2-UL19-3308 + CGCACGAGCGACAGGGUGUUGCAG 24 7691
HSV2-UL19-3309 + CAGGGCCUCCCCCGUGAG 18 7692
HSV2-UL19-3310 + CCAGGGCCUCCCCCGUGAG 19 7693
HSV2-UL19-259 + UCCAGGGCCUCCCCCGUGAG 20 2281
HSV2-UL19-3311 + GUCCAGGGCCUCCCCCGUGAG 21 7694
HSV2-UL19-3312 + CGUCCAGGGCCUCCCCCGUGAG 22 7695
HSV2-UL19-3313 + CCGUCCAGGGCCUCCCCCGUGAG 23 7696
HSV2-UL19-3314 + CCCGUCCAGGGCCUCCCCCGUGAG 24 7697
HSV2-UL19-3315 + GUACUCAGGAUGGAGCCG 18 7698
HSV2-UL19-3316 + CGUACUCAGGAUGGAGCCG 19 7699
HSV2-UL19-291 + UCGUACUCAGGAUGGAGCCG 20 2306
HSV2-UL19-3317 + AUCGUACUCAGGAUGGAGCCG 21 7700
HSV2-UL19-3318 + GAU CGUACUCAGGAUGGAGCCG 22 7701
HSV2-UL19-3319 + CG AUCGUACUCAGGAUGGAGCCG 23 7702
HSV2-UL19-3320 + UCG AUCGUACUCAGGAUGGAGCCG 24 7703 HSV2-UL19-3321 + UCGUCGGAGCGCACGGCG 18 7704
HSV2-UL19-3322 + UUCGUCGGAGCGCACGGCG 19 7705
HSV2-UL19-284 + UU UCGUCGGAGCGCACGGCG 20 2301
HSV2-UL19-3323 + UUUUCGUCGGAGCGCACGGCG 21 7706
HSV2-UL19-3324 + GUU UUCGUCGGAGCGCACGGCG 22 7707
HSV2-UL19-3325 + UGUUUUCGUCGGAGCGCACGGCG 23 7708
HSV2-UL19-3326 + CUGU UUUCGUCGGAGCGCACGGCG 24 7709
HSV2-UL19-3327 + UGCGGGCCGUCGCGGGCG 18 7710
HSV2-UL19-3328 + GUGCGGGCCGUCGCGGGCG 19 7711
HSV2-UL19-267 + GGUGCGGGCCGUCGCGGGCG 20 2288
HSV2-UL19-3329 + GGGUGCGGGCCGUCGCGGGCG 21 7712
HSV2-UL19-3330 + GGGGUGCGGGCCGUCGCGGGCG 22 7713
HSV2-UL19-3331 + CGGGGUGCGGGCCGUCGCGGGCG 23 7714
HSV2-UL19-3332 + ACGGGGUGCGGGCCGUCGCGGGCG 24 7715
HSV2-UL19-3333 + AAAAU CAAAG AG U CU GCG 18 7716
HSV2-UL19-3334 + AAAAAUCAAAGAGUCUGCG 19 7717
HSV2-UL19-286 + AAAAAAU CAAAG AG U CU GCG 20 2303
HSV2-UL19-3335 + GAAAAAAUCAAAGAGUCUGCG 21 7718
HSV2-UL19-3336 + CGAAAAAAUCAAAGAGUCUGCG 22 7719
HSV2-UL19-3337 + GCG AAAAAAU CAAAG AG U CUG CG 23 7720
HSV2-UL19-3338 + GGCGAAAAAAUCAAAGAGUCUGCG 24 7721
HSV2-UL19-3339 + UUAUGCACGGGCUGCUCG 18 7722
HSV2-UL19-3340 + AUUAUGCACGGGCUGCUCG 19 7723
HSV2-UL19-263 + AAU UAUGCACGGGCUGCUCG 20 2285
HSV2-UL19-3341 + UAAUUAUGCACGGGCUGCUCG 21 7724
HSV2-UL19-3342 + GUAAUUAUGCACGGGCUGCUCG 22 7725
HSV2-UL19-3343 + UGUAAUUAUGCACGGGCUGCUCG 23 7726
HSV2-UL19-3344 + AUGUAAUUAUGCACGGGCUGCUCG 24 7727
HSV2-UL19-3345 + UCAUACAGGCUGUUUUCG 18 7728
HSV2-UL19-3346 + GUCAUACAGGCUGUUUUCG 19 7729
HSV2-UL19-282 + CGUCAUACAGGCUGUUUUCG 20 2300
HSV2-UL19-3347 + ACGUCAUACAGGCUGUUUUCG 21 7730
HSV2-UL19-3348 + UACGUCAUACAGGCUGUUUUCG 22 7731
HSV2-UL19-3349 + CUACGUCAUACAGGCUGUUUUCG 23 7732
HSV2-UL19-3350 + UCUACGUCAUACAGGCUGUUUUCG 24 7733
HSV2-UL19-3351 + ACGCACGCCACGGACAGG 18 7734
HSV2-UL19-3352 + CACGCACGCCACGGACAGG 19 7735
HSV2-UL19-276 + ACACGCACGCCACGGACAGG 20 2294
HSV2-UL19-3353 + CACACGCACGCCACGGACAGG 21 7736
HSV2-UL19-3354 + G CACACG CACG CCACG G ACAG G 22 7737
HSV2-UL19-3355 + UGCACACGCACGCCACGGACAGG 23 7738
HSV2-UL19-3356 + GUGCA CACGCACGCCACGGACAGG 24 7739
HSV2-UL19-3357 + AUGGCCUCGGUGGCCAGG 18 7740
HSV2-UL19-3358 + AAUGGCCUCGGUGGCCAGG 19 7741
HSV2-UL19-260 + CAAUGGCCUCGGUGGCCAGG 20 2282
HSV2-UL19-3359 + GCAAUGGCCUCGGUGGCCAGG 21 7742 HSV2-UL19-3360 + GGCAAUGGCCUCGGUGGCCAGG 22 7743
HSV2-UL19-3361 + GGGCAAUGGCCUCGGUGGCCAGG 23 7744
HSV2-UL19-3362 + AGGGCAAUGGCCUCGGUGGCCAGG 24 7745
HSV2-UL19-3363 + ACCUCGAUCGUACUCAGG 18 7746
HSV2-UL19-3364 + CACCUCGAUCGUACUCAGG 19 7747
HSV2-UL19-289 + CCACCUCGAUCGUACUCAGG 20 2305
HSV2-UL19-3365 + GCCACCUCGAUCGUACUCAGG 21 7748
HSV2-UL19-3366 + CGCCACCUCGAUCGUACUCAGG 22 7749
HSV2-UL19-3367 + ACGCCACCUCGAUCGUACUCAGG 23 7750
HSV2-UL19-3368 + GACGCCACCUCGAUCGUACUCAGG 24 7751
HSV2-UL19-3369 + AAAUCAAAGAGUCUGCGG 18 7752
HSV2-UL19-3370 + AAAAU CAAAG AG UCU G CGG 19 7753
HSV2-UL19-80 + AAAAAUCAAAGAGUCUGCGG 20 498
HSV2-UL19-3371 + AAAAAAUCAAAGAGUCUGCGG 21 7754
HSV2-UL19-3372 + GAAAAAAUCAAAGAGUCUGCGG 22 7755
HSV2-UL19-3373 + CG AAA AAAU CAAAG AGUCUGCGG 23 7756
HSV2-UL19-3374 + G CG AAAAAAU CAAAG AG UCU GCG G 24 7757
HSV2-UL19-3375 + AACCCGGGGGGUCGCGGG 18 7758
HSV2-UL19-3376 + UAACCCGGGGGGUCGCGGG 19 7759
HSV2-UL19-298 + GU AACCCGGGGGGUCGCGGG 20 2310
HSV2-UL19-3377 + GGU AACCCGGGGGGUCGCGGG 21 7760
HSV2-UL19-3378 + CGG UAACCCGGGGGGUCGCGGG 22 7761
HSV2-UL19-3379 + CCGGU AACCCGGGGGGUCGCGGG 23 7762
HSV2-UL19-3380 + ACCGG UAACCCGGGGGGUCGCGGG 24 7763
HSV2-UL19-3381 + GGGCCGUCGCGGGCGAUG 18 7764
HSV2-UL19-3382 + CGGGCCGUCGCGGGCGAUG 19 7765
HSV2-UL19-60 + GCGGGCCGUCGCGGGCGAUG 20 483
HSV2-UL19-3383 + UGCGGGCCGUCGCGGGCGAUG 21 7766
HSV2-UL19-3384 + GUGCGGGCCGUCGCGGGCGAUG 22 7767
HSV2-UL19-3385 + GG UGCGGGCCGUCGCGGGCGAUG 23 7768
HSV2-UL19-3386 + GGGUGCGGGCCGUCGCGGGCGAUG 24 7769
HSV2-UL19-3387 + GCGGGCGAUGAGGGGCUG 18 7770
HSV2-UL19-3388 + CGCGGGCGAUGAGGGGCUG 19 7771
HSV2-UL19-270 + UCGCGGGCGAUGAGGGGCUG 20 2290
HSV2-UL19-3389 + GUCGCGGGCGAUGAGGGGCUG 21 7772
HSV2-UL19-3390 + CGUCGCGGGCGAUGAGGGGCUG 22 7773
HSV2-UL19-3391 + CCGUCGCGGGCGAUGAGGGGCUG 23 7774
HSV2-UL19-3392 + GCCGUCGCGGGCGAUGAGGGGCUG 24 7775
HSV2-UL19-3393 + CGGGCCGUCGCGGGCGAU 18 7776
HSV2-UL19-3394 + GCGGGCCGUCGCGGGCGAU 19 7777
HSV2-UL19-268 + UGCGGGCCGUCGCGGGCGAU 20 2289
HSV2-UL19-3395 + GUGCGGGCCGUCGCGGGCGAU 21 7778
HSV2-UL19-3396 + GGUGCGGGCCGUCGCGGGCGAU 22 7779
HSV2-UL19-3397 + GGGUGCGGGCCGUCGCGGGCGAU 23 7780
HSV2-UL19-3398 + GGGGUGCGGGCCGUCGCGGGCGAU 24 7781
HSV2-UL19-3399 + AGCGGCCAU UGGGUUCCU 18 7782 HSV2-UL19-3400 + GAGCGGCCAUUGGGUUCCU 19 7783
HSV2-UL19-3094 + GGAGCGGCCAUUGGGUUCCU 20 7477
HSV2-UL19-3401 + AGGAGCGGCCAUUGGGUUCCU 21 7784
HSV2-UL19-3402 + CAGGAGCGGCCAUUGGGUUCCU 22 7785
HSV2-UL19-3403 + GCAGGAGCGGCCAUUGGGUUCCU 23 7786
HSV2-UL19-3404 + GGCAGGAGCGGCCAUUGGGUUCCU 24 7787
HSV2-UL19-3405 + CGUUCAUGUAAGCCAGCU 18 7788
HSV2-UL19-3406 + UCGU UCAUGUAAGCCAGCU 19 7789
HSV2-UL19-272 + U U CG U U CAU G U AAG CCAGCU 20 2292
HSV2-UL19-3407 + CUUCGUUCAUGUAAGCCAGCU 21 7790
HSV2-UL19-3408 + CCUUCGUUCAUGUAAGCCAGCU 22 7791
HSV2-UL19-3409 + CCCUUCGUUCAUGUAAGCCAGCU 23 7792
HSV2-UL19-3410 + GCCCUUCGUUCAUGUAAGCCAGCU 24 7793
HSV2-UL19-3411 + CAUACAGGCUGUUUUCGU 18 7794
HSV2-UL19-3412 + UCAUACAGGCUGUUUUCGU 19 7795
HSV2-UL19-76 + GUCAUACAGGCUGUUUUCGU 20 494
HSV2-UL19-3413 + CGUCAUACAGGCUGUUUUCGU 21 7796
HSV2-UL19-3414 + ACGUCAUACAGGCUGUUUUCGU 22 7797
HSV2-UL19-3415 + UACGUCAUACAGGCUGUUUUCGU 23 7798
HSV2-UL19-3416 + CUACGUCAUACAGGCUGUUUUCGU 24 7799
HSV2-UL19-3417 + CGGGCUGCUCGACGGGGU 18 7800
HSV2-UL19-3418 + ACGGGCUGCUCGACGGGGU 19 7801
HSV2-UL19-265 + CACGGGCUGCUCGACGGGGU 20 2286
HSV2-UL19-3419 + GCACGGGCUGCUCGACGGGGU 21 7802
HSV2-UL19-3420 + UGCACGGGCUGCUCGACGGGGU 22 7803
HSV2-UL19-3421 + AUGCACGGGCUGCUCGACGGGGU 23 7804
HSV2-UL19-3422 + UAUGCACGGGCUGCUCGACGGGGU 24 7805
HSV2-UL19-3423 + GCGGCCAUUGGGUUCCUU 18 7806
HSV2-UL19-3424 + AGCGGCCAUUGGGUUCCUU 19 7807
HSV2-UL19-3095 + GAGCGGCCAU UGGGUUCCUU 20 7478
HSV2-UL19-3425 + GGAGCGGCCAUUGGGUUCCUU 21 7808
HSV2-UL19-3426 + AGGAGCGGCCAUUGGGUUCCUU 22 7809
HSV2-UL19-3427 + CAGGAGCGGCCAUUGGGUUCCUU 23 7810
HSV2-UL19-3428 + GCAGGAGCGGCCAUUGGGUUCCUU 24 7811
HSV2-UL19-3429 + CAGGCUGAAGGCGGCGUU 18 7812
HSV2-UL19-3430 + CCAGGCUGAAGGCGGCGUU 19 7813
HSV2-UL19-261 + GCCAGGCUGAAGGCGGCGUU 20 2283
HSV2-UL19-3431 + GGCCAGGCUGAAGGCGGCGUU 21 7814
HSV2-UL19-3432 + UGGCCAGGCUGAAGGCGGCGUU 22 7815
HSV2-UL19-3433 + GUGGCCAGGCUGAAGGCGGCGUU 23 7816
HSV2-UL19-3434 + GGUGGCCAGGCUGAAGGCGGCGUU 24 7817
HSV2-UL19-3435 - GAGCCUGCGAAUCCCCCA 18 7818
HSV2-UL19-3436 - GGAGCCUGCGAAUCCCCCA 19 7819
HSV2-UL19-3100 - UGGAGCCUGCGAAUCCCCCA 20 7483
HSV2-UL19-3437 - CCGCCUUCAGCCUGGCCA 18 7820
HSV2-UL19-3438 - GCCGCCUUCAGCCUGGCCA 19 7821 HSV2-UL19-218 - CGCCGCCUUCAGCCUGGCCA 20 2253
HSV2-UL19-3439 - ACGCCGCCUUCAGCCUGGCCA 21 7822
HSV2-UL19-3440 - AACGCCGCCUUCAGCCUGGCCA 22 7823
HSV2-UL19-3441 - GAACGCCGCCUUCAGCCUGGCCA 23 7824
HSV2-UL19-3442 - UGAACGCCGCCUUCAGCCUGGCCA 24 7825
HSV2-UL19-3443 - AGGCCAUUGCCCUGCUCA 18 7826
HSV2-UL19-3444 - GAGGCCAU UGCCCUGCUCA 19 7827
HSV2-UL19-25 - CGAGGCCAUUGCCCUGCUCA 20 453
HSV2-UL19-3445 - CCGAGGCCAUUGCCCUGCUCA 21 7828
HSV2-UL19-3446 - ACCGAGGCCAUUGCCCUGCUCA 22 7829
HSV2-UL19-3447 - CACCGAGGCCAUUGCCCUGCUCA 23 7830
HSV2-UL19-3448 - CCACCGAGGCCAUUGCCCUGCUCA 24 7831
HSV2-UL19-3449 - GCUCCAUCCUGAGUACGA 18 7832
HSV2-UL19-3450 - GGCUCCAUCCUGAGUACGA 19 7833
HSV2-UL19-201 - CGGCUCCAUCCUGAGUACGA 20 2239
HSV2-UL19-3451 - CCGGCUCCAUCCUGAGUACGA 21 7834
HSV2-UL19-3452 - ACCGGCUCCAUCCUGAGUACGA 22 7835
HSV2-UL19-3453 - CACCGGCUCCAUCCUGAGUACGA 23 7836
HSV2-UL19-3454 - CCACCGGCUCCAUCCUGAGUACGA 24 7837
HSV2-UL19-3455 - CACGGGGGAGGCCCUGGA 18 7838
HSV2-UL19-3456 - UCACGGGGGAGGCCCUGGA 19 7839
HSV2-UL19-31 - CUCACGGGGGAGGCCCUGGA 20 459
HSV2-UL19-3457 - GCUCACGGGGGAGGCCCUGGA 21 7840
HSV2-UL19-3458 - UGCUCACGGGGGAGGCCCUGGA 22 7841
HSV2-UL19-3459 - CUGCUCACGGGGGAGGCCCUGGA 23 7842
HSV2-UL19-3460 - CCUGCUCACGGGGGAGGCCCUGGA 24 7843
HSV2-UL19-3461 - CGGAGCUGGCUUACAUGA 18 7844
HSV2-UL19-3462 - CCGGAGCUGGCUUACAUGA 19 7845
HSV2-UL19-211 - CCCGGAGCUGGCUUACAUGA 20 2246
HSV2-UL19-3463 - UCCCGGAGCUGGCUUACAUGA 21 7846
HSV2-UL19-3464 - UUCCCGGAGCUGGCUUACAUGA 22 7847
HSV2-UL19-3465 - GUUCCCGGAGCUGGCUUACAUGA 23 7848
HSV2-UL19-3466 - AGU UCCCGGAGCUGGCUUACAUGA 24 7849
HSV2-UL19-3467 - GGCCAUUGCCCUGCUCAC 18 7850
HSV2-UL19-3468 - AGGCCAU UGCCCUGCUCAC 19 7851
HSV2-UL19-26 - GAGGCCAUUGCCCUGCUCAC 20 454
HSV2-UL19-3469 - CGAGGCCAUUGCCCUGCUCAC 21 7852
HSV2-UL19-3470 - CCGAGGCCAUUGCCCUGCUCAC 22 7853
HSV2-UL19-3471 - ACCGAGGCCAU UGCCCUGCUCAC 23 7854
HSV2-UL19-3472 - CACCGAGGCCAUUGCCCUGCUCAC 24 7855
HSV2-UL19-3473 - UUCCCGGAGCUGGCUUAC 18 7856
HSV2-UL19-3474 - GUUCCCGGAGCUGGCUUAC 19 7857
HSV2-UL19-210 - AGUUCCCGGAGCUGGCUUAC 20 2245
HSV2-UL19-3475 - AAGUUCCCGGAGCUGGCUUAC 21 7858
HSV2-UL19-3476 - CAAGUUCCCGGAGCUGGCUUAC 22 7859
HSV2-UL19-3477 - CCAAGUUCCCGGAGCUGGCUUAC 23 7860 HSV2-UL19-3478 - ACCAAGUUCCCGGAGCUGGCUUAC 24 7861
HSV2-UL19-3479 - GGAGCCUGCGAAUCCCCC 18 7862
HSV2-UL19-3480 - UGGAGCCUGCGAAUCCCCC 19 7863
HSV2-UL19-3481 - AUGGAGCCUGCGAAUCCCCC 20 7864
HSV2-UL19-3482 - CUGCUCACGGGGGAGGCC 18 7865
HSV2-UL19-3483 - CCUGCUCACGGGGGAGGCC 19 7866
HSV2-UL19-224 - CCCUGCUCACGGGGGAGGCC 20 2255
HSV2-UL19-3484 - GCCCUGCUCACGGGGGAGGCC 21 7867
HSV2-UL19-3485 - UGCCCUGCUCACGGGGGAGGCC 22 7868
HSV2-UL19-3486 - UUGCCCUGCUCACGGGGGAGGCC 23 7869
HSV2-UL19-3487 - AUUGCCCUGCUCACGGGGGAGGCC 24 7870
HSV2-UL19-3488 - GUCAUCGACCGCCGGGCC 18 7871
HSV2-UL19-3489 - GGUCAUCGACCGCCGGGCC 19 7872
HSV2-UL19-217 - AGGUCAUCGACCGCCGGGCC 20 2252
HSV2-UL19-3490 - AAGGUCAUCGACCGCCGGGCC 21 7873
HSV2-UL19-3491 - GAAGGUCAUCGACCGCCGGGCC 22 7874
HSV2-UL19-3492 - CGAAGGUCAUCGACCGCCGGGCC 23 7875
HSV2-UL19-3493 - ACGAAGGUCAUCGACCGCCGGGCC 24 7876
HSV2-UL19-3494 - G CAACG UCCAGGCCGUCC 18 7877
HSV2-UL19-3495 - CGCAACGUCCAGGCCGUCC 19 7878
HSV2-UL19-3092 - G CG CAACG UCCAGGCCGUCC 20 7475
HSV2-UL19-3496 - CGCGCAACGUCCAGGCCGUCC 21 7879
HSV2-UL19-3497 - GCGCGCAACGUCCAGGCCGUCC 22 7880
HSV2-UL19-3498 - CGCGCGCAACGUCCAGGCCGUCC 23 7881
HSV2-UL19-3499 - UCGCGCGCAACGUCCAGGCCGUCC 24 7882
HSV2-UL19-3500 - GCGUGUGCACCAAGUUCC 18 7883
HSV2-UL19-3501 - UGCGUGUGCACCAAGUUCC 19 7884
HSV2-UL19-14 - GUGCGUGUGCACCAAGUUCC 20 393
HSV2-UL19-3502 - CGUGCGUGUG CACCAAG U U CC 21 7885
HSV2-UL19-3503 - GCGUGCGUGUGCACCAAGUUCC 22 7886
HSV2-UL19-3504 - GGCGUGCGUGUGCACCAAGUUCC 23 7887
HSV2-UL19-3505 - UGGCGUGCGUGUGCACCAAGUUCC 24 7888
HSV2-UL19-3506 - GAGGCCAUUGCCCUGCUC 18 7889
HSV2-UL19-3507 - CGAGGCCAUUGCCCUGCUC 19 7890
HSV2-UL19-219 - CCGAGGCCAUUGCCCUGCUC 20 2254
HSV2-UL19-3508 - ACCGAGGCCAU UGCCCUGCUC 21 7891
HSV2-UL19-3509 - CACCGAGGCCAUUGCCCUGCUC 22 7892
HSV2-UL19-3510 - CCACCGAGGCCAUUGCCCUGCUC 23 7893
HSV2-UL19-3511 - GCCACCGAGGCCAUUGCCCUGCUC 24 7894
HSV2-UL19-3512 - CGCAACGUCCAGGCCGUC 18 7895
HSV2-UL19-3513 - GCGCAACGUCCAGGCCGUC 19 7896
HSV2-UL19-3514 - CGCGCAACGUCCAGGCCGUC 20 7897
HSV2-UL19-3515 - GCGCGCAACGUCCAGGCCGUC 21 7898
HSV2-UL19-3516 - CGCGCGCAACGUCCAGGCCGUC 22 7899
HSV2-UL19-3517 - UCGCGCGCAACGUCCAGGCCGUC 23 7900
HSV2-UL19-3518 - CUCGCGCGCAACGUCCAGGCCGUC 24 7901 HSV2-UL19-3519 - UGCGUGUGCACCAAGUUC 18 7902
HSV2-UL19-3520 - GUGCGUGUGCACCAAGUUC 19 7903
HSV2-UL19-208 - CGUGCGUGUGCACCAAGUUC 20 2244
HSV2-UL19-3521 - GCGUGCGUGUGCACCAAGUUC 21 7904
HSV2-UL19-3522 - GGCGUGCGUGUGCACCAAGUUC 22 7905
HSV2-UL19-3523 - UGGCGUGCGUGUGCACCAAGUUC 23 7906
HSV2-UL19-3524 - GUGGCGUGCGUGUGCACCAAGUUC 24 7907
HSV2-UL19-3525 - UGUCGCUCGUGCGCUUUC 18 7908
HSV2-UL19-3526 - CUGUCGCUCGUGCGCUUUC 19 7909
HSV2-UL19-11 - CCUGUCGCUCGUGCGCUUUC 20 391
HSV2-UL19-3527 - CCCUGUCGCUCGUGCGCUUUC 21 7910
HSV2-UL19-3528 - ACCCUGUCGCUCGUGCGCUUUC 22 7911
HSV2-UL19-3529 - CACCCUGUCGCUCGUGCGCUUUC 23 7912
HSV2-UL19-3530 - ACACCCUGUCGCUCGUGCGCUUUC 24 7913
HSV2-UL19-3531 - AGCUGGCUUACAUGAACG 18 7914
HSV2-UL19-3532 - GAGCUGGCUUACAUGAACG 19 7915
HSV2-UL19-212 - GG AGCUGGCUUACAUGAACG 20 2247
HSV2-UL19-3533 - CGGAGCUGGCU UACAUGAACG 21 7916
HSV2-UL19-3534 - CCGG AGCUGGCUUACAUGAACG 22 7917
HSV2-UL19-3535 - CCCGGAGCUGGCUUACAUGAACG 23 7918
HSV2-UL19-3536 - UCCCGGAGCUGGCU UACAUGAACG 24 7919
HSV2-UL19-3537 - GCCAUUGCCCUGCUCACG 18 7920
HSV2-UL19-3538 - GGCCAUUGCCCUGCUCACG 19 7921
HSV2-UL19-27 - AGGCCAUUGCCCUGCUCACG 20 455
HSV2-UL19-3539 - GAGGCCAU UGCCCUGCUCACG 21 7922
HSV2-UL19-3540 - CGAGGCCAUUGCCCUGCUCACG 22 7923
HSV2-UL19-3541 - CCGAGGCCAUUGCCCUGCUCACG 23 7924
HSV2-UL19-3542 - ACCGAGGCCAUUGCCCUGCUCACG 24 7925
HSV2-UL19-3543 - GACGAAGGUCAUCGACCG 18 7926
HSV2-UL19-3544 - UGACGAAGGUCAUCGACCG 19 7927
HSV2-UL19-216 - AUGACGAAGGUCAUCGACCG 20 2251
HSV2-UL19-3545 - CAUGACGAAGGUCAUCGACCG 21 7928
HSV2-UL19-3546 - ACAU GACGAAGGUCAUCGACCG 22 7929
HSV2-UL19-3547 - UACAUGACGAAGGUCAUCGACCG 23 7930
HSV2-UL19-3548 - UUACAUGACGAAGGUCAUCGACCG 24 7931
HSV2-UL19-3549 - GCGACGGCCCGCACCCCG 18 7932
HSV2-UL19-3550 - CGCGACGGCCCGCACCCCG 19 7933
HSV2-UL19-214 - CCGCGACGGCCCGCACCCCG 20 2249
HSV2-UL19-3551 - CCCGCGACGGCCCGCACCCCG 21 7934
HSV2-UL19-3552 - GCCCGCGACGGCCCGCACCCCG 22 7935
HSV2-UL19-3553 - CGCCCGCGACGGCCCGCACCCCG 23 7936
HSV2-UL19-3554 - UCGCCCGCGACGGCCCGCACCCCG 24 7937
HSV2-UL19-3555 - UCGCCGCCGUGCGCUCCG 18 7938
HSV2-UL19-3556 - UUCGCCGCCGUGCGCUCCG 19 7939
HSV2-UL19-202 - UUUCGCCGCCGUGCGCUCCG 20 2240
HSV2-UL19-3557 - UU UUCGCCGCCGUGCGCUCCG 21 7940 HSV2-UL19-3558 - UUUUUCGCCGCCGUGCGCUCCG 22 7941
HSV2-UL19-3559 - UUUUUUCGCCGCCGUGCGCUCCG 23 7942
HSV2-UL19-3560 - AUU UUUUCGCCGCCGUGCGCUCCG 24 7943
HSV2-UL19-3561 - CCAUUGCCCUGCUCACGG 18 7944
HSV2-UL19-3562 - GCCAUUGCCCUGCUCACGG 19 7945
HSV2-UL19-28 - GGCCAUUGCCCUGCUCACGG 20 456
HSV2-UL19-3563 - AGGCCAUUGCCCUGCUCACGG 21 7946
HSV2-UL19-3564 - GAGGCCAUUGCCCUGCUCACGG 22 7947
HSV2-UL19-3565 - CGAGGCCAUUGCCCUGCUCACGG 23 7948
HSV2-UL19-3566 - CCGAGGCCAUUGCCCUGCUCACGG 24 7949
HSV2-UL19-3567 - GGGGAGGCCCUGGACGGG 18 7950
HSV2-UL19-3568 - GGGGGAGGCCCUGGACGGG 19 7951
HSV2-UL19-227 - CGGGGGAGGCCCUGGACGGG 20 2257
HSV2-UL19-3569 - ACGGGGGAGGCCCUGGACGGG 21 7952
HSV2-UL19-3570 - CACGGGGGAGGCCCUGGACGGG 22 7953
HSV2-UL19-3571 - UCACGGGGGAGGCCCUGGACGGG 23 7954
HSV2-UL19-3572 - CUCACGGGGGAGGCCCUGGACGGG 24 7955
HSV2-UL19-3573 - UCACGGGGGAGGCCCUGG 18 7956
HSV2-UL19-3574 - CUCACGGGGGAGGCCCUGG 19 7957
HSV2-UL19-225 - GCUCACGGGGGAGGCCCUGG 20 2256
HSV2-UL19-3575 - UGCUCACGGGGGAGGCCCUGG 21 7958
HSV2-UL19-3576 - CUGCUCACGGGGGAGGCCCUGG 22 7959
HSV2-UL19-3577 - CCUGCUCACGGGGGAGGCCCUGG 23 7960
HSV2-UL19-3578 - CCCUGCUCACGGGGGAGGCCCUGG 24 7961
HSV2-UL19-3579 - CCCGUGCAUAAUUACAUG 18 7962
HSV2-UL19-3580 - GCCCGUGCAUAAUUACAUG 19 7963
HSV2-UL19-215 - AGCCCGUGCAUAAUUACAUG 20 2250
HSV2-UL19-3581 - CAGCCCGUGCAUAAUUACAUG 21 7964
HSV2-UL19-3582 - GCAGCCCGUGCAUAAUUACAUG 22 7965
HSV2-UL19-3583 - AGCAG CCCG UGCAUAAU U ACAU G 23 7966
HSV2-UL19-3584 - GAGCAGCCCGUGCAUAAUUACAUG 24 7967
HSV2-UL19-3585 - GUAGAGUUUGACGCCCUG 18 7968
HSV2-UL19-3586 - CGUAGAGUUUGACGCCCUG 19 7969
HSV2-UL19-204 - ACGUAGAGUUUGACGCCCUG 20 2242
HSV2-UL19-3587 - GACGUAGAGUUUGACGCCCUG 21 7970
HSV2-UL19-3588 - UGACGUAGAGUUUGACGCCCUG 22 7971
HSV2-UL19-3589 - AUGACGUAGAGUUUGACGCCCUG 23 7972
HSV2-UL19-3590 - UAUGACGUAGAGUUUGACGCCCUG 24 7973
HSV2-UL19-3591 - CAACG U CCAG G CCG U CCU 18 7974
HSV2-UL19-3592 - GCAACGUCCAGGCCGUCCU 19 7975
HSV2-UL19-3085 - CGCAACGUCCAGGCCGUCCU 20 7468
HSV2-UL19-3593 - GCGCAACGUCCAGGCCGUCCU 21 7976
HSV2-UL19-3594 - CGCGCAACGUCCAGGCCGUCCU 22 7977
HSV2-UL19-3595 - GCGCGCAACGUCCAGGCCGUCCU 23 7978
HSV2-UL19-3596 - CGCGCGCAACGUCCAGGCCGUCCU 24 7979
HSV2-UL19-3597 - ACGAAGGGCGUGUGCAGU 18 7980 HSV2-UL19-3598 - AACGAAGGGCGUGUGCAGU 19 7981
HSV2-UL19-213 - GAACGAAGGGCGUGUGCAGU 20 2248
HSV2-UL19-3599 - UGAACGAAGGGCGUGUGCAGU 21 7982
HSV2-UL19-3600 - AUG AACGAAGGGCGUGUGCAGU 22 7983
HSV2-UL19-3601 - CAUG AACGAAGGGCGUGUGCAGU 23 7984
HSV2-UL19-3602 - ACAU G AACG AAG GGCGUGUGCAGU 24 7985
HSV2-UL19-3603 - CUGUCGCUCGUGCGCUUU 18 7986
HSV2-UL19-3604 - CCUGUCGCUCGUGCGCUUU 19 7987
HSV2-UL19-206 - CCCUGUCGCUCGUGCGCUUU 20 2243
HSV2-UL19-3605 - ACCCUGUCGCUCGUGCGCUUU 21 7988
HSV2-UL19-3606 - CACCCUGUCGCUCGUGCGCUUU 22 7989
HSV2-UL19-3607 - ACACCCUGUCGCUCGUGCGCUUU 23 7990
HSV2-UL19-3608 - AACACCCU G U CG CU CG UG CG CU U U 24 7991
Table 6E provides exemplary targeting domains for knocking out the UL19 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene), and start with a 5'G. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 6E
Figure imgf000352_0001
HSV2-UL19-3623 + GGCCACCAGAUUGGCGGGAUGCA 23 8006
HSV2-UL19-3624 + GUUCCAGUAGCUGGUGAUGCA 21 8007
HSV2-UL19-3625 + GU UGUUCCAGUAGCUGGUGAUGCA 24
8008
HSV2-UL19-3626 + GGUGGGCGGGGUCGGUCA 18 8009
HSV2-UL19-3627 + GGGUGGGCGGGGUCGGUCA 19 8010
HSV2-UL19-3628 + GCGGGUGGGCGGGGUCGGUCA 21 8011
HSV2-UL19-3629 + GCAGCGGGUGGGCGGGGUCGGUCA 24
8012
HSV2-UL19-1436 + GUACGGAUUCGCGGCCUCGA 20 1676
HSV2-UL19-3630 + GGUCGCUGGCGCAGGUGA 18 8013
HSV2-UL19-3631 + GGGUCGCUGGCGCAGGUGA 19 8014
HSV2-UL19-2516 + GGGGUCGCUGGCGCAGGUGA 20 2680
HSV2-UL19-3632 + GCGGGG UCGCUGGCGCAGGUGA 22 8015
HSV2-UL19-3633 + GGCGGGGUCGCUGGCGCAGGUGA 23 8016
HSV2-UL19-3634 + GGGCGGGGUCGCUGGCGCAGG UGA 24
8017
HSV2-UL19-3635 + GU UGAUGUCCGUGGCCAC 18 8018
HSV2-UL19-3636 + GUAGUUGAUGUCCGUGGCCAC 21 8019
HSV2-UL19-3637 + GCUCCGCU UCAGCUCGGCGAC 21 8020
HSV2-UL19-3638 + GCACGACGGUGAACCCGAACC 21 8021
HSV2-UL19-3639 + GCCGCACGACGGUGAACCCGAACC 24 8022
HSV2-UL19-2541 + GCCGCCGGCCGCGCGUCCCC 20 2704
HSV2-UL19-3640 + GAGAACCGCUGCGACGCCC 19 8023
HSV2-UL19-3641 + GUACGAGAACCGCUGCGACGCCC 23 8024
HSV2-UL19-3642 + GUCGCUGGCAGCGGUGGCC 19 8025
HSV2-UL19-3643 + GCACGUCGCUGGCAGCGGUGGCC 23 8026
HSV2-UL19-3644 + GAACACGUGCUCGUUGCC 18 8027
HSV2-UL19-3645 + GCAGAACACGUGCUCGU UGCC 21 8028
HSV2-UL19-3646 + GCGCAGAACACGUGCUCGUUGCC 23 8029
HSV2-UL19-3647 + GGCGCAGAACACGUGCUCGU UGCC 24 8030
HSV2-UL19-3648 + GCU UCCUGAAACAGGCCGC 19 8031
HSV2-UL19-2518 + GGCUUCCUGAAACAGGCCGC 20 2682
HSV2-UL19-3649 + GUAGGCUUCCUGAAACAGGCCGC 23 8032
HSV2-UL19-3650 + GGUAGGCUUCCUGAAACAGGCCGC 24 8033
HSV2-UL19-3651 + GGCGUCGGCCGCGCGGGC 18 8034
HSV2-UL19-2655 + GCGGCGUCGGCCGCGCGGGC 20 2774
HSV2-UL19-3652 + GGCGGCGUCGGCCGCGCGGGC 21 8035
HSV2-UL19-3653 + GUCGGCGGCGUCGGCCGCGCGGGC 24 8036
HSV2-UL19-3654 + GACCACG CG CCAG G U GG C 18 8037
HSV2-UL19-3655 + GUUGACCACGCGCCAGGUGGC 21 8038
HSV2-UL19-3656 + GCCGUUGACCACGCGCCAGGUGGC 24 8039
HSV2-UL19-1411 + G CCCGCG A AG AAG U CG AACG 20 1651
HSV2-UL19-3657 + G CAG CAG G U AA AACACCG 18 8040
HSV2-UL19-3658 + GCU UGCAGCAGGUAAAACACCG 22 8041
HSV2-UL19-3659 + G G C U U G CAG CAG G U AA AACACCG 23 8042 HSV2-UL19-3660 + GCGUCGAUGU UCAUGAGCG 19 8043
HSV2-UL19-3661 + GCCGCGUCGAUGUUCAUGAGCG 22 8044
HSV2-UL19-3662 + GGCCGCG UCGAUGUUCAUGAGCG 23 8045
HSV2-UL19-3663 + GUGGCCGCGAAGGGCCGCG 19 8046
HSV2-UL19-3664 + GCCGUGGCCGCGAAGGGCCGCG 22 8047
HSV2-UL19-3665 + GGCCGUGGCCGCGAAGGGCCGCG 23 8048
HSV2-UL19-3666 + GCCCAGCUCCGGGCCCGG 18 8049
HSV2-UL19-3667 + GCCCGCCCAGCUCCGGGCCCGG 22 8050
HSV2-UL19-3668 + GUCCACGUUUCCGCGCGG 18 8051
HSV2-UL19-3669 + GGUCCACGU UUCCGCGCGG 19 8052
HSV2-UL19-3670 + GGGCGCUGCGUAGCAGGG 18 8053
HSV2-UL19-1113 + GCGGGCGCUGCG UAGCAGGG 20 1353
HSV2-UL19-3671 + GCGGGAUGCAGCGGGUGGG 19 8054
HSV2-UL19-1300 + GGCGGGAUGCAGCGGGUGGG 20 1540
HSV2-UL19-3672 + GAU UGGCGGGAUGCAGCGGGUGGG 24
8055
HSV2-UL19-3673 + GCGGCGAAGCGCUCCAUGG 19 8056
HSV2-UL19-3674 + GCGCGGCGAAGCGCUCCAUGG 21 8057
HSV2-UL19-3675 + GUGCGCGGCGAAGCGCUCCAUGG 23 8058
HSV2-UL19-3676 + GUGUUGGCCACCAGAUUGG 19 8059
HSV2-UL19-3677 + GACCGUGUUGGCCACCAGAUUGG 23 8060
HSV2-UL19-3118 + GACGUUGCGCGCGAGCUG 18 7501
HSV2-UL19-3119 + GGACGUUGCGCGCGAGCUG 19 7502
HSV2-UL19-3120 + GCCUGGACGUUGCGCGCGAGCUG 23 7503
HSV2-UL19-3121 + GGCCUGGACGUUGCGCGCGAGCUG 24 7504
HSV2-UL19-3678 + GUGCUGCACCACGGGCUG 18 8061
HSV2-UL19-2593 + GCGUGCUGCACCACGGGCUG 20 2737
HSV2-UL19-3679 + GGCGUGCUGCACCACGGGCUG 21 8062
HSV2-UL19-3680 + GGGCGUGCUGCACCACGGGCUG 22 8063
HSV2-UL19-3681 + GCGGGCGUGCUGCACCACGGGCUG 24 8064
HSV2-UL19-3682 + GAGGGAACGCGCGGGGCU 18 8065
HSV2-UL19-3683 + GGAGGGAACGCGCGGGGCU 19 8066
HSV2-UL19-2733 + GGGAGGGAACGCGCGGGGCU 20 2831
HSV2-UL19-3684 + GGGGAGGGAACGCGCGGGGCU 21 8067
HSV2-UL19-3685 + GCCGGGGAGGGAACGCGCGGGGCU 24 8068
HSV2-UL19-3686 + GCCGCGACGUACGCCCCGU 19 8069
HSV2-UL19-2716 + GGCCGCGACGUACGCCCCGU 20 2821
HSV2-UL19-3687 + GGGCCGCGACGUACGCCCCGU 21 8070
HSV2-UL19-3688 + GGGGCCGCGACGUACGCCCCGU 22 8071
HSV2-UL19-3689 + G U AG AAG U AU U CGCCAU U 18 8072
HSV2-UL19-3690 + GACGUAGAAGUAUUCGCCAU U 21 8073
HSV2-UL19-3691 + GGACGUAGAAGUAUUCGCCAUU 22 8074
HSV2-UL19-3692 + GUUGUCUGGGGGGCGCU U 18 8075
HSV2-UL19-2756 + GCGU UGUCUGGGGGGCGCUU 20 2845
HSV2-UL19-3693 + GCGCGU UGUCUGGGGGGCGCUU 22 8076
HSV2-UL19-3694 - GAGCGUCUCAUCGUGGAAA 19 8077 HSV2-UL19-706 - GGAGCGUCUCAUCGUGGAAA 20 946
HSV2-UL19-3695 - GCCUGGAGCGUCUCAUCGUGGAAA 24 8078
HSV2-UL19-3696 - GCGCGGGCGGCCGGUCGA 18 8079
HSV2-UL19-3697 - GACACGCGCGGGCGGCCGGUCGA 23 8080
HSV2-UL19-2002 - GACAACGGGCGCCUGGCGAC 20 2347
HSV2-UL19-3698 - GCCGCGCGGAAACGUGGAC 19 8081
HSV2-UL19-2173 - GCUCAAGACGGGCCUCCACC 20 2462
HSV2-UL19-3699 - GAACCACGACCCCGUCGAGGCC 22 8082
HSV2-UL19-3700 - GUGAACCACGACCCCGUCGAGGCC 24 8083
HSV2-UL19-3701 - GGGGCGCUGCUGCACCGC 18 8084
HSV2-UL19-3702 - GGGGGCGCUGCUGCACCGC 19 8085
HSV2-UL19-3703 - GCGGGGGCGCUGCUGCACCGC 21 8086
HSV2-UL19-3704 - GUGCAGUUUAAGCGCCCGC 19 8087
HSV2-UL19-3705 - G ACG UGCAGU U U AAGCGCCCGC 22 8088
HSV2-UL19-3706 - GCGACGUGCAGUUUAAGCGCCCGC 24 8089
HSV2-UL19-3707 - GCCCCCCAGACAACGCGCGUGCGC 24 8090
HSV2-UL19-3708 - GGGCAGGCUCAGGCCGAG 18 8091
HSV2-UL19-2123 - GCGGGCAGGCUCAGGCCGAG 20 2431
HSV2-UL19-3709 - GGCGGGCAGGCUCAGGCCGAG 21 8092
HSV2-UL19-3710 - GGGCGGGCAGGCUCAGGCCGAG 22 8093
HSV2-UL19-3711 - GAGGCGAACCGGGAGACG 18 8094
HSV2-UL19-3712 - GCCUCGCCCACGGCCGGGUCCG 22 8095
HSV2-UL19-3713 - GCGCCUCGCCCACGGCCGGGUCCG 24 8096
HSV2-UL19-3714 - GCCGGGUCCGGUGGGUCG 18 8097
HSV2-UL19-3715 - GGCCGGGUCCGGUGGGUCG 19 8098
HSV2-UL19-3716 - GCAGCGCCUCGCCCACGG 18 8099
HSV2-UL19-3717 - GGCAGCGCCUCGCCCACGG 19 8100
HSV2-UL19-3718 - GCGGCAGCGCCUCGCCCACGG 21 8101
HSV2-UL19-3719 - GGCGGCAGCGCCUCGCCCACGG 22 8102
HSV2-UL19-629 - GCCCGCCACGAAACGGGCGG 20 869
HSV2-UL19-3720 - GGCCCGCCACGAAACGGGCGG 21 8103
HSV2-UL19-3721 - GUGGCCCGCCACGAAACGGGCGG 23 8104
HSV2-UL19-3722 - GGUGGCCCGCCACGAAACGGGCGG 24 8105
HSV2-UL19-3723 - GCCGGCAUGGACCACGGG 18 8106
HSV2-UL19-2206 - GCGCCGGCAUGGACCACGGG 20 2485
HSV2-UL19-3724 - GCGCGCCGGCAUGGACCACGGG 22 8107
HSV2-UL19-3725 - GGCGCGCCGGCAUGGACCACGGG 23 8108
HSV2-UL19-606 - GCUGACCUACGCGCUCAUGG 20 846
HSV2-UL19-3726 - GCGCUGACCUACGCGCUCAUGG 22 8109
HSV2-UL19-3727 - GACCACACCAUCCAAAAUG 19 8110
HSV2-UL19-2156 - GGACCACACCAUCCAAAAUG 20 2452
HSV2-UL19-3728 - GGACCGCCACCGAGACUG 18 8111
HSV2-UL19-3729 - GCCCUGGACCGCCACCGAGACUG 23 8112
HSV2-UL19-3730 - GGCCCUGGACCGCCACCGAGACUG 24 8113
HSV2-UL19-3731 - GACG UGGGCCGCCACCUG 18 8114
HSV2-UL19-3732 - GACGACGUGGGCCGCCACCUG 21 8115 HSV2-UL19-3733 - GGACGACGUGGGCCGCCACCUG 22 8116
HSV2-UL19-3734 - GUCCCGGAGAUCGCCCCCGGUG 22 8117
HSV2-UL19-3735 - GGUCCCGGAGAUCGCCCCCGGUG 23 8118
HSV2-UL19-2174 - GACGGGCCUCCACCCCGGGU 20 2463
HSV2-UL19-3736 - GACCACGGGCAGGAUGCCGUGU 22 8119
HSV2-UL19-3737 - GGACCACGGGCAGGAUGCCGUGU 23 8120
Table 6F provides exemplary targeting domains for knocking out the UL19 gene selected according to the six tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 6F
Figure imgf000356_0001
HSV2-UL19-3756 + UUGUUCCAGUAGCUGGUGAUGCA 23 8139
HSV2-UL19-1304 + CGGGUGGGCGGGGUCGGUCA 20 1544
HSV2-UL19-3757 + AGCGGGUGGGCGGGGUCGGUCA 22 8140
HSV2-UL19-3758 + CAGCGGGUGGGCGGGGUCGGUCA 23 8141
HSV2-U L19-3759 + ACGGAUUCGCGGCCUCGA 18 8142
HSV2-U L19-3760 + UACGGAUUCGCGGCCUCGA 19 8143
HSV2-UL19-3761 + CGUACGGAU UCGCGGCCUCGA 21 8144
HSV2-U L19-3762 + CCGUACGGAUUCGCGGCCUCGA 22 8145
HSV2-U L19-3763 + CCCGUACGGAUUCGCGGCCUCGA 23 8146
HSV2-UL19-3764 + CCCCGUACGGAUUCGCGGCCUCGA 24 8147
HSV2-U L19-3765 + CGGGGUCGCUGGCGCAGGUGA 21 8148
HSV2-UL19-3766 + AGUUGAUG UCCGUGGCCAC 19 8149
HSV2-UL19-1166 + UAGUUGAUGUCCGUGGCCAC 20 1406
HSV2-U L19-3767 + AGUAGUUGAUGUCCGUGGCCAC 22 8150
HSV2-UL19-3768 + AAG UAGU UGAUGUCCGUGGCCAC 23 8151
HSV2-U L19-3769 + AAAGUAGUUGAUG UCCGUGGCCAC 24 8152
HSV2-U L19-3770 + CCGCUUCAGCUCGGCGAC 18 8153
HSV2-UL19-3771 + UCCGCUUCAGCUCGGCGAC 19 8154
HSV2-U L19-2771 + CUCCGCU UCAGCUCGGCG AC 20 2856
HSV2-UL19-3772 + AGCUCCGCUUCAGCUCGGCGAC 22 8155
HSV2-UL19-3773 + AAGCUCCGCUUCAGCUCGGCGAC 23 8156
HSV2-U L19-3774 + AAAGCUCCGCUUCAGCUCGGCGAC 24 8157
HSV2-UL19-3775 + CGACGGUGAACCCGAACC 18 8158
HSV2-UL19-3776 + ACGACGGUGAACCCGAACC 19 8159
HSV2-U L19-1222 + CACGACGGUGAACCCGAACC 20 1462
HSV2-UL19-3777 + CGCACG ACGG U G AACCCG AACC 22 8160
HSV2-U L19-3778 + CCGCACGACGGUGAACCCGAACC 23 8161
HSV2-U L19-3779 + CG CCG G CCGCG CG U CCCC 18 8162
HSV2-UL19-3780 + CCGCCGGCCGCGCGUCCCC 19 8163
HSV2-U L19-3781 + CGCCGCCGGCCGCGCGUCCCC 21 8164
HSV2-U L19-3782 + ACGCCGCCGGCCGCGCGUCCCC 22 8165
HSV2-UL19-3783 + CACGCCGCCGGCCGCGCGUCCCC 23 8166
HSV2-U L19-3784 + ACACGCCGCCGGCCGCGCGUCCCC 24 8167
HSV2-UL19-3785 + AGAACCGCUGCGACGCCC 18 8168
HSV2-UL19-2535 + CGAGAACCGCUGCGACGCCC 20 2698
HSV2-U L19-3786 + ACG AGAACCGCUGCGACGCCC 21 8169
HSV2-UL19-3787 + UACGAGAACCGCUGCGACGCCC 22 8170
HSV2-U L19-3788 + CGUACGAGAACCGCUGCGACGCCC 24 8171
HSV2-U L19-3789 + AGCGUCUCCCGGUUCGCC 18 8172
HSV2-UL19-3790 + CAGCGUCUCCCGGUUCGCC 19 8173
HSV2-UL19-2757 + CCAGCGUCUCCCGGUUCGCC 20 2846
HSV2-UL19-3791 + UCCAGCGUCUCCCGGUUCGCC 21 8174
HSV2-UL19-3792 + AUCCAGCGUCUCCCGGU UCGCC 22 8175
HSV2-U L19-3793 + CAUCCAGCGUCUCCCGG UUCGCC 23 8176
HSV2-UL19-3794 + UCAUCCAGCGUCUCCCGGU UCGCC 24 8177
HSV2-UL19-3795 + UCGCUGGCAGCGGUGGCC 18 8178 HSV2-UL19-2521 + CGUCGCUGGCAGCGGUGGCC 20 2685
HSV2-UL19-3796 + ACGUCGCUGGCAGCGGUGGCC 21 8179
HSV2-UL19-3797 + CACGUCGCUGGCAGCGG UGGCC 22 8180
HSV2-UL19-3798 + UGCACGUCGCUGGCAGCGGUGGCC 24 8181
HSV2-U L19-3799 + AGAACACGUGCUCGUUGCC 19 8182
HSV2-U L19-2680 + CAGAACACGUGCUCGU UGCC 20 2795
HSV2-UL19-3800 + CGCAGAACACGUGCUCGUUGCC 22 8183
HSV2-U L19-3801 + CUUCCUGAAACAGGCCGC 18 8184
HSV2-U L19-3802 + AGGCUUCCUGAAACAGGCCGC 21 8185
HSV2-UL19-3803 + UAGGCUUCCUGAAACAGGCCGC 22 8186
HSV2-U L19-3804 + CGGCGUCGGCCGCGCGGGC 19 8187
HSV2-UL19-3805 + CGGCGGCGUCGGCCGCGCGGGC 22 8188
HSV2-UL19-3806 + UCGGCGGCGUCGGCCGCGCGGGC 23 8189
HSV2-U L19-3807 + UGACCACGCGCCAGGUGGC 19 8190
HSV2-UL19-2690 + UUGACCACGCGCCAGGUGGC 20 2804
HSV2-U L19-3808 + CGU UGACCACGCGCCAGGUGGC 22 8191
HSV2-U L19-3809 + CCG U UGACCACGCGCCAGGUGGC 23 8192
HSV2-UL19-3810 + CCGCGAAGAAGUCGAACG 18 8193
HSV2-U L19-3811 + CCCGCGAAGAAGUCGAACG 19 8194
HSV2-UL19-3812 + CGCCCGCGAAGAAGUCGAACG 21 8195
HSV2-UL19-3813 + ACGCCCGCGAAGAAGUCGAACG 22 8196
HSV2-U L19-3814 + CACGCCCGCGAAGAAGUCGAACG 23 8197
HSV2-UL19-3815 + CCACGCCCGCG AAG AAG UCGAACG 24 8198
HSV2-UL19-3816 + U G C AG C AG G U A AAACACCG 19 8199
HSV2-U L19-2681 + U U G CAG CAG G U A AAACACCG 20 2796
HSV2-UL19-3817 + CUUGCAGCAGGUAAAACACCG 21 8200
HSV2-U L19-3818 + CG G CU U G CAG CAG G U A AAACACCG 24 8201
HSV2-U L19-3819 + CGAGGGGCGGCAGCAGCG 18 8202
HSV2-UL19-3820 + ACGAGGGGCGGCAGCAGCG 19 8203
HSV2-U L19-2661 + CACGAGGGGCGGCAGCAGCG 20 2779
HSV2-U L19-3821 + ACACGAGGGGCGGCAGCAGCG 21 8204
HSV2-UL19-3822 + CACACGAGGGGCGGCAGCAGCG 22 8205
HSV2-U L19-3823 + CCACACGAGGGGCGGCAGCAGCG 23 8206
HSV2-UL19-3824 + CCCACACGAGGGGCGGCAGCAGCG 24 8207
HSV2-UL19-3825 + CGUCGAUGU UCAUGAGCG 18 8208
HSV2-U L19-2721 + CGCGUCGAUGU UCAUGAGCG 20 2825
HSV2-UL19-3826 + CCGCGUCGAUGUUCAUGAGCG 21 8209
HSV2-U L19-3827 + CGGCCGCGUCGAUG UUCAUGAGCG 24 8210
HSV2-U L19-3828 + UGGCCGCGAAGGGCCGCG 18 8211
HSV2-UL19-2538 + CGUGGCCGCGAAGGGCCGCG 20 2701
HSV2-UL19-3829 + CCGUGGCCGCGAAGGGCCGCG 21 8212
HSV2-UL19-3830 + UGGCCGUGGCCGCGAAGGGCCGCG 24 8213
HSV2-UL19-3831 + CGCCCAGCUCCGGGCCCGG 19 8214
HSV2-U L19-2664 + CCGCCCAGCUCCGGGCCCGG 20 2782
HSV2-UL19-3832 + CCCGCCCAGCUCCGGGCCCGG 21 8215
HSV2-UL19-3833 + UGCCCGCCCAGCUCCGGGCCCGG 23 8216 HSV2-UL19-3834 + CUGCCCGCCCAGCUCCGGGCCCGG 24 8217
HSV2-UL19-2569 + AGG UCCACGU U UCCGCGCGG 20 2718
HSV2-UL19-3835 + CAG G U CCACG U UUCCGCGCGG 21 8218
HSV2-UL19-3836 + CCAGGUCCACGUUUCCGCGCGG 22 8219
HSV2-U L19-3837 + CCCAGGUCCACGUU UCCGCGCGG 23 8220
HSV2-U L19-3838 + ACCC AG G U CCACG U U U CCG CG CG G 24 8221
HSV2-UL19-3839 + CGGGCGCUGCGUAGCAGGG 19 8222
HSV2-U L19-3840 + CGCGGGCGCUGCGUAGCAGGG 21 8223
HSV2-U L19-3841 + UCGCGGGCGCUGCGUAGCAGGG 22 8224
HSV2-UL19-3842 + AUCGCGGGCGCUGCGUAGCAGGG 23 8225
HSV2-U L19-3843 + CAUCGCGGGCGCUGCGUAGCAGGG 24 8226
HSV2-UL19-3844 + CGGGAUGCAGCGGGUGGG 18 8227
HSV2-UL19-3845 + UGGCGGGAUGCAGCGGGUGGG 21 8228
HSV2-U L19-3846 + UUGGCGGGAUGCAGCGGGUGGG 22 8229
HSV2-UL19-3847 + AU UGGCGGGAUGCAGCGGGUGGG 23 8230
HSV2-U L19-3848 + CGGCGAAGCGCUCCAUGG 18 8231
HSV2-U L19-2739 + CGCGGCGAAGCGCUCCAUGG 20 2835
HSV2-UL19-3849 + UGCGCGGCGAAGCGCUCCAUGG 22 8232
HSV2-U L19-3850 + CGUGCGCGGCGAAGCGCUCCAUGG 24 8233
HSV2-UL19-3851 + UGU UGGCCACCAGAU UGG 18 8234
HSV2-UL19-1294 + CGUGUUGGCCACCAGAUUGG 20 1534
HSV2-U L19-3852 + CCGUGUUGGCCACCAGAUUGG 21 8235
HSV2-UL19-3853 + ACCGUGUUGGCCACCAGAUUGG 22 8236
HSV2-UL19-3854 + U G ACCG UG U U GGCCACCAG AU U GG 24 8237
HSV2-U L19-3155 + UGGACGUUGCGCGCGAGCUG 20 7538
HSV2-UL19-3156 + CUGGACGUUGCGCGCGAGCUG 21 7539
HSV2-U L19-3157 + CCUGGACGUUGCGCGCGAGCUG 22 7540
HSV2-U L19-3855 + CGUGCUGCACCACGGGCUG 19 8238
HSV2-UL19-3856 + CGGGCGUGCUGCACCACGGGCUG 23 8239
HSV2-U L19-3857 + CGGGGAGGGAACGCGCGGGGCU 22 8240
HSV2-U L19-3858 + CCGGGGAGGGAACGCGCGGGGCU 23 8241
HSV2-UL19-3859 + CCGCGACG UACGCCCCGU 18 8242
HSV2-U L19-3860 + CGGGGCCGCGACGUACGCCCCGU 23 8243
HSV2-UL19-3861 + CCGGGGCCGCGACGUACGCCCCGU 24 8244
HSV2-UL19-3862 + CGUAGAAG UAUUCGCCAUU 19 8245
HSV2-U L19-2621 + ACGUAGAAGUAU UCGCCAUU 20 2751
HSV2-UL19-3863 + AGGACGUAGAAGUAU UCGCCAUU 23 8246
HSV2-U L19-3864 + CAGGACGUAGAAGUAUUCGCCAUU 24 8247
HSV2-U L19-3865 + CGUUGUCUGGGGGGCGCUU 19 8248
HSV2-UL19-3866 + CGCGUUGUCUGGGGGGCGCUU 21 8249
HSV2-UL19-3867 + CGCGCGU UGUCUGGGGGGCGCUU 23 8250
HSV2-UL19-3868 + ACGCGCGUUGUCUGGGGGGCGCUU 24 8251
HSV2-UL19-3869 - AGCGUCUCAUCGUGGAAA 18 8252
HSV2-U L19-3870 - UGGAGCGUCUCAUCGUGGAAA 21 8253
HSV2-UL19-3871 - CUGG AGCGUCUCAUCGUGGAAA 22 8254
HSV2-UL19-3872 - CCUGG AGCGUCUCAUCGUGGAAA 23 8255 HSV2-UL19-3873 - CGCGCGGGCGGCCGGUCGA 19 8256
HSV2-UL19-375 - ACGCGCGGGCGGCCGGUCGA 20 615
HSV2-UL19-3874 - CACGCGCGGGCGGCCGGUCGA 21 8257
HSV2-UL19-3875 - ACACGCGCGGGCGGCCGGUCGA 22 8258
HSV2-U L19-3876 - CGACACGCGCGGGCGGCCGGUCGA 24 8259
HSV2-U L19-3877 - CAACGGGCGCCUGGCGAC 18 8260
HSV2-UL19-3878 - ACAACGGGCGCCUGGCGAC 19 8261
HSV2-U L19-3879 - CGACAACGGGCGCCUGGCGAC 21 8262
HSV2-U L19-3880 - UCG ACAACGGGCGCCUGGCGAC 22 8263
HSV2-UL19-3881 - CUCG ACAACGGGCGCCUGGCGAC 23 8264
HSV2-U L19-3882 - UCUCGACAACGGGCGCCUGGCGAC 24 8265
HSV2-UL19-3883 - CCGCGCGGAAACGUGGAC 18 8266
HSV2-UL19-2192 - AGCCGCGCGGAAACGUGGAC 20 2475
HSV2-U L19-3884 - CAGCCGCGCGGAAACGUGGAC 21 8267
HSV2-UL19-3885 - CCAGCCGCGCGGAAACGUGGAC 22 8268
HSV2-U L19-3886 - CCCAGCCGCGCGGAAACGUGGAC 23 8269
HSV2-U L19-3887 - ACCCAGCCGCGCGGAAACGUGGAC 24 8270
HSV2-UL19-3888 - UCAAGACGGGCCUCCACC 18 8271
HSV2-U L19-3889 - CUCAAGACGGGCCUCCACC 19 8272
HSV2-UL19-3890 - AGCUCAAGACGGGCCUCCACC 21 8273
HSV2-UL19-3891 - CAGCUCAAGACGGGCCUCCACC 22 8274
HSV2-U L19-3892 - CCAGCUCAAGACGGGCCUCCACC 23 8275
HSV2-UL19-3893 - ACCAGCUCAAGACGGGCCUCCACC 24 8276
HSV2-UL19-3894 - CACGACCCCGUCGAGGCC 18 8277
HSV2-U L19-3895 - CCACGACCCCGUCGAGGCC 19 8278
HSV2-UL19-2077 - ACCACGACCCCGUCGAGGCC 20 2399
HSV2-U L19-3896 - AACCACGACCCCGUCGAGGCC 21 8279
HSV2-U L19-3897 - UGAACCACGACCCCGUCGAGGCC 23 8280
HSV2-UL19-558 - CGGGGGCGCUGCUGCACCGC 20 798
HSV2-U L19-3898 - CGCGGGGGCGCUGCUGCACCGC 22 8281
HSV2-U L19-3899 - UCGCGGGGGCGCUGCUGCACCGC 23 8282
HSV2-UL19-3900 - CUCGCGGGGGCGCUGCUGCACCGC 24 8283
HSV2-U L19-3901 - UGCAGUUUAAGCGCCCGC 18 8284
HSV2-UL19-711 - CGUGCAGU UUAAGCGCCCGC 20 951
HSV2-UL19-3902 - ACG UGCAG U U U AAGCGCCCGC 21 8285
HSV2-U L19-3903 - CGACGUGCAGU UUAAGCGCCCGC 23 8286
HSV2-UL19-3904 - CAGACAACGCGCGUGCGC 18 8287
HSV2-U L19-3905 - CCAGACAACGCGCGUGCGC 19 8288
HSV2-U L19-2044 - CCCAGACAACGCGCGUGCGC 20 2380
HSV2-UL19-3906 - CCCCAGACAACGCGCGUGCGC 21 8289
HSV2-UL19-3907 - CCCCCAGACAACGCGCGUGCGC 22 8290
HSV2-UL19-3908 - CCCCCCAG AC A ACG CGCGUGCGC 23 8291
HSV2-UL19-3909 - CGGGCAGGCUCAGGCCGAG 19 8292
HSV2-U L19-3910 - UGGGCGGGCAGGCUCAGGCCGAG 23 8293
HSV2-UL19-3911 - CUGGGCGGGCAGGCUCAGGCCGAG 24 8294
HSV2-UL19-3912 - CGAGGCGAACCGGGAGACG 19 8295 HSV2-UL19-2041 - UCGAGGCGAACCGGGAGACG 20 2377
HSV2-UL19-3913 - CUCGAGGCGAACCGGGAGACG 21 8296
HSV2-UL19-3914 - ACUCGAGGCGAACCGGGAGACG 22 8297
HSV2-UL19-3915 - AACUCGAGGCGAACCGGGAGACG 23 8298
HSV2-U L19-3916 - CAACUCGAGGCGAACCGGGAGACG 24 8299
HSV2-U L19-3917 - UCGGGGGCGACCUCCCCG 18 8300
HSV2-UL19-3918 - CUCGGGGGCGACCUCCCCG 19 8301
HSV2-UL19-507 - CCUCGGGGGCGACCUCCCCG 20 747
HSV2-U L19-3919 - ACCUCGGGGGCGACCUCCCCG 21 8302
HSV2-UL19-3920 - UACCUCGGGGGCGACCUCCCCG 22 8303
HSV2-U L19-3921 - CUACCUCGGGGGCGACCUCCCCG 23 8304
HSV2-UL19-3922 - CCUACCUCGGGGGCGACCUCCCCG 24 8305
HSV2-UL19-3923 - CGCCCACGGCCGGGUCCG 18 8306
HSV2-U L19-3924 - UCGCCCACGGCCGGGUCCG 19 8307
HSV2-UL19-2083 - CUCGCCCACGGCCGGGUCCG 20 2404
HSV2-U L19-3925 - CCUCGCCCACGGCCGGGUCCG 21 8308
HSV2-U L19-3926 - CGCCUCGCCCACGGCCGGGUCCG 23 8309
HSV2-UL19-2084 - CGGCCGGGUCCGGUGGGUCG 20 2405
HSV2-U L19-3927 - ACGGCCGGGUCCGGUGGGUCG 21 8310
HSV2-UL19-3928 - CACGGCCGGGUCCGGUGGGUCG 22 8311
HSV2-UL19-3929 - CCACGGCCGGGUCCGGUGGGUCG 23 8312
HSV2-U L19-3930 - CCCACGGCCGGGUCCGGUGGGUCG 24 8313
HSV2-UL19-2082 - CGGCAGCGCCUCGCCCACGG 20 2403
HSV2-UL19-3931 - UGGCGGCAGCGCCUCGCCCACGG 23 8314
HSV2-U L19-3932 - CUGGCGGCAGCGCCUCGCCCACGG 24 8315
HSV2-UL19-3933 - CCGCCACGAAACGGGCGG 18 8316
HSV2-U L19-3934 - CCCGCCACGAAACGGGCGG 19 8317
HSV2-U L19-3935 - UGGCCCGCCACGAAACGGGCGG 22 8318
HSV2-UL19-3936 - CGCCGGCAUGGACCACGGG 19 8319
HSV2-U L19-3937 - CGCGCCGGCAUGGACCACGGG 21 8320
HSV2-U L19-3938 - CGGCGCGCCGGCAUGGACCACGGG 24 8321
HSV2-UL19-3939 - UGACCUACGCGCUCAUGG 18 8322
HSV2-U L19-3940 - CUGACCUACGCGCUCAUGG 19 8323
HSV2-UL19-3941 - CGCUGACCUACGCGCUCAUGG 21 8324
HSV2-UL19-3942 - CGCGCUGACCUACGCGCUCAUGG 23 8325
HSV2-U L19-3943 - ACGCGCUGACCUACGCGCUCAUGG 24 8326
HSV2-UL19-3944 - ACCACACC AU CCA AAA U G 18 8327
HSV2-U L19-3945 - U G G ACC AC ACC A U CC A A A AU G 21 8328
HSV2-U L19-3946 - CUGGACCACACCAUCCAAAAUG 22 8329
HSV2-UL19-3947 - CCUGGACCACACCAUCCAAAAUG 23 8330
HSV2-UL19-3948 - ACCUGGACCACACCAUCCAAAAUG 24 8331
HSV2-UL19-3949 - UGGACCGCCACCGAGACUG 19 8332
HSV2-UL19-2128 - CUGGACCGCCACCGAGACUG 20 2435
HSV2-U L19-3950 - CCUGGACCGCCACCGAGACUG 21 8333
HSV2-UL19-3951 - CCCUGGACCGCCACCGAGACUG 22 8334
HSV2-UL19-3952 - CGACGUGGGCCGCCACCUG 19 8335 HSV2-UL19-2031 - ACGACGUGGGCCGCCACCUG 20 2371
HSV2-UL19-3953 - UGGACGACGUGGGCCGCCACCUG 23 8336
HSV2-UL19-3954 - CUGGACGACGUGGGCCGCCACCUG 24 8337
HSV2-UL19-3955 - CGGAGAUCGCCCCCGGUG 18 8338
HSV2-U L19-3956 - CCGGAGAUCGCCCCCGGUG 19 8339
HSV2-UL19-565 - CCCGGAGAUCGCCCCCGGUG 20 805
HSV2-UL19-3957 - UCCCGGAGAUCGCCCCCGGUG 21 8340
HSV2-U L19-3958 - UGGUCCCGGAGAUCGCCCCCGGUG 24 8341
HSV2-U L19-3959 - CGGGCCUCCACCCCGGGU 18 8342
HSV2-UL19-3960 - ACGGGCCUCCACCCCGGGU 19 8343
HSV2-U L19-3961 - AGACGGGCCUCCACCCCGGGU 21 8344
HSV2-UL19-3962 - AAGACGGGCCUCCACCCCGGGU 22 8345
HSV2-UL19-3963 - CAAGACGGGCCUCCACCCCGGGU 23 8346
HSV2-U L19-3964 - U C A AG ACGGGCCUCCACCCCGGGU 24 8347
HSV2-UL19-3965 - ACGGGCAGGAUGCCG UGU 18 8348
HSV2-U L19-3966 - CACGGGCAGGAUGCCGUGU 19 8349
HSV2-U L19-2207 - CCACGGGCAGGAUGCCGUGU 20 2486
HSV2-UL19-3967 - ACCACGGGCAGGAUGCCGUGU 21 8350
HSV2-U L19-3968 - UGGACCACGGGCAGGAUGCCGUGU 24 8351
Table 6G provides exemplary targeting domains for knocking out the UL19 gene selected according to the seven tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). The PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 6G
Figure imgf000362_0001
HSV2-UL19-3977 + CCCCCAGGGCCGGGGGGACCA 21 8360
HSV2-UL19-3978 + GCCCCCAGGGCCGGGGGGACCA 22 8361
HSV2-UL19-3979 + GGCCCCCAGGGCCGGGGGGACCA 23 8362
HSV2-UL19-3980 + UGGCCCCCAGGGCCGGGGGGACCA 24 8363
HSV2-UL19-3981 + CUGGCACUCGGCGACCCA 18 8364
HSV2-UL19-3982 + UCUGGCACUCGGCGACCCA 19 8365
HSV2-UL19-2708 + AUCUGGCACUCGGCGACCCA 20 2815
HSV2-UL19-3983 + CAUCUGGCACUCGGCGACCCA 21 8366
HSV2-UL19-3984 + UCAUCUGGCACUCGGCGACCCA 22 8367
HSV2-UL19-3985 + GUCAUCUGGCACUCGGCGACCCA 23 8368
HSV2-UL19-3986 + GGUCAUCUGGCACUCGGCGACCCA 24 8369
HSV2-UL19-3987 + GGGCGUCACGAAACGCCA 18 8370
HSV2-UL19-3988 + CGGGCGUCACGAAACGCCA 19 8371
HSV2-UL19-2687 + CCGGGCGUCACGAAACGCCA 20 2802
HSV2-UL19-3989 + CCCGGGCGUCACGAAACGCCA 21 8372
HSV2-UL19-3990 + CCCCGGGCGUCACGAAACGCCA 22 8373
HSV2-UL19-3991 + GCCCCGGGCGUCACGAAACGCCA 23 8374
HSV2-UL19-3992 + GGCCCCGGGCGUCACGAAACGCCA 24 8375
HSV2-UL19-3993 + GCUGGUGAUACAGGGCCA 18 8376
HSV2-UL19-3994 + AGCUGGUGAUACAGGGCCA 19 8377
HSV2-UL19-1230 + GAGCUGGUGAUACAGGGCCA 20 1470
HSV2-UL19-3995 + UGAGCUGGUGAUACAGGGCCA 21 8378
HSV2-UL19-3996 + UUGAGCUGGUGAUACAGGGCCA 22 8379
HSV2-UL19-3997 + CU UGAGCUGGUGAUACAGGGCCA 23 8380
HSV2-UL19-3998 + UCUUGAGCUGGUGAUACAGGGCCA 24 8381
HSV2-UL19-3999 + U G G G CAACAG CAG G G CCA 18 8382
HSV2-UL19-4000 + AU G G G CAACAG CAG G G CCA 19 8383
HSV2-UL19-1541 + CAU G G G CAACAG C AG G G CCA 20 1781
HSV2-UL19-4001 + G CAU G G G CAACAG CAG G G CCA 21 8384
HSV2-UL19-4002 + U G CAU G G G CAACAG CAG GG CCA 22 8385
HSV2-UL19-4003 + UUGCAUGGG CAACAG CAG G G CCA 23 8386
HSV2-UL19-4004 + GUUGCAUGGGCAACAGCAGGGCCA 24 8387
HSV2-UL19-4005 + AGU UGAUGUCCGUGGCCA 18 8388
HSV2-UL19-4006 + UAGUUGAUGUCCGUGGCCA 19 8389
HSV2-UL19-1165 + GUAGUUGAUGUCCGUGGCCA 20 1405
HSV2-UL19-4007 + AGU AGUUGAUGUCCGUGGCCA 21 8390
HSV2-UL19-4008 + AAG UAGUUGAUGUCCGUGGCCA 22 8391
HSV2-UL19-4009 + AAAGU AGUUGAUGUCCGUGGCCA 23 8392
HSV2-UL19-4010 + GAAAGUAGUUGAUGUCCGUGGCCA 24 8393
HSV2-UL19-4011 + CGGCCGCGUUGUCUAGCA 18 8394
HSV2-UL19-4012 + GCGGCCGCGUUGUCUAGCA 19 8395
HSV2-UL19-2555 + GGCGGCCGCGUUGUCUAGCA 20 2713
HSV2-UL19-4013 + CGGCGGCCGCGUUGUCUAGCA 21 8396
HSV2-UL19-4014 + ACGGCGGCCGCGUUGUCUAGCA 22 8397
HSV2-UL19-4015 + CACGGCGGCCGCGUUGUCUAGCA 23 8398
HSV2-UL19-4016 + ACACGGCGGCCGCGUUGUCUAGCA 24 8399 HSV2-UL19-4017 + UCGCUCGGGCACUCCUCA 18 8400
HSV2-UL19-4018 + AUCGCUCGGGCACUCCUCA 19 8401
HSV2-UL19-2644 + GAUCGCUCGGGCACUCCUCA 20 2766
HSV2-UL19-4019 + GGAUCGCUCGGGCACUCCUCA 21 8402
HSV2-UL19-4020 + GGGAUCGCUCGGGCACUCCUCA 22 8403
HSV2-UL19-4021 + CGGGAUCGCUCGGGCACUCCUCA 23 8404
HSV2-UL19-4022 + ACGGGAUCGCUCGGGCACUCCUCA 24 8405
HSV2-UL19-4023 + CCUGGGCGCAGCCAAAGA 18 8406
HSV2-UL19-4024 + ACCUGGGCGCAGCCAAAGA 19 8407
HSV2-UL19-2549 + CACCUGGGCGCAGCCAAAGA 20 2710
HSV2-UL19-4025 + GCACCUGGGCGCAGCCAAAGA 21 8408
HSV2-UL19-4026 + GGCACCUGGGCGCAG CCAAAG A 22 8409
HSV2-UL19-4027 + CGGCACCUGGGCGCAGCCAAAGA 23 8410
HSV2-UL19-4028 + GCGGCACCUGGGCGCAGCCAAAGA 24 8411
HSV2-UL19-4029 + GCACCACGGGCUGGCGGA 18 8412
HSV2-UL19-4030 + UGCACCACGGGCUGGCGGA 19 8413
HSV2-UL19-1240 + CUGCACCACGGGCUGGCGGA 20 1480
HSV2-UL19-4031 + GCUGCACCACGGGCUGGCGGA 21 8414
HSV2-UL19-4032 + UGCUGCACCACGGGCUGGCGGA 22 8415
HSV2-UL19-4033 + GUGCUGCACCACGGGCUGGCGGA 23 8416
HSV2-UL19-4034 + CGUGCUGCACCACGGGCUGGCGGA 24 8417
HSV2-UL19-4035 + AAAAACAG CUGCCGGGGA 18 8418
HSV2-UL19-4036 + AAAAAACAGCUGCCGGGGA 19 8419
HSV2-UL19-1450 + AAAAAAACAG CUGCCGGGGA 20 1690
HSV2-UL19-4037 + CAAAAAAACAGCUGCCGGGGA 21 8420
HSV2-UL19-4038 + CCAAAAAAACAG CU G CCG G G G A 22 8421
HSV2-UL19-4039 + CCCAAAAA AACAG CU G CCG G G G A 23 8422
HSV2-UL19-4040 + CCCCAAAAAAACAG CU G CCG G G G A 24 8423
HSV2-UL19-4041 + CCGCGUCGAUGUUCAUGA 18 8424
HSV2-UL19-4042 + GCCGCGUCGAUGUUCAUGA 19 8425
HSV2-UL19-2720 + GGCCGCGUCGAUGUUCAUGA 20 2824
HSV2-UL19-4043 + CGGCCGCGUCGAUGUUCAUGA 21 8426
HSV2-UL19-4044 + ACGGCCGCGUCGAUGUUCAUGA 22 8427
HSV2-UL19-4045 + GACGGCCGCGUCGAUGUUCAUGA 23 8428
HSV2-UL19-4046 + CGACGGCCGCGUCGAUGUUCAUGA 24 8429
HSV2-UL19-4047 + CGUCUUGAGCUGGUGAUA 18 8430
HSV2-UL19-4048 + CCGUCUUGAGCUGGUGAUA 19 8431
HSV2-UL19-2586 + CCCGUCUUGAGCUGGUGAUA 20 2731
HSV2-UL19-4049 + GCCCGUCUUGAGCUGGUGAUA 21 8432
HSV2-UL19-4050 + GGCCCGUCUUGAGCUGGUGAUA 22 8433
HSV2-UL19-4051 + AGGCCCGUCUUGAGCUGGUGAUA 23 8434
HSV2-UL19-4052 + GAGGCCCGUCUUGAGCUGGUGAUA 24 8435
HSV2-UL19-4053 + AGGUUGCCCAUGUCCGUA 18 8436
HSV2-UL19-4054 + GAGGUUGCCCAUGUCCGUA 19 8437
HSV2-UL19-2566 + GGAGGUUGCCCAUGUCCGUA 20 2716
HSV2-UL19-4055 + GGG AGGUUGCCCAUGUCCGUA 21 8438 HSV2-UL19-4056 + GGGGAGGUUGCCCAUGUCCGUA 22 8439
HSV2-UL19-4057 + GGGGGAGGUUGCCCAUGUCCGUA 23 8440
HSV2-UL19-4058 + UGGGGGAGGUUGCCCAUGUCCGUA 24 8441
HSV2-UL19-4059 + ACAG AGACAGGCCCU UU A 18 8442
HSV2-UL19-4060 + UACAGAGACAGGCCCUUUA 19 8443
HSV2-UL19-2505 + UUACAGAGACAGGCCCUUUA 20 2673
HSV2-UL19-4061 + UUUACAGAGACAGGCCCUUUA 21 8444
HSV2-UL19-4062 + U U U U ACAGAGACAGGCCCU U U A 22 8445
HSV2-UL19-4063 + AUUUUACAGAGACAGGCCCUUUA 23 8446
HSV2-UL19-4064 + AAU U U UACAG AGACAGGCCCU U U A 24 8447
HSV2-UL19-4065 + AAGAAGAAGCCAAUUUUA 18 8448
HSV2-UL19-4066 + GAAGAAGAAGCCAAUUUUA 19 8449
HSV2-UL19-4067 + GGAAGAAGAAGCCAAUUUUA 20 8450
HSV2-UL19-4068 + GGGAAGAAGAAGCCAAUUUUA 21 8451
HSV2-UL19-4069 + GGGGAAGAAGAAGCCAAUUUUA 22 8452
HSV2-UL19-4070 + UGGGGAAGAAGAAGCCAAUUUUA 23 8453
HSV2-UL19-4071 + CUGGGGAAGAAGAAGCCAAUUUUA 24 8454
HSV2-UL19-4072 + UCGGCCGCGGUGAAGAAC 18 8455
HSV2-UL19-4073 + GUCGGCCGCGGUGAAGAAC 19 8456
HSV2-UL19-2525 + UG UCGGCCGCGGUGAAGAAC 20 2689
HSV2-UL19-4074 + AU GUCGGCCGCGGUGAAGAAC 21 8457
HSV2-UL19-4075 + GAUG UCGGCCGCGGUGAAGAAC 22 8458
HSV2-UL19-4076 + UGAUGUCGGCCGCGGUGAAGAAC 23 8459
HSV2-UL19-4077 + GUGAUGUCGGCCGCGGUGAAGAAC 24 8460
HSV2-UL19-4078 + ACGACGGUGAACCCGAAC 18 8461
HSV2-UL19-4079 + CACGACGGUGAACCCGAAC 19 8462
HSV2-UL19-2581 + GCACGACGGUGAACCCGAAC 20 2728
HSV2-UL19-4080 + CGCACGACGGUGAACCCGAAC 21 8463
HSV2-UL19-4081 + CCGCACGACGGUGAACCCGAAC 22 8464
HSV2-UL19-4082 + GCCGCACGACGGUGAACCCGAAC 23 8465
HSV2-UL19-4083 + UGCCGCACGACGGUGAACCCGAAC 24 8466
HSV2-UL19-4084 + CCCGCGAAGAAGUCGAAC 18 8467
HSV2-UL19-4085 + GCCCGCGAAGAAGUCGAAC 19 8468
HSV2-UL19-2703 + CGCCCGCGAAGAAGUCGAAC 20 2811
HSV2-UL19-4086 + ACGCCCGCGAAGAAGUCGAAC 21 8469
HSV2-UL19-4087 + CACGCCCGCGAAGAAGUCGAAC 22 8470
HSV2-UL19-4088 + CCACGCCCGCGAAGAAGUCGAAC 23 8471
HSV2-UL19-4089 + GCCACGCCCGCGAAGAAGUCGAAC 24 8472
HSV2-UL19-4090 + UGCCGCACGACGGUGAAC 18 8473
HSV2-UL19-4091 + CUGCCGCACGACGGUGAAC 19 8474
HSV2-UL19-2580 + CCUGCCGCACGACGGUGAAC 20 2727
HSV2-UL19-4092 + UCCUGCCGCACGACGGUGAAC 21 8475
HSV2-UL19-4093 + GUCCUGCCGCACGACGGUGAAC 22 8476
HSV2-UL19-4094 + GGUCCUGCCGCACGACGGUGAAC 23 8477
HSV2-UL19-4095 + CGGUCCUGCCGCACGACGGUGAAC 24 8478
HSV2-UL19-4096 + GCCGUCGCAGUCCCACAC 18 8479 HSV2-UL19-4097 + GGCCGUCGCAGUCCCACAC 19 8480
HSV2-UL19-2659 + AGGCCGUCGCAGUCCCACAC 20 2778
HSV2-UL19-4098 + AAGGCCGUCGCAGUCCCACAC 21 8481
HSV2-UL19-4099 + UAAGGCCGUCGCAGUCCCACAC 22 8482
HSV2-UL19-4100 + AUAAGGCCGUCGCAGUCCCACAC 23 8483
HSV2-UL19-4101 + CAUAAGGCCGUCGCAGUCCCACAC 24 8484
HSV2-UL19-4102 + CAGGUCCAUGGCGCCCAC 18 8485
HSV2-UL19-4103 + UCAGGUCCAUGGCGCCCAC 19 8486
HSV2-UL19-2745 + GUCAGGUCCAUGGCGCCCAC 20 2840
HSV2-UL19-4104 + CGUCAGGUCCAUGGCGCCCAC 21 8487
HSV2-UL19-4105 + ACGUCAGGUCCAUGGCGCCCAC 22 8488
HSV2-UL19-4106 + AACGUCAGGUCCAUGGCGCCCAC 23 8489
HSV2-UL19-4107 + GAACGUCAGGUCCAUGGCGCCCAC 24 8490
HSV2-UL19-4108 + AGGCCGUCGCAGUCCCAC 18 8491
HSV2-UL19-4109 + AAGGCCGUCGCAGUCCCAC 19 8492
HSV2-UL19-2658 + UAAGGCCGUCGCAGUCCCAC 20 2777
HSV2-UL19-4110 + AUAAGGCCGUCGCAGUCCCAC 21 8493
HSV2-UL19-4111 + CAUAAGGCCGUCGCAGUCCCAC 22 8494
HSV2-UL19-4112 + GCAUAAGGCCGUCGCAGUCCCAC 23 8495
HSV2-UL19-4113 + CGCAUAAGGCCGUCGCAGUCCCAC 24 8496
HSV2-UL19-4114 + CGUUUCGUGGCGGGCCAC 18 8497
HSV2-UL19-4115 + CCGUUUCGUGGCGGGCCAC 19 8498
HSV2-UL19-2573 + CCCGUUUCGUGGCGGGCCAC 20 2722
HSV2-UL19-4116 + GCCCGUUUCGUGGCGGGCCAC 21 8499
HSV2-UL19-4117 + CGCCCGUUUCGUGGCGGGCCAC 22 8500
HSV2-UL19-4118 + CCGCCCGUUUCGUGGCGGGCCAC 23 8501
HSV2-UL19-4119 + CCCGCCCGUUUCGUGGCGGGCCAC 24 8502
HSV2-UL19-4120 + GCCGGCGCGCCGCGGCAC 18 8503
HSV2-UL19-4121 + UGCCGGCGCGCCGCGGCAC 19 8504
HSV2-UL19-2548 + AUGCCGGCGCGCCGCGGCAC 20 2709
HSV2-UL19-4122 + CAUGCCGGCGCGCCGCGGCAC 21 8505
HSV2-UL19-4123 + CCAUGCCGGCGCGCCGCGGCAC 22 8506
HSV2-UL19-4124 + UCCAUGCCGGCGCGCCGCGGCAC 23 8507
HSV2-UL19-4125 + GUCCAUGCCGGCGCGCCGCGGCAC 24 8508
HSV2-UL19-4126 + CGCUCGGGCACUCCUCAC 18 8509
HSV2-UL19-4127 + UCGCUCGGGCACUCCUCAC 19 8510
HSV2-UL19-1308 + AUCGCUCGGGCACUCCUCAC 20 1548
HSV2-UL19-4128 + GAUCGCUCGGGCACUCCUCAC 21 8511
HSV2-UL19-4129 + GGAUCGCUCGGGCACUCCUCAC 22 8512
HSV2-UL19-4130 + GGGAUCGCUCGGGCACUCCUCAC 23 8513
HSV2-UL19-4131 + CGGGAUCGCUCGGGCACUCCUCAC 24 8514
HSV2-UL19-4132 + CUGGGCGCAGCCAAAGAC 18 8515
HSV2-UL19-4133 + CCUGGGCGCAGCCAAAGAC 19 8516
HSV2-UL19-1176 + ACCUGGGCGCAGCCAAAGAC 20 1416
HSV2-UL19-4134 + CACCUGGGCGCAGCCAAAGAC 21 8517
HSV2-UL19-4135 + GCACCUGGGCGCAGCCAAAGAC 22 8518 HSV2-UL19-4136 + GGCACCUGGGCGCAG CCAAAG AC 23 8519
HSV2-UL19-4137 + CGGCACCUGGGCGCAGCCAAAGAC 24 8520
HSV2-UL19-4138 + CUGGGCCAGGGCCUCGAC 18 8521
HSV2-UL19-4139 + GCUGGGCCAGGGCCUCGAC 19 8522
HSV2-UL19-2667 + AGCUGGGCCAGGGCCUCGAC 20 2785
HSV2-UL19-4140 + CAGCUGGGCCAGGGCCUCGAC 21 8523
HSV2-UL19-4141 + CCAGCUGGGCCAGGGCCUCGAC 22 8524
HSV2-UL19-4142 + ACCAGCUGGGCCAGGGCCUCGAC 23 8525
HSV2-UL19-4143 + CACCAGCUGGGCCAGGGCCUCGAC 24 8526
HSV2-UL19-4144 + CCCCAGGGCCGGGGGGAC 18 8527
HSV2-UL19-4145 + CCCCCAGGGCCGGGGGGAC 19 8528
HSV2-UL19-2605 + GCCCCCAGGGCCGGGGGGAC 20 2743
HSV2-UL19-4146 + GGCCCCCAGGGCCGGGGGGAC 21 8529
HSV2-UL19-4147 + UGGCCCCCAGGGCCGGGGGGAC 22 8530
HSV2-UL19-4148 + UU GGCCCCCAGGGCCGGGGGGAC 23 8531
HSV2-UL19-4149 + GUUGGCCCCCAGGGCCGGGGGGAC 24 8532
HSV2-UL19-4150 + UACAGCAGGUCCCCGUAC 18 8533
HSV2-UL19-4151 + GUACAGCAGGUCCCCGUAC 19 8534
HSV2-UL19-2534 + UGUACAGCAGGUCCCCGUAC 20 2697
HSV2-UL19-4152 + UUGUACAGCAGGUCCCCGUAC 21 8535
HSV2-UL19-4153 + GUUGUACAGCAGGUCCCCGUAC 22 8536
HSV2-UL19-4154 + CGUUGUACAGCAGGUCCCCGUAC 23 8537
HSV2-UL19-4155 + CCGUUGUACAGCAGGUCCCCGUAC 24 8538
HSV2-UL19-4156 + CUCUGGCCGUGGUCGUAC 18 8539
HSV2-UL19-4157 + GCUCUGGCCGUGGUCGUAC 19 8540
HSV2-UL19-2539 + CGCUCUGGCCGUGGUCGUAC 20 2702
HSV2-UL19-4158 + UCGCUCUGGCCGUGGUCGUAC 21 8541
HSV2-UL19-4159 + GUCGCUCUGGCCGUGGUCGUAC 22 8542
HSV2-UL19-4160 + GGUCGCUCUGGCCGUGGUCGUAC 23 8543
HSV2-UL19-4161 + GGGUCGCUCUGGCCGUGGUCGUAC 24 8544
HSV2-UL19-4162 + AGGUCCAUGGCGCCCACC 18 8545
HSV2-UL19-4163 + CAGGUCCAUGGCGCCCACC 19 8546
HSV2-UL19-1475 + UCAGGUCCAUGGCGCCCACC 20 1715
HSV2-UL19-4164 + GUCAGGUCCAUGGCGCCCACC 21 8547
HSV2-UL19-4165 + CGUCAGGUCCAUGGCGCCCACC 22 8548
HSV2-UL19-4166 + ACGUCAGGUCCAUGGCGCCCACC 23 8549
HSV2-UL19-4167 + AACGUCAGGUCCAUGGCGCCCACC 24 8550
HSV2-UL19-4168 + GUUUCGUGGCGGGCCACC 18 8551
HSV2-UL19-4169 + CGUU UCGUGGCGGGCCACC 19 8552
HSV2-UL19-1216 + CCGUUUCGUGGCGGGCCACC 20 1456
HSV2-UL19-4170 + CCCGUUUCGUGGCGGGCCACC 21 8553
HSV2-UL19-4171 + GCCCGUUUCGUGGCGGGCCACC 22 8554
HSV2-UL19-4172 + CGCCCGUUUCGUGGCGGGCCACC 23 8555
HSV2-UL19-4173 + CCGCCCGUUUCGUGGCGGGCCACC 24 8556
HSV2-UL19-4174 + UCGCGGGCGUGCUGCACC 18 8557
HSV2-UL19-4175 + CUCGCGGGCGUGCUGCACC 19 8558 HSV2-UL19-2592 + UCUCGCGGGCGUGCUGCACC 20 2736
HSV2-UL19-4176 + CUCUCGCGGGCGUGCUGCACC 21 8559
HSV2-UL19-4177 + GCUCUCGCGGGCGUGCUGCACC 22 8560
HSV2-UL19-4178 + CGCUCUCGCGGGCGUGCUGCACC 23 8561
HSV2-UL19-4179 + GCGCUCUCGCGGGCGUGCUGCACC 24 8562
HSV2-UL19-4180 + GCUCGGGCACUCCUCACC 18 8563
HSV2-UL19-4181 + CGCUCGGGCACUCCUCACC 19 8564
HSV2-UL19-1309 + UCGCUCGGGCACUCCUCACC 20 1549
HSV2-UL19-4182 + AUCGCUCGGGCACUCCUCACC 21 8565
HSV2-UL19-4183 + GAUCGCUCGGGCACUCCUCACC 22 8566
HSV2-UL19-4184 + GGAUCGCUCGGGCACUCCUCACC 23 8567
HSV2-UL19-4185 + GGGAUCGCUCGGGCACUCCUCACC 24 8568
HSV2-UL19-4186 + UGGGCGCAGCCAAAGACC 18 8569
HSV2-UL19-4187 + CUGGGCGCAGCCAAAGACC 19 8570
HSV2-UL19-1177 + CCUGGGCGCAGCCAAAGACC 20 1417
HSV2-UL19-4188 + ACCUGGGCGCAGCCAAAGACC 21 8571
HSV2-UL19-4189 + CACCUGGGCGCAGCCAAAGACC 22 8572
HSV2-UL19-4190 + GCACCUGGGCGCAGCCAAAGACC 23 8573
HSV2-UL19-4191 + GGCACCUGGGCGCAG CCAAAG ACC 24 8574
HSV2-UL19-4192 + CCCAGGGCCGGGGGGACC 18 8575
HSV2-UL19-4193 + CCCCAGGGCCGGGGGGACC 19 8576
HSV2-UL19-1250 + CCCCCAGGGCCGGGGGGACC 20 1490
HSV2-UL19-4194 + GCCCCCAGGGCCGGGGGGACC 21 8577
HSV2-UL19-4195 + GGCCCCCAGGGCCGGGGGGACC 22 8578
HSV2-UL19-4196 + UGGCCCCCAGGGCCGGGGGGACC 23 8579
HSV2-UL19-4197 + UUGGCCCCCAGGGCCGGGGGGACC 24 8580
HSV2-UL19-4198 + CGGUGCAGCAGCGCCCCC 18 8581
HSV2-UL19-4199 + GCGGUGCAGCAGCGCCCCC 19 8582
HSV2-UL19-2651 + CGCGGUGCAGCAGCGCCCCC 20 2770
HSV2-UL19-4200 + CCGCGGUGCAGCAGCGCCCCC 21 8583
HSV2-UL19-4201 + CCCGCGGUGCAGCAGCGCCCCC 22 8584
HSV2-UL19-4202 + CCCCGCGGUGCAGCAGCGCCCCC 23 8585
HSV2-UL19-4203 + CCCCCGCGGUGCAGCAGCGCCCCC 24 8586
HSV2-UL19-4204 + GCCGGGUUGAACAGCCCC 18 8587
HSV2-UL19-4205 + GGCCGGGUUGAACAGCCCC 19 8588
HSV2-UL19-1469 + UGGCCGGGUUGAACAGCCCC 20 1709
HSV2-UL19-4206 + AU GGCCGGGUUGAACAGCCCC 21 8589
HSV2-UL19-4207 + CAUGGCCGGGUUGAACAGCCCC 22 8590
HSV2-UL19-4208 + CCAUGGCCGGGUUGAACAGCCCC 23 8591
HSV2-UL19-4209 + UCCAUGGCCGGGUUGAACAGCCCC 24 8592
HSV2-UL19-4210 + GCCGCGCUCAAACGCCCC 18 8593
HSV2-UL19-4211 + UGCCGCGCUCAAACGCCCC 19 8594
HSV2-UL19-2780 + GUGCCGCGCUCAAACGCCCC 20 2862
HSV2-UL19-4212 + CGUGCCGCGCUCAAACGCCCC 21 8595
HSV2-UL19-4213 + CCG U GCCG CGCU CAAACG CCCC 22 8596
HSV2-UL19-4214 + GCCGUGCCGCGCUCAAACGCCCC 23 8597 HSV2-UL19-4215 + GGCCGUGCCGCGCUCAAACGCCCC 24 8598
HSV2-UL19-4216 + GCGGUCCUCGAACGCCCC 18 8599
HSV2-UL19-4217 + UGCGGUCCUCGAACGCCCC 19 8600
HSV2-UL19-2683 + CUGCGGUCCUCGAACGCCCC 20 2798
HSV2-UL19-4218 + GCUGCGGUCCUCGAACGCCCC 21 8601
HSV2-UL19-4219 + AGCUGCGGUCCUCGAACGCCCC 22 8602
HSV2-UL19-4220 + UAGCUGCGGUCCUCGAACGCCCC 23 8603
HSV2-UL19-4221 + GUAGCUGCGGUCCUCGAACGCCCC 24 8604
HSV2-UL19-4222 + GGAGAAGUAGUUGGCCCC 18 8605
HSV2-UL19-4223 + AGGAGAAGUAGUUGGCCCC 19 8606
HSV2-UL19-2599 + GAGGAGAAGUAGUUGGCCCC 20 2741
HSV2-UL19-4224 + GG AGGAGAAGUAGUUGGCCCC 21 8607
HSV2-UL19-4225 + UGGAGGAGAAGUAGUUGGCCCC 22 8608
HSV2-UL19-4226 + AUGGAGGAGAAGUAGUUGGCCCC 23 8609
HSV2-UL19-4227 + GAUGGAGGAGAAGUAGUUGGCCCC 24 8610
HSV2-UL19-4228 + GGCCGGGUUGAACAGCCC 18 8611
HSV2-UL19-4229 + UGGCCGGGUUGAACAGCCC 19 8612
HSV2-UL19-2741 + AUGGCCGGGUUGAACAGCCC 20 2837
HSV2-UL19-4230 + CAUGGCCGGGU UGAACAGCCC 21 8613
HSV2-UL19-4231 + CCAUGGCCGGGUUGAACAGCCC 22 8614
HSV2-UL19-4232 + U CCAU GG CCG GG U U G AACAGCCC 23 8615
HSV2-UL19-4233 + CUCCAUGGCCGGGU UGAACAGCCC 24 8616
HSV2-UL19-4234 + UCGACGUCGGCCACGCCC 18 8617
HSV2-UL19-4235 + CUCGACGUCGGCCACGCCC 19 8618
HSV2-UL19-2700 + GCUCGACGUCGGCCACGCCC 20 2808
HSV2-UL19-4236 + AGCUCGACGUCGGCCACGCCC 21 8619
HSV2-UL19-4237 + AAGCUCGACGUCGGCCACGCCC 22 8620
HSV2-UL19-4238 + GAAGCUCGACGUCGGCCACGCCC 23 8621
HSV2-UL19-4239 + GGAAGCUCGACGUCGGCCACGCCC 24 8622
HSV2-UL19-4240 + AGGUGGCCUGGAUCGCCC 18 8623
HSV2-UL19-4241 + CAGGUGGCCUGGAUCGCCC 19 8624
HSV2-UL19-2691 + CCAGGUGGCCUGGAUCGCCC 20 2805
HSV2-UL19-4242 + GCCAGGUGGCCUGGAUCGCCC 21 8625
HSV2-UL19-4243 + CGCCAGGUGGCCUGGAUCGCCC 22 8626
HSV2-UL19-4244 + GCGCCAGGUGGCCUGGAUCGCCC 23 8627
HSV2-UL19-4245 + CGCGCCAGGUGGCCUGGAUCGCCC 24 8628
HSV2-UL19-4246 + UCCUCGGGGAGGUCGCCC 18 8629
HSV2-UL19-4247 + CUCCUCGGGGAGGUCGCCC 19 8630
HSV2-UL19-2672 + ACUCCUCGGGGAGGUCGCCC 20 2787
HSV2-UL19-4248 + CACUCCUCGGGGAGGUCGCCC 21 8631
HSV2-UL19-4249 + GCACUCCUCGGGGAGGUCGCCC 22 8632
HSV2-UL19-4250 + UGCACUCCUCGGGGAGGUCGCCC 23 8633
HSV2-UL19-4251 + AUGCACUCCUCGGGGAGGUCGCCC 24 8634
HSV2-UL19-4252 + CGAUGGCCCGCCUUGCCC 18 8635
HSV2-UL19-4253 + GCGAUGGCCCGCCUUGCCC 19 8636
HSV2-UL19-1528 + GGCGAUGGCCCGCCUUGCCC 20 1768 HSV2-UL19-4254 + CGGCGAUGGCCCGCCUUGCCC 21 8637
HSV2-UL19-4255 + GCGGCGAUGGCCCGCCUUGCCC 22 8638
HSV2-UL19-4256 + CGCGGCGAUGGCCCGCCUUGCCC 23 8639
HSV2-UL19-4257 + UCGCGGCGAUGGCCCGCCUUGCCC 24 8640
HSV2-UL19-4258 + AUCUUGAAGUACCCCGCC 18 8641
HSV2-UL19-4259 + CAUCUUGAAGUACCCCGCC 19 8642
HSV2-UL19-2590 + UCAUCU UGAAGUACCCCGCC 20 2734
HSV2-UL19-4260 + CUCAUCUUGAAGUACCCCGCC 21 8643
HSV2-UL19-4261 + GCUCAUCU UGAAGUACCCCGCC 22 8644
HSV2-UL19-4262 + GGCUCAUCUUGAAGUACCCCGCC 23 8645
HSV2-UL19-4263 + GGGCUCAUCUUGAAGUACCCCGCC 24 8646
HSV2-UL19-4264 + CGGGGGGACUUCGCCGCC 18 8647
HSV2-UL19-4265 + CCGGGGGGACUUCGCCGCC 19 8648
HSV2-UL19-1409 + GCCGGGGGGACUUCGCCGCC 20 1649
HSV2-UL19-4266 + GGCCGGGGGGACUUCGCCGCC 21 8649
HSV2-UL19-4267 + CGGCCGGGGGGACU UCGCCGCC 22 8650
HSV2-UL19-4268 + CCGGCCGGGGGGACUUCGCCGCC 23 8651
HSV2-UL19-4269 + ACCGGCCGGGGGGACU UCGCCGCC 24 8652
HSV2-UL19-4270 + GCCACCGGACACAGCGCC 18 8653
HSV2-UL19-4271 + CGCCACCGGACACAGCGCC 19 8654
HSV2-UL19-1394 + ACGCCACCGGACACAGCGCC 20 1634
HSV2-UL19-4272 + AACGCCACCGGACACAGCGCC 21 8655
HSV2-UL19-4273 + AAACG CCACCG G ACACAGCG CC 22 8656
HSV2-UL19-4274 + GAAACGCCACCGGACACAGCGCC 23 8657
HSV2-UL19-4275 + CGAAACGCCACCGGACACAGCGCC 24 8658
HSV2-UL19-4276 + GCGCCCGCGUCGGGCGCC 18 8659
HSV2-UL19-4277 + GGCGCCCGCGUCGGGCGCC 19 8660
HSV2-UL19-2629 + UGGCGCCCGCGUCGGGCGCC 20 2756
HSV2-UL19-4278 + UUGGCGCCCGCGUCGGGCGCC 21 8661
HSV2-UL19-4279 + GUUGGCGCCCGCGUCGGGCGCC 22 8662
HSV2-UL19-4280 + UGUUGGCGCCCGCGUCGGGCGCC 23 8663
HSV2-UL19-4281 + GUGUUGGCGCCCGCGUCGGGCGCC 24 8664
HSV2-UL19-4282 + AACGCCGAGCUCCAGGCC 18 8665
HSV2-UL19-4283 + CAACGCCGAGCUCCAGGCC 19 8666
HSV2-UL19-2685 + CCAACGCCGAGCUCCAGGCC 20 2800
HSV2-UL19-4284 + GCCAACGCCGAGCUCCAGGCC 21 8667
HSV2-UL19-4285 + GGCCAACGCCGAGCUCCAGGCC 22 8668
HSV2-UL19-4286 + CGGCCAACGCCGAGCUCCAGGCC 23 8669
HSV2-UL19-4287 + GCGGCCAACGCCGAGCUCCAGGCC 24 8670
HSV2-UL19-4288 + GUCAGGCGGGGCACGGCC 18 8671
HSV2-UL19-4289 + CGUCAGGCGGGGCACGGCC 19 8672
HSV2-UL19-2766 + GCGUCAGGCGGGGCACGGCC 20 2852
HSV2-UL19-4290 + UGCGUCAGGCGGGGCACGGCC 21 8673
HSV2-UL19-4291 + GUGCGUCAGGCGGGGCACGGCC 22 8674
HSV2-UL19-4292 + CGUGCGUCAGGCGGGGCACGGCC 23 8675
HSV2-UL19-4293 + GCGUGCGUCAGGCGGGGCACGGCC 24 8676 HSV2-UL19-4294 + AUCGCCCCCGGACCGGCC 18 8677
HSV2-UL19-4295 + GAUCGCCCCCGGACCGGCC 19 8678
HSV2-UL19-1404 + GGAUCGCCCCCGGACCGGCC 20 1644
HSV2-UL19-4296 + UGGAUCGCCCCCGGACCGGCC 21 8679
HSV2-UL19-4297 + CUGGAUCGCCCCCGGACCGGCC 22 8680
HSV2-UL19-4298 + CCUGGAUCGCCCCCGGACCGGCC 23 8681
HSV2-UL19-4299 + GCCUGGAUCGCCCCCGGACCGGCC 24 8682
HSV2-UL19-4300 + GACCCACCGGACCCGGCC 18 8683
HSV2-UL19-4301 + CGACCCACCGGACCCGGCC 19 8684
HSV2-UL19-2709 + GCGACCCACCGGACCCGGCC 20 2816
HSV2-UL19-4302 + GGCGACCCACCGGACCCGGCC 21 8685
HSV2-UL19-4303 + CGGCGACCCACCGGACCCGGCC 22 8686
HSV2-UL19-4304 + UCGGCGACCCACCGGACCCGGCC 23 8687
HSV2-UL19-4305 + CUCGGCGACCCACCGGACCCGGCC 24 8688
HSV2-UL19-4306 + AGCUGGUGAUACAGGGCC 18 8689
HSV2-UL19-4307 + GAGCUGGUGAUACAGGGCC 19 8690
HSV2-UL19-2587 + UGAGCUGGUGAUACAGGGCC 20 2732
HSV2-UL19-4308 + UU GAGCUGGUGAUACAGGGCC 21 8691
HSV2-UL19-4309 + CU UGAGCUGGUGAUACAGGGCC 22 8692
HSV2-UL19-4310 + UCU UGAGCUGGUGAUACAGGGCC 23 8693
HSV2-UL19-4311 + GUCUUGAGCUGGUGAUACAGGGCC 24 8694
HSV2-UL19-4312 + UAGUUGGCCCCCAGGGCC 18 8695
HSV2-UL19-4313 + GUAGUUGGCCCCCAGGGCC 19 8696
HSV2-UL19-1246 + AGUAGUUGGCCCCCAGGGCC 20 1486
HSV2-UL19-4314 + AAGUAGUUGGCCCCCAGGGCC 21 8697
HSV2-UL19-4315 + GAAGUAGUUGGCCCCCAGGGCC 22 8698
HSV2-UL19-4316 + AG AAGUAGUUGGCCCCCAGGGCC 23 8699
HSV2-UL19-4317 + GAGAAGUAGUUGGCCCCCAGGGCC 24 8700
HSV2-UL19-4318 + AUGGGCAACAGCAGGGCC 18 8701
HSV2-UL19-4319 + CAU G G G CAACAG CAG G G CC 19 8702
HSV2-UL19-1540 + GCAUGGGCAACAGCAGGGCC 20 1780
HSV2-UL19-4320 + UGCAUGGGCAACAGCAGGGCC 21 8703
HSV2-UL19-4321 + UUGCAUGGGCAACAGCAGGGCC 22 8704
HSV2-UL19-4322 + GU UGCAUGGGCAACAGCAGGGCC 23 8705
HSV2-UL19-4323 + CGUUGCAUGGGCAACAGCAGGGCC 24 8706
HSV2-UL19-4324 + GCCAGGUCGCGCAGGGCC 18 8707
HSV2-UL19-4325 + CGCCAGGUCGCGCAGGGCC 19 8708
HSV2-UL19-1258 + GCGCCAGGUCGCGCAGGGCC 20 1498
HSV2-UL19-4326 + CGCGCCAGGUCGCGCAGGGCC 21 8709
HSV2-UL19-4327 + GCGCGCCAGGUCGCGCAGGGCC 22 8710
HSV2-UL19-4328 + CGCGCGCCAGGUCGCGCAGGGCC 23 8711
HSV2-UL19-4329 + UCGCGCGCCAGGUCGCGCAGGGCC 24 8712
HSV2-UL19-4330 + UCCAGGUGCUGGGGGGCC 18 8713
HSV2-UL19-4331 + GUCCAGGUGCUGGGGGGCC 19 8714
HSV2-UL19-2626 + GGUCCAGGUGCUGGGGGGCC 20 2753
HSV2-UL19-4332 + UGGUCCAGGUGCUGGGGGGCC 21 8715 HSV2-UL19-4333 + GUGGUCCAGGUGCUGGGGGGCC 22 8716
HSV2-UL19-4334 + UGUGGUCCAGGUGCUGGGGGGCC 23 8717
HSV2-UL19-4335 + GUGUGGUCCAGGUGCUGGGGGGCC 24
8718
HSV2-UL19-4336 + GGCCACCUGGAGCUGGCC 18 8719
HSV2-UL19-4337 + GGGCCACCUGGAGCUGGCC 19 8720
HSV2-UL19-2575 + CGGGCCACCUGGAGCUGGCC 20 2723
HSV2-UL19-4338 + GCGGGCCACCUGGAGCUGGCC 21 8721
HSV2-UL19-4339 + GGCGGGCCACCUGGAGCUGGCC 22 8722
HSV2-UL19-4340 + UGGCGGGCCACCUGGAGCUGGCC 23 8723
HSV2-UL19-4341 + GUGGCGGGCCACCUGGAGCUGGCC 24 8724
HSV2-UL19-4342 + CACGGGUUGGCCGUGGCC 18 8725
HSV2-UL19-4343 + CCACGGGUUGGCCGUGGCC 19 8726
HSV2-UL19-2536 + CCCACGGGUUGGCCGUGGCC 20 2699
HSV2-UL19-4344 + GCCCACGGGUUGGCCGUGGCC 21 8727
HSV2-UL19-4345 + CGCCCACGGGUUGGCCGUGGCC 22 8728
HSV2-UL19-4346 + ACGCCCACGGGUUGGCCGUGGCC 23 8729
HSV2-UL19-4347 + GACGCCCACGGGUUGGCCGUGGCC 24 8730
HSV2-UL19-4348 + UAGUUGAUGUCCGUGGCC 18 8731
HSV2-UL19-4349 + GUAGUUGAUGUCCGUGGCC 19 8732
HSV2-UL19-2544 + AGUAGUUGAUGUCCGUGGCC 20 2707
HSV2-UL19-4350 + AAGUAGUUGAUGUCCGUGGCC 21 8733
HSV2-UL19-4351 + AAAG UAGUUGAUGUCCGUGGCC 22 8734
HSV2-UL19-4352 + GAAAGUAGUUGAUGUCCGUGGCC 23 8735
HSV2-UL19-4353 + CGAAAGUAGUUGAUGUCCGUGGCC 24 8736
HSV2-UL19-4354 + GCGGGGCUCCGGGUGGCC 18 8737
HSV2-UL19-4355 + CGCGGGGCUCCGGGUGGCC 19 8738
HSV2-UL19-1458 + GCGCGGGGCUCCGGGUGGCC 20 1698
HSV2-UL19-4356 + CGCGCGGGGCUCCGGGUGGCC 21 8739
HSV2-UL19-4357 + ACGCGCGGGGCUCCGGGUGGCC 22 8740
HSV2-UL19-4358 + AACGCGCGGGGCUCCGGGUGGCC 23 8741
HSV2-UL19-4359 + GAACGCGCGGGGCUCCGGGUGGCC 24 8742
HSV2-UL19-4360 + CCCAAAAAAACAGCUGCC 18 8743
HSV2-UL19-4361 + CCCCAAAAAAACAGCUGCC 19 8744
HSV2-UL19-1447 + U CCCCAAAAAAACAG CU G CC 20 1687
HSV2-UL19-4362 + UUCCCCAAAAAAACAGCUGCC 21 8745
HSV2-UL19-4363 + UUUCCCCAAAAAAACAGCUGCC 22 8746
HSV2-UL19-4364 + CUUUCCCCAAAAAAACAGCUGCC 23 8747
HSV2-UL19-4365 + CCUUUCCCCAAAAAAACAGCUGCC 24 8748
HSV2-UL19-4366 + GCGAUGGCCCGCCUUGCC 18 8749
HSV2-UL19-4367 + GGCGAUGGCCCGCCUUGCC 19 8750
HSV2-UL19-2768 + CGGCGAUGGCCCGCCUUGCC 20 2854
HSV2-UL19-4368 + GCGGCGAUGGCCCGCCUUGCC 21 8751
HSV2-UL19-4369 + CGCGGCGAUGGCCCGCCUUGCC 22 8752
HSV2-UL19-4370 + UCGCGGCGAUGGCCCGCCUUGCC 23 8753
HSV2-UL19-4371 + CUCGCGGCGAUGGCCCGCCUUGCC 24 8754 HSV2-UL19-4372 + UACACGGCCAUGCACUCC 18 8755
HSV2-UL19-4373 + AUACACGGCCAUGCACUCC 19 8756
HSV2-UL19-2668 + GAUACACGGCCAUGCACUCC 20 2786
HSV2-UL19-4374 + CGAUACACGGCCAUGCACUCC 21 8757
HSV2-UL19-4375 + CCGAUACACGGCCAUGCACUCC 22 8758
HSV2-UL19-4376 + CCCGAUACACGGCCAUGCACUCC 23 8759
HSV2-UL19-4377 + UCCCGAUACACGGCCAUGCACUCC 24 8760
HSV2-UL19-4378 + CGUCUCUCCAGGGCCUCC 18 8761
HSV2-UL19-4379 + GCGUCUCUCCAGGGCCUCC 19 8762
HSV2-UL19-1486 + UGCGUCUCUCCAGGGCCUCC 20 1726
HSV2-UL19-4380 + AUGCGUCUCUCCAGGGCCUCC 21 8763
HSV2-UL19-4381 + GAUGCGUCUCUCCAGGGCCUCC 22 8764
HSV2-UL19-4382 + AGAUGCGUCUCUCCAGGGCCUCC 23 8765
HSV2-UL19-4383 + UAGAUGCGUCUCUCCAGGGCCUCC 24 8766
HSV2-UL19-4384 + G U CCCG ACCG CG U U CU CC 18 8767
HSV2-UL19-4385 + GGUCCCGACCGCGUUCUCC 19 8768
HSV2-UL19-2722 + CGGUCCCGACCGCGUUCUCC 20 2826
HSV2-UL19-4386 + ACGGUCCCGACCGCGUUCUCC 21 8769
HSV2-UL19-4387 + CACGGUCCCGACCGCGUUCUCC 22 8770
HSV2-UL19-4388 + ACACGGUCCCGACCGCGUUCUCC 23 8771
HSV2-UL19-4389 + CACACGGUCCCGACCGCGUUCUCC 24 8772
HSV2-UL19-4390 + GUCGCCGUGGUCAGGUCC 18 8773
HSV2-UL19-4391 + CGUCGCCGUGGUCAGGUCC 19 8774
HSV2-UL19-2767 + GCGUCGCCGUGGUCAGGUCC 20 2853
HSV2-UL19-4392 + UGCGUCGCCGUGGUCAGGUCC 21 8775
HSV2-UL19-4393 + CUGCGUCGCCGUGGUCAGGUCC 22 8776
HSV2-UL19-4394 + GCUGCGUCGCCGUGGUCAGGUCC 23 8777
HSV2-UL19-4395 + GGCUGCGUCGCCGUGGUCAGGUCC 24 8778
HSV2-UL19-4396 + GCCGGGUAGCUGCGGUCC 18 8779
HSV2-UL19-4397 + CGCCGGGUAGCUGCGGUCC 19 8780
HSV2-UL19-2682 + CCGCCGGGUAGCUGCGGUCC 20 2797
HSV2-UL19-4398 + ACCGCCGGGUAGCUGCGGUCC 21 8781
HSV2-UL19-4399 + CACCGCCGGGUAGCUGCGGUCC 22 8782
HSV2-UL19-4400 + ACACCGCCGGGUAGCUGCGGUCC 23 8783
HSV2-UL19-4401 + AACACCGCCGGGUAGCUGCGGUCC 24 8784
HSV2-UL19-4402 + AGGCCGCACGGGUCU UCC 18 8785
HSV2-UL19-4403 + CAGGCCGCACGGGUCUUCC 19 8786
HSV2-UL19-2519 + ACAGGCCGCACGGGUCUUCC 20 2683
HSV2-UL19-4404 + AACAGGCCGCACGGGUCUUCC 21 8787
HSV2-UL19-4405 + AAACAGGCCGCACGGGUCUUCC 22 8788
HSV2-UL19-4406 + GAAACAGGCCGCACGGGUCUUCC 23 8789
HSV2-UL19-4407 + UGAAACAGGCCGCACGGGUCUUCC 24 8790
HSV2-UL19-4408 + CGGUGAAGAACUUGAAGC 18 8791
HSV2-UL19-4409 + GCGGUGAAGAACUUGAAGC 19 8792
HSV2-UL19-1136 + CGCGGUGAAGAACUUGAAGC 20 1376
HSV2-UL19-4410 + CCGCGGUGAAGAACUUGAAGC 21 8793 HSV2-UL19-4411 + GCCGCGGUGAAGAACUUGAAGC 22 8794
HSV2-UL19-4412 + GGCCGCGGUGAAGAACUUGAAGC 23 8795
HSV2-UL19-4413 + CGGCCGCGGUGAAGAACUUGAAGC 24 8796
HSV2-UL19-4414 + GCCGCGUUGUCUAGCAGC 18 8797
HSV2-UL19-4415 + GGCCGCGUUGUCUAGCAGC 19 8798
HSV2-UL19-1189 + CGGCCGCGUUGUCUAGCAGC 20 1429
HSV2-UL19-4416 + GCGGCCGCGUUGUCUAGCAGC 21 8799
HSV2-UL19-4417 + GGCGGCCGCGUUGUCUAGCAGC 22 8800
HSV2-UL19-4418 + CGGCGGCCGCGUUGUCUAGCAGC 23 8801
HSV2-UL19-4419 + ACGGCGGCCGCGUUGUCUAGCAGC 24 8802
HSV2-UL19-4420 + UGCGCCAGCACCUGCAGC 18 8803
HSV2-UL19-4421 + GUGCGCCAGCACCUGCAGC 19 8804
HSV2-UL19-2631 + UGUGCGCCAGCACCUGCAGC 20 2757
HSV2-UL19-4422 + UUGUGCGCCAGCACCUGCAGC 21 8805
HSV2-UL19-4423 + G U U G U GCG CCAG CACCU GCAG C 22 8806
HSV2-UL19-4424 + UGUUGUGCGCCAGCACCUGCAGC 23 8807
HSV2-UL19-4425 + AUGUUGUGCGCCAGCACCUGCAGC 24 8808
HSV2-UL19-4426 + CCGCGCGGCUGGGUGAGC 18 8809
HSV2-UL19-4427 + UCCGCGCGGCUGGGUGAGC 19 8810
HSV2-UL19-2571 + UUCCGCGCGGCUGGGUGAGC 20 2720
HSV2-UL19-4428 + UU UCCGCGCGGCUGGGUGAGC 21 8811
HSV2-UL19-4429 + GUUUCCGCGCGGCUGGGUGAGC 22 8812
HSV2-UL19-4430 + CGUUUCCGCGCGGCUGGGUGAGC 23 8813
HSV2-UL19-4431 + ACGUUUCCGCGCGGCUGGGUGAGC 24 8814
HSV2-UL19-4432 + AGAGACAGGCCCUUUAGC 18 8815
HSV2-UL19-4433 + CAGAGACAGGCCCUUUAGC 19 8816
HSV2-UL19-1102 + ACAGAGACAGGCCCUUUAGC 20 1342
HSV2-UL19-4434 + UACAGAGACAGGCCCUUUAGC 21 8817
HSV2-UL19-4435 + UUACAGAGACAGGCCCUUUAGC 22 8818
HSV2-UL19-4436 + UUUACAGAGACAGGCCCUUUAGC 23 8819
HSV2-UL19-4437 + UUUUACAGAGACAGGCCCUUUAGC 24 8820
HSV2-UL19-4438 + CUGCCGGGGAGGGAACGC 18 8821
HSV2-UL19-4439 + GCUGCCGGGGAGGGAACGC 19 8822
HSV2-UL19-2731 + AGCUGCCGGGGAGGGAACGC 20 2830
HSV2-UL19-4440 + CAGCUGCCGGGGAGGGAACGC 21 8823
HSV2-UL19-4441 + ACAGCUGCCGGGGAGGGAACGC 22 8824
HSV2-UL19-4442 + AACAGCUGCCGGGGAGGGAACGC 23 8825
HSV2-UL19-4443 + AAACAGCUGCCGGGGAGGGAACGC 24 8826
HSV2-UL19-4444 + GUGCAGCAGCGCCCCCGC 18 8827
HSV2-UL19-4445 + GGUGCAGCAGCGCCCCCGC 19 8828
HSV2-UL19-2652 + CGGUGCAGCAGCGCCCCCGC 20 2771
HSV2-UL19-4446 + GCGGUGCAGCAGCGCCCCCGC 21 8829
HSV2-UL19-4447 + CGCGGUGCAGCAGCGCCCCCGC 22 8830
HSV2-UL19-4448 + CCGCGGUGCAGCAGCGCCCCCGC 23 8831
HSV2-UL19-4449 + CCCGCGGUGCAGCAGCGCCCCCGC 24 8832
HSV2-UL19-4450 + CCGGGGGGACUUCGCCGC 18 8833 HSV2-UL19-4451 + GCCGGGGGGACUUCGCCGC 19 8834
HSV2-UL19-1408 + GGCCGGGGGGACU UCGCCGC 20 1648
HSV2-UL19-4452 + CGGCCGGGGGGACUUCGCCGC 21 8835
HSV2-UL19-4453 + CCGGCCGGGGGGACUUCGCCGC 22 8836
HSV2-UL19-4454 + ACCGGCCGGGGGGACUUCGCCGC 23 8837
HSV2-UL19-4455 + GACCGGCCGGGGGGACU UCGCCGC 24 8838
HSV2-UL19-4456 + GUCGGCGGCGUCGGCCGC 18 8839
HSV2-UL19-4457 + CGUCGGCGGCGUCGGCCGC 19 8840
HSV2-UL19-2654 + UCGUCGGCGGCGUCGGCCGC 20 2773
HSV2-UL19-4458 + GUCGUCGGCGGCGUCGGCCGC 21 8841
HSV2-UL19-4459 + GGUCGUCGGCGGCGUCGGCCGC 22 8842
HSV2-UL19-4460 + CGGUCGUCGGCGGCGUCGGCCGC 23 8843
HSV2-UL19-4461 + CCGGUCGUCGGCGGCGUCGGCCGC 24 8844
HSV2-UL19-4462 + GGCGCCCGCAAACAGCGC 18 8845
HSV2-UL19-4463 + CGGCGCCCGCAAACAGCGC 19 8846
HSV2-UL19-2617 + UCGGCGCCCGCAAACAGCGC 20 2747
HSV2-UL19-4464 + GUCGGCGCCCGCAAACAGCGC 21 8847
HSV2-UL19-4465 + G G U CG G CG CCCG CAAACAG CG C 22 8848
HSV2-UL19-4466 + UGGUCGGCGCCCGCAAACAGCGC 23 8849
HSV2-UL19-4467 + GUGGUCGGCGCCCG CAAACAG CG C 24 8850
HSV2-UL19-4468 + CGCCACCGGACACAGCGC 18 8851
HSV2-UL19-4469 + ACGCCACCGGACACAGCGC 19 8852
HSV2-UL19-2688 + AACGCCACCGGACACAGCGC 20 2803
HSV2-UL19-4470 + AAACG CCACCG G ACACAG CG C 21 8853
HSV2-UL19-4471 + GAAACGCCACCGGACACAGCGC 22 8854
HSV2-UL19-4472 + CGAAACGCCACCGGACACAGCGC 23 8855
HSV2-UL19-4473 + ACGAAACGCCACCGGACACAGCGC 24 8856
HSV2-UL19-4474 + CUGAGUCACGAGCCGCGC 18 8857
HSV2-UL19-4475 + ACUGAGUCACGAGCCGCGC 19 8858
HSV2-UL19-2678 + CACUGAGUCACGAGCCGCGC 20 2793
HSV2-UL19-4476 + GCACUGAGUCACGAGCCGCGC 21 8859
HSV2-UL19-4477 + UGCACUGAGUCACGAGCCGCGC 22 8860
HSV2-UL19-4478 + AU GCACU G AG U CACG AG CCG CGC 23 8861
HSV2-UL19-4479 + GAUGCACUGAGUCACGAGCCGCGC 24 8862
HSV2-UL19-4480 + GCUGCUGCAUGUCCGCGC 18 8863
HSV2-UL19-4481 + CGCUGCUGCAUGUCCGCGC 19 8864
HSV2-UL19-1427 + ACGCUGCUGCAUGUCCGCGC 20 1667
HSV2-UL19-4482 + AACGCUGCUGCAUGUCCGCGC 21 8865
HSV2-UL19-4483 + AAACGCUGCUGCAUGUCCGCGC 22 8866
HSV2-UL19-4484 + AAAACGCUGCUGCAUGUCCGCGC 23 8867
HSV2-UL19-4485 + GAAAACGCUGCUGCAUGUCCGCGC 24 8868
HSV2-UL19-4486 + UACGCCUCCGACGCGCGC 18 8869
HSV2-UL19-4487 + GUACGCCUCCGACGCGCGC 19 8870
HSV2-UL19-2576 + AGUACGCCUCCGACGCGCGC 20 2724
HSV2-UL19-4488 + AAGUACGCCUCCGACGCGCGC 21 8871
HSV2-UL19-4489 + AAAGUACGCCUCCGACGCGCGC 22 8872 HSV2-UL19-4490 + GAAAGUACGCCUCCGACGCGCGC 23 8873
HSV2-UL19-4491 + AGAAAGUACGCCUCCGACGCGCGC 24 8874
HSV2-UL19-4492 + AAAGUGGGUCUCUCGCGC 18 8875
HSV2-UL19-4493 + UAAAGUGGGUCUCUCGCGC 19 8876
HSV2-UL19-2511 + GUAAAGUGGGUCUCUCGCGC 20 2676
HSV2-UL19-4494 + CGUAAAGUGGGUCUCUCGCGC 21 8877
HSV2-UL19-4495 + GCGUAAAGUGGGUCUCUCGCGC 22 8878
HSV2-UL19-4496 + UGCGUAAAGUGGGUCUCUCGCGC 23 8879
HSV2-UL19-4497 + CUGCGUAAAGUGGGUCUCUCGCGC 24 8880
HSV2-UL19-3246 + ACGGCCUGGACGUUGCGC 18 7629
HSV2-UL19-3247 + GACGGCCUGGACGUUGCGC 19 7630
HSV2-UL19-3248 + GGACGGCCUGGACGUUGCGC 20 7631
HSV2-UL19-3249 + AGGACGGCCUGGACGUUGCGC 21 7632
HSV2-UL19-3250 + CAGGACGGCCUGGACGUUGCGC 22 7633
HSV2-UL19-3251 + CCAGGACGGCCUGGACGUUGCGC 23 7634
HSV2-UL19-3252 + CCCAGGACGGCCUGGACGUUGCGC 24 7635
HSV2-UL19-4498 + GGUCGGUCACGGGAUCGC 18 8881
HSV2-UL19-4499 + GGGUCGGUCACGGGAUCGC 19 8882
HSV2-UL19-2643 + GGGGUCGGUCACGGGAUCGC 20 2765
HSV2-UL19-4500 + CGGGGUCGGUCACGGGAUCGC 21 8883
HSV2-UL19-4501 + GCGGGGUCGGUCACGGGAUCGC 22 8884
HSV2-UL19-4502 + GGCGGGGUCGGUCACGGGAUCGC 23 8885
HSV2-UL19-4503 + GGGCGGGGUCGGUCACGGGAUCGC 24 8886
HSV2-UL19-4504 + CUCGGCGACCAGGGUCGC 18 8887
HSV2-UL19-4505 + GCUCGGCGACCAGGGUCGC 19 8888
HSV2-UL19-2772 + AGCUCGGCGACCAGGGUCGC 20 2857
HSV2-UL19-4506 + CAGCUCGGCGACCAGGGUCGC 21 8889
HSV2-UL19-4507 + UCAGCUCGGCGACCAGGGUCGC 22 8890
HSV2-UL19-4508 + UUCAGCUCGGCGACCAGGGUCGC 23 8891
HSV2-UL19-4509 + CUUCAGCUCGGCGACCAGGGUCGC 24 8892
HSV2-UL19-3253 + AAACGCCCCCAGGACGGC 18 7636
HSV2-UL19-3254 + CAAACGCCCCCAGGACGGC 19 7637
HSV2-UL19-2781 + UCAAACGCCCCCAGGACGGC 20 2863
HSV2-UL19-4510 + CUCAAACGCCCCCAGGACGGC 21 8893
HSV2-UL19-4511 + GCUCAAACGCCCCCAGGACGGC 22 8894
HSV2-UL19-4512 + CGCUCAAACGCCCCCAGGACGGC 23 8895
HSV2-UL19-4513 + GCGCUCAAACGCCCCCAGGACGGC 24 8896
HSV2-UL19-4514 + GAUCGCCCCCGGACCGGC 18 8897
HSV2-UL19-4515 + GGAUCGCCCCCGGACCGGC 19 8898
HSV2-UL19-1403 + UGGAUCGCCCCCGGACCGGC 20 1643
HSV2-UL19-4516 + CUGGAUCGCCCCCGGACCGGC 21 8899
HSV2-UL19-4517 + CCUGGAUCGCCCCCGGACCGGC 22 8900
HSV2-UL19-4518 + GCCUGGAUCGCCCCCGGACCGGC 23 8901
HSV2-UL19-4519 + GGCCUGGAUCGCCCCCGGACCGGC 24 8902
HSV2-UL19-4520 + GUCCGCGCCGGGGCCGGC 18 8903
HSV2-UL19-4521 + UGUCCGCGCCGGGGCCGGC 19 8904 HSV2-UL19-1431 + AUGUCCGCGCCGGGGCCGGC 20 1671
HSV2-UL19-4522 + CAUGUCCGCGCCGGGGCCGGC 21 8905
HSV2-UL19-4523 + GCAUGUCCGCGCCGGGGCCGGC 22 8906
HSV2-UL19-4524 + UGCAUGUCCGCGCCGGGGCCGGC 23 8907
HSV2-UL19-4525 + CUGCAUGUCCGCGCCGGGGCCGGC 24 8908
HSV2-UL19-4526 + CAGGUGAUUCAGCUCGGC 18 8909
HSV2-UL19-4527 + UCAGGUGAUUCAGCUCGGC 19 8910
HSV2-UL19-2662 + AUCAGGUGAUUCAGCUCGGC 20 2780
HSV2-UL19-4528 + CAUCAGGUGAUUCAGCUCGGC 21 8911
HSV2-UL19-4529 + GCAUCAGGUGAUUCAGCUCGGC 22 8912
HSV2-UL19-4530 + CGCAUCAGGUGAUUCAGCUCGGC 23 8913
HSV2-UL19-4531 + GCGCAUCAGGUGAUUCAGCUCGGC 24 8914
HSV2-UL19-4532 + GUAGUUGGCCCCCAGGGC 18 8915
HSV2-UL19-4533 + AGUAGUUGGCCCCCAGGGC 19 8916
HSV2-UL19-1245 + AAGUAGUUGGCCCCCAGGGC 20 1485
HSV2-UL19-4534 + GAAGUAGUUGGCCCCCAGGGC 21 8917
HSV2-UL19-4535 + AGAAGUAGUUGGCCCCCAGGGC 22 8918
HSV2-UL19-4536 + GAGAAGUAGUUGGCCCCCAGGGC 23 8919
HSV2-UL19-4537 + GGAGAAGUAGUUGGCCCCCAGGGC 24 8920
HSV2-UL19-4538 + CAU G G G CAACAG C AG G G C 18 8921
HSV2-UL19-4539 + GCAUGGGCAACAGCAGGGC 19 8922
HSV2-UL19-2776 + UGCAUGGGCAACAGCAGGGC 20 2861
HSV2-UL19-4540 + UU GCAUGGGCAACAGCAGGGC 21 8923
HSV2-UL19-4541 + GU UGCAUGGGCAACAGCAGGGC 22 8924
HSV2-UL19-4542 + CGU UGCAUGGGCAACAGCAGGGC 23 8925
HSV2-UL19-4543 + UCGUUGCAUGGGCAACAGCAGGGC 24 8926
HSV2-UL19-4544 + CGCCAGGUCGCGCAGGGC 18 8927
HSV2-UL19-4545 + GCGCCAGGUCGCGCAGGGC 19 8928
HSV2-UL19-1257 + CGCGCCAGGUCGCGCAGGGC 20 1497
HSV2-UL19-4546 + GCGCGCCAGGUCGCGCAGGGC 21 8929
HSV2-UL19-4547 + CGCGCGCCAGGUCGCGCAGGGC 22 8930
HSV2-UL19-4548 + UCGCGCGCCAGGUCGCGCAGGGC 23 8931
HSV2-UL19-4549 + GUCGCGCGCCAGGUCGCGCAGGGC 24 8932
HSV2-UL19-4550 + GUCGUCCACCAGCUGGGC 18 8933
HSV2-UL19-4551 + AGUCGUCCACCAGCUGGGC 19 8934
HSV2-UL19-2666 + AAGUCGUCCACCAGCUGGGC 20 2784
HSV2-UL19-4552 + AAAGUCGUCCACCAGCUGGGC 21 8935
HSV2-UL19-4553 + UAAAGUCGUCCACCAGCUGGGC 22 8936
HSV2-UL19-4554 + GUAAAGUCGUCCACCAGCUGGGC 23 8937
HSV2-UL19-4555 + GGUAAAGUCGUCCACCAGCUGGGC 24 8938
HSV2-UL19-4556 + CGCGGGGCUCCGGGUGGC 18 8939
HSV2-UL19-4557 + GCGCGGGGCUCCGGGUGGC 19 8940
HSV2-UL19-1457 + CGCGCGGGGCUCCGGGUGGC 20 1697
HSV2-UL19-4558 + ACGCGCGGGGCUCCGGGUGGC 21 8941
HSV2-UL19-4559 + AACGCGCGGGGCUCCGGGUGGC 22 8942
HSV2-UL19-4560 + GAACGCGCGGGGCUCCGGGUGGC 23 8943 HSV2-UL19-4561 + GGAACGCGCGGGGCUCCGGGUGGC 24 8944
HSV2-UL19-4562 + ACCUUCAGGAAGGACUGC 18 8945
HSV2-UL19-4563 + CACCUUCAGGAAGGACUGC 19 8946
HSV2-UL19-1507 + CCACCUUCAGGAAGGACUGC 20 1747
HSV2-UL19-4564 + UCCACCUUCAGGAAGGACUGC 21 8947
HSV2-UL19-4565 + CUCCACCUUCAGGAAGGACUGC 22 8948
HSV2-UL19-4566 + CCUCCACCUUCAGGAAGGACUGC 23 8949
HSV2-UL19-4567 + UCCUCCACCUUCAGGAAGGACUGC 24 8950
HSV2-UL19-4568 + CCCCAAAAAAACAGCUGC 18 8951
HSV2-UL19-4569 + U CCCCAAAA AAACAG CU G C 19 8952
HSV2-UL19-1446 + UUCCCCAAAAAAACAGCUGC 20 1686
HSV2-UL19-4570 + UU UCCCCAAAAAAACAGCUGC 21 8953
HSV2-UL19-4571 + CUUUCCCCAAAAAAACAGCUGC 22 8954
HSV2-UL19-4572 + CCUUUCCCCAAAAAAACAGCUGC 23 8955
HSV2-UL19-4573 + U CCU U U CCCCAAAAAAACAGCU G C 24 8956
HSV2-UL19-4574 + UUGGCGUUGUCGGGCUGC 18 8957
HSV2-UL19-4575 + GUUGGCGUUGUCGGGCUGC 19 8958
HSV2-UL19-2707 + GGUUGGCGUUGUCGGGCUGC 20 2814
HSV2-UL19-4576 + AGGU UGGCGUUGUCGGGCUGC 21 8959
HSV2-UL19-4577 + CAGGU UGGCGUUGUCGGGCUGC 22 8960
HSV2-UL19-4578 + CCAGGUUGGCGUUGUCGGGCUGC 23 8961
HSV2-UL19-4579 + GCCAGGUUGGCGUUGUCGGGCUGC 24 8962
HSV2-UL19-4580 + AUGGUGUGGUCCAGGUGC 18 8963
HSV2-UL19-4581 + GAUGGUGUGGUCCAGGUGC 19 8964
HSV2-UL19-1275 + GGAUGGUGUGGUCCAGGUGC 20 1515
HSV2-UL19-4582 + UGGAUGGUGUGGUCCAGGUGC 21 8965
HSV2-UL19-4583 + UUGGAUGGUGUGGUCCAGGUGC 22 8966
HSV2-UL19-4584 + UU UGGAUGGUGUGGUCCAGGUGC 23 8967
HSV2-UL19-4585 + UU UUGGAUGGUGUGGUCCAGGUGC 24
8968
HSV2-UL19-4586 + UUGUCGAGAUAUCGUUGC 18 8969
HSV2-UL19-4587 + GUUGUCGAGAUAUCGUUGC 19 8970
HSV2-UL19-2774 + CGUUGUCGAGAUAUCGUUGC 20 2859
HSV2-UL19-4588 + CCGUUGUCGAGAUAUCGUUGC 21 8971
HSV2-UL19-4589 + CCCGUUGUCGAGAUAUCGUUGC 22 8972
HSV2-UL19-4590 + GCCCGUUGUCGAGAUAUCGUUGC 23 8973
HSV2-UL19-4591 + CGCCCGUUGUCGAGAUAUCGUUGC 24 8974
HSV2-UL19-4592 + CGCGUGGGCCUCCCCAUC 18 8975
HSV2-UL19-4593 + GCGCGUGGGCCUCCCCAUC 19 8976
HSV2-UL19-2512 + CGCGCGUGGGCCUCCCCAUC 20 2677
HSV2-UL19-4594 + UCGCGCGUGGGCCUCCCCAUC 21 8977
HSV2-UL19-4595 + CUCGCGCGUGGGCCUCCCCAUC 22 8978
HSV2-UL19-4596 + UCUCGCGCGUGGGCCUCCCCAUC 23 8979
HSV2-UL19-4597 + CUCUCGCGCGUGGGCCUCCCCAUC 24 8980
HSV2-UL19-4598 + AGGGCCACGGGGCUCAUC 18 8981
HSV2-UL19-4599 + CAGGGCCACGGGGCUCAUC 19 8982 HSV2-UL19-2589 + ACAG GGCCACG G GG CU CAU C 20 2733
HSV2-UL19-4600 + UACAGGGCCACGGGGCUCAUC 21 8983
HSV2-UL19-4601 + AUACAGGGCCACGGGGCUCAUC 22 8984
HSV2-UL19-4602 + GAUACAGGGCCACGGGGCUCAUC 23 8985
HSV2-UL19-4603 + UGAUACAGGGCCACGGGGCUCAUC 24 8986
HSV2-UL19-4604 + GCGUCUCUCCAGGGCCUC 18 8987
HSV2-UL19-4605 + UGCGUCUCUCCAGGGCCUC 19 8988
HSV2-UL19-2750 + AUGCGUCUCUCCAGGGCCUC 20 2843
HSV2-UL19-4606 + GAUGCGUCUCUCCAGGGCCUC 21 8989
HSV2-UL19-4607 + AGAUGCGUCUCUCCAGGGCCUC 22 8990
HSV2-UL19-4608 + UAGAUGCGUCUCUCCAGGGCCUC 23 8991
HSV2-UL19-4609 + GUAGAUGCGUCUCUCCAGGGCCUC 24 8992
HSV2-UL19-4610 + CACGGCCAUGCACUCCUC 18 8993
HSV2-UL19-4611 + ACACGGCCAUGCACUCCUC 19 8994
HSV2-UL19-1369 + UACACGGCCAUGCACUCCUC 20 1609
HSV2-UL19-4612 + AUACACGGCCAUGCACUCCUC 21 8995
HSV2-UL19-4613 + GAUACACGGCCAUGCACUCCUC 22 8996
HSV2-UL19-4614 + CGAUACACGGCCAUGCACUCCUC 23 8997
HSV2-UL19-4615 + CCGAUACACGGCCAUGCACUCCUC 24 8998
HSV2-UL19-4616 + GAACGCGGGGUGCAGCUC 18 8999
HSV2-UL19-4617 + CGAACGCGGGGUGCAGCUC 19 9000
HSV2-UL19-2705 + UCGAACGCGGGGUGCAGCUC 20 2812
HSV2-UL19-4618 + GUCGAACGCGGGGUGCAGCUC 21 9001
HSV2-UL19-4619 + AGUCGAACGCGGGGUGCAGCUC 22 9002
HSV2-UL19-4620 + AAGUCGAACGCGGGGUGCAGCUC 23 9003
HSV2-UL19-4621 + GAAGUCGAACGCGGGGUGCAGCUC 24 9004
HSV2-UL19-4622 + CUCACCGGGGGCGAUCUC 18 9005
HSV2-UL19-4623 + CCUCACCGGGGGCGAUCUC 19 9006
HSV2-UL19-1312 + UCCUCACCGGGGGCGAUCUC 20 1552
HSV2-UL19-4624 + CUCCUCACCGGGGGCGAUCUC 21 9007
HSV2-UL19-4625 + ACUCCUCACCGGGGGCGAUCUC 22 9008
HSV2-UL19-4626 + CACUCCUCACCGGGGGCGAUCUC 23 9009
HSV2-UL19-4627 + GCACUCCUCACCGGGGGCGAUCUC 24 9010
HSV2-UL19-4628 + CUCCCCCGCCGCGCUCUC 18 9011
HSV2-UL19-4629 + UCUCCCCCGCCGCGCUCUC 19 9012
HSV2-UL19-2591 + UUCUCCCCCGCCGCGCUCUC 20 2735
HSV2-UL19-4630 + GUUCUCCCCCGCCGCGCUCUC 21 9013
HSV2-UL19-4631 + CGUUCUCCCCCGCCGCGCUCUC 22 9014
HSV2-UL19-4632 + GCGUUCUCCCCCGCCGCGCUCUC 23 9015
HSV2-UL19-4633 + CGCGUUCUCCCCCGCCGCGCUCUC 24 9016
HSV2-UL19-4634 + GGCGUAGAUGCGUCUCUC 18 9017
HSV2-UL19-4635 + CGGCGUAGAUGCGUCUCUC 19 9018
HSV2-UL19-2749 + GCGGCGUAGAUGCGUCUCUC 20 2842
HSV2-UL19-4636 + GGCGGCGUAGAUGCGUCUCUC 21 9019
HSV2-UL19-4637 + UGGCGGCGUAGAUGCGUCUCUC 22 9020
HSV2-UL19-4638 + GUGGCGGCGUAGAUGCGUCUCUC 23 9021 HSV2-UL19-4639 + GGUGGCGGCGUAGAUGCGUCUCUC 24 9022
HSV2-UL19-4640 + CUGGUGAUGCACUGAGUC 18 9023
HSV2-UL19-4641 + GCUGGUGAUGCACUGAGUC 19 9024
HSV2-UL19-2677 + AGCUGGUGAUGCACUGAGUC 20 2792
HSV2-UL19-4642 + UAGCUGGUGAUGCACUGAGUC 21 9025
HSV2-UL19-4643 + GU AGCUGGUGAUGCACUGAGUC 22 9026
HSV2-UL19-4644 + AG UAGCUGGUGAUGCACUGAGUC 23 9027
HSV2-UL19-4645 + CAGUAGCUGGUGAUGCACUGAGUC 24 9028
HSV2-UL19-4646 + CCGGGGUGGAGGCCCGUC 18 9029
HSV2-UL19-4647 + CCCGGGGUGGAGGCCCGUC 19 9030
HSV2-UL19-2585 + ACCCGGGGUGGAGGCCCGUC 20 2730
HSV2-UL19-4648 + AACCCGGGGUGGAGGCCCGUC 21 9031
HSV2-UL19-4649 + GAACCCGGGGUGGAGGCCCGUC 22 9032
HSV2-UL19-4650 + CG AACCCGGGGUGGAGGCCCGUC 23 9033
HSV2-UL19-4651 + CCG AACCCGGGGUGGAGGCCCGUC 24 9034
HSV2-UL19-4652 + CUCCAGGCCCCGGGCGUC 18 9035
HSV2-UL19-4653 + GCUCCAGGCCCCGGGCGUC 19 9036
HSV2-UL19-2686 + AGCUCCAGGCCCCGGGCGUC 20 2801
HSV2-UL19-4654 + GAGCUCCAGGCCCCGGGCGUC 21 9037
HSV2-UL19-4655 + CGAGCUCCAGGCCCCGGGCGUC 22 9038
HSV2-UL19-4656 + CCGAGCUCCAGGCCCCGGGCGUC 23 9039
HSV2-UL19-4657 + GCCGAGCUCCAGGCCCCGGGCGUC 24 9040
HSV2-UL19-4658 + GCAGUCUCGGUGGCGGUC 18 9041
HSV2-UL19-4659 + GGCAGUCUCGGUGGCGGUC 19 9042
HSV2-UL19-2657 + CGGCAGUCUCGGUGGCGGUC 20 2776
HSV2-UL19-4660 + CCGGCAGUCUCGGUGGCGGUC 21 9043
HSV2-UL19-4661 + UCCGGCAGUCUCGGUGGCGGUC 22 9044
HSV2-UL19-4662 + AUCCGGCAGUCUCGGUGGCGGUC 23 9045
HSV2-UL19-4663 + AAUCCGGCAGUCUCGGUGGCGGUC 24 9046
HSV2-UL19-4664 + AACAGCACGUUCUCGGUC 18 9047
HSV2-UL19-4665 + AAACAGCACGUUCUCGGUC 19 9048
HSV2-UL19-2578 + AAAACAGCACGUUCUCGGUC 20 2725
HSV2-UL19-4666 + G AAAACAG CACGUUCUCGGUC 21 9049
HSV2-UL19-4667 + G G AAAACAG CACGUUCUCGGUC 22 9050
HSV2-UL19-4668 + CG G AAAACAG CACGUUCUCGGUC 23 9051
HSV2-UL19-4669 + UCGGAAAACAGCACGUUCUCGGUC 24 9052
HSV2-UL19-4670 + GGGUGGGCGGGGUCGGUC 18 9053
HSV2-UL19-4671 + CGGGUGGGCGGGGUCGGUC 19 9054
HSV2-UL19-2641 + GCGGGUGGGCGGGGUCGGUC 20 2764
HSV2-UL19-4672 + AGCGGGUGGGCGGGGUCGGUC 21 9055
HSV2-UL19-4673 + CAGCGGGUGGGCGGGGUCGGUC 22 9056
HSV2-UL19-4674 + GCAGCGGGUGGGCGGGGUCGGUC 23 9057
HSV2-UL19-4675 + UGCAGCGGGUGGGCGGGGUCGGUC 24
9058
HSV2-UL19-4676 + GCGCGCACGCGCGUUGUC 18 9059
HSV2-UL19-4677 + CGCGCGCACGCGCGUUGUC 19 9060 HSV2-UL19-1488 + CCGCGCGCACGCGCGUUGUC 20 1728
HSV2-UL19-4678 + UCCGCGCGCACGCGCGUUGUC 21 9061
HSV2-UL19-4679 + AUCCGCGCGCACGCGCGUUGUC 22 9062
HSV2-UL19-4680 + GAUCCGCGCGCACGCGCGUUGUC 23 9063
HSV2-UL19-4681 + AGAUCCGCGCGCACGCGCGUUGUC 24 9064
HSV2-UL19-4682 + UCGGUGUCCUCCACCU UC 18 9065
HSV2-UL19-4683 + CUCGGUGUCCUCCACCUUC 19 9066
HSV2-UL19-1505 + CCU CG G U G U CCU CCACCU U C 20 1745
HSV2-UL19-4684 + GCCUCGGUGUCCUCCACCUUC 21 9067
HSV2-UL19-4685 + GGCCUCGGUGUCCUCCACCUUC 22 9068
HSV2-UL19-4686 + CGGCCUCGGUGUCCUCCACCUUC 23 9069
HSV2-UL19-4687 + UCGGCCUCGGUGUCCUCCACCUUC 24 9070
HSV2-UL19-4688 + GGUGAUCGGGUAGGCUUC 18 9071
HSV2-UL19-4689 + AGGUGAUCGGGUAGGCUUC 19 9072
HSV2-UL19-2517 + CAGGUGAUCGGGUAGGCUUC 20 2681
HSV2-UL19-4690 + GCAGGUGAUCGGGUAGGCUUC 21 9073
HSV2-UL19-4691 + CGCAGGUGAUCGGGUAGGCUUC 22 9074
HSV2-UL19-4692 + GCGCAGGUGAUCGGGUAGGCUUC 23 9075
HSV2-UL19-4693 + GGCGCAGGUGAUCGGGUAGGCUUC 24 9076
HSV2-UL19-4694 + ACCAGCGAGUAGUCGUUC 18 9077
HSV2-UL19-4695 + GACCAGCGAGUAGUCGUUC 19 9078
HSV2-UL19-2675 + AGACCAGCGAGUAGUCGUUC 20 2790
HSV2-UL19-4696 + GAG ACCAGCGAGUAGUCGUUC 21 9079
HSV2-UL19-4697 + CGAGACCAGCGAGUAGUCGUUC 22 9080
HSV2-UL19-4698 + ACGAGACCAGCGAGUAGUCGUUC 23 9081
HSV2-UL19-4699 + UACGAGACCAGCGAGUAGUCGUUC 24 9082
HSV2-UL19-4700 + ACGGCCGCGUCGAUGUUC 18 9083
HSV2-UL19-4701 + GACGGCCGCGUCGAUGUUC 19 9084
HSV2-UL19-2719 + CGACGGCCGCGUCGAUGUUC 20 2823
HSV2-UL19-4702 + CCGACGGCCGCGUCGAUGUUC 21 9085
HSV2-UL19-4703 + CCCGACGGCCGCGUCGAUGUUC 22 9086
HSV2-UL19-4704 + CCCCGACGGCCGCGUCGAUGUUC 23 9087
HSV2-UL19-4705 + CCCCCGACGGCCGCGUCGAUGUUC 24 9088
HSV2-UL19-4706 + GCCACGCCCGCGAAGAAG 18 9089
HSV2-UL19-4707 + GGCCACGCCCGCGAAGAAG 19 9090
HSV2-UL19-2702 + CGGCCACGCCCGCGAAGAAG 20 2810
HSV2-UL19-4708 + UCGGCCACGCCCGCGAAGAAG 21 9091
HSV2-UL19-4709 + GUCGGCCACGCCCGCGAAGAAG 22 9092
HSV2-UL19-4710 + CGUCGGCCACGCCCGCGAAGAAG 23 9093
HSV2-UL19-4711 + ACGUCGGCCACGCCCGCGAAGAAG 24 9094
HSV2-UL19-4712 + CGCAGGGCCGGGGGGAAG 18 9095
HSV2-UL19-4713 + GCGCAGGGCCGGGGGGAAG 19 9096
HSV2-UL19-2616 + CGCGCAGGGCCGGGGGGAAG 20 2746
HSV2-UL19-4714 + UCGCGCAGGGCCGGGGGGAAG 21 9097
HSV2-UL19-4715 + GUCGCGCAGGGCCGGGGGGAAG 22 9098
HSV2-UL19-4716 + GGUCGCGCAGGGCCGGGGGGAAG 23 9099 HSV2-UL19-4717 + AGGUCGCGCAGGGCCGGGGGGAAG 24 9100
HSV2-UL19-4718 + GCGGUGAAGAACUUGAAG 18 9101
HSV2-UL19-4719 + CGCGGUGAAGAACUUGAAG 19 9102
HSV2-UL19-2526 + CCGCGGUGAAGAACUUGAAG 20 2690
HSV2-UL19-4720 + GCCGCGGUGAAGAACUUGAAG 21 9103
HSV2-UL19-4721 + GGCCGCGGUGAAGAACUUGAAG 22 9104
HSV2-UL19-4722 + CGGCCGCGGUGAAGAACUUGAAG 23 9105
HSV2-UL19-4723 + UCGGCCGCGGUGAAGAACUUGAAG 24 9106
HSV2-UL19-4724 + UCGUUGCAUGGGCAACAG 18 9107
HSV2-UL19-4725 + AUCGUUGCAUGGGCAACAG 19 9108
HSV2-UL19-2775 + UAUCGUUGCAUGGGCAACAG 20 2860
HSV2-UL19-4726 + AU AUCGUUGCAUGGGCAACAG 21 9109
HSV2-UL19-4727 + GAU AUCGUUGCAUGGGCAACAG 22 9110
HSV2-UL19-4728 + AGAU AUCGUUGCAUGGGCAACAG 23 9111
HSV2-UL19-4729 + GAGAUAUCGUUGCAUGGGCAACAG 24 9112
HSV2-UL19-4730 + GGUAAAGUCGUCCACCAG 18 9113
HSV2-UL19-4731 + G G G U AAAG U CG U CCACCAG 19 9114
HSV2-UL19-2665 + AGGGUAAAGUCGUCCACCAG 20 2783
HSV2-UL19-4732 + CAG G G U AAAG U CG U CCACCAG 21 9115
HSV2-UL19-4733 + GCAGGGUAAAGUCGUCCACCAG 22 9116
HSV2-UL19-4734 + G G CAG G G U AAAG UCGUCCACCAG 23 9117
HSV2-UL19-4735 + CGGCAGGGUAAAGUCGUCCACCAG 24 9118
HSV2-UL19-4736 + CAGGGCCGGGGGGACCAG 18 9119
HSV2-UL19-4737 + CCAGGGCCGGGGGGACCAG 19 9120
HSV2-UL19-1252 + CCCAGGGCCGGGGGGACCAG 20 1492
HSV2-UL19-4738 + CCCCAGGGCCGGGGGGACCAG 21 9121
HSV2-UL19-4739 + CCCCCAGGGCCGGGGGGACCAG 22 9122
HSV2-UL19-4740 + GCCCCCAGGGCCGGGGGGACCAG 23 9123
HSV2-UL19-4741 + GGCCCCCAGGGCCGGGGGGACCAG 24 9124
HSV2-UL19-4742 + G G G CAACAG CAG G G CCAG 18 9125
HSV2-UL19-4743 + U G G G CAACAG CAG G G CCAG 19 9126
HSV2-UL19-1542 + AUGGGCAACAGCAGGGCCAG 20 1782
HSV2-UL19-4744 + CAU G G G CAACAG CAG G G CCAG 21 9127
HSV2-UL19-4745 + GCAUGGGCAACAGCAGGGCCAG 22 9128
HSV2-UL19-4746 + U G CAU G G G CAACAG CAG G G CCAG 23 9129
HSV2-UL19-4747 + UUGCAUGGGCAACAGCAGGGCCAG 24 9130
HSV2-UL19-4748 + GGCCGCGUUGUCUAGCAG 18 9131
HSV2-UL19-4749 + CGGCCGCGUUGUCUAGCAG 19 9132
HSV2-UL19-1188 + GCGGCCGCGUUGUCUAGCAG 20 1428
HSV2-UL19-4750 + GGCGGCCGCGUUGUCUAGCAG 21 9133
HSV2-UL19-4751 + CGGCGGCCGCGUUGUCUAGCAG 22 9134
HSV2-UL19-4752 + ACGGCGGCCGCGUUGUCUAGCAG 23 9135
HSV2-UL19-4753 + CACGGCGGCCGCGUUGUCUAGCAG 24 9136
HSV2-UL19-4754 + CGUGUCGGCGUGCGUCAG 18 9137
HSV2-UL19-4755 + GCGUGUCGGCGUGCGUCAG 19 9138
HSV2-UL19-2764 + CGCGUGUCGGCGUGCGUCAG 20 2851 HSV2-UL19-4756 + GCGCGUGUCGGCGUGCGUCAG 21 9139
HSV2-UL19-4757 + CGCGCGUGUCGGCGUGCGUCAG 22 9140
HSV2-UL19-4758 + CCGCGCGUGUCGGCGUGCGUCAG 23 9141
HSV2-UL19-4759 + CCCGCGCGUGUCGGCGUGCGUCAG 24 9142
HSV2-UL19-4760 + ACGGGCUGGCGGAUGGAG 18 9143
HSV2-UL19-4761 + CACGGGCUGGCGGAUGGAG 19 9144
HSV2-UL19-2598 + CCACGGGCUGGCGGAUGGAG 20 2740
HSV2-UL19-4762 + ACCACGGGCUGGCGGAUGGAG 21 9145
HSV2-UL19-4763 + CACCACGGGCUGGCGGAUGGAG 22 9146
HSV2-UL19-4764 + GCACCACGGGCUGGCGGAUGGAG 23 9147
HSV2-UL19-4765 + UGCACCACGGGCUGGCGGAUGGAG 24 9148
HSV2-UL19-4766 + UUGCACGCCGCCGCGUAG 18 9149
HSV2-UL19-4767 + GUUGCACGCCGCCGCGUAG 19 9150
HSV2-UL19-2656 + CGUUGCACGCCGCCGCGUAG 20 2775
HSV2-UL19-4768 + ACG UU GCACGCCGCCGCG UAG 21 9151
HSV2-UL19-4769 + CACGUUGCACGCCGCCGCGUAG 22 9152
HSV2-UL19-4770 + CCACGUUGCACGCCGCCGCGUAG 23 9153
HSV2-UL19-4771 + GCCACGUUGCACGCCGCCGCGUAG 24 9154
HSV2-UL19-4772 + AUCGCGGGCGCUGCGUAG 18 9155
HSV2-UL19-4773 + CAUCGCGGGCGCUGCGUAG 19 9156
HSV2-UL19-2513 + CCAUCGCGGGCGCUGCGUAG 20 2678
HSV2-UL19-4774 + CCCAUCGCGGGCGCUGCGUAG 21 9157
HSV2-UL19-4775 + CCCCAUCGCGGGCGCUGCGUAG 22 9158
HSV2-UL19-4776 + UCCCCAUCGCGGGCGCUGCGUAG 23 9159
HSV2-UL19-4777 + CUCCCCAUCGCGGGCGCUGCGUAG 24 9160
HSV2-UL19-4778 + AGCGGGGAGGCGUCGUAG 18 9161
HSV2-UL19-4779 + UAGCGGGGAGGCGUCGUAG 19 9162
HSV2-UL19-2509 + UU AGCGGGGAGGCGUCGUAG 20 2674
HSV2-UL19-4780 + UUUAGCGGGGAGGCGUCGUAG 21 9163
HSV2-UL19-4781 + CUU UAGCGGGGAGGCGUCGUAG 22 9164
HSV2-UL19-4782 + CCU U UAGCGGGGAGGCGUCGUAG 23 9165
HSV2-UL19-4783 + CCCUUUAGCGGGGAGGCGUCGUAG 24 9166
HSV2-UL19-4784 + CAGAGACAGGCCCUUUAG 18 9167
HSV2-UL19-4785 + ACAGAGACAGGCCCUUUAG 19 9168
HSV2-UL19-1101 + UACAGAGACAGGCCCUUUAG 20 1341
HSV2-UL19-4786 + UU ACAGAGACAGGCCCUUUAG 21 9169
HSV2-UL19-4787 + UUUACAGAGACAGGCCCUUUAG 22 9170
HSV2-UL19-4788 + UU UUACAGAGACAGGCCCUUUAG 23 9171
HSV2-UL19-4789 + AU U U UACAG AGACAGGCCCU UU AG 24 9172
HSV2-UL19-4790 + AUGGCGUGGCGGCCAACG 18 9173
HSV2-UL19-4791 + CAUGGCGUGGCGG CCAACG 19 9174
HSV2-UL19-2684 + CCAUGGCGUGGCGGCCAACG 20 2799
HSV2-UL19-4792 + GCCAUGGCGUGGCGGCCAACG 21 9175
HSV2-UL19-4793 + CGCCAUGGCGUGGCGGCCAACG 22 9176
HSV2-UL19-4794 + GCGCCAUGGCGUGGCGGCCAACG 23 9177
HSV2-UL19-4795 + GGCGCCAUGGCGUGGCGGCCAACG 24 9178 HSV2-UL19-4796 + CCGUCGCAGUCCCACACG 18 9179
HSV2-UL19-4797 + GCCGUCGCAGUCCCACACG 19 9180
HSV2-UL19-1347 + GGCCGUCGCAGUCCCACACG 20 1587
HSV2-UL19-4798 + AGGCCGUCGCAGUCCCACACG 21 9181
HSV2-UL19-4799 + AAGGCCGUCGCAGUCCCACACG 22 9182
HSV2-UL19-4800 + UAAGGCCGUCGCAGUCCCACACG 23 9183
HSV2-UL19-4801 + AUAAGGCCGUCGCAGUCCCACACG 24 9184
HSV2-UL19-4802 + GCCGAUCCCGUUUCCACG 18 9185
HSV2-UL19-4803 + CGCCGAUCCCGUUUCCACG 19 9186
HSV2-UL19-2522 + CCGCCG AUCCCGU U UCCACG 20 2686
HSV2-UL19-4804 + ACCGCCGAUCCCGUUUCCACG 21 9187
HSV2-UL19-4805 + UACCGCCGAUCCCGUUUCCACG 22 9188
HSV2-UL19-4806 + AUACCGCCGAUCCCGU UUCCACG 23 9189
HSV2-UL19-4807 + GAUACCGCCGAUCCCGUUUCCACG 24 9190
HSV2-UL19-4808 + CGGUCCUGCCGCACGACG 18 9191
HSV2-UL19-4809 + GCGGUCCUGCCGCACGACG 19 9192
HSV2-UL19-2579 + AGCGGUCCUGCCGCACGACG 20 2726
HSV2-UL19-4810 + AAGCGGUCCUGCCGCACGACG 21 9193
HSV2-UL19-4811 + GAAGCGGUCCUGCCGCACGACG 22 9194
HSV2-UL19-4812 + CGAAG CG G U CCU GCCGCACG ACG 23 9195
HSV2-UL19-4813 + ACGAAGCGGUCCUGCCGCACGACG 24 9196
HSV2-UL19-4814 + GCGUGGACGGGCAGGACG 18 9197
HSV2-UL19-4815 + CGCGUGGACGGGCAGGACG 19 9198
HSV2-UL19-2620 + GCGCGUGGACGGGCAGGACG 20 2750
HSV2-UL19-4816 + AGCGCGUGGACGGGCAGGACG 21 9199
HSV2-UL19-4817 + CAGCGCGUGGACGGGCAGGACG 22 9200
HSV2-UL19-4818 + ACAGCGCGUGGACGGGCAGGACG 23 9201
HSV2-UL19-4819 + AACAGCGCGUGGACGGGCAGGACG 24 9202
HSV2-UL19-4820 + CGAGCUCGCGGCACCCCG 18 9203
HSV2-UL19-4821 + ACGAGCUCGCGGCACCCCG 19 9204
HSV2-UL19-2520 + CACGAGCUCGCGGCACCCCG 20 2684
HSV2-UL19-4822 + CCACGAGCUCGCGGCACCCCG 21 9205
HSV2-UL19-4823 + UCCACGAGCUCGCGGCACCCCG 22 9206
HSV2-UL19-4824 + UUCCACGAGCUCGCGGCACCCCG 23 9207
HSV2-UL19-4825 + CUUCCACGAGCUCGCGGCACCCCG 24 9208
HSV2-UL19-4826 + CCGGCGUGCAGCGCCCCG 18 9209
HSV2-UL19-4827 + GCCGGCGUGCAGCGCCCCG 19 9210
HSV2-UL19-2627 + CGCCGGCGUGCAGCGCCCCG 20 2754
HSV2-UL19-4828 + ACGCCGGCGUGCAGCGCCCCG 21 9211
HSV2-UL19-4829 + CACGCCGGCGUGCAGCGCCCCG 22 9212
HSV2-UL19-4830 + GCACGCCGGCGUGCAGCGCCCCG 23 9213
HSV2-UL19-4831 + AGCACGCCGGCGUGCAGCGCCCCG 24 9214
HSV2-UL19-4832 + AGGACGGGCGAGGCCCCG 18 9215
HSV2-UL19-4833 + GAGGACGGGCGAGGCCCCG 19 9216
HSV2-UL19-2532 + UGAGGACGGGCGAGGCCCCG 20 2695
HSV2-UL19-4834 + CUGAGGACGGGCGAGGCCCCG 21 9217 HSV2-UL19-4835 + GCUGAGGACGGGCGAGGCCCCG 22 9218
HSV2-UL19-4836 + GGCUGAGGACGGGCGAGGCCCCG 23 9219
HSV2-UL19-4837 + GGGCUGAGGACGGGCGAGGCCCCG 24 9220
HSV2-UL19-4838 + GUUCUCCAUGGACAGCCG 18 9221
HSV2-UL19-4839 + CGUUCUCCAUGGACAGCCG 19 9222
HSV2-UL19-2723 + GCGUUCUCCAUGGACAGCCG 20 2827
HSV2-UL19-4840 + CG CG U U CU CCAU G G ACAGCCG 21 9223
HSV2-UL19-4841 + CCGCGUUCUCCAUGGACAGCCG 22 9224
HSV2-UL19-4842 + ACCG CG U U CU CCAU G G ACAG CCG 23 9225
HSV2-UL19-4843 + GACCGCGUUCUCCAUGGACAGCCG 24 9226
HSV2-UL19-4844 + CGCCCGCGUCGGGCGCCG 18 9227
HSV2-UL19-4845 + GCGCCCGCGUCGGGCGCCG 19 9228
HSV2-UL19-1286 + GGCGCCCGCGUCGGGCGCCG 20 1526
HSV2-UL19-4846 + UGGCGCCCGCGUCGGGCGCCG 21 9229
HSV2-UL19-4847 + UUGGCGCCCGCGUCGGGCGCCG 22 9230
HSV2-UL19-4848 + GUUGGCGCCCGCGUCGGGCGCCG 23 9231
HSV2-UL19-4849 + UGU UGGCGCCCGCGUCGGGCGCCG 24 9232
HSV2-UL19-4850 + GCCGGGGGGACUUCGCCG 18 9233
HSV2-UL19-4851 + GGCCGGGGGGACUUCGCCG 19 9234
HSV2-UL19-2697 + CGGCCGGGGGGACU UCGCCG 20 2807
HSV2-UL19-4852 + CCGGCCGGGGGGACUUCGCCG 21 9235
HSV2-UL19-4853 + ACCGGCCGGGGGGACU UCGCCG 22 9236
HSV2-UL19-4854 + GACCGGCCGGGGGGACUUCGCCG 23 9237
HSV2-UL19-4855 + GGACCGGCCGGGGGGACUUCGCCG 24 9238
HSV2-UL19-4856 + UCGCCCCCGGACCGGCCG 18 9239
HSV2-UL19-4857 + AUCGCCCCCGGACCGGCCG 19 9240
HSV2-UL19-1405 + GAUCGCCCCCGGACCGGCCG 20 1645
HSV2-UL19-4858 + GGAUCGCCCCCGGACCGGCCG 21 9241
HSV2-UL19-4859 + UGGAUCGCCCCCGGACCGGCCG 22 9242
HSV2-UL19-4860 + CUGGAUCGCCCCCGGACCGGCCG 23 9243
HSV2-UL19-4861 + CCUGGAUCGCCCCCGGACCGGCCG 24 9244
HSV2-UL19-4862 + AGUUGGCCCCCAGGGCCG 18 9245
HSV2-UL19-4863 + UAGUUGGCCCCCAGGGCCG 19 9246
HSV2-UL19-1247 + GUAGUUGGCCCCCAGGGCCG 20 1487
HSV2-UL19-4864 + AG UAGUUGGCCCCCAGGGCCG 21 9247
HSV2-UL19-4865 + AAGU AGUUGGCCCCCAGGGCCG 22 9248
HSV2-UL19-4866 + GAAGU AGUUGGCCCCCAGGGCCG 23 9249
HSV2-UL19-4867 + AGAAG UAG U UGGCCCCCAGGGCCG 24 9250
HSV2-UL19-4868 + CCAGGUCGCGCAGGGCCG 18 9251
HSV2-UL19-4869 + GCCAGGUCGCGCAGGGCCG 19 9252
HSV2-UL19-1259 + CGCCAGGUCGCGCAGGGCCG 20 1499
HSV2-UL19-4870 + GCGCCAGGUCGCGCAGGGCCG 21 9253
HSV2-UL19-4871 + CGCGCCAGGUCGCGCAGGGCCG 22 9254
HSV2-UL19-4872 + GCGCGCCAGGUCGCGCAGGGCCG 23 9255
HSV2-UL19-4873 + CGCGCGCCAGGUCGCGCAGGGCCG 24 9256
HSV2-UL19-4874 + CCGCGGGUUGCAGGGCCG 18 9257 HSV2-UL19-4875 + CCCGCGGGUUGCAGGGCCG 19 9258
HSV2-UL19-2543 + CCCCGCGGGUUGCAGGGCCG 20 2706
HSV2-UL19-4876 + UCCCCGCGGGUUGCAGGGCCG 21 9259
HSV2-UL19-4877 + GUCCCCGCGGGUUGCAGGGCCG 22 9260
HSV2-UL19-4878 + CGUCCCCGCGGGUUGCAGGGCCG 23 9261
HSV2-UL19-4879 + GCGUCCCCGCGGGUUGCAGGGCCG 24 9262
HSV2-UL19-4880 + CCAAAA AAACAG CU G CCG 18 9263
HSV2-UL19-4881 + CCCAAAAAAACAG C U G CCG 19 9264
HSV2-UL19-1448 + CCCCAAAAAAACAGCUGCCG 20 1688
HSV2-UL19-4882 + UCCCCAAAAAAACAGCUGCCG 21 9265
HSV2-UL19-4883 + UUCCCCAAAAAAACAGCUGCCG 22 9266
HSV2-UL19-4884 + UU UCCCCAAAAAAACAGCUGCCG 23 9267
HSV2-UL19-4885 + CUUUCCCCAAAAAAACAGCUGCCG 24 9268
HSV2-UL19-4886 + CCGCGUUGUCUAGCAGCG 18 9269
HSV2-UL19-4887 + GCCGCGUUGUCUAGCAGCG 19 9270
HSV2-UL19-1190 + GGCCGCGUUGUCUAGCAGCG 20 1430
HSV2-UL19-4888 + CGGCCGCGUUGUCUAGCAGCG 21 9271
HSV2-UL19-4889 + GCGGCCGCGUUGUCUAGCAGCG 22 9272
HSV2-UL19-4890 + GGCGGCCGCGUUGUCUAGCAGCG 23 9273
HSV2-UL19-4891 + CGGCGGCCGCGUUGUCUAGCAGCG 24 9274
HSV2-UL19-4892 + GAGACAGGCCCU UUAGCG 18 9275
HSV2-UL19-4893 + AGAGACAGGCCCUUUAGCG 19 9276
HSV2-UL19-1103 + CAGAGACAGGCCCUUUAGCG 20 1343
HSV2-UL19-4894 + ACAGAGACAGGCCCUUUAGCG 21 9277
HSV2-UL19-4895 + UACAGAGACAGGCCCUUUAGCG 22 9278
HSV2-UL19-4896 + UU ACAGAGACAGGCCCUUUAGCG 23 9279
HSV2-UL19-4897 + UUUACAGAGACAGGCCCUUUAGCG 24 9280
HSV2-UL19-4898 + UGCCGGGGAGGGAACGCG 18 9281
HSV2-UL19-4899 + CUGCCGGGGAGGGAACGCG 19 9282
HSV2-UL19-1451 + GCUGCCGGGGAGGGAACGCG 20 1691
HSV2-UL19-4900 + AGCUGCCGGGGAGGGAACGCG 21 9283
HSV2-UL19-4901 + CAGCUGCCGGGGAGGGAACGCG 22 9284
HSV2-UL19-4902 + ACAGCUGCCGGGGAGGGAACGCG 23 9285
HSV2-UL19-4903 + AACAGCUGCCGGGGAGGGAACGCG 24 9286
HSV2-UL19-4904 + ACGUCGGCCACGCCCGCG 18 9287
HSV2-UL19-4905 + GACGUCGGCCACGCCCGCG 19 9288
HSV2-UL19-2701 + CGACGUCGGCCACGCCCGCG 20 2809
HSV2-UL19-4906 + UCGACGUCGGCCACGCCCGCG 21 9289
HSV2-UL19-4907 + CUCGACGUCGGCCACGCCCGCG 22 9290
HSV2-UL19-4908 + GCUCGACGUCGGCCACGCCCGCG 23 9291
HSV2-UL19-4909 + AGCUCGACGUCGGCCACGCCCGCG 24 9292
HSV2-UL19-4910 + GCGGUGUUGGCGCCCGCG 18 9293
HSV2-UL19-4911 + CGCGGUGUUGGCGCCCGCG 19 9294
HSV2-UL19-2628 + ACGCGGUGUUGGCGCCCGCG 20 2755
HSV2-UL19-4912 + GACGCGGUGUUGGCGCCCGCG 21 9295
HSV2-UL19-4913 + CGACGCGGUGUUGGCGCCCGCG 22 9296 HSV2-UL19-4914 + UCGACGCGGUGUUGGCGCCCGCG 23 9297
HSV2-UL19-4915 + GUCGACGCGGUGUUGGCGCCCGCG 24 9298
HSV2-UL19-4916 + GCCGUGAUGUCGGCCGCG 18 9299
HSV2-UL19-4917 + GGCCGUGAUGUCGGCCGCG 19 9300
HSV2-UL19-2523 + UGGCCGUGAUGUCGGCCGCG 20 2687
HSV2-UL19-4918 + UUGGCCGUGAUGUCGGCCGCG 21 9301
HSV2-UL19-4919 + UUUGGCCGUGAUGUCGGCCGCG 22 9302
HSV2-UL19-4920 + GUU UGGCCGUGAUGUCGGCCGCG 23 9303
HSV2-UL19-4921 + UGU UUGGCCGUGAUGUCGGCCGCG 24 9304
HSV2-UL19-4922 + GGGUUGGCCGUGGCCGCG 18 9305
HSV2-UL19-4923 + CGGGUUGGCCGUGGCCGCG 19 9306
HSV2-UL19-2537 + ACGGGUUGGCCGUGGCCGCG 20 2700
HSV2-UL19-4924 + CACGGGUUGGCCGUGGCCGCG 21 9307
HSV2-UL19-4925 + CCACGGGUUGGCCGUGGCCGCG 22 9308
HSV2-UL19-4926 + CCCACGGGUUGGCCGUGGCCGCG 23 9309
HSV2-UL19-4927 + GCCCACGGGUUGGCCGUGGCCGCG 24 9310
HSV2-UL19-4928 + CGCUGCUGCAUGUCCGCG 18 9311
HSV2-UL19-4929 + ACGCUGCUGCAUGUCCGCG 19 9312
HSV2-UL19-2712 + AACGCUGCUGCAUGUCCGCG 20 2819
HSV2-UL19-4930 + AAACGCUGCUGCAUGUCCGCG 21 9313
HSV2-UL19-4931 + AAAACGCUGCUGCAUGUCCGCG 22 9314
HSV2-UL19-4932 + GAAAACGCUGCUGCAUGUCCGCG 23 9315
HSV2-UL19-4933 + AGAAAACGCUGCUGCAUGUCCGCG 24 9316
HSV2-UL19-4934 + AGGUCCCCGGCGUGCGCG 18 9317
HSV2-UL19-4935 + CAGGUCCCCGGCGUGCGCG 19 9318
HSV2-UL19-2738 + CCAGGUCCCCGGCGUGCGCG 20 2834
HSV2-UL19-4936 + ACCAGGUCCCCGGCGUGCGCG 21 9319
HSV2-UL19-4937 + CACCAGGUCCCCGGCGUGCGCG 22 9320
HSV2-UL19-4938 + GCACCAGGUCCCCGGCGUGCGCG 23 9321
HSV2-UL19-4939 + GGCACCAGGUCCCCGGCGUGCGCG 24 9322
HSV2-UL19-4940 + GUCGCGCGCCAGGUCGCG 18 9323
HSV2-UL19-4941 + CGUCGCGCGCCAGGUCGCG 19 9324
HSV2-UL19-2609 + ACGUCGCGCGCCAGGUCGCG 20 2744
HSV2-UL19-4942 + GACGUCGCGCGCCAGGUCGCG 21 9325
HSV2-UL19-4943 + GG ACGUCGCGCGCCAGGUCGCG 22 9326
HSV2-UL19-4944 + GGGACGUCGCGCGCCAGGUCGCG 23 9327
HSV2-UL19-4945 + GGGGACGUCGCGCGCCAGGUCGCG 24 9328
HSV2-UL19-4946 + ACGAGCCGCGCCAGGGCG 18 9329
HSV2-UL19-4947 + CACGAGCCGCGCCAGGGCG 19 9330
HSV2-UL19-2679 + UCACGAGCCGCGCCAGGGCG 20 2794
HSV2-UL19-4948 + GUCACGAGCCGCGCCAGGGCG 21 9331
HSV2-UL19-4949 + AG UCACGAGCCGCGCCAGGGCG 22 9332
HSV2-UL19-4950 + GAGU CACGAGCCGCGCCAGGGCG 23 9333
HSV2-UL19-4951 + UGAGUCACGAGCCGCGCCAGGGCG 24 9334
HSV2-UL19-4952 + GUGGCCACGGGGGUGGCG 18 9335
HSV2-UL19-4953 + CGUGGCCACGGGGGUGGCG 19 9336 HSV2-UL19-2547 + CCGUGGCCACGGGGGUGGCG 20 2708
HSV2-UL19-4954 + UCCGUGGCCACGGGGGUGGCG 21 9337
HSV2-UL19-4955 + GUCCGUGGCCACGGGGGUGGCG 22 9338
HSV2-UL19-4956 + UGUCCGUGGCCACGGGGGUGGCG 23 9339
HSV2-UL19-4957 + AUGUCCGUGGCCACGGGGGUGGCG 24 9340
HSV2-UL19-4958 + UACGGAUUCGCGGCCUCG 18 9341
HSV2-UL19-4959 + GUACGGAUUCGCGGCCUCG 19 9342
HSV2-UL19-2717 + CGUACGGAUUCGCGGCCUCG 20 2822
HSV2-UL19-4960 + CCGUACGGAUUCGCGGCCUCG 21 9343
HSV2-UL19-4961 + CCCGUACGGAU UCGCGGCCUCG 22 9344
HSV2-UL19-4962 + CCCCGUACGGAUUCGCGGCCUCG 23 9345
HSV2-UL19-4963 + GCCCCGUACGGAU UCGCGGCCUCG 24 9346
HSV2-UL19-4964 + ACGGCCAUGCACUCCUCG 18 9347
HSV2-UL19-4965 + CACGGCCAUGCACUCCUCG 19 9348
HSV2-UL19-1370 + ACACGGCCAUGCACUCCUCG 20 1610
HSV2-UL19-4966 + UACACGGCCAUGCACUCCUCG 21 9349
HSV2-UL19-4967 + AUACACGGCCAUGCACUCCUCG 22 9350
HSV2-UL19-4968 + GAUACACGGCCAUGCACUCCUCG 23 9351
HSV2-UL19-4969 + CGAUACACGGCCAUGCACUCCUCG 24 9352
HSV2-UL19-4970 + UGGCCCGCCUUGCCCAGG 18 9353
HSV2-UL19-4971 + AUGGCCCGCCUUGCCCAGG 19 9354
HSV2-UL19-2770 + GAUGGCCCGCCUUGCCCAGG 20 2855
HSV2-UL19-4972 + CGAUGGCCCGCCUUGCCCAGG 21 9355
HSV2-UL19-4973 + GCGAUGGCCCGCCUUGCCCAGG 22 9356
HSV2-UL19-4974 + GGCGAUGGCCCGCCUUGCCCAGG 23 9357
HSV2-UL19-4975 + CGGCGAUGGCCCGCCUUGCCCAGG 24 9358
HSV2-UL19-4976 + CGGGCGCUGCGUAGCAGG 18 9359
HSV2-UL19-4977 + GCGGGCGCUGCGUAGCAGG 19 9360
HSV2-UL19-2514 + CGCGGGCGCUGCGUAGCAGG 20 2679
HSV2-UL19-4978 + UCGCGGGCGCUGCGUAGCAGG 21 9361
HSV2-UL19-4979 + AU CGCGGGCGCUGCGUAGCAGG 22 9362
HSV2-UL19-4980 + CAUCGCGGGCGCUGCGUAGCAGG 23 9363
HSV2-UL19-4981 + CCAUCGCGGGCGCUGCGUAGCAGG 24 9364
HSV2-UL19-4982 + AACAGCCCCAGGGGCAGG 18 9365
HSV2-UL19-4983 + GAACAGCCCCAGGGGCAGG 19 9366
HSV2-UL19-2744 + UG AACAGCCCCAGGGGCAGG 20 2839
HSV2-UL19-4984 + UUGAACAGCCCCAGGGGCAGG 21 9367
HSV2-UL19-4985 + GUU GAACAGCCCCAGGGGCAGG 22 9368
HSV2-UL19-4986 + GGUUGAACAGCCCCAGGGGCAGG 23 9369
HSV2-UL19-4987 + GGGUUGAACAGCCCCAGGGGCAGG 24 9370
HSV2-UL19-4988 + GUGUCGGCGUGCGUCAGG 18 9371
HSV2-UL19-4989 + CGUGUCGGCGUGCGUCAGG 19 9372
HSV2-UL19-1516 + GCGUGUCGGCGUGCGUCAGG 20 1756
HSV2-UL19-4990 + CGCGUGUCGGCGUGCGUCAGG 21 9373
HSV2-UL19-4991 + GCGCGUGUCGGCGUGCGUCAGG 22 9374
HSV2-UL19-4992 + CGCGCGUGUCGGCGUGCGUCAGG 23 9375 HSV2-UL19-4993 + CCGCGCGUGUCGGCGUGCGUCAGG 24 9376
HSV2-UL19-4994 + G U G U CCU CCACCU UCAG G 18 9377
HSV2-UL19-4995 + GGUGUCCUCCACCUUCAGG 19 9378
HSV2-UL19-2761 + CGGUGUCCUCCACCUUCAGG 20 2849
HSV2-UL19-4996 + UCGGUGUCCUCCACCUUCAGG 21 9379
HSV2-UL19-4997 + CUCGGUGUCCUCCACCUUCAGG 22 9380
HSV2-UL19-4998 + CCUCGGUGUCCUCCACCUUCAGG 23 9381
HSV2-UL19-4999 + GCCUCGGUGUCCUCCACCUUCAGG 24 9382
HSV2-UL19-5000 + UUGAAGCAGGGGCUGAGG 18 9383
HSV2-UL19-5001 + CUUGAAGCAGGGGCUGAGG 19 9384
HSV2-UL19-2530 + ACUUGAAGCAGGGGCUGAGG 20 2693
HSV2-UL19-5002 + AACUUGAAGCAGGGGCUGAGG 21 9385
HSV2-UL19-5003 + GAACUUGAAGCAGGGGCUGAGG 22 9386
HSV2-UL19-5004 + AGAACUUGAAGCAGGGGCUGAGG 23 9387
HSV2-UL19-5005 + AAGAACUUGAAGCAGGGGCUGAGG 24 9388
HSV2-UL19-5006 + AGCAGGGGCUGAGGACGG 18 9389
HSV2-UL19-5007 + AAGCAGGGGCUGAGGACGG 19 9390
HSV2-UL19-2531 + GAAGCAGGGGCUGAGGACGG 20 2694
HSV2-UL19-5008 + UGAAGCAGGGGCUGAGGACGG 21 9391
HSV2-UL19-5009 + UU GAAGCAGGGGCUGAGGACGG 22 9392
HSV2-UL19-5010 + CU UGAAGCAGGGGCUGAGGACGG 23 9393
HSV2-UL19-5011 + ACUUGAAGCAGGGGCUGAGGACGG 24 9394
HSV2-UL19-5012 + GGCGCAGCCAAAGACCGG 18 9395
HSV2-UL19-5013 + GGGCGCAGCCAAAGACCGG 19 9396
HSV2-UL19-2552 + U G G G CG CAG CCAAAG ACCG G 20 2711
HSV2-UL19-5014 + CUGGGCGCAGCCAAAGACCGG 21 9397
HSV2-UL19-5015 + CCUGGGCGCAGCCAAAGACCGG 22 9398
HSV2-UL19-5016 + ACCUGGGCGCAGCCAAAGACCGG 23 9399
HSV2-UL19-5017 + CACCUGGGCGCAGCCAAAGACCGG 24 9400
HSV2-UL19-5018 + GGAUCGCCCCCGGACCGG 18 9401
HSV2-UL19-5019 + UGGAUCGCCCCCGGACCGG 19 9402
HSV2-UL19-2692 + CUGGAUCGCCCCCGGACCGG 20 2806
HSV2-UL19-5020 + CCUGGAUCGCCCCCGGACCGG 21 9403
HSV2-UL19-5021 + GCCUGGAUCGCCCCCGGACCGG 22 9404
HSV2-UL19-5022 + GGCCUGGAUCGCCCCCGGACCGG 23 9405
HSV2-UL19-5023 + UGGCCUGGAUCGCCCCCGGACCGG 24 9406
HSV2-UL19-5024 + CGCCCCCGGACCGGCCGG 18 9407
HSV2-UL19-5025 + UCGCCCCCGGACCGGCCGG 19 9408
HSV2-UL19-1406 + AUCGCCCCCGGACCGGCCGG 20 1646
HSV2-UL19-5026 + GAUCGCCCCCGGACCGGCCGG 21 9409
HSV2-UL19-5027 + GGAUCGCCCCCGGACCGGCCGG 22 9410
HSV2-UL19-5028 + UGGAUCGCCCCCGGACCGGCCGG 23 9411
HSV2-UL19-5029 + CUGGAUCGCCCCCGGACCGGCCGG 24 9412
HSV2-UL19-5030 + GUUGGCCCCCAGGGCCGG 18 9413
HSV2-UL19-5031 + AGUUGGCCCCCAGGGCCGG 19 9414
HSV2-UL19-1248 + UAGUUGGCCCCCAGGGCCGG 20 1488 HSV2-UL19-5032 + GUAGUUGGCCCCCAGGGCCGG 21 9415
HSV2-UL19-5033 + AGUAGUUGGCCCCCAGGGCCGG 22 9416
HSV2-UL19-5034 + AAGUAGUUGGCCCCCAGGGCCGG 23 9417
HSV2-UL19-5035 + GAAGUAGUUGGCCCCCAGGGCCGG 24 9418
HSV2-UL19-5036 + CAGGUCGCGCAGGGCCGG 18 9419
HSV2-UL19-5037 + CCAGGUCGCGCAGGGCCGG 19 9420
HSV2-UL19-1260 + GCCAGGUCGCGCAGGGCCGG 20 1500
HSV2-UL19-5038 + CGCCAGGUCGCGCAGGGCCGG 21 9421
HSV2-UL19-5039 + GCGCCAGGUCGCGCAGGGCCGG 22 9422
HSV2-UL19-5040 + CGCGCCAGGUCGCGCAGGGCCGG 23 9423
HSV2-UL19-5041 + GCGCGCCAGGUCGCGCAGGGCCGG 24 9424
HSV2-UL19-5042 + UGUCCGCGCCGGGGCCGG 18 9425
HSV2-UL19-5043 + AUGUCCGCGCCGGGGCCGG 19 9426
HSV2-UL19-2714 + CAUGUCCGCGCCGGGGCCGG 20 2820
HSV2-UL19-5044 + GCAUGUCCGCGCCGGGGCCGG 21 9427
HSV2-UL19-5045 + UGCAUGUCCGCGCCGGGGCCGG 22 9428
HSV2-UL19-5046 + CUGCAUGUCCGCGCCGGGGCCGG 23 9429
HSV2-UL19-5047 + GCUGCAUGUCCGCGCCGGGGCCGG 24 9430
HSV2-UL19-5048 + CGCGUUGUCUAGCAGCGG 18 9431
HSV2-UL19-5049 + CCGCGUUGUCUAGCAGCGG 19 9432
HSV2-UL19-1191 + GCCGCGUUGUCUAGCAGCGG 20 1431
HSV2-UL19-5050 + GGCCGCGUUGUCUAGCAGCGG 21 9433
HSV2-UL19-5051 + CGGCCGCGUUGUCUAGCAGCGG 22 9434
HSV2-UL19-5052 + GCGGCCGCGUUGUCUAGCAGCGG 23 9435
HSV2-UL19-5053 + GGCGGCCGCGUUGUCUAGCAGCGG 24 9436
HSV2-UL19-5054 + AUUGGCGGGAUGCAGCGG 18 9437
HSV2-UL19-5055 + GAU UGGCGGGAUGCAGCGG 19 9438
HSV2-UL19-2638 + AG AUUGGCGGGAUGCAGCGG 20 2762
HSV2-UL19-5056 + CAG AU UGGCGGGAUGCAGCGG 21 9439
HSV2-UL19-5057 + CCAGAUUGGCGGGAUGCAGCGG 22 9440
HSV2-UL19-5058 + ACCAGAUUGGCGGGAUGCAGCGG 23 9441
HSV2-UL19-5059 + CACCAGAU UGGCGGGAUGCAGCGG 24 9442
HSV2-UL19-5060 + AGCGUGGCGUACACGCGG 18 9443
HSV2-UL19-5061 + CAGCGUGGCGUACACGCGG 19 9444
HSV2-UL19-2649 + GCAGCGUGGCGUACACGCGG 20 2768
HSV2-UL19-5062 + UGCAGCGUGGCGUACACGCGG 21 9445
HSV2-UL19-5063 + CUGCAGCGUGGCGUACACGCGG 22 9446
HSV2-UL19-5064 + UCUGCAGCGUGGCGUACACGCGG 23 9447
HSV2-UL19-5065 + UUCUGCAGCGUGGCGUACACGCGG 24 9448
HSV2-UL19-5066 + AGCGGGGGGGCCCCGCGG 18 9449
HSV2-UL19-5067 + CAGCGGGGGGGCCCCGCGG 19 9450
HSV2-UL19-2560 + GCAGCGGGGGGGCCCCGCGG 20 2714
HSV2-UL19-5068 + AGCAGCGGGGGGGCCCCGCGG 21 9451
HSV2-UL19-5069 + UAGCAGCGGGGGGGCCCCGCGG 22 9452
HSV2-UL19-5070 + CUAGCAGCGGGGGGGCCCCGCGG 23 9453
HSV2-UL19-5071 + UCUAGCAGCGGGGGGGCCCCGCGG 24 9454 HSV2-UL19-5072 + UGCACCACGGGCUGGCGG 18 9455
HSV2-UL19-5073 + CUGCACCACGGGCUGGCGG 19 9456
HSV2-UL19-2594 + GCUGCACCACGGGCUGGCGG 20 2738
HSV2-UL19-5074 + UGCUGCACCACGGGCUGGCGG 21 9457
HSV2-UL19-5075 + GUGCUGCACCACGGGCUGGCGG 22 9458
HSV2-UL19-5076 + CGUGCUGCACCACGGGCUGGCGG 23 9459
HSV2-UL19-5077 + GCGUGCUGCACCACGGGCUGGCGG 24 9460
HSV2-UL19-5078 + AGUAGUUGGCCCCCAGGG 18 9461
HSV2-UL19-5079 + AAGUAGUUGGCCCCCAGGG 19 9462
HSV2-UL19-2600 + GAAGUAGUUGGCCCCCAGGG 20 2742
HSV2-UL19-5080 + AG AAGUAGUUGGCCCCCAGGG 21 9463
HSV2-UL19-5081 + GAGAAGUAGUUGGCCCCCAGGG 22 9464
HSV2-UL19-5082 + GG AG AAGUAGUUGGCCCCCAGGG 23 9465
HSV2-UL19-5083 + AGGAGAAGUAGUUGGCCCCCAGGG 24 9466
HSV2-UL19-5084 + GCGCCAGGUCGCGCAGGG 18 9467
HSV2-UL19-5085 + CGCGCCAGGUCGCGCAGGG 19 9468
HSV2-UL19-2610 + GCGCGCCAGGUCGCGCAGGG 20 2745
HSV2-UL19-5086 + CGCGCGCCAGGUCGCGCAGGG 21 9469
HSV2-UL19-5087 + UCGCGCGCCAGGUCGCGCAGGG 22 9470
HSV2-UL19-5088 + GUCGCGCGCCAGGUCGCGCAGGG 23 9471
HSV2-UL19-5089 + CGUCGCGCGCCAGGUCGCGCAGGG 24 9472
HSV2-UL19-5090 + AAACAGCGCGUGGACGGG 18 9473
HSV2-UL19-5091 + CAAACAGCGCGUGGACGGG 19 9474
HSV2-UL19-2619 + G CAAACAG CGCGUGGACGGG 20 2749
HSV2-UL19-5092 + CGCAAACAGCGCGUGGACGGG 21 9475
HSV2-UL19-5093 + CCGCAAACAGCGCGUGGACGGG 22 9476
HSV2-UL19-5094 + CCCGCAAACAGCGCGUGGACGGG 23 9477
HSV2-UL19-5095 + GCCCGCAAACAGCGCGUGGACGGG 24 9478
HSV2-UL19-5096 + GCGCAGCCAAAGACCGGG 18 9479
HSV2-UL19-5097 + GGCGCAGCCAAAGACCGGG 19 9480
HSV2-UL19-1178 + GGGCGCAGCCAAAGACCGGG 20 1418
HSV2-UL19-5098 + UGGGCGCAGCCAAAGACCGGG 21 9481
HSV2-UL19-5099 + CUGGGCGCAGCCAAAGACCGGG 22 9482
HSV2-UL19-5100 + CCUGGGCGCAGCCAAAGACCGGG 23 9483
HSV2-UL19-5101 + ACCUGGGCGCAGCCAAAGACCGGG 24 9484
HSV2-UL19-5102 + GGUGAACCCGAACCCGGG 18 9485
HSV2-UL19-5103 + CGGUGAACCCGAACCCGGG 19 9486
HSV2-UL19-2583 + ACGGUGAACCCGAACCCGGG 20 2729
HSV2-UL19-5104 + GACGGUGAACCCGAACCCGGG 21 9487
HSV2-UL19-5105 + CGACGGUGAACCCGAACCCGGG 22 9488
HSV2-UL19-5106 + ACG ACGGUGAACCCGAACCCGGG 23 9489
HSV2-UL19-5107 + CACGACG G U G AACCCG AACCCGG G 24 9490
HSV2-UL19-5108 + AGGUCGCGCAGGGCCGGG 18 9491
HSV2-UL19-5109 + CAGGUCGCGCAGGGCCGGG 19 9492
HSV2-UL19-1261 + CCAGGUCGCGCAGGGCCGGG 20 1501
HSV2-UL19-5110 + GCCAGGUCGCGCAGGGCCGGG 21 9493 HSV2-UL19-5111 + CGCCAGGUCGCGCAGGGCCGGG 22 9494
HSV2-UL19-5112 + GCGCCAGGUCGCGCAGGGCCGGG 23 9495
HSV2-UL19-5113 + CGCGCCAGGUCGCGCAGGGCCGGG 24 9496
HSV2-UL19-5114 + AAGCGCUCCAUGGCCGGG 18 9497
HSV2-UL19-5115 + GAAGCGCUCCAUGGCCGGG 19 9498
HSV2-UL19-2740 + CGAAGCGCUCCAUGGCCGGG 20 2836
HSV2-UL19-5116 + GCG AAGCGCUCCAUGGCCGGG 21 9499
HSV2-UL19-5117 + GGCGAAGCGCUCCAUGGCCGGG 22 9500
HSV2-UL19-5118 + CGGCGAAGCGCUCCAUGGCCGGG 23 9501
HSV2-UL19-5119 + GCGGCGAAGCGCUCCAUGGCCGGG 24 9502
HSV2-UL19-5120 + AAAAAAACAGCUGCCGGG 18 9503
HSV2-UL19-5121 + CAAAAAAACAG CU G CCG G G 19 9504
HSV2-UL19-2728 + CCAAAAAAACAG CU G CCG G G 20 2829
HSV2-UL19-5122 + CCCAAAAAAACAGCUGCCGGG 21 9505
HSV2-UL19-5123 + CCCCAAAAAAACAGCUGCCGGG 22 9506
HSV2-UL19-5124 + U CCCCAAAAAAACAG CU G CCG G G 23 9507
HSV2-UL19-5125 + U U CCCCAAAAAAACAG CU GCCGGG 24 9508
HSV2-UL19-5126 + GUUGAACAGCCCCAGGGG 18 9509
HSV2-UL19-5127 + GGU UGAACAGCCCCAGGGG 19 9510
HSV2-UL19-2743 + GGGUUGAACAGCCCCAGGGG 20 2838
HSV2-UL19-5128 + CGGGUUGAACAGCCCCAGGGG 21 9511
HSV2-UL19-5129 + CCGGGUUGAACAGCCCCAGGGG 22 9512
HSV2-UL19-5130 + GCCGGGUUGAACAGCCCCAGGGG 23 9513
HSV2-UL19-5131 + GGCCGGGUUGAACAGCCCCAGGGG 24 9514
HSV2-UL19-5132 + AAGAACUUGAAGCAGGGG 18 9515
HSV2-UL19-5133 + GAAGAACUUGAAGCAGGGG 19 9516
HSV2-UL19-2528 + UGAAGAACUUGAAGCAGGGG 20 2691
HSV2-UL19-5134 + GUG AAGAACUUGAAGCAGGGG 21 9517
HSV2-UL19-5135 + GGUG AAGAACUUGAAGCAGGGG 22 9518
HSV2-UL19-5136 + CGGUGAAGAACUUGAAGCAGGGG 23 9519
HSV2-UL19-5137 + GCGGUGAAGAACUUGAAGCAGGGG 24 9520
HSV2-UL19-5138 + GCCAAAGACCGGGAGGGG 18 9521
HSV2-UL19-5139 + AGCCAAAGACCGGGAGGGG 19 9522
HSV2-UL19-2554 + CAGCCAAAGACCGGGAGGGG 20 2712
HSV2-UL19-5140 + GCAGCCAAAGACCGGGAGGGG 21 9523
HSV2-UL19-5141 + CG CAG CCAAAG ACCGGGAGGGG 22 9524
HSV2-UL19-5142 + GCGCAGCCAAAGACCGGGAGGGG 23 9525
HSV2-UL19-5143 + GGCGCAGCCAAAGACCGGGAGGGG 24 9526
HSV2-UL19-5144 + GUGAACCCGAACCCGGGG 18 9527
HSV2-UL19-5145 + GGUGAACCCGAACCCGGGG 19 9528
HSV2-UL19-1225 + CGGUGAACCCGAACCCGGGG 20 1465
HSV2-UL19-5146 + ACG G U G AACCCG AACCCG GGG 21 9529
HSV2-UL19-5147 + GACGGUGAACCCGAACCCGGGG 22 9530
HSV2-UL19-5148 + CGACGGUGAACCCGAACCCGGGG 23 9531
HSV2-UL19-5149 + ACGACGGUGAACCCGAACCCGGGG 24 9532
HSV2-UL19-5150 + GGCUCCGGGUGGCCGGGG 18 9533 HSV2-UL19-5151 + GGGCUCCGGGUGGCCGGGG 19 9534
HSV2-UL19-2737 + GGGGCUCCGGGUGGCCGGGG 20 2833
HSV2-UL19-5152 + CGGGGCUCCGGGUGGCCGGGG 21 9535
HSV2-UL19-5153 + GCGGGGCUCCGGGUGGCCGGGG 22 9536
HSV2-UL19-5154 + CGCGGGGCUCCGGGUGGCCGGGG 23 9537
HSV2-UL19-5155 + GCGCGGGGCUCCGGGUGGCCGGGG 24 9538
HSV2-UL19-5156 + AAAAAACAG CUGCCGGGG 18 9539
HSV2-UL19-5157 + AAAAAAACAGCUGCCGGGG 19 9540
HSV2-UL19-1449 + CAAAAAAACAG CUGCCGGGG 20 1689
HSV2-UL19-5158 + CCAAAA AAAC AG CU G CCG G G G 21 9541
HSV2-UL19-5159 + CCCAAAAAAACAG CU G CCG G G G 22 9542
HSV2-UL19-5160 + CCCCAAAAAAACAG CU G CCG G G G 23 9543
HSV2-UL19-5161 + UCCCCAAAAAAACAGCUGCCGGGG 24 9544
HSV2-UL19-5162 + AUGGCGCCCACCAGGGGG 18 9545
HSV2-UL19-5163 + CAUGGCGCCCACCAGGGGG 19 9546
HSV2-UL19-2748 + CCAUGGCGCCCACCAGGGGG 20 2841
HSV2-UL19-5164 + UCCAUGGCGCCCACCAGGGGG 21 9547
HSV2-UL19-5165 + GUCCAUGGCGCCCACCAGGGGG 22 9548
HSV2-UL19-5166 + GGUCCAUGGCGCCCACCAGGGGG 23 9549
HSV2-UL19-5167 + AGGUCCAUGGCGCCCACCAGGGGG 24 9550
HSV2-UL19-5168 + CCACGGGCUGGCGGAUGG 18 9551
HSV2-UL19-5169 + ACCACGGGCUGGCGGAUGG 19 9552
HSV2-UL19-1241 + CACCACGGGCUGGCGGAUGG 20 1481
HSV2-UL19-5170 + GCACCACGGGCUGGCGGAUGG 21 9553
HSV2-UL19-5171 + UGCACCACGGGCUGGCGGAUGG 22 9554
HSV2-UL19-5172 + CUGCACCACGGGCUGGCGGAUGG 23 9555
HSV2-UL19-5173 + GCUGCACCACGGGCUGGCGGAUGG 24 9556
HSV2-UL19-5174 + ACGUUUCCGCGCGGCUGG 18 9557
HSV2-UL19-5175 + CACGUU UCCGCGCGGCUGG 19 9558
HSV2-UL19-2570 + CCACGUUUCCGCGCGGCUGG 20 2719
HSV2-UL19-5176 + UCCACGUUUCCGCGCGGCUGG 21 9559
HSV2-UL19-5177 + GUCCACGUUUCCGCGCGGCUGG 22 9560
HSV2-UL19-5178 + GGUCCACGU UUCCGCGCGGCUGG 23 9561
HSV2-UL19-5179 + AGGUCCACGUUUCCGCGCGGCUGG 24 9562
HSV2-UL19-5180 + CACCGGACCCGGCCGUGG 18 9563
HSV2-UL19-5181 + CCACCGGACCCGGCCGUGG 19 9564
HSV2-UL19-2710 + CCCACCGGACCCGGCCGUGG 20 2817
HSV2-UL19-5182 + ACCCACCGGACCCGGCCGUGG 21 9565
HSV2-UL19-5183 + GACCCACCGGACCCGGCCGUGG 22 9566
HSV2-UL19-5184 + CGACCCACCGGACCCGGCCGUGG 23 9567
HSV2-UL19-5185 + GCGACCCACCGGACCCGGCCGUGG 24 9568
HSV2-UL19-5186 + CCCGCAAACAGCGCGUGG 18 9569
HSV2-UL19-5187 + GCCCGCAAACAGCGCGUGG 19 9570
HSV2-UL19-2618 + CGCCCGCAAACAGCGCGUGG 20 2748
HSV2-UL19-5188 + GCGCCCGCAAACAGCGCGUGG 21 9571
HSV2-UL19-5189 + GGCGCCCGCAAACAGCGCGUGG 22 9572 HSV2-UL19-5190 + CGGCGCCCGCAAACAGCGCGUGG 23 9573
HSV2-UL19-5191 + UCGGCGCCCGCAAACAGCGCGUGG 24 9574
HSV2-UL19-5192 + GCGCGGGGCUCCGGGUGG 18 9575
HSV2-UL19-5193 + CGCGCGGGGCUCCGGGUGG 19 9576
HSV2-UL19-2734 + ACGCGCGGGGCUCCGGGUGG 20 2832
HSV2-UL19-5194 + AACGCGCGGGGCUCCGGGUGG 21 9577
HSV2-UL19-5195 + GAACGCGCGGGGCUCCGGGUGG 22 9578
HSV2-UL19-5196 + GGAACGCGCGGGGCUCCGGGUGG 23 9579
HSV2-UL19-5197 + GGGAACGCGCGGGGCUCCGGGUGG 24 9580
HSV2-UL19-5198 + GCGGGAUGCAGCGGGUGG 18 9581
HSV2-UL19-5199 + GGCGGGAUGCAGCGGGUGG 19 9582
HSV2-UL19-2639 + UGGCGGGAUGCAGCGGGUGG 20 2763
HSV2-UL19-5200 + UU GGCGGGAUGCAGCGGGUGG 21 9583
HSV2-UL19-5201 + AU UGGCGGGAUGCAGCGGGUGG 22 9584
HSV2-UL19-5202 + GAU UGGCGGGAUGCAGCGGGUGG 23 9585
HSV2-UL19-5203 + AGAUUGGCGGGAUGCAGCGGGUGG 24
9586
HSV2-UL19-5204 + CCGAGGUAAAAGUUUUGG 18 9587
HSV2-UL19-5205 + GCCGAGGUAAAAGUUUUGG 19 9588
HSV2-UL19-1199 + GGCCGAGGUAAAAGUUUUGG 20 1439
HSV2-UL19-5206 + CGGCCGAGGUAAAAGUUUUGG 21 9589
HSV2-UL19-5207 + GCGGCCGAGGUAAAAGUUUUGG 22 9590
HSV2-UL19-5208 + CGCGGCCGAGGUAAAAGUUUUGG 23 9591
HSV2-UL19-5209 + CCGCGGCCGAGGUAAAAGUUUUGG 24 9592
HSV2-UL19-5210 + ACCUGCAGCGUGAGCAUG 18 9593
HSV2-UL19-5211 + CACCUGCAGCGUGAGCAUG 19 9594
HSV2-UL19-2632 + GCACCUGCAGCGUGAGCAUG 20 2758
HSV2-UL19-5212 + AGCACCUGCAGCGUGAGCAUG 21 9595
HSV2-UL19-5213 + CAGCACCUGCAGCGUGAGCAUG 22 9596
HSV2-UL19-5214 + CCAGCACCUGCAGCGUGAGCAUG 23 9597
HSV2-UL19-5215 + GCCAGCACCUGCAGCGUGAGCAUG 24 9598
HSV2-UL19-5216 + ACCACGGGCUGGCGGAUG 18 9599
HSV2-UL19-5217 + CACCACGGGCUGGCGGAUG 19 9600
HSV2-UL19-2596 + GCACCACGGGCUGGCGGAUG 20 2739
HSV2-UL19-5218 + UGCACCACGGGCUGGCGGAUG 21 9601
HSV2-UL19-5219 + CUGCACCACGGGCUGGCGGAUG 22 9602
HSV2-UL19-5220 + GCUGCACCACGGGCUGGCGGAUG 23 9603
HSV2-UL19-5221 + UGCUGCACCACGGGCUGGCGGAUG 24 9604
HSV2-UL19-5222 + CACCUUCAGGAAGGACUG 18 9605
HSV2-UL19-5223 + CCACCUUCAGGAAGGACUG 19 9606
HSV2-UL19-2762 + UCCACCUUCAGGAAGGACUG 20 2850
HSV2-UL19-5224 + CUCCACCUUCAGGAAGGACUG 21 9607
HSV2-UL19-5225 + CCUCCACCUUCAGGAAGGACUG 22 9608
HSV2-UL19-5226 + UCCUCCACCUUCAGGAAGGACUG 23 9609
HSV2-UL19-5227 + GUCCUCCACCUUCAGGAAGGACUG 24 9610
HSV2-UL19-5228 + U CCCCAAAAAAACAG CU G 18 9611 HSV2-UL19-5229 + U U CCCCAAAAAAACAG CU G 19 9612
HSV2-UL19-2724 + UUUCCCCAAAAAAACAGCUG 20 2828
HSV2-UL19-5230 + CU U U CCCCAAAAAAACAG CU G 21 9613
HSV2-UL19-5231 + CCU U U CCCCAAAAAAACAGCU G 22 9614
HSV2-UL19-5232 + UCCUU UCCCCAAAAAAACAGCUG 23 9615
HSV2-UL19-5233 + G U CCU U U CCCCAAAAAAACAGCU G 24 9616
HSV2-UL19-5234 + GGUGUGGUCCAGGUGCUG 18 9617
HSV2-UL19-5235 + UGGUGUGGUCCAGGUGCUG 19 9618
HSV2-UL19-1277 + AUGGUGUGGUCCAGGUGCUG 20 1517
HSV2-UL19-5236 + GAU GGUGUGGUCCAGGUGCUG 21 9619
HSV2-UL19-5237 + GGAU GGUGUGGUCCAGGUGCUG 22 9620
HSV2-UL19-5238 + UGGAUGGUGUGGUCCAGGUGCUG 23 9621
HSV2-UL19-5239 + UUGGAUGGUGUGGUCCAGGUGCUG 24
9622
HSV2-UL19-5240 + GCGCACGCGCGUUGUCUG 18 9623
HSV2-UL19-5241 + CGCGCACGCGCGUUGUCUG 19 9624
HSV2-UL19-1490 + GCGCGCACGCGCGUUGUCUG 20 1730
HSV2-UL19-5242 + CGCGCGCACGCGCGUUGUCUG 21 9625
HSV2-UL19-5243 + CCGCGCGCACGCGCGUUGUCUG 22 9626
HSV2-UL19-5244 + UCCGCGCGCACGCGCGUUGUCUG 23 9627
HSV2-UL19-5245 + AUCCGCGCGCACGCGCGUUGUCUG 24 9628
HSV2-UL19-5246 + CCCAUCACCAGCGCCGUG 18 9629
HSV2-UL19-5247 + GCCCAU CACCAG CGCCGUG 19 9630
HSV2-UL19-2758 + UGCCCAUCACCAGCGCCGUG 20 2847
HSV2-UL19-5248 + UUGCCCAUCACCAGCGCCGUG 21 9631
HSV2-UL19-5249 + CU U G CCCAU CACCAG CGCCGUG 22 9632
HSV2-UL19-5250 + CCUUGCCCAUCACCAGCGCCGUG 23 9633
HSV2-UL19-5251 + GCCUUGCCCAUCACCAGCGCCGUG 24 9634
HSV2-UL19-5252 + CCCCCCGCCCGUUUCGUG 18 9635
HSV2-UL19-5253 + CCCCCCCGCCCGUUUCGUG 19 9636
HSV2-UL19-2572 + ACCCCCCCGCCCGUUUCGUG 20 2721
HSV2-UL19-5254 + GACCCCCCCGCCCGUUUCGUG 21 9637
HSV2-UL19-5255 + UGACCCCCCCGCCCGUUUCGUG 22 9638
HSV2-UL19-5256 + UUGACCCCCCCGCCCGUUUCGUG 23 9639
HSV2-UL19-5257 + GUUGACCCCCCCGCCCGUUUCGUG 24 9640
HSV2-UL19-5258 + GAUGGUGUGGUCCAGGUG 18 9641
HSV2-UL19-5259 + GGAUGGUGUGGUCCAGGUG 19 9642
HSV2-UL19-2622 + UGGAUGGUGUGGUCCAGGUG 20 2752
HSV2-UL19-5260 + UUGGAUGGUGUGGUCCAGGUG 21 9643
HSV2-UL19-5261 + UU UGGAUGGUGUGGUCCAGGUG 22 9644
HSV2-UL19-5262 + UUUUGGAUGGUGUGGUCCAGGUG 23 9645
HSV2-UL19-5263 + AUUUUGGAUGGUGUGGUCCAGGUG 24
9646
HSV2-UL19-5264 + GUGAUGUCGGCCGCGGUG 18 9647
HSV2-UL19-5265 + CGUGAUGUCGGCCGCGGUG 19 9648
HSV2-UL19-2524 + CCGUGAUGUCGGCCGCGGUG 20 2688 HSV2-UL19-5266 + GCCGUGAUGUCGGCCGCGGUG 21 9649
HSV2-UL19-5267 + GGCCGUGAUGUCGGCCGCGGUG 22 9650
HSV2-UL19-5268 + UGGCCGUGAUGUCGGCCGCGGUG 23 9651
HSV2-UL19-5269 + UUGGCCGUGAUGUCGGCCGCGGUG 24 9652
HSV2-UL19-5270 + GUAAUAGUAGAUUUUGUG 18 9653
HSV2-UL19-5271 + CGUAAUAGUAGAUUUUGUG 19 9654
HSV2-UL19-2653 + ACGUAAUAGUAGAUUUUGUG 20 2772
HSV2-UL19-5272 + CACGUAAUAGUAGAUUUUGUG 21 9655
HSV2-UL19-5273 + GCACGUAAUAGUAGAUUUUGUG 22 9656
HSV2-UL19-5274 + AGCACGUAAUAGUAGAUUUUGUG 23 9657
HSV2-UL19-5275 + CAGCACGUAAUAGUAGAUUUUGUG 24 9658
HSV2-UL19-5276 + GUGUUGGCCACCAGAUUG 18 9659
HSV2-UL19-5277 + CGUGU UGGCCACCAGAUUG 19 9660
HSV2-UL19-2635 + CCGUGUUGGCCACCAGAUUG 20 2760
HSV2-UL19-5278 + ACCGUGU UGGCCACCAGAUUG 21 9661
HSV2-UL19-5279 + GACCGUGUUGGCCACCAGAUUG 22 9662
HSV2-UL19-5280 + UGACCGUGUUGGCCACCAGAUUG 23 9663
HSV2-UL19-5281 + UUGACCGUGUUGGCCACCAGAUUG 24 9664
HSV2-UL19-5282 + ACGACGACGCGCCCGUUG 18 9665
HSV2-UL19-5283 + GACGACGACGCGCCCGUUG 19 9666
HSV2-UL19-1291 + CGACGACGACGCGCCCGUUG 20 1531
HSV2-UL19-5284 + UCGACGACGACGCGCCCGUUG 21 9667
HSV2-UL19-5285 + GUCGACGACGACGCGCCCGU UG 22 9668
HSV2-UL19-5286 + CG UCG ACGACGACGCGCCCG U UG 23 9669
HSV2-UL19-5287 + CCGUCGACGACGACGCGCCCGUUG 24 9670
HSV2-UL19-5288 + GUCGCCAGGCGCCCGUUG 18 9671
HSV2-UL19-5289 + GGUCGCCAGGCGCCCGUUG 19 9672
HSV2-UL19-2773 + UGGUCGCCAGGCGCCCGUUG 20 2858
HSV2-UL19-5290 + CU GG U CG CCAGG CG CCCG U U G 21 9673
HSV2-UL19-5291 + CCUGGUCGCCAGGCGCCCGUUG 22 9674
HSV2-UL19-5292 + CCCUGGUCGCCAGGCGCCCGUUG 23 9675
HSV2-UL19-5293 + ACCCUGGUCGCCAGGCGCCCGUUG 24 9676
HSV2-UL19-5294 + AGAGCCAGGUUGGCGUUG 18 9677
HSV2-UL19-5295 + CAGAGCCAGGUUGGCGUUG 19 9678
HSV2-UL19-2706 + CCAGAGCCAGGUUGGCGUUG 20 2813
HSV2-UL19-5296 + UCCAGAGCCAGGUUGGCGUUG 21 9679
HSV2-UL19-5297 + CUCCAGAGCCAGGUUGGCGUUG 22 9680
HSV2-UL19-5298 + GCUCCAGAGCCAGGUUGGCGUUG 23 9681
HSV2-UL19-5299 + AGCUCCAGAGCCAGGUUGGCGUUG 24 9682
HSV2-UL19-5300 + GCGCGUCCCCGCGGGUUG 18 9683
HSV2-UL19-5301 + CGCGCGUCCCCGCGGGUUG 19 9684
HSV2-UL19-2542 + CCGCGCGUCCCCGCGGGUUG 20 2705
HSV2-UL19-5302 + GCCGCGCGUCCCCGCGGGUUG 21 9685
HSV2-UL19-5303 + GGCCGCGCGUCCCCGCGGGUUG 22 9686
HSV2-UL19-5304 + CGGCCGCGCGUCCCCGCGGGUUG 23 9687
HSV2-UL19-5305 + CCGGCCGCGCGUCCCCGCGGGUUG 24 9688 HSV2-UL19-5306 + GCCGAGGUAAAAGUUUUG 18 9689
HSV2-UL19-5307 + GGCCGAGGUAAAAGUUUUG 19 9690
HSV2-UL19-1198 + CGGCCGAGGUAAAAGUUUUG 20 1438
HSV2-UL19-5308 + GCGGCCGAGGUAAAAGUUUUG 21 9691
HSV2-UL19-5309 + CGCGGCCGAGGUAAAAGUUUUG 22 9692
HSV2-UL19-5310 + CCGCGGCCGAGGUAAAAGUUUUG 23 9693
HSV2-UL19-5311 + CCCGCGGCCGAGGUAAAAGUUUUG 24 9694
HSV2-UL19-5312 + CUGGCCGUGGUCGUACAU 18 9695
HSV2-UL19-5313 + UCUGGCCGUGGUCGUACAU 19 9696
HSV2-UL19-2540 + CUCUGGCCGUGGUCGUACAU 20 2703
HSV2-UL19-5314 + GCUCUGGCCGUGGUCGUACAU 21 9697
HSV2-UL19-5315 + CGCUCUGGCCGUGGUCGUACAU 22 9698
HSV2-UL19-5316 + UCGCUCUGGCCGUGGUCGUACAU 23 9699
HSV2-UL19-5317 + GUCGCUCUGGCCGUGGUCGUACAU 24 9700
HSV2-UL19-5318 + ACACGGCCAUGCACUCCU 18 9701
HSV2-UL19-5319 + UACACGGCCAUGCACUCCU 19 9702
HSV2-UL19-1368 + AUACACGGCCAUGCACUCCU 20 1608
HSV2-UL19-5320 + GAUACACGGCCAUGCACUCCU 21 9703
HSV2-UL19-5321 + CGAUACACGGCCAUGCACUCCU 22 9704
HSV2-UL19-5322 + CCGAUACACGGCCAUGCACUCCU 23 9705
HSV2-UL19-5323 + CCCGAUACACGGCCAUGCACUCCU 24 9706
HSV2-UL19-5324 + GAGCCUGCCCGCCCAGCU 18 9707
HSV2-UL19-5325 + UGAGCCUGCCCGCCCAGCU 19 9708
HSV2-UL19-2663 + CUGAGCCUGCCCGCCCAGCU 20 2781
HSV2-UL19-5326 + CCUGAGCCUGCCCGCCCAGCU 21 9709
HSV2-UL19-5327 + GCCUGAGCCUGCCCGCCCAGCU 22 9710
HSV2-UL19-5328 + GGCCUGAGCCUGCCCGCCCAGCU 23 9711
HSV2-UL19-5329 + CGGCCUGAGCCUGCCCGCCCAGCU 24 9712
HSV2-UL19-5330 + ACGCCUCCGACGCGCGCU 18 9713
HSV2-UL19-5331 + UACGCCUCCGACGCGCGCU 19 9714
HSV2-UL19-1218 + GUACGCCUCCGACGCGCGCU 20 1458
HSV2-UL19-5332 + AGUACGCCUCCGACGCGCGCU 21 9715
HSV2-UL19-5333 + AAGUACGCCUCCGACGCGCGCU 22 9716
HSV2-UL19-5334 + AAAGUACGCCUCCGACGCGCGCU 23 9717
HSV2-UL19-5335 + GAAAGUACGCCUCCGACGCGCGCU 24 9718
HSV2-UL19-5336 + GAACU UGAAGCAGGGGCU 18 9719
HSV2-UL19-5337 + AGAACUUGAAGCAGGGGCU 19 9720
HSV2-UL19-2529 + AAGAACUUGAAGCAGGGGCU 20 2692
HSV2-UL19-5338 + GAAGAACUUGAAGCAGGGGCU 21 9721
HSV2-UL19-5339 + UG AAGAACUUGAAGCAGGGGCU 22 9722
HSV2-UL19-5340 + GUGAAGAACUUGAAGCAGGGGCU 23 9723
HSV2-UL19-5341 + GGUGAAGAACUUGAAGCAGGGGCU 24 9724
HSV2-UL19-5342 + UGGUGUGGUCCAGGUGCU 18 9725
HSV2-UL19-5343 + AUGGUGUGGUCCAGGUGCU 19 9726
HSV2-UL19-1276 + GAUGGUGUGGUCCAGGUGCU 20 1516
HSV2-UL19-5344 + GG AUGGUGUGGUCCAGGUGCU 21 9727 HSV2-UL19-5345 + UGGAUGGUGUGGUCCAGGUGCU 22 9728
HSV2-UL19-5346 + UUGGAUGGUGUGGUCCAGGUGCU 23 9729
HSV2-UL19-5347 + UU UGGAUGGUGUGGUCCAGGUGCU 24
9730
HSV2-UL19-5348 + CCUCACCGGGGGCGAUCU 18 9731
HSV2-UL19-5349 + UCCUCACCGGGGGCGAUCU 19 9732
HSV2-UL19-2647 + CUCCUCACCGGGGGCGAUCU 20 2767
HSV2-UL19-5350 + ACUCCUCACCGGGGGCGAUCU 21 9733
HSV2-UL19-5351 + CACUCCUCACCGGGGGCGAUCU 22 9734
HSV2-UL19-5352 + GCACUCCUCACCGGGGGCGAUCU 23 9735
HSV2-UL19-5353 + GGCACUCCUCACCGGGGGCGAUCU 24 9736
HSV2-UL19-5354 + CGCGCACGCGCGUUGUCU 18 9737
HSV2-UL19-5355 + GCGCGCACGCGCGUUGUCU 19 9738
HSV2-UL19-1489 + CGCGCGCACGCGCGUUGUCU 20 1729
HSV2-UL19-5356 + CCGCGCGCACGCGCGUUGUCU 21 9739
HSV2-UL19-5357 + UCCGCGCGCACGCGCGUUGUCU 22 9740
HSV2-UL19-5358 + AUCCGCGCGCACGCGCGUUGUCU 23 9741
HSV2-UL19-5359 + GAUCCGCGCGCACGCGCGUUGUCU 24 9742
HSV2-UL19-5360 + UGUACAGCAGGUCCCCGU 18 9743
HSV2-UL19-5361 + UUGUACAGCAGGUCCCCGU 19 9744
HSV2-UL19-2533 + GUUGUACAGCAGGUCCCCGU 20 2696
HSV2-UL19-5362 + CGUUGUACAGCAGGUCCCCGU 21 9745
HSV2-UL19-5363 + CCGUUGUACAGCAGGUCCCCGU 22 9746
HSV2-UL19-5364 + CCCGUUGUACAGCAGGUCCCCGU 23 9747
HSV2-UL19-5365 + CCCCGUUGUACAGCAGGUCCCCGU 24 9748
HSV2-UL19-5366 + CGAGGUAGGUCACGAUGU 18 9749
HSV2-UL19-5367 + CCGAGGUAGGUCACGAUGU 19 9750
HSV2-UL19-2673 + CCCGAGGUAGGUCACGAUGU 20 2788
HSV2-UL19-5368 + CCCCGAGGUAGGUCACGAUGU 21 9751
HSV2-UL19-5369 + CCCCCGAGGUAGGUCACGAUGU 22 9752
HSV2-UL19-5370 + GCCCCCGAGGUAGGUCACGAUGU 23 9753
HSV2-UL19-5371 + CGCCCCCGAGGUAGGUCACGAUGU 24 9754
HSV2-UL19-5372 + CGCGCGCACGCGCGUUGU 18 9755
HSV2-UL19-5373 + CCGCGCGCACGCGCGUUGU 19 9756
HSV2-UL19-2752 + UCCGCGCGCACGCGCGUUGU 20 2844
HSV2-UL19-5374 + AUCCGCGCGCACGCGCGUUGU 21 9757
HSV2-UL19-5375 + GAUCCGCGCGCACGCGCGUUGU 22 9758
HSV2-UL19-5376 + AGAUCCGCGCGCACGCGCGU UGU 23 9759
HSV2-UL19-5377 + CAGAUCCGCGCGCACGCGCGUUGU 24 9760
HSV2-UL19-5378 + CU CG G U G U CCU CCACCU U 18 9761
HSV2-UL19-5379 + CCUCGGUGUCCUCCACCUU 19 9762
HSV2-UL19-2759 + GCCUCGGUGUCCUCCACCUU 20 2848
HSV2-UL19-5380 + GGCCUCGGUGUCCUCCACCUU 21 9763
HSV2-UL19-5381 + CGGCCUCGGUGUCCUCCACCUU 22 9764
HSV2-UL19-5382 + UCGGCCUCGGUGUCCUCCACCUU 23 9765
HSV2-UL19-5383 + GUCGGCCUCGGUGUCCUCCACCUU 24 9766 HSV2-UL19-5384 + GCGGCCGAGGUAAAAGUU 18 9767
HSV2-UL19-5385 + CGCGGCCGAGGUAAAAGUU 19 9768
HSV2-UL19-2561 + CCGCGGCCGAGGUAAAAGUU 20 2715
HSV2-UL19-5386 + CCCGCGGCCGAGGUAAAAGUU 21 9769
HSV2-UL19-5387 + CCCCGCGGCCGAGGUAAAAGUU 22 9770
HSV2-UL19-5388 + GCCCCGCGGCCGAGGUAAAAGUU 23 9771
HSV2-UL19-5389 + GGCCCCGCGGCCGAGGUAAAAGUU 24 9772
HSV2-UL19-5390 + GACGACGACGCGCCCGUU 18 9773
HSV2-UL19-5391 + CGACGACGACGCGCCCGUU 19 9774
HSV2-UL19-2633 + UCGACGACGACGCGCCCGUU 20 2759
HSV2-UL19-5392 + GUCGACGACGACGCGCCCGUU 21 9775
HSV2-UL19-5393 + CGUCGACGACGACGCGCCCGUU 22 9776
HSV2-UL19-5394 + CCGUCGACGACGACGCGCCCGUU 23 9777
HSV2-UL19-5395 + CCCGUCGACGACGACGCGCCCGUU 24 9778
HSV2-UL19-5396 + GCGCUGCCGCCAGGCGUU 18 9779
HSV2-UL19-5397 + GGCGCUGCCGCCAGGCGUU 19 9780
HSV2-UL19-2711 + AGGCGCUGCCGCCAGGCGU U 20 2818
HSV2-UL19-5398 + GAGGCGCUGCCGCCAGGCGU U 21 9781
HSV2-UL19-5399 + CGAGGCGCUGCCGCCAGGCGUU 22 9782
HSV2-UL19-5400 + GCG AGGCGCUGCCGCCAGGCGU U 23 9783
HSV2-UL19-5401 + GGCGAGGCGCUGCCGCCAGGCGUU 24 9784
HSV2-UL19-5402 + CAUGUCCGUAACGGGGUU 18 9785
HSV2-UL19-5403 + CCAUGUCCGUAACGGGGUU 19 9786
HSV2-UL19-2568 + CCCAUGUCCGUAACGGGGUU 20 2717
HSV2-UL19-5404 + GCCCAUGUCCGUAACGGGGUU 21 9787
HSV2-UL19-5405 + UGCCCAUGUCCGUAACGGGGUU 22 9788
HSV2-UL19-5406 + UUGCCCAUGUCCGUAACGGGGUU 23 9789
HSV2-UL19-5407 + GUUGCCCAUGUCCGUAACGGGGUU 24 9790
HSV2-UL19-5408 + CGGCCGAGGUAAAAGUUU 18 9791
HSV2-UL19-5409 + GCGGCCGAGGUAAAAGUUU 19 9792
HSV2-UL19-1196 + CGCGGCCGAGGUAAAAGUU U 20 1436
HSV2-UL19-5410 + CCGCGGCCGAGGUAAAAGUU U 21 9793
HSV2-UL19-5411 + CCCGCGGCCGAGGUAAAAGUU U 22 9794
HSV2-UL19-5412 + CCCCGCGGCCGAGGUAAAAGUU U 23 9795
HSV2-UL19-5413 + GCCCCGCGGCCGAGGUAAAAGUUU 24 9796
HSV2-UL19-5414 + GGCCGAGGUAAAAGUUUU 18 9797
HSV2-UL19-5415 + CGGCCGAGGUAAAAGUUUU 19 9798
HSV2-UL19-1197 + GCGGCCGAGGUAAAAGUUUU 20 1437
HSV2-UL19-5416 + CGCGGCCGAGGUAAAAGUU UU 21 9799
HSV2-UL19-5417 + CCGCGGCCGAGGUAAAAGUU UU 22 9800
HSV2-UL19-5418 + CCCGCGGCCGAGGUAAAAGUUUU 23 9801
HSV2-UL19-5419 + CCCCGCGGCCGAGGUAAAAGUUUU 24 9802
HSV2-UL19-5420 - CGGGGACCUGCUGUACAA 18 9803
HSV2-UL19-5421 - ACGGGGACCUGCUGUACAA 19 9804
HSV2-UL19-696 - UACGGGGACCUGCUGUACAA 20 936
HSV2-UL19-5422 - GU ACGGGGACCUGCUGUACAA 21 9805 HSV2-UL19-5423 - CGUACGGGGACCUGCUGUACAA 22 9806
HSV2-UL19-5424 - UCGUACGGGGACCUGCUGUACAA 23 9807
HSV2-UL19-5425 - CUCGUACGGGGACCUGCUGUACAA 24 9808
HSV2-UL19-5426 - CGGGGCCUAUCACCUCAA 18 9809
HSV2-UL19-5427 - ACGGGGCCUAUCACCUCAA 19 9810
HSV2-UL19-699 - AACGGGGCCUAUCACCUCAA 20 939
HSV2-UL19-5428 - CAACGGGGCCUAUCACCUCAA 21 9811
HSV2-UL19-5429 - ACAACGGGGCCUAUCACCUCAA 22 9812
HSV2-UL19-5430 - UACAACGGGGCCUAUCACCUCAA 23 9813
HSV2-UL19-5431 - GUACAACGGGGCCUAUCACCUCAA 24 9814
HSV2-UL19-5432 - CAGGUGGCCCGCCACGAA 18 9815
HSV2-UL19-5433 - CCAGGUGGCCCGCCACGAA 19 9816
HSV2-UL19-2183 - UCCAGGUGGCCCGCCACGAA 20 2471
HSV2-UL19-5434 - CUCCAGGUGGCCCGCCACGAA 21 9817
HSV2-UL19-5435 - GCUCCAGGUGGCCCGCCACGAA 22 9818
HSV2-UL19-5436 - AGCUCCAGGUGGCCCGCCACGAA 23 9819
HSV2-UL19-5437 - CAGCUCCAGGUGGCCCGCCACGAA 24 9820
HSV2-UL19-5438 - GGAGCAACUCGAGGCGAA 18 9821
HSV2-UL19-5439 - AGGAGCAACUCGAGGCGAA 19 9822
HSV2-UL19-2038 - GAGGAGCAACUCGAGGCGAA 20 2376
HSV2-UL19-5440 - GG AGGAGCAACUCGAGGCGAA 21 9823
HSV2-UL19-5441 - AGGAGGAGCAACUCGAGGCGAA 22 9824
HSV2-UL19-5442 - CAGG AGGAGCAACUCGAGGCGAA 23 9825
HSV2-UL19-5443 - GCAGGAGGAGCAACUCGAGGCGAA 24 9826
HSV2-UL19-5444 - G AGCG U CU CAU CG U G G AA 18 9827
HSV2-UL19-5445 - GGAGCGUCUCAUCGUGGAA 19 9828
HSV2-UL19-2235 - UGGAGCGUCUCAUCGUGGAA 20 2499
HSV2-UL19-5446 - CUGGAGCGUCUCAUCGUGGAA 21 9829
HSV2-UL19-5447 - CCUGGAGCGUCUCAUCGUGGAA 22 9830
HSV2-UL19-5448 - GCCUGGAGCGUCUCAUCGUGGAA 23 9831
HSV2-UL19-5449 - UGCCUGGAGCGUCUCAUCGUGGAA 24 9832
HSV2-UL19-5450 - CCUGGUCGCCGAGCUGAA 18 9833
HSV2-UL19-5451 - CCCUGGUCGCCGAGCUGAA 19 9834
HSV2-UL19-2006 - ACCCUGGUCGCCGAGCUGAA 20 2351
HSV2-UL19-5452 - GACCCUGGUCGCCGAGCUGAA 21 9835
HSV2-UL19-5453 - CGACCCUGGUCGCCGAGCUGAA 22 9836
HSV2-UL19-5454 - GCGACCCUGGUCGCCGAGCUGAA 23 9837
HSV2-UL19-5455 - GGCG ACCCUGGUCGCCGAGCUGAA 24 9838
HSV2-UL19-5456 - CGGCGAGAUGGUCUUGAA 18 9839
HSV2-UL19-5457 - ACGGCGAGAUGGUCUUGAA 19 9840
HSV2-UL19-386 - UACGGCGAGAUGGUCUUGAA 20 626
HSV2-UL19-5458 - CUACGGCGAGAUGGUCUUGAA 21 9841
HSV2-UL19-5459 - CCU ACGGCGAGAUGGUCUUGAA 22 9842
HSV2-UL19-5460 - ACCUACGGCGAGAUGGUCUUGAA 23 9843
HSV2-UL19-5461 - GACCUACGGCGAGAUGGUCUUGAA 24 9844
HSV2-UL19-5462 - UCAAGCGCAUGUUCCACA 18 9845 HSV2-UL19-5463 - GUCAAGCGCAUGUUCCACA 19 9846
HSV2-UL19-2149 - GGUCAAGCGCAUGUUCCACA 20 2446
HSV2-UL19-5464 - CGGUCAAGCGCAUGUUCCACA 21 9847
HSV2-UL19-5465 - ACGGUCAAGCGCAUGUUCCACA 22 9848
HSV2-UL19-5466 - CACGGUCAAGCGCAUGUUCCACA 23 9849
HSV2-UL19-5467 - ACACGGUCAAGCGCAUGUUCCACA 24 9850
HSV2-UL19-5468 - UGCAACGAUAUCUCGACA 18 9851
HSV2-UL19-5469 - AUGCAACGAUAUCUCGACA 19 9852
HSV2-UL19-2001 - CAUGCAACGAUAUCUCGACA 20 2346
HSV2-UL19-5470 - CCAUGCAACGAUAUCUCGACA 21 9853
HSV2-UL19-5471 - CCCAUGCAACGAUAUCUCGACA 22 9854
HSV2-UL19-5472 - GCCCAUGCAACGAUAUCUCGACA 23 9855
HSV2-UL19-5473 - UGCCCAUGCAACGAUAUCUCGACA 24 9856
HSV2-UL19-5474 - UCCUGAAGGUGGAGGACA 18 9857
HSV2-UL19-5475 - UUCCUGAAGGUGGAGGACA 19 9858
HSV2-UL19-2021 - CU UCCUGAAGGUGGAGGACA 20 2363
HSV2-UL19-5476 - CCU UCCUGAAGGUGGAGGACA 21 9859
HSV2-UL19-5477 - UCCU UCCUGAAGGUGGAGGACA 22 9860
HSV2-UL19-5478 - GUCCU UCCUGAAGGUGGAGGACA 23 9861
HSV2-UL19-5479 - AGUCCUUCCUGAAGGUGGAGGACA 24 9862
HSV2-UL19-5480 - GCGUGUACGCGGGGGACA 18 9863
HSV2-UL19-5481 - GGCGUGUACGCGGGGGACA 19 9864
HSV2-UL19-680 - CGGCGUGUACGCGGGGGACA 20 920
HSV2-UL19-5482 - GCGGCGUGUACGCGGGGGACA 21 9865
HSV2-UL19-5483 - GGCGGCGUGUACGCGGGGGACA 22 9866
HSV2-UL19-5484 - CGGCGGCGUGUACGCGGGGGACA 23 9867
HSV2-UL19-5485 - CCGGCGGCGUGUACGCGGGGGACA 24 9868
HSV2-UL19-5486 - ACGGGGACCUGCUGUACA 18 9869
HSV2-UL19-5487 - UACGGGGACCUGCUGUACA 19 9870
HSV2-UL19-2227 - GU ACGGGGACCUGCUGUACA 20 2495
HSV2-UL19-5488 - CGU ACGGGGACCUGCUGUACA 21 9871
HSV2-UL19-5489 - UCGUACGGGGACCUGCUGUACA 22 9872
HSV2-UL19-5490 - CUCGUACGGGGACCUGCUGUACA 23 9873
HSV2-UL19-5491 - UCUCGUACGGGGACCUGCUGUACA 24 9874
HSV2-UL19-5492 - CGCGGCCCUGGACCGCCA 18 9875
HSV2-UL19-5493 - ACGCGGCCCUGGACCGCCA 19 9876
HSV2-UL19-2127 - CACGCGGCCCUGGACCGCCA 20 2434
HSV2-UL19-5494 - ACACGCGGCCCUGGACCGCCA 21 9877
HSV2-UL19-5495 - GACACGCGGCCCUGGACCGCCA 22 9878
HSV2-UL19-5496 - CGACACGCGGCCCUGGACCGCCA 23 9879
HSV2-UL19-5497 - GCGACACGCGGCCCUGGACCGCCA 24 9880
HSV2-UL19-5498 - GCCAUCGCCGCGAGGCCA 18 9881
HSV2-UL19-5499 - GGCCAUCGCCGCGAGGCCA 19 9882
HSV2-UL19-2012 - GGGCCAUCGCCGCGAGGCCA 20 2356
HSV2-UL19-5500 - CGGGCCAUCGCCGCGAGGCCA 21 9883
HSV2-UL19-5501 - GCGGGCCAUCGCCGCGAGGCCA 22 9884 HSV2-UL19-5502 - GGCGGGCCAUCGCCGCGAGGCCA 23 9885
HSV2-UL19-5503 - AGGCGGGCCAUCGCCGCGAGGCCA 24 9886
HSV2-UL19-5504 - GGCUGUUCAACCCGGCCA 18 9887
HSV2-UL19-5505 - GGGCUGUUCAACCCGGCCA 19 9888
HSV2-UL19-422 - GGGGCUGU UCAACCCGGCCA 20 662
HSV2-UL19-5506 - UGGGGCUGUUCAACCCGGCCA 21 9889
HSV2-UL19-5507 - CUGGGGCUGUUCAACCCGGCCA 22 9890
HSV2-UL19-5508 - CCUGGGGCUGUUCAACCCGGCCA 23 9891
HSV2-UL19-5509 - CCCUGGGGCUGU UCAACCCGGCCA 24 9892
HSV2-UL19-5510 - AGGUUCUGCGGCUGUCCA 18 9893
HSV2-UL19-5511 - CAGGUUCUGCGGCUGUCCA 19 9894
HSV2-UL19-436 - CCAGGUUCUGCGGCUGUCCA 20 676
HSV2-UL19-5512 - ACCAGGUUCUGCGGCUGUCCA 21 9895
HSV2-UL19-5513 - CACCAGGUUCUGCGGCUGUCCA 22 9896
HSV2-UL19-5514 - CCACCAGGUUCUGCGGCUGUCCA 23 9897
HSV2-UL19-5515 - ACCACCAGGUUCUGCGGCUGUCCA 24 9898
HSV2-UL19-5516 - AAGCCGCGAUUCACGGCA 18 9899
HSV2-UL19-5517 - CAAGCCGCGAUUCACGGCA 19 9900
HSV2-UL19-2103 - G CAAG CCGCGAUU CACG G CA 20 2417
HSV2-UL19-5518 - UGCAAGCCGCGAUUCACGGCA 21 9901
HSV2-UL19-5519 - CUGCAAGCCGCGAUUCACGGCA 22 9902
HSV2-UL19-5520 - G CU G CAAG CCGCGAUUCACGGCA 23 9903
HSV2-UL19-5521 - UGCUGCAAGCCGCGAUUCACGGCA 24 9904
HSV2-UL19-5522 - ACGGGGCCUAUCACCUCA 18 9905
HSV2-UL19-5523 - AACGGGGCCUAUCACCUCA 19 9906
HSV2-UL19-2229 - CAACGGGGCCUAUCACCUCA 20 2496
HSV2-UL19-5524 - ACAACGGGGCCUAUCACCUCA 21 9907
HSV2-UL19-5525 - UACAACGGGGCCUAUCACCUCA 22 9908
HSV2-UL19-5526 - GUACAACGGGGCCUAUCACCUCA 23 9909
HSV2-UL19-5527 - UGUACAACGGGGCCUAUCACCUCA 24 9910
HSV2-UL19-5528 - GCCGCACCGGCCGGCCGA 18 9911
HSV2-UL19-5529 - GGCCGCACCGGCCGGCCGA 19 9912
HSV2-UL19-2135 - CGGCCGCACCGGCCGGCCGA 20 2438
HSV2-UL19-5530 - CCGGCCGCACCGGCCGGCCGA 21 9913
HSV2-UL19-5531 - ACCGGCCGCACCGGCCGGCCGA 22 9914
HSV2-UL19-5532 - GACCGGCCGCACCGGCCGGCCGA 23 9915
HSV2-UL19-5533 - CGACCGGCCGCACCGGCCGGCCGA 24 9916
HSV2-UL19-5534 - GCUACGCAGCGCCCGCGA 18 9917
HSV2-UL19-5535 - UGCUACGCAGCGCCCGCGA 19 9918
HSV2-UL19-717 - CUGCUACGCAGCGCCCGCGA 20 957
HSV2-UL19-5536 - CCUGCUACGCAGCGCCCGCGA 21 9919
HSV2-UL19-5537 - CCCUGCUACGCAGCGCCCGCGA 22 9920
HSV2-UL19-5538 - GCCCUGCUACGCAGCGCCCGCGA 23 9921
HSV2-UL19-5539 - CGCCCUGCUACGCAGCGCCCGCGA 24 9922
HSV2-UL19-5540 - CAACAUGCGCAUCUUCGA 18 9923
HSV2-UL19-5541 - CCAACAUGCGCAUCUUCGA 19 9924 HSV2-UL19-581 - GCCAACAU G CG CAU CU U CG A 20 821
HSV2-UL19-5542 - GGCCAACAUGCGCAUCUUCGA 21 9925
HSV2-UL19-5543 - CGGCCAACAUGCGCAUCUUCGA 22 9926
HSV2-UL19-5544 - ACGGCCAACAUGCGCAUCUUCGA 23 9927
HSV2-UL19-5545 - GACGGCCAACAUGCGCAUCUUCGA 24 9928
HSV2-UL19-5546 - GUACGCGGGGGACAAGGA 18 9929
HSV2-UL19-5547 - UGUACGCGGGGGACAAGGA 19 9930
HSV2-UL19-682 - GUGUACGCGGGGGACAAGGA 20 922
HSV2-UL19-5548 - CGUGUACGCGGGGGACAAGGA 21 9931
HSV2-UL19-5549 - GCG UGUACGCGGGGGACAAGGA 22 9932
HSV2-UL19-5550 - GGCGUGUACGCGGGGGACAAGGA 23 9933
HSV2-UL19-5551 - CGGCGUGUACGCGGGGGACAAGGA 24 9934
HSV2-UL19-5552 - CAGCUGUUUUUUUGGGGA 18 9935
HSV2-UL19-5553 - GCAGCUGUUUUUUUGGGGA 19 9936
HSV2-UL19-2065 - GGCAGCUGU UUUUUUGGGGA 20 2391
HSV2-UL19-5554 - CGGCAGCUGUUUUUUUGGGGA 21 9937
HSV2-UL19-5555 - CCGGCAGCUGUUUUUUUGGGGA 22 9938
HSV2-UL19-5556 - CCCGGCAGCUGUUUUUUUGGGGA 23 9939
HSV2-UL19-5557 - CCCCGGCAGCUGUUUUUUUGGGGA 24 9940
HSV2-UL19-5558 - GGCAGGACCGCUUCGUGA 18 9941
HSV2-UL19-5559 - CGGCAGGACCGCUUCGUGA 19 9942
HSV2-UL19-2176 - GCGGCAGGACCGCUUCGUGA 20 2465
HSV2-UL19-5560 - UGCGGCAGGACCGCU UCGUGA 21 9943
HSV2-UL19-5561 - GUGCGGCAGGACCGCUUCGUGA 22 9944
HSV2-UL19-5562 - CGUGCGGCAGGACCGCUUCGUGA 23 9945
HSV2-UL19-5563 - UCGUGCGGCAGGACCGCUUCGUGA 24 9946
HSV2-UL19-5564 - ACGGCGAGAUGGUCUUGA 18 9947
HSV2-UL19-5565 - UACGGCGAGAUGGUCUUGA 19 9948
HSV2-UL19-2024 - CU ACGGCGAGAUGGUCUUGA 20 2366
HSV2-UL19-5566 - CCUACGGCGAGAUGGUCUUGA 21 9949
HSV2-UL19-5567 - ACCU ACGGCGAGAUGGUCUUGA 22 9950
HSV2-UL19-5568 - GACCU ACGGCGAGAUGGUCUUGA 23 9951
HSV2-UL19-5569 - UGACCUACGGCGAGAUGGUCUUGA 24 9952
HSV2-UL19-5570 - UCAGUGCAUCACCAGCUA 18 9953
HSV2-UL19-5571 - CUCAGUGCAUCACCAGCUA 19 9954
HSV2-UL19-2104 - ACU CAG U GCAU CACCAG CU A 20 2418
HSV2-UL19-5572 - GACUCAGUGCAUCACCAGCUA 21 9955
HSV2-UL19-5573 - UGACUCAGUGCAUCACCAGCUA 22 9956
HSV2-UL19-5574 - GUGACUCAGUGCAUCACCAGCUA 23 9957
HSV2-UL19-5575 - CGUGACUCAGUGCAUCACCAGCUA 24 9958
HSV2-UL19-5576 - UACGACGCCUCCCCGCUA 18 9959
HSV2-UL19-5577 - CUACGACGCCUCCCCGCUA 19 9960
HSV2-UL19-2250 - UCUACGACGCCUCCCCGCUA 20 2507
HSV2-UL19-5578 - AUCUACGACGCCUCCCCGCUA 21 9961
HSV2-UL19-5579 - CAUCUACGACGCCUCCCCGCUA 22 9962
HSV2-UL19-5580 - UCAUCUACGACGCCUCCCCGCUA 23 9963 HSV2-UL19-5581 - CUCAUCUACGACGCCUCCCCGCUA 24 9964
HSV2-UL19-5582 - CGAGGCCGCGAAUCCGUA 18 9965
HSV2-UL19-5583 - UCGAGGCCGCGAAUCCGUA 19 9966
HSV2-UL19-446 - GUCGAGGCCGCGAAUCCGUA 20 686
HSV2-UL19-5584 - CG UCGAGGCCGCGAAUCCGUA 21 9967
HSV2-UL19-5585 - CCGUCGAGGCCGCGAAUCCGUA 22 9968
HSV2-UL19-5586 - CCCGUCGAGGCCGCGAAUCCGUA 23 9969
HSV2-UL19-5587 - CCCCGUCGAGGCCGCGAAUCCGUA 24 9970
HSV2-UL19-5588 - GUCGCAGCGGUUCUCGUA 18 9971
HSV2-UL19-5589 - CGUCGCAGCGGUUCUCGUA 19 9972
HSV2-UL19-693 - GCGUCGCAGCGGUUCUCGUA 20 933
HSV2-UL19-5590 - GGCGUCGCAGCGGU UCUCGUA 21 9973
HSV2-UL19-5591 - GGGCGUCGCAGCGGUUCUCGUA 22 9974
HSV2-UL19-5592 - UGGGCGUCGCAGCGGUUCUCGUA 23 9975
HSV2-UL19-5593 - GUGGGCGUCGCAGCGGUUCUCGUA 24 9976
HSV2-UL19-5594 - GGAGUGCAUGGCCGUGUA 18 9977
HSV2-UL19-5595 - AGGAGUGCAUGGCCGUGUA 19 9978
HSV2-UL19-2113 - GAGGAGUGCAUGGCCGUGUA 20 2423
HSV2-UL19-5596 - CGAGGAGUGCAUGGCCGUGUA 21 9979
HSV2-UL19-5597 - CCGAGGAGUGCAUGGCCGUGUA 22 9980
HSV2-UL19-5598 - CCCG AGGAGUGCAUGGCCGUGUA 23 9981
HSV2-UL19-5599 - CCCCGAGGAGUGCAUGGCCGUGUA 24 9982
HSV2-UL19-5600 - ACCCAGCCGCGCGGAAAC 18 9983
HSV2-UL19-5601 - CACCCAGCCGCGCGGAAAC 19 9984
HSV2-UL19-2191 - UCACCCAGCCGCGCGGAAAC 20 2474
HSV2-UL19-5602 - CUCACCCAGCCGCGCGGAAAC 21 9985
HSV2-UL19-5603 - GCUCACCCAGCCGCGCGGAAAC 22 9986
HSV2-UL19-5604 - CGCUCACCCAGCCGCGCGGAAAC 23 9987
HSV2-UL19-5605 - ACGCUCACCCAGCCGCGCGGAAAC 24 9988
HSV2-UL19-5606 - AUAUGCAGGAGGAGCAAC 18 9989
HSV2-UL19-5607 - GAUAUGCAGGAGGAGCAAC 19 9990
HSV2-UL19-2036 - GGAUAUGCAGGAGGAGCAAC 20 2374
HSV2-UL19-5608 - UGGAUAUGCAGGAGGAGCAAC 21 9991
HSV2-UL19-5609 - CUGGAUAUGCAGGAGGAGCAAC 22 9992
HSV2-UL19-5610 - GCUGGAUAUGCAGGAGGAGCAAC 23 9993
HSV2-UL19-5611 - UGCUGGAUAUGCAGGAGGAGCAAC 24 9994
HSV2-UL19-5612 - GAGCAACUCGAGGCGAAC 18 9995
HSV2-UL19-5613 - GGAGCAACUCGAGGCGAAC 19 9996
HSV2-UL19-402 - AGGAGCAACUCGAGGCGAAC 20 642
HSV2-UL19-5614 - GAGGAGCAACUCGAGGCGAAC 21 9997
HSV2-UL19-5615 - GGAGGAGCAACUCGAGGCGAAC 22 9998
HSV2-UL19-5616 - AGGAGGAGCAACUCGAGGCGAAC 23 9999
HSV2-UL19-5617 - CAGGAGGAGCAACUCGAGGCGAAC 24 10000
HSV2-UL19-5618 - GGGAGACGCUGGAUGAAC 18 10001
HSV2-UL19-5619 - CGGGAGACGCUGGAUGAAC 19 10002
HSV2-UL19-2043 - CCGGGAGACGCUGGAUGAAC 20 2379 HSV2-UL19-5620 - ACCGGGAGACGCUGGAUGAAC 21 10003
HSV2-UL19-5621 - AACCGGGAGACGCUGGAUGAAC 22 10004
HSV2-UL19-5622 - GAACCGGGAGACGCUGGAUGAAC 23 10005
HSV2-UL19-5623 - CGAACCGGGAGACGCUGGAUGAAC 24 10006
HSV2-UL19-5624 - GUGCCCGCCCCCGGCCAC 18 10007
HSV2-UL19-5625 - GGUGCCCGCCCCCGGCCAC 19 10008
HSV2-UL19-2059 - UGGUGCCCGCCCCCGGCCAC 20 2389
HSV2-UL19-5626 - CUGGUGCCCGCCCCCGGCCAC 21 10009
HSV2-UL19-5627 - CCUGGUGCCCGCCCCCGGCCAC 22 10010
HSV2-UL19-5628 - ACCUGGUGCCCGCCCCCGGCCAC 23 10011
HSV2-UL19-5629 - GACCUGGUGCCCGCCCCCGGCCAC 24 10012
HSV2-UL19-5630 - CUCAUGGCCCCCCAGCAC 18 10013
HSV2-UL19-5631 - GCUCAUGGCCCCCCAGCAC 19 10014
HSV2-UL19-2155 - UGCUCAUGGCCCCCCAGCAC 20 2451
HSV2-UL19-5632 - CUGCUCAUGGCCCCCCAGCAC 21 10015
HSV2-UL19-5633 - GCUGCUCAUGGCCCCCCAGCAC 22 10016
HSV2-UL19-5634 - UGCUGCUCAUGGCCCCCCAGCAC 23 10017
HSV2-UL19-5635 - GUGCUGCUCAUGGCCCCCCAGCAC 24 10018
HSV2-UL19-5636 - GUGCGGAGCCUGGACGAC 18 10019
HSV2-UL19-5637 - CGUGCGGAGCCUGGACGAC 19 10020
HSV2-UL19-2030 - CCGUGCGGAGCCUGGACGAC 20 2370
HSV2-UL19-5638 - GCCGUGCGGAGCCUGGACGAC 21 10021
HSV2-UL19-5639 - GGCCGUGCGGAGCCUGGACGAC 22 10022
HSV2-UL19-5640 - AGGCCGUGCGGAGCCUGGACGAC 23 10023
HSV2-UL19-5641 - AAGGCCGUGCGGAGCCUGGACGAC 24 10024
HSV2-UL19-5642 - UGCUCCGCGGCGCCCGAC 18 10025
HSV2-UL19-5643 - GUGCUCCGCGGCGCCCGAC 19 10026
HSV2-UL19-2152 - UGUGCUCCGCGGCGCCCGAC 20 2449
HSV2-UL19-5644 - CUGUGCUCCGCGGCGCCCGAC 21 10027
HSV2-UL19-5645 - GCUGUGCUCCGCGGCGCCCGAC 22 10028
HSV2-UL19-5646 - UGCUGUGCUCCGCGGCGCCCGAC 23 10029
HSV2-UL19-5647 - CUGCUGUGCUCCGCGGCGCCCGAC 24 10030
HSV2-UL19-5648 - AAGCGGAGCUUUUGCGAC 18 10031
HSV2-UL19-5649 - GAAGCGGAGCUUUUGCGAC 19 10032
HSV2-UL19-2008 - UGAAGCGGAGCUUUUGCGAC 20 2352
HSV2-UL19-5650 - CUGAAGCGGAGCUUUUGCGAC 21 10033
HSV2-UL19-5651 - GCUGAAGCGGAGCUUUUGCGAC 22 10034
HSV2-UL19-5652 - AGCUGAAGCGGAGCUUUUGCGAC 23 10035
HSV2-UL19-5653 - GAGCUGAAGCGGAGCUUUUGCGAC 24 10036
HSV2-UL19-5654 - CGCAACCCCGUUACGGAC 18 10037
HSV2-UL19-5655 - CCG CAACCCCG U U ACG G AC 19 10038
HSV2-UL19-2196 - UCCGCAACCCCGUUACGGAC 20 2479
HSV2-UL19-5656 - GUCCGCAACCCCGUUACGGAC 21 10039
HSV2-UL19-5657 - CG UCCGCAACCCCGU U ACGG AC 22 10040
HSV2-UL19-5658 - CCG U CCG CAACCCCG U U ACG G AC 23 10041
HSV2-UL19-5659 - ACCG UCCGCAACCCCGU UACGG AC 24 10042 HSV2-UL19-5660 - GGCGUGUACGCGGGGGAC 18 10043
HSV2-UL19-5661 - CGGCGUGUACGCGGGGGAC 19 10044
HSV2-UL19-2216 - GCGGCGUGUACGCGGGGGAC 20 2490
HSV2-UL19-5662 - GGCGGCGUGUACGCGGGGGAC 21 10045
HSV2-UL19-5663 - CGGCGGCGUGUACGCGGGGGAC 22 10046
HSV2-UL19-5664 - CCGGCGGCGUGUACGCGGGGGAC 23 10047
HSV2-UL19-5665 - GCCGGCGGCGUGUACGCGGGGGAC 24 10048
HSV2-UL19-5666 - CGAGACUGCCGGAUUGAC 18 10049
HSV2-UL19-5667 - CCGAGACUGCCGGAUUGAC 19 10050
HSV2-UL19-2129 - ACCGAGACUGCCGGAUUGAC 20 2436
HSV2-UL19-5668 - CACCGAGACUGCCGGAUUGAC 21 10051
HSV2-UL19-5669 - CCACCGAGACUGCCGGAUUGAC 22 10052
HSV2-UL19-5670 - GCCACCGAGACUGCCGGAUUGAC 23 10053
HSV2-UL19-5671 - CGCCACCGAGACUGCCGGAUUGAC 24 10054
HSV2-UL19-5672 - CAGUGCAUCACCAGCUAC 18 10055
HSV2-UL19-5673 - UCAGUGCAUCACCAGCUAC 19 10056
HSV2-UL19-500 - CU CAG U G CAU CACCAG CU AC 20 740
HSV2-UL19-5674 - ACUCAGUGCAUCACCAGCUAC 21 10057
HSV2-UL19-5675 - G ACU CAG U GCAU CACCAG CU AC 22 10058
HSV2-UL19-5676 - UGACU CAGUGCAUCACCAGCUAC 23 10059
HSV2-UL19-5677 - GUGACUCAGUGCAUCACCAGCUAC 24 10060
HSV2-UL19-5678 - UCGCAGCGGUUCUCGUAC 18 10061
HSV2-UL19-5679 - GUCGCAGCGGUUCUCGUAC 19 10062
HSV2-UL19-694 - CGUCGCAGCGGUUCUCGUAC 20 934
HSV2-UL19-5680 - GCGUCGCAGCGGU UCUCGUAC 21 10063
HSV2-UL19-5681 - GGCGUCGCAGCGGUUCUCGUAC 22 10064
HSV2-UL19-5682 - GGGCGUCGCAGCGGUUCUCGUAC 23 10065
HSV2-UL19-5683 - UGGGCGUCGCAGCGGUUCUCGUAC 24 10066
HSV2-UL19-5684 - GCGGCCGGCGGCGUGUAC 18 10067
HSV2-UL19-5685 - CGCGGCCGGCGGCGUGUAC 19 10068
HSV2-UL19-2212 - GCGCGGCCGGCGGCGUGUAC 20 2489
HSV2-UL19-5686 - CGCGCGGCCGGCGGCGUGUAC 21 10069
HSV2-UL19-5687 - ACGCGCGGCCGGCGGCGUGUAC 22 10070
HSV2-UL19-5688 - GACGCGCGGCCGGCGGCGUGUAC 23 10071
HSV2-UL19-5689 - GGACGCGCGGCCGGCGGCGUGUAC 24 10072
HSV2-UL19-5690 - AGCAACUCGAGGCGAACC 18 10073
HSV2-UL19-5691 - GAGCAACUCGAGGCGAACC 19 10074
HSV2-UL19-403 - GG AGCAACUCGAGGCGAACC 20 643
HSV2-UL19-5692 - AGG AGCAACUCGAGGCGAACC 21 10075
HSV2-UL19-5693 - GAGGAGCAACUCGAGGCGAACC 22 10076
HSV2-UL19-5694 - GGAGG AGCAACUCGAGGCGAACC 23 10077
HSV2-UL19-5695 - AGGAGGAGCAACUCGAGGCGAACC 24 10078
HSV2-UL19-5696 - UGCCCGCCCCCGGCCACC 18 10079
HSV2-UL19-5697 - GUGCCCGCCCCCGGCCACC 19 10080
HSV2-UL19-428 - GGUGCCCGCCCCCGGCCACC 20 668
HSV2-UL19-5698 - UGGUGCCCGCCCCCGGCCACC 21 10081 HSV2-UL19-5699 - CUGGUGCCCGCCCCCGGCCACC 22 10082
HSV2-UL19-5700 - CCUGGUGCCCGCCCCCGGCCACC 23 10083
HSV2-UL19-5701 - ACCUGGUGCCCGCCCCCGGCCACC 24 10084
HSV2-UL19-5702 - CGGGGGCGCUGCUGCACC 18 10085
HSV2-UL19-5703 - GCGGGGGCGCUGCUGCACC 19 10086
HSV2-UL19-2139 - CGCGGGGGCGCUGCUGCACC 20 2440
HSV2-UL19-5704 - UCGCGGGGGCGCUGCUGCACC 21 10087
HSV2-UL19-5705 - CUCGCGGGGGCGCUGCUGCACC 22 10088
HSV2-UL19-5706 - UCUCGCGGGGGCGCUGCUGCACC 23 10089
HSV2-UL19-5707 - UUCUCGCGGGGGCGCUGCUGCACC 24 10090
HSV2-UL19-5708 - GGCGCGCCGGCAUGGACC 18 10091
HSV2-UL19-5709 - CGGCGCGCCGGCAUGGACC 19 10092
HSV2-UL19-2205 - GCGGCGCGCCGGCAUGGACC 20 2484
HSV2-UL19-5710 - CGCGGCGCGCCGGCAUGGACC 21 10093
HSV2-UL19-5711 - CCGCGGCGCGCCGGCAUGGACC 22 10094
HSV2-UL19-5712 - GCCGCGGCGCGCCGGCAUGGACC 23 10095
HSV2-UL19-5713 - UGCCGCGGCGCGCCGGCAUGGACC 24 10096
HSV2-UL19-5714 - GCCGAGUGCCAGAUGACC 18 10097
HSV2-UL19-5715 - CGCCGAGUGCCAGAUGACC 19 10098
HSV2-UL19-2085 - UCGCCGAGUGCCAGAUGACC 20 2406
HSV2-UL19-5716 - GUCGCCGAGUGCCAGAUGACC 21 10099
HSV2-UL19-5717 - GGUCGCCGAGUGCCAGAUGACC 22 10100
HSV2-UL19-5718 - GGGU CGCCGAGUGCCAGAUGACC 23 10101
HSV2-UL19-5719 - UGGGUCGCCGAGUGCCAGAUGACC 24 10102
HSV2-UL19-5720 - CAGGACCGCUUCGUGACC 18 10103
HSV2-UL19-5721 - GCAGGACCGCUUCGUGACC 19 10104
HSV2-UL19-2177 - GGCAGGACCGCUUCGUGACC 20 2466
HSV2-UL19-5722 - CGGCAGGACCGCUUCGUGACC 21 10105
HSV2-UL19-5723 - GCGGCAGGACCGCUUCGUGACC 22 10106
HSV2-UL19-5724 - UGCGGCAGGACCGCU UCGUGACC 23 10107
HSV2-UL19-5725 - GUGCGGCAGGACCGCUUCGUGACC 24 10108
HSV2-UL19-5726 - CGUACAUCGUGACCUACC 18 10109
HSV2-UL19-5727 - UCGUACAUCGUGACCUACC 19 10110
HSV2-UL19-2107 - CUCGUACAUCGUGACCUACC 20 2420
HSV2-UL19-5728 - UCUCGUACAUCGUGACCUACC 21 10111
HSV2-UL19-5729 - GUCUCGUACAUCGUGACCUACC 22 10112
HSV2-UL19-5730 - GGUCUCGUACAUCGUGACCUACC 23 10113
HSV2-UL19-5731 - UGGUCUCGUACAUCGUGACCUACC 24 10114
HSV2-UL19-5732 - CGCGGCCACGGCCAACCC 18 10115
HSV2-UL19-5733 - UCGCGGCCACGGCCAACCC 19 10116
HSV2-UL19-2223 - UUCGCGGCCACGGCCAACCC 20 2493
HSV2-UL19-5734 - CUUCGCGGCCACGGCCAACCC 21 10117
HSV2-UL19-5735 - CCUUCGCGGCCACGGCCAACCC 22 10118
HSV2-UL19-5736 - CCCUUCGCGGCCACGGCCAACCC 23 10119
HSV2-UL19-5737 - GCCCUUCGCGGCCACGGCCAACCC 24 10120
HSV2-UL19-5738 - UCGCCGGCCCUGCAACCC 18 10121 HSV2-UL19-5739 - UUCGCCGGCCCUGCAACCC 19 10122
HSV2-UL19-2209 - UU UCGCCGGCCCUGCAACCC 20 2488
HSV2-UL19-5740 - CUUUCGCCGGCCCUGCAACCC 21 10123
HSV2-UL19-5741 - ACUUUCGCCGGCCCUGCAACCC 22 10124
HSV2-UL19-5742 - UACUUUCGCCGGCCCUGCAACCC 23 10125
HSV2-UL19-5743 - CUACUU UCGCCGGCCCUGCAACCC 24 10126
HSV2-UL19-5744 - UGACGUUCGUCCUGCCCC 18 10127
HSV2-UL19-5745 - CUGACGUUCGUCCUGCCCC 19 10128
HSV2-UL19-418 - CCUGACGUUCGUCCUGCCCC 20 658
HSV2-UL19-5746 - ACCUGACGUUCGUCCUGCCCC 21 10129
HSV2-UL19-5747 - GACCUGACGUUCGUCCUGCCCC 22 10130
HSV2-UL19-5748 - GGACCUGACGUUCGUCCUGCCCC 23 10131
HSV2-UL19-5749 - UGGACCUGACGUUCGUCCUGCCCC 24 10132
HSV2-UL19-5750 - CUCGGGGGCGACCUCCCC 18 10133
HSV2-UL19-5751 - CCUCGGGGGCGACCUCCCC 19 10134
HSV2-UL19-2111 - ACCUCGGGGGCGACCUCCCC 20 2422
HSV2-UL19-5752 - UACCUCGGGGGCGACCUCCCC 21 10135
HSV2-UL19-5753 - CUACCUCGGGGGCGACCUCCCC 22 10136
HSV2-UL19-5754 - CCUACCUCGGGGGCGACCUCCCC 23 10137
HSV2-UL19-5755 - ACCUACCUCGGGGGCGACCUCCCC 24 10138
HSV2-UL19-5756 - CCGUGGUGCAGCACGCCC 18 10139
HSV2-UL19-5757 - CCCGUGGUGCAGCACGCCC 19 10140
HSV2-UL19-2161 - GCCCGUGGUGCAGCACGCCC 20 2455
HSV2-UL19-5758 - AGCCCGUGGUGCAGCACGCCC 21 10141
HSV2-UL19-5759 - CAGCCCGUGGUGCAGCACGCCC 22 10142
HSV2-UL19-5760 - CCAGCCCGUGGUGCAGCACGCCC 23 10143
HSV2-UL19-5761 - GCCAGCCCGUGGUGCAGCACGCCC 24 10144
HSV2-UL19-5762 - UGGUCUUCCUGGAGGCCC 18 10145
HSV2-UL19-5763 - CUGGUCUUCCUGGAGGCCC 19 10146
HSV2-UL19-413 - GCUGGUCUUCCUGGAGGCCC 20 653
HSV2-UL19-5764 - GGCUGGUCUUCCUGGAGGCCC 21 10147
HSV2-UL19-5765 - AGGCUGGUCUUCCUGGAGGCCC 22 10148
HSV2-UL19-5766 - CAGGCUGGUCUUCCUGGAGGCCC 23 10149
HSV2-UL19-5767 - ACAGGCUGGUCUUCCUGGAGGCCC 24 10150
HSV2-UL19-5768 - CCCUGGUCCCCCCGGCCC 18 10151
HSV2-UL19-5769 - CCCCUGGUCCCCCCGGCCC 19 10152
HSV2-UL19-595 - CCCCCUGGUCCCCCCGGCCC 20 835
HSV2-UL19-5770 - UCCCCCUGGUCCCCCCGGCCC 21 10153
HSV2-UL19-5771 - GUCCCCCUGGUCCCCCCGGCCC 22 10154
HSV2-UL19-5772 - CGUCCCCCUGGUCCCCCCGGCCC 23 10155
HSV2-UL19-5773 - ACGUCCCCCUGGUCCCCCCGGCCC 24 10156
HSV2-UL19-5774 - CUGACGUUCGUCCUGCCC 18 10157
HSV2-UL19-5775 - CCUGACGUUCGUCCUGCCC 19 10158
HSV2-UL19-2052 - ACCUGACGUUCGUCCUGCCC 20 2386
HSV2-UL19-5776 - GACCUGACGUUCGUCCUGCCC 21 10159
HSV2-UL19-5777 - GGACCUGACGUUCGUCCUGCCC 22 10160 HSV2-UL19-5778 - UGGACCUGACGUUCGUCCUGCCC 23 10161
HSV2-UL19-5779 - AUGGACCUGACGUUCGUCCUGCCC 24 10162
HSV2-UL19-5780 - CGCUUCGCCGCGCACGCC 18 10163
HSV2-UL19-5781 - GCGCUUCGCCGCGCACGCC 19 10164
HSV2-UL19-424 - AGCGCUUCGCCGCGCACGCC 20 664
HSV2-UL19-5782 - GAGCGCUUCGCCGCGCACGCC 21 10165
HSV2-UL19-5783 - GGAGCGCUUCGCCGCGCACGCC 22 10166
HSV2-UL19-5784 - UGGAGCGCU UCGCCGCGCACGCC 23 10167
HSV2-UL19-5785 - AUGGAGCGCUUCGCCGCGCACGCC 24 10168
HSV2-UL19-5786 - GUGGCGU UUCGUGACGCC 18 10169
HSV2-UL19-5787 - GGUGGCGUUUCGUGACGCC 19 10170
HSV2-UL19-483 - CGGUGGCGUUUCGUGACGCC 20 723
HSV2-UL19-5788 - CCGGUGGCGUU UCGUGACGCC 21 10171
HSV2-UL19-5789 - UCCGGUGGCGUUUCGUGACGCC 22 10172
HSV2-UL19-5790 - GUCCGGUGGCGUUUCGUGACGCC 23 10173
HSV2-UL19-5791 - UGUCCGGUGGCGUUUCGUGACGCC 24 10174
HSV2-UL19-5792 - AGCUCCAGGUGGCCCGCC 18 10175
HSV2-UL19-5793 - CAGCUCCAGGUGGCCCGCC 19 10176
HSV2-UL19-2182 - CCAGCUCCAGGUGGCCCGCC 20 2470
HSV2-UL19-5794 - GCCAGCUCCAGGUGGCCCGCC 21 10177
HSV2-UL19-5795 - GGCCAGCUCCAGGUGGCCCGCC 22 10178
HSV2-UL19-5796 - GGGCCAGCUCCAGGUGGCCCGCC 23 10179
HSV2-UL19-5797 - UGGGCCAGCUCCAGGUGGCCCGCC 24 10180
HSV2-UL19-5798 - UACCCCCUGGUGGGCGCC 18 10181
HSV2-UL19-5799 - CUACCCCCUGGUGGGCGCC 19 10182
HSV2-UL19-2051 - CCUACCCCCUGGUGGGCGCC 20 2385
HSV2-UL19-5800 - CCCUACCCCCUGGUGGGCGCC 21 10183
HSV2-UL19-5801 - GCCCUACCCCCUGGUGGGCGCC 22 10184
HSV2-UL19-5802 - UGCCCUACCCCCUGGUGGGCGCC 23 10185
HSV2-UL19-5803 - GUGCCCUACCCCCUGGUGGGCGCC 24 10186
HSV2-UL19-5804 - GCAAGGCGGGCCAUCGCC 18 10187
HSV2-UL19-5805 - GGCAAGGCGGGCCAUCGCC 19 10188
HSV2-UL19-2011 - GGGCAAGGCGGGCCAUCGCC 20 2355
HSV2-UL19-5806 - UGGGCAAGGCGGGCCAUCGCC 21 10189
HSV2-UL19-5807 - CUGGGCAAGGCGGGCCAUCGCC 22 10190
HSV2-UL19-5808 - CCUGGGCAAGGCGGGCCAUCGCC 23 10191
HSV2-UL19-5809 - UCCUGGGCAAGGCGGGCCAUCGCC 24 10192
HSV2-UL19-5810 - CUGGUCUUCCUGGAGGCC 18 10193
HSV2-UL19-5811 - GCUGGUCUUCCUGGAGGCC 19 10194
HSV2-UL19-2047 - GGCUGGUCUUCCUGGAGGCC 20 2382
HSV2-UL19-5812 - AGGCUGGUCUUCCUGGAGGCC 21 10195
HSV2-UL19-5813 - CAGGCUGGUCUUCCUGGAGGCC 22 10196
HSV2-UL19-5814 - ACAGGCUGGUCUUCCUGGAGGCC 23 10197
HSV2-UL19-5815 - GACAGGCUGGUCUUCCUGGAGGCC 24 10198
HSV2-UL19-5816 - GGGCUGUUCAACCCGGCC 18 10199
HSV2-UL19-5817 - GGGGCUGUUCAACCCGGCC 19 10200 HSV2-UL19-2054 - UGGGGCUGUUCAACCCGGCC 20 2387
HSV2-UL19-5818 - CUGGGGCUGUUCAACCCGGCC 21 10201
HSV2-UL19-5819 - CCUGGGGCUGU UCAACCCGGCC 22 10202
HSV2-UL19-5820 - CCCUGGGGCUGUUCAACCCGGCC 23 10203
HSV2-UL19-5821 - CCCCUGGGGCUGUUCAACCCGGCC 24 10204
HSV2-UL19-5822 - CCCCUGGUCCCCCCGGCC 18 10205
HSV2-UL19-5823 - CCCCCUGGUCCCCCCGGCC 19 10206
HSV2-UL19-2158 - UCCCCCUGGUCCCCCCGGCC 20 2454
HSV2-UL19-5824 - GUCCCCCUGGUCCCCCCGGCC 21 10207
HSV2-UL19-5825 - CGUCCCCCUGGUCCCCCCGGCC 22 10208
HSV2-UL19-5826 - ACGUCCCCCUGGUCCCCCCGGCC 23 10209
HSV2-UL19-5827 - GACGUCCCCCUGGUCCCCCCGGCC 24 10210
HSV2-UL19-5828 - CUUAUGCGACACGCGGCC 18 10211
HSV2-UL19-5829 - CCUUAUGCGACACGCGGCC 19 10212
HSV2-UL19-2126 - GCCUUAUGCGACACGCGGCC 20 2433
HSV2-UL19-5830 - GGCCUUAUGCGACACGCGGCC 21 10213
HSV2-UL19-5831 - CGGCCUUAUGCGACACGCGGCC 22 10214
HSV2-UL19-5832 - ACGGCCUUAUGCGACACGCGGCC 23 10215
HSV2-UL19-5833 - GACGGCCUUAUGCGACACGCGGCC 24 10216
HSV2-UL19-5834 - UACACCGCCGUCGCGGCC 18 10217
HSV2-UL19-5835 - CUACACCGCCGUCGCGGCC 19 10218
HSV2-UL19-2194 - GCUACACCGCCGUCGCGGCC 20 2477
HSV2-UL19-5836 - GGCUACACCGCCGUCGCGGCC 21 10219
HSV2-UL19-5837 - GGGCUACACCGCCGUCGCGGCC 22 10220
HSV2-UL19-5838 - UGGGCUACACCGCCGUCGCGGCC 23 10221
HSV2-UL19-5839 - GUGGGCUACACCGCCGUCGCGGCC 24 10222
HSV2-UL19-5840 - AAAACU U U UACCUCGGCC 18 10223
HSV2-UL19-5841 - CAAAACUUUUACCUCGGCC 19 10224
HSV2-UL19-2197 - CCAAAACUUUUACCUCGGCC 20 2480
HSV2-UL19-5842 - CCCAAAACUUUUACCUCGGCC 21 10225
HSV2-UL19-5843 - CCCCAAAACU U U UACCUCGGCC 22 10226
HSV2-UL19-5844 - CCCCCAAAACU U U U ACCU CG GCC 23 10227
HSV2-UL19-5845 - U CCCCCAAAACU U U U ACCUCG GCC 24 10228
HSV2-UL19-5846 - ACUUUACCCUGCCGGGCC 18 10229
HSV2-UL19-5847 - GACUU UACCCUGCCGGGCC 19 10230
HSV2-UL19-519 - CGACUUUACCCUGCCGGGCC 20 759
HSV2-UL19-5848 - ACGACUU UACCCUGCCGGGCC 21 10231
HSV2-UL19-5849 - GACGACUUUACCCUGCCGGGCC 22 10232
HSV2-UL19-5850 - GGACGACU UUACCCUGCCGGGCC 23 10233
HSV2-UL19-5851 - UGGACGACUUUACCCUGCCGGGCC 24 10234
HSV2-UL19-5852 - UUCGUGACGCCCGGGGCC 18 10235
HSV2-UL19-5853 - UUUCGUGACGCCCGGGGCC 19 10236
HSV2-UL19-486 - GUUUCGUGACGCCCGGGGCC 20 726
HSV2-UL19-5854 - CGUUUCGUGACGCCCGGGGCC 21 10237
HSV2-UL19-5855 - GCGUUUCGUGACGCCCGGGGCC 22 10238
HSV2-UL19-5856 - GGCGUUUCGUGACGCCCGGGGCC 23 10239 HSV2-UL19-5857 - UGGCGUUUCGUGACGCCCGGGGCC 24 10240
HSV2-UL19-5858 - AUCGCCACCCCCGUGGCC 18 10241
HSV2-UL19-5859 - CAUCGCCACCCCCGUGGCC 19 10242
HSV2-UL19-2208 - UCAUCGCCACCCCCGUGGCC 20 2487
HSV2-UL19-5860 - UUCAUCGCCACCCCCGUGGCC 21 10243
HSV2-UL19-5861 - GUUCAUCGCCACCCCCGUGGCC 22 10244
HSV2-UL19-5862 - AGUUCAUCGCCACCCCCGUGGCC 23 10245
HSV2-UL19-5863 - GAGU UCAUCGCCACCCCCGUGGCC 24 10246
HSV2-UL19-5864 - CGGCCAAACAUCGCUGCC 18 10247
HSV2-UL19-5865 - ACGGCCAAACAUCGCUGCC 19 10248
HSV2-UL19-704 - CACGGCCAAACAUCGCUGCC 20 944
HSV2-UL19-5866 - UCACGGCCAAACAUCGCUGCC 21 10249
HSV2-UL19-5867 - AUCACGGCCAAACAUCGCUGCC 22 10250
HSV2-UL19-5868 - CAUCACGGCCAAACAUCGCUGCC 23 10251
HSV2-UL19-5869 - ACAUCACGGCCAAACAUCGCUGCC 24 10252
HSV2-UL19-5870 - AGCGCCCGCCGGGGUGCC 18 10253
HSV2-UL19-5871 - AAGCGCCCGCCGGGGUGCC 19 10254
HSV2-UL19-2239 - UAAGCGCCCGCCGGGGUGCC 20 2501
HSV2-UL19-5872 - UUAAGCGCCCGCCGGGGUGCC 21 10255
HSV2-UL19-5873 - UU UAAGCGCCCGCCGGGGUGCC 22 10256
HSV2-UL19-5874 - GUUUAAGCGCCCGCCGGGGUGCC 23 10257
HSV2-UL19-5875 - AGUUUAAGCGCCCGCCGGGGUGCC 24 10258
HSV2-UL19-5876 - ACCUCGGGGGCGACCUCC 18 10259
HSV2-UL19-5877 - UACCUCGGGGGCGACCUCC 19 10260
HSV2-UL19-2110 - CUACCUCGGGGGCGACCUCC 20 2421
HSV2-UL19-5878 - CCUACCUCGGGGGCGACCUCC 21 10261
HSV2-UL19-5879 - ACCUACCUCGGGGGCGACCUCC 22 10262
HSV2-UL19-5880 - GACCUACCUCGGGGGCGACCUCC 23 10263
HSV2-UL19-5881 - UGACCUACCUCGGGGGCGACCUCC 24 10264
HSV2-UL19-5882 - CUACCAUAGCCGCCGUCC 18 10265
HSV2-UL19-5883 - GCUACCAUAGCCGCCGUCC 19 10266
HSV2-UL19-2099 - GGCUACCAUAGCCGCCGUCC 20 2414
HSV2-UL19-5884 - CGGCUACCAUAGCCGCCGUCC 21 10267
HSV2-UL19-5885 - CCGGCUACCAUAGCCGCCGUCC 22 10268
HSV2-UL19-5886 - GCCGGCUACCAUAGCCGCCGUCC 23 10269
HSV2-UL19-5887 - CGCCGGCUACCAUAGCCGCCGUCC 24 10270
HSV2-UL19-3494 - GCAACGUCCAGGCCGUCC 18 7877
HSV2-UL19-3495 - CGCAACGUCCAGGCCGUCC 19 7878
HSV2-UL19-3092 - GCGCAACGUCCAGGCCGUCC 20 7475
HSV2-UL19-3496 - CGCGCAACGUCCAGGCCGUCC 21 7879
HSV2-UL19-3497 - GCGCGCAACGUCCAGGCCGUCC 22 7880
HSV2-UL19-3498 - CGCGCGCAACGUCCAGGCCGUCC 23 7881
HSV2-UL19-3499 - UCGCGCGCAACGUCCAGGCCGUCC 24 7882
HSV2-UL19-5888 - AGUCCCCCCGGCCGGUCC 18 10271
HSV2-UL19-5889 - AAGUCCCCCCGGCCGGUCC 19 10272
HSV2-UL19-473 - GAAGUCCCCCCGGCCGGUCC 20 713 HSV2-UL19-5890 - CGAAGU CCCCCCGGCCGG UCC 21 10273
HSV2-UL19-5891 - GCGAAGUCCCCCCGGCCGGUCC 22 10274
HSV2-UL19-5892 - GGCGAAGUCCCCCCGGCCGGUCC 23 10275
HSV2-UL19-5893 - CGGCGAAGUCCCCCCGGCCGGUCC 24 10276
HSV2-UL19-5894 - UGCAGAACAUGGUGGUCC 18 10277
HSV2-UL19-5895 - CUGCAGAACAUGGUGGUCC 19 10278
HSV2-UL19-563 - GCUGCAGAACAUGGUGGUCC 20 803
HSV2-UL19-5896 - CGCUGCAGAACAUGGUGGUCC 21 10279
HSV2-UL19-5897 - ACGCUGCAGAACAUGGUGGUCC 22 10280
HSV2-UL19-5898 - CACGCUGCAGAACAUGGUGGUCC 23 10281
HSV2-UL19-5899 - CCACGCUGCAGAACAUGGUGGUCC 24 10282
HSV2-UL19-5900 - CAGGUUCUGCGGCUGUCC 18 10283
HSV2-UL19-5901 - CCAGGUUCUGCGGCUGUCC 19 10284
HSV2-UL19-2066 - ACCAGGUUCUGCGGCUGUCC 20 2392
HSV2-UL19-5902 - CACCAGGUUCUGCGGCUGUCC 21 10285
HSV2-UL19-5903 - CCACCAGGUUCUGCGGCUGUCC 22 10286
HSV2-UL19-5904 - ACCACCAGGUUCUGCGGCUGUCC 23 10287
HSV2-UL19-5905 - GACCACCAGGUUCUGCGGCUGUCC 24 10288
HSV2-UL19-5906 - GCGACAGGCUGGUCUUCC 18 10289
HSV2-UL19-5907 - GGCGACAGGCUGGUCUUCC 19 10290
HSV2-UL19-411 - AGGCGACAGGCUGGUCUUCC 20 651
HSV2-UL19-5908 - UAGGCGACAGGCUGGUCUUCC 21 10291
HSV2-UL19-5909 - AUAGGCGACAGGCUGGUCUUCC 22 10292
HSV2-UL19-5910 - CAUAGGCGACAGGCUGGUCUUCC 23 10293
HSV2-UL19-5911 - CCAUAGGCGACAGGCUGGUCUUCC 24 10294
HSV2-UL19-5912 - GGCAAGGCCGUGCGGAGC 18 10295
HSV2-UL19-5913 - GGGCAAGGCCGUGCGGAGC 19 10296
HSV2-UL19-2029 - UGGGCAAGGCCGUGCGGAGC 20 2369
HSV2-UL19-5914 - AUGGGCAAGGCCGUGCGGAGC 21 10297
HSV2-UL19-5915 - GAUGGGCAAGGCCGUGCGGAGC 22 10298
HSV2-UL19-5916 - UGAUGGGCAAGGCCGUGCGGAGC 23 10299
HSV2-UL19-5917 - GUGAUGGGCAAGGCCGUGCGGAGC 24 10300
HSV2-UL19-5918 - UGACGCACGCCGACACGC 18 10301
HSV2-UL19-5919 - CUGACGCACGCCGACACGC 19 10302
HSV2-UL19-2014 - CCUGACGCACGCCGACACGC 20 2358
HSV2-UL19-5920 - GCCUGACGCACGCCGACACGC 21 10303
HSV2-UL19-5921 - CGCCUGACGCACGCCGACACGC 22 10304
HSV2-UL19-5922 - CCGCCUGACGCACGCCGACACGC 23 10305
HSV2-UL19-5923 - CCCGCCU G ACG CACG CCG ACACGC 24 10306
HSV2-UL19-5924 - CGAUGGGGAGGCCCACGC 18 10307
HSV2-UL19-5925 - GCGAUGGGGAGGCCCACGC 19 10308
HSV2-UL19-2248 - CGCGAUGGGGAGGCCCACGC 20 2505
HSV2-UL19-5926 - CCGCGAUGGGGAGGCCCACGC 21 10309
HSV2-UL19-5927 - CCCGCGAUGGGGAGGCCCACGC 22 10310
HSV2-UL19-5928 - GCCCGCGAUGGGGAGGCCCACGC 23 10311
HSV2-UL19-5929 - CGCCCGCGAUGGGGAGGCCCACGC 24 10312 HSV2-UL19-5930 - GCGCUUCGCCGCGCACGC 18 10313
HSV2-UL19-5931 - AGCGCUUCGCCGCGCACGC 19 10314
HSV2-UL19-423 - GAGCGCUUCGCCGCGCACGC 20 663
HSV2-UL19-5932 - GGAGCGCUUCGCCGCGCACGC 21 10315
HSV2-UL19-5933 - UGGAGCGCUUCGCCGCGCACGC 22 10316
HSV2-UL19-5934 - AUGGAGCGCUUCGCCGCGCACGC 23 10317
HSV2-UL19-5935 - CAUGGAGCGCUUCGCCGCGCACGC 24 10318
HSV2-UL19-5936 - GGUGGCGUUUCGUGACGC 18 10319
HSV2-UL19-5937 - CGGUGGCGUUUCGUGACGC 19 10320
HSV2-UL19-2095 - CCGGUGGCGUUUCGUGACGC 20 2412
HSV2-UL19-5938 - UCCGGUGGCGUUUCGUGACGC 21 10321
HSV2-UL19-5939 - GUCCGGUGGCGUUUCGUGACGC 22 10322
HSV2-UL19-5940 - UGUCCGGUGGCGUUUCGUGACGC 23 10323
HSV2-UL19-5941 - GUGUCCGGUGGCGUUUCGUGACGC 24 10324
HSV2-UL19-5942 - AGACUGCCGGAUUGACGC 18 10325
HSV2-UL19-5943 - GAGACUGCCGGAUUGACGC 19 10326
HSV2-UL19-534 - CGAGACUGCCGGAUUGACGC 20 774
HSV2-UL19-5944 - CCG AGACUGCCGGAUUGACGC 21 10327
HSV2-UL19-5945 - ACCGAGACUGCCGGAUUGACGC 22 10328
HSV2-UL19-5946 - CACCGAGACUGCCGGAUUGACGC 23 10329
HSV2-UL19-5947 - CCACCGAGACUGCCGGAUUGACGC 24 10330
HSV2-UL19-5948 - GGCCGGCGGCGUGUACGC 18 10331
HSV2-UL19-5949 - CGGCCGGCGGCGUGUACGC 19 10332
HSV2-UL19-677 - GCGGCCGGCGGCGUGUACGC 20 917
HSV2-UL19-5950 - CGCGGCCGGCGGCGUGUACGC 21 10333
HSV2-UL19-5951 - GCGCGGCCGGCGGCGUGUACGC 22 10334
HSV2-UL19-5952 - CGCGCGGCCGGCGGCGUGUACGC 23 10335
HSV2-UL19-5953 - ACGCGCGGCCGGCGGCGUGUACGC 24 10336
HSV2-UL19-5954 - GCCGGCCCUGCAACCCGC 18 10337
HSV2-UL19-5955 - CGCCGGCCCUGCAACCCGC 19 10338
HSV2-UL19-671 - UCGCCGGCCCUGCAACCCGC 20 911
HSV2-UL19-5956 - UUCGCCGGCCCUGCAACCCGC 21 10339
HSV2-UL19-5957 - UUUCGCCGGCCCUGCAACCCGC 22 10340
HSV2-UL19-5958 - CUUUCGCCGGCCCUGCAACCCGC 23 10341
HSV2-UL19-5959 - ACUUUCGCCGGCCCUGCAACCCGC 24 10342
HSV2-UL19-5960 - GUGGUGCAGCACGCCCGC 18 10343
HSV2-UL19-5961 - CGUGGUGCAGCACGCCCGC 19 10344
HSV2-UL19-2162 - CCGUGGUGCAGCACGCCCGC 20 2456
HSV2-UL19-5962 - CCCGUGGUGCAGCACGCCCGC 21 10345
HSV2-UL19-5963 - GCCCGUGGUGCAGCACGCCCGC 22 10346
HSV2-UL19-5964 - AGCCCGUGGUGCAGCACGCCCGC 23 10347
HSV2-UL19-5965 - CAGCCCGUGGUGCAGCACGCCCGC 24 10348
HSV2-UL19-5966 - UCACGCUCACCCAGCCGC 18 10349
HSV2-UL19-5967 - U U CACG CU CACCCAG CCGC 19 10350
HSV2-UL19-2189 - CUUCACGCUCACCCAGCCGC 20 2473
HSV2-UL19-5968 - ACU U CACG CU CACCCAG CCG C 21 10351 HSV2-UL19-5969 - AACU UCACGCUCACCCAGCCGC 22 10352
HSV2-UL19-5970 - CAACUUCACGCUCACCCAGCCGC 23 10353
HSV2-UL19-5971 - UCAACUUCACGCUCACCCAGCCGC 24 10354
HSV2-UL19-5972 - AUGGGGAGGCCCACGCGC 18 10355
HSV2-UL19-5973 - GAUGGGGAGGCCCACGCGC 19 10356
HSV2-UL19-2249 - CGAUGGGGAGGCCCACGCGC 20 2506
HSV2-UL19-5974 - GCG AUGGGGAGGCCCACGCGC 21 10357
HSV2-UL19-5975 - CGCGAUGGGGAGGCCCACGCGC 22 10358
HSV2-UL19-5976 - CCGCG AUGGGGAGGCCCACGCGC 23 10359
HSV2-UL19-5977 - CCCGCGAUGGGGAGGCCCACGCGC 24 10360
HSV2-UL19-5978 - UGGUGCCGGCCU UCUCGC 18 10361
HSV2-UL19-5979 - CUGGUGCCGGCCUUCUCGC 19 10362
HSV2-UL19-554 - GCUGGUGCCGGCCUUCUCGC 20 794
HSV2-UL19-5980 - UGCUGGUGCCGGCCUUCUCGC 21 10363
HSV2-UL19-5981 - GUGCUGGUGCCGGCCUUCUCGC 22 10364
HSV2-UL19-5982 - CGUGCUGGUGCCGGCCU UCUCGC 23 10365
HSV2-UL19-5983 - ACGUGCUGGUGCCGGCCUUCUCGC 24 10366
HSV2-UL19-5984 - CUCAUGUACGACCACGGC 18 10367
HSV2-UL19-5985 - CCUCAUGUACGACCACGGC 19 10368
HSV2-UL19-2222 - CCCUCAUGUACGACCACGGC 20 2492
HSV2-UL19-5986 - GCCCUCAUGUACGACCACGGC 21 10369
HSV2-UL19-5987 - AGCCCUCAUGUACGACCACGGC 22 10370
HSV2-UL19-5988 - UAGCCCUCAUGUACGACCACGGC 23 10371
HSV2-UL19-5989 - AUAGCCCUCAUGUACGACCACGGC 24 10372
HSV2-UL19-5990 - UCGUGGCGGGAAACCGGC 18 10373
HSV2-UL19-5991 - GUCGUGGCGGGAAACCGGC 19 10374
HSV2-UL19-654 - GGUCGUGGCGGGAAACCGGC 20 894
HSV2-UL19-5992 - CGGUCGUGGCGGGAAACCGGC 21 10375
HSV2-UL19-5993 - GCGG UCGUGGCGGGAAACCGGC 22 10376
HSV2-UL19-5994 - CGCGG UCGUGGCGGGAAACCGGC 23 10377
HSV2-UL19-5995 - ACGCGGUCGUGGCGGGAAACCGGC 24 10378
HSV2-UL19-5996 - GCCCCGGCCGGCCCCGGC 18 10379
HSV2-UL19-5997 - GGCCCCGGCCGGCCCCGGC 19 10380
HSV2-UL19-2080 - CGGCCCCGGCCGGCCCCGGC 20 2401
HSV2-UL19-5998 - GCGGCCCCGGCCGGCCCCGGC 21 10381
HSV2-UL19-5999 - CGCGGCCCCGGCCGGCCCCGGC 22 10382
HSV2-UL19-6000 - UCGCGGCCCCGGCCGGCCCCGGC 23 10383
HSV2-UL19-6001 - GUCGCGGCCCCGGCCGGCCCCGGC 24 10384
HSV2-UL19-6002 - GUGCCGCGGCGCGCCGGC 18 10385
HSV2-UL19-6003 - GGUGCCGCGGCGCGCCGGC 19 10386
HSV2-UL19-2204 - AGGUGCCGCGGCGCGCCGGC 20 2483
HSV2-UL19-6004 - CAGGUGCCGCGGCGCGCCGGC 21 10387
HSV2-UL19-6005 - CCAGGUGCCGCGGCGCGCCGGC 22 10388
HSV2-UL19-6006 - CCCAGGUGCCGCGGCGCGCCGGC 23 10389
HSV2-UL19-6007 - GCCCAGGUGCCGCGGCGCGCCGGC 24 10390
HSV2-UL19-6008 - CGCCCGCGAGAGCGCGGC 18 10391 HSV2-UL19-6009 - ACGCCCGCGAGAGCGCGGC 19 10392
HSV2-UL19-602 - CACGCCCGCGAGAGCGCGGC 20 842
HSV2-UL19-6010 - GCACGCCCGCGAGAGCGCGGC 21 10393
HSV2-UL19-6011 - AGCACGCCCGCGAGAGCGCGGC 22 10394
HSV2-UL19-6012 - CAGCACGCCCGCGAGAGCGCGGC 23 10395
HSV2-UL19-6013 - GCAGCACGCCCGCGAGAGCGCGGC 24 10396
HSV2-UL19-6014 - GCCCGCCACGAAACGGGC 18 10397
HSV2-UL19-6015 - GGCCCGCCACGAAACGGGC 19 10398
HSV2-UL19-627 - UGGCCCGCCACGAAACGGGC 20 867
HSV2-UL19-6016 - GUGGCCCGCCACGAAACGGGC 21 10399
HSV2-UL19-6017 - GGUGGCCCGCCACGAAACGGGC 22 10400
HSV2-UL19-6018 - AGG UGGCCCGCCACGAAACGGGC 23 10401
HSV2-UL19-6019 - CAGGUGGCCCGCCACGAAACGGGC 24 10402
HSV2-UL19-6020 - GACUUUACCCUGCCGGGC 18 10403
HSV2-UL19-6021 - CGACUU UACCCUGCCGGGC 19 10404
HSV2-UL19-2118 - ACGACUUUACCCUGCCGGGC 20 2427
HSV2-UL19-6022 - GACGACUUUACCCUGCCGGGC 21 10405
HSV2-UL19-6023 - GGACGACUUUACCCUGCCGGGC 22 10406
HSV2-UL19-6024 - UGGACGACUUUACCCUGCCGGGC 23 10407
HSV2-UL19-6025 - GUGGACGACUUUACCCUGCCGGGC 24 10408
HSV2-UL19-6026 - UU UCGUGACGCCCGGGGC 18 10409
HSV2-UL19-6027 - GUUUCGUGACGCCCGGGGC 19 10410
HSV2-UL19-2097 - CGUUUCGUGACGCCCGGGGC 20 2413
HSV2-UL19-6028 - GCGUU UCGUGACGCCCGGGGC 21 10411
HSV2-UL19-6029 - GGCGUUUCGUGACGCCCGGGGC 22 10412
HSV2-UL19-6030 - UGGCGU UUCGUGACGCCCGGGGC 23 10413
HSV2-UL19-6031 - GUGGCGUUUCGUGACGCCCGGGGC 24 10414
HSV2-UL19-6032 - GACGCGGCCGUCGGGGGC 18 10415
HSV2-UL19-6033 - CGACGCGGCCGUCGGGGGC 19 10416
HSV2-UL19-2075 - UCGACGCGGCCGUCGGGGGC 20 2397
HSV2-UL19-6034 - AUCGACGCGGCCGUCGGGGGC 21 10417
HSV2-UL19-6035 - CAUCGACGCGGCCGUCGGGGGC 22 10418
HSV2-UL19-6036 - ACAU CGACGCGGCCGUCGGGGGC 23 10419
HSV2-UL19-6037 - AACAUCGACGCGGCCGUCGGGGGC 24 10420
HSV2-UL19-6038 - GGAU UGACGCGGGGGGGC 18 10421
HSV2-UL19-6039 - CGGAUUGACGCGGGGGGGC 19 10422
HSV2-UL19-2134 - CCGGAUUGACGCGGGGGGGC 20 2437
HSV2-UL19-6040 - GCCGGAUUGACGCGGGGGGGC 21 10423
HSV2-UL19-6041 - UGCCGGAU UGACGCGGGGGGGC 22 10424
HSV2-UL19-6042 - CUGCCGGAUUGACGCGGGGGGGC 23 10425
HSV2-UL19-6043 - ACUGCCGGAU UGACGCGGGGGGGC 24 10426
HSV2-UL19-6044 - GCGCAACGCGGUCGUGGC 18 10427
HSV2-UL19-6045 - UGCGCAACGCGGUCGUGGC 19 10428
HSV2-UL19-652 - CUGCGCAACGCGGUCGUGGC 20 892
HSV2-UL19-6046 - CCUGCGCAACGCGGUCGUGGC 21 10429
HSV2-UL19-6047 - ACCUGCGCAACGCGGUCGUGGC 22 10430 HSV2-UL19-6048 - UACCUGCGCAACGCGGUCGUGGC 23 10431
HSV2-UL19-6049 - GUACCUGCGCAACGCGGUCGUGGC 24 10432
HSV2-UL19-6050 - GCCACCUGCUGGAUAUGC 18 10433
HSV2-UL19-6051 - CGCCACCUGCUGGAUAUGC 19 10434
HSV2-UL19-399 - CCGCCACCUGCUGGAUAUGC 20 639
HSV2-UL19-6052 - GCCGCCACCUGCUGGAUAUGC 21 10435
HSV2-UL19-6053 - GGCCGCCACCUGCUGGAUAUGC 22 10436
HSV2-UL19-6054 - GGGCCGCCACCUGCUGGAUAUGC 23 10437
HSV2-UL19-6055 - UGGGCCGCCACCUGCUGGAUAUGC 24 10438
HSV2-UL19-6056 - ACGGCCAAACAUCGCUGC 18 10439
HSV2-UL19-6057 - CACGGCCAAACAUCGCUGC 19 10440
HSV2-UL19-2231 - UCACGGCCAAACAUCGCUGC 20 2497
HSV2-UL19-6058 - AUCACGGCCAAACAUCGCUGC 21 10441
HSV2-UL19-6059 - CAUCACGGCCAAACAUCGCUGC 22 10442
HSV2-UL19-6060 - ACAUCACGGCCAAACAUCGCUGC 23 10443
HSV2-UL19-6061 - GACAUCACGGCCAAACAUCGCUGC 24 10444
HSV2-UL19-6062 - GCCCCCGGUGAGGAGUGC 18 10445
HSV2-UL19-6063 - CGCCCCCGGUGAGGAGUGC 19 10446
HSV2-UL19-2148 - UCGCCCCCGGUGAGGAGUGC 20 2445
HSV2-UL19-6064 - AUCGCCCCCGGUGAGGAGUGC 21 10447
HSV2-UL19-6065 - GAUCGCCCCCGGUGAGGAGUGC 22 10448
HSV2-UL19-6066 - AG AUCGCCCCCGGUGAGGAGUGC 23 10449
HSV2-UL19-6067 - GAGAUCGCCCCCGGUGAGGAGUGC 24 10450
HSV2-UL19-6068 - CCUGGCGACCAGGGU UGC 18 10451
HSV2-UL19-6069 - GCCUGGCGACCAGGGUUGC 19 10452
HSV2-UL19-2003 - CGCCUGGCGACCAGGGU UGC 20 2348
HSV2-UL19-6070 - GCGCCUGGCGACCAGGGUUGC 21 10453
HSV2-UL19-6071 - GGCGCCUGGCGACCAGGGUUGC 22 10454
HSV2-UL19-6072 - GGGCGCCUGGCGACCAGGGUUGC 23 10455
HSV2-UL19-6073 - CGGGCGCCUGGCGACCAGGGUUGC 24 10456
HSV2-UL19-6074 - UGCCUGGAGCGUCUCAUC 18 10457
HSV2-UL19-6075 - CUGCCUGGAGCGUCUCAUC 19 10458
HSV2-UL19-2233 - GCUGCCUGGAGCGUCUCAUC 20 2498
HSV2-UL19-6076 - CGCUGCCUGGAGCGUCUCAUC 21 10459
HSV2-UL19-6077 - UCGCUGCCUGGAGCGUCUCAUC 22 10460
HSV2-UL19-6078 - AUCGCUGCCUGGAGCGUCUCAUC 23 10461
HSV2-UL19-6079 - CAUCGCUGCCUGGAGCGUCUCAUC 24 10462
HSV2-UL19-6080 - UACAUCGUGACCUACCUC 18 10463
HSV2-UL19-6081 - GUACAUCGUGACCUACCUC 19 10464
HSV2-UL19-504 - CGUACAUCGUGACCUACCUC 20 744
HSV2-UL19-6082 - UCGUACAUCGUGACCUACCUC 21 10465
HSV2-UL19-6083 - CUCGUACAUCGUGACCUACCUC 22 10466
HSV2-UL19-6084 - UCUCGUACAUCGUGACCUACCUC 23 10467
HSV2-UL19-6085 - GUCUCGUACAUCGUGACCUACCUC 24 10468
HSV2-UL19-6086 - CCGGGGUGCCGCGAGCUC 18 10469
HSV2-UL19-6087 - GCCGGGGUGCCGCGAGCUC 19 10470 HSV2-UL19-2240 - CGCCGGGGUGCCGCGAGCUC 20 2502
HSV2-UL19-6088 - CCGCCGGGGUGCCGCGAGCUC 21 10471
HSV2-UL19-6089 - CCCGCCGGGGUGCCGCGAGCUC 22 10472
HSV2-UL19-6090 - GCCCGCCGGGGUGCCGCGAGCUC 23 10473
HSV2-UL19-6091 - CGCCCGCCGGGGUGCCGCGAGCUC 24 10474
HSV2-UL19-6092 - GUGUGUCAUCCUUCGCUC 18 10475
HSV2-UL19-6093 - CGUGUGUCAUCCUUCGCUC 19 10476
HSV2-UL19-2071 - CCGUGUGUCAUCCUUCGCUC 20 2395
HSV2-UL19-6094 - ACCGUGUGUCAUCCUUCGCUC 21 10477
HSV2-UL19-6095 - GACCGUGUGUCAUCCUUCGCUC 22 10478
HSV2-UL19-6096 - GGACCGUGUGUCAUCCUUCGCUC 23 10479
HSV2-UL19-6097 - GGGACCGUGUGUCAUCCUUCGCUC 24 10480
HSV2-UL19-6098 - ACAACGCCAACCUGGCUC 18 10481
HSV2-UL19-6099 - GACAACGCCAACCUGGCUC 19 10482
HSV2-UL19-464 - CGACAACGCCAACCUGGCUC 20 704
HSV2-UL19-6100 - CCGACAACGCCAACCUGGCUC 21 10483
HSV2-UL19-6101 - CCCGACAACGCCAACCUGGCUC 22 10484
HSV2-UL19-6102 - GCCCGACAACGCCAACCUGGCUC 23 10485
HSV2-UL19-6103 - AGCCCGACAACGCCAACCUGGCUC 24 10486
HSV2-UL19-6104 - GCCAUCGAGGCCUGGCUC 18 10487
HSV2-UL19-6105 - GGCCAUCGAGGCCUGGCUC 19 10488
HSV2-UL19-2013 - AGGCCAUCGAGGCCUGGCUC 20 2357
HSV2-UL19-6106 - GAGGCCAUCGAGGCCUGGCUC 21 10489
HSV2-UL19-6107 - CGAGGCCAUCGAGGCCUGGCUC 22 10490
HSV2-UL19-6108 - GCGAGGCCAUCGAGGCCUGGCUC 23 10491
HSV2-UL19-6109 - CGCGAGGCCAUCGAGGCCUGGCUC 24 10492
HSV2-UL19-6110 - GCUGGUGCCGGCCUUCUC 18 10493
HSV2-UL19-6111 - UGCUGGUGCCGGCCUUCUC 19 10494
HSV2-UL19-2136 - GUGCUGGUGCCGGCCUUCUC 20 2439
HSV2-UL19-6112 - CGUGCUGGUGCCGGCCU UCUC 21 10495
HSV2-UL19-6113 - ACGUGCUGGUGCCGGCCUUCUC 22 10496
HSV2-UL19-6114 - UACGUGCUGGUGCCGGCCUUCUC 23 10497
HSV2-UL19-6115 - UUACGUGCUGGUGCCGGCCUUCUC 24 10498
HSV2-UL19-3512 - CGCAACGUCCAGGCCGUC 18 7895
HSV2-UL19-3513 - GCGCAACGUCCAGGCCGUC 19 7896
HSV2-UL19-3514 - CGCGCAACGUCCAGGCCGUC 20 7897
HSV2-UL19-3515 - GCGCGCAACGUCCAGGCCGUC 21 7898
HSV2-UL19-3516 - CGCGCGCAACGUCCAGGCCGUC 22 7899
HSV2-UL19-3517 - UCGCGCGCAACGUCCAGGCCGUC 23 7900
HSV2-UL19-3518 - CUCGCGCGCAACGUCCAGGCCGUC 24 7901
HSV2-UL19-6116 - AACAUCGACGCGGCCGUC 18 10499
HSV2-UL19-6117 - GAACAUCGACGCGGCCGUC 19 10500
HSV2-UL19-442 - UGAACAUCGACGCGGCCGUC 20 682
HSV2-UL19-6118 - AUG AACAUCGACGCGGCCGUC 21 10501
HSV2-UL19-6119 - CAUGAACAUCGACGCGGCCGUC 22 10502
HSV2-UL19-6120 - UCAUGAACAUCGACGCGGCCGUC 23 10503 HSV2-UL19-6121 - CUCAUGAACAUCGACGCGGCCGUC 24 10504
HSV2-UL19-6122 - AAGUCCCCCCGGCCGGUC 18 10505
HSV2-UL19-6123 - GAAGUCCCCCCGGCCGGUC 19 10506
HSV2-UL19-472 - CGAAGUCCCCCCGGCCGGUC 20 712
HSV2-UL19-6124 - GCGAAGUCCCCCCGGCCGGUC 21 10507
HSV2-UL19-6125 - GGCGAAGUCCCCCCGGCCGGUC 22 10508
HSV2-UL19-6126 - CGGCGAAGUCCCCCCGGCCGGUC 23 10509
HSV2-UL19-6127 - GCGGCGAAGUCCCCCCGGCCGGUC 24 10510
HSV2-UL19-6128 - ACCUACGGCGAGAUGGUC 18 10511
HSV2-UL19-6129 - GACCUACGGCGAGAUGGUC 19 10512
HSV2-UL19-2023 - UG ACCUACGGCGAGAUGGUC 20 2365
HSV2-UL19-6130 - GUGACCUACGGCGAGAUGGUC 21 10513
HSV2-UL19-6131 - GGUG ACCUACGGCGAGAUGGUC 22 10514
HSV2-UL19-6132 - CGGUGACCUACGGCGAGAUGGUC 23 10515
HSV2-UL19-6133 - CCGGUGACCUACGGCGAGAUGGUC 24 10516
HSV2-UL19-6134 - CUGCAGAACAUGGUGGUC 18 10517
HSV2-UL19-6135 - GCUGCAGAACAUGGUGGUC 19 10518
HSV2-UL19-2143 - CGCUGCAGAACAUGGUGGUC 20 2442
HSV2-UL19-6136 - ACGCUGCAGAACAUGGUGGUC 21 10519
HSV2-UL19-6137 - CACGCUGCAGAACAUGGUGGUC 22 10520
HSV2-UL19-6138 - CCACGCUGCAGAACAUGGUGGUC 23 10521
HSV2-UL19-6139 - GCCACGCUGCAGAACAUGGUGGUC 24 10522
HSV2-UL19-6140 - CGCCUCCUGCAGUCCUUC 18 10523
HSV2-UL19-6141 - GCGCCUCCUGCAGUCCUUC 19 10524
HSV2-UL19-2017 - AGCGCCUCCUGCAGUCCUUC 20 2360
HSV2-UL19-6142 - CAGCGCCUCCUGCAGUCCUUC 21 10525
HSV2-UL19-6143 - ACAGCGCCUCCUGCAGUCCU UC 22 10526
HSV2-UL19-6144 - AACAGCGCCUCCUGCAGUCCUUC 23 10527
HSV2-UL19-6145 - AAACAGCGCCUCCUGCAGUCCUUC 24 10528
HSV2-UL19-6146 - GGCGACAGGCUGGUCUUC 18 10529
HSV2-UL19-6147 - AGGCGACAGGCUGGUCUUC 19 10530
HSV2-UL19-2045 - UAGGCGACAGGCUGGUCUUC 20 2381
HSV2-UL19-6148 - AUAGGCGACAGGCUGGUCUUC 21 10531
HSV2-UL19-6149 - CAUAGGCGACAGGCUGGUCUUC 22 10532
HSV2-UL19-6150 - CCAUAGGCGACAGGCUGGUCUUC 23 10533
HSV2-UL19-6151 - GCCAUAGGCGACAGGCUGGUCUUC 24 10534
HSV2-UL19-6152 - CCCGCGUUCGACUUCU UC 18 10535
HSV2-UL19-6153 - CCCCGCGUUCGACUUCUUC 19 10536
HSV2-UL19-2089 - ACCCCGCGUUCGACUUCUUC 20 2408
HSV2-UL19-6154 - CACCCCGCGUUCGACUUCUUC 21 10537
HSV2-UL19-6155 - GCACCCCGCGUUCGACUUCUUC 22 10538
HSV2-UL19-6156 - UGCACCCCGCGUUCGACUUCUUC 23 10539
HSV2-UL19-6157 - CUGCACCCCGCGUUCGACUUCUUC 24 10540
HSV2-UL19-6158 - UGCGACACGAGCUUCUUC 18 10541
HSV2-UL19-6159 - UUGCGACACGAGCUUCUUC 19 10542
HSV2-UL19-2009 - UU UGCGACACGAGCUUCUUC 20 2353 HSV2-UL19-6160 - UUUUGCGACACGAGCUUCUUC 21 10543
HSV2-UL19-6161 - CUUU UGCGACACGAGCUUCUUC 22 10544
HSV2-UL19-6162 - GCUUUUGCGACACGAGCUUCUUC 23 10545
HSV2-UL19-6163 - AGCUUUUGCGACACGAGCUUCUUC 24 10546
HSV2-UL19-6164 - ACGCGAUGCGCGGCGUUC 18 10547
HSV2-UL19-6165 - CACGCGAUGCGCGGCGUUC 19 10548
HSV2-UL19-2106 - ACACGCGAUGCGCGGCGUUC 20 2419
HSV2-UL19-6166 - AACACGCGAUGCGCGGCGUUC 21 10549
HSV2-UL19-6167 - CAACACGCGAUGCGCGGCGUUC 22 10550
HSV2-UL19-6168 - ACAACACGCGAUGCGCGGCGUUC 23 10551
HSV2-UL19-6169 - AACAACACGCGAUGCGCGGCGUUC 24 10552
HSV2-UL19-6170 - GCCGUCCGCGGGGCGUUC 18 10553
HSV2-UL19-6171 - CGCCGUCCGCGGGGCGUUC 19 10554
HSV2-UL19-2102 - CCGCCGUCCGCGGGGCGUUC 20 2416
HSV2-UL19-6172 - GCCGCCGUCCGCGGGGCGUUC 21 10555
HSV2-UL19-6173 - AGCCGCCGUCCGCGGGGCGUUC 22 10556
HSV2-UL19-6174 - UAGCCGCCGUCCGCGGGGCGUUC 23 10557
HSV2-UL19-6175 - AUAGCCGCCGUCCGCGGGGCGUUC 24 10558
HSV2-UL19-6176 - ACCCGUGCGGCCUGUU UC 18 10559
HSV2-UL19-6177 - GACCCGUGCGGCCUGUUUC 19 10560
HSV2-UL19-716 - AGACCCGUGCGGCCUGU UUC 20 956
HSV2-UL19-6178 - AAGACCCGUGCGGCCUGUUUC 21 10561
HSV2-UL19-6179 - GAAGACCCGUGCGGCCUGUUUC 22 10562
HSV2-UL19-6180 - GGAAGACCCGUGCGGCCUGUUUC 23 10563
HSV2-UL19-6181 - UGGAAGACCCGUGCGGCCUGUUUC 24 10564
HSV2-UL19-6182 - GUGUACGCGGGGGACAAG 18 10565
HSV2-UL19-6183 - CGUGUACGCGGGGGACAAG 19 10566
HSV2-UL19-2218 - GCGUGUACGCGGGGGACAAG 20 2491
HSV2-UL19-6184 - GGCGUGUACGCGGGGGACAAG 21 10567
HSV2-UL19-6185 - CGGCGUGUACGCGGGGGACAAG 22 10568
HSV2-UL19-6186 - GCGGCGUGUACGCGGGGGACAAG 23 10569
HSV2-UL19-6187 - GGCGGCGUGUACGCGGGGGACAAG 24 10570
HSV2-UL19-6188 - AGCUUCUUCCUGGGCAAG 18 10571
HSV2-UL19-6189 - GAGCUUCUUCCUGGGCAAG 19 10572
HSV2-UL19-2010 - CGAGCUUCUUCCUGGGCAAG 20 2354
HSV2-UL19-6190 - ACGAGCUUCUUCCUGGGCAAG 21 10573
HSV2-UL19-6191 - CACGAGCUUCUUCCUGGGCAAG 22 10574
HSV2-UL19-6192 - ACACGAGCUUCUUCCUGGGCAAG 23 10575
HSV2-UL19-6193 - GACACGAGCU UCUUCCUGGGCAAG 24 10576
HSV2-UL19-6194 - CUGUAUCACCAGCUCAAG 18 10577
HSV2-UL19-6195 - CCUGUAUCACCAGCUCAAG 19 10578
HSV2-UL19-2172 - CCCUGUAUCACCAGCUCAAG 20 2461
HSV2-UL19-6196 - GCCCUGUAUCACCAGCUCAAG 21 10579
HSV2-UL19-6197 - GGCCCUGUAUCACCAGCUCAAG 22 10580
HSV2-UL19-6198 - UGGCCCUGUAUCACCAGCUCAAG 23 10581
HSV2-UL19-6199 - GUGGCCCUGUAUCACCAGCUCAAG 24 10582 HSV2-UL19-6200 - AUGGCGGGGUACUUCAAG 18 10583
HSV2-UL19-6201 - CAUGGCGGGGUACUUCAAG 19 10584
HSV2-UL19-2171 - UCAUGGCGGGGUACUUCAAG 20 2460
HSV2-UL19-6202 - CUCAUGGCGGGGUACUUCAAG 21 10585
HSV2-UL19-6203 - GCUCAUGGCGGGGUACUUCAAG 22 10586
HSV2-UL19-6204 - CGCUCAUGGCGGGGUACUUCAAG 23 10587
HSV2-UL19-6205 - GCGCUCAUGGCGGGGUACUUCAAG 24 10588
HSV2-UL19-6206 - CUGCAGUCCUUCCUGAAG 18 10589
HSV2-UL19-6207 - CCUGCAGUCCUUCCUGAAG 19 10590
HSV2-UL19-2018 - UCCUGCAGUCCUUCCUGAAG 20 2361
HSV2-UL19-6208 - CUCCUGCAGUCCUUCCUGAAG 21 10591
HSV2-UL19-6209 - CCUCCUGCAGUCCUUCCUGAAG 22 10592
HSV2-UL19-6210 - GCCUCCUGCAGUCCUUCCUGAAG 23 10593
HSV2-UL19-6211 - CGCCUCCUGCAGUCCUUCCUGAAG 24 10594
HSV2-UL19-6212 - CUGGUCGCCGAGCUGAAG 18 10595
HSV2-UL19-6213 - CCUGGUCGCCGAGCUGAAG 19 10596
HSV2-UL19-359 - CCCUGGUCGCCGAGCUGAAG 20 599
HSV2-UL19-6214 - ACCCUGGUCGCCGAGCUGAAG 21 10597
HSV2-UL19-6215 - GACCCUGGUCGCCGAGCUGAAG 22 10598
HSV2-UL19-6216 - CG ACCCUGGUCGCCGAGCUGAAG 23 10599
HSV2-UL19-6217 - GCGACCCUGGUCGCCGAGCUGAAG 24 10600
HSV2-UL19-6218 - CACCUGCUGGAUAUGCAG 18 10601
HSV2-UL19-6219 - CCACCUGCUGGAUAUGCAG 19 10602
HSV2-UL19-2034 - GCCACCUGCUGGAUAUGCAG 20 2373
HSV2-UL19-6220 - CGCCACCUGCUGGAUAUGCAG 21 10603
HSV2-UL19-6221 - CCGCCACCUGCUGGAUAUGCAG 22 10604
HSV2-UL19-6222 - GCCGCCACCUGCUGGAUAUGCAG 23 10605
HSV2-UL19-6223 - GGCCGCCACCUGCUGGAUAUGCAG 24 10606
HSV2-UL19-6224 - GCGACCCUGGUCGCCGAG 18 10607
HSV2-UL19-6225 - GGCGACCCUGGUCGCCGAG 19 10608
HSV2-UL19-2005 - GGGCGACCCUGGUCGCCGAG 20 2350
HSV2-UL19-6226 - CGGGCGACCCUGGUCGCCGAG 21 10609
HSV2-UL19-6227 - CCGGGCGACCCUGGUCGCCGAG 22 10610
HSV2-UL19-6228 - CCCGGGCGACCCUGGUCGCCGAG 23 10611
HSV2-UL19-6229 - GCCCGGGCGACCCUGGUCGCCGAG 24 10612
HSV2-UL19-6230 - CAGGAGGAGCAACUCGAG 18 10613
HSV2-UL19-6231 - GCAGGAGGAGCAACUCGAG 19 10614
HSV2-UL19-2037 - UGCAGGAGGAGCAACUCGAG 20 2375
HSV2-UL19-6232 - AUGCAGGAGGAGCAACUCGAG 21 10615
HSV2-UL19-6233 - UAUGCAGGAGGAGCAACUCGAG 22 10616
HSV2-UL19-6234 - AUAUGCAGGAGGAGCAACUCGAG 23 10617
HSV2-UL19-6235 - GAUAUGCAGGAGGAGCAACUCGAG 24 10618
HSV2-UL19-6236 - UACGCGGGGGACAAGGAG 18 10619
HSV2-UL19-6237 - GUACGCGGGGGACAAGGAG 19 10620
HSV2-UL19-683 - UGUACGCGGGGGACAAGGAG 20 923
HSV2-UL19-6238 - GUG UACGCGGGGGACAAGGAG 21 10621 HSV2-UL19-6239 - CGUGUACGCGGGGGACAAGGAG 22 10622
HSV2-UL19-6240 - GCGUGUACGCGGGGGACAAGGAG 23 10623
HSV2-UL19-6241 - GGCGUGUACGCGGGGGACAAGGAG 24 10624
HSV2-UL19-6242 - ACCCUGCCGGGCCCGGAG 18 10625
HSV2-UL19-6243 - UACCCUGCCGGGCCCGGAG 19 10626
HSV2-UL19-2120 - UUACCCUGCCGGGCCCGGAG 20 2428
HSV2-UL19-6244 - UUUACCCUGCCGGGCCCGGAG 21 10627
HSV2-UL19-6245 - CUUUACCCUGCCGGGCCCGGAG 22 10628
HSV2-UL19-6246 - ACUUUACCCUGCCGGGCCCGGAG 23 10629
HSV2-UL19-6247 - GACUUUACCCUGCCGGGCCCGGAG 24 10630
HSV2-UL19-6248 - GGGACCUGGUGGCCCACG 18 10631
HSV2-UL19-6249 - CGGGACCUGGUGGCCCACG 19 10632
HSV2-UL19-2115 - UCGGGACCUGGUGGCCCACG 20 2424
HSV2-UL19-6250 - AUCGGGACCUGGUGGCCCACG 21 10633
HSV2-UL19-6251 - UAUCGGGACCUGGUGGCCCACG 22 10634
HSV2-UL19-6252 - GU AUCGGGACCUGGUGGCCCACG 23 10635
HSV2-UL19-6253 - UGUAUCGGGACCUGGUGGCCCACG 24 10636
HSV2-UL19-6254 - AGCGCUUCGCCGCGCACG 18 10637
HSV2-UL19-6255 - GAGCGCUUCGCCGCGCACG 19 10638
HSV2-UL19-2056 - GGAGCGCUUCGCCGCGCACG 20 2388
HSV2-UL19-6256 - UGGAGCGCU UCGCCGCGCACG 21 10639
HSV2-UL19-6257 - AUGGAGCGCUUCGCCGCGCACG 22 10640
HSV2-UL19-6258 - CAUGGAGCGCUUCGCCGCGCACG 23 10641
HSV2-UL19-6259 - CCAUGGAGCGCUUCGCCGCGCACG 24 10642
HSV2-UL19-6260 - UCGCGGGCGUGGCCGACG 18 10643
HSV2-UL19-6261 - UUCGCGGGCGUGGCCGACG 19 10644
HSV2-UL19-2090 - CUUCGCGGGCGUGGCCGACG 20 2409
HSV2-UL19-6262 - UCUUCGCGGGCGUGGCCGACG 21 10645
HSV2-UL19-6263 - UUCU UCGCGGGCGUGGCCGACG 22 10646
HSV2-UL19-6264 - CUUCUUCGCGGGCGUGGCCGACG 23 10647
HSV2-UL19-6265 - ACUUCUUCGCGGGCGUGGCCGACG 24 10648
HSV2-UL19-6266 - GAGACUGCCGGAUUGACG 18 10649
HSV2-UL19-6267 - CGAGACUGCCGGAUUGACG 19 10650
HSV2-UL19-533 - CCGAGACUGCCGGAUUGACG 20 773
HSV2-UL19-6268 - ACCGAGACUGCCGGAUUGACG 21 10651
HSV2-UL19-6269 - CACCGAGACUGCCGGAUUGACG 22 10652
HSV2-UL19-6270 - CCACCGAGACUGCCGGAU UGACG 23 10653
HSV2-UL19-6271 - GCCACCGAGACUGCCGGAUUGACG 24 10654
HSV2-UL19-6272 - ACGUGCCGGUGACCUACG 18 10655
HSV2-UL19-6273 - GACGUGCCGGUGACCUACG 19 10656
HSV2-UL19-2022 - CGACGUGCCGGUGACCUACG 20 2364
HSV2-UL19-6274 - CCGACGUGCCGGUGACCUACG 21 10657
HSV2-UL19-6275 - GCCGACGUGCCGGUGACCUACG 22 10658
HSV2-UL19-6276 - GGCCGACGUGCCGGUGACCUACG 23 10659
HSV2-UL19-6277 - AGGCCGACGUGCCGGUGACCUACG 24 10660
HSV2-UL19-6278 - CGGCCGGCGGCGUGUACG 18 10661 HSV2-UL19-6279 - GCGGCCGGCGGCGUGUACG 19 10662
HSV2-UL19-676 - CGCGGCCGGCGGCGUGUACG 20 916
HSV2-UL19-6280 - GCGCGGCCGGCGGCGUGUACG 21 10663
HSV2-UL19-6281 - CGCGCGGCCGGCGGCGUGUACG 22 10664
HSV2-UL19-6282 - ACGCGCGGCCGGCGGCGUGUACG 23 10665
HSV2-UL19-6283 - GACGCGCGGCCGGCGGCGUGUACG 24 10666
HSV2-UL19-6284 - GGGGGCGCUGCUGCACCG 18 10667
HSV2-UL19-6285 - CGGGGGCGCUGCUGCACCG 19 10668
HSV2-UL19-557 - GCGGGGGCGCUGCUGCACCG 20 797
HSV2-UL19-6286 - CGCGGGGGCGCUGCUGCACCG 21 10669
HSV2-UL19-6287 - UCGCGGGGGCGCUGCUGCACCG 22 10670
HSV2-UL19-6288 - CUCGCGGGGGCGCUGCUGCACCG 23 10671
HSV2-UL19-6289 - UCUCGCGGGGGCGCUGCUGCACCG 24 10672
HSV2-UL19-6290 - CCGAGUGCCAGAUGACCG 18 10673
HSV2-UL19-6291 - GCCGAGUGCCAGAUGACCG 19 10674
HSV2-UL19-462 - CGCCGAGUGCCAGAUGACCG 20 702
HSV2-UL19-6292 - UCGCCGAGUGCCAGAUGACCG 21 10675
HSV2-UL19-6293 - GUCGCCGAGUGCCAGAUGACCG 22 10676
HSV2-UL19-6294 - GGUCGCCGAGUGCCAGAUGACCG 23 10677
HSV2-UL19-6295 - GGGUCGCCGAGUGCCAGAUGACCG 24 10678
HSV2-UL19-6296 - CGCCGGCCCUGCAACCCG 18 10679
HSV2-UL19-6297 - UCGCCGGCCCUGCAACCCG 19 10680
HSV2-UL19-670 - UUCGCCGGCCCUGCAACCCG 20 910
HSV2-UL19-6298 - UUUCGCCGGCCCUGCAACCCG 21 10681
HSV2-UL19-6299 - CUUUCGCCGGCCCUGCAACCCG 22 10682
HSV2-UL19-6300 - ACUU UCGCCGGCCCUGCAACCCG 23 10683
HSV2-UL19-6301 - U ACU U UCGCCGGCCCU GCAACCCG 24 10684
HSV2-UL19-6302 - GCGUGAACCACGACCCCG 18 10685
HSV2-UL19-6303 - GGCGUGAACCACGACCCCG 19 10686
HSV2-UL19-2076 - GGGCGUGAACCACGACCCCG 20 2398
HSV2-UL19-6304 - GGGGCGUGAACCACGACCCCG 21 10687
HSV2-UL19-6305 - GGGGGCGUGAACCACGACCCCG 22 10688
HSV2-UL19-6306 - CGGGGGCGUGAACCACGACCCCG 23 10689
HSV2-UL19-6307 - UCGGGGGCGUGAACCACGACCCCG 24 10690
HSV2-UL19-6308 - UCCCGGAGAUCGCCCCCG 18 10691
HSV2-UL19-6309 - GUCCCGGAGAUCGCCCCCG 19 10692
HSV2-UL19-2145 - GGUCCCGGAGAUCGCCCCCG 20 2443
HSV2-UL19-6310 - UGGUCCCGGAGAUCGCCCCCG 21 10693
HSV2-UL19-6311 - GUGGUCCCGGAGAUCGCCCCCG 22 10694
HSV2-UL19-6312 - GGUGGUCCCGGAGAUCGCCCCCG 23 10695
HSV2-UL19-6313 - UGGUGGUCCCGGAGAUCGCCCCCG 24 10696
HSV2-UL19-6314 - GUGCAGUUUAAGCGCCCG 18 10697
HSV2-UL19-6315 - CGUGCAGUUUAAGCGCCCG 19 10698
HSV2-UL19-2237 - ACGUGCAGUUUAAGCGCCCG 20 2500
HSV2-UL19-6316 - GACGUGCAGUUUAAGCGCCCG 21 10699
HSV2-UL19-6317 - CGACGUGCAGUUUAAGCGCCCG 22 10700 HSV2-UL19-6318 - GCGACGUGCAGUUUAAGCGCCCG 23 10701
HSV2-UL19-6319 - AGCGACGUGCAGUUUAAGCGCCCG 24 10702
HSV2-UL19-6320 - UGAACAUCGACGCGGCCG 18 10703
HSV2-UL19-6321 - AUGAACAUCGACGCGGCCG 19 10704
HSV2-UL19-2072 - CAUGAACAUCGACGCGGCCG 20 2396
HSV2-UL19-6322 - UCAUGAACAUCGACGCGGCCG 21 10705
HSV2-UL19-6323 - CUCAUGAACAUCGACGCGGCCG 22 10706
HSV2-UL19-6324 - GCUCAUGAACAUCGACGCGGCCG 23 10707
HSV2-UL19-6325 - CGCUCAUGAACAUCGACGCGGCCG 24 10708
HSV2-UL19-6326 - AAACU U U UACCUCGGCCG 18 10709
HSV2-UL19-6327 - AAAACUUUUACCUCGGCCG 19 10710
HSV2-UL19-645 - CAAAACUUUUACCUCGGCCG 20 885
HSV2-UL19-6328 - CCAAAACUUUUACCUCGGCCG 21 10711
HSV2-UL19-6329 - CCCAAAACUUUUACCUCGGCCG 22 10712
HSV2-UL19-6330 - CCCCAAAACUU UUACCUCGGCCG 23 10713
HSV2-UL19-6331 - CCCCCAAAACU U U UACCUCGGCCG 24 10714
HSV2-UL19-6332 - UACCAUAGCCGCCGUCCG 18 10715
HSV2-UL19-6333 - CUACCAUAGCCGCCGUCCG 19 10716
HSV2-UL19-491 - GCUACCAUAGCCGCCGUCCG 20 731
HSV2-UL19-6334 - GGCUACCAUAGCCGCCGUCCG 21 10717
HSV2-UL19-6335 - CGGCUACCAUAGCCGCCGUCCG 22 10718
HSV2-UL19-6336 - CCGGCUACCAUAGCCGCCGUCCG 23 10719
HSV2-UL19-6337 - GCCGGCUACCAUAGCCGCCGUCCG 24 10720
HSV2-UL19-6338 - GACUGCCGGAUUGACGCG 18 10721
HSV2-UL19-6339 - AGACUGCCGGAUUGACGCG 19 10722
HSV2-UL19-535 - GAGACUGCCGGAUUGACGCG 20 775
HSV2-UL19-6340 - CG AGACUGCCGGAUUGACGCG 21 10723
HSV2-UL19-6341 - CCG AGACUGCCGGAUUGACGCG 22 10724
HSV2-UL19-6342 - ACCG AGACUGCCGGAUUGACGCG 23 10725
HSV2-UL19-6343 - CACCGAGACUGCCGGAUUGACGCG 24 10726
HSV2-UL19-6344 - GCCGGCGGCGUGUACGCG 18 10727
HSV2-UL19-6345 - GGCCGGCGGCGUGUACGCG 19 10728
HSV2-UL19-678 - CGGCCGGCGGCGUGUACGCG 20 918
HSV2-UL19-6346 - GCGGCCGGCGGCGUGUACGCG 21 10729
HSV2-UL19-6347 - CGCGGCCGGCGGCGUGUACGCG 22 10730
HSV2-UL19-6348 - GCGCGGCCGGCGGCGUGUACGCG 23 10731
HSV2-UL19-6349 - CGCGCGGCCGGCGGCGUGUACGCG 24 10732
HSV2-UL19-6350 - UGCUACGCAGCGCCCGCG 18 10733
HSV2-UL19-6351 - CUGCUACGCAGCGCCCGCG 19 10734
HSV2-UL19-2244 - CCUGCUACGCAGCGCCCGCG 20 2504
HSV2-UL19-6352 - CCCUGCUACGCAGCGCCCGCG 21 10735
HSV2-UL19-6353 - GCCCUGCUACGCAGCGCCCGCG 22 10736
HSV2-UL19-6354 - CGCCCUGCUACGCAGCGCCCGCG 23 10737
HSV2-UL19-6355 - CCGCCCUGCUACGCAGCGCCCGCG 24 10738
HSV2-UL19-6356 - CACG CU CACCCAG CCG CG 18 10739
HSV2-UL19-6357 - UCACGCUCACCCAGCCGCG 19 10740 HSV2-UL19-632 - UUCACGCUCACCCAGCCGCG 20 872
HSV2-UL19-6358 - CUUCACGCUCACCCAGCCGCG 21 10741
HSV2-UL19-6359 - ACUUCACGCUCACCCAGCCGCG 22 10742
HSV2-UL19-6360 - AACUUCACGCUCACCCAGCCGCG 23 10743
HSV2-UL19-6361 - CAACUUCACGCUCACCCAGCCGCG 24 10744
HSV2-UL19-6362 - CACGCCCGCGAGAGCGCG 18 10745
HSV2-UL19-6363 - GCACGCCCGCGAGAGCGCG 19 10746
HSV2-UL19-2163 - AGCACGCCCGCGAGAGCGCG 20 2457
HSV2-UL19-6364 - CAGCACGCCCGCGAGAGCGCG 21 10747
HSV2-UL19-6365 - GCAGCACGCCCGCGAGAGCGCG 22 10748
HSV2-UL19-6366 - UGCAGCACGCCCGCGAGAGCGCG 23 10749
HSV2-UL19-6367 - G U GCAG CACG CCCG CG AG AG CGCG 24 10750
HSV2-UL19-6368 - CUGUUUUCCGAGCGCGCG 18 10751
HSV2-UL19-6369 - GCUGU UUUCCGAGCGCGCG 19 10752
HSV2-UL19-2179 - UGCUGUUUUCCGAGCGCGCG 20 2468
HSV2-UL19-6370 - GUGCUGUUUUCCGAGCGCGCG 21 10753
HSV2-UL19-6371 - CGUGCUGU UUUCCGAGCGCGCG 22 10754
HSV2-UL19-6372 - ACGUGCUGUUUUCCGAGCGCGCG 23 10755
HSV2-UL19-6373 - AACGUGCUGUUUUCCGAGCGCGCG 24 10756
HSV2-UL19-6374 - ACGUCGAGCUUCCCGGCG 18 10757
HSV2-UL19-6375 - GACGUCGAGCUUCCCGGCG 19 10758
HSV2-UL19-2091 - CGACGUCGAGCUUCCCGGCG 20 2410
HSV2-UL19-6376 - CCGACGUCGAGCUUCCCGGCG 21 10759
HSV2-UL19-6377 - GCCGACGUCGAGCUUCCCGGCG 22 10760
HSV2-UL19-6378 - GGCCGACGUCGAGCUUCCCGGCG 23 10761
HSV2-UL19-6379 - UGGCCGACGUCGAGCUUCCCGGCG 24 10762
HSV2-UL19-6380 - GCCCGCGAGAGCGCGGCG 18 10763
HSV2-UL19-6381 - CGCCCGCGAGAGCGCGGCG 19 10764
HSV2-UL19-603 - ACGCCCGCGAGAGCGCGGCG 20 843
HSV2-UL19-6382 - CACGCCCGCGAGAGCGCGGCG 21 10765
HSV2-UL19-6383 - GCACGCCCGCGAGAGCGCGGCG 22 10766
HSV2-UL19-6384 - AGCACGCCCGCGAGAGCGCGGCG 23 10767
HSV2-UL19-6385 - CAGCACGCCCGCGAGAGCGCGGCG 24 10768
HSV2-UL19-6386 - CCCG CCACG AAACGG GCG 18 10769
HSV2-UL19-6387 - GCCCGCCACGAAACGGGCG 19 10770
HSV2-UL19-628 - GGCCCGCCACGAAACGGGCG 20 868
HSV2-UL19-6388 - UGGCCCGCCACGAAACGGGCG 21 10771
HSV2-UL19-6389 - GUGGCCCGCCACGAAACGGGCG 22 10772
HSV2-UL19-6390 - GGUGGCCCGCCACGAAACGGGCG 23 10773
HSV2-UL19-6391 - AGGUGGCCCGCCACGAAACGGGCG 24 10774
HSV2-UL19-6392 - GCCUGGAGCGUCUCAUCG 18 10775
HSV2-UL19-6393 - UGCCUGGAGCGUCUCAUCG 19 10776
HSV2-UL19-705 - CUGCCUGGAGCGUCUCAUCG 20 945
HSV2-UL19-6394 - GCUGCCUGGAGCGUCUCAUCG 21 10777
HSV2-UL19-6395 - CGCUGCCUGGAGCGUCUCAUCG 22 10778
HSV2-UL19-6396 - UCGCUGCCUGGAGCGUCUCAUCG 23 10779 HSV2-UL19-6397 - AUCGCUGCCUGGAGCGUCUCAUCG 24 10780
HSV2-UL19-6398 - CGGGGUGCCGCGAGCUCG 18 10781
HSV2-UL19-6399 - CCGGGGUGCCGCGAGCUCG 19 10782
HSV2-UL19-714 - GCCGGGGUGCCGCGAGCUCG 20 954
HSV2-UL19-6400 - CGCCGGGGUGCCGCGAGCUCG 21 10783
HSV2-UL19-6401 - CCGCCGGGGUGCCGCGAGCUCG 22 10784
HSV2-UL19-6402 - CCCGCCGGGGUGCCGCGAGCUCG 23 10785
HSV2-UL19-6403 - GCCCGCCGGGGUGCCGCGAGCUCG 24 10786
HSV2-UL19-6404 - CUGGUGCCGGCCUUCUCG 18 10787
HSV2-UL19-6405 - GCUGGUGCCGGCCUUCUCG 19 10788
HSV2-UL19-553 - UGCUGGUGCCGGCCUUCUCG 20 793
HSV2-UL19-6406 - GUGCUGGUGCCGGCCUUCUCG 21 10789
HSV2-UL19-6407 - CGUGCUGGUGCCGGCCUUCUCG 22 10790
HSV2-UL19-6408 - ACGUGCUGGUGCCGGCCUUCUCG 23 10791
HSV2-UL19-6409 - UACGUGCUGGUGCCGGCCUUCUCG 24 10792
HSV2-UL19-6410 - ACGGGCGCGUCGUCGUCG 18 10793
HSV2-UL19-6411 - AACGGGCGCGUCGUCGUCG 19 10794
HSV2-UL19-2150 - CAACGGGCGCGUCGUCGUCG 20 2447
HSV2-UL19-6412 - ACAACGGGCGCGUCGUCGUCG 21 10795
HSV2-UL19-6413 - CACAACGGGCGCGUCGUCGUCG 22 10796
HSV2-UL19-6414 - CCACAACGGGCGCGUCGUCGUCG 23 10797
HSV2-UL19-6415 - UCCACAACGGGCGCGUCGUCGUCG 24 10798
HSV2-UL19-6416 - CGCGCGGGCGGCCGGUCG 18 10799
HSV2-UL19-6417 - ACGCGCGGGCGGCCGGUCG 19 10800
HSV2-UL19-2015 - CACGCGCGGGCGGCCGGUCG 20 2359
HSV2-UL19-6418 - ACACGCGCGGGCGGCCGGUCG 21 10801
HSV2-UL19-6419 - GACACGCGCGGGCGGCCGGUCG 22 10802
HSV2-UL19-6420 - CGACACGCGCGGGCGGCCGGUCG 23 10803
HSV2-UL19-6421 - CCGACACGCGCGGGCGGCCGGUCG 24 10804
HSV2-UL19-6422 - CCCGGGCGACCCUGGUCG 18 10805
HSV2-UL19-6423 - GCCCGGGCGACCCUGGUCG 19 10806
HSV2-UL19-2004 - UGCCCGGGCGACCCUGGUCG 20 2349
HSV2-UL19-6424 - UUGCCCGGGCGACCCUGGUCG 21 10807
HSV2-UL19-6425 - GUUGCCCGGGCGACCCUGGUCG 22 10808
HSV2-UL19-6426 - GGUUGCCCGGGCGACCCUGGUCG 23 10809
HSV2-UL19-6427 - GGGUUGCCCGGGCGACCCUGGUCG 24 10810
HSV2-UL19-6428 - CCAACAU G CG CAU CU U CG 18 10811
HSV2-UL19-6429 - GCCAACAU G CG CAU CU U CG 19 10812
HSV2-UL19-2153 - GGCCAACAUGCGCAUCUUCG 20 2450
HSV2-UL19-6430 - CGGCCAACAUGCGCAUCUUCG 21 10813
HSV2-UL19-6431 - ACGG CCAACAU G CGCAUCUUCG 22 10814
HSV2-UL19-6432 - GACGGCCAACAUGCGCAUCUUCG 23 10815
HSV2-UL19-6433 - CGACGGCCAACAUGCGCAUCUUCG 24 10816
HSV2-UL19-6434 - UGUACGCGGGGGACAAGG 18 10817
HSV2-UL19-6435 - GUGUACGCGGGGGACAAGG 19 10818
HSV2-UL19-681 - CGUGUACGCGGGGGACAAGG 20 921 HSV2-UL19-6436 - GCGUGUACGCGGGGGACAAGG 21 10819
HSV2-UL19-6437 - GGCGUGUACGCGGGGGACAAGG 22 10820
HSV2-UL19-6438 - CGGCGUGUACGCGGGGGACAAGG 23 10821
HSV2-UL19-6439 - GCGGCGUGUACGCGGGGGACAAGG 24 10822
HSV2-UL19-6440 - UGCAGUCCUUCCUGAAGG 18 10823
HSV2-UL19-6441 - CUGCAGUCCU UCCUGAAGG 19 10824
HSV2-UL19-380 - CCUGCAGUCCUUCCUGAAGG 20 620
HSV2-UL19-6442 - UCCUGCAGUCCUUCCUGAAGG 21 10825
HSV2-UL19-6443 - CUCCUGCAGUCCUUCCUGAAGG 22 10826
HSV2-UL19-6444 - CCUCCUGCAGUCCUUCCUGAAGG 23 10827
HSV2-UL19-6445 - GCCUCCUGCAGUCCUUCCUGAAGG 24 10828
HSV2-UL19-6446 - ACCUGCUGGAUAUGCAGG 18 10829
HSV2-UL19-6447 - CACCUGCUGGAUAUGCAGG 19 10830
HSV2-UL19-400 - CCACCUGCUGGAUAUGCAGG 20 640
HSV2-UL19-6448 - GCCACCUGCUGGAUAUGCAGG 21 10831
HSV2-UL19-6449 - CGCCACCUGCUGGAUAUGCAGG 22 10832
HSV2-UL19-6450 - CCGCCACCUGCUGGAUAUGCAGG 23 10833
HSV2-UL19-6451 - GCCGCCACCUGCUGGAUAUGCAGG 24 10834
HSV2-UL19-6452 - UGGGCGGGCAGGCUCAGG 18 10835
HSV2-UL19-6453 - CUGGGCGGGCAGGCUCAGG 19 10836
HSV2-UL19-2122 - GCUGGGCGGGCAGGCUCAGG 20 2430
HSV2-UL19-6454 - AGCUGGGCGGGCAGGCUCAGG 21 10837
HSV2-UL19-6455 - GAGCUGGGCGGGCAGGCUCAGG 22 10838
HSV2-UL19-6456 - GGAGCUGGGCGGGCAGGCUCAGG 23 10839
HSV2-UL19-6457 - CGGAGCUGGGCGGGCAGGCUCAGG 24 10840
HSV2-UL19-6458 - UGGCCCGCCACGAAACGG 18 10841
HSV2-UL19-6459 - GUGGCCCGCCACGAAACGG 19 10842
HSV2-UL19-2184 - GGUGGCCCGCCACGAAACGG 20 2472
HSV2-UL19-6460 - AGG UGGCCCGCCACGAAACGG 21 10843
HSV2-UL19-6461 - CAG G U G GCCCGCCACG AAACGG 22 10844
HSV2-UL19-6462 - CCAGGUGGCCCGCCACGAAACGG 23 10845
HSV2-UL19-6463 - UCCAGGUGGCCCGCCACGAAACGG 24 10846
HSV2-UL19-6464 - GUCGUGGCGGGAAACCGG 18 10847
HSV2-UL19-6465 - GGUCGUGGCGGGAAACCGG 19 10848
HSV2-UL19-2202 - CGGUCGUGGCGGGAAACCGG 20 2482
HSV2-UL19-6466 - GCGGUCGUGGCGGGAAACCGG 21 10849
HSV2-UL19-6467 - CGCGGUCGUGGCGGGAAACCGG 22 10850
HSV2-UL19-6468 - ACGCGGUCGUGGCGGGAAACCGG 23 10851
HSV2-UL19-6469 - AACGCGGUCGUGGCGGGAAACCGG 24 10852
HSV2-UL19-6470 - UGUCCAUGGAGAACGCGG 18 10853
HSV2-UL19-6471 - CUGUCCAUGGAGAACGCGG 19 10854
HSV2-UL19-2069 - GCUGUCCAUGGAGAACGCGG 20 2394
HSV2-UL19-6472 - GGCUGUCCAUGGAGAACGCGG 21 10855
HSV2-UL19-6473 - CGGCUGUCCAUGGAGAACGCGG 22 10856
HSV2-UL19-6474 - GCGGCUGUCCAUGGAGAACGCGG 23 10857
HSV2-UL19-6475 - UGCGGCUGUCCAUGGAGAACGCGG 24 10858 HSV2-UL19-6476 - ACUGCCGGAUUGACGCGG 18 10859
HSV2-UL19-6477 - GACUGCCGGAUUGACGCGG 19 10860
HSV2-UL19-536 - AGACUGCCGGAUUGACGCGG 20 776
HSV2-UL19-6478 - GAG ACUGCCGGAUUGACGCGG 21 10861
HSV2-UL19-6479 - CGAGACUGCCGGAUUGACGCGG 22 10862
HSV2-UL19-6480 - CCGAGACUGCCGGAUUGACGCGG 23 10863
HSV2-UL19-6481 - ACCGAGACUGCCGGAUUGACGCGG 24 10864
HSV2-UL19-6482 - ACGCCCGCGAGAGCGCGG 18 10865
HSV2-UL19-6483 - CACGCCCGCGAGAGCGCGG 19 10866
HSV2-UL19-601 - GCACGCCCGCGAGAGCGCGG 20 841
HSV2-UL19-6484 - AGCACGCCCGCGAGAGCGCGG 21 10867
HSV2-UL19-6485 - CAGCACGCCCGCGAGAGCGCGG 22 10868
HSV2-UL19-6486 - GCAGCACGCCCGCGAGAGCGCGG 23 10869
HSV2-UL19-6487 - UGCAGCACGCCCGCGAGAGCGCGG 24 10870
HSV2-UL19-6488 - CCCGCGAGAGCGCGGCGG 18 10871
HSV2-UL19-6489 - GCCCGCGAGAGCGCGGCGG 19 10872
HSV2-UL19-604 - CGCCCGCGAGAGCGCGGCGG 20 844
HSV2-UL19-6490 - ACGCCCGCGAGAGCGCGGCGG 21 10873
HSV2-UL19-6491 - CACGCCCGCGAGAGCGCGGCGG 22 10874
HSV2-UL19-6492 - GCACGCCCGCGAGAGCGCGGCGG 23 10875
HSV2-UL19-6493 - AGCACGCCCGCGAGAGCGCGGCGG 24 10876
HSV2-UL19-6494 - GGGUUCACCGUCGUGCGG 18 10877
HSV2-UL19-6495 - CGGGUUCACCGUCGUGCGG 19 10878
HSV2-UL19-2175 - UCGGGUUCACCGUCGUGCGG 20 2464
HSV2-UL19-6496 - UUCGGGUUCACCGUCGUGCGG 21 10879
HSV2-UL19-6497 - GUUCGGGUUCACCGUCGUGCGG 22 10880
HSV2-UL19-6498 - GGUUCGGGUUCACCGUCGUGCGG 23 10881
HSV2-UL19-6499 - GGGUUCGGGUUCACCGUCGUGCGG 24 10882
HSV2-UL19-6500 - GGCCCGCCACGAAACGGG 18 10883
HSV2-UL19-6501 - UGGCCCGCCACGAAACGGG 19 10884
HSV2-UL19-626 - GUGGCCCGCCACGAAACGGG 20 866
HSV2-UL19-6502 - GGUGGCCCGCCACGAAACGGG 21 10885
HSV2-UL19-6503 - AGGUGGCCCGCCACGAAACGGG 22 10886
HSV2-UL19-6504 - CAGGUGGCCCGCCACGAAACGGG 23 10887
HSV2-UL19-6505 - CCAGGUGGCCCGCCACGAAACGGG 24 10888
HSV2-UL19-6506 - CGCGAGAGCGCGGCGGGG 18 10889
HSV2-UL19-6507 - CCGCGAGAGCGCGGCGGGG 19 10890
HSV2-UL19-2168 - CCCGCGAGAGCGCGGCGGGG 20 2458
HSV2-UL19-6508 - GCCCGCGAGAGCGCGGCGGGG 21 10891
HSV2-UL19-6509 - CGCCCGCGAGAGCGCGGCGGGG 22 10892
HSV2-UL19-6510 - ACGCCCGCGAGAGCGCGGCGGGG 23 10893
HSV2-UL19-6511 - CACGCCCGCGAGAGCGCGGCGGGG 24 10894
HSV2-UL19-6512 - UGCUGGCGCACAACAUGG 18 10895
HSV2-UL19-6513 - GUGCUGGCGCACAACAUGG 19 10896
HSV2-UL19-2151 - GGUGCUGGCGCACAACAUGG 20 2448
HSV2-UL19-6514 - AGGUGCUGGCGCACAACAUGG 21 10897 HSV2-UL19-6515 - CAGGUGCUGGCG CACAACAU G G 22 10898
HSV2-UL19-6516 - GCAGGUGCUGGCGCACAACAUGG 23 10899
HSV2-UL19-6517 - UGCAGGUGCUGGCGCACAACAUGG 24 10900
HSV2-UL19-6518 - UGCCGGGCCCGGAGCUGG 18 10901
HSV2-UL19-6519 - CUGCCGGGCCCGGAGCUGG 19 10902
HSV2-UL19-2121 - CCUGCCGGGCCCGGAGCUGG 20 2429
HSV2-UL19-6520 - CCCUGCCGGGCCCGGAGCUGG 21 10903
HSV2-UL19-6521 - ACCCUGCCGGGCCCGGAGCUGG 22 10904
HSV2-UL19-6522 - UACCCUGCCGGGCCCGGAGCUGG 23 10905
HSV2-UL19-6523 - UUACCCUGCCGGGCCCGGAGCUGG 24 10906
HSV2-UL19-6524 - CGAACCGGGAGACGCUGG 18 10907
HSV2-UL19-6525 - GCGAACCGGGAGACGCUGG 19 10908
HSV2-UL19-2042 - GGCGAACCGGGAGACGCUGG 20 2378
HSV2-UL19-6526 - AGGCGAACCGGGAGACGCUGG 21 10909
HSV2-UL19-6527 - GAGGCGAACCGGGAGACGCUGG 22 10910
HSV2-UL19-6528 - CGAGGCGAACCGGGAGACGCUGG 23 10911
HSV2-UL19-6529 - UCGAGGCGAACCGGGAGACGCUGG 24 10912
HSV2-UL19-6530 - UGCGCAACGCGGUCGUGG 18 10913
HSV2-UL19-6531 - CUGCGCAACGCGGUCGUGG 19 10914
HSV2-UL19-651 - CCUGCGCAACGCGGUCGUGG 20 891
HSV2-UL19-6532 - ACCUGCGCAACGCGGUCGUGG 21 10915
HSV2-UL19-6533 - UACCUGCGCAACGCGGUCGUGG 22 10916
HSV2-UL19-6534 - GUACCUGCGCAACGCGGUCGUGG 23 10917
HSV2-UL19-6535 - UGUACCUGCGCAACGCGGUCGUGG 24 10918
HSV2-UL19-6536 - GUUCUGCGGCUGUCCAUG 18 10919
HSV2-UL19-6537 - GGUUCUGCGGCUGUCCAUG 19 10920
HSV2-UL19-2068 - AGGU UCUGCGGCUGUCCAUG 20 2393
HSV2-UL19-6538 - CAGGUUCUGCGGCUGUCCAUG 21 10921
HSV2-UL19-6539 - CCAGGUUCUGCGGCUGUCCAUG 22 10922
HSV2-UL19-6540 - ACCAGGU UCUGCGGCUGUCCAUG 23 10923
HSV2-UL19-6541 - CACCAGGUUCUGCGGCUGUCCAUG 24 10924
HSV2-UL19-6542 - CUGACCUACGCGCUCAUG 18 10925
HSV2-UL19-6543 - GCUGACCUACGCGCUCAUG 19 10926
HSV2-UL19-2169 - CGCUGACCUACGCGCUCAUG 20 2459
HSV2-UL19-6544 - GCGCUGACCUACGCGCUCAUG 21 10927
HSV2-UL19-6545 - CGCGCUGACCUACGCGCUCAUG 22 10928
HSV2-UL19-6546 - ACGCGCUGACCUACGCGCUCAUG 23 10929
HSV2-UL19-6547 - AACGCGCUGACCUACGCGCUCAUG 24 10930
HSV2-UL19-6548 - UACGCAGCGCCCGCGAUG 18 10931
HSV2-UL19-6549 - CUACGCAGCGCCCGCGAUG 19 10932
HSV2-UL19-719 - GCUACGCAGCGCCCGCGAUG 20 959
HSV2-UL19-6550 - UGCUACGCAGCGCCCGCGAUG 21 10933
HSV2-UL19-6551 - CUGCUACGCAGCGCCCGCGAUG 22 10934
HSV2-UL19-6552 - CCUGCUACGCAGCGCCCGCGAUG 23 10935
HSV2-UL19-6553 - CCCUGCUACGCAGCGCCCGCGAUG 24 10936
HSV2-UL19-6554 - CGCCACCUGCUGGAUAUG 18 10937 HSV2-UL19-6555 - CCGCCACCUGCUGGAUAUG 19 10938
HSV2-UL19-2032 - GCCGCCACCUGCUGGAUAUG 20 2372
HSV2-UL19-6556 - GGCCGCCACCUGCUGGAUAUG 21 10939
HSV2-UL19-6557 - GGGCCGCCACCUGCUGGAUAUG 22 10940
HSV2-UL19-6558 - UGGGCCGCCACCUGCUGGAUAUG 23 10941
HSV2-UL19-6559 - GUGGGCCGCCACCUGCUGGAUAUG 24 10942
HSV2-UL19-6560 - GUGGACGACUUUACCCUG 18 10943
HSV2-UL19-6561 - GGUGGACGACUUUACCCUG 19 10944
HSV2-UL19-2117 - UGGUGGACGACUUUACCCUG 20 2426
HSV2-UL19-6562 - CUGGUGGACGACUUUACCCUG 21 10945
HSV2-UL19-6563 - GCUGGUGGACGACUUUACCCUG 22 10946
HSV2-UL19-6564 - AGCUGGUGGACGACUUUACCCUG 23 10947
HSV2-UL19-6565 - CAGCUGGUGGACGACUUUACCCUG 24 10948
HSV2-UL19-6566 - AACGUGCCCUACCCCCUG 18 10949
HSV2-UL19-6567 - CAACG U G CCCU ACCCCCU G 19 10950
HSV2-UL19-2050 - CCAACGUGCCCUACCCCCUG 20 2384
HSV2-UL19-6568 - ACCAACG U G CCCU ACCCCCUG 21 10951
HSV2-UL19-6569 - CACCAACG U GCCCU ACCCCCU G 22 10952
HSV2-UL19-6570 - CCACCAACG UG CCCU ACCCCCU G 23 10953
HSV2-UL19-6571 - GCCACCAACGUGCCCUACCCCCUG 24 10954
HSV2-UL19-6572 - GUCUUCCUGGAGGCCCUG 18 10955
HSV2-UL19-6573 - GGUCU UCCUGGAGGCCCUG 19 10956
HSV2-UL19-2049 - UGGUCUUCCUGGAGGCCCUG 20 2383
HSV2-UL19-6574 - CUGGUCUUCCUGGAGGCCCUG 21 10957
HSV2-UL19-6575 - GCUGGUCU UCCUGGAGGCCCUG 22 10958
HSV2-UL19-6576 - GGCUGGUCUUCCUGGAGGCCCUG 23 10959
HSV2-UL19-6577 - AGGCUGGUCUUCCUGGAGGCCCUG 24 10960
HSV2-UL19-6578 - GAGGCCCUGGCCCAGCUG 18 10961
HSV2-UL19-6579 - CGAGGCCCUGGCCCAGCUG 19 10962
HSV2-UL19-2116 - UCGAGGCCCUGGCCCAGCUG 20 2425
HSV2-UL19-6580 - GUCGAGGCCCUGGCCCAGCUG 21 10963
HSV2-UL19-6581 - CGUCGAGGCCCUGGCCCAGCUG 22 10964
HSV2-UL19-6582 - ACGUCGAGGCCCUGGCCCAGCUG 23 10965
HSV2-UL19-6583 - CACGUCGAGGCCCUGGCCCAGCUG 24 10966
HSV2-UL19-6584 - CGCGUGUACGCCACGCUG 18 10967
HSV2-UL19-6585 - CCGCGUGUACGCCACGCUG 19 10968
HSV2-UL19-2142 - ACCGCGUGUACGCCACGCUG 20 2441
HSV2-UL19-6586 - GACCGCGUGUACGCCACGCUG 21 10969
HSV2-UL19-6587 - CGACCGCGUGUACGCCACGCUG 22 10970
HSV2-UL19-6588 - UCGACCGCGUGUACGCCACGCUG 23 10971
HSV2-UL19-6589 - UUCGACCGCGUGUACGCCACGCUG 24 10972
HSV2-UL19-6590 - CAGAUGCUGCACGUGCUG 18 10973
HSV2-UL19-6591 - CCAGAUGCUGCACGUGCUG 19 10974
HSV2-UL19-1998 - ACCAGAUGCUGCACGUGCUG 20 2344
HSV2-UL19-6592 - GACCAGAUGCUGCACGUGCUG 21 10975
HSV2-UL19-6593 - CGACCAGAUGCUGCACGUGCUG 22 10976 HSV2-UL19-6594 - CCGACCAGAUGCUGCACGUGCUG 23 10977
HSV2-UL19-6595 - GCCGACCAGAUGCUGCACGUGCUG 24 10978
HSV2-UL19-6596 - GUGAUGGGCAAGGCCGUG 18 10979
HSV2-UL19-6597 - GGUGAUGGGCAAGGCCGUG 19 10980
HSV2-UL19-394 - UGGUGAUGGGCAAGGCCGUG 20 634
HSV2-UL19-6598 - CUGGUGAUGGGCAAGGCCGUG 21 10981
HSV2-UL19-6599 - GCUGGUGAUGGGCAAGGCCGUG 22 10982
HSV2-UL19-6600 - CGCUGGUGAUGGGCAAGGCCGUG 23 10983
HSV2-UL19-6601 - GCGCUGGUGAUGGGCAAGGCCGUG 24 10984
HSV2-UL19-6602 - CUGCUGCCGCCCCUCGUG 18 10985
HSV2-UL19-6603 - GCUGCUGCCGCCCCUCGUG 19 10986
HSV2-UL19-527 - CGCUGCUGCCGCCCCUCGUG 20 767
HSV2-UL19-6604 - GCGCUGCUGCCGCCCCUCGUG 21 10987
HSV2-UL19-6605 - GGCGCUGCUGCCGCCCCUCGUG 22 10988
HSV2-UL19-6606 - CGGCGCUGCUGCCGCCCCUCGUG 23 10989
HSV2-UL19-6607 - CCGGCGCUGCUGCCGCCCCUCGUG 24 10990
HSV2-UL19-6608 - CUGCGCAACGCGGUCGUG 18 10991
HSV2-UL19-6609 - CCUGCGCAACGCGGUCGUG 19 10992
HSV2-UL19-2199 - ACCUGCGCAACGCGGUCGUG 20 2481
HSV2-UL19-6610 - UACCUGCGCAACGCGGUCGUG 21 10993
HSV2-UL19-6611 - GUACCUGCGCAACGCGGUCGUG 22 10994
HSV2-UL19-6612 - UGUACCUGCGCAACGCGGUCGUG 23 10995
HSV2-UL19-6613 - GUGUACCUGCGCAACGCGGUCGUG 24 10996
HSV2-UL19-6614 - CAGUCCUUCCUGAAGGUG 18 10997
HSV2-UL19-6615 - GCAGUCCUUCCUGAAGGUG 19 10998
HSV2-UL19-2020 - UGCAGUCCUUCCUGAAGGUG 20 2362
HSV2-UL19-6616 - CUGCAGUCCUUCCUGAAGGUG 21 10999
HSV2-UL19-6617 - CCUGCAGUCCUUCCUGAAGGUG 22 11000
HSV2-UL19-6618 - UCCUGCAGUCCUUCCUGAAGGUG 23 11001
HSV2-UL19-6619 - CUCCUGCAGUCCUUCCUGAAGGUG 24 11002
HSV2-UL19-6620 - CUCGUCACGGCGCUGGUG 18 11003
HSV2-UL19-6621 - CCUCGUCACGGCGCUGGUG 19 11004
HSV2-UL19-2026 - ACCUCGUCACGGCGCUGGUG 20 2367
HSV2-UL19-6622 - AACCUCGUCACGGCGCUGGUG 21 11005
HSV2-UL19-6623 - CAACCUCGUCACGGCGCUGGUG 22 11006
HSV2-UL19-6624 - CCAACCUCGUCACGGCGCUGGUG 23 11007
HSV2-UL19-6625 - GCCAACCUCGUCACGGCGCUGGUG 24 11008
HSV2-UL19-6626 - AUGCUGCACGUGCUGUUG 18 11009
HSV2-UL19-6627 - GAUGCUGCACGUGCUGUUG 19 11010
HSV2-UL19-2000 - AGAUGCUGCACGUGCUGUUG 20 2345
HSV2-UL19-6628 - CAGAUGCUGCACGUGCUGUUG 21 11011
HSV2-UL19-6629 - CCAGAUGCUGCACGUGCUGUUG 22 11012
HSV2-UL19-6630 - ACCAGAUGCUGCACGUGCUGUUG 23 11013
HSV2-UL19-6631 - GACCAGAUGCUGCACGUGCUGUUG 24 11014
HSV2-UL19-6632 - CCGGCAGCUGUUUUUUUG 18 11015
HSV2-UL19-6633 - CCCGGCAGCUGUUUUUUUG 19 11016 HSV2-UL19-432 - CCCCGGCAGCUGUUUUUUUG 20 672
HSV2-UL19-6634 - UCCCCGGCAGCUGUUUUUUUG 21 11017
HSV2-UL19-6635 - CUCCCCGGCAGCUGUUUUUUUG 22 11018
HSV2-UL19-6636 - CCUCCCCGGCAGCUGUUUUUUUG 23 11019
HSV2-UL19-6637 - CCCUCCCCGGCAGCUGUUUUUUUG 24 11020
HSV2-UL19-6638 - CUACGCAGCGCCCGCGAU 18 11021
HSV2-UL19-6639 - GCUACGCAGCGCCCGCGAU 19 11022
HSV2-UL19-718 - UGCUACGCAGCGCCCGCGAU 20 958
HSV2-UL19-6640 - CUGCUACGCAGCGCCCGCGAU 21 11023
HSV2-UL19-6641 - CCUGCUACGCAGCGCCCGCGAU 22 11024
HSV2-UL19-6642 - CCCUGCUACGCAGCGCCCGCGAU 23 11025
HSV2-UL19-6643 - GCCCUGCUACGCAGCGCCCGCGAU 24 11026
HSV2-UL19-6644 - GAGUGCAUGGCCGUGUAU 18 11027
HSV2-UL19-6645 - GGAGUGCAUGGCCGUGUAU 19 11028
HSV2-UL19-509 - AGGAGUGCAUGGCCGUGUAU 20 749
HSV2-UL19-6646 - GAGGAGUGCAUGGCCGUGUAU 21 11029
HSV2-UL19-6647 - CGAGGAGUGCAUGGCCGUGUAU 22 11030
HSV2-UL19-6648 - CCGAGGAGUGCAUGGCCGUGUAU 23 11031
HSV2-UL19-6649 - CCCGAGGAGUGCAUGGCCGUGUAU 24 11032
HSV2-UL19-6650 - GUACAUCGUGACCUACCU 18 11033
HSV2-UL19-6651 - CGUACAUCGUGACCUACCU 19 11034
HSV2-UL19-503 - UCGUACAUCGUGACCUACCU 20 743
HSV2-UL19-6652 - CUCGUACAUCGUGACCUACCU 21 11035
HSV2-UL19-6653 - UCUCGUACAUCGUGACCUACCU 22 11036
HSV2-UL19-6654 - GUCUCGUACAUCGUGACCUACCU 23 11037
HSV2-UL19-6655 - GGUCUCGUACAUCGUGACCUACCU 24 11038
HSV2-UL19-6656 - CCUGGUCCCCCCGGCCCU 18 11039
HSV2-UL19-6657 - CCCUGGUCCCCCCGGCCCU 19 11040
HSV2-UL19-596 - CCCCUGGUCCCCCCGGCCCU 20 836
HSV2-UL19-6658 - CCCCCUGGUCCCCCCGGCCCU 21 11041
HSV2-UL19-6659 - UCCCCCUGGUCCCCCCGGCCCU 22 11042
HSV2-UL19-6660 - GUCCCCCUGGUCCCCCCGGCCCU 23 11043
HSV2-UL19-6661 - CGUCCCCCUGGUCCCCCCGGCCCU 24 11044
HSV2-UL19-3591 - CAACG UCCAGGCCGUCCU 18 7974
HSV2-UL19-3592 - GCAACGUCCAGGCCGUCCU 19 7975
HSV2-UL19-3085 - CGCAACGUCCAGGCCGUCCU 20 7468
HSV2-UL19-3593 - GCGCAACGUCCAGGCCGUCCU 21 7976
HSV2-UL19-3594 - CGCGCAACGUCCAGGCCGUCCU 22 7977
HSV2-UL19-3595 - GCGCGCAACGUCCAGGCCGUCCU 23 7978
HSV2-UL19-3596 - CGCGCGCAACGUCCAGGCCGUCCU 24 7979
HSV2-UL19-6662 - GACAACGCCAACCUGGCU 18 11045
HSV2-UL19-6663 - CGACAACGCCAACCUGGCU 19 11046
HSV2-UL19-2087 - CCGACAACGCCAACCUGGCU 20 2407
HSV2-UL19-6664 - CCCGACAACGCCAACCUGGCU 21 11047
HSV2-UL19-6665 - GCCCGACAACGCCAACCUGGCU 22 11048
HSV2-UL19-6666 - AGCCCGACAACGCCAACCUGGCU 23 11049 HSV2-UL19-6667 - CAG CCCG ACAACG CCAACCU G G CU 24 11050
HSV2-UL19-6668 - GGUGAUGGGCAAGGCCGU 18 11051
HSV2-UL19-6669 - UGGUGAUGGGCAAGGCCGU 19 11052
HSV2-UL19-2027 - CUGGUGAUGGGCAAGGCCGU 20 2368
HSV2-UL19-6670 - GCUGGUGAUGGGCAAGGCCGU 21 11053
HSV2-UL19-6671 - CGCUGGUGAUGGGCAAGGCCGU 22 11054
HSV2-UL19-6672 - GCGCUGGUGAUGGGCAAGGCCGU 23 11055
HSV2-UL19-6673 - GGCGCUGGUGAUGGGCAAGGCCGU 24 11056
HSV2-UL19-6674 - GAACAUCGACGCGGCCGU 18 11057
HSV2-UL19-6675 - UGAACAUCGACGCGGCCGU 19 11058
HSV2-UL19-441 - AUGAACAUCGACGCGGCCGU 20 681
HSV2-UL19-6676 - CAUGAACAUCGACGCGGCCGU 21 11059
HSV2-UL19-6677 - UCAUGAACAUCGACGCGGCCGU 22 11060
HSV2-UL19-6678 - CUCAUGAACAUCGACGCGGCCGU 23 11061
HSV2-UL19-6679 - GCUCAUGAACAUCGACGCGGCCGU 24 11062
HSV2-UL19-6680 - UCGAGGCCGCGAAUCCGU 18 11063
HSV2-UL19-6681 - GUCGAGGCCGCGAAUCCGU 19 11064
HSV2-UL19-2078 - CGUCGAGGCCGCGAAUCCGU 20 2400
HSV2-UL19-6682 - CCGUCGAGGCCGCGAAUCCGU 21 11065
HSV2-UL19-6683 - CCCGUCGAGGCCGCGAAUCCGU 22 11066
HSV2-UL19-6684 - CCCCGUCGAGGCCGCGAAUCCGU 23 11067
HSV2-UL19-6685 - ACCCCGUCGAGGCCGCGAAUCCGU 24 11068
HSV2-UL19-6686 - UGU UUUCCGAGCGCGCGU 18 11069
HSV2-UL19-6687 - CUGUU UUCCGAGCGCGCGU 19 11070
HSV2-UL19-618 - GCUGUUUUCCGAGCGCGCGU 20 858
HSV2-UL19-6688 - UGCUGUUUUCCGAGCGCGCGU 21 11071
HSV2-UL19-6689 - GUGCUGUUUUCCGAGCGCGCGU 22 11072
HSV2-UL19-6690 - CGUGCUGUUUUCCGAGCGCGCGU 23 11073
HSV2-UL19-6691 - ACGUGCUGUUUUCCGAGCGCGCGU 24 11074
HSV2-UL19-6692 - CCGCCGUCCGCGGGGCGU 18 11075
HSV2-UL19-6693 - GCCGCCGUCCGCGGGGCGU 19 11076
HSV2-UL19-2101 - AGCCGCCGUCCGCGGGGCGU 20 2415
HSV2-UL19-6694 - UAGCCGCCGUCCGCGGGGCGU 21 11077
HSV2-UL19-6695 - AUAGCCGCCGUCCGCGGGGCGU 22 11078
HSV2-UL19-6696 - CAUAGCCGCCGUCCGCGGGGCGU 23 11079
HSV2-UL19-6697 - CCAUAGCCGCCGUCCGCGGGGCGU 24 11080
HSV2-UL19-6698 - AGGCCGUCCUGGGGGCGU 18 11081
HSV2-UL19-6699 - CAGGCCGUCCUGGGGGCGU 19 11082
HSV2-UL19-1997 - CCAGGCCGUCCUGGGGGCGU 20 2343
HSV2-UL19-6700 - UCCAGGCCGUCCUGGGGGCGU 21 11083
HSV2-UL19-6701 - GUCCAGGCCGUCCUGGGGGCGU 22 11084
HSV2-UL19-6702 - CGUCCAGGCCGUCCUGGGGGCGU 23 11085
HSV2-UL19-6703 - ACGUCCAGGCCGUCCUGGGGGCGU 24 11086
HSV2-UL19-6704 - GCUGCUGCCGCCCCUCGU 18 11087
HSV2-UL19-6705 - CGCUGCUGCCGCCCCUCGU 19 11088
HSV2-UL19-2124 - GCGCUGCUGCCGCCCCUCGU 20 2432 HSV2-UL19-6706 - GGCGCUGCUGCCGCCCCUCGU 21 11089
HSV2-UL19-6707 - CGGCGCUGCUGCCGCCCCUCGU 22 11090
HSV2-UL19-6708 - CCGGCGCUGCUGCCGCCCCUCGU 23 11091
HSV2-UL19-6709 - CCCGGCGCUGCUGCCGCCCCUCGU 24 11092
HSV2-UL19-6710 - CGUCGCAGCGGUUCUCGU 18 11093
HSV2-UL19-6711 - GCGUCGCAGCGGUUCUCGU 19 11094
HSV2-UL19-2224 - GGCGUCGCAGCGGUUCUCGU 20 2494
HSV2-UL19-6712 - GGGCGUCGCAGCGGUUCUCGU 21 11095
HSV2-UL19-6713 - UGGGCGUCGCAGCGGUUCUCGU 22 11096
HSV2-UL19-6714 - GUGGGCGUCGCAGCGGUUCUCGU 23 11097
HSV2-UL19-6715 - CGUGGGCGUCGCAGCGGUUCUCGU 24 11098
HSV2-UL19-6716 - CCGGAGAUCGCCCCCGGU 18 11099
HSV2-UL19-6717 - CCCGGAGAUCGCCCCCGGU 19 11100
HSV2-UL19-2146 - UCCCGGAGAUCGCCCCCGGU 20 2444
HSV2-UL19-6718 - GUCCCGGAGAUCGCCCCCGGU 21 11101
HSV2-UL19-6719 - GGUCCCGGAGAUCGCCCCCGGU 22 11102
HSV2-UL19-6720 - UGGUCCCGGAGAUCGCCCCCGGU 23 11103
HSV2-UL19-6721 - GUGGUCCCGGAGAUCGCCCCCGGU 24 11104
HSV2-UL19-6722 - GAAGUCCCCCCGGCCGGU 18 11105
HSV2-UL19-6723 - CGAAG UCCCCCCGGCCGG U 19 11106
HSV2-UL19-2092 - GCGAAGUCCCCCCGGCCGGU 20 2411
HSV2-UL19-6724 - GGCGAAGUCCCCCCGGCCGGU 21 11107
HSV2-UL19-6725 - CGGCGAAGUCCCCCCGGCCGGU 22 11108
HSV2-UL19-6726 - GCGGCGAAGUCCCCCCGGCCGGU 23 11109
HSV2-UL19-6727 - GGCGGCGAAGUCCCCCCGGCCGGU 24 11110
HSV2-UL19-6728 - G U CCAU GG AG AACG CG G U 18 11111
HSV2-UL19-6729 - UGUCCAUGGAGAACGCGGU 19 11112
HSV2-UL19-438 - CUGUCCAUGGAGAACGCGGU 20 678
HSV2-UL19-6730 - GCUGUCCAUGGAGAACGCGGU 21 11113
HSV2-UL19-6731 - GGCUGUCCAUGGAGAACGCGGU 22 11114
HSV2-UL19-6732 - CGGCUGUCCAUGGAGAACGCGGU 23 11115
HSV2-UL19-6733 - GCGGCUGUCCAUGGAGAACGCGGU 24 11116
HSV2-UL19-6734 - GGAAACGUGGACCUGGGU 18 11117
HSV2-UL19-6735 - CGGAAACGUGGACCUGGGU 19 11118
HSV2-UL19-2193 - GCGGAAACGUGGACCUGGGU 20 2476
HSV2-UL19-6736 - CGCGGAAACGUGGACCUGGGU 21 11119
HSV2-UL19-6737 - GCGCGGAAACGUGGACCUGGGU 22 11120
HSV2-UL19-6738 - CGCGCGGAAACGUGGACCUGGGU 23 11121
HSV2-UL19-6739 - CCGCGCGGAAACGUGGACCUGGGU 24 11122
HSV2-UL19-6740 - AGAUGCUGCACGUGCUGU 18 11123
HSV2-UL19-6741 - CAGAUGCUGCACGUGCUGU 19 11124
HSV2-UL19-348 - CCAGAUGCUGCACGUGCUGU 20 588
HSV2-UL19-6742 - ACCAGAUGCUGCACGUGCUGU 21 11125
HSV2-UL19-6743 - GACCAGAUGCUGCACGUGCUGU 22 11126
HSV2-UL19-6744 - CGACCAGAUGCUGCACGUGCUGU 23 11127
HSV2-UL19-6745 - CCGACCAGAUGCUGCACGUGCUGU 24 11128 HSV2-UL19-6746 - ACCGUCCG CAACCCCG U U 18 11129
HSV2-UL19-6747 - CACCGUCCGCAACCCCGUU 19 11130
HSV2-UL19-2195 - GCACCGUCCGCAACCCCGUU 20 2478
HSV2-UL19-6748 - GGCACCG UCCGCAACCCCGU U 21 11131
HSV2-UL19-6749 - GGGCACCGUCCGCAACCCCGUU 22 11132
HSV2-UL19-6750 - CGGGCACCGUCCG CAACCCCG U U 23 11133
HSV2-UL19-6751 - ACGGGCACCGUCCGCAACCCCGUU 24 11134
HSV2-UL19-6752 - GCGUCGGAGGCGUACUUU 18 11135
HSV2-UL19-6753 - CGCGUCGGAGGCGUACUUU 19 11136
HSV2-UL19-2181 - GCGCGUCGGAGGCGUACUUU 20 2469
HSV2-UL19-6754 - CGCGCGUCGGAGGCGUACUUU 21 11137
HSV2-UL19-6755 - GCGCGCGUCGGAGGCGUACUUU 22 11138
HSV2-UL19-6756 - AGCGCGCGUCGGAGGCGUACUUU 23 11139
HSV2-UL19-6757 - GAGCGCGCGUCGGAGGCGUACUUU 24 11140
HSV2-UL19-6758 - GACCCGUGCGGCCUGUUU 18 11141
HSV2-UL19-6759 - AGACCCGUGCGGCCUGUUU 19 11142
HSV2-UL19-2242 - AAGACCCGUGCGGCCUGUUU 20 2503
HSV2-UL19-6760 - GAAGACCCGUGCGGCCUGUUU 21 11143
HSV2-UL19-6761 - GGAAGACCCGUGCGGCCUGUUU 22 11144
HSV2-UL19-6762 - UGGAAGACCCGUGCGGCCUGUUU 23 11145
HSV2-UL19-6763 - GUGGAAGACCCGUGCGGCCUGUUU 24 11146
HSV2-UL19-6764 - CCCGUCCACGCGCUGUUU 18 11147
HSV2-UL19-6765 - GCCCGUCCACGCGCUGUUU 19 11148
HSV2-UL19-2157 - UGCCCGUCCACGCGCUGUUU 20 2453
HSV2-UL19-6766 - CUGCCCGUCCACGCGCUGUUU 21 11149
HSV2-UL19-6767 - CCUGCCCGUCCACGCGCUGUUU 22 11150
HSV2-UL19-6768 - UCCUGCCCGUCCACGCGCUGUUU 23 11151
HSV2-UL19-6769 - GUCCUGCCCGUCCACGCGCUGUUU 24 11152
HSV2-UL19-6770 - GACAUGCAGCAGCGUUUU 18 11153
HSV2-UL19-6771 - GGACAUGCAGCAGCGUUUU 19 11154
HSV2-UL19-2081 - CGGACAUGCAGCAGCGUUUU 20 2402
HSV2-UL19-6772 - GCGGACAUGCAGCAGCGUUUU 21 11155
HSV2-UL19-6773 - CGCGGACAUGCAGCAGCGUUUU 22 11156
HSV2-UL19-6774 - GCGCGGACAUGCAGCAGCGUUUU 23 11157
HSV2-UL19-6775 - GGCGCGGACAUGCAGCAGCGUUUU 24 11158
HSV2-UL19-6776 - CCGAGAACGUGCUGUUUU 18 11159
HSV2-UL19-6777 - ACCGAGAACGUGCUGUUUU 19 11160
HSV2-UL19-2178 - GACCGAGAACGUGCUGUUUU 20 2467
HSV2-UL19-6778 - UGACCGAGAACGUGCUGUUUU 21 11161
HSV2-UL19-6779 - GUGACCGAGAACGUGCUGUUUU 22 11162
HSV2-UL19-6780 - CGUGACCGAGAACGUGCUGUUUU 23 11163
HSV2-UL19-6781 - UCGUGACCGAGAACGUGCUGUUUU 24 11164
HSV2-UL19-6782 - UCCCCGGCAGCUGUUUUU 18 11165
HSV2-UL19-6783 - CUCCCCGGCAGCUGUUUUU 19 11166
HSV2-UL19-2061 - CCUCCCCGGCAGCUGUUUUU 20 2390
HSV2-UL19-6784 - CCCUCCCCGGCAGCUGUUUUU 21 11167 HSV2-UL19-6785 - UCCCUCCCCGGCAGCUGUUUUU 22 11168
HSV2-UL19-6786 - UUCCCUCCCCGGCAGCUGUUUUU 23 11169
HSV2-UL19-6787 - GUUCCCUCCCCGGCAGCUGUUUUU 24 11170
HSV2-UL19-6788 - CCCCGGCAGCUGUUUUUU 18 11171
HSV2-UL19-6789 - UCCCCGGCAGCUGUUUUUU 19 11172
HSV2-UL19-430 - CUCCCCGGCAGCUGUUUUUU 20 670
HSV2-UL19-6790 - CCUCCCCGGCAGCUGUUUUUU 21 11173
HSV2-UL19-6791 - CCCUCCCCGGCAGCUGUUUUUU 22 11174
HSV2-UL19-6792 - UCCCUCCCCGGCAGCUGUUUUUU 23 11175
HSV2-UL19-6793 - UUCCCUCCCCGGCAGCUGUUUUUU 24 11176
HSV2-UL19-6794 - CCCGGCAGCUGUUUUUUU 18 11177
HSV2-UL19-6795 - CCCCGGCAGCUGUUUUUUU 19 11178
HSV2-UL19-431 - UCCCCGGCAGCUGUUUUUUU 20 671
HSV2-UL19-6796 - CUCCCCGGCAGCUGUUUUUUU 21 11179
HSV2-UL19-6797 - CCUCCCCGGCAGCUGUUUUUUU 22 11180
HSV2-UL19-6798 - CCCUCCCCGGCAGCUGUUUUUUU 23 11181
HSV2-UL19-6799 - UCCCUCCCCGGCAGCUGUUUUUUU 24 11182
Table 7 A provides exemplary targeting domains for knocking out the UL19 gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 7A
Figure imgf000435_0001
Table 7B provides exemplary targeting domains for knocking out the UL19 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase)
Table 7B
Figure imgf000436_0001
Table 7C provides exemplary targeting domains for knocking out the UL19 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 7C
Figure imgf000436_0002
HSV2-UL19-6812 - UGU UCAACCCGGCCAUG 17 11195
HSV2-UL19-6813 + UGCUCGUUGCCGUGAAU 17 11196
HSV2-UL19-3068 + CGGCACCAGCACGUAAU 17 3065
HSV2-UL19-3062 - GGACCGCCACCGAGACU 17 3060
HSV2-UL19-6814 - AAAGGGCCUGUCUCUGUAAA 20 11197
HSV2-UL19-6815 + CGACG CG CCCG U U G U G G AAC 20 11198
HSV2-UL19-2008 - UGAAGCGGAGCUU UUGCGAC 20 2352
HSV2-UL19-3063 + UGCGCUUGACCGUGU UGGCC 20 3061
HSV2-UL19-6816 - GGGCCUCGCCCGUCCUCAGC 20 11199
HSV2-UL19-1127 + CGAGCUCGCGGCACCCCGGC 20 1367
HSV2-UL19-1353 + GCAGCGCCGGGUCGCGCAUC 20 1593
HSV2-UL19-6817 - GUAAAAUUGGCUUCU UCUUC 20 11200
HSV2-UL19-6818 + AGAAGCUCGUGUCGCAAAAG 20 11201
HSV2-UL19-3059 - GGUGUUUUACCUGCUGCAAG 20 3057
HSV2-UL19-359 - CCCUGGUCGCCGAGCUGAAG 20 599
HSV2-UL19-6819 - GGUUCACCGUCGUGCGGCAG 20 11202
HSV2-UL19-3066 + GGGCCGCGACG UACGCCCCG 20 3063
HSV2-UL19-6820 + UCGCUGGCGCAGGUGAUCGG 20 11203
HSV2-UL19-6821 - GGCGCUGCUGCACCGCGGGG 20 11204
HSV2-UL19-1492 + GCGCACGCGCGUUGUCUGGG 20 1732
HSV2-UL19-6822 - GGCUGUUCAACCCGGCCAUG 20 11205
HSV2-UL19-3064 + GGCCGGCACCAGCACG UAAU 20 3062
HSV2-UL19-3060 - CCUGGACCGCCACCGAGACU 20 3058
Table 8A provides exemplary targeting domains for knocking out the UL30 gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 8A
Figure imgf000437_0001
HSV2-U L30-217 + GCGUUCCGGUCUGAGCG 17 3148
HSV2-U L30-162 - GCGCGACGUCCUCCGCG 17 3121
HSV2-U L30-207 + GGUGCGCUGCUCCGCGG 17 3142
HSV2-U L30-188 + GGGGUCGAACCCCUCGG 17 3134
HSV2-UL30-156 - GCCCCUAAGGUGUACUG 17 3116
HSV2-UL30-169 - GCGUCGCU UGCGCCUGU 17 3124
HSV2-UL30-66 + GGUCGAACCCCUCGGGGGCA 20 3090
HSV2-UL30-51 - GGUGCGGACCAUGCCCCCGA 20 3083
HSV2-UL30-58 + GUACACGUGGAAGACGGUGA 20 3196
HSV2-UL30-27 - GCCCCCGCGGAGCAGCGCAC 20 3180
HSV2-UL30-2855 - GCGUAUAGCAGGACAACGAC 20 11209
HSV2-U L30-122 + GCUUCCCCCCGGGGGAAGCC 20 3233
HSV2-UL30-1 - GUU UUGUGCCGCGGGCGGCC 20 3157
HSV2-UL30-70 + GACGCGGCCAGAAGCCCUCC 20 3200
HSV2-UL30-7 - GGCUUCCCCCGGGGGGAAGC 20 3163
HSV2-UL30-2856 + GCGGCACAAAACAUCGCCGC 20 11210
HSV2-UL30-2857 - GCGGCGAUGUU UUGUGCCGC 20 11211
HSV2-UL30-34 - GCGCCCCUAAGGUGUACUGC 20 3072
HSV2-UL30-31 - GGGUCCACGACGGCCGCCUC 20 3070
HSV2-U L30-104 + GGCAAGGCGGCGGUGCCGUC 20 3109
HSV2-UL30-85 + GCGUCCUCGUCCAGCGAACG 20 3098
HSV2-UL30-2858 - GGCGGCGAUGU UUUGUGCCG 20 11212
HSV2-UL30-94 + GCUGCGUUCCGGUCUGAGCG 20 3103
HSV2-UL30-87 + GUCCUCG UCCAGCGAACGCG 20 3210
HSV2-UL30-95 + GCGUUCCGGUCUGAGCGAGG 20 3104
HSV2-UL30-36 - GCCCCUAAGGUGUACUGCGG 20 3073
HSV2-UL30-65 + GGUGGGGUCGAACCCCUCGG 20 3089
HSV2-UL30-2859 - GCGAUGUU UUGUGCCGCGGG 20 11213
HSV2-UL30-97 + GU UCCGGUCUGAGCGAGGUG 20 3105
HSV2-UL30-62 + GACGGUGGGGUCGAACCCCU 20 3086
HSV2-UL30-105 + GCAAGGCGGCGGUGCCGUCU 20 3110
HSV2-UL30-40 - GAGCGCGACGUCCUCCGCGU 20 3077
HSV2-UL30-46 - GCCGCGUCGCU UGCGCCUGU 20 3079
HSV2-U L30-112 + GGUGGCUCCCCGGGGGUUGU 20 3223
Table 8B provides exemplary targeting domains for knocking out the UL30 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase). Table 8B
Figure imgf000439_0001
HSV2-U L30-118 + CGAGCCGCCGGCUUCCCCCC 20 3229
HSV2-U L30-117 + CCGAGCCGCCGGCUUCCCCC 20 3228
HSV2-UL30-41 - CGACGUCCUCCGCGUGGGCC 20 3186
HSV2-UL30-53 - CUUCCACGUGUACGACAUCC 20 3084
HSV2-UL30-55 + ACGCGUGUUCCACGUGCUCC 20 3193
HSV2-UL30-2862 + CCAUAAAUCGCUCGUGGAGC 20 11216
HSV2-UL30-89 + UAGUACGUAUGGCGCUGAGC 20 3100
HSV2-UL30-86 + CGUCCUCGUCCAGCGAACGC 20 3099
HSV2-UL30-18 - CGGCACCGCCGCCUUGCCGC 20 3067
HSV2-UL30-76 + AGUACACCU UAGGGGCGCGC 20 3095
HSV2-UL30-24 - AUUUAUCGCCCCGCGUUCGC 20 3178
HSV2-UL30-63 + ACGGUGGGGUCGAACCCCUC 20 3087
HSV2-UL30-69 + CGACGCGGCCAGAAGCCCUC 20 3092
HSV2-UL30-10 - CGGGGGGAAGCCGGCGGCUC 20 3166
HSV2-UL30-75 + CCCCCCGCAG U ACACCU U AG 20 3094
HSV2-UL30-68 + CCCCACAGGCGCAAGCGACG 20 3091
HSV2-UL30-25 - CGCCCCGCGUUCGCUGGACG 20 3069
HSV2-UL30-29 - CCCCGCGGAGCAGCGCACCG 20 3182
HSV2-UL30-50 - CGGUGCGGACCAUGCCCCCG 20 3082
HSV2-UL30-90 + UAUGGCGCUGAGCCGGCCCG 20 3212
HSV2-UL30-39 - CGAGCGCGACGUCCUCCGCG 20 3076
HSV2-UL30-35 - CGCCCCUAAGGUGUACUGCG 20 3185
HSV2-UL30-64 + CGGUGGGGUCGAACCCCUCG 20 3088
HSV2-UL30-1438 + UGGCGUCCAUAAAUCGCUCG 20 4308
HSV2-UL30-102 + AAGUUCUGCCGGCGGCAAGG 20 3108
HSV2-UL30-78 + CCUUAGGGGCGCGCCGGAGG 20 3204
HSV2-UL30-2863 - UAUAGCAGGACAACGACCGG 20 11217
HSV2-UL30-110 + CCGUCUGGGUGGCUCCCCGG 20 3111
HSV2-UL30-77 + ACACCU UAGGGGCGCGCCGG 20 3096
HSV2-UL30-84 + CCCGGUGCGCUGCUCCGCGG 20 3097
HSV2-UL30-37 - CCCCUAAGGUGUACUGCGGG 20 3074
HSV2-UL30-38 - CCCUAAGGUGUACUGCGGGG 20 3075
HSV2-UL30-48 - CGUCGCU UGCGCCUGUGGGG 20 3081
HSV2-UL30-2864 + AAAUCGCUCGUGGAGCUGGG 20 11218
HSV2-UL30-33 - CGCGCCCCUAAGGUGUACUG 20 3071
HSV2-UL30-49 - CUUGCGCCUGUGGGGCGGUG 20 3190
HSV2-UL30-47 - CCGCGUCGCUUGCGCCUGUG 20 3080
HSV2-UL30-9 - CCGGGGGGAAGCCGGCGGCU 20 3165
HSV2-UL30-96 + CGUUCCGGUCUGAGCGAGGU 20 3214
HSV2-UL30-60 + ACGUGGAAGACGGUGACGGU 20 3085
Table 8C provides exemplary targeting domains for knocking out the UL30 gene selected according to the third tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 8C
Figure imgf000441_0001
HSV2-UL30-121 + GGCU UCCCCCCGGGGG AAGC 20 3232
HSV2-UL30-23 - G C AG CCA A AG GCCCUCGGGC 20 3177
HSV2-UL30-99 + GGGGGUUGUAGAAGUUCUGC 20 3216
HSV2-UL30-22 - GAACGCAGCCAAAGGCCCUC 20 3176
HSV2-UL30-44 - GCGUGGGCCCGGAGGGCUUC 20 3188
HSV2-UL30-93 + GAGGGCCUUUGGCUGCGUUC 20 3102
HSV2-UL30-52 - GUGCGGACCAUGCCCCCGAG 20 3191
HSV2-UL30-56 + GCUCCAGGAUGUCGUACACG 20 3194
HSV2-UL30-54 - GUACGACAUCCUGGAGCACG 20 3192
HSV2-UL30-119 + GAGCCGCCGGCUUCCCCCCG 20 3230
HSV2-UL30-26 - GCUGGACGAGGACGCCCCCG 20 3179
HSV2-UL30-4 - GGGCGGCCCGGCU UCCCCCG 20 3160
HSV2-UL30-109 + GCCGUCUGGGUGGCUCCCCG 20 3221
HSV2-UL30-123 + GGGGGAAGCCGGGCCGCCCG 20 3234
HSV2-UL30-81 + GACCCCGGUGCGCUGCUCCG 20 3207
HSV2-UL30-5 - GGCGGCCCGGCUUCCCCCGG 20 3161
HSV2-UL30-100 + GGUUGUAGAAGUUCUGCCGG 20 3106
HSV2-UL30-6 - GCGGCCCGGCUUCCCCCGGG 20 3162
HSV2-UL30-11 - GGGGAAGCCGGCGGCUCGGG 20 3167
HSV2-UL30-115 + GGCUCCCCGGGGGUUGUGGG 20 3226
HSV2-UL30-45 - GGCCGCGUCGCU UGCGCCUG 20 3189
HSV2-UL30-113 + GUGGCUCCCCGGGGGUUGUG 20 3224
HSV2-UL30-111 + GGGUGGCUCCCCGGGGGU UG 20 3222
HSV2-UL30-21 - GGAACGCAGCCAAAGGCCCU 20 3175
Table 8D provides exemplary targeting domains for knocking out the UL30 gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 8D
Figure imgf000442_0001
HSV2-U L30-150 - CCCGCGGAGCAGCGCAC 17 3258
HSV2-U L30-142 - CCCCACCUCGCUCAGAC 17 3252
HSV2-UL30-2866 - UAUAGCAGGACAACGAC 17 11220
HSV2-U L30-151 - CCGCGGAGCAGCGCACC 17 3259
HSV2-UL30-137 - UUGCCCCCCACAACCCC 17 3248
HSV2-UL30-138 - UGCCCCCCACAACCCCC 17 3249
HSV2-U L30-240 + AGCCGCCGGCUUCCCCC 17 3306
HSV2-UL30-231 + CGUCUGGGUGGCUCCCC 17 3298
HSV2-UL30-230 + CCGUCUGGGUGGCUCCC 17 3297
HSV2-U L30-245 + UCCCCCCGGGGGAAGCC 17 3311
HSV2-UL30-124 - UUGUGCCGCGGGCGGCC 17 3235
HSV2-U L30-164 - CGUCCUCCGCGUGGGCC 17 3264
HSV2-U L30-176 - CCACG UG U ACG ACAU CC 17 3129
HSV2-UL30-178 + CGUGU UCCACGUGCUCC 17 3271
HSV2-U L30-244 + U UCCCCCCGGGGG AAGC 17 3310
HSV2-UL30-130 - UUCCCCCGGGGGGAAGC 17 3241
HSV2-UL30-141 - CACCGCCGCCUUGCCGC 17 3112
HSV2-U L30-157 - CCCCUAAGGUGUACUGC 17 3117
HSV2-UL30-192 + CGCGGCCAGAAGCCCUC 17 3137
HSV2-U L30-145 - CG C AG CCA A AG G CCC U C 17 3254
HSV2-U L30-154 - UCCACGACGGCCGCCUC 17 3115
HSV2-UL30-167 - UGGGCCCGGAGGGCUUC 17 3266
HSV2-U L30-198 + CCCGCAGUACACCUUAG 17 3139
HSV2-U L30-179 + CCAGGAUGUCGUACACG 17 3272
HSV2-UL30-194 + AG CCC U CCG G G CCC ACG 17 3279
HSV2-U L30-177 - CGACAUCCUGGAGCACG 17 3270
HSV2-UL30-242 + CCGCCGGCUUCCCCCCG 17 3308
HSV2-UL30-127 - CGGCCCGGCUUCCCCCG 17 3238
HSV2-U L30-204 + CCCGGUGCGCUGCUCCG 17 3285
HSV2-UL30-225 + UUCUGCCGGCGGCAAGG 17 3153
HSV2-UL30-218 + UUCCGGUCUGAGCGAGG 17 3149
HSV2-UL30-2867 - AGCAGGACAACGACCGG 17 11221
HSV2-UL30-243 + CGCCGGCUUCCCCCCGG 17 3309
HSV2-U L30-233 + UCUGGGUGGCUCCCCGG 17 3156
HSV2-U L30-165 - CCUCCGCGUGGGCCCGG 17 3265
HSV2-UL30-131 - CCCCGGGGGGAAGCCGG 17 3242
HSV2-U L30-223 + UGUAGAAGUUCUGCCGG 17 3151
HSV2-UL30-195 + CCUCCGGGCCCACGCGG 17 3280
HSV2-UL30-226 + UGCCGGCGGCAAGGCGG 17 3295
HSV2-U L30-160 - CUAAGGUGUACUGCGGG 17 3119
HSV2-U L30-161 - UAAGG UGUACUGCGGGG 17 3120
HSV2-U L30-171 - CGCU UGCGCCUG UGGGG 17 3126
HSV2-UL30-2868 + UCGCUCGUGGAGCUGGG 17 11222
HSV2-UL30-229 + CGGCGGUGCCGUCUGGG 17 3296
HSV2-U L30-238 + UCCCCGGGGGUUG UGGG 17 3304
HSV2-U L30-221 + CGGUCUGAGCGAGGUGG 17 3293 HSV2-U L30-237 + CUCCCCGGGGGUUGUGG 17 3303
HSV2-U L30-220 + CCGGUCUGAGCGAGGUG 17 3150
HSV2-U L30-234 + UGGCUCCCCGGGGGU UG 17 3300
HSV2-U L30-144 - ACG CAG CCA AAGG CCCU 17 3253
HSV2-UL30-2869 + AAAUCGCUCGUGGAGCU 17 11223
HSV2-UL30-136 - CGGCUCGGGCGGCGUCU 17 3247
HSV2-U L30-183 + UGGAAGACGGUGACGG U 17 3130
HSV2-UL30-196 + CCCCCGCAGUACACCU U 17 3281
HSV2-UL30-30 - CAGCGCACCGGGGUCCACGA 20 3183
HSV2-UL30-2870 - CCAGCUCCACGAGCGAU UUA 20 11224
HSV2-UL30-19 - AACCCCCACCUCGCUCAGAC 20 3174
HSV2-UL30-14 - U U U U UGCCCCCCACAACCCC 20 3170
HSV2-UL30-15 - U U U U G CCCCCCACA ACCCCC 20 3171
HSV2-UL30-3 - CGGGCGGCCCGGCUUCCCCC 20 3159
HSV2-U L30-108 + UGCCGUCUGGGUGGCUCCCC 20 3220
HSV2-UL30-116 + CCAGACGCCGCCCGAGCCGC 20 3227
HSV2-UL30-82 + ACCCCGGUGCGCUGCUCCGC 20 3208
HSV2-UL30-12 - CCGGCGGCUCGGGCGGCGUC 20 3168
HSV2-UL30-71 + AGAAGCCCUCCGGGCCCACG 20 3201
HSV2-UL30-16 - U U U G CCCCCCAC AACCCCCG 20 3172
HSV2-UL30-83 + CCCCGG UGCGCUGCUCCGCG 20 3209
HSV2-UL30-79 + CGCGCCGGAGGCGGCCGUCG 20 3205
HSV2-UL30-59 + CACGUGGAAGACGGUGACGG 20 3197
HSV2-U L30-120 + AGCCGCCGGCUUCCCCCCGG 20 3231
HSV2-UL30-42 - CGUCCUCCGCGUGGGCCCGG 20 3187
HSV2-U L30-8 - UUCCCCCGGGGGGAAGCCGG 20 3164
HSV2-UL30-72 + AGCCCUCCGGGCCCACGCGG 20 3202
HSV2-UL30-103 + UUCUGCCGGCGGCAAGGCGG 20 3217
HSV2-U L30-106 + AGGCGGCGGUGCCGUCUGGG 20 3218
HSV2-UL30-98 + UUCCGGUCUGAGCGAGGUGG 20 3215
HSV2-UL30-114 + UGGCUCCCCGGGGGUUGUGG 20 3225
HSV2-UL30-61 + CGUGGAAGACGGUGACGGUG 20 3198
HSV2-UL30-2871 + CAU AAAUCGCUCG UGG AGCU 20 11225
HSV2-UL30-13 - CGGCGGCUCGGGCGGCGUCU 20 3169
HSV2-UL30-73 + UCCCCCCCGCAGUACACCU U 20 3203
HSV2-UL30-92 + UGAGCCGGCCCGAGGGCCUU 20 3213
Table 8E provides exemplary targeting domains for knocking out the UL30 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 8E
Figure imgf000445_0001
HSV2-UL30-1485 + CU UGGCCGGGGAGGGCA 17 4355
HSV2-UL30-1537 + CUGCAGUCCCUCGGGCA 17 4407
HSV2-UL30-1777 + AGAGAUCGCGCGGGGCA 17 4647
HSV2-UL30-821 - CUUCGAUAUCGAAUGCA 17 3691
HSV2-UL30-813 - CGUCGAGUUUAACUGCA 17 3683
HSV2-UL30-966 - GCAACAGGCCGCCAUCA 17 3836
HSV2-UL30-1031 - GCAGGUCCCGUCCAUCA 17 3901
HSV2-UL30-1004 - GGGCAAGAUGCUCAUCA 17 3874
HSV2-UL30-857 - GAAGCGCAGCAAGAUCA 17 3727
HSV2-UL30-991 - UU UGUGCCGCGGCCUCA 17 3861
HSV2-UL30-1029 - GGUGUAU UACAAGCUCA 17 3899
HSV2-UL30-1072 - CGUGGCCGCGCGGCUCA 17 3942
HSV2-UL30-1580 + GCGGCCGAUGGUCGUCA 17 4450
HSV2-UL30-1064 - GGCCUGCGUGACGUUCA 17 3934
HSV2-UL30-998 - GGCCAUGGGCGACAAGA 17 3868
HSV2-UL30-1673 + CUUCUUGUCCU UCAAGA 17 4543
HSV2-UL30-865 - CU UG AAGG ACAAG AAG A 17 3735
HSV2-UL30-883 - GCGCCUUGCGGGCCAGA 17 3753
HSV2-UL30-1036 - CCGCGAGGUAGAGGAGA 17 3906
HSV2-UL30-1025 - CAUCACCGACCCGGAGA 17 3895
HSV2-UL30-1656 + CUGCUGGCCGUCGUAGA 17 4526
HSV2-UL30-1695 + G U C A A AC U CCAGGACGA 17 4565
HSV2-UL30-1686 + CAGCUUGGUCAGGACGA 17 4556
HSV2-UL30-1692 + GCCGUACUGCUUGACGA 17 4562
HSV2-UL30-880 - ACCCGCACCAUCUACGA 17 3750
HSV2-UL30-796 - GCGAUCAGGAAGUACGA 17 3666
HSV2-UL30-769 - CUGGGUCUGACCCCCGA 17 3639
HSV2-UL30-811 - CCAACCGCGCCCCCCGA 17 3681
HSV2-UL30-1017 - GCGCGACCCCUGCCCGA 17 3887
HSV2-UL30-1748 + GAGGCGGUACCAGCCGA 17 4618
HSV2-UL30-1530 + GGUCGGUGAUGCGCCGA 17 4400
HSV2-UL30-1579 + GAGCAUCUCGCGGCCGA 17 4449
HSV2-UL30-958 - UCGAGGUGGGGGGCCGA 17 3828
HSV2-UL30-1780 + CGUGAACGGCGACGCGA 17 4650
HSV2-UL30-1660 + GCCCGCCAGGCGCGCGA 17 4530
HSV2-UL30-1610 + CGCCUCCAGGUGCGCGA 17 4480
HSV2-UL30-1675 + CAAGACGGCCUCGGCGA 17 4545
HSV2-UL30-1459 + CGGAACGCCCCGGGCGA 17 4329
HSV2-UL30-1473 + GGGGGGUCGGCAUGCGA 17 4343
HSV2-UL30-1731 + ACACAUGGCCCCCUCGA 17 4601
HSV2-UL30-846 - U ACAAG GUCCCGCUCGA 17 3716
HSV2-UL30-1714 + CAGGAGGAUGUGCUCGA 17 4584
HSV2-UL30-817 - GACAACCUGGCCGUCGA 17 3687
HSV2-UL30-2873 + CGGGACAUCAGCUUCGA 17 11227
HSV2-UL30-917 - AAGGACGACGACGAGGA 17 3787
HSV2-UL30-921 - GAGGACGGGGACGAGGA 17 3791 HSV2-UL30-1533 + AUGGGCGUCUACGAGGA 17 4403
HSV2-UL30-1591 + UUGCU UGUCGAGGAGGA 17 4461
HSV2-UL30-1501 + GGCGUCUAGCUCGCGGA 17 4371
HSV2-UL30-860 - GAUCAAGGUGAACGGGA 17 3730
HSV2-UL30-1483 + GGGCGCUUGGCCGGGGA 17 4353
HSV2-UL30-909 - GGGGAGCGGCCGGGGGA 17 3779
HSV2-UL30-901 - GCCGUGCCUCGGGGGGA 17 3771
HSV2-UL30-1511 + AUCCGGUCCUUGAUGGA 17 4381
HSV2-UL30-1693 + CU UGACGAAGGUCAUGA 17 4563
HSV2-UL30-1785 + ACCCAGAAGCGUGAUGA 17 4655
HSV2-UL30-1028 - GCGCCUGGCCCACCUGA 17 3898
HSV2-UL30-844 - CGUCCUGACCAAGCUGA 17 3714
HSV2-UL30-1789 + GGUCCCGGCGGGCGUGA 17 4659
HSV2-UL30-959 - ACGGCUGUUCUUCGUGA 17 3829
HSV2-UL30-1587 + GUUGCACACCACCUUGA 17 4457
HSV2-UL30-1510 + CGGGAUCCGGUCCU UGA 17 4380
HSV2-UL30-864 - CGCCGAGGCCGUCU UGA 17 3734
HSV2-UL30-915 - GAACGGGGACGAGGAUA 17 3785
HSV2-UL30-1546 + GGCGGCCGCUCCGGAUA 17 4416
HSV2-UL30-1084 - GGCGGGGGCCGGCGCUA 17 3954
HSV2-UL30-986 - UCCAUGCGCAUCAUCUA 17 3856
HSV2-UL30-770 - GUCGCCGUUCACGUCUA 17 3640
HSV2-UL30-840 - ACCUUCGU C A AG C AG U A 17 3710
HSV2-UL30-1569 + AUGAUGCGCAUGGAGUA 17 4439
HSV2-UL30-1507 + UGGGCCACGAUCACGUA 17 4377
HSV2-UL30-848 - GUCCCGCUCGACGGGUA 17 3718
HSV2-UL30-861 - GUGAACAUCGACAUGUA 17 3731
HSV2-UL30-969 - GUGUGCAACUCGGUGUA 17 3839
HSV2-UL30-2865 - GCUCCACGAGCGAUUUA 17 11219
HSV2-UL30-1711 + AGGAUCCGAGCGAAAAC 17 4581
HSV2-UL30-1452 + UGGCGU UAUUUCCAAAC 17 4322
HSV2-UL30-1752 + GGUUGUCCAGGAUAAAC 17 4622
HSV2-UL30-965 - CCUCCUCGACAAGCAAC 17 3835
HSV2-UL30-912 - GGCCGGGGGACGGGAAC 17 3782
HSV2-UL30-859 - G C A AG A U C A AG G U G A AC 17 3729
HSV2-UL30-1625 + AAG U CAA AC ACC ACC AC 17 4495
HSV2-UL30-1615 + AGAGCGUACUGAAGCAC 17 4485
HSV2-UL30-1759 + G G CAA A AG UUGUCGCAC 17 4629
HSV2-UL30-971 - UCGGUGUACGGGUUCAC 17 3841
HSV2-UL30-1719 + CAGGUCGUAGAGCAGAC 17 4589
HSV2-UL30-926 - GAGGUCGCGCGCGAGAC 17 3796
HSV2-UL30-1696 + UCAAACUCCAGGACGAC 17 4566
HSV2-UL30-1724 + UCCGGGCGUUCCGCGAC 17 4594
HSV2-UL30-960 - GCAUCCUGCUGCGCGAC 17 3830
HSV2-UL30-847 - ACAAGGUCCCGCUCGAC 17 3717
HSV2-UL30-843 - ACAUCAUCAACUUCGAC 17 3713 HSV2-UL30-2874 + GGGACAUCAGCUUCGAC 17 11228
HSV2-UL30-1032 - UCCCGUCCAUCAAGGAC 17 3902
HSV2-UL30-918 - AGGACGACGACGAGGAC 17 3788
HSV2-UL30-922 - AGGACGGGGACGAGGAC 17 3792
HSV2-UL30-1570 + GCGCAUGGAGUACGGAC 17 4440
HSV2-UL30-949 - CGCACCUGGAGGCGGAC 17 3819
HSV2-UL30-910 - GGGAGCGGCCGGGGGAC 17 3780
HSV2-UL30-1512 + UCCGGUCCUUGAUGGAC 17 4382
HSV2-UL30-1718 + CGAGGGCGGUGGUGGAC 17 4588
HSV2-UL30-841 - GGCCCCGAGUUCGUGAC 17 3711
HSV2-UL30-987 - CCAUGCGCAUCAUCUAC 17 3857
HSV2-UL30-1762 + CGAAGACGCGGUAGUAC 17 4632
HSV2-UL30-1508 + GGGCCACGAUCACGUAC 17 4378
HSV2-UL30-849 - UCCCGCUCGACGGGUAC 17 3719
HSV2-UL30-1622 + GGAUGAUGCUGGGGUAC 17 4492
HSV2-UL30-970 - UGUGCAACUCGGUGUAC 17 3840
HSV2-UL30-1627 + GGGGUCGACGUGAAACC 17 4497
HSV2-UL30-1753 + GU UGUCCAGGAUAAACC 17 4623
HSV2-UL30-815 - CU GCACGG CGG ACAACC 17 3685
HSV2-UL30-802 - GUU UAUCCUGGACAACC 17 3672
HSV2-UL30-800 - GCGUCGACGCCACCACC 17 3670
HSV2-UL30-1563 + UGUCGCCCAUGGCCACC 17 4433
HSV2-UL30-876 - CAAGUU UCUGCCGCACC 17 3746
HSV2-UL30-946 - CGAGGCCGUCGCGCACC 17 3816
HSV2-UL30-972 - CGGUGUACGGGUUCACC 17 3842
HSV2-UL30-927 - AGGUCGCGCGCGAGACC 17 3797
HSV2-UL30-1023 - UCGGCGCAUCACCGACC 17 3893
HSV2-UL30-1548 + A A AAC AG C AG G U CG ACC 17 4418
HSV2-UL30-1633 + AGGUGGGGUCGAGGACC 17 4503
HSV2-UL30-1571 + CGCAUGGAGUACGGACC 17 4441
HSV2-UL30-950 - GCACCUGGAGGCGGACC 17 3820
HSV2-UL30-842 - GCCCCGAG UUCGUGACC 17 3712
HSV2-UL30-951 - GGCGGACCGGGACUACC 17 3821
HSV2-UL30-1460 + CCGGGCGAUGGCGUACC 17 4330
HSV2-UL30-933 - CCGGCACGUUGGGUACC 17 3803
HSV2-UL30-1688 + GUUGAUGAUGUUGUACC 17 4558
HSV2-UL30-1749 + CCGAAGGUGACAAACCC 17 4619
HSV2-UL30-803 - UUUAUCCUGGACAACCC 17 3673
HSV2-UL30-1681 + AC ACG CG G A AC AC ACCC 17 4551
HSV2-UL30-886 - CAUCCUGCCGGACACCC 17 3756
HSV2-UL30-1586 + AAGACCGUGCUGCACCC 17 4456
HSV2-UL30-1634 + GGUGGGGUCGAGGACCC 17 4504
HSV2-UL30-1461 + CGGGCGAUGGCGUACCC 17 4331
HSV2-UL30-1750 + CGAAGGUGACAAACCCC 17 4620
HSV2-UL30-1068 - CGAGACGUGGCACCCCC 17 3938
HSV2-UL30-1046 - GUCGCAUGCCGACCCCC 17 3916 HSV2-UL30-1047 - UCGCAUGCCGACCCCCC 17 3917
HSV2-UL30-1726 + CAGCUCGUCCUCCCCCC 17 4596
HSV2-UL30-1045 - CCCGGCCAAGCGCCCCC 17 3915
HSV2-UL30-1635 + CGAGGACCCGGGCCCCC 17 4505
HSV2-UL30-1458 + GUUGAGCGGAACGCCCC 17 4328
HSV2-UL30-1770 + CCGCGGAACGACGCCCC 17 4640
HSV2-UL30-1646 + GGCCCCGAAACCGCCCC 17 4516
HSV2-UL30-1039 - CUAGACGCCGCCGCCCC 17 3909
HSV2-UL30-1044 - CCCCGGCCAAGCGCCCC 17 3914
HSV2-UL30-985 - GCCGGCAUGCGCGCCCC 17 3855
HSV2-UL30-1701 + GGGGGCCGGCAGGCCCC 17 4571
HSV2-UL30-1637 + CCCAACGUGCCGGCCCC 17 4507
HSV2-UL30-1638 + UCCCCGUUCCCGUCCCC 17 4508
HSV2-UL30-1494 + GGGGCGGGCUCGUCCCC 17 4364
HSV2-UL30-1457 + UGUUGAGCGGAACGCCC 17 4327
HSV2-UL30-1056 - CGGGUACGCCAUCGCCC 17 3926
HSV2-UL30-1550 + CAGGUCGACCAGGGCCC 17 4420
HSV2-UL30-1010 - CCGCACCUCCAGGGCCC 17 3880
HSV2-UL30-938 - UGGGUACCAGGGGGCCC 17 3808
HSV2-UL30-1054 - AGCUGGCGGAGGAUCCC 17 3924
HSV2-UL30-1043 - AGCGGCCCUGCCCUCCC 17 3913
HSV2-UL30-1468 + GCU UGGACGCGCCUCCC 17 4338
HSV2-UL30-1475 + AUGCGACGGCGUCUCCC 17 4345
HSV2-UL30-807 - UGGUACCGCCUCAAGCC 17 3677
HSV2-UL30-832 - UCCGGUCGCGGAACGCC 17 3702
HSV2-UL30-766 - ACGCCAUCACGCCCGCC 17 3636
HSV2-UL30-1659 + UGAUGUUGAUGCCCGCC 17 4529
HSV2-UL30-1773 + CGCGCAGGGCCGCCGCC 17 4643
HSV2-UL30-1027 - GUACACCAACAAGCGCC 17 3897
HSV2-UL30-895 - GGAGGCGCCCAAGCGCC 17 3765
HSV2-UL30-777 - CGAUCUCUGCGAGCGCC 17 3647
HSV2-UL30-877 - U UCCGCCGUCGCGCGCC 17 3747
HSV2-UL30-1055 - CCGGGUACGCCAUCGCC 17 3925
HSV2-UL30-781 - GCCCUGCGCGAGUCGCC 17 3651
HSV2-UL30-823 - AUAUCGAAUGCAAGGCC 17 3693
HSV2-UL30-852 - CGGGCGCAUGAACGGCC 17 3722
HSV2-UL30-1642 + CCCCCCGAGGCACGGCC 17 4512
HSV2-UL30-1732 + UGGCCCCCUCGACGGCC 17 4602
HSV2-UL30-906 - GGGGAAGGGGAGCGGCC 17 3776
HSV2-UL30-1745 + GGCGCGUUCCCGCGGCC 17 4615
HSV2-UL30-994 - CCUCACGGCCGCGGGCC 17 3864
HSV2-UL30-1666 + CCCGCGCUGCGCGGGCC 17 4536
HSV2-UL30-937 - U UGGGUACCAGGGGGCC 17 3807
HSV2-UL30-1519 + ACACCGUCAGGUGGGCC 17 4389
HSV2-UL30-1618 + AGCACAGGU UGUGGGCC 17 4488
HSV2-UL30-1480 + CCCGGGGGCGCU UGGCC 17 4350 HSV2-UL30-1026 - CCCGGAGAGGGACAUCC 17 3896
HSV2-UL30-943 - G U ACCCCAG C AU CAU CC 17 3813
HSV2-UL30-1053 - GAGCUGGCGGAGGAUCC 17 3923
HSV2-UL30-801 - CACCACCCGGU UUAUCC 17 3671
HSV2-UL30-1694 + AU UCGCUGUCAAACUCC 17 4564
HSV2-UL30-940 - UCCUCGACCCCACCUCC 17 3810
HSV2-UL30-1008 - UUAUCAACCGCACCUCC 17 3878
HSV2-UL30-867 - CCGCCUACUACGCCUCC 17 3737
HSV2-UL30-1609 + AGUCCCGGUCCGCCUCC 17 4479
HSV2-UL30-1467 + GGCU UGGACGCGCCUCC 17 4337
HSV2-UL30-834 - UCAGCGAUCUCGCCUCC 17 3704
HSV2-UL30-1662 + CGACGGCGGAAAGCUCC 17 4532
HSV2-UL30-1607 + CCCCCACCUCGAUCUCC 17 4477
HSV2-UL30-1528 + CCUGGAUGUCCCUCUCC 17 4398
HSV2-UL30-1474 + CAUGCGACGGCGUCUCC 17 4344
HSV2-UL30-1526 + CGGUGAGGACAAAGUCC 17 4396
HSV2-UL30-1608 + CGAUCUCCAGGUAGUCC 17 4478
HSV2-UL30-1444 + GCGCGGCCACGUCGUCC 17 4314
HSV2-UL30-838 - GCCGGCCCCCGUCGUCC 17 3708
HSV2-UL30-1786 + AAGCGUGAUGACGGUCC 17 4656
HSV2-UL30-1751 + CA AACCCCG GGUUGUCC 17 4621
HSV2-UL30-1723 + GGAUGACGAGGUCUUCC 17 4593
HSV2-UL30-792 - GCGUCUUCGUGCGAAGC 17 3662
HSV2-UL30-1547 + UAUCGUCGUAAAACAGC 17 4417
HSV2-UL30-1455 + CG CAG G CCGCCCCCAG C 17 4325
HSV2-UL30-1602 + CCAGCCAGUCGCGCAGC 17 4472
HSV2-UL30-1603 + GCAGCAGGAUGCUCAGC 17 4473
HSV2-UL30-829 - CGGGGGGGAGGACGAGC 17 3699
HSV2-UL30-1050 - GCUGCUGGUGUCCGAGC 17 3920
HSV2-UL30-1683 + GCCCGUACCCGUCGAGC 17 4553
HSV2-UL30-2860 + UAAAUCGCUCGUGGAGC 17 11214
HSV2-UL30-1676 + GGCGUUCAGCUUGUAGC 17 4546
HSV2-UL30-1454 + GGCCU UGAACGUCACGC 17 4324
HSV2-UL30-1440 + GUAGCGCCGGCCCCCGC 17 4310
HSV2-UL30-765 - GACGCCAUCACGCCCGC 17 3635
HSV2-UL30-993 - CGCGGCCUCACGGCCGC 17 3863
HSV2-UL30-809 - GCCUCAAGCCCGGCCGC 17 3679
HSV2-UL30-1486 + GGGGAGGGCAGGGCCGC 17 4356
HSV2-UL30-1074 - GCGCGGCUCAGGGCCGC 17 3944
HSV2-UL30-1613 + CGACGGCCUCGGGCCGC 17 4483
HSV2-UL30-869 - CCGGGCCCGCGCAGCGC 17 3739
HSV2-UL30-1439 + UUCCUCCGCCGUAGCGC 17 4309
HSV2-UL30-810 - CGGCCGCGGGAACGCGC 17 3680
HSV2-UL30-977 - CGUACGUGCACGCGCGC 17 3847
HSV2-UL30-1522 + UGU UGGUGUACGCGCGC 17 4392
HSV2-UL30-1030 - CAUGGCCCGCCGCGCGC 17 3900 HSV2-UL30-793 - GCGAAGCGGGCGCGCGC 17 3663
HSV2-UL30-1775 + GCUCGCAGAGAUCGCGC 17 4645
HSV2-UL30-1771 + CCCCCGGCGACUCGCGC 17 4641
HSV2-UL30-1652 + UCUGGCCCGCAAGGCGC 17 4522
HSV2-UL30-1665 + AUCACCCCGCGCUGCGC 17 4535
HSV2-UL30-1757 + UCGUACUUCCUGAUCGC 17 4627
HSV2-UL30-1504 + CGUCUCCUCUACCUCGC 17 4374
HSV2-UL30-780 - GGCCCUGCGCGAGUCGC 17 3650
HSV2-UL30-1710 + GGACUCGGGGAGGUCGC 17 4580
HSV2-UL30-822 - GAUAUCGAAUGCAAGGC 17 3692
HSV2-UL30-1623 + GAUGCUGGGGUACAGGC 17 4493
HSV2-UL30-1584 + GGCGGCCACGUGCAGGC 17 4454
HSV2-UL30-1670 + CCGGAGGCGUAGUAGGC 17 4540
HSV2-UL30-1728 + CACAUGAGCUUG UAGGC 17 4598
HSV2-UL30-851 - ACGGGCGCAUGAACGGC 17 3721
HSV2-UL30-1641 + UCCCCCCGAGGCACGGC 17 4511
HSV2-UL30-1788 + GUGAUGACGGUCCCGGC 17 4658
HSV2-UL30-1729 + UGAGCUUGUAGGCCGGC 17 4599
HSV2-UL30-1080 - GCGGGGUUCGGGCCGGC 17 3950
HSV2-UL30-1700 + GGACGACGGGGGCCGGC 17 4570
HSV2-UL30-1649 + GCCCCUGGGUGUCCGGC 17 4519
HSV2-UL30-905 - GGGGGAAGGGGAGCGGC 17 3775
HSV2-UL30-1744 + CGGCGCGUUCCCGCGGC 17 4614
HSV2-UL30-1515 + CGGGACCUGCGCGCGGC 17 4385
HSV2-UL30-1038 - GGAGACGGUCGCGCGGC 17 3908
HSV2-UL30-984 - GACU UUCCGGAGGCGGC 17 3854
HSV2-UL30-806 - GGUU UGUCACCUUCGGC 17 3676
HSV2-UL30-1484 + GCU UGGCCGGGGAGGGC 17 4354
HSV2-UL30-1536 + CCUGCAGUCCCUCGGGC 17 4406
HSV2-UL30-1078 - GGCCGCGGGGUUCGGGC 17 3948
HSV2-UL30-1699 + UCCAGGACGACGGGGGC 17 4569
HSV2-UL30-930 - CGCGCGAGACCGGGGGC 17 3800
HSV2-UL30-1083 - UUCGGGCCGGCGGGGGC 17 3953
HSV2-UL30-1493 + AGGGCCGCUGGGGGGGC 17 4363
HSV2-UL30-1742 + GGGGGGCGCGGUUGGGC 17 4612
HSV2-UL30-961 - CCUGCUGCGCGACUGGC 17 3831
HSV2-UL30-879 - GCCGUCGCGCGCCUGGC 17 3749
HSV2-UL30-1015 - CCCCGCAGAGGAGUGGC 17 3885
HSV2-UL30-1479 + UCCCGGGGGCGCU UGGC 17 4349
HSV2-UL30-1574 + ACCGGGGGCGCGCAUGC 17 4444
HSV2-UL30-1619 + GUGGGCCUGGAUGAUGC 17 4489
HSV2-UL30-1778 + GCGGGGCACGGCACUGC 17 4648
HSV2-UL30-1018 - CCUGCCCGAGGGACUGC 17 3888
HSV2-UL30-1059 - UUACUUCUCGCACCUGC 17 3929
HSV2-UL30-820 - GGCCAUGUGUGACCUGC 17 3690
HSV2-UL30-837 - CGCCUCCAGGGGCCUGC 17 3707 HSV2-UL30-885 - GAAGGGCU UCAUCCUGC 17 3755
HSV2-UL30-1049 - CAAGCCCCGCAAGCUGC 17 3919
HSV2-UL30-980 - GGAGUUCGAUCAGCUGC 17 3850
HSV2-UL30-873 - UGUGCAGGACUCGCUGC 17 3743
HSV2-UL30-839 - CGAAUUCGAGAUGCUGC 17 3709
HSV2-UL30-1001 - ACAUCGGCGUCAUCUGC 17 3871
HSV2-UL30-1655 + UGAAGACGCGGAUCUGC 17 4525
HSV2-UL30-1540 + GCCAGCCACUCCUCUGC 17 4410
HSV2-UL30-1636 + CCUGGUACCCAACGUGC 17 4506
HSV2-UL30-1583 + CGGUGGCGGCCACGUGC 17 4453
HSV2-UL30-1658 + GCCGUCG UAGAUGGUGC 17 4528
HSV2-UL30-872 - CGGCGAGUAU UGUGUGC 17 3742
HSV2-UL30-882 - UGCCUCCUGCGCCUUGC 17 3752
HSV2-UL30-1464 + GGACACCAGCAGCUUGC 17 4334
HSV2-UL30-1720 + AGAGCAGACAGGAGAUC 17 4590
HSV2-UL30-794 - ACUU UUGCCCCGCGAUC 17 3664
HSV2-UL30-1509 + CGAUCACGUACGGGAUC 17 4379
HSV2-UL30-1007 - CAUCAAGGGCGUGGAUC 17 3877
HSV2-UL30-1556 + CGCACUCGAGCUUGAUC 17 4426
HSV2-UL30-1011 - UACGACGAUACCGUAUC 17 3881
HSV2-UL30-1690 + UACCCGGUCACGAACUC 17 4560
HSV2-UL30-1707 + UCGCUGAGGUGGGACUC 17 4577
HSV2-UL30-939 - GUCCUCGACCCCACCUC 17 3809
HSV2-UL30-1535 + AACGCCUGCAGUCCCUC 17 4405
HSV2-UL30-866 - CCCGCCUACUACGCCUC 17 3736
HSV2-UL30-1575 + CGCAUGCCGGCCGCCUC 17 4445
HSV2-UL30-1612 + AGGUGCGCGACGGCCUC 17 4482
HSV2-UL30-897 - GCGCCCGGCCGUGCCUC 17 3767
HSV2-UL30-1593 + AGGAGGACGGCCUCCUC 17 4463
HSV2-UL30-1545 + UAACGCGGCGGCCGCUC 17 4415
HSV2-UL30-1071 - ACGUGGCCGCGCGGCUC 17 3941
HSV2-UL30-1679 + GCUUCUGAAAGUGGCUC 17 4549
HSV2-UL30-1596 + CCUCCUCGGGGGUGCUC 17 4466
HSV2-UL30-1527 + UCCUGGAUGUCCCUCUC 17 4397
HSV2-UL30-1449 + GGGGGGUGCCACGUCUC 17 4319
HSV2-UL30-1516 + GCU UGUAAUACACCGUC 17 4386
HSV2-UL30-1735 + AGGUUCCGAACGCCGUC 17 4605
HSV2-UL30-1443 + CGCGCGGCCACGUCGUC 17 4313
HSV2-UL30-1765 + CGCGGUAGUACAGGGUC 17 4635
HSV2-UL30-1505 + CCUCUACCUCGCGGGUC 17 4375
HSV2-UL30-875 - AGGACUCGCUGCUGGUC 17 3745
HSV2-UL30-1685 + UCUCCGUCAGCU UGGUC 17 4555
HSV2-UL30-1648 + AACCGCCCCUGGGUGUC 17 4518
HSV2-UL30-1650 + GCAGGAUGAAGCCCUUC 17 4520
HSV2-UL30-1782 + GCGACGCGAUGGCCUUC 17 4652
HSV2-UL30-767 - GACCGUCAUCACGCU UC 17 3637 HSV2-UL30-1722 + UGGAUGACGAGGUCU UC 17 4592
HSV2-UL30-1020 - AGGGACUGCAGGCGUUC 17 3890
HSV2-UL30-1077 - UCAGGGCCGCGGGGU UC 17 3947
HSV2-UL30-981 - GCUGCUGGCCGACU U UC 17 3851
HSV2-UL30-830 - GGACGAGCUGGCCUUUC 17 3700
HSV2-UL30-891 - CACCCAGGGGCGGUUUC 17 3761
HSV2-UL30-1678 + UGCUGCGCUUCUGAAAG 17 4548
HSV2-UL30-1066 - CCGAGAGUCUGUUAAAG 17 3936
HSV2-UL30-791 - CGCGUCU UCGUGCGAAG 17 3661
HSV2-UL30-1767 + CCACCUCCGCCUCGAAG 17 4637
HSV2-UL30-903 - CGUGCCUCGGGGGGAAG 17 3773
HSV2-UL30-935 - GGCACGUUGGGUACCAG 17 3805
HSV2-UL30-888 - UCCUGCCGGACACCCAG 17 3758
HSV2-UL30-1042 - CGAGCCCGCCCCCCCAG 17 3912
HSV2-UL30-1041 - AG ACG CCG CCG CCCC AG 17 3911
HSV2-UL30-836 - AGCGAUCUCGCCUCCAG 17 3706
HSV2-UL30-1013 - AGCCGAGCGCCCCGCAG 17 3883
HSV2-UL30-1538 + UGCAGUCCCUCGGGCAG 17 4408
HSV2-UL30-797 - CGAUCAGGAAGUACGAG 17 3667
HSV2-UL30-1600 + UCUGGGGGAUCCGCGAG 17 4470
HSV2-UL30-1682 + CGCCCG UACCCGUCGAG 17 4552
HSV2-UL30-818 - ACAACCUGGCCGUCGAG 17 3688
HSV2-UL30-1014 - AGCGCCCCGCAGAGGAG 17 3884
HSV2-UL30-1024 - GCAUCACCGACCCGGAG 17 3894
HSV2-UL30-1012 - CGAUACCGUAUCCGGAG 17 3882
HSV2-UL30-904 - CUCGGGGGGAAGGGGAG 17 3774
HSV2-UL30-1456 + UAAUAGUCCGUGU UGAG 17 4326
HSV2-UL30-1035 - CCAGACCCGCGAGGUAG 17 3905
HSV2-UL30-913 - GCCGGGGGACGGGAACG 17 3783
HSV2-UL30-1543 + GGGGCGCUCGGCUAACG 17 4413
HSV2-UL30-1680 + GGCCGAUGUCCCACACG 17 4550
HSV2-UL30-1626 + AG U C A A AC ACC ACC ACG 17 4496
HSV2-UL30-771 - UUCACGUCUACGGCACG 17 3641
HSV2-UL30-975 - UCUGCCCUGCCUGCACG 17 3845
HSV2-UL30-1761 + CGCUUCGCACGAAGACG 17 4631
HSV2-UL30-1654 + GGAGGCACGUGAAGACG 17 4524
HSV2-UL30-1067 - GGU U U AU UCCCG AG ACG 17 3937
HSV2-UL30-916 - GGAUAAGGACGACGACG 17 3786
HSV2-UL30-1697 + CAAACUCCAGGACGACG 17 4567
HSV2-UL30-1069 - GCACCCCCCGGACGACG 17 3939
HSV2-UL30-2875 + GGACAUCAGCUUCGACG 17 11229
HSV2-UL30-919 - GGACGACGACGAGGACG 17 3789
HSV2-UL30-923 - GGACGGGGACGAGGACG 17 3793
HSV2-UL30-914 - GGACGGGAACGGGGACG 17 3784
HSV2-UL30-920 - CGACGAGGACGGGGACG 17 3790
HSV2-UL30-1721 + AGGAGAUCUGGAUGACG 17 4591 HSV2-UL30-988 - CAUGCGCAUCAUCUACG 17 3858
HSV2-UL30-1532 + GCCGAUGGGCGUCUACG 17 4402
HSV2-UL30-795 - CGCGAUCAGGAAGUACG 17 3665
HSV2-UL30-1604 + GCAGGCUCUCGCGUACG 17 4474
HSV2-UL30-973 - GGUGUACGGGUUCACCG 17 3843
HSV2-UL30-928 - GGUCGCGCGCGAGACCG 17 3798
HSV2-UL30-1572 + GCAUGGAGUACGGACCG 17 4442
HSV2-UL30-804 - UUAUCCUGGACAACCCG 17 3674
HSV2-UL30-1441 + CGCCGGCCCGAACCCCG 17 4311
HSV2-UL30-941 - GUUUCACGUCGACCCCG 17 3811
HSV2-UL30-963 - CCCCCAGAGCACCCCCG 17 3833
HSV2-UL30-1639 + CGCUCCCCU UCCCCCCG 17 4509
HSV2-UL30-1057 - GGGUACGCCAUCGCCCG 17 3927
HSV2-UL30-1564 + CAUGGCCACCAGGCCCG 17 4434
HSV2-UL30-945 - GCUCUCCCUGCGGCCCG 17 3815
HSV2-UL30-1016 - GGCGCGACCCCUGCCCG 17 3886
HSV2-UL30-1469 + CU UGGACGCGCCUCCCG 17 4339
HSV2-UL30-1476 + UGCGACGGCGUCUCCCG 17 4346
HSV2-UL30-1743 + GGGCCGGCGCGU UCCCG 17 4613
HSV2-UL30-782 - CCCUGCGCGAGUCGCCG 17 3652
HSV2-UL30-863 - GCUGAACGCCGUCGCCG 17 3733
HSV2-UL30-824 - UAUCGAAUGCAAGGCCG 17 3694
HSV2-UL30-1566 + CCGCGGCCGUGAGGCCG 17 4436
HSV2-UL30-853 - GGGCGCAUGAACGGCCG 17 3723
HSV2-UL30-992 - CCGCGGCCUCACGGCCG 17 3862
HSV2-UL30-808 - CGCCUCAAGCCCGGCCG 17 3678
HSV2-UL30-907 - GGGAAGGGGAGCGGCCG 17 3777
HSV2-UL30-1073 - CGCGCGGCUCAGGGCCG 17 3943
HSV2-UL30-1481 + CCGGGGGCGCUUGGCCG 17 4351
HSV2-UL30-1769 + GGUCCGCGGAGAUGCCG 17 4639
HSV2-UL30-990 - AUUU UCGUU UUGUGCCG 17 3860
HSV2-UL30-785 - GUUCCGCGGCAUCUCCG 17 3655
HSV2-UL30-1445 + CGCGGCCACGUCGUCCG 17 4315
HSV2-UL30-1768 + CGCCUCGAAGUGGUCCG 17 4638
HSV2-UL30-784 - CCGGGGGCGUCGU UCCG 17 3654
HSV2-UL30-868 - UCCGGGCCCGCGCAGCG 17 3738
HSV2-UL30-1034 - CGUGGCCCAGACCCGCG 17 3904
HSV2-UL30-1442 + CGCGGCCCUGAGCCGCG 17 4312
HSV2-UL30-1075 - CGCGGCUCAGGGCCGCG 17 3945
HSV2-UL30-1070 - CGGACGACGUGGCCGCG 17 3940
HSV2-UL30-870 - CGGGCCCGCGCAGCGCG 17 3740
HSV2-UL30-924 - GGACGGGGACGAGCGCG 17 3794
HSV2-UL30-1521 + UUGU UGGUGUACGCGCG 17 4391
HSV2-UL30-1776 + CUCGCAGAGAUCGCGCG 17 4646
HSV2-UL30-1513 + UGGACGGGACCUGCGCG 17 4383
HSV2-UL30-1774 + CGCUCGCAGAGAUCGCG 17 4644 HSV2-UL30-1758 + CGUACUUCCUGAUCGCG 17 4628
HSV2-UL30-1577 + CGUACGCGCGCGUCGCG 17 4447
HSV2-UL30-1037 - UAGAGGAGACGGUCGCG 17 3907
HSV2-UL30-1671 + CGGAGGCGUAGUAGGCG 17 4541
HSV2-UL30-1081 - CGGGGUUCGGGCCGGCG 17 3951
HSV2-UL30-1006 - GAUGCUCAUCAAGGGCG 17 3876
HSV2-UL30-1739 + AACGCCGUCGGGGGGCG 17 4609
HSV2-UL30-1664 + GAUCACCCCGCGCUGCG 17 4534
HSV2-UL30-1002 - CAUCGGCGUCAUCUGCG 17 3872
HSV2-UL30-1541 + CCAGCCACUCCUCUGCG 17 4411
HSV2-UL30-1465 + GACACCAGCAGCUUGCG 17 4335
HSV2-UL30-952 - GGACUACCUGGAGAUCG 17 3822
HSV2-UL30-1756 + CUCGUACU UCCUGAUCG 17 4626
HSV2-UL30-1033 - GAUCCCGUACGUGAUCG 17 3903
HSV2-UL30-1557 + GCACUCGAGCUUGAUCG 17 4427
HSV2-UL30-1691 + ACCCGGUCACGAACUCG 17 4561
HSV2-UL30-1708 + CGCUGAGGUGGGACUCG 17 4578
HSV2-UL30-1503 + CCGUCUCCUCUACCUCG 17 4373
HSV2-UL30-898 - CGCCCGGCCGUGCCUCG 17 3768
HSV2-UL30-1594 + GGAGGACGGCCUCCUCG 17 4464
HSV2-UL30-1499 + CGGCGGCGUCUAGCUCG 17 4369
HSV2-UL30-962 - GAAAGCAGAUCCGCUCG 17 3832
HSV2-UL30-1790 + CGUCCAUAAAUCGCUCG 17 4660
HSV2-UL30-1733 + AAACUCGACGUCGCUCG 17 4603
HSV2-UL30-1713 + ACAGGAGGAUG UGCUCG 17 4583
HSV2-UL30-1578 + UCGCGAGGAGCAUCUCG 17 4448
HSV2-UL30-1736 + GGUUCCGAACGCCGUCG 17 4606
HSV2-UL30-816 - GGACAACCUGGCCGUCG 17 3686
HSV2-UL30-831 - GCUGGCCUU UCCGGUCG 17 3701
HSV2-UL30-1632 + ACCCGGAGGUGGGGUCG 17 4502
HSV2-UL30-1672 + AGUAGGCGGGGAUGUCG 17 4542
HSV2-UL30-1645 + UGGGCGCCUCCU UGUCG 17 4515
HSV2-UL30-1589 + CGGCCUGU UGCUUGUCG 17 4459
HSV2-UL30-786 - CUCCGCGGACCACUUCG 17 3656
HSV2-UL30-1783 + CGACGCGAUGGCCUUCG 17 4653
HSV2-UL30-1021 - GGGACUGCAGGCGUUCG 17 3891
HSV2-UL30-892 - ACCCAGGGGCGGUUUCG 17 3762
HSV2-UL30-773 - CU UUUACAUGAACAAGG 17 3643
HSV2-UL30-894 - UCGGGGCCUCGACAAGG 17 3764
HSV2-UL30-967 - ACAGGCCGCCAUCAAGG 17 3837
HSV2-UL30-1712 + AUCCGAGCGAAAACAGG 17 4582
HSV2-UL30-936 - GCACGUUGGGUACCAGG 17 3806
HSV2-UL30-1653 + GGCCCGCAAGGCGCAGG 17 4523
HSV2-UL30-1517 + U G U A AU ACACCG U CAG G 17 4387
HSV2-UL30-798 - GAUCAGGAAGUACGAGG 17 3668
HSV2-UL30-964 - CCAGAGCACCCCCGAGG 17 3834 HSV2-UL30-925 - CGGGGACGAGCGCGAGG 17 3795
HSV2-UL30-953 - CUACCUGGAGAUCGAGG 17 3823
HSV2-UL30-819 - CAACCUGGCCGUCGAGG 17 3689
HSV2-UL30-1590 + CCUGUUGCU UGUCGAGG 17 4460
HSV2-UL30-787 - CGCGG ACCACU UCG AGG 17 3657
HSV2-UL30-1629 + GACGUGAAACCCGGAGG 17 4499
HSV2-UL30-983 - GGCCGACUU UCCGGAGG 17 3853
HSV2-UL30-775 - CAUGAACAAGGCGGAGG 17 3645
HSV2-UL30-789 - CCACU UCGAGGCGG AGG 17 3659
HSV2-UL30-948 - CGUCGCGCACCUGGAGG 17 3818
HSV2-UL30-1704 + AGGCGAGAUCGCUGAGG 17 4574
HSV2-UL30-1747 + CGCGGCCGGGCUUGAGG 17 4617
HSV2-UL30-1669 + CCCGGAGGCGUAGUAGG 17 4539
HSV2-UL30-814 - CGAGU UUAACUGCACGG 17 3684
HSV2-UL30-1581 + GCCGAUGGUCGUCACGG 17 4451
HSV2-UL30-1698 + AAACUCCAGGACGACGG 17 4568
HSV2-UL30-1661 + CGCCAGGCGCGCGACGG 17 4531
HSV2-UL30-2876 + GACAUCAGCU UCGACGG 17 11230
HSV2-UL30-1085 - GGGGGCCGGCGCUACGG 17 3955
HSV2-UL30-929 - GUCGCGCGCGAGACCGG 17 3799
HSV2-UL30-1573 + CAUGGAGUACGGACCGG 17 4443
HSV2-UL30-1628 + GUCGACGUGAAACCCGG 17 4498
HSV2-UL30-1667 + GCGCUGCGCGGGCCCGG 17 4537
HSV2-UL30-1470 + UUGGACGCGCCUCCCGG 17 4340
HSV2-UL30-1477 + GCGACGGCGUCUCCCGG 17 4347
HSV2-UL30-1787 + CGUGAUGACGGUCCCGG 17 4657
HSV2-UL30-783 - CCUGCGCGAGUCGCCGG 17 3653
HSV2-UL30-825 - AUCGAAUGCAAGGCCGG 17 3695
HSV2-UL30-908 - GGAAGGGGAGCGGCCGG 17 3778
HSV2-UL30-1079 - CGCGGGGUUCGGGCCGG 17 3949
HSV2-UL30-1446 + GCGGCCACGUCGUCCGG 17 4316
HSV2-UL30-982 - GCUGGCCGACUUUCCGG 17 3852
HSV2-UL30-1544 + GCGCUCGGCUAACGCGG 17 4414
HSV2-UL30-1514 + ACGGGACCUGCGCGCGG 17 4384
HSV2-UL30-1500 + CGGCGUCUAGCUCGCGG 17 4370
HSV2-UL30-774 - U U AC A U G A AC A AG G CG G 17 3644
HSV2-UL30-788 - GG ACCACU UCGAGGCGG 17 3658
HSV2-UL30-1086 - GGCCGGCGCUACGGCGG 17 3956
HSV2-UL30-1082 - GGGGUUCGGGCCGGCGG 17 3952
HSV2-UL30-1716 + GAUGUGCUCGAGGGCGG 17 4586
HSV2-UL30-1498 + CUCGUCCCCUGGGGCGG 17 4368
HSV2-UL30-779 - CUGCGAGCGCCUGGCGG 17 3649
HSV2-UL30-1052 - GGUGUCCGAGCUGGCGG 17 3922
HSV2-UL30-1003 - AUCGGCGUCAUCUGCGG 17 3873
HSV2-UL30-1558 + CACUCGAGCUUGAUCGG 17 4428
HSV2-UL30-899 - GCCCGGCCGUGCCUCGG 17 3769 HSV2-UL30-1595 + GAGGACGGCCUCCUCGG 17 4465
HSV2-UL30-1737 + GUUCCGAACGCCGUCGG 17 4607
HSV2-UL30-1784 + GACGCGAUGGCCU UCGG 17 4654
HSV2-UL30-1524 + GUGUCUGCUCAGU UCGG 17 4394
HSV2-UL30-799 - AUCAGGAAGUACGAGGG 17 3669
HSV2-UL30-1715 + GAGGAUGUGCUCGAGGG 17 4585
HSV2-UL30-1502 + GUCUAGCUCGCGGAGGG 17 4372
HSV2-UL30-2877 + ACAUCAGCUUCGACGGG 17 11231
HSV2-UL30-1754 + GUCCAGGAUAAACCGGG 17 4624
HSV2-UL30-1048 - CAUGCCGACCCCCCGGG 17 3918
HSV2-UL30-1471 + UGGACGCGCCUCCCGGG 17 4341
HSV2-UL30-826 - UCGAAUGCAAGGCCGGG 17 3696
HSV2-UL30-1447 + CGGCCACGUCGUCCGGG 17 4317
HSV2-UL30-1559 + ACUCGAGCUUGAUCGGG 17 4429
HSV2-UL30-900 - CCCGGCCGUGCCUCGGG 17 3770
HSV2-UL30-1738 + UUCCGAACGCCGUCGGG 17 4608
HSV2-UL30-889 - UGCCGGACACCCAGGGG 17 3759
HSV2-UL30-827 - CGAAUGCAAGGCCGGGG 17 3697
HSV2-UL30-1482 + GGGGCGCUUGGCCGGGG 17 4352
HSV2-UL30-1709 + UGAGGUGGGACUCGGGG 17 4579
HSV2-UL30-1560 + CGAGCUUGAUCGGGGGG 17 4430
HSV2-UL30-828 - AUGCAAGGCCGGGGGGG 17 3698
HSV2-UL30-1492 + CAGGGCCGCUGGGGGGG 17 4362
HSV2-UL30-1063 - CUCGCACCUGCUGGGGG 17 3933
HSV2-UL30-1497 + GGGCUCGUCCCCUGGGG 17 4367
HSV2-UL30-1491 + GGGCAGGGCCGCUGGGG 17 4361
HSV2-UL30-2868 + UCGCUCGUGGAGCUGGG 17 11222
HSV2-UL30-1490 + AGGGCAGGGCCGCUGGG 17 4360
HSV2-UL30-979 - CGUGCACGCGCGCUGGG 17 3849
HSV2-UL30-957 - CUGGAGAUCGAGGUGGG 17 3827
HSV2-UL30-1588 + GCACACCACCU UG AUGG 17 4458
HSV2-UL30-947 - GGCCGUCGCGCACCUGG 17 3817
HSV2-UL30-1702 + GGCCGGCAGGCCCCUGG 17 4572
HSV2-UL30-1551 + GUCGACCAGGGCCCUGG 17 4421
HSV2-UL30-778 - UCUCUGCGAGCGCCUGG 17 3648
HSV2-UL30-878 - CGCCGUCGCGCGCCUGG 17 3748
HSV2-UL30-995 - CACGGCCGCGGGCCUGG 17 3865
HSV2-UL30-1051 - GCUGGUGUCCGAGCUGG 17 3921
HSV2-UL30-1489 + GAGGGCAGGGCCGCUGG 17 4359
HSV2-UL30-1062 - CUUCUCGCACCUGCUGG 17 3932
HSV2-UL30-1599 + CCUCGGGGGUGCUCUGG 17 4469
HSV2-UL30-942 - UCACGUCGACCCCGUGG 17 3812
HSV2-UL30-956 - CCUGGAGAUCGAGGUGG 17 3826
HSV2-UL30-790 - CU UCGAGGCGGAGGUGG 17 3660
HSV2-UL30-1582 + GAUGGUCGUCACGGUGG 17 4452
HSV2-UL30-1717 + GUGCUCGAGGGCGGUGG 17 4587 HSV2-UL30-1755 + CAGGAUAAACCGGGUGG 17 4625
HSV2-UL30-1561 + ACAGCGCGCGCGAGAUG 17 4431
HSV2-UL30-1496 + GGCGGGCUCGUCCCCUG 17 4366
HSV2-UL30-944 - UCAGUACGCUCUCCCUG 17 3814
HSV2-UL30-1488 + GGAGGGCAGGGCCGCUG 17 4358
HSV2-UL30-1703 + UGGAGGCGAGAUCGCUG 17 4573
HSV2-UL30-1621 + GGGCCUGGAUGAUGCUG 17 4491
HSV2-UL30-1061 - ACUUCUCGCACCUGCUG 17 3931
HSV2-UL30-1000 - UACAUCGGCGUCAUCUG 17 3870
HSV2-UL30-1539 + CGCCAGCCACUCCUCUG 17 4409
HSV2-UL30-1598 + UCCUCGGGGGUGCUCUG 17 4468
HSV2-UL30-1565 + CCAGGCCCGCGGCCGUG 17 4435
HSV2-UL30-854 - GGGGUGUGUUCCGCGUG 17 3724
HSV2-UL30-1663 + GCGGAAAGCUCCAGGUG 17 4533
HSV2-UL30-955 - ACCUGGAGAUCGAGGUG 17 3825
HSV2-UL30-1631 + CGUGAAACCCGGAGGUG 17 4501
HSV2-UL30-1552 + CCAGGGCCCUGGAGGUG 17 4422
HSV2-UL30-1525 + UGCUCAGU UCGGCGGUG 17 4395
HSV2-UL30-1657 + GGCCGUCGUAGAUGGUG 17 4527
HSV2-UL30-881 - GUGCCUCCUGCGCCUUG 17 3751
HSV2-UL30-1463 + CGGACACCAGCAGCUUG 17 4333
HSV2-UL30-1746 + UCCCGCGGCCGGGCU UG 17 4616
HSV2-UL30-1616 + UACUGAAGCACAGGUUG 17 4486
HSV2-UL30-856 - UUCCGCGUGUGGGACAU 17 3726
HSV2-UL30-999 - GCCAAGAAAAAGUACAU 17 3869
HSV2-UL30-976 - GCCACCGUGACGACCAU 17 3846
HSV2-UL30-1022 - UCCUCGUAGACGCCCAU 17 3892
HSV2-UL30-997 - GCGGGCCUGGUGGCCAU 17 3867
HSV2-UL30-1531 + GUCGGUGAUGCGCCGAU 17 4401
HSV2-UL30-776 - ACAAGGCGGAGGUGGAU 17 3646
HSV2-UL30-871 - GCGCAGCGCGGGGUGAU 17 3741
HSV2-UL30-1555 + UCGCACUCGAGCU UGAU 17 4425
HSV2-UL30-968 - CAAGGUGGUGUGCAACU 17 3838
HSV2-UL30-1689 + GUACCCGGUCACGAACU 17 4559
HSV2-UL30-1706 + AUCGCUGAGGUGGGACU 17 4576
HSV2-UL30-1647 + GCCCCGAAACCGCCCCU 17 4517
HSV2-UL30-1495 + GGGCGGGCUCGUCCCCU 17 4365
HSV2-UL30-1534 + GAACGCCUGCAGUCCCU 17 4404
HSV2-UL30-1674 + GUCCUUCAAGACGGCCU 17 4544
HSV2-UL30-1611 + CAGGUGCGCGACGGCCU 17 4481
HSV2-UL30-896 - AGCGCCCGGCCGUGCCU 17 3766
HSV2-UL30-1592 + GAGGAGGACGGCCUCCU 17 4462
HSV2-UL30-1462 + GGGAUCCUCCGCCAGCU 17 4332
HSV2-UL30-1554 + GGCGAUGAGCAGCAGCU 17 4424
HSV2-UL30-1684 + GUAGAUCUCCGUCAGCU 17 4554
HSV2-UL30-2869 + AAAUCGCUCGUGGAGCU 17 11223 HSV2-UL30-1487 + GGGAGGGCAGGGCCGCU 17 4357
HSV2-UL30-978 - GUACGUGCACGCGCGCU 17 3848
HSV2-UL30-1643 + AGGCACGGCCGGGCGCU 17 4513
HSV2-UL30-1542 + CUCCUCUGCGGGGCGCU 17 4412
HSV2-UL30-1478 + CGUCUCCCGGGGGCGCU 17 4348
HSV2-UL30-833 - AUCCUCCUGUUUUCGCU 17 3703
HSV2-UL30-1466 + CAGCAGCUUGCGGGGCU 17 4336
HSV2-UL30-1620 + UGGGCCUGGAUGAUGCU 17 4490
HSV2-UL30-1060 - UACU UCUCGCACCUGCU 17 3930
HSV2-UL30-1451 + CAGACUCUCGGUGAUCU 17 4321
HSV2-UL30-1450 + CCUCUU UAACAGACUCU 17 4320
HSV2-UL30-1597 + CUCCUCGGGGGUGCUCU 17 4467
HSV2-UL30-1448 + CGGGGGGUGCCACGUCU 17 4318
HSV2-UL30-1506 + CUCUACCUCGCGGGUCU 17 4376
HSV2-UL30-768 - ACCGUCAUCACGCUUCU 17 3638
HSV2-UL30-1553 + GCCGAUGUACU UUUUCU 17 4423
HSV2-UL30-1576 + GGCCGCCUCCGGAAAGU 17 4446
HSV2-UL30-1668 + GGGCCCGGAGGCGUAGU 17 4538
HSV2-UL30-1766 + U UCGUAAUAGUACACGU 17 4636
HSV2-UL30-931 - ACCGGGGGCCGGCACGU 17 3801
HSV2-UL30-1605 + CAGGCUCUCGCGUACGU 17 4475
HSV2-UL30-1606 + U CACG AAG A ACAG CCG U 17 4476
HSV2-UL30-1734 + G AG G U U CCG AACG CCG U 17 4604
HSV2-UL30-1760 + AAAG U UG U CGCACAGG U 17 4630
HSV2-UL30-1518 + GUAAUACACCGUCAGGU 17 4388
HSV2-UL30-954 - UACCUGGAGAUCGAGGU 17 3824
HSV2-UL30-1630 + ACGUGAAACCCGGAGGU 17 4500
HSV2-UL30-1705 + GGCGAGAUCGCUGAGGU 17 4575
HSV2-UL30-1740 + CCGUCGGGGGGCGCGGU 17 4610
HSV2-UL30-1764 + ACGCGGUAGUACAGGGU 17 4634
HSV2-UL30-1529 + GAUGUCCCUCUCCGGGU 17 4399
HSV2-UL30-1472 + CGCGCCUCCCGGGGGGU 17 4342
HSV2-UL30-874 - CAGGACUCGCUGCUGG U 17 3744
HSV2-UL30-855 - GGGUGUGUUCCGCGUG U 17 3725
HSV2-UL30-1677 + GGAGAG UUUGACCU UGU 17 4547
HSV2-UL30-1727 + GAAGCACAUGAGCUUGU 17 4597
HSV2-UL30-1520 + GUGGGCCAGGCGCU UGU 17 4390
HSV2-UL30-1617 + ACUGAAGCACAGGUUGU 17 4487
HSV2-UL30-805 - CCGGGG UUUGUCACCUU 17 3675
HSV2-UL30-1781 + GGCGACGCGAUGGCCU U 17 4651
HSV2-UL30-1644 + GGCACGGCCGGGCGCUU 17 4514
HSV2-UL30-1523 + CGGGUGUCUGCUCAGU U 17 4393
HSV2-UL30-932 - CCGGGGGCCGGCACGUU 17 3802
HSV2-UL30-1019 - GAGGGACUGCAGGCGU U 17 3889
HSV2-UL30-812 - CGCCCCCCGACGGCGU U 17 3682
HSV2-UL30-1741 + CGUCGGGGGGCGCGGU U 17 4611 HSV2-UL30-1076 - CUCAGGGCCGCGGGGUU 17 3946
HSV2-UL30-1065 - ACGUUCAAGGCCCUGUU 17 3935
HSV2-UL30-890 - ACACCCAGGGG CGG U U U 17 3760
HSV2-UL30-1215 + G CCG CG G C AC A A A ACG A A A A 20 4085
HSV2-UL30-683 - GGGGGCAAGAUGCUCAUCAA 20 3553
HSV2-UL30-2878 + GGCUCAUGCUAGAGUAUCAA 20 11232
HSV2-UL30-562 - CUGCGCCU UGCGGGCCAGAA 20 3432
HSV2-UL30-1335 + GUCAGCUUGGUCAGGACGAA 20 4205
HSV2-UL30-1373 + CGGGCGUUCCGCGACCGGAA 20 4243
HSV2-UL30-589 - GAGCGGCCGGGGGACGGGAA 20 3459
HSV2-UL30-580 - CGGCCGUGCCUCGGGGGGAA 20 3450
HSV2-UL30-528 - GACGGGUACGGGCGCAUGAA 20 3398
HSV2-UL30-1427 + CCGCGUGCCGUAGACGUGAA 20 4297
HSV2-UL30-536 - CG C AG C A AG A U C A AG G U G A A 20 3406
HSV2-UL30-1101 + CUUGGCGU UAUUUCCAAACA 20 3971
HSV2-UL30-736 - CCGGGGCGUUCCGCUCAACA 20 3606
HSV2-UL30-450 - GCAGUACU UUUACAUGAACA 20 3320
HSV2-UL30-1378 + G U AGG CCGGCAG G U CACACA 20 4248
HSV2-UL30-540 - GUACGGCAUCAUCACCGACA 20 3410
HSV2-UL30-571 - GCGGUUUCGGGGCCUCGACA 20 3441
HSV2-UL30-667 - GCGCAUCAUCUACGGGGACA 20 3537
HSV2-UL30-523 - CAAGCUGACGGAGAUCUACA 20 3393
HSV2-UL30-1411 + CACGAAGACGCGGUAGUACA 20 4281
HSV2-UL30-1272 + GGCAAAG UCAAACACCACCA 20 4142
HSV2-UL30-1197 + GUAAAACAGCAGGUCGACCA 20 4067
HSV2-UL30-612 - GGCCGGCACGUUGGGUACCA 20 3482
HSV2-UL30-565 - UUCAUCCUGCCGGACACCCA 20 3435
HSV2-UL30-718 - AGCUAGACGCCGCCGCCCCA 20 3588
HSV2-UL30-1210 + GCUCGCCAUCUUG UCGCCCA 20 4080
HSV2-UL30-674 - GGCCGCGGGCCUGGUGGCCA 20 3544
HSV2-UL30-687 - GUUUAUCAACCGCACCUCCA 20 3557
HSV2-UL30-513 - CCUCAGCGAUCUCGCCUCCA 20 3383
HSV2-UL30-652 - GGGUUCACCGGGGUGCAGCA 20 3522
HSV2-UL30-1299 + UGAAGCCCUUCUGGCCCGCA 20 4169
HSV2-UL30-1262 + CGCGACGGCCUCGGGCCGCA 20 4132
HSV2-UL30-1420 + CGCCCCCGGCGACUCGCGCA 20 4290
HSV2-UL30-1216 + GUCCCCGUAGAUGAUGCGCA 20 4086
HSV2-UL30-1249 + CGAGCGGAUCUGCUUUCGCA 20 4119
HSV2-UL30-1233 + GUGGCGGCCACGUGCAGGCA 20 4103
HSV2-UL30-1288 + CUCCCCU UCCCCCCGAGGCA 20 4158
HSV2-UL30-1133 + GCGCUUGGCCGGGGAGGGCA 20 4003
HSV2-UL30-1185 + CGCCUGCAGUCCCUCGGGCA 20 4055
HSV2-UL30-1425 + CGCAGAGAUCGCGCGGGGCA 20 4295
HSV2-UL30-499 - GUGCU UCGAUAUCGAAUGCA 20 3369
HSV2-UL30-491 - CGACGUCGAGU UUAACUGCA 20 3361
HSV2-UL30-644 - CAAGCAACAGGCCGCCAUCA 20 3514 HSV2-UL30-709 - CGCGCAGGUCCCGUCCAUCA 20 3579
HSV2-UL30-682 - CGGGGGCAAGAUGCUCAUCA 20 3552
HSV2-UL30-535 - UCAGAAGCGCAGCAAGAUCA 20 3405
HSV2-UL30-669 - CGUUUUGUGCCGCGGCCUCA 20 3539
HSV2-UL30-707 - GACGGUGUAU UACAAGCUCA 20 3577
HSV2-UL30-750 - CGACGUGGCCGCGCGGCUCA 20 3620
HSV2-UL30-1228 + CUCGCGGCCGAUGG UCGUCA 20 4098
HSV2-UL30-742 - GGCGGCCUGCGUGACGU UCA 20 3612
HSV2-UL30-676 - GGUGGCCAUGGGCGACAAGA 20 3546
HSV2-UL30-1321 + CUUCUUCUUGUCCUUCAAGA 20 4191
HSV2-UL30-543 - CGUCUUGAAGGACAAGAAGA 20 3413
HSV2-UL30-561 - CCUGCGCCU UGCGGGCCAGA 20 3431
HSV2-UL30-714 - GACCCGCGAGGUAGAGGAGA 20 3584
HSV2-UL30-703 - GCGCAUCACCGACCCGGAGA 20 3573
HSV2-UL30-1304 + GAUCUGCUGGCCGUCGUAGA 20 4174
HSV2-UL30-1343 + GCUGUCAAACUCCAGGACGA 20 4213
HSV2-UL30-1334 + CGUCAGCUUGGUCAGGACGA 20 4204
HSV2-UL30-1340 + GGGGCCGUACUGCU UGACGA 20 4210
HSV2-UL30-558 - AUCACCCGCACCAUCUACGA 20 3428
HSV2-UL30-474 - CCCGCGAUCAGGAAGUACGA 20 3344
HSV2-UL30-447 - CUUCUGGGUCUGACCCCCGA 20 3317
HSV2-UL30-489 - GGCCCAACCGCGCCCCCCGA 20 3359
HSV2-UL30-695 - CUGGCGCGACCCCUGCCCGA 20 3565
HSV2-UL30-1396 + CUUGAGGCGGUACCAGCCGA 20 4266
HSV2-UL30-1178 + CCGGGUCGGUGAUGCGCCGA 20 4048
HSV2-UL30-1227 + GAGGAGCAUCUCGCGGCCGA 20 4097
HSV2-UL30-636 - AGAUCGAGGUGGGGGGCCGA 20 3506
HSV2-UL30-1428 + AGACGUGAACGGCGACGCGA 20 4298
HSV2-UL30-1308 + GAUGCCCGCCAGGCGCGCGA 20 4178
HSV2-UL30-1258 + GUCCGCCUCCAGGUGCGCGA 20 4128
HSV2-UL30-1323 + CU UCAAG ACGGCCUCGGCG A 20 4193
HSV2-UL30-1107 + GAGCGGAACGCCCCGGGCGA 20 3977
HSV2-UL30-1121 + CCCGGGGGGUCGGCAUGCGA 20 3991
HSV2-UL30-1379 + GUCACACAUGGCCCCCUCGA 20 4249
HSV2-UL30-524 - AUCUACAAGGUCCCGCUCGA 20 3394
HSV2-UL30-1362 + AAACAGGAGGAUGUGCUCGA 20 4232
HSV2-UL30-495 - GCGGACAACCUGGCCGUCGA 20 3365
HSV2-UL30-2879 + AUGCGGGACAUCAGCUUCGA 20 11233
HSV2-UL30-595 - GAUAAGGACGACGACGAGGA 20 3465
HSV2-UL30-599 - GACGAGGACGGGGACGAGGA 20 3469
HSV2-UL30-1181 + CCGAUGGGCG UCUACGAGGA 20 4051
HSV2-UL30-1239 + CUGUUGCU UGUCGAGGAGGA 20 4109
HSV2-UL30-1149 + GGCGGCGUCUAGCUCGCGGA 20 4019
HSV2-UL30-538 - CAAGAUCAAGGUGAACGGGA 20 3408
HSV2-UL30-1131 + CGGGGGCGCU UGGCCGGGGA 20 4001
HSV2-UL30-587 - GAAGGGGAGCGGCCGGGGGA 20 3457 HSV2-UL30-579 - CCGGCCGUGCCUCGGGGGGA 20 3449
HSV2-UL30-1159 + GGGAUCCGGUCCUUGAUGGA 20 4029
HSV2-UL30-1341 + CUGCUUGACGAAGGUCAUGA 20 4211
HSV2-UL30-1433 + CAGACCCAGAAGCGUGAUGA 20 4303
HSV2-UL30-706 - CAAGCGCCUGGCCCACCUGA 20 3576
HSV2-UL30-522 - CUUCGUCCUGACCAAGCUGA 20 3392
HSV2-UL30-1437 + GACGGUCCCGGCGGGCGUGA 20 4307
HSV2-UL30-637 - CCGACGGCUGU UCUUCGUGA 20 3507
HSV2-UL30-1235 + CGAGUUGCACACCACCUUGA 20 4105
HSV2-UL30-1158 + GUACGGGAUCCGGUCCUUGA 20 4028
HSV2-UL30-542 - CGUCGCCGAGGCCGUCU UGA 20 3412
HSV2-UL30-593 - CGGGAACGGGGACGAGGAUA 20 3463
HSV2-UL30-1194 + CGCGGCGGCCGCUCCGGAUA 20 4064
HSV2-UL30-762 - GCCGGCGGGGGCCGGCGCUA 20 3632
HSV2-UL30-664 - UACUCCAUGCGCAUCAUCUA 20 3534
HSV2-UL30-448 - CGCGUCGCCGUUCACGUCUA 20 3318
HSV2-UL30-518 - AUGACCUUCG UCAAGCAGUA 20 3388
HSV2-UL30-1217 + UAGAUGAUGCGCAUGGAGUA 20 4087
HSV2-UL30-1155 + GUCUGGGCCACGAUCACGUA 20 4025
HSV2-UL30-526 - AAGGUCCCGCUCGACGGGUA 20 3396
HSV2-UL30-539 - AUGGUGAACAUCGACAUGUA 20 3409
HSV2-UL30-647 - GUGGUGUGCAACUCGGUGUA 20 3517
HSV2-UL30-2870 - CCAGCUCCACG AGCG AU U U A 20 11224
HSV2-UL30-1359 + CGCAGGAUCCGAGCGAAAAC 20 4229
HSV2-UL30-1100 + UCUUGGCGUUAUUUCCAAAC 20 3970
HSV2-UL30-1400 + CCGGGUUGUCCAGGAUAAAC 20 4270
HSV2-UL30-643 - CG U CCU CCU CG ACAAGCAAC 20 3513
HSV2-UL30-590 - AGCGGCCGGGGGACGGGAAC 20 3460
HSV2-UL30-537 - G C AG C A AG AUCAAGGUGAAC 20 3407
HSV2-UL30-1273 + GCAAAG U CAAACACCACCAC 20 4143
HSV2-UL30-1263 + GGGAGAGCGUACUGAAGCAC 20 4133
HSV2-UL30-1407 + CGGGGCAAAAGUUGUCGCAC 20 4277
HSV2-UL30-649 - AACUCGGUGUACGGGU UCAC 20 3519
HSV2-UL30-1367 + GGACAGGUCGUAGAGCAGAC 20 4237
HSV2-UL30-604 - GAGGAGGUCGCGCGCGAGAC 20 3474
HSV2-UL30-1344 + CUGUCAAACUCCAGGACGAC 20 4214
HSV2-UL30-1372 + UCUUCCGGGCGUUCCGCGAC 20 4242
HSV2-UL30-638 - UGAGCAUCCUGCUGCGCGAC 20 3508
HSV2-UL30-525 - UCUACAAGGUCCCGCUCGAC 20 3395
HSV2-UL30-521 - ACAACAUCAUCAACUUCGAC 20 3391
HSV2-UL30-2880 + UGCGGGACAUCAGCUUCGAC 20 11234
HSV2-UL30-710 - AGGUCCCGUCCAUCAAGGAC 20 3580
HSV2-UL30-596 - AUAAGGACGACGACGAGGAC 20 3466
HSV2-UL30-600 - ACGAGGACGGGGACGAGGAC 20 3470
HSV2-UL30-1218 + GAUGCGCAUGGAGUACGGAC 20 4088
HSV2-UL30-627 - UCGCGCACCUGGAGGCGGAC 20 3497 HSV2-UL30-588 - AAGGGGAGCGGCCGGGGGAC 20 3458
HSV2-UL30-1160 + GGAUCCGGUCCUUGAUGGAC 20 4030
HSV2-UL30-1366 + GCUCGAGGGCGGUGGUGGAC 20 4236
HSV2-UL30-519 - UACGGCCCCGAGU UCGUGAC 20 3389
HSV2-UL30-665 - ACUCCAUGCGCAUCAUCUAC 20 3535
HSV2-UL30-1410 + GCACGAAGACGCGGUAGUAC 20 4280
HSV2-UL30-1156 + UCUGGGCCACGAUCACGUAC 20 4026
HSV2-UL30-527 - AGGUCCCGCUCGACGGGUAC 20 3397
HSV2-UL30-1270 + CCUGGAUGAUGCUGGGGUAC 20 4140
HSV2-UL30-648 - UGGUGUGCAACUCGGUGUAC 20 3518
HSV2-UL30-1275 + CACGGGGUCGACGUGAAACC 20 4145
HSV2-UL30-1401 + CGGGUUGUCCAGGAUAAACC 20 4271
HSV2-UL30-493 - UAACUGCACGGCGGACAACC 20 3363
HSV2-UL30-480 - CCGGU UUAUCCUGGACAACC 20 3350
HSV2-UL30-478 - GGGGCGUCGACGCCACCACC 20 3348
HSV2-UL30-1211 + UCUUGUCGCCCAUGGCCACC 20 4081
HSV2-UL30-554 - CU UCAAGUUUCUGCCGCACC 20 3424
HSV2-UL30-624 - GCCCGAGGCCGUCGCGCACC 20 3494
HSV2-UL30-650 - ACUCGGUGUACGGGUUCACC 20 3520
HSV2-UL30-605 - AGGAGGUCGCGCGCGAGACC 20 3475
HSV2-UL30-701 - CCAUCGGCGCAUCACCGACC 20 3571
HSV2-UL30-1196 + CG U A A A AC AG CAGGUCGACC 20 4066
HSV2-UL30-1281 + CGGAGGUGGGGUCGAGGACC 20 4151
HSV2-UL30-1219 + AUGCGCAUGGAGUACGGACC 20 4089
HSV2-UL30-628 - CGCGCACCUGGAGGCGGACC 20 3498
HSV2-UL30-520 - ACGGCCCCGAGUUCGUGACC 20 3390
HSV2-UL30-629 - GGAGGCGGACCGGGACUACC 20 3499
HSV2-UL30-1108 + GCCCCGGGCGAUGGCGUACC 20 3978
HSV2-UL30-611 - GGGCCGGCACGUUGGGUACC 20 3481
HSV2-UL30-1336 + GAAGUUGAUGAUGU UGUACC 20 4206
HSV2-UL30-1397 + CAG CCG A AG G U G AC AAACCC 20 4267
HSV2-UL30-481 - CGGUUUAUCCUGGACAACCC 20 3351
HSV2-UL30-1329 + CCCACACGCGGAACACACCC 20 4199
HSV2-UL30-564 - CUUCAUCCUGCCGGACACCC 20 3434
HSV2-UL30-1234 + CAGAAGACCGUGCUGCACCC 20 4104
HSV2-UL30-1282 + GGAGGUGGGGUCGAGGACCC 20 4152
HSV2-UL30-1109 + CCCCGGGCGAUGGCGUACCC 20 3979
HSV2-UL30-1398 + AGCCG AAGG U G ACAAACCCC 20 4268
HSV2-UL30-746 - UCCCGAGACGUGGCACCCCC 20 3616
HSV2-UL30-724 - GCCGUCGCAUGCCGACCCCC 20 3594
HSV2-UL30-725 - CCGUCGCAUGCCGACCCCCC 20 3595
HSV2-UL30-1374 + GGCCAGCUCGUCCUCCCCCC 20 4244
HSV2-UL30-723 - CUCCCCGG CCA AG CG CCCCC 20 3593
HSV2-UL30-1283 + GGUCGAGGACCCGGGCCCCC 20 4153
HSV2-UL30-1106 + CGUGUUGAGCGGAACGCCCC 20 3976
HSV2-UL30-1418 + AUGCCGCGGAACGACGCCCC 20 4288 HSV2-UL30-1294 + CGAGGCCCCGAAACCGCCCC 20 4164
HSV2-UL30-717 - GAGCUAGACGCCGCCGCCCC 20 3587
HSV2-UL30-722 - CCUCCCCGGCCAAGCGCCCC 20 3592
HSV2-UL30-663 - GCGGCCGGCAUGCGCGCCCC 20 3533
HSV2-UL30-1349 + GACGGGGGCCGGCAGGCCCC 20 4219
HSV2-UL30-1285 + GUACCCAACGUGCCGGCCCC 20 4155
HSV2-UL30-1286 + U CG U CCCCG U U CCCG U CCCC 20 4156
HSV2-UL30-1142 + GGGGGGGCGGGCUCGUCCCC 20 4012
HSV2-UL30-1105 + CCGUGUUGAGCGGAACGCCC 20 3975
HSV2-UL30-734 - UCCCGGGUACGCCAUCGCCC 20 3604
HSV2-UL30-1198 + CAGCAGGUCGACCAGGGCCC 20 4068
HSV2-UL30-688 - CAACCGCACCUCCAGGGCCC 20 3558
HSV2-UL30-616 - CGUUGGGUACCAGGGGGCCC 20 3486
HSV2-UL30-732 - CCGAGCUGGCGGAGGAUCCC 20 3602
HSV2-UL30-721 - CCCAGCGGCCCUGCCCUCCC 20 3591
HSV2-UL30-1116 + GGGGCUUGGACGCGCCUCCC 20 3986
HSV2-UL30-1123 + GGCAUGCGACGGCGUCUCCC 20 3993
HSV2-UL30-485 - GGCUGGUACCGCCUCAAGCC 20 3355
HSV2-UL30-510 - CUUUCCGGUCGCGGAACGCC 20 3380
HSV2-UL30-444 - UGGACGCCAUCACGCCCGCC 20 3314
HSV2-UL30-1307 + GGGUGAUGUUGAUGCCCGCC 20 4177
HSV2-UL30-1421 + ACUCGCGCAGGGCCGCCGCC 20 4291
HSV2-UL30-705 - CGCGUACACCAACAAGCGCC 20 3575
HSV2-UL30-573 - CAAGGAGGCGCCCAAGCGCC 20 3443
HSV2-UL30-455 - GCGCGAUCUCUGCGAGCGCC 20 3325
HSV2-UL30-555 - GCUUUCCGCCGUCGCGCGCC 20 3425
HSV2-UL30-733 - AUCCCGGGUACGCCAUCGCC 20 3603
HSV2-UL30-459 - GCGGCCCUGCGCGAGUCGCC 20 3329
HSV2-UL30-501 - UCGAUAUCGAAUGCAAGGCC 20 3371
HSV2-UL30-530 - GUACGGGCGCAUGAACGGCC 20 3400
HSV2-UL30-1290 + CU UCCCCCCG AGGCACGGCC 20 4160
HSV2-UL30-1380 + ACAUGGCCCCCUCGACGGCC 20 4250
HSV2-UL30-584 - CGGGGGGAAGGGGAGCGGCC 20 3454
HSV2-UL30-1393 + GCCGGCGCGUUCCCGCGGCC 20 4263
HSV2-UL30-672 - CGGCCUCACGGCCGCGGGCC 20 3542
HSV2-UL30-1314 + CACCCCGCGCUGCGCGGGCC 20 4184
HSV2-UL30-615 - ACGUUGGGUACCAGGGGGCC 20 3485
HSV2-UL30-1167 + A AU ACACCG U C AGG U G G G CC 20 4037
HSV2-UL30-1266 + UGAAGCACAGGUUGUGGGCC 20 4136
HSV2-UL30-1128 + UCUCCCGGGGGCGCUUGGCC 20 3998
HSV2-UL30-704 - CGACCCGGAGAGGGACAUCC 20 3574
HSV2-UL30-621 - CCUGUACCCCAGCAUCAUCC 20 3491
HSV2-UL30-731 - UCCGAGCUGGCGGAGGAUCC 20 3601
HSV2-UL30-479 - CGCCACCACCCGGUUUAUCC 20 3349
HSV2-UL30-1342 + CGAAU UCGCUGUCAAACUCC 20 4212
HSV2-UL30-618 - GGGUCCUCGACCCCACCUCC 20 3488 HSV2-UL30-686 - CGUUUAUCAACCGCACCUCC 20 3556
HSV2-UL30-545 - UCCCCGCCUACUACGCCUCC 20 3415
HSV2-UL30-1257 + GGUAGUCCCGGUCCGCCUCC 20 4127
HSV2-UL30-1115 + CGGGGCUUGGACGCGCCUCC 20 3985
HSV2-UL30-512 - ACCUCAGCGAUCUCGCCUCC 20 3382
HSV2-UL30-1310 + GCGCGACGGCGGAAAGCUCC 20 4180
HSV2-UL30-1255 + GGCCCCCCACCUCGAUCUCC 20 4125
HSV2-UL30-1176 + AGUCCUGGAUGUCCCUCUCC 20 4046
HSV2-UL30-1122 + CGGCAUGCGACGGCGUCUCC 20 3992
HSV2-UL30-1174 + CGGCGGUGAGGACAAAGUCC 20 4044
HSV2-UL30-1256 + CCUCGAUCUCCAGGUAGUCC 20 4126
HSV2-UL30-1092 + GCCGCGCGGCCACGUCG UCC 20 3962
HSV2-UL30-516 - CCUGCCGGCCCCCG UCGUCC 20 3386
HSV2-UL30-1434 + CAGAAGCGUGAUGACGGUCC 20 4304
HSV2-UL30-1399 + UGACAAACCCCGGGU UGUCC 20 4269
HSV2-UL30-1371 + UCUGGAUGACGAGGUCUUCC 20 4241
HSV2-UL30-470 - ACCGCGUCUUCGUGCGAAGC 20 3340
HSV2-UL30-1195 + CGGUAUCGUCGUAAAACAGC 20 4065
HSV2-UL30-1103 + U CACG C AG G CCG CCCCCAG C 20 3973
HSV2-UL30-1250 + UGGCCAGCCAGUCGCGCAGC 20 4120
HSV2-UL30-1251 + CGCGCAGCAGGAUGCUCAGC 20 4121
HSV2-UL30-507 - GGCCGGGGGGGAGGACGAGC 20 3377
HSV2-UL30-728 - CAAGCUGCUGG UGUCCGAGC 20 3598
HSV2-UL30-1331 + UGCGCCCGUACCCGUCGAGC 20 4201
HSV2-UL30-2862 + CCAUAAAUCGCUCGUGGAGC 20 11216
HSV2-UL30-1324 + GACGGCGUUCAGCUUGUAGC 20 4194
HSV2-UL30-1102 + CAGGGCCUUGAACGUCACGC 20 3972
HSV2-UL30-1088 + GCCGUAGCGCCGGCCCCCGC 20 3958
HSV2-UL30-443 - AUGGACGCCAUCACGCCCGC 20 3313
HSV2-UL30-671 - UGCCGCGGCCUCACGGCCGC 20 3541
HSV2-UL30-487 - ACCGCCUCAAGCCCGGCCGC 20 3357
HSV2-UL30-1134 + GCCGGGGAGGGCAGGGCCGC 20 4004
HSV2-UL30-752 - GCCGCGCGGCUCAGGGCCGC 20 3622
HSV2-UL30-1261 + GCGCGACGGCCUCGGGCCGC 20 4131
HSV2-UL30-547 - CCUCCGGGCCCGCGCAGCGC 20 3417
HSV2-UL30-1087 + AGUUUCCUCCGCCGUAGCGC 20 3957
HSV2-UL30-488 - GCCCGGCCGCGGGAACGCGC 20 3358
HSV2-UL30-655 - GCGCGUACGUGCACGCGCGC 20 3525
HSV2-UL30-1170 + GCUUGUUGGUGUACGCGCGC 20 4040
HSV2-UL30-708 - GCUCAUGGCCCGCCGCGCGC 20 3578
HSV2-UL30-471 - CGUGCGAAGCGGGCGCGCGC 20 3341
HSV2-UL30-1423 + GGCGCUCGCAGAGAUCGCGC 20 4293
HSV2-UL30-1419 + ACGCCCCCGGCGACUCGCGC 20 4289
HSV2-UL30-1300 + CCUUCUGGCCCGCAAGGCGC 20 4170
HSV2-UL30-1313 + CCGAUCACCCCGCGCUGCGC 20 4183
HSV2-UL30-1405 + CCCUCGUACUUCCUGAUCGC 20 4275 HSV2-UL30-1152 + GACCGUCUCCUCUACCUCGC 20 4022
HSV2-UL30-458 - GGCGGCCCUGCGCGAGUCGC 20 3328
HSV2-UL30-1358 + GUGGGACUCGGGGAGG UCGC 20 4228
HSV2-UL30-500 - UUCGAUAUCGAAUGCAAGGC 20 3370
HSV2-UL30-1271 + GAUGAUGCUGGGGUACAGGC 20 4141
HSV2-UL30-1232 + GGUGGCGGCCACGUGCAGGC 20 4102
HSV2-UL30-1318 + GGCCCGGAGGCGUAGUAGGC 20 4188
HSV2-UL30-1376 + AAGCACAUGAGCU UGUAGGC 20 4246
HSV2-UL30-529 - GGUACGGGCGCAUGAACGGC 20 3399
HSV2-UL30-1289 + CCUUCCCCCCGAGGCACGGC 20 4159
HSV2-UL30-1436 + AGCGUGAUGACGGUCCCGGC 20 4306
HSV2-UL30-1377 + ACAUGAGCUUGUAGGCCGGC 20 4247
HSV2-UL30-758 - GCCGCGGGGUUCGGGCCGGC 20 3628
HSV2-UL30-1348 + CCAGGACGACGGGGGCCGGC 20 4218
HSV2-UL30-1297 + ACCGCCCCUGGGUGUCCGGC 20 4167
HSV2-UL30-583 - UCGGGGGGAAGGGGAGCGGC 20 3453
HSV2-UL30-1392 + GGCCGGCGCGU UCCCGCGGC 20 4262
HSV2-UL30-1163 + GGACGGGACCUGCGCGCGGC 20 4033
HSV2-UL30-716 - AGAGGAGACGGUCGCGCGGC 20 3586
HSV2-UL30-662 - GCCGACUU UCCGGAGGCGGC 20 3532
HSV2-UL30-484 - CGGGGUUUGUCACCU UCGGC 20 3354
HSV2-UL30-1132 + GGCGCU UGGCCGGGGAGGGC 20 4002
HSV2-UL30-1184 + ACGCCUGCAGUCCCUCGGGC 20 4054
HSV2-UL30-756 - CAGGGCCGCGGGGUUCGGGC 20 3626
HSV2-UL30-1347 + AACUCCAGGACGACGGGGGC 20 4217
HSV2-UL30-608 - UCGCGCGCGAGACCGGGGGC 20 3478
HSV2-UL30-761 - GGGUUCGGGCCGGCGGGGGC 20 3631
HSV2-UL30-1141 + GGCAGGGCCGCUGGGGGGGC 20 4011
HSV2-UL30-1390 + GUCGGGGGGCGCGGU UGGGC 20 4260
HSV2-UL30-639 - CAUCCUGCUGCGCGACUGGC 20 3509
HSV2-UL30-557 - UCCGCCGUCGCGCGCCUGGC 20 3427
HSV2-UL30-693 - GCGCCCCGCAGAGGAGUGGC 20 3563
HSV2-UL30-1127 + GUCUCCCGGGGGCGCUUGGC 20 3997
HSV2-UL30-1222 + CGGACCGGGGGCGCGCAUGC 20 4092
HSV2-UL30-1267 + GUUGUGGGCCUGGAUGAUGC 20 4137
HSV2-UL30-1426 + CGCGCGGGGCACGGCACUGC 20 4296
HSV2-UL30-696 - ACCCCUGCCCGAGGGACUGC 20 3566
HSV2-UL30-737 - CUAUUACUUCUCGCACCUGC 20 3607
HSV2-UL30-498 - GGGGGCCAUGUGUGACCUGC 20 3368
HSV2-UL30-515 - UCUCGCCUCCAGGGGCCUGC 20 3385
HSV2-UL30-563 - CCAGAAGGGCUUCAUCCUGC 20 3433
HSV2-UL30-727 - G U CCA AG CCCCGCAAGCUGC 20 3597
HSV2-UL30-658 - GGCGGAGUUCGAUCAGCUGC 20 3528
HSV2-UL30-551 - UUGUGUGCAGGACUCGCUGC 20 3421
HSV2-UL30-517 - CAGCGAAUUCGAGAUGCUGC 20 3387
HSV2-UL30-679 - AGUACAUCGGCGUCAUCUGC 20 3549 HSV2-UL30-1303 + ACGUGAAGACGCGGAUCUGC 20 4173
HSV2-UL30-1188 + CGCGCCAGCCACUCCUCUGC 20 4058
HSV2-UL30-1284 + CCCCCUGGUACCCAACGUGC 20 4154
HSV2-UL30-1231 + UCACGGUGGCGGCCACGUGC 20 4101
HSV2-UL30-1306 + CUGGCCG UCGUAGAUGGUGC 20 4176
HSV2-UL30-550 - GAUCGGCGAGUAUUGUGUGC 20 3420
HSV2-UL30-560 - ACGUGCCUCCUGCGCCUUGC 20 3430
HSV2-UL30-1112 + CUCGGACACCAGCAGCU UGC 20 3982
HSV2-UL30-1368 + CGUAGAGCAGACAGGAGAUC 20 4238
HSV2-UL30-472 - ACAACU U U UGCCCCGCG AUC 20 3342
HSV2-UL30-1157 + CCACGAUCACGUACGGGAUC 20 4027
HSV2-UL30-685 - GCUCAUCAAGGGCGUGGAUC 20 3555
HSV2-UL30-1204 + U UUCGCACUCGAGCU UGAUC 20 4074
HSV2-UL30-689 - U UUUACGACGAUACCGUAUC 20 3559
HSV2-UL30-1338 + UUGUACCCGGUCACGAACUC 20 4208
HSV2-UL30-1355 + AGAUCGCUGAGGUGGGACUC 20 4225
HSV2-UL30-617 - CGGGUCCUCGACCCCACCUC 20 3487
HSV2-UL30-1183 + CCGAACGCCUGCAGUCCCUC 20 4053
HSV2-UL30-544 - AUCCCCGCCUACUACGCCUC 20 3414
HSV2-UL30-1223 + GCGCGCAUGCCGGCCGCCUC 20 4093
HSV2-UL30-1260 + UCCAGGUGCGCGACGGCCUC 20 4130
HSV2-UL30-575 - CAAGCGCCCGGCCGUGCCUC 20 3445
HSV2-UL30-1241 + UCGAGGAGGACGGCCUCCUC 20 4111
HSV2-UL30-1193 + GGCUAACGCGGCGGCCGCUC 20 4063
HSV2-UL30-749 - ACGACGUGGCCGCGCGGCUC 20 3619
HSV2-UL30-1327 + UGCGCUUCUGAAAGUGGCUC 20 4197
HSV2-UL30-1244 + CGGCCUCCUCGGGGGUGCUC 20 4114
HSV2-UL30-1175 + AAGUCCUGGAUGUCCCUCUC 20 4045
HSV2-UL30-1097 + UCCGGGGGGUGCCACGUCUC 20 3967
HSV2-UL30-1164 + UGAGCUUGUAAUACACCGUC 20 4034
HSV2-UL30-1383 + UCGAGGUUCCGAACGCCGUC 20 4253
HSV2-UL30-1091 + AGCCGCGCGGCCACGUCGUC 20 3961
HSV2-UL30-1413 + AGACGCGGUAGUACAGGGUC 20 4283
HSV2-UL30-1153 + UCUCCUCUACCUCGCGGGUC 20 4023
HSV2-UL30-553 - UGCAGGACUCGCUGCUGGUC 20 3423
HSV2-UL30-1333 + AGAUCUCCGUCAGCUUGGUC 20 4203
HSV2-UL30-1296 + CGAAACCGCCCCUGGGUGUC 20 4166
HSV2-UL30-1298 + CCGGCAGGAUGAAGCCCUUC 20 4168
HSV2-UL30-1430 + ACGGCGACGCGAUGGCCUUC 20 4300
HSV2-UL30-445 - CGGGACCGUCAUCACGCUUC 20 3315
HSV2-UL30-1370 + AUCUGGAUGACGAGGUCUUC 20 4240
HSV2-UL30-698 - CCGAGGGACUGCAGGCGU UC 20 3568
HSV2-UL30-755 - GGCUCAGGGCCGCGGGGUUC 20 3625
HSV2-UL30-659 - UCAGCUGCUGGCCGACU UUC 20 3529
HSV2-UL30-508 - GGAGGACGAGCUGGCCU UUC 20 3378
HSV2-UL30-569 - GGACACCCAGGGGCGGUU UC 20 3439 HSV2-UL30-1326 + UCUUGCUGCGCU UCUGAAAG 20 4196
HSV2-UL30-744 - UCACCGAGAGUCUGUUAAAG 20 3614
HSV2-UL30-469 - UACCGCGUCUUCGUGCGAAG 20 3339
HSV2-UL30-1415 + CCACCACCU CCGCCU CGAAG 20 4285
HSV2-UL30-581 - GGCCGUGCCUCGGGGGGAAG 20 3451
HSV2-UL30-613 - GCCGGCACGU UGGGUACCAG 20 3483
HSV2-UL30-566 - UCAUCCUGCCGGACACCCAG 20 3436
HSV2-UL30-720 - GGACGAGCCCGCCCCCCCAG 20 3590
HSV2-UL30-719 - GCUAGACGCCGCCGCCCCAG 20 3589
HSV2-UL30-514 - CUCAGCGAUCUCGCCUCCAG 20 3384
HSV2-UL30-691 - GUUAGCCGAGCGCCCCGCAG 20 3561
HSV2-UL30-1186 + GCCUGCAGUCCCUCGGGCAG 20 4056
HSV2-UL30-475 - CCGCGAUCAGGAAGUACGAG 20 3345
HSV2-UL30-1248 + UGCUCUGGGGGAUCCGCGAG 20 4118
HSV2-UL30-1330 + AUGCGCCCGUACCCGUCGAG 20 4200
HSV2-UL30-496 - CGGACAACCUGGCCGUCGAG 20 3366
HSV2-UL30-692 - CCGAGCGCCCCGCAGAGGAG 20 3562
HSV2-UL30-702 - GGCGCAUCACCGACCCGGAG 20 3572
HSV2-UL30-690 - CGACGAUACCGUAUCCGGAG 20 3560
HSV2-UL30-582 - UGCCUCGGGGGGAAGGGGAG 20 3452
HSV2-UL30-1104 + AAGUAAUAGUCCGUGU UGAG 20 3974
HSV2-UL30-713 - GGCCCAGACCCGCGAGGUAG 20 3583
HSV2-UL30-591 - GCGGCCGGGGGACGGGAACG 20 3461
HSV2-UL30-1191 + UGCGGGGCGCUCGGCUAACG 20 4061
HSV2-UL30-1328 + UCUGGCCGAUGUCCCACACG 20 4198
HSV2-UL30-1274 + CAA AG U CA AACACC ACCACG 20 4144
HSV2-UL30-449 - CCGUUCACGUCUACGGCACG 20 3319
HSV2-UL30-653 - UCUUCUGCCCUGCCUGCACG 20 3523
HSV2-UL30-1409 + GCCCGCUUCGCACGAAGACG 20 4279
HSV2-UL30-1302 + GCAGGAGGCACGUGAAGACG 20 4172
HSV2-UL30-745 - AGAGGUUUAUUCCCGAGACG 20 3615
HSV2-UL30-594 - CGAGGAUAAGGACGACGACG 20 3464
HSV2-UL30-1345 + UGUCAAACUCCAGGACGACG 20 4215
HSV2-UL30-747 - GUGGCACCCCCCGGACGACG 20 3617
HSV2-UL30-2881 + GCGGGACAUCAGCUUCGACG 20 11235
HSV2-UL30-597 - UAAGGACGACGACGAGGACG 20 3467
HSV2-UL30-601 - CGAGGACGGGGACGAGGACG 20 3471
HSV2-UL30-592 - GGGGGACGGGAACGGGGACG 20 3462
HSV2-UL30-598 - CGACGACGAGGACGGGGACG 20 3468
HSV2-UL30-1369 + GACAGGAGAUCUGGAUGACG 20 4239
HSV2-UL30-666 - CUCCAUGCGCAUCAUCUACG 20 3536
HSV2-UL30-1180 + UGCGCCGAUGGGCGUCUACG 20 4050
HSV2-UL30-473 - CCCCG CG AU C AG G A AG U ACG 20 3343
HSV2-UL30-1252 + UCAGCAGGCUCUCGCGUACG 20 4122
HSV2-UL30-651 - CUCGGUGUACGGGUUCACCG 20 3521
HSV2-UL30-606 - GGAGGUCGCGCGCGAGACCG 20 3476 HSV2-UL30-1220 + UGCGCAUGGAGUACGGACCG 20 4090
HSV2-UL30-482 - GGUUUAUCCUGGACAACCCG 20 3352
HSV2-UL30-1089 + CCCCGCCGGCCCGAACCCCG 20 3959
HSV2-UL30-619 - CGGGUUUCACGUCGACCCCG 20 3489
HSV2-UL30-641 - GAUCCCCCAGAGCACCCCCG 20 3511
HSV2-UL30-1287 + GGCCGCUCCCCUUCCCCCCG 20 4157
HSV2-UL30-735 - CCCGGGUACGCCAUCGCCCG 20 3605
HSV2-UL30-1212 + GCCCAUGGCCACCAGGCCCG 20 4082
HSV2-UL30-623 - UACGCUCUCCCUGCGGCCCG 20 3493
HSV2-UL30-694 - GCUGGCGCGACCCCUGCCCG 20 3564
HSV2-UL30-1117 + GGGCUUGGACGCGCCUCCCG 20 3987
HSV2-UL30-1124 + GCAUGCGACGGCGUCUCCCG 20 3994
HSV2-UL30-1391 + GUUGGGCCGGCGCGU UCCCG 20 4261
HSV2-UL30-460 - CG G CCC U G CG CG AG U CG CCG 20 3330
HSV2-UL30-541 - CAAGCUGAACGCCGUCGCCG 20 3411
HSV2-UL30-502 - CGAUAUCGAAUGCAAGGCCG 20 3372
HSV2-UL30-1214 + GGCCCGCGGCCGUGAGGCCG 20 4084
HSV2-UL30-531 - UACGGGCGCAUGAACGGCCG 20 3401
HSV2-UL30-670 - GUGCCGCGGCCUCACGGCCG 20 3540
HSV2-UL30-486 - UACCGCCUCAAGCCCGGCCG 20 3356
HSV2-UL30-585 - GGGGGGAAGGGGAGCGGCCG 20 3455
HSV2-UL30-751 - GGCCGCGCGGCUCAGGGCCG 20 3621
HSV2-UL30-1129 + CUCCCGGGGGCGCUUGGCCG 20 3999
HSV2-UL30-1417 + AGUGG UCCGCGGAGAUGCCG 20 4287
HSV2-UL30-668 - UCCAUUUUCGUU UUGUGCCG 20 3538
HSV2-UL30-463 - GUCGUUCCGCGGCAUCUCCG 20 3333
HSV2-UL30-1093 + CCGCGCGGCCACGUCGUCCG 20 3963
HSV2-UL30-1416 + CUCCGCCUCGAAGUGGUCCG 20 4286
HSV2-UL30-462 - UCGCCGGGGGCGUCGU UCCG 20 3332
HSV2-UL30-546 - GCCUCCGGGCCCGCGCAGCG 20 3416
HSV2-UL30-712 - GAUCGUGGCCCAGACCCGCG 20 3582
HSV2-UL30-1090 + CCCCGCGGCCCUGAGCCGCG 20 3960
HSV2-UL30-753 - CCG CG CG G CU CAG GGCCGCG 20 3623
HSV2-UL30-748 - CCCCGGACGACGUGGCCGCG 20 3618
HSV2-UL30-548 - CUCCGGGCCCGCGCAGCGCG 20 3418
HSV2-UL30-602 - CGAGGACGGGGACGAGCGCG 20 3472
HSV2-UL30-1169 + CGCUUGUUGGUGUACGCGCG 20 4039
HSV2-UL30-1424 + GCGCUCGCAGAGAUCGCGCG 20 4294
HSV2-UL30-1161 + UGAUGGACGGGACCUGCGCG 20 4031
HSV2-UL30-1422 + AGGCGCUCGCAGAGAUCGCG 20 4292
HSV2-UL30-1406 + CCUCGUACUUCCUGAUCGCG 20 4276
HSV2-UL30-1225 + GCACGUACGCGCGCG UCGCG 20 4095
HSV2-UL30-715 - AGGUAGAGGAGACGGUCGCG 20 3585
HSV2-UL30-1319 + GCCCGGAGGCG UAGUAGGCG 20 4189
HSV2-UL30-759 - CCGCGGGGUUCGGGCCGGCG 20 3629
HSV2-UL30-684 - CAAGAUGCUCAUCAAGGGCG 20 3554 HSV2-UL30-1387 + CCGAACGCCGUCGGGGGGCG 20 4257
HSV2-UL30-1312 + GCCGAUCACCCCGCGCUGCG 20 4182
HSV2-UL30-680 - GUACAUCGGCGUCAUCUGCG 20 3550
HSV2-UL30-1189 + GCGCCAGCCACUCCUCUGCG 20 4059
HSV2-UL30-1113 + UCGGACACCAGCAGCUUGCG 20 3983
HSV2-UL30-630 - CCGGGACUACCUGGAGAUCG 20 3500
HSV2-UL30-1404 + CCCCUCGUACU UCCUGAUCG 20 4274
HSV2-UL30-711 - CCGGAUCCCGUACGUGAUCG 20 3581
HSV2-UL30-1205 + U UCGCACUCGAGCUUGAUCG 20 4075
HSV2-UL30-1339 + UGUACCCGG UCACGAACUCG 20 4209
HSV2-UL30-1356 + GAUCGCUGAGGUGGGACUCG 20 4226
HSV2-UL30-1151 + CGACCGUCUCCUCUACCUCG 20 4021
HSV2-UL30-576 - AAGCGCCCGGCCGUGCCUCG 20 3446
HSV2-UL30-1242 + CGAGGAGGACGGCCUCCUCG 20 4112
HSV2-UL30-1147 + GGGCGGCGGCGUCUAGCUCG 20 4017
HSV2-UL30-640 - UGCGAAAGCAGAUCCGCUCG 20 3510
HSV2-UL30-1438 + UGGCGUCCAUAAAUCGCUCG 20 4308
HSV2-UL30-1381 + GUUAAACUCGACGUCGCUCG 20 4251
HSV2-UL30-1361 + AAAACAGGAGGAUGUGCUCG 20 4231
HSV2-UL30-1226 + GCGUCGCGAGGAGCAUCUCG 20 4096
HSV2-UL30-1384 + CGAGGUUCCGAACGCCG UCG 20 4254
HSV2-UL30-494 - GGCGGACAACCUGGCCGUCG 20 3364
HSV2-UL30-509 - CGAGCUGGCCUU UCCGGUCG 20 3379
HSV2-UL30-1280 + GAAACCCGGAGGUGGGGUCG 20 4150
HSV2-UL30-1320 + CGUAGUAGGCGGGGAUGUCG 20 4190
HSV2-UL30-1293 + GCUUGGGCGCCUCCUUGUCG 20 4163
HSV2-UL30-1237 + UGGCGGCCUGUUGCUUGUCG 20 4107
HSV2-UL30-464 - CAUCUCCGCGGACCACU UCG 20 3334
HSV2-UL30-1431 + CGGCGACGCGAUGGCCU UCG 20 4301
HSV2-UL30-699 - CGAGGGACUGCAGGCGU UCG 20 3569
HSV2-UL30-570 - GACACCCAGGGGCGGUUUCG 20 3440
HSV2-UL30-451 - GUACUU UUACAUGAACAAGG 20 3321
HSV2-UL30-572 - GUUUCGGGGCCUCGACAAGG 20 3442
HSV2-UL30-645 - G C A AC AG GCCGCCAUCAAGG 20 3515
HSV2-UL30-1360 + AGGAUCCGAGCGAAAACAGG 20 4230
HSV2-UL30-614 - CCGGCACGU UGGGUACCAGG 20 3484
HSV2-UL30-1301 + UCUGGCCCGCAAGGCGCAGG 20 4171
HSV2-UL30-1165 + GCU UGUAAUACACCGUCAGG 20 4035
HSV2-UL30-476 - CGCGAUCAGGAAGUACGAGG 20 3346
HSV2-UL30-642 - CCCCCAGAGCACCCCCGAGG 20 3512
HSV2-UL30-603 - GGACGGGGACGAGCGCGAGG 20 3473
HSV2-UL30-631 - GGACUACCUGGAGAUCGAGG 20 3501
HSV2-UL30-497 - GGACAACCUGGCCGUCGAGG 20 3367
HSV2-UL30-1238 + CGGCCUGUUGCUUGUCGAGG 20 4108
HSV2-UL30-465 - CUCCGCGG ACCACU UCG AGG 20 3335
HSV2-UL30-1277 + GUCGACGUGAAACCCGGAGG 20 4147 HSV2-UL30-661 - GCUGGCCGACUU UCCGGAGG 20 3531
HSV2-UL30-453 - UUACAUGAACAAGGCGGAGG 20 3323
HSV2-UL30-467 - GGACCACUUCGAGGCGGAGG 20 3337
HSV2-UL30-626 - GGCCGUCGCGCACCUGGAGG 20 3496
HSV2-UL30-1352 + UGGAGGCGAGAUCGCUGAGG 20 4222
HSV2-UL30-1395 + UCCCGCGGCCGGGCUUGAGG 20 4265
HSV2-UL30-1317 + GGGCCCGGAGGCGUAG UAGG 20 4187
HSV2-UL30-492 - CGUCGAGUUUAACUGCACGG 20 3362
HSV2-UL30-1229 + GCGGCCGAUGGUCGUCACGG 20 4099
HSV2-UL30-1346 + GUCAAACUCCAGGACGACGG 20 4216
HSV2-UL30-1309 + GCCCGCCAGGCGCGCGACGG 20 4179
HSV2-UL30-2882 + CGGGACAUCAGCUUCGACGG 20 11236
HSV2-UL30-763 - GGCGGGGGCCGGCGCUACGG 20 3633
HSV2-UL30-607 - GAGGUCGCGCGCGAGACCGG 20 3477
HSV2-UL30-1221 + GCGCAUGGAGUACGGACCGG 20 4091
HSV2-UL30-1276 + GGGGUCGACGUGAAACCCGG 20 4146
HSV2-UL30-1315 + CCCGCGCUGCGCGGGCCCGG 20 4185
HSV2-UL30-1118 + GGCUUGGACGCGCCUCCCGG 20 3988
HSV2-UL30-1125 + CAUGCGACGGCGUCUCCCGG 20 3995
HSV2-UL30-1435 + AAGCGUGAUGACGGUCCCGG 20 4305
HSV2-UL30-461 - GGCCCUGCGCGAGUCGCCGG 20 3331
HSV2-UL30-503 - GAUAUCGAAUGCAAGGCCGG 20 3373
HSV2-UL30-586 - GGGGGAAGGGGAGCGGCCGG 20 3456
HSV2-UL30-757 - GGCCGCGGGGUUCGGGCCGG 20 3627
HSV2-UL30-1094 + CGCGCGGCCACGUCGUCCGG 20 3964
HSV2-UL30-660 - GCUGCUGGCCGACU UUCCGG 20 3530
HSV2-UL30-1192 + GGGGCGCUCGGCUAACGCGG 20 4062
HSV2-UL30-1162 + UGGACGGGACCUGCGCGCGG 20 4032
HSV2-UL30-1148 + CGGCGGCGUCUAGCUCGCGG 20 4018
HSV2-UL30-452 - CU UUUACAUGAACAAGGCGG 20 3322
HSV2-UL30-466 - CGCGGACCACU UCGAGGCGG 20 3336
HSV2-UL30-764 - GGGGGCCGGCGCUACGGCGG 20 3634
HSV2-UL30-760 - CGCGGGGUUCGGGCCGGCGG 20 3630
HSV2-UL30-1364 + GAGGAUGUGCUCGAGGGCGG 20 4234
HSV2-UL30-1146 + GGGCUCGUCCCCUGGGGCGG 20 4016
HSV2-UL30-457 - UCUCUGCGAGCGCCUGGCGG 20 3327
HSV2-UL30-730 - GCUGGUGUCCGAGCUGGCGG 20 3600
HSV2-UL30-681 - UACAUCGGCGUCAUCUGCGG 20 3551
HSV2-UL30-1206 + UCGCACUCGAGCUUGAUCGG 20 4076
HSV2-UL30-577 - AGCGCCCGGCCGUGCCUCGG 20 3447
HSV2-UL30-1243 + GAGGAGGACGGCCUCCUCGG 20 4113
HSV2-UL30-1385 + GAGGU UCCGAACGCCGUCGG 20 4255
HSV2-UL30-1432 + GGCGACGCGAUGGCCU UCGG 20 4302
HSV2-UL30-1172 + CGGGUGUCUGCUCAGUUCGG 20 4042
HSV2-UL30-477 - GCGAUCAGGAAGUACGAGGG 20 3347
HSV2-UL30-1363 + CAGGAGGAUGUGCUCGAGGG 20 4233 HSV2-UL30-1150 + GGCGUCUAGCUCGCGGAGGG 20 4020
HSV2-UL30-2883 + GGGACAUCAGCUUCGACGGG 20 11237
HSV2-UL30-1402 + GUUGUCCAGGAUAAACCGGG 20 4272
HSV2-UL30-726 - UCGCAUGCCGACCCCCCGGG 20 3596
HSV2-UL30-1119 + GCU UGGACGCGCCUCCCGGG 20 3989
HSV2-UL30-504 - AUAUCGAAUGCAAGGCCGGG 20 3374
HSV2-UL30-1095 + GCGCGGCCACGUCGUCCGGG 20 3965
HSV2-UL30-1207 + CGCACUCGAGCUUGAUCGGG 20 4077
HSV2-UL30-578 - GCGCCCGGCCGUGCCUCGGG 20 3448
HSV2-UL30-1386 + AGGUUCCGAACGCCGUCGGG 20 4256
HSV2-UL30-567 - UCCUGCCGGACACCCAGGGG 20 3437
HSV2-UL30-505 - UAUCGAAUGCAAGGCCGGGG 20 3375
HSV2-UL30-1130 + CCGGGGGCGCU UGGCCGGGG 20 4000
HSV2-UL30-1357 + CGCUGAGGUGGGACUCGGGG 20 4227
HSV2-UL30-1208 + ACUCGAGCUUGAUCGGGGGG 20 4078
HSV2-UL30-506 - CGAAUGCAAGGCCGGGGGGG 20 3376
HSV2-UL30-1140 + GGGCAGGGCCGCUGGGGGGG 20 4010
HSV2-UL30-741 - CUUCUCGCACCUGCUGGGGG 20 3611
HSV2-UL30-1145 + GGCGGGCUCGUCCCCUGGGG 20 4015
HSV2-UL30-1139 + GGAGGGCAGGGCCGCUGGGG 20 4009
HSV2-UL30-2864 + AAAUCGCUCGUGGAGCUGGG 20 11218
HSV2-UL30-1138 + GGGAGGGCAGGGCCGCUGGG 20 4008
HSV2-UL30-657 - GUACGUGCACGCGCGCUGGG 20 3527
HSV2-UL30-635 - UACCUGGAGAUCGAGGUGGG 20 3505
HSV2-UL30-1236 + GU UGCACACCACCUUGAUGG 20 4106
HSV2-UL30-625 - CGAGGCCGUCGCGCACCUGG 20 3495
HSV2-UL30-1350 + GGGGGCCGGCAGGCCCCUGG 20 4220
HSV2-UL30-1199 + CAGGUCGACCAGGGCCCUGG 20 4069
HSV2-UL30-456 - CGAUCUCUGCGAGCGCCUGG 20 3326
HSV2-UL30-556 - UUCCGCCGUCGCGCGCCUGG 20 3426
HSV2-UL30-673 - CCUCACGGCCGCGGGCCUGG 20 3543
HSV2-UL30-729 - GCUGCUGGUGUCCGAGCUGG 20 3599
HSV2-UL30-1137 + GGGGAGGGCAGGGCCGCUGG 20 4007
HSV2-UL30-740 - UUACU UCUCGCACCUGCUGG 20 3610
HSV2-UL30-1247 + CCUCCUCGGGGGUGCUCUGG 20 4117
HSV2-UL30-620 - GU UUCACGUCGACCCCGUGG 20 3490
HSV2-UL30-634 - CUACCUGGAGAUCGAGGUGG 20 3504
HSV2-UL30-468 - CCACUUCGAGGCGGAGG UGG 20 3338
HSV2-UL30-1230 + GCCGAUGGUCGUCACGGUGG 20 4100
HSV2-UL30-1365 + GAUGUGCUCGAGGGCGGUGG 20 4235
HSV2-UL30-1403 + GUCCAGGAUAAACCGGG UGG 20 4273
HSV2-UL30-1209 + G G A AC AG CG CG CG CG AG A U G 20 4079
HSV2-UL30-1144 + GGGGGCGGGCUCGUCCCCUG 20 4014
HSV2-UL30-622 - GCUUCAGUACGCUCUCCCUG 20 3492
HSV2-UL30-1136 + CGGGGAGGGCAGGGCCGCUG 20 4006
HSV2-UL30-1351 + CCCUGGAGGCGAGAUCGCUG 20 4221 HSV2-UL30-1269 + UGUGGGCCUGGAUGAUGCUG 20 4139
HSV2-UL30-739 - AUUACUUCUCGCACCUGCUG 20 3609
HSV2-UL30-678 - AAGUACAUCGGCGUCAUCUG 20 3548
HSV2-UL30-1187 + UCGCGCCAGCCACUCCUCUG 20 4057
HSV2-UL30-1246 + GCCUCCUCGGGGGUGCUCUG 20 4116
HSV2-UL30-1213 + CCACCAGGCCCGCGGCCGUG 20 4083
HSV2-UL30-532 - GCCGGGGUGUGU UCCGCGUG 20 3402
HSV2-UL30-1311 + ACGGCGGAAAGCUCCAGGUG 20 4181
HSV2-UL30-633 - ACUACCUGGAGAUCGAGGUG 20 3503
HSV2-UL30-1279 + CGACG U G AAACCCG G AGG U G 20 4149
HSV2-UL30-1200 + CGACCAGGGCCCUGGAGGUG 20 4070
HSV2-UL30-1173 + GUCUGCUCAGUUCGGCGGUG 20 4043
HSV2-UL30-1305 + GCUGGCCGUCGUAGAUGGUG 20 4175
HSV2-UL30-559 - CACGUGCCUCCUGCGCCU UG 20 3429
HSV2-UL30-1111 + GCUCGG ACACCAGCAGCU UG 20 3981
HSV2-UL30-1394 + CGU UCCCGCGGCCGGGCUUG 20 4264
HSV2-UL30-1264 + GCGUACUGAAGCACAGGUUG 20 4134
HSV2-UL30-534 - GUGUUCCGCGUGUGGGACAU 20 3404
HSV2-UL30-677 - AUCGCCAAG A A A A AG U ACAU 20 3547
HSV2-UL30-654 - GCCGCCACCGUGACGACCAU 20 3524
HSV2-UL30-700 - CCGUCCUCGUAGACGCCCAU 20 3570
HSV2-UL30-675 - GCCGCGGGCCUGGUGGCCAU 20 3545
HSV2-UL30-1179 + CGGGUCGGUGAUGCGCCGAU 20 4049
HSV2-UL30-454 - UGAACAAGGCGGAGGUGGAU 20 3324
HSV2-UL30-549 - CCCGCGCAGCGCGGGGUGAU 20 3419
HSV2-UL30-1203 + UUU UCGCACUCGAGCUUGAU 20 4073
HSV2-UL30-646 - CAUCAAGGUGGUGUGCAACU 20 3516
HSV2-UL30-1337 + GU UGUACCCGGUCACGAACU 20 4207
HSV2-UL30-1354 + GAGAUCGCUGAGGUGGGACU 20 4224
HSV2-UL30-1295 + GAGGCCCCGAAACCGCCCCU 20 4165
HSV2-UL30-1143 + GGGGGGCGGGCUCGUCCCCU 20 4013
HSV2-UL30-1182 + CCCGAACGCCUGCAGUCCCU 20 4052
HSV2-UL30-1322 + CU UGUCCUUCAAGACGGCCU 20 4192
HSV2-UL30-1259 + CUCCAGGUGCGCGACGGCCU 20 4129
HSV2-UL30-574 - CCAAGCGCCCGGCCGUGCCU 20 3444
HSV2-UL30-1240 + GUCGAGGAGGACGGCCUCCU 20 4110
HSV2-UL30-1110 + CCCGGGAUCCUCCGCCAGCU 20 3980
HSV2-UL30-1202 + CU UGGCGAUGAGCAGCAGCU 20 4072
HSV2-UL30-1332 + CU UGUAGAUCUCCGUCAGCU 20 4202
HSV2-UL30-2871 + CAUAAAUCGCUCGUGGAGCU 20 11225
HSV2-UL30-1135 + CCGGGGAGGGCAGGGCCGCU 20 4005
HSV2-UL30-656 - CGCGUACGUGCACGCGCGCU 20 3526
HSV2-UL30-1291 + CCGAGGCACGGCCGGGCGCU 20 4161
HSV2-UL30-1190 + CCACUCCUCUGCGGGGCGCU 20 4060
HSV2-UL30-1126 + CGGCGUCUCCCGGGGGCGCU 20 3996
HSV2-UL30-511 - CACAUCCUCCUGUU UUCGCU 20 3381 HSV2-UL30-1114 + CACCAGCAGCUUGCGGGGCU 20 3984
HSV2-UL30-1268 + U UGUGGGCCUGGAUGAUGCU 20 4138
HSV2-UL30-738 - UAUUACUUCUCGCACCUGCU 20 3608
HSV2-UL30-1099 + UAACAGACUCUCGGUGAUCU 20 3969
HSV2-UL30-1098 + AAACCUCUUUAACAGACUCU 20 3968
HSV2-UL30-1245 + GGCCUCCUCGGGGGUGCUCU 20 4115
HSV2-UL30-1096 + GUCCGGGGGGUGCCACGUCU 20 3966
HSV2-UL30-1154 + CUCCUCUACCUCGCGGGUCU 20 4024
HSV2-UL30-446 - GGGACCGUCAUCACGCU UCU 20 3316
HSV2-UL30-1201 + GACGCCGAUGUACUUU UUCU 20 4071
HSV2-UL30-1224 + GCCGGCCGCCUCCGGAAAGU 20 4094
HSV2-UL30-1316 + CGCGGGCCCGGAGGCGUAGU 20 4186
HSV2-UL30-1414 + CGUUUCGUAAUAGUACACGU 20 4284
HSV2-UL30-609 - GAGACCGGGGGCCGGCACGU 20 3479
HSV2-UL30-1253 + CAGCAGGCUCUCGCG UACGU 20 4123
HSV2-UL30-1254 + CCU UCACGAAGAACAGCCGU 20 4124
HSV2-UL30-1382 + CUCGAGGUUCCGAACGCCGU 20 4252
HSV2-UL30-1408 + G C A A A AG UUGUCGCACAGGU 20 4278
HSV2-UL30-1166 + CU UGUAAUACACCGUCAGGU 20 4036
HSV2-UL30-632 - GACUACCUGGAGAUCGAGGU 20 3502
HSV2-UL30-1278 + UCGACGUGAAACCCGGAGGU 20 4148
HSV2-UL30-1353 + GGAGGCGAGAUCGCUGAGGU 20 4223
HSV2-UL30-1388 + ACGCCGUCGGGGGGCGCGGU 20 4258
HSV2-UL30-1412 + AAG ACGCGG U AG UACAGGG U 20 4282
HSV2-UL30-1177 + CUGGAUGUCCCUCUCCGGGU 20 4047
HSV2-UL30-1120 + GGACGCGCCUCCCGGGGGGU 20 3990
HSV2-UL30-552 - GUGCAGGACUCGCUGCUGGU 20 3422
HSV2-UL30-533 - CCGGGGUGUGUUCCGCGUGU 20 3403
HSV2-UL30-1325 + GCUGGAGAGUUUGACCUUGU 20 4195
HSV2-UL30-1375 + AUCGAAGCACAUGAGCUUGU 20 4245
HSV2-UL30-1168 + CAGGUGGGCCAGGCGCU UGU 20 4038
HSV2-UL30-1265 + CGUACUGAAGCACAGGU UGU 20 4135
HSV2-UL30-483 - AACCCGGGGUUUGUCACCUU 20 3353
HSV2-UL30-1429 + AACGGCGACGCGAUGGCCUU 20 4299
HSV2-UL30-1292 + CGAGGCACGGCCGGGCGCUU 20 4162
HSV2-UL30-1171 + GCGCGGGUGUCUGCUCAGUU 20 4041
HSV2-UL30-610 - AGACCGGGGGCCGGCACGU U 20 3480
HSV2-UL30-697 - CCCGAGGGACUGCAGGCGU U 20 3567
HSV2-UL30-490 - CCGCGCCCCCCGACGGCGU U 20 3360
HSV2-UL30-1389 + CGCCGUCGGGGGGCGCGGUU 20 4259
HSV2-UL30-754 - CGGCUCAGGGCCGCGGGGUU 20 3624
HSV2-UL30-743 - GUGACGU UCAAGGCCCUGUU 20 3613
HSV2-UL30-568 - CGGACACCCAGGGGCGGUU U 20 3438 Table 9A provides exemplary targeting domains for knocking out the UL30 gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), have a high level of orthogonality, and start with a 5'G. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 9A
Figure imgf000475_0001
Table 9B provides exemplary targeting domains for knocking out the UL30 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), and have a high level of orthogonality. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 9B
Figure imgf000476_0001
HSV2-U L30-2934 - ACGCCCCCGCGGAGCAGCGCAC 22 11288
HSV2-U L30-50 - CGGUGCGGACCAUGCCCCCG 20 3082
HSV2-U L30-2935 - CGUACUACAGCGAGUGCG 18 11289
HSV2-U L30-2936 - ACGUACUACAGCGAGUGCG 19 11290
HSV2-UL30-264 - UACG UACUACAGCGAGUGCG 20 4669
HSV2-UL30-2937 - AU ACGUACUACAGCGAGUGCG 21 11291
HSV2-U L30-2938 - CAU ACGUACUACAGCGAGUGCG 22 11292
HSV2-UL30-2939 - CCAU ACGUACUACAGCGAGUGCG 23 11293
HSV2-UL30-2940 - AGCCGGCGGCUCGGGCGGCGU 21 11294
HSV2-U L30-2941 - AAGCCGGCGGCUCGGGCGGCGU 22 11295
Table 9C provides exemplary targeting domains for knocking out the UL30 gene selected according to the third tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon). The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 9C
Figure imgf000477_0001
Table 9D provides exemplary targeting domains for knocking out the UL30 gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon). The PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 9D
Figure imgf000477_0002
HSV2-UL30-364 + AGCGAACGCGGGGCGAUAAA 20 4726
HSV2-UL30-2946 + CAGCGAACGCGGGGCGAUAAA 21 11300
HSV2-UL30-2947 + CCAGCGAACGCGGGGCGAUAAA 22 11301
HSV2-UL30-2948 + UCCAGCGAACGCGGGGCGAUAAA 23 11302
HSV2-UL30-2949 + GUCCAGCGAACGCGGGGCGAUAAA 24 11303
HSV2-UL30-2950 + CGGGGGCGUCCUCGUCCA 18 11304
HSV2-UL30-2951 + GCGGGGGCGUCCUCGUCCA 19 11305
HSV2-UL30-361 + CGCGGGGGCGUCCUCGUCCA 20 4724
HSV2-UL30-2952 + CCGCGGGGGCGUCCUCGUCCA 21 11306
HSV2-UL30-2953 + UCCGCGGGGGCGUCCUCGUCCA 22 11307
HSV2-UL30-2954 + CUCCGCGGGGGCGUCCUCGUCCA 23 11308
HSV2-UL30-2955 + GCUCCGCGGGGGCGUCCUCGUCCA 24 11309
HSV2-UL30-2956 + GGCUGCGUUCCGGUCUGA 18 11310
HSV2-UL30-2957 + UGGCUGCGUUCCGGUCUGA 19 11311
HSV2-UL30-369 + UUGGCUGCGUUCCGGUCUGA 20 4731
HSV2-UL30-2958 + UUUGGCUGCGUUCCGGUCUGA 21 11312
HSV2-UL30-2959 + CUUUGGCUGCGUUCCGGUCUGA 22 11313
HSV2-UL30-2960 + CCUUUGGCUGCGUUCCGGUCUGA 23 11314
HSV2-UL30-2961 + GCCUUUGGCUGCGUUCCGGUCUGA 24 11315
HSV2-UL30-2962 + CGUCCUCGUCCAGCGAAC 18 11316
HSV2-UL30-2963 + GCGUCCUCGUCCAGCGAAC 19 11317
HSV2-UL30-362 + GGCGUCCUCGUCCAGCGAAC 20 4725
HSV2-UL30-2964 + GGGCGUCCUCGUCCAGCGAAC 21 11318
HSV2-UL30-2965 + GGGGCGUCCUCGUCCAGCGAAC 22 11319
HSV2-UL30-2966 + GGGGGCGUCCUCGUCCAGCGAAC 23 11320
HSV2-UL30-2967 + CGGGGGCGUCCUCGUCCAGCGAAC 24 11321
HSV2-UL30-2968 + CUCCAGGAUGUCGUACAC 18 11322
HSV2-UL30-2969 + GCUCCAGGAUGUCGUACAC 19 11323
HSV2-UL30-340 + UGCUCCAGGAUGUCGUACAC 20 4712
HSV2-UL30-2970 + GUGCUCCAGGAUGUCGUACAC 21 11324
HSV2-UL30-2971 + CGUGCUCCAGGAUGUCGUACAC 22 11325
HSV2-UL30-2972 + ACGUGCUCCAGGAUGUCGUACAC 23 11326
HSV2-UL30-2973 + CACGUGCUCCAGGAUGUCGUACAC 24 11327
HSV2-UL30-2974 + GAAG CCCU CCG GG CCCAC 18 11328
HSV2-UL30-2975 + AG AAG CCCU CCG GGCCCAC 19 11329
HSV2-UL30-350 + CAG AAG CCCU CCG GG CCCAC 20 4718
HSV2-UL30-2976 + CCAGAAGCCCUCCGGGCCCAC 21 11330
HSV2-UL30-2977 + GCCAGAAGCCCUCCGGGCCCAC 22 11331
HSV2-UL30-2978 + GGCCAGAAGCCCUCCGGGCCCAC 23 11332
HSV2-UL30-2979 + CGGCCAGAAGCCCUCCGGGCCCAC 24 11333
HSV2-UL30-2980 + ACGGUGGGGUCGAACCCC 18 11334
HSV2-UL30-2981 + GACGGUGGGGUCGAACCCC 19 11335
HSV2-UL30-345 + UGACGGUGGGGUCGAACCCC 20 4715
HSV2-UL30-2982 + GUGACGGUGGGGUCGAACCCC 21 11336
HSV2-UL30-2983 + GGUG ACGGUGGGGUCGAACCCC 22 11337
HSV2-UL30-2984 + CGGUGACGGUGGGGUCGAACCCC 23 11338 HSV2-UL30-2985 + ACGGUGACGGUGGGGUCGAACCCC 24 11339
HSV2-UL30-2986 + AGCCGCCGGCUUCCCCCC 18 11340
HSV2-UL30-2987 + GAGCCGCCGGCUUCCCCCC 19 11341
HSV2-UL30-118 + CGAGCCGCCGGCUUCCCCCC 20 3229
HSV2-UL30-2988 + CCGAGCCGCCGGCUUCCCCCC 21 11342
HSV2-UL30-2989 + CCCGAGCCGCCGGCUUCCCCCC 22 11343
HSV2-UL30-2990 + GCCCGAGCCGCCGGCUUCCCCCC 23 11344
HSV2-UL30-2991 + CGCCCGAGCCGCCGGCUUCCCCCC 24 11345
HSV2-UL30-2992 + GAGCCGCCGGCUUCCCCC 18 11346
HSV2-UL30-2993 + CGAGCCGCCGGCUUCCCCC 19 11347
HSV2-UL30-117 + CCGAGCCGCCGGCUUCCCCC 20 3228
HSV2-UL30-2994 + CCCGAGCCGCCGGCUUCCCCC 21 11348
HSV2-UL30-2995 + GCCCGAGCCGCCGGCUUCCCCC 22 11349
HSV2-UL30-2996 + CGCCCGAGCCGCCGGCUUCCCCC 23 11350
HSV2-UL30-2997 + CCGCCCGAGCCGCCGGCUUCCCCC 24 11351
HSV2-UL30-2998 + CGAGCCGCCGGCUUCCCC 18 11352
HSV2-UL30-2999 + CCGAGCCGCCGGCUUCCCC 19 11353
HSV2-UL30-383 + CCCGAGCCGCCGGCUUCCCC 20 4738
HSV2-UL30-3000 + GCCCGAGCCGCCGGCUUCCCC 21 11354
HSV2-UL30-3001 + CGCCCGAGCCGCCGGCUUCCCC 22 11355
HSV2-UL30-3002 + CCGCCCGAGCCGCCGGCUUCCCC 23 11356
HSV2-UL30-3003 + GCCGCCCGAGCCGCCGGCUUCCCC 24 11357
HSV2-UL30-3004 + AUGGCGCUGAGCCGGCCC 18 11358
HSV2-UL30-3005 + UAUGGCGCUGAGCCGGCCC 19 11359
HSV2-UL30-367 + GUAUGGCGCUGAGCCGGCCC 20 4729
HSV2-UL30-3006 + CGUAUGGCGCUGAGCCGGCCC 21 11360
HSV2-UL30-3007 + ACGUAUGGCGCUGAGCCGGCCC 22 11361
HSV2-UL30-3008 + UACGUAUGGCGCUGAGCCGGCCC 23 11362
HSV2-UL30-3009 + GUACGUAUGGCGCUGAGCCGGCCC 24 11363
HSV2-UL30-3010 + GCCGUCUGGGUGGCUCCC 18 11364
HSV2-UL30-3011 + UGCCGUCUGGGUGGCUCCC 19 11365
HSV2-UL30-107 + GUGCCGUCUGGGUGGCUCCC 20 3219
HSV2-UL30-3012 + GGUGCCGUCUGGGUGGCUCCC 21 11366
HSV2-UL30-3013 + CGGUGCCGUCUGGGUGGCUCCC 22 11367
HSV2-UL30-3014 + GCGGUGCCGUCUGGGUGGCUCCC 23 11368
HSV2-UL30-3015 + GGCGGUGCCGUCUGGGUGGCUCCC 24 11369
HSV2-UL30-3016 + UGCCGUCUGGGUGGCUCC 18 11370
HSV2-UL30-3017 + GUGCCGUCUGGGUGGCUCC 19 11371
HSV2-UL30-375 + GGUGCCGUCUGGGUGGCUCC 20 4735
HSV2-UL30-3018 + CGGUGCCGUCUGGGUGGCUCC 21 11372
HSV2-UL30-3019 + GCGGUGCCGUCUGGGUGGCUCC 22 11373
HSV2-UL30-3020 + GGCGGUGCCGUCUGGGUGGCUCC 23 11374
HSV2-UL30-3021 + CGGCGGUGCCGUCUGGGUGGCUCC 24 11375
HSV2-UL30-3022 + ACCCCGGUGCGCUGCUCC 18 11376
HSV2-UL30-3023 + GACCCCGGUGCGCUGCUCC 19 11377
HSV2-UL30-358 + GGACCCCGGUGCGCUGCUCC 20 4723 HSV2-UL30-3024 + UGGACCCCGGUGCGCUGCUCC 21 11378
HSV2-UL30-3025 + GUGGACCCCGGUGCGCUGCUCC 22 11379
HSV2-UL30-3026 + CGUGGACCCCGGUGCGCUGCUCC 23 11380
HSV2-UL30-3027 + UCGUGGACCCCGGUGCGCUGCUCC 24 11381
HSV2-UL30-3028 + AAAAAACCCAGACGCCGC 18 11382
HSV2-UL30-3029 + CAAAAAACCCAGACGCCGC 19 11383
HSV2-UL30-382 + GCAAAAAACCCAGACGCCGC 20 4737
HSV2-UL30-3030 + GGCAAAAAACCCAGACGCCGC 21 11384
HSV2-UL30-3031 + G G G CAAAAAACCCAG ACG CCG C 22 11385
HSV2-UL30-3032 + GGGGCAAAAAACCCAGACGCCGC 23 11386
HSV2-UL30-3033 + G G G G G CAAAAAACCCAG ACG CCG C 24 11387
HSV2-UL30-3034 + CCCGGUGCGCUGCUCCGC 18 11388
HSV2-UL30-3035 + CCCCGGUGCGCUGCUCCGC 19 11389
HSV2-UL30-82 + ACCCCGGUGCGCUGCUCCGC 20 3208
HSV2-UL30-3036 + GACCCCGGUGCGCUGCUCCGC 21 11390
HSV2-UL30-3037 + GGACCCCGGUGCGCUGCUCCGC 22 11391
HSV2-UL30-3038 + UGGACCCCGGUGCGCUGCUCCGC 23 11392
HSV2-UL30-3039 + GUGGACCCCGGUGCGCUGCUCCGC 24 11393
HSV2-UL30-3040 + UACACCU UAGGGGCGCGC 18 11394
HSV2-UL30-3041 + GUACACCUUAGGGGCGCGC 19 11395
HSV2-UL30-76 + AGUACACCUUAGGGGCGCGC 20 3095
HSV2-UL30-3042 + CAGUACACCUUAGGGGCGCGC 21 11396
HSV2-UL30-3043 + GCAGUACACCUUAGGGGCGCGC 22 11397
HSV2-UL30-3044 + CGCAG UACACCU UAGGGGCGCGC 23 11398
HSV2-UL30-3045 + CCGCAGUACACCUUAGGGGCGCGC 24 11399
HSV2-UL30-3046 + GUAUGGCGCUGAGCCGGC 18 11400
HSV2-UL30-3047 + CGUAUGGCGCUGAGCCGGC 19 11401
HSV2-UL30-366 + ACGUAUGGCGCUGAGCCGGC 20 4728
HSV2-UL30-3048 + UACGUAUGGCGCUGAGCCGGC 21 11402
HSV2-UL30-3049 + GU ACGUAUGGCGCUGAGCCGGC 22 11403
HSV2-UL30-3050 + AGU ACGUAUGGCGCUGAGCCGGC 23 11404
HSV2-UL30-3051 + UAGUACGUAUGGCGCUGAGCCGGC 24 11405
HSV2-UL30-3052 + AGGCGCAAGCGACGCGGC 18 11406
HSV2-UL30-3053 + CAGGCGCAAGCGACGCGGC 19 11407
HSV2-UL30-348 + ACAGGCGCAAGCGACGCGGC 20 4716
HSV2-UL30-3054 + CACAGGCGCAAGCGACGCGGC 21 11408
HSV2-UL30-3055 + CCACAGGCGCAAGCGACGCGGC 22 11409
HSV2-UL30-3056 + CCCACAGGCGCAAGCGACGCGGC 23 11410
HSV2-UL30-3057 + CCCCACAGGCGCAAGCGACGCGGC 24 11411
HSV2-UL30-3058 + GGUGGGGUCGAACCCCUC 18 11412
HSV2-UL30-3059 + CGGUGGGGUCGAACCCCUC 19 11413
HSV2-UL30-63 + ACGGUGGGGUCGAACCCCUC 20 3087
HSV2-UL30-3060 + GACGGUGGGGUCGAACCCCUC 21 11414
HSV2-UL30-3061 + UGACGGUGGGGUCGAACCCCUC 22 11415
HSV2-UL30-3062 + GUGACGGUGGGGUCGAACCCCUC 23 11416
HSV2-UL30-3063 + GGUGACGGUGGGGUCGAACCCCUC 24 11417 HSV2-UL30-3064 + GGCGUCCAUAAAUCGCUC 18 11418
HSV2-UL30-3065 + UGGCGUCCAUAAAUCGCUC 19 11419
HSV2-UL30-2593 + AUGGCGUCCAUAAAUCGCUC 20 5300
HSV2-UL30-3066 + GCGCCGGAGGCGGCCGUC 18 11420
HSV2-UL30-3067 + CGCGCCGGAGGCGGCCGUC 19 11421
HSV2-UL30-357 + GCGCGCCGGAGGCGGCCGUC 20 4722
HSV2-UL30-3068 + GGCGCGCCGGAGGCGGCCGUC 21 11422
HSV2-UL30-3069 + GGGCGCGCCGGAGGCGGCCGUC 22 11423
HSV2-UL30-3070 + GGGGCGCGCCGGAGGCGGCCGUC 23 11424
HSV2-UL30-3071 + AGGGGCGCGCCGGAGGCGGCCGUC 24 11425
HSV2-UL30-3072 + GCUUCCCCCCGGGGGAAG 18 11426
HSV2-UL30-3073 + GGCUUCCCCCCGGGGGAAG 19 11427
HSV2-UL30-388 + CGGCUUCCCCCCGGGGGAAG 20 4739
HSV2-UL30-3074 + CCGGCUUCCCCCCGGGGGAAG 21 11428
HSV2-UL30-3075 + GCCGGCUUCCCCCCGGGGGAAG 22 11429
HSV2-UL30-3076 + CGCCGGCUUCCCCCCGGGGGAAG 23 11430
HSV2-UL30-3077 + CCGCCGGCUUCCCCCCGGGGGAAG 24 11431
HSV2-UL30-3078 + CGUUCCGGUCUGAGCGAG 18 11432
HSV2-UL30-3079 + GCGUUCCGGUCUGAGCGAG 19 11433
HSV2-UL30-370 + UGCGU UCCGGUCUGAGCGAG 20 4732
HSV2-UL30-3080 + CUGCGUUCCGGUCUGAGCGAG 21 11434
HSV2-UL30-3081 + GCUGCGU UCCGGUCUGAGCGAG 22 11435
HSV2-UL30-3082 + GGCUGCGU UCCGGUCUGAGCGAG 23 11436
HSV2-UL30-3083 + UGGCUGCGUUCCGGUCUGAGCGAG 24 11437
HSV2-UL30-3084 + CAUAAAUCGCUCGUGGAG 18 11438
HSV2-UL30-3085 + CCAUAAAUCGCUCGUGGAG 19 11439
HSV2-UL30-3086 + UCCAUAAAUCGCUCGUGGAG 20 11440
HSV2-UL30-3087 + GUCCAUAAAUCGCUCGUGGAG 21 11441
HSV2-UL30-3088 + CGUCCAUAAAUCGCUCGUGGAG 22 11442
HSV2-UL30-3089 + GCGUCCAUAAAUCGCUCGUGGAG 23 11443
HSV2-UL30-3090 + GGCGUCCAUAAAUCGCUCGUGGAG 24 11444
HSV2-UL30-3091 + GUCCUCGUCCAGCGAACG 18 11445
HSV2-UL30-3092 + CGUCCUCGUCCAGCGAACG 19 11446
HSV2-UL30-85 + GCGUCCUCGUCCAGCGAACG 20 3098
HSV2-UL30-3093 + GGCGUCCUCGUCCAGCGAACG 21 11447
HSV2-UL30-3094 + GGGCGUCCUCGUCCAGCGAACG 22 11448
HSV2-UL30-3095 + GGGGCGUCCUCGUCCAGCGAACG 23 11449
HSV2-UL30-3096 + GGGGGCGUCCUCGUCCAGCGAACG 24 11450
HSV2-UL30-3097 + UCCAGGAUGUCGUACACG 18 11451
HSV2-UL30-3098 + CUCCAGGAUGUCGUACACG 19 11452
HSV2-UL30-56 + GCUCCAGGAUGUCGUACACG 20 3194
HSV2-UL30-3099 + UGCUCCAGGAUGUCGUACACG 21 11453
HSV2-UL30-3100 + GUGCU CCAG G AU G U CGUACACG 22 11454
HSV2-UL30-3101 + CGUGCUCCAGGAUGUCGUACACG 23 11455
HSV2-UL30-3102 + ACGUGCUCCAGGAUGUCGUACACG 24 11456
HSV2-UL30-3103 + AAGCCCUCCGGGCCCACG 18 11457 HSV2-UL30-3104 + GAAGCCCUCCGGGCCCACG 19 11458
HSV2-UL30-71 + AGAAGCCCUCCGGGCCCACG 20 3201
HSV2-UL30-3105 + CAGAAGCCCUCCGGGCCCACG 21 11459
HSV2-UL30-3106 + CCAGAAGCCCUCCGGGCCCACG 22 11460
HSV2-UL30-3107 + GCCAGAAGCCCUCCGGGCCCACG 23 11461
HSV2-UL30-3108 + GGCCAGAAGCCCUCCGGGCCCACG 24 11462
HSV2-UL30-3109 + ACGUGGAAGACGGUGACG 18 11463
HSV2-UL30-3110 + CACGUGGAAGACGGUGACG 19 11464
HSV2-UL30-342 + ACACGUGGAAGACGGUGACG 20 4713
HSV2-UL30-3111 + UACACGUGGAAGACGGUGACG 21 11465
HSV2-UL30-3112 + GUACACGUGGAAGACGGUGACG 22 11466
HSV2-UL30-3113 + CGU ACACGUGGAAGACGGUGACG 23 11467
HSV2-UL30-3114 + UCGUACACGUGGAAGACGGUGACG 24 11468
HSV2-UL30-3115 + GCCGCCGGCUUCCCCCCG 18 11469
HSV2-UL30-3116 + AGCCGCCGGCUUCCCCCCG 19 11470
HSV2-UL30-119 + GAGCCGCCGGCUUCCCCCCG 20 3230
HSV2-UL30-3117 + CGAGCCGCCGGCUUCCCCCCG 21 11471
HSV2-UL30-3118 + CCGAGCCGCCGGCUUCCCCCCG 22 11472
HSV2-UL30-3119 + CCCGAGCCGCCGGCUUCCCCCCG 23 11473
HSV2-UL30-3120 + GCCCGAGCCGCCGGCUUCCCCCCG 24 11474
HSV2-UL30-3121 + CCCCGGUGCGCUGCUCCG 18 11475
HSV2-UL30-3122 + ACCCCGGUGCGCUGCUCCG 19 11476
HSV2-UL30-81 + GACCCCGGUGCGCUGCUCCG 20 3207
HSV2-UL30-3123 + GGACCCCGGUGCGCUGCUCCG 21 11477
HSV2-UL30-3124 + UGGACCCCGGUGCGCUGCUCCG 22 11478
HSV2-UL30-3125 + GUGGACCCCGGUGCGCUGCUCCG 23 11479
HSV2-UL30-3126 + CGUGGACCCCGGUGCGCUGCUCCG 24 11480
HSV2-UL30-3127 + GCCCUCCGGGCCCACGCG 18 11481
HSV2-UL30-3128 + AGCCCUCCGGGCCCACGCG 19 11482
HSV2-UL30-352 + AAGCCCUCCGGGCCCACGCG 20 4719
HSV2-UL30-3129 + GAAGCCCUCCGGGCCCACGCG 21 11483
HSV2-UL30-3130 + AGAAGCCCUCCGGGCCCACGCG 22 11484
HSV2-UL30-3131 + CAGAAGCCCUCCGGGCCCACGCG 23 11485
HSV2-UL30-3132 + CCAGAAGCCCUCCGGGCCCACGCG 24 11486
HSV2-UL30-3133 + GUACACCUUAGGGGCGCG 18 11487
HSV2-UL30-3134 + AGUACACCUUAGGGGCGCG 19 11488
HSV2-UL30-355 + CAGUACACCUUAGGGGCGCG 20 4721
HSV2-UL30-3135 + GCAGUACACCUUAGGGGCGCG 21 11489
HSV2-UL30-3136 + CGCAGUACACCU UAGGGGCGCG 22 11490
HSV2-UL30-3137 + CCGCAGUACACCUUAGGGGCGCG 23 11491
HSV2-UL30-3138 + CCCGCAGUACACCUUAGGGGCGCG 24 11492
HSV2-UL30-3139 + GCUGUAGUACGUAUGGCG 18 11493
HSV2-UL30-3140 + CGCUGUAGUACGUAUGGCG 19 11494
HSV2-UL30-365 + UCGCUGUAGUACGUAUGGCG 20 4727
HSV2-UL30-3141 + CUCGCUGUAGUACGUAUGGCG 21 11495
HSV2-UL30-3142 + ACUCGCUGUAGUACGUAUGGCG 22 11496 HSV2-UL30-3143 + CACUCGCUGUAGUACGUAUGGCG 23 11497
HSV2-UL30-3144 + GCACUCGCUGUAGUACGUAUGGCG 24 11498
HSV2-UL30-3145 + GCGUCCAUAAAUCGCUCG 18 11499
HSV2-UL30-3146 + GGCGUCCAUAAAUCGCUCG 19 11500
HSV2-UL30-1438 + UGGCGUCCAUAAAUCGCUCG 20 4308
HSV2-UL30-3147 + AUGGCGUCCAUAAAUCGCUCG 21 11501
HSV2-UL30-3148 + GAUGGCGUCCAUAAAUCGCUCG 22 11502
HSV2-UL30-3149 + UGAUGGCGUCCAUAAAUCGCUCG 23 11503
HSV2-UL30-3150 + GUGAUGGCGUCCAUAAAUCGCUCG 24 11504
HSV2-UL30-3151 + GUUCCGGUCUGAGCGAGG 18 11505
HSV2-UL30-3152 + CGUUCCGGUCUGAGCGAGG 19 11506
HSV2-UL30-95 + GCGUUCCGGUCUGAGCGAGG 20 3104
HSV2-UL30-3153 + UGCGUUCCGGUCUGAGCGAGG 21 11507
HSV2-UL30-3154 + CUGCGUUCCGGUCUGAGCGAGG 22 11508
HSV2-UL30-3155 + GCUGCGUUCCGGUCUGAGCGAGG 23 11509
HSV2-UL30-3156 + GGCUGCGUUCCGGUCUGAGCGAGG 24 11510
HSV2-UL30-3157 + CCGCCGGCUUCCCCCCGG 18 11511
HSV2-UL30-3158 + GCCGCCGGCUUCCCCCCGG 19 11512
HSV2-UL30-120 + AGCCGCCGGCUUCCCCCCGG 20 3231
HSV2-UL30-3159 + GAGCCGCCGGCUUCCCCCCGG 21 11513
HSV2-UL30-3160 + CGAGCCGCCGGCUUCCCCCCGG 22 11514
HSV2-UL30-3161 + CCGAGCCGCCGGCUUCCCCCCGG 23 11515
HSV2-UL30-3162 + CCCGAGCCGCCGGCUUCCCCCCGG 24 11516
HSV2-UL30-3163 + AAGACGGUGACGGUGGGG 18 11517
HSV2-UL30-3164 + GAAGACGGUGACGGUGGGG 19 11518
HSV2-UL30-344 + GG AAGACGGUGACGGUGGGG 20 4714
HSV2-UL30-3165 + UGGAAGACGGUGACGGUGGGG 21 11519
HSV2-UL30-3166 + GUGG AAGACGGUGACGGUGGGG 22 11520
HSV2-UL30-3167 + CGUGGAAGACGGUGACGGUGGGG 23 11521
HSV2-UL30-3168 + ACGUGGAAGACGGUGACGGUGGGG 24
11522
HSV2-UL30-3169 + GGCUCCCCGGGGGUUGUG 18 11523
HSV2-UL30-3170 + UGGCUCCCCGGGGGUUGUG 19 11524
HSV2-UL30-113 + GUGGCUCCCCGGGGGUUGUG 20 3224
HSV2-UL30-3171 + GGUGGCUCCCCGGGGGUUGUG 21 11525
HSV2-UL30-3172 + GGGUGGCUCCCCGGGGGUUGUG 22 11526
HSV2-UL30-3173 + UGGGUGGCUCCCCGGGGGUUGUG 23 11527
HSV2-UL30-3174 + CUGGGUGGCUCCCCGGGGGUUGUG 24
11528
HSV2-UL30-3175 + GUGGCUCCCCGGGGGUUG 18 11529
HSV2-UL30-3176 + GGUGGCUCCCCGGGGGUUG 19 11530
HSV2-UL30-111 + GGGUGGCUCCCCGGGGGUUG 20 3222
HSV2-UL30-3177 + UGGGUGGCUCCCCGGGGGUUG 21 11531
HSV2-UL30-3178 + CUGGGUGGCUCCCCGGGGGUUG 22 11532
HSV2-UL30-3179 + UCUGGGUGGCUCCCCGGGGGUUG 23 11533 HSV2-UL30-3180 + GUCUGGGUGGCUCCCCGGGGGUUG 24
11534
HSV2-UL30-3181 + UGAGCGAGGUGGGGGUUG 18 11535
HSV2-UL30-3182 + CUGAGCGAGGUGGGGGUUG 19 11536
HSV2-UL30-373 + UCUGAGCGAGGUGGGGGUUG 20 4733
HSV2-UL30-3183 + GUCUGAGCGAGGUGGGGGUUG 21 11537
HSV2-UL30-3184 + GGUCUGAGCGAGGUGGGGGUUG 22 11538
HSV2-UL30-3185 + CGGUCUGAGCGAGGUGGGGGUUG 23 11539
HSV2-UL30-3186 + CCGGUCUGAGCGAGGUGGGGGUUG 24
11540
HSV2-UL30-3187 + CCCCCCCGCAGUACACCU 18 11541
HSV2-UL30-3188 + UCCCCCCCGCAGUACACCU 19 11542
HSV2-UL30-353 + GUCCCCCCCGCAGUACACCU 20 4720
HSV2-UL30-3189 + CGUCCCCCCCGCAGUACACCU 21 11543
HSV2-UL30-3190 + UCGUCCCCCCCGCAGUACACCU 22 11544
HSV2-UL30-3191 + CUCGUCCCCCCCGCAGUACACCU 23 11545
HSV2-UL30-3192 + GCUCGUCCCCCCCGCAGUACACCU 24 11546
HSV2-UL30-3193 + CGGUGGGGUCGAACCCCU 18 11547
HSV2-UL30-3194 + ACGGUGGGGUCGAACCCCU 19 11548
HSV2-UL30-62 + GACGGUGGGGUCGAACCCCU 20 3086
HSV2-UL30-3195 + UG ACGGUGGGGUCGAACCCCU 21 11549
HSV2-UL30-3196 + GUGACGGUGGGGUCGAACCCCU 22 11550
HSV2-UL30-3197 + GGUGACGGUGGGGUCGAACCCCU 23 11551
HSV2-UL30-3198 + CGGUG ACGGUGGGGUCGAACCCCU 24 11552
HSV2-UL30-3199 + GACGCGGCCAGAAGCCCU 18 11553
HSV2-UL30-3200 + CGACGCGGCCAGAAGCCCU 19 11554
HSV2-UL30-349 + GCGACGCGGCCAGAAGCCCU 20 4717
HSV2-UL30-3201 + AGCGACGCGGCCAGAAGCCCU 21 11555
HSV2-UL30-3202 + AAGCGACGCGGCCAGAAGCCCU 22 11556
HSV2-UL30-3203 + CAAGCGACGCGGCCAGAAGCCCU 23 11557
HSV2-UL30-3204 + GCAAGCGACGCGGCCAGAAGCCCU 24 11558
HSV2-UL30-3205 + CUUUGGCUGCGUUCCGGU 18 11559
HSV2-UL30-3206 + CCUUUGGCUGCGUUCCGGU 19 11560
HSV2-UL30-368 + GCCUUUGGCUGCGUUCCGGU 20 4730
HSV2-UL30-3207 + GGCCUUUGGCUGCGUUCCGGU 21 11561
HSV2-UL30-3208 + GGGCCUUUGGCUGCGUUCCGGU 22 11562
HSV2-UL30-3209 + AGGGCCUUUGGCUGCGUUCCGGU 23 11563
HSV2-UL30-3210 + GAGGGCCUUUGGCUGCGUUCCGGU 24 11564
HSV2-UL30-3211 + UGGCUCCCCGGGGGU UGU 18 11565
HSV2-UL30-3212 + GUGGCUCCCCGGGGGUUGU 19 11566
HSV2-UL30-112 + GGUGGCUCCCCGGGGGU UGU 20 3223
HSV2-UL30-3213 + GGGUGGCUCCCCGGGGGUUGU 21 11567
HSV2-UL30-3214 + UGGGUGGCUCCCCGGGGGUUGU 22 11568
HSV2-UL30-3215 + CUGGGUGGCUCCCCGGGGGUUGU 23 11569
HSV2-UL30-3216 + UCUGGGUGGCUCCCCGGGGGUUGU 24
11570 HSV2-UL30-3217 + CCCCCCGCAGUACACCUU 18 11571
HSV2-UL30-3218 + CCCCCCCGCAG U ACACCU U 19 11572
HSV2-UL30-73 + UCCCCCCCGCAGUACACCUU 20 3203
HSV2-UL30-3219 + G U CCCCCCCG CAG U ACACCU U 21 11573
HSV2-UL30-3220 + CGUCCCCCCCGCAGUACACCUU 22 11574
HSV2-UL30-3221 + U CG U CCCCCCCGCAG U ACACCU U 23 11575
HSV2-UL30-3222 + CUCGUCCCCCCCGCAGUACACCUU 24 11576
HSV2-UL30-3223 + GGUGGCUCCCCGGGGGUU 18 11577
HSV2-UL30-3224 + GGGUGGCUCCCCGGGGGUU 19 11578
HSV2-UL30-378 + UGGGUGGCUCCCCGGGGGUU 20 4736
HSV2-UL30-3225 + CUGGGUGGCUCCCCGGGGGUU 21 11579
HSV2-UL30-3226 + UCUGGGUGGCUCCCCGGGGGUU 22 11580
HSV2-UL30-3227 + GUCUGGGUGGCUCCCCGGGGGUU 23 11581
HSV2-UL30-3228 + CGUCUGGGUGGCUCCCCGGGGGUU 24 11582
HSV2-UL30-3229 - CCCCCGCGGAGCAGCGCA 18 11583
HSV2-UL30-3230 - GCCCCCGCGGAGCAGCGCA 19 11584
HSV2-UL30-270 - CGCCCCCGCGGAGCAGCGCA 20 4674
HSV2-UL30-3231 - ACGCCCCCGCGGAGCAGCGCA 21 11585
HSV2-UL30-3232 - GACGCCCCCGCGGAGCAGCGCA 22 11586
HSV2-UL30-3233 - GGACGCCCCCGCGGAGCAGCGCA 23 11587
HSV2-UL30-3234 - AGGACGCCCCCGCGGAGCAGCGCA 24 11588
HSV2-UL30-3235 - ACCCCCACCUCGCUCAGA 18 11589
HSV2-UL30-3236 - AACCCCCACCU CG CUCAG A 19 11590
HSV2-UL30-260 - CAACCCCCACCUCGCUCAGA 20 4666
HSV2-UL30-3237 - ACAACCCCCACCU CG CU CAG A 21 11591
HSV2-UL30-3238 - UACAACCCCCACCUCGCUCAGA 22 11592
HSV2-UL30-3239 - CUACAACCCCCACCUCGCUCAGA 23 11593
HSV2-UL30-3240 - UCUACAACCCCCACCUCGCUCAGA 24 11594
HSV2-UL30-3241 - UACGACAUCCUGGAGCAC 18 11595
HSV2-UL30-3242 - GUACGACAUCCUGGAGCAC 19 11596
HSV2-UL30-291 - UGUACGACAUCCUGGAGCAC 20 4685
HSV2-UL30-3243 - GUGUACGACAUCCUGGAGCAC 21 11597
HSV2-UL30-3244 - CGUGUACGACAUCCUGGAGCAC 22 11598
HSV2-UL30-3245 - ACGUGUACGACAUCCUGGAGCAC 23 11599
HSV2-UL30-3246 - CACGUGUACGACAUCCUGGAGCAC 24 11600
HSV2-UL30-3247 - CCCCCACCUCGCUCAGAC 18 11601
HSV2-UL30-3248 - ACCCCCACCU CG CU CAG AC 19 11602
HSV2-UL30-19 - AACCCCCACCUCGCUCAGAC 20 3174
HSV2-UL30-3249 - CAACCCCCACCU CG CU CAG AC 21 11603
HSV2-UL30-3250 - ACAACCCCCACCUCGCUCAGAC 22 11604
HSV2-UL30-3251 - UACAACCCCCACCUCGCUCAGAC 23 11605
HSV2-UL30-3252 - CUACAACCCCCACCUCGCUCAGAC 24 11606
HSV2-UL30-3253 - GCCCCGCGUUCGCUGGAC 18 11607
HSV2-UL30-3254 - CGCCCCGCGUUCGCUGGAC 19 11608
HSV2-UL30-267 - UCGCCCCGCGUUCGCUGGAC 20 4672
HSV2-UL30-3255 - AUCGCCCCGCGUUCGCUGGAC 21 11609 HSV2-UL30-3256 - UAUCGCCCCGCGUUCGCUGGAC 22 11610
HSV2-UL30-3257 - UUAUCGCCCCGCGUUCGCUGGAC 23 11611
HSV2-UL30-3258 - UUUAUCGCCCCGCGUUCGCUGGAC 24 11612
HSV2-UL30-3259 - U U U U GCCCCCCACAACCC 18 11613
HSV2-UL30-3260 - U U U U U G CCCCCCACAACCC 19 11614
HSV2-UL30-255 - U U U U U UG CCCCCCACAACCC 20 4664
HSV2-UL30-3261 - GUUUUUUG CCCCCCACAACCC 21 11615
HSV2-UL30-3262 - GGUU UUUUGCCCCCCACAACCC 22 11616
HSV2-UL30-3263 - GGGUUUUUUG CCCCCCACAACCC 23 11617
HSV2-UL30-3264 - UGGGUUUUUUGCCCCCCACAACCC 24 11618
HSV2-UL30-3265 - U U U GCCCCCCACAACCCC 18 11619
HSV2-UL30-3266 - U U U U GCCCCCCACAACCCC 19 11620
HSV2-UL30-14 - U U U U U G CCCCCCACAACCCC 20 3170
HSV2-UL30-3267 - U U U U U U GCCCCCCACAACCCC 21 11621
HSV2-UL30-3268 - GUUUUUUGCCCCCCACAACCCC 22 11622
HSV2-UL30-3269 - GG U U U U U UG CCCCCCACAACCCC 23 11623
HSV2-UL30-3270 - GGGUUUUUUG CCCCCCACAACCCC 24 11624
HSV2-UL30-3271 - UUGCCCCCCACAACCCCC 18 11625
HSV2-UL30-3272 - U U U G CCCCCCACAACCCCC 19 11626
HSV2-UL30-15 - U U U U G CCCCCCACAACCCCC 20 3171
HSV2-UL30-3273 - U U U U U G CCCCCCACAACCCCC 21 11627
HSV2-UL30-3274 - U U U U U UG CCCCCCACAACCCCC 22 11628
HSV2-UL30-3275 - GUUUUUUG CCCCCCACAACCCCC 23 11629
HSV2-UL30-3276 - GGU U U U U UGCCCCCCACAACCCCC 24 11630
HSV2-UL30-3277 - CUGGACGAGGACGCCCCC 18 11631
HSV2-UL30-3278 - GCUGGACGAGGACGCCCCC 19 11632
HSV2-UL30-268 - CGCUGGACGAGGACGCCCCC 20 4673
HSV2-UL30-3279 - UCGCUGGACGAGGACGCCCCC 21 11633
HSV2-UL30-3280 - UUCGCUGGACGAGGACGCCCCC 22 11634
HSV2-UL30-3281 - GUUCGCUGGACGAGGACGCCCCC 23 11635
HSV2-UL30-3282 - CGUUCGCUGGACGAGGACGCCCCC 24 11636
HSV2-UL30-3283 - GGUGCGGACCAUGCCCCC 18 11637
HSV2-UL30-3284 - CGGUGCGGACCAUGCCCCC 19 11638
HSV2-UL30-287 - GCGGUGCGGACCAUGCCCCC 20 4683
HSV2-UL30-3285 - GGCGGUGCGGACCAUGCCCCC 21 11639
HSV2-UL30-3286 - GGGCGGUGCGGACCAUGCCCCC 22 11640
HSV2-UL30-3287 - GGGGCGGUGCGGACCAUGCCCCC 23 11641
HSV2-UL30-3288 - UGGGGCGGUGCGGACCAUGCCCCC 24 11642
HSV2-UL30-3289 - GGCGGCCCGGCUUCCCCC 18 11643
HSV2-UL30-3290 - GGGCGGCCCGGCUUCCCCC 19 11644
HSV2-UL30-3 - CGGGCGGCCCGGCUUCCCCC 20 3159
HSV2-UL30-3291 - GCGGGCGGCCCGGCUUCCCCC 21 11645
HSV2-UL30-3292 - CGCGGGCGGCCCGGCUUCCCCC 22 11646
HSV2-UL30-3293 - CCGCGGGCGGCCCGGCUUCCCCC 23 11647
HSV2-UL30-3294 - GCCGCGGGCGGCCCGGCUUCCCCC 24 11648
HSV2-UL30-3295 - GGGCGGCCCGGCUUCCCC 18 11649 HSV2-UL30-3296 - CGGGCGGCCCGGCUUCCCC 19 11650
HSV2-UL30-2 - GCGGGCGGCCCGGCUUCCCC 20 3158
HSV2-UL30-3297 - CGCGGGCGGCCCGGCUUCCCC 21 11651
HSV2-UL30-3298 - CCGCGGGCGGCCCGGCUUCCCC 22 11652
HSV2-UL30-3299 - GCCGCGGGCGGCCCGGCUUCCCC 23 11653
HSV2-UL30-3300 - UGCCGCGGGCGGCCCGGCUUCCCC 24 11654
HSV2-UL30-3301 - GAACGCAGCCAAAGGCCC 18 11655
HSV2-UL30-3302 - GGAACGCAGCCAAAGGCCC 19 11656
HSV2-UL30-262 - CGGAACGCAGCCAAAGGCCC 20 4667
HSV2-UL30-3303 - CCGGAACGCAGCCAAAGGCCC 21 11657
HSV2-UL30-3304 - ACCGGAACGCAGCCAAAGGCCC 22 11658
HSV2-UL30-3305 - GACCGGAACGCAGCCAAAGGCCC 23 11659
HSV2-UL30-3306 - AGACCGGAACGCAGCCAAAGGCCC 24 11660
HSV2-UL30-3307 - GCGGUGCGGACCAUGCCC 18 11661
HSV2-UL30-3308 - GGCGGUGCGGACCAUGCCC 19 11662
HSV2-UL30-286 - GGGCGGUGCGGACCAUGCCC 20 4682
HSV2-UL30-3309 - GGGGCGGUGCGGACCAUGCCC 21 11663
HSV2-UL30-3310 - UGGGGCGGUGCGGACCAUGCCC 22 11664
HSV2-UL30-3311 - GUGGGGCGGUGCGGACCAUGCCC 23 11665
HSV2-UL30-3312 - UGUGGGGCGGUGCGGACCAUGCCC 24 11666
HSV2-UL30-3313 - CGGGCGGCCCGGCUUCCC 18 11667
HSV2-UL30-3314 - GCGGGCGGCCCGGCUUCCC 19 11668
HSV2-UL30-247 - CGCGGGCGGCCCGGCUUCCC 20 4661
HSV2-UL30-3315 - CCGCGGGCGGCCCGGCUUCCC 21 11669
HSV2-UL30-3316 - GCCGCGGGCGGCCCGGCUUCCC 22 11670
HSV2-UL30-3317 - UGCCGCGGGCGGCCCGGCUUCCC 23 11671
HSV2-UL30-3318 - GUGCCGCGGGCGGCCCGGCUUCCC 24 11672
HSV2-UL30-3319 - ACGUCCUCCGCGUGGGCC 18 11673
HSV2-UL30-3320 - GACGUCCUCCGCGUGGGCC 19 11674
HSV2-UL30-41 - CGACGUCCUCCGCGUGGGCC 20 3186
HSV2-UL30-3321 - GCGACGUCCUCCGCGUGGGCC 21 11675
HSV2-UL30-3322 - CGCGACGUCCUCCGCGUGGGCC 22 11676
HSV2-UL30-3323 - GCGCGACGUCCUCCGCGUGGGCC 23 11677
HSV2-UL30-3324 - AGCGCGACGUCCUCCGCGUGGGCC 24 11678
HSV2-UL30-3325 - GCGGCGAUGUUUUGUGCC 18 11679
HSV2-UL30-3326 - GGCGGCGAUGUUUUGUGCC 19 11680
HSV2-UL30-3327 - CGGCGGCGAUGUUUUGUGCC 20 11681
HSV2-UL30-3328 - CCGGCGGCGAUGUUUUGUGCC 21 11682
HSV2-UL30-3329 - ACCGGCGGCGAUGUUUUGUGCC 22 11683
HSV2-UL30-3330 - GACCGGCGGCGAUGUUUUGUGCC 23 11684
HSV2-UL30-3331 - CGACCGGCGGCGAUGUUUUGUGCC 24 11685
HSV2-UL30-3332 - UCCACGUGUACGACAUCC 18 11686
HSV2-UL30-3333 - U U CCACG U G U ACG ACAU CC 19 11687
HSV2-UL30-53 - CUUCCACGUGUACGACAUCC 20 3084
HSV2-UL30-3334 - UCUUCCACGUGUACGACAUCC 21 11688
HSV2-UL30-3335 - GUCUUCCACGUGUACGACAUCC 22 11689 HSV2-UL30-3336 - CG UCU U CCACG U G U ACG ACAU CC 23 11690
HSV2-UL30-3337 - CCGUCUUCCACGUGUACGACAUCC 24 11691
HSV2-UL30-3338 - UGCGCGCCGCCCAGCUCC 18 11692
HSV2-UL30-3339 - AUGCGCGCCGCCCAGCUCC 19 11693
HSV2-UL30-3340 - CAUGCGCGCCGCCCAGCUCC 20 11694
HSV2-UL30-3341 - GCAUGCGCGCCGCCCAGCUCC 21 11695
HSV2-UL30-3342 - AGCAUGCGCGCCGCCCAGCUCC 22 11696
HSV2-UL30-3343 - CAGCAUGCGCGCCGCCCAGCUCC 23 11697
HSV2-UL30-3344 - ACAGCAUGCGCGCCGCCCAGCUCC 24 11698
HSV2-UL30-3345 - GAGCGCGACGUCCUCCGC 18 11699
HSV2-UL30-3346 - CGAGCGCGACGUCCUCCGC 19 11700
HSV2-UL30-279 - ACGAGCGCGACGUCCUCCGC 20 4677
HSV2-UL30-3347 - GACGAGCGCGACGUCCUCCGC 21 11701
HSV2-UL30-3348 - GGACGAGCGCGACGUCCUCCGC 22 11702
HSV2-UL30-3349 - GGGACGAGCGCGACGUCCUCCGC 23 11703
HSV2-UL30-3350 - GGGGACGAGCGCGACGUCCUCCGC 24 11704
HSV2-UL30-3351 - CGGGGGGAAGCCGGCGGC 18 11705
HSV2-UL30-3352 - CCGGGGGGAAGCCGGCGGC 19 11706
HSV2-UL30-253 - CCCGGGGGGAAGCCGGCGGC 20 4662
HSV2-UL30-3353 - CCCCGGGGGGAAGCCGGCGGC 21 11707
HSV2-UL30-3354 - CCCCCGGGGGGAAGCCGGCGGC 22 11708
HSV2-UL30-3355 - UCCCCCGGGGGGAAGCCGGCGGC 23 11709
HSV2-UL30-3356 - UUCCCCCGGGGGGAAGCCGGCGGC 24 11710
HSV2-UL30-3357 - GACGUCCUCCGCGUGGGC 18 11711
HSV2-UL30-3358 - CGACGUCCUCCGCGUGGGC 19 11712
HSV2-UL30-280 - GCGACGUCCUCCGCGUGGGC 20 4678
HSV2-UL30-3359 - CGCGACGUCCUCCGCGUGGGC 21 11713
HSV2-UL30-3360 - GCGCGACGUCCUCCGCGUGGGC 22 11714
HSV2-UL30-3361 - AGCGCGACGUCCUCCGCGUGGGC 23 11715
HSV2-UL30-3362 - GAGCGCGACGUCCUCCGCGUGGGC 24 11716
HSV2-UL30-3363 - GCCCCUAAGGUGUACUGC 18 11717
HSV2-UL30-3364 - CGCCCCUAAGGUGUACUGC 19 11718
HSV2-UL30-34 - GCGCCCCUAAGGUGUACUGC 20 3072
HSV2-UL30-3365 - CGCGCCCCUAAGGUGUACUGC 21 11719
HSV2-UL30-3366 - GCGCGCCCCUAAGGUGUACUGC 22 11720
HSV2-UL30-3367 - GGCGCGCCCCUAAGGUGUACUGC 23 11721
HSV2-UL30-3368 - CGGCGCGCCCCUAAGGUGUACUGC 24 11722
HSV2-UL30-3369 - UUCCACGUGUACGACAUC 18 11723
HSV2-UL30-3370 - CUUCCACGUGUACGACAUC 19 11724
HSV2-UL30-289 - UCUUCCACGUGUACGACAUC 20 4684
HSV2-UL30-3371 - GUCUUCCACGUGUACGACAUC 21 11725
HSV2-UL30-3372 - CGUCUUCCACGUGUACGACAUC 22 11726
HSV2-UL30-3373 - CCGUCUUCCACGUGUACGACAUC 23 11727
HSV2-UL30-3374 - ACCGUCUUCCACGUGUACGACAUC 24 11728
HSV2-UL30-3375 - ACGACAUCCUGGAGCACG 18 11729
HSV2-UL30-3376 - UACGACAUCCUGGAGCACG 19 11730 HSV2-UL30-54 - GUACGACAUCCUGGAGCACG 20 3192
HSV2-UL30-3377 - UGUACGACAUCCUGGAGCACG 21 11731
HSV2-UL30-3378 - GUGUACGACAUCCUGGAGCACG 22 11732
HSV2-UL30-3379 - CG U G U ACG ACAU CCU G G AG CACG 23 11733
HSV2-UL30-3380 - ACGUGUACGACAUCCUGGAGCACG 24 11734
HSV2-UL30-3381 - UGCCCCCCACAACCCCCG 18 11735
HSV2-UL30-3382 - UUGCCCCCCACAACCCCCG 19 11736
HSV2-UL30-16 - U U U GCCCCCCACAACCCCCG 20 3172
HSV2-UL30-3383 - U U U U GCCCCCCACAACCCCCG 21 11737
HSV2-UL30-3384 - U U U U U GCCCCCCACAACCCCCG 22 11738
HSV2-UL30-3385 - U U U U U U G CCCCCCACAACCCCCG 23 11739
HSV2-UL30-3386 - GU U U U U UGCCCCCCACAACCCCCG 24 11740
HSV2-UL30-3387 - UGGACGAGGACGCCCCCG 18 11741
HSV2-UL30-3388 - CUGGACGAGGACGCCCCCG 19 11742
HSV2-UL30-26 - GCUGGACGAGGACGCCCCCG 20 3179
HSV2-UL30-3389 - CGCUGGACGAGGACGCCCCCG 21 11743
HSV2-UL30-3390 - UCGCUGGACGAGGACGCCCCCG 22 11744
HSV2-UL30-3391 - UUCGCUGGACGAGGACGCCCCCG 23 11745
HSV2-UL30-3392 - GU U CGCU GGACGAGG ACGCCCCCG 24 11746
HSV2-UL30-3393 - GCGGCCCGGCUUCCCCCG 18 11747
HSV2-UL30-3394 - GGCGGCCCGGCUUCCCCCG 19 11748
HSV2-UL30-4 - GGGCGGCCCGGCUUCCCCCG 20 3160
HSV2-UL30-3395 - CGGGCGGCCCGGCUUCCCCCG 21 11749
HSV2-UL30-3396 - GCGGGCGGCCCGGCUUCCCCCG 22 11750
HSV2-UL30-3397 - CGCGGGCGGCCCGGCUUCCCCCG 23 11751
HSV2-UL30-3398 - CCGCGGGCGGCCCGGCUUCCCCCG 24 11752
HSV2-UL30-3399 - GUCCUCCGCGUGGGCCCG 18 11753
HSV2-UL30-3400 - CGUCCUCCGCGUGGGCCCG 19 11754
HSV2-UL30-282 - ACGUCCUCCGCGUGGGCCCG 20 4679
HSV2-UL30-3401 - GACGUCCUCCGCGUGGGCCCG 21 11755
HSV2-UL30-3402 - CGACGUCCUCCGCGUGGGCCCG 22 11756
HSV2-UL30-3403 - GCGACGUCCUCCGCGUGGGCCCG 23 11757
HSV2-UL30-3404 - CGCGACGUCCUCCGCGUGGGCCCG 24 11758
HSV2-UL30-3405 - CCCCUAAGGUGUACUGCG 18 11759
HSV2-UL30-3406 - GCCCCUAAGGUGUACUGCG 19 11760
HSV2-UL30-35 - CGCCCCUAAGGUGUACUGCG 20 3185
HSV2-UL30-3407 - GCGCCCCUAAGGUGUACUGCG 21 11761
HSV2-UL30-3408 - CGCGCCCCUAAGGUGUACUGCG 22 11762
HSV2-UL30-3409 - GCGCGCCCCUAAGGUGUACUGCG 23 11763
HSV2-UL30-3410 - GGCGCGCCCCUAAGGUGUACUGCG 24 11764
HSV2-UL30-3411 - UUUAUCGCCCCGCGUUCG 18 11765
HSV2-UL30-3412 - AUUUAUCGCCCCGCGUUCG 19 11766
HSV2-UL30-265 - GAUUUAUCGCCCCGCGUUCG 20 4670
HSV2-UL30-3413 - CGAUUUAUCGCCCCGCGUUCG 21 11767
HSV2-UL30-3414 - UCGAU UUAUCGCCCCGCGUUCG 22 11768
HSV2-UL30-3415 - UUCGAUUUAUCGCCCCGCGUUCG 23 11769 HSV2-UL30-3416 - UUUCGAUUUAUCGCCCCGCGUUCG 24 11770
HSV2-UL30-3417 - CGGCCCGGCUUCCCCCGG 18 11771
HSV2-UL30-3418 - GCGGCCCGGCUUCCCCCGG 19 11772
HSV2-UL30-5 - GGCGGCCCGGCUUCCCCCGG 20 3161
HSV2-UL30-3419 - GGGCGGCCCGGCUUCCCCCGG 21 11773
HSV2-UL30-3420 - CGGGCGGCCCGGCUUCCCCCGG 22 11774
HSV2-UL30-3421 - GCGGGCGGCCCGGCUUCCCCCGG 23 11775
HSV2-UL30-3422 - CGCGGGCGGCCCGGCUUCCCCCGG 24 11776
HSV2-UL30-3423 - CCGCCGCCUUGCCGCCGG 18 11777
HSV2-UL30-3424 - ACCGCCGCCUUGCCGCCGG 19 11778
HSV2-UL30-259 - CACCGCCGCCUUGCCGCCGG 20 4665
HSV2-UL30-3425 - GCACCGCCGCCUUGCCGCCGG 21 11779
HSV2-UL30-3426 - GGCACCGCCGCCUUGCCGCCGG 22 11780
HSV2-UL30-3427 - CGGCACCGCCGCCUUGCCGCCGG 23 11781
HSV2-UL30-3428 - ACGGCACCGCCGCCUUGCCGCCGG 24 11782
HSV2-UL30-3429 - CCCUAAGGUGUACUGCGG 18 11783
HSV2-UL30-3430 - CCCCUAAGGUGUACUGCGG 19 11784
HSV2-UL30-36 - GCCCCUAAGGUGUACUGCGG 20 3073
HSV2-UL30-3431 - CGCCCCUAAGGUGUACUGCGG 21 11785
HSV2-UL30-3432 - GCGCCCCUAAGGUGUACUGCGG 22 11786
HSV2-UL30-3433 - CGCGCCCCUAAGGUGUACUGCGG 23 11787
HSV2-UL30-3434 - GCGCGCCCCUAAGGUGUACUGCGG 24 11788
HSV2-UL30-3435 - GGCCCGGCUUCCCCCGGG 18 11789
HSV2-UL30-3436 - CGGCCCGGCUUCCCCCGGG 19 11790
HSV2-UL30-6 - GCGGCCCGGCUUCCCCCGGG 20 3162
HSV2-UL30-3437 - GGCGGCCCGGCUUCCCCCGGG 21 11791
HSV2-UL30-3438 - GGGCGGCCCGGCUUCCCCCGGG 22 11792
HSV2-UL30-3439 - CGGGCGGCCCGGCUUCCCCCGGG 23 11793
HSV2-UL30-3440 - GCGGGCGGCCCGGCUUCCCCCGGG 24 11794
HSV2-UL30-3441 - CCUAAGGUGUACUGCGGG 18 11795
HSV2-UL30-3442 - CCCUAAGGUGUACUGCGGG 19 11796
HSV2-UL30-37 - CCCCUAAGGUGUACUGCGGG 20 3074
HSV2-UL30-3443 - GCCCCUAAGGUGUACUGCGGG 21 11797
HSV2-UL30-3444 - CGCCCCUAAGGUGUACUGCGGG 22 11798
HSV2-UL30-3445 - GCGCCCCUAAGGUGUACUGCGGG 23 11799
HSV2-UL30-3446 - CGCGCCCCUAAGGUGUACUGCGGG 24 11800
HSV2-UL30-3447 - AGGUGUACUGCGGGGGGG 18 11801
HSV2-UL30-3448 - AAGGUGUACUGCGGGGGGG 19 11802
HSV2-UL30-278 - UAAGGUGUACUGCGGGGGGG 20 4676
HSV2-UL30-3449 - CU AAGGUGUACUGCGGGGGGG 21 11803
HSV2-UL30-3450 - CCUAAGGUGUACUGCGGGGGGG 22 11804
HSV2-UL30-3451 - CCCUAAGGUGUACUGCGGGGGGG 23 11805
HSV2-UL30-3452 - CCCCUAAGGUGUACUGCGGGGGGG 24 11806
HSV2-UL30-3453 - UCGCCCCGCGUUCGCUGG 18 11807
HSV2-UL30-3454 - AUCGCCCCGCGUUCGCUGG 19 11808
HSV2-UL30-266 - UAUCGCCCCGCGUUCGCUGG 20 4671 HSV2-UL30-3455 - UUAUCGCCCCGCGUUCGCUGG 21 11809
HSV2-UL30-3456 - UUUAUCGCCCCGCGUUCGCUGG 22 11810
HSV2-UL30-3457 - AUU UAUCGCCCCGCGUUCGCUGG 23 11811
HSV2-UL30-3458 - GAUUUAUCGCCCCGCGUUCGCUGG 24 11812
HSV2-UL30-3459 - CGCCCCUAAGGUGUACUG 18 11813
HSV2-UL30-3460 - GCGCCCCUAAGGUGUACUG 19 11814
HSV2-UL30-33 - CGCGCCCCUAAGGUGUACUG 20 3071
HSV2-UL30-3461 - GCGCGCCCCUAAGGUGUACUG 21 11815
HSV2-UL30-3462 - GGCGCGCCCCUAAGGUGUACUG 22 11816
HSV2-UL30-3463 - CGGCGCGCCCCUAAGGUGUACUG 23 11817
HSV2-UL30-3464 - CCGGCGCGCCCCUAAGGUGUACUG 24 11818
HSV2-UL30-3465 - CCGCGUCGCUUGCGCCUG 18 11819
HSV2-UL30-3466 - GCCGCGUCGCUUGCGCCUG 19 11820
HSV2-UL30-45 - GGCCGCGUCGCUUGCGCCUG 20 3189
HSV2-UL30-3467 - UGGCCGCGUCGCUUGCGCCUG 21 11821
HSV2-UL30-3468 - CUGGCCGCGUCGCUUGCGCCUG 22 11822
HSV2-UL30-3469 - UCUGGCCGCGUCGCUUGCGCCUG 23 11823
HSV2-UL30-3470 - UUCUGGCCGCGUCGCUUGCGCCUG 24 11824
HSV2-UL30-3471 - GCGCCCCUAAGGUGUACU 18 11825
HSV2-UL30-3472 - CGCGCCCCUAAGGUGUACU 19 11826
HSV2-UL30-272 - GCGCGCCCCUAAGGUGUACU 20 4675
HSV2-UL30-3473 - GGCGCGCCCCUAAGGUGUACU 21 11827
HSV2-UL30-3474 - CGGCGCGCCCCUAAGGUGUACU 22 11828
HSV2-UL30-3475 - CCGGCGCGCCCCUAAGGUGUACU 23 11829
HSV2-UL30-3476 - UCCGGCGCGCCCCUAAGGUGUACU 24 11830
HSV2-UL30-3477 - GCCGCGUCGCUUGCGCCU 18 11831
HSV2-UL30-3478 - GGCCGCGUCGCUUGCGCCU 19 11832
HSV2-UL30-283 - UGGCCGCGUCGCUUGCGCCU 20 4680
HSV2-UL30-3479 - CUGGCCGCGUCGCUUGCGCCU 21 11833
HSV2-UL30-3480 - UCUGGCCGCGUCGCUUGCGCCU 22 11834
HSV2-UL30-3481 - UUCUGGCCGCGUCGCUUGCGCCU 23 11835
HSV2-UL30-3482 - CUUCUGGCCGCGUCGCU UGCGCCU 24 11836
HSV2-UL30-3483 - UUGCGCCUGUGGGGCGGU 18 11837
HSV2-UL30-3484 - CUUGCGCCUGUGGGGCGGU 19 11838
HSV2-UL30-285 - GCUUGCGCCUGUGGGGCGGU 20 4681
HSV2-UL30-3485 - CGCUUGCGCCUGUGGGGCGGU 21 11839
HSV2-UL30-3486 - UCGCUUGCGCCUGUGGGGCGGU 22 11840
HSV2-UL30-3487 - GUCGCUUGCGCCUGUGGGGCGGU 23 11841
HSV2-UL30-3488 - CGUCGCUUGCGCCUGUGGGGCGGU 24 11842
HSV2-UL30-3489 - CAGCUCCACGAGCGAUUU 18 11843
HSV2-UL30-3490 - CCAGCUCCACGAGCGAU U U 19 11844
HSV2-UL30-3491 - CCCAGCUCCACGAGCGAU U U 20 11845
HSV2-UL30-3492 - GCCCAGCUCCACGAGCGAUUU 21 11846
HSV2-UL30-3493 - CGCCCAGCUCCACGAGCGAUUU 22 11847
HSV2-UL30-3494 - CCGCCCAGCUCCACGAGCGAUUU 23 11848
HSV2-UL30-3495 - GCCGCCCAGCUCCACGAGCGAUU U 24 11849 Table 9E provides exemplary targeting domains for knocking out the UL30 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene), and start with a 5'G. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 9E
Figure imgf000492_0001
HSV2-UL30-3517 + GGCGCAGGAGGCACGUGAAGAC 22 11871
HSV2-UL30-3518 + GUACCAGCCGAAGGUGACAAACC 23 11872
HSV2-UL30-3519 + GGUACCAGCCGAAGGUGACAAACC 24 11873
HSV2-UL30-1108 + GCCCCGGGCGAUGGCGUACC 20 3978
HSV2-UL30-3520 + GAACGCCCCGGGCGAUGGCGUACC 24 11874
HSV2-UL30-3521 + GAGGCCCCGAAACCGCCC 18 11875
HSV2-UL30-3522 + GUCGAGGCCCCGAAACCGCCC 21 11876
HSV2-UL30-3523 + GCU UGUUGGUGUACGCGC 18 11877
HSV2-UL30-2395 + GCGCU UGUUGGUGUACGCGC 20 5157
HSV2-UL30-3524 + GGCGCUUG UUGGUGUACGCGC 21 11878
HSV2-UL30-3525 + GCCCGGAGGCGUAGUAGGC 19 11879
HSV2-UL30-1318 + GGCCCGGAGGCGUAGUAGGC 20 4188
HSV2-UL30-3526 + GGGCCCGGAGGCGUAG UAGGC 21 11880
HSV2-UL30-3527 + GCGGGCCCGGAGGCGUAGUAGGC 23 11881
HSV2-UL30-3528 + GCCUGCAGUCCCUCGGGC 18 11882
HSV2-UL30-3529 + GAACGCCUGCAGUCCCUCGGGC 22 11883
HSV2-UL30-3530 + GAAGCACAGGUUGUGGGC 18 11884
HSV2-UL30-3531 + GUACUGAAGCACAGGUUGUGGGC 23 11885
HSV2-UL30-3532 + GCUUCGACGGGGGGCUCAUGC 21 11886
HSV2-UL30-1267 + GUUGUGGGCCUGGAUGAUGC 20 4137
HSV2-UL30-3533 + GGUUGUGGGCCUGGAUGAUGC 21 11887
HSV2-UL30-3534 + G U C A U G A AG G CC AG C AG C A U C 21 11888
HSV2-UL30-3535 + G G U C A U G A AG G CC AG C AG C A U C 22 11889
HSV2-UL30-3536 + GACCGUCUCCUCUACCUC 18 11890
HSV2-UL30-2385 + GCGACCGUCUCCUCUACCUC 20 5149
HSV2-UL30-3537 + GCGCGACCGUCUCCUCUACCUC 22 11891
HSV2-UL30-3538 + GAGGAGGACGGCCUCCUC 18 11892
HSV2-UL30-3539 + GUCGAGGAGGACGGCCUCCUC 21 11893
HSV2-UL30-3540 + GUCCGGGGGGUGCCACGUCUC 21 11894
HSV2-UL30-3541 + GUCGUCCGGGGGGUGCCACGUCUC 24 11895
HSV2-UL30-3542 + GGCGGUGAGGACAAAGUC 18 11896
HSV2-UL30-3543 + GUUCGGCGG UGAGGACAAAGUC 22 11897
HSV2-UL30-3544 + G ACAAACCCCGGG U U G U C 18 11898
HSV2-UL30-2571 + GUGACAAACCCCGGGUUGUC 20 5284
HSV2-UL30-3545 + GGUG ACAAACCCCGGG UUGUC 21 11899
HSV2-UL30-3546 + GAAGGUGACAAACCCCGGGUUGUC 24 11900
HSV2-UL30-3547 + GGCGACGCGAUGGCCU UC 18 11901
HSV2-UL30-3548 + GAACGGCGACGCGAUGGCCUUC 22 11902
HSV2-UL30-3549 + GUGAACGGCGACGCGAUGGCCUUC 24 11903
HSV2-UL30-3550 + GGAUCCGAGCGAAAACAG 18 11904
HSV2-UL30-3551 + GCAGGAUCCGAGCGAAAACAG 21 11905
HSV2-UL30-3552 + GUCGCAGGAUCCGAGCGAAAACAG 24 11906
HSV2-UL30-3553 + GGCCAGCCAG UCGCGCAG 18 11907
HSV2-UL30-3554 + GCAUGGCCAGCCAGUCGCGCAG 22 11908
HSV2-UL30-3555 + GCUUGGACGCGCCUCCCG 18 11909
HSV2-UL30-3556 + GGCUUGGACGCGCCUCCCG 19 11910 HSV2-UL30-1117 + GGGCU UGGACGCGCCUCCCG 20 3987
HSV2-UL30-3557 + GGGGCU UGGACGCGCCUCCCG 21 11911
HSV2-UL30-3558 + GCGGGGCUUGGACGCGCCUCCCG 23 11912
HSV2-UL30-3559 + GCGCGGCCACGUCGUCCG 18 11913
HSV2-UL30-3560 + GCCGCGCGGCCACGUCGUCCG 21 11914
HSV2-UL30-3561 + GAGCCGCGCGGCCACGUCGUCCG 23 11915
HSV2-UL30-3562 + GUGGGACUCGGGGAGGUCG 19 11916
HSV2-UL30-2541 + GGUGGGACUCGGGGAGGUCG 20 5260
HSV2-UL30-3563 + GAGGUGGGACUCGGGGAGGUCG 22 11917
HSV2-UL30-3564 + GGCUCUAUGCAACAUUCG 18 11918
HSV2-UL30-1277 + GUCGACGUGAAACCCGGAGG 20 4147
HSV2-UL30-3565 + G G U CG ACG U G AAACCCG G AG G 21 11919
HSV2-UL30-3566 + G G G U CG ACG U G AAACCCG GAG G 22 11920
HSV2-UL30-3567 + GGGGUCGACGUGAAACCCGGAGG 23 11921
HSV2-UL30-3568 + GAAACCGCCCCUGGGUG UCCGG 22 11922
HSV2-UL30-3569 + GCGU UCAGCUUGUAGCUG 18 11923
HSV2-UL30-3570 + GGCGUUCAGCUUGUAGCUG 19 11924
HSV2-UL30-3571 + GACGGCGUUCAGCUUGUAGCUG 22 11925
HSV2-UL30-3572 + GCGACGGCGU UCAGCU UGUAGCUG 24 11926
HSV2-UL30-1246 + GCCUCCUCGGGGGUGCUCUG 20 4116
HSV2-UL30-3573 + GGCCUCCUCGGGGGUGCUCUG 21 11927
HSV2-UL30-3574 + GACGGCCUCCUCGGGGGUGCUCUG 24 11928
HSV2-UL30-3575 + GUAGAGCAGACAGGAGAU 18 11929
HSV2-UL30-3576 + GUCGUAGAGCAGACAGGAGAU 21 11930
HSV2-UL30-3577 + GGUCGUAGAGCAGACAGGAGAU 22 11931
HSV2-UL30-3578 + GCUAACGCGGCGGCCGCU 18 11932
HSV2-UL30-3579 + GGCUAACGCGGCGGCCGCU 19 11933
HSV2-UL30-3580 + GCUCGGCUAACGCGGCGGCCGCU 23 11934
HSV2-UL30-3581 + GACAAAGUCCUGGAUGUCCCUCU 23 11935
HSV2-UL30-3582 + GGACAAAGUCCUGGAUGUCCCUCU 24 11936
HSV2-UL30-3583 + GCUGGCCGUCGUAGAUGGU 19 11937
HSV2-UL30-3584 + GAUCUGCUGGCCGUCGUAGAUGGU 24 11938
HSV2-UL30-3585 - GCAGCAAGAUCAAGGUGAA 19 11939
HSV2-UL30-3586 - G CG C AG C A AG A U C A AG G U G A A 21 11940
HSV2-UL30-3587 - GAAGCGCAGCAAGAUCAAGGUGAA 24 11941
HSV2-UL30-3588 - GUCGUCCUGGAGUUUGACA 19 11942
HSV2-UL30-3589 - GGUCCCGUCCAUCAAGGA 18 11943
HSV2-UL30-3590 - GCAGGUCCCGUCCAUCAAGGA 21 11944
HSV2-UL30-3591 - GCGCAGGUCCCGUCCAU C A AG G A 23 11945
HSV2-UL30-1859 - GUACGGCCCCGAGU UCGUGA 20 4811
HSV2-UL30-3592 - GCAGUACGGCCCCGAGU UCGUGA 23 11946
HSV2-UL30-3593 - GCAACUCGGUG UACGGG UUCAC 22 11947
HSV2-UL30-3594 - GUGCAACUCGG UGUACGGGUUCAC 24 11948
HSV2-UL30-3595 - GGGGACGGGAACGGGGAC 18 11949
HSV2-UL30-3596 - GGGGGACGGGAACGGGGAC 19 11950
HSV2-UL30-3597 - GCCGGGGGACGGGAACGGGGAC 22 11951 HSV2-UL30-3598 - GGCCGGGGGACGGGAACGGGGAC 23 11952
HSV2-UL30-3599 - GGUUUAUCCUGGACAACC 18 11953
HSV2-UL30-2047 - GAAAUAACGCCAAGAUCACC 20 4934
HSV2-UL30-3600 - GGAAAUAACG CC AAG A U CACC 21 11954
HSV2-UL30-3601 - GACCUUCGUCAAGCAGUACGGCC 23 11955
HSV2-UL30-1851 - GCUCGGAUCCUGCGACCUCC 20 4805
HSV2-UL30-3602 - GCCUGCCGGCCCCCGUCGUCC 21 11956
HSV2-UL30-3603 - G G CCU GCCG G CCCCCG U CG U CC 22 11957
HSV2-UL30-3604 - GGGCCUGCCGGCCCCCGUCGUCC 23 11958
HSV2-UL30-3605 - GGGGCCUGCCGGCCCCCGUCGUCC 24 11959
HSV2-UL30-1988 - GUUCCUCCCCCCGAUCAAGC 20 4895
HSV2-UL30-3606 - GCUGUUCCUCCCCCCGAUCAAGC 23 11960
HSV2-UL30-1850 - GCACAUCCUCCUGUU UUCGC 20 4804
HSV2-UL30-3607 - GAGCACAUCCUCCUGU UU UCGC 22 11961
HSV2-UL30-3608 - GUACGGGCGCAUGAACGGC 19 11962
HSV2-UL30-529 - GGUACGGGCGCAUGAACGGC 20 3399
HSV2-UL30-3609 - GGGUACGGGCGCAUGAACGGC 21 11963
HSV2-UL30-3610 - GACGGGUACGGGCGCAUGAACGGC 24 11964
HSV2-UL30-1995 - GCAAGAUGCUCAUCAAGGGC 20 4900
HSV2-UL30-3611 - GGCAAGAUGCUCAUCAAGGGC 21 11965
HSV2-UL30-3612 - GGGCAAGAUGCUCAUCAAGGGC 22 11966
HSV2-UL30-3613 - GGGGCAAGAUGCUCAUCAAGGGC 23 11967
HSV2-UL30-3614 - GGGGGCAAGAUGCUCAUCAAGGGC 24 11968
HSV2-UL30-3615 - GCACGUUGGGUACCAGGGGGC 21 11969
HSV2-UL30-3616 - GGCACGUUGGGUACCAGGGGGC 22 11970
HSV2-UL30-3617 - GCCUGGCGGCGGCCCUGC 18 11971
HSV2-UL30-1800 - GCGCCUGGCGGCGGCCCUGC 20 4776
HSV2-UL30-3618 - GAGCGCCUGGCGGCGGCCCUGC 22 11972
HSV2-UL30-3619 - GCGAGCGCCUGGCGGCGGCCCUGC 24 11973
HSV2-UL30-2037 - GUCCGAGCUGGCGGAGGAUC 20 4928
HSV2-UL30-3620 - GUGUCCGAGCUGGCGGAGGAUC 22 11974
HSV2-UL30-3621 - GGUGUCCGAGCUGGCGGAGGAUC 23 11975
HSV2-UL30-3622 - GCGAAAGCAGAUCCGCUC 18 11976
HSV2-UL30-3623 - GCCAUGCGAAAGCAGAUCCGCUC 23 11977
HSV2-UL30-3624 - GGCCAUGCGAAAGCAGAUCCGCUC 24 11978
HSV2-UL30-3625 - G U C U U G A AG G AC A AG A AG 18 11979
HSV2-UL30-3626 - GCCGUCU UGAAGGACAAGAAG 21 11980
HSV2-UL30-3627 - GGCCGUCUUGAAGGACAAGAAG 22 11981
HSV2-UL30-3628 - GAGGCCGUCUUGAAGGACAAGAAG 24 11982
HSV2-UL30-691 - GUUAGCCGAGCGCCCCGCAG 20 3561
HSV2-UL30-3629 - GCGUUAGCCGAGCGCCCCGCAG 22 11983
HSV2-UL30-3630 - GAGACCGGGGGCCGGCACG 19 11984
HSV2-UL30-3631 - GCGAGACCGGGGGCCGGCACG 21 11985
HSV2-UL30-3632 - GCGCGAGACCGGGGGCCGGCACG 23 11986
HSV2-UL30-1829 - GUUCGGAACCUCGAGCGACG 20 4793
HSV2-UL30-3633 - GCGUUCGGAACCUCGAGCGACG 22 11987 HSV2-UL30-3634 - GGCGUUCGGAACCUCGAGCGACG 23 11988
HSV2-UL30-3635 - GCCGCGCGGCUCAGGGCCG 19 11989
HSV2-UL30-751 - GGCCGCGCGGCUCAGGGCCG 20 3621
HSV2-UL30-3636 - GUGGCCGCGCGGCUCAGGGCCG 22 11990
HSV2-UL30-546 - GCCUCCGGGCCCGCGCAGCG 20 3416
HSV2-UL30-3637 - GCUGGUGUCCGAGCUGGCG 19 11991
HSV2-UL30-3638 - GCUGCUGGUGUCCGAGCUGGCG 22 11992
HSV2-UL30-3639 - GCGCAGCGCGGGGUGAUCG 19 11993
HSV2-UL30-3640 - GCCCGCGCAGCGCGGGGUGAUCG 23 11994
HSV2-UL30-3641 - GGCCCGCGCAGCGCGGGGUGAUCG 24 11995
HSV2-UL30-2062 - GCUACGGCGGAGGAAACUCG 20 4944
HSV2-UL30-3642 - GCGCUACGGCGGAGGAAACUCG 22 11996
HSV2-UL30-3643 - GGCGCUACGGCGGAGGAAACUCG 23 11997
HSV2-UL30-1862 - GAUCUACAAGGUCCCGCUCG 20 4813
HSV2-UL30-3644 - GAGAUCUACAAGGUCCCGCUCG 22 11998
HSV2-UL30-3645 - GGAGAUCUACAAGGUCCCGCUCG 23 11999
HSV2-UL30-657 - GUACGUGCACGCGCGCUGGG 20 3527
HSV2-UL30-3646 - GCGUACGUGCACGCGCGCUGGG 22 12000
HSV2-UL30-3647 - GCGCGUACGUGCACGCGCGCUGGG 24 12001
HSV2-UL30-3648 - GGGUCCUCGACCCCACCU 18 12002
HSV2-UL30-3649 - GCCCGGGUCCUCGACCCCACCU 22 12003
HSV2-UL30-3650 - GGCCCGGGUCCUCGACCCCACCU 23 12004
HSV2-UL30-3651 - GGGCCCGGGUCCUCGACCCCACCU 24 12005
HSV2-UL30-3652 - GUGGUGUGCAACUCGGUGU 19 12006
HSV2-UL30-1972 - GGUGGUGUGCAACUCGGUGU 20 4884
HSV2-UL30-3653 - G GGACCG U C AU CACG CU U 18 12007
HSV2-UL30-3654 - GCCGGGACCGUCAUCACGCU U 21 12008
Table 9F provides exemplary targeting domains for knocking out the UL30 gene selected according to the six tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 9F
Figure imgf000496_0001
HSV2-UL30-3656 + CCGCGGCACAAAACGAAAA 19 12010
HSV2-UL30-3657 + AGGCCGCGG C AC A A A ACG A A A A 22 12011
HSV2-UL30-3658 + UGAGGCCGCGGCACAAAACGAAAA 24 12012
HSV2-UL30-3659 + CGGGUUGUCCAGGAUAAA 18 12013
HSV2-UL30-3660 + CCGGGUUGUCCAGGAUAAA 19 12014
HSV2-UL30-2572 + CCCGGGU UGUCCAGGAUAAA 20 5285
HSV2-UL30-3661 + CCCCGGGUUGUCCAGGAUAAA 21 12015
HSV2-UL30-3662 + ACCCCGGGU UGUCCAGGAUAAA 22 12016
HSV2-UL30-3663 + AACCCCGGGU UGUCCAGGAUAAA 23 12017
HSV2-UL30-3664 + AAACCCCGGGUUGUCCAGGAUAAA 24 12018
HSV2-UL30-3665 + CCCCGG U G AACCCG U ACA 18 12019
HSV2-UL30-3666 + ACCCCGG U G AACCCG U ACA 19 12020
HSV2-UL30-2445 + CACCCCGGUGAACCCGUACA 20 5192
HSV2-UL30-3667 + UGCACCCCGGUGAACCCGUACA 22 12021
HSV2-UL30-3668 + CUGCACCCCGGUG AACCCG U ACA 23 12022
HSV2-UL30-3669 + C A A AG U C A A AC ACC ACC A 18 12023
HSV2-UL30-3670 + U G GC AA AG U CA AACACCACCA 21 12024
HSV2-UL30-3671 + C U G G C A A AG U C A A AC ACC ACC A 22 12025
HSV2-UL30-3672 + ACAGCUGCCCGACCAGCA 18 12026
HSV2-UL30-3673 + AACAGCUGCCCGACCAGCA 19 12027
HSV2-UL30-3674 + AGAACAGCUGCCCGACCAGCA 21 12028
HSV2-UL30-3675 + AAG AACAGCUGCCCGACCAGCA 22 12029
HSV2-UL30-3676 + UGAAG AACAGCUGCCCGACCAGCA 24 12030
HSV2-UL30-3677 + CCCCGUAGAUGAUGCGCA 18 12031
HSV2-UL30-3678 + UCCCCGUAGAUGAUGCGCA 19 12032
HSV2-UL30-3679 + UGUCCCCGUAGAUGAUGCGCA 21 12033
HSV2-UL30-3680 + CGUGUCCCCG UAGAUGAUGCGCA 23 12034
HSV2-UL30-3681 + CCGUGUCCCCGUAGAUGAUGCGCA 24 12035
HSV2-UL30-3682 + UGCUCUGGGGGAUCCGCGA 19 12036
HSV2-UL30-3683 + CACGAAGACGCGGUAG UA 18 12037
HSV2-UL30-2576 + CGCACGAAGACGCGGUAGUA 20 5288
HSV2-UL30-3684 + UCGCACGAAGACGCGGUAGUA 21 12038
HSV2-UL30-3685 + UUCGCACGAAGACGCGGUAGUA 22 12039
HSV2-UL30-3686 + CU UCGCACGAAGACGCGGUAGUA 23 12040
HSV2-UL30-3687 + CUGGGCCACGAUCACGUA 18 12041
HSV2-UL30-3688 + UCUGGGCCACGAUCACGUA 19 12042
HSV2-UL30-3689 + CGGGUCUGGGCCACGAUCACGUA 23 12043
HSV2-UL30-3690 + CAGGAGGCACGUGAAGAC 18 12044
HSV2-UL30-2494 + CGCAGGAGGCACG UGAAG AC 20 5228
HSV2-UL30-3691 + AGGCGCAGGAGGCACG UGAAG AC 23 12045
HSV2-UL30-3692 + AAGGCGCAGGAGGCACGUGAAGAC 24 12046
HSV2-UL30-3693 + AGCCGAAGGUGACAAACC 18 12047
HSV2-UL30-3694 + CAGCCGAAGGUGACAAACC 19 12048
HSV2-UL30-2570 + CCAGCCGAAGGUGACAAACC 20 5283
HSV2-UL30-3695 + ACC AG CCG A AG G U G AC A A ACC 21 12049
HSV2-UL30-3696 + UACCAGCCGAAGGUG AC A A ACC 22 12050 HSV2-UL30-3697 + CCCGGGCGAUGGCGUACC 18 12051
HSV2-UL30-3698 + CCCCGGGCGAUGGCGUACC 19 12052
HSV2-UL30-3699 + CGCCCCGGGCGAUGGCGUACC 21 12053
HSV2-UL30-3700 + ACGCCCCGGGCGAUGGCGUACC 22 12054
HSV2-UL30-3701 + AACGCCCCGGGCGAUGGCGUACC 23 12055
HSV2-UL30-3702 + CG AGG CCCCG AAACCG CCC 19 12056
HSV2-UL30-2488 + UCGAGGCCCCGAAACCGCCC 20 5223
HSV2-UL30-3703 + UGUCGAGGCCCCGAAACCGCCC 22 12057
HSV2-UL30-3704 + UUG UCGAGGCCCCGAAACCGCCC 23 12058
HSV2-UL30-3705 + CUUGUCGAGGCCCCGAAACCGCCC 24 12059
HSV2-UL30-3706 + CGCU UGU UGGUGUACGCGC 19 12060
HSV2-UL30-3707 + AGGCGCU UGUUGGUGUACGCGC 22 12061
HSV2-UL30-3708 + CAGGCGCU UGUUGGUGUACGCGC 23 12062
HSV2-UL30-3709 + CCAGGCGCUUGUUGGUGUACGCGC 24 12063
HSV2-UL30-3710 + CCCGGAGGCGUAGUAGGC 18 12064
HSV2-UL30-3711 + CGGGCCCGGAGGCGUAGUAGGC 22 12065
HSV2-UL30-3712 + CGCGGGCCCGGAGGCGUAGUAGGC 24 12066
HSV2-UL30-3713 + CGCCUGCAGUCCCUCGGGC 19 12067
HSV2-UL30-1184 + ACGCCUGCAGUCCCUCGGGC 20 4054
HSV2-UL30-3714 + AACGCCUGCAGUCCCUCGGGC 21 12068
HSV2-UL30-3715 + CGAACGCCUGCAGUCCCUCGGGC 23 12069
HSV2-UL30-3716 + CCGAACGCCUGCAGUCCCUCGGGC 24 12070
HSV2-UL30-3717 + UGAAGCACAGGUUGUGGGC 19 12071
HSV2-UL30-2470 + CUGAAGCACAGGUUGUGGGC 20 5209
HSV2-UL30-3718 + ACUGAAGCACAGGUUGUGGGC 21 12072
HSV2-UL30-3719 + UACUGAAGCACAGGUUGUGGGC 22 12073
HSV2-UL30-3720 + CGUACUGAAGCACAGGU UGUGGGC 24 12074
HSV2-UL30-3721 + UCGACGGGGGGCUCAUGC 18 12075
HSV2-UL30-3722 + U UCGACGGGGGGCUCAUGC 19 12076
HSV2-UL30-3723 + CUUCGACGGGGGGCUCAUGC 20 12077
HSV2-UL30-3724 + AGCU UCGACGGGGGGCUCAUGC 22 12078
HSV2-UL30-3725 + CAGCU UCGACGGGGGGCUCAUGC 23 12079
HSV2-UL30-3726 + UCAGCUUCGACGGGGGGCUCAUGC 24 12080
HSV2-UL30-3727 + UGUGGGCCUGGAUGAUGC 18 12081
HSV2-UL30-3728 + U UGUGGGCCUGGAUGAUGC 19 12082
HSV2-UL30-3729 + AGGU UGUGGGCCUGGAUGAUGC 22 12083
HSV2-UL30-3730 + CAGG UUGUGGGCCUGGAUGAUGC 23 12084
HSV2-UL30-3731 + ACAGGU UGUGGGCCUGGAUGAUGC 24
12085
HSV2-UL30-3732 + A U G A AG G CC AG C AG C A U C 18 12086
HSV2-UL30-3733 + C A U G A AG G CC AG C AG C A U C 19 12087
HSV2-UL30-2526 + UCAUGAAGGCCAGCAGCAUC 20 5252
HSV2-UL30-3734 + AGGUCAUGAAGGCCAGCAGCAUC 23 12088
HSV2-UL30-3735 + AAGG UCAUGAAGGCCAGCAGCAUC 24 12089
HSV2-UL30-3736 + CGACCGUCUCCUCUACCUC 19 12090
HSV2-UL30-3737 + CGCGACCGUCUCCUCUACCUC 21 12091 HSV2-UL30-3738 + CGCGCGACCGUCUCCUCUACCUC 23 12092
HSV2-UL30-3739 + CCGCGCGACCGUCUCCUCUACCUC 24 12093
HSV2-UL30-3740 + CGAGGAGGACGGCCUCCUC 19 12094
HSV2-UL30-1241 + UCGAGGAGGACGGCCUCCUC 20 4111
HSV2-UL30-3741 + UGUCGAGGAGGACGGCCUCCUC 22 12095
HSV2-UL30-3742 + UUGUCGAGGAGGACGGCCUCCUC 23 12096
HSV2-UL30-3743 + CUUGUCGAGGAGGACGGCCUCCUC 24 12097
HSV2-UL30-3744 + CGGGGGGUGCCACGUCUC 18 12098
HSV2-UL30-3745 + CCGGGGGGUGCCACGUCUC 19 12099
HSV2-UL30-1097 + UCCGGGGGG UGCCACGUCUC 20 3967
HSV2-UL30-3746 + CGUCCGGGGGGUGCCACGUCUC 22 12100
HSV2-UL30-3747 + UCGUCCGGGGGGUGCCACGUCUC 23 12101
HSV2-UL30-3748 + CGGCGGUGAGGACAAAGUC 19 12102
HSV2-UL30-2398 + UCGGCGGUGAGGACAAAGUC 20 5160
HSV2-UL30-3749 + U UCGGCGGUGAGGACAAAGUC 21 12103
HSV2-UL30-3750 + AGUUCGGCGGUG AG G AC A A AG U C 23 12104
HSV2-UL30-3751 + CAGU UCGGCGGUGAGGACAAAGUC 24 12105
HSV2-UL30-3752 + U G AC AAACCCCG G G U U G U C 19 12106
HSV2-UL30-3753 + AG G U G AC AAACCCCG G G U U G U C 22 12107
HSV2-UL30-3754 + A AG G U G AC AAACCCCG G G U U G U C 23 12108
HSV2-UL30-3755 + CGGCGACGCGAUGGCCUUC 19 12109
HSV2-UL30-1430 + ACGGCGACGCGAUGGCCUUC 20 4300
HSV2-UL30-3756 + AACGGCGACGCGAUGGCCUUC 21 12110
HSV2-UL30-3757 + UGAACGGCGACGCGAUGGCCUUC 23 12111
HSV2-UL30-3758 + AGGAUCCGAGCGAAAACAG 19 12112
HSV2-UL30-2546 + CAGGAUCCGAGCGAAAACAG 20 5264
HSV2-UL30-3759 + CGCAGGAUCCGAGCGAAAACAG 22 12113
HSV2-UL30-3760 + UCGCAGGAUCCGAGCG A A A AC AG 23 12114
HSV2-UL30-3761 + UGGCCAGCCAGUCGCGCAG 19 12115
HSV2-UL30-2459 + AUGGCCAGCCAGUCGCGCAG 20 5200
HSV2-UL30-3762 + CAUGGCCAGCCAGUCGCGCAG 21 12116
HSV2-UL30-3763 + CGCAUGGCCAGCCAGUCGCGCAG 23 12117
HSV2-UL30-3764 + UCGCAUGGCCAGCCAGUCGCGCAG 24 12118
HSV2-UL30-3765 + CGGGGCUUGGACGCGCCUCCCG 22 12119
HSV2-UL30-3766 + UGCGGGGCUUGGACGCGCCUCCCG 24 12120
HSV2-UL30-3767 + CGCGCGGCCACGUCGUCCG 19 12121
HSV2-UL30-1093 + CCGCGCGGCCACGUCGUCCG 20 3963
HSV2-UL30-3768 + AGCCGCGCGGCCACGUCGUCCG 22 12122
HSV2-UL30-3769 + UGAGCCGCGCGGCCACGUCGUCCG 24 12123
HSV2-UL30-3770 + UGGGACUCGGGGAGGUCG 18 12124
HSV2-UL30-3771 + AGGUGGGACUCGGGGAGGUCG 21 12125
HSV2-UL30-3772 + UGAGG UGGGACUCGGGGAGGUCG 23 12126
HSV2-UL30-3773 + CUGAGGUGGGACUCGGGGAGGUCG 24
12127
HSV2-UL30-3774 + AGGCUCUAUGCAACAUUCG 19 12128
HSV2-UL30-2337 + AAGGCUCU AUGCAACAU UCG 20 5123 HSV2-UL30-3775 + AAAGGCUCUAUGCAACAUUCG 21 12129
HSV2-UL30-3776 + CAAAGGCUCUAUGCAACAUUCG 22 12130
HSV2-UL30-3777 + UCAAAGGCUCUAUGCAACAU UCG 23 12131
HSV2-UL30-3778 + AUCAAAGGCUCUAUGCAACAUUCG 24 12132
HSV2-UL30-3779 + CGACGUGAAACCCGGAGG 18 12133
HSV2-UL30-3780 + UCGACGUGAAACCCGGAGG 19 12134
HSV2-UL30-3781 + CGGGGUCGACGUGAAACCCGGAGG 24 12135
HSV2-UL30-3782 + CCGCCCCUGGGUGUCCGG 18 12136
HSV2-UL30-3783 + ACCGCCCCUGGGUGUCCGG 19 12137
HSV2-UL30-2489 + AACCGCCCCUGGGUG UCCGG 20 5224
HSV2-UL30-3784 + A A ACCG CCCCUGGGUGUCCGG 21 12138
HSV2-UL30-3785 + CGAAACCGCCCCUGGGUGUCCGG 23 12139
HSV2-UL30-3786 + CCGAAACCGCCCCUGGGUGUCCGG 24 12140
HSV2-UL30-2510 + CGGCGUUCAGCUUGUAGCUG 20 5239
HSV2-UL30-3787 + ACGGCGU UCAGCU UGUAGCUG 21 12141
HSV2-UL30-3788 + CGACGGCGU UCAGCUUG UAGCUG 23 12142
HSV2-UL30-3789 + CUCCUCGGGGGUGCUCUG 18 12143
HSV2-UL30-3790 + CCUCCUCGGGGG UGCUCUG 19 12144
HSV2-UL30-3791 + CGGCCUCCUCGGGGGUGCUCUG 22 12145
HSV2-UL30-3792 + ACGGCCUCCUCGGGGGUGCUCUG 23 12146
HSV2-UL30-3793 + CGUAGAGCAGACAGGAGAU 19 12147
HSV2-UL30-2553 + UCGUAGAGCAGACAGGAGAU 20 5270
HSV2-UL30-3794 + AGGUCGUAGAGCAGACAGGAGAU 23 12148
HSV2-UL30-3795 + CAGGUCGUAGAGCAGACAGGAGAU 24 12149
HSV2-UL30-2409 + CGGCUAACGCGGCGGCCGCU 20 5169
HSV2-UL30-3796 + UCGGCUAACGCGGCGGCCGCU 21 12150
HSV2-UL30-3797 + CUCGGCUAACGCGGCGGCCGCU 22 12151
HSV2-UL30-3798 + CGCUCGGCUAACGCGGCGGCCGCU 24 12152
HSV2-UL30-3799 + AGUCCUGGAUGUCCCUCU 18 12153
HSV2-UL30-3800 + AAGUCCUGGAUGUCCCUCU 19 12154
HSV2-UL30-2399 + AAAGUCCUGGAUGUCCCUCU 20 5161
HSV2-UL30-3801 + CAAAGUCCUGGAUGUCCCUCU 21 12155
HSV2-UL30-3802 + ACAAAGUCCUGGAUGUCCCUCU 22 12156
HSV2-UL30-3803 + CUGGCCGUCGUAGAUGGU 18 12157
HSV2-UL30-2495 + UGCUGGCCGUCGUAGAUGGU 20 5229
HSV2-UL30-3804 + CUGCUGGCCGUCGUAGAUGGU 21 12158
HSV2-UL30-3805 + UCUGCUGGCCGUCGUAGAUGGU 22 12159
HSV2-UL30-3806 + AUCUGCUGGCCGUCGUAGAUGGU 23 12160
HSV2-UL30-3807 - CAG C A AG AUCAAGGUGAA 18 12161
HSV2-UL30-536 - CGCAGCAAGAUCAAGGUGAA 20 3406
HSV2-UL30-3808 - AGCGCAGCAAG AUCAAGGUGAA 22 12162
HSV2-UL30-3809 - AAGCGCAGCAAG AUCAAGGUGAA 23 12163
HSV2-UL30-3810 - UCGUCCUGGAGUUUGACA 18 12164
HSV2-UL30-1856 - CGUCGUCCUGGAGUU UGACA 20 4808
HSV2-UL30-3811 - CCGUCGUCCUGGAGUUUGACA 21 12165
HSV2-UL30-3812 - CCCGUCGUCCUGGAGU UUGACA 22 12166 HSV2-UL30-3813 - CCCCGUCGUCCUGGAGUUUGACA 23 12167
HSV2-UL30-3814 - CCCCCGUCGUCCUGGAGUU UGACA 24 12168
HSV2-UL30-3815 - AGGUCCCGUCCAUCAAGGA 19 12169
HSV2-UL30-2017 - CAGG UCCCGUCCAUCAAGGA 20 4916
HSV2-UL30-3816 - CGCAGGUCCCGUCCAUCAAGGA 22 12170
HSV2-UL30-3817 - CGCGCAGGUCCCGUCCAU C A AG G A 24 12171
HSV2-UL30-3818 - ACGGCCCCGAGU UCGUGA 18 12172
HSV2-UL30-3819 - UACGGCCCCGAGUUCGUGA 19 12173
HSV2-UL30-3820 - AGU ACGGCCCCGAGU UCGUGA 21 12174
HSV2-UL30-3821 - C AG UACGGCCCCGAGUUCGUGA 22 12175
HSV2-UL30-3822 - AGCAGUACGGCCCCGAGUUCGUGA 24 12176
HSV2-UL30-3823 - AGCUCAUGUGCUUCGAUA 18 12177
HSV2-UL30-3824 - AAGCUCAUGUGCU UCGAUA 19 12178
HSV2-UL30-1835 - CAAGCUCAUGUGCUUCGAUA 20 4797
HSV2-UL30-3825 - ACAAGCUCAUGUGCUUCGAUA 21 12179
HSV2-UL30-3826 - UACAAGCUCAUGUGCUUCGAUA 22 12180
HSV2-UL30-3827 - CUACAAGCUCAUGUGCU UCGAUA 23 12181
HSV2-UL30-3828 - CCUACAAGCUCAUGUGCUUCGAUA 24 12182
HSV2-UL30-3829 - CUCGGUGUACGGGU UCAC 18 12183
HSV2-UL30-3830 - ACUCGGUGUACGGGUUCAC 19 12184
HSV2-UL30-649 - AACUCGGUGUACGGGUUCAC 20 3519
HSV2-UL30-3831 - CAACUCGGUGUACGGGU UCAC 21 12185
HSV2-UL30-3832 - UGCAACUCGGUGUACGGGUUCAC 23 12186
HSV2-UL30-1923 - CGGGGGACGGGAACGGGGAC 20 4851
HSV2-UL30-3833 - CCGGGGGACGGGAACGGGGAC 21 12187
HSV2-UL30-3834 - CGGCCGGGGGACGGGAACGGGGAC 24 12188
HSV2-UL30-3835 - CGGUU UAUCCUGGACAACC 19 12189
HSV2-UL30-480 - CCGGU UUAUCCUGGACAACC 20 3350
HSV2-UL30-3836 - CCCG GUU UAUCCU GGACAACC 21 12190
HSV2-UL30-3837 - ACCCGGU U U AUCCUGG ACAACC 22 12191
HSV2-UL30-3838 - CACCCGGU UUAUCCUGGACAACC 23 12192
HSV2-UL30-3839 - CCACCCGGUUUAUCCUGGACAACC 24 12193
HSV2-UL30-3840 - AAUAACGCCAAGAUCACC 18 12194
HSV2-UL30-3841 - AAAUAACGCCAAGAUCACC 19 12195
HSV2-UL30-3842 - UGGAAAUAACGCCAAGAUCACC 22 12196
HSV2-UL30-3843 - UUGG AAAUAACGCCAAGAUCACC 23 12197
HSV2-UL30-3844 - UU UGGAAAUAACGCCAAGAUCACC 24 12198
HSV2-UL30-3845 - UCGUCAAGCAGUACGGCC 18 12199
HSV2-UL30-3846 - U UCGUCAAGCAGUACGGCC 19 12200
HSV2-UL30-1858 - C U U CG U C A AG CAGUACGGCC 20 4810
HSV2-UL30-3847 - CCUUCGUCAAGCAGUACGGCC 21 12201
HSV2-UL30-3848 - ACCUUCGUCAAGCAGUACGGCC 22 12202
HSV2-UL30-3849 - UGACCUUCGUCAAGCAGUACGGCC 24 12203
HSV2-UL30-3850 - UCGGAUCCUGCGACCUCC 18 12204
HSV2-UL30-3851 - CUCGGAUCCUGCGACCUCC 19 12205
HSV2-UL30-3852 - CGCUCGGAUCCUGCGACCUCC 21 12206 HSV2-UL30-3853 - UCGCUCGGAUCCUGCGACCUCC 22 12207
HSV2-UL30-3854 - UUCGCUCGGAUCCUGCGACCUCC 23 12208
HSV2-UL30-3855 - UUUCGCUCGGAUCCUGCGACCUCC 24 12209
HSV2-UL30-3856 - UGCCGGCCCCCGUCGUCC 18 12210
HSV2-UL30-3857 - CUGCCGGCCCCCGUCGUCC 19 12211
HSV2-UL30-516 - CCUGCCGGCCCCCGUCGUCC 20 3386
HSV2-UL30-3858 - UCCUCCCCCCGAUCAAGC 18 12212
HSV2-UL30-3859 - U UCCUCCCCCCGAUCAAGC 19 12213
HSV2-UL30-3860 - UGUUCCUCCCCCCGAUCAAGC 21 12214
HSV2-UL30-3861 - CUGU UCCUCCCCCCGAUCAAGC 22 12215
HSV2-UL30-3862 - CGCUGUUCCUCCCCCCGAUCAAGC 24 12216
HSV2-UL30-3863 - ACAUCCUCCUGUUUUCGC 18 12217
HSV2-UL30-3864 - CACAUCCUCCUGUU UUCGC 19 12218
HSV2-UL30-3865 - AGCACAUCCUCCUGU UUUCGC 21 12219
HSV2-UL30-3866 - CGAGCACAUCCUCCUGUU UUCGC 23 12220
HSV2-UL30-3867 - UCGAGCACAUCCUCCUGUU UUCGC 24 12221
HSV2-UL30-3868 - UACGGGCGCAUGAACGGC 18 12222
HSV2-UL30-3869 - CGGGUACGGGCGCAUGAACGGC 22 12223
HSV2-UL30-3870 - ACGGG UACGGGCGCAUGAACGGC 23 12224
HSV2-UL30-3871 - AAGAUGCUCAUCAAGGGC 18 12225
HSV2-UL30-3872 - CAAGAUGCUCAUCAAGGGC 19 12226
HSV2-UL30-3873 - CGUUGGGUACCAGGGGGC 18 12227
HSV2-UL30-3874 - ACGU UGGGUACCAGGGGGC 19 12228
HSV2-UL30-1947 - CACGU UGGGUACCAGGGGGC 20 4866
HSV2-UL30-3875 - CGGCACGU UGGGUACCAGGGGGC 23 12229
HSV2-UL30-3876 - CCGGCACG UUGGGUACCAGGGGGC 24 12230
HSV2-UL30-3877 - CGCCUGGCGGCGGCCCUGC 19 12231
HSV2-UL30-3878 - AGCGCCUGGCGGCGGCCCUGC 21 12232
HSV2-UL30-3879 - CGAGCGCCUGGCGGCGGCCCUGC 23 12233
HSV2-UL30-3880 - CCGAGCUGGCGGAGGAUC 18 12234
HSV2-UL30-3881 - UCCGAGCUGGCGGAGGAUC 19 12235
HSV2-UL30-3882 - UGUCCGAGCUGGCGGAGGAUC 21 12236
HSV2-UL30-3883 - UGGUGUCCGAGCUGGCGGAGGAUC 24 12237
HSV2-UL30-3884 - UGCGAAAGCAGAUCCGCUC 19 12238
HSV2-UL30-1967 - AUGCGAAAGCAGAUCCGCUC 20 4880
HSV2-UL30-3885 - CAUGCGAAAGCAGAUCCGCUC 21 12239
HSV2-UL30-3886 - CCAUGCGAAAGCAGAUCCGCUC 22 12240
HSV2-UL30-3887 - CGUCU UGAAGG AC A AG A AG 19 12241
HSV2-UL30-1881 - CCGUCU UGAAGGACAAGAAG 20 4829
HSV2-UL30-3888 - AGGCCGUCU UGAAGGACAAGAAG 23 12242
HSV2-UL30-3889 - UAGCCGAGCGCCCCGCAG 18 12243
HSV2-UL30-3890 - UUAGCCGAGCGCCCCGCAG 19 12244
HSV2-UL30-3891 - CGU UAGCCGAGCGCCCCGCAG 21 12245
HSV2-UL30-3892 - CG CG U U AG CCG AG CG CCCCG CAG 23 12246
HSV2-UL30-3893 - CCGCG UUAGCCGAGCGCCCCGCAG 24 12247
HSV2-UL30-3894 - UACAUGAACAAGGCGGAG 18 12248 HSV2-UL30-3895 - U U ACAUG AACAAGGCGG AG 19 12249
HSV2-UL30-1798 - U UUACAUGAACAAGGCGGAG 20 4774
HSV2-UL30-3896 - U UUUACAUGAACAAGGCGGAG 21 12250
HSV2-UL30-3897 - CUU UUACAUGAACAAGGCGGAG 22 12251
HSV2-UL30-3898 - ACU UUUACAUGAACAAGGCGGAG 23 12252
HSV2-UL30-3899 - UACUUUUACAUGAACAAGGCGGAG 24 12253
HSV2-UL30-3900 - AGACCGGGGGCCGGCACG 18 12254
HSV2-UL30-1943 - CGAGACCGGGGGCCGGCACG 20 4864
HSV2-UL30-3901 - CGCG AGACCGGGGGCCGGCACG 22 12255
HSV2-UL30-3902 - CGCGCG AGACCGGGGGCCGGCACG 24 12256
HSV2-UL30-3903 - UCGGAACCUCGAGCGACG 18 12257
HSV2-UL30-3904 - U UCGGAACCUCGAGCGACG 19 12258
HSV2-UL30-3905 - CGU UCGGAACCUCGAGCGACG 21 12259
HSV2-UL30-3906 - CGGCGU UCGGAACCUCGAGCGACG 24 12260
HSV2-UL30-3907 - CCGCGCGGCUCAGGGCCG 18 12261
HSV2-UL30-3908 - UGGCCGCGCGGCUCAGGGCCG 21 12262
HSV2-UL30-3909 - CGUGGCCGCGCGGCUCAGGGCCG 23 12263
HSV2-UL30-3910 - ACGUGGCCGCGCGGCUCAGGGCCG 24 12264
HSV2-UL30-3911 - CUCCGGGCCCGCGCAGCG 18 12265
HSV2-UL30-3912 - CCUCCGGGCCCGCGCAGCG 19 12266
HSV2-UL30-3913 - CGCCUCCGGGCCCGCGCAGCG 21 12267
HSV2-UL30-3914 - ACGCCUCCGGGCCCGCGCAGCG 22 12268
HSV2-UL30-3915 - UACGCCUCCGGGCCCGCGCAGCG 23 12269
HSV2-UL30-3916 - CUACGCCUCCGGGCCCGCGCAGCG 24 12270
HSV2-UL30-3917 - CUGGUGUCCGAGCUGGCG 18 12271
HSV2-UL30-2036 - UGCUGGUGUCCGAGCUGGCG 20 4927
HSV2-UL30-3918 - CUGCUGGUGUCCGAGCUGGCG 21 12272
HSV2-UL30-3919 - AGCUGCUGGUGUCCGAGCUGGCG 23 12273
HSV2-UL30-3920 - AAGCUGCUGGUGUCCGAGCUGGCG 24 12274
HSV2-UL30-3921 - CGCAGCGCGGGGUGAUCG 18 12275
HSV2-UL30-1886 - CGCGCAGCGCGGGGUGAUCG 20 4833
HSV2-UL30-3922 - CCGCGCAGCGCGGGGUGAUCG 21 12276
HSV2-UL30-3923 - CCCGCGCAGCGCGGGGUGAUCG 22 12277
HSV2-UL30-3924 - UACGGCGGAGGAAACUCG 18 12278
HSV2-UL30-3925 - CUACGGCGGAGGAAACUCG 19 12279
HSV2-UL30-3926 - CGCUACGGCGGAGGAAACUCG 21 12280
HSV2-UL30-3927 - CGGCGCUACGGCGGAGGAAACUCG 24 12281
HSV2-UL30-3928 - UCUACAAGGUCCCGCUCG 18 12282
HSV2-UL30-3929 - AUCUACAAGGUCCCGCUCG 19 12283
HSV2-UL30-3930 - AGAUCUACAAGGUCCCGCUCG 21 12284
HSV2-UL30-3931 - CGGAGAUCUACAAGGUCCCGCUCG 24 12285
HSV2-UL30-3932 - ACGUGCACGCGCGCUGGG 18 12286
HSV2-UL30-3933 - UACGUGCACGCGCGCUGGG 19 12287
HSV2-UL30-3934 - CGU ACGUGCACGCGCGCUGGG 21 12288
HSV2-UL30-3935 - CGCGU ACGUGCACGCGCGCUGGG 23 12289
HSV2-UL30-3936 - CGGGUCCUCGACCCCACCU 19 12290 HSV2-UL30-1948 - CCGGGUCCUCGACCCCACCU 20 4867
HSV2-UL30-3937 - CCCGGGUCCUCGACCCCACCU 21 12291
HSV2-UL30-3938 - UGGUGUGCAACUCGGUGU 18 12292
HSV2-UL30-3939 - AGGUGGUGUGCAACUCGGUGU 21 12293
HSV2-UL30-3940 - AAGGUGGUGUGCAACUCGGUGU 22 12294
HSV2-UL30-3941 - CAAGGUGGUGUGCAACUCGGUGU 23 12295
HSV2-UL30-3942 - UCAAGG UGGUGUGCAACUCGGUGU 24
12296
HSV2-UL30-3943 - CGGGACCGUCAUCACGCUU 19 12297
HSV2-UL30-1793 - CCGGGACCGUCAUCACGCUU 20 4770
HSV2-UL30-3944 - CGCCGGGACCGUCAUCACGCUU 22 12298
HSV2-UL30-3945 - CCGCCGGGACCGUCAUCACGCUU 23 12299
HSV2-UL30-3946 - CCCGCCGGGACCGUCAUCACGCU U 24 12300
Table 9G provides exemplary targeting domains for knocking out the UL30 gene selected according to the seven tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). The PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 9G
Figure imgf000504_0001
HSV2-UL30-3960 + UCUUGGCG UUAUU UCCAAA 19 12314
HSV2-UL30-2347 + AUCUUGGCGU UAU UUCCAAA 20 5128
HSV2-UL30-3961 + GAUCUUGGCGU UAUUUCCAAA 21 12315
HSV2-UL30-3962 + UGAUCU UGGCGU UAUU UCCAAA 22 12316
HSV2-UL30-3963 + GUGAUCU UGGCGUUAUUUCCAAA 23 12317
HSV2-UL30-3964 + GGUGAUCU UGGCGUUAUUUCCAAA 24 12318
HSV2-UL30-3965 + CCGCGGCACAAAACGAAA 18 12319
HSV2-UL30-3966 + GCCGCGGCACAAAACGAAA 19 12320
HSV2-UL30-2428 + GGCCGCGGCACAAAACGAAA 20 5181
HSV2-UL30-3967 + AG G CCG CGG CACAAA ACG A AA 21 12321
HSV2-UL30-3968 + GAGGCCGCGGCACAAAACGAAA 22 12322
HSV2-UL30-3969 + U G AG G CCG CG G CACAAA ACG AAA 23 12323
HSV2-UL30-3970 + GUGAGGCCGCGGCACAAAACGAAA 24 12324
HSV2-UL30-3971 + CGACGGCCUCGGGCCGCA 18 12325
HSV2-UL30-3972 + GCGACGGCCUCGGGCCGCA 19 12326
HSV2-UL30-1262 + CGCGACGGCCUCGGGCCGCA 20 4132
HSV2-UL30-3973 + GCGCGACGGCCUCGGGCCGCA 21 12327
HSV2-UL30-3974 + UGCGCGACGGCCUCGGGCCGCA 22 12328
HSV2-UL30-3975 + GUGCGCGACGGCCUCGGGCCGCA 23 12329
HSV2-UL30-3976 + GGUGCGCGACGGCCUCGGGCCGCA 24 12330
HSV2-UL30-3977 + GACAGGUCGUAGAGCAGA 18 12331
HSV2-UL30-3978 + GGACAGGUCGUAGAGCAGA 19 12332
HSV2-UL30-2551 + UGGACAGGUCGUAGAGCAGA 20 5269
HSV2-UL30-3979 + GUGGACAGGUCGUAGAGCAGA 21 12333
HSV2-UL30-3980 + GGUGGACAGGUCGUAGAGCAGA 22 12334
HSV2-UL30-3981 + UGG UGGACAGGUCGUAGAGCAGA 23 12335
HSV2-UL30-3982 + GUGGUGGACAGGUCGUAGAGCAGA 24
12336
HSV2-UL30-3983 + UGUCAAACUCCAGGACGA 18 12337
HSV2-UL30-3984 + CUGUCAAACUCCAGGACGA 19 12338
HSV2-UL30-1343 + GCUGUCAAACUCCAGGACGA 20 4213
HSV2-UL30-3985 + CGCUGUCAAACUCCAGGACGA 21 12339
HSV2-UL30-3986 + UCGCUGUCAAACUCCAGGACGA 22 12340
HSV2-UL30-3987 + UUCGCUGUCAAACUCCAGGACGA 23 12341
HSV2-UL30-3988 + AUUCGCUGUCAAACUCCAGGACGA 24 12342
HSV2-UL30-3989 + GGAGGUCGCAGGAUCCGA 18 12343
HSV2-UL30-3990 + GGGAGGUCGCAGGAUCCGA 19 12344
HSV2-UL30-2543 + GGGGAGG UCGCAGGAUCCGA 20 5262
HSV2-UL30-3991 + CGGGGAGGUCGCAGGAUCCGA 21 12345
HSV2-UL30-3992 + UCGGGGAGGUCGCAGGAUCCGA 22 12346
HSV2-UL30-3993 + CUCGGGGAGGUCGCAGGAUCCGA 23 12347
HSV2-UL30-3994 + ACUCGGGGAGGUCGCAGGAUCCGA 24 12348
HSV2-UL30-3995 + CUUCCGGGCGU UCCGCGA 18 12349
HSV2-UL30-3996 + UCUUCCGGGCGU UCCGCGA 19 12350
HSV2-UL30-2556 + GUCUUCCGGGCGUUCCGCGA 20 5273
HSV2-UL30-3997 + GGUCU UCCGGGCGU UCCGCGA 21 12351 HSV2-UL30-3998 + AGGUCU UCCGGGCGUUCCGCGA 22 12352
HSV2-UL30-3999 + GAGGUCU UCCGGGCGUUCCGCGA 23 12353
HSV2-UL30-4000 + CGAGGUCUUCCGGGCG UUCCGCGA 24 12354
HSV2-UL30-4001 + UGCGCCCGUACCCGUCGA 18 12355
HSV2-UL30-4002 + AUGCGCCCGUACCCGUCGA 19 12356
HSV2-UL30-2515 + CAUGCGCCCGUACCCGUCGA 20 5243
HSV2-UL30-4003 + UCAUGCGCCCGUACCCGUCGA 21 12357
HSV2-UL30-4004 + U UCA UGCGCCCGUACCCGUCGA 22 12358
HSV2-UL30-4005 + GUUCAUGCGCCCGUACCCGUCGA 23 12359
HSV2-UL30-4006 + CG U U CAUG CGCCCG U ACCCG U CG A 24 12360
HSV2-UL30-4007 + GCGGG ACAUCAGCU UCG A 18 12361
HSV2-UL30-4008 + UGCGGGACAUCAGCU UCGA 19 12362
HSV2-UL30-2879 + AUGCGGG ACAUCAGCU UCGA 20 11233
HSV2-UL30-4009 + AUGCGCAUGGAGUACGGA 18 12363
HSV2-UL30-4010 + GAUGCGCAUGGAGUACGGA 19 12364
HSV2-UL30-2433 + UG AUGCGCAUGGAGUACGGA 20 5184
HSV2-UL30-4011 + AUG AUGCGCAUGGAGUACGGA 21 12365
HSV2-UL30-4012 + GAUG AUGCGCAUGGAGUACGGA 22 12366
HSV2-UL30-4013 + AG AUG AUGCGCAUGGAGUACGGA 23 12367
HSV2-UL30-4014 + UAGAUGAUGCGCAUGGAGUACGGA 24 12368
HSV2-UL30-4015 + GAUCCGGUCCUUGAUGGA 18 12369
HSV2-UL30-4016 + GGAUCCGGUCCU UGAUGGA 19 12370
HSV2-UL30-1159 + GGGAUCCGGUCCUUGAUGGA 20 4029
HSV2-UL30-4017 + CGGGAUCCGGUCCUUGAUGGA 21 12371
HSV2-UL30-4018 + ACGGGAUCCGGUCCUUGAUGGA 22 12372
HSV2-UL30-4019 + UACGGGAUCCGGUCCU UGAUGGA 23 12373
HSV2-UL30-4020 + GUACGGGAUCCGGUCCUUGAUGGA 24 12374
HSV2-UL30-4021 + AAGUCGGCCAGCAGCUGA 18 12375
HSV2-UL30-4022 + AAAG UCGGCCAGCAGCUG A 19 12376
HSV2-UL30-2438 + GAAAGUCGGCCAGCAGCUGA 20 5186
HSV2-UL30-4023 + GGAAAGUCGGCCAGCAGCUGA 21 12377
HSV2-UL30-4024 + CGG AAAG UCGGCCAGCAGCUG A 22 12378
HSV2-UL30-4025 + CCGG AAAG UCGGCCAGCAGCUG A 23 12379
HSV2-UL30-4026 + U CCG G AAAG U CG G CC AG C AG C U G A 24 12380
HSV2-UL30-4027 + UUUCGCACUCGAGCUUGA 18 12381
HSV2-UL30-4028 + UU UUCGCACUCGAGCUUGA 19 12382
HSV2-UL30-2417 + UUU UUCGCACUCGAGCU UGA 20 5176
HSV2-UL30-4029 + UUU UUUCGCACUCGAGCUUGA 21 12383
HSV2-UL30-4030 + GUU UUUUCGCACUCGAGCU UGA 22 12384
HSV2-UL30-4031 + CGUUU UUUCGCACUCGAGCUUGA 23 12385
HSV2-UL30-4032 + ACGU UU UUUCGCACUCGAGCU UGA 24 12386
HSV2-UL30-4033 + AGUAAUAGUCCGUGU UGA 18 12387
HSV2-UL30-4034 + AAGUAAUAGUCCGUGU UGA 19 12388
HSV2-UL30-2352 + GAAGUAAUAGUCCGUGUUGA 20 5133
HSV2-UL30-4035 + AGAAGUAAUAGUCCGUGUUGA 21 12389
HSV2-UL30-4036 + GAGAAGUAAUAGUCCGUGUUGA 22 12390 HSV2-UL30-4037 + CGAGAAGUAAUAGUCCGUGUUGA 23 12391
HSV2-UL30-4038 + GCGAGAAGUAAUAGUCCGUGUUGA 24 12392
HSV2-UL30-4039 + CCGGCCUUGCAUUCGAUA 18 12393
HSV2-UL30-4040 + CCCGGCCUUGCAUUCGAUA 19 12394
HSV2-UL30-2558 + CCCCGGCCUUGCAU UCGAUA 20 5274
HSV2-UL30-4041 + CCCCCGGCCUUGCAU UCGAUA 21 12395
HSV2-UL30-4042 + CCCCCCGGCCUUGCAUUCGAUA 22 12396
HSV2-UL30-4043 + CCCCCCCGGCCUUGCAUUCGAUA 23 12397
HSV2-UL30-4044 + UCCCCCCCGGCCUUGCAUUCGAUA 24 12398
HSV2-UL30-4045 + GGCCGCAGGGAGAGCGUA 18 12399
HSV2-UL30-4046 + GGGCCGCAGGGAGAGCGUA 19 12400
HSV2-UL30-2468 + CGGGCCGCAGGGAGAGCGUA 20 5207
HSV2-UL30-4047 + UCGGGCCGCAGGGAGAGCGUA 21 12401
HSV2-UL30-4048 + CUCGGGCCGCAGGGAGAGCGUA 22 12402
HSV2-UL30-4049 + CCUCGGGCCGCAGGGAGAGCGUA 23 12403
HSV2-UL30-4050 + GCCUCGGGCCGCAGGGAGAGCGUA 24 12404
HSV2-UL30-4051 + CAGGAUCCGAGCGAAAAC 18 12405
HSV2-UL30-4052 + G C AG G A U CCG AG CG A A A AC 19 12406
HSV2-UL30-1359 + CGCAGGAUCCGAGCGAAAAC 20 4229
HSV2-UL30-4053 + UCGCAGGAUCCGAGCGAAAAC 21 12407
HSV2-UL30-4054 + GUCGCAGGAUCCGAGCGAAAAC 22 12408
HSV2-UL30-4055 + GG UCGCAGGAUCCGAGCGAAAAC 23 12409
HSV2-UL30-4056 + AGGUCGCAGGAUCCGAGCGAAAAC 24 12410
HSV2-UL30-4057 + UCCAGGUGCGGCAGAAAC 18 12411
HSV2-UL30-4058 + C U CC AG G U G CG G C AG A A AC 19 12412
HSV2-UL30-2499 + GCUCCAGGUGCGGCAGAAAC 20 5232
HSV2-UL30-4059 + AGCUCCAGGUGCGGCAGAAAC 21 12413
HSV2-UL30-4060 + AAGCUCCAGGUGCGGCAGAAAC 22 12414
HSV2-UL30-4061 + A A AG CU CC AG G UGCGGCAGAAAC 23 12415
HSV2-UL30-4062 + GAAAGCUCCAGGUGCGGCAG A A AC 24 12416
HSV2-UL30-4063 + ACGGGGUCGACGUGAAAC 18 12417
HSV2-UL30-4064 + CACGGGGUCGACGUGAAAC 19 12418
HSV2-UL30-2476 + CCACGGGGUCGACGUGAAAC 20 5213
HSV2-UL30-4065 + ACCACGGGGUCGACGUGAAAC 21 12419
HSV2-UL30-4066 + CACCACGGGG UCGACGUGAAAC 22 12420
HSV2-UL30-4067 + CCACCACGGGGUCGACGUGAAAC 23 12421
HSV2-UL30-4068 + ACCACCACGGGGUCGACGUGAAAC 24 12422
HSV2-UL30-4069 + UUGUACCCGGUCACGAAC 18 12423
HSV2-UL30-4070 + GUUGUACCCGGUCACGAAC 19 12424
HSV2-UL30-2522 + UGUUGUACCCGGUCACGAAC 20 5249
HSV2-UL30-4071 + AUGU UGUACCCGGUCACGAAC 21 12425
HSV2-UL30-4072 + GAUGU UGUACCCGGUCACGAAC 22 12426
HSV2-UL30-4073 + UGAUGUUGUACCCGGUCACGAAC 23 12427
HSV2-UL30-4074 + AUGAUGU UGUACCCGGUCACGAAC 24 12428
HSV2-UL30-4075 + CUGGCCGAUGUCCCACAC 18 12429
HSV2-UL30-4076 + UCUGGCCGAUGUCCCACAC 19 12430 HSV2-UL30-2512 + CUCUGGCCGAUGUCCCACAC 20 5241
HSV2-UL30-4077 + GCUCUGGCCGAUGUCCCACAC 21 12431
HSV2-UL30-4078 + GGCUCUGGCCGAUGUCCCACAC 22 12432
HSV2-UL30-4079 + UGGCUCUGGCCGAUGUCCCACAC 23 12433
HSV2-UL30-4080 + GUGGCUCUGGCCGAUGUCCCACAC 24 12434
HSV2-UL30-4081 + CAU UCGAUAUCGAAGCAC 18 12435
HSV2-UL30-4082 + GCAU UCG AU AUCG AAGCAC 19 12436
HSV2-UL30-2559 + UGCAUUCGAUAUCGAAGCAC 20 5275
HSV2-UL30-4083 + UUGCAUUCGAUAUCGAAGCAC 21 12437
HSV2-UL30-4084 + CUUGCAUUCGAUAUCGAAGCAC 22 12438
HSV2-UL30-4085 + CCUUGCAU UCGAUAUCGAAGCAC 23 12439
HSV2-UL30-4086 + GCCUUGCAUUCGAUAUCGAAGCAC 24 12440
HSV2-UL30-4087 + GUGAACG UUUUUUCGCAC 18 12441
HSV2-UL30-4088 + GGUGAACGUU UUUUCGCAC 19 12442
HSV2-UL30-2416 + UGGUGAACGU UUUU UCGCAC 20 5175
HSV2-UL30-4089 + UUGGUGAACGU UUUU UCGCAC 21 12443
HSV2-UL30-4090 + CU UGGUGAACGU UUUU UCGCAC 22 12444
HSV2-UL30-4091 + GCUUGGUGAACGUUU UUUCGCAC 23 12445
HSV2-UL30-4092 + AGCU UGGUGAACGU UU UUUCGCAC 24 12446
HSV2-UL30-4093 + GCAAGGCGCAGGAGGCAC 18 12447
HSV2-UL30-4094 + CG C A AG G CG C AG G AG G C AC 19 12448
HSV2-UL30-2493 + CCGCAAGGCGCAGGAGGCAC 20 5227
HSV2-UL30-4095 + CCCGCAAGGCGCAGGAGGCAC 21 12449
HSV2-UL30-4096 + GCCCG C A AG GCGCAGGAGGCAC 22 12450
HSV2-UL30-4097 + GGCCCGCAAGGCGCAGGAGGCAC 23 12451
HSV2-UL30-4098 + UGGCCCGCAAGGCGCAGGAGGCAC 24 12452
HSV2-UL30-4099 + ACAGGUCGUAGAGCAGAC 18 12453
HSV2-UL30-4100 + GACAGGUCGUAGAGCAGAC 19 12454
HSV2-UL30-1367 + GGACAGGUCG UAGAGCAGAC 20 4237
HSV2-UL30-4101 + UGG ACAGGUCGUAGAGCAGAC 21 12455
HSV2-UL30-4102 + GUGG ACAGGUCGUAGAGCAGAC 22 12456
HSV2-UL30-4103 + GG UGG ACAGGUCGUAGAGCAGAC 23 12457
HSV2-UL30-4104 + UGGUGGACAGGUCGUAGAGCAGAC 24 12458
HSV2-UL30-4105 + CUGCCGCGUGCCGUAGAC 18 12459
HSV2-UL30-4106 + ACUGCCGCGUGCCGUAGAC 19 12460
HSV2-UL30-2587 + UACUGCCGCGUGCCGUAGAC 20 5296
HSV2-UL30-4107 + GUACUGCCGCGUGCCGUAGAC 21 12461
HSV2-UL30-4108 + AGUACUGCCGCGUGCCGUAGAC 22 12462
HSV2-UL30-4109 + AAG UACUGCCGCGUGCCGUAGAC 23 12463
HSV2-UL30-4110 + AAAGUACUGCCGCGUGCCGUAGAC 24 12464
HSV2-UL30-4111 + GUCAAACUCCAGGACGAC 18 12465
HSV2-UL30-4112 + UGUCAAACUCCAGGACGAC 19 12466
HSV2-UL30-1344 + CUGUCAAACUCCAGGACGAC 20 4214
HSV2-UL30-4113 + GCUGUCAAACUCCAGGACGAC 21 12467
HSV2-UL30-4114 + CGCUGUCAAACUCCAGGACGAC 22 12468
HSV2-UL30-4115 + UCGCUGUCAAACUCCAGGACGAC 23 12469 HSV2-UL30-4116 + UUCGCUGUCAAACUCCAGGACGAC 24 12470
HSV2-UL30-4117 + UUCCGGGCGUUCCGCGAC 18 12471
HSV2-UL30-4118 + CU UCCGGGCGUUCCGCGAC 19 12472
HSV2-UL30-1372 + UCUUCCGGGCGU UCCGCGAC 20 4242
HSV2-UL30-4119 + GUCUUCCGGGCGUUCCGCGAC 21 12473
HSV2-UL30-4120 + GGUCUUCCGGGCGUUCCGCGAC 22 12474
HSV2-UL30-4121 + AGGUCU UCCGGGCGU UCCGCGAC 23 12475
HSV2-UL30-4122 + GAGGUCUUCCGGGCGU UCCGCGAC 24 12476
HSV2-UL30-4123 + GUAAAACAGCAGGUCGAC 18 12477
HSV2-UL30-4124 + CGUAAAACAGCAGGUCGAC 19 12478
HSV2-UL30-2410 + UCGUAAAACAGCAGGUCGAC 20 5170
HSV2-UL30-4125 + GUCG U AAAACAGCAGG U CG AC 21 12479
HSV2-UL30-4126 + CGUCGUAAAACAGCAGGUCGAC 22 12480
HSV2-UL30-4127 + UCGUCGUAAAACAGCAGGUCGAC 23 12481
HSV2-UL30-4128 + AUCG UCGUAAAACAGCAGGUCGAC 24 12482
HSV2-UL30-4129 + CACCACCACGGGGUCGAC 18 12483
HSV2-UL30-4130 + ACACCACCACGGGGUCGAC 19 12484
HSV2-UL30-2475 + AACACCACCACGGGGUCGAC 20 5212
HSV2-UL30-4131 + A A AC ACC ACC ACG GGGUCGAC 21 12485
HSV2-UL30-4132 + CAAACACCACCACGGGGUCGAC 22 12486
HSV2-UL30-4133 + U C A A AC ACC ACC ACG GGGUCGAC 23 12487
HSV2-UL30-4134 + G U C A A AC ACC ACC ACG G G G U CG AC 24 12488
HSV2-UL30-4135 + CGGGACAUCAGCUUCGAC 18 12489
HSV2-UL30-4136 + GCGGG ACAUCAGCU UCG AC 19 12490
HSV2-UL30-2880 + UGCGGGACAUCAGCUUCGAC 20 11234
HSV2-UL30-4137 + GGAGGUGGGGUCGAGGAC 18 12491
HSV2-UL30-4138 + CGGAGGUGGGGUCGAGGAC 19 12492
HSV2-UL30-2482 + CCGGAGGUGGGGUCGAGGAC 20 5217
HSV2-UL30-4139 + CCCGGAGGUGGGGUCGAGGAC 21 12493
HSV2-UL30-4140 + ACCCGGAGGUGGGGUCGAGGAC 22 12494
HSV2-UL30-4141 + AACCCGGAGGUGGGGUCGAGGAC 23 12495
HSV2-UL30-4142 + AAACCCGGAGGUGGGGUCGAGGAC 24 12496
HSV2-UL30-4143 + UGCGCAUGGAGUACGGAC 18 12497
HSV2-UL30-4144 + AUGCGCAUGGAGUACGGAC 19 12498
HSV2-UL30-1218 + GAUGCGCAUGGAGUACGGAC 20 4088
HSV2-UL30-4145 + UGAUGCGCAUGGAGUACGGAC 21 12499
HSV2-UL30-4146 + AUG AUGCGCAUGGAGUACGGAC 22 12500
HSV2-UL30-4147 + G AUG AUGCGCAUGGAGUACGGAC 23 12501
HSV2-UL30-4148 + AGAUGAUGCGCAUGGAGUACGGAC 24 12502
HSV2-UL30-4149 + AGAUCGCUGAGGUGGGAC 18 12503
HSV2-UL30-4150 + GAGAUCGCUGAGGUGGGAC 19 12504
HSV2-UL30-2537 + CG AGAUCGCUGAGGUGGGAC 20 5259
HSV2-UL30-4151 + GCGAGAUCGCUGAGGUGGGAC 21 12505
HSV2-UL30-4152 + GGCG AGAUCGCUGAGGUGGGAC 22 12506
HSV2-UL30-4153 + AGGCG AGAUCGCUGAGGUGGGAC 23 12507
HSV2-UL30-4154 + GAGGCGAGAUCGCUGAGGUGGGAC 24 12508 HSV2-UL30-4155 + GCGCCGAUGGGCGUCUAC 18 12509
HSV2-UL30-4156 + UGCGCCGAUGGGCGUCUAC 19 12510
HSV2-UL30-2402 + AUGCGCCGAUGGGCGUCUAC 20 5164
HSV2-UL30-4157 + GAUGCGCCGAUGGGCGUCUAC 21 12511
HSV2-UL30-4158 + UGAUGCGCCGAUGGGCGUCUAC 22 12512
HSV2-UL30-4159 + GUGAUGCGCCGAUGGGCGUCUAC 23 12513
HSV2-UL30-4160 + GGUGAUGCGCCGAUGGGCGUCUAC 24 12514
HSV2-UL30-4161 + CAGCAGGCUCUCGCGUAC 18 12515
HSV2-UL30-4162 + UCAGCAGGCUCUCGCGUAC 19 12516
HSV2-UL30-2460 + CUCAGCAGGCUCUCGCGUAC 20 5201
HSV2-UL30-4163 + GCUCAGCAGGCUCUCGCGUAC 21 12517
HSV2-UL30-4164 + UGCUCAGCAGGCUCUCGCGUAC 22 12518
HSV2-UL30-4165 + AUGCUCAGCAGGCUCUCGCGUAC 23 12519
HSV2-UL30-4166 + GAUGCUCAGCAGGCUCUCGCGUAC 24 12520
HSV2-UL30-4167 + CCCCGGGCGAUGGCGUAC 18 12521
HSV2-UL30-4168 + GCCCCGGGCGAUGGCGUAC 19 12522
HSV2-UL30-2355 + CGCCCCGGGCGAUGGCG UAC 20 5135
HSV2-UL30-4169 + ACGCCCCGGGCGAUGGCGUAC 21 12523
HSV2-UL30-4170 + AACGCCCCGGGCGAUGGCGUAC 22 12524
HSV2-UL30-4171 + GAACGCCCCGGGCGAUGGCGUAC 23 12525
HSV2-UL30-4172 + GGAACGCCCCGGGCGAUGGCGUAC 24 12526
HSV2-UL30-4173 + CGGGGUCGACGUGAAACC 18 12527
HSV2-UL30-4174 + ACGGGGUCGACGUGAAACC 19 12528
HSV2-UL30-1275 + CACGGGGUCGACGUGAAACC 20 4145
HSV2-UL30-4175 + CCACGGGGUCGACGUGAAACC 21 12529
HSV2-UL30-4176 + ACCACGGGGUCGACGUGAAACC 22 12530
HSV2-UL30-4177 + CACCACGGGGUCGACGUG A A ACC 23 12531
HSV2-UL30-4178 + CCACCACGGGGUCGACGUGAAACC 24 12532
HSV2-UL30-4179 + G CAAAG U CAA ACACCACC 18 12533
HSV2-UL30-4180 + GGCAAAGUCAAACACCACC 19 12534
HSV2-UL30-2473 + U GG CAA AG U CAAAC ACCACC 20 5211
HSV2-UL30-4181 + CUGGCAAAGUCAAACACCACC 21 12535
HSV2-UL30-4182 + G CU GGCAAAG U CA AACACC ACC 22 12536
HSV2-UL30-4183 + G G C U G G C A A AG U C A A AC ACC ACC 23 12537
HSV2-UL30-4184 + AGGCUGGCAAAGU CAA AC ACC ACC 24 12538
HSV2-UL30-4185 + GCCUUCGGGGGUCAGACC 18 12539
HSV2-UL30-4186 + GGCCU UCGGGGGUCAGACC 19 12540
HSV2-UL30-2591 + UGGCCUUCGGGGGUCAGACC 20 5298
HSV2-UL30-4187 + AUGGCCUUCGGGGGUCAGACC 21 12541
HSV2-UL30-4188 + GAUGGCCUUCGGGGGUCAGACC 22 12542
HSV2-UL30-4189 + CG AUGGCCU UCGGGGGUCAGACC 23 12543
HSV2-UL30-4190 + GCGAUGGCCUUCGGGGGUCAGACC 24 12544
HSV2-UL30-4191 + GCGCAUGGAGUACGGACC 18 12545
HSV2-UL30-4192 + UGCGCAUGGAGUACGGACC 19 12546
HSV2-UL30-1219 + AUGCGCAUGGAGUACGGACC 20 4089
HSV2-UL30-4193 + GAUGCGCAUGGAGUACGGACC 21 12547 HSV2-UL30-4194 + UGAUGCGCAUGGAGUACGGACC 22 12548
HSV2-UL30-4195 + AUGAUGCGCAUGGAGUACGGACC 23 12549
HSV2-UL30-4196 + GAUGAUGCGCAUGGAGUACGGACC 24 12550
HSV2-UL30-4197 + CGGGGGCCGGCAGGCCCC 18 12551
HSV2-UL30-4198 + ACGGGGGCCGGCAGGCCCC 19 12552
HSV2-UL30-1349 + GACGGGGGCCGGCAGGCCCC 20 4219
HSV2-UL30-4199 + CG ACGGGGGCCGGCAGGCCCC 21 12553
HSV2-UL30-4200 + ACG ACGGGGGCCGGCAGGCCCC 22 12554
HSV2-UL30-4201 + GACG ACGGGGGCCGGCAGGCCCC 23 12555
HSV2-UL30-4202 + GG ACG ACGGGGGCCGGCAGGCCCC 24 12556
HSV2-UL30-4203 + GGGGGCGGGCUCGUCCCC 18 12557
HSV2-UL30-4204 + GGGGGGCGGGCUCGUCCCC 19 12558
HSV2-UL30-1142 + GGGGGGGCGGGCUCGUCCCC 20 4012
HSV2-UL30-4205 + UGGGGGGGCGGGCUCGUCCCC 21 12559
HSV2-UL30-4206 + CUGGGGGGGCGGGCUCGUCCCC 22 12560
HSV2-UL30-4207 + GCUGGGGGGGCGGGCUCGUCCCC 23 12561
HSV2-UL30-4208 + CGCUGGGGGGGCGGGCUCGUCCCC 24 12562
HSV2-UL30-4209 + CGGCCGCUCCCCUUCCCC 18 12563
HSV2-UL30-4210 + CCGGCCGCUCCCCUUCCCC 19 12564
HSV2-UL30-2483 + CCCGGCCGCUCCCCUUCCCC 20 5218
HSV2-UL30-4211 + CCCCGGCCGCUCCCCU UCCCC 21 12565
HSV2-UL30-4212 + CCCCCGGCCGCUCCCCU UCCCC 22 12566
HSV2-UL30-4213 + UCCCCCGGCCGCUCCCCUUCCCC 23 12567
HSV2-UL30-4214 + GUCCCCCGGCCGCUCCCCUUCCCC 24 12568
HSV2-UL30-4215 + ACGGGGGCCGGCAGGCCC 18 12569
HSV2-UL30-4216 + GACGGGGGCCGGCAGGCCC 19 12570
HSV2-UL30-2531 + CGACGGGGGCCGGCAGGCCC 20 5255
HSV2-UL30-4217 + ACG ACGGGGGCCGGCAGGCCC 21 12571
HSV2-UL30-4218 + GACG ACGGGGGCCGGCAGGCCC 22 12572
HSV2-UL30-4219 + GGACG ACGGGGGCCGGCAGGCCC 23 12573
HSV2-UL30-4220 + AGGACGACGGGGGCCGGCAGGCCC 24 12574
HSV2-UL30-4221 + GCAGGUCGACCAGGGCCC 18 12575
HSV2-UL30-4222 + AGCAGGUCGACCAGGGCCC 19 12576
HSV2-UL30-1198 + C AG CAGGUCGACCAGGGCCC 20 4068
HSV2-UL30-4223 + ACAG CAG G U CG ACCAG G G CCC 21 12577
HSV2-UL30-4224 + AACAGCAGGUCGACCAGGGCCC 22 12578
HSV2-UL30-4225 + AAACAGCAGGUCGACCAGGGCCC 23 12579
HSV2-UL30-4226 + AAAACAGCAGGUCGACCAGGGCCC 24 12580
HSV2-UL30-4227 + GGCUUGGACGCGCCUCCC 18 12581
HSV2-UL30-4228 + GGGCU UGGACGCGCCUCCC 19 12582
HSV2-UL30-1116 + GGGGCUUGGACGCGCCUCCC 20 3986
HSV2-UL30-4229 + CGGGGCUUGGACGCGCCUCCC 21 12583
HSV2-UL30-4230 + GCGGGGCUUGGACGCGCCUCCC 22 12584
HSV2-UL30-4231 + UGCGGGGCUUGGACGCGCCUCCC 23 12585
HSV2-UL30-4232 + UUGCGGGGCU UGGACGCGCCUCCC 24 12586
HSV2-UL30-4233 + CAUGCGACGGCGUCUCCC 18 12587 HSV2-UL30-4234 + GCAUGCGACGGCGUCUCCC 19 12588
HSV2-UL30-1123 + GGCAUGCGACGGCGUCUCCC 20 3993
HSV2-UL30-4235 + CGGCAUGCGACGGCGUCUCCC 21 12589
HSV2-UL30-4236 + UCGGCAUGCGACGGCGUCUCCC 22 12590
HSV2-UL30-4237 + GUCGGCAUGCGACGGCGUCUCCC 23 12591
HSV2-UL30-4238 + GGUCGGCAUGCGACGGCGUCUCCC 24 12592
HSV2-UL30-4239 + CCG AACGCCU GCAG U CCC 18 12593
HSV2-UL30-4240 + CCCGAACGCCUGCAGUCCC 19 12594
HSV2-UL30-2404 + CCCCG AACGCCU GCAG U CCC 20 5166
HSV2-UL30-4241 + GCCCCGAACGCCUGCAGUCCC 21 12595
HSV2-UL30-4242 + GGCCCCGAACGCCUGCAGUCCC 22 12596
HSV2-UL30-4243 + CGGCCCCGAACGCCUGCAGUCCC 23 12597
HSV2-UL30-4244 + ACGGCCCCGAACGCCUGCAGUCCC 24 12598
HSV2-UL30-4245 + GGGGGGCGGGCUCGUCCC 18 12599
HSV2-UL30-4246 + GGGGGGGCGGGCUCGUCCC 19 12600
HSV2-UL30-2380 + UGGGGGGGCGGGCUCG UCCC 20 5146
HSV2-UL30-4247 + CUGGGGGGGCGGGCUCGUCCC 21 12601
HSV2-UL30-4248 + GCUGGGGGGGCGGGCUCGUCCC 22 12602
HSV2-UL30-4249 + CGCUGGGGGGGCGGGCUCGUCCC 23 12603
HSV2-UL30-4250 + CCGCUGGGGGGGCGGGCUCGUCCC 24 12604
HSV2-UL30-4251 + CGUGUUGAGCGGAACGCC 18 12605
HSV2-UL30-4252 + CCGUGUUGAGCGGAACGCC 19 12606
HSV2-UL30-2354 + UCCGUGUUGAGCGGAACGCC 20 5134
HSV2-UL30-4253 + GUCCGUGU UGAGCGGAACGCC 21 12607
HSV2-UL30-4254 + AGUCCGUGUUGAGCGGAACGCC 22 12608
HSV2-UL30-4255 + UAGUCCGUGUUGAGCGGAACGCC 23 12609
HSV2-UL30-4256 + AUAGUCCGUGU UGAGCGGAACGCC 24 12610
HSV2-UL30-4257 + CG CU CCACC ACCU CCG CC 18 12611
HSV2-UL30-4258 + GCGCUCCACCACCUCCGCC 19 12612
HSV2-UL30-2578 + CGCGCUCCACCACCUCCGCC 20 5290
HSV2-UL30-4259 + GCGCGCUCCACCACCUCCGCC 21 12613
HSV2-UL30-4260 + GGCGCGCUCCACCACCUCCGCC 22 12614
HSV2-UL30-4261 + CGGCGCGCUCCACCACCUCCGCC 23 12615
HSV2-UL30-4262 + UCGGCGCGCUCCACCACCUCCGCC 24 12616
HSV2-UL30-4263 + CGCCUCCUUGUCGAGGCC 18 12617
HSV2-UL30-4264 + GCGCCUCCUUG UCGAGGCC 19 12618
HSV2-UL30-2487 + GGCGCCUCCUUGUCGAGGCC 20 5222
HSV2-UL30-4265 + GGGCGCCUCCU UGUCGAGGCC 21 12619
HSV2-UL30-4266 + UGGGCGCCUCCU UGUCGAGGCC 22 12620
HSV2-UL30-4267 + UUGGGCGCCUCCUUGUCGAGGCC 23 12621
HSV2-UL30-4268 + CUUGGGCGCCUCCUUGUCGAGGCC 24 12622
HSV2-UL30-4269 + UCCAGGUGCGCGACGGCC 18 12623
HSV2-UL30-4270 + CUCCAGGUGCGCGACGGCC 19 12624
HSV2-UL30-2463 + CCUCCAGGUGCGCGACGGCC 20 5204
HSV2-UL30-4271 + GCCUCCAGGUGCGCGACGGCC 21 12625
HSV2-UL30-4272 + CGCCUCCAGGUGCGCGACGGCC 22 12626 HSV2-UL30-4273 + CCGCCUCCAGGUGCGCGACGGCC 23 12627
HSV2-UL30-4274 + UCCGCCUCCAGGUGCGCGACGGCC 24 12628
HSV2-UL30-4275 + GCGUCUACGAGGACGGCC 18 12629
HSV2-UL30-4276 + GGCGUCUACGAGGACGGCC 19 12630
HSV2-UL30-2403 + GGGCGUCUACGAGGACGGCC 20 5165
HSV2-UL30-4277 + UGGGCGUCUACGAGGACGGCC 21 12631
HSV2-UL30-4278 + AUGGGCGUCUACGAGGACGGCC 22 12632
HSV2-UL30-4279 + GAUGGGCGUCUACGAGGACGGCC 23 12633
HSV2-UL30-4280 + CGAUGGGCGUCUACGAGGACGGCC 24 12634
HSV2-UL30-4281 + GGCCCGAACCCCGCGGCC 18 12635
HSV2-UL30-4282 + CGGCCCGAACCCCGCGGCC 19 12636
HSV2-UL30-2339 + CCGGCCCGAACCCCGCGGCC 20 5125
HSV2-UL30-4283 + GCCGGCCCGAACCCCGCGGCC 21 12637
HSV2-UL30-4284 + CGCCGGCCCGAACCCCGCGGCC 22 12638
HSV2-UL30-4285 + CCGCCGGCCCGAACCCCGCGGCC 23 12639
HSV2-UL30-4286 + CCCGCCGGCCCGAACCCCGCGGCC 24 12640
HSV2-UL30-4287 + GCCACCAGGCCCGCGGCC 18 12641
HSV2-UL30-4288 + GGCCACCAGGCCCGCGGCC 19 12642
HSV2-UL30-2426 + UGGCCACCAGGCCCGCGGCC 20 5179
HSV2-UL30-4289 + AUGGCCACCAGGCCCGCGGCC 21 12643
HSV2-UL30-4290 + CAUGGCCACCAGGCCCGCGGCC 22 12644
HSV2-UL30-4291 + CCAUGGCCACCAGGCCCGCGGCC 23 12645
HSV2-UL30-4292 + CCCAUGGCCACCAGGCCCGCGGCC 24 12646
HSV2-UL30-4293 + UUAU UUCCAAACAGGGCC 18 12647
HSV2-UL30-4294 + G U U AU U U CC AAAC AG G G CC 19 12648
HSV2-UL30-2348 + CG UUAUUUCCAAACAGGGCC 20 5129
HSV2-UL30-4295 + GCGUUAUUUCCAAACAGGGCC 21 12649
HSV2-UL30-4296 + GGCGUUAUUU CCA A AC AG G G CC 22 12650
HSV2-UL30-4297 + UGGCGUUAUUUCCAAACAGGGCC 23 12651
HSV2-UL30-4298 + UUGGCGUUAUU UCCAAACAGGGCC 24 12652
HSV2-UL30-4299 + AGCAGGUCGACCAGGGCC 18 12653
HSV2-UL30-4300 + CAGCAGGUCGACCAGGGCC 19 12654
HSV2-UL30-2411 + ACAGCAGGUCGACCAGGGCC 20 5171
HSV2-UL30-4301 + AACAGCAGGUCGACCAGGGCC 21 12655
HSV2-UL30-4302 + AAACAGCAGGUCGACCAGGGCC 22 12656
HSV2-UL30-4303 + A A A AC AG CAGGUCGACCAGGGCC 23 12657
HSV2-UL30-4304 + UAAAACAGCAGGUCGACCAGGGCC 24 12658
HSV2-UL30-4305 + CCCCGCGCUGCGCGGGCC 18 12659
HSV2-UL30-4306 + ACCCCGCGCUGCGCGGGCC 19 12660
HSV2-UL30-1314 + CACCCCGCGCUGCGCGGGCC 20 4184
HSV2-UL30-4307 + UCACCCCGCGCUGCGCGGGCC 21 12661
HSV2-UL30-4308 + AUCACCCCGCGCUGCGCGGGCC 22 12662
HSV2-UL30-4309 + GAUCACCCCGCGCUGCGCGGGCC 23 12663
HSV2-UL30-4310 + CGAUCACCCCGCGCUGCGCGGGCC 24 12664
HSV2-UL30-4311 + ACCUGCGCGCGGCGGGCC 18 12665
HSV2-UL30-4312 + GACCUGCGCGCGGCGGGCC 19 12666 HSV2-UL30-2393 + GGACCUGCGCGCGGCGGGCC 20 5155
HSV2-UL30-4313 + GGGACCUGCGCGCGGCGGGCC 21 12667
HSV2-UL30-4314 + CGGGACCUGCGCGCGGCGGGCC 22 12668
HSV2-UL30-4315 + ACGGGACCUGCGCGCGGCGGGCC 23 12669
HSV2-UL30-4316 + GACGGGACCUGCGCGCGGCGGGCC 24 12670
HSV2-UL30-4317 + UCCCGGGGGCGCU UGGCC 18 12671
HSV2-UL30-4318 + CUCCCGGGGGCGCUUGGCC 19 12672
HSV2-UL30-1128 + UCUCCCGGGGGCGCU UGGCC 20 3998
HSV2-UL30-4319 + GUCUCCCGGGGGCGCU UGGCC 21 12673
HSV2-UL30-4320 + CGUCUCCCGGGGGCGCU UGGCC 22 12674
HSV2-UL30-4321 + GCGUCUCCCGGGGGCGCUUGGCC 23 12675
HSV2-UL30-4322 + GGCGUCUCCCGGGGGCGCUUGGCC 24 12676
HSV2-UL30-4323 + GUGGUCCGCGGAGAUGCC 18 12677
HSV2-UL30-4324 + AGUGGUCCGCGGAGAUGCC 19 12678
HSV2-UL30-2581 + AAGUGGUCCGCGGAGAUGCC 20 5292
HSV2-UL30-4325 + GAAGUGGUCCGCGGAGAUGCC 21 12679
HSV2-UL30-4326 + CGAAGUGGUCCGCGGAGAUGCC 22 12680
HSV2-UL30-4327 + UCGAAGUGGUCCGCGGAGAUGCC 23 12681
HSV2-UL30-4328 + CUCGAAGUGGUCCGCGGAGAUGCC 24 12682
HSV2-UL30-4329 + GGGUGCUCUGGGGGAUCC 18 12683
HSV2-UL30-4330 + GGGGUGCUCUGGGGGAUCC 19 12684
HSV2-UL30-2457 + GGGGGUGCUCUGGGGGAUCC 20 5198
HSV2-UL30-4331 + CGGGGGUGCUCUGGGGGAUCC 21 12685
HSV2-UL30-4332 + UCGGGGGUGCUCUGGGGGAUCC 22 12686
HSV2-UL30-4333 + CUCGGGGGUGCUCUGGGGGAUCC 23 12687
HSV2-UL30-4334 + CCUCGGGGGUGCUCUGGGGGAUCC 24 12688
HSV2-UL30-4335 + GGGCUUGGACGCGCCUCC 18 12689
HSV2-UL30-4336 + GGGGCUUGGACGCGCCUCC 19 12690
HSV2-UL30-1115 + CGGGGCUUGGACGCGCCUCC 20 3985
HSV2-UL30-4337 + GCGGGGCUUGGACGCGCCUCC 21 12691
HSV2-UL30-4338 + UGCGGGGCUUGGACGCGCCUCC 22 12692
HSV2-UL30-4339 + UUGCGGGGCUUGGACGCGCCUCC 23 12693
HSV2-UL30-4340 + CU UGCGGGGCUUGGACGCGCCUCC 24 12694
HSV2-UL30-4341 + UCGAGGAGGACGGCCUCC 18 12695
HSV2-UL30-4342 + GUCGAGGAGGACGGCCUCC 19 12696
HSV2-UL30-2450 + UG UCGAGGAGGACGGCCUCC 20 5196
HSV2-UL30-4343 + U UGUCGAGGAGGACGGCCUCC 21 12697
HSV2-UL30-4344 + CUUGUCGAGGAGGACGGCCUCC 22 12698
HSV2-UL30-4345 + GCU UG UCGAGGAGGACGGCCUCC 23 12699
HSV2-UL30-4346 + UGCUUGUCGAGGAGGACGGCCUCC 24 12700
HSV2-UL30-4347 + GCAUGCGACGGCGUCUCC 18 12701
HSV2-UL30-4348 + GGCAUGCGACGGCGUCUCC 19 12702
HSV2-UL30-1122 + CGGCAUGCGACGGCGUCUCC 20 3992
HSV2-UL30-4349 + UCGGCAUGCGACGGCGUCUCC 21 12703
HSV2-UL30-4350 + GUCGGCAUGCGACGGCG UCUCC 22 12704
HSV2-UL30-4351 + GGUCGGCAUGCGACGGCGUCUCC 23 12705 HSV2-UL30-4352 + GGGUCGGCAUGCGACGGCGUCUCC 24 12706
HSV2-UL30-4353 + CGCGCGGCCACGUCGUCC 18 12707
HSV2-UL30-4354 + CCGCGCGGCCACGUCGUCC 19 12708
HSV2-UL30-1092 + GCCGCGCGGCCACGUCGUCC 20 3962
HSV2-UL30-4355 + AGCCGCGCGGCCACGUCGUCC 21 12709
HSV2-UL30-4356 + GAGCCGCGCGGCCACGUCGUCC 22 12710
HSV2-UL30-4357 + UGAGCCGCGCGGCCACGUCGUCC 23 12711
HSV2-UL30-4358 + CUGAGCCGCGCGGCCACGUCGUCC 24 12712
HSV2-UL30-4359 + UCCGCCUCGAAGUGGUCC 18 12713
HSV2-UL30-4360 + CUCCGCCUCGAAGUGGUCC 19 12714
HSV2-UL30-2579 + CCUCCGCCUCGAAGUGG UCC 20 5291
HSV2-UL30-4361 + ACCUCCGCCUCGAAGUGGUCC 21 12715
HSV2-UL30-4362 + CACCUCCGCCUCGAAGUGGUCC 22 12716
HSV2-UL30-4363 + CCACCUCCGCCUCGAAGUGGUCC 23 12717
HSV2-UL30-4364 + ACCACCUCCGCCUCGAAGUGGUCC 24 12718
HSV2-UL30-4365 + CCGGGAUCCUCCGCCAGC 18 12719
HSV2-UL30-4366 + CCCGGGAUCCUCCGCCAGC 19 12720
HSV2-UL30-2357 + ACCCGGGAUCCUCCGCCAGC 20 5136
HSV2-UL30-4367 + UACCCGGGAUCCUCCGCCAGC 21 12721
HSV2-UL30-4368 + GUACCCGGGAUCCUCCGCCAGC 22 12722
HSV2-UL30-4369 + CGUACCCGGGAUCCUCCGCCAGC 23 12723
HSV2-UL30-4370 + GCGUACCCGGGAUCCUCCGCCAGC 24 12724
HSV2-UL30-4371 + CGGCGUUCAGCUUGUAGC 18 12725
HSV2-UL30-4372 + ACGGCGUUCAGCUUGUAGC 19 12726
HSV2-UL30-1324 + GACGGCGUUCAGCUUGUAGC 20 4194
HSV2-UL30-4373 + CGACGGCGUUCAGCU UGUAGC 21 12727
HSV2-UL30-4374 + GCGACGGCGU UCAGCUUGUAGC 22 12728
HSV2-UL30-4375 + GGCGACGGCGU UCAGCUUGUAGC 23 12729
HSV2-UL30-4376 + CGGCGACGGCGUUCAGCU UGUAGC 24 12730
HSV2-UL30-4377 + CGGGGAGGGCAGGGCCGC 18 12731
HSV2-UL30-4378 + CCGGGGAGGGCAGGGCCGC 19 12732
HSV2-UL30-1134 + GCCGGGGAGGGCAGGGCCGC 20 4004
HSV2-UL30-4379 + GGCCGGGGAGGGCAGGGCCGC 21 12733
HSV2-UL30-4380 + UGGCCGGGGAGGGCAGGGCCGC 22 12734
HSV2-UL30-4381 + UUGGCCGGGGAGGGCAGGGCCGC 23 12735
HSV2-UL30-4382 + CUUGGCCGGGGAGGGCAGGGCCGC 24 12736
HSV2-UL30-4383 + GCGACGGCCUCGGGCCGC 18 12737
HSV2-UL30-4384 + CGCGACGGCCUCGGGCCGC 19 12738
HSV2-UL30-1261 + GCGCGACGGCCUCGGGCCGC 20 4131
HSV2-UL30-4385 + UGCGCGACGGCCUCGGGCCGC 21 12739
HSV2-UL30-4386 + GUGCGCGACGGCCUCGGGCCGC 22 12740
HSV2-UL30-4387 + GG UGCGCGACGGCCUCGGGCCGC 23 12741
HSV2-UL30-4388 + AGGUGCGCGACGGCCUCGGGCCGC 24 12742
HSV2-UL30-4389 + GGGGGAGGAACAGCGCGC 18 12743
HSV2-UL30-4390 + GGGGGGAGGAACAGCGCGC 19 12744
HSV2-UL30-2425 + CGGGGGGAGGAACAGCGCGC 20 5178 HSV2-UL30-4391 + UCGGGGGGAGGAACAGCGCGC 21 12745
HSV2-UL30-4392 + AUCGGGGGGAGGAACAGCGCGC 22 12746
HSV2-UL30-4393 + GAUCGGGGGGAGGAACAGCGCGC 23 12747
HSV2-UL30-4394 + UGAUCGGGGGGAGGAACAGCGCGC 24 12748
HSV2-UL30-4395 + UUCUGGCCCGCAAGGCGC 18 12749
HSV2-UL30-4396 + CUUCUGGCCCGCAAGGCGC 19 12750
HSV2-UL30-1300 + CCUUCUGGCCCGCAAGGCGC 20 4170
HSV2-UL30-4397 + CCCUUCUGGCCCGCAAGGCGC 21 12751
HSV2-UL30-4398 + GCCCU UCUGGCCCGCAAGGCGC 22 12752
HSV2-UL30-4399 + AGCCCUUCUGGCCCGCAAGGCGC 23 12753
HSV2-UL30-4400 + AAGCCCUUCUGGCCCGCAAGGCGC 24 12754
HSV2-UL30-4401 + CGAGGCACGGCCGGGCGC 18 12755
HSV2-UL30-4402 + CCGAGGCACGGCCGGGCGC 19 12756
HSV2-UL30-2485 + CCCGAGGCACGGCCGGGCGC 20 5220
HSV2-UL30-4403 + CCCCGAGGCACGGCCGGGCGC 21 12757
HSV2-UL30-4404 + CCCCCGAGGCACGGCCGGGCGC 22 12758
HSV2-UL30-4405 + CCCCCCGAGGCACGGCCGGGCGC 23 12759
HSV2-UL30-4406 + UCCCCCCGAGGCACGGCCGGGCGC 24 12760
HSV2-UL30-4407 + UCCCCGUAGAUGAUGCGC 18 12761
HSV2-UL30-4408 + GUCCCCGUAGAUGAUGCGC 19 12762
HSV2-UL30-2430 + UGUCCCCGUAGAUGAUGCGC 20 5182
HSV2-UL30-4409 + GUGUCCCCGUAGAUGAUGCGC 21 12763
HSV2-UL30-4410 + CGUGUCCCCGUAGAUGAUGCGC 22 12764
HSV2-UL30-4411 + CCGUGUCCCCGUAGAUGAUGCGC 23 12765
HSV2-UL30-4412 + UCCGUGUCCCCGUAGAUGAUGCGC 24 12766
HSV2-UL30-4413 + GGCGCUCGCAGAGAUCGC 18 12767
HSV2-UL30-4414 + AGGCGCUCGCAGAGAUCGC 19 12768
HSV2-UL30-2585 + CAGGCGCUCGCAGAGAUCGC 20 5295
HSV2-UL30-4415 + CCAGGCGCUCGCAGAGAUCGC 21 12769
HSV2-UL30-4416 + GCCAGGCGCUCGCAGAGAUCGC 22 12770
HSV2-UL30-4417 + CG CCAG G CG CU CG CAG AG AU CG C 23 12771
HSV2-UL30-4418 + CCGCCAGGCGCUCGCAGAGAUCGC 24 12772
HSV2-UL30-4419 + AGUUAAACUCGACGUCGC 18 12773
HSV2-UL30-4420 + CAGU UAAACUCGACGUCGC 19 12774
HSV2-UL30-2560 + GCAGUUAAACUCGACGUCGC 20 5276
HSV2-UL30-4421 + UGCAGUUAAACUCGACGUCGC 21 12775
HSV2-UL30-4422 + GUGCAGU UAAACUCGACGUCGC 22 12776
HSV2-UL30-4423 + CGUGCAGUUAAACUCGACGUCGC 23 12777
HSV2-UL30-4424 + CCGUGCAGUUAAACUCGACGUCGC 24 12778
HSV2-UL30-4425 + CACGUACGCGCGCGUCGC 18 12779
HSV2-UL30-4426 + GCACGUACGCGCGCGUCGC 19 12780
HSV2-UL30-2440 + UGCACGUACGCGCGCGUCGC 20 5188
HSV2-UL30-4427 + GUGCACGUACGCGCGCGUCGC 21 12781
HSV2-UL30-4428 + CGUGCACGUACGCGCGCGUCGC 22 12782
HSV2-UL30-4429 + GCGUGCACGUACGCGCGCGUCGC 23 12783
HSV2-UL30-4430 + CGCGUGCACGUACGCGCGCGUCGC 24 12784 HSV2-UL30-4431 + AGCGCGCGCCCGCUUCGC 18 12785
HSV2-UL30-4432 + CAGCGCGCGCCCGCU UCGC 19 12786
HSV2-UL30-2575 + CCAGCGCGCGCCCGCUUCGC 20 5287
HSV2-UL30-4433 + GCC AGCGCGCGCCCGCUUCGC 21 12787
HSV2-UL30-4434 + GGCCAGCGCGCGCCCGCUUCGC 22 12788
HSV2-UL30-4435 + AGGCCAGCGCGCGCCCGCUUCGC 23 12789
HSV2-UL30-4436 + UAGGCCAGCGCGCGCCCGCUUCGC 24 12790
HSV2-UL30-4437 + GCGCCGGCCCCCGCCGGC 18 12791
HSV2-UL30-4438 + AGCGCCGGCCCCCGCCGGC 19 12792
HSV2-UL30-2338 + UAGCGCCGGCCCCCGCCGGC 20 5124
HSV2-UL30-4439 + GUAGCGCCGGCCCCCGCCGGC 21 12793
HSV2-UL30-4440 + CGUAGCGCCGGCCCCCGCCGGC 22 12794
HSV2-UL30-4441 + CCGUAGCGCCGGCCCCCGCCGGC 23 12795
HSV2-UL30-4442 + GCCGUAGCGCCGGCCCCCGCCGGC 24 12796
HSV2-UL30-4443 + GCGUUCCCGCGGCCGGGC 18 12797
HSV2-UL30-4444 + CGCGU UCCCGCGGCCGGGC 19 12798
HSV2-UL30-2568 + GCGCGUUCCCGCGGCCGGGC 20 5281
HSV2-UL30-4445 + GGCGCGUUCCCGCGGCCGGGC 21 12799
HSV2-UL30-4446 + CGGCGCGU UCCCGCGGCCGGGC 22 12800
HSV2-UL30-4447 + CCGGCGCGUUCCCGCGGCCGGGC 23 12801
HSV2-UL30-4448 + GCCGGCGCGUUCCCGCGGCCGGGC 24 12802
HSV2-UL30-4449 + ACCCCGCGCUGCGCGGGC 18 12803
HSV2-UL30-4450 + CACCCCGCGCUGCGCGGGC 19 12804
HSV2-UL30-2503 + UCACCCCGCGCUGCGCGGGC 20 5236
HSV2-UL30-4451 + AUCACCCCGCGCUGCGCGGGC 21 12805
HSV2-UL30-4452 + GAUCACCCCGCGCUGCGCGGGC 22 12806
HSV2-UL30-4453 + CGAUCACCCCGCGCUGCGCGGGC 23 12807
HSV2-UL30-4454 + CCGAUCACCCCGCGCUGCGCGGGC 24 12808
HSV2-UL30-4455 + ACCAGCAGCU UGCGGGGC 18 12809
HSV2-UL30-4456 + CACCAGCAGCU UGCGGGGC 19 12810
HSV2-UL30-2360 + ACACCAGCAGCU UGCGGGGC 20 5138
HSV2-UL30-4457 + G ACACCAGCAGCU UGCGGGGC 21 12811
HSV2-UL30-4458 + GGACACCAGCAGCU UGCGGGGC 22 12812
HSV2-UL30-4459 + CGGACACCAGCAGCUUGCGGGGC 23 12813
HSV2-UL30-4460 + UCGG ACACCAGCAGCU UGCGGGGC 24 12814
HSV2-UL30-4461 + CUCCCGGGGGCGCUUGGC 18 12815
HSV2-UL30-4462 + UCUCCCGGGGGCGCUUGGC 19 12816
HSV2-UL30-1127 + GUCUCCCGGGGGCGCUUGGC 20 3997
HSV2-UL30-4463 + CGUCUCCCGGGGGCGCU UGGC 21 12817
HSV2-UL30-4464 + GCGUCUCCCGGGGGCGCUUGGC 22 12818
HSV2-UL30-4465 + GGCGUCUCCCGGGGGCGCUUGGC 23 12819
HSV2-UL30-4466 + CGGCGUCUCCCGGGGGCGCUUGGC 24 12820
HSV2-UL30-4467 + CCGAUCACCCCGCGCUGC 18 12821
HSV2-UL30-4468 + GCCGAUCACCCCGCGCUGC 19 12822
HSV2-UL30-2502 + CG CCG AU CACCCCGCG C U G C 20 5235
HSV2-UL30-4469 + UCGCCGAUCACCCCGCGCUGC 21 12823 HSV2-UL30-4470 + CUCGCCGAUCACCCCGCGCUGC 22 12824
HSV2-UL30-4471 + ACUCGCCGAUCACCCCGCGCUGC 23 12825
HSV2-UL30-4472 + UACUCGCCGAUCACCCCGCGCUGC 24 12826
HSV2-UL30-4473 + G CCG CCCCCAG C AG G U G C 18 12827
HSV2-UL30-4474 + GGCCGCCCCCAGCAGGUGC 19 12828
HSV2-UL30-2350 + AGGCCGCCCCCAGCAGG UGC 20 5131
HSV2-UL30-4475 + CAGGCCGCCCCCAGCAGGUGC 21 12829
HSV2-UL30-4476 + GCAGGCCGCCCCCAGCAGGUGC 22 12830
HSV2-UL30-4477 + CGCAGGCCGCCCCCAGCAGGUGC 23 12831
HSV2-UL30-4478 + ACGCAGGCCGCCCCCAGCAGGUGC 24 12832
HSV2-UL30-4479 + GAAAACAGGAGGAUGUGC 18 12833
HSV2-UL30-4480 + CGAAAACAGGAGGAUGUGC 19 12834
HSV2-UL30-2547 + GCGAAAACAGGAGGAUGUGC 20 5265
HSV2-UL30-4481 + AGCGAAAACAGGAGGAUGUGC 21 12835
HSV2-UL30-4482 + GAGCGAAAACAGGAGGAUGUGC 22 12836
HSV2-UL30-4483 + CGAGCGAAAACAGGAGGAUGUGC 23 12837
HSV2-UL30-4484 + CCGAGCGAAAACAGGAGGAUGUGC 24 12838
HSV2-UL30-4485 + CCCUCGUACU UCCUGAUC 18 12839
HSV2-UL30-4486 + CCCCUCGUACU UCCUGAUC 19 12840
HSV2-UL30-2573 + CCCCCUCGUACU UCCUGAUC 20 5286
HSV2-UL30-4487 + CCCCCCUCGUACUUCCUGAUC 21 12841
HSV2-UL30-4488 + GCCCCCCUCGUACUUCCUGAUC 22 12842
HSV2-UL30-4489 + CGCCCCCCUCGUACU UCCUGAUC 23 12843
HSV2-UL30-4490 + ACGCCCCCCUCGUACUUCCUGAUC 24 12844
HSV2-UL30-4491 + UCGCACUCGAGCUUGAUC 18 12845
HSV2-UL30-4492 + UUCGCACUCGAGCU UGAUC 19 12846
HSV2-UL30-1204 + UUUCGCACUCGAGCU UGAUC 20 4074
HSV2-UL30-4493 + UUUUCGCACUCGAGCUUGAUC 21 12847
HSV2-UL30-4494 + UUU UUCGCACUCGAGCUUGAUC 22 12848
HSV2-UL30-4495 + U UUUUUCGCACUCGAGCUUGAUC 23 12849
HSV2-UL30-4496 + GU UUUUUCGCACUCGAGCUUGAUC 24 12850
HSV2-UL30-4497 + GAAUUCGCUGUCAAACUC 18 12851
HSV2-UL30-4498 + CGAAUUCGCUGUCAAACUC 19 12852
HSV2-UL30-2527 + UCGAAU UCGCUGUCAAACUC 20 5253
HSV2-UL30-4499 + CUCGAAU UCGCUGUCAAACUC 21 12853
HSV2-UL30-4500 + UCUCGAAUUCGCUGUCAAACUC 22 12854
HSV2-UL30-4501 + AUCUCGAAUUCGCUGUCAAACUC 23 12855
HSV2-UL30-4502 + CAUCUCGAAU UCGCUGUCAAACUC 24 12856
HSV2-UL30-4503 + AUCGCUGAGGUGGGACUC 18 12857
HSV2-UL30-4504 + GAUCGCUGAGGUGGGACUC 19 12858
HSV2-UL30-1355 + AG AUCGCUGAGGUGGGACUC 20 4225
HSV2-UL30-4505 + GAG AUCGCUGAGGUGGGACUC 21 12859
HSV2-UL30-4506 + CG AG AUCGCUGAGGUGGGACUC 22 12860
HSV2-UL30-4507 + GCG AG AUCGCUGAGGUGGGACUC 23 12861
HSV2-UL30-4508 + GGCGAGAUCGCUGAGG UGGGACUC 24 12862
HSV2-UL30-4509 + GCGCAUGCCGGCCGCCUC 18 12863 HSV2-UL30-4510 + CGCGCAUGCCGGCCGCCUC 19 12864
HSV2-UL30-1223 + GCGCGCAUGCCGGCCGCCUC 20 4093
HSV2-UL30-4511 + GGCGCGCAUGCCGGCCGCCUC 21 12865
HSV2-UL30-4512 + GGGCGCGCAUGCCGGCCGCCUC 22 12866
HSV2-UL30-4513 + GGGGCGCGCAUGCCGGCCGCCUC 23 12867
HSV2-UL30-4514 + GGGGGCGCGCAUGCCGGCCGCCUC 24 12868
HSV2-UL30-4515 + GGGGCU UGGACGCGCCUC 18 12869
HSV2-UL30-4516 + CGGGGCUUGGACGCGCCUC 19 12870
HSV2-UL30-2361 + GCGGGGCUUGGACGCGCCUC 20 5139
HSV2-UL30-4517 + UGCGGGGCUUGGACGCGCCUC 21 12871
HSV2-UL30-4518 + U UGCGGGGCU UGGACGCGCCUC 22 12872
HSV2-UL30-4519 + CUUGCGGGGCUUGGACGCGCCUC 23 12873
HSV2-UL30-4520 + GCUUGCGGGGCU UGGACGCGCCUC 24 12874
HSV2-UL30-4521 + GGCGGCGGCGUCUAGCUC 18 12875
HSV2-UL30-4522 + GGGCGGCGGCGUCUAGCUC 19 12876
HSV2-UL30-2382 + GGGGCGGCGGCGUCUAGCUC 20 5147
HSV2-UL30-4523 + UGGGGCGGCGGCGUCUAGCUC 21 12877
HSV2-UL30-4524 + CUGGGGCGGCGGCGUCUAGCUC 22 12878
HSV2-UL30-4525 + CCUGGGGCGGCGGCGUCUAGCUC 23 12879
HSV2-UL30-4526 + CCCUGGGGCGGCGGCGUCUAGCUC 24 12880
HSV2-UL30-3064 + GGCGUCCAUAAAUCGCUC 18 11418
HSV2-UL30-3065 + UGGCGUCCAUAAAUCGCUC 19 11419
HSV2-UL30-2593 + AUGGCGUCCAUAAAUCGCUC 20 5300
HSV2-UL30-4527 + GAUGGCGUCCAUAAAUCGCUC 21 12881
HSV2-UL30-4528 + UGAUGGCGUCCAUAAAUCGCUC 22 12882
HSV2-UL30-4529 + GUGAUGGCGUCCAUAAAUCGCUC 23 12883
HSV2-UL30-4530 + CGUGAUGGCGUCCAUAAAUCGCUC 24 12884
HSV2-UL30-4531 + GCCUCCUCGGGGGUGCUC 18 12885
HSV2-UL30-4532 + GGCCUCCUCGGGGGUGCUC 19 12886
HSV2-UL30-1244 + CGGCCUCCUCGGGGGUGCUC 20 4114
HSV2-UL30-4533 + ACGGCCUCCUCGGGGGUGCUC 21 12887
HSV2-UL30-4534 + GACGGCCUCCUCGGGGGUGCUC 22 12888
HSV2-UL30-4535 + GGACGGCCUCCUCGGGGGUGCUC 23 12889
HSV2-UL30-4536 + AGGACGGCCUCCUCGGGGGUGCUC 24 12890
HSV2-UL30-4537 + AAACAGGAGGAUGUGCUC 18 12891
HSV2-UL30-4538 + AAAACAGGAGGAUGUGCUC 19 12892
HSV2-UL30-2548 + GAAAACAGGAGGAUGUGCUC 20 5266
HSV2-UL30-4539 + CG AAAACAGG AGG AUG UGCUC 21 12893
HSV2-UL30-4540 + GCG AAAACAGGAGGAUGUGCUC 22 12894
HSV2-UL30-4541 + AGCG AAAACAGGAGGAUGUGCUC 23 12895
HSV2-UL30-4542 + GAGCGAAAACAGGAGGAUGUGCUC 24 12896
HSV2-UL30-4543 + GGCAUGCGACGGCGUCUC 18 12897
HSV2-UL30-4544 + CGGCAUGCGACGGCGUCUC 19 12898
HSV2-UL30-2365 + UCGGCAUGCGACGGCGUCUC 20 5140
HSV2-UL30-4545 + GUCGGCAUGCGACGGCGUCUC 21 12899
HSV2-UL30-4546 + GGUCGGCAUGCGACGGCGUCUC 22 12900 HSV2-UL30-4547 + GGGUCGGCAUGCGACGGCGUCUC 23 12901
HSV2-UL30-4548 + GGGGUCGGCAUGCGACGGCGUCUC 24 12902
HSV2-UL30-4549 + UCCGGGGGGUGCCACGUC 18 12903
HSV2-UL30-4550 + GUCCGGGGGGUGCCACGUC 19 12904
HSV2-UL30-2344 + CGUCCGGGGGGUGCCACGUC 20 5127
HSV2-UL30-4551 + UCGUCCGGGGGGUGCCACGUC 21 12905
HSV2-UL30-4552 + GUCGUCCGGGGGGUGCCACGUC 22 12906
HSV2-UL30-4553 + CGUCGUCCGGGGGGUGCCACGUC 23 12907
HSV2-UL30-4554 + ACGUCGUCCGGGGGGUGCCACGUC 24 12908
HSV2-UL30-4555 + G AGG U U CCGAACG CCG U C 18 12909
HSV2-UL30-4556 + CGAGGUUCCGAACGCCGUC 19 12910
HSV2-UL30-1383 + UCGAGGUUCCGAACGCCGUC 20 4253
HSV2-UL30-4557 + CUCGAGGUUCCGAACGCCGUC 21 12911
HSV2-UL30-4558 + GCUCGAGGUUCCGAACGCCGUC 22 12912
HSV2-UL30-4559 + CGCUCGAGGUUCCGAACGCCGUC 23 12913
HSV2-UL30-4560 + UCGCUCGAGGU UCCGAACGCCGUC 24 12914
HSV2-UL30-4561 + UGCACGUACGCGCGCGUC 18 12915
HSV2-UL30-4562 + GUGCACGUACGCGCGCGUC 19 12916
HSV2-UL30-2439 + CGUGCACGUACGCGCGCGUC 20 5187
HSV2-UL30-4563 + GCGUGCACGUACGCGCGCGUC 21 12917
HSV2-UL30-4564 + CGCGUGCACGUACGCGCGCGUC 22 12918
HSV2-UL30-4565 + GCGCGUGCACGUACGCGCGCGUC 23 12919
HSV2-UL30-4566 + CGCGCGUGCACGUACGCGCGCGUC 24 12920
HSV2-UL30-4567 + CCGCGCGGCCACGUCGUC 18 12921
HSV2-UL30-4568 + GCCGCGCGGCCACGUCGUC 19 12922
HSV2-UL30-1091 + AGCCGCGCGGCCACGUCGUC 20 3961
HSV2-UL30-4569 + GAGCCGCGCGGCCACGUCGUC 21 12923
HSV2-UL30-4570 + UGAGCCGCGCGGCCACGUCGUC 22 12924
HSV2-UL30-4571 + CUGAGCCGCGCGGCCACGUCGUC 23 12925
HSV2-UL30-4572 + CCUGAGCCGCGCGGCCACGUCGUC 24 12926
HSV2-UL30-4573 + UACUGCUUGACGAAGGUC 18 12927
HSV2-UL30-4574 + GUACUGCU UGACGAAGGUC 19 12928
HSV2-UL30-2525 + CGUACUGCU UGACGAAGGUC 20 5251
HSV2-UL30-4575 + CCGUACUGCUUGACGAAGGUC 21 12929
HSV2-UL30-4576 + GCCGUACUGCUUGACGAAGGUC 22 12930
HSV2-UL30-4577 + GGCCG UACUGCUUGACGAAGGUC 23 12931
HSV2-UL30-4578 + GGGCCGUACUGCUUGACGAAGGUC 24 12932
HSV2-UL30-4579 + AUGAUGU UGUACCCGGUC 18 12933
HSV2-UL30-4580 + GAUGAUGUUGUACCCGGUC 19 12934
HSV2-UL30-2521 + UGAUGAUGUUGUACCCGGUC 20 5248
HSV2-UL30-4581 + UUGAUGAUGU UGUACCCGGUC 21 12935
HSV2-UL30-4582 + GU UGAUGAUGUUGUACCCGGUC 22 12936
HSV2-UL30-4583 + AGUUGAUGAUGUUGUACCCGGUC 23 12937
HSV2-UL30-4584 + AAGUUGAUGAUGUUGUACCCGGUC 24 12938
HSV2-UL30-4585 + AAACCCGGAGG UGGGGUC 18 12939
HSV2-UL30-4586 + GAAACCCGGAGGUGGGGUC 19 12940 HSV2-UL30-2481 + UGAAACCCGGAGGUGGGGUC 20 5216
HSV2-UL30-4587 + GUGAAACCCGGAGGUGGGGUC 21 12941
HSV2-UL30-4588 + CG UGAAACCCGGAGG UGGGGUC 22 12942
HSV2-UL30-4589 + ACGUGAAACCCGGAGGUGGGGUC 23 12943
HSV2-UL30-4590 + GACGUGAAACCCGGAGGUGGGGUC 24 12944
HSV2-UL30-4591 + GGCGGCCUGUUGCUUG UC 18 12945
HSV2-UL30-4592 + UGGCGGCCUGUUGCUUGUC 19 12946
HSV2-UL30-2447 + AUGGCGGCCUGUUGCU UGUC 20 5194
HSV2-UL30-4593 + GAUGGCGGCCUGUUGCUUGUC 21 12947
HSV2-UL30-4594 + UGAUGGCGGCCUGUUGCUUGUC 22 12948
HSV2-UL30-4595 + UUGAUGGCGGCCUGUUGCUUGUC 23 12949
HSV2-UL30-4596 + CUUGAUGGCGGCCUGU UGCU UGUC 24 12950
HSV2-UL30-4597 + UCGCGUACGUGGGCCU UC 18 12951
HSV2-UL30-4598 + CUCGCGUACGUGGGCCU UC 19 12952
HSV2-UL30-2461 + UCUCGCG UACGUGGGCCUUC 20 5202
HSV2-UL30-4599 + CUCUCGCGUACGUGGGCCUUC 21 12953
HSV2-UL30-4600 + GCUCUCGCGUACGUGGGCCUUC 22 12954
HSV2-UL30-4601 + GGCUCUCGCGUACGUGGGCCUUC 23 12955
HSV2-UL30-4602 + AGGCUCUCGCGUACGUGGGCCUUC 24 12956
HSV2-UL30-4603 + GGCUUGAGGCGG UACCAG 18 12957
HSV2-UL30-4604 + GGGCUUGAGGCGGUACCAG 19 12958
HSV2-UL30-2569 + CGGGCU UGAGGCGGUACCAG 20 5282
HSV2-UL30-4605 + CCGGGCUUGAGGCGG UACCAG 21 12959
HSV2-UL30-4606 + GCCGGGCUUGAGGCGGUACCAG 22 12960
HSV2-UL30-4607 + GGCCGGGCU UGAGGCGGUACCAG 23 12961
HSV2-UL30-4608 + CGGCCGGGCUUGAGGCGGUACCAG 24 12962
HSV2-UL30-4609 + GUCAGGACGAAGGGCCAG 18 12963
HSV2-UL30-4610 + GGUCAGGACGAAGGGCCAG 19 12964
HSV2-UL30-2520 + UGGUCAGGACGAAGGGCCAG 20 5247
HSV2-UL30-4611 + UUGGUCAGGACGAAGGGCCAG 21 12965
HSV2-UL30-4612 + CU UGGUCAGGACGAAGGGCCAG 22 12966
HSV2-UL30-4613 + GCU UGGUCAGGACGAAGGGCCAG 23 12967
HSV2-UL30-4614 + AGCUUGGUCAGGACGAAGGGCCAG 24 12968
HSV2-UL30-4615 + CUUGUAAUACACCGUCAG 18 12969
HSV2-UL30-4616 + GCUUGUAAUACACCGUCAG 19 12970
HSV2-UL30-2394 + AGCU UGUAAUACACCGUCAG 20 5156
HSV2-UL30-4617 + GAGCUUGUAAUACACCGUCAG 21 12971
HSV2-UL30-4618 + UGAGCUUGUAAUACACCGUCAG 22 12972
HSV2-UL30-4619 + AUGAGCUUGUAAUACACCGUCAG 23 12973
HSV2-UL30-4620 + CAUGAGCU UGUAAUACACCGUCAG 24 12974
HSV2-UL30-4621 + GCGCCCGUACCCGUCGAG 18 12975
HSV2-UL30-4622 + UGCGCCCGUACCCGUCGAG 19 12976
HSV2-UL30-1330 + AUGCGCCCGUACCCGUCGAG 20 4200
HSV2-UL30-4623 + CA U G CG CCCG U ACCCG U CG AG 21 12977
HSV2-UL30-4624 + UCAUGCGCCCGUACCCGUCGAG 22 12978
HSV2-UL30-4625 + U UCAUGCGCCCGUACCCGUCGAG 23 12979 HSV2-UL30-4626 + GUUCAUGCGCCCGUACCCGUCGAG 24 12980
HSV2-UL30-4627 + GGCCUGUUGCUUGUCGAG 18 12981
HSV2-UL30-4628 + CGGCCUGU UGCU UGUCGAG 19 12982
HSV2-UL30-2449 + GCGGCCUGUUGCU UGUCGAG 20 5195
HSV2-UL30-4629 + GGCGGCCUGUUGCU UGUCGAG 21 12983
HSV2-UL30-4630 + UGGCGGCCUGUUGCUUGUCGAG 22 12984
HSV2-UL30-4631 + AUGGCGGCCUGU UGCU UGUCGAG 23 12985
HSV2-UL30-4632 + GAUGGCGGCCUGUUGCUUGUCGAG 24
12986
HSV2-UL30-4633 + UCGACGUGAAACCCGGAG 18 12987
HSV2-UL30-4634 + GUCGACGUGAAACCCGGAG 19 12988
HSV2-UL30-2478 + GG UCGACGUGAAACCCGGAG 20 5214
HSV2-UL30-4635 + GGG UCGACGUGAAACCCGGAG 21 12989
HSV2-UL30-4636 + GGGG UCGACGUGAAACCCGGAG 22 12990
HSV2-UL30-4637 + CGGGG UCGACGUGAAACCCGGAG 23 12991
HSV2-UL30-4638 + ACGGGGUCGACGUGAAACCCGGAG 24 12992
HSV2-UL30-4639 + GCCGGCAGGCCCCUGGAG 18 12993
HSV2-UL30-4640 + GGCCGGCAGGCCCCUGGAG 19 12994
HSV2-UL30-2533 + GGGCCGGCAGGCCCCUGGAG 20 5256
HSV2-UL30-4641 + GGGGCCGGCAGGCCCCUGGAG 21 12995
HSV2-UL30-4642 + GGGGGCCGGCAGGCCCCUGGAG 22 12996
HSV2-UL30-4643 + CGGGGGCCGGCAGGCCCCUGGAG 23 12997
HSV2-UL30-4644 + ACGGGGGCCGGCAGGCCCCUGGAG 24 12998
HSV2-UL30-3084 + CAU AAAUCGCUCG UGG AG 18 11438
HSV2-UL30-3085 + CCAUAAAUCGCUCGUGGAG 19 11439
HSV2-UL30-3086 + UCCAUAAAUCGCUCGUGGAG 20 11440
HSV2-UL30-3087 + GUCCAU AAAUCGCUCG UGG AG 21 11441
HSV2-UL30-3088 + CGUCCAUAAAUCGCUCGUGGAG 22 11442
HSV2-UL30-3089 + GCG UCCAUAAAUCGCUCGUGGAG 23 11443
HSV2-UL30-3090 + GGCGUCCAUAAAUCGCUCGUGGAG 24 11444
HSV2-UL30-4645 + GGAGGCGAGAUCGCUGAG 18 12999
HSV2-UL30-4646 + UGGAGGCGAGAUCGCUGAG 19 13000
HSV2-UL30-2535 + CUGGAGGCGAGAUCGCUGAG 20 5258
HSV2-UL30-4647 + CCUGGAGGCGAGAUCGCUGAG 21 13001
HSV2-UL30-4648 + CCCUGGAGGCGAGAUCGCUGAG 22 13002
HSV2-UL30-4649 + CCCCUGGAGGCGAGAUCGCUGAG 23 13003
HSV2-UL30-4650 + GCCCCUGGAGGCGAGAUCGCUGAG 24 13004
HSV2-UL30-4651 + GUAAUAGUCCGUGUUGAG 18 13005
HSV2-UL30-4652 + AGUAAUAGUCCGUGUUGAG 19 13006
HSV2-UL30-1104 + AAGUAAUAGUCCGUGUUGAG 20 3974
HSV2-UL30-4653 + GAAGUAAUAGUCCGUG UUGAG 21 13007
HSV2-UL30-4654 + AGAAGUAAUAGUCCGUGUUGAG 22 13008
HSV2-UL30-4655 + GAGAAGUAAUAGUCCGUGUUGAG 23 13009
HSV2-UL30-4656 + CGAGAAGUAAUAGUCCGUGUUGAG 24 13010
HSV2-UL30-4657 + GGCCCGGAGGCGUAGUAG 18 13011
HSV2-UL30-4658 + GGGCCCGGAGGCGUAG UAG 19 13012 HSV2-UL30-2505 + CGGGCCCGGAGGCGUAGUAG 20 5237
HSV2-UL30-4659 + GCGGGCCCGGAGGCGUAGUAG 21 13013
HSV2-UL30-4660 + CGCGGGCCCGGAGGCGUAGUAG 22 13014
HSV2-UL30-4661 + GCGCGGGCCCGGAGGCGUAGUAG 23 13015
HSV2-UL30-4662 + UGCGCGGGCCCGGAGGCGUAGUAG 24 13016
HSV2-UL30-4663 + ACGGCGUUCAGCUUGUAG 18 13017
HSV2-UL30-4664 + GACGGCGUUCAGCU UGUAG 19 13018
HSV2-UL30-2508 + CGACGGCGU UCAGCUUG UAG 20 5238
HSV2-UL30-4665 + GCG ACGGCGUUCAGCU UGUAG 21 13019
HSV2-UL30-4666 + GGCG ACGGCGUUCAGCU UGUAG 22 13020
HSV2-UL30-4667 + CGGCG ACGGCG U UCAGCU UGU AG 23 13021
HSV2-UL30-4668 + UCGGCGACGGCGUUCAGCUUGUAG 24 13022
HSV2-UL30-4669 + UGGCCGAUGUCCCACACG 18 13023
HSV2-UL30-4670 + CUGGCCGAUGUCCCACACG 19 13024
HSV2-UL30-1328 + UCUGGCCGAUGUCCCACACG 20 4198
HSV2-UL30-4671 + CUCUGGCCGAUGUCCCACACG 21 13025
HSV2-UL30-4672 + GCUCUGGCCGAUGUCCCACACG 22 13026
HSV2-UL30-4673 + GGCUCUGGCCGAUGUCCCACACG 23 13027
HSV2-UL30-4674 + UGGCUCUGGCCGAUGUCCCACACG 24 13028
HSV2-UL30-4675 + CGUACGUGGGCCU UCACG 18 13029
HSV2-UL30-4676 + GCGUACGUGGGCCUUCACG 19 13030
HSV2-UL30-2462 + CGCGUACGUGGGCCUUCACG 20 5203
HSV2-UL30-4677 + UCGCGUACGUGGGCCU UCACG 21 13031
HSV2-UL30-4678 + CUCGCGUACGUGGGCCU UCACG 22 13032
HSV2-UL30-4679 + UCUCGCGUACGUGGGCCUUCACG 23 13033
HSV2-UL30-4680 + CUCUCGCGUACGUGGGCCUUCACG 24 13034
HSV2-UL30-4681 + CCCGCCAGGCGCGCGACG 18 13035
HSV2-UL30-4682 + GCCCGCCAGGCGCGCGACG 19 13036
HSV2-UL30-2496 + UGCCCGCCAGGCGCGCGACG 20 5230
HSV2-UL30-4683 + AUGCCCGCCAGGCGCGCGACG 21 13037
HSV2-UL30-4684 + GAUGCCCGCCAGGCGCGCGACG 22 13038
HSV2-UL30-4685 + UG AUGCCCGCCAGGCGCGCGACG 23 13039
HSV2-UL30-4686 + UUGAUGCCCGCCAGGCGCGCGACG 24 13040
HSV2-UL30-4687 + GGGACAUCAGCUUCGACG 18 13041
HSV2-UL30-4688 + CGGGACAUCAGCUUCGACG 19 13042
HSV2-UL30-2881 + GCGGGACAUCAGCUUCGACG 20 11235
HSV2-UL30-4689 + UGCGGGACAUCAGCUUCGACG 21 13043
HSV2-UL30-4690 + AUGCGGGACAUCAGCUUCGACG 22 13044
HSV2-UL30-4691 + GAUGCGGG ACAUCAGCU UCG ACG 23 13045
HSV2-UL30-4692 + AGAUGCGGGACAUCAGCUUCGACG 24 13046
HSV2-UL30-4693 + CUGUCAAACUCCAGGACG 18 13047
HSV2-UL30-4694 + GCUGUCAAACUCCAGGACG 19 13048
HSV2-UL30-2528 + CGCUGUCAAACUCCAGGACG 20 5254
HSV2-UL30-4695 + UCGCUGUCAAACUCCAGGACG 21 13049
HSV2-UL30-4696 + UUCGCUGUCAAACUCCAGGACG 22 13050
HSV2-UL30-4697 + AU UCGCUGUCAAACUCCAGGACG 23 13051 HSV2-UL30-4698 + AAU UCGCUGUCAAACUCCAGGACG 24 13052
HSV2-UL30-4699 + GUCAGCUUGGUCAGGACG 18 13053
HSV2-UL30-4700 + CGUCAGCU UGGUCAGGACG 19 13054
HSV2-UL30-2519 + CCGUCAGCUUGGUCAGGACG 20 5246
HSV2-UL30-4701 + UCCGUCAGCUUGGUCAGGACG 21 13055
HSV2-UL30-4702 + CUCCGUCAGCU UGGUCAGGACG 22 13056
HSV2-UL30-4703 + UCUCCGUCAGCUUGGUCAGGACG 23 13057
HSV2-UL30-4704 + AUCUCCGUCAGCUUGGUCAGGACG 24 13058
HSV2-UL30-4705 + UUCAUGCGCCCGUACCCG 18 13059
HSV2-UL30-4706 + GUUCAUGCGCCCGUACCCG 19 13060
HSV2-UL30-2514 + CGU UCAUGCGCCCGUACCCG 20 5242
HSV2-UL30-4707 + CCGUUCAUGCGCCCGUACCCG 21 13061
HSV2-UL30-4708 + GCCGUUCAUGCGCCCGUACCCG 22 13062
HSV2-UL30-4709 + GGCCGUUCAUGCGCCCGUACCCG 23 13063
HSV2-UL30-4710 + CGGCCG U UCAUGCGCCCGUACCCG 24 13064
HSV2-UL30-4711 + AGACCGUGCUGCACCCCG 18 13065
HSV2-UL30-4712 + AAGACCGUGCUGCACCCCG 19 13066
HSV2-UL30-2444 + G A AG ACCG U G CU G CACCCCG 20 5191
HSV2-UL30-4713 + AGAAGACCG UGCUGCACCCCG 21 13067
HSV2-UL30-4714 + CAGAAGACCGUGCUGCACCCCG 22 13068
HSV2-UL30-4715 + GCAG AAGACCGUGCUGCACCCCG 23 13069
HSV2-UL30-4716 + GGCAG AAGACCGUGCUGCACCCCG 24 13070
HSV2-UL30-4717 + AGCGUGAUGACGGUCCCG 18 13071
HSV2-UL30-4718 + AAGCGUGAUGACGGUCCCG 19 13072
HSV2-UL30-2592 + GAAGCGUGAUGACGGUCCCG 20 5299
HSV2-UL30-4719 + AGAAGCGUGAUGACGGUCCCG 21 13073
HSV2-UL30-4720 + CAG AAGCGUGAUGACGGUCCCG 22 13074
HSV2-UL30-4721 + CCAG AAGCGUGAUGACGGUCCCG 23 13075
HSV2-UL30-4722 + CCCAGAAGCGUGAUGACGGUCCCG 24 13076
HSV2-UL30-4723 + UCGAGGUUCCGAACGCCG 18 13077
HSV2-UL30-4724 + CUCGAGGUUCCGAACGCCG 19 13078
HSV2-UL30-2562 + GCUCGAGGUUCCGAACGCCG 20 5278
HSV2-UL30-4725 + CGCUCGAGGUUCCGAACGCCG 21 13079
HSV2-UL30-4726 + UCGCUCGAGGUUCCGAACGCCG 22 13080
HSV2-UL30-4727 + GUCGCUCGAGGU UCCGAACGCCG 23 13081
HSV2-UL30-4728 + CGUCGCUCGAGGU UCCGAACGCCG 24 13082
HSV2-UL30-4729 + CGGGUCGGUGAUGCGCCG 18 13083
HSV2-UL30-4730 + CCGGGUCGGUGAUGCGCCG 19 13084
HSV2-UL30-2400 + UCCGGGUCGGUGAUGCGCCG 20 5162
HSV2-UL30-4731 + CUCCGGGUCGGUGAUGCGCCG 21 13085
HSV2-UL30-4732 + UCUCCGGGUCGGUGAUGCGCCG 22 13086
HSV2-UL30-4733 + CUCUCCGGGUCGGUGAUGCGCCG 23 13087
HSV2-UL30-4734 + CCUCUCCGGGUCGGUGAUGCGCCG 24 13088
HSV2-UL30-4735 + CCGGGGAGGGCAGGGCCG 18 13089
HSV2-UL30-4736 + GCCGGGGAGGGCAGGGCCG 19 13090
HSV2-UL30-2374 + GGCCGGGGAGGGCAGGGCCG 20 5144 HSV2-UL30-4737 + UGGCCGGGGAGGGCAGGGCCG 21 13091
HSV2-UL30-4738 + UUGGCCGGGGAGGGCAGGGCCG 22 13092
HSV2-UL30-4739 + CU UGGCCGGGGAGGGCAGGGCCG 23 13093
HSV2-UL30-4740 + GCUUGGCCGGGGAGGGCAGGGCCG 24 13094
HSV2-UL30-4741 + CGCGACGGCCUCGGGCCG 18 13095
HSV2-UL30-4742 + GCGCGACGGCCUCGGGCCG 19 13096
HSV2-UL30-2464 + UGCGCGACGGCCUCGGGCCG 20 5205
HSV2-UL30-4743 + GUGCGCGACGGCCUCGGGCCG 21 13097
HSV2-UL30-4744 + GG UGCGCGACGGCCUCGGGCCG 22 13098
HSV2-UL30-4745 + AGG UGCGCGACGGCCUCGGGCCG 23 13099
HSV2-UL30-4746 + CAGG UGCGCGACGGCCUCGGGCCG 24 13100
HSV2-UL30-4747 + CCCGGGGGCGCU UGGCCG 18 13101
HSV2-UL30-4748 + UCCCGGGGGCGCUUGGCCG 19 13102
HSV2-UL30-1129 + CUCCCGGGGGCGCU UGGCCG 20 3999
HSV2-UL30-4749 + UCUCCCGGGGGCGCUUGGCCG 21 13103
HSV2-UL30-4750 + GUCUCCCGGGGGCGCU UGGCCG 22 13104
HSV2-UL30-4751 + CGUCUCCCGGGGGCGCU UGGCCG 23 13105
HSV2-UL30-4752 + GCGUCUCCCGGGGGCGCUUGGCCG 24 13106
HSV2-UL30-4753 + UGGUCCGCGGAGAUGCCG 18 13107
HSV2-UL30-4754 + GUGGUCCGCGGAGAUGCCG 19 13108
HSV2-UL30-1417 + AG UGGUCCGCGGAGAUGCCG 20 4287
HSV2-UL30-4755 + AAG UGGUCCGCGGAGAUGCCG 21 13109
HSV2-UL30-4756 + GAAG UGGUCCGCGGAGAUGCCG 22 13110
HSV2-UL30-4757 + CG AAG UGGUCCGCGGAGAUGCCG 23 13111
HSV2-UL30-4758 + UCGAAGUGGUCCGCGGAGAUGCCG 24 13112
HSV2-UL30-4759 + CCGCCUCGAAGUGGUCCG 18 13113
HSV2-UL30-4760 + UCCGCCUCGAAGUGGUCCG 19 13114
HSV2-UL30-1416 + CUCCGCCUCGAAGUGGUCCG 20 4286
HSV2-UL30-4761 + CCUCCGCCUCGAAGUGG UCCG 21 13115
HSV2-UL30-4762 + ACCUCCGCCUCGAAGUGGUCCG 22 13116
HSV2-UL30-4763 + CACCU CCGCCU CG AAG U GG UCCG 23 13117
HSV2-UL30-4764 + CCACCUCCGCCUCGAAGUGGUCCG 24 13118
HSV2-UL30-4765 + GGACGGGACCUGCGCGCG 18 13119
HSV2-UL30-4766 + UGGACGGGACCUGCGCGCG 19 13120
HSV2-UL30-2392 + AUGGACGGGACCUGCGCGCG 20 5154
HSV2-UL30-4767 + GAUGGACGGGACCUGCGCGCG 21 13121
HSV2-UL30-4768 + UG AUGGACGGGACCUGCGCGCG 22 13122
HSV2-UL30-4769 + UUGAUGGACGGGACCUGCGCGCG 23 13123
HSV2-UL30-4770 + CU UGAUGGACGGGACCUGCGCGCG 24 13124
HSV2-UL30-4771 + GCGCUCGCAGAGAUCGCG 18 13125
HSV2-UL30-4772 + GGCGCUCGCAGAGAUCGCG 19 13126
HSV2-UL30-1422 + AGGCGCUCGCAGAGAUCGCG 20 4292
HSV2-UL30-4773 + CAGGCGCUCGCAGAGAUCGCG 21 13127
HSV2-UL30-4774 + CCAGGCGCUCGCAGAGAUCGCG 22 13128
HSV2-UL30-4775 + GCCAGGCGCUCGCAGAGAUCGCG 23 13129
HSV2-UL30-4776 + CGCCAGGCGCUCGCAGAGAUCGCG 24 13130 HSV2-UL30-4777 + CGCCCCCGGCGACUCGCG 18 13131
HSV2-UL30-4778 + ACGCCCCCGGCGACUCGCG 19 13132
HSV2-UL30-2583 + GACG CCCCCGG CG ACU CGCG 20 5293
HSV2-UL30-4779 + CGACGCCCCCGGCGACUCGCG 21 13133
HSV2-UL30-4780 + ACGACGCCCCCGGCGACUCGCG 22 13134
HSV2-UL30-4781 + AACGACGCCCCCGGCGACUCGCG 23 13135
HSV2-UL30-4782 + GAACGACGCCCCCGGCGACUCGCG 24 13136
HSV2-UL30-4783 + GGCGGCG UCUAGCUCGCG 18 13137
HSV2-UL30-4784 + CGGCGGCGUCUAGCUCGCG 19 13138
HSV2-UL30-2384 + GCGGCGGCGUCUAGCUCGCG 20 5148
HSV2-UL30-4785 + GGCGGCGGCGUCUAGCUCGCG 21 13139
HSV2-UL30-4786 + GGGCGGCGGCGUCUAGCUCGCG 22 13140
HSV2-UL30-4787 + GGGGCGGCGGCGUCUAGCUCGCG 23 13141
HSV2-UL30-4788 + UGGGGCGGCGGCGUCUAGCUCGCG 24 13142
HSV2-UL30-4789 + ACGUACGCGCGCGUCGCG 18 13143
HSV2-UL30-4790 + CACGUACGCGCGCGUCGCG 19 13144
HSV2-UL30-1225 + GCACGUACGCGCGCGUCGCG 20 4095
HSV2-UL30-4791 + UGCACGUACGCGCGCGUCGCG 21 13145
HSV2-UL30-4792 + GUGCACGUACGCGCGCGUCGCG 22 13146
HSV2-UL30-4793 + CGUGCACGUACGCGCGCGUCGCG 23 13147
HSV2-UL30-4794 + GCGUGCACGUACGCGCGCGUCGCG 24 13148
HSV2-UL30-4795 + CU UCUGGCCCGCAAGGCG 18 13149
HSV2-UL30-4796 + CCUUCUGGCCCGCAAGGCG 19 13150
HSV2-UL30-2491 + CCCUUCUGGCCCGCAAGGCG 20 5226
HSV2-UL30-4797 + GCCCUUCUGGCCCGCAAGGCG 21 13151
HSV2-UL30-4798 + AGCCCUUCUGGCCCGCAAGGCG 22 13152
HSV2-UL30-4799 + AAGCCCUUCUGGCCCGCAAGGCG 23 13153
HSV2-UL30-4800 + GAAGCCCUUCUGGCCCGCAAGGCG 24 13154
HSV2-UL30-4801 + UGUCUGCUCAGUUCGGCG 18 13155
HSV2-UL30-4802 + GUGUCUGCUCAGUUCGGCG 19 13156
HSV2-UL30-2396 + GGUGUCUGCUCAGUUCGGCG 20 5158
HSV2-UL30-4803 + GGGUGUCUGCUCAGUUCGGCG 21 13157
HSV2-UL30-4804 + CGGGUGUCUGCUCAG UUCGGCG 22 13158
HSV2-UL30-4805 + GCGGGUGUCUGCUCAGUUCGGCG 23 13159
HSV2-UL30-4806 + CGCGGGUGUCUGCUCAGU UCGGCG 24 13160
HSV2-UL30-4807 + AUGUACUUUUUCUUGGCG 18 13161
HSV2-UL30-4808 + GAUGUACUU UUUCU UGGCG 19 13162
HSV2-UL30-2414 + CGAUGUACUUUU UCUUGGCG 20 5173
HSV2-UL30-4809 + CCGAUGUACUU UUUCU UGGCG 21 13163
HSV2-UL30-4810 + GCCGAUGUACU UUUUCU UGGCG 22 13164
HSV2-UL30-4811 + CGCCGAUGUACU UUUUCUUGGCG 23 13165
HSV2-UL30-4812 + ACGCCGAUGUACUUUU UCUUGGCG 24 13166
HSV2-UL30-4813 + CCCCUGGAGGCGAGAUCG 18 13167
HSV2-UL30-4814 + GCCCCUGGAGGCGAGAUCG 19 13168
HSV2-UL30-2534 + GGCCCCUGGAGGCGAGAUCG 20 5257
HSV2-UL30-4815 + AGGCCCCUGGAGGCGAGAUCG 21 13169 HSV2-UL30-4816 + CAGGCCCCUGGAGGCGAGAUCG 22 13170
HSV2-UL30-4817 + GCAGGCCCCUGGAGGCGAGAUCG 23 13171
HSV2-UL30-4818 + GGCAGGCCCCUGGAGGCGAGAUCG 24 13172
HSV2-UL30-4819 + CCUCGUACUUCCUGAUCG 18 13173
HSV2-UL30-4820 + CCCUCGUACUUCCUGAUCG 19 13174
HSV2-UL30-1404 + CCCCUCGUACU UCCUGAUCG 20 4274
HSV2-UL30-4821 + CCCCCUCGUACUUCCUGAUCG 21 13175
HSV2-UL30-4822 + CCCCCCUCGUACUUCCUGAUCG 22 13176
HSV2-UL30-4823 + GCCCCCCUCGUACUUCCUGAUCG 23 13177
HSV2-UL30-4824 + CGCCCCCCUCGUACU UCCUGAUCG 24 13178
HSV2-UL30-4825 + CGCACUCGAGCUUGAUCG 18 13179
HSV2-UL30-4826 + UCGCACUCGAGCUUGAUCG 19 13180
HSV2-UL30-1205 + UUCGCACUCGAGCUUGAUCG 20 4075
HSV2-UL30-4827 + UUUCGCACUCGAGCU UGAUCG 21 13181
HSV2-UL30-4828 + U UUUCGCACUCGAGCUUGAUCG 22 13182
HSV2-UL30-4829 + UUUUUCGCACUCGAGCU UGAUCG 23 13183
HSV2-UL30-4830 + UUUUUUCGCACUCGAGCUUGAUCG 24 13184
HSV2-UL30-4831 + UCGCUGAGGUGGGACUCG 18 13185
HSV2-UL30-4832 + AUCGCUGAGGUGGGACUCG 19 13186
HSV2-UL30-1356 + GAUCGCUGAGGUGGGACUCG 20 4226
HSV2-UL30-4833 + AG AUCGCUGAGGUGGGACUCG 21 13187
HSV2-UL30-4834 + GAG AUCGCUGAGGUGGGACUCG 22 13188
HSV2-UL30-4835 + CG AG AUCGCUGAGGUGGGACUCG 23 13189
HSV2-UL30-4836 + GCGAGAUCGCUGAGGUGGGACUCG 24 13190
HSV2-UL30-4837 + GCGGCGGCGUCUAGCUCG 18 13191
HSV2-UL30-4838 + GGCGGCGGCGUCUAGCUCG 19 13192
HSV2-UL30-1147 + GGGCGGCGGCGUCUAGCUCG 20 4017
HSV2-UL30-4839 + GGGGCGGCGGCGUCUAGCUCG 21 13193
HSV2-UL30-4840 + UGGGGCGGCGGCGUCUAGCUCG 22 13194
HSV2-UL30-4841 + CUGGGGCGGCGGCGUCUAGCUCG 23 13195
HSV2-UL30-4842 + CCUGGGGCGGCGGCGUCUAGCUCG 24 13196
HSV2-UL30-4843 + GCCGCCGCCAGGCGCUCG 18 13197
HSV2-UL30-4844 + GGCCGCCGCCAGGCGCUCG 19 13198
HSV2-UL30-2584 + GGGCCGCCGCCAGGCGCUCG 20 5294
HSV2-UL30-4845 + AGGGCCGCCGCCAGGCGCUCG 21 13199
HSV2-UL30-4846 + CAGGGCCGCCGCCAGGCGCUCG 22 13200
HSV2-UL30-4847 + GCAGGGCCGCCGCCAGGCGCUCG 23 13201
HSV2-UL30-4848 + CGCAGGGCCGCCGCCAGGCGCUCG 24 13202
HSV2-UL30-3145 + GCGUCCAUAAAUCGCUCG 18 11499
HSV2-UL30-3146 + GGCGUCCAUAAAUCGCUCG 19 11500
HSV2-UL30-1438 + UGGCGUCCAUAAAUCGCUCG 20 4308
HSV2-UL30-3147 + AUGGCGUCCAUAAAUCGCUCG 21 11501
HSV2-UL30-3148 + GAUGGCGUCCAUAAAUCGCUCG 22 11502
HSV2-UL30-3149 + UGAUGGCGUCCAUAAAUCGCUCG 23 11503
HSV2-UL30-3150 + GUGAUGGCGUCCAUAAAUCGCUCG 24 11504
HSV2-UL30-4849 + AGGUUCCGAACGCCGUCG 18 13203 HSV2-UL30-4850 + G AG G U U CCG AACG CCG U CG 19 13204
HSV2-UL30-1384 + CGAGGUUCCGAACGCCGUCG 20 4254
HSV2-UL30-4851 + UCGAGGU UCCGAACGCCGUCG 21 13205
HSV2-UL30-4852 + CUCGAGGU UCCGAACGCCGUCG 22 13206
HSV2-UL30-4853 + GCUCGAGGUUCCGAACGCCGUCG 23 13207
HSV2-UL30-4854 + CGCUCGAGGUUCCGAACGCCGUCG 24 13208
HSV2-UL30-4855 + GCGGUGGUGGACAGGUCG 18 13209
HSV2-UL30-4856 + GGCGGUGGUGGACAGGUCG 19 13210
HSV2-UL30-2550 + GGGCGGUGGUGGACAGGUCG 20 5268
HSV2-UL30-4857 + AGGGCGGUGGUGGACAGGUCG 21 13211
HSV2-UL30-4858 + GAGGGCGGUGGUGGACAGGUCG 22 13212
HSV2-UL30-4859 + CGAGGGCGGUGG UGGACAGG UCG 23 13213
HSV2-UL30-4860 + UCGAGGGCGGUGGUGGACAGGUCG 24
13214
HSV2-UL30-4861 + GCGGCCUGUUGCU UGUCG 18 13215
HSV2-UL30-4862 + GGCGGCCUGUUGCUUG UCG 19 13216
HSV2-UL30-1237 + UGGCGGCCUGUUGCUUGUCG 20 4107
HSV2-UL30-4863 + AUGGCGGCCUGUUGCUUGUCG 21 13217
HSV2-UL30-4864 + GAUGGCGGCCUG UUGCUUGUCG 22 13218
HSV2-UL30-4865 + UGAUGGCGGCCUGUUGCUUGUCG 23 13219
HSV2-UL30-4866 + UUGAUGGCGGCCUGUUGCUUGUCG 24
13220
HSV2-UL30-4867 + UGCGGGACAUCAGCUUCG 18 13221
HSV2-UL30-4868 + AUGCGGGACAUCAGCUUCG 19 13222
HSV2-UL30-4869 + GAUGCGGGACAUCAGCU UCG 20 13223
HSV2-UL30-4870 + ACGGCCUCGGGCCGCAGG 18 13224
HSV2-UL30-4871 + GACGGCCUCGGGCCGCAGG 19 13225
HSV2-UL30-2467 + CG ACGGCCUCGGGCCGCAGG 20 5206
HSV2-UL30-4872 + GCG ACGGCCUCGGGCCGCAGG 21 13226
HSV2-UL30-4873 + CGCG ACGGCCUCGGGCCGCAGG 22 13227
HSV2-UL30-4874 + GCGCG ACGGCCUCGGGCCGCAGG 23 13228
HSV2-UL30-4875 + UGCGCGACGGCCUCGGGCCGCAGG 24 13229
HSV2-UL30-4876 + CCCUGGG UGUCCGGCAGG 18 13230
HSV2-UL30-4877 + CCCCUGGGUGUCCGGCAGG 19 13231
HSV2-UL30-2490 + GCCCCUGGGUGUCCGGCAGG 20 5225
HSV2-UL30-4878 + CGCCCCUGGGUGUCCGGCAGG 21 13232
HSV2-UL30-4879 + CCGCCCCUGGG UGUCCGGCAGG 22 13233
HSV2-UL30-4880 + ACCGCCCCUGGGUGUCCGGCAGG 23 13234
HSV2-UL30-4881 + AACCGCCCCUGGGUGUCCGGCAGG 24 13235
HSV2-UL30-4882 + GUGGCGGCCACGUGCAGG 18 13236
HSV2-UL30-4883 + GGUGGCGGCCACGUGCAGG 19 13237
HSV2-UL30-2442 + CGGUGGCGGCCACGUGCAGG 20 5189
HSV2-UL30-4884 + ACGGUGGCGGCCACGUGCAGG 21 13238
HSV2-UL30-4885 + CACGGUGGCGGCCACGUGCAGG 22 13239
HSV2-UL30-4886 + UCACGGUGGCGGCCACGUGCAGG 23 13240
HSV2-UL30-4887 + GUCACGGUGGCGGCCACGUGCAGG 24 13241 HSV2-UL30-4888 + UCCGUCAGCUUGGUCAGG 18 13242
HSV2-UL30-4889 + CUCCGUCAGCUUGGUCAGG 19 13243
HSV2-UL30-2518 + UCUCCGUCAGCUUGGUCAGG 20 5245
HSV2-UL30-4890 + AUCUCCGUCAGCUUGGUCAGG 21 13244
HSV2-UL30-4891 + GAUCUCCGUCAGCUUGGUCAGG 22 13245
HSV2-UL30-4892 + AGAUCUCCGUCAGCUUGGUCAGG 23 13246
HSV2-UL30-4893 + UAGAUCUCCGUCAGCU UGGUCAGG 24 13247
HSV2-UL30-4894 + GAGGCGAGAUCGCUGAGG 18 13248
HSV2-UL30-4895 + GGAGGCGAGAUCGCUGAGG 19 13249
HSV2-UL30-1352 + UGGAGGCGAGAUCGCUGAGG 20 4222
HSV2-UL30-4896 + CUGGAGGCGAGAUCGCUGAGG 21 13250
HSV2-UL30-4897 + CCUGGAGGCGAGAUCGCUGAGG 22 13251
HSV2-UL30-4898 + CCCUGGAGGCGAGAUCGCUGAGG 23 13252
HSV2-UL30-4899 + CCCCUGGAGGCGAGAUCGCUGAGG 24 13253
HSV2-UL30-4900 + GCCCGGAGGCGUAGUAGG 18 13254
HSV2-UL30-4901 + GGCCCGGAGGCGUAGUAGG 19 13255
HSV2-UL30-1317 + GGGCCCGGAGGCGUAGUAGG 20 4187
HSV2-UL30-4902 + CGGGCCCGGAGGCGUAGUAGG 21 13256
HSV2-UL30-4903 + GCGGGCCCGGAGGCGUAGUAGG 22 13257
HSV2-UL30-4904 + CGCGGGCCCGGAGGCGUAGUAGG 23 13258
HSV2-UL30-4905 + GCGCGGGCCCGGAGGCGUAGUAGG 24 13259
HSV2-UL30-4906 + CU UCCCCCCG AGGCACGG 18 13260
HSV2-UL30-4907 + CCU U CCCCCCG AG GCACGG 19 13261
HSV2-UL30-2484 + CCCU UCCCCCCG AGGCACGG 20 5219
HSV2-UL30-4908 + CCCCU UCCCCCCG AGGCACGG 21 13262
HSV2-UL30-4909 + U CCCC U U CCCCCCG AG G CACG G 22 13263
HSV2-UL30-4910 + CUCCCCUUCCCCCCGAGGCACGG 23 13264
HSV2-UL30-4911 + GCUCCCCUUCCCCCCGAGGCACGG 24 13265
HSV2-UL30-4912 + CCGCCAGGCGCGCGACGG 18 13266
HSV2-UL30-4913 + CCCGCCAGGCGCGCGACGG 19 13267
HSV2-UL30-1309 + GCCCGCCAGGCGCGCGACGG 20 4179
HSV2-UL30-4914 + UGCCCGCCAGGCGCGCGACGG 21 13268
HSV2-UL30-4915 + AUGCCCGCCAGGCGCGCGACGG 22 13269
HSV2-UL30-4916 + GAUGCCCGCCAGGCGCGCGACGG 23 13270
HSV2-UL30-4917 + UG AUGCCCGCCAGGCGCGCGACGG 24 13271
HSV2-UL30-4918 + GCCGGCGCGUUCCCGCGG 18 13272
HSV2-UL30-4919 + GGCCGGCGCGUUCCCGCGG 19 13273
HSV2-UL30-2567 + GGGCCGGCGCGU UCCCGCGG 20 5280
HSV2-UL30-4920 + UGGGCCGGCGCGUUCCCGCGG 21 13274
HSV2-UL30-4921 + UUGGGCCGGCGCGUUCCCGCGG 22 13275
HSV2-UL30-4922 + GUUGGGCCGGCGCG UUCCCGCGG 23 13276
HSV2-UL30-4923 + GGUUGGGCCGGCGCGU UCCCGCGG 24 13277
HSV2-UL30-4924 + CGCCGUCGGGGGGCGCGG 18 13278
HSV2-UL30-4925 + ACGCCGUCGGGGGGCGCGG 19 13279
HSV2-UL30-2566 + AACGCCGUCGGGGGGCGCGG 20 5279
HSV2-UL30-4926 + GAACGCCGUCGGGGGGCGCGG 21 13280 HSV2-UL30-4927 + CGAACGCCGUCGGGGGGCGCGG 22 13281
HSV2-UL30-4928 + CCGAACGCCGUCGGGGGGCGCGG 23 13282
HSV2-UL30-4929 + UCCGAACGCCGUCGGGGGGCGCGG 24 13283
HSV2-UL30-4930 + GGAAAGCUCCAGGUGCGG 18 13284
HSV2-UL30-4931 + CGGAAAGCUCCAGGUGCGG 19 13285
HSV2-UL30-2498 + GCGGAAAGCUCCAGGUGCGG 20 5231
HSV2-UL30-4932 + GGCGGAAAGCUCCAGGUGCGG 21 13286
HSV2-UL30-4933 + CGGCGGAAAGCUCCAGGUGCGG 22 13287
HSV2-UL30-4934 + ACGGCGGAAAGCUCCAGGUGCGG 23 13288
HSV2-UL30-4935 + GACGGCGGAAAGCUCCAGGUGCGG 24 13289
HSV2-UL30-4936 + GCACUCGAGCUUGAUCGG 18 13290
HSV2-UL30-4937 + CGCACUCGAGCUUGAUCGG 19 13291
HSV2-UL30-1206 + UCGCACUCGAGCUUGAUCGG 20 4076
HSV2-UL30-4938 + U UCGCACUCGAGCUUGAUCGG 21 13292
HSV2-UL30-4939 + U UUCGCACUCGAGCU UGAUCGG 22 13293
HSV2-UL30-4940 + UUUUCGCACUCGAGCUUGAUCGG 23 13294
HSV2-UL30-4941 + UUUUUCGCACUCGAGCU UGAUCGG 24 13295
HSV2-UL30-4942 + AGACGCGGUAGUACAGGG 18 13296
HSV2-UL30-4943 + AAGACGCGGUAGUACAGGG 19 13297
HSV2-UL30-2577 + GAAGACGCGGUAGUACAGGG 20 5289
HSV2-UL30-4944 + CG AAGACGCGGUAGUACAGGG 21 13298
HSV2-UL30-4945 + ACG AAGACGCGGUAGUACAGGG 22 13299
HSV2-UL30-4946 + CACGAAGACGCGGUAGUACAGGG 23 13300
HSV2-UL30-4947 + GCACG AAGACGCGGUAGUACAGGG 24 13301
HSV2-UL30-4948 + GGCCACGUGCAGGCAGGG 18 13302
HSV2-UL30-4949 + CGGCCACG UGCAGGCAGGG 19 13303
HSV2-UL30-2443 + GCGGCCACGUGCAGGCAGGG 20 5190
HSV2-UL30-4950 + GGCGGCCACG UGCAGGCAGGG 21 13304
HSV2-UL30-4951 + UGGCGGCCACGUGCAGGCAGGG 22 13305
HSV2-UL30-4952 + GUGGCGGCCACGUGCAGGCAGGG 23 13306
HSV2-UL30-4953 + GGUGGCGGCCACGUGCAGGCAGGG 24 13307
HSV2-UL30-4954 + GCGCUUGGCCGGGGAGGG 18 13308
HSV2-UL30-4955 + GGCGCU UGGCCGGGGAGGG 19 13309
HSV2-UL30-2373 + GGGCGCUUGGCCGGGGAGGG 20 5143
HSV2-UL30-4956 + GGGGCGCUUGGCCGGGGAGGG 21 13310
HSV2-UL30-4957 + GGGGGCGCU UGGCCGGGGAGGG 22 13311
HSV2-UL30-4958 + CGGGGGCGCUUGGCCGGGGAGGG 23 13312
HSV2-UL30-4959 + CCGGGGGCGCU UGGCCGGGGAGGG 24 13313
HSV2-UL30-4960 + CGGGGGCGCUUGGCCGGG 18 13314
HSV2-UL30-4961 + CCGGGGGCGCUUGGCCGGG 19 13315
HSV2-UL30-2372 + CCCGGGGGCGCUUGGCCGGG 20 5142
HSV2-UL30-4962 + UCCCGGGGGCGCU UGGCCGGG 21 13316
HSV2-UL30-4963 + CUCCCGGGGGCGCUUGGCCGGG 22 13317
HSV2-UL30-4964 + UCUCCCGGGGGCGCUUGGCCGGG 23 13318
HSV2-UL30-4965 + GUCUCCCGGGGGCGCUUGGCCGGG 24 13319
HSV2-UL30-4966 + CACUCGAGCUUGAUCGGG 18 13320 HSV2-UL30-4967 + GCACUCGAGCUUGAUCGGG 19 13321
HSV2-UL30-1207 + CGCACUCGAGCUUGAUCGGG 20 4077
HSV2-UL30-4968 + UCGCACUCGAGCUUGAUCGGG 21 13322
HSV2-UL30-4969 + UUCGCACUCGAGCU UGAUCGGG 22 13323
HSV2-UL30-4970 + UU UCGCACUCGAGCUUGAUCGGG 23 13324
HSV2-UL30-4971 + UU UUCGCACUCGAGCUUGAUCGGG 24 13325
HSV2-UL30-4972 + CGCCUGCAGUCCCUCGGG 18 13326
HSV2-UL30-4973 + ACGCCUGCAGUCCCUCGGG 19 13327
HSV2-UL30-2405 + AACGCCUGCAGUCCCUCGGG 20 5167
HSV2-UL30-4974 + GAACGCCUGCAGUCCCUCGGG 21 13328
HSV2-UL30-4975 + CGAACGCCUGCAGUCCCUCGGG 22 13329
HSV2-UL30-4976 + CCGAACGCCUGCAGUCCCUCGGG 23 13330
HSV2-UL30-4977 + CCCGAACGCCUGCAGUCCCUCGGG 24 13331
HSV2-UL30-4978 + CUCGAGCU UGAUCGGGGG 18 13332
HSV2-UL30-4979 + ACUCGAGCUUGAUCGGGGG 19 13333
HSV2-UL30-2423 + CACUCGAGCUUGAUCGGGGG 20 5177
HSV2-UL30-4980 + GCACUCGAGCUUGAUCGGGGG 21 13334
HSV2-UL30-4981 + CGCACUCGAGCU UGAUCGGGGG 22 13335
HSV2-UL30-4982 + UCGCACUCGAGCUUGAUCGGGGG 23 13336
HSV2-UL30-4983 + UUCGCACUCGAGCUUGAUCGGGGG 24 13337
HSV2-UL30-4984 + UCGAGCU UGAUCGGGGGG 18 13338
HSV2-UL30-4985 + CUCGAGCUUGAUCGGGGGG 19 13339
HSV2-UL30-1208 + ACUCGAGCUUGAUCGGGGGG 20 4078
HSV2-UL30-4986 + CACUCGAGCU UGAUCGGGGGG 21 13340
HSV2-UL30-4987 + GCACUCGAGCUUGAUCGGGGGG 22 13341
HSV2-UL30-4988 + CGCACUCGAGCUUGAUCGGGGGG 23 13342
HSV2-UL30-4989 + UCGCACUCGAGCUUGAUCGGGGGG 24 13343
HSV2-UL30-4990 + GGCAGGGCCGCUGGGGGG 18 13344
HSV2-UL30-4991 + GGGCAGGGCCGCUGGGGGG 19 13345
HSV2-UL30-2379 + AGGGCAGGGCCGCUGGGGGG 20 5145
HSV2-UL30-4992 + GAGGGCAGGGCCGCUGGGGGG 21 13346
HSV2-UL30-4993 + GG AGGGCAGGGCCGCUGGGGGG 22 13347
HSV2-UL30-4994 + GGG AGGGCAGGGCCGCUGGGGGG 23 13348
HSV2-UL30-4995 + GGGGAGGGCAGGGCCGCUGGGGGG 24
13349
HSV2-UL30-4996 + UGAAACCCGGAGGUGGGG 18 13350
HSV2-UL30-4997 + GUGAAACCCGGAGGUGGGG 19 13351
HSV2-UL30-2480 + CG UGAAACCCGGAGGUGGGG 20 5215
HSV2-UL30-4998 + ACG UGAAACCCGGAGGUGGGG 21 13352
HSV2-UL30-4999 + GACG UGAAACCCGGAGGUGGGG 22 13353
HSV2-UL30-5000 + CG ACG UGAAACCCGGAGGUGGGG 23 13354
HSV2-UL30-5001 + UCGACGUGAAACCCGGAGGUGGGG 24 13355
HSV2-UL30-5002 + GGAUCCGGUCCUUGAUGG 18 13356
HSV2-UL30-5003 + GGGAUCCGGUCCU UGAUGG 19 13357
HSV2-UL30-2390 + CGGGAUCCGGUCCU UGAUGG 20 5153
HSV2-UL30-5004 + ACGGGAUCCGGUCCU UGAUGG 21 13358 HSV2-UL30-5005 + UACGGGAUCCGG UCCUUGAUGG 22 13359
HSV2-UL30-5006 + GUACGGGAUCCGGUCCU UGAUGG 23 13360
HSV2-UL30-5007 + CGUACGGGAUCCGGUCCUUGAUGG 24 13361
HSV2-UL30-5008 + GGAGGGCAGGGCCGCUGG 18 13362
HSV2-UL30-5009 + GGGAGGGCAGGGCCGCUGG 19 13363
HSV2-UL30-1137 + GGGGAGGGCAGGGCCGCUGG 20 4007
HSV2-UL30-5010 + CGGGGAGGGCAGGGCCGCUGG 21 13364
HSV2-UL30-5011 + CCGGGGAGGGCAGGGCCGCUGG 22 13365
HSV2-UL30-5012 + GCCGGGGAGGGCAGGGCCGCUGG 23 13366
HSV2-UL30-5013 + GGCCGGGGAGGGCAGGGCCGCUGG 24 13367
HSV2-UL30-5014 + UCUCCCGGGGGCGCUUGG 18 13368
HSV2-UL30-5015 + GUCUCCCGGGGGCGCUUGG 19 13369
HSV2-UL30-2368 + CGUCUCCCGGGGGCGCUUGG 20 5141
HSV2-UL30-5016 + GCGUCUCCCGGGGGCGCUUGG 21 13370
HSV2-UL30-5017 + GGCGUCUCCCGGGGGCGCUUGG 22 13371
HSV2-UL30-5018 + CGGCGUCUCCCGGGGGCGCU UGG 23 13372
HSV2-UL30-5019 + ACGGCGUCUCCCGGGGGCGCUUGG 24 13373
HSV2-UL30-5020 + AGACAGGAGAUCUGGAUG 18 13374
HSV2-UL30-5021 + CAGACAGGAGAUCUGGAUG 19 13375
HSV2-UL30-2554 + GCAGACAGGAGAUCUGGAUG 20 5271
HSV2-UL30-5022 + AGCAGACAGGAGAUCUGGAUG 21 13376
HSV2-UL30-5023 + GAGCAGACAGGAGAUCUGGAUG 22 13377
HSV2-UL30-5024 + AGAGCAGACAGGAGAUCUGGAUG 23 13378
HSV2-UL30-5025 + U AG AGCAGACAGGAGAUCUGGAUG 24 13379
HSV2-UL30-5026 + U UGUGGGCCUGGAUGAUG 18 13380
HSV2-UL30-5027 + GUUGUGGGCCUGGAUGAUG 19 13381
HSV2-UL30-2471 + GG UUGUGGGCCUGGAUGAUG 20 5210
HSV2-UL30-5028 + AGGUUGUGGGCCUGGAUGAUG 21 13382
HSV2-UL30-5029 + CAGG UUGUGGGCCUGGAUGAUG 22 13383
HSV2-UL30-5030 + ACAGG UUGUGGGCCUGGAUGAUG 23 13384
HSV2-UL30-5031 + CACAGGUUGUGGGCCUGGAUGAUG 24
13385
HSV2-UL30-5032 + GGGAGGGCAGGGCCGCUG 18 13386
HSV2-UL30-5033 + GGGGAGGGCAGGGCCGCUG 19 13387
HSV2-UL30-1136 + CGGGGAGGGCAGGGCCGCUG 20 4006
HSV2-UL30-5034 + CCGGGGAGGGCAGGGCCGCUG 21 13388
HSV2-UL30-5035 + GCCGGGGAGGGCAGGGCCGCUG 22 13389
HSV2-UL30-5036 + GGCCGGGGAGGGCAGGGCCGCUG 23 13390
HSV2-UL30-5037 + UGGCCGGGGAGGGCAGGGCCGCUG 24 13391
HSV2-UL30-5038 + GCGCCAGCCACUCCUCUG 18 13392
HSV2-UL30-5039 + CGCGCCAGCCACUCCUCUG 19 13393
HSV2-UL30-1187 + UCGCGCCAGCCACUCCUCUG 20 4057
HSV2-UL30-5040 + GUCGCGCCAGCCACUCCUCUG 21 13394
HSV2-UL30-5041 + GGUCGCGCCAGCCACUCCUCUG 22 13395
HSV2-UL30-5042 + GGGUCGCGCCAGCCACUCCUCUG 23 13396
HSV2-UL30-5043 + GGGGUCGCGCCAGCCACUCCUCUG 24 13397 HSV2-UL30-5044 + GAGAAGUAAUAGUCCGUG 18 13398
HSV2-UL30-5045 + CGAGAAGUAAUAGUCCGUG 19 13399
HSV2-UL30-2351 + GCGAGAAGUAAUAGUCCGUG 20 5132
HSV2-UL30-5046 + UGCGAGAAGUAAUAGUCCGUG 21 13400
HSV2-UL30-5047 + GUGCGAGAAGUAAUAGUCCGUG 22 13401
HSV2-UL30-5048 + GG UGCGAGAAGUAAUAGUCCGUG 23 13402
HSV2-UL30-5049 + AGGUGCGAGAAGUAAUAGUCCGUG 24 13403
HSV2-UL30-5050 + AUGUGCUCGAGGGCGGUG 18 13404
HSV2-UL30-5051 + GAUGUGCUCGAGGGCGGUG 19 13405
HSV2-UL30-2549 + GGAUGUGCUCGAGGGCGGUG 20 5267
HSV2-UL30-5052 + AGG AUGUGCUCGAGGGCGGUG 21 13406
HSV2-UL30-5053 + GAGG AUGUGCUCGAGGGCGGUG 22 13407
HSV2-UL30-5054 + GGAGGAUGUGCUCGAGGGCGGUG 23 13408
HSV2-UL30-5055 + AGGAGGAUGUGCUCGAGGGCGGUG 24
13409
HSV2-UL30-5056 + AGGUGCGGCAGAAACUUG 18 13410
HSV2-UL30-5057 + CAGGUGCGGCAGAAACUUG 19 13411
HSV2-UL30-2500 + CCAGGUGCGGCAGAAACU UG 20 5233
HSV2-UL30-5058 + UCCAGGUGCGGCAGAAACU UG 21 13412
HSV2-UL30-5059 + CUCCAGGUGCGGCAGAAACU UG 22 13413
HSV2-UL30-5060 + GCUCCAGGUGCGGCAGAAACUUG 23 13414
HSV2-UL30-5061 + AGCUCCAGGUGCGGCAGAAACUUG 24 13415
HSV2-UL30-5062 + ACCAGAUCCACGCCCUUG 18 13416
HSV2-UL30-5063 + CACCAGAUCCACGCCCUUG 19 13417
HSV2-UL30-2413 + GCACCAGAUCCACGCCCUUG 20 5172
HSV2-UL30-5064 + CGCACCAGAUCCACGCCCUUG 21 13418
HSV2-UL30-5065 + GCGCACCAGAUCCACGCCCUUG 22 13419
HSV2-UL30-5066 + UGCGCACCAGAUCCACGCCCUUG 23 13420
HSV2-UL30-5067 + UUGCGCACCAGAUCCACGCCCUUG 24 13421
HSV2-UL30-5068 + CGCUUGGGCGCCUCCUUG 18 13422
HSV2-UL30-5069 + GCGCUUGGGCGCCUCCUUG 19 13423
HSV2-UL30-2486 + GGCGCUUGGGCGCCUCCUUG 20 5221
HSV2-UL30-5070 + GGGCGCUUGGGCGCCUCCU UG 21 13424
HSV2-UL30-5071 + CGGGCGCU UGGGCGCCUCCUUG 22 13425
HSV2-UL30-5072 + CCGGGCGCUUGGGCGCCUCCUUG 23 13426
HSV2-UL30-5073 + GCCGGGCGCUUGGGCGCCUCCUUG 24 13427
HSV2-UL30-5074 + UACGGGAUCCGGUCCU UG 18 13428
HSV2-UL30-5075 + GUACGGGAUCCGGUCCUUG 19 13429
HSV2-UL30-2389 + CGUACGGGAUCCGGUCCUUG 20 5152
HSV2-UL30-5076 + ACGUACGGGAUCCGGUCCU UG 21 13430
HSV2-UL30-5077 + CACGUACGGGAUCCGGUCCUUG 22 13431
HSV2-UL30-5078 + UCACGUACGGGAUCCGGUCCUUG 23 13432
HSV2-UL30-5079 + AUCACGUACGGGAUCCGGUCCUUG 24 13433
HSV2-UL30-5080 + UCGGACACCAGCAGCUUG 18 13434
HSV2-UL30-5081 + CUCGGACACCAGCAGCUUG 19 13435
HSV2-UL30-1111 + GCUCGGACACCAGCAGCUUG 20 3981 HSV2-UL30-5082 + AGCUCGGACACCAGCAGCUUG 21 13436
HSV2-UL30-5083 + CAGCUCGG ACACCAGCAGCU UG 22 13437
HSV2-UL30-5084 + CCAGCUCGGACACCAGCAGCUUG 23 13438
HSV2-UL30-5085 + GCCAGCUCGGACACCAGCAGCUUG 24 13439
HSV2-UL30-5086 + GCGAUGAGCAGCAGCUUG 18 13440
HSV2-UL30-5087 + GGCGAUGAGCAGCAGCUUG 19 13441
HSV2-UL30-2415 + UGGCGAUGAGCAGCAGCUUG 20 5174
HSV2-UL30-5088 + UUGGCGAUGAGCAGCAGCUUG 21 13442
HSV2-UL30-5089 + CU UGGCGAUGAGCAGCAGCU UG 22 13443
HSV2-UL30-5090 + UCU UGGCGAUGAGCAGCAGCU UG 23 13444
HSV2-UL30-5091 + UUCUUGGCGAUGAGCAGCAGCUUG 24 13445
HSV2-UL30-5092 + UCGGGGCCGUACUGCU UG 18 13446
HSV2-UL30-5093 + CUCGGGGCCGUACUGCU UG 19 13447
HSV2-UL30-2524 + ACUCGGGGCCGUACUGCUUG 20 5250
HSV2-UL30-5094 + AACUCGGGGCCGUACUGCU UG 21 13448
HSV2-UL30-5095 + GAACUCGGGGCCGUACUGCUUG 22 13449
HSV2-UL30-5096 + CGAACUCGGGGCCGUACUGCUUG 23 13450
HSV2-UL30-5097 + ACGAACUCGGGGCCGUACUGCU UG 24 13451
HSV2-UL30-5098 + AUGGCGGCCUGUUGCU UG 18 13452
HSV2-UL30-5099 + GAUGGCGGCCUGUUGCUUG 19 13453
HSV2-UL30-2446 + UGAUGGCGGCCUGUUGCU UG 20 5193
HSV2-UL30-5100 + UUGAUGGCGGCCUGUUGCU UG 21 13454
HSV2-UL30-5101 + CUUGAUGGCGGCCUGUUGCUUG 22 13455
HSV2-UL30-5102 + CCUUGAUGGCGGCCUG UUGCU UG 23 13456
HSV2-UL30-5103 + ACCUUGAUGGCGGCCUGUUGCUUG 24 13457
HSV2-UL30-5104 + UCGGGGAGGUCGCAGGAU 18 13458
HSV2-UL30-5105 + CUCGGGGAGGUCGCAGGAU 19 13459
HSV2-UL30-2542 + ACUCGGGGAGGUCGCAGGAU 20 5261
HSV2-UL30-5106 + GACUCGGGGAGGUCGCAGGAU 21 13460
HSV2-UL30-5107 + GGACUCGGGGAGGUCGCAGGAU 22 13461
HSV2-UL30-5108 + GGG ACUCGGGGAGGUCGCAGGAU 23 13462
HSV2-UL30-5109 + UGGGACUCGGGGAGGUCGCAGGAU 24
13463
HSV2-UL30-5110 + UUCGCACUCGAGCUUGAU 18 13464
HSV2-UL30-5111 + UUUCGCACUCGAGCUUGAU 19 13465
HSV2-UL30-1203 + UUU UCGCACUCGAGCUUGAU 20 4073
HSV2-UL30-5112 + UUU UUCGCACUCGAGCU UGAU 21 13466
HSV2-UL30-5113 + UUU UUUCGCACUCGAGCUUGAU 22 13467
HSV2-UL30-5114 + GUUU UUUCGCACUCGAGCU UGAU 23 13468
HSV2-UL30-5115 + CGU UUUUUCGCACUCGAGCUUGAU 24 13469
HSV2-UL30-5116 + U G U ACCCG G U C ACG A AC U 18 13470
HSV2-UL30-5117 + UUGUACCCGGUCACGAACU 19 13471
HSV2-UL30-1337 + GUUGUACCCGGUCACGAACU 20 4207
HSV2-UL30-5118 + UGUUGUACCCGGUCACGAACU 21 13472
HSV2-UL30-5119 + AUGUUGUACCCGGUCACGAACU 22 13473
HSV2-UL30-5120 + GAUGU UGUACCCGGUCACGAACU 23 13474 HSV2-UL30-5121 + UGAUGUUGUACCCGGUCACGAACU 24 13475
HSV2-UL30-5122 + GAUCGCUGAGGUGGGACU 18 13476
HSV2-UL30-5123 + AGAUCGCUGAGGUGGGACU 19 13477
HSV2-UL30-1354 + GAGAUCGCUGAGGUGGGACU 20 4224
HSV2-UL30-5124 + CGAGAUCGCUGAGGUGGGACU 21 13478
HSV2-UL30-5125 + GCG AGAUCGCUGAGGUGGGACU 22 13479
HSV2-UL30-5126 + GGCG AGAUCGCUGAGGUGGGACU 23 13480
HSV2-UL30-5127 + AGGCGAGAUCGCUGAGGUGGGACU 24 13481
HSV2-UL30-5128 + CGCGCAUGCCGGCCGCCU 18 13482
HSV2-UL30-5129 + GCGCGCAUGCCGGCCGCCU 19 13483
HSV2-UL30-2436 + GGCGCGCAUGCCGGCCGCCU 20 5185
HSV2-UL30-5130 + GGGCGCGCAUGCCGGCCGCCU 21 13484
HSV2-UL30-5131 + GGGGCGCGCAUGCCGGCCGCCU 22 13485
HSV2-UL30-5132 + GGGGGCGCGCAUGCCGGCCGCCU 23 13486
HSV2-UL30-5133 + CGGGGGCGCGCAUGCCGGCCGCCU 24 13487
HSV2-UL30-5134 + ACGGCGACGCGAUGGCCU 18 13488
HSV2-UL30-5135 + AACGGCGACGCGAUGGCCU 19 13489
HSV2-UL30-2588 + GAACGGCGACGCGAUGGCCU 20 5297
HSV2-UL30-5136 + UG AACGGCGACGCGAUGGCCU 21 13490
HSV2-UL30-5137 + GUGAACGGCGACGCGAUGGCCU 22 13491
HSV2-UL30-5138 + CGUG AACGGCGACGCGAUGGCCU 23 13492
HSV2-UL30-5139 + ACGUG AACGGCGACGCGAUGGCCU 24 13493
HSV2-UL30-5140 + CGAGGAGGACGGCCUCCU 18 13494
HSV2-UL30-5141 + UCGAGGAGGACGGCCUCCU 19 13495
HSV2-UL30-1240 + GUCGAGGAGGACGGCCUCCU 20 4110
HSV2-UL30-5142 + UGUCGAGGAGGACGGCCUCCU 21 13496
HSV2-UL30-5143 + UUGUCGAGGAGGACGGCCUCCU 22 13497
HSV2-UL30-5144 + CUUGUCGAGGAGGACGGCCUCCU 23 13498
HSV2-UL30-5145 + GCUUGUCGAGGAGGACGGCCUCCU 24 13499
HSV2-UL30-5146 + GGGGAGGGCAGGGCCGCU 18 13500
HSV2-UL30-5147 + CGGGGAGGGCAGGGCCGCU 19 13501
HSV2-UL30-1135 + CCGGGGAGGGCAGGGCCGCU 20 4005
HSV2-UL30-5148 + GCCGGGGAGGGCAGGGCCGCU 21 13502
HSV2-UL30-5149 + GGCCGGGGAGGGCAGGGCCGCU 22 13503
HSV2-UL30-5150 + UGGCCGGGGAGGGCAGGGCCGCU 23 13504
HSV2-UL30-5151 + UUGGCCGGGGAGGGCAGGGCCGCU 24 13505
HSV2-UL30-5152 + GGCCUCCUCGGGGGUGCU 18 13506
HSV2-UL30-5153 + CGGCCUCCUCGGGGGUGCU 19 13507
HSV2-UL30-2453 + ACGGCCUCCUCGGGGGUGCU 20 5197
HSV2-UL30-5154 + GACGGCCUCCUCGGGGGUGCU 21 13508
HSV2-UL30-5155 + GGACGGCCUCCUCGGGGGUGCU 22 13509
HSV2-UL30-5156 + AGG ACGGCCUCCUCGGGGGUGCU 23 13510
HSV2-UL30-5157 + GAGGACGGCCUCCUCGGGGGUGCU 24 13511
HSV2-UL30-5158 + CGCGCCAGCCACUCCUCU 18 13512
HSV2-UL30-5159 + UCGCGCCAGCCACUCCUCU 19 13513
HSV2-UL30-2407 + GUCGCGCCAGCCACUCCUCU 20 5168 HSV2-UL30-5160 + GGUCGCGCCAGCCACUCCUCU 21 13514
HSV2-UL30-5161 + GGGUCGCGCCAGCCACUCCUCU 22 13515
HSV2-UL30-5162 + GGGGUCGCGCCAGCCACUCCUCU 23 13516
HSV2-UL30-5163 + AG GG G U CG CG CCAG CCACU CCU CU 24 13517
HSV2-UL30-5164 + CCUCCUCGGGGGUGCUCU 18 13518
HSV2-UL30-5165 + GCCUCCUCGGGGGUGCUCU 19 13519
HSV2-UL30-1245 + GGCCUCCUCGGGGGUGCUCU 20 4115
HSV2-UL30-5166 + CGGCCUCCUCGGGGGUGCUCU 21 13520
HSV2-UL30-5167 + ACGGCCUCCUCGGGGGUGCUCU 22 13521
HSV2-UL30-5168 + GACGGCCUCCUCGGGGGUGCUCU 23 13522
HSV2-UL30-5169 + GGACGGCCUCCUCGGGGGUGCUCU 24 13523
HSV2-UL30-5170 + CCGGGGGGUGCCACGUCU 18 13524
HSV2-UL30-5171 + UCCGGGGGGUGCCACGUCU 19 13525
HSV2-UL30-1096 + GUCCGGGGGGUGCCACGUCU 20 3966
HSV2-UL30-5172 + CGUCCGGGGGGUGCCACGUCU 21 13526
HSV2-UL30-5173 + UCGUCCGGGGGGUGCCACGUCU 22 13527
HSV2-UL30-5174 + GUCGUCCGGGGGGUGCCACGUCU 23 13528
HSV2-UL30-5175 + CGUCGUCCGGGGGGUGCCACGUCU 24 13529
HSV2-UL30-5176 + AUGCGCCGAUGGGCGUCU 18 13530
HSV2-UL30-5177 + GAUGCGCCGAUGGGCGUCU 19 13531
HSV2-UL30-2401 + UGAUGCGCCGAUGGGCGUCU 20 5163
HSV2-UL30-5178 + GUG AUGCGCCGAUGGGCGUCU 21 13532
HSV2-UL30-5179 + GG UGAUGCGCCGAUGGGCGUCU 22 13533
HSV2-UL30-5180 + CGG UGAUGCGCCGAUGGGCGUCU 23 13534
HSV2-UL30-5181 + UCGGUGAUGCGCCGAUGGGCGUCU 24 13535
HSV2-UL30-5182 + AGAUGAUGCGCAUGGAGU 18 13536
HSV2-UL30-5183 + UAGAUGAUGCGCAUGGAGU 19 13537
HSV2-UL30-2432 + GU AGAUGAUGCGCAUGGAGU 20 5183
HSV2-UL30-5184 + CGU AGAUGAUGCGCAUGGAGU 21 13538
HSV2-UL30-5185 + CCG UAGAUGAUGCGCAUGGAGU 22 13539
HSV2-UL30-5186 + CCCGU AGAUGAUGCGCAUGGAGU 23 13540
HSV2-UL30-5187 + CCCCGUAGAUGAUGCGCAUGGAGU 24 13541
HSV2-UL30-5188 + UCUGGGCCACGAUCACGU 18 13542
HSV2-UL30-5189 + GUCUGGGCCACGAUCACGU 19 13543
HSV2-UL30-2387 + GGUCUGGGCCACGAUCACGU 20 5151
HSV2-UL30-5190 + GGG UCUGGGCCACGAUCACGU 21 13544
HSV2-UL30-5191 + CGGGUCUGGGCCACGAUCACGU 22 13545
HSV2-UL30-5192 + GCGGGUCUGGGCCACGAUCACGU 23 13546
HSV2-UL30-5193 + CGCGGGUCUGGGCCACGAUCACGU 24 13547
HSV2-UL30-5194 + CG AGG U UCCG AACGCCG U 18 13548
HSV2-UL30-5195 + UCGAGGU UCCGAACGCCGU 19 13549
HSV2-UL30-1382 + CUCGAGGUUCCGAACGCCGU 20 4252
HSV2-UL30-5196 + GCUCGAGGUUCCGAACGCCGU 21 13550
HSV2-UL30-5197 + CGCUCGAGGUUCCGAACGCCGU 22 13551
HSV2-UL30-5198 + UCGCUCGAGGUUCCGAACGCCGU 23 13552
HSV2-UL30-5199 + GUCGCUCGAGGU UCCGAACGCCGU 24 13553 HSV2-UL30-5200 + GCCGCGCGGCCACGUCGU 18 13554
HSV2-UL30-5201 + AGCCGCGCGGCCACGUCGU 19 13555
HSV2-UL30-2340 + GAGCCGCGCGGCCACGUCGU 20 5126
HSV2-UL30-5202 + UGAGCCGCGCGGCCACGUCGU 21 13556
HSV2-UL30-5203 + CUGAGCCGCGCGGCCACGUCGU 22 13557
HSV2-UL30-5204 + CCUGAGCCGCGCGGCCACGUCGU 23 13558
HSV2-UL30-5205 + CCCUGAGCCGCGCGGCCACGUCGU 24 13559
HSV2-UL30-5206 + AGGCCGCCCCCAGCAGGU 18 13560
HSV2-UL30-5207 + CAGGCCGCCCCCAGCAGGU 19 13561
HSV2-UL30-2349 + GCAGGCCGCCCCCAGCAGGU 20 5130
HSV2-UL30-5208 + CGCAGGCCGCCCCCAGCAGGU 21 13562
HSV2-UL30-5209 + ACGCAGGCCGCCCCCAGCAGGU 22 13563
HSV2-UL30-5210 + CACGCAGGCCGCCCCCAGCAGGU 23 13564
HSV2-UL30-5211 + UCACGCAGGCCGCCCCCAGCAGGU 24 13565
HSV2-UL30-5212 + UCUGCUCAGU UCGGCGGU 18 13566
HSV2-UL30-5213 + GUCUGCUCAGU UCGGCGGU 19 13567
HSV2-UL30-2397 + UGUCUGCUCAGUUCGGCGGU 20 5159
HSV2-UL30-5214 + GUGUCUGCUCAGUUCGGCGGU 21 13568
HSV2-UL30-5215 + GGUGUCUGCUCAGUUCGGCGGU 22 13569
HSV2-UL30-5216 + GGGUGUCUGCUCAGUUCGGCGGU 23 13570
HSV2-UL30-5217 + CGGGUGUCUGCUCAGU UCGGCGGU 24 13571
HSV2-UL30-5218 + CUCCUCUACCUCGCGGGU 18 13572
HSV2-UL30-5219 + UCUCCUCUACCUCGCGGGU 19 13573
HSV2-UL30-2386 + GUCUCCUCUACCUCGCGGGU 20 5150
HSV2-UL30-5220 + CGUCUCCUCUACCUCGCGGGU 21 13574
HSV2-UL30-5221 + CCGUCUCCUCUACCUCGCGGGU 22 13575
HSV2-UL30-5222 + ACCGUCUCCUCUACCUCGCGGGU 23 13576
HSV2-UL30-5223 + GACCGUCUCCUCUACCUCGCGGGU 24 13577
HSV2-UL30-5224 + GAUCUCCGUCAGCU UGGU 18 13578
HSV2-UL30-5225 + AGAUCUCCGUCAGCUUGGU 19 13579
HSV2-UL30-2517 + UAGAUCUCCGUCAGCU UGGU 20 5244
HSV2-UL30-5226 + GUAGAUCUCCGUCAGCU UGGU 21 13580
HSV2-UL30-5227 + UGUAGAUCUCCGUCAGCUUGGU 22 13581
HSV2-UL30-5228 + UUGUAGAUCUCCGUCAGCUUGGU 23 13582
HSV2-UL30-5229 + CUUGUAGAUCUCCGUCAGCUUGGU 24 13583
HSV2-UL30-5230 + CGGCGACGCGAUGGCCU U 18 13584
HSV2-UL30-5231 + ACGGCG ACGCG AUGGCCU U 19 13585
HSV2-UL30-1429 + AACGGCGACGCGAUGGCCUU 20 4299
HSV2-UL30-5232 + G AACGGCG ACGCG AUGGCCU U 21 13586
HSV2-UL30-5233 + UG AACGGCGACGCGAUGGCCUU 22 13587
HSV2-UL30-5234 + GUGAACGGCG ACGCG AUGGCCU U 23 13588
HSV2-UL30-5235 + CGUGAACGGCGACGCGAUGGCCUU 24 13589
HSV2-UL30-5236 + CUCGG ACACCAGCAGCU U 18 13590
HSV2-UL30-5237 + GCUCGGACACCAGCAGCUU 19 13591
HSV2-UL30-2358 + AGCUCGGACACCAGCAGCUU 20 5137
HSV2-UL30-5238 + CAGCUCGGACACCAGCAGCU U 21 13592 HSV2-UL30-5239 + CCAGCUCGG ACACCAGCAGCU U 22 13593
HSV2-UL30-5240 + GCCAGCUCGGACACCAGCAGCU U 23 13594
HSV2-UL30-5241 + CGCCAGCUCGGACACCAGCAGCUU 24 13595
HSV2-UL30-5242 + CUUGAUCUUGCUGCGCU U 18 13596
HSV2-UL30-5243 + CCUUGAUCUUGCUGCGCUU 19 13597
HSV2-UL30-2511 + ACCU UGAUCUUGCUGCGCU U 20 5240
HSV2-UL30-5244 + CACCUUGAUCUUGCUGCGCUU 21 13598
HSV2-UL30-5245 + UCACCUUGAUCUUGCUGCGCUU 22 13599
HSV2-UL30-5246 + UUCACCUUGAUCUUGCUGCGCUU 23 13600
HSV2-UL30-5247 + GUUCACCU UGAUCUUGCUGCGCUU 24 13601
HSV2-UL30-5248 + UCUGGAUGACGAGGUCU U 18 13602
HSV2-UL30-5249 + AUCUGGAUGACGAGGUCUU 19 13603
HSV2-UL30-2555 + GAUCUGGAUGACGAGGUCUU 20 5272
HSV2-UL30-5250 + AGAUCUGGAUGACGAGGUCUU 21 13604
HSV2-UL30-5251 + GAGAUCUGGAUGACGAGGUCUU 22 13605
HSV2-UL30-5252 + GGAGAUCUGGAUGACGAGGUCU U 23 13606
HSV2-UL30-5253 + AGGAGAUCUGGAUGACGAGGUCUU 24
13607
HSV2-UL30-5254 + CGUACUGAAGCACAGGUU 18 13608
HSV2-UL30-5255 + GCG UACUGAAGCACAGGUU 19 13609
HSV2-UL30-2469 + AGCGUACUGAAGCACAGGU U 20 5208
HSV2-UL30-5256 + GAGCGUACUGAAGCACAGGUU 21 13610
HSV2-UL30-5257 + AG AGCGUACUGAAGCACAGGUU 22 13611
HSV2-UL30-5258 + GAGAGCGUACUGAAGCACAGGUU 23 13612
HSV2-UL30-5259 + GGAGAGCGUACUGAAGCACAGGU U 24 13613
HSV2-UL30-5260 + UCGACGUCGCUCGAGGU U 18 13614
HSV2-UL30-5261 + CUCGACGUCGCUCGAGGUU 19 13615
HSV2-UL30-2561 + ACUCGACGUCGCUCGAGGUU 20 5277
HSV2-UL30-5262 + AACUCGACGUCGCUCGAGGUU 21 13616
HSV2-UL30-5263 + AAACUCGACGUCGCUCGAGGUU 22 13617
HSV2-UL30-5264 + UAAACUCGACGUCGCUCGAGGU U 23 13618
HSV2-UL30-5265 + UUAAACUCGACGUCGCUCGAGGUU 24 13619
HSV2-UL30-5266 - UUUGUCCUCACCGCCGAA 18 13620
HSV2-UL30-5267 - CU UUGUCCUCACCGCCGAA 19 13621
HSV2-UL30-2015 - ACU UUGUCCUCACCGCCGAA 20 4914
HSV2-UL30-5268 - GACUUUGUCCUCACCGCCGAA 21 13622
HSV2-UL30-5269 - GGACUUUGUCCUCACCGCCGAA 22 13623
HSV2-UL30-5270 - AGGACUU UGUCCUCACCGCCGAA 23 13624
HSV2-UL30-5271 - CAGGACUUUGUCCUCACCGCCGAA 24 13625
HSV2-UL30-5272 - ACCGCGUCUUCGUGCGAA 18 13626
HSV2-UL30-5273 - UACCGCGUCUUCGUGCGAA 19 13627
HSV2-UL30-1812 - CUACCGCGUCUUCGUGCGAA 20 4784
HSV2-UL30-5274 - ACUACCGCG UCUUCGUGCGAA 21 13628
HSV2-UL30-5275 - UACUACCGCGUCU UCGUGCGAA 22 13629
HSV2-UL30-5276 - GUACUACCGCGUCUUCGUGCGAA 23 13630
HSV2-UL30-5277 - UGUACUACCGCGUCU UCGUGCGAA 24 13631 HSV2-UL30-5278 - GCGGCCGGGGGACGGGAA 18 13632
HSV2-UL30-5279 - AGCGGCCGGGGGACGGGAA 19 13633
HSV2-UL30-589 - GAGCGGCCGGGGGACGGGAA 20 3459
HSV2-UL30-5280 - GGAGCGGCCGGGGGACGGGAA 21 13634
HSV2-UL30-5281 - GGG AGCGGCCGGGGGACGGGAA 22 13635
HSV2-UL30-5282 - GGGG AGCGGCCGGGGGACGGGAA 23 13636
HSV2-UL30-5283 - AGGGGAGCGGCCGGGGGACGGGAA 24 13637
HSV2-UL30-5284 - GCCGUGCCUCGGGGGGAA 18 13638
HSV2-UL30-5285 - GGCCGUGCCUCGGGGGGAA 19 13639
HSV2-UL30-580 - CGGCCGUGCCUCGGGGGGAA 20 3450
HSV2-UL30-5286 - CCGGCCGUGCCUCGGGGGGAA 21 13640
HSV2-UL30-5287 - CCCGGCCGUGCCUCGGGGGGAA 22 13641
HSV2-UL30-5288 - GCCCGGCCGUGCCUCGGGGGGAA 23 13642
HSV2-UL30-5289 - CGCCCGGCCGUGCCUCGGGGGGAA 24 13643
HSV2-UL30-5290 - GGUUUCGGGGCCUCGACA 18 13644
HSV2-UL30-5291 - CGGU UUCGGGGCCUCGACA 19 13645
HSV2-UL30-571 - GCGGUUUCGGGGCCUCGACA 20 3441
HSV2-UL30-5292 - GGCGGUUUCGGGGCCUCGACA 21 13646
HSV2-UL30-5293 - GGGCGGUUUCGGGGCCUCGACA 22 13647
HSV2-UL30-5294 - GGGGCGGUU UCGGGGCCUCGACA 23 13648
HSV2-UL30-5295 - AGGGGCGGUU UCGGGGCCUCGACA 24 13649
HSV2-UL30-5296 - CCGGCACGUUGGGUACCA 18 13650
HSV2-UL30-5297 - GCCGGCACGUUGGGUACCA 19 13651
HSV2-UL30-612 - GGCCGGCACGU UGGGUACCA 20 3482
HSV2-UL30-5298 - GGGCCGGCACG UUGGGUACCA 21 13652
HSV2-UL30-5299 - GGGGCCGGCACGUUGGGUACCA 22 13653
HSV2-UL30-5300 - GGGGGCCGGCACGUUGGGUACCA 23 13654
HSV2-UL30-5301 - CGGGGGCCGGCACGU UGGGUACCA 24 13655
HSV2-UL30-5302 - CUAGACGCCGCCGCCCCA 18 13656
HSV2-UL30-5303 - GCUAGACGCCGCCGCCCCA 19 13657
HSV2-UL30-718 - AGCUAGACGCCGCCGCCCCA 20 3588
HSV2-UL30-5304 - GAGCUAGACGCCGCCGCCCCA 21 13658
HSV2-UL30-5305 - CGAGCUAGACGCCGCCGCCCCA 22 13659
HSV2-UL30-5306 - GCGAGCUAGACGCCGCCGCCCCA 23 13660
HSV2-UL30-5307 - CGCGAGCUAGACGCCGCCGCCCCA 24 13661
HSV2-UL30-5308 - U UAGCCGAGCGCCCCGCA 18 13662
HSV2-UL30-5309 - GUUAGCCGAGCGCCCCGCA 19 13663
HSV2-UL30-2001 - CGU UAGCCGAGCGCCCCGCA 20 4905
HSV2-UL30-5310 - G CG U U AG CCG AG CG CCCCG CA 21 13664
HSV2-UL30-5311 - CGCGU UAGCCGAGCGCCCCGCA 22 13665
HSV2-UL30-5312 - CCGCGUUAGCCGAGCGCCCCGCA 23 13666
HSV2-UL30-5313 - GCCGCGU UAGCCGAGCGCCCCGCA 24 13667
HSV2-UL30-5314 - AACUCGUCGAAUGU UGCA 18 13668
HSV2-UL30-5315 - AAACUCGUCGAAUGU UGCA 19 13669
HSV2-UL30-2063 - GAAACUCGUCGAAUGUUGCA 20 4945
HSV2-UL30-5316 - GGAAACUCGUCGAAUGU UGCA 21 13670 HSV2-UL30-5317 - AGGAAACUCGUCGAAUGUUGCA 22 13671
HSV2-UL30-5318 - GAGGAAACUCGUCGAAUGUUGCA 23 13672
HSV2-UL30-5319 - GGAGGAAACUCGUCGAAUGU UGCA 24 13673
HSV2-UL30-5320 - GAAAUAACGCCAAGAUCA 18 13674
HSV2-UL30-5321 - GGAAAUAACGCCAAGAUCA 19 13675
HSV2-UL30-2046 - UGGAAAUAACG CCA AG A U C A 20 4933
HSV2-UL30-5322 - UUGGAAAUAACGCCAAGAUCA 21 13676
HSV2-UL30-5323 - UUUGGAAAUAACGCCAAGAUCA 22 13677
HSV2-UL30-5324 - GU U UGGAAAUAACGCCAAGAUCA 23 13678
HSV2-UL30-5325 - UGUU UGGAAAUAACGCCAAGAUCA 24 13679
HSV2-UL30-5326 - ACUCGGUGUACGGGUUCA 18 13680
HSV2-UL30-5327 - AACUCGGUGUACGGGU UCA 19 13681
HSV2-UL30-1973 - CAACUCGGUGUACGGGU UCA 20 4885
HSV2-UL30-5328 - GCAACUCGGUGUACGGGUUCA 21 13682
HSV2-UL30-5329 - UGCAACUCGGUGUACGGGUUCA 22 13683
HSV2-UL30-5330 - GUGCAACUCGGUGUACGGGUUCA 23 13684
HSV2-UL30-5331 - UGUGCAACUCGGUGUACGGGUUCA 24 13685
HSV2-UL30-5332 - AGGAGGUCGCGCGCGAGA 18 13686
HSV2-UL30-5333 - GAGGAGGUCGCGCGCGAGA 19 13687
HSV2-UL30-1940 - CG AGGAGGUCGCGCGCGAGA 20 4863
HSV2-UL30-5334 - GCGAGGAGGUCGCGCGCGAGA 21 13688
HSV2-UL30-5335 - CGCG AGGAGGUCGCGCGCGAGA 22 13689
HSV2-UL30-5336 - GCGCG AGGAGGUCGCGCGCGAGA 23 13690
HSV2-UL30-5337 - AGCGCGAGGAGGUCGCGCGCGAGA 24 13691
HSV2-UL30-5338 - ACCGGGACUACCUGGAGA 18 13692
HSV2-UL30-5339 - GACCGGGACUACCUGGAGA 19 13693
HSV2-UL30-1957 - GG ACCGGGACUACCUGGAGA 20 4873
HSV2-UL30-5340 - CGG ACCGGGACUACCUGGAGA 21 13694
HSV2-UL30-5341 - GCGG ACCGGGACUACCUGGAGA 22 13695
HSV2-UL30-5342 - GGCGG ACCGGGACUACCUGGAGA 23 13696
HSV2-UL30-5343 - AGGCGGACCGGGACUACCUGGAGA 24 13697
HSV2-UL30-5344 - CGCGAUCAGGAAGUACGA 18 13698
HSV2-UL30-5345 - CCGCGAUCAGGAAGUACGA 19 13699
HSV2-UL30-474 - CCCGCGAUCAGGAAGUACGA 20 3344
HSV2-UL30-5346 - CCCCGCGAUCAGGAAGUACGA 21 13700
HSV2-UL30-5347 - GCCCCGCGAUCAGGAAGUACGA 22 13701
HSV2-UL30-5348 - UGCCCCGCGAUCAGGAAGUACGA 23 13702
HSV2-UL30-5349 - UUGCCCCGCGAUCAGGAAGUACGA 24 13703
HSV2-UL30-5350 - GGACAACCUGGCCGUCGA 18 13704
HSV2-UL30-5351 - CGGACAACCUGGCCGUCGA 19 13705
HSV2-UL30-495 - GCGGACAACCUGGCCGUCGA 20 3365
HSV2-UL30-5352 - GGCGGACAACCUGGCCGUCGA 21 13706
HSV2-UL30-5353 - CGGCGGACAACCUGGCCGUCGA 22 13707
HSV2-UL30-5354 - ACGGCGGACAACCUGGCCGUCGA 23 13708
HSV2-UL30-5355 - CACGGCGGACAACCUGGCCGUCGA 24 13709
HSV2-UL30-5356 - UAAGGACGACGACGAGGA 18 13710 HSV2-UL30-5357 - AUAAGGACGACGACGAGGA 19 13711
HSV2-UL30-595 - GAUAAGGACGACGACGAGGA 20 3465
HSV2-UL30-5358 - GG AUAAGGACGACGACGAGGA 21 13712
HSV2-UL30-5359 - AGG AUAAGGACGACGACGAGGA 22 13713
HSV2-UL30-5360 - GAGG AUAAGGACGACGACGAGGA 23 13714
HSV2-UL30-5361 - CGAGGAUAAGGACGACGACGAGGA 24 13715
HSV2-UL30-5362 - CGAGGACGGGGACGAGGA 18 13716
HSV2-UL30-5363 - ACGAGGACGGGGACGAGGA 19 13717
HSV2-UL30-599 - GACGAGGACGGGGACGAGGA 20 3469
HSV2-UL30-5364 - CG ACGAGGACGGGGACGAGGA 21 13718
HSV2-UL30-5365 - ACG ACGAGGACGGGGACGAGGA 22 13719
HSV2-UL30-5366 - GACG ACGAGGACGGGGACGAGGA 23 13720
HSV2-UL30-5367 - CGACGACGAGGACGGGGACGAGGA 24 13721
HSV2-UL30-5368 - GCGCAUCACCGACCCGGA 18 13722
HSV2-UL30-5369 - GGCGCAUCACCGACCCGGA 19 13723
HSV2-UL30-2011 - CG G CG CA U CACCG ACCCGG A 20 4911
HSV2-UL30-5370 - UCGGCGCAUCACCGACCCGGA 21 13724
HSV2-UL30-5371 - AUCGGCGCAUCACCGACCCGGA 22 13725
HSV2-UL30-5372 - CAUCGGCGCAUCACCGACCCGGA 23 13726
HSV2-UL30-5373 - CCAUCGGCGCAUCACCGACCCGGA 24 13727
HSV2-UL30-5374 - CGCGCACCUGGAGGCGGA 18 13728
HSV2-UL30-5375 - UCGCGCACCUGGAGGCGGA 19 13729
HSV2-UL30-1953 - GUCGCGCACCUGGAGGCGGA 20 4871
HSV2-UL30-5376 - CG UCGCGCACCUGGAGGCGGA 21 13730
HSV2-UL30-5377 - CCG UCGCGCACCUGGAGGCGGA 22 13731
HSV2-UL30-5378 - GCCG UCGCGCACCUGGAGGCGGA 23 13732
HSV2-UL30-5379 - GGCCG UCGCGCACCUGGAGGCGGA 24 13733
HSV2-UL30-5380 - AGCGGCCGGGGGACGGGA 18 13734
HSV2-UL30-5381 - GAGCGGCCGGGGGACGGGA 19 13735
HSV2-UL30-1919 - GG AGCGGCCGGGGGACGGGA 20 4849
HSV2-UL30-5382 - GGG AGCGGCCGGGGGACGGGA 21 13736
HSV2-UL30-5383 - GGGG AGCGGCCGGGGGACGGGA 22 13737
HSV2-UL30-5384 - AGGGG AGCGGCCGGGGGACGGGA 23 13738
HSV2-UL30-5385 - AAGGGGAGCGGCCGGGGGACGGGA 24 13739
HSV2-UL30-5386 - AGGGGAGCGGCCGGGGGA 18 13740
HSV2-UL30-5387 - AAGGGGAGCGGCCGGGGGA 19 13741
HSV2-UL30-587 - GAAGGGGAGCGGCCGGGGGA 20 3457
HSV2-UL30-5388 - GG AAGGGGAGCGGCCGGGGGA 21 13742
HSV2-UL30-5389 - GGG AAGGGGAGCGGCCGGGGGA 22 13743
HSV2-UL30-5390 - GGGG AAGGGGAGCGGCCGGGGGA 23 13744
HSV2-UL30-5391 - GGGGGAAGGGGAGCGGCCGGGGGA 24
13745
HSV2-UL30-5392 - GGCCGUGCCUCGGGGGGA 18 13746
HSV2-UL30-5393 - CGGCCGUGCCUCGGGGGGA 19 13747
HSV2-UL30-579 - CCGGCCGUGCCUCGGGGGGA 20 3449
HSV2-UL30-5394 - CCCGGCCGUGCCUCGGGGGGA 21 13748 HSV2-UL30-5395 - GCCCGGCCGUGCCUCGGGGGGA 22 13749
HSV2-UL30-5396 - CGCCCGGCCGUGCCUCGGGGGGA 23 13750
HSV2-UL30-5397 - GCGCCCGGCCGUGCCUCGGGGGGA 24 13751
HSV2-UL30-5398 - UCGUCCUGACCAAGCUGA 18 13752
HSV2-UL30-5399 - UUCGUCCUGACCAAGCUGA 19 13753
HSV2-UL30-522 - CU UCGUCCUGACCAAGCUGA 20 3392
HSV2-UL30-5400 - CCUUCGUCCUGACCAAGCUGA 21 13754
HSV2-UL30-5401 - CCCUUCGUCCUGACCAAGCUGA 22 13755
HSV2-UL30-5402 - GCCCUUCGUCCUGACCAAGCUGA 23 13756
HSV2-UL30-5403 - GGCCCUUCGUCCUGACCAAGCUGA 24 13757
HSV2-UL30-5404 - GCAGCAAGAUCAAGGUGA 18 13758
HSV2-UL30-5405 - CG C AG C A AG A U C A AG G U G A 19 13759
HSV2-UL30-1872 - GCGCAGCAAGAUCAAGGUGA 20 4821
HSV2-UL30-5406 - AGCGCAGCAAGAUCAAGGUGA 21 13760
HSV2-UL30-5407 - AAGCGCAGCAAGAUCAAGGUGA 22 13761
HSV2-UL30-5408 - GAAGCGCAGCAAGAUCAAGGUGA 23 13762
HSV2-UL30-5409 - AGAAGCGCAGCAAGAUCAAGGUGA 24 13763
HSV2-UL30-5410 - CUCCAUGCGCAUCAUCUA 18 13764
HSV2-UL30-5411 - ACUCCAUGCGCAUCAUCUA 19 13765
HSV2-UL30-664 - UACUCCAUGCGCAUCAUCUA 20 3534
HSV2-UL30-5412 - GUACUCCAUGCGCAUCAUCUA 21 13766
HSV2-UL30-5413 - CGUACUCCAUGCGCAUCAUCUA 22 13767
HSV2-UL30-5414 - CCGUACUCCAUGCGCAUCAUCUA 23 13768
HSV2-UL30-5415 - UCCGUACUCCAUGCGCAUCAUCUA 24 13769
HSV2-UL30-5416 - GCCCAG ACCCGCG AGG U A 18 13770
HSV2-UL30-5417 - GGCCCAGACCCGCGAGGUA 19 13771
HSV2-UL30-2020 - UGGCCCAG ACCCGCG AGG U A 20 4919
HSV2-UL30-5418 - GUGGCCCAG ACCCGCG AGGU A 21 13772
HSV2-UL30-5419 - CG UGGCCCAG ACCCGCG AGG U A 22 13773
HSV2-UL30-5420 - UCGUGGCCCAGACCCGCGAGGUA 23 13774
HSV2-UL30-5421 - AUCGUGGCCCAGACCCGCGAGG UA 24 13775
HSV2-UL30-5422 - AUCACCGAGAGUCUGU UA 18 13776
HSV2-UL30-5423 - GAUCACCGAGAGUCUGU UA 19 13777
HSV2-UL30-2048 - AGAUCACCGAGAGUCUG UUA 20 4935
HSV2-UL30-5424 - AAGAUCACCGAGAGUCUGUUA 21 13778
HSV2-UL30-5425 - CAAGAUCACCGAGAGUCUGUUA 22 13779
HSV2-UL30-5426 - CCAAGAUCACCGAGAGUCUGUUA 23 13780
HSV2-UL30-5427 - GCCAAGAUCACCGAGAGUCUGUUA 24 13781
HSV2-UL30-5428 - CGG UUUAUCCUGGACAAC 18 13782
HSV2-UL30-5429 - CCGGUU UAUCCUGGACAAC 19 13783
HSV2-UL30-1821 - CCCGGUUUAUCCUGGACAAC 20 4789
HSV2-UL30-5430 - ACCCGGUUUAUCCUGGACAAC 21 13784
HSV2-UL30-5431 - CACCCGGU UUAUCCUGGACAAC 22 13785
HSV2-UL30-5432 - CCACCCGGUUUAUCCUGGACAAC 23 13786
HSV2-UL30-5433 - ACCACCCGGUU UAUCCUGGACAAC 24 13787
HSV2-UL30-5434 - CGGGGCGUUCCGCUCAAC 18 13788 HSV2-UL30-5435 - CCGGGGCG UUCCGCUCAAC 19 13789
HSV2-UL30-2040 - CCCGGGGCGUUCCGCUCAAC 20 4930
HSV2-UL30-5436 - GCCCGGGGCGUUCCGCUCAAC 21 13790
HSV2-UL30-5437 - CGCCCGGGGCGUUCCGCUCAAC 22 13791
HSV2-UL30-5438 - UCGCCCGGGGCGU UCCGCU C A AC 23 13792
HSV2-UL30-5439 - AUCGCCCGGGGCGU UCCGCUCAAC 24 13793
HSV2-UL30-5440 - CGGCCGGGGGACGGGAAC 18 13794
HSV2-UL30-5441 - GCGGCCGGGGGACGGGAAC 19 13795
HSV2-UL30-590 - AGCGGCCGGGGGACGGGAAC 20 3460
HSV2-UL30-5442 - GAGCGGCCGGGGGACGGGAAC 21 13796
HSV2-UL30-5443 - GGAGCGGCCGGGGGACGGGAAC 22 13797
HSV2-UL30-5444 - GGG AGCGGCCGGGGGACGGGAAC 23 13798
HSV2-UL30-5445 - GGGGAGCGGCCGGGGGACGGGAAC 24 13799
HSV2-UL30-5446 - UUCAAGUUUCUGCCGCAC 18 13800
HSV2-UL30-5447 - CUUCAAGU UUCUGCCGCAC 19 13801
HSV2-UL30-1889 - UCUUCAAGUUUCUGCCGCAC 20 4836
HSV2-UL30-5448 - UUCUUCAAGUUUCUGCCGCAC 21 13802
HSV2-UL30-5449 - GU UCUUCAAGUUUCUGCCGCAC 22 13803
HSV2-UL30-5450 - UGUUCUUCAAGUUUCUGCCGCAC 23 13804
HSV2-UL30-5451 - CUGUUCU UCAAGU UUCUGCCGCAC 24 13805
HSV2-UL30-5452 - CCCGAGGCCGUCGCGCAC 18 13806
HSV2-UL30-5453 - GCCCGAGGCCGUCGCGCAC 19 13807
HSV2-UL30-1950 - GGCCCGAGGCCGUCGCGCAC 20 4869
HSV2-UL30-5454 - CGGCCCGAGGCCGUCGCGCAC 21 13808
HSV2-UL30-5455 - GCGGCCCGAGGCCGUCGCGCAC 22 13809
HSV2-UL30-5456 - UGCGGCCCGAGGCCGUCGCGCAC 23 13810
HSV2-UL30-5457 - CUGCGGCCCGAGGCCGUCGCGCAC 24 13811
HSV2-UL30-5458 - GGAGGUCGCGCGCGAGAC 18 13812
HSV2-UL30-5459 - AGGAGGUCGCGCGCGAGAC 19 13813
HSV2-UL30-604 - GAGGAGGUCGCGCGCGAGAC 20 3474
HSV2-UL30-5460 - CG AGGAGGUCGCGCGCGAGAC 21 13814
HSV2-UL30-5461 - GCG AGGAGGUCGCGCGCGAGAC 22 13815
HSV2-UL30-5462 - CGCG AGGAGGUCGCGCGCGAGAC 23 13816
HSV2-UL30-5463 - GCGCGAGGAGGUCGCGCGCGAGAC 24 13817
HSV2-UL30-5464 - GAGGAUAAGGACGACGAC 18 13818
HSV2-UL30-5465 - CGAGGAUAAGGACGACGAC 19 13819
HSV2-UL30-1926 - ACGAGGAUAAGGACGACGAC 20 4854
HSV2-UL30-5466 - GACGAGGAUAAGGACGACGAC 21 13820
HSV2-UL30-5467 - GG ACGAGGAUAAGGACGACGAC 22 13821
HSV2-UL30-5468 - GGG ACGAGGAUAAGGACGACGAC 23 13822
HSV2-UL30-5469 - GGGGACGAGGAUAAGGACGACGAC 24 13823
HSV2-UL30-5470 - CAUCGGCGCAUCACCGAC 18 13824
HSV2-UL30-5471 - CCAUCGGCGCAUCACCGAC 19 13825
HSV2-UL30-2008 - CCCAUCGGCGCAUCACCGAC 20 4909
HSV2-UL30-5472 - GCCCAUCGGCGCAUCACCGAC 21 13826
HSV2-UL30-5473 - CGCCCAUCGGCGCAUCACCGAC 22 13827 HSV2-UL30-5474 - ACGCCCAUCGGCGCAUCACCGAC 23 13828
HSV2-UL30-5475 - GACGCCCAUCGGCGCAUCACCGAC 24 13829
HSV2-UL30-5476 - CGGUUUCGGGGCCUCGAC 18 13830
HSV2-UL30-5477 - GCGGUUUCGGGGCCUCGAC 19 13831
HSV2-UL30-1900 - GGCGGUUUCGGGGCCUCGAC 20 4844
HSV2-UL30-5478 - GGGCGGU UUCGGGGCCUCGAC 21 13832
HSV2-UL30-5479 - GGGGCGGUU UCGGGGCCUCGAC 22 13833
HSV2-UL30-5480 - AGGGGCGGUUUCGGGGCCUCGAC 23 13834
HSV2-UL30-5481 - CAGGGGCGGUU UCGGGGCCUCGAC 24 13835
HSV2-UL30-5482 - GAGGCCGUCUUGAAGGAC 18 13836
HSV2-UL30-5483 - CGAGGCCGUCUUGAAGGAC 19 13837
HSV2-UL30-1879 - CCGAGGCCGUCUUGAAGGAC 20 4827
HSV2-UL30-5484 - GCCGAGGCCGUCUUGAAGGAC 21 13838
HSV2-UL30-5485 - CGCCGAGGCCGUCUUGAAGGAC 22 13839
HSV2-UL30-5486 - UCGCCGAGGCCGUCUUGAAGGAC 23 13840
HSV2-UL30-5487 - GUCGCCGAGGCCGUCUUGAAGGAC 24 13841
HSV2-UL30-5488 - AAGGACGACGACGAGGAC 18 13842
HSV2-UL30-5489 - UAAGGACGACGACGAGGAC 19 13843
HSV2-UL30-596 - AU AAGGACGACGACGAGGAC 20 3466
HSV2-UL30-5490 - GAU AAGGACGACGACGAGGAC 21 13844
HSV2-UL30-5491 - GGAU AAGGACGACGACGAGGAC 22 13845
HSV2-UL30-5492 - AGGAU AAGGACGACGACGAGGAC 23 13846
HSV2-UL30-5493 - GAGGAUAAGGACGACGACGAGGAC 24 13847
HSV2-UL30-5494 - GAGGACGGGGACGAGGAC 18 13848
HSV2-UL30-5495 - CGAGGACGGGGACGAGGAC 19 13849
HSV2-UL30-600 - ACGAGGACGGGGACGAGGAC 20 3470
HSV2-UL30-5496 - GACGAGGACGGGGACGAGGAC 21 13850
HSV2-UL30-5497 - CGACGAGGACGGGGACGAGGAC 22 13851
HSV2-UL30-5498 - ACG ACGAGGACGGGGACGAGGAC 23 13852
HSV2-UL30-5499 - GACGACGAGGACGGGGACGAGGAC 24 13853
HSV2-UL30-5500 - GCGCACCUGGAGGCGGAC 18 13854
HSV2-UL30-5501 - CGCGCACCUGGAGGCGGAC 19 13855
HSV2-UL30-627 - UCGCGCACCUGGAGGCGGAC 20 3497
HSV2-UL30-5502 - GUCGCGCACCUGGAGGCGGAC 21 13856
HSV2-UL30-5503 - CGUCGCGCACCUGGAGGCGGAC 22 13857
HSV2-UL30-5504 - CCGUCGCGCACCUGGAGGCGGAC 23 13858
HSV2-UL30-5505 - GCCGUCGCGCACCUGGAGGCGGAC 24 13859
HSV2-UL30-5506 - GACGACGAGGACGGGGAC 18 13860
HSV2-UL30-5507 - CGACGACGAGGACGGGGAC 19 13861
HSV2-UL30-1931 - ACGACGACGAGGACGGGGAC 20 4857
HSV2-UL30-5508 - GACGACGACGAGGACGGGGAC 21 13862
HSV2-UL30-5509 - GG ACGACGACGAGGACGGGGAC 22 13863
HSV2-UL30-5510 - AGG ACGACGACGAGGACGGGGAC 23 13864
HSV2-UL30-5511 - AAGG ACGACGACGAGGACGGGGAC 24 13865
HSV2-UL30-5512 - CGCAUCAUCUACGGGGAC 18 13866
HSV2-UL30-5513 - GCGCAUCAUCUACGGGGAC 19 13867 HSV2-UL30-1984 - UGCGCAUCAUCUACGGGGAC 20 4891
HSV2-UL30-5514 - AUGCGCAUCAUCUACGGGGAC 21 13868
HSV2-UL30-5515 - CAUGCGCAUCAUCUACGGGGAC 22 13869
HSV2-UL30-5516 - CCAUGCGCAUCAUCUACGGGGAC 23 13870
HSV2-UL30-5517 - UCCAUGCGCAUCAUCUACGGGGAC 24 13871
HSV2-UL30-5518 - GGGGAGCGGCCGGGGGAC 18 13872
HSV2-UL30-5519 - AGGGGAGCGGCCGGGGGAC 19 13873
HSV2-UL30-588 - AAGGGGAGCGGCCGGGGGAC 20 3458
HSV2-UL30-5520 - GAAGGGGAGCGGCCGGGGGAC 21 13874
HSV2-UL30-5521 - GGAAGGGGAGCGGCCGGGGGAC 22 13875
HSV2-UL30-5522 - GGG AAGGGGAGCGGCCGGGGGAC 23 13876
HSV2-UL30-5523 - GGGGAAGGGGAGCGGCCGGGGGAC 24
13877
HSV2-UL30-5524 - GAGGCGGACCGGGACUAC 18 13878
HSV2-UL30-5525 - GGAGGCGGACCGGGACUAC 19 13879
HSV2-UL30-1955 - UGGAGGCGGACCGGGACUAC 20 4872
HSV2-UL30-5526 - CUGGAGGCGGACCGGGACUAC 21 13880
HSV2-UL30-5527 - CCUGGAGGCGGACCGGGACUAC 22 13881
HSV2-UL30-5528 - ACCUGGAGGCGGACCGGGACUAC 23 13882
HSV2-UL30-5529 - CACCUGGAGGCGGACCGGGACUAC 24 13883
HSV2-UL30-5530 - UCCAUGCGCAUCAUCUAC 18 13884
HSV2-UL30-5531 - CUCCAUGCGCAUCAUCUAC 19 13885
HSV2-UL30-665 - ACUCCAUGCGCAUCAUCUAC 20 3535
HSV2-UL30-5532 - UACUCCAUGCGCAUCAUCUAC 21 13886
HSV2-UL30-5533 - GUACUCCAUGCGCAUCAUCUAC 22 13887
HSV2-UL30-5534 - CGUACUCCAUGCGCAUCAUCUAC 23 13888
HSV2-UL30-5535 - CCGUACUCCAUGCGCAUCAUCUAC 24 13889
HSV2-UL30-5536 - CCCGCGAUCAGGAAGUAC 18 13890
HSV2-UL30-5537 - CCCCGCGAUCAGGAAGUAC 19 13891
HSV2-UL30-1816 - GCCCCGCGAUCAGGAAGUAC 20 4787
HSV2-UL30-5538 - UGCCCCGCGAUCAGGAAGUAC 21 13892
HSV2-UL30-5539 - UUGCCCCGCGAUCAGGAAGUAC 22 13893
HSV2-UL30-5540 - UUUGCCCCGCGAUCAGGAAGUAC 23 13894
HSV2-UL30-5541 - U UUUGCCCCGCGAUCAGGAAGUAC 24 13895
HSV2-UL30-5542 - UCGUGAAGGCCCACGUAC 18 13896
HSV2-UL30-5543 - UUCGUGAAGGCCCACGUAC 19 13897
HSV2-UL30-1963 - CUUCGUGAAGGCCCACG UAC 20 4876
HSV2-UL30-5544 - UCUUCGUGAAGGCCCACGUAC 21 13898
HSV2-UL30-5545 - UUCU UCGUGAAGGCCCACGUAC 22 13899
HSV2-UL30-5546 - GUUCUUCGUGAAGGCCCACGUAC 23 13900
HSV2-UL30-5547 - UGUUCUUCGUGAAGGCCCACGUAC 24 13901
HSV2-UL30-5548 - GGCCGGCACGUUGGGUAC 18 13902
HSV2-UL30-5549 - GGGCCGGCACGUUGGG UAC 19 13903
HSV2-UL30-1944 - GGGGCCGGCACGU UGGGUAC 20 4865
HSV2-UL30-5550 - GGGGGCCGGCACGUUGGGUAC 21 13904
HSV2-UL30-5551 - CGGGGGCCGGCACGU UGGGUAC 22 13905 HSV2-UL30-5552 - CCGGGGGCCGGCACGUUGGGUAC 23 13906
HSV2-UL30-5553 - ACCGGGGGCCGGCACGUUGGGUAC 24 13907
HSV2-UL30-5554 - ACGCGGCAGUACUU UUAC 18 13908
HSV2-UL30-5555 - CACGCGGCAG UACUU UUAC 19 13909
HSV2-UL30-1795 - GCACGCGGCAGUACUUUUAC 20 4772
HSV2-UL30-5556 - GGCACGCGGCAGUACUU UUAC 21 13910
HSV2-UL30-5557 - CGGCACGCGGCAGUACU UUUAC 22 13911
HSV2-UL30-5558 - ACGGCACGCGGCAGUACUUUUAC 23 13912
HSV2-UL30-5559 - UACGGCACGCGGCAGUACUUUUAC 24 13913
HSV2-UL30-5560 - CCGACGGCGUUCGGAACC 18 13914
HSV2-UL30-5561 - CCCGACGGCGU UCGGAACC 19 13915
HSV2-UL30-1828 - CCCCGACGGCGUUCGGAACC 20 4792
HSV2-UL30-5562 - CCCCCGACGGCGUUCGGAACC 21 13916
HSV2-UL30-5563 - CCCCCCGACGGCGUUCGGAACC 22 13917
HSV2-UL30-5564 - GCCCCCCGACGGCGUUCGGAACC 23 13918
HSV2-UL30-5565 - CGCCCCCCGACGGCGU UCGGAACC 24 13919
HSV2-UL30-5566 - UUCAUCCUGCCGGACACC 18 13920
HSV2-UL30-5567 - CUUCAUCCUGCCGGACACC 19 13921
HSV2-UL30-1896 - GCUUCAUCCUGCCGGACACC 20 4842
HSV2-UL30-5568 - GGCUUCAUCCUGCCGGACACC 21 13922
HSV2-UL30-5569 - GGGCU UCAUCCUGCCGGACACC 22 13923
HSV2-UL30-5570 - AGGGCUUCAUCCUGCCGGACACC 23 13924
HSV2-UL30-5571 - AAGGGCU UCAUCCUGCCGGACACC 24 13925
HSV2-UL30-5572 - U C A AG U UUCUGCCGCACC 18 13926
HSV2-UL30-5573 - U U C A AG UUUCUGCCGCACC 19 13927
HSV2-UL30-554 - CUUCAAGUU UCUGCCGCACC 20 3424
HSV2-UL30-5574 - UCUUCAAGUU UCUGCCGCACC 21 13928
HSV2-UL30-5575 - UUCUUCAAGUU UCUGCCGCACC 22 13929
HSV2-UL30-5576 - GUUCUUCAAGU UUCUGCCGCACC 23 13930
HSV2-UL30-5577 - UGUUCUUCAAG UUUCUGCCGCACC 24 13931
HSV2-UL30-5578 - CCGAGGCCGUCGCGCACC 18 13932
HSV2-UL30-5579 - CCCGAGGCCGUCGCGCACC 19 13933
HSV2-UL30-624 - GCCCGAGGCCGUCGCGCACC 20 3494
HSV2-UL30-5580 - GGCCCGAGGCCGUCGCGCACC 21 13934
HSV2-UL30-5581 - CGGCCCG AGGCCG UCGCGCACC 22 13935
HSV2-UL30-5582 - G CG G CCCG AG G CCG U CG CG C ACC 23 13936
HSV2-UL30-5583 - UGCGGCCCGAGGCCGUCGCGCACC 24 13937
HSV2-UL30-5584 - GAGGUCGCGCGCGAGACC 18 13938
HSV2-UL30-5585 - GGAGGUCGCGCGCGAGACC 19 13939
HSV2-UL30-605 - AGGAGGUCGCGCGCGAGACC 20 3475
HSV2-UL30-5586 - GAGGAGGUCGCGCGCGAGACC 21 13940
HSV2-UL30-5587 - CG AGGAGGUCGCGCGCGAGACC 22 13941
HSV2-UL30-5588 - GCGAGGAGGUCGCGCGCGAGACC 23 13942
HSV2-UL30-5589 - CGCGAGGAGGUCGCGCGCGAGACC 24 13943
HSV2-UL30-5590 - AUCGGCGCAUCACCGACC 18 13944
HSV2-UL30-5591 - CAUCGGCGCAUCACCGACC 19 13945 HSV2-UL30-701 - CCAUCGGCGCAUCACCGACC 20 3571
HSV2-UL30-5592 - CCCAUCGGCGCAUCACCGACC 21 13946
HSV2-UL30-5593 - GCCCAUCGGCGCAUCACCGACC 22 13947
HSV2-UL30-5594 - CGCCCAUCGGCGCAUCACCGACC 23 13948
HSV2-UL30-5595 - ACGCCCAUCGGCGCAUCACCGACC 24 13949
HSV2-UL30-5596 - AGGCGGACCGGGACUACC 18 13950
HSV2-UL30-5597 - GAGGCGGACCGGGACUACC 19 13951
HSV2-UL30-629 - GG AGGCGGACCGGGACUACC 20 3499
HSV2-UL30-5598 - UGG AGGCGGACCGGGACUACC 21 13952
HSV2-UL30-5599 - CUGG AGGCGGACCGGGACUACC 22 13953
HSV2-UL30-5600 - CCUGG AGGCGGACCGGGACUACC 23 13954
HSV2-UL30-5601 - ACCUGGAGGCGGACCGGGACUACC 24 13955
HSV2-UL30-5602 - GCCGGCACGU UGGGUACC 18 13956
HSV2-UL30-5603 - GGCCGGCACGU UGGGUACC 19 13957
HSV2-UL30-611 - GGGCCGGCACGUUGGGUACC 20 3481
HSV2-UL30-5604 - GGGGCCGGCACGUUGGGUACC 21 13958
HSV2-UL30-5605 - GGGGGCCGGCACGUUGGGUACC 22 13959
HSV2-UL30-5606 - CGGGGGCCGGCACGUUGGGUACC 23 13960
HSV2-UL30-5607 - CCGGGGGCCGGCACGUUGGGUACC 24 13961
HSV2-UL30-5608 - UCAUCCUGCCGGACACCC 18 13962
HSV2-UL30-5609 - UUCAUCCUGCCGGACACCC 19 13963
HSV2-UL30-564 - CU UCAUCCUGCCGGACACCC 20 3434
HSV2-UL30-5610 - GCUUCAUCCUGCCGGACACCC 21 13964
HSV2-UL30-5611 - GGCUUCAUCCUGCCGGACACCC 22 13965
HSV2-UL30-5612 - GGGCUUCAUCCUGCCGGACACCC 23 13966
HSV2-UL30-5613 - AGGGCUUCAUCCUGCCGGACACCC 24 13967
HSV2-UL30-5614 - G G AU CCCCCAG AG C ACCC 18 13968
HSV2-UL30-5615 - CGGAUCCCCCAGAGCACCC 19 13969
HSV2-UL30-1969 - G CG G A U CCCCCAG AG CACCC 20 4882
HSV2-UL30-5616 - CGCGGAUCCCCCAGAGCACCC 21 13970
HSV2-UL30-5617 - U CG CG G AU CCCCCAG AG CACCC 22 13971
HSV2-UL30-5618 - CUCGCGGAUCCCCCAGAGCACCC 23 13972
HSV2-UL30-5619 - GCUCGCGGAUCCCCCAGAGCACCC 24 13973
HSV2-UL30-5620 - UGAUCGUGGCCCAGACCC 18 13974
HSV2-UL30-5621 - GUGAUCG UGGCCCAGACCC 19 13975
HSV2-UL30-2018 - CGUGAUCGUGG CCCAG ACCC 20 4917
HSV2-UL30-5622 - ACGUGAUCGUGGCCCAGACCC 21 13976
HSV2-UL30-5623 - UACGUGAUCGUGGCCCAGACCC 22 13977
HSV2-UL30-5624 - GUACGUGAUCGUGGCCCAGACCC 23 13978
HSV2-UL30-5625 - CGUACGUGAUCGUGGCCCAGACCC 24 13979
HSV2-UL30-5626 - CGCUUCUGGGUCUGACCC 18 13980
HSV2-UL30-5627 - ACGCU UCUGGGUCUGACCC 19 13981
HSV2-UL30-1794 - CACGCUUCUGGGUCUGACCC 20 4771
HSV2-UL30-5628 - UCACGCUUCUGGGUCUGACCC 21 13982
HSV2-UL30-5629 - AUCACGCUUCUGGGUCUGACCC 22 13983
HSV2-UL30-5630 - CAUCACGCU UCUGGGUCUGACCC 23 13984 HSV2-UL30-5631 - UCAUCACGCUUCUGGGUCUGACCC 24 13985
HSV2-UL30-5632 - CCCGAGACGUGGCACCCC 18 13986
HSV2-UL30-5633 - UCCCGAGACGUGGCACCCC 19 13987
HSV2-UL30-2050 - UUCCCGAGACGUGGCACCCC 20 4937
HSV2-UL30-5634 - AUUCCCGAGACGUGGCACCCC 21 13988
HSV2-UL30-5635 - UAUUCCCGAGACGUGGCACCCC 22 13989
HSV2-UL30-5636 - UU AU UCCCGAGACGUGGCACCCC 23 13990
HSV2-UL30-5637 - UUUAU UCCCGAGACGUGGCACCCC 24 13991
HSV2-UL30-5638 - CCGUCGCAUGCCGACCCC 18 13992
HSV2-UL30-5639 - GCCGUCGCAUGCCGACCCC 19 13993
HSV2-UL30-2030 - CGCCGUCGCAUGCCGACCCC 20 4924
HSV2-UL30-5640 - ACGCCGUCGCAUGCCGACCCC 21 13994
HSV2-UL30-5641 - GACG CCG U CG CAU G CCG ACCCC 22 13995
HSV2-UL30-5642 - AGACGCCGUCGCAUGCCGACCCC 23 13996
HSV2-UL30-5643 - GAGACGCCGUCGCAUGCCGACCCC 24 13997
HSV2-UL30-5644 - AUCCCCCAGAGCACCCCC 18 13998
HSV2-UL30-5645 - GAUCCCCCAGAGCACCCCC 19 13999
HSV2-UL30-1970 - GGAUCCCCCAGAGCACCCCC 20 4883
HSV2-UL30-5646 - CGGAUCCCCCAGAGCACCCCC 21 14000
HSV2-UL30-5647 - G CG G A U CCCCCAG AG CACCCCC 22 14001
HSV2-UL30-5648 - CGCGGAUCCCCCAGAGCACCCCC 23 14002
HSV2-UL30-5649 - U CG CG G AU CCCCCAG AG CACCCCC 24 14003
HSV2-UL30-5650 - CGUCGCAUGCCGACCCCC 18 14004
HSV2-UL30-5651 - CCGUCGCAUGCCGACCCCC 19 14005
HSV2-UL30-724 - GCCGUCGCAUGCCGACCCCC 20 3594
HSV2-UL30-5652 - CGCCGUCGCAUGCCGACCCCC 21 14006
HSV2-UL30-5653 - ACGCCGUCGCAUGCCGACCCCC 22 14007
HSV2-UL30-5654 - G ACGCCG UCGCAUGCCG ACCCCC 23 14008
HSV2-UL30-5655 - AGACGCCGUCGCAUGCCGACCCCC 24 14009
HSV2-UL30-5656 - G UCGCAUGCCG ACCCCCC 18 14010
HSV2-UL30-5657 - CG UCGCAUGCCG ACCCCCC 19 14011
HSV2-UL30-725 - CCG UCGCAUGCCG ACCCCCC 20 3595
HSV2-UL30-5658 - GCCGUCGCAUGCCGACCCCCC 21 14012
HSV2-UL30-5659 - CGCCGUCGCAUGCCGACCCCCC 22 14013
HSV2-UL30-5660 - ACGCCGUCGCAUGCCGACCCCCC 23 14014
HSV2-UL30-5661 - GACGCCG UCGCAUGCCG ACCCCCC 24 14015
HSV2-UL30-5662 - CCCCG G CCA AG CG CCCCC 18 14016
HSV2-UL30-5663 - UCCCCGGCCAAGCGCCCCC 19 14017
HSV2-UL30-723 - CUCCCCGGCCAAGCGCCCCC 20 3593
HSV2-UL30-5664 - CCUCCCCGGCCAAGCGCCCCC 21 14018
HSV2-UL30-5665 - CCCUCCCCGG CCA AG CG CCCCC 22 14019
HSV2-UL30-5666 - GCCCUCCCCGGCCAAGCGCCCCC 23 14020
HSV2-UL30-5667 - U G CCC U CCCCG G CCA AG CG CCCCC 24 14021
HSV2-UL30-5668 - GCUAGACGCCGCCGCCCC 18 14022
HSV2-UL30-5669 - AGCUAGACGCCGCCGCCCC 19 14023
HSV2-UL30-717 - GAGCUAGACGCCGCCGCCCC 20 3587 HSV2-UL30-5670 - CGAGCUAGACGCCGCCGCCCC 21 14024
HSV2-UL30-5671 - GCGAGCUAGACGCCGCCGCCCC 22 14025
HSV2-UL30-5672 - CGCGAGCUAGACGCCGCCGCCCC 23 14026
HSV2-UL30-5673 - CCGCGAGCUAGACGCCGCCGCCCC 24 14027
HSV2-UL30-5674 - UCCCCGG CCA AG CG CCCC 18 14028
HSV2-UL30-5675 - CUCCCCGGCCAAGCGCCCC 19 14029
HSV2-UL30-722 - CCU CCCCG G CCAAG CG CCCC 20 3592
HSV2-UL30-5676 - CCCUCCCCGGCCAAGCGCCCC 21 14030
HSV2-UL30-5677 - GCCCUCCCCGGCCAAGCGCCCC 22 14031
HSV2-UL30-5678 - UGCCCUCCCCGGCCAAGCGCCCC 23 14032
HSV2-UL30-5679 - CUGCCCUCCCCGG CC A AG CG CCCC 24 14033
HSV2-UL30-5680 - AUCCGCUCGCGGAUCCCC 18 14034
HSV2-UL30-5681 - GAUCCGCUCGCGGAUCCCC 19 14035
HSV2-UL30-1968 - AGAUCCGCUCGCGGAUCCCC 20 4881
HSV2-UL30-5682 - CAGAUCCGCUCGCGGAUCCCC 21 14036
HSV2-UL30-5683 - GCAGAUCCGCUCGCGGAUCCCC 22 14037
HSV2-UL30-5684 - AGCAGAUCCGCUCGCGGAUCCCC 23 14038
HSV2-UL30-5685 - AAGCAGAUCCGCUCGCGGAUCCCC 24 14039
HSV2-UL30-5686 - ACCUGU CCACC ACCG CCC 18 14040
HSV2-UL30-5687 - GACCUGUCCACCACCGCCC 19 14041
HSV2-UL30-1849 - CG ACCU G U CCACCACCG CCC 20 4803
HSV2-UL30-5688 - ACGACCUGUCCACCACCGCCC 21 14042
HSV2-UL30-5689 - UACGACCUGUCCACCACCGCCC 22 14043
HSV2-UL30-5690 - CUACGACCUGUCCACCACCGCCC 23 14044
HSV2-UL30-5691 - UCUACGACCUGUCCACCACCGCCC 24 14045
HSV2-UL30-5692 - AGCUAGACGCCGCCGCCC 18 14046
HSV2-UL30-5693 - GAGCUAGACGCCGCCGCCC 19 14047
HSV2-UL30-2023 - CGAGCUAGACGCCGCCGCCC 20 4921
HSV2-UL30-5694 - GCGAGCUAGACGCCGCCGCCC 21 14048
HSV2-UL30-5695 - CGCGAGCUAGACGCCGCCGCCC 22 14049
HSV2-UL30-5696 - CCGCGAGCUAGACGCCGCCGCCC 23 14050
HSV2-UL30-5697 - UCCGCGAGCUAGACGCCGCCGCCC 24 14051
HSV2-UL30-5698 - CU CCCCG G CCAAG CG CCC 18 14052
HSV2-UL30-5699 - CCUCCCCGGCCAAGCGCCC 19 14053
HSV2-UL30-2027 - CCC UCCCCGG CCAAG CG CCC 20 4923
HSV2-UL30-5700 - GCCCUCCCCGG CCA AG CG CCC 21 14054
HSV2-UL30-5701 - UGCCCUCCCCGG CCAAG CG CCC 22 14055
HSV2-UL30-5702 - CU GCCCU CCCCGG CCAAGCGCCC 23 14056
HSV2-UL30-5703 - CCUGCCCUCCCCGGCCAAGCGCCC 24 14057
HSV2-UL30-5704 - CUGGCGCGACCCCUGCCC 18 14058
HSV2-UL30-5705 - GCUGGCGCGACCCCUGCCC 19 14059
HSV2-UL30-2004 - GGCUGGCGCGACCCCUGCCC 20 4907
HSV2-UL30-5706 - UGGCUGGCGCGACCCCUGCCC 21 14060
HSV2-UL30-5707 - GUGGCUGGCGCGACCCCUGCCC 22 14061
HSV2-UL30-5708 - AGUGGCUGGCGCGACCCCUGCCC 23 14062
HSV2-UL30-5709 - GAGUGGCUGGCGCGACCCCUGCCC 24 14063 HSV2-UL30-5710 - UUCCGGUCGCGGAACGCC 18 14064
HSV2-UL30-5711 - UUUCCGGUCGCGGAACGCC 19 14065
HSV2-UL30-510 - CUU UCCGGUCGCGGAACGCC 20 3380
HSV2-UL30-5712 - CCUUUCCGGUCGCGGAACGCC 21 14066
HSV2-UL30-5713 - GCCUUUCCGGUCGCGGAACGCC 22 14067
HSV2-UL30-5714 - GGCCUUUCCGGUCGCGGAACGCC 23 14068
HSV2-UL30-5715 - UGGCCUUUCCGGUCGCGGAACGCC 24 14069
HSV2-UL30-5716 - CCCGGGUACGCCAUCGCC 18 14070
HSV2-UL30-5717 - UCCCGGG UACGCCAUCGCC 19 14071
HSV2-UL30-733 - AUCCCGGGUACGCCAUCGCC 20 3603
HSV2-UL30-5718 - GAUCCCGGGUACGCCAUCGCC 21 14072
HSV2-UL30-5719 - GGAUCCCGGGUACGCCAUCGCC 22 14073
HSV2-UL30-5720 - AGGAUCCCGGGUACGCCAUCGCC 23 14074
HSV2-UL30-5721 - GAGGAUCCCGGGUACGCCAUCGCC 24 14075
HSV2-UL30-5722 - AAGCUGCUGCUCAUCGCC 18 14076
HSV2-UL30-5723 - CAAGCUGCUGCUCAUCGCC 19 14077
HSV2-UL30-1990 - CCAAGCUGCUGCUCAUCGCC 20 4897
HSV2-UL30-5724 - ACCAAGCUGCUGCUCAUCGCC 21 14078
HSV2-UL30-5725 - CACCAAGCUGCUGCUCAUCGCC 22 14079
HSV2-UL30-5726 - UCACCAAGCUGCUGCUCAUCGCC 23 14080
HSV2-UL30-5727 - UUCACCAAGCUGCUGCUCAUCGCC 24 14081
HSV2-UL30-5728 - GGCCCUGCGCGAGUCGCC 18 14082
HSV2-UL30-5729 - CGGCCCUGCGCGAGUCGCC 19 14083
HSV2-UL30-459 - GCGGCCCUGCGCGAGUCGCC 20 3329
HSV2-UL30-5730 - GGCGGCCCUGCGCGAGUCGCC 21 14084
HSV2-UL30-5731 - CGGCGGCCCUGCGCGAGUCGCC 22 14085
HSV2-UL30-5732 - GCGGCGGCCCUGCGCGAGUCGCC 23 14086
HSV2-UL30-5733 - GGCGGCGGCCCUGCGCGAGUCGCC 24 14087
HSV2-UL30-5734 - GAUAUCGAAUGCAAGGCC 18 14088
HSV2-UL30-5735 - CGAUAUCGAAUGCAAGGCC 19 14089
HSV2-UL30-501 - UCGAUAUCGAAUGCAAGGCC 20 3371
HSV2-UL30-5736 - U UCG AU AUCG AAUGCAAGGCC 21 14090
HSV2-UL30-5737 - CUUCGAUAUCGAAUGCAAGGCC 22 14091
HSV2-UL30-5738 - GCU UCGAUAUCGAAUGCAAGGCC 23 14092
HSV2-UL30-5739 - UGCUUCGAUAUCGAAUGCAAGGCC 24 14093
HSV2-UL30-5740 - UGCCGCGGCCUCACGGCC 18 14094
HSV2-UL30-5741 - GUGCCGCGGCCUCACGGCC 19 14095
HSV2-UL30-1985 - UGUGCCGCGGCCUCACGGCC 20 4892
HSV2-UL30-5742 - UUGUGCCGCGGCCUCACGGCC 21 14096
HSV2-UL30-5743 - UUUGUGCCGCGGCCUCACGGCC 22 14097
HSV2-UL30-5744 - UUUUGUGCCGCGGCCUCACGGCC 23 14098
HSV2-UL30-5745 - GUUU UGUGCCGCGGCCUCACGGCC 24 14099
HSV2-UL30-5746 - ACCGCCUCAAGCCCGGCC 18 14100
HSV2-UL30-5747 - UACCGCCUCAAGCCCGGCC 19 14101
HSV2-UL30-1823 - GU ACCGCCUCAAGCCCGGCC 20 4790
HSV2-UL30-5748 - GGUACCGCCUCAAGCCCGGCC 21 14102 HSV2-UL30-5749 - UGGUACCGCCUCAAGCCCGGCC 22 14103
HSV2-UL30-5750 - CUGGUACCGCCUCAAGCCCGGCC 23 14104
HSV2-UL30-5751 - GCUGGUACCGCCUCAAGCCCGGCC 24 14105
HSV2-UL30-5752 - GGGGGAAGGGGAGCGGCC 18 14106
HSV2-UL30-5753 - GGGGGGAAGGGGAGCGGCC 19 14107
HSV2-UL30-584 - CGGGGGGAAGGGGAGCGGCC 20 3454
HSV2-UL30-5754 - UCGGGGGGAAGGGGAGCGGCC 21 14108
HSV2-UL30-5755 - CUCGGGGGGAAGGGGAGCGGCC 22 14109
HSV2-UL30-5756 - CCUCGGGGGGAAGGGGAGCGGCC 23 14110
HSV2-UL30-5757 - GCCUCGGGGGGAAGGGGAGCGGCC 24 14111
HSV2-UL30-5758 - CCGUGACGACCAUCGGCC 18 14112
HSV2-UL30-5759 - ACCGUGACGACCAUCGGCC 19 14113
HSV2-UL30-1975 - CACCGUGACGACCAUCGGCC 20 4886
HSV2-UL30-5760 - CCACCGUGACGACCAUCGGCC 21 14114
HSV2-UL30-5761 - GCCACCG UGACG ACCAUCGGCC 22 14115
HSV2-UL30-5762 - CGCCACCGUGACGACCAUCGGCC 23 14116
HSV2-UL30-5763 - CCGCCACCGUGACGACCAUCGGCC 24 14117
HSV2-UL30-5764 - GCCGCGCGGCUCAGGGCC 18 14118
HSV2-UL30-5765 - GGCCGCGCGGCUCAGGGCC 19 14119
HSV2-UL30-2052 - UGGCCGCGCGGCUCAGGGCC 20 4939
HSV2-UL30-5766 - GUGGCCGCGCGGCUCAGGGCC 21 14120
HSV2-UL30-5767 - CGUGGCCGCGCGGCUCAGGGCC 22 14121
HSV2-UL30-5768 - ACGUGGCCGCGCGGCUCAGGGCC 23 14122
HSV2-UL30-5769 - GACGUGGCCGCGCGGCUCAGGGCC 24 14123
HSV2-UL30-5770 - GCCGCGGGCCUGGUGGCC 18 14124
HSV2-UL30-5771 - GGCCGCGGGCCUGGUGGCC 19 14125
HSV2-UL30-1986 - CGGCCGCGGGCCUGGUGGCC 20 4893
HSV2-UL30-5772 - ACGGCCGCGGGCCUGGUGGCC 21 14126
HSV2-UL30-5773 - CACGGCCGCGGGCCUGGUGGCC 22 14127
HSV2-UL30-5774 - UCACGGCCGCGGGCCUGGUGGCC 23 14128
HSV2-UL30-5775 - CUCACGGCCGCGGGCCUGGUGGCC 24 14129
HSV2-UL30-5776 - CA AG CG CCCG G CCG U G CC 18 14130
HSV2-UL30-5777 - CCA AG CGCCCGGCCGUGCC 19 14131
HSV2-UL30-1902 - CCCAAGCGCCCGGCCGUGCC 20 4845
HSV2-UL30-5778 - GCCCA AG CGCCCGGCCGUGCC 21 14132
HSV2-UL30-5779 - CG CCC A AG CGCCCGGCCGUGCC 22 14133
HSV2-UL30-5780 - GCGCCCAAGCGCCCGGCCGUGCC 23 14134
HSV2-UL30-5781 - GGCGCCCAAGCGCCCGGCCGUGCC 24 14135
HSV2-UL30-5782 - CGCGGCUGGCCGCCCUCC 18 14136
HSV2-UL30-5783 - GCGCGGCUGGCCGCCCUCC 19 14137
HSV2-UL30-2022 - CGCGCGGCUGGCCGCCCUCC 20 4920
HSV2-UL30-5784 - UCGCGCGGCUGGCCGCCCUCC 21 14138
HSV2-UL30-5785 - GUCGCGCGGCUGGCCGCCCUCC 22 14139
HSV2-UL30-5786 - GGUCGCGCGGCUGGCCGCCCUCC 23 14140
HSV2-UL30-5787 - CGGUCGCGCGGCUGGCCGCCCUCC 24 14141
HSV2-UL30-5788 - CUCAGCGAUCUCGCCUCC 18 14142 HSV2-UL30-5789 - CCUCAGCGAUCUCGCCUCC 19 14143
HSV2-UL30-512 - ACCUCAGCGAUCUCGCCUCC 20 3382
HSV2-UL30-5790 - CACCUCAGCGAUCUCGCCUCC 21 14144
HSV2-UL30-5791 - CCACCUCAGCGAUCUCGCCUCC 22 14145
HSV2-UL30-5792 - CCCACCUCAGCGAUCUCGCCUCC 23 14146
HSV2-UL30-5793 - UCCCACCUCAGCGAUCUCGCCUCC 24 14147
HSV2-UL30-3338 - UGCGCGCCGCCCAGCUCC 18 11692
HSV2-UL30-3339 - AUGCGCGCCGCCCAGCUCC 19 11693
HSV2-UL30-3340 - CAUGCGCGCCGCCCAGCUCC 20 11694
HSV2-UL30-3341 - GCAUGCGCGCCGCCCAGCUCC 21 11695
HSV2-UL30-3342 - AGCAUGCGCGCCGCCCAGCUCC 22 11696
HSV2-UL30-3343 - CAGCAUGCGCGCCGCCCAGCUCC 23 11697
HSV2-UL30-3344 - ACAGCAUGCGCGCCGCCCAGCUCC 24 11698
HSV2-UL30-5794 - UCGUUCCGCGGCAUCUCC 18 14148
HSV2-UL30-5795 - GUCGU UCCGCGGCAUCUCC 19 14149
HSV2-UL30-1804 - CGUCGUUCCGCGGCAUCUCC 20 4778
HSV2-UL30-5796 - GCGUCGUUCCGCGGCAUCUCC 21 14150
HSV2-UL30-5797 - GGCGUCGU UCCGCGGCAUCUCC 22 14151
HSV2-UL30-5798 - GGGCGUCGUUCCGCGGCAUCUCC 23 14152
HSV2-UL30-5799 - GGGGCGUCGU UCCGCGGCAUCUCC 24 14153
HSV2-UL30-5800 - CCUCCGGGCCCGCGCAGC 18 14154
HSV2-UL30-5801 - GCCUCCGGGCCCGCGCAGC 19 14155
HSV2-UL30-1884 - CGCCUCCGGGCCCGCGCAGC 20 4832
HSV2-UL30-5802 - ACGCCUCCGGGCCCGCGCAGC 21 14156
HSV2-UL30-5803 - UACGCCUCCGGGCCCGCGCAGC 22 14157
HSV2-UL30-5804 - CUACGCCUCCGGGCCCGCGCAGC 23 14158
HSV2-UL30-5805 - ACUACGCCUCCGGGCCCGCGCAGC 24 14159
HSV2-UL30-5806 - ACGAGGACGGGGACGAGC 18 14160
HSV2-UL30-5807 - GACGAGGACGGGGACGAGC 19 14161
HSV2-UL30-1936 - GG ACGAGGACGGGGACGAGC 20 4860
HSV2-UL30-5808 - GGG ACGAGGACGGGGACGAGC 21 14162
HSV2-UL30-5809 - GGGG ACGAGGACGGGGACGAGC 22 14163
HSV2-UL30-5810 - CGGGG ACGAGGACGGGGACGAGC 23 14164
HSV2-UL30-5811 - ACGGGGACGAGGACGGGGACGAGC 24 14165
HSV2-UL30-5812 - AGCCUUUGAUACUCUAGC 18 14166
HSV2-UL30-5813 - GAGCCUUUGAUACUCUAGC 19 14167
HSV2-UL30-5814 - AGAGCCUU UGAUACUCUAGC 20 14168
HSV2-UL30-5815 - UAGAGCCU UUGAUACUCUAGC 21 14169
HSV2-UL30-5816 - AUAGAGCCUUUGAUACUCUAGC 22 14170
HSV2-UL30-5817 - CAUAGAGCCUU UGAUACUCUAGC 23 14171
HSV2-UL30-5818 - GCAUAGAGCCU UUGAUACUCUAGC 24 14172
HSV2-UL30-5819 - UUUCCGGUCGCGGAACGC 18 14173
HSV2-UL30-5820 - CUUUCCGGUCGCGGAACGC 19 14174
HSV2-UL30-1847 - CCUU UCCGGUCGCGGAACGC 20 4802
HSV2-UL30-5821 - GCCUU UCCGGUCGCGGAACGC 21 14175
HSV2-UL30-5822 - GGCCU UUCCGGUCGCGGAACGC 22 14176 HSV2-UL30-5823 - UGGCCUUUCCGG UCGCGGAACGC 23 14177
HSV2-UL30-5824 - CUGGCCU UUCCGGUCGCGGAACGC 24 14178
HSV2-UL30-5825 - GUGAAGGCCCACGUACGC 18 14179
HSV2-UL30-5826 - CGUGAAGGCCCACGUACGC 19 14180
HSV2-UL30-1964 - UCGUGAAGGCCCACGUACGC 20 4877
HSV2-UL30-5827 - UUCGUGAAGGCCCACGUACGC 21 14181
HSV2-UL30-5828 - CU UCGUGAAGGCCCACGUACGC 22 14182
HSV2-UL30-5829 - UCUUCGUGAAGGCCCACGUACGC 23 14183
HSV2-UL30-5830 - UUCUUCGUGAAGGCCCACGUACGC 24 14184
HSV2-UL30-5831 - GGACGCCAUCACGCCCGC 18 14185
HSV2-UL30-5832 - UGGACGCCAUCACGCCCGC 19 14186
HSV2-UL30-443 - AUGGACGCCAUCACGCCCGC 20 3313
HSV2-UL30-5833 - UAUGGACGCCAUCACGCCCGC 21 14187
HSV2-UL30-5834 - UUAUGGACGCCAUCACGCCCGC 22 14188
HSV2-UL30-5835 - UUUAUGGACGCCAUCACGCCCGC 23 14189
HSV2-UL30-5836 - AUUUAUGGACGCCAUCACGCCCGC 24 14190
HSV2-UL30-5837 - CGCCUCAAGCCCGGCCGC 18 14191
HSV2-UL30-5838 - CCGCCUCAAGCCCGGCCGC 19 14192
HSV2-UL30-487 - ACCGCCUCAAGCCCGGCCGC 20 3357
HSV2-UL30-5839 - UACCGCCU C A AG CCCGGCCGC 21 14193
HSV2-UL30-5840 - GUACCGCCUCAAGCCCGGCCGC 22 14194
HSV2-UL30-5841 - GGUACCGCCUCAAGCCCGGCCGC 23 14195
HSV2-UL30-5842 - UGGUACCGCCUCAAGCCCGGCCGC 24 14196
HSV2-UL30-5843 - GAGGACGGGGACGAGCGC 18 14197
HSV2-UL30-5844 - CGAGGACGGGGACGAGCGC 19 14198
HSV2-UL30-1937 - ACGAGGACGGGGACGAGCGC 20 4861
HSV2-UL30-5845 - GACGAGGACGGGGACGAGCGC 21 14199
HSV2-UL30-5846 - GG ACGAGGACGGGGACGAGCGC 22 14200
HSV2-UL30-5847 - GGG ACGAGGACGGGGACGAGCGC 23 14201
HSV2-UL30-5848 - GGGGACGAGGACGGGGACGAGCGC 24 14202
HSV2-UL30-5849 - AGCGCGAGGAGGUCGCGC 18 14203
HSV2-UL30-5850 - GAGCGCGAGGAGGUCGCGC 19 14204
HSV2-UL30-1939 - CG AGCGCGAGGAGGUCGCGC 20 4862
HSV2-UL30-5851 - ACG AGCGCGAGGAGGUCGCGC 21 14205
HSV2-UL30-5852 - GACG AGCGCGAGGAGGUCGCGC 22 14206
HSV2-UL30-5853 - GGACG AGCGCGAGGAGGUCGCGC 23 14207
HSV2-UL30-5854 - GGGACGAGCGCGAGGAGGUCGCGC 24 14208
HSV2-UL30-5855 - CUCGACGGGUACGGGCGC 18 14209
HSV2-UL30-5856 - GCUCGACGGGUACGGGCGC 19 14210
HSV2-UL30-1864 - CGCUCGACGGGUACGGGCGC 20 4815
HSV2-UL30-5857 - CCGCUCGACGGGUACGGGCGC 21 14211
HSV2-UL30-5858 - CCCGCUCGACGGGUACGGGCGC 22 14212
HSV2-UL30-5859 - UCCCGCUCGACGGGUACGGGCGC 23 14213
HSV2-UL30-5860 - GUCCCGCUCGACGGGUACGGGCGC 24 14214
HSV2-UL30-5861 - UCCCGGGUACGCCAUCGC 18 14215
HSV2-UL30-5862 - AUCCCGGGUACGCCAUCGC 19 14216 HSV2-UL30-2038 - GAUCCCGGGUACGCCAUCGC 20 4929
HSV2-UL30-5863 - GGAUCCCGGGUACGCCAUCGC 21 14217
HSV2-UL30-5864 - AGGAUCCCGGGUACGCCAUCGC 22 14218
HSV2-UL30-5865 - GAGGAUCCCGGGUACGCCAUCGC 23 14219
HSV2-UL30-5866 - GG AGGAUCCCGGGUACGCCAUCGC 24 14220
HSV2-UL30-5867 - CGGCCCUGCGCGAGUCGC 18 14221
HSV2-UL30-5868 - GCGGCCCUGCGCGAGUCGC 19 14222
HSV2-UL30-458 - GGCGGCCCUGCGCGAGUCGC 20 3328
HSV2-UL30-5869 - CGGCGGCCCUGCGCG AG UCGC 21 14223
HSV2-UL30-5870 - GCGGCGGCCCUGCGCGAGUCGC 22 14224
HSV2-UL30-5871 - GGCGGCGGCCCUGCGCGAGUCGC 23 14225
HSV2-UL30-5872 - UGGCGGCGGCCCUGCGCGAGUCGC 24 14226
HSV2-UL30-5873 - CGAUAUCGAAUGCAAGGC 18 14227
HSV2-UL30-5874 - UCGAUAUCGAAUGCAAGGC 19 14228
HSV2-UL30-500 - UUCGAUAUCGAAUGCAAGGC 20 3370
HSV2-UL30-5875 - CU UCGAUAUCGAAUGCAAGGC 21 14229
HSV2-UL30-5876 - GCU UCGAUAUCGAAUGCAAGGC 22 14230
HSV2-UL30-5877 - UGCU UCGAUAUCGAAUGCAAGGC 23 14231
HSV2-UL30-5878 - GUGCUUCGAUAUCGAAUGCAAGGC 24 14232
HSV2-UL30-5879 - CGCGGGGUUCGGGCCGGC 18 14233
HSV2-UL30-5880 - CCGCGGGGUUCGGGCCGGC 19 14234
HSV2-UL30-758 - GCCGCGGGGU UCGGGCCGGC 20 3628
HSV2-UL30-5881 - GGCCGCGGGGU UCGGGCCGGC 21 14235
HSV2-UL30-5882 - GGGCCGCGGGGUUCGGGCCGGC 22 14236
HSV2-UL30-5883 - AGGGCCGCGGGGUUCGGGCCGGC 23 14237
HSV2-UL30-5884 - CAGGGCCGCGGGGU UCGGGCCGGC 24 14238
HSV2-UL30-5885 - GGGGGGAAGGGGAGCGGC 18 14239
HSV2-UL30-5886 - CGGGGGGAAGGGGAGCGGC 19 14240
HSV2-UL30-583 - UCGGGGGGAAGGGGAGCGGC 20 3453
HSV2-UL30-5887 - CUCGGGGGGAAGGGGAGCGGC 21 14241
HSV2-UL30-5888 - CCUCGGGGGGAAGGGGAGCGGC 22 14242
HSV2-UL30-5889 - GCCUCGGGGGGAAGGGGAGCGGC 23 14243
HSV2-UL30-5890 - UGCCUCGGGGGGAAGGGGAGCGGC 24 14244
HSV2-UL30-5891 - GUACGCUCUCCCUGCGGC 18 14245
HSV2-UL30-5892 - AGUACGCUCUCCCUGCGGC 19 14246
HSV2-UL30-1949 - CAGUACGCUCUCCCUGCGGC 20 4868
HSV2-UL30-5893 - UCAGUACGCUCUCCCUGCGGC 21 14247
HSV2-UL30-5894 - UUCAGUACGCUCUCCCUGCGGC 22 14248
HSV2-UL30-5895 - CU UCAGUACGCUCUCCCUGCGGC 23 14249
HSV2-UL30-5896 - GCUUCAGUACGCUCUCCCUGCGGC 24 14250
HSV2-UL30-5897 - CGCGUGUGGGACAUCGGC 18 14251
HSV2-UL30-5898 - CCGCGUG UGGGACAUCGGC 19 14252
HSV2-UL30-1869 - UCCGCGUGUGGGACAUCGGC 20 4818
HSV2-UL30-5899 - UUCCGCGUGUGGGACAUCGGC 21 14253
HSV2-UL30-5900 - GUUCCGCGUGUGGGACAUCGGC 22 14254
HSV2-UL30-5901 - UGUUCCGCGUGUGGGACAUCGGC 23 14255 HSV2-UL30-5902 - GUGUUCCGCGUGUGGGACAUCGGC 24 14256
HSV2-UL30-5903 - CUCCUGCGCCU UGCGGGC 18 14257
HSV2-UL30-5904 - CCUCCUGCGCCUUGCGGGC 19 14258
HSV2-UL30-1893 - GCCUCCUGCGCCUUGCGGGC 20 4839
HSV2-UL30-5905 - UGCCUCCUGCGCCU UGCGGGC 21 14259
HSV2-UL30-5906 - GUGCCUCCUGCGCCU UGCGGGC 22 14260
HSV2-UL30-5907 - CGUGCCUCCUGCGCCUUGCGGGC 23 14261
HSV2-UL30-5908 - ACGUGCCUCCUGCGCCUUGCGGGC 24 14262
HSV2-UL30-5909 - AUUACUUCUCGCACCUGC 18 14263
HSV2-UL30-5910 - UAU UACUUCUCGCACCUGC 19 14264
HSV2-UL30-737 - CUAUUACUUCUCGCACCUGC 20 3607
HSV2-UL30-5911 - ACUAU UACU UCUCGCACCUGC 21 14265
HSV2-UL30-5912 - GACUAU UACUUCUCGCACCUGC 22 14266
HSV2-UL30-5913 - GGACUAUUACUUCUCGCACCUGC 23 14267
HSV2-UL30-5914 - CGGACUAU UACU UCUCGCACCUGC 24 14268
HSV2-UL30-5915 - GGCUGGCGCGACCCCUGC 18 14269
HSV2-UL30-5916 - UGGCUGGCGCGACCCCUGC 19 14270
HSV2-UL30-2003 - GUGGCUGGCGCGACCCCUGC 20 4906
HSV2-UL30-5917 - AGUGGCUGGCGCGACCCCUGC 21 14271
HSV2-UL30-5918 - GAGUGGCUGGCGCGACCCCUGC 22 14272
HSV2-UL30-5919 - GGAG UGGCUGGCGCGACCCCUGC 23 14273
HSV2-UL30-5920 - AGGAGUGGCUGGCGCGACCCCUGC 24 14274
HSV2-UL30-5921 - UACAUCGGCGUCAUCUGC 18 14275
HSV2-UL30-5922 - GUACAUCGGCGUCAUCUGC 19 14276
HSV2-UL30-679 - AGUACAUCGGCGUCAUCUGC 20 3549
HSV2-UL30-5923 - AAGUACAUCGGCGUCAUCUGC 21 14277
HSV2-UL30-5924 - AAAGUACAUCGGCGUCAUCUGC 22 14278
HSV2-UL30-5925 - AAAAGUACAUCGGCGUCAUCUGC 23 14279
HSV2-UL30-5926 - AAAAAGUACAUCGGCGUCAUCUGC 24 14280
HSV2-UL30-5927 - GACCCGGAGAGGGACAUC 18 14281
HSV2-UL30-5928 - CGACCCGGAGAGGGACAUC 19 14282
HSV2-UL30-2013 - CCGACCCGGAGAGGGACAUC 20 4912
HSV2-UL30-5929 - ACCGACCCGGAGAGGGACAUC 21 14283
HSV2-UL30-5930 - C ACCG ACCCG G AG AG G G AC A U C 22 14284
HSV2-UL30-5931 - UCACCGACCCGGAGAGGGACAUC 23 14285
HSV2-UL30-5932 - AUCACCGACCCGGAGAGGGACAUC 24 14286
HSV2-UL30-5933 - GCGCAGGUCCCGUCCAUC 18 14287
HSV2-UL30-5934 - CGCGCAGGUCCCGUCCAUC 19 14288
HSV2-UL30-2016 - GCGCGCAGGUCCCGUCCAUC 20 4915
HSV2-UL30-5935 - CGCGCGCAGGUCCCGUCCAUC 21 14289
HSV2-UL30-5936 - CCGCGCGCAGGUCCCGUCCAUC 22 14290
HSV2-UL30-5937 - GCCGCGCGCAGGUCCCGUCCAUC 23 14291
HSV2-UL30-5938 - CG CCG CGCG CAG G U CCCG U CC AU C 24 14292
HSV2-UL30-5939 - GGGGGCAAGAUGCUCAUC 18 14293
HSV2-UL30-5940 - CGGGGGCAAGAUGCUCAUC 19 14294
HSV2-UL30-1994 - GCGGGGGCAAGAUGCUCAUC 20 4899 HSV2-UL30-5941 - UGCGGGGGCAAGAUGCUCAUC 21 14295
HSV2-UL30-5942 - CUGCGGGGGCAAGAUGCUCAUC 22 14296
HSV2-UL30-5943 - UCUGCGGGGGCAAGAUGCUCAUC 23 14297
HSV2-UL30-5944 - AUCUGCGGGGGCAAGAUGCUCAUC 24 14298
HSV2-UL30-5945 - AACUUU UGCCCCGCGAUC 18 14299
HSV2-UL30-5946 - CAACU UUUGCCCCGCGAUC 19 14300
HSV2-UL30-472 - ACAACU UUUGCCCCGCGAUC 20 3342
HSV2-UL30-5947 - GACAACUUU UGCCCCGCGAUC 21 14301
HSV2-UL30-5948 - CGACAACUU UUGCCCCGCGAUC 22 14302
HSV2-UL30-5949 - GCGACAACU UUUGCCCCGCGAUC 23 14303
HSV2-UL30-5950 - UGCGACAACUUU UGCCCCGCGAUC 24 14304
HSV2-UL30-5951 - UUACGACGAUACCGUAUC 18 14305
HSV2-UL30-5952 - UUUACGACGAUACCGUAUC 19 14306
HSV2-UL30-689 - UUUUACGACGAUACCGUAUC 20 3559
HSV2-UL30-5953 - GUUU UACGACGAUACCGUAUC 21 14307
HSV2-UL30-5954 - UGUUUUACGACGAUACCGUAUC 22 14308
HSV2-UL30-5955 - CU G U U U UACGACGAUACCG U AUC 23 14309
HSV2-UL30-5956 - GCUGUUUUACGACGAUACCGUAUC 24 14310
HSV2-UL30-5957 - GCCACCACCCGGU UUAUC 18 14311
HSV2-UL30-5958 - CGCCACCACCCGGUU UAUC 19 14312
HSV2-UL30-1820 - ACGCCACCACCCGGUUUAUC 20 4788
HSV2-UL30-5959 - GACGCCACCACCCGGUU UAUC 21 14313
HSV2-UL30-5960 - CG ACGCCACCACCCGG U U U AU C 22 14314
HSV2-UL30-5961 - UCGACGCCACCACCCGGU UUAUC 23 14315
HSV2-UL30-5962 - GUCGACGCCACCACCCGGU UUAUC 24 14316
HSV2-UL30-5963 - GUUUAUCAACCGCACCUC 18 14317
HSV2-UL30-5964 - CGU UUAUCAACCGCACCUC 19 14318
HSV2-UL30-1996 - GCGU UUAUCAACCGCACCUC 20 4901
HSV2-UL30-5965 - CGCGUUUAUCAACCGCACCUC 21 14319
HSV2-UL30-5966 - GCGCGU UUAUCAACCGCACCUC 22 14320
HSV2-UL30-5967 - UGCGCGUU UAUCAACCGCACCUC 23 14321
HSV2-UL30-5968 - CUGCGCGUUUAUCAACCGCACCUC 24 14322
HSV2-UL30-5969 - CCUCAGCGAUCUCGCCUC 18 14323
HSV2-UL30-5970 - ACCUCAGCGAUCUCGCCUC 19 14324
HSV2-UL30-1852 - CACCUCAGCGAUCUCGCCUC 20 4806
HSV2-UL30-5971 - CCACCUCAGCGAUCUCGCCUC 21 14325
HSV2-UL30-5972 - CCCACCUCAGCGAUCUCGCCUC 22 14326
HSV2-UL30-5973 - UCCCACCUCAGCGAUCUCGCCUC 23 14327
HSV2-UL30-5974 - GUCCCACCUCAGCGAUCUCGCCUC 24 14328
HSV2-UL30-5975 - AGCGCCCGGCCGUGCCUC 18 14329
HSV2-UL30-5976 - AAGCGCCCGGCCGUGCCUC 19 14330
HSV2-UL30-575 - CAAGCGCCCGGCCGUGCCUC 20 3445
HSV2-UL30-5977 - CCA AG CGCCCGGCCGUGCCUC 21 14331
HSV2-UL30-5978 - CCCAAGCGCCCGGCCGUGCCUC 22 14332
HSV2-UL30-5979 - GCCCAAGCGCCCGGCCG UGCCUC 23 14333
HSV2-UL30-5980 - CGCCCA AG CGCCCGGCCGUGCCUC 24 14334 HSV2-UL30-5981 - GCCGUCGCCGAGGCCGUC 18 14335
HSV2-UL30-5982 - CGCCGUCGCCGAGGCCGUC 19 14336
HSV2-UL30-1877 - ACGCCGUCGCCGAGGCCGUC 20 4825
HSV2-UL30-5983 - AACGCCG U CG CCG AG G CCG U C 21 14337
HSV2-UL30-5984 - GAACGCCGUCGCCGAGGCCGUC 22 14338
HSV2-UL30-5985 - UGAACGCCGUCGCCGAGGCCGUC 23 14339
HSV2-UL30-5986 - CUGAACGCCGUCGCCGAGGCCGUC 24 14340
HSV2-UL30-5987 - GCGGACAACCUGGCCGUC 18 14341
HSV2-UL30-5988 - GGCGGACAACCUGGCCGUC 19 14342
HSV2-UL30-1832 - CGGCGGACAACCUGGCCGUC 20 4796
HSV2-UL30-5989 - ACGGCGGACAACCUGGCCGUC 21 14343
HSV2-UL30-5990 - CACGGCGGACAACCUGGCCGUC 22 14344
HSV2-UL30-5991 - GCACGGCGGACAACCUGGCCGUC 23 14345
HSV2-UL30-5992 - UGCACGGCGGACAACCUGGCCGUC 24 14346
HSV2-UL30-5993 - CUGCCGGCCCCCGUCGUC 18 14347
HSV2-UL30-5994 - CCUGCCGGCCCCCGUCGUC 19 14348
HSV2-UL30-1854 - GCCUGCCGGCCCCCGUCGUC 20 4807
HSV2-UL30-5995 - GGCCUGCCGGCCCCCGUCGUC 21 14349
HSV2-UL30-5996 - GGGCCUGCCGGCCCCCG UCGUC 22 14350
HSV2-UL30-5997 - GGGGCCUGCCGGCCCCCGUCGUC 23 14351
HSV2-UL30-5998 - AGGGGCCUGCCGGCCCCCGUCGUC 24 14352
HSV2-UL30-5999 - GAGCUGGCCUU UCCGGUC 18 14353
HSV2-UL30-6000 - CGAGCUGGCCUUUCCGG UC 19 14354
HSV2-UL30-1845 - ACGAGCUGGCCUUUCCGGUC 20 4801
HSV2-UL30-6001 - GACGAGCUGGCCUUUCCGGUC 21 14355
HSV2-UL30-6002 - GGACGAGCUGGCCU UUCCGGUC 22 14356
HSV2-UL30-6003 - AGGACGAGCUGGCCU UUCCGGUC 23 14357
HSV2-UL30-6004 - GAGGACGAGCUGGCCUUUCCGGUC 24 14358
HSV2-UL30-6005 - UGUUAAAGAGGU UUAU UC 18 14359
HSV2-UL30-6006 - CUGUUAAAGAGGUUUAUUC 19 14360
HSV2-UL30-2049 - UCUGU UAAAGAGGUUUAUUC 20 4936
HSV2-UL30-6007 - GUCUGU UAAAGAGGUU UAUUC 21 14361
HSV2-UL30-6008 - AGUCUGUUAAAGAGGUUUAU UC 22 14362
HSV2-UL30-6009 - GAGUCUGUUAAAGAGGUUUAU UC 23 14363
HSV2-UL30-6010 - AGAGUCUGU UAAAGAGGUU UAUUC 24
14364
HSV2-UL30-6011 - GGCCGACGGCUGUUCU UC 18 14365
HSV2-UL30-6012 - GGGCCGACGGCUGUUCU UC 19 14366
HSV2-UL30-1962 - GGGGCCGACGGCUGUUCUUC 20 4875
HSV2-UL30-6013 - GGGGGCCGACGGCUGUUCUUC 21 14367
HSV2-UL30-6014 - GGGGGGCCGACGGCUGU UCUUC 22 14368
HSV2-UL30-6015 - UGGGGGGCCGACGGCUGU UCUUC 23 14369
HSV2-UL30-6016 - GUGGGGGGCCGACGGCUGUUCUUC 24 14370
HSV2-UL30-6017 - AGCUGCUGGCCGACUU UC 18 14371
HSV2-UL30-6018 - CAGCUGCUGGCCGACU UUC 19 14372
HSV2-UL30-659 - UCAGCUGCUGGCCGACU UUC 20 3529 HSV2-UL30-6019 - AUCAGCUGCUGGCCGACUUUC 21 14373
HSV2-UL30-6020 - GAUCAGCUGCUGGCCGACUUUC 22 14374
HSV2-UL30-6021 - CGAUCAGCUGCUGGCCGACU UUC 23 14375
HSV2-UL30-6022 - UCGAUCAGCUGCUGGCCGACU UUC 24 14376
HSV2-UL30-6023 - UACUU UUACAUGAACAAG 18 14377
HSV2-UL30-6024 - G U ACU U U U ACAU G AACAAG 19 14378
HSV2-UL30-1796 - AGUACU UUUACAUGAACAAG 20 4773
HSV2-UL30-6025 - CAGUACUUU UACAUG AACAAG 21 14379
HSV2-UL30-6026 - GCAG U ACU U U U ACAU G AACAAG 22 14380
HSV2-UL30-6027 - GGCAGUACU UUUACAUGAACAAG 23 14381
HSV2-UL30-6028 - CGGCAGUACUU UUACAUGAACAAG 24 14382
HSV2-UL30-6029 - GCCGUCU UGAAGGACAAG 18 14383
HSV2-UL30-6030 - GGCCGUCUUGAAGGACAAG 19 14384
HSV2-UL30-1880 - AGGCCGUCU UGAAGGACAAG 20 4828
HSV2-UL30-6031 - GAGGCCGUCUUGAAGGACAAG 21 14385
HSV2-UL30-6032 - CGAGGCCGUCUUGAAGGACAAG 22 14386
HSV2-UL30-6033 - CCGAGGCCGUCU UGAAGGACAAG 23 14387
HSV2-UL30-6034 - GCCGAGGCCGUCUUGAAGGACAAG 24 14388
HSV2-UL30-6035 - AAACUCUCCAGCUACAAG 18 14389
HSV2-UL30-6036 - CAAACUCUCCAGCUACAAG 19 14390
HSV2-UL30-1875 - UCAAACUCUCCAGCUACAAG 20 4823
HSV2-UL30-6037 - GUCAAACUCUCCAGCUACAAG 21 14391
HSV2-UL30-6038 - GGUCAAACUCUCCAGCUACAAG 22 14392
HSV2-UL30-6039 - AGGUCAAACUCUCCAGCUACAAG 23 14393
HSV2-UL30-6040 - A AG G U C A A AC UCUCCAGCU AC A AG 24 14394
HSV2-UL30-6041 - AAGCGCAGCAAGAUCAAG 18 14395
HSV2-UL30-6042 - GAAGCGCAGCAAGAUCAAG 19 14396
HSV2-UL30-1871 - AG A AG CG C AG C A AG A U C A AG 20 4820
HSV2-UL30-6043 - CAG AAGCGCAGCAAGAUCAAG 21 14397
HSV2-UL30-6044 - U C AG A AG CG C AG C A AG A U C A AG 22 14398
HSV2-UL30-6045 - U UCAG AAGCGCAGCAAGAUCAAG 23 14399
HSV2-UL30-6046 - U U U C AG A AG CG C AG C A AG A U C A AG 24 14400
HSV2-UL30-6047 - CCGUGCCUCGGGGGGAAG 18 14401
HSV2-UL30-6048 - GCCGUGCCUCGGGGGGAAG 19 14402
HSV2-UL30-581 - GGCCGUGCCUCGGGGGGAAG 20 3451
HSV2-UL30-6049 - CGGCCGUGCCUCGGGGGGAAG 21 14403
HSV2-UL30-6050 - CCGGCCGUGCCUCGGGGGGAAG 22 14404
HSV2-UL30-6051 - CCCGGCCGUGCCUCGGGGGGAAG 23 14405
HSV2-UL30-6052 - GCCCGGCCGUGCCUCGGGGGGAAG 24 14406
HSV2-UL30-6053 - CUGCGCCUUGCGGGCCAG 18 14407
HSV2-UL30-6054 - CCUGCGCCUUGCGGGCCAG 19 14408
HSV2-UL30-1894 - UCCUGCGCCUUGCGGGCCAG 20 4840
HSV2-UL30-6055 - CUCCUGCGCCUUGCGGGCCAG 21 14409
HSV2-UL30-6056 - CCUCCUGCGCCUUGCGGGCCAG 22 14410
HSV2-UL30-6057 - GCCUCCUGCGCCUUGCGGGCCAG 23 14411
HSV2-UL30-6058 - UGCCUCCUGCGCCUUGCGGGCCAG 24 14412 HSV2-UL30-6059 - GCGAUCAGGAAGUACGAG 18 14413
HSV2-UL30-6060 - CGCGAUCAGGAAGUACGAG 19 14414
HSV2-UL30-475 - CCGCGAUCAGGAAGUACGAG 20 3345
HSV2-UL30-6061 - CCCGCGAUCAGGAAGUACGAG 21 14415
HSV2-UL30-6062 - CCCCGCGAUCAGGAAGUACGAG 22 14416
HSV2-UL30-6063 - GCCCCGCGAUCAGGAAGUACGAG 23 14417
HSV2-UL30-6064 - UGCCCCGCGAUCAGGAAGUACGAG 24 14418
HSV2-UL30-6065 - GACUACCUGGAGAUCGAG 18 14419
HSV2-UL30-6066 - GGACUACCUGGAGAUCGAG 19 14420
HSV2-UL30-1958 - GGGACUACCUGGAGAUCGAG 20 4874
HSV2-UL30-6067 - CGGGACUACCUGGAGAUCGAG 21 14421
HSV2-UL30-6068 - CCGGGACUACCUGGAGAUCGAG 22 14422
HSV2-UL30-6069 - ACCGGGACUACCUGGAGAUCGAG 23 14423
HSV2-UL30-6070 - GACCGGGACUACCUGGAGAUCGAG 24 14424
HSV2-UL30-6071 - UCCGCGG ACCACU UCG AG 18 14425
HSV2-UL30-6072 - CUCCGCGG ACCACU UCG AG 19 14426
HSV2-UL30-1806 - UCUCCGCGGACCACUUCGAG 20 4780
HSV2-UL30-6073 - AUCUCCGCGGACCACUUCGAG 21 14427
HSV2-UL30-6074 - CAUCUCCGCGGACCACUUCGAG 22 14428
HSV2-UL30-6075 - GCAUCUCCGCGGACCACUUCGAG 23 14429
HSV2-UL30-6076 - GGCAUCUCCGCGGACCACUUCGAG 24 14430
HSV2-UL30-6077 - CG CA U CACCG ACCCG G AG 18 14431
HSV2-UL30-6078 - GCGCAUCACCGACCCGGAG 19 14432
HSV2-UL30-702 - GGCGCAUCACCGACCCGGAG 20 3572
HSV2-UL30-6079 - CGGCGCAUCACCGACCCGGAG 21 14433
HSV2-UL30-6080 - UCGGCGCAUCACCGACCCGGAG 22 14434
HSV2-UL30-6081 - AUCGGCGCAUCACCGACCCGGAG 23 14435
HSV2-UL30-6082 - CAUCGGCGCAUCACCGACCCGGAG 24 14436
HSV2-UL30-6083 - GCCGUCGCGCACCUGGAG 18 14437
HSV2-UL30-6084 - GGCCGUCGCGCACCUGGAG 19 14438
HSV2-UL30-1952 - AGGCCGUCGCGCACCUGGAG 20 4870
HSV2-UL30-6085 - GAGGCCGUCGCGCACCUGGAG 21 14439
HSV2-UL30-6086 - CGAGGCCGUCGCGCACCUGGAG 22 14440
HSV2-UL30-6087 - CCG AGGCCGUCGCGCACCUGGAG 23 14441
HSV2-UL30-6088 - CCCGAGGCCGUCGCGCACCUGGAG 24 14442
HSV2-UL30-6089 - CCCAGACCCGCGAGGUAG 18 14443
HSV2-UL30-6090 - GCCCAGACCCGCGAGGUAG 19 14444
HSV2-UL30-713 - GGCCCAGACCCGCGAGGUAG 20 3583
HSV2-UL30-6091 - UGGCCCAGACCCGCGAGGUAG 21 14445
HSV2-UL30-6092 - GUGGCCCAGACCCGCGAGGUAG 22 14446
HSV2-UL30-6093 - CG UGGCCCAGACCCGCGAGGUAG 23 14447
HSV2-UL30-6094 - UCGUGGCCCAGACCCGCGAGGUAG 24 14448
HSV2-UL30-6095 - GAGCGGCCGCCGCGUUAG 18 14449
HSV2-UL30-6096 - GGAGCGGCCGCCGCGU UAG 19 14450
HSV2-UL30-1999 - CGGAGCGGCCGCCGCGU UAG 20 4903
HSV2-UL30-6097 - CCGGAGCGGCCGCCGCGUUAG 21 14451 HSV2-UL30-6098 - UCCGGAGCGGCCGCCGCGUUAG 22 14452
HSV2-UL30-6099 - AUCCGGAGCGGCCGCCGCGUUAG 23 14453
HSV2-UL30-6100 - UAUCCGGAGCGGCCGCCGCGUUAG 24 14454
HSV2-UL30-6101 - GUCGAGUU UAACUGCACG 18 14455
HSV2-UL30-6102 - CGUCGAGUUUAACUGCACG 19 14456
HSV2-UL30-1830 - ACGUCGAGUUUAACUGCACG 20 4794
HSV2-UL30-6103 - GACG UCGAGU UUAACUGCACG 21 14457
HSV2-UL30-6104 - CGACGUCGAGU UUAACUGCACG 22 14458
HSV2-UL30-6105 - GCGACGUCGAGU UUAACUGCACG 23 14459
HSV2-UL30-6106 - AGCGACGUCGAGU UUAACUGCACG 24 14460
HSV2-UL30-6107 - ACGAGGAUAAGGACGACG 18 14461
HSV2-UL30-6108 - GACGAGGAUAAGGACGACG 19 14462
HSV2-UL30-1925 - GGACGAGGAUAAGGACGACG 20 4853
HSV2-UL30-6109 - GGG ACGAGGAUAAGGACGACG 21 14463
HSV2-UL30-6110 - GGGG ACGAGGAUAAGGACGACG 22 14464
HSV2-UL30-6111 - CGGGG ACGAGGAUAAGGACGACG 23 14465
HSV2-UL30-6112 - ACGGGGACGAGGAUAAGGACGACG 24 14466
HSV2-UL30-6113 - GCGGGGGCCGGCGCUACG 18 14467
HSV2-UL30-6114 - GGCGGGGGCCGGCGCUACG 19 14468
HSV2-UL30-2058 - CGGCGGGGGCCGGCGCUACG 20 4942
HSV2-UL30-6115 - CCGGCGGGGGCCGGCGCUACG 21 14469
HSV2-UL30-6116 - GCCGGCGGGGGCCGGCGCUACG 22 14470
HSV2-UL30-6117 - GGCCGGCGGGGGCCGGCGCUACG 23 14471
HSV2-UL30-6118 - GGGCCGGCGGGGGCCGGCGCUACG 24 14472
HSV2-UL30-6119 - CCGCGAUCAGGAAGUACG 18 14473
HSV2-UL30-6120 - CCCGCGAUCAGGAAGUACG 19 14474
HSV2-UL30-473 - CCCCGCGAUCAGGAAGUACG 20 3343
HSV2-UL30-6121 - GCCCCGCGAUCAGGAAGUACG 21 14475
HSV2-UL30-6122 - UGCCCCGCGAUCAGGAAGUACG 22 14476
HSV2-UL30-6123 - UUGCCCCGCGAUCAGGAAGUACG 23 14477
HSV2-UL30-6124 - UUUGCCCCGCGAUCAGGAAGUACG 24 14478
HSV2-UL30-6125 - AGGACU UUGUCCUCACCG 18 14479
HSV2-UL30-6126 - CAGGACUU UGUCCUCACCG 19 14480
HSV2-UL30-2014 - CCAGGACUUUGUCCUCACCG 20 4913
HSV2-UL30-6127 - UCCAGGACUU UGUCCUCACCG 21 14481
HSV2-UL30-6128 - AUCCAGGACUUUGUCCUCACCG 22 14482
HSV2-UL30-6129 - CAUCCAGGACUU UGUCCUCACCG 23 14483
HSV2-UL30-6130 - ACAUCCAGGACUUUGUCCUCACCG 24 14484
HSV2-UL30-6131 - CGGCGCAUCACCGACCCG 18 14485
HSV2-UL30-6132 - UCGGCGCAUCACCGACCCG 19 14486
HSV2-UL30-2010 - AUCGGCGCAUCACCGACCCG 20 4910
HSV2-UL30-6133 - CAUCGGCGCAUCACCGACCCG 21 14487
HSV2-UL30-6134 - CCAUCGGCGCAUCACCGACCCG 22 14488
HSV2-UL30-6135 - CCC AU CG G CG CA U CACCG ACCCG 23 14489
HSV2-UL30-6136 - GCCCAUCGGCGCAUCACCGACCCG 24 14490
HSV2-UL30-6137 - UCCCCCAGAGCACCCCCG 18 14491 HSV2-UL30-6138 - AUCCCCCAGAGCACCCCCG 19 14492
HSV2-UL30-641 - GAUCCCCCAGAGCACCCCCG 20 3511
HSV2-UL30-6139 - GGAUCCCCCAGAGCACCCCCG 21 14493
HSV2-UL30-6140 - CGGAUCCCCCAGAGCACCCCCG 22 14494
HSV2-UL30-6141 - GCGGAUCCCCCAGAGCACCCCCG 23 14495
HSV2-UL30-6142 - CGCGGAUCCCCCAGAGCACCCCCG 24 14496
HSV2-UL30-6143 - UCUAGCAUGAGCCCCCCG 18 14497
HSV2-UL30-6144 - CUCUAGCAUGAGCCCCCCG 19 14498
HSV2-UL30-6145 - ACUCUAGCAUGAGCCCCCCG 20 14499
HSV2-UL30-6146 - UACUCUAGCAUGAGCCCCCCG 21 14500
HSV2-UL30-6147 - AUACUCUAGCAUGAGCCCCCCG 22 14501
HSV2-UL30-6148 - GAUACUCUAGCAUGAGCCCCCCG 23 14502
HSV2-UL30-6149 - UGAUACUCUAGCAUGAGCCCCCCG 24 14503
HSV2-UL30-6150 - CGUUAGCCGAGCGCCCCG 18 14504
HSV2-UL30-6151 - GCGUUAGCCGAGCGCCCCG 19 14505
HSV2-UL30-2000 - CG CG U U AG CCG AG CG CCCCG 20 4904
HSV2-UL30-6152 - CCGCGUUAGCCGAGCGCCCCG 21 14506
HSV2-UL30-6153 - GCCGCGUUAGCCGAGCGCCCCG 22 14507
HSV2-UL30-6154 - CGCCGCGUUAGCCGAGCGCCCCG 23 14508
HSV2-UL30-6155 - CCGCCGCGUUAGCCGAGCGCCCCG 24 14509
HSV2-UL30-6156 - UGGACGCCAUCACGCCCG 18 14510
HSV2-UL30-6157 - AUGGACGCCAUCACGCCCG 19 14511
HSV2-UL30-1791 - UAUGGACGCCAUCACGCCCG 20 4769
HSV2-UL30-6158 - UUAUGGACGCCAUCACGCCCG 21 14512
HSV2-UL30-6159 - UUUAUGGACGCCAUCACGCCCG 22 14513
HSV2-UL30-6160 - AUUUAUGGACGCCAUCACGCCCG 23 14514
HSV2-UL30-6161 - GAUUUAUGGACGCCAUCACGCCCG 24 14515
HSV2-UL30-6162 - UGGCGCGACCCCUGCCCG 18 14516
HSV2-UL30-6163 - CUGGCGCGACCCCUGCCCG 19 14517
HSV2-UL30-694 - GCUGGCGCGACCCCUGCCCG 20 3564
HSV2-UL30-6164 - GGCUGGCGCGACCCCUGCCCG 21 14518
HSV2-UL30-6165 - UGGCUGGCGCGACCCCUGCCCG 22 14519
HSV2-UL30-6166 - GUGGCUGGCGCGACCCCUGCCCG 23 14520
HSV2-UL30-6167 - AGUGGCUGGCGCGACCCCUGCCCG 24 14521
HSV2-UL30-6168 - AUAUCGAAUGCAAGGCCG 18 14522
HSV2-UL30-6169 - GAUAUCGAAUGCAAGGCCG 19 14523
HSV2-UL30-502 - CG AUAUCGAAUGCAAGGCCG 20 3372
HSV2-UL30-6170 - UCG AUAUCGAAUGCAAGGCCG 21 14524
HSV2-UL30-6171 - UUCG AUAUCGAAUGCAAGGCCG 22 14525
HSV2-UL30-6172 - CU UCG AUAUCGAAUGCAAGGCCG 23 14526
HSV2-UL30-6173 - GCUUCGAUAUCGAAUGCAAGGCCG 24 14527
HSV2-UL30-6174 - CCG CC U C A AG CCCGGCCG 18 14528
HSV2-UL30-6175 - ACCGCCUCAAGCCCGGCCG 19 14529
HSV2-UL30-486 - UACCGCCUCAAGCCCGGCCG 20 3356
HSV2-UL30-6176 - GU ACCGCCUCAAGCCCGGCCG 21 14530
HSV2-UL30-6177 - GG UACCGCCUCAAGCCCGGCCG 22 14531 HSV2-UL30-6178 - UGGUACCGCCUCAAGCCCGGCCG 23 14532
HSV2-UL30-6179 - CUGGUACCGCCUCAAGCCCGGCCG 24 14533
HSV2-UL30-6180 - GGGGAAGGGGAGCGGCCG 18 14534
HSV2-UL30-6181 - GGGGGAAGGGGAGCGGCCG 19 14535
HSV2-UL30-585 - GGGGGGAAGGGGAGCGGCCG 20 3455
HSV2-UL30-6182 - CGGGGGGAAGGGGAGCGGCCG 21 14536
HSV2-UL30-6183 - UCGGGGGGAAGGGGAGCGGCCG 22 14537
HSV2-UL30-6184 - CUCGGGGGGAAGGGGAGCGGCCG 23 14538
HSV2-UL30-6185 - CCUCGGGGGGAAGGGGAGCGGCCG 24 14539
HSV2-UL30-6186 - GCCGCGGGGUUCGGGCCG 18 14540
HSV2-UL30-6187 - GGCCGCGGGGUUCGGGCCG 19 14541
HSV2-UL30-2055 - GGGCCGCGGGGU UCGGGCCG 20 4941
HSV2-UL30-6188 - AGGGCCGCGGGGUUCGGGCCG 21 14542
HSV2-UL30-6189 - CAGGGCCGCGGGGUUCGGGCCG 22 14543
HSV2-UL30-6190 - UCAGGGCCGCGGGGUUCGGGCCG 23 14544
HSV2-UL30-6191 - CUCAGGGCCGCGGGGUUCGGGCCG 24 14545
HSV2-UL30-6192 - CGGCGGACAACCUGGCCG 18 14546
HSV2-UL30-6193 - ACGGCGGACAACCUGGCCG 19 14547
HSV2-UL30-1831 - CACGGCGGACAACCUGGCCG 20 4795
HSV2-UL30-6194 - GCACGGCGGACAACCUGGCCG 21 14548
HSV2-UL30-6195 - UGCACGGCGGACAACCUGGCCG 22 14549
HSV2-UL30-6196 - CUGCACGGCGGACAACCUGGCCG 23 14550
HSV2-UL30-6197 - ACUGCACGGCGGACAACCUGGCCG 24 14551
HSV2-UL30-6198 - AGGACGGGGACGAGCGCG 18 14552
HSV2-UL30-6199 - GAGGACGGGGACGAGCGCG 19 14553
HSV2-UL30-602 - CG AGGACGGGGACGAGCGCG 20 3472
HSV2-UL30-6200 - ACG AGGACGGGGACGAGCGCG 21 14554
HSV2-UL30-6201 - GACG AGGACGGGGACGAGCGCG 22 14555
HSV2-UL30-6202 - GG ACG AGGACGGGGACGAGCGCG 23 14556
HSV2-UL30-6203 - GGGACGAGGACGGGGACGAGCGCG 24 14557
HSV2-UL30-6204 - CGCGUACGUGCACGCGCG 18 14558
HSV2-UL30-6205 - GCGCGUACGUGCACGCGCG 19 14559
HSV2-UL30-1976 - CGCGCGUACGUGCACGCGCG 20 4887
HSV2-UL30-6206 - G CG CG CG U ACG U G CACG CG CG 21 14560
HSV2-UL30-6207 - CGCGCGCGUACGUGCACGCGCG 22 14561
HSV2-UL30-6208 - ACGCGCGCGUACGUGCACGCGCG 23 14562
HSV2-UL30-6209 - GACGCGCGCGUACGUGCACGCGCG 24 14563
HSV2-UL30-6210 - GGGGCCGGCGCUACGGCG 18 14564
HSV2-UL30-6211 - GGGGGCCGGCGCUACGGCG 19 14565
HSV2-UL30-2060 - CGGGGGCCGGCGCUACGGCG 20 4943
HSV2-UL30-6212 - GCGGGGGCCGGCGCUACGGCG 21 14566
HSV2-UL30-6213 - GGCGGGGGCCGGCGCUACGGCG 22 14567
HSV2-UL30-6214 - CGGCGGGGGCCGGCGCUACGGCG 23 14568
HSV2-UL30-6215 - CCGGCGGGGGCCGGCGCUACGGCG 24 14569
HSV2-UL30-6216 - GCGCCCGGCCGUGCCUCG 18 14570
HSV2-UL30-6217 - AGCGCCCGGCCGUGCCUCG 19 14571 HSV2-UL30-576 - AAGCGCCCGGCCGUGCCUCG 20 3446
HSV2-UL30-6218 - CAAGCGCCCGGCCGUGCCUCG 21 14572
HSV2-UL30-6219 - CCAAGCGCCCGGCCGUGCCUCG 22 14573
HSV2-UL30-6220 - CCCAAGCGCCCGGCCGUGCCUCG 23 14574
HSV2-UL30-6221 - GCCCAAGCGCCCGGCCG UGCCUCG 24 14575
HSV2-UL30-6222 - GCGGCCCUGCGCGAGUCG 18 14576
HSV2-UL30-6223 - GGCGGCCCUGCGCGAGUCG 19 14577
HSV2-UL30-1801 - CGGCGGCCCUGCGCGAGUCG 20 4777
HSV2-UL30-6224 - GCGGCGGCCCUGCGCGAGUCG 21 14578
HSV2-UL30-6225 - GGCGGCGGCCCUGCGCGAGUCG 22 14579
HSV2-UL30-6226 - UGGCGGCGGCCCUGCGCGAGUCG 23 14580
HSV2-UL30-6227 - CUGGCGGCGGCCCUGCGCGAGUCG 24 14581
HSV2-UL30-6228 - ACAAGCUGAACGCCGUCG 18 14582
HSV2-UL30-6229 - UACAAGCUGAACGCCGUCG 19 14583
HSV2-UL30-1876 - CUACAAGCUGAACGCCGUCG 20 4824
HSV2-UL30-6230 - GCU ACAAGCUGAACGCCGUCG 21 14584
HSV2-UL30-6231 - AGCU ACAAGCUGAACGCCGUCG 22 14585
HSV2-UL30-6232 - CAGCU ACAAGCUGAACGCCGUCG 23 14586
HSV2-UL30-6233 - CCAGCU ACAAGCUGAACGCCGUCG 24 14587
HSV2-UL30-6234 - CGGACAACCUGGCCGUCG 18 14588
HSV2-UL30-6235 - GCGGACAACCUGGCCGUCG 19 14589
HSV2-UL30-494 - GGCGGACAACCUGGCCGUCG 20 3364
HSV2-UL30-6236 - CGGCGGACAACCUGGCCGUCG 21 14590
HSV2-UL30-6237 - ACGGCGGACAACCUGGCCGUCG 22 14591
HSV2-UL30-6238 - CACGGCGGACAACCUGGCCGUCG 23 14592
HSV2-UL30-6239 - GCACGGCGGACAACCUGGCCGUCG 24 14593
HSV2-UL30-6240 - AGCUGGCCU UUCCGGUCG 18 14594
HSV2-UL30-6241 - GAGCUGGCCUUUCCGGUCG 19 14595
HSV2-UL30-509 - CGAGCUGGCCUUUCCGG UCG 20 3379
HSV2-UL30-6242 - ACGAGCUGGCCUUUCCGGUCG 21 14596
HSV2-UL30-6243 - GACGAGCUGGCCUUUCCGGUCG 22 14597
HSV2-UL30-6244 - GGACGAGCUGGCCU UUCCGGUCG 23 14598
HSV2-UL30-6245 - AGGACGAGCUGGCCUUUCCGGUCG 24 14599
HSV2-UL30-6246 - ACUUU UACAUGAACAAGG 18 14600
HSV2-UL30-6247 - UACUU UUACAUGAACAAGG 19 14601
HSV2-UL30-451 - GUACUU UUACAUGAACAAGG 20 3321
HSV2-UL30-6248 - AGUACU UUUACAUGAACAAGG 21 14602
HSV2-UL30-6249 - CAG U ACU U U U ACAUG AACAAGG 22 14603
HSV2-UL30-6250 - GCAGUACUUU UACAUGAACAAGG 23 14604
HSV2-UL30-6251 - GGCAGUACU UUUACAUGAACAAGG 24 14605
HSV2-UL30-6252 - UCGAUAUCGAAUGCAAGG 18 14606
HSV2-UL30-6253 - UUCGAUAUCGAAUGCAAGG 19 14607
HSV2-UL30-1836 - CU UCGAUAUCGAAUGCAAGG 20 4798
HSV2-UL30-6254 - GCU UCGAUAUCGAAUGCAAGG 21 14608
HSV2-UL30-6255 - UGCU UCGAUAUCGAAUGCAAGG 22 14609
HSV2-UL30-6256 - GUGCU UCGAUAUCGAAUGCAAGG 23 14610 HSV2-UL30-6257 - UGUGCUUCGAUAUCGAAUGCAAGG 24 14611
HSV2-UL30-6258 - AUAAGGACGACGACGAGG 18 14612
HSV2-UL30-6259 - GAUAAGGACGACGACGAGG 19 14613
HSV2-UL30-1927 - GGAUAAGGACGACGACGAGG 20 4855
HSV2-UL30-6260 - AGGAUAAGGACGACGACGAGG 21 14614
HSV2-UL30-6261 - GAGGAUAAGGACGACGACGAGG 22 14615
HSV2-UL30-6262 - CG AGGAUAAGGACGACGACGAGG 23 14616
HSV2-UL30-6263 - ACGAGGAUAAGGACGACGACGAGG 24 14617
HSV2-UL30-6264 - ACGAGGACGGGGACGAGG 18 14618
HSV2-UL30-6265 - GACGAGGACGGGGACGAGG 19 14619
HSV2-UL30-1932 - CG ACGAGGACGGGGACGAGG 20 4858
HSV2-UL30-6266 - ACG ACGAGGACGGGGACGAGG 21 14620
HSV2-UL30-6267 - GACG ACGAGGACGGGGACGAGG 22 14621
HSV2-UL30-6268 - CG ACG ACGAGGACGGGGACGAGG 23 14622
HSV2-UL30-6269 - ACGACGACGAGGACGGGGACGAGG 24 14623
HSV2-UL30-6270 - UGGCCCAGACCCGCGAGG 18 14624
HSV2-UL30-6271 - GUGGCCCAGACCCGCGAGG 19 14625
HSV2-UL30-2019 - CGUGGCCCAGACCCGCGAGG 20 4918
HSV2-UL30-6272 - UCG UGGCCCAGACCCGCGAGG 21 14626
HSV2-UL30-6273 - AUCG UGGCCCAGACCCGCGAGG 22 14627
HSV2-UL30-6274 - GAUCG UGGCCCAGACCCGCGAGG 23 14628
HSV2-UL30-6275 - UGAUCGUGGCCCAGACCCGCGAGG 24 14629
HSV2-UL30-6276 - ACUACCUGGAGAUCGAGG 18 14630
HSV2-UL30-6277 - GACUACCUGGAGAUCGAGG 19 14631
HSV2-UL30-631 - GG ACUACCUGGAGAUCGAGG 20 3501
HSV2-UL30-6278 - GGG ACUACCUGGAGAUCGAGG 21 14632
HSV2-UL30-6279 - CGGGACUACCUGGAGAUCGAGG 22 14633
HSV2-UL30-6280 - CCGGG ACUACCUGGAGAUCGAGG 23 14634
HSV2-UL30-6281 - ACCGGG ACUACCUGGAGAUCGAGG 24 14635
HSV2-UL30-6282 - CCGCGGACCACU UCGAGG 18 14636
HSV2-UL30-6283 - UCCGCGGACCACUUCGAGG 19 14637
HSV2-UL30-465 - CUCCGCGGACCACUUCGAGG 20 3335
HSV2-UL30-6284 - UCUCCGCGGACCACUUCGAGG 21 14638
HSV2-UL30-6285 - AUCUCCGCGGACCACUUCGAGG 22 14639
HSV2-UL30-6286 - CAUCUCCGCGGACCACUUCGAGG 23 14640
HSV2-UL30-6287 - GCAUCUCCGCGGACCACUUCGAGG 24 14641
HSV2-UL30-6288 - GCAAGGCCGGGGGGGAGG 18 14642
HSV2-UL30-6289 - UGCAAGGCCGGGGGGGAGG 19 14643
HSV2-UL30-1844 - AUGCAAGGCCGGGGGGGAGG 20 4800
HSV2-UL30-6290 - AAUGCAAGGCCGGGGGGGAGG 21 14644
HSV2-UL30-6291 - GAAUGCAAGGCCGGGGGGGAGG 22 14645
HSV2-UL30-6292 - CG AAUGCAAGGCCGGGGGGGAGG 23 14646
HSV2-UL30-6293 - UCGAAUGCAAGGCCGGGGGGGAGG 24 14647
HSV2-UL30-6294 - GUACGGGCGCAUGAACGG 18 14648
HSV2-UL30-6295 - GGUACGGGCGCAUGAACGG 19 14649
HSV2-UL30-1865 - GGGUACGGGCGCAUGAACGG 20 4816 HSV2-UL30-6296 - CGGGUACGGGCGCAUGAACGG 21 14650
HSV2-UL30-6297 - ACGGG U ACGGGCGCAUG AACGG 22 14651
HSV2-UL30-6298 - GACGGGUACGGGCGCAUGAACGG 23 14652
HSV2-UL30-6299 - CGACGGGUACGGGCGCAUGAACGG 24 14653
HSV2-UL30-6300 - CGGGGGCCGGCGCUACGG 18 14654
HSV2-UL30-6301 - GCGGGGGCCGGCGCUACGG 19 14655
HSV2-UL30-763 - GGCGGGGGCCGGCGCUACGG 20 3633
HSV2-UL30-6302 - CGGCGGGGGCCGGCGCUACGG 21 14656
HSV2-UL30-6303 - CCGGCGGGGGCCGGCGCUACGG 22 14657
HSV2-UL30-6304 - GCCGGCGGGGGCCGGCGCUACGG 23 14658
HSV2-UL30-6305 - GGCCGGCGGGGGCCGGCGCUACGG 24 14659
HSV2-UL30-6306 - UAUCGAAUGCAAGGCCGG 18 14660
HSV2-UL30-6307 - AUAUCGAAUGCAAGGCCGG 19 14661
HSV2-UL30-503 - GAUAUCGAAUGCAAGGCCGG 20 3373
HSV2-UL30-6308 - CGAUAUCGAAUGCAAGGCCGG 21 14662
HSV2-UL30-6309 - UCG AUAUCGAAUGCAAGGCCGG 22 14663
HSV2-UL30-6310 - UUCG AUAUCGAAUGCAAGGCCGG 23 14664
HSV2-UL30-6311 - CU UCG AUAUCGAAUGCAAGGCCGG 24 14665
HSV2-UL30-6312 - CCGCGGGG UUCGGGCCGG 18 14666
HSV2-UL30-6313 - GCCGCGGGGUUCGGGCCGG 19 14667
HSV2-UL30-757 - GGCCGCGGGGUUCGGGCCGG 20 3627
HSV2-UL30-6314 - GGGCCGCGGGGUUCGGGCCGG 21 14668
HSV2-UL30-6315 - AGGGCCGCGGGGU UCGGGCCGG 22 14669
HSV2-UL30-6316 - CAGGGCCGCGGGGUUCGGGCCGG 23 14670
HSV2-UL30-6317 - UCAGGGCCGCGGGGUUCGGGCCGG 24 14671
HSV2-UL30-6318 - CGGGGGGAAGGGGAGCGG 18 14672
HSV2-UL30-6319 - UCGGGGGGAAGGGGAGCGG 19 14673
HSV2-UL30-1912 - CUCGGGGGGAAGGGGAGCGG 20 4847
HSV2-UL30-6320 - CCUCGGGGGGAAGGGGAGCGG 21 14674
HSV2-UL30-6321 - GCCUCGGGGGGAAGGGGAGCGG 22 14675
HSV2-UL30-6322 - UGCCUCGGGGGGAAGGGGAGCGG 23 14676
HSV2-UL30-6323 - GUGCCUCGGGGGGAAGGGGAGCGG 24
14677
HSV2-UL30-6324 - GGGCCGGCGCUACGGCGG 18 14678
HSV2-UL30-6325 - GGGGCCGGCGCUACGGCGG 19 14679
HSV2-UL30-764 - GGGGGCCGGCGCUACGGCGG 20 3634
HSV2-UL30-6326 - CGGGGGCCGGCGCUACGGCGG 21 14680
HSV2-UL30-6327 - GCGGGGGCCGGCGCUACGGCGG 22 14681
HSV2-UL30-6328 - GGCGGGGGCCGGCGCUACGGCGG 23 14682
HSV2-UL30-6329 - CGGCGGGGGCCGGCGCUACGGCGG 24 14683
HSV2-UL30-6330 - CGCCCGGCCGUGCCUCGG 18 14684
HSV2-UL30-6331 - GCGCCCGGCCGUGCCUCGG 19 14685
HSV2-UL30-577 - AGCGCCCGGCCGUGCCUCGG 20 3447
HSV2-UL30-6332 - AAGCGCCCGGCCGUGCCUCGG 21 14686
HSV2-UL30-6333 - CAAGCGCCCGGCCGUGCCUCGG 22 14687
HSV2-UL30-6334 - CCAAGCGCCCGGCCGUGCCUCGG 23 14688 HSV2-UL30-6335 - CCCAAGCGCCCGGCCGUGCCUCGG 24 14689
HSV2-UL30-6336 - AUCGAAUGCAAGGCCGGG 18 14690
HSV2-UL30-6337 - UAUCGAAUGCAAGGCCGGG 19 14691
HSV2-UL30-504 - AU AUCGAAUGCAAGGCCGGG 20 3374
HSV2-UL30-6338 - GAU AUCGAAUGCAAGGCCGGG 21 14692
HSV2-UL30-6339 - CGAU AUCGAAUGCAAGGCCGGG 22 14693
HSV2-UL30-6340 - UCGAU AUCGAAUGCAAGGCCGGG 23 14694
HSV2-UL30-6341 - UUCGAUAUCGAAUGCAAGGCCGGG 24 14695
HSV2-UL30-6342 - GCCCGGCCGUGCCUCGGG 18 14696
HSV2-UL30-6343 - CGCCCGGCCGUGCCUCGGG 19 14697
HSV2-UL30-578 - GCGCCCGGCCGUGCCUCGGG 20 3448
HSV2-UL30-6344 - AGCGCCCGGCCGUGCCUCGGG 21 14698
HSV2-UL30-6345 - AAGCGCCCGGCCGUGCCUCGGG 22 14699
HSV2-UL30-6346 - CAAGCGCCCGGCCGUGCCUCGGG 23 14700
HSV2-UL30-6347 - CCAAGCGCCCGGCCGUGCCUCGGG 24 14701
HSV2-UL30-6348 - ACGCCGCCGCCCCAGGGG 18 14702
HSV2-UL30-6349 - GACGCCGCCGCCCCAGGGG 19 14703
HSV2-UL30-2026 - AGACGCCGCCGCCCCAGGGG 20 4922
HSV2-UL30-6350 - U AG ACGCCGCCGCCCCAGGGG 21 14704
HSV2-UL30-6351 - CUAGACGCCGCCGCCCCAGGGG 22 14705
HSV2-UL30-6352 - GCU AGACGCCGCCGCCCCAGGGG 23 14706
HSV2-UL30-6353 - AGCU AG ACGCCGCCGCCCCAGGGG 24 14707
HSV2-UL30-6354 - CGGGGGACGGGAACGGGG 18 14708
HSV2-UL30-6355 - CCGGGGGACGGGAACGGGG 19 14709
HSV2-UL30-1922 - GCCGGGGGACGGGAACGGGG 20 4850
HSV2-UL30-6356 - GGCCGGGGGACGGGAACGGGG 21 14710
HSV2-UL30-6357 - CGGCCGGGGGACGGGAACGGGG 22 14711
HSV2-UL30-6358 - GCGGCCGGGGGACGGGAACGGGG 23 14712
HSV2-UL30-6359 - AGCGGCCGGGGGACGGGAACGGGG 24 14713
HSV2-UL30-6360 - ACGACGACGAGGACGGGG 18 14714
HSV2-UL30-6361 - GACGACGACGAGGACGGGG 19 14715
HSV2-UL30-1930 - GGACGACGACGAGGACGGGG 20 4856
HSV2-UL30-6362 - AGG ACGACGACGAGGACGGGG 21 14716
HSV2-UL30-6363 - AAGG ACGACGACGAGGACGGGG 22 14717
HSV2-UL30-6364 - UAAGG ACGACGACGAGGACGGGG 23 14718
HSV2-UL30-6365 - AUAAGGACGACGACGAGGACGGGG 24 14719
HSV2-UL30-6366 - ACGGGGACGAGGACGGGG 18 14720
HSV2-UL30-6367 - GACGGGGACGAGGACGGGG 19 14721
HSV2-UL30-1935 - GG ACGGGGACGAGGACGGGG 20 4859
HSV2-UL30-6368 - AGG ACGGGGACGAGGACGGGG 21 14722
HSV2-UL30-6369 - G AGG ACGGGGACGAGGACGGGG 22 14723
HSV2-UL30-6370 - CG AGG ACGGGGACGAGGACGGGG 23 14724
HSV2-UL30-6371 - ACGAGGACGGGGACGAGGACGGGG 24 14725
HSV2-UL30-6372 - UCGAAUGCAAGGCCGGGG 18 14726
HSV2-UL30-6373 - AUCGAAUGCAAGGCCGGGG 19 14727
HSV2-UL30-505 - UAUCGAAUGCAAGGCCGGGG 20 3375 HSV2-UL30-6374 - AUAUCGAAUGCAAGGCCGGGG 21 14728
HSV2-UL30-6375 - GAUAUCGAAUGCAAGGCCGGGG 22 14729
HSV2-UL30-6376 - CG AUAUCGAAUGCAAGGCCGGGG 23 14730
HSV2-UL30-6377 - UCGAUAUCGAAUGCAAGGCCGGGG 24 14731
HSV2-UL30-6378 - AAGGGGAGCGGCCGGGGG 18 14732
HSV2-UL30-6379 - GAAGGGGAGCGGCCGGGGG 19 14733
HSV2-UL30-1916 - GG AAGGGGAGCGGCCGGGGG 20 4848
HSV2-UL30-6380 - GGGAAGGGGAGCGGCCGGGGG 21 14734
HSV2-UL30-6381 - GGGG AAGGGGAGCGGCCGGGGG 22 14735
HSV2-UL30-6382 - GGGGG AAGGGGAGCGGCCGGGGG 23 14736
HSV2-UL30-6383 - GGGGGGAAGGGGAGCGGCCGGGGG 24
14737
HSV2-UL30-6384 - GAAUGCAAGGCCGGGGGG 18 14738
HSV2-UL30-6385 - CGAAUGCAAGGCCGGGGGG 19 14739
HSV2-UL30-1843 - UCGAAUGCAAGGCCGGGGGG 20 4799
HSV2-UL30-6386 - AUCGAAUGCAAGGCCGGGGGG 21 14740
HSV2-UL30-6387 - UAUCGAAUGCAAGGCCGGGGGG 22 14741
HSV2-UL30-6388 - AU AUCGAAUGCAAGGCCGGGGGG 23 14742
HSV2-UL30-6389 - GAUAUCGAAUGCAAGGCCGGGGGG 24 14743
HSV2-UL30-6390 - CGGCCGUGCCUCGGGGGG 18 14744
HSV2-UL30-6391 - CCGGCCGUGCCUCGGGGGG 19 14745
HSV2-UL30-1908 - CCCGGCCGUGCCUCGGGGGG 20 4846
HSV2-UL30-6392 - GCCCGGCCGUGCCUCGGGGGG 21 14746
HSV2-UL30-6393 - CGCCCGGCCGUGCCUCGGGGGG 22 14747
HSV2-UL30-6394 - GCGCCCGGCCGUGCCUCGGGGGG 23 14748
HSV2-UL30-6395 - AGCGCCCGGCCGUGCCUCGGGGGG 24 14749
HSV2-UL30-6396 - UGCUGGUGUCCGAGCUGG 18 14750
HSV2-UL30-6397 - CUGCUGGUGUCCGAGCUGG 19 14751
HSV2-UL30-729 - GCUGCUGGUGUCCGAGCUGG 20 3599
HSV2-UL30-6398 - AGCUGCUGGUG UCCGAGCUGG 21 14752
HSV2-UL30-6399 - AAGCUGCUGGUGUCCGAGCUGG 22 14753
HSV2-UL30-6400 - CAAGCUGCUGGUGUCCGAGCUGG 23 14754
HSV2-UL30-6401 - GCAAGCUGCUGGUGUCCGAGCUGG 24 14755
HSV2-UL30-6402 - UACGUGCACGCGCGCUGG 18 14756
HSV2-UL30-6403 - GUACGUGCACGCGCGCUGG 19 14757
HSV2-UL30-1977 - CGUACGUGCACGCGCGCUGG 20 4888
HSV2-UL30-6404 - GCG UACGUGCACGCGCGCUGG 21 14758
HSV2-UL30-6405 - CGCGUACGUGCACGCGCGCUGG 22 14759
HSV2-UL30-6406 - GCGCG UACGUGCACGCGCGCUGG 23 14760
HSV2-UL30-6407 - CGCGCGUACGUGCACGCGCGCUGG 24 14761
HSV2-UL30-6408 - UGCAGGACUCGCUGCUGG 18 14762
HSV2-UL30-6409 - GUGCAGGACUCGCUGCUGG 19 14763
HSV2-UL30-1888 - UGUGCAGGACUCGCUGCUGG 20 4835
HSV2-UL30-6410 - GUG UGCAGGACUCGCUGCUGG 21 14764
HSV2-UL30-6411 - UGUGUGCAGGACUCGCUGCUGG 22 14765
HSV2-UL30-6412 - UUGUGUGCAGGACUCGCUGCUGG 23 14766 HSV2-UL30-6413 - AUUGUGUGCAGGACUCGCUGCUGG 24 14767
HSV2-UL30-6414 - ACU UCGAGGCGGAGGUGG 18 14768
HSV2-UL30-6415 - CACUUCGAGGCGGAGGUGG 19 14769
HSV2-UL30-468 - CCACUUCGAGGCGGAGGUGG 20 3338
HSV2-UL30-6416 - ACCACU UCGAGGCGGAGGUGG 21 14770
HSV2-UL30-6417 - GACCACUUCGAGGCGGAGGUGG 22 14771
HSV2-UL30-6418 - GGACCACUUCGAGGCGGAGGUGG 23 14772
HSV2-UL30-6419 - CGGACCACUUCGAGGCGGAGGUGG 24 14773
HSV2-UL30-6420 - GCCAUGGGCGACAAGAUG 18 14774
HSV2-UL30-6421 - GGCCAUGGGCGACAAGAUG 19 14775
HSV2-UL30-1987 - UGGCCAUGGGCGACAAGAUG 20 4894
HSV2-UL30-6422 - GUGGCCAUGGGCGACAAGAUG 21 14776
HSV2-UL30-6423 - GG UGGCCAUGGGCGACAAGAUG 22 14777
HSV2-UL30-6424 - UGGUGGCCAUGGGCGACAAGAUG 23 14778
HSV2-UL30-6425 - CUGGUGGCCAUGGGCGACAAGAUG 24 14779
HSV2-UL30-6426 - AUCAAGGUGAACGGGAUG 18 14780
HSV2-UL30-6427 - GAUCAAGGUGAACGGGAUG 19 14781
HSV2-UL30-1874 - AG AUCAAGGUGAACGGGAUG 20 4822
HSV2-UL30-6428 - AAG AUCAAGGUGAACGGGAUG 21 14782
HSV2-UL30-6429 - CAAG AUCAAGGUGAACGGGAUG 22 14783
HSV2-UL30-6430 - GCAAG AUCAAGGUGAACGGGAUG 23 14784
HSV2-UL30-6431 - AGCAAGAUCAAGGUGAACGGGAUG 24 14785
HSV2-UL30-6432 - UAUUACUUCUCGCACCUG 18 14786
HSV2-UL30-6433 - CUAUUACUUCUCGCACCUG 19 14787
HSV2-UL30-2041 - ACUAUUACUUCUCGCACCUG 20 4931
HSV2-UL30-6434 - GACUAU UACUUCUCGCACCUG 21 14788
HSV2-UL30-6435 - GGACUAUUACUUCUCGCACCUG 22 14789
HSV2-UL30-6436 - CGG ACU AU U ACU UCUCGCACCUG 23 14790
HSV2-UL30-6437 - ACGGACUAUUACUUCUCGCACCUG 24 14791
HSV2-UL30-6438 - CACGUACGCGAGAGCCUG 18 14792
HSV2-UL30-6439 - CCACGUACGCGAGAGCCUG 19 14793
HSV2-UL30-1965 - CCCACGUACGCGAGAGCCUG 20 4878
HSV2-UL30-6440 - GCCCACGUACGCGAGAGCCUG 21 14794
HSV2-UL30-6441 - GGCCCACG U ACGCG AG AGCCUG 22 14795
HSV2-UL30-6442 - AGGCCCACGUACGCGAGAGCCUG 23 14796
HSV2-UL30-6443 - AAGGCCCACGUACGCGAGAGCCUG 24 14797
HSV2-UL30-6444 - UCCGCCGUCGCGCGCCUG 18 14798
HSV2-UL30-6445 - UUCCGCCGUCGCGCGCCUG 19 14799
HSV2-UL30-1891 - UU UCCGCCGUCGCGCGCCUG 20 4837
HSV2-UL30-6446 - CUUUCCGCCGUCGCGCGCCUG 21 14800
HSV2-UL30-6447 - GCUUUCCGCCGUCGCGCGCCUG 22 14801
HSV2-UL30-6448 - AGCUU UCCGCCGUCGCGCGCCUG 23 14802
HSV2-UL30-6449 - GAGCUUUCCGCCGUCGCGCGCCUG 24 14803
HSV2-UL30-6450 - CAGAAGGGCUUCAUCCUG 18 14804
HSV2-UL30-6451 - CCAGAAGGGCUUCAUCCUG 19 14805
HSV2-UL30-1895 - GCCAGAAGGGCUUCAUCCUG 20 4841 HSV2-UL30-6452 - GGCCAGAAGGGCU UCAUCCUG 21 14806
HSV2-UL30-6453 - GGGCCAGAAGGGCU UCAUCCUG 22 14807
HSV2-UL30-6454 - CGGGCCAGAAGGGCU UCAUCCUG 23 14808
HSV2-UL30-6455 - GCGGGCCAGAAGGGCU UCAUCCUG 24 14809
HSV2-UL30-6456 - UUCGUCCUGACCAAGCUG 18 14810
HSV2-UL30-6457 - CU UCGUCCUGACCAAGCUG 19 14811
HSV2-UL30-1860 - CCUUCG UCCUGACCAAGCUG 20 4812
HSV2-UL30-6458 - CCCUUCGUCCUGACCAAGCUG 21 14812
HSV2-UL30-6459 - GCCCUUCGUCCUGACCAAGCUG 22 14813
HSV2-UL30-6460 - GGCCCUUCGUCCUGACCAAGCUG 23 14814
HSV2-UL30-6461 - UGGCCCU UCGUCCUGACCAAGCUG 24 14815
HSV2-UL30-6462 - CUGCUGGUGUCCGAGCUG 18 14816
HSV2-UL30-6463 - GCUGCUGGUGUCCGAGCUG 19 14817
HSV2-UL30-2034 - AGCUGCUGGUGUCCGAGCUG 20 4926
HSV2-UL30-6464 - AAGCUGCUGGUGUCCGAGCUG 21 14818
HSV2-UL30-6465 - CAAGCUGCUGGUGUCCGAGCUG 22 14819
HSV2-UL30-6466 - GCAAGCUGCUGGUGUCCGAGCUG 23 14820
HSV2-UL30-6467 - CGCAAGCUGCUGGUGUCCGAGCUG 24 14821
HSV2-UL30-6468 - GUACAUCGGCGUCAUCUG 18 14822
HSV2-UL30-6469 - AGUACAUCGGCGUCAUCUG 19 14823
HSV2-UL30-678 - AAGUACAUCGGCGUCAUCUG 20 3548
HSV2-UL30-6470 - AAAGUACAUCGGCGUCAUCUG 21 14824
HSV2-UL30-6471 - AAAAGUACAUCGGCGUCAUCUG 22 14825
HSV2-UL30-6472 - A A A A AG UACAUCGGCGUCAUCUG 23 14826
HSV2-UL30-6473 - GAAAAAGUACAUCGGCGUCAUCUG 24 14827
HSV2-UL30-6474 - CGGGGUGUGU UCCGCGUG 18 14828
HSV2-UL30-6475 - CCGGGGUGUGUUCCGCGUG 19 14829
HSV2-UL30-532 - GCCGGGG UGUGUUCCGCGUG 20 3402
HSV2-UL30-6476 - GGCCGGGGUGUGUUCCGCGUG 21 14830
HSV2-UL30-6477 - CGGCCGGGGUGUGUUCCGCGUG 22 14831
HSV2-UL30-6478 - ACGGCCGGGGUGUGUUCCGCGUG 23 14832
HSV2-UL30-6479 - AACGGCCGGGGUGUGU UCCGCGUG 24 14833
HSV2-UL30-6480 - UACCUGGAGAUCGAGGUG 18 14834
HSV2-UL30-6481 - CUACCUGGAGAUCGAGGUG 19 14835
HSV2-UL30-633 - ACUACCUGGAGAUCGAGGUG 20 3503
HSV2-UL30-6482 - GACUACCUGGAGAUCGAGGUG 21 14836
HSV2-UL30-6483 - GG ACUACCUGGAGAUCGAGGUG 22 14837
HSV2-UL30-6484 - GGG ACUACCUGGAGAUCGAGGUG 23 14838
HSV2-UL30-6485 - CGGGACUACCUGGAGAUCGAGGUG 24 14839
HSV2-UL30-6486 - CACUUCGAGGCGGAGGUG 18 14840
HSV2-UL30-6487 - CCACU UCGAGGCGGAGGUG 19 14841
HSV2-UL30-1808 - ACCACUUCGAGGCGGAGGUG 20 4781
HSV2-UL30-6488 - GACCACUUCGAGGCGGAGGUG 21 14842
HSV2-UL30-6489 - GGACCACUUCGAGGCGGAGGUG 22 14843
HSV2-UL30-6490 - CGGACCACU UCGAGGCGGAGGUG 23 14844
HSV2-UL30-6491 - GCGGACCACU UCGAGGCGGAGGUG 24 14845 HSV2-UL30-6492 - AUCGGCGAGUAUUGUGUG 18 14846
HSV2-UL30-6493 - GAUCGGCGAGUAUUG UGUG 19 14847
HSV2-UL30-1887 - UGAUCGGCGAGUAU UGUGUG 20 4834
HSV2-UL30-6494 - GUG AUCGGCGAGUAUUGUGUG 21 14848
HSV2-UL30-6495 - GGUGAUCGGCGAGUAU UGUGUG 22 14849
HSV2-UL30-6496 - GGGUGAUCGGCGAGUAU UGUGUG 23 14850
HSV2-UL30-6497 - GGGGUGAUCGGCGAGUAUUGUGUG 24
14851
HSV2-UL30-6498 - GUCGCCGAGGCCGUCUUG 18 14852
HSV2-UL30-6499 - CGUCGCCGAGGCCGUCU UG 19 14853
HSV2-UL30-1878 - CCGUCGCCGAGGCCGUCUUG 20 4826
HSV2-UL30-6500 - GCCGUCGCCGAGGCCGUCUUG 21 14854
HSV2-UL30-6501 - CGCCGUCGCCGAGGCCGUCUUG 22 14855
HSV2-UL30-6502 - ACGCCGUCGCCGAGGCCGUCUUG 23 14856
HSV2-UL30-6503 - AACGCCGUCGCCGAGGCCGUCUUG 24 14857
HSV2-UL30-6504 - UGGAGU UUGACAGCGAAU 18 14858
HSV2-UL30-6505 - CUGGAGUU UGACAGCGAAU 19 14859
HSV2-UL30-1857 - CCUGGAGUUUGACAGCGAAU 20 4809
HSV2-UL30-6506 - UCCUGGAGU UUGACAGCGAAU 21 14860
HSV2-UL30-6507 - GUCCUGGAGUUUGACAGCGAAU 22 14861
HSV2-UL30-6508 - CG UCCUGGAGU UUGACAGCGAAU 23 14862
HSV2-UL30-6509 - UCGUCCUGGAGU UUGACAGCGAAU 24 14863
HSV2-UL30-6510 - GCGCGACUGGCUGGCCAU 18 14864
HSV2-UL30-6511 - UGCGCGACUGGCUGGCCAU 19 14865
HSV2-UL30-1966 - CUGCGCGACUGGCUGGCCAU 20 4879
HSV2-UL30-6512 - GCUGCGCGACUGGCUGGCCAU 21 14866
HSV2-UL30-6513 - UGCUGCGCGACUGGCUGGCCAU 22 14867
HSV2-UL30-6514 - CUGCUGCGCGACUGGCUGGCCAU 23 14868
HSV2-UL30-6515 - CCUGCUGCGCGACUGGCUGGCCAU 24 14869
HSV2-UL30-6516 - CAACUUU UGCCCCGCGAU 18 14870
HSV2-UL30-6517 - ACAACUU UUGCCCCGCGAU 19 14871
HSV2-UL30-1813 - GACAACUU UUGCCCCGCGAU 20 4785
HSV2-UL30-6518 - CGACAACUUUUGCCCCGCGAU 21 14872
HSV2-UL30-6519 - GCGACAACUUUUGCCCCGCGAU 22 14873
HSV2-UL30-6520 - UGCG ACAACU U U UGCCCCGCG AU 23 14874
HSV2-UL30-6521 - GUGCGACAACU U UUGCCCCGCGAU 24 14875
HSV2-UL30-6522 - AAGGACAAGAAGAAGGAU 18 14876
HSV2-UL30-6523 - GAAGGACAAGAAGAAGGAU 19 14877
HSV2-UL30-1882 - UG AAGGACAAGAAGAAGGAU 20 4830
HSV2-UL30-6524 - UUG AAGGACAAGAAGAAGGAU 21 14878
HSV2-UL30-6525 - CUUGAAGGACAAG A AG A AG G A U 22 14879
HSV2-UL30-6526 - UCU UG AAGGACAAGAAGAAGGAU 23 14880
HSV2-UL30-6527 - GUCUUGAAGGACAAGAAGAAGGAU 24 14881
HSV2-UL30-6528 - GGGAACGGGGACGAGGAU 18 14882
HSV2-UL30-6529 - CGGGAACGGGGACGAGGAU 19 14883
HSV2-UL30-1924 - ACGGGAACGGGGACGAGGAU 20 4852 HSV2-UL30-6530 - GACGGGAACGGGGACGAGGAU 21 14884
HSV2-UL30-6531 - GGACGGGAACGGGGACGAGGAU 22 14885
HSV2-UL30-6532 - GGGACGGGAACGGGGACGAGGAU 23 14886
HSV2-UL30-6533 - GGGGACGGGAACGGGGACGAGGAU 24
14887
HSV2-UL30-6534 - UUUACGACGAUACCGUAU 18 14888
HSV2-UL30-6535 - UUUUACGACGAUACCGUAU 19 14889
HSV2-UL30-1997 - G U U U UACGACGAUACCG U AU 20 4902
HSV2-UL30-6536 - UGU UUUACGACGAUACCGUAU 21 14890
HSV2-UL30-6537 - CUGUUU UACGACGAUACCGUAU 22 14891
HSV2-UL30-6538 - GCUGUU UUACGACGAUACCGUAU 23 14892
HSV2-UL30-6539 - UGCUGUUUUACGACGAUACCGUAU 24 14893
HSV2-UL30-6540 - GCAUCUCCGCGGACCACU 18 14894
HSV2-UL30-6541 - GGCAUCUCCGCGGACCACU 19 14895
HSV2-UL30-1805 - CGGCAUCUCCGCGGACCACU 20 4779
HSV2-UL30-6542 - GCGGCAUCUCCGCGGACCACU 21 14896
HSV2-UL30-6543 - CGCGGCAUCUCCGCGGACCACU 22 14897
HSV2-UL30-6544 - CCGCGGCAUCUCCGCGGACCACU 23 14898
HSV2-UL30-6545 - UCCGCGGCAUCUCCGCGGACCACU 24 14899
HSV2-UL30-6546 - UCCCCGCCUACUACGCCU 18 14900
HSV2-UL30-6547 - AUCCCCGCCUACUACGCCU 19 14901
HSV2-UL30-1883 - CAUCCCCGCCUACUACGCCU 20 4831
HSV2-UL30-6548 - ACAUCCCCGCCUACUACGCCU 21 14902
HSV2-UL30-6549 - GACAUCCCCGCCUACUACGCCU 22 14903
HSV2-UL30-6550 - CGACAUCCCCGCCUACUACGCCU 23 14904
HSV2-UL30-6551 - GCGACAUCCCCGCCUACUACGCCU 24 14905
HSV2-UL30-6552 - AAGCGCCCGGCCGUGCCU 18 14906
HSV2-UL30-6553 - CAAGCGCCCGGCCGUGCCU 19 14907
HSV2-UL30-574 - CCAAGCGCCCGGCCGUGCCU 20 3444
HSV2-UL30-6554 - CCCAAGCGCCCGGCCGUGCCU 21 14908
HSV2-UL30-6555 - G CCCA AG CG CCCG GCCGUGCCU 22 14909
HSV2-UL30-6556 - CGCCCAAGCGCCCGGCCGUGCCU 23 14910
HSV2-UL30-6557 - GCGCCCAAGCGCCCGGCCGUGCCU 24 14911
HSV2-UL30-6558 - CGACGUGGCCGCGCGGCU 18 14912
HSV2-UL30-6559 - ACGACGUGGCCGCGCGGCU 19 14913
HSV2-UL30-2051 - GACGACGUGGCCGCGCGGCU 20 4938
HSV2-UL30-6560 - GG ACGACGUGGCCGCGCGGCU 21 14914
HSV2-UL30-6561 - CGGACGACGUGGCCGCGCGGCU 22 14915
HSV2-UL30-6562 - CCGG ACGACGUGGCCGCGCGGCU 23 14916
HSV2-UL30-6563 - CCCGGACGACGUGGCCGCGCGGCU 24 14917
HSV2-UL30-6564 - UUACUUCUCGCACCUGCU 18 14918
HSV2-UL30-6565 - AUUACUUCUCGCACCUGCU 19 14919
HSV2-UL30-738 - UAUUACUUCUCGCACCUGCU 20 3608
HSV2-UL30-6566 - CUAUUACUUCUCGCACCUGCU 21 14920
HSV2-UL30-6567 - ACUAU UACUUCUCGCACCUGCU 22 14921
HSV2-UL30-6568 - GACUAU UACUUCUCGCACCUGCU 23 14922 HSV2-UL30-6569 - GGACUAU UACUUCUCGCACCUGCU 24 14923
HSV2-UL30-6570 - ACUCCAUGCGCAUCAUCU 18 14924
HSV2-UL30-6571 - UACUCCAUGCGCAUCAUCU 19 14925
HSV2-UL30-1981 - GUACUCCAUGCGCAUCAUCU 20 4890
HSV2-UL30-6572 - CGUACUCCAUGCGCAUCAUCU 21 14926
HSV2-UL30-6573 - CCGUACUCCAUGCGCAUCAUCU 22 14927
HSV2-UL30-6574 - UCCGUACUCCAUGCGCAUCAUCU 23 14928
HSV2-UL30-6575 - GUCCGUACUCCAUGCGCAUCAUCU 24 14929
HSV2-UL30-6576 - AGUACAUCGGCGUCAUCU 18 14930
HSV2-UL30-6577 - AAGUACAUCGGCGUCAUCU 19 14931
HSV2-UL30-1991 - AAAGUACAUCGGCGUCAUCU 20 4898
HSV2-UL30-6578 - AAAAGUACAUCGGCGUCAUCU 21 14932
HSV2-UL30-6579 - A A A A AG UACAUCGGCGUCAUCU 22 14933
HSV2-UL30-6580 - G A A A A AG UACAUCGGCGUCAUCU 23 14934
HSV2-UL30-6581 - AGAAAAAG UACAUCGGCGUCAUCU 24 14935
HSV2-UL30-6582 - GUGCCCCGCGCGAUCUCU 18 14936
HSV2-UL30-6583 - CGUGCCCCGCGCGAUCUCU 19 14937
HSV2-UL30-1799 - CCGUGCCCCGCGCGAUCUCU 20 4775
HSV2-UL30-6584 - GCCGUGCCCCGCGCGAUCUCU 21 14938
HSV2-UL30-6585 - UGCCGUGCCCCGCGCGAUCUCU 22 14939
HSV2-UL30-6586 - GUGCCGUGCCCCGCGCGAUCUCU 23 14940
HSV2-UL30-6587 - AGUGCCGUGCCCCGCGCGAUCUCU 24 14941
HSV2-UL30-6588 - GCCCCGCG AUCAGG AAG U 18 14942
HSV2-UL30-6589 - UGCCCCGCGAUCAGGAAGU 19 14943
HSV2-UL30-1815 - UUGCCCCGCGAUCAGGAAGU 20 4786
HSV2-UL30-6590 - U UUGCCCCGCGAUCAGGAAGU 21 14944
HSV2-UL30-6591 - UUUUGCCCCGCGAUCAGGAAGU 22 14945
HSV2-UL30-6592 - CUUUUGCCCCGCGAUCAGGAAGU 23 14946
HSV2-UL30-6593 - ACUUU UGCCCCGCGAUCAGGAAGU 24 14947
HSV2-UL30-6594 - CCCCGAUCAAGCUCGAGU 18 14948
HSV2-UL30-6595 - CCCCCGAUCAAGCUCGAGU 19 14949
HSV2-UL30-1989 - CCCCCCG AUCAAG CU CG AG U 20 4896
HSV2-UL30-6596 - UCCCCCCGAUCAAGCUCGAGU 21 14950
HSV2-UL30-6597 - CUCCCCCCGAUCAAGCUCGAGU 22 14951
HSV2-UL30-6598 - CCUCCCCCCGAUCAAGCUCGAGU 23 14952
HSV2-UL30-6599 - UCCUCCCCCCGAUCAAGCUCGAGU 24 14953
HSV2-UL30-6600 - CCGGGGUGUGU UCCGCGU 18 14954
HSV2-UL30-6601 - GCCGGGGUG UGUUCCGCGU 19 14955
HSV2-UL30-1867 - GGCCGGGGUG UGU UCCGCGU 20 4817
HSV2-UL30-6602 - CGGCCGGGGUGUGU UCCGCGU 21 14956
HSV2-UL30-6603 - ACGGCCGGGGUGUGUUCCGCGU 22 14957
HSV2-UL30-6604 - AACGGCCGGGGUGUGU UCCGCGU 23 14958
HSV2-UL30-6605 - GAACGGCCGGGGUGUGU UCCGCGU 24 14959
HSV2-UL30-6606 - CCGAGGGACUGCAGGCGU 18 14960
HSV2-UL30-6607 - CCCGAGGGACUGCAGGCGU 19 14961
HSV2-UL30-2006 - GCCCGAGGGACUGCAGGCGU 20 4908 HSV2-UL30-6608 - UGCCCGAGGGACUGCAGGCGU 21 14962
HSV2-UL30-6609 - CUGCCCGAGGGACUGCAGGCGU 22 14963
HSV2-UL30-6610 - CCUGCCCGAGGGACUGCAGGCGU 23 14964
HSV2-UL30-6611 - CCCUGCCCGAGGGACUGCAGGCGU 24 14965
HSV2-UL30-6612 - CGCGCCCCCCGACGGCGU 18 14966
HSV2-UL30-6613 - CCGCGCCCCCCGACGGCGU 19 14967
HSV2-UL30-1826 - ACCGCGCCCCCCGACGGCGU 20 4791
HSV2-UL30-6614 - AACCGCGCCCCCCGACGGCGU 21 14968
HSV2-UL30-6615 - CA ACCG CG CCCCCCG ACG G CG U 22 14969
HSV2-UL30-6616 - CCAACCGCGCCCCCCGACGGCGU 23 14970
HSV2-UL30-6617 - CCCA ACCG CG CCCCCCG ACG G CG U 24 14971
HSV2-UL30-6618 - GUACUACCGCGUCUUCGU 18 14972
HSV2-UL30-6619 - UGUACUACCGCGUCU UCGU 19 14973
HSV2-UL30-1811 - CUGUACUACCGCGUCUUCGU 20 4783
HSV2-UL30-6620 - CCUGUACUACCGCGUCU UCGU 21 14974
HSV2-UL30-6621 - CCCUGUACUACCGCGUCUUCGU 22 14975
HSV2-UL30-6622 - ACCCUGUACUACCGCGUCUUCGU 23 14976
HSV2-UL30-6623 - GACCCUGUACUACCGCGUCUUCGU 24 14977
HSV2-UL30-6624 - CUACCUGGAGAUCGAGGU 18 14978
HSV2-UL30-6625 - ACUACCUGGAGAUCGAGGU 19 14979
HSV2-UL30-632 - GACUACCUGGAGAUCGAGGU 20 3502
HSV2-UL30-6626 - GG ACUACCUGGAGAUCGAGGU 21 14980
HSV2-UL30-6627 - GGG ACUACCUGGAGAUCGAGGU 22 14981
HSV2-UL30-6628 - CGGG ACUACCUGGAGAUCGAGGU 23 14982
HSV2-UL30-6629 - CCGGGACUACCUGGAGAUCGAGGU 24 14983
HSV2-UL30-6630 - AGGUCCCGCUCGACGGGU 18 14984
HSV2-UL30-6631 - AAGGUCCCGCUCGACGGGU 19 14985
HSV2-UL30-1863 - CAAGGUCCCGCUCGACGGGU 20 4814
HSV2-UL30-6632 - ACAAGGUCCCGCUCGACGGGU 21 14986
HSV2-UL30-6633 - UACAAGGUCCCGCUCGACGGGU 22 14987
HSV2-UL30-6634 - CUACAAGGUCCCGCUCGACGGGU 23 14988
HSV2-UL30-6635 - UCUACAAGGUCCCGCUCGACGGGU 24 14989
HSV2-UL30-6636 - GGCUCAGGGCCGCGGGGU 18 14990
HSV2-UL30-6637 - CGGCUCAGGGCCGCGGGGU 19 14991
HSV2-UL30-2054 - GCGGCUCAGGGCCGCGGGGU 20 4940
HSV2-UL30-6638 - CGCGGCUCAGGGCCGCGGGGU 21 14992
HSV2-UL30-6639 - GCGCGGCUCAGGGCCGCGGGGU 22 14993
HSV2-UL30-6640 - CGCGCGGCUCAGGGCCGCGGGGU 23 14994
HSV2-UL30-6641 - CCGCGCGGCUCAGGGCCGCGGGGU 24 14995
HSV2-UL30-6642 - UGACGUUCAAGGCCCUGU 18 14996
HSV2-UL30-6643 - G U G ACG U U CA AG GCCCUGU 19 14997
HSV2-UL30-2044 - CGUGACGU U C A AG G CCC U G U 20 4932
HSV2-UL30-6644 - GCGUGACGUUCAAGGCCCUGU 21 14998
HSV2-UL30-6645 - UGCGUGACGUUCAAGGCCCUGU 22 14999
HSV2-UL30-6646 - CUGCGUGACGU UCAAGGCCCUGU 23 15000
HSV2-UL30-6647 - CCUGCGUGACGU UCAAGGCCCUGU 24 15001 HSV2-UL30-6648 - CCCGCAAGCUGCUGG UGU 18 15002
HSV2-UL30-6649 - CCCCGCAAGCUGCUGGUGU 19 15003
HSV2-UL30-2033 - GCCCCGCAAGCUGCUGGUGU 20 4925
HSV2-UL30-6650 - AGCCCCGCAAGCUGCUGGUGU 21 15004
HSV2-UL30-6651 - AAGCCCCGCAAGCUGCUGGUGU 22 15005
HSV2-UL30-6652 - CAAGCCCCGCAAGCUGCUGGUGU 23 15006
HSV2-UL30-6653 - CCA AG CCCCGCAAGCUGCUGGUG U 24 15007
HSV2-UL30-6654 - GCGCCGACGUGUACUAUU 18 15008
HSV2-UL30-6655 - CGCGCCGACGUGUACUAUU 19 15009
HSV2-UL30-1810 - GCGCGCCGACGUGUACUAUU 20 4782
HSV2-UL30-6656 - AGCGCGCCGACGUGUACUAUU 21 15010
HSV2-UL30-6657 - GAGCGCGCCGACGUGUACUAUU 22 15011
HSV2-UL30-6658 - GGAGCGCGCCGACGUGUACUAU U 23 15012
HSV2-UL30-6659 - UGGAGCGCGCCGACGUGUACUAUU 24 15013
HSV2-UL30-6660 - ACGUGCCUCCUGCGCCU U 18 15014
HSV2-UL30-6661 - CACGUGCCUCCUGCGCCU U 19 15015
HSV2-UL30-1892 - UCACGUGCCUCCUGCGCCUU 20 4838
HSV2-UL30-6662 - UUCACGUGCCUCCUGCGCCUU 21 15016
HSV2-UL30-6663 - CU UCACGUGCCUCCUGCGCCUU 22 15017
HSV2-UL30-6664 - UCUUCACGUGCCUCCUGCGCCU U 23 15018
HSV2-UL30-6665 - GUCUUCACGUGCCUCCUGCGCCU U 24 15019
HSV2-UL30-6666 - CGAGGGACUGCAGGCGUU 18 15020
HSV2-UL30-6667 - CCGAGGGACUGCAGGCGU U 19 15021
HSV2-UL30-697 - CCCGAGGGACUGCAGGCGUU 20 3567
HSV2-UL30-6668 - GCCCGAGGGACUGCAGGCGUU 21 15022
HSV2-UL30-6669 - UGCCCGAGGGACUGCAGGCGUU 22 15023
HSV2-UL30-6670 - CUGCCCGAGGGACUGCAGGCGU U 23 15024
HSV2-UL30-6671 - CCUGCCCGAGGGACUGCAGGCGUU 24 15025
HSV2-UL30-6672 - GCGCCCCCCGACGGCG U U 18 15026
HSV2-UL30-6673 - CGCGCCCCCCGACGGCGUU 19 15027
HSV2-UL30-490 - CCGCGCCCCCCGACGGCG UU 20 3360
HSV2-UL30-6674 - ACCGCGCCCCCCGACGGCGUU 21 15028
HSV2-UL30-6675 - AACCGCGCCCCCCGACGGCGU U 22 15029
HSV2-UL30-6676 - CAACCG CGCCCCCCGACGGCGUU 23 15030
HSV2-UL30-6677 - CCAACCGCGCCCCCCGACGGCGU U 24 15031
HSV2-UL30-6678 - GGACACCCAGGGGCGGU U 18 15032
HSV2-UL30-6679 - CGGACACCCAGGGGCGGU U 19 15033
HSV2-UL30-1898 - CCGGACACCCAGGGGCGGUU 20 4843
HSV2-UL30-6680 - GCCGGACACCCAGGGGCGGUU 21 15034
HSV2-UL30-6681 - UGCCGGACACCCAGGGGCGGUU 22 15035
HSV2-UL30-6682 - CUGCCGGACACCCAGGGGCGGUU 23 15036
HSV2-UL30-6683 - CCUGCCGGACACCCAGGGGCGGUU 24 15037
HSV2-UL30-6684 - GACGUUCAAGGCCCUGUU 18 15038
HSV2-UL30-6685 - UGACGUUCAAGGCCCUGUU 19 15039
HSV2-UL30-743 - GUGACGUUCAAGGCCCUGUU 20 3613
HSV2-UL30-6686 - CGUGACGUUCAAGGCCCUGUU 21 15040 HSV2-UL30-6687 - GCGUGACGUUCAAGGCCCUGUU 22 15041
HSV2-UL30-6688 - UGCGUGACGU UCAAGGCCCUGUU 23 15042
HSV2-UL30-6689 - CUGCGUGACGUUCAAGGCCCUGU U 24 15043
HSV2-UL30-3489 - CAGCUCCACG AGCG AU U U 18 11843
HSV2-UL30-3490 - CCAGCUCCACGAGCGAUUU 19 11844
HSV2-UL30-3491 - CCCAGCUCCACGAGCGAUUU 20 11845
HSV2-UL30-3492 - GCCCAGCUCCACGAGCGAUU U 21 11846
HSV2-UL30-3493 - CGCCCAGCUCCACGAGCGAUUU 22 11847
HSV2-UL30-3494 - CCGCCCAGCUCCACGAGCGAUUU 23 11848
HSV2-UL30-3495 - GCCGCCCAGCUCCACGAGCGAU UU 24 11849
HSV2-UL30-6690 - AUCGGCCAGAGCCACUU U 18 15044
HSV2-UL30-6691 - CAUCGGCCAGAGCCACU UU 19 15045
HSV2-UL30-1870 - ACAUCGGCCAGAGCCACU UU 20 4819
HSV2-UL30-6692 - GACAUCGGCCAGAGCCACUU U 21 15046
HSV2-UL30-6693 - GGACAUCGGCCAGAGCCACU UU 22 15047
HSV2-UL30-6694 - GGGACAUCGGCCAGAGCCACUUU 23 15048
HSV2-UL30-6695 - UGGGACAUCGGCCAGAGCCACUUU 24 15049
HSV2-UL30-6696 - CAGCUGCUGGCCGACUU U 18 15050
HSV2-UL30-6697 - UCAGCUGCUGGCCGACUUU 19 15051
HSV2-UL30-1979 - AUCAGCUGCUGGCCGACUUU 20 4889
HSV2-UL30-6698 - GAUCAGCUGCUGGCCGACU UU 21 15052
HSV2-UL30-6699 - CGAUCAGCUGCUGGCCGACUUU 22 15053
HSV2-UL30-6700 - UCGAUCAGCUGCUGGCCGACUUU 23 15054
HSV2-UL30-6701 - UUCGAUCAGCUGCUGGCCGACUU U 24 15055
HSV2-UL30-6702 - GACACCCAGGGGCGGUU U 18 15056
HSV2-UL30-6703 - GGACACCCAGGGGCGGUU U 19 15057
HSV2-UL30-568 - CGGACACCCAGGGGCGGUUU 20 3438
HSV2-UL30-6704 - CCGGACACCCAGGGGCGGUUU 21 15058
HSV2-UL30-6705 - GCCGGACACCCAGGGGCGGUUU 22 15059
HSV2-UL30-6706 - UGCCGGACACCCAGGGGCGGUU U 23 15060
HSV2-UL30-6707 - CUGCCGGACACCCAGGGGCGGUUU 24 15061
Table 10A provides exemplary targeting domains for knocking out the UL30 gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 10A
1st Tier DNA Target Site gRNA Name Targeting Domain
Strand Length Seq ID
HSV2-UL30-442 - GCGCCGCCCAGCUCCAC 17 5482
HSV2-UL30-6708 - GCCCGGAGGGCUUCUGGCCG 20 15062
Table 10B provides exemplary targeting domains for knocking out the UL30 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase). Table 10B
Figure imgf000576_0001
Table IOC provides exemplary targeting domains for knocking out the UL30 gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table IOC
Figure imgf000576_0002
Table 10D provides exemplary targeting domains for knocking out the UL30 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 10D
Figure imgf000577_0001
HSV2-UL30-6728 + CCUCCGCCAGCUCGGACACC 20 15082
HSV2-U L30-554 - CU UCAAGU UUCUGCCGCACC 20 3424
HSV2-UL30-1290 + CU UCCCCCCG AGGCACGGCC 20 4160
HSV2-UL30-6729 + ACACCACCU UG AUGGCGGCC 20 15083
HSV2-UL30-2393 + GGACCUGCGCGCGGCGGGCC 20 5155
HSV2-UL30-1167 + AAUACACCGUCAGGUGGGCC 20 4037
HSV2-UL30-6730 + GCGGGACCU UGUAGAUCUCC 20 15084
HSV2-UL30-6731 + ACU UUUUCUUGGCGAUGAGC 20 15085
HSV2-UL30-6732 + GCACAGGUAGGCCAGCGCGC 20 15086
HSV2-UL30-6733 - ACCUGCCGGCCUACAAGCUC 20 15087
HSV2-UL30-1894 - UCCUGCGCCUUGCGGGCCAG 20 4840
HSV2-UL30-6734 + CGGUCACGAACUCGGGGCCG 20 15088
HSV2-UL30-6735 + AGACGGCCUCGGCGACGGCG 20 15089
HSV2-UL30-1125 + CAUGCGACGGCGUCUCCCGG 20 3995
HSV2-UL30-6736 + UCUGGGGGAUCCGCGAGCGG 20 15090
HSV2-UL30-2567 + GGGCCGGCGCGU UCCCGCGG 20 5280
HSV2-UL30-1111 + GCUCGGACACCAGCAGCUUG 20 3981
HSV2-UL30-6737 + UCCCGU UCACCUUGAUCUUG 20 15091
Table 11A provides exemplary targeting domains for knocking out the UL48 gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase). Table 11A
Figure imgf000578_0001
HSV2-U L48-179 + GCACUCCCGGUACAUGU 17 5558
HSV2-UL48-1134 - GAGCUACCGGACCGUGU 17 15093
HSV2-UL48-77 + GUCGAGGAGACGGUU A A AC A 20 5567
HSV2-UL48-33 - GCCU UCGUACUACGAGGCCA 20 5508
HSV2-UL48-43 + GCCAUGGCCUCGUAGUACGA 20 5521
HSV2-UL48-3 - GAUCUGUUUGCGGACGCGGA 20 5484
HSV2-UL48-11 - GCCCCUCCGCUGUACGCCAC 20 5489
HSV2-UL48-24 - GACCAACGCCGACAUGUACC 20 5500
HSV2-UL48-6 - G G G U U U CG CCACCG CCCCCC 20 5596
HSV2-UL48-18 - GACGAUCUGGGCUUCAGCGC 20 5495
HSV2-UL48-45 + GUACGAAGGCAGCUCGUCGC 20 5523
HSV2-U L48-106 + GUGUUCUUGGGACCCCCGGC 20 5590
HSV2-U L48-100 + GCGUACAGCGGAGGGGCGGC 20 5640
HSV2-UL48-48 + GGCAGCUCGUCGCGGGUGGC 20 5526
HSV2-UL48-36 - GUUUU UCCGCGGUGAGCUGC 20 5511
HSV2-UL48-68 + GGUACAUGUCGGCGUUGGUC 20 5557
HSV2-UL48-14 - GCCCAUGCCCGUCCCCCCCG 20 5601
HSV2-UL48-78 + GAGACGGU UAAACAGGGCCG 20 5568
HSV2-UL48-34 - GCCAUGGCGCAGUUUU UCCG 20 5509
HSV2-UL48-80 + GACGGUUAAACAGGGCCGCG 20 5570
HSV2-UL48-58 + GUGGGCGCGAAUGUCGAUCG 20 5539
HSV2-UL48-94 + GGCCUGACUCAGCCGACCGG 20 5580
HSV2-UL48-83 + GGUUAAACAGGGCCGCGGGG 20 5627
HSV2-UL48-1135 + GUCGACCAACAGGUCCAUGG 20 15094
HSV2-UL48-1 - GUUGGUCGACGAUCUGUUUG 20 5594
HSV2-UL48-92 + GGGCGGCGAGGGCAUCAGCU 20 5636
HSV2-UL48-22 - GGAACGAGGACCUGUUCUCU 20 5606
HSV2-UL48-55 + GGGGAACGCCACGUCGCCGU 20 5536
HSV2-UL48-1136 - GGAGAGCUACCGGACCGUGU 20 15095
Table 11B provides exemplary targeting domains for knocking out the UL48 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 11B
Figure imgf000579_0001
HSV2-U L48-144 - AUCG ACAU UCGCGCCCA 17 5513
HSV2-U L48-147 - UUCGUACUACGAGGCCA 17 5516
HSV2-U L48-157 + AUGGCCUCGUAGUACGA 17 5528
HSV2-U L48-211 + CGGUGGCGUACAGCGGA 17 5586
HSV2-UL48-117 - CUGUUUGCGGACGCGGA 17 5486
HSV2-UL48-190 + CGAGGAGACGGUUAAAC 17 5573
HSV2-U L48-228 + ACAGAUCG UCGACCAAC 17 5593
HSV2-UL48-125 - CCUCCGCUGUACGCCAC 17 5492
HSV2-UL48-139 - CCAGCGACGUGAUCGAC 17 5503
HSV2-U L48-118 - UGUU UGCGGACGCGGAC 17 5653
HSV2-UL48-137 - CCAACGCCGACAUGUAC 17 5665
HSV2-U L48-138 - CAACGCCGACAUGUACC 17 5502
HSV2-U L48-193 + CGGU UAAACAGGGCCGC 17 5576
HSV2-UL48-176 + CCAGUCGAUCACGUCGC 17 5552
HSV2-U L48-159 + CGAAGGCAGCUCGUCGC 17 5530
HSV2-UL48-214 + UACAGCGGAGGGGCGGC 17 5698
HSV2-UL48-162 + AGCUCGUCGCGGGUGGC 17 5533
HSV2-U L48-150 - UUUCCGCGGUGAGCUGC 17 5519
HSV2-UL48-129 - CCGUCUCCUCGACGAUC 17 5660
HSV2-U L48-174 + UCGAUCGGGGAGCGCUC 17 5550
HSV2-UL48-1137 + AAU UUGCCAACACGGUC 17 15096
HSV2-UL48-182 + ACAUGUCGGCGUUGGUC 17 5561
HSV2-U L48-116 - CGAUCUGUU UGCGGACG 17 5485
HSV2-U L48-192 + ACG G U U A A AC AG G GCCG 17 5575
HSV2-UL48-148 - AUGGCGCAGUU UUUCCG 17 5517
HSV2-U L48-131 - CGAUCUGGGCUUCAGCG 17 5496
HSV2-UL48-175 + CGAUCGGGGAGCGCUCG 17 5551
HSV2-UL48-188 + UGAAGCCCAGAUCGUCG 17 5683
HSV2-U L48-158 + ACGAAGGCAGCUCG UCG 17 5529
HSV2-UL48-210 + CCGGUGGCGUACAGCGG 17 5696
HSV2-UL48-196 + UUAAACAGGGCCGCGGG 17 5579
HSV2-U L48-160 + AGGCAGCUCGUCGCGGG 17 5531
HSV2-UL48-143 - CGACGUGAUCGACUGGG 17 5512
HSV2-U L48-161 + CAGCUCGUCGCGGG UGG 17 5532
HSV2-U L48-141 - AGCGACGUGAUCGACUG 17 5667
HSV2-UL48-149 - UUUUCCGCGGUGAGCUG 17 5518
HSV2-UL48-1138 + U CG ACC AACAG GUCCAU 17 15097
HSV2-UL48-170 + UGGGCGCGAAUGUCGAU 17 5546
HSV2-UL48-140 - CAGCG ACG UG AUCG ACU 17 5666
HSV2-U L48-206 + CGGCGAGGGCAUCAGCU 17 5694
HSV2-U L48-177 + CAGUCGAUCACG UCGCU 17 5553
HSV2-U L48-130 - CGUCUCCUCGACGAUCU 17 5661
HSV2-U L48-180 + CCGGUACAUGUCGGCG U 17 5559
HSV2-UL48-126 - CGCUGUACGCCACCGGU 17 5493
HSV2-UL48-1139 + CGAGCAAAAAUUUGCCAACA 20 15098
HSV2-UL48-1140 - CCCGGACCCAACCGCCCCCA 20 15099 HSV2-UL48-30 - CCGAUCGACAUUCGCGCCCA 20 5505
HSV2-UL48-42 + ACCGCGGAAAAACUGCGCCA 20 5520
HSV2-UL48-1141 + AUCG UCGACCAACAGGUCCA 20 15100
HSV2-UL48-71 + CUCGUUCCAGGUAUCUAGCA 20 5562
HSV2-UL48-50 + CUCGUCGCGGGUGGCGGGCA 20 5534
HSV2-UL48-84 + AAACAGGGCCGCGGGGGGGA 20 5628
HSV2-UL48-76 + CGUCGAGGAGACGGUUAAAC 20 5566
HSV2-UL48-114 + CAAACAGAUCGUCGACCAAC 20 5591
HSV2-UL48-93 + CUGGGCCUGACUCAGCCGAC 20 5637
HSV2-UL48-25 - UGCCCAGCGACGUGAUCGAC 20 5501
HSV2-UL48-4 - AUCUGUUUGCGGACGCGGAC 20 5595
HSV2-UL48-85 + AACAGGGCCGCGGGGGGGAC 20 5629
HSV2-UL48-23 - CGACCAACGCCGACAUGUAC 20 5607
HSV2-UL48-107 + CU UGGGACCCCCGGCUGGCC 20 5645
HSV2-UL48-1142 + CCAUGGGGGCGGU UGGGUCC 20 15101
HSV2-UL48-91 + UGGGCGGCGAGGGCAUCAGC 20 5635
HSV2-UL48-79 + AGACGGUUAAACAGGGCCGC 20 5569
HSV2-UL48-73 + UCUAGCAUGGUACACAGCGC 20 5564
HSV2-UL48-62 + CCCCCAG UCG AU CACG U CGC 20 5543
HSV2-UL48-15 - UAACCGUCUCCUCGACGAUC 20 5602
HSV2-UL48-57 + CGUGGGCGCGAAUGUCGAUC 20 5538
HSV2-UL48-60 + AUGUCGAUCGGGGAGCGCUC 20 5541
HSV2-UL48-13 - CGCCACCGGUCGGCUGAGUC 20 5491
HSV2-UL48-1143 + A A A A A U U U G CC A AC ACG G U C 20 15102
HSV2-UL48-1144 + UCCAUGGGGGCGGUUGGGUC 20 15103
HSV2-UL48-95 + AGCCGACCGGUGGCGUACAG 20 5581
HSV2-UL48-98 + ACCGGUGGCGUACAGCGGAG 20 5583
HSV2-UL48-20 - CAUGCUAGAUACCUGGAACG 20 5498
HSV2-UL48-31 - CAUUCGCGCCCACGGCGACG 20 5506
HSV2-UL48-5 - UCUGUUUGCGGACGCGGACG 20 5487
HSV2-UL48-2 - CGACGAUCUGU UUGCGGACG 20 5483
HSV2-UL48-32 - CGAGCUGCCUUCGUACUACG 20 5507
HSV2-UL48-54 + UGGGGAACGCCACGUCGCCG 20 5620
HSV2-UL48-17 - CGACGAUCUGGGCUUCAGCG 20 5494
HSV2-UL48-61 + UGUCGAUCGGGGAGCGCUCG 20 5542
HSV2-UL48-74 + CGCUGAAGCCCAGAUCGUCG 20 5625
HSV2-UL48-96 + CGACCGGUGGCGUACAGCGG 20 5638
HSV2-UL48-81 + ACGGUUAAACAGGGCCGCGG 20 5571
HSV2-UL48-82 + CGG UUAAACAGGGCCGCGGG 20 5572
HSV2-UL48-46 + CGAAGGCAGCUCGUCGCGGG 20 5524
HSV2-UL48-29 - CAGCGACGUGAUCGACUGGG 20 5504
HSV2-UL48-28 - CCAGCGACGUGAUCGACUGG 20 5610
HSV2-UL48-1145 + CG U CG ACC A AC AG G U CC A U G 20 15104
HSV2-UL48-27 - CCCAGCGACGUGAUCGACUG 20 5609
HSV2-UL48-35 - AGUU U UUCCGCGGUGAGCUG 20 5510
HSV2-UL48-1146 + UCGUCGACCAACAGGUCCAU 20 15105 HSV2-UL48-56 + CCGUGGGCGCGAAUGUCGAU 20 5537
HSV2-UL48-59 + AAUGUCGAUCGGGGAGCGCU 20 5540
HSV2-UL48-63 + CCCCAGUCGAUCACGUCGCU 20 5544
HSV2-U L48-101 + CGUACAGCGGAGGGGCGGCU 20 5588
HSV2-UL48-16 - AACCGUCUCCUCGACGAUCU 20 5603
HSV2-UL48-103 + AGGGGCGGCUGGGGUGUUCU 20 5642
HSV2-UL48-66 + CUCCCGGUACAUGUCGGCGU 20 5555
HSV2-UL48-12 - CUCCGCUGUACGCCACCGGU 20 5490
HSV2-UL48-1147 + AACAGGUCCAUGGGGGCGGU 20 15106
HSV2-UL48-67 + CGGUACAUGUCGGCGUUGGU 20 5556
HSV2-UL48-1148 - AACCGCCCCCAUGGACCUGU 20 15107
HSV2-UL48-1149 + ACAGGUCCAUGGGGGCGGUU 20 15108
Table 11C provides exemplary targeting domains for knocking out the UL48 gene selected according to the third tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 11C
Figure imgf000582_0001
HSV2-U L48-151 - GCGGUGAGCUGCGGGCG 17 5669
HSV2-U L48-227 + GCUGGCCUGGGGGGCGG 17 5709
HSV2-U L48-165 + GCGGGUGGCGGGCAGGG 17 5675
HSV2-U L48-213 + GGCGUACAGCGGAGGGG 17 5697
HSV2-UL48-202 + GGGGGGACGGGCAUGGG 17 5690
HSV2-UL48-1152 + GACCAACAGGUCCAUGG 17 15111
HSV2-U L48-223 + GACCCCCGGCUGGCCUG 17 5705
HSV2-UL48-167 + GGGUGGCGGGCAGGGUG 17 5677
HSV2-UL48-201 + GCGGGGGGGACGGGCAU 17 5689
HSV2-U L48-222 + GGACCCCCGGCUGGCCU 17 5704
HSV2-UL48-422 - GUUGGCAAAUU UUUGCU 17 5904
HSV2-U L48-217 + GGCGGCUGGGGUGUUCU 17 5700
HSV2-U L48-169 + G AACGCCACG U CGCCG U 17 5545
HSV2-UL48-218 + GCGGCUGGGGUGUUCUU 17 5701
HSV2-UL48-1153 + GGUCCAUGGGGGCGGU U 17 15112
HSV2-UL48-86 + GGCCGCGGGGGGGACGGGCA 20 5630
HSV2-UL48-90 + GGGACGGGCAUGGGCGGCGA 20 5634
HSV2-UL48-97 + GACCGGUGGCGUACAGCGGA 20 5582
HSV2-UL48-40 - GGGCGCGGGAGGAGAGCUAC 20 5614
HSV2-UL48-49 + GCUCGUCGCGGGUGGCGGGC 20 5616
HSV2-UL48-89 + GGGGACGGGCAUGGGCGGCG 20 5633
HSV2-UL48-51 + GUCGCGGGUGGCGGGCAGGG 20 5617
HSV2-UL48-99 + GGUGGCGUACAGCGGAGGGG 20 5639
HSV2-UL48-1154 + G ACCAAC AG GUCCAUGGGGG 20 15113
HSV2-UL48-88 + GCGGGGGGGACGGGCAUGGG 20 5632
HSV2-U L48-111 + GGACCCCCGGCUGGCCUGGG 20 5649
HSV2-UL48-110 + GGGACCCCCGGCUGGCCUGG 20 5648
HSV2-UL48-102 + GUACAGCGGAGGGGCGGCUG 20 5641
HSV2-UL48-87 + GCCGCGGGGGGGACGGGCAU 20 5631
HSV2-UL48-26 - GCCCAGCGACGUGAUCGACU 20 5608
HSV2-UL48-104 + GGGGCGGCUGGGGUGU UCUU 20 5643
Table 11D provides exemplary targeting domains for knocking out the UL48 gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 11D
Figure imgf000583_0001
Strand Site
Length
HSV2-UL48-200 + CGCGGGGGGGACGGGCA 17 5688
HSV2-UL48-189 + CCAGAUCGUCGAGGAGA 17 5684
HSV2-UL48-204 + ACGGGCAUGGGCGGCGA 17 5692
HSV2-UL48-198 + CAGGGCCGCGGGGGGGA 17 5686
HSV2-UL48-183 + UCGGGAACCCAGAGAAC 17 5680
HSV2-UL48-199 + AGGGCCGCGGGGGGGAC 17 5687
HSV2-UL48-154 - CGCGGGAGGAGAGCUAC 17 5672
HSV2-UL48-120 - UUUCGCCACCGCCCCCC 17 5654
HSV2-UL48-122 - CGCCCCCCAGGCCAGCC 17 5656
HSV2-UL48-178 + ACAGAAACUUGCACUCC 17 5679
HSV2-UL48-1155 + UGGGGGCGGUUGGGUCC 17 15114
HSV2-UL48-121 - CCGCCCCCCAGGCCAGC 17 5655
HSV2-UL48-187 + AGCAUGGUACACAGCGC 17 5565
HSV2-UL48-152 - CGGUGAGCUGCGGGCGC 17 5670
HSV2-UL48-220 + UUCUUGGGACCCCCGGC 17 5592
HSV2-UL48-163 + CGUCGCGGGUGGCGGGC 17 5674
HSV2-UL48-135 - AACGAGGACCUGUUCUC 17 5663
HSV2-UL48-1156 - CACCGGUCGGCUGAGUC 17 15115
HSV2-UL48-1157 + AUGGGGGCGGUUGGGUC 17 15116
HSV2-UL48-209 + CGACCGGUGGCGUACAG 17 5585
HSV2-UL48-145 - UCGCGCCCACGGCGACG 17 5514
HSV2-UL48-128 - CAUGCCCGUCCCCCCCG 17 5659
HSV2-UL48-186 + UAGCAUGGUACACAGCG 17 5682
HSV2-UL48-208 + CUGACUCAGCCGACCGG 17 5584
HSV2-UL48-124 - CCCCCCAGGCCAGCCGG 17 5658
HSV2-UL48-153 - UGAGCUGCGGGCGCGGG 17 5671
HSV2-UL48-197 + UAAACAGGGCCGCGGGG 17 5685
HSV2-UL48-226 + CCGGCUGGCCUGGGGGG 17 5708
HSV2-UL48-1158 + CAACAGGUCCAUGGGGG 17 15117
HSV2-UL48-225 + CCCCCGGCUGGCCUGGG 17 5707
HSV2-UL48-224 + ACCCCCGGCUGGCCUGG 17 5706
HSV2-UL48-1159 + CGACCAACAGGUCCAUG 17 15118
HSV2-UL48-216 + CAGCGGAGGGGCGGCUG 17 5699
HSV2-UL48-215 + ACAGCGGAGGGGCGGCU 17 5589
HSV2-UL48-136 - ACGAGGACCUGUUCUCU 17 5664
HSV2-UL48-1160 + AGGUCCAUGGGGGCGGU 17 15119
HSV2-UL48-166 + CGGGUGGCGGGCAGGGU 17 5676
HSV2-UL48-181 + UACAUGUCGGCGUUGGU 17 5560
HSV2-UL48-1161 - CGCCCCCAUGGACCUGU 17 15120
HSV2-UL48-75 + AGCCCAGAUCGUCGAGGAGA 20 5626
HSV2-UL48-69 + UGGUCGGGAACCCAGAGAAC 20 5622
HSV2-UL48-19 - UGUGUACCAUGCUAGAUACC 20 5604
HSV2-UL48-105 + UGGGGUGUUCUUGGGACCCC 20 5644
HSV2-UL48-8 - CACCGCCCCCCAGGCCAGCC 20 5598 HSV2-UL48-64 + UCGACAGAAACUUGCACUCC 20 5621
HSV2-UL48-70 + AGAGAACAGGUCCUCGU UCC 20 5623
HSV2-UL48-7 - CCACCGCCCCCCAGGCCAGC 20 5597
HSV2-UL48-38 - CCGCGGUGAGCUGCGGGCGC 20 5612
HSV2-UL48-21 - UGGAACGAGGACCUGU UCUC 20 5605
HSV2-UL48-41 + CCCGCGCCCGCAGCUCACCG 20 5615
HSV2-UL48-9 - ACCG CCCCCCAG G CCAG CCG 20 5599
HSV2-UL48-72 + AUCUAGCAUGGUACACAGCG 20 5624
HSV2-UL48-37 - UCCGCGG UGAGCUGCGGGCG 20 5611
HSV2-UL48-44 + AGUACGAAGGCAGCUCGUCG 20 5522
HSV2-UL48-10 - CCGCCCCCCAGGCCAGCCGG 20 5600
HSV2-UL48-113 + CCGGCUGGCCUGGGGGGCGG 20 5651
HSV2-UL48-39 - CGGUGAGCUGCGGGCGCGGG 20 5613
HSV2-UL48-112 + CCCCCGGCUGGCCUGGGGGG 20 5650
HSV2-UL48-47 + AGGCAGCUCGUCGCGGG UGG 20 5525
HSV2-UL48-109 + UGGGACCCCCGGCUGGCCUG 20 5647
HSV2-UL48-53 + CGCGGG UGGCGGGCAGGGUG 20 5619
HSV2-UL48-108 + UUGGGACCCCCGGCUGGCCU 20 5646
HSV2-UL48-1132 - CGUGU UGGCAAAUU UUUGCU 20 5710
HSV2-UL48-52 + UCGCGGGUGGCGGGCAGGGU 20 5618
HSV2-UL48-65 + CUUGCACUCCCGGUACAUGU 20 5554
Table HE provides exemplary targeting domains for knocking out the UL48 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table HE
Figure imgf000585_0001
HSV2-U L48-529 + CA AG U CGAAG U CG U CCA 17 6011
HSV2-U L48-587 + CACGGGAACUCCCCGCA 17 6069
HSV2-U L48-459 - ACCCCGCCCGUCCUGCA 17 5941
HSV2-U L48-589 + UCCGUUGAUAAACAUCA 17 6071
HSV2-UL48-516 + CAAAGCCCCAUACGAGA 17 5998
HSV2-UL48-476 - UACGGAUCGACAAUCGA 17 5958
HSV2-U L48-437 - CGGCCCGAUCUGU UCGA 17 5919
HSV2-UL48-568 + CUGGUUGCCCUGCAGGA 17 6050
HSV2-UL48-468 - AGCGUCGCGACCUCGGA 17 5950
HSV2-U L48-525 + UGGGUCAUUCCCGGGGA 17 6007
HSV2-UL48-489 - GACGAACUCCGCCUGGA 17 5971
HSV2-U L48-558 + CGCGUGCUCCCGCAUGA 17 6040
HSV2-U L48-574 + GACGGGCGGGGUCGUGA 17 6056
HSV2-UL48-434 - UGAGCCGCGAGAUCCUA 17 5916
HSV2-U L48-502 - CACGACCCCGUCUCGUA 17 5984
HSV2-UL48-474 - CG G ACC AG A A AC A A U U A 17 5956
HSV2-UL48-601 + GGUAUAGAUGCAGAAAC 17 6083
HSV2-U L48-591 + GAAACAGACACGCCAAC 17 6073
HSV2-UL48-586 + AGUCGCCGGGCCUCCAC 17 6068
HSV2-U L48-517 + AAAGCCCCAUACGAGAC 17 5999
HSV2-UL48-1162 - GGGGUAGGAUGUGCGAC 17 15121
HSV2-UL48-569 + UGGUUGCCCUGCAGGAC 17 6051
HSV2-U L48-432 - GCACCACGAUCGCGGAC 17 5914
HSV2-U L48-154 - CGCGGGAGGAGAGCUAC 17 5672
HSV2-UL48-613 + CGCUGGCGCGCAGGUAC 17 6095
HSV2-U L48-614 + CGCGCAGGUACCGGUAC 17 6096
HSV2-UL48-423 - UUUGCUCGGCCCUGUAC 17 5905
HSV2-UL48-460 - CGUCCUGCAGGGCAACC 17 5942
HSV2-U L48-455 - GCGGCGGCGGAGGAACC 17 5937
HSV2-UL48-438 - CGGCCUCUGCUGCGACC 17 5920
HSV2-UL48-1163 - GGGUAGGAUGUGCGACC 17 15122
HSV2-U L48-456 - CGGCGGCGGAGGAACCC 17 5938
HSV2-UL48-577 + GUCGUGAGGGGCGCCCC 17 6059
HSV2-U L48-501 - GUGGAGUCCCCCUCCCC 17 5983
HSV2-U L48-493 - GACGCCCGCCGACGCCC 17 5975
HSV2-UL48-576 + GGUCGUGAGGGGCGCCC 17 6058
HSV2-U L48-500 - CGUGGAGUCCCCCUCCC 17 5982
HSV2-UL48-535 + GGCGGAGUUCGUCUCCC 17 6017
HSV2-UL48-522 + GGUCGUGGGUCAUUCCC 17 6004
HSV2-U L48-550 + GCGCGGCGCCACCAGCC 17 6032
HSV2-U L48-486 - CAU U ACCG ACG U C AG CC 17 5968
HSV2-U L48-425 - UCGGCAGCUACACCGCC 17 5907
HSV2-UL48-1164 + GGGGGGGGCGCGCCGCC 17 15123
HSV2-UL48-488 - GGGAGACGAACUCCGCC 17 5970
HSV2-U L48-602 + GAAACAGGACGCGCGCC 17 6084
HSV2-U L48-433 - CCGCGAGACCGCGCGCC 17 5915 HSV2-U L48-584 + UAGCUCCCGCAGUCGCC 17 6066
HSV2-U L48-481 - ACGCUCCUGCGGAGGCC 17 5963
HSV2-U L48-447 - GAGUUCCCGUGGAGGCC 17 5929
HSV2-U L48-566 + ACCCAGAGGAGCGGGCC 17 6048
HSV2-UL48-562 + ACGAGUCCAACUUGGCC 17 6044
HSV2-UL48-609 + GGCCCCGCAUGUGUGCC 17 6091
HSV2-U L48-464 - CUUUAUGCUGCUGAUCC 17 5946
HSV2-UL48-477 - GGGCCUGCUCGACCUCC 17 5959
HSV2-UL48-592 + ACUGGCGCCAGCUCUCC 17 6074
HSV2-U L48-533 + CCACCUCCUCGCCGUCC 17 6015
HSV2-UL48-528 + CCA AG UCGAAGUCGUCC 17 6010
HSV2-U L48-553 + GAGCGUCAUCGUCGUCC 17 6035
HSV2-U L48-521 + GGGUCGUGGGUCAUUCC 17 6003
HSV2-UL48-579 + CCGCACU UCGCACCAGC 17 6061
HSV2-U L48-439 - GCUGCGACCUGGAGAGC 17 5921
HSV2-UL48-555 + CGUCCGGGAGGUCGAGC 17 6037
HSV2-UL48-565 + AAAGUACCCAGAGGAGC 17 6047
HSV2-U L48-611 + GUGUAGCUGCCGAACGC 17 6093
HSV2-UL48-560 + CUCCGAGGUCGCGACGC 17 6042
HSV2-U L48-450 - GCACCUGAACCUCCCGC 17 5932
HSV2-U L48-606 + UGCGCAGCAUCUCCCGC 17 6088
HSV2-UL48-472 - AGCACGCGUAUAGCCGC 17 5954
HSV2-U L48-551 + ACCAGCCCGGCCUCCGC 17 6033
HSV2-U L48-485 - AUGUCGU UUCUCUCCGC 17 5967
HSV2-UL48-612 + GCCGAACGCUGGCGCGC 17 6094
HSV2-U L48-583 + UUAGCUCCCGCAGUCGC 17 6065
HSV2-UL48-480 - GACGCUCCUGCGGAGGC 17 5962
HSV2-UL48-532 + UCGUCCAGGGCGUCGGC 17 6014
HSV2-U L48-571 + UGCCCUGCAGGACGGGC 17 6053
HSV2-UL48-482 - UCCUGCGGAGGCCGGGC 17 5964
HSV2-UL48-427 - CCG CC AG G C AC AC A U G C 17 5909
HSV2-U L48-470 - GGGCGAGUCCGUCAUGC 17 5952
HSV2-UL48-495 - CU UCGACUUGGAGAUGC 17 5977
HSV2-U L48-449 - GGAGGCCCGGCGACUGC 17 5931
HSV2-U L48-430 - CCGCAACCGCGACCUGC 17 5912
HSV2-UL48-567 + GGGCCUGGU UGCCCUGC 17 6049
HSV2-U L48-458 - GACCCCGCCCGUCCUGC 17 5940
HSV2-UL48-545 + GGUGGUGGACAGUCUGC 17 6027
HSV2-UL48-443 - CGGAUCGCUCACCGUGC 17 5925
HSV2-U L48-588 + AUCCGUUGAUAAACAUC 17 6070
HSV2-U L48-595 + AGGCCGUCGAACAGAUC 17 6077
HSV2-U L48-463 - ACUUUAUGCUGCUGAUC 17 5945
HSV2-U L48-461 - AACCAGGCCCGCUCCUC 17 5943
HSV2-UL48-552 + GGAGCGUCAUCGUCGUC 17 6034
HSV2-UL48-1137 + A A U U U G CC A AC ACG G U C 17 15096
HSV2-U L48-581 + GCACCAGCGGGAGGU UC 17 6063 HSV2-U L48-556 + CGAUCCGUAAUUGUUUC 17 6038
HSV2-U L48-600 + UCUCGCGGCUCAGAAAG 17 6082
HSV2-U L48-578 + GCCGCACUUCGCACCAG 17 6060
HSV2-U L48-563 + C AG C A U A A AG U ACCC AG 17 6045
HSV2-UL48-593 + UCUCCAGGUCGCAGCAG 17 6075
HSV2-UL48-590 + CCG U U G A U A A AC A U C AG 17 6072
HSV2-U L48-564 + UAAAGUACCCAGAGGAG 17 6046
HSV2-UL48-526 + GGGUCAUUCCCGGGGAG 17 6008
HSV2-UL48-575 + ACGGGCGGGGUCGUGAG 17 6057
HSV2-U L48-518 + AAGCCCCAUACGAGACG 17 6000
HSV2-UL48-499 - GGAGAUGCUGGGGGACG 17 5981
HSV2-U L48-506 - GUAUGGGGCUUUGGACG 17 5988
HSV2-U L48-597 + CAUCUGCUCGGCGUACG 17 6079
HSV2-UL48-457 - GGCGGCGGAGGAACCCG 17 5939
HSV2-U L48-557 + UGUU UCUGGUCCGCCCG 17 6039
HSV2-UL48-548 + GCGGGGGCGU UGUCCCG 17 6030
HSV2-UL48-523 + GUCGUGGGUCAUUCCCG 17 6005
HSV2-U L48-445 - CGUGCGGGGAGU UCCCG 17 5927
HSV2-UL48-471 - GAGCACGCGUAUAGCCG 17 5953
HSV2-U L48-559 + GACGGACUCGCCCUCCG 17 6041
HSV2-U L48-484 - CAUGUCGU UUCUCUCCG 17 5966
HSV2-UL48-603 + GACG CG CG CCAG G CG CG 17 6085
HSV2-U L48-490 - ACUCCGCCUGGACGGCG 17 5972
HSV2-U L48-572 + GCCCUGCAGGACGGGCG 17 6054
HSV2-UL48-428 - CGCCAGGCACACAUGCG 17 5910
HSV2-U L48-549 + G AG AG A A ACG AC A U G CG 17 6031
HSV2-UL48-546 + GUGGUGGACAGUCUGCG 17 6028
HSV2-UL48-444 - GGAUCGCUCACCGUGCG 17 5926
HSV2-U L48-475 - UUACGGAUCGACAAUCG 17 5957
HSV2-UL48-431 - GCUGCGCACCACGAUCG 17 5913
HSV2-UL48-605 + GUACCUGUCCGCGAUCG 17 6087
HSV2-U L48-599 + CGGCCCAUAGGAUCUCG 17 6081
HSV2-UL48-604 + CCAGGCGCGCGGUCUCG 17 6086
HSV2-U L48-607 + GCAUCUCCCGCAGG UCG 17 6089
HSV2-U L48-519 + CAUACGAGACGGGGUCG 17 6001
HSV2-UL48-534 + CCUCCUCGCCGUCCAGG 17 6016
HSV2-U L48-491 - CCGCCUGGACGGCGAGG 17 5973
HSV2-UL48-492 - CCUGGACGGCGAGGAGG 17 5974
HSV2-UL48-527 + GGUCAUUCCCGGGGAGG 17 6009
HSV2-U L48-454 - GCGAAGUGCGGCGGCGG 17 5936
HSV2-U L48-453 - GGUGCGAAGUGCGGCGG 17 5935
HSV2-U L48-542 + GUCGGUAAUGGGGGCGG 17 6024
HSV2-U L48-479 - CGAUGACGCUCCUGCGG 17 5961
HSV2-UL48-547 + UGGUGGACAGUCUGCGG 17 6029
HSV2-U L48-452 - GCUGGUGCGAAGUGCGG 17 5934
HSV2-U L48-467 - CAGCGUCGCGACCUCGG 17 5949 HSV2-U L48-531 + GUCGUCCAGGGCGUCGG 17 6013
HSV2-U L48-570 + UUGCCCUGCAGGACGGG 17 6052
HSV2-UL48-1165 - UAGGAUGUGCGACCGGG 17 15124
HSV2-U L48-554 + CGUCAUCGUCGUCCGGG 17 6036
HSV2-UL48-580 + CACU UCGCACCAGCGGG 17 6062
HSV2-UL48-473 - ACGCGUAUAGCCGCGGG 17 5955
HSV2-U L48-153 - UGAGCUGCGGGCGCGGG 17 5671
HSV2-UL48-524 + GUGGGUCAUUCCCGGGG 17 6006
HSV2-UL48-541 + GACG UCGGUAAUGGGGG 17 6023
HSV2-U L48-513 - GCAU UGACGACU UUGGG 17 5995
HSV2-UL48-540 + GCUGACGUCGGUAAUGG 17 6022
HSV2-U L48-610 + CCCGCAUGUGUGCCUGG 17 6092
HSV2-U L48-483 - UGCGGAGGCCGGGCUGG 17 5965
HSV2-UL48-498 - CGACUUGGAGAUGCUGG 17 5980
HSV2-U L48-446 - GCGGGGAGUUCCCGUGG 17 5928
HSV2-UL48-543 + GGUAAUGGGGGCGGUGG 17 6025
HSV2-UL48-512 - GGCAUUGACGACU UUGG 17 5994
HSV2-U L48-582 + UCAGGUGCUCGCGAAUG 17 6064
HSV2-UL48-539 + GGCUGACGUCGGUAAUG 17 6021
HSV2-U L48-426 - ACCGCCAGGCACACAUG 17 5908
HSV2-U L48-469 - AGGGCGAGUCCGUCAUG 17 5951
HSV2-UL48-436 - ACGCCGAGCAGAUGAUG 17 5918
HSV2-U L48-504 - CGACCCCGUCUCGUAUG 17 5986
HSV2-U L48-448 - UGGAGGCCCGGCGACUG 17 5930
HSV2-UL48-429 - GCCGCAACCGCGACCUG 17 5911
HSV2-U L48-478 - CGACGAUGACGCUCCUG 17 5960
HSV2-UL48-497 - UCGACU UGGAGAUGCUG 17 5979
HSV2-UL48-544 + CGGUGGUGGACAGUCUG 17 6026
HSV2-U L48-451 - CCCGCUGGUGCGAAGUG 17 5933
HSV2-UL48-442 - ACGGAUCGCUCACCGUG 17 5924
HSV2-UL48-573 + GGACGGGCGGGGUCGUG 17 6055
HSV2-U L48-608 + CCCGCAGG UCGCGGUUG 17 6090
HSV2-UL48-511 - GGGCAUUGACGACUUUG 17 5993
HSV2-U L48-538 + AGGCUGACGUCGGUAAU 17 6020
HSV2-U L48-598 + CGGCGUACGCGGCCCAU 17 6080
HSV2-UL48-508 - AUGUU UACCGAUGCCAU 17 5990
HSV2-U L48-515 + GUCAAUGCCCAUGGCAU 17 5997
HSV2-UL48-594 + GAGGCCGUCGAACAGAU 17 6076
HSV2-UL48-435 - GAGCCGCGAGAUCCUAU 17 5917
HSV2-U L48-503 - ACGACCCCGUCUCGUAU 17 5985
HSV2-U L48-561 + GGAGUACGAGUCCAACU 17 6043
HSV2-U L48-494 - CCUGGACGACUUCGACU 17 5976
HSV2-U L48-466 - CUCCAGCGUCGCGACCU 17 5948
HSV2-UL48-487 - AUUACCGACGUCAGCCU 17 5969
HSV2-U L48-496 - UUCGACUUGGAGAUGCU 17 5978
HSV2-U L48-596 + GGGCCGCAUCAUCUGCU 17 6078 HSV2-U L48-422 - GUUGGCAAAUUUUUGCU 17 5904
HSV2-U L48-462 - ACCAGGCCCGCUCCUCU 17 5944
HSV2-U L48-465 - GCUGAUCCGGGCCAAGU 17 5947
HSV2-U L48-440 - GGAGAGCUGGCGCCAGU 17 5922
HSV2-UL48-536 + GUCUCCCAGGCUGACGU 17 6018
HSV2-UL48-530 + GAAGUCGUCCAGGGCGU 17 6012
HSV2-U L48-520 + AUACGAGACGGGGUCGU 17 6002
HSV2-UL48-1166 - UGACGACUUUGGGGGGU 17 15125
HSV2-UL48-1134 - GAGCUACCGGACCGUGU 17 15093
HSV2-U L48-509 - AUGGGCAU UGACGACU U 17 5991
HSV2-UL48-505 - CGUCUCGUAUGGGGCU U 17 5987
HSV2-U L48-424 - ACCUGCGCGCCAGCGUU 17 5906
HSV2-U L48-510 - UGGGCAU UGACGACUU U 17 5992
HSV2-UL48-247 - CAGCCCCUGAUGUUUAUCAA 20 5729
HSV2-U L48-343 + UCCCAGGCUGACGUCGGUAA 20 5825
HSV2-UL48-1139 + CGAGCAAAAAUU UGCCAACA 20 15098
HSV2-UL48-421 + GGCGCGCAGGUACCGGUACA 20 5903
HSV2-U L48-320 + CCCAAAGUCGUCAAUGCCCA 20 5802
HSV2-UL48-313 - ACAGAUGU UUACCGAUGCCA 20 5795
HSV2-U L48-391 + CCGCAGUCGCCGGGCCUCCA 20 5873
HSV2-U L48-335 + CUCCAAGUCGAAGUCGUCCA 20 5817
HSV2-UL48-393 + CUCCACGGGAACUCCCCGCA 20 5875
HSV2-U L48-265 - ACGACCCCGCCCGUCCUGCA 20 5747
HSV2-U L48-395 + CGAUCCGUUGAUAAACAUCA 20 5877
HSV2-UL48-322 + GUCCAAAGCCCCAUACGAGA 20 5804
HSV2-U L48-282 - AAUUACGGAUCGACAAUCGA 20 5764
HSV2-UL48-243 - AUGCGGCCCGAUCUGU UCGA 20 5725
HSV2-UL48-374 + GGCCUGGU UGCCCUGCAGGA 20 5856
HSV2-U L48-274 - UCCAGCGUCGCGACCUCGGA 20 5756
HSV2-UL48-331 + UCGUGGGUCAUUCCCGGGGA 20 5813
HSV2-UL48-295 - GGAGACGAACUCCGCCUGGA 20 5777
HSV2-U L48-364 + AUACGCGUGCUCCCGCAUGA 20 5846
HSV2-UL48-380 + CAGGACGGGCGGGGUCGUGA 20 5862
HSV2-U L48-240 - UUCUGAGCCGCGAGAUCCUA 20 5722
HSV2-U L48-308 - ACCCACG ACCCCG UCU CG U A 20 5790
HSV2-UL48-280 - GGGCGG ACCAG AAACAAU U A 20 5762
HSV2-U L48-407 + AGAGGUAUAGAUGCAGAAAC 20 5889
HSV2-UL48-397 + G CU G AAACAG ACACG CCA AC 20 5879
HSV2-UL48-392 + CG CAG U CG CCG GGCCU CCAC 20 5874
HSV2-U L48-323 + UCCAAAGCCCCAUACGAGAC 20 5805
HSV2-UL48-1167 - UGGGGGGUAGGAUGUGCGAC 20 15126
HSV2-U L48-375 + GCCUGGUUGCCCUGCAGGAC 20 5857
HSV2-U L48-238 - UGCGCACCACGAUCGCGGAC 20 5720
HSV2-UL48-40 - GGGCGCGGGAGGAGAGCUAC 20 5614
HSV2-U L48-419 + GAACGCUGGCGCGCAGG UAC 20 5901
HSV2-U L48-420 + UGGCGCGCAGGUACCGG UAC 20 5902 HSV2-U L48-229 - AUUU UUGCUCGGCCCUGUAC 20 5711
HSV2-U L48-266 - GCCCGUCCUGCAGGGCAACC 20 5748
HSV2-U L48-261 - AGUGCGGCGGCGGAGGAACC 20 5743
HSV2-U L48-244 - CGACGGCCUCUGCUGCGACC 20 5726
HSV2-UL48-1168 - GGGGGGUAGGAUGUGCGACC 20 15127
HSV2-UL48-262 - GUGCGGCGGCGGAGGAACCC 20 5744
HSV2-U L48-383 + GGGGUCGUGAGGGGCGCCCC 20 5865
HSV2-UL48-307 - GACGUGGAGUCCCCCUCCCC 20 5789
HSV2-UL48-299 - UAUGACGCCCGCCGACGCCC 20 5781
HSV2-U L48-382 + CGGGGUCGUGAGGGGCGCCC 20 5864
HSV2-UL48-306 - GGACGUGGAGUCCCCCUCCC 20 5788
HSV2-U L48-341 + CCAGGCGGAGUUCG UCUCCC 20 5823
HSV2-U L48-328 + CGGGGUCGUGGGUCAUUCCC 20 5810
HSV2-UL48-356 + CAUGCGCGGCGCCACCAGCC 20 5838
HSV2-U L48-292 - CCCCAUUACCGACGUCAGCC 20 5774
HSV2-UL48-231 - CGU UCGGCAGCUACACCGCC 20 5713
HSV2-UL48-294 - CCUGGGAGACGAACUCCGCC 20 5776
HSV2-U L48-408 + GCAGAAACAGGACGCGCGCC 20 5890
HSV2-UL48-239 - CUACCGCGAGACCGCGCGCC 20 5721
HSV2-U L48-390 + GUUUAGCUCCCGCAGUCGCC 20 5872
HSV2-U L48-287 - AUGACGCUCCUGCGGAGGCC 20 5769
HSV2-UL48-253 - GGGGAGU UCCCGUGGAGGCC 20 5735
HSV2-U L48-372 + AGUACCCAGAGGAGCGGGCC 20 5854
HSV2-U L48-368 + AG U ACG AG UCCAACU UGGCC 20 5850
HSV2-UL48-415 + UGCGGCCCCGCAUGUGUGCC 20 5897
HSV2-U L48-270 - GUACU UUAUGCUGCUGAUCC 20 5752
HSV2-UL48-283 - CGAGGGCCUGCUCGACCUCC 20 5765
HSV2-UL48-398 + CCAACUGGCGCCAGCUCUCC 20 5880
HSV2-U L48-339 + UAUCCACCUCCUCGCCGUCC 20 5821
HSV2-UL48-334 + U C U CCA AG UCGAAGUCG UCC 20 5816
HSV2-UL48-359 + CAGGAGCGUCAUCGUCG UCC 20 5841
HSV2-U L48-327 + ACGGGGUCGUGGGUCAUUCC 20 5809
HSV2-UL48-385 + CCGCCGCACUUCGCACCAGC 20 5867
HSV2-U L48-245 - UCUGCUGCGACCUGGAGAGC 20 5727
HSV2-U L48-361 + CGUCGUCCGGGAGGUCGAGC 20 5843
HSV2-UL48-371 + C A U A A AG UACCCAGAGGAGC 20 5853
HSV2-U L48-417 + GCGGUGUAGCUGCCGAACGC 20 5899
HSV2-UL48-366 + GCCCUCCGAGG UCGCGACGC 20 5848
HSV2-UL48-256 - CGAGCACCUGAACCUCCCGC 20 5738
HSV2-U L48-412 + UGGUGCGCAGCAUCUCCCGC 20 5894
HSV2-U L48-278 - GGGAGCACGCGUAUAGCCGC 20 5760
HSV2-U L48-357 + GCCACCAGCCCGGCCUCCGC 20 5839
HSV2-U L48-291 - CGCAUGUCGUU UCUCUCCGC 20 5773
HSV2-UL48-418 + GCUGCCGAACGCUGGCGCGC 20 5900
HSV2-U L48-389 + GGU UUAGCUCCCGCAGUCGC 20 5871
HSV2-U L48-286 - GAUGACGCUCCUGCGGAGGC 20 5768 HSV2-U L48-338 + AAGUCGUCCAGGGCGUCGGC 20 5820
HSV2-U L48-377 + GGUUGCCCUGCAGGACGGGC 20 5859
HSV2-U L48-288 - CGCUCCUGCGGAGGCCGGGC 20 5770
HSV2-U L48-233 - ACACCGCCAGGCACACAUGC 20 5715
HSV2-UL48-276 - GGAGGGCGAGUCCGUCAUGC 20 5758
HSV2-UL48-301 - CGACUUCGACUUGGAGAUGC 20 5783
HSV2-U L48-255 - CGUGGAGGCCCGGCGACUGC 20 5737
HSV2-UL48-236 - GGGCCGCAACCGCGACCUGC 20 5718
HSV2-UL48-373 + AGCGGGCCUGGU UGCCCUGC 20 5855
HSV2-U L48-264 - CACGACCCCGCCCGUCCUGC 20 5746
HSV2-UL48-351 + GGCGGUGGUGGACAGUCUGC 20 5833
HSV2-U L48-249 - CAACGGAUCGCUCACCG UGC 20 5731
HSV2-U L48-394 + GCGAUCCGU UGAUAAACAUC 20 5876
HSV2-UL48-401 + CAGAGGCCGUCGAACAGAUC 20 5883
HSV2-U L48-269 - GGUACUU UAUGCUGCUGAUC 20 5751
HSV2-UL48-267 - GGCAACCAGGCCCGCUCCUC 20 5749
HSV2-UL48-358 + GCAGGAGCGUCAUCGUCGUC 20 5840
HSV2-UL48-1143 + A A A A A UUUGCCAACACGGUC 20 15102
HSV2-UL48-387 + UUCGCACCAGCGGGAGGUUC 20 5869
HSV2-U L48-362 + UGUCGAUCCGUAAUUGUUUC 20 5844
HSV2-U L48-406 + GGAUCUCGCGGCUCAGAAAG 20 5888
HSV2-UL48-384 + GCCGCCGCACUUCGCACCAG 20 5866
HSV2-U L48-369 + CAGCAGCAUAAAGUACCCAG 20 5851
HSV2-U L48-399 + AGCUCUCCAGGUCGCAGCAG 20 5881
HSV2-UL48-396 + GAUCCGUUGAUAAACAUCAG 20 5878
HSV2-U L48-370 + GCAUAAAGUACCCAGAGGAG 20 5852
HSV2-UL48-332 + CGUGGGUCAUUCCCGGGGAG 20 5814
HSV2-UL48-381 + AGGACGGGCGGGGUCGUGAG 20 5863
HSV2-U L48-324 + CCAAAGCCCCAUACGAGACG 20 5806
HSV2-UL48-305 - CUUGGAGAUGCUGGGGGACG 20 5787
HSV2-UL48-312 - CUCGUAUGGGGCU UUGGACG 20 5794
HSV2-U L48-403 + CAUCAUCUGCUCGGCGUACG 20 5885
HSV2-UL48-263 - UGCGGCGGCGGAGGAACCCG 20 5745
HSV2-U L48-363 + AAUUGUU UCUGGUCCGCCCG 20 5845
HSV2-U L48-354 + UCUGCGGGGGCGUUG UCCCG 20 5836
HSV2-UL48-329 + GGGGUCGUGGGUCAU UCCCG 20 5811
HSV2-U L48-251 - CACCGUGCGGGGAGUUCCCG 20 5733
HSV2-UL48-277 - CGGGAGCACGCGUAUAGCCG 20 5759
HSV2-UL48-365 + CAUGACGGACUCGCCCUCCG 20 5847
HSV2-U L48-290 - GCGCAUGUCGU UUCUCUCCG 20 5772
HSV2-U L48-409 + CAGGACGCGCGCCAGGCGCG 20 5891
HSV2-U L48-296 - CGAACUCCGCCUGGACGGCG 20 5778
HSV2-U L48-378 + GU UGCCCUGCAGGACGGGCG 20 5860
HSV2-UL48-234 - CACCGCCAGGCACACAUGCG 20 5716
HSV2-U L48-355 + GCGGAGAGAAACGACAUGCG 20 5837
HSV2-U L48-352 + GCGGUGGUGGACAG UCUGCG 20 5834 HSV2-U L48-250 - AACGGAUCGCUCACCGUGCG 20 5732
HSV2-U L48-281 - CAAUUACGGAUCGACAAUCG 20 5763
HSV2-U L48-237 - GAUGCUGCGCACCACGAUCG 20 5719
HSV2-U L48-411 + GUAGUACCUGUCCGCGAUCG 20 5893
HSV2-UL48-405 + ACGCGGCCCAUAGGAUCUCG 20 5887
HSV2-UL48-410 + GCGCCAGGCGCGCGGUCUCG 20 5892
HSV2-U L48-413 + GCAGCAUCUCCCGCAGGUCG 20 5895
HSV2-UL48-325 + CCCCAUACGAGACGGGGUCG 20 5807
HSV2-UL48-340 + CCACCUCCUCGCCGUCCAGG 20 5822
HSV2-U L48-297 - ACUCCGCCUGGACGGCGAGG 20 5779
HSV2-UL48-298 - CCGCCUGGACGGCGAGGAGG 20 5780
HSV2-U L48-333 + GUGGGUCAUUCCCGGGGAGG 20 5815
HSV2-U L48-260 - GGUGCGAAGUGCGGCGGCGG 20 5742
HSV2-UL48-259 - GCUGGUGCGAAGUGCGGCGG 20 5741
HSV2-U L48-348 + GACGUCGGUAAUGGGGGCGG 20 5830
HSV2-UL48-285 - CGACGAUGACGCUCCUGCGG 20 5767
HSV2-UL48-353 + CGGUGGUGGACAGUCUGCGG 20 5835
HSV2-U L48-258 - CCCGCUGGUGCGAAGUGCGG 20 5740
HSV2-UL48-273 - CUCCAGCGUCGCGACCUCGG 20 5755
HSV2-U L48-337 + GAAGUCGUCCAGGGCGUCGG 20 5819
HSV2-U L48-376 + UGGUUGCCCUGCAGGACGGG 20 5858
HSV2-UL48-1169 - GGGUAGGAUGUGCGACCGGG 20 15128
HSV2-U L48-360 + GAGCGUCAUCG UCGUCCGGG 20 5842
HSV2-U L48-386 + CCGCACU UCGCACCAGCGGG 20 5868
HSV2-UL48-279 - AGCACGCGUAUAGCCGCGGG 20 5761
HSV2-U L48-330 + GUCGUGGGUCAU UCCCGGGG 20 5812
HSV2-UL48-347 + GCUGACGUCGGUAAUGGGGG 20 5829
HSV2-UL48-319 - UGGGCAUUGACGACUUUGGG 20 5801
HSV2-U L48-346 + CAGGCUGACGUCGGUAAUGG 20 5828
HSV2-UL48-416 + GGCCCCGCAUG UGUGCCUGG 20 5898
HSV2-UL48-289 - UCCUGCGGAGGCCGGGCUGG 20 5771
HSV2-U L48-304 - CU UCGACUUGGAGAUGCUGG 20 5786
HSV2-UL48-252 - CGUGCGGGGAGU UCCCGUGG 20 5734
HSV2-U L48-349 + GUCGGUAAUGGGGGCGGUGG 20 5831
HSV2-U L48-318 - AUGGGCAUUGACGACUU UGG 20 5800
HSV2-UL48-388 + GGUUCAGGUGCUCGCGAAUG 20 5870
HSV2-U L48-345 + CCAGGCUGACGUCGGUAAUG 20 5827
HSV2-UL48-232 - UACACCGCCAGGCACACAUG 20 5714
HSV2-UL48-275 - CGGAGGGCGAGUCCGUCAUG 20 5757
HSV2-U L48-242 - CGUACGCCGAGCAGAUGAUG 20 5724
HSV2-U L48-310 - CCACGACCCCGUCUCGUAUG 20 5792
HSV2-U L48-254 - CCGUGGAGGCCCGGCGACUG 20 5736
HSV2-U L48-235 - GGGGCCGCAACCGCGACCUG 20 5717
HSV2-UL48-284 - GGACGACGAUGACGCUCCUG 20 5766
HSV2-U L48-303 - ACU UCGACUUGGAGAUGCUG 20 5785
HSV2-U L48-350 + GGGCGGUGGUGGACAGUCUG 20 5832 HSV2-U L48-257 - CCUCCCGCUGGUGCGAAGUG 20 5739
HSV2-U L48-248 - UCAACGGAUCGCUCACCGUG 20 5730
HSV2-U L48-379 + GCAGGACGGGCGGGGUCGUG 20 5861
HSV2-U L48-414 + UCUCCCGCAGGUCGCGGUUG 20 5896
HSV2-UL48-317 - CAUGGGCAUUGACGACUUUG 20 5799
HSV2-UL48-344 + CCCAGGCUGACGUCGGUAAU 20 5826
HSV2-U L48-404 + GCUCGGCGUACGCGGCCCAU 20 5886
HSV2-UL48-314 - CAGAUGUUUACCGAUGCCAU 20 5796
HSV2-UL48-321 + GUCGUCAAUGCCCAUGGCAU 20 5803
HSV2-U L48-400 + GCAGAGGCCGUCGAACAGAU 20 5882
HSV2-UL48-241 - UCUGAGCCGCGAGAUCCUAU 20 5723
HSV2-U L48-309 - CCCACGACCCCGUCUCGUAU 20 5791
HSV2-U L48-367 + GCUGGAGUACGAGUCCAACU 20 5849
HSV2-UL48-300 - CGCCCUGG ACG ACU UCG ACU 20 5782
HSV2-U L48-272 - GUACUCCAGCGUCGCGACCU 20 5754
HSV2-UL48-293 - CCCAUUACCGACGUCAGCCU 20 5775
HSV2-UL48-302 - GACU UCGACU UGGAGAUGCU 20 5784
HSV2-U L48-402 + AUCGGGCCGCAUCAUCUGCU 20 5884
HSV2-UL48-1132 - CGUGUUGGCAAAUUUU UGCU 20 5710
HSV2-U L48-268 - GCAACCAGGCCCGCUCCUCU 20 5750
HSV2-U L48-271 - GCUGCUGAUCCGGGCCAAGU 20 5753
HSV2-UL48-246 - CCUGGAGAGCUGGCGCCAGU 20 5728
HSV2-U L48-342 + UUCGUCUCCCAGGCUGACGU 20 5824
HSV2-U L48-336 + GUCGAAGUCGUCCAGGGCGU 20 5818
HSV2-UL48-326 + CCCAUACGAGACGGGGUCGU 20 5808
HSV2-UL48-1170 - CAU UGACGACUU UGGGGGGU 20 15129
HSV2-UL48-1136 - GGAGAGCUACCGGACCGUGU 20 15095
HSV2-UL48-315 - GCCAUGGGCAU UGACGACUU 20 5797
HSV2-U L48-311 - CCCCGUCUCGUAUGGGGCUU 20 5793
HSV2-UL48-230 - GGUACCUGCGCGCCAGCGUU 20 5712
HSV2-UL48-316 - CCAUGGGCAUUGACGACU UU 20 5798
Table 12A provides exemplary targeting domains for knocking out the UL48 gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), have a high level of orthogonality, and start with a 5'G. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 12A
1st Tier Target
DNA
gRNA Name Targeting Domain Site
Strand
Length Seq ID
HSV2-UL48-1171 + GUCCAUGGGGGCGGUUGGGUCC 22 15130
HSV2-UL48-1172 + GGUCCAUGGGGGCGGU UGGGUCC 23 15131
HSV2-UL48-1173 + GUACAGCGGAGGGGCGGC 18 15132
HSV2-UL48-100 + GCGUACAGCGGAGGGGCGGC 20 5640
HSV2-UL48-1174 + GGCGUACAGCGGAGGGGCGGC 21 15133
HSV2-UL48-1175 + GUGGCGUACAGCGGAGGGGCGGC 23 15134
HSV2-UL48-1176 + GGUGGCGUACAGCGGAGGGGCGGC 24 15135
HSV2-UL48-1177 + GAACGCCACGUCGCCGUGGGC 21 15136
HSV2-UL48-1178 + GGAACGCCACGUCGCCGUGGGC 22 15137
HSV2-UL48-1179 + GGGAACGCCACGUCGCCGUGGGC 23 15138
HSV2-UL48-1180 + GGGGAACGCCACGUCGCCGUGGGC 24 15139
HSV2-UL48-1181 + GUACGAAGGCAGCUCGUC 18 15140
HSV2-UL48-1182 + GUAGUACGAAGGCAGCUCGUC 21 15141
HSV2-UL48-1183 + GACCAACAGGUCCAUGGGGGCGG 23 15142
HSV2-UL48-1184 + GCUCGUCGCGGGUGGCGGG 19 15143
HSV2-UL48-1185 + GCAGCUCGUCGCGGGUGGCGGG 22 15144
HSV2-UL48-1186 + GGCAGCUCGUCGCGGGUGGCGGG 23 15145
HSV2-UL48-3 - GAUCUGUUUGCGGACGCGGA 20 5484
HSV2-UL48-1187 - GACGAUCUGUUUGCGGACGCGGA 23 15146
HSV2-UL48-24 - GACCAACGCCGACAUGUACC 20 5500
HSV2-UL48-1188 - GCCACCGCCCCCCAGGCCAGCC 22 15147
HSV2-UL48-1189 - GACGAUCUGGGCUUCAGC 18 15148
HSV2-UL48-1190 - GCUGUACGCCACCGGUCGG 19 15149
HSV2-UL48-1191 - GCCCAGCGACGUGAUCGACUGG 22 15150
Table 12B provides exemplary targeting domains for knocking out the UL48 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), and have a high level of orthogonality. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 12B
Figure imgf000595_0001
HSV2-UL48-1142 + CCAUGGGGGCGGU UGGGUCC 20 15101
HSV2-UL48-1194 + UCCAUGGGGGCGGUUGGGUCC 21 15153
HSV2-UL48-1195 + AGGUCCAUGGGGGCGG UUGGGUCC 24
15154
HSV2-UL48-1196 + CGUACAGCGGAGGGGCGGC 19 15155
HSV2-UL48-1197 + UGGCGUACAGCGGAGGGGCGGC 22 15156
HSV2-UL48-1198 + CGCCACGUCGCCGUGGGC 18 15157
HSV2-UL48-1199 + ACGCCACGUCGCCGUGGGC 19 15158
HSV2-UL48-733 + AACGCCACGUCGCCGUGGGC 20 6168
HSV2-UL48-1200 + AGUACGAAGGCAGCUCG UC 19 15159
HSV2-UL48-741 + UAGUACGAAGGCAGCUCGUC 20 6173
HSV2-UL48-1201 + CGU AGUACGAAGGCAGCUCGUC 22 15160
HSV2-UL48-1202 + UCG UAGUACGAAGGCAGCUCGUC 23 15161
HSV2-UL48-1203 + CUCGUAGUACGAAGGCAGCUCGUC 24 15162
HSV2-UL48-1204 + ACAGGUCCAUGGGGGCGG 18 15163
HSV2-UL48-1205 + AACAGGUCCAUGGGGGCGG 19 15164
HSV2-UL48-1206 + CAACAGGUCCAUGGGGGCGG 20 15165
HSV2-UL48-1207 + CCAACAGGUCCAUGGGGGCGG 21 15166
HSV2-UL48-1208 + ACCAACAGGUCCAUGGGGGCGG 22 15167
HSV2-UL48-1209 + CGACCAACAGGUCCAUGGGGGCGG 24 15168
HSV2-UL48-1210 + CUCGUCGCGGGUGGCGGG 18 15169
HSV2-UL48-739 + AGCUCGUCGCGGGUGGCGGG 20 6171
HSV2-UL48-1211 + CAGCUCGUCGCGGGUGGCGGG 21 15170
HSV2-UL48-1212 + AGGCAGCUCGUCGCGGGUGGCGGG 24 15171
HSV2-UL48-1213 - UCUGUU UGCGGACGCGGA 18 15172
HSV2-UL48-1214 - AUCUGUUUGCGGACGCGGA 19 15173
HSV2-UL48-1215 - CGAUCUGU UUGCGGACGCGGA 21 15174
HSV2-UL48-1216 - ACG AUCUGUUUGCGGACGCGGA 22 15175
HSV2-UL48-1217 - CGACGAUCUGU UUGCGGACGCGGA 24 15176
HSV2-UL48-1218 - CCAACG CCG AC AU G U ACC 18 15177
HSV2-UL48-1219 - ACCAACGCCGACAUGUACC 19 15178
HSV2-UL48-1220 - CGACCAACGCCGACAUGUACC 21 15179
HSV2-UL48-1221 - CCGACCAACGCCGACAUGUACC 22 15180
HSV2-UL48-1222 - CCCGACCAACGCCGACAUGUACC 23 15181
HSV2-UL48-1223 - UCCCG ACCAACGCCGACAUGUACC 24 15182
HSV2-UL48-1224 - CCACCGCCCCCCAGGCCAGCC 21 15183
HSV2-UL48-1225 - CG CCACCGCCCCCCAG G CCAG CC 23 15184
HSV2-UL48-1226 - U CG CCACCGCCCCCCAG G CCAG CC 24 15185
HSV2-UL48-1227 - CGACGAUCUGGGCUUCAGC 19 15186
HSV2-UL48-626 - UCGACGAUCUGGGCUUCAGC 20 6105
HSV2-UL48-1228 - CUCGACGAUCUGGGCU UCAGC 21 15187
HSV2-UL48-1229 - CCUCGACGAUCUGGGCUUCAGC 22 15188
HSV2-UL48-1230 - UCCUCGACGAUCUGGGCUUCAGC 23 15189
HSV2-UL48-1231 - CUCCUCGACGAUCUGGGCU UCAGC 24 15190
HSV2-UL48-1232 - CUGUACGCCACCGGUCGG 18 15191
HSV2-UL48-624 - CGCUGUACGCCACCGGUCGG 20 6103 HSV2-UL48-1233 - CCGCUGUACGCCACCGGUCGG 21 15192
HSV2-UL48-1234 - UCCGCUGUACGCCACCGGUCGG 22 15193
HSV2-UL48-1235 - CUCCGCUGUACGCCACCGGUCGG 23 15194
HSV2-UL48-1236 - CCUCCGCUGUACGCCACCGGUCGG 24 15195
HSV2-UL48-1237 - AGCGACGUGAUCGACUGG 18 15196
HSV2-UL48-1238 - CAGCGACGUGAUCGACUGG 19 15197
HSV2-UL48-28 - CCAGCGACGUGAUCGACUGG 20 5610
HSV2-UL48-1239 - CCCAGCGACGUGAUCGACUGG 21 15198
HSV2-UL48-1240 - UGCCCAGCGACGUGAUCGACUGG 23 15199
HSV2-UL48-1241 - CUGCCCAGCGACGUGAUCGACUGG 24 15200
HSV2-UL48-1242 - CCUGGAACGAGGACCUGUUCU 21 15201
HSV2-UL48-1243 - ACCUGGAACGAGGACCUGUUCU 22 15202
HSV2-UL48-1244 - UACCUGGAACGAGGACCUGUUCU 23 15203
HSV2-UL48-1245 - AUACCUGGAACGAGGACCUGU UCU 24 15204
Table 12C provides exemplary targeting domains for knocking out the UL48 gene selected according to the third tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon). The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 12C
Figure imgf000597_0001
Table 12D provides exemplary targeting domains for knocking out the UL48 gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon). The PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase). Table 12D
Figure imgf000598_0001
HSV2-UL48-1284 + GUCGCCGUGGGCGCGAAUGUCGA 23 15243
HSV2-UL48-1285 + CGUCGCCGUGGGCGCGAAUGUCGA 24 15244
HSV2-UL48-1286 + CGGCGUUGGUCGGGAACC 18 15245
HSV2-UL48-1287 + UCGGCGUUGGUCGGGAACC 19 15246
HSV2-UL48-720 + GUCGGCGU UGGUCGGGAACC 20 6162
HSV2-UL48-1288 + UGUCGGCGUUGGUCGGGAACC 21 15247
HSV2-UL48-1289 + AUG UCGGCGU UGGUCGGGAACC 22 15248
HSV2-UL48-1290 + CAUG UCGGCGUUGGUCGGGAACC 23 15249
HSV2-UL48-1291 + ACAUGUCGGCGU UGGUCGGGAACC 24 15250
HSV2-UL48-1292 + CCGCGCCCGCAGCUCACC 18 15251
HSV2-UL48-1293 + CCCGCGCCCGCAGCUCACC 19 15252
HSV2-UL48-744 + UCCCGCGCCCGCAGCUCACC 20 6175
HSV2-UL48-1294 + CUCCCGCGCCCGCAGCUCACC 21 15253
HSV2-UL48-1295 + CCUCCCGCGCCCGCAGCUCACC 22 15254
HSV2-UL48-1296 + UCCUCCCGCGCCCGCAGCUCACC 23 15255
HSV2-UL48-1297 + CUCCUCCCGCGCCCGCAGCUCACC 24 15256
HSV2-UL48-1298 + GGGGAACGCCACGUCGCC 18 15257
HSV2-UL48-1299 + UGGGGAACGCCACGUCGCC 19 15258
HSV2-UL48-734 + GUGGGGAACGCCACGUCGCC 20 6169
HSV2-UL48-1300 + GG UGGGGAACGCCACGUCGCC 21 15259
HSV2-UL48-1301 + GGG UGGGGAACGCCACGUCGCC 22 15260
HSV2-UL48-1302 + AGGGUGGGGAACGCCACGUCGCC 23 15261
HSV2-UL48-1303 + CAGGG UGGGGAACGCCACGUCGCC 24 15262
HSV2-UL48-1304 + AGACGGU UAAACAGGGCC 18 15263
HSV2-UL48-1305 + GAGACGGUUAAACAGGGCC 19 15264
HSV2-UL48-711 + GGAGACGGU UAAACAGGGCC 20 6155
HSV2-UL48-1306 + AGGAGACGGUUAAACAGGGCC 21 15265
HSV2-UL48-1307 + GAGGAGACGGUUAAACAGGGCC 22 15266
HSV2-UL48-1308 + CG AGGAGACGGUUAAACAGGGCC 23 15267
HSV2-UL48-1309 + UCGAGGAGACGGU UAAACAGGGCC 24 15268
HSV2-UL48-1310 + UGGGACCCCCGGCUGGCC 18 15269
HSV2-UL48-1311 + UUGGGACCCCCGGCUGGCC 19 15270
HSV2-UL48-107 + CU UGGGACCCCCGGCUGGCC 20 5645
HSV2-UL48-1312 + UCUUGGGACCCCCGGCUGGCC 21 15271
HSV2-UL48-1313 + UUCUUGGGACCCCCGGCUGGCC 22 15272
HSV2-UL48-1314 + GUUCUUGGGACCCCCGGCUGGCC 23 15273
HSV2-UL48-1315 + UGUUCUUGGGACCCCCGGCUGGCC 24 15274
HSV2-UL48-1316 + UCGUCGACCAACAGGUCC 18 15275
HSV2-UL48-1317 + AUCGUCGACCAACAGGUCC 19 15276
HSV2-UL48-1318 + G AU CG U CG ACCA ACAG G U CC 20 15277
HSV2-UL48-1319 + AGAUCGUCGACCAACAGGUCC 21 15278
HSV2-UL48-1320 + CAGAUCGUCGACCAACAGGUCC 22 15279
HSV2-UL48-1321 + ACAGAUCGUCGACCAACAGGUCC 23 15280
HSV2-UL48-1322 + AACAGAUCG UCGACCAACAGGUCC 24 15281
HSV2-UL48-1323 + UCUAGCAUGGUACACAGC 18 15282
HSV2-UL48-1324 + AUCUAGCAUGGUACACAGC 19 15283 HSV2-UL48-718 + UAUCUAGCAUGGUACACAGC 20 6160
HSV2-UL48-1325 + GUAUCUAGCAUGGUACACAGC 21 15284
HSV2-UL48-1326 + GG UAUCUAGCAUGGUACACAGC 22 15285
HSV2-UL48-1327 + AGG UAUCUAGCAUGGUACACAGC 23 15286
HSV2-UL48-1328 + CAGG UAUCUAGCAUGGUACACAGC 24 15287
HSV2-UL48-1329 + ACG G U U A A AC AG G GCCGC 18 15288
HSV2-UL48-1330 + G ACG G U U A A AC AG G G CCG C 19 15289
HSV2-UL48-79 + AGACGGU UAAACAGGGCCGC 20 5569
HSV2-UL48-1331 + GAGACGGU UAAACAGGGCCGC 21 15290
HSV2-UL48-1332 + GGAGACGGUUAAACAGGGCCGC 22 15291
HSV2-UL48-1333 + AGGAGACGGUUAAACAGGGCCGC 23 15292
HSV2-UL48-1334 + GAGGAGACGGUUAAACAGGGCCGC 24 15293
HSV2-UL48-1335 + AUGUCGAUCGGGGAGCGC 18 15294
HSV2-UL48-1336 + AAUGUCGAUCGGGGAGCGC 19 15295
HSV2-UL48-728 + GAAUGUCGAUCGGGGAGCGC 20 6166
HSV2-UL48-1337 + CG AAUGUCGAUCGGGGAGCGC 21 15296
HSV2-UL48-1338 + GCG AAUGUCGAUCGGGGAGCGC 22 15297
HSV2-UL48-1339 + CGCG AAUGUCGAUCGGGGAGCGC 23 15298
HSV2-UL48-1340 + GCGCGAAUGUCGAUCGGGGAGCGC 24 15299
HSV2-UL48-1341 + GGGACGGGCAUGGGCGGC 18 15300
HSV2-UL48-1342 + GGGGACGGGCAUGGGCGGC 19 15301
HSV2-UL48-702 + GGGGGACGGGCAUGGGCGGC 20 6151
HSV2-UL48-1343 + GGGGGGACGGGCAUGGGCGGC 21 15302
HSV2-UL48-1344 + GGGGGGGACGGGCAUGGGCGGC 22 15303
HSV2-UL48-1345 + CGGGGGGGACGGGCAUGGGCGGC 23 15304
HSV2-UL48-1346 + GCGGGGGGGACGGGCAUGGGCGGC 24
15305
HSV2-UL48-1347 + GCCGCGGGGGGGACGGGC 18 15306
HSV2-UL48-1348 + GGCCGCGGGGGGGACGGGC 19 15307
HSV2-UL48-704 + GGGCCGCGGGGGGGACGGGC 20 6153
HSV2-UL48-1349 + AGGGCCGCGGGGGGGACGGGC 21 15308
HSV2-UL48-1350 + CAGGGCCGCGGGGGGGACGGGC 22 15309
HSV2-UL48-1351 + ACAGGGCCGCGGGGGGGACGGGC 23 15310
HSV2-UL48-1352 + AACAGGGCCGCGGGGGGGACGGGC 24 15311
HSV2-UL48-1353 + UUGGGACCCCCGGCUGGC 18 15312
HSV2-UL48-1354 + CUUGGGACCCCCGGCUGGC 19 15313
HSV2-UL48-692 + UCU UGGGACCCCCGGCUGGC 20 6145
HSV2-UL48-1355 + UUCUUGGGACCCCCGGCUGGC 21 15314
HSV2-UL48-1356 + GUUCUUGGGACCCCCGGCUGGC 22 15315
HSV2-UL48-1357 + UGUUCUUGGGACCCCCGGCUGGC 23 15316
HSV2-UL48-1358 + GUGU UCUUGGGACCCCCGGCUGGC 24 15317
HSV2-UL48-1359 + UGGGCGCGAAUGUCGAUC 18 15318
HSV2-UL48-1360 + GUGGGCGCGAAUGUCGAUC 19 15319
HSV2-UL48-57 + CGUGGGCGCGAAUGUCGAUC 20 5538
HSV2-UL48-1361 + CCGUGGGCGCGAAUGUCGAUC 21 15320
HSV2-UL48-1362 + GCCG UGGGCGCGAAUGUCGAUC 22 15321 HSV2-UL48-1363 + CGCCGUGGGCGCGAAUGUCGAUC 23 15322
HSV2-UL48-1364 + UCGCCGUGGGCGCGAAUGUCGAUC 24 15323
HSV2-UL48-1365 + GUCGAUCGGGGAGCGCUC 18 15324
HSV2-UL48-1366 + UGUCGAUCGGGGAGCGCUC 19 15325
HSV2-UL48-60 + AUGUCGAUCGGGGAGCGCUC 20 5541
HSV2-UL48-1367 + AAUGUCGAUCGGGGAGCGCUC 21 15326
HSV2-UL48-1368 + GAAUGUCGAUCGGGGAGCGCUC 22 15327
HSV2-UL48-1369 + CG AAUGUCGAUCGGGGAGCGCUC 23 15328
HSV2-UL48-1370 + GCGAAUGUCGAUCGGGGAGCGCUC 24 15329
HSV2-UL48-1371 + GCUGAAGCCCAGAUCGUC 18 15330
HSV2-UL48-1372 + CGCUGAAGCCCAGAUCGUC 19 15331
HSV2-UL48-714 + GCGCUGAAGCCCAGAUCGUC 20 6157
HSV2-UL48-1373 + CGCGCUGAAGCCCAGAUCGUC 21 15332
HSV2-UL48-1374 + CCGCGCUGAAGCCCAGAUCGUC 22 15333
HSV2-UL48-1375 + CCCGCGCUGAAGCCCAGAUCGUC 23 15334
HSV2-UL48-1376 + ACCCGCGCUGAAGCCCAGAUCGUC 24 15335
HSV2-UL48-1377 + CAUGGGGGCGGUUGGGUC 18 15336
HSV2-UL48-1378 + CCAUGGGGGCGGU UGGGUC 19 15337
HSV2-UL48-1144 + UCCAUGGGGGCGGU UGGGUC 20 15103
HSV2-UL48-1379 + GUCCAUGGGGGCGGUUGGGUC 21 15338
HSV2-UL48-1380 + GG UCCAUGGGGGCGGU UGGGUC 22 15339
HSV2-UL48-1381 + AGG UCCAUGGGGGCGGUUGGGUC 23 15340
HSV2-UL48-1382 + CAGGUCCAUGGGGGCGGU UGGGUC 24
15341
HSV2-UL48-1383 + UACAUGUCGGCGUUGG UC 18 15342
HSV2-UL48-1384 + GUACAUGUCGGCGUUGGUC 19 15343
HSV2-UL48-68 + GGUACAUGUCGGCGUUGGUC 20 5557
HSV2-UL48-1385 + CGGUACAUGUCGGCGU UGGUC 21 15344
HSV2-UL48-1386 + CCGGUACAUGUCGGCGU UGGUC 22 15345
HSV2-UL48-1387 + CCCGGUACAUGUCGGCGUUGGUC 23 15346
HSV2-UL48-1388 + UCCCGGUACAUGUCGGCGU UGGUC 24 15347
HSV2-UL48-1389 + GGGGCGGCUGGGGUGU UC 18 15348
HSV2-UL48-1390 + AGGGGCGGCUGGGGUGUUC 19 15349
HSV2-UL48-694 + GAGGGGCGGCUGGGGUGUUC 20 6146
HSV2-UL48-1391 + GGAGGGGCGGCUGGGGUGUUC 21 15350
HSV2-UL48-1392 + CGG AGGGGCGGCUGGGGUGUUC 22 15351
HSV2-UL48-1393 + GCGG AGGGGCGGCUGGGGUGUUC 23 15352
HSV2-UL48-1394 + AGCGGAGGGGCGGCUGGGGUGUUC 24
15353
HSV2-UL48-1395 + CCGACCGGUGGCGUACAG 18 15354
HSV2-UL48-1396 + GCCGACCGGUGGCGUACAG 19 15355
HSV2-UL48-95 + AGCCGACCGGUGGCGUACAG 20 5581
HSV2-UL48-1397 + CAGCCGACCGGUGGCGUACAG 21 15356
HSV2-UL48-1398 + UCAGCCGACCGGUGGCGUACAG 22 15357
HSV2-UL48-1399 + CUCAGCCGACCGGUGGCGUACAG 23 15358
HSV2-UL48-1400 + ACUCAGCCGACCGGUGGCGUACAG 24 15359 HSV2-UL48-1401 + GGGCGGCGAGGGCAUCAG 18 15360
HSV2-UL48-1402 + UGGGCGGCGAGGGCAUCAG 19 15361
HSV2-UL48-701 + AUGGGCGGCGAGGGCAUCAG 20 6150
HSV2-UL48-1403 + CAUGGGCGGCGAGGGCAUCAG 21 15362
HSV2-UL48-1404 + GCAUGGGCGGCGAGGGCAUCAG 22 15363
HSV2-UL48-1405 + GGCAUGGGCGGCGAGGGCAUCAG 23 15364
HSV2-UL48-1406 + GGGCAUGGGCGGCGAGGGCAUCAG 24 15365
HSV2-UL48-1407 + CGCGCCCGCAGCUCACCG 18 15366
HSV2-UL48-1408 + CCGCGCCCGCAGCUCACCG 19 15367
HSV2-UL48-41 + CCCGCGCCCGCAGCUCACCG 20 5615
HSV2-UL48-1409 + UCCCGCGCCCGCAGCUCACCG 21 15368
HSV2-UL48-1410 + CUCCCGCGCCCGCAGCUCACCG 22 15369
HSV2-UL48-1411 + CCUCCCGCGCCCGCAGCUCACCG 23 15370
HSV2-UL48-1412 + UCCUCCCGCGCCCGCAGCUCACCG 24 15371
HSV2-UL48-1413 + GACGGUUAAACAGGGCCG 18 15372
HSV2-UL48-1414 + AG ACG G U U A A AC AG G GCCG 19 15373
HSV2-UL48-78 + GAGACGGUUAAACAGGGCCG 20 5568
HSV2-UL48-1415 + GGAGACGGU UAAACAGGGCCG 21 15374
HSV2-UL48-1416 + AGGAGACGGU UAAACAGGGCCG 22 15375
HSV2-UL48-1417 + GAGGAGACGGUUAAACAGGGCCG 23 15376
HSV2-UL48-1418 + CGAGGAGACGGUUAAACAGGGCCG 24 15377
HSV2-UL48-1419 + CUAGCAUGGUACACAGCG 18 15378
HSV2-UL48-1420 + UCUAGCAUGGUACACAGCG 19 15379
HSV2-UL48-72 + AUCUAGCAUGGUACACAGCG 20 5624
HSV2-UL48-1421 + UAUCUAGCAUGGUACACAGCG 21 15380
HSV2-UL48-1422 + GU AUCUAGCAUGGUACACAGCG 22 15381
HSV2-UL48-1423 + GG UAUCUAGCAUGGUACACAGCG 23 15382
HSV2-UL48-1424 + AGGUAUCUAGCAUGGUACACAGCG 24 15383
HSV2-UL48-1425 + GACCGGUGGCGUACAGCG 18 15384
HSV2-UL48-1426 + CGACCGGUGGCGUACAGCG 19 15385
HSV2-UL48-698 + CCGACCGGUGGCGUACAGCG 20 6148
HSV2-UL48-1427 + GCCGACCGGUGGCGUACAGCG 21 15386
HSV2-UL48-1428 + AGCCGACCGGUGGCGUACAGCG 22 15387
HSV2-UL48-1429 + CAGCCGACCGGUGGCGUACAGCG 23 15388
HSV2-UL48-1430 + UCAGCCGACCGGUGGCGUACAGCG 24 15389
HSV2-UL48-1431 + CACAGCGCGGGACCCGCG 18 15390
HSV2-UL48-1432 + ACACAGCGCGGGACCCGCG 19 15391
HSV2-UL48-716 + UACACAGCGCGGGACCCGCG 20 6159
HSV2-UL48-1433 + GU ACACAGCGCGGGACCCGCG 21 15392
HSV2-UL48-1434 + GGUACACAGCGCGGGACCCGCG 22 15393
HSV2-UL48-1435 + UGG UACACAGCGCGGGACCCGCG 23 15394
HSV2-UL48-1436 + AUGG UACACAGCGCGGGACCCGCG 24 15395
HSV2-UL48-1437 + CGGUUAAACAGGGCCGCG 18 15396
HSV2-UL48-1438 + ACG G U U AAACAGG G CCG CG 19 15397
HSV2-UL48-80 + GACGGUUAAACAGGGCCGCG 20 5570
HSV2-UL48-1439 + AGACGGU UAAACAGGGCCGCG 21 15398 HSV2-UL48-1440 + GAGACGGU UAAACAGGGCCGCG 22 15399
HSV2-UL48-1441 + GGAGACGGU UAAACAGGGCCGCG 23 15400
HSV2-UL48-1442 + AGGAGACGGUUAAACAGGGCCGCG 24 15401
HSV2-UL48-1443 + GGGGGACGGGCAUGGGCG 18 15402
HSV2-UL48-1444 + GGGGGGACGGGCAUGGGCG 19 15403
HSV2-UL48-703 + GGGGGGGACGGGCAUGGGCG 20 6152
HSV2-UL48-1445 + CGGGGGGGACGGGCAUGGGCG 21 15404
HSV2-UL48-1446 + GCGGGGGGGACGGGCAUGGGCG 22 15405
HSV2-UL48-1447 + CGCGGGGGGGACGGGCAUGGGCG 23 15406
HSV2-UL48-1448 + CCGCGGGGGGGACGGGCAUGGGCG 24 15407
HSV2-UL48-1449 + GCGCUGAAGCCCAGAUCG 18 15408
HSV2-UL48-1450 + CGCGCUGAAGCCCAGAUCG 19 15409
HSV2-UL48-715 + CCGCGCUGAAGCCCAGAUCG 20 6158
HSV2-UL48-1451 + CCCGCGCUGAAGCCCAGAUCG 21 15410
HSV2-UL48-1452 + ACCCGCGCUGAAGCCCAGAUCG 22 15411
HSV2-UL48-1453 + GACCCGCGCUGAAGCCCAGAUCG 23 15412
HSV2-UL48-1454 + GG ACCCGCGCUGAAGCCCAGAUCG 24 15413
HSV2-UL48-1455 + GGGCGCGAAUGUCGAUCG 18 15414
HSV2-UL48-1456 + UGGGCGCGAAUGUCGAUCG 19 15415
HSV2-UL48-58 + GUGGGCGCGAAUGUCGAUCG 20 5539
HSV2-UL48-1457 + CG UGGGCGCGAAUGUCGAUCG 21 15416
HSV2-UL48-1458 + CCGUGGGCGCGAAUGUCGAUCG 22 15417
HSV2-UL48-1459 + GCCGUGGGCGCGAAUGUCGAUCG 23 15418
HSV2-UL48-1460 + CGCCGUGGGCGCGAAUGUCGAUCG 24 15419
HSV2-UL48-1461 + CCCCAGUCGAUCACG UCG 18 15420
HSV2-UL48-1462 + CCCCCAGUCGAUCACGUCG 19 15421
HSV2-UL48-725 + CCCCCCAGUCGAUCACG UCG 20 6165
HSV2-UL48-1463 + UCCCCCCAGUCGAUCACGUCG 21 15422
HSV2-UL48-1464 + AUCCCCCCAGUCGAUCACGUCG 22 15423
HSV2-UL48-1465 + CAUCCCCCCAGUCGAUCACGUCG 23 15424
HSV2-UL48-1466 + GCAUCCCCCCAG UCGAUCACGUCG 24 15425
HSV2-UL48-1467 + CUGAAGCCCAGAUCGUCG 18 15426
HSV2-UL48-1468 + GCUGAAGCCCAGAUCGUCG 19 15427
HSV2-UL48-74 + CGCUGAAGCCCAGAUCGUCG 20 5625
HSV2-UL48-1469 + GCGCUGAAGCCCAGAUCGUCG 21 15428
HSV2-UL48-1470 + CGCGCUGAAGCCCAGAUCGUCG 22 15429
HSV2-UL48-1471 + CCGCGCUGAAGCCCAGAUCGUCG 23 15430
HSV2-UL48-1472 + CCCGCGCUGAAGCCCAGAUCGUCG 24 15431
HSV2-UL48-1473 + UCGCGGGUGGCGGGCAGG 18 15432
HSV2-UL48-1474 + GUCGCGGGUGGCGGGCAGG 19 15433
HSV2-UL48-738 + CG UCGCGGGUGGCGGGCAGG 20 6170
HSV2-UL48-1475 + UCG UCGCGGGUGGCGGGCAGG 21 15434
HSV2-UL48-1476 + CUCG UCGCGGGUGGCGGGCAGG 22 15435
HSV2-UL48-1477 + GCUCG UCGCGGGUGGCGGGCAGG 23 15436
HSV2-UL48-1478 + AGCUCGUCGCGGGUGGCGGGCAGG 24 15437
HSV2-UL48-1479 + ACCGGUGGCGUACAGCGG 18 15438 HSV2-UL48-1480 + GACCGGUGGCGUACAGCGG 19 15439
HSV2-UL48-96 + CGACCGGUGGCGUACAGCGG 20 5638
HSV2-UL48-1481 + CCGACCGGUGGCGUACAGCGG 21 15440
HSV2-UL48-1482 + GCCGACCGGUGGCGUACAGCGG 22 15441
HSV2-UL48-1483 + AGCCGACCGGUGGCGUACAGCGG 23 15442
HSV2-UL48-1484 + CAGCCGACCGGUGGCGUACAGCGG 24 15443
HSV2-UL48-1485 + GGUUAAACAGGGCCGCGG 18 15444
HSV2-UL48-1486 + CGGUUAAACAGGGCCGCGG 19 15445
HSV2-UL48-81 + ACG G U U A A AC AG GGCCGCGG 20 5571
HSV2-UL48-1487 + GACGG UUAAACAGGGCCGCGG 21 15446
HSV2-UL48-1488 + AGACGGU UAAACAGGGCCGCGG 22 15447
HSV2-UL48-1489 + GAGACGGU UAAACAGGGCCGCGG 23 15448
HSV2-UL48-1490 + GGAGACGGU UAAACAGGGCCGCGG 24 15449
HSV2-UL48-1491 + CGUACAGCGGAGGGGCGG 18 15450
HSV2-UL48-1492 + GCGUACAGCGGAGGGGCGG 19 15451
HSV2-UL48-696 + GGCGUACAGCGGAGGGGCGG 20 6147
HSV2-UL48-1493 + UGGCGUACAGCGGAGGGGCGG 21 15452
HSV2-UL48-1494 + GUGGCGUACAGCGGAGGGGCGG 22 15453
HSV2-UL48-1495 + GG UGGCGUACAGCGGAGGGGCGG 23 15454
HSV2-UL48-1496 + CGGUGGCGUACAGCGGAGGGGCGG 24 15455
HSV2-UL48-1497 + CGCGGGUGGCGGGCAGGG 18 15456
HSV2-UL48-1498 + UCGCGGGUGGCGGGCAGGG 19 15457
HSV2-UL48-51 + GUCGCGGGUGGCGGGCAGGG 20 5617
HSV2-UL48-1499 + CGUCGCGGGUGGCGGGCAGGG 21 15458
HSV2-UL48-1500 + UCGUCGCGGGUGGCGGGCAGGG 22 15459
HSV2-UL48-1501 + CUCG UCGCGGGUGGCGGGCAGGG 23 15460
HSV2-UL48-1502 + GCUCGUCGCGGGUGGCGGGCAGGG 24 15461
HSV2-UL48-1503 + G U U A A AC AG GGCCGCGGG 18 15462
HSV2-UL48-1504 + GGUUAAACAGGGCCGCGGG 19 15463
HSV2-UL48-82 + CGGUUAAACAGGGCCGCGGG 20 5572
HSV2-UL48-1505 + ACGGU UAAACAGGGCCGCGGG 21 15464
HSV2-UL48-1506 + GACGG UUAAACAGGGCCGCGGG 22 15465
HSV2-UL48-1507 + AG ACG G U U A A AC AG G GCCGCGGG 23 15466
HSV2-UL48-1508 + GAGACGGU UAAACAGGGCCGCGGG 24 15467
HSV2-UL48-1509 + AACAGGGCCGCGGGGGGG 18 15468
HSV2-UL48-1510 + AAACAGGGCCGCGGGGGGG 19 15469
HSV2-UL48-705 + UAAACAGGGCCGCGGGGGGG 20 6154
HSV2-UL48-1511 + UU AAACAGGGCCGCGGGGGGG 21 15470
HSV2-UL48-1512 + GUUAAACAGGGCCGCGGGGGGG 22 15471
HSV2-UL48-1513 + GGU UAAACAGGGCCGCGGGGGGG 23 15472
HSV2-UL48-1514 + CGGUUAAACAGGGCCGCGGGGGGG 24 15473
HSV2-UL48-1515 + GGUACAUGUCGGCGUUGG 18 15474
HSV2-UL48-1516 + CGGUACAUGUCGGCGU UGG 19 15475
HSV2-UL48-723 + CCGGUACAUGUCGGCGU UGG 20 6163
HSV2-UL48-1517 + CCCGGUACAUGUCGGCG UUGG 21 15476
HSV2-UL48-1518 + UCCCGGUACAUGUCGGCGUUGG 22 15477 HSV2-UL48-1519 + CUCCCGGUACAUGUCGGCGU UGG 23 15478
HSV2-UL48-1520 + ACUCCCGGUACAUGUCGGCGUUGG 24 15479
HSV2-UL48-1521 + GGACCCCCGGCUGGCCUG 18 15480
HSV2-UL48-1522 + GGGACCCCCGGCUGGCCUG 19 15481
HSV2-UL48-109 + UGGGACCCCCGGCUGGCCUG 20 5647
HSV2-UL48-1523 + UUGGGACCCCCGGCUGGCCUG 21 15482
HSV2-UL48-1524 + CU UGGGACCCCCGGCUGGCCUG 22 15483
HSV2-UL48-1525 + UCUUGGGACCCCCGGCUGGCCUG 23 15484
HSV2-UL48-1526 + UUCUUGGGACCCCCGGCUGGCCUG 24 15485
HSV2-UL48-1527 + CUGGCCUGGGGGGCGGUG 18 15486
HSV2-UL48-1528 + GCUGGCCUGGGGGGCGGUG 19 15487
HSV2-UL48-688 + GGCUGGCCUGGGGGGCGGUG 20 6144
HSV2-UL48-1529 + CGGCUGGCCUGGGGGGCGGUG 21 15488
HSV2-UL48-1530 + CCGGCUGGCCUGGGGGGCGGUG 22 15489
HSV2-UL48-1531 + CCCGGCUGGCCUGGGGGGCGGUG 23 15490
HSV2-UL48-1532 + CCCCGGCUGGCCUGGGGGGCGGUG 24 15491
HSV2-UL48-1533 + CGGGUGGCGGGCAGGGUG 18 15492
HSV2-UL48-1534 + GCGGGUGGCGGGCAGGGUG 19 15493
HSV2-UL48-53 + CGCGGGUGGCGGGCAGGGUG 20 5619
HSV2-UL48-1535 + UCGCGGGUGGCGGGCAGGGUG 21 15494
HSV2-UL48-1536 + GUCGCGGGUGGCGGGCAGGGUG 22 15495
HSV2-UL48-1537 + CG UCGCGGGUGGCGGGCAGGGUG 23 15496
HSV2-UL48-1538 + UCGUCGCGGGUGGCGGGCAGGGUG 24
15497
HSV2-UL48-1539 + GGCAGCUCGUCGCGGGUG 18 15498
HSV2-UL48-1540 + AGGCAGCUCGUCGCGGG UG 19 15499
HSV2-UL48-740 + AAGGCAGCUCGUCGCGGGUG 20 6172
HSV2-UL48-1541 + GAAGGCAGCUCGUCGCGGGUG 21 15500
HSV2-UL48-1542 + CG AAGGCAGCUCGUCGCGGGUG 22 15501
HSV2-UL48-1543 + ACG AAGGCAGCUCGUCGCGGGUG 23 15502
HSV2-UL48-1544 + UACG AAGGCAGCUCGUCGCGGGUG 24 15503
HSV2-UL48-1545 + GUCGACCAACAGGUCCAU 18 15504
HSV2-UL48-1546 + CG U CG ACCAACAGG U CCA U 19 15505
HSV2-UL48-1146 + UCGUCGACCAACAGGUCCAU 20 15105
HSV2-UL48-1547 + AUCG UCG ACCAACAGG UCCAU 21 15506
HSV2-UL48-1548 + GAUCGUCGACCAACAGGUCCAU 22 15507
HSV2-UL48-1549 + AG AUCGUCG ACCAACAGG UCCAU 23 15508
HSV2-UL48-1550 + CAGAUCGUCGACCAACAGGUCCAU 24 15509
HSV2-UL48-1551 + GUGGGCGCGAAUGUCGAU 18 15510
HSV2-UL48-1552 + CGUGGGCGCGAAUGUCGAU 19 15511
HSV2-UL48-56 + CCGUGGGCGCGAAUGUCGAU 20 5537
HSV2-UL48-1553 + GCCGUGGGCGCGAAUGUCGAU 21 15512
HSV2-UL48-1554 + CGCCGUGGGCGCGAAUGUCGAU 22 15513
HSV2-UL48-1555 + UCGCCGUGGGCGCGAAUGUCGAU 23 15514
HSV2-UL48-1556 + GUCGCCG UGGGCGCGAAUGUCGAU 24 15515
HSV2-UL48-1557 + GGGACCCCCGGCUGGCCU 18 15516 HSV2-UL48-1558 + UGGGACCCCCGGCUGGCCU 19 15517
HSV2-UL48-108 + UUGGGACCCCCGGCUGGCCU 20 5646
HSV2-UL48-1559 + CUUGGGACCCCCGGCUGGCCU 21 15518
HSV2-UL48-1560 + UCUUGGGACCCCCGGCUGGCCU 22 15519
HSV2-UL48-1561 + U UCUUGGGACCCCCGGCUGGCCU 23 15520
HSV2-UL48-1562 + GUUCUUGGGACCCCCGGCUGGCCU 24 15521
HSV2-UL48-1563 + UGUCGAUCGGGGAGCGCU 18 15522
HSV2-UL48-1564 + AUGUCGAUCGGGGAGCGCU 19 15523
HSV2-UL48-59 + AAUGUCGAUCGGGGAGCGCU 20 5540
HSV2-UL48-1565 + GAAUGUCGAUCGGGGAGCGCU 21 15524
HSV2-UL48-1566 + CGAAUGUCGAUCGGGGAGCGCU 22 15525
HSV2-UL48-1567 + GCG AAUG UCGAUCGGGGAGCGCU 23 15526
HSV2-UL48-1568 + CGCGAAUGUCGAUCGGGGAGCGCU 24 15527
HSV2-UL48-1569 + GGGCGGCUGGGGUGUUCU 18 15528
HSV2-UL48-1570 + GGGGCGGCUGGGGUGU UCU 19 15529
HSV2-UL48-103 + AGGGGCGGCUGGGGUGUUCU 20 5642
HSV2-UL48-1571 + GAGGGGCGGCUGGGGUGUUCU 21 15530
HSV2-UL48-1572 + GGAGGGGCGGCUGGGGUGUUCU 22 15531
HSV2-UL48-1573 + CGG AGGGGCGGCUGGGGUGUUCU 23 15532
HSV2-UL48-1574 + GCGGAGGGGCGGCUGGGGUGUUCU 24
15533
HSV2-UL48-1575 + GCGCCAUGGCCUCGUAG U 18 15534
HSV2-UL48-1576 + UGCGCCAUGGCCUCGUAGU 19 15535
HSV2-UL48-742 + CUGCGCCAUGGCCUCGUAGU 20 6174
HSV2-UL48-1577 + ACUGCGCCAUGGCCUCGUAGU 21 15536
HSV2-UL48-1578 + AACUGCGCCAUGGCCUCGUAGU 22 15537
HSV2-UL48-1579 + AAACUGCGCCAUGGCCUCGUAGU 23 15538
HSV2-UL48-1580 + AAAACUGCGCCAUGGCCUCGUAGU 24 15539
HSV2-UL48-1581 + GCGGGUGGCGGGCAGGGU 18 15540
HSV2-UL48-1582 + CGCGGGUGGCGGGCAGGG U 19 15541
HSV2-UL48-52 + UCGCGGGUGGCGGGCAGGGU 20 5618
HSV2-UL48-1583 + GUCGCGGGUGGCGGGCAGGGU 21 15542
HSV2-UL48-1584 + CG UCGCGGGUGGCGGGCAGGGU 22 15543
HSV2-UL48-1585 + UCGUCGCGGGUGGCGGGCAGGGU 23 15544
HSV2-UL48-1586 + CUCGUCGCGGGUGGCGGGCAGGGU 24 15545
HSV2-UL48-1587 + CCAUGGGGGCGGUUGGGU 18 15546
HSV2-UL48-1588 + UCCAUGGGGGCGGUUGGGU 19 15547
HSV2-UL48-1589 + GUCCAUGGGGGCGGUUGGGU 20 15548
HSV2-UL48-1590 + GG UCCAUGGGGGCGGU UGGGU 21 15549
HSV2-UL48-1591 + AGG UCCAUGGGGGCGGU UGGGU 22 15550
HSV2-UL48-1592 + CAGG UCCAUGGGGGCGGUUGGGU 23 15551
HSV2-UL48-1593 + ACAGGUCCAUGGGGGCGGUUGGGU 24
15552
HSV2-UL48-1594 + GUACAUGUCGGCGUUGGU 18 15553
HSV2-UL48-1595 + GGUACAUGUCGGCGUUGGU 19 15554
HSV2-UL48-67 + CGGUACAUGUCGGCGU UGGU 20 5556 HSV2-UL48-1596 + CCGGUACAUGUCGGCGUUGGU 21 15555
HSV2-UL48-1597 + CCCGGUACAUGUCGGCG UUGGU 22 15556
HSV2-UL48-1598 + UCCCGGUACAUGUCGGCGUUGGU 23 15557
HSV2-UL48-1599 + CUCCCGGUACAUGUCGGCGUUGGU 24 15558
HSV2-UL48-1600 - GCCCAGCGACGUGAUCGA 18 15559
HSV2-UL48-1601 - UGCCCAGCGACGUGAUCGA 19 15560
HSV2-UL48-635 - CUGCCCAGCGACGUGAUCGA 20 6111
HSV2-UL48-1602 - GCUGCCCAGCGACGUGAUCGA 21 15561
HSV2-UL48-1603 - CGCUGCCCAGCGACGUGAUCGA 22 15562
HSV2-UL48-1604 - ACGCUGCCCAGCGACGUGAUCGA 23 15563
HSV2-UL48-1605 - GACGCUGCCCAGCGACGUGAUCGA 24 15564
HSV2-UL48-1606 - CCAUGCUAGAUACCUGGA 18 15565
HSV2-UL48-1607 - ACCAUGCUAGAUACCUGGA 19 15566
HSV2-UL48-629 - UACCAUGCUAGAUACCUGGA 20 6107
HSV2-UL48-1608 - GU ACCAUGCUAGAUACCUGGA 21 15567
HSV2-UL48-1609 - UGUACCAUGCUAGAUACCUGGA 22 15568
HSV2-UL48-1610 - GUG UACCAUGCUAGAUACCUGGA 23 15569
HSV2-UL48-1611 - UGUGUACCAUGCUAGAUACCUGGA 24 15570
HSV2-UL48-1612 - GGCGCGGGAGGAGAGCUA 18 15571
HSV2-UL48-1613 - GGGCGCGGGAGGAGAGCUA 19 15572
HSV2-UL48-651 - CGGGCGCGGGAGGAGAGCUA 20 6120
HSV2-UL48-1614 - GCGGGCGCGGGAGGAGAGCUA 21 15573
HSV2-UL48-1615 - UGCGGGCGCGGGAGGAGAGCUA 22 15574
HSV2-UL48-1616 - CUGCGGGCGCGGGAGGAGAGCUA 23 15575
HSV2-UL48-1617 - GCUGCGGGCGCGGGAGGAGAGCUA 24 15576
HSV2-UL48-1618 - GACCAACGCCGACAUGUA 18 15577
HSV2-UL48-1619 - CG ACCAACGCCG ACAUG U A 19 15578
HSV2-UL48-632 - CCGACCAACGCCGACAUGUA 20 6110
HSV2-UL48-1620 - CCCG ACCAACGCCG ACAUG U A 21 15579
HSV2-UL48-1621 - UCCCGACCAACGCCGACAUGUA 22 15580
HSV2-UL48-1622 - UUCCCGACCAACGCCGACAUGUA 23 15581
HSV2-UL48-1623 - GUUCCCGACCAACGCCGACAUGUA 24 15582
HSV2-UL48-1624 - AUGCUAGAUACCUGGAAC 18 15583
HSV2-UL48-1625 - CAUGCUAGAUACCUGGAAC 19 15584
HSV2-UL48-630 - CCAUGCUAGAUACCUGGAAC 20 6108
HSV2-UL48-1626 - ACCAUGCUAGAUACCUGGAAC 21 15585
HSV2-UL48-1627 - UACCAUGCUAGAUACCUGGAAC 22 15586
HSV2-UL48-1628 - GUACCAUGCUAGAUACCUGGAAC 23 15587
HSV2-UL48-1629 - UGUACCAUGCUAGAUACCUGGAAC 24 15588
HSV2-UL48-1630 - CCCAGCGACGUGAUCGAC 18 15589
HSV2-UL48-1631 - GCCCAGCGACGUGAUCGAC 19 15590
HSV2-UL48-25 - UGCCCAGCGACGUGAUCGAC 20 5501
HSV2-UL48-1632 - CUGCCCAGCGACGUGAUCGAC 21 15591
HSV2-UL48-1633 - GCUGCCCAGCGACGUGAUCGAC 22 15592
HSV2-UL48-1634 - CGCUGCCCAGCGACGUGAUCGAC 23 15593
HSV2-UL48-1635 - ACGCUGCCCAGCGACG UGAUCGAC 24 15594 HSV2-UL48-1636 - GACGAUCUGUUUGCGGAC 18 15595
HSV2-UL48-1637 - CGACGAUCUGU UUGCGGAC 19 15596
HSV2-UL48-617 - UCGACGAUCUGUUUGCGGAC 20 6099
HSV2-UL48-1638 - GUCGACGAUCUGUUUGCGGAC 21 15597
HSV2-UL48-1639 - GGUCGACGAUCUGUUUGCGGAC 22 15598
HSV2-UL48-1640 - UGGUCGACGAUCUGUU UGCGGAC 23 15599
HSV2-UL48-1641 - UUGGUCGACGAUCUGU UUGCGGAC 24 15600
HSV2-UL48-1642 - GUGUACCAUGCUAGAUAC 18 15601
HSV2-UL48-1643 - UGUGUACCAUGCUAGAUAC 19 15602
HSV2-UL48-627 - CUGUGUACCAUGCUAGAUAC 20 6106
HSV2-UL48-1644 - GCUGUGUACCAUGCUAGAUAC 21 15603
HSV2-UL48-1645 - CGCUGUGUACCAUGCUAGAUAC 22 15604
HSV2-UL48-1646 - GCGCUGUGUACCAUGCUAGAUAC 23 15605
HSV2-UL48-1647 - CGCGCUGUGUACCAUGCUAGAUAC 24 15606
HSV2-UL48-1648 - ACCAACGCCGACAUGUAC 18 15607
HSV2-UL48-1649 - GACCAACGCCGACAUGUAC 19 15608
HSV2-UL48-23 - CG ACCAACGCCGACAUGUAC 20 5607
HSV2-UL48-1650 - CCG ACCAACGCCGACAUGUAC 21 15609
HSV2-UL48-1651 - CCCGACCAACGCCGACAUGUAC 22 15610
HSV2-UL48-1652 - UCCCGACCAACGCCGACAUGUAC 23 15611
HSV2-UL48-1653 - UUCCCG ACCAACGCCGACAUG UAC 24 15612
HSV2-UL48-1654 - UGUACCAUGCUAGAUACC 18 15613
HSV2-UL48-1655 - GUGUACCAUGCUAGAUACC 19 15614
HSV2-UL48-19 - UGUGUACCAUGCUAGAUACC 20 5604
HSV2-UL48-1656 - CUGUGUACCAUGCUAGAUACC 21 15615
HSV2-UL48-1657 - GCUGUGUACCAUGCUAGAUACC 22 15616
HSV2-UL48-1658 - CGCUGUGUACCAUGCUAGAUACC 23 15617
HSV2-UL48-1659 - GCGCUGUGUACCAUGCUAGAUACC 24 15618
HSV2-UL48-1660 - CCGGACCCAACCGCCCCC 18 15619
HSV2-UL48-1661 - CCCGGACCCAACCGCCCCC 19 15620
HSV2-UL48-1662 - U CCCG G ACCC AACCG CCCCC 20 15621
HSV2-UL48-1663 - U U CCCG G ACCCAACCG CCCCC 21 15622
HSV2-UL48-1664 - AUUCCCGGACCCAACCGCCCCC 22 15623
HSV2-UL48-1665 - UAUUCCCGGACCCAACCGCCCCC 23 15624
HSV2-UL48-1666 - UU AU UCCCGGACCCAACCGCCCCC 24 15625
HSV2-UL48-1667 - AGGCCAGCCGGGGGUCCC 18 15626
HSV2-UL48-1668 - CAGGCCAGCCGGGGGUCCC 19 15627
HSV2-UL48-623 - CCAGGCCAGCCGGGGGUCCC 20 6102
HSV2-UL48-1669 - CCCAGGCCAGCCGGGGGUCCC 21 15628
HSV2-UL48-1670 - CCCCAGGCCAGCCGGGGGUCCC 22 15629
HSV2-UL48-1671 - CCCCCAGGCCAGCCGGGGGUCCC 23 15630
HSV2-UL48-1672 - CCCCCCAGGCCAGCCGGGGGUCCC 24 15631
HSV2-UL48-1673 - GGGGGGAUGCGCACGUCC 18 15632
HSV2-UL48-1674 - UGGGGGGAUGCGCACGUCC 19 15633
HSV2-UL48-640 - CUGGGGGGAUGCGCACGUCC 20 6112
HSV2-UL48-1675 - ACUGGGGGGAUGCGCACGUCC 21 15634 HSV2-UL48-1676 - GACUGGGGGGAUGCGCACGUCC 22 15635
HSV2-UL48-1677 - CGACUGGGGGGAUGCGCACGUCC 23 15636
HSV2-UL48-1678 - UCGACUGGGGGGAUGCGCACGUCC 24 15637
HSV2-UL48-1679 - ACCGCCCCCCAGGCCAGC 18 15638
HSV2-UL48-1680 - CACCG CCCCCCAG GCCAG C 19 15639
HSV2-UL48-7 - CCACCGCCCCCCAGGCCAGC 20 5597
HSV2-UL48-1681 - GCCACCGCCCCCCAGGCCAGC 21 15640
HSV2-UL48-1682 - CG CCACCG CCCCCCAG GCCAG C 22 15641
HSV2-UL48-1683 - U CGCCACCG CCCCCCAG G CCAG C 23 15642
HSV2-UL48-1684 - U U CG CCACCG CCCCCCAG G CCAG C 24 15643
HSV2-UL48-1685 - GCGGUGAGCUGCGGGCGC 18 15644
HSV2-UL48-1686 - CGCGGUGAGCUGCGGGCGC 19 15645
HSV2-UL48-38 - CCGCGGUGAGCUGCGGGCGC 20 5612
HSV2-UL48-1687 - UCCGCGG UGAGCUGCGGGCGC 21 15646
HSV2-UL48-1688 - UUCCGCGGUGAGCUGCGGGCGC 22 15647
HSV2-UL48-1689 - UU UCCGCGGUGAGCUGCGGGCGC 23 15648
HSV2-UL48-1690 - UUU UCCGCGGUGAGCUGCGGGCGC 24 15649
HSV2-UL48-1691 - CCGCGGUGAGCUGCGGGC 18 15650
HSV2-UL48-1692 - UCCGCGG UGAGCUGCGGGC 19 15651
HSV2-UL48-645 - UUCCGCGGUGAGCUGCGGGC 20 6117
HSV2-UL48-1693 - UUUCCGCGGUGAGCUGCGGGC 21 15652
HSV2-UL48-1694 - U UUUCCGCGGUGAGCUGCGGGC 22 15653
HSV2-UL48-1695 - UUU UUCCGCGGUGAGCUGCGGGC 23 15654
HSV2-UL48-1696 - GUUUU UCCGCGGUGAGCUGCGGGC 24 15655
HSV2-UL48-1697 - CACCG CCCCCC AGG CCAG 18 15656
HSV2-UL48-1698 - CCACCG CCCCCCAG G CCAG 19 15657
HSV2-UL48-620 - G CCACCG CCCCCCAG G CCAG 20 6101
HSV2-UL48-1699 - CGCCACCGCCCCCCAGGCCAG 21 15658
HSV2-UL48-1700 - UCGCCACCGCCCCCCAGGCCAG 22 15659
HSV2-UL48-1701 - U U CG CCACCGCCCCCCAG G CCAG 23 15660
HSV2-UL48-1702 - U U U CG CCACCGCCCCCCAG G CCAG 24 15661
HSV2-UL48-1703 - GAGCUGCGGGCGCGGGAG 18 15662
HSV2-UL48-1704 - UGAGCUGCGGGCGCGGGAG 19 15663
HSV2-UL48-650 - GUGAGCUGCGGGCGCGGGAG 20 6119
HSV2-UL48-1705 - GG UGAGCUGCGGGCGCGGGAG 21 15664
HSV2-UL48-1706 - CGG UGAGCUGCGGGCGCGGGAG 22 15665
HSV2-UL48-1707 - GCGG UGAGCUGCGGGCGCGGGAG 23 15666
HSV2-UL48-1708 - CGCGGUGAGCUGCGGGCGCGGGAG 24 15667
HSV2-UL48-1709 - CCCUGCCCGCCACCCGCG 18 15668
HSV2-UL48-1710 - ACCCUGCCCGCCACCCGCG 19 15669
HSV2-UL48-641 - CACCCUG CCCG CCACCCG CG 20 6113
HSV2-UL48-1711 - CCACCCUGCCCGCCACCCGCG 21 15670
HSV2-UL48-1712 - CCCACCCUGCCCGCCACCCGCG 22 15671
HSV2-UL48-1713 - CCCCACCCUGCCCGCCACCCGCG 23 15672
HSV2-UL48-1714 - UCCCCACCCUGCCCGCCACCCGCG 24 15673
HSV2-UL48-1715 - UGGCGCAGUU UUUCCGCG 18 15674 HSV2-UL48-1716 - AUGGCGCAGUUU UUCCGCG 19 15675
HSV2-UL48-643 - CAUGGCGCAGUU UUUCCGCG 20 6115
HSV2-UL48-1717 - CCAUGGCGCAGUU UUUCCGCG 21 15676
HSV2-UL48-1718 - GCCAUGGCGCAGUU UU UCCGCG 22 15677
HSV2-UL48-1719 - GGCCAUGGCGCAGUUU UUCCGCG 23 15678
HSV2-UL48-1720 - AGGCCAUGGCGCAGUUU UUCCGCG 24 15679
HSV2-UL48-1721 - CGCGGUGAGCUGCGGGCG 18 15680
HSV2-UL48-1722 - CCGCGGUGAGCUGCGGGCG 19 15681
HSV2-UL48-37 - UCCGCGG UGAGCUGCGGGCG 20 5611
HSV2-UL48-1723 - UUCCGCGGUGAGCUGCGGGCG 21 15682
HSV2-UL48-1724 - U UUCCGCGGUGAGCUGCGGGCG 22 15683
HSV2-UL48-1725 - UUU UCCGCGGUGAGCUGCGGGCG 23 15684
HSV2-UL48-1726 - UUU UUCCGCGGUGAGCUGCGGGCG 24 15685
HSV2-UL48-1727 - AUCUGUUUGCGGACGCGG 18 15686
HSV2-UL48-1728 - GAUCUGU UUGCGGACGCGG 19 15687
HSV2-UL48-618 - CGAUCUGUU UGCGGACGCGG 20 6100
HSV2-UL48-1729 - ACGAUCUGUUUGCGGACGCGG 21 15688
HSV2-UL48-1730 - GACGAUCUGUUUGCGGACGCGG 22 15689
HSV2-UL48-1731 - CGACGAUCUGU UUGCGGACGCGG 23 15690
HSV2-UL48-1732 - UCGACGAUCUG UUUGCGGACGCGG 24 15691
HSV2-UL48-1733 - GGUGAGCUGCGGGCGCGG 18 15692
HSV2-UL48-1734 - CGGUGAGCUGCGGGCGCGG 19 15693
HSV2-UL48-648 - GCGGUGAGCUGCGGGCGCGG 20 6118
HSV2-UL48-1735 - CGCGGUGAGCUGCGGGCGCGG 21 15694
HSV2-UL48-1736 - CCGCGGUGAGCUGCGGGCGCGG 22 15695
HSV2-UL48-1737 - UCCGCGGUGAGCUGCGGGCGCGG 23 15696
HSV2-UL48-1738 - UUCCGCGGUGAGCUGCGGGCGCGG 24 15697
HSV2-UL48-1739 - GUGAGCUGCGGGCGCGGG 18 15698
HSV2-UL48-1740 - GGUGAGCUGCGGGCGCGGG 19 15699
HSV2-UL48-39 - CGGUGAGCUGCGGGCGCGGG 20 5613
HSV2-UL48-1741 - GCGGUGAGCUGCGGGCGCGGG 21 15700
HSV2-UL48-1742 - CGCGGUGAGCUGCGGGCGCGGG 22 15701
HSV2-UL48-1743 - CCGCGGUGAGCUGCGGGCGCGGG 23 15702
HSV2-UL48-1744 - UCCGCGG UGAGCUGCGGGCGCGGG 24 15703
HSV2-UL48-1745 - CAGCGACGUGAUCGACUG 18 15704
HSV2-UL48-1746 - CCAGCGACGUGAUCGACUG 19 15705
HSV2-UL48-27 - CCCAGCGACGUGAUCGACUG 20 5609
HSV2-UL48-1747 - GCCCAGCGACGUGAUCGACUG 21 15706
HSV2-UL48-1748 - UGCCCAGCGACGUGAUCGACUG 22 15707
HSV2-UL48-1749 - CUGCCCAGCGACGUGAUCGACUG 23 15708
HSV2-UL48-1750 - GCUGCCCAGCGACGUGAUCGACUG 24 15709
HSV2-UL48-1751 - AACCGUCUCCUCGACGAU 18 15710
HSV2-UL48-1752 - UAACCGUCUCCUCGACGAU 19 15711
HSV2-UL48-625 - UUAACCGUCUCCUCGACGAU 20 6104
HSV2-UL48-1753 - UUUAACCGUCUCCUCGACGAU 21 15712
HSV2-UL48-1754 - GUU UAACCGUCUCCUCGACGAU 22 15713 HSV2-UL48-1755 - UGU UUAACCGUCUCCUCGACGAU 23 15714
HSV2-UL48-1756 - CUGUUUAACCGUCUCCUCGACGAU 24 15715
HSV2-UL48-1757 - CCAGCGACGUGAUCGACU 18 15716
HSV2-UL48-1758 - CCCAGCGACGUGAUCGACU 19 15717
HSV2-UL48-26 - GCCCAGCGACGUGAUCGACU 20 5608
HSV2-UL48-1759 - UGCCCAGCGACGUGAUCGACU 21 15718
HSV2-UL48-1760 - CUGCCCAGCGACGUGAUCGACU 22 15719
HSV2-UL48-1761 - GCUGCCCAGCGACGUGAUCGACU 23 15720
HSV2-UL48-1762 - CGCUGCCCAGCGACGUGAUCGACU 24 15721
HSV2-UL48-1763 - ACGAGCUGCCUUCGUACU 18 15722
HSV2-UL48-1764 - GACGAGCUGCCUUCGUACU 19 15723
HSV2-UL48-642 - CGACGAGCUGCCU UCGUACU 20 6114
HSV2-UL48-1765 - GCGACGAGCUGCCUUCGUACU 21 15724
HSV2-UL48-1766 - CGCGACGAGCUGCCUUCGUACU 22 15725
HSV2-UL48-1767 - CCGCGACGAGCUGCCU UCGUACU 23 15726
HSV2-UL48-1768 - CCCGCGACGAGCUGCCU UCGUACU 24 15727
HSV2-UL48-1769 - GUUUUUCCGCGGUGAGCU 18 15728
HSV2-UL48-1770 - AGU UU UUCCGCGGUGAGCU 19 15729
HSV2-UL48-644 - CAGU UUUUCCGCGGUGAGCU 20 6116
HSV2-UL48-1771 - GCAGUUU UUCCGCGGUGAGCU 21 15730
HSV2-UL48-1772 - CGCAGU UUU UCCGCGGUGAGCU 22 15731
HSV2-UL48-1773 - GCGCAGUUUU UCCGCGGUGAGCU 23 15732
HSV2-UL48-1774 - GGCGCAGUUU UUCCGCGGUGAGCU 24 15733
HSV2-UL48-1775 - UUGGUCGACGAUCUGUUU 18 15734
HSV2-UL48-1776 - GUUGGUCGACGAUCUGUUU 19 15735
HSV2-UL48-616 - UGUUGGUCGACGAUCUGUUU 20 6098
HSV2-UL48-1777 - CUGUUGGUCGACGAUCUGU UU 21 15736
HSV2-UL48-1778 - CCUGUUGGUCGACGAUCUGUUU 22 15737
HSV2-UL48-1779 - ACCUGU UGGUCGACGAUCUGUU U 23 15738
HSV2-UL48-1780 - GACCUGUUGGUCGACGAUCUGU UU 24 15739
Table 12E provides exemplary targeting domains for knocking out the UL48 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene), and start with a 5'G. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 12E
Figure imgf000611_0001
Strand Site
Length
HSV2-UL48-1781 + GCUCGGCGUACGCGGCCCA 19 15740
HSV2-UL48-322 + GUCCAAAGCCCCAUACGAGA 20 5804
HSV2-U L48-1782 + GGGGUCGUGAGGGGCGCC 18 15741
HSV2-UL48-1001 + GCGGGGUCGUGAGGGGCGCC 20 6338
HSV2-UL48-1783 + GGCGGGGUCGUGAGGGGCGCC 21 15742
HSV2-U L48-1784 + GGGCGGGGUCGUGAGGGGCGCC 22 15743
HSV2-UL48-366 + GCCCUCCGAGGUCGCGACGC 20 5848
HSV2-U L48-1785 + GUACGAG UCCAACUUGGC 18 15744
HSV2-U L48-1013 + GAGUACGAGUCCAACUUGGC 20 6347
HSV2-U L48-1786 + GGAGUACGAGUCCAACUUGGC 21 15745
HSV2-U L48-1787 + GCUGGAGUACGAGUCCAACU UGGC 24 15746
HSV2-UL48-1788 + GCGGGAGGUUCAGGUGCUC 19 15747
HSV2-UL48-1049 + GCCCCAUACGAGACGGGGUC 20 6367
HSV2-U L48-1789 + GUUGCCCUGCAGGACGGG 18 15748
HSV2-UL48-1790 + GGUUGCCCUGCAGGACGGG 19 15749
HSV2-U L48-1791 + GCCUGGUUGCCCUGCAGGACGGG 23 15750
HSV2-U L48-1792 + GGCCUGGU UGCCCUGCAGGACGGG 24 15751
HSV2-UL48-1793 + GAGGUCGCGACGCUGGAGU 19 15752
HSV2-U L48-1794 - GUUUCAGCCCCUGAUGU UUAUCA 23 15753
HSV2-UL48-307 - GACG UGGAGUCCCCCUCCCC 20 5789
HSV2-UL48-1795 - GGACGUGGAGUCCCCCUCCCC 21 15754
HSV2-U L48-1796 - GGGACGUGGAGUCCCCCUCCCC 22 15755
HSV2-UL48-1797 - GGGGACGUGGAGUCCCCCUCCCC 23 15756
HSV2-UL48-1798 - GGGGGACGUGGAGUCCCCCUCCCC 24 15757
HSV2-U L48-1799 - GAACUCCGCCUGGACGGCGAGGAG 24 15758
HSV2-UL48-1800 - GACU UGGAGAUGCUGGGGGACG 22 15759
HSV2-U L48-1801 - GCGUCGCGACCUCGGAGG 18 15760
HSV2-U L48-1802 - GCAU UGACGACU UUGGGGGG 20 15761
HSV2-UL48-1803 - GGCAUUGACGACU UUGGGGGG 21 15762
HSV2-U L48-1804 - GGGCAUUGACGACUUUGGGGGG 22 15763
HSV2-U L48-1805 - GCCAUGGGCAU UGACGACUUUG 22 15764
HSV2-UL48-1806 - GCAACCAGGCCCGCUCCU 18 15765
HSV2-U L48-1807 - GGCAACCAGGCCCGCUCCU 19 15766
HSV2-UL48-836 - GGGCAACCAGGCCCGCUCCU 20 6229
HSV2-UL48-1808 - GCAGGGCAACCAGGCCCGCUCCU 23 15767
HSV2-U L48-1809 - GGCGG ACCAG AAACAAU U 18 15768
HSV2-UL48-1810 - GGGCGG ACCAG AAACAAU U 19 15769
HSV2-U L48-1811 - GCGGGCGG ACCAG AAACAAU U 21 15770
HSV2-U L48-1812 - GCCGCGGGCGG ACCAG AAACAAU U 24 15771
HSV2-UL48-1813 - GCU UUGGACGUGGACGAU U 19 15772
HSV2-UL48-883 - GGCUUUGGACGUGGACGAUU 20 6260
HSV2-U L48-1814 - GGGCUU UGGACGUGGACGAUU 21 15773
HSV2-UL48-1815 - GGGGCUUUGGACGUGGACGAUU 22 15774 Table 12F provides exemplary targeting domains for knocking out the UL48 gene selected according to the six tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 12F
Figure imgf000613_0001
HSV2-UL48-1843 + CACCAGCGGGAGGUUCAGGUGCUC 24 15802
HSV2-UL48-1844 + CCCAUACGAGACGGGGUC 18 15803
HSV2-UL48-1845 + CCCCAUACGAGACGGGGUC 19 15804
HSV2-UL48-1846 + AGCCCCAUACGAGACGGGGUC 21 15805
HSV2-U L48-1847 + AAGCCCCAUACGAGACGGGGUC 22 15806
HSV2-U L48-1848 + AAAGCCCCAUACGAGACGGGGUC 23 15807
HSV2-UL48-1849 + CAAAGCCCCAUACGAGACGGGGUC 24 15808
HSV2-U L48-1850 + ACCUCCUCGCCGUCCAGG 18 15809
HSV2-U L48-1851 + CACCUCCUCGCCGUCCAGG 19 15810
HSV2-UL48-340 + CCACCUCCUCGCCGUCCAGG 20 5822
HSV2-U L48-1852 + UCCACCUCCUCGCCGUCCAGG 21 15811
HSV2-UL48-1853 + AUCCACCUCCUCGCCGUCCAGG 22 15812
HSV2-UL48-1854 + UAUCCACCUCCUCGCCGUCCAGG 23 15813
HSV2-U L48-1855 + AUAUCCACCUCCUCGCCGUCCAGG 24 15814
HSV2-UL48-376 + UGGUUGCCCUGCAGGACGGG 20 5858
HSV2-U L48-1856 + CUGGUUGCCCUGCAGGACGGG 21 15815
HSV2-U L48-1857 + CCUGGUUGCCCUGCAGGACGGG 22 15816
HSV2-UL48-1858 + AGGUCGCGACGCUGGAGU 18 15817
HSV2-U L48-1014 + CGAGGUCGCGACGCUGGAGU 20 6348
HSV2-UL48-1859 + CCG AGGUCGCGACGCUGGAGU 21 15818
HSV2-UL48-1860 + UCCG AGGUCGCGACGCUGGAGU 22 15819
HSV2-U L48-1861 + CUCCG AGGUCGCGACGCUGGAGU 23 15820
HSV2-UL48-1862 + CCUCCGAGGUCGCGACGCUGGAGU 24 15821
HSV2-UL48-1863 - AGCCCCUGAUGU UUAUCA 18 15822
HSV2-U L48-1864 - CAGCCCCUGAUGUUUAUCA 19 15823
HSV2-UL48-816 - UCAGCCCCUGAUGU U UAUCA 20 6218
HSV2-U L48-1865 - U UCAGCCCCUGAUGUU UAUCA 21 15824
HSV2-U L48-1866 - U UUCAGCCCCUGAUGU UUAUCA 22 15825
HSV2-UL48-1867 - UGUUUCAGCCCCUGAUG UUUAUCA 24 15826
HSV2-U L48-1868 - CGUGGAGUCCCCCUCCCC 18 15827
HSV2-U L48-1869 - ACGUGGAGUCCCCCUCCCC 19 15828
HSV2-UL48-1870 - CGCCUGGACGGCGAGGAG 18 15829
HSV2-U L48-1871 - CCGCCUGGACGGCGAGGAG 19 15830
HSV2-UL48-866 - UCCGCCUGGACGGCGAGGAG 20 6251
HSV2-UL48-1872 - CUCCGCCUGGACGGCGAGGAG 21 15831
HSV2-U L48-1873 - ACUCCGCCUGGACGGCGAGGAG 22 15832
HSV2-UL48-1874 - AACUCCGCCUGGACGGCGAGGAG 23 15833
HSV2-U L48-1875 - UGGAGAUGCUGGGGGACG 18 15834
HSV2-U L48-1876 - UUGGAGAUGCUGGGGGACG 19 15835
HSV2-UL48-305 - CU UGGAGAUGCUGGGGGACG 20 5787
HSV2-UL48-1877 - ACU UGGAGAUGCUGGGGGACG 21 15836
HSV2-UL48-1878 - CGACU UGGAGAUGCUGGGGGACG 23 15837
HSV2-UL48-1879 - UCGACUUGGAGAUGCUGGGGGACG 24
15838
HSV2-U L48-1880 - CGGAUCGCUCACCGUGCG 18 15839
HSV2-UL48-1881 - ACGGAUCGCUCACCGUGCG 19 15840 HSV2-UL48-250 - AACGGAUCGCUCACCGUGCG 20 5732
HSV2-UL48-1882 - CAACGGAUCGCUCACCGUGCG 21 15841
HSV2-UL48-1883 - U CAACGGAU CG C U CACCG UGCG 22 15842
HSV2-UL48-1884 - AUCAACGGAUCGCUCACCGUGCG 23 15843
HSV2-U L48-1885 - UAUCAACGGAUCGCUCACCGUGCG 24 15844
HSV2-U L48-1886 - AGCGUCGCGACCUCGGAGG 19 15845
HSV2-UL48-842 - CAGCGUCGCGACCUCGGAGG 20 6234
HSV2-U L48-1887 - CCAGCGUCGCGACCUCGGAGG 21 15846
HSV2-U L48-1888 - UCCAGCGUCGCGACCUCGGAGG 22 15847
HSV2-UL48-1889 - CUCCAGCGUCGCGACCUCGGAGG 23 15848
HSV2-U L48-1890 - ACUCCAGCGUCGCGACCUCGGAGG 24 15849
HSV2-UL48-1891 - AUUGACGACUUUGGGGGG 18 15850
HSV2-UL48-1892 - CAU UGACGACUU UGGGGGG 19 15851
HSV2-U L48-1893 - UGGGCAUUGACGACUU UGGGGGG 23 15852
HSV2-UL48-1894 - AUGGGCAUUGACGACU UUGGGGGG 24
15853
HSV2-U L48-1895 - UGGGCAUUGACGACUU UG 18 15854
HSV2-U L48-1896 - AUGGGCAUUGACGACUU UG 19 15855
HSV2-UL48-317 - CAUGGGCAU UGACGACUUUG 20 5799
HSV2-U L48-1897 - CCAUGGGCAUUGACGACUU UG 21 15856
HSV2-U L48-1898 - UGCCAUGGGCAUUGACGACU UUG 23 15857
HSV2-UL48-1899 - AUGCCAUGGGCAUUGACGACU UUG 24 15858
HSV2-U L48-1900 - AGGGCAACCAGGCCCGCUCCU 21 15859
HSV2-UL48-1901 - CAGGGCAACCAGGCCCGCUCCU 22 15860
HSV2-UL48-1902 - UGCAGGGCAACCAGGCCCGCUCCU 24 15861
HSV2-UL48-849 - CGGGCGGACCAGAAACAAUU 20 6239
HSV2-UL48-1903 - CGCGGGCGGACCAGAAACAAUU 22 15862
HSV2-U L48-1904 - CCGCGGGCGGACCAGAAACAAUU 23 15863
HSV2-U L48-1905 - CUUUGGACGUGGACGAU U 18 15864
HSV2-UL48-1906 - UGGGGCUUUGGACGUGGACGAU U 23 15865
HSV2-UL48-1907 - AUGGGGCUUUGGACGUGGACGAU U 24
15866
Table 12G provides exemplary targeting domains for knocking out the UL48 gene selected according to the seven tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). The PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase). Table 12G
Figure imgf000616_0001
HSV2-UL48-1942 + CGCAGCAGAGGCCGUCGAACAGA 23 15901
HSV2-UL48-1943 + UCGCAGCAGAGGCCGUCGAACAGA 24 15902
HSV2-UL48-1944 + AGGAUCUCGCGGCUCAGA 18 15903
HSV2-UL48-1945 + UAGGAUCUCGCGGCUCAGA 19 15904
HSV2-UL48-983 + AU AGGAUCUCGCGGCUCAGA 20 6325
HSV2-UL48-1946 + CAU AGGAUCUCGCGGCUCAGA 21 15905
HSV2-UL48-1947 + CCAUAGGAUCUCGCGGCUCAGA 22 15906
HSV2-UL48-1948 + CCCAUAGGAUCUCGCGGCUCAGA 23 15907
HSV2-UL48-1949 + GCCCAUAGGAUCUCGCGGCUCAGA 24 15908
HSV2-UL48-1950 + CAUAAAGUACCCAGAGGA 18 15909
HSV2-UL48-1951 + GCAUAAAGUACCCAGAGGA 19 15910
HSV2-UL48-1009 + AGCAUAAAGUACCCAGAGGA 20 6344
HSV2-UL48-1952 + C AG C A U A A AG U ACCC AG AG G A 21 15911
HSV2-UL48-1953 + GCAGCAUAAAGUACCCAGAGGA 22 15912
HSV2-UL48-1954 + AGCAGCAUAAAGUACCCAGAGGA 23 15913
HSV2-UL48-1955 + CAG C AG C A U A A AG U ACCC AG AG G A 24 15914
HSV2-UL48-1956 + GGGGCGUUGUCCCGCGGA 18 15915
HSV2-UL48-1957 + GGGGGCGUUGUCCCGCGGA 19 15916
HSV2-UL48-1025 + CGGGGGCGUUGUCCCGCGGA 20 6355
HSV2-UL48-1958 + GCGGGGGCGU UGUCCCGCGGA 21 15917
HSV2-UL48-1959 + UGCGGGGGCG UUGUCCCGCGGA 22 15918
HSV2-UL48-1960 + CUGCGGGGGCGUUGUCCCGCGGA 23 15919
HSV2-UL48-1961 + UCUGCGGGGGCGU UGUCCCGCGGA 24 15920
HSV2-UL48-1962 + GUGGGUCAUUCCCGGGGA 18 15921
HSV2-UL48-1963 + CGUGGGUCAUUCCCGGGGA 19 15922
HSV2-UL48-331 + UCGUGGGUCAUUCCCGGGGA 20 5813
HSV2-UL48-1964 + GUCGUGGGUCAUUCCCGGGGA 21 15923
HSV2-UL48-1965 + GG UCGUGGGUCAU UCCCGGGGA 22 15924
HSV2-UL48-1966 + GGGUCGUGGGUCAUUCCCGGGGA 23 15925
HSV2-UL48-1967 + GGGGUCGUGGGUCAUUCCCGGGGA 24
15926
HSV2-UL48-1968 + GGCGCGCAGGUACCGGUA 18 15927
HSV2-UL48-1969 + UGGCGCGCAGGUACCGGUA 19 15928
HSV2-UL48-979 + CUGGCGCGCAGGUACCGGUA 20 6321
HSV2-UL48-1970 + GCUGGCGCGCAGGUACCGGUA 21 15929
HSV2-UL48-1971 + CGCUGGCGCGCAGGUACCGGUA 22 15930
HSV2-UL48-1972 + ACGCUGGCGCGCAGGUACCGGUA 23 15931
HSV2-UL48-1973 + AACGCUGGCGCGCAGGUACCGGUA 24 15932
HSV2-UL48-1974 + CCCAGGCUGACGUCGGUA 18 15933
HSV2-UL48-1975 + UCCCAGGCUGACGUCGGUA 19 15934
HSV2-UL48-1035 + CUCCCAGGCUGACGUCGGUA 20 6360
HSV2-UL48-1976 + UCUCCCAGGCUGACGUCGGUA 21 15935
HSV2-UL48-1977 + GUCUCCCAGGCUGACGUCGGUA 22 15936
HSV2-UL48-1978 + CGUCUCCCAGGCUGACGUCGGUA 23 15937
HSV2-UL48-1979 + UCGUCUCCCAGGCUGACGUCGGUA 24 15938
HSV2-UL48-1980 + CAGUCGCCGGGCCUCCAC 18 15939 HSV2-UL48-1981 + GCAG UCGCCGGGCCUCCAC 19 15940
HSV2-UL48-392 + CGCAGUCGCCGGGCCUCCAC 20 5874
HSV2-UL48-1982 + CCGCAGUCGCCGGGCCUCCAC 21 15941
HSV2-UL48-1983 + CCCGCAGUCGCCGGGCCUCCAC 22 15942
HSV2-UL48-1984 + UCCCGCAGUCGCCGGGCCUCCAC 23 15943
HSV2-UL48-1985 + CUCCCGCAGUCGCCGGGCCUCCAC 24 15944
HSV2-UL48-1986 + UCAGCAGCAUAAAGUACC 18 15945
HSV2-UL48-1987 + AUCAGCAGCAUAAAGUACC 19 15946
HSV2-UL48-1012 + G A U C AG C AG C A U A A AG U ACC 20 6346
HSV2-UL48-1988 + GGAUCAGCAGCAUAAAG UACC 21 15947
HSV2-UL48-1989 + CGG AUCAGCAGCAUAAAGUACC 22 15948
HSV2-UL48-1990 + CCG G A U C AG C AG C A U A A AG U ACC 23 15949
HSV2-UL48-1991 + CCCGGAUCAGCAGCAUAAAGUACC 24 15950
HSV2-UL48-1992 + CUGCGGGGGCGUUGUCCC 18 15951
HSV2-UL48-1993 + UCUGCGGGGGCGU UGUCCC 19 15952
HSV2-UL48-1028 + GUCUGCGGGGGCGU UGUCCC 20 6357
HSV2-UL48-1994 + AGUCUGCGGGGGCGUUGUCCC 21 15953
HSV2-UL48-1995 + CAGUCUGCGGGGGCGU UGUCCC 22 15954
HSV2-UL48-1996 + ACAGUCUGCGGGGGCGU UGUCCC 23 15955
HSV2-UL48-1997 + GACAGUCUGCGGGGGCGUUGUCCC 24 15956
HSV2-UL48-1998 + GGGUCGUGGGUCAUUCCC 18 15957
HSV2-UL48-1999 + GGGGUCGUGGGUCAUUCCC 19 15958
HSV2-UL48-328 + CGGGGUCGUGGGUCAUUCCC 20 5810
HSV2-UL48-2000 + ACGGGGUCGUGGGUCAUUCCC 21 15959
HSV2-UL48-2001 + GACGGGGUCGUGGGUCAUUCCC 22 15960
HSV2-UL48-2002 + AGACGGGGUCGUGGGUCAU UCCC 23 15961
HSV2-UL48-2003 + GAGACGGGGUCGUGGGUCAUUCCC 24 15962
HSV2-UL48-2004 + CGCAGUCGCCGGGCCUCC 18 15963
HSV2-UL48-2005 + CCGCAGUCGCCGGGCCUCC 19 15964
HSV2-UL48-995 + CCCGCAGUCGCCGGGCCUCC 20 6334
HSV2-UL48-2006 + UCCCGCAGUCGCCGGGCCUCC 21 15965
HSV2-UL48-2007 + CUCCCGCAGUCGCCGGGCCUCC 22 15966
HSV2-UL48-2008 + GCUCCCGCAGUCGCCGGGCCUCC 23 15967
HSV2-UL48-2009 + AGCUCCCGCAGUCGCCGGGCCUCC 24 15968
HSV2-UL48-2010 + GGAGCGUCAUCGUCGUCC 18 15969
HSV2-UL48-2011 + AGGAGCGUCAUCGUCGUCC 19 15970
HSV2-UL48-359 + CAGGAGCGUCAUCGUCGUCC 20 5841
HSV2-UL48-2012 + GCAGGAGCGUCAUCGUCGUCC 21 15971
HSV2-UL48-2013 + CGCAGGAGCGUCAUCGUCGUCC 22 15972
HSV2-UL48-2014 + CCGCAGGAGCGUCAUCG UCGUCC 23 15973
HSV2-UL48-2015 + UCCGCAGGAGCGUCAUCGUCGUCC 24 15974
HSV2-UL48-2016 + GGGGUCGUGGGUCAUUCC 18 15975
HSV2-UL48-2017 + CGGGGUCGUGGGUCAUUCC 19 15976
HSV2-UL48-327 + ACGGGGUCGUGGGUCAUUCC 20 5809
HSV2-UL48-2018 + GACGGGGUCGUGGGUCAUUCC 21 15977
HSV2-UL48-2019 + AGACGGGGUCGUGGGUCAU UCC 22 15978 HSV2-UL48-2020 + GAGACGGGGUCGUGGG UCAUUCC 23 15979
HSV2-UL48-2021 + CGAGACGGGGUCGUGGGUCAUUCC 24 15980
HSV2-UL48-2022 + GCCGCACUUCGCACCAGC 18 15981
HSV2-UL48-2023 + CGCCGCACUUCGCACCAGC 19 15982
HSV2-UL48-385 + CCGCCGCACU UCGCACCAGC 20 5867
HSV2-UL48-2024 + GCCGCCGCACUUCGCACCAGC 21 15983
HSV2-UL48-2025 + CGCCGCCGCACUUCGCACCAGC 22 15984
HSV2-UL48-2026 + CCGCCGCCGCACU UCGCACCAGC 23 15985
HSV2-UL48-2027 + UCCGCCGCCGCACUUCGCACCAGC 24 15986
HSV2-UL48-2028 + CACCAGCCCGGCCUCCGC 18 15987
HSV2-UL48-2029 + CCACCAGCCCGGCCUCCGC 19 15988
HSV2-UL48-357 + GCCACCAGCCCGGCCUCCGC 20 5839
HSV2-UL48-2030 + CGCCACCAGCCCGGCCUCCGC 21 15989
HSV2-UL48-2031 + GCGCCACCAGCCCGGCCUCCGC 22 15990
HSV2-UL48-2032 + GGCGCCACCAGCCCGGCCUCCGC 23 15991
HSV2-UL48-2033 + CGGCGCCACCAGCCCGGCCUCCGC 24 15992
HSV2-UL48-2034 + CGG UGGUGGACAGUCUGC 18 15993
HSV2-UL48-2035 + GCGGUGGUGGACAGUCUGC 19 15994
HSV2-UL48-351 + GGCGGUGGUGGACAGUCUGC 20 5833
HSV2-UL48-2036 + GGGCGGUGGUGGACAGUCUGC 21 15995
HSV2-UL48-2037 + GGGGCGGUGGUGGACAGUCUGC 22 15996
HSV2-UL48-2038 + GGGGGCGGUGGUGGACAGUCUGC 23 15997
HSV2-UL48-2039 + UGGGGGCGGUGG UGGACAGUCUGC 24
15998
HSV2-UL48-2040 + GAUCCGUUGAUAAACAUC 18 15999
HSV2-UL48-2041 + CGAUCCGU UGAUAAACAUC 19 16000
HSV2-UL48-394 + GCGAUCCGU UGAUAAACAUC 20 5876
HSV2-UL48-2042 + AGCGAUCCGUUGAUAAACAUC 21 16001
HSV2-UL48-2043 + GAGCGAUCCGU UGAUAAACAUC 22 16002
HSV2-UL48-2044 + UGAGCGAUCCGUUGAUAAACAUC 23 16003
HSV2-UL48-2045 + GUGAGCGAUCCGU UGAUAAACAUC 24 16004
HSV2-UL48-2046 + CUCCAAGUCGAAGUCGUC 18 16005
HSV2-UL48-2047 + UCUCCAAGUCGAAGUCGUC 19 16006
HSV2-UL48-1039 + AUCUCCAAGUCGAAGUCGUC 20 6363
HSV2-UL48-2048 + CAUCUCCAAGUCGAAGUCGUC 21 16007
HSV2-UL48-2049 + GCAUCUCCAAG UCGAAGUCGUC 22 16008
HSV2-UL48-2050 + AG C A U C U CCA AG UCGAAGUCGUC 23 16009
HSV2-UL48-2051 + CAGCAUCUCCAAGUCGAAGUCGUC 24 16010
HSV2-UL48-2052 + AGGAGCGUCAUCGUCGUC 18 16011
HSV2-UL48-2053 + CAGGAGCGUCAUCGUCGUC 19 16012
HSV2-UL48-358 + GCAGGAGCGUCAUCGUCGUC 20 5840
HSV2-UL48-2054 + CGCAGGAGCGUCAUCGUCGUC 21 16013
HSV2-UL48-2055 + CCGCAGGAGCG UCAUCGUCGUC 22 16014
HSV2-UL48-2056 + UCCGCAGGAGCGUCAUCGUCGUC 23 16015
HSV2-UL48-2057 + CUCCGCAGGAGCGUCAUCGUCGUC 24 16016
HSV2-UL48-2058 + UGCAGGACGGGCGGGGUC 18 16017 HSV2-UL48-2059 + CUGCAGGACGGGCGGGGUC 19 16018
HSV2-UL48-1004 + CCUGCAGGACGGGCGGGGUC 20 6340
HSV2-UL48-2060 + CCCUGCAGGACGGGCGGGGUC 21 16019
HSV2-UL48-2061 + GCCCUGCAGGACGGGCGGGGUC 22 16020
HSV2-UL48-2062 + UGCCCUGCAGGACGGGCGGGGUC 23 16021
HSV2-UL48-2063 + UUGCCCUGCAGGACGGGCGGGGUC 24 16022
HSV2-UL48-2064 + CGGGGUCGUGGGUCAU UC 18 16023
HSV2-UL48-2065 + ACGGGGUCGUGGGUCAUUC 19 16024
HSV2-UL48-1048 + GACGGGGUCGUGGGUCAUUC 20 6366
HSV2-UL48-2066 + AGACGGGGUCGUGGGUCAU UC 21 16025
HSV2-UL48-2067 + GAGACGGGGUCGUGGGUCAUUC 22 16026
HSV2-UL48-2068 + CGAGACGGGGUCGUGGGUCAUUC 23 16027
HSV2-UL48-2069 + ACGAGACGGGGUCGUGGGUCAUUC 24 16028
HSV2-UL48-2070 + UCCCCCAGCAUCUCCAAG 18 16029
HSV2-UL48-2071 + GUCCCCCAGCAUCUCCAAG 19 16030
HSV2-UL48-1040 + CG UCCCCCAGCAU CU CCAAG 20 6364
HSV2-UL48-2072 + ACG U CCCCCAGCAU CUCCAAG 21 16031
HSV2-UL48-2073 + CACGUCCCCCAGCAUCU CCAAG 22 16032
HSV2-UL48-2074 + CCACG U CCCCCAGCAU CU CCAAG 23 16033
HSV2-UL48-2075 + UCCACGUCCCCCAGCAUCUCCAAG 24 16034
HSV2-UL48-2076 + CGCCGCACUUCGCACCAG 18 16035
HSV2-UL48-2077 + CCGCCGCACUUCGCACCAG 19 16036
HSV2-UL48-384 + GCCGCCGCACUUCGCACCAG 20 5866
HSV2-UL48-2078 + CGCCGCCGCACUUCGCACCAG 21 16037
HSV2-UL48-2079 + CCGCCGCCGCACUUCGCACCAG 22 16038
HSV2-UL48-2080 + UCCGCCGCCGCACUUCGCACCAG 23 16039
HSV2-UL48-2081 + CUCCGCCGCCGCACU UCGCACCAG 24 16040
HSV2-UL48-2082 + GCAGCAUAAAGUACCCAG 18 16041
HSV2-UL48-2083 + AG C AG C A U A A AG U ACCC AG 19 16042
HSV2-UL48-369 + CAGCAGCAUAAAGUACCCAG 20 5851
HSV2-UL48-2084 + U C AG C AG C A U A A AG U ACCC AG 21 16043
HSV2-UL48-2085 + AUCAGCAGCAUAAAGUACCCAG 22 16044
HSV2-UL48-2086 + GAUCAGCAGCAUAAAGUACCCAG 23 16045
HSV2-UL48-2087 + GGAUCAGCAGCAUAAAG UACCCAG 24 16046
HSV2-UL48-2088 + CACCUCCUCGCCGUCCAG 18 16047
HSV2-UL48-2089 + CCACCUCCUCGCCGUCCAG 19 16048
HSV2-UL48-1037 + UCCACCUCCUCGCCGUCCAG 20 6361
HSV2-UL48-2090 + AUCCACCUCCUCGCCGUCCAG 21 16049
HSV2-UL48-2091 + UAUCCACCUCCUCGCCGUCCAG 22 16050
HSV2-UL48-2092 + AU AU CCACCU CCU CGCCG UCCAG 23 16051
HSV2-UL48-2093 + CAUAUCCACCUCCUCGCCGUCCAG 24 16052
HSV2-UL48-2094 + CAGCUCUCCAGGUCGCAG 18 16053
HSV2-UL48-2095 + CCAGCUCUCCAGGUCGCAG 19 16054
HSV2-UL48-988 + GCCAGCUCUCCAGGUCGCAG 20 6330
HSV2-UL48-2096 + CGCCAGCUCUCCAGGUCGCAG 21 16055
HSV2-UL48-2097 + GCGCCAGCUCUCCAGGUCGCAG 22 16056 HSV2-UL48-2098 + GGCGCCAGCUCUCCAGGUCGCAG 23 16057
HSV2-UL48-2099 + UGGCGCCAGCUCUCCAGGUCGCAG 24 16058
HSV2-UL48-2100 + UCCAAAGCCCCAUACGAG 18 16059
HSV2-UL48-2101 + GUCCAAAGCCCCAUACGAG 19 16060
HSV2-UL48-1051 + CGUCCAAAGCCCCAUACGAG 20 6368
HSV2-UL48-2102 + ACG U CCAAAGCCCCAU ACG AG 21 16061
HSV2-UL48-2103 + CACGU CCA A AG CCCCAUACGAG 22 16062
HSV2-UL48-2104 + CC ACG U CCA A AG CCCCAUACGAG 23 16063
HSV2-UL48-2105 + UCCACGUCCAAAGCCCCAUACGAG 24 16064
HSV2-UL48-2106 + UGGGUCAUUCCCGGGGAG 18 16065
HSV2-UL48-2107 + GUGGGUCAU UCCCGGGGAG 19 16066
HSV2-UL48-332 + CG UGGGUCAU UCCCGGGGAG 20 5814
HSV2-UL48-2108 + UCG UGGGUCAUUCCCGGGGAG 21 16067
HSV2-UL48-2109 + GUCGUGGGUCAUUCCCGGGGAG 22 16068
HSV2-UL48-2110 + GGUCGUGGGUCAUUCCCGGGGAG 23 16069
HSV2-UL48-2111 + GGGUCGUGGGUCAUUCCCGGGGAG 24
16070
HSV2-UL48-2112 + ACGGGAACUCCCCGCACG 18 16071
HSV2-UL48-2113 + CACGGGAACUCCCCGCACG 19 16072
HSV2-UL48-992 + CCACGGGAACUCCCCGCACG 20 6333
HSV2-UL48-2114 + UCCACGGGAACUCCCCGCACG 21 16073
HSV2-UL48-2115 + CUCCACGGGAACUCCCCGCACG 22 16074
HSV2-UL48-2116 + CCUCCACGGGAACUCCCCGCACG 23 16075
HSV2-UL48-2117 + GCCUCCACGGGAACUCCCCGCACG 24 16076
HSV2-UL48-2118 + CCCUCCGAGGUCGCGACG 18 16077
HSV2-UL48-2119 + GCCCUCCGAGG UCGCGACG 19 16078
HSV2-UL48-1016 + CGCCCUCCGAGGUCGCGACG 20 6349
HSV2-UL48-2120 + UCGCCCUCCGAGGUCGCGACG 21 16079
HSV2-UL48-2121 + CUCGCCCUCCGAGG UCGCGACG 22 16080
HSV2-UL48-2122 + ACUCGCCCUCCGAGGUCGCGACG 23 16081
HSV2-UL48-2123 + GACUCGCCCUCCGAGGUCGCGACG 24 16082
HSV2-UL48-2124 + UGCGGGGGCGUUGUCCCG 18 16083
HSV2-UL48-2125 + CUGCGGGGGCGUUGUCCCG 19 16084
HSV2-UL48-354 + UCUGCGGGGGCGUUGUCCCG 20 5836
HSV2-UL48-2126 + GUCUGCGGGGGCGU UGUCCCG 21 16085
HSV2-UL48-2127 + AGUCUGCGGGGGCGUUGUCCCG 22 16086
HSV2-UL48-2128 + CAGUCUGCGGGGGCGUUGUCCCG 23 16087
HSV2-UL48-2129 + ACAGUCUGCGGGGGCGU UGUCCCG 24 16088
HSV2-UL48-2130 + GGUCGUGGGUCAUUCCCG 18 16089
HSV2-UL48-2131 + GGGUCGUGGGUCAUUCCCG 19 16090
HSV2-UL48-329 + GGGGUCGUGGGUCAUUCCCG 20 5811
HSV2-UL48-2132 + CGGGGUCGUGGGUCAU UCCCG 21 16091
HSV2-UL48-2133 + ACGGGGUCGUGGGUCAU UCCCG 22 16092
HSV2-UL48-2134 + GACGGGGUCGUGGGUCAUUCCCG 23 16093
HSV2-UL48-2135 + AGACGGGGUCGUGGGUCAU UCCCG 24 16094
HSV2-UL48-2136 + AGGUCGCAGCAGAGGCCG 18 16095 HSV2-UL48-2137 + CAGG U CG C AG CAG AG G CCG 19 16096
HSV2-UL48-987 + CCAGGUCGCAGCAGAGGCCG 20 6329
HSV2-UL48-2138 + UCCAGGUCGCAGCAGAGGCCG 21 16097
HSV2-UL48-2139 + CUCCAGGUCGCAGCAGAGGCCG 22 16098
HSV2-UL48-2140 + UCUCCAGGUCGCAGCAGAGGCCG 23 16099
HSV2-UL48-2141 + CUCUCCAGGUCGCAGCAGAGGCCG 24 16100
HSV2-UL48-2142 + CCACCAGCCCGG CCU CCG 18 16101
HSV2-UL48-2143 + GCCACCAGCCCGGCCUCCG 19 16102
HSV2-UL48-1024 + CGCCACCAGCCCGGCCUCCG 20 6354
HSV2-UL48-2144 + GCGCCACCAGCCCGGCCUCCG 21 16103
HSV2-UL48-2145 + GGCGCCACCAGCCCGGCCUCCG 22 16104
HSV2-UL48-2146 + CGGCGCCACCAGCCCGGCCUCCG 23 16105
HSV2-UL48-2147 + GCGGCGCCACCAGCCCGGCCUCCG 24 16106
HSV2-UL48-2148 + CGGGGGCGUUGUCCCGCG 18 16107
HSV2-UL48-2149 + GCGGGGGCGUUGUCCCGCG 19 16108
HSV2-UL48-1026 + UGCGGGGGCGUUGUCCCGCG 20 6356
HSV2-UL48-2150 + CUGCGGGGGCGUUGUCCCGCG 21 16109
HSV2-UL48-2151 + UCUGCGGGGGCGUUGUCCCGCG 22 16110
HSV2-UL48-2152 + GUCUGCGGGGGCGUUG UCCCGCG 23 16111
HSV2-UL48-2153 + AGUCUGCGGGGGCGUUGUCCCGCG 24 16112
HSV2-UL48-2154 + GUUUAGCUCCCGCAGUCG 18 16113
HSV2-UL48-2155 + GGUUUAGCUCCCGCAGUCG 19 16114
HSV2-UL48-996 + UGGU UUAGCUCCCGCAGUCG 20 6335
HSV2-UL48-2156 + GUGGU UUAGCUCCCGCAGUCG 21 16115
HSV2-UL48-2157 + UGUGGUUUAGCUCCCGCAGUCG 22 16116
HSV2-UL48-2158 + AUGUGGUUUAGCUCCCGCAG UCG 23 16117
HSV2-UL48-2159 + AAUGUGGUU UAGCUCCCGCAGUCG 24 16118
HSV2-UL48-2160 + AAGUCGUCCAGGGCGUCG 18 16119
HSV2-UL48-2161 + GAAGUCG UCCAGGGCGUCG 19 16120
HSV2-UL48-1038 + CGAAGUCGUCCAGGGCGUCG 20 6362
HSV2-UL48-2162 + UCGAAGUCGUCCAGGGCGUCG 21 16121
HSV2-UL48-2163 + GUCGAAGUCGUCCAGGGCGUCG 22 16122
HSV2-UL48-2164 + AGUCGAAGUCGUCCAGGGCGUCG 23 16123
HSV2-UL48-2165 + AAGUCGAAGUCGUCCAGGGCGUCG 24 16124
HSV2-UL48-2166 + GCCUGGUUGCCCUGCAGG 18 16125
HSV2-UL48-2167 + GGCCUGGU UGCCCUGCAGG 19 16126
HSV2-UL48-1007 + GGGCCUGGUUGCCCUGCAGG 20 6342
HSV2-UL48-2168 + CGGGCCUGGUUGCCCUGCAGG 21 16127
HSV2-UL48-2169 + GCGGGCCUGGUUGCCCUGCAGG 22 16128
HSV2-UL48-2170 + AGCGGGCCUGGUUGCCCUGCAGG 23 16129
HSV2-UL48-2171 + GAGCGGGCCUGGUUGCCCUGCAGG 24 16130
HSV2-UL48-2172 + UCAUCGUCG UCCGGGAGG 18 16131
HSV2-UL48-2173 + GUCAUCGUCGUCCGGGAGG 19 16132
HSV2-UL48-1019 + CGUCAUCGUCGUCCGGGAGG 20 6352
HSV2-UL48-2174 + GCG UCAUCGUCGUCCGGGAGG 21 16133
HSV2-UL48-2175 + AGCG UCAUCGUCGUCCGGGAGG 22 16134 HSV2-UL48-2176 + GAGCGUCAUCGUCGUCCGGGAGG 23 16135
HSV2-UL48-2177 + GGAGCGUCAUCGUCGUCCGGGAGG 24 16136
HSV2-UL48-2178 + GGUUGCCCUGCAGGACGG 18 16137
HSV2-UL48-2179 + UGGUUGCCCUGCAGGACGG 19 16138
HSV2-UL48-1006 + CUGGUUGCCCUGCAGGACGG 20 6341
HSV2-UL48-2180 + CCUGGUUGCCCUGCAGGACGG 21 16139
HSV2-UL48-2181 + GCCUGGUUGCCCUGCAGGACGG 22 16140
HSV2-UL48-2182 + GGCCUGGU UGCCCUGCAGGACGG 23 16141
HSV2-UL48-2183 + GGGCCUGGU UGCCCUGCAGGACGG 24 16142
HSV2-UL48-2184 + GCAGGUACCGGUACAGGG 18 16143
HSV2-UL48-2185 + CGCAGGUACCGGUACAGGG 19 16144
HSV2-UL48-978 + GCGCAGGUACCGGUACAGGG 20 6320
HSV2-UL48-2186 + CGCGCAGGUACCGGUACAGGG 21 16145
HSV2-UL48-2187 + GCGCGCAGGUACCGGUACAGGG 22 16146
HSV2-UL48-2188 + GGCGCGCAGG UACCGGUACAGGG 23 16147
HSV2-UL48-2189 + UGGCGCGCAGGUACCGGUACAGGG 24 16148
HSV2-UL48-2190 + UCGUGGGUCAUUCCCGGG 18 16149
HSV2-UL48-2191 + GUCGUGGGUCAUUCCCGGG 19 16150
HSV2-UL48-1044 + GGUCGUGGGUCAUUCCCGGG 20 6365
HSV2-UL48-2192 + GGG UCGUGGGUCAUUCCCGGG 21 16151
HSV2-UL48-2193 + GGGG UCGUGGGUCAUUCCCGGG 22 16152
HSV2-UL48-2194 + CGGGG UCGUGGGUCAUUCCCGGG 23 16153
HSV2-UL48-2195 + ACGGGGUCGUGGGUCAUUCCCGGG 24 16154
HSV2-UL48-2196 + GUUGAUAAACAUCAGGGG 18 16155
HSV2-UL48-2197 + CGU UGAUAAACAUCAGGGG 19 16156
HSV2-UL48-989 + CCGU UGAUAAACAUCAGGGG 20 6331
HSV2-UL48-2198 + UCCGUUGAUAAACAUCAGGGG 21 16157
HSV2-UL48-2199 + AUCCGUUGAUAAACAUCAGGGG 22 16158
HSV2-UL48-2200 + GAUCCGUUGAUAAACAUCAGGGG 23 16159
HSV2-UL48-2201 + CGAUCCGU UGAUAAACAUCAGGGG 24 16160
HSV2-UL48-2202 + CGUGGGUCAU UCCCGGGG 18 16161
HSV2-UL48-2203 + UCGUGGGUCAUUCCCGGGG 19 16162
HSV2-UL48-330 + GUCGUGGGUCAUUCCCGGGG 20 5812
HSV2-UL48-2204 + GG UCGUGGGUCAUUCCCGGGG 21 16163
HSV2-UL48-2205 + GGG UCGUGGGUCAUUCCCGGGG 22 16164
HSV2-UL48-2206 + GGGG UCGUGGGUCAUUCCCGGGG 23 16165
HSV2-UL48-2207 + CGGGGUCGUGGGUCAUUCCCGGGG 24 16166
HSV2-UL48-2208 + UACGCGUGCUCCCGCAUG 18 16167
HSV2-UL48-2209 + AUACGCGUGCUCCCGCAUG 19 16168
HSV2-UL48-1018 + UAUACGCGUGCUCCCGCAUG 20 6351
HSV2-UL48-2210 + CUAUACGCGUGCUCCCGCAUG 21 16169
HSV2-UL48-2211 + GCUAUACGCG UGCUCCCGCAUG 22 16170
HSV2-UL48-2212 + GGCUAUACGCGUGCUCCCGCAUG 23 16171
HSV2-UL48-2213 + CGGCUAUACGCGUGCUCCCGCAUG 24 16172
HSV2-UL48-2214 + CAGAAAGAGGUAUAGAUG 18 16173
HSV2-UL48-2215 + UCAGAAAGAGGUAUAGAUG 19 16174 HSV2-UL48-982 + CUCAGAAAGAGGUAUAGAUG 20 6324
HSV2-UL48-2216 + GCUCAGAAAGAGGUAUAGAUG 21 16175
HSV2-UL48-2217 + GGCUCAGAAAGAGGUAUAGAUG 22 16176
HSV2-UL48-2218 + CGGCUCAGAAAGAGGUAUAGAUG 23 16177
HSV2-UL48-2219 + GCGGCUCAGAAAGAGGUAUAGAUG 24 16178
HSV2-UL48-2220 + GCGGGCCUGGUUGCCCUG 18 16179
HSV2-UL48-2221 + AGCGGGCCUGGUUGCCCUG 19 16180
HSV2-UL48-1008 + GAGCGGGCCUGGUUGCCCUG 20 6343
HSV2-UL48-2222 + GGAGCGGGCCUGGUUGCCCUG 21 16181
HSV2-UL48-2223 + AGGAGCGGGCCUGGUUGCCCUG 22 16182
HSV2-UL48-2224 + GAGGAGCGGGCCUGGUUGCCCUG 23 16183
HSV2-UL48-2225 + AGAGGAGCGGGCCUGGU UGCCCUG 24 16184
HSV2-UL48-2226 + UGCCUGGCGGUG UAGCUG 18 16185
HSV2-UL48-2227 + GUGCCUGGCGGUGUAGCUG 19 16186
HSV2-UL48-980 + UGUGCCUGGCGG UGUAGCUG 20 6322
HSV2-UL48-2228 + GUGUGCCUGGCGGUGUAGCUG 21 16187
HSV2-UL48-2229 + UGUGUGCCUGGCGGUGUAGCUG 22 16188
HSV2-UL48-2230 + AUG UGUGCCUGGCGGUGUAGCUG 23 16189
HSV2-UL48-2231 + CAUGUG UGCCUGGCGGUGUAGCUG 24
16190
HSV2-UL48-2232 + GCGGUGGUGGACAG UCUG 18 16191
HSV2-UL48-2233 + GGCGGUGGUGGACAGUCUG 19 16192
HSV2-UL48-350 + GGGCGGUGGUGGACAGUCUG 20 5832
HSV2-UL48-2234 + GGGGCGGUGGUGGACAGUCUG 21 16193
HSV2-UL48-2235 + GGGGGCGGUGGUGGACAGUCUG 22 16194
HSV2-UL48-2236 + UGGGGGCGGUGGUGGACAGUCUG 23 16195
HSV2-UL48-2237 + AUGGGGGCGGUGGUGGACAGUCUG 24
16196
HSV2-UL48-2238 + AGGACGGGCGGGGUCG UG 18 16197
HSV2-UL48-2239 + CAGGACGGGCGGGGUCGUG 19 16198
HSV2-UL48-379 + GCAGGACGGGCGGGGUCGUG 20 5861
HSV2-UL48-2240 + UGCAGGACGGGCGGGGUCGUG 21 16199
HSV2-UL48-2241 + CUGCAGGACGGGCGGGGUCGUG 22 16200
HSV2-UL48-2242 + CCUGCAGGACGGGCGGGGUCGUG 23 16201
HSV2-UL48-2243 + CCCUGCAGGACGGGCGGGGUCGUG 24 16202
HSV2-UL48-2244 + UCGGUAAUGGGGGCGGUG 18 16203
HSV2-UL48-2245 + GUCGGUAAUGGGGGCGGUG 19 16204
HSV2-UL48-1032 + CGUCGGUAAUGGGGGCGGUG 20 6359
HSV2-UL48-2246 + ACG UCGGUAAUGGGGGCGGUG 21 16205
HSV2-UL48-2247 + GACG UCGGUAAUGGGGGCGGUG 22 16206
HSV2-UL48-2248 + UGACGUCGGUAAUGGGGGCGGUG 23 16207
HSV2-UL48-2249 + CUGACGUCGGUAAUGGGGGCGGUG 24
16208
HSV2-UL48-2250 + CAGGCUGACGUCGGUAAU 18 16209
HSV2-UL48-2251 + CCAGGCUGACGUCGGUAAU 19 16210
HSV2-UL48-344 + CCCAGGCUGACGUCGGUAAU 20 5826 HSV2-UL48-2252 + UCCCAGGCUGACGUCGGUAAU 21 16211
HSV2-UL48-2253 + CUCCCAGGCUGACGUCGGUAAU 22 16212
HSV2-UL48-2254 + UCUCCCAGGCUGACGUCGGUAAU 23 16213
HSV2-UL48-2255 + GUCUCCCAGGCUGACGUCGGUAAU 24 16214
HSV2-UL48-2256 + CGAUCCGUUGAUAAACAU 18 16215
HSV2-UL48-2257 + GCGAUCCGU UGAUAAACAU 19 16216
HSV2-UL48-991 + AGCGAUCCGU UGAUAAACAU 20 6332
HSV2-UL48-2258 + GAGCGAUCCGU UGAUAAACAU 21 16217
HSV2-UL48-2259 + UGAGCGAUCCGUUGAUAAACAU 22 16218
HSV2-UL48-2260 + GUG AGCGAUCCGUUGAUAAACAU 23 16219
HSV2-UL48-2261 + GGUGAGCGAUCCGUUGAUAAACAU 24 16220
HSV2-UL48-2262 + CCACG UCCAAAG CCCCAU 18 16221
HSV2-UL48-2263 + UCCACGUCCAAAGCCCCAU 19 16222
HSV2-UL48-1052 + G U CCACG U CCAAAGCCCCAU 20 6369
HSV2-UL48-2264 + CGUCCACGU CCA A AG CCCCAU 21 16223
HSV2-UL48-2265 + U CG U CCACG U CCAAAG CCCCAU 22 16224
HSV2-UL48-2266 + AUCGUCCACGU CCAAAG CCCCAU 23 16225
HSV2-UL48-2267 + A A U CG U CC ACG U CC A A AG CCCC A U 24 16226
HSV2-UL48-2268 + GCAUGACGGACUCGCCCU 18 16227
HSV2-UL48-2269 + CGCAUGACGGACUCGCCCU 19 16228
HSV2-UL48-1017 + CCGCAUGACGGACUCGCCCU 20 6350
HSV2-UL48-2270 + CCCGCAUGACGGACUCGCCCU 21 16229
HSV2-UL48-2271 + UCCCGCAUGACGGACUCGCCCU 22 16230
HSV2-UL48-2272 + CUCCCGCAUGACGGACUCGCCCU 23 16231
HSV2-UL48-2273 + GCUCCCGCAUGACGGACUCGCCCU 24 16232
HSV2-UL48-2274 + CCAUAGGAUCUCGCGGCU 18 16233
HSV2-UL48-2275 + CCCAUAGGAUCUCGCGGCU 19 16234
HSV2-UL48-984 + GCCCAUAGGAUCUCGCGGCU 20 6326
HSV2-UL48-2276 + GGCCCAUAGGAUCUCGCGGCU 21 16235
HSV2-UL48-2277 + CGGCCCAUAGGAUCUCGCGGCU 22 16236
HSV2-UL48-2278 + GCGGCCCAUAGGAUCUCGCGGCU 23 16237
HSV2-UL48-2279 + CGCGGCCCAUAGGAUCUCGCGGCU 24 16238
HSV2-UL48-2280 + GGCGGUGGUGGACAGUCU 18 16239
HSV2-UL48-2281 + GGGCGGUGGUGGACAGUCU 19 16240
HSV2-UL48-1031 + GGGGCGGUGGUGGACAGUCU 20 6358
HSV2-UL48-2282 + GGGGGCGGUGGUGGACAGUCU 21 16241
HSV2-UL48-2283 + UGGGGGCGGUGGUGGACAGUCU 22 16242
HSV2-UL48-2284 + AUGGGGGCGGUGG UGGACAGUCU 23 16243
HSV2-UL48-2285 + AAUGGGGGCGGUGGUGGACAGUCU 24
16244
HSV2-UL48-2286 + CAGGAGCGUCAUCGUCGU 18 16245
HSV2-UL48-2287 + GCAGGAGCGUCAUCGUCGU 19 16246
HSV2-UL48-1022 + CGCAGGAGCGUCAUCGUCGU 20 6353
HSV2-UL48-2288 + CCGCAGGAGCGUCAUCGUCGU 21 16247
HSV2-UL48-2289 + UCCGCAGGAGCGUCAUCGUCGU 22 16248
HSV2-UL48-2290 + CUCCGCAGGAGCGUCAUCGUCGU 23 16249 HSV2-UL48-2291 + CCUCCGCAGGAGCGUCAUCGUCGU 24 16250
HSV2-UL48-2292 + CAGGACGGGCGGGGUCGU 18 16251
HSV2-UL48-2293 + GCAGGACGGGCGGGGUCGU 19 16252
HSV2-UL48-1003 + UGCAGGACGGGCGGGGUCGU 20 6339
HSV2-UL48-2294 + CUGCAGGACGGGCGGGGUCGU 21 16253
HSV2-UL48-2295 + CCUGCAGGACGGGCGGGGUCGU 22 16254
HSV2-UL48-2296 + CCCUGCAGGACGGGCGGGGUCGU 23 16255
HSV2-UL48-2297 + GCCCUGCAGGACGGGCGGGGUCGU 24 16256
HSV2-UL48-2298 - ACAAUUACGGAUCGACAA 18 16257
HSV2-UL48-2299 - AACAAU U ACGG AUCG ACAA 19 16258
HSV2-UL48-850 - A A AC A A UUACGGAU CG AC A A 20 6240
HSV2-UL48-2300 - GAAACAAUU ACGG AUCG ACAA 21 16259
HSV2-UL48-2301 - AG AAACAAUU ACGG AUCG ACAA 22 16260
HSV2-UL48-2302 - CAGAAACAAUUACGGAUCGACAA 23 16261
HSV2-UL48-2303 - CCAGAAACAAUU ACGG AUCG ACAA 24 16262
HSV2-UL48-2304 - GGGGGGUAGGAUGUGCGA 18 16263
HSV2-UL48-2305 - UGGGGGGUAGGAUGUGCGA 19 16264
HSV2-UL48-2306 - UUGGGGGGUAGGAUGUGCGA 20 16265
HSV2-UL48-2307 - U U UGGGGGGUAGGAUGUGCGA 21 16266
HSV2-UL48-2308 - CU U UGGGGGG UAGGAUGUGCGA 22 16267
HSV2-UL48-2309 - ACU UUGGGGGGUAGGAUGUGCGA 23 16268
HSV2-UL48-2310 - GACUUUGGGGGGUAGGAUGUGCGA 24
16269
HSV2-UL48-1612 - GGCGCGGGAGGAGAGCUA 18 15571
HSV2-UL48-1613 - GGGCGCGGGAGGAGAGCUA 19 15572
HSV2-UL48-651 - CGGGCGCGGGAGGAGAGCUA 20 6120
HSV2-UL48-1614 - GCGGGCGCGGGAGGAGAGCUA 21 15573
HSV2-UL48-1615 - UGCGGGCGCGGGAGGAGAGCUA 22 15574
HSV2-UL48-1616 - CUGCGGGCGCGGGAGGAGAGCUA 23 15575
HSV2-UL48-1617 - GCUGCGGGCGCGGGAGGAGAGCUA 24 15576
HSV2-UL48-2311 - CCACGACCCCGUCUCGUA 18 16270
HSV2-UL48-2312 - CCCACG ACCCCG U CU CG U A 19 16271
HSV2-UL48-308 - ACCCACG ACCCCG UCUCGUA 20 5790
HSV2-UL48-2313 - GACCCACGACCCCGUCUCGUA 21 16272
HSV2-UL48-2314 - UGACCCACGACCCCGUCUCGUA 22 16273
HSV2-UL48-2315 - AUG ACCCACG ACCCCG UCUCGUA 23 16274
HSV2-UL48-2316 - AAUG ACCCACG ACCCCG UCUCGUA 24 16275
HSV2-UL48-2317 - GUGCGGCGGCGGAGGAAC 18 16276
HSV2-UL48-2318 - AGUGCGGCGGCGGAGGAAC 19 16277
HSV2-UL48-833 - AAGUGCGGCGGCGGAGGAAC 20 6227
HSV2-UL48-2319 - GAAGUGCGGCGGCGGAGGAAC 21 16278
HSV2-UL48-2320 - CG AAGUGCGGCGGCGGAGGAAC 22 16279
HSV2-UL48-2321 - GCG AAGUGCGGCGGCGGAGGAAC 23 16280
HSV2-UL48-2322 - UGCGAAGUGCGGCGGCGGAGGAAC 24 16281
HSV2-UL48-2323 - A ACC AC A U U CG CG AG C AC 18 16282
HSV2-UL48-2324 - AAACCACAU UCGCGAGCAC 19 16283 HSV2-UL48-827 - UAAACCACAUUCGCGAGCAC 20 6223
HSV2-UL48-2325 - CUAAACCACAUUCGCGAGCAC 21 16284
HSV2-UL48-2326 - GCUAAACCACAUUCGCGAGCAC 22 16285
HSV2-UL48-2327 - AGCUAAACCACAUUCGCGAGCAC 23 16286
HSV2-UL48-2328 - G AG CU AAACC ACAU U CG CG AG C AC 24 16287
HSV2-UL48-2329 - GACGGCCUCUGCUGCGAC 18 16288
HSV2-UL48-2330 - CGACGGCCUCUGCUGCGAC 19 16289
HSV2-UL48-813 - UCGACGGCCUCUGCUGCGAC 20 6216
HSV2-UL48-2331 - UUCGACGGCCUCUGCUGCGAC 21 16290
HSV2-UL48-2332 - GUUCGACGGCCUCUGCUGCGAC 22 16291
HSV2-UL48-2333 - UGUUCGACGGCCUCUGCUGCGAC 23 16292
HSV2-UL48-2334 - CUGU UCGACGGCCUCUGCUGCGAC 24 16293
HSV2-UL48-2335 - GCCCUGGACGACUUCGAC 18 16294
HSV2-UL48-2336 - CGCCCUGGACGACUUCGAC 19 16295
HSV2-UL48-868 - ACGCCCUGGACGACUUCGAC 20 6253
HSV2-UL48-2337 - GACGCCCUGGACGACUUCGAC 21 16296
HSV2-UL48-2338 - CGACGCCCUGGACGACUUCGAC 22 16297
HSV2-UL48-2339 - CCGACGCCCUGGACGACUUCGAC 23 16298
HSV2-UL48-2340 - GCCG ACGCCCUGGACGACU UCGAC 24 16299
HSV2-UL48-2341 - GUAUAGCCGCGGGCGGAC 18 16300
HSV2-UL48-2342 - CGUAUAGCCGCGGGCGGAC 19 16301
HSV2-UL48-848 - GCGUAUAGCCGCGGGCGGAC 20 6238
HSV2-UL48-2343 - CGCGUAUAGCCGCGGGCGGAC 21 16302
HSV2-UL48-2344 - ACGCGUAUAGCCGCGGGCGGAC 22 16303
HSV2-UL48-2345 - CACGCGUAUAGCCGCGGGCGGAC 23 16304
HSV2-UL48-2346 - GCACGCGUAUAGCCGCGGGCGGAC 24 16305
HSV2-UL48-2347 - UUGGAGAUGCUGGGGGAC 18 16306
HSV2-UL48-2348 - CUUGGAGAUGCUGGGGGAC 19 16307
HSV2-UL48-874 - ACU UGGAGAUGCUGGGGGAC 20 6255
HSV2-UL48-2349 - GACU UGGAGAUGCUGGGGGAC 21 16308
HSV2-UL48-2350 - CG ACUUGGAGAUGCUGGGGGAC 22 16309
HSV2-UL48-2351 - UCG ACUUGGAGAUGCUGGGGGAC 23 16310
HSV2-UL48-2352 - UUCGACU UGGAGAUGCUGGGGGAC 24
16311
HSV2-UL48-2353 - UCGUAUGGGGCUUUGGAC 18 16312
HSV2-UL48-2354 - CUCGUAUGGGGCUUUGGAC 19 16313
HSV2-UL48-882 - UCUCGUAUGGGGCUUUGGAC 20 6259
HSV2-UL48-2355 - GUCUCGUAUGGGGCUU UGGAC 21 16314
HSV2-UL48-2356 - CGUCUCGUAUGGGGCUUUGGAC 22 16315
HSV2-UL48-2357 - CCGUCUCGUAUGGGGCUUUGGAC 23 16316
HSV2-UL48-2358 - CCCGUCUCGUAUGGGGCUUUGGAC 24 16317
HSV2-UL48-2359 - UGCGGCGGCGGAGGAACC 18 16318
HSV2-UL48-2360 - GUGCGGCGGCGGAGGAACC 19 16319
HSV2-UL48-261 - AG UGCGGCGGCGGAGGAACC 20 5743
HSV2-UL48-2361 - AAG UGCGGCGGCGGAGGAACC 21 16320
HSV2-UL48-2362 - GAAG UGCGGCGGCGGAGGAACC 22 16321 HSV2-UL48-2363 - CGAAGUGCGGCGGCGGAGGAACC 23 16322
HSV2-UL48-2364 - GCGAAGUGCGGCGGCGGAGGAACC 24 16323
HSV2-UL48-2365 - UACUCCAGCGUCGCGACC 18 16324
HSV2-UL48-2366 - GUACUCCAGCGUCGCGACC 19 16325
HSV2-UL48-839 - CGUACUCCAGCGUCGCGACC 20 6232
HSV2-UL48-2367 - UCGUACUCCAGCGUCGCGACC 21 16326
HSV2-UL48-2368 - CUCGUACUCCAGCGUCGCGACC 22 16327
HSV2-UL48-2369 - ACUCGUACUCCAGCGUCGCGACC 23 16328
HSV2-UL48-2370 - GACUCGUACUCCAGCGUCGCGACC 24 16329
HSV2-UL48-2371 - ACGGCCUCUGCUGCGACC 18 16330
HSV2-UL48-2372 - GACGGCCUCUGCUGCGACC 19 16331
HSV2-UL48-244 - CGACGGCCUCUGCUGCGACC 20 5726
HSV2-UL48-2373 - UCGACGGCCUCUGCUGCGACC 21 16332
HSV2-UL48-2374 - UUCGACGGCCUCUGCUGCGACC 22 16333
HSV2-UL48-2375 - GU UCGACGGCCUCUGCUGCGACC 23 16334
HSV2-UL48-2376 - UGUUCGACGGCCUCUGCUGCGACC 24 16335
HSV2-UL48-2377 - UCGCGGACAGGUACUACC 18 16336
HSV2-UL48-2378 - AUCGCGGACAGGUACUACC 19 16337
HSV2-UL48-808 - GAUCGCGGACAGGUACUACC 20 6211
HSV2-UL48-2379 - CG AUCGCGGACAGGUACUACC 21 16338
HSV2-UL48-2380 - ACG AUCGCGGACAGGUACUACC 22 16339
HSV2-UL48-2381 - CACG AUCGCGGACAGGUACUACC 23 16340
HSV2-UL48-2382 - CCACGAUCGCGGACAGGUACUACC 24 16341
HSV2-UL48-2383 - ACGUGGAGUCCCCCUCCC 18 16342
HSV2-UL48-2384 - GACGUGGAGUCCCCCUCCC 19 16343
HSV2-UL48-306 - GGACGUGGAGUCCCCCUCCC 20 5788
HSV2-UL48-2385 - GGGACGUGGAGUCCCCCUCCC 21 16344
HSV2-UL48-2386 - GGGGACGUGGAGUCCCCCUCCC 22 16345
HSV2-UL48-2387 - GGGGGACGUGGAGUCCCCCUCCC 23 16346
HSV2-UL48-2388 - UGGGGGACGUGGAGUCCCCCUCCC 24 16347
HSV2-UL48-2389 - ACCGUGCGGGGAGUUCCC 18 16348
HSV2-UL48-2390 - CACCGUGCGGGGAGUUCCC 19 16349
HSV2-UL48-821 - UCACCGUGCGGGGAGU UCCC 20 6220
HSV2-UL48-2391 - CUCACCGUGCGGGGAGU UCCC 21 16350
HSV2-UL48-2392 - GCUCACCGUGCGGGGAG UUCCC 22 16351
HSV2-UL48-2393 - CGCUCACCGUGCGGGGAGUUCCC 23 16352
HSV2-UL48-2394 - UCGCUCACCGUGCGGGGAGUUCCC 24 16353
HSV2-UL48-2395 - CCAUUACCGACGUCAGCC 18 16354
HSV2-UL48-2396 - CCCAU UACCGACGUCAGCC 19 16355
HSV2-UL48-292 - CCCCAUUACCGACGUCAGCC 20 5774
HSV2-UL48-2397 - CCCCCAUUACCGACGUCAGCC 21 16356
HSV2-UL48-2398 - GCCCCCAUUACCGACGUCAGCC 22 16357
HSV2-UL48-2399 - CGCCCCCAUUACCGACGUCAGCC 23 16358
HSV2-UL48-2400 - CCGCCCCCAU UACCGACGUCAGCC 24 16359
HSV2-UL48-2401 - UAUACCUCU UUCUGAGCC 18 16360
HSV2-UL48-2402 - CUAUACCUCU UUCUGAGCC 19 16361 HSV2-UL48-810 - UCUAUACCUCUUUCUGAGCC 20 6213
HSV2-UL48-2403 - AUCUAUACCUCUU UCUGAGCC 21 16362
HSV2-UL48-2404 - CAUCUAUACCUCUUUCUGAGCC 22 16363
HSV2-UL48-2405 - GCAUCUAUACCUCUUUCUGAGCC 23 16364
HSV2-UL48-2406 - UGCAUCUAUACCUCUUUCUGAGCC 24 16365
HSV2-UL48-2407 - GGGAGCACGCGUAUAGCC 18 16366
HSV2-UL48-2408 - CGGGAGCACGCGUAUAGCC 19 16367
HSV2-UL48-846 - GCGGGAGCACGCGUAUAGCC 20 6236
HSV2-UL48-2409 - UGCGGGAGCACGCGUAUAGCC 21 16368
HSV2-UL48-2410 - AUGCGGGAGCACGCGUAUAGCC 22 16369
HSV2-UL48-2411 - CAUGCGGGAGCACGCGUAUAGCC 23 16370
HSV2-UL48-2412 - UCAUGCGGGAGCACGCGUAUAGCC 24 16371
HSV2-UL48-2413 - AUGACGCCCGCCGACGCC 18 16372
HSV2-UL48-2414 - UAUGACGCCCGCCGACGCC 19 16373
HSV2-UL48-867 - AUAUGACGCCCGCCGACGCC 20 6252
HSV2-UL48-2415 - GAUAUGACGCCCGCCGACGCC 21 16374
HSV2-UL48-2416 - GGAUAUGACGCCCGCCGACGCC 22 16375
HSV2-UL48-2417 - UGGAUAUGACGCCCGCCGACGCC 23 16376
HSV2-UL48-2418 - GUGGAUAUGACGCCCGCCGACGCC 24 16377
HSV2-UL48-2419 - CAGAUGU UUACCGAUGCC 18 16378
HSV2-UL48-2420 - ACAGAUGUU UACCGAUGCC 19 16379
HSV2-UL48-885 - AACAGAUGU UUACCGAUGCC 20 6262
HSV2-UL48-2421 - GAACAGAUGUUUACCGAUGCC 21 16380
HSV2-UL48-2422 - UGAACAGAUGUUUACCGAUGCC 22 16381
HSV2-UL48-2423 - UUGAACAGAUGUUUACCGAUGCC 23 16382
HSV2-UL48-2424 - UUUGAACAGAUGUUUACCGAUGCC 24 16383
HSV2-UL48-2425 - GACGUGGAGUCCCCCUCC 18 16384
HSV2-UL48-2426 - GGACGUGGAGUCCCCCUCC 19 16385
HSV2-UL48-876 - GGGACGUGGAGUCCCCCUCC 20 6256
HSV2-UL48-2427 - GGGGACGUGGAGUCCCCCUCC 21 16386
HSV2-UL48-2428 - GGGGGACGUGGAGUCCCCCUCC 22 16387
HSV2-UL48-2429 - UGGGGGACGUGGAGUCCCCCUCC 23 16388
HSV2-UL48-2430 - CUGGGGGACGUGGAGUCCCCCUCC 24 16389
HSV2-UL48-2431 - CGCAUGUCGU UUCUCUCC 18 16390
HSV2-UL48-2432 - GCGCAUGUCGU UUCUCUCC 19 16391
HSV2-UL48-856 - CGCGCAUGUCGUU UCUCUCC 20 6245
HSV2-UL48-2433 - CCGCGCAUGUCGU UUCUCUCC 21 16392
HSV2-UL48-2434 - GCCGCGCAUGUCGUUUCUCUCC 22 16393
HSV2-UL48-2435 - CGCCGCGCAUGUCGUU UCUCUCC 23 16394
HSV2-UL48-2436 - GCGCCGCGCAUGUCGU U UCUCUCC 24 16395
HSV2-UL48-2437 - CCCAUUACCGACGUCAGC 18 16396
HSV2-UL48-2438 - CCCCAUUACCGACGUCAGC 19 16397
HSV2-UL48-858 - CCCCCAUUACCGACGUCAGC 20 6246
HSV2-UL48-2439 - GCCCCCAUUACCGACGUCAGC 21 16398
HSV2-UL48-2440 - CGCCCCCAUUACCGACGUCAGC 22 16399
HSV2-UL48-2441 - CCGCCCCCAUUACCGACGUCAGC 23 16400 HSV2-UL48-2442 - ACCGCCCCCAU UACCGACGUCAGC 24 16401
HSV2-UL48-2443 - CUGGGAGACGAACUCCGC 18 16402
HSV2-UL48-2444 - CCUGGGAGACGAACUCCGC 19 16403
HSV2-UL48-862 - GCCUGGGAGACGAACUCCGC 20 6248
HSV2-UL48-2445 - AGCCUGGGAGACGAACUCCGC 21 16404
HSV2-UL48-2446 - CAGCCUGGGAGACGAACUCCGC 22 16405
HSV2-UL48-2447 - UCAGCCUGGGAGACGAACUCCGC 23 16406
HSV2-UL48-2448 - GUCAGCCUGGGAGACGAACUCCGC 24 16407
HSV2-UL48-2449 - GAACUCCGCCUGGACGGC 18 16408
HSV2-UL48-2450 - CGAACUCCGCCUGGACGGC 19 16409
HSV2-UL48-864 - ACGAACUCCGCCUGGACGGC 20 6250
HSV2-UL48-2451 - GACGAACUCCGCCUGGACGGC 21 16410
HSV2-UL48-2452 - AG ACGAACUCCGCCUGGACGGC 22 16411
HSV2-UL48-2453 - GAG ACGAACUCCGCCUGGACGGC 23 16412
HSV2-UL48-2454 - GGAG ACGAACUCCGCCUGGACGGC 24 16413
HSV2-UL48-2455 - AGGGCGAGUCCGUCAUGC 18 16414
HSV2-UL48-2456 - GAGGGCGAGUCCGUCAUGC 19 16415
HSV2-UL48-276 - GGAGGGCGAGUCCGUCAUGC 20 5758
HSV2-UL48-2457 - CGGAGGGCGAGUCCGUCAUGC 21 16416
HSV2-UL48-2458 - UCGGAGGGCGAGUCCG UCAUGC 22 16417
HSV2-UL48-2459 - CUCGG AGGGCGAGUCCG UCAUGC 23 16418
HSV2-UL48-2460 - CCUCGGAGGGCGAGUCCGUCAUGC 24 16419
HSV2-UL48-2461 - ACUUCGACU UGGAGAUGC 18 16420
HSV2-UL48-2462 - GACU UCGACU UGGAGAUGC 19 16421
HSV2-UL48-301 - CGACUUCGACU UGGAGAUGC 20 5783
HSV2-UL48-2463 - ACG ACUUCGACUUGGAGAUGC 21 16422
HSV2-UL48-2464 - GACG ACUUCGACUUGGAGAUGC 22 16423
HSV2-UL48-2465 - GG ACG ACUUCGACUUGGAGAUGC 23 16424
HSV2-UL48-2466 - UGGACGACUUCGACUUGGAGAUGC 24 16425
HSV2-UL48-2467 - UGGAGGCCCGGCGACUGC 18 16426
HSV2-UL48-2468 - GUGGAGGCCCGGCGACUGC 19 16427
HSV2-UL48-255 - CG UGGAGGCCCGGCGACUGC 20 5737
HSV2-UL48-2469 - CCG UGGAGGCCCGGCGACUGC 21 16428
HSV2-UL48-2470 - CCCGUGGAGGCCCGGCGACUGC 22 16429
HSV2-UL48-2471 - UCCCGUGGAGGCCCGGCGACUGC 23 16430
HSV2-UL48-2472 - UUCCCGUGGAGGCCCGGCGACUGC 24 16431
HSV2-UL48-2473 - GCCGCAACCGCGACCUGC 18 16432
HSV2-UL48-2474 - GGCCGCAACCGCGACCUGC 19 16433
HSV2-UL48-236 - GGGCCGCAACCGCGACCUGC 20 5718
HSV2-UL48-2475 - GGGGCCGCAACCGCGACCUGC 21 16434
HSV2-UL48-2476 - CGGGGCCGCAACCGCGACCUGC 22 16435
HSV2-UL48-2477 - GCGGGGCCGCAACCGCGACCUGC 23 16436
HSV2-UL48-2478 - UGCGGGGCCGCAACCGCGACCUGC 24 16437
HSV2-UL48-2479 - ACGGAUCGCUCACCGUGC 18 16438
HSV2-UL48-2480 - AACGGAUCGCUCACCG UGC 19 16439
HSV2-UL48-249 - CAACGGAUCGCUCACCGUGC 20 5731 HSV2-UL48-2481 - UCAACGGAUCGCUCACCGUGC 21 16440
HSV2-UL48-2482 - AUCAACGGAUCGCUCACCGUGC 22 16441
HSV2-UL48-2483 - UAUCAACGGAUCGCUCACCGUGC 23 16442
HSV2-UL48-2484 - UUAUCAACGGAUCGCUCACCGUGC 24 16443
HSV2-UL48-2485 - AAUUACGGAUCGACAAUC 18 16444
HSV2-UL48-2486 - CAAUUACGGAUCGACAAUC 19 16445
HSV2-UL48-851 - ACAAUUACGGAUCGACAAUC 20 6241
HSV2-UL48-2487 - AACAAUUACGGAUCGACAAUC 21 16446
HSV2-UL48-2488 - A A AC A A UUACGGAUCG AC A A U C 22 16447
HSV2-UL48-2489 - GAAACAAUUACGGAUCGACAAUC 23 16448
HSV2-UL48-2490 - AGAAACAAUUACGGAUCGACAAUC 24 16449
HSV2-UL48-2491 - AUGCUGCGCACCACGAUC 18 16450
HSV2-UL48-2492 - GAUGCUGCGCACCACGAUC 19 16451
HSV2-UL48-807 - AGAUGCUGCGCACCACGAUC 20 6210
HSV2-UL48-2493 - GAG AUGCUGCGCACCACGAUC 21 16452
HSV2-UL48-2494 - GG AG AUGCUGCGCACCACGAUC 22 16453
HSV2-UL48-2495 - GGG AG AUGCUGCGCACCACGAUC 23 16454
HSV2-UL48-2496 - CGGGAGAUGCUGCGCACCACGAUC 24 16455
HSV2-UL48-2497 - GAGGGCCUGCUCGACCUC 18 16456
HSV2-UL48-2498 - CGAGGGCCUGCUCGACCUC 19 16457
HSV2-UL48-852 - UCGAGGGCCUGCUCGACCUC 20 6242
HSV2-UL48-2499 - AUCGAGGGCCUGCUCGACCUC 21 16458
HSV2-UL48-2500 - AAUCGAGGGCCUGCUCGACCUC 22 16459
HSV2-UL48-2501 - CAAUCGAGGGCCUGCUCGACCUC 23 16460
HSV2-UL48-2502 - ACAAUCGAGGGCCUGCUCGACCUC 24 16461
HSV2-UL48-2503 - G G G AG CU AA ACCAC AU U C 18 16462
HSV2-UL48-2504 - CGGG AGCU AAACCACAU UC 19 16463
HSV2-UL48-826 - GCGGGAGCUAAACCACAUUC 20 6222
HSV2-UL48-2505 - UGCGGG AGCU AAACCACAU UC 21 16464
HSV2-UL48-2506 - CUGCGGG AGCU AAACCACAU UC 22 16465
HSV2-UL48-2507 - ACUGCGGG AGCU AAACCACAU UC 23 16466
HSV2-UL48-2508 - GACUGCGGGAGCUAAACCACAUUC 24 16467
HSV2-UL48-2509 - CUGCUGAUCCGGGCCAAG 18 16468
HSV2-UL48-2510 - GCUGCUGAUCCGGGCCAAG 19 16469
HSV2-UL48-838 - UGCUGCUGAUCCGGGCCAAG 20 6231
HSV2-UL48-2511 - AUGCUGCUGAUCCGGGCCAAG 21 16470
HSV2-UL48-2512 - UAUGCUGCUGAUCCGGGCCAAG 22 16471
HSV2-UL48-2513 - UUAUGCUGCUGAUCCGGGCCAAG 23 16472
HSV2-UL48-2514 - U UUAUGCUGCUGAUCCGGGCCAAG 24 16473
HSV2-UL48-2515 - CCGACGUCAGCCUGGGAG 18 16474
HSV2-UL48-2516 - ACCGACGUCAGCCUGGGAG 19 16475
HSV2-UL48-861 - UACCGACGUCAGCCUGGGAG 20 6247
HSV2-UL48-2517 - UU ACCGACGUCAGCCUGGGAG 21 16476
HSV2-UL48-2518 - AU UACCGACGUCAGCCUGGGAG 22 16477
HSV2-UL48-2519 - CAU UACCGACG UCAGCCUGGGAG 23 16478
HSV2-UL48-2520 - CCAUUACCGACGUCAGCCUGGGAG 24 16479 HSV2-UL48-2521 - ACGAACUCCGCCUGGACG 18 16480
HSV2-UL48-2522 - GACGAACUCCGCCUGGACG 19 16481
HSV2-UL48-863 - AG ACGAACUCCGCCUGGACG 20 6249
HSV2-UL48-2523 - GAG ACGAACUCCGCCUGGACG 21 16482
HSV2-UL48-2524 - GGAG ACGAACUCCGCCUGGACG 22 16483
HSV2-UL48-2525 - GGG AG ACGAACUCCGCCUGGACG 23 16484
HSV2-UL48-2526 - UGGGAGACGAACUCCGCCUGGACG 24 16485
HSV2-UL48-2527 - UCCUAUGGGCCGCGUACG 18 16486
HSV2-UL48-2528 - AUCCUAUGGGCCGCGUACG 19 16487
HSV2-UL48-812 - GAUCCUAUGGGCCGCGUACG 20 6215
HSV2-UL48-2529 - AG AUCCUAUGGGCCGCGUACG 21 16488
HSV2-UL48-2530 - GAG AUCCUAUGGGCCGCGUACG 22 16489
HSV2-UL48-2531 - CGAG AUCCUAUGGGCCGCGUACG 23 16490
HSV2-UL48-2532 - GCGAGAUCCUAUGGGCCGCGUACG 24 16491
HSV2-UL48-2533 - CCGUGCGGGGAGUUCCCG 18 16492
HSV2-UL48-2534 - ACCGUGCGGGGAGUUCCCG 19 16493
HSV2-UL48-251 - CACCGUGCGGGGAGU UCCCG 20 5733
HSV2-UL48-2535 - UCACCGUGCGGGGAGU UCCCG 21 16494
HSV2-UL48-2536 - CUCACCGUGCGGGGAGUUCCCG 22 16495
HSV2-UL48-2537 - GCUCACCGUGCGGGGAGUUCCCG 23 16496
HSV2-UL48-2538 - CGCUCACCGUGCGGGGAGU UCCCG 24 16497
HSV2-UL48-2539 - GCAUGUCGUU UCUCUCCG 18 16498
HSV2-UL48-2540 - CGCAUGUCGUU UCUCUCCG 19 16499
HSV2-UL48-290 - GCGCAUGUCGU UUCUCUCCG 20 5772
HSV2-UL48-2541 - CGCGCAUGUCGUUUCUCUCCG 21 16500
HSV2-UL48-2542 - CCGCGCAUG UCGU U UCUCUCCG 22 16501
HSV2-UL48-2543 - GCCGCGCAUGUCGU UUCUCUCCG 23 16502
HSV2-UL48-2544 - CGCCGCGCAUGUCGUUUCUCUCCG 24 16503
HSV2-UL48-2545 - AACUCCGCCUGGACGGCG 18 16504
HSV2-UL48-2546 - GAACUCCGCCUGGACGGCG 19 16505
HSV2-UL48-296 - CGAACUCCGCCUGGACGGCG 20 5778
HSV2-UL48-2547 - ACG AACUCCGCCUGGACGGCG 21 16506
HSV2-UL48-2548 - GACG AACUCCGCCUGGACGGCG 22 16507
HSV2-UL48-2549 - AGACGAACUCCGCCUGGACGGCG 23 16508
HSV2-UL48-2550 - GAG ACG AACUCCGCCUGGACGGCG 24 16509
HSV2-UL48-2551 - GUGCGAAGUGCGGCGGCG 18 16510
HSV2-UL48-2552 - GGUGCGAAGUGCGGCGGCG 19 16511
HSV2-UL48-831 - UGGUGCGAAGUGCGGCGGCG 20 6226
HSV2-UL48-2553 - CUGGUGCGAAGUGCGGCGGCG 21 16512
HSV2-UL48-2554 - GCUGGUGCGAAGUGCGGCGGCG 22 16513
HSV2-UL48-2555 - CGCUGGUGCGAAGUGCGGCGGCG 23 16514
HSV2-UL48-2556 - CCGCUGGUGCGAAG UGCGGCGGCG 24 16515
HSV2-UL48-2557 - CUGGUGCGAAGUGCGGCG 18 16516
HSV2-UL48-2558 - GCUGGUGCGAAGUGCGGCG 19 16517
HSV2-UL48-829 - CGCUGGUGCGAAGUGCGGCG 20 6225
HSV2-UL48-2559 - CCGCUGGUGCGAAGUGCGGCG 21 16518 HSV2-UL48-2560 - CCCGCUGGUGCGAAGUGCGGCG 22 16519
HSV2-UL48-2561 - UCCCGCUGGUGCGAAGUGCGGCG 23 16520
HSV2-UL48-2562 - CUCCCGCUGGUGCGAAGUGCGGCG 24 16521
HSV2-UL48-2563 - UCCAGCGUCGCGACCUCG 18 16522
HSV2-UL48-2564 - CUCCAGCGUCGCGACCUCG 19 16523
HSV2-UL48-841 - ACUCCAGCGUCGCGACCUCG 20 6233
HSV2-UL48-2565 - UACUCCAGCGUCGCGACCUCG 21 16524
HSV2-UL48-2566 - GUACUCCAGCGUCGCGACCUCG 22 16525
HSV2-UL48-2567 - CGUACUCCAGCGUCGCGACCUCG 23 16526
HSV2-UL48-2568 - UCGUACUCCAGCGUCGCGACCUCG 24 16527
HSV2-UL48-2569 - AUGACGCUCCUGCGGAGG 18 16528
HSV2-UL48-2570 - GAUGACGCUCCUGCGGAGG 19 16529
HSV2-UL48-855 - CGAUGACGCUCCUGCGGAGG 20 6244
HSV2-UL48-2571 - ACG AUGACGCUCCUGCGGAGG 21 16530
HSV2-UL48-2572 - GACG AUGACGCUCCUGCGGAGG 22 16531
HSV2-UL48-2573 - CGACG AUGACGCUCCUGCGGAGG 23 16532
HSV2-UL48-2574 - ACG ACG AUGACGCUCCUGCGGAGG 24 16533
HSV2-UL48-2575 - GCACGCGUAUAGCCGCGG 18 16534
HSV2-UL48-2576 - AGCACGCGUAUAGCCGCGG 19 16535
HSV2-UL48-847 - GAGCACGCGUAUAGCCGCGG 20 6237
HSV2-UL48-2577 - GG AGCACGCGUAUAGCCGCGG 21 16536
HSV2-UL48-2578 - GGG AGCACGCGUAUAGCCGCGG 22 16537
HSV2-UL48-2579 - CGGGAGCACGCGUAUAGCCGCGG 23 16538
HSV2-UL48-2580 - GCGGGAGCACGCGUAUAGCCGCGG 24 16539
HSV2-UL48-2581 - UGCGAAG UGCGGCGGCGG 18 16540
HSV2-UL48-2582 - GUGCGAAGUGCGGCGGCGG 19 16541
HSV2-UL48-260 - GG UGCGAAGUGCGGCGGCGG 20 5742
HSV2-UL48-2583 - UGG UGCGAAGUGCGGCGGCGG 21 16542
HSV2-UL48-2584 - CUGGUGCGAAGUGCGGCGGCGG 22 16543
HSV2-UL48-2585 - GCUGGUGCGAAGUGCGGCGGCGG 23 16544
HSV2-UL48-2586 - CGCUGGUGCGAAGUGCGGCGGCGG 24 16545
HSV2-UL48-2587 - UGGUGCGAAGUGCGGCGG 18 16546
HSV2-UL48-2588 - CUGGUGCGAAGUGCGGCGG 19 16547
HSV2-UL48-259 - GCUGGUGCGAAGUGCGGCGG 20 5741
HSV2-UL48-2589 - CGCUGGUGCGAAGUGCGGCGG 21 16548
HSV2-UL48-2590 - CCGCUGGUGCGAAGUGCGGCGG 22 16549
HSV2-UL48-2591 - CCCGCUGGUGCGAAGUGCGGCGG 23 16550
HSV2-UL48-2592 - UCCCGCUGGUGCGAAGUGCGGCGG 24 16551
HSV2-UL48-2593 - CACCGCCAGGCACACAUG 18 16552
HSV2-UL48-2594 - ACACCGCCAGGCACACAUG 19 16553
HSV2-UL48-232 - UACACCGCCAGGCACACAUG 20 5714
HSV2-UL48-2595 - CUACACCGCCAGGCACACAUG 21 16554
HSV2-UL48-2596 - GCUACACCGCCAGGCACACAUG 22 16555
HSV2-UL48-2597 - AGCU ACACCGCCAGGCACACAUG 23 16556
HSV2-UL48-2598 - CAGCUACACCGCCAGGCACACAUG 24 16557
HSV2-UL48-2599 - GAGGGCGAGUCCGUCAUG 18 16558 HSV2-UL48-2600 - GGAGGGCGAGUCCGUCAUG 19 16559
HSV2-UL48-275 - CGGAGGGCGAGUCCGUCAUG 20 5757
HSV2-UL48-2601 - UCGGAGGGCGAGUCCGUCAUG 21 16560
HSV2-UL48-2602 - CUCGGAGGGCGAGUCCG UCAUG 22 16561
HSV2-UL48-2603 - CCUCGGAGGGCGAGUCCGUCAUG 23 16562
HSV2-UL48-2604 - ACCUCGGAGGGCGAGUCCGUCAUG 24 16563
HSV2-UL48-2605 - GACUUCGACU UGGAGAUG 18 16564
HSV2-UL48-2606 - CGACUUCGACUUGGAGAUG 19 16565
HSV2-UL48-870 - ACGACUUCGACUUGGAGAUG 20 6254
HSV2-UL48-2607 - GACGACUUCGACU UGGAGAUG 21 16566
HSV2-UL48-2608 - GG ACGACUUCGACU UGGAGAUG 22 16567
HSV2-UL48-2609 - UGGACGACU UCGACU UGGAGAUG 23 16568
HSV2-UL48-2610 - CUGGACGACUUCGACUUGGAGAUG 24 16569
HSV2-UL48-2611 - GUGGAGGCCCGGCGACUG 18 16570
HSV2-UL48-2612 - CGUGGAGGCCCGGCGACUG 19 16571
HSV2-UL48-254 - CCGUGGAGGCCCGGCGACUG 20 5736
HSV2-UL48-2613 - CCCGUGGAGGCCCGGCGACUG 21 16572
HSV2-UL48-2614 - UCCCGUGGAGGCCCGGCGACUG 22 16573
HSV2-UL48-2615 - UUCCCGUGGAGGCCCGGCGACUG 23 16574
HSV2-UL48-2616 - GU UCCCGUGGAGGCCCGGCGACUG 24 16575
HSV2-UL48-2617 - GGCCGCAACCGCGACCUG 18 16576
HSV2-UL48-2618 - GGGCCGCAACCGCGACCUG 19 16577
HSV2-UL48-235 - GGGGCCGCAACCGCGACCUG 20 5717
HSV2-UL48-2619 - CGGGGCCGCAACCGCGACCUG 21 16578
HSV2-UL48-2620 - GCGGGGCCGCAACCGCGACCUG 22 16579
HSV2-UL48-2621 - UGCGGGGCCGCAACCGCGACCUG 23 16580
HSV2-UL48-2622 - AUGCGGGGCCGCAACCGCGACCUG 24 16581
HSV2-UL48-2623 - GGCCUCUGCUGCGACCUG 18 16582
HSV2-UL48-2624 - CGGCCUCUGCUGCGACCUG 19 16583
HSV2-UL48-815 - ACGGCCUCUGCUGCGACCUG 20 6217
HSV2-UL48-2625 - GACGGCCUCUGCUGCGACCUG 21 16584
HSV2-UL48-2626 - CGACGGCCUCUGCUGCGACCUG 22 16585
HSV2-UL48-2627 - UCGACGGCCUCUGCUGCGACCUG 23 16586
HSV2-UL48-2628 - UUCGACGGCCUCUGCUGCGACCUG 24 16587
HSV2-UL48-2629 - ACGACGAUGACGCUCCUG 18 16588
HSV2-UL48-2630 - GACGACGAUGACGCUCCUG 19 16589
HSV2-UL48-284 - GG ACGACGAUGACGCUCCUG 20 5766
HSV2-UL48-2631 - CGG ACGACGAUGACGCUCCUG 21 16590
HSV2-UL48-2632 - CCGGACGACGAUGACGCUCCUG 22 16591
HSV2-UL48-2633 - CCCGGACGACGAUGACGCUCCUG 23 16592
HSV2-UL48-2634 - UCCCGGACGACGAUGACGCUCCUG 24 16593
HSV2-UL48-2635 - ACGACCCCGCCCGUCCUG 18 16594
HSV2-UL48-2636 - CACG ACCCCGCCCG UCCUG 19 16595
HSV2-UL48-835 - UCACG ACCCCGCCCG UCCUG 20 6228
HSV2-UL48-2637 - CUCACGACCCCGCCCGUCCUG 21 16596
HSV2-UL48-2638 - CCUCACGACCCCGCCCGUCCUG 22 16597 HSV2-UL48-2639 - CCCUCACGACCCCGCCCG UCCUG 23 16598
HSV2-UL48-2640 - CCCCUCACGACCCCGCCCGUCCUG 24 16599
HSV2-UL48-2641 - UUCGACU UGGAGAUGCUG 18 16600
HSV2-UL48-2642 - CUUCGACUUGGAGAUGCUG 19 16601
HSV2-UL48-303 - ACU UCGACUUGGAGAUGCUG 20 5785
HSV2-UL48-2643 - GACU UCGACUUGGAGAUGCUG 21 16602
HSV2-UL48-2644 - CGACUUCGACUUGGAGAUGCUG 22 16603
HSV2-UL48-2645 - ACG ACUUCGACUUGGAGAUGCUG 23 16604
HSV2-UL48-2646 - GACGACU UCGACUUGGAGAUGCUG 24 16605
HSV2-UL48-2647 - AACGGAUCGCUCACCGUG 18 16606
HSV2-UL48-2648 - CAACGGAUCGCUCACCGUG 19 16607
HSV2-UL48-248 - UCAACGGAUCGCUCACCGUG 20 5730
HSV2-UL48-2649 - AUCAACGGAUCGCUCACCGUG 21 16608
HSV2-UL48-2650 - UAUCAACGGAUCGCUCACCGUG 22 16609
HSV2-UL48-2651 - UUAUCAACGGAUCGCUCACCGUG 23 16610
HSV2-UL48-2652 - UUUAUCAACGGAUCGCUCACCGUG 24 16611
HSV2-UL48-2653 - AC ACCG CC AG G C AC AC A U 18 16612
HSV2-UL48-2654 - UACACCGCCAGGCACACAU 19 16613
HSV2-UL48-802 - CUACACCGCCAGGCACACAU 20 6208
HSV2-UL48-2655 - GCUACACCGCCAGGCACACAU 21 16614
HSV2-UL48-2656 - AGCUACACCGCCAGGCACACAU 22 16615
HSV2-UL48-2657 - CAGCUACACCGCCAGGCACACAU 23 16616
HSV2-UL48-2658 - GCAGCUACACCGCCAGGCACACAU 24 16617
HSV2-UL48-2659 - GGAGGGCGAGUCCGUCAU 18 16618
HSV2-UL48-2660 - CGGAGGGCGAGUCCGUCAU 19 16619
HSV2-UL48-843 - UCGGAGGGCGAGUCCGUCAU 20 6235
HSV2-UL48-2661 - CUCGGAGGGCGAGUCCGUCAU 21 16620
HSV2-UL48-2662 - CCUCGGAGGGCGAGUCCGUCAU 22 16621
HSV2-UL48-2663 - ACCUCGGAGGGCGAGUCCGUCAU 23 16622
HSV2-UL48-2664 - GACCUCGGAGGGCGAGUCCGUCAU 24 16623
HSV2-UL48-2665 - GUACUUUAUGCUGCUGAU 18 16624
HSV2-UL48-2666 - GGUACUUUAUGCUGCUGAU 19 16625
HSV2-UL48-837 - GGGUACUUUAUGCUGCUGAU 20 6230
HSV2-UL48-2667 - UGGGUACUUUAUGCUGCUGAU 21 16626
HSV2-UL48-2668 - CUGGGUACUU UAUGCUGCUGAU 22 16627
HSV2-UL48-2669 - UCUGGGUACU UUAUGCUGCUGAU 23 16628
HSV2-UL48-2670 - CUCUGGGUACUU UAUGCUGCUGAU 24 16629
HSV2-UL48-2671 - CCAUGGGCAUUGACGACU 18 16630
HSV2-UL48-2672 - GCCAUGGGCAU UG ACG ACU 19 16631
HSV2-UL48-886 - UGCCAUGGGCAUUGACGACU 20 6263
HSV2-UL48-2673 - AUGCCAUGGGCAU UGACGACU 21 16632
HSV2-UL48-2674 - GAUGCCAUGGGCAUUGACGACU 22 16633
HSV2-UL48-2675 - CG AUGCCAUGGGCAUUGACGACU 23 16634
HSV2-UL48-2676 - CCGAUGCCAUGGGCAUUGACGACU 24 16635
HSV2-UL48-2677 - CGUGGAGGCCCGGCGACU 18 16636
HSV2-UL48-2678 - CCGUGGAGGCCCGGCGACU 19 16637 HSV2-UL48-823 - CCCGUGGAGGCCCGGCGACU 20 6221
HSV2-UL48-2679 - UCCCGUGGAGGCCCGGCGACU 21 16638
HSV2-UL48-2680 - U UCCCGUGGAGGCCCGGCGACU 22 16639
HSV2-UL48-2681 - GUUCCCGUGGAGGCCCGGCGACU 23 16640
HSV2-UL48-2682 - AGUUCCCGUGGAGGCCCGGCGACU 24 16641
HSV2-UL48-2683 - CCCUGGACGACUUCGACU 18 16642
HSV2-UL48-2684 - GCCCUGGACGACUUCGACU 19 16643
HSV2-UL48-300 - CGCCCUGGACGACUUCGACU 20 5782
HSV2-UL48-2685 - ACGCCCUGGACGACUUCGACU 21 16644
HSV2-UL48-2686 - GACGCCCUGGACGACU UCGACU 22 16645
HSV2-UL48-2687 - CGACGCCCUGGACGACUUCGACU 23 16646
HSV2-UL48-2688 - CCGACGCCCUGGACGACUUCGACU 24 16647
HSV2-UL48-2689 - GGGCCGCAACCGCGACCU 18 16648
HSV2-UL48-2690 - GGGGCCGCAACCGCGACCU 19 16649
HSV2-UL48-804 - CGGGGCCGCAACCGCGACCU 20 6209
HSV2-UL48-2691 - GCGGGGCCGCAACCGCGACCU 21 16650
HSV2-UL48-2692 - UGCGGGGCCGCAACCGCGACCU 22 16651
HSV2-UL48-2693 - AUGCGGGGCCGCAACCGCGACCU 23 16652
HSV2-UL48-2694 - CAUGCGGGGCCGCAACCGCGACCU 24 16653
HSV2-UL48-2695 - ACUCCAGCG UCGCGACCU 18 16654
HSV2-UL48-2696 - UACUCCAGCGUCGCGACCU 19 16655
HSV2-UL48-272 - GUACUCCAGCGUCGCGACCU 20 5754
HSV2-UL48-2697 - CGUACUCCAGCGUCGCGACCU 21 16656
HSV2-UL48-2698 - UCGUACUCCAGCGUCGCGACCU 22 16657
HSV2-UL48-2699 - CUCGUACUCCAGCGUCGCGACCU 23 16658
HSV2-UL48-2700 - ACUCGUACUCCAGCGUCGCGACCU 24 16659
HSV2-UL48-2701 - CAU UACCGACGUCAGCCU 18 16660
HSV2-UL48-2702 - CCAUUACCGACGUCAGCCU 19 16661
HSV2-UL48-293 - CCCAUUACCGACGUCAGCCU 20 5775
HSV2-UL48-2703 - CCCCAUUACCGACGUCAGCCU 21 16662
HSV2-UL48-2704 - CCCCCAU UACCGACGUCAGCCU 22 16663
HSV2-UL48-2705 - GCCCCCAUUACCGACGUCAGCCU 23 16664
HSV2-UL48-2706 - CGCCCCCAUUACCGACGUCAGCCU 24 16665
HSV2-UL48-2707 - UCUGAGCCGCGAGAUCCU 18 16666
HSV2-UL48-2708 - U UCUGAGCCGCGAGAUCCU 19 16667
HSV2-UL48-811 - UUUCUGAGCCGCGAGAUCCU 20 6214
HSV2-UL48-2709 - CUUUCUGAGCCGCGAGAUCCU 21 16668
HSV2-UL48-2710 - UCUUUCUGAGCCGCGAGAUCCU 22 16669
HSV2-UL48-2711 - CUCU UUCUGAGCCGCGAGAUCCU 23 16670
HSV2-UL48-2712 - CCUCUUUCUGAGCCGCGAGAUCCU 24 16671
HSV2-UL48-2713 - GACGACGAUGACGCUCCU 18 16672
HSV2-UL48-2714 - GGACGACGAUGACGCUCCU 19 16673
HSV2-UL48-853 - CGGACGACGAUGACGCUCCU 20 6243
HSV2-UL48-2715 - CCGGACGACGAUGACGCUCCU 21 16674
HSV2-UL48-2716 - CCCGGACGACGAUGACGCUCCU 22 16675
HSV2-UL48-2717 - UCCCGGACGACGAUGACGCUCCU 23 16676 HSV2-UL48-2718 - CUCCCGGACGACGAUGACGCUCCU 24 16677
HSV2-UL48-2719 - CCCGUCUCGUAUGGGGCU 18 16678
HSV2-UL48-2720 - CCCCGUCUCGUAUGGGGCU 19 16679
HSV2-UL48-881 - ACCCCGUCUCGUAUGGGGCU 20 6258
HSV2-UL48-2721 - GACCCCG UCUCGUAUGGGGCU 21 16680
HSV2-UL48-2722 - CGACCCCGUCUCGUAUGGGGCU 22 16681
HSV2-UL48-2723 - ACGACCCCGUCUCGUAUGGGGCU 23 16682
HSV2-UL48-2724 - CACGACCCCGUCUCGUAUGGGGCU 24 16683
HSV2-UL48-2725 - CU UCGACU UGGAGAUGCU 18 16684
HSV2-UL48-2726 - ACU UCGACU UGGAGAUGCU 19 16685
HSV2-UL48-302 - GACUUCGACU UGGAGAUGCU 20 5784
HSV2-UL48-2727 - CGACUUCGACUUGGAGAUGCU 21 16686
HSV2-UL48-2728 - ACGACUUCGACUUGGAGAUGCU 22 16687
HSV2-UL48-2729 - GACG ACUUCGACUUGGAGAUGCU 23 16688
HSV2-UL48-2730 - GGACGACUUCGACUUGGAGAUGCU 24 16689
HSV2-UL48-2731 - ACGUGGACGAUUU UGAGU 18 16690
HSV2-UL48-2732 - GACGUGGACGAUUU UGAGU 19 16691
HSV2-UL48-884 - GGACG UGGACGAUUU UGAGU 20 6261
HSV2-UL48-2733 - UGGACGUGGACGAUU UUGAGU 21 16692
HSV2-UL48-2734 - UUGGACGUGGACGAU U UUGAG U 22 16693
HSV2-UL48-2735 - UUUGGACGUGGACGAU UUUGAGU 23 16694
HSV2-UL48-2736 - CU UUGGACGUGGACGAUUU UGAGU 24
16695
HSV2-UL48-2737 - CAACGGAUCGCUCACCGU 18 16696
HSV2-UL48-2738 - UCAACGGAUCGCUCACCGU 19 16697
HSV2-UL48-817 - AUCAACGGAUCGCUCACCGU 20 6219
HSV2-UL48-2739 - UAUCAACGGAUCGCUCACCGU 21 16698
HSV2-UL48-2740 - UUAUCAACGGAUCGCUCACCGU 22 16699
HSV2-UL48-2741 - UUUAUCAACGGAUCGCUCACCGU 23 16700
HSV2-UL48-2742 - GUUUAUCAACGGAUCGCUCACCGU 24 16701
HSV2-UL48-2743 - CCCACG ACCCCG UCUCG U 18 16702
HSV2-UL48-2744 - ACCCACG ACCCCG UCU CG U 19 16703
HSV2-UL48-879 - G ACCCACG ACCCCG UCUCG U 20 6257
HSV2-UL48-2745 - UGACCCACG ACCCCG UCUCG U 21 16704
HSV2-UL48-2746 - AUGACCCACGACCCCGUCUCGU 22 16705
HSV2-UL48-2747 - AAUG ACCCACG ACCCCG UCUCG U 23 16706
HSV2-UL48-2748 - GAAUG ACCCACG ACCCCG UCUCG U 24 16707
HSV2-UL48-2749 - CCUGAACCUCCCGCUGG U 18 16708
HSV2-UL48-2750 - ACCUGAACCUCCCGCUGGU 19 16709
HSV2-UL48-828 - CACCUGAACCUCCCGCUGGU 20 6224
HSV2-UL48-2751 - GCACCUGAACCUCCCGCUGGU 21 16710
HSV2-UL48-2752 - AGCACCUGAACCUCCCGCUGGU 22 16711
HSV2-UL48-2753 - GAGCACCUGAACCUCCCGCUGGU 23 16712
HSV2-UL48-2754 - CGAGCACCUGAACCUCCCGCUGGU 24 16713
HSV2-UL48-2755 - CAUGGGCAUUGACGACU U 18 16714
HSV2-UL48-2756 - CCAUGGGCAUUGACGACUU 19 16715 HSV2-UL48-315 - GCCAUGGGCAU UGACGACUU 20 5797
HSV2-UL48-2757 - UGCCAUGGGCAUUGACGACUU 21 16716
HSV2-UL48-2758 - AUGCCAUGGGCAU UGACGACU U 22 16717
HSV2-UL48-2759 - GAUGCCAUGGGCAUUGACGACUU 23 16718
HSV2-UL48-2760 - CGAUGCCAUGGGCAUUGACGACUU 24 16719
HSV2-UL48-2761 - AUGGGCAUUGACGACU UU 18 16720
HSV2-UL48-2762 - CAUGGGCAU UG ACG ACU U U 19 16721
HSV2-UL48-316 - CCAUGGGCAUUGACGACUUU 20 5798
HSV2-UL48-2763 - GCCAUGGGCAU UGACGACUUU 21 16722
HSV2-UL48-2764 - UGCCAUGGGCAUUGACGACUU U 22 16723
HSV2-UL48-2765 - AUGCCAUGGGCAUUGACGACU UU 23 16724
HSV2-UL48-2766 - GAUGCCAUGGGCAUUGACGACUUU 24 16725
HSV2-UL48-2767 - CUGCAUCUAUACCUCUU U 18 16726
HSV2-UL48-2768 - UCUGCAUCUAUACCUCU UU 19 16727
HSV2-UL48-809 - U UCUGCAUCUAUACCUCUUU 20 6212
HSV2-UL48-2769 - U UUCUGCAUCUAUACCUCUUU 21 16728
HSV2-UL48-2770 - GU UUCUGCAUCUAUACCUCUU U 22 16729
HSV2-UL48-2771 - UGUU UCUGCAUCUAUACCUCUU U 23 16730
HSV2-UL48-2772 - CUGUUUCUGCAUCUAUACCUCUUU 24 16731
Table 13A provides exemplary targeting domains for knocking out the UL48 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase) Table 13A
Figure imgf000638_0001
Table 13B provides exemplary targeting domains for knocking out the UL48 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 13B
Figure imgf000639_0001
Table 14A provides exemplary targeting domains for knocking out the UL54 gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 14A
Figure imgf000639_0002
HSV-UL54-1202 + GUCGGUAGCCAUGUUGU 17 16733
HSV-UL54-93 + GCGAGGCGUCGAGGCUU 17 6516
HSV-UL54-16 - GCUUCCCCCCGGGAACCGCA 20 6439
HSV-UL54-27 + GGAUGCGGUGCCUUGGUCGA 20 6450
HSV-UL54-1203 + GUAGGUCGCCGGGGCUGGGA 20 16734
HSV-UL54-11 - GAUCCGCCACCCGCGACCAC 20 6434
HSV-UL54-28 + GAUGCGGUGCCUUGGUCGAC 20 6451
HSV-UL54-121 - GGCGAUUCCCAAAGGUCCCC 20 6544
HSV-UL54-22 - GGCCGGGGUCGAUACGGCCC 20 6445
HSV-UL54-25 + GGCCGUAUCGACCCCGGCCC 20 6448
HSV-UL54-150 + GGUGUGGAGUCGGCGCCGCC 20 6573
HSV-UL54-1204 + GGGCGUUUCUGGAGACGCGC 20 16735
HSV-UL54-1205 + GUAGCCAUGUUGUAGGUCGC 20 16736
HSV-UL54-40 + GACCACACGCCGGUGGUCGC 20 6463
HSV-UL54-1206 + GUU UCUGGAGACGCGCCGGC 20 16737
HSV-UL54-32 + GGUCGACGGGGGUUGGAUGC 20 6455
HSV-UL54-169 + GGGCGAGGCGUCGAGGCUUC 20 6592
HSV-UL54-114 - GGAGUGUUCCUCGUCGGACG 20 6537
HSV-UL54-151 + GUGUGGAGUCGGCGCCGCCG 20 6574
HSV-UL54-42 + GGCGAGGCGUCGAGGCUUCG 20 6465
HSV-UL54-134 - GGAACCGCACGGGGGGAAGG 20 6557
HSV-UL54-15 - GGUCGCGCCUCGGGACCAGG 20 6438
HSV-UL54-38 + GAGGCGCGACCACACGCCGG 20 6461
HSV-UL54-178 + GCGUCCUCGGGGCGGGCCGG 20 6601
HSV-UL54-43 + GCGAGGCGUCGAGGCUUCGG 20 6466
HSV-UL54-23 + GCGCCGGCGGGGUUUUGGUG 20 6446
HSV-UL54-50 + GUCCUCCUCGAGCUCGCUGU 20 6473
HSV-UL54-45 + GGGCGGGCCGGGGGACCUUU 20 6468
HSV-UL54-1207 + GAGACGCGCCGGCGGGGUUU 20 16738
Table 14B provides exemplary targeting domains for knocking out the UL54 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 14B
Figure imgf000640_0001
HSV-UL54-218 - CCAACCCCCG U CG ACCA 17 6641
HSV-UL54-79 + UGCGGUGCCUUGGUCGA 17 6502
HSV-UL54-59 - ACCCCUGCGGAGACGGA 17 6482
HSV-UL54-73 - CGGGGCCGGGGUCGAUA 17 6496
HSV-UL54-103 + CGAGCUCGCUGUCGGAC 17 6526
HSV-UL54-76 + CGGGGCCGUAUCGACCC 17 6499
HSV-UL54-74 - CGGGGUCGAUACGGCCC 17 6497
HSV-UL54-77 + CGUAUCGACCCCGGCCC 17 6500
HSV-UL54-242 + CCCCCCGUGCGGUUCCC 17 6665
HSV-UL54-241 + UCCCCCCGUGCGGUUCC 17 6664
HSV-UL54-194 - CCG AG U CCGACAG CAG C 17 6617
HSV-UL54-232 + UGUGGAGUCGGCGCCGC 17 6655
HSV-UL54-1208 + CGUUUCUGGAGACGCGC 17 16739
HSV-UL54-92 + CACACGCCGGUGGUCGC 17 6515
HSV-UL54-1209 + UCUGGAGACGCGCCGGC 17 16740
HSV-UL54-1210 + UUGUAGGUCGCCGGGGC 17 16741
HSV-UL54-84 + CGACGGGGGUUGGAUGC 17 6507
HSV-UL54-252 + CGAGGCGUCGAGGCUUC 17 6675
HSV-UL54-99 + CAUGUCCUCGUCCGACG 17 6522
HSV-UL54-81 + CGGUGCCUUGGUCGACG 17 6504
HSV-UL54-243 + CCCCCGUGCGGUUCCCG 17 6666
HSV-UL54-1211 + CAUGUUGUAGGUCGCCG 17 16742
HSV-UL54-195 - CG AG U CCGACAG CAGCG 17 6618
HSV-UL54-1212 + CUGGAGACGCGCCGGCG 17 16743
HSV-UL54-101 + CGCUGCUGUCGGACUCG 17 6524
HSV-UL54-67 - CGCGCCUCGGGACCAGG 17 6490
HSV-UL54-70 - CCCCGGGAACCGCACGG 17 6493
HSV-UL54-86 + CCCCGUGCGGUUCCCGG 17 6509
HSV-UL54-1213 + UUCUGGAGACGCGCCGG 17 16744
HSV-UL54-95 + AGGCGUCGAGGCUUCGG 17 6518
HSV-UL54-245 + ACGCCGGUGGUCGCGGG 17 6668
HSV-UL54-240 + UCGACGGGGGUUGGAUG 17 6663
HSV-UL54-64 - CCGCGACCACCGGCGUG 17 6487
HSV-UL54-100 + CCCGCUGCUGUCGGACU 17 6523
HSV-UL54-1214 + UGUAGGUCGCCGGGGCU 17 16745
HSV-UL54-247 + CGCGGGUGGCGGAUCGU 17 6670
HSV-UL54-196 - CGGGGAGUGUUCCUCGU 17 6619
HSV-UL54-102 + CUCCUCGAGCUCGCUGU 17 6525
HSV-UL54-97 + CGGGCCGGGGGACCUUU 17 6520
HSV-UL54-1215 + ACGCGCCGGCGGGGUUU 17 16746
HSV-UL54-9 - AUCGACGCGGCGAU UCCCAA 20 6432
HSV-UL54-6 - UUCCUCGUCGGACGAGGACA 20 6429
HSV-UL54-1216 - UCCAGAAACGCCCACAACCA 20 16747
HSV-UL54-135 - CAU CCAACCCCCG U CG ACCA 20 6558
HSV-UL54-181 + UCCGCCCCUCCGUCUCCGCA 20 6604
HSV-UL54-116 - AUGGAAGACCCCUGCGGAGA 20 6539 HSV-UL54-46 + UUUGGGAAUCGCCGCGUCGA 20 6469
HSV-UL54-7 - AAGACCCCUGCGGAGACGGA 20 6430
HSV-UL54-133 - CCGGGAACCGCACGGGGGGA 20 6556
HSV-UL54-21 - CGCCGGGGCCGGGGUCGAUA 20 6444
HSV-UL54-132 - CUUCCCCCCGGGAACCGCAC 20 6555
HSV-UL54-14 - UGUGGUCGCGCCUCGGGACC 20 6437
HSV-UL54-24 + CGCCGGGGCCGUAUCGACCC 20 6447
HSV-UL54-130 - CCAGGCGGUCGGCUUCCCCC 20 6553
HSV-UL54-159 + CUUCCCCCCGUGCGGUUCCC 20 6582
HSV-UL54-1217 + UAGCCAUGUUGUAGGUCGCC 20 16748
HSV-UL54-158 + CCUUCCCCCCGUGCGGUUCC 20 6581
HSV-UL54-111 - ACCCCGAGUCCGACAGCAGC 20 6534
HSV-UL54-37 + CCCGAGGCGCGACCACACGC 20 6460
HSV-UL54-170 + CGUCGAGGCUUCGGGGGUGC 20 6593
HSV-UL54-184 + UCCCCGCUGCUGUCGGACUC 20 6607
HSV-UL54-13 - CCGGCGUGUGGUCGCGCCUC 20 6436
HSV-UL54-44 + UCGGGGGUGCCGGCGUCCUC 20 6467
HSV-UL54-5 - CGAGCUCGAGGAGGACGCUC 20 6428
HSV-UL54-182 + CCG CCCCU CCG UCU CCG CAG 20 6605
HSV-UL54-17 - UUCCCCCCGGGAACCGCACG 20 6440
HSV-UL54-47 + UUCCAUGUCCUCGUCCGACG 20 6470
HSV-UL54-8 - AGGGGCGGAGGCCAUCGACG 20 6431
HSV-UL54-29 + AUGCGGUGCCU UGGUCGACG 20 6452
HSV-UL54-136 - ACCAAGGCACCGCAUCCCCG 20 6559
HSV-UL54-36 + AAGCCGACCGCCUGGUCCCG 20 6459
HSV-UL54-160 + UUCCCCCCGUGCGGUUCCCG 20 6583
HSV-UL54-1218 + AGCCAUGUUGUAGGUCGCCG 20 16749
HSV-UL54-145 - CGAGGUCGCCGCCGGGGCCG 20 6568
HSV-UL54-112 - CCCCGAGUCCGACAGCAGCG 20 6535
HSV-UL54-124 - CGACGCCUCGCCCGGCAGCG 20 6547
HSV-UL54-1219 + UUUCUGGAGACGCGCCGGCG 20 16750
HSV-UL54-139 - CAUCCCCGAGGCGGGCGGCG 20 6562
HSV-UL54-49 + CCCCGCUGCUGUCGGACUCG 20 6472
HSV-UL54-3 - CCUGUCCGACAGCGAGCUCG 20 6426
HSV-UL54-39 + CGACCACACGCCGGUGGUCG 20 6462
HSV-UL54-272 - AGAAACGCCCACAACCAAGG 20 6695
HSV-UL54-137 - AAGGCACCGCAUCCCCGAGG 20 6560
HSV-UL54-18 - UCCCCCCGGGAACCGCACGG 20 6441
HSV-UL54-30 + UGCGGUGCCUUGGUCGACGG 20 6453
HSV-UL54-146 - CGGGGUCGAUACGGCCCCGG 20 6569
HSV-UL54-26 + CGUAUCGACCCCGGCCCCGG 20 6449
HSV-UL54-34 + UCCCCCCGUGCGGUUCCCGG 20 6457
HSV-UL54-1220 + CGUUUCUGGAGACGCGCCGG 20 16751
HSV-UL54-35 + CCCCCCGUGCGGUUCCCGGG 20 6458
HSV-UL54-162 + CACACGCCGGUGGUCGCGGG 20 6585
HSV-UL54-20 - CACCGCAUCCCCGAGGCGGG 20 6443 HSV-UL54-157 + UGGUCGACGGGGGUUGGAUG 20 6580
HSV-UL54-33 + CGGGCCACCUUCCCCCCGUG 20 6456
HSV-UL54-12 - CACCCGCGACCACCGGCGUG 20 6435
HSV-UL54-2 - UAUGCUAAUCGACCUAGGAU 20 6425
HSV-UL54-1 - AUUGAUAUGCUAAUCGACCU 20 6424
HSV-UL54-128 - ACCGGCGUGUGGUCGCGCCU 20 6551
HSV-UL54-52 + UGUCGGACAGGUCCAAUCCU 20 6475
HSV-UL54-171 + UUCGGGGGUGCCGGCGUCCU 20 6594
HSV-UL54-1221 + UGUUGUAGGUCGCCGGGGCU 20 16752
HSV-UL54-113 - CAGCGGGGAGUGUUCCUCGU 20 6536
HSV-UL54-1222 + AAUGUCGGUAGCCAUGUUGU 20 16753
HSV-UL54-41 + CGGGCGAGGCGUCGAGGCUU 20 6464
Table 14C provides exemplary targeting domains for knocking out the UL54 gene selected according to the third tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 14C
Figure imgf000643_0001
HSV-UL54-248 + GCUCCCCGCCGCGCUGC 17 6671
HSV-UL54-96 + GGGGUGCCGGCGUCCUC 17 6519
HSV-UL54-57 - GCUCGAGGAGGACGCUC 17 6480
HSV-UL54-260 + GUCCUCGGGGCGGGCCG 17 6683
HSV-UL54-228 - GGUCGCCGCCGGGGCCG 17 6651
HSV-UL54-255 + GGGUGCCGGCGUCCUCG 17 6678
HSV-UL54-55 - GUCCGACAGCGAGCUCG 17 6478
HSV-UL54-220 - GCACCGCAUCCCCGAGG 17 6643
HSV-UL54-200 - GACCCCUGCGGAGACGG 17 6623
HSV-UL54-198 - GACAUGGAAGACCCCUG 17 6621
HSV-UL54-85 + G CCACCU U CCCCCCG U G 17 6508
HSV-UL54-235 + GACCUCGCCGCCCGCCU 17 6658
HSV-UL54-211 - GGCGUGUGGUCGCGCCU 17 6634
HSV-UL54-254 + GGGGGUGCCGGCGUCCU 17 6677
HSV-UL54-231 + GGGUUUUGGUGUGGAGU 17 6654
HSV-UL54-270 + GAUUAGCAUAUCAAUGU 17 6693
HSV-UL54-1227 + GCGACCCCCUUGGUUGU 17 16758
HSV-UL54-262 + GCGGGCCGGGGGACCUU 17 6685
HSV-UL54-109 - GCUCUGGAGCGGGACGAGGA 20 6532
HSV-UL54-144 - GCGAGGUCGCCGCCGGGGCC 20 6567
HSV-UL54-140 - GCGGGCGGCGAGGUCGCCGC 20 6563
HSV-UL54-126 - GCCUCGCCCGGCAGCGCGGC 20 6549
HSV-UL54-143 - GGCGAGGUCGCCGCCGGGGC 20 6566
HSV-UL54-174 + GGUGCCGGCGUCCUCGGGGC 20 6597
HSV-UL54-1228 + GUCGCCGGGGCUGGGAUGGC 20 16759
HSV-UL54-153 + GCGACCUCGCCGCCCGCCUC 20 6576
HSV-UL54-110 - GACCCCGAGUCCGACAGCAG 20 6533
HSV-UL54-107 - GGACGCUCUGGAGCGGGACG 20 6530
HSV-UL54-142 - GGGCGGCGAGGUCGCCGCCG 20 6565
HSV-UL54-177 + GGCGUCCUCGGGGCGGGCCG 20 6600
HSV-UL54-4 - GUCCGACAGCGAGCUCGAGG 20 6427
HSV-UL54-117 - GAAGACCCCUGCGGAGACGG 20 6540
HSV-UL54-173 + GGGUGCCGGCGUCCUCGGGG 20 6596
HSV-UL54-1229 + GGUCGCCGGGGCUGGGAUGG 20 16760
HSV-UL54-115 - GAGGACAUGGAAGACCCCUG 20 6538
HSV-UL54-152 + GGCGACCUCGCCGCCCGCCU 20 6575
HSV-UL54-156 + GCCUCGGGGAUGCGGUGCCU 20 6579
HSV-UL54-148 + GCGGGGUUUUGGUGUGGAGU 20 6571
HSV-UL54-164 + GGUCGCGGGUGGCGGAUCGU 20 6587
HSV-UL54-129 - GCGCCUCGGGACCAGGCGGU 20 6552
HSV-UL54-31 + GUGCCUUGGUCGACGGGGGU 20 6454
HSV-UL54-187 + GUCGAUUAGCAUAUCAAUGU 20 6610
HSV-UL54-183 + GGAACACUCCCCGCUGCUGU 20 6606
HSV-UL54-179 + GGGGCGGGCCGGGGGACCUU 20 6602 Table 14D provides exemplary targeting domains for knocking out the UL54 gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 14D
Figure imgf000645_0001
HSV-UL54-207 - CGCCUCGCCCGGCAGCG 17 6630
HSV-UL54-210 - CGCCCGGCAGCGCGGCG 17 6633
HSV-UL54-222 - CCCCGAGGCGGGCGGCG 17 6645
HSV-UL54-250 + CGCCGCGCUGCCGGGCG 17 6673
HSV-UL54-237 + CCUCGCCGCCCGCCUCG 17 6660
HSV-UL54-251 + UGCCGGGCGAGGCGUCG 17 6674
HSV-UL54-268 + CGGACUCGGGGUCGUCG 17 6691
HSV-UL54-91 + CCACACGCCGGUGGUCG 17 6514
HSV-UL54-468 - AACG CCCACAACCAAG G 17 6889
HSV-UL54-217 - ACCGCACGGGGGGAAGG 17 6640
HSV-UL54-191 - UCUGGAGCGGGACGAGG 17 6614
HSV-UL54-56 - CGACAGCGAGCUCGAGG 17 6479
HSV-UL54-78 + AUCGACCCCGGCCCCGG 17 6501
HSV-UL54-261 + UCCUCGGGGCGGGCCGG 17 6684
HSV-UL54-208 - CUCGCCCGGCAGCGCGG 17 6631
HSV-UL54-269 + ACUCGGGGUCGUCGCGG 17 6692
HSV-UL54-203 - CGGAGACGGAGGGGCGG 17 6626
HSV-UL54-71 - CCCGGGAACCGCACGGG 17 6494
HSV-UL54-87 + CCCGUGCGGUUCCCGGG 17 6510
HSV-UL54-72 - CGCAUCCCCGAGGCGGG 17 6495
HSV-UL54-202 - CUGCGGAGACGGAGGGG 17 6625
HSV-UL54-256 + UGCCGGCGUCCUCGGGG 17 6679
HSV-UL54-1233 + CGCCGGGGCUGGGAUGG 17 16764
HSV-UL54-246 + CCGGUGGUCGCGGGUGG 17 6669
HSV-UL54-238 + CGCCCGCCUCGGGGAUG 17 6661
HSV-UL54-75 + CCGGCGGGGUUU UGGUG 17 6498
HSV-UL54-239 + UCGGGGAUGCGGUGCCU 17 6662
HSV-UL54-104 + CGGACAGGUCCAAUCCU 17 6527
HSV-UL54-212 - CCUCGGGACCAGGCGGU 17 6635
HSV-UL54-83 + CCUUGGUCGACGGGGGU 17 6506
HSV-UL54-266 + ACACUCCCCGCUGCUGU 17 6689
HSV-UL54-1234 - CCAGAAACGCCCACAACCAA 20 16765
HSV-UL54-1235 - AG CCCCGG CG ACCU ACAACA 20 16766
HSV-UL54-51 + CCUCGAGCUCGCUGUCGGAC 20 6474
HSV-UL54-131 - CAGGCGGUCGGCUUCCCCCC 20 6554
HSV-UL54-161 + CCGGGGGGAAGCCGACCGCC 20 6584
HSV-UL54-141 - CGGGCGGCGAGGUCGCCGCC 20 6564
HSV-UL54-10 - CGAAGCCUCGACGCCUCGCC 20 6433
HSV-UL54-176 + CGGCGUCCUCGGGGCGGGCC 20 6599
HSV-UL54-166 + CGGCUCCCCGCCGCGCUGCC 20 6589
HSV-UL54-106 - CGAGGAGGACGCUCUGGAGC 20 6529
HSV-UL54-123 - CCGGCCCGCCCCGAGGACGC 20 6546
HSV-UL54-147 - ACUCCACACCAAAACCCCGC 20 6570
HSV-UL54-149 + UGGUGUGGAGUCGGCGCCGC 20 6572
HSV-UL54-180 + CUCCGCCCCUCCGUCUCCGC 20 6603
HSV-UL54-138 - AGGCACCGCAUCCCCGAGGC 20 6561 HSV-UL54-175 + CCGGCGUCCUCGGGGCGGGC 20 6598
HSV-UL54-1236 + AUGUUGUAGGUCGCCGGGGC 20 16767
HSV-UL54-165 + UCGGCUCCCCGCCGCGCUGC 20 6588
HSV-UL54-1237 + CCCUUGGUUGUGGGCGUUUC 20 16768
HSV-UL54-271 - CAGAAACG CCCACAACCAAG 20 6694
HSV-UL54-118 - AGACCCCUGCGGAGACGGAG 20 6541
HSV-UL54-105 - UCGAGGAGGACGCUCUGGAG 20 6528
HSV-UL54-122 - AGGUCCCCCGGCCCGCCCCG 20 6545
HSV-UL54-127 - CCUCGCCCGGCAGCGCGGCG 20 6550
HSV-UL54-167 + CCCCGCCGCGCUGCCGGGCG 20 6590
HSV-UL54-154 + CGACCUCGCCGCCCGCCUCG 20 6577
HSV-UL54-172 + CGGGGGUGCCGGCGUCCUCG 20 6595
HSV-UL54-168 + CGCUGCCGGGCGAGGCGUCG 20 6591
HSV-UL54-185 + UGUCGGACUCGGGGUCGUCG 20 6608
HSV-UL54-108 - CGCUCUGGAGCGGGACGAGG 20 6531
HSV-UL54-125 - CGCCUCGCCCGGCAGCGCGG 20 6548
HSV-UL54-186 + CGGACUCGGGGUCGUCGCGG 20 6609
HSV-UL54-120 - CUGCGGAGACGGAGGGGCGG 20 6543
HSV-UL54-19 - CCCCCCGGGAACCGCACGGG 20 6442
HSV-UL54-119 - CCCCUGCGGAGACGGAGGGG 20 6542
HSV-UL54-163 + ACGCCGGUGGUCGCGGGUGG 20 6586
HSV-UL54-155 + CGCCGCCCGCCUCGGGGAUG 20 6578
HSV-UL54-48 + CUCCCCGCUGCUGUCGGACU 20 6471
Table 14E provides exemplary targeting domains for knocking out the UL54 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the table can be used with a S. pyogenes Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 14E
Figure imgf000647_0001
HSV-UL54-1242 + AAACGGCAUCCCGCCAA 17 16773
HSV-UL54-1243 + CAGGUAGCACUGCAGAA 17 16774
HSV-UL54-1244 + U CGCAG AACCG CCCGAA 17 16775
HSV-UL54-493 - CCCGGUCCCGGAGCGAA 17 6914
HSV-UL54-530 - GGACCCUAUCAUCGGAA 17 6951
HSV-UL54-1245 + UUGCCGUGCACAUAUAA 17 16776
HSV-UL54-1231 - AGAAACGCCCACAACCA 17 16762
HSV-UL54-1246 + CGGGCCGUGAGCGACCA 17 16777
HSV-UL54-1247 + GGGGUCU UGCAUGACCA 17 16778
HSV-UL54-474 - GGCCCCGGCGCCACCCA 17 6895
HSV-UL54-1248 + GCCGGCCCCAACCCCCA 17 16779
HSV-UL54-1249 + GCCAGCACGGGAGCCCA 17 16780
HSV-UL54-521 - GGCCGCGUCGACAGCCA 17 6942
HSV-UL54-1250 + CUCAUCCGCGGACGCCA 17 16781
HSV-UL54-618 + CGCUUGGGUGGCCAGCA 17 7039
HSV-UL54-1251 + GGCGAGGUUUUCCAGCA 17 16782
HSV-UL54-1252 + CAG CACG CAG U CG CG CA 17 16783
HSV-UL54-557 - CAUCCCGGGGGCCUGCA 17 6978
HSV-UL54-563 - GCCCCCUUAUAUGUGCA 17 6984
HSV-UL54-518 - G AAACCCU G G U CGCU CA 17 6939
HSV-UL54-1253 + CGCGUGCGGGGGGGUCA 17 16784
HSV-UL54-1254 + UCGAUGGUGUCGGCAGA 17 16785
HSV-UL54-1255 + UUUCCCAGGAAACCCGA 17 16786
HSV-UL54-1256 + CCGAACGGCGGGGUCGA 17 16787
HSV-UL54-472 - GCGUCGGCGCGGACGGA 17 6893
HSV-UL54-1257 + ACAGCGCCAUCAGCGGA 17 16788
HSV-UL54-490 - ACCCCCCCGCACGCGGA 17 6911
HSV-UL54-479 - GCGAGGCGCGGCGCGGA 17 6900
HSV-UL54-471 - CCCCGCGUCGGCGCGGA 17 6892
HSV-UL54-533 - UCUGCAGUGCUACCUGA 17 6954
HSV-UL54-562 - UCGCGUGUGCGAGCUGA 17 6983
HSV-UL54-488 - GGCCCCCCCUCCGCUGA 17 6909
HSV-UL54-1258 + UAUUCUUGCCUAAAAUA 17 16789
HSV-UL54-1259 + CGCCGCGCGCUCGGAUA 17 16790
HSV-UL54-1260 + CCGCCGUUCCGAUGAUA 17 16791
HSV-UL54-1261 + UUUGCCGUGCACAUAUA 17 16792
HSV-UL54-540 - ACGCCUGUCGGACAUUA 17 6961
HSV-UL54-619 + GCUUGGGUGGCCAGCAC 17 7040
HSV-UL54-1262 + GGCGUCGCCGCGAGCAC 17 16793
HSV-UL54-1263 + GGUCGUCCAGCCCGCAC 17 16794
HSV-UL54-1264 + UUCCCAGGAAACCCGAC 17 16795
HSV-UL54-1265 + UAUCCUUAAUGUCCGAC 17 16796
HSV-UL54-1266 + CAGCUCGCACACGCGAC 17 16797
HSV-UL54-1267 + GCCUUUCGCUCCGGGAC 17 16798
HSV-UL54-1268 + GGGGGCGAUAGUGUGAC 17 16799
HSV-UL54-560 - GGGUCUCAUUGAAAUAC 17 6981 HSV-UL54-1269 + UCGGGCCGUGAGCGACC 17 16800
HSV-UL54-1270 + CCUUUCGCUCCGGGACC 17 16801
HSV-UL54-1271 + AGGGGUCUUGCAUGACC 17 16802
HSV-UL54-517 - G G U U U CCU GGGAAACCC 17 6938
HSV-UL54-528 - UCUGCCGCUCCGCCCCC 17 6949
HSV-UL54-1272 + CCGCCAUGCAGGCCCCC 17 16803
HSV-UL54-504 - CCGCCGCGAACAGCCCC 17 6925
HSV-UL54-1273 + CCCGCCAUGCAGGCCCC 17 16804
HSV-UL54-1274 + UCGUGGCCGCGGGCCCC 17 16805
HSV-UL54-1275 + GGCCAGCACGGGAGCCC 17 16806
HSV-UL54-491 - CGCGGACGGCCGCGCCC 17 6912
HSV-UL54-524 - AAAU CU CAU CG AGG CCC 17 6945
HSV-UL54-473 - GCGCGGACGGACGGCCC 17 6894
HSV-UL54-500 - CUUUGGACGCAGUGCCC 17 6921
HSV-UL54-554 - AUGCACU UUUACAUCCC 17 6975
HSV-UL54-1276 + AGCGACCAGGGUUUCCC 17 16807
HSV-UL54-1277 + U CU CAU CCG CGGACG CC 17 16808
HSV-UL54-561 - ACUGGACACGCACCGCC 17 6982
HSV-UL54-487 - GCCACGAGGCACGCGCC 17 6908
HSV-UL54-1278 + UCGCCGUGGGUGGCGCC 17 16809
HSV-UL54-522 - CGACUGCGUGCUGCGCC 17 6943
HSV-UL54-1279 + GGUUGGCGAGGCGGGCC 17 16810
HSV-UL54-639 + UCAGCGGAGGGGGGGCC 17 7060
HSV-UL54-553 - GAUGCACUUUUACAUCC 17 6974
HSV-UL54-542 - CUUUGUGUUGGUCAUCC 17 6963
HSV-UL54-1280 + CGCGACUGGAACACUCC 17 16811
HSV-UL54-1281 + AGGGCGCCUUUCGCUCC 17 16812
HSV-UL54-482 - AGCAGCUCGACGUCUCC 17 6903
HSV-UL54-492 - CGGCCGCGCCCCGGUCC 17 6913
HSV-UL54-597 + UUCCGAUGAUAGGGUCC 17 7018
HSV-UL54-515 - AGACCCGUCGGGU UUCC 17 6936
HSV-UL54-1282 + CCUCGAUGAGAUUUUCC 17 16813
HSV-UL54-508 - GUGCUGGCCACCCAAGC 17 6929
HSV-UL54-526 - GUCCGCGGAUGAGACGC 17 6947
HSV-UL54-655 + UCCGUCCGCGCCGACGC 17 7076
HSV-UL54-520 - AUUCGCAGCCAACCCGC 17 6941
HSV-UL54-230 - CCACACCAAAACCCCGC 17 6653
HSV-UL54-1283 + CUGUCGACGCGGCCCGC 17 16814
HSV-UL54-1284 + GCGUGCCUCGUGGCCGC 17 16815
HSV-UL54-1208 + CGUUUCUGGAGACGCGC 17 16739
HSV-UL54-1285 + ACUGCAGAAAGGGGCGC 17 16816
HSV-UL54-1286 + CUCGCCGUGGGUGGCGC 17 16817
HSV-UL54-1287 + AAAGUGCAUCGUCUCGC 17 16818
HSV-UL54-1288 + GACGCGGUUGGCGAGGC 17 16819
HSV-UL54-1289 + AG AACCG CCCG AACGG C 17 16820
HSV-UL54-1209 + UCUGGAGACGCGCCGGC 17 16740 HSV-UL54-1290 + CAGGGGCUGUUCGCGGC 17 16821
HSV-UL54-537 - CCGAGGCCUGUGCGGGC 17 6958
HSV-UL54-552 - ACCGUGGGGGU UGGGGC 17 6973
HSV-UL54-559 - CCGGGGGCCUGCAUGGC 17 6980
HSV-UL54-503 - UGCAAGACCCCUUUGGC 17 6924
HSV-UL54-1291 + AAUGAGACCCGCCAUGC 17 16822
HSV-UL54-506 - CCCCUGGGCUCCCGUGC 17 6927
HSV-UL54-532 - AACGGCGGCCGCCGUGC 17 6953
HSV-UL54-1292 + CGCGGCCGUCCGCGUGC 17 16823
HSV-UL54-536 - AGGCCCGAGGCCUGUGC 17 6957
HSV-UL54-1293 + CAGCCCGCACAGGCCUC 17 16824
HSV-UL54-1294 + GAGGGCGCCUU UCGCUC 17 16825
HSV-UL54-1295 + AUGUGCGGUAGAGGCUC 17 16826
HSV-UL54-481 - GAGCAGCUCGACGUCUC 17 6902
HSV-UL54-514 - UGACGCCGAGACCCGUC 17 6935
HSV-UL54-1296 + CCGCGUGCGGGGGGGUC 17 16827
HSV-UL54-1147 + ACAGGCCUCGGGCCUUC 17 7419
HSV-UL54-495 - CAU CG ACCCCG CCG U U C 17 6916
HSV-UL54-661 + UUGGUUGUGGGCGUUUC 17 7082
HSV-UL54-1297 + ACGGCAUCCCGCCAAAG 17 16828
HSV-UL54-1298 + GGUAGCACUGCAGAAAG 17 16829
HSV-UL54-467 - AAACGCCCACAACCAAG 17 6888
HSV-UL54-507 - CGUGCUGGCCACCCAAG 17 6928
HSV-UL54-1299 + UGCCGUGCACAUAUAAG 17 16830
HSV-UL54-1300 + CCAGCACGGGAGCCCAG 17 16831
HSV-UL54-1301 + GUCGAUGGUGUCGGCAG 17 16832
HSV-UL54-1302 + AGGGACAGCGCCAUCAG 17 16833
HSV-UL54-1303 + CAGCGCCAUCAGCGGAG 17 16834
HSV-UL54-480 - CGAGGCGCGGCGCGGAG 17 6901
HSV-UL54-1304 + GGGUCCUGGGGGCGGAG 17 16835
HSV-UL54-1305 + CUGCGAAUGUGCGGUAG 17 16836
HSV-UL54-486 - GGGGGCCCGCGGCCACG 17 6907
HSV-UL54-489 - CCUGACCCCCCCGCACG 17 6910
HSV-UL54-1306 + GUCCGUCCGCGCCGACG 17 16837
HSV-UL54-583 + ACACGCCGCGCUCGACG 17 7004
HSV-UL54-1307 + GGCCUUGGCUGUCGACG 17 16838
HSV-UL54-545 - GAUCGACUACACGACCG 17 6966
HSV-UL54-1308 + CUUUCGCUCCGGGACCG 17 16839
HSV-UL54-519 - CAU U CG CAG CCAACCCG 17 6940
HSV-UL54-534 - UGCUACCUGAAGGCCCG 17 6955
HSV-UL54-1309 + GCUGUCGACGCGGCCCG 17 16840
HSV-UL54-485 - ACGUCUCCGGGGGCCCG 17 6906
HSV-UL54-555 - UGCACUUUUACAUCCCG 17 6976
HSV-UL54-652 + CGCCGUGGGUGGCGCCG 17 7073
HSV-UL54-1192 + CGCGCCGCGCCUCGCCG 17 7448
HSV-UL54-1310 + CGCGUGCCUCGUGGCCG 17 16841 HSV-UL54-600 + CGCCAGCGUCUCAUCCG 17 7021
HSV-UL54-483 - GCAGCUCGACGUCUCCG 17 6904
HSV-UL54-525 - CGAGGCCCUGGCGUCCG 17 6946
HSV-UL54-509 - UGCUGGCCACCCAAGCG 17 6930
HSV-UL54-543 - GCCAACCGCGUCGAGCG 17 6964
HSV-UL54-1311 + CCGUCCGCGCCGACGCG 17 16842
HSV-UL54-497 - AUCCAUAUCCGAGCGCG 17 6918
HSV-UL54-1312 + AAAGGGGCGCAGGCGCG 17 16843
HSV-UL54-476 - CCACCCACGGCGAGGCG 17 6897
HSV-UL54-1313 + GAACCG CCCG AACGG CG 17 16844
HSV-UL54-475 - CGGCGCCACCCACGGCG 17 6896
HSV-UL54-1212 + CUGGAGACGCGCCGGCG 17 16743
HSV-UL54-477 - CACGGCGAGGCGCGGCG 17 6898
HSV-UL54-470 - GCCACCCCGCGUCGGCG 17 6891
HSV-UL54-1314 + GCUCCGGGACCGGGGCG 17 16845
HSV-UL54-527 - CGGAUGAGACGCUGGCG 17 6948
HSV-UL54-1315 + GGCGCAGGCGCGUGGCG 17 16846
HSV-UL54-1316 + GCUCGACGCGGU UGGCG 17 16847
HSV-UL54-1317 + GCGGCCGUCCGCGUGCG 17 16848
HSV-UL54-523 - CCAGGAAAAUCUCAUCG 17 6944
HSV-UL54-1318 + GCCUGGCGCGUGCCUCG 17 16849
HSV-UL54-538 - UGGACGACCUGUGCUCG 17 6959
HSV-UL54-1319 + AGCCCAGGGGCUGUUCG 17 16850
HSV-UL54-1320 + G AU G ACCAACACAAAG G 17 16851
HSV-UL54-468 - AACGCCCACAACCAAGG 17 6889
HSV-UL54-1321 + GCCGUGCACAUAUAAGG 17 16852
HSV-UL54-1322 + CGACGCGGUUGGCGAGG 17 16853
HSV-UL54-1323 + AGCGCCAUCAGCGGAGG 17 16854
HSV-UL54-1324 + CAGAACCGCCCGAACGG 17 16855
HSV-UL54-531 - CCCUAUCAUCGGAACGG 17 6952
HSV-UL54-1325 + GAGGU UUUCCAGCACGG 17 16856
HSV-UL54-556 - GCACUUUUACAUCCCGG 17 6977
HSV-UL54-1213 + UUCUGGAGACGCGCCGG 17 16744
HSV-UL54-484 - CAGCUCGACGUCUCCGG 17 6905
HSV-UL54-510 - GCUGGCCACCCAAGCGG 17 6931
HSV-UL54-1326 + GACAGCGCCAUCAGCGG 17 16857
HSV-UL54-498 - CAUAUCCGAGCGCGCGG 17 6919
HSV-UL54-478 - GGCGAGGCGCGGCGCGG 17 6899
HSV-UL54-1327 + CCAGGGGCUGU UCGCGG 17 16858
HSV-UL54-1328 + CGGCCGUCCGCGUGCGG 17 16859
HSV-UL54-1329 + GCGCCAUCAGCGGAGGG 17 16860
HSV-UL54-511 - CUGGCCACCCAAGCGGG 17 6932
HSV-UL54-1330 + GGCCGUCCGCGUGCGGG 17 16861
HSV-UL54-496 - CGACCCCGCCGUUCGGG 17 6917
HSV-UL54-1331 + CGCCAUCAGCGGAGGGG 17 16862
HSV-UL54-512 - UGGCCACCCAAGCGGGG 17 6933 HSV-UL54-656 + UCCGCGCCGACGCGGGG 17 7077
HSV-UL54-1332 + GCCGUCCGCGUGCGGGG 17 16863
HSV-UL54-1153 + UGAUAGGGUCCUGGGGG 17 7423
HSV-UL54-1333 + CCGCGCCUCGCCGUGGG 17 16864
HSV-UL54-1334 + AAACCCCCCCGCUUGGG 17 16865
HSV-UL54-558 - CCCGGGGGCCUGCAUGG 17 6979
HSV-UL54-1335 + GACUGGAACACUCCUGG 17 16866
HSV-UL54-1336 + CGAUGAUAGGGUCCUGG 17 16867
HSV-UL54-548 - CGACUACACGACCGUGG 17 6969
HSV-UL54-502 - AUGCAAGACCCCU UUGG 17 6923
HSV-UL54-1337 + CCGAUGAUAGGGUCCUG 17 16868
HSV-UL54-547 - UCGACUACACGACCGUG 17 6968
HSV-UL54-1338 + GCGCGGCCGUCCGCGUG 17 16869
HSV-UL54-75 + CCGGCGGGGUUUUGGUG 17 6498
HSV-UL54-1339 + GGUUGGCUGCGAAUGUG 17 16870
HSV-UL54-535 - AAGGCCCGAGGCCUGUG 17 6956
HSV-UL54-1340 + GGCGGAGCGGCAGAUUG 17 16871
HSV-UL54-551 - CACGACCGUGGGGGUUG 17 6972
HSV-UL54-1201 + GGCGACCCCCUUGGUUG 17 16732
HSV-UL54-1341 + UUAUUCUUGCCUAAAAU 17 16872
HSV-UL54-529 - CCCCAGGACCCUAUCAU 17 6950
HSV-UL54-1342 + GCCGCCGUUCCGAUGAU 17 16873
HSV-UL54-1343 + CGGGGUGGCGACCCCCU 17 16874
HSV-UL54-505 - CGCCGCGAACAGCCCCU 17 6926
HSV-UL54-1344 + CCAGCCCGCACAGGCCU 17 16875
HSV-UL54-1345 + GCAGUCGCGCAUGGCCU 17 16876
HSV-UL54-1346 + UCCGAUGAUAGGGUCCU 17 16877
HSV-UL54-516 - GACCCGUCGGGUUUCCU 17 6937
HSV-UL54-1166 + CG U CAAACCCCCCCG CU 17 7433
HSV-UL54-1347 + CUCGACCGCCGCGCGCU 17 16878
HSV-UL54-1348 + AAUGUGCGGUAGAGGCU 17 16879
HSV-UL54-612 + GGAAACCCGACGGGUCU 17 7033
HSV-UL54-546 - AUCGACUACACGACCGU 17 6967
HSV-UL54-513 - UUGACGCCGAGACCCGU 17 6934
HSV-UL54-1349 + GCGCCGCGCCUCGCCGU 17 16880
HSV-UL54-469 - GGGUCGCCACCCCGCGU 17 6890
HSV-UL54-1350 + GCCGCGCUCGACGCGGU 17 16881
HSV-UL54-1351 + CGACGCGGCCCGCGGGU 17 16882
HSV-UL54-549 - UACACGACCGUGGGGGU 17 6970
HSV-UL54-539 - CUCGCGGCGACGCCUGU 17 6960
HSV-UL54-544 - CGUCGAGCGCGGCGUGU 17 6965
HSV-UL54-1352 + GGCGGGGUCGAUGGUGU 17 16883
HSV-UL54-541 - UAUUGCCUCCUUUGUGU 17 6962
HSV-UL54-1227 + GCGACCCCCUUGGUUGU 17 16758
HSV-UL54-501 - GUCAUGCAAGACCCCUU 17 6922
HSV-UL54-499 - CGCAUCAGCGAAAGCUU 17 6920 HSV-UL54-1353 + GUCAAACCCCCCCGCUU 17 16884
HSV-UL54-494 - CCAU CG ACCCCG CCG U U 17 6915
HSV-UL54-550 - ACACGACCGUGGGGGUU 17 6971
HSV-UL54-1215 + ACGCGCCGGCGGGGUU U 17 16746
HSV-UL54-1354 - CUGCAACUCCCUAUUUU 17 16885
HSV-UL54-1355 + GGAAACGGCAUCCCGCCAAA 20 16886
HSV-UL54-1356 + UUCAGGUAGCACUGCAGAAA 20 16887
HSV-UL54-1025 + GGGCUGUUCGCGGCGGGAAA 20 7339
HSV-UL54-1357 + GGCCAGGAUGACCAACACAA 20 16888
HSV-UL54-1234 - CCAG AAACG CCCACAACCAA 20 16765
HSV-UL54-1358 + G G G AAACG G CAU CCCG CCAA 20 16889
HSV-UL54-1359 + CUUCAGGUAGCACUGCAGAA 20 16890
HSV-UL54-1360 + GGAUCGCAGAACCGCCCGAA 20 16891
HSV-UL54-297 - CGCCCCGGUCCCGGAGCGAA 20 6720
HSV-UL54-334 - CCAGGACCCUAUCAUCGGAA 20 6757
HSV-UL54-1361 + UAUUUGCCGUGCACAUAUAA 20 16892
HSV-UL54-1216 - UCCAGAAACGCCCACAACCA 20 16747
HSV-UL54-1362 + GCUCGGGCCGUGAGCGACCA 20 16893
HSV-UL54-1363 + AAAGGGGUCUUGCAUGACCA 20 16894
HSV-UL54-278 - GACGGCCCCGGCGCCACCCA 20 6701
HSV-UL54-1364 + CUCGCCGGCCCCAACCCCCA 20 16895
HSV-UL54-1365 + GUGGCCAGCACGGGAGCCCA 20 16896
HSV-UL54-325 - GCGGGCCGCGUCGACAGCCA 20 6748
HSV-UL54-1366 + CGUCUCAUCCGCGGACGCCA 20 16897
HSV-UL54-419 + CCCCGCUUGGGUGGCCAGCA 20 6842
HSV-UL54-1367 + CGUGGCGAGGUUUUCCAGCA 20 16898
HSV-UL54-1012 + GCGCAGCACGCAGUCGCGCA 20 7332
HSV-UL54-361 - UUACAUCCCGGGGGCCUGCA 20 6784
HSV-UL54-367 - AUCGCCCCCUUAUAUGUGCA 20 6790
HSV-UL54-322 - UGGGAAACCCUGGUCGCUCA 20 6745
HSV-UL54-1368 + GUCCGCGUGCGGGGGGGUCA 20 16899
HSV-UL54-1369 + GGGUCGAUGGUGUCGGCAGA 20 16900
HSV-UL54-414 + GG G U U U CCCAG G AAACCCG A 20 6837
HSV-UL54-1370 + CGCCCGAACGGCGGGGUCGA 20 16901
HSV-UL54-276 - CCCGCGUCGGCGCGGACGGA 20 6699
HSV-UL54-1371 + GGGACAGCGCCAUCAGCGGA 20 16902
HSV-UL54-294 - CUGACCCCCCCGCACGCGGA 20 6717
HSV-UL54-283 - ACGGCGAGGCGCGGCGCGGA 20 6706
HSV-UL54-275 - CCACCCCGCGUCGGCGCGGA 20 6698
HSV-UL54-337 - CUUUCUGCAGUGCUACCUGA 20 6760
HSV-UL54-366 - CAGUCGCGUGUGCGAGCUGA 20 6789
HSV-UL54-292 - CCAGGCCCCCCCUCCGCUGA 20 6715
HSV-UL54-1372 + GUUUAUUCUUGCCUAAAAUA 20 16903
HSV-UL54-1373 + GACCGCCGCGCGCUCGGAUA 20 16904
HSV-UL54-1374 + CGGCCGCCGUUCCGAUGAUA 20 16905
HSV-UL54-1375 + GUAUUUGCCGUGCACAUAUA 20 16906 HSV-UL54-344 - GCGACGCCUGUCGGACAUUA 20 6767
HSV-UL54-420 + CCCGCUUGGGUGGCCAGCAC 20 6843
HSV-UL54-392 + ACAGGCGUCGCCGCGAGCAC 20 6815
HSV-UL54-1376 + ACAGGUCGUCCAGCCCGCAC 20 16907
HSV-UL54-1377 + G G U U U CCCAGG AAACCCG AC 20 16908
HSV-UL54-1378 + CAAUAUCCUUAAUGUCCGAC 20 16909
HSV-UL54-1379 + CGUCAGCUCGCACACGCGAC 20 16910
HSV-UL54-1380 + GGCGCCUUUCGCUCCGGGAC 20 16911
HSV-UL54-1381 + UAAGGGGGCGAUAGUGUGAC 20 16912
HSV-UL54-364 - GGCGGGUCUCAUUGAAAUAC 20 6787
HSV-UL54-1382 + GGCUCGGGCCGUGAGCGACC 20 16913
HSV-UL54-1383 + GCGCCUUUCGCUCCGGGACC 20 16914
HSV-UL54-1028 + CAAAGGGGUCUUGCAUGACC 20 7341
HSV-UL54-321 - UCGGGUUUCCUGGGAAACCC 20 6744
HSV-UL54-332 - CAAUCUG CCG CUCCG CCCCC 20 6755
HSV-UL54-1384 + GACCCGCCAUGCAGGCCCCC 20 16915
HSV-UL54-308 - UUCCCGCCGCGAACAGCCCC 20 6731
HSV-UL54-1385 + AGACCCGCCAUGCAGGCCCC 20 16916
HSV-UL54-1386 + GCCUCGUGGCCGCGGGCCCC 20 16917
HSV-UL54-1387 + GGUGGCCAGCACGGGAGCCC 20 16918
HSV-UL54-295 - GCACGCGGACGGCCGCGCCC 20 6718
HSV-UL54-328 - GGAAAAUCUCAUCGAGGCCC 20 6751
HSV-UL54-277 - UCGGCGCGGACGGACGGCCC 20 6700
HSV-UL54-304 - AAGCUUUGGACGCAGUGCCC 20 6727
HSV-UL54-358 - ACGAUGCACUUUUACAUCCC 20 6781
HSV-UL54-1388 + GUGAGCGACCAGGGUUUCCC 20 16919
HSV-UL54-405 + GCGUCUCAUCCGCGGACGCC 20 6828
HSV-UL54-365 - AAUACUGGACACGCACCGCC 20 6788
HSV-UL54-291 - GCGGCCACGAGGCACGCGCC 20 6714
HSV-UL54-1389 + GCCUCGCCGUGGGUGGCGCC 20 16920
HSV-UL54-326 - GCGCGACUGCGUGCUGCGCC 20 6749
HSV-UL54-996 + CGCGGUUGGCGAGGCGGGCC 20 7319
HSV-UL54-1390 + CCAUCAGCGGAGGGGGGGCC 20 16921
HSV-UL54-357 - GACGAUGCACUUUUACAUCC 20 6780
HSV-UL54-346 - CUCCUUUGUGUUGGUCAUCC 20 6769
HSV-UL54-981 + ACACGCG ACU G G AACACU CC 20 7309
HSV-UL54-1391 + CAGAGGGCGCCUUUCGCUCC 20 16922
HSV-UL54-286 - GGGAGCAGCUCGACGUCUCC 20 6709
HSV-UL54-296 - GGACGGCCGCGCCCCGGUCC 20 6719
HSV-UL54-400 + CCGUUCCGAUGAUAGGGUCC 20 6823
HSV-UL54-319 - CCGAGACCCGUCGGGUUUCC 20 6742
HSV-UL54-407 + GGGCCUCGAUGAGAUUUUCC 20 6830
HSV-UL54-312 - CCCGUGCUGGCCACCCAAGC 20 6735
HSV-UL54-330 - GGCGUCCGCGGAUGAGACGC 20 6753
HSV-UL54-1392 + CCGUCCGUCCGCGCCGACGC 20 16923
HSV-UL54-324 - CACAUUCGCAGCCAACCCGC 20 6747 HSV-UL54-410 + UGGCUGUCGACGCGGCCCGC 20 6833
HSV-UL54-444 + GGCGCGUGCCUCGUGGCCGC 20 6867
HSV-UL54-1204 + GGGCGUU UCUGGAGACGCGC 20 16735
HSV-UL54-1393 + AGCACUGCAGAAAGGGGCGC 20 16924
HSV-UL54-455 + CGCCUCGCCGUGGGUGGCGC 20 6878
HSV-UL54-1394 + GUAAAAGUGCAUCGUCUCGC 20 16925
HSV-UL54-1395 + CUCGACGCGGUUGGCGAGGC 20 16926
HSV-UL54-1396 + CGCAGAACCGCCCGAACGGC 20 16927
HSV-UL54-1206 + GUU UCUGGAGACGCGCCGGC 20 16737
HSV-UL54-1397 + GCCCAGGGGCUGUUCGCGGC 20 16928
HSV-UL54-341 - GGCCCGAGGCCUGUGCGGGC 20 6764
HSV-UL54-356 - ACGACCGUGGGGGUUGGGGC 20 6779
HSV-UL54-363 - AUCCCGGGGGCCUGCAUGGC 20 6786
HSV-UL54-307 - UCAUGCAAGACCCCUUUGGC 20 6730
HSV-UL54-1398 + U U CAAU G AG ACCCG CCAU GC 20 16929
HSV-UL54-310 - CAGCCCCUGGGCUCCCGUGC 20 6733
HSV-UL54-336 - CGGAACGGCGGCCGCCGUGC 20 6759
HSV-UL54-440 + GGGCGCGGCCGUCCGCGUGC 20 6863
HSV-UL54-340 - UGAAGGCCCGAGGCCUGUGC 20 6763
HSV-UL54-1399 + GUCCAGCCCGCACAGGCCUC 20 16930
HSV-UL54-1400 + GCAGAGGGCGCCUUUCGCUC 20 16931
HSV-UL54-1401 + CGAAUGUGCGGUAGAGGCUC 20 16932
HSV-UL54-285 - GGGGAGCAGCUCGACGUCUC 20 6708
HSV-UL54-318 - GUUUGACGCCGAGACCCGUC 20 6741
HSV-UL54-1402 + CGUCCGCGUGCGGGGGGGUC 20 16933
HSV-UL54-1403 + CGCACAGGCCUCGGGCCUUC 20 16934
HSV-UL54-299 - CACCAUCGACCCCGCCGUUC 20 6722
HSV-UL54-1237 + CCCUUGGUUGUGGGCGUUUC 20 16768
HSV-UL54-1404 + GAAACGGCAUCCCGCCAAAG 20 16935
HSV-UL54-398 + UCAGGUAGCACUGCAGAAAG 20 6821
HSV-UL54-271 - CAG AAACG CCCACAACCA AG 20 6694
HSV-UL54-311 - UCCCGUGCUGGCCACCCAAG 20 6734
HSV-UL54-1405 + AUUUGCCGUGCACAUAUAAG 20 16936
HSV-UL54-1406 + UGGCCAGCACGGGAGCCCAG 20 16937
HSV-UL54-1407 + GGGGUCGAUGGUGUCGGCAG 20 16938
HSV-UL54-1408 + GUCAGGGACAGCGCCAUCAG 20 16939
HSV-UL54-1409 + GGACAGCGCCAUCAGCGGAG 20 16940
HSV-UL54-284 - CGGCGAGGCGCGGCGCGGAG 20 6707
HSV-UL54-1410 + AUAGGGUCCUGGGGGCGGAG 20 16941
HSV-UL54-1411 + UGGCUGCGAAUGUGCGGUAG 20 16942
HSV-UL54-290 - UCCGGGGGCCCGCGGCCACG 20 6713
HSV-UL54-293 - GUCCCUGACCCCCCCGCACG 20 6716
HSV-UL54-1412 + GCCGUCCGUCCGCGCCGACG 20 16943
HSV-UL54-1413 + CCGACACGCCGCGCUCGACG 20 16944
HSV-UL54-1414 + CAUGGCCUUGGCUGUCGACG 20 16945
HSV-UL54-349 - GGAGAUCGACUACACGACCG 20 6772 HSV-UL54-1415 + CGCCUUUCGCUCCGGGACCG 20 16946
HSV-UL54-323 - GCACAUUCGCAGCCAACCCG 20 6746
HSV-UL54-338 - CAGUGCUACCUGAAGGCCCG 20 6761
HSV-UL54-1416 + UUGGCUGUCGACGCGGCCCG 20 16947
HSV-UL54-289 - UCGACGUCUCCGGGGGCCCG 20 6712
HSV-UL54-359 - CGAUGCACUUUUACAUCCCG 20 6782
HSV-UL54-1417 + CCUCGCCGUGGGUGGCGCCG 20 16948
HSV-UL54-451 + CUCCGCGCCGCGCCUCGCCG 20 6874
HSV-UL54-1418 + UGGCGCGUGCCUCGUGGCCG 20 16949
HSV-UL54-1419 + CCACGCCAGCGUCUCAUCCG 20 16950
HSV-UL54-287 - GGAGCAGCUCGACGUCUCCG 20 6710
HSV-UL54-329 - CAUCGAGGCCCUGGCGUCCG 20 6752
HSV-UL54-313 - CCGUGCUGGCCACCCAAGCG 20 6736
HSV-UL54-347 - CUCGCCAACCGCGUCGAGCG 20 6770
HSV-UL54-1420 + CGUCCGUCCGCGCCGACGCG 20 16951
HSV-UL54-301 - GCGAUCCAUAUCCGAGCGCG 20 6724
HSV-UL54-1421 + CAGAAAGGGGCGCAGGCGCG 20 16952
HSV-UL54-280 - GCGCCACCCACGGCGAGGCG 20 6703
HSV-UL54-1422 + GCAGAACCGCCCGAACGGCG 20 16953
HSV-UL54-279 - CCCCGGCGCCACCCACGGCG 20 6702
HSV-UL54-1219 + UUUCUGGAGACGCGCCGGCG 20 16750
HSV-UL54-281 - ACCCACGGCGAGGCGCGGCG 20 6704
HSV-UL54-274 - GUCGCCACCCCGCGUCGGCG 20 6697
HSV-UL54-438 + UUCGCUCCGGGACCGGGGCG 20 6861
HSV-UL54-331 - CCGCGGAUGAGACGCUGGCG 20 6754
HSV-UL54-1423 + AGGGGCGCAGGCGCGUGGCG 20 16954
HSV-UL54-1424 + CGCGCUCGACGCGGUUGGCG 20 16955
HSV-UL54-1425 + GGCGCGGCCGUCCGCGUGCG 20 16956
HSV-UL54-327 - G CGCCAG G AAAAU CU CAU CG 20 6750
HSV-UL54-1426 + GGGGCCUGGCGCGUGCCUCG 20 16957
HSV-UL54-342 - GGCUGGACGACCUGUGCUCG 20 6765
HSV-UL54-1427 + GGGAGCCCAGGGGCUGUUCG 20 16958
HSV-UL54-1428 + CAGGAUGACCAACACAAAGG 20 16959
HSV-UL54-272 - AGAAACGCCCACAACCAAGG 20 6695
HSV-UL54-1429 + UUUGCCGUGCACAUAUAAGG 20 16960
HSV-UL54-1430 + GCUCGACGCGGUUGGCGAGG 20 16961
HSV-UL54-1431 + GACAGCGCCAUCAGCGGAGG 20 16962
HSV-UL54-1432 + UCGCAGAACCGCCCGAACGG 20 16963
HSV-UL54-335 - GGACCCUAUCAUCGGAACGG 20 6758
HSV-UL54-1433 + GGCGAGGUUUUCCAGCACGG 20 16964
HSV-UL54-360 - GAUGCACUUUUACAUCCCGG 20 6783
HSV-UL54-1220 + CGUUUCUGGAGACGCGCCGG 20 16751
HSV-UL54-288 - GAGCAGCUCGACGUCUCCGG 20 6711
HSV-UL54-314 - CGUGCUGGCCACCCAAGCGG 20 6737
HSV-UL54-1434 + AGGGACAGCGCCAUCAGCGG 20 16965
HSV-UL54-302 - AUCCAUAUCCGAGCGCGCGG 20 6725 HSV-UL54-282 - CACGGCGAGGCGCGGCGCGG 20 6705
HSV-UL54-1435 + AGCCCAGGGGCUGUUCGCGG 20 16966
HSV-UL54-1436 + GCGCGGCCGUCCGCGUGCGG 20 16967
HSV-UL54-1437 + ACAGCGCCAUCAGCGGAGGG 20 16968
HSV-UL54-315 - GUGCUGGCCACCCAAGCGGG 20 6738
HSV-UL54-1438 + CGCGGCCGUCCGCGUGCGGG 20 16969
HSV-UL54-300 - CAUCGACCCCGCCGUUCGGG 20 6723
HSV-UL54-1439 + CAGCGCCAUCAGCGGAGGGG 20 16970
HSV-UL54-316 - UGCUGGCCACCCAAGCGGGG 20 6739
HSV-UL54-1440 + CCGUCCGCGCCGACGCGGGG 20 16971
HSV-UL54-1441 + GCGGCCGUCCGCGUGCGGGG 20 16972
HSV-UL54-1442 + CGAUGAUAGGGUCCUGGGGG 20 16973
HSV-UL54-1443 + GCGCCGCGCCUCGCCGUGGG 20 16974
HSV-UL54-1444 + GUCAAACCCCCCCGCUUGGG 20 16975
HSV-UL54-362 - CAUCCCGGGGGCCUGCAUGG 20 6785
HSV-UL54-1445 + CGCGACUGGAACACUCCUGG 20 16976
HSV-UL54-401 + UUCCGAUGAUAGGGUCCUGG 20 6824
HSV-UL54-352 - GAUCGACUACACGACCGUGG 20 6775
HSV-UL54-306 - GUCAUGCAAGACCCCUUUGG 20 6729
HSV-UL54-1446 + GUUCCGAUGAUAGGGUCCUG 20 16977
HSV-UL54-351 - AGAUCGACUACACGACCGUG 20 6774
HSV-UL54-1447 + GGGGCGCGGCCGUCCGCGUG 20 16978
HSV-UL54-23 + GCGCCGGCGGGGUUUUGGUG 20 6446
HSV-UL54-411 + GCGGGUUGGCUGCGAAUGUG 20 6834
HSV-UL54-339 - CUGAAGGCCCGAGGCCUGUG 20 6762
HSV-UL54-403 + GGGGGCGGAGCGGCAGAUUG 20 6826
HSV-UL54-355 - CUACACGACCGUGGGGGUUG 20 6778
HSV-UL54-1448 + GGUGGCGACCCCCUUGGUUG 20 16979
HSV-UL54-1449 + UGUUUAUUCUUGCCUAAAAU 20 16980
HSV-UL54-333 - CGCCCCCAGGACCCUAUCAU 20 6756
HSV-UL54-1450 + GCGGCCGCCGUUCCGAUGAU 20 16981
HSV-UL54-462 + ACGCGGGGUGGCGACCCCCU 20 6885
HSV-UL54-309 - UCCCGCCGCGAACAGCCCCU 20 6732
HSV-UL54-1451 + CGUCCAGCCCGCACAGGCCU 20 16982
HSV-UL54-1452 + CACGCAGUCGCGCAUGGCCU 20 16983
HSV-UL54-1453 + CGUUCCGAUGAUAGGGUCCU 20 16984
HSV-UL54-320 - CGAGACCCGUCGGGUU UCCU 20 6743
HSV-UL54-1454 + CGGCGUCAAACCCCCCCGCU 20 16985
HSV-UL54-1455 + GCGCUCGACCGCCGCGCGCU 20 16986
HSV-UL54-1456 + GCGAAUGUGCGGUAGAGGCU 20 16987
HSV-UL54-1457 + CCAG G AAACCCG ACG G GU CU 20 16988
HSV-UL54-350 - GAGAUCGACUACACGACCGU 20 6773
HSV-UL54-317 - GGUUUGACGCCGAGACCCGU 20 6740
HSV-UL54-452 + UCCGCGCCGCGCCUCGCCGU 20 6875
HSV-UL54-273 - AGGGGGUCGCCACCCCGCGU 20 6696
HSV-UL54-995 + CACGCCGCGCUCGACGCGGU 20 7318 HSV-UL54-1458 + UGUCGACGCGGCCCGCGGGU 20 16989
HSV-UL54-353 - GACUACACGACCGUGGGGGU 20 6776
HSV-UL54-343 - GUGCUCGCGGCGACGCCUGU 20 6766
HSV-UL54-348 - CCGCGUCGAGCGCGGCGUGU 20 6771
HSV-UL54-437 + AACGGCGGGGUCGAUGGUGU 20 6860
HSV-UL54-345 - GGAUAUUGCCUCCUUUGUGU 20 6768
HSV-UL54-1459 + GUGGCGACCCCCUUGGUUGU 20 16990
HSV-UL54-305 - CUGGUCAUGCAAGACCCCUU 20 6728
HSV-UL54-303 - GAGCGCAUCAGCGAAAGCUU 20 6726
HSV-UL54-1460 + GGCGUCAAACCCCCCCGCUU 20 16991
HSV-UL54-298 - ACACCAUCGACCCCGCCGUU 20 6721
HSV-UL54-354 - ACUACACGACCGUGGGGGUU 20 6777
HSV-UL54-1207 + GAGACGCGCCGGCGGGGUUU 20 16738
HSV-UL54-1461 - CUACUGCAACUCCCUAUUUU 20 16992
Table 15A provides exemplary targeting domains for knocking out the UL54 gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), have a high level of orthogonality, and start with a 5'G. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 15A
Figure imgf000658_0001
HSV-UL54-1474 + G CG ACC ACACG CCG G U G G U C 20 17005
HSV-UL54-1475 + GCGCGACCACACGCCGG UGGUC 22 17006
HSV-UL54-1476 + GGCGCGACCACACGCCGGUGGUC 23 17007
HSV-UL54-1477 + GCGAGGCGUCGAGGCU UC 18 17008
HSV-UL54-1478 + GGCGAGGCGUCGAGGCU UC 19 17009
HSV-UL54-169 + GGGCGAGGCGUCGAGGCUUC 20 6592
HSV-UL54-1479 + GCCGGGCGAGGCGUCGAGGCUUC 23 17010
HSV-UL54-1480 + GUUUCUGGAGACGCGCCGG 19 17011
HSV-UL54-1481 + GCGUUUCUGGAGACGCGCCGG 21 17012
HSV-UL54-1482 + GGCGUUUCUGGAGACGCGCCGG 22 17013
HSV-UL54-1483 + GGGCGUUUCUGGAGACGCGCCGG 23 17014
HSV-UL54-1484 + GCGGUGCCUUGGUCGACGGGGG 22 17015
HSV-UL54-1485 + GCCGGCGGGGUUU UGGUG 18 17016
HSV-UL54-23 + GCGCCGGCGGGGU U UUGGUG 20 6446
HSV-UL54-1486 + GACGCGCCGGCGGGGUU U UGGUG 23 17017
HSV-UL54-1487 + GCGGGCCGGGGGACCU UU 18 17018
HSV-UL54-1488 + GGCGGGCCGGGGGACCUUU 19 17019
HSV-UL54-45 + GGGCGGGCCGGGGGACCUU U 20 6468
HSV-UL54-1489 + GGGGCGGGCCGGGGGACCUU U 21 17020
HSV-UL54-1490 - GUCUCCAGAAACGCCCACAACCAA 24 17021
HSV-UL54-1491 - GAGGAGGGCCGCCGCGACGACC 22 17022
HSV-UL54-1492 - GACAUUGAUAUGCUAAUCGACC 22 17023
HSV-UL54-1493 - GCGGCGAGGUCGCCGCCGGGGC 22 17024
HSV-UL54-1494 - GGCGGCGAGGUCGCCGCCGGGGC 23 17025
HSV-UL54-1495 - GGGCGGCGAGGUCGCCGCCGGGGC 24 17026
HSV-UL54-1496 - GACCCCGAGUCCGACAGCAGCG 22 17027
Table 15B provides exemplary targeting domains for knocking out the UL54 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), and have a high level of orthogonality. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 15B
Figure imgf000659_0001
HSV-UL54-1499 + CGGGGAUGCGGUGCCUUGGUCGAC 24 17030
HSV-UL54-1500 + CCGCCCCUCCGUCUCCGC 18 17031
HSV-UL54-1501 + UCCGCCCCUCCGUCUCCGC 19 17032
HSV-UL54-180 + CUCCGCCCCUCCGUCUCCGC 20 6603
HSV-UL54-1502 + CCUCCGCCCCUCCGUCUCCGC 21 17033
HSV-UL54-1503 + UGGCCUCCGCCCCUCCGUCUCCGC 24 17034
HSV-UL54-1504 + UGUUGUAGGUCGCCGGGGC 19 17035
HSV-UL54-1236 + AUGUUGUAGGUCGCCGGGGC 20 16767
HSV-UL54-1505 + CAUGUUGUAGGUCGCCGGGGC 21 17036
HSV-UL54-1506 + CCAUGUUGUAGGUCGCCGGGGC 22 17037
HSV-UL54-1507 + AGCCAUGUUGUAGGUCGCCGGGGC 24 17038
HSV-UL54-1508 + CGACCUCGCCGCCCGCCUC 19 17039
HSV-UL54-1509 + CGGCGACCUCGCCGCCCGCCUC 22 17040
HSV-UL54-1510 + CGACCACACGCCGGUGGUC 19 17041
HSV-UL54-1511 + CGCGACCACACGCCGGUGGUC 21 17042
HSV-UL54-1512 + AGGCGCGACCACACGCCGGUGGUC 24 17043
HSV-UL54-1513 + CGGGCGAGGCGUCGAGGCUUC 21 17044
HSV-UL54-1514 + CCGGGCGAGGCGUCGAGGCUUC 22 17045
HSV-UL54-1515 + UGCCGGGCGAGGCGUCGAGGCUUC 24 17046
HSV-UL54-1516 + UUUCUGGAGACGCGCCGG 18 17047
HSV-UL54-1220 + CGUUUCUGGAGACGCGCCGG 20 16751
HSV-UL54-1517 + UGGGCGU UUCUGGAGACGCGCCGG 24 17048
HSV-UL54-1518 + CGGUGCCUUGGUCGACGGGGG 21 17049
HSV-UL54-1519 + UGCGGUGCCUUGGUCGACGGGGG 23 17050
HSV-UL54-1520 + AUGCGGUGCCUUGGUCGACGGGGG 24
17051
HSV-UL54-1521 + CGCCGGUGGUCGCGGGUG 18 17052
HSV-UL54-1522 + ACGCCGGUGGUCGCGGGUG 19 17053
HSV-UL54-1523 + CACGCCGGUGGUCGCGGGUG 20 17054
HSV-UL54-1524 + ACACGCCGGUGGUCGCGGGUG 21 17055
HSV-UL54-1525 + CACACGCCGGUGGUCGCGGGUG 22 17056
HSV-UL54-1526 + CCACACGCCGGUGGUCGCGGGUG 23 17057
HSV-UL54-1527 + ACCACACGCCGGUGGUCGCGGGUG 24 17058
HSV-UL54-1528 + CGCCGGCGGGGUUUUGGUG 19 17059
HSV-UL54-1529 + CGCGCCGGCGGGGUUUUGGUG 21 17060
HSV-UL54-1530 + ACGCGCCGGCGGGGUU UUGGUG 22 17061
HSV-UL54-1531 + AGACGCGCCGGCGGGGUUUUGGUG 24
17062
HSV-UL54-1532 + ACUCCCCGCUGCUGUCGGACU 21 17063
HSV-UL54-1533 + CACUCCCCGCUGCUGUCGGACU 22 17064
HSV-UL54-1534 + ACACUCCCCGCUGCUGUCGGACU 23 17065
HSV-UL54-1535 + AACACUCCCCGCUGCUGUCGGACU 24 17066
HSV-UL54-1536 + CGGGGCGGGCCGGGGGACCU UU 22 17067
HSV-UL54-1537 + UCGGGGCGGGCCGGGGGACCUUU 23 17068
HSV-UL54-1538 + CUCGGGGCGGGCCGGGGGACCUUU 24 17069
HSV-UL54-1539 - U CCAG AAACG CCCACAACCAA 21 17070 HSV-UL54-1540 - CUCCAGAAACGCCCACAACCAA 22 17071
HSV-UL54-1541 - U CU CCAG AAACGCCCACAACCAA 23 17072
HSV-UL54-1542 - AGGAGGGCCGCCGCGACGACC 21 17073
HSV-UL54-1543 - CGAGGAGGGCCGCCGCGACGACC 23 17074
HSV-UL54-1544 - ACGAGGAGGGCCGCCGCGACGACC 24 17075
HSV-UL54-1545 - UUGAUAUGCUAAUCGACC 18 17076
HSV-UL54-1546 - AUUGAUAUGCUAAUCGACC 19 17077
HSV-UL54-677 - CAUUGAUAUGCUAAUCGACC 20 7092
HSV-UL54-1547 - ACAUUGAUAUGCUAAUCGACC 21 17078
HSV-UL54-1548 - CGACAUUGAUAUGCUAAUCGACC 23 17079
HSV-UL54-1549 - CCGACAUUGAUAUGCUAAUCGACC 24 17080
HSV-UL54-1550 - CGGCGAGGUCGCCGCCGGGGC 21 17081
HSV-UL54-1551 - CCGAGUCCGACAGCAGCG 18 17082
HSV-UL54-1552 - CCCG AG U CCG ACAGCAG CG 19 17083
HSV-UL54-112 - CCCCGAGUCCGACAGCAGCG 20 6535
HSV-UL54-1553 - ACCCCGAGUCCGACAGCAGCG 21 17084
HSV-UL54-1554 - CGACCCCGAGUCCGACAGCAGCG 23 17085
HSV-UL54-1555 - ACGACCCCGAGUCCGACAGCAGCG 24 17086
Table 15C provides exemplary targeting domains for knocking out the UL54 gene selected according to the third tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon). The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 15C
Figure imgf000661_0001
HSV-UL54-693 - GGAGGGCCGCCGCGACGACC 20 7105
HSV-UL54-1565 - CG AGG UCGCCGCCGGGGC 18 17096
HSV-UL54-1566 - GCGAGGUCGCCGCCGGGGC 19 17097
HSV-UL54-143 - GGCG AGG UCGCCGCCGGGGC 20 6566
Table 15D provides exemplary targeting domains for knocking out the UL54 gene selected according to the fourth tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon). The PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 15D
Figure imgf000662_0001
HSV-UL54-1590 + ACCUUCCCCCCGUGCGGUUCCC 22 17121
HSV-UL54-1591 + CACCUUCCCCCCGUGCGGUUCCC 23 17122
HSV-UL54-1592 + CCACCUUCCCCCCGUGCGGUUCCC 24 17123
HSV-UL54-1593 + GCGACCUCGCCGCCCGCC 18 17124
HSV-UL54-1594 + GGCGACCUCGCCGCCCGCC 19 17125
HSV-UL54-739 + CGGCGACCUCGCCGCCCGCC 20 7130
HSV-UL54-1595 + GCGGCGACCUCGCCGCCCGCC 21 17126
HSV-UL54-1596 + GGCGGCGACCUCGCCGCCCGCC 22 17127
HSV-UL54-1597 + CGGCGGCGACCUCGCCGCCCGCC 23 17128
HSV-UL54-1598 + CCGGCGGCGACCUCGCCGCCCGCC 24 17129
HSV-UL54-1599 + GCGUCCUCGGGGCGGGCC 18 17130
HSV-UL54-1600 + GGCGUCCUCGGGGCGGGCC 19 17131
HSV-UL54-176 + CGGCGUCCUCGGGGCGGGCC 20 6599
HSV-UL54-1601 + CCGGCGUCCUCGGGGCGGGCC 21 17132
HSV-UL54-1602 + GCCGGCGUCCUCGGGGCGGGCC 22 17133
HSV-UL54-1603 + UGCCGGCGUCCUCGGGGCGGGCC 23 17134
HSV-UL54-1604 + GUGCCGGCGUCCUCGGGGCGGGCC 24 17135
HSV-UL54-1605 + CGCUCCAGAGCGUCCUCC 18 17136
HSV-UL54-1606 + CCGCUCCAGAGCGUCCUCC 19 17137
HSV-UL54-779 + CCCGCUCCAGAGCGUCCUCC 20 7168
HSV-UL54-1607 + UCCCGCUCCAGAGCGUCCUCC 21 17138
HSV-UL54-1608 + GUCCCGCUCCAGAGCGUCCUCC 22 17139
HSV-UL54-1609 + CGUCCCGCUCCAGAGCGUCCUCC 23 17140
HSV-UL54-1610 + U CG U CCCG CUCCAG AG CG U CCU CC 24 17141
HSV-UL54-1611 + UCGGGGGUGCCGGCGUCC 18 17142
HSV-UL54-1612 + UUCGGGGGUGCCGGCGUCC 19 17143
HSV-UL54-1613 + CUUCGGGGGUGCCGGCGUCC 20 17144
HSV-UL54-1614 + GCUUCGGGGGUGCCGGCGUCC 21 17145
HSV-UL54-1615 + GGCUUCGGGGGUGCCGGCGUCC 22 17146
HSV-UL54-1616 + AGGCU UCGGGGGUGCCGGCGUCC 23 17147
HSV-UL54-1617 + GAGGCUUCGGGGGUGCCGGCGUCC 24 17148
HSV-UL54-1618 + UUCCCCCCGUGCGGUUCC 18 17149
HSV-UL54-1619 + CUUCCCCCCGUGCGGUUCC 19 17150
HSV-UL54-158 + CCUUCCCCCCGUGCGGUUCC 20 6581
HSV-UL54-1620 + ACCUUCCCCCCGUGCGGUUCC 21 17151
HSV-UL54-1621 + CACCUUCCCCCCGUGCGGUUCC 22 17152
HSV-UL54-1622 + CCACCUUCCCCCCGUGCGGUUCC 23 17153
HSV-UL54-1623 + GCCACCUUCCCCCCGUGCGGUUCC 24 17154
HSV-UL54-1624 + GUGUGGAGUCGGCGCCGC 18 17155
HSV-UL54-1625 + GGUGUGGAGUCGGCGCCGC 19 17156
HSV-UL54-149 + UGGUGUGGAGUCGGCGCCGC 20 6572
HSV-UL54-1626 + UUGGUGUGGAGUCGGCGCCGC 21 17157
HSV-UL54-1627 + UUUGGUGUGGAGUCGGCGCCGC 22 17158
HSV-UL54-1628 + UUUUGGUGUGGAGUCGGCGCCGC 23 17159
HSV-UL54-1629 + GUUUUGGUGUGGAGUCGGCGCCGC 24
17160 HSV-UL54-1630 + AGCCAUGUUGUAGGUCGC 18 17161
HSV-UL54-1631 + UAGCCAUGUUGUAGGUCGC 19 17162
HSV-UL54-1205 + GUAGCCAUGUUGUAGGUCGC 20 16736
HSV-UL54-1632 + GG UAGCCAUGUUGUAGGUCGC 21 17163
HSV-UL54-1633 + CGGUAGCCAUGUUGUAGGUCGC 22 17164
HSV-UL54-1634 + UCGGUAGCCAUGUUGUAGGUCGC 23 17165
HSV-UL54-1635 + GUCGGUAGCCAUGUUGUAGGUCGC 24 17166
HSV-UL54-1636 + GGCGUCCUCGGGGCGGGC 18 17167
HSV-UL54-1637 + CGGCGUCCUCGGGGCGGGC 19 17168
HSV-UL54-175 + CCGGCGUCCUCGGGGCGGGC 20 6598
HSV-UL54-1638 + GCCGGCGUCCUCGGGGCGGGC 21 17169
HSV-UL54-1639 + UGCCGGCGUCCUCGGGGCGGGC 22 17170
HSV-UL54-1640 + GUGCCGGCGUCCUCGGGGCGGGC 23 17171
HSV-UL54-1641 + GGUGCCGGCGUCCUCGGGGCGGGC 24 17172
HSV-UL54-1642 + GCCCUCCUCGUCCCGCUC 18 17173
HSV-UL54-1643 + GGCCCUCCUCGUCCCGCUC 19 17174
HSV-UL54-1644 + CGGCCCUCCUCGUCCCGCUC 20 17175
HSV-UL54-1645 + GCGGCCCUCCUCGUCCCGCUC 21 17176
HSV-UL54-1646 + GGCGGCCCUCCUCGUCCCGCUC 22 17177
HSV-UL54-1647 + CGGCGGCCCUCCUCGUCCCGCUC 23 17178
HSV-UL54-1648 + GCGGCGGCCCUCCUCGUCCCGCUC 24 17179
HSV-UL54-1649 + GAAGCCGACCGCCUGGUC 18 17180
HSV-UL54-1650 + GGAAGCCGACCGCCUGGUC 19 17181
HSV-UL54-1651 + GGGAAGCCGACCGCCUGGUC 20 17182
HSV-UL54-1652 + GGGGAAGCCGACCGCCUGGUC 21 17183
HSV-UL54-1653 + GGGGGAAGCCGACCGCCUGGUC 22 17184
HSV-UL54-1654 + GGGGGGAAGCCGACCGCCUGGUC 23 17185
HSV-UL54-1655 + CGGGGGGAAGCCGACCGCCUGGUC 24 17186
HSV-UL54-1656 + CUUCCCCCCGUGCGGUUC 18 17187
HSV-UL54-1657 + CCUUCCCCCCGUGCGGUUC 19 17188
HSV-UL54-1658 + ACCUUCCCCCCGUGCGGUUC 20 17189
HSV-UL54-1659 + CACCUUCCCCCCGUGCGGUUC 21 17190
HSV-UL54-1660 + CCACCUUCCCCCCGUGCGGUUC 22 17191
HSV-UL54-1661 + GCCACCUUCCCCCCGUGCGGUUC 23 17192
HSV-UL54-1662 + GGCCACCUUCCCCCCGUGCGGUUC 24 17193
HSV-UL54-1663 + CUUGGUUGUGGGCGUUUC 18 17194
HSV-UL54-1664 + CCUUGGUUGUGGGCGUUUC 19 17195
HSV-UL54-1237 + CCCUUGGUUGUGGGCGUUUC 20 16768
HSV-UL54-1665 + CCCCUUGGUUGUGGGCGUUUC 21 17196
HSV-UL54-1666 + CCCCCUUGGUUGUGGGCGUUUC 22 17197
HSV-UL54-1667 + ACCCCCUUGGUUGUGGGCGUUUC 23 17198
HSV-UL54-1668 + GACCCCCUUGGUUGUGGGCGUUUC 24 17199
HSV-UL54-1669 + CCAUGUCCUCGUCCGACG 18 17200
HSV-UL54-1670 + UCCAUGUCCUCGUCCGACG 19 17201
HSV-UL54-47 + UUCCAUGUCCUCGUCCGACG 20 6470
HSV-UL54-1671 + CUUCCAUGUCCUCGUCCGACG 21 17202 HSV-UL54-1672 + UCUUCCAUGUCCUCGUCCGACG 22 17203
HSV-UL54-1673 + GUCUUCCAUGUCCUCGUCCGACG 23 17204
HSV-UL54-1674 + GGUCUUCCAUGUCCUCGUCCGACG 24 17205
HSV-UL54-1675 + CCCCCCGUGCGGUUCCCG 18 17206
HSV-UL54-1676 + U CCCCCCG U GCG G U U CCCG 19 17207
HSV-UL54-160 + UUCCCCCCGUGCGGUUCCCG 20 6583
HSV-UL54-1677 + CUUCCCCCCGUGCGGUUCCCG 21 17208
HSV-UL54-1678 + CCUUCCCCCCGUGCGGUUCCCG 22 17209
HSV-UL54-1679 + ACCUUCCCCCCGUGCGGUUCCCG 23 17210
HSV-UL54-1680 + CACCUUCCCCCCGUGCGGUUCCCG 24 17211
HSV-UL54-1681 + GUUUCUGGAGACGCGCCG 18 17212
HSV-UL54-1682 + CGUUUCUGGAGACGCGCCG 19 17213
HSV-UL54-1683 + GCGUU UCUGGAGACGCGCCG 20 17214
HSV-UL54-1684 + GGCGUUUCUGGAGACGCGCCG 21 17215
HSV-UL54-1685 + GGGCGUU UCUGGAGACGCGCCG 22 17216
HSV-UL54-1686 + UGGGCGUUUCUGGAGACGCGCCG 23 17217
HSV-UL54-1687 + GUGGGCGUUUCUGGAGACGCGCCG 24 17218
HSV-UL54-1688 + GGUGUGGAGUCGGCGCCG 18 17219
HSV-UL54-1689 + UGGUGUGGAGUCGGCGCCG 19 17220
HSV-UL54-1690 + UUGGUGUGGAGUCGGCGCCG 20 17221
HSV-UL54-1691 + UU UGGUGUGGAGUCGGCGCCG 21 17222
HSV-UL54-1692 + UUUUGGUGUGGAGUCGGCGCCG 22 17223
HSV-UL54-1693 + GUU UUGGUGUGGAGUCGGCGCCG 23 17224
HSV-UL54-1694 + GGUUUUGGUGUGGAGUCGGCGCCG 24
17225
HSV-UL54-1695 + CGUCCUCGGGGCGGGCCG 18 17226
HSV-UL54-1696 + GCGUCCUCGGGGCGGGCCG 19 17227
HSV-UL54-177 + GGCGUCCUCGGGGCGGGCCG 20 6600
HSV-UL54-1697 + CGGCGUCCUCGGGGCGGGCCG 21 17228
HSV-UL54-1698 + CCGGCGUCCUCGGGGCGGGCCG 22 17229
HSV-UL54-1699 + GCCGGCGUCCUCGGGGCGGGCCG 23 17230
HSV-UL54-1700 + UGCCGGCGUCCUCGGGGCGGGCCG 24 17231
HSV-UL54-1701 + UCCGCCCCUCCGUCUCCG 18 17232
HSV-UL54-1702 + CUCCGCCCCUCCGUCUCCG 19 17233
HSV-UL54-1703 + CCUCCGCCCCUCCGUCUCCG 20 17234
HSV-UL54-1704 + GCCUCCGCCCCUCCGUCUCCG 21 17235
HSV-UL54-1705 + GGCCUCCGCCCCUCCGUCUCCG 22 17236
HSV-UL54-1706 + UGGCCUCCGCCCCUCCGUCUCCG 23 17237
HSV-UL54-1707 + AUGGCCUCCGCCCCUCCGUCUCCG 24 17238
HSV-UL54-1708 + CUUCCAUGUCCUCGUCCG 18 17239
HSV-UL54-1709 + UCUUCCAUGUCCUCGUCCG 19 17240
HSV-UL54-1710 + GUCUUCCAUGUCCUCGUCCG 20 17241
HSV-UL54-1711 + GGUCUUCCAUGUCCUCGUCCG 21 17242
HSV-UL54-1712 + GGGUCU UCCAUGUCCUCGUCCG 22 17243
HSV-UL54-1713 + GGGGUCUUCCAUGUCCUCGUCCG 23 17244
HSV-UL54-1714 + AGGGGUCUUCCAUGUCCUCGUCCG 24 17245 HSV-UL54-1715 + GCGCUGCCGGGCGAGGCG 18 17246
HSV-UL54-1716 + CGCGCUGCCGGGCGAGGCG 19 17247
HSV-UL54-753 + CCGCGCUGCCGGGCGAGGCG 20 7144
HSV-UL54-1717 + GCCGCGCUGCCGGGCGAGGCG 21 17248
HSV-UL54-1718 + CGCCGCGCUGCCGGGCGAGGCG 22 17249
HSV-UL54-1719 + CCGCCGCGCUGCCGGGCGAGGCG 23 17250
HSV-UL54-1720 + CCCGCCGCGCUGCCGGGCGAGGCG 24 17251
HSV-UL54-1721 + UAGCCAUGUUGUAGGUCG 18 17252
HSV-UL54-1722 + GUAGCCAUGUUGUAGGUCG 19 17253
HSV-UL54-1723 + GGUAGCCAUGUUGUAGGUCG 20 17254
HSV-UL54-1724 + CGG UAGCCAUGUUGUAGGUCG 21 17255
HSV-UL54-1725 + UCGGUAGCCAUGUUGUAGGUCG 22 17256
HSV-UL54-1726 + GUCGGUAGCCAUGUUGUAGGUCG 23 17257
HSV-UL54-1727 + UGUCGGUAGCCAUGUUGUAGGUCG 24
17258
HSV-UL54-1728 + GAUGCGGUGCCUUGGUCG 18 17259
HSV-UL54-1729 + GGAUGCGGUGCCUUGGUCG 19 17260
HSV-UL54-1730 + GGGAUGCGGUGCCUUGGUCG 20 17261
HSV-UL54-1731 + GGGGAUGCGGUGCCUUGGUCG 21 17262
HSV-UL54-1732 + CGGGGAUGCGGUGCCUUGGUCG 22 17263
HSV-UL54-1733 + UCGGGGAUGCGGUGCCUUGGUCG 23 17264
HSV-UL54-1734 + CUCGGGGAUGCGGUGCCUUGGUCG 24 17265
HSV-UL54-1735 + CCCCCGUGCGGUUCCCGG 18 17266
HSV-UL54-1736 + CCCCCCGUGCGGUUCCCGG 19 17267
HSV-UL54-34 + UCCCCCCGUGCGGUUCCCGG 20 6457
HSV-UL54-1737 + U U CCCCCCG UGCGGU UCCCGG 21 17268
HSV-UL54-1738 + CUUCCCCCCGUGCGGUUCCCGG 22 17269
HSV-UL54-1739 + CCUUCCCCCCGUGCGGUUCCCGG 23 17270
HSV-UL54-1740 + ACCUUCCCCCCGUGCGGUUCCCGG 24 17271
HSV-UL54-1741 + UCCCCGCCGCGCUGCCGG 18 17272
HSV-UL54-1742 + CUCCCCGCCGCGCUGCCGG 19 17273
HSV-UL54-1743 + GCUCCCCGCCGCGCUGCCGG 20 17274
HSV-UL54-1744 + GGCUCCCCGCCGCGCUGCCGG 21 17275
HSV-UL54-1745 + CGGCUCCCCGCCGCGCUGCCGG 22 17276
HSV-UL54-1746 + UCGGCUCCCCGCCGCGCUGCCGG 23 17277
HSV-UL54-1747 + GUCGGCUCCCCGCCGCGCUGCCGG 24 17278
HSV-UL54-1748 + CCCCGUGCGGUUCCCGGG 18 17279
HSV-UL54-1749 + CCCCCGUGCGGUUCCCGGG 19 17280
HSV-UL54-35 + CCCCCCGUGCGGUUCCCGGG 20 6458
HSV-UL54-1750 + UCCCCCCGUGCGGUUCCCGGG 21 17281
HSV-UL54-1751 + UUCCCCCCGUGCGGUUCCCGGG 22 17282
HSV-UL54-1752 + CUUCCCCCCGUGCGGUUCCCGGG 23 17283
HSV-UL54-1753 + CCUUCCCCCCGUGCGGUUCCCGGG 24 17284
HSV-UL54-1754 + CGGCGUCCUCGGGGCGGG 18 17285
HSV-UL54-1755 + CCGGCGUCCUCGGGGCGGG 19 17286
HSV-UL54-1756 + GCCGGCGUCCUCGGGGCGGG 20 17287 HSV-UL54-1757 + UGCCGGCGUCCUCGGGGCGGG 21 17288
HSV-UL54-1758 + GUGCCGGCGUCCUCGGGGCGGG 22 17289
HSV-UL54-1759 + GGUGCCGGCGUCCUCGGGGCGGG 23 17290
HSV-UL54-1760 + GGGUGCCGGCGUCCUCGGGGCGGG 24 17291
HSV-UL54-1761 + GGUGCCGGCGUCCUCGGG 18 17292
HSV-UL54-1762 + GGGUGCCGGCGUCCUCGGG 19 17293
HSV-UL54-1763 + GGGGUGCCGGCGUCCUCGGG 20 17294
HSV-UL54-1764 + GGGGGUGCCGGCGUCCUCGGG 21 17295
HSV-UL54-1765 + CGGGGGUGCCGGCGUCCUCGGG 22 17296
HSV-UL54-1766 + UCGGGGGUGCCGGCGUCCUCGGG 23 17297
HSV-UL54-1767 + UUCGGGGGUGCCGGCGUCCUCGGG 24 17298
HSV-UL54-1768 + UGUUGUAGGUCGCCGGGG 18 17299
HSV-UL54-1769 + AUGUUGUAGGUCGCCGGGG 19 17300
HSV-UL54-1770 + CAUGUUGUAGGUCGCCGGGG 20 17301
HSV-UL54-1771 + CCAUGUUGUAGGUCGCCGGGG 21 17302
HSV-UL54-1772 + GCCAUGU UGUAGGUCGCCGGGG 22 17303
HSV-UL54-1773 + AGCCAUGUUGUAGGUCGCCGGGG 23 17304
HSV-UL54-1774 + UAGCCAUGUUGUAGGUCGCCGGGG 24 17305
HSV-UL54-1775 + GUCGCCGGGGCUGGGAUG 18 17306
HSV-UL54-1776 + GGUCGCCGGGGCUGGGAUG 19 17307
HSV-UL54-1777 + AGGUCGCCGGGGCUGGGAUG 20 17308
HSV-UL54-1778 + UAGGUCGCCGGGGCUGGGAUG 21 17309
HSV-UL54-1779 + GU AGGUCGCCGGGGCUGGGAUG 22 17310
HSV-UL54-1780 + UGU AGGUCGCCGGGGCUGGGAUG 23 17311
HSV-UL54-1781 + UUGUAGGUCGCCGGGGCUGGGAUG 24
17312
HSV-UL54-1782 + CGGCUCCCCGCCGCGCUG 18 17313
HSV-UL54-1783 + UCGGCUCCCCGCCGCGCUG 19 17314
HSV-UL54-1784 + GUCGGCUCCCCGCCGCGCUG 20 17315
HSV-UL54-1785 + CGUCGGCUCCCCGCCGCGCUG 21 17316
HSV-UL54-1786 + UCGUCGGCUCCCCGCCGCGCUG 22 17317
HSV-UL54-1787 + AUCGUCGGCUCCCCGCCGCGCUG 23 17318
HSV-UL54-1788 + GAUCGUCGGCUCCCCGCCGCGCUG 24 17319
HSV-UL54-1789 + UCCUCCUCGAGCUCGCUG 18 17320
HSV-UL54-1790 + GUCCUCCUCGAGCUCGCUG 19 17321
HSV-UL54-1791 + CGUCCUCCUCGAGCUCGCUG 20 17322
HSV-UL54-1792 + GCGUCCUCCUCGAGCUCGCUG 21 17323
HSV-UL54-1793 + AGCGUCCUCCUCGAGCUCGCUG 22 17324
HSV-UL54-1794 + GAGCGUCCUCCUCGAGCUCGCUG 23 17325
HSV-UL54-1795 + AGAGCGUCCUCCUCGAGCUCGCUG 24 17326
HSV-UL54-1796 + GAACACUCCCCGCUGCUG 18 17327
HSV-UL54-1797 + GGAACACUCCCCGCUGCUG 19 17328
HSV-UL54-1798 + AGGAACACUCCCCGCUGCUG 20 17329
HSV-UL54-1799 + GAGGAACACUCCCCGCUGCUG 21 17330
HSV-UL54-1800 + CGAGGAACACUCCCCGCUGCUG 22 17331
HSV-UL54-1801 + ACGAGGAACACUCCCCGCUGCUG 23 17332 HSV-UL54-1802 + GACGAGGAACACUCCCCGCUGCUG 24 17333
HSV-UL54-1803 + GGUCGACGGGGGUUGGAU 18 17334
HSV-UL54-1804 + UGGUCGACGGGGGUUGGAU 19 17335
HSV-UL54-1805 + UU GGUCGACGGGGGUUGGAU 20 17336
HSV-UL54-1806 + CU UGGUCGACGGGGGUUGGAU 21 17337
HSV-UL54-1807 + CCUUGGUCGACGGGGGUUGGAU 22 17338
HSV-UL54-1808 + GCCU UGGUCGACGGGGGUUGGAU 23 17339
HSV-UL54-1809 + UGCCUUGGUCGACGGGGGUUGGAU 24
17340
HSV-UL54-1810 + GGGCGGGCCGGGGGACCU 18 17341
HSV-UL54-1811 + GGGGCGGGCCGGGGGACCU 19 17342
HSV-UL54-1812 + CGGGGCGGGCCGGGGGACCU 20 17343
HSV-UL54-1813 + UCGGGGCGGGCCGGGGGACCU 21 17344
HSV-UL54-1814 + CUCGGGGCGGGCCGGGGGACCU 22 17345
HSV-UL54-1815 + CCUCGGGGCGGGCCGGGGGACCU 23 17346
HSV-UL54-1816 + UCCUCGGGGCGGGCCGGGGGACCU 24 17347
HSV-UL54-1817 + CGACCUCGCCGCCCGCCU 18 17348
HSV-UL54-1818 + GCGACCUCGCCGCCCGCCU 19 17349
HSV-UL54-152 + GGCGACCUCGCCGCCCGCCU 20 6575
HSV-UL54-1819 + CGGCGACCUCGCCGCCCGCCU 21 17350
HSV-UL54-1820 + GCGGCGACCUCGCCGCCCGCCU 22 17351
HSV-UL54-1821 + GGCGGCGACCUCGCCGCCCGCCU 23 17352
HSV-UL54-1822 + CGGCGGCGACCUCGCCGCCCGCCU 24 17353
HSV-UL54-1823 + CGGGGGUGCCGGCGUCCU 18 17354
HSV-UL54-1824 + UCGGGGGUGCCGGCGUCCU 19 17355
HSV-UL54-171 + UUCGGGGGUGCCGGCGUCCU 20 6594
HSV-UL54-1825 + CUUCGGGGGUGCCGGCGUCCU 21 17356
HSV-UL54-1826 + GCUUCGGGGGUGCCGGCGUCCU 22 17357
HSV-UL54-1827 + GGCUUCGGGGGUGCCGGCGUCCU 23 17358
HSV-UL54-1828 + AGGCUUCGGGGGUGCCGGCGUCCU 24 17359
HSV-UL54-1829 + GGGCGAGGCGUCGAGGCU 18 17360
HSV-UL54-1830 + CGGGCGAGGCGUCGAGGCU 19 17361
HSV-UL54-1831 + CCGGGCGAGGCGUCGAGGCU 20 17362
HSV-UL54-1832 + GCCGGGCGAGGCGUCGAGGCU 21 17363
HSV-UL54-1833 + UGCCGGGCGAGGCGUCGAGGCU 22 17364
HSV-UL54-1834 + CUGCCGGGCGAGGCGUCGAGGCU 23 17365
HSV-UL54-1835 + GCUGCCGGGCGAGGCGUCGAGGCU 24 17366
HSV-UL54-1836 + CGCCGGCGGGGUUU UGGU 18 17367
HSV-UL54-1837 + GCGCCGGCGGGGUUUUGGU 19 17368
HSV-UL54-1838 + CGCGCCGGCGGGGUUUUGGU 20 17369
HSV-UL54-1839 + ACGCGCCGGCGGGGUUUUGGU 21 17370
HSV-UL54-1840 + GACGCGCCGGCGGGGUUUUGGU 22 17371
HSV-UL54-1841 + AGACGCGCCGGCGGGGUUUUGGU 23 17372
HSV-UL54-1842 + GAGACGCGCCGGCGGGGUUUUGGU 24
17373
HSV-UL54-1843 + GGCGGGCCGGGGGACCUU 18 17374 HSV-UL54-1844 + GGGCGGGCCGGGGGACCUU 19 17375
HSV-UL54-179 + GGGGCGGGCCGGGGGACCU U 20 6602
HSV-UL54-1845 + CGGGGCGGGCCGGGGGACCUU 21 17376
HSV-UL54-1846 + UCGGGGCGGGCCGGGGGACCUU 22 17377
HSV-UL54-1847 + CUCGGGGCGGGCCGGGGGACCU U 23 17378
HSV-UL54-1848 + CCUCGGGGCGGGCCGGGGGACCUU 24 17379
HSV-UL54-1849 + GGCGAGGCGUCGAGGCUU 18 17380
HSV-UL54-1850 + GGGCGAGGCGUCGAGGCUU 19 17381
HSV-UL54-41 + CGGGCGAGGCGUCGAGGCUU 20 6464
HSV-UL54-1851 + CCGGGCGAGGCGUCGAGGCUU 21 17382
HSV-UL54-1852 + GCCGGGCGAGGCGUCGAGGCUU 22 17383
HSV-UL54-1853 + UGCCGGGCGAGGCGUCGAGGCUU 23 17384
HSV-UL54-1854 + CUGCCGGGCGAGGCGUCGAGGCUU 24 17385
HSV-UL54-1855 + CCUUGGU UGUGGGCGUUU 18 17386
HSV-UL54-1856 + CCCUUGGUUGUGGGCGUUU 19 17387
HSV-UL54-1857 + CCCCUUGGUUGUGGGCGUUU 20 17388
HSV-UL54-1858 + CCCCCUUGGUUGUGGGCGUUU 21 17389
HSV-UL54-1859 + ACCCCCUUGGUUGUGGGCGUUU 22 17390
HSV-UL54-1860 + GACCCCCUUGGUUGUGGGCGUUU 23 17391
HSV-UL54-1861 + CGACCCCCUUGGUUGUGGGCGUUU 24 17392
HSV-UL54-1862 - GAUUGGACCUGUCCGACA 18 17393
HSV-UL54-1863 - GGAUUGGACCUGUCCGACA 19 17394
HSV-UL54-686 - AGGAUUGGACCUGUCCGACA 20 7099
HSV-UL54-1864 - UAGGAUUGGACCUGUCCGACA 21 17395
HSV-UL54-1865 - CUAGGAUUGGACCUGUCCGACA 22 17396
HSV-UL54-1866 - CCUAGGAUUGGACCUGUCCGACA 23 17397
HSV-UL54-1867 - ACCUAGGAUUGGACCUGUCCGACA 24 17398
HSV-UL54-1868 - CCUCGUCGGACGAGGACA 18 17399
HSV-UL54-1869 - UCCUCGUCGGACGAGGACA 19 17400
HSV-UL54-6 - UUCCUCGUCGGACGAGGACA 20 6429
HSV-UL54-1870 - GU UCCUCGUCGGACGAGGACA 21 17401
HSV-UL54-1871 - UGUUCCUCGUCGGACGAGGACA 22 17402
HSV-UL54-1872 - GUGU UCCUCGUCGGACGAGGACA 23 17403
HSV-UL54-1873 - AGUGUUCCUCGUCGGACGAGGACA 24 17404
HSV-UL54-1874 - CAGAAACG CCCACAACCA 18 17405
HSV-UL54-1875 - CCAG AAACG CCCACAACCA 19 17406
HSV-UL54-1216 - UCCAGAAACGCCCACAACCA 20 16747
HSV-UL54-1876 - CUCCAGAAACGCCCACAACCA 21 17407
HSV-UL54-1877 - UCUCCAGAAACGCCCACAACCA 22 17408
HSV-UL54-1878 - G U CU CCAG AAACGCCCACAACCA 23 17409
HSV-UL54-1879 - CG U CU CCAG AAACGCCCACAACCA 24 17410
HSV-UL54-1880 - ACCCCGAGUCCGACAGCA 18 17411
HSV-UL54-1881 - GACCCCGAGUCCGACAGCA 19 17412
HSV-UL54-694 - CGACCCCGAGUCCGACAGCA 20 7106
HSV-UL54-1882 - ACGACCCCGAGUCCGACAGCA 21 17413
HSV-UL54-1883 - GACGACCCCGAGUCCGACAGCA 22 17414 HSV-UL54-1884 - CG ACGACCCCGAG UCCGACAGCA 23 17415
HSV-UL54-1885 - GCGACGACCCCGAGUCCGACAGCA 24 17416
HSV-UL54-1886 - UUCCCCCCGGGAACCGCA 18 17417
HSV-UL54-1887 - CUUCCCCCCGGGAACCGCA 19 17418
HSV-UL54-16 - GCUUCCCCCCGGGAACCGCA 20 6439
HSV-UL54-1888 - GGCUUCCCCCCGGGAACCGCA 21 17419
HSV-UL54-1889 - CGGCUUCCCCCCGGGAACCGCA 22 17420
HSV-UL54-1890 - UCGGCUUCCCCCCGGGAACCGCA 23 17421
HSV-UL54-1891 - GUCGGCUUCCCCCCGGGAACCGCA 24 17422
HSV-UL54-1892 - GGAAGACCCCUGCGGAGA 18 17423
HSV-UL54-1893 - UGGAAGACCCCUGCGGAGA 19 17424
HSV-UL54-116 - AUGGAAGACCCCUGCGGAGA 20 6539
HSV-UL54-1894 - CAUGGAAGACCCCUGCGGAGA 21 17425
HSV-UL54-1895 - ACAUGGAAGACCCCUGCGGAGA 22 17426
HSV-UL54-1896 - GACAUGGAAGACCCCUGCGGAGA 23 17427
HSV-UL54-1897 - GGACAUGGAAGACCCCUGCGGAGA 24 17428
HSV-UL54-1898 - AUGCUAAUCGACCUAGGA 18 17429
HSV-UL54-1899 - UAUGCUAAUCGACCUAGGA 19 17430
HSV-UL54-685 - AU AUGCUAAUCGACCUAGGA 20 7098
HSV-UL54-1900 - GAU AUGCUAAUCGACCUAGGA 21 17431
HSV-UL54-1901 - UGAUAUGCUAAUCGACCUAGGA 22 17432
HSV-UL54-1902 - UUGAU AUGCUAAUCGACCUAGGA 23 17433
HSV-UL54-1903 - AUUGAUAUGCUAAUCGACCUAGGA 24 17434
HSV-UL54-1904 - CGAGGAGGACGCUCUGGA 18 17435
HSV-UL54-1905 - UCGAGGAGGACGCUCUGGA 19 17436
HSV-UL54-690 - CUCGAGGAGGACGCUCUGGA 20 7102
HSV-UL54-1906 - GCUCGAGGAGGACGCUCUGGA 21 17437
HSV-UL54-1907 - AGCUCGAGGAGGACGCUCUGGA 22 17438
HSV-UL54-1908 - GAGCUCGAGGAGGACGCUCUGGA 23 17439
HSV-UL54-1909 - CGAGCUCGAGGAGGACGCUCUGGA 24 17440
HSV-UL54-1910 - UCCCCCCGGGAACCGCAC 18 17441
HSV-UL54-1911 - UUCCCCCCGGGAACCGCAC 19 17442
HSV-UL54-132 - CUUCCCCCCGGGAACCGCAC 20 6555
HSV-UL54-1912 - GCUUCCCCCCGGGAACCGCAC 21 17443
HSV-UL54-1913 - GGCUUCCCCCCGGGAACCGCAC 22 17444
HSV-UL54-1914 - CGGCUUCCCCCCGGGAACCGCAC 23 17445
HSV-UL54-1915 - UCGGCUUCCCCCCGGGAACCGCAC 24 17446
HSV-UL54-1916 - UCCUCGUCGGACGAGGAC 18 17447
HSV-UL54-1917 - UUCCUCGUCGGACGAGGAC 19 17448
HSV-UL54-700 - GUUCCUCGUCGGACGAGGAC 20 7110
HSV-UL54-1918 - UGU UCCUCGUCGGACGAGGAC 21 17449
HSV-UL54-1919 - GUGUUCCUCGUCGGACGAGGAC 22 17450
HSV-UL54-1920 - AG UGUUCCUCGUCGGACGAGGAC 23 17451
HSV-UL54-1921 - GAGUGUUCCUCGUCGGACGAGGAC 24 17452
HSV-UL54-1922 - GAGUGUUCCUCGUCGGAC 18 17453
HSV-UL54-1923 - GGAGUGUUCCUCGUCGGAC 19 17454 HSV-UL54-699 - GGGAGUGUUCCUCGUCGGAC 20 7109
HSV-UL54-1924 - GGGGAGUGUUCCUCGUCGGAC 21 17455
HSV-UL54-1925 - CGGGGAGUGUUCCUCGUCGGAC 22 17456
HSV-UL54-1926 - GCGGGGAGUGUUCCUCGUCGGAC 23 17457
HSV-UL54-1927 - AGCGGGGAGUGUUCCUCGUCGGAC 24 17458
HSV-UL54-1928 - GACGCUCUGGAGCGGGAC 18 17459
HSV-UL54-1929 - GGACGCUCUGGAGCGGGAC 19 17460
HSV-UL54-683 - AGGACGCUCUGGAGCGGGAC 20 7097
HSV-UL54-1930 - GAGGACGCUCUGGAGCGGGAC 21 17461
HSV-UL54-1931 - GGAGGACGCUCUGGAGCGGGAC 22 17462
HSV-UL54-1932 - AGGAGGACGCUCUGGAGCGGGAC 23 17463
HSV-UL54-1933 - GAGGAGGACGCUCUGGAGCGGGAC 24 17464
HSV-UL54-1934 - CCAG AAACG CCCACAACC 18 17465
HSV-UL54-1935 - UCCAGAAACGCCCACAACC 19 17466
HSV-UL54-1936 - CUCCAGAAACGCCCACAACC 20 17467
HSV-UL54-1937 - U CU CCAG AAACG CCCACAACC 21 17468
HSV-UL54-1938 - G U CU CCAG AAACGCCCACAACC 22 17469
HSV-UL54-1939 - CG U CU CCAG AAACGCCCACAACC 23 17470
HSV-UL54-1940 - G CG U CU CCAG AAACGCCCACAACC 24 17471
HSV-UL54-1941 - CCGAGGACGCCGGCACCC 18 17472
HSV-UL54-1942 - CCCGAGGACGCCGGCACCC 19 17473
HSV-UL54-710 - CCCCGAGGACGCCGGCACCC 20 7115
HSV-UL54-1943 - GCCCCGAGGACGCCGGCACCC 21 17474
HSV-UL54-1944 - CGCCCCGAGGACGCCGGCACCC 22 17475
HSV-UL54-1945 - CCGCCCCGAGGACGCCGGCACCC 23 17476
HSV-UL54-1946 - CCCGCCCCGAGGACGCCGGCACCC 24 17477
HSV-UL54-1947 - GGCGGUCGGCUUCCCCCC 18 17478
HSV-UL54-1948 - AGGCGGUCGGCUUCCCCCC 19 17479
HSV-UL54-131 - CAGGCGGUCGGCUUCCCCCC 20 6554
HSV-UL54-1949 - CCAGGCGGUCGGCUUCCCCCC 21 17480
HSV-UL54-1950 - ACCAGGCGGUCGGCUUCCCCCC 22 17481
HSV-UL54-1951 - GACCAGGCGGUCGGCUUCCCCCC 23 17482
HSV-UL54-1952 - GGACCAGGCGGUCGGCUUCCCCCC 24 17483
HSV-UL54-1953 - AGGCGGUCGGCUUCCCCC 18 17484
HSV-UL54-1954 - CAGGCGGUCGGCUUCCCCC 19 17485
HSV-UL54-130 - CCAGGCGGUCGGCUUCCCCC 20 6553
HSV-UL54-1955 - ACCAGGCGGUCGGCUUCCCCC 21 17486
HSV-UL54-1956 - GACCAGGCGGUCGGCU UCCCCC 22 17487
HSV-UL54-1957 - GGACCAGGCGGUCGGCUUCCCCC 23 17488
HSV-UL54-1958 - GGGACCAGGCGGUCGGCUUCCCCC 24 17489
HSV-UL54-1959 - GGUCCCCCGGCCCGCCCC 18 17490
HSV-UL54-1960 - AGGUCCCCCGGCCCGCCCC 19 17491
HSV-UL54-709 - AAGGUCCCCCGGCCCGCCCC 20 7114
HSV-UL54-1961 - AAAGGUCCCCCGGCCCGCCCC 21 17492
HSV-UL54-1962 - CAAAGGUCCCCCGGCCCGCCCC 22 17493
HSV-UL54-1963 - CCAAAGGUCCCCCGGCCCGCCCC 23 17494 HSV-UL54-1964 - CCCAAAG GUCCCCCGGCCCGCCCC 24 17495
HSV-UL54-1965 - CAGGCGGUCGGCUUCCCC 18 17496
HSV-UL54-1966 - CCAGGCGGUCGGCUUCCCC 19 17497
HSV-UL54-717 - ACCAGGCGGUCGGCUUCCCC 20 7118
HSV-UL54-1967 - GACCAGGCGGUCGGCUUCCCC 21 17498
HSV-UL54-1968 - GGACCAGGCGGUCGGCU UCCCC 22 17499
HSV-UL54-1969 - GGGACCAGGCGGUCGGCUUCCCC 23 17500
HSV-UL54-1970 - CGGGACCAGGCGGUCGGCU UCCCC 24 17501
HSV-UL54-1971 - AAGGUCCCCCGGCCCGCC 18 17502
HSV-UL54-1972 - AAAGGUCCCCCGGCCCGCC 19 17503
HSV-UL54-708 - CAAAGGUCCCCCGGCCCGCC 20 7113
HSV-UL54-1973 - CCAAAGGUCCCCCGGCCCGCC 21 17504
HSV-UL54-1974 - CCCAAAG GUCCCCCGGCCCGCC 22 17505
HSV-UL54-1975 - UCCCAAAGGUCCCCCGGCCCGCC 23 17506
HSV-UL54-1976 - UUCCCAAAGGUCCCCCGGCCCGCC 24 17507
HSV-UL54-1977 - CCGGCGUGUGGUCGCGCC 18 17508
HSV-UL54-1978 - ACCGGCGUGUGGUCGCGCC 19 17509
HSV-UL54-715 - CACCGGCGUGUGGUCGCGCC 20 7117
HSV-UL54-1979 - CCACCGGCGUGUGGUCGCGCC 21 17510
HSV-UL54-1980 - ACCACCGGCGUGUGGUCGCGCC 22 17511
HSV-UL54-1981 - GACCACCGGCGUGUGGUCGCGCC 23 17512
HSV-UL54-1982 - CGACCACCGGCGUGUGGUCGCGCC 24 17513
HSV-UL54-1983 - GACCAAGGCACCGCAUCC 18 17514
HSV-UL54-1984 - CGACCAAGGCACCGCAUCC 19 17515
HSV-UL54-726 - UCGACCAAGGCACCGCAUCC 20 7120
HSV-UL54-1985 - GUCGACCAAGGCACCGCAUCC 21 17516
HSV-UL54-1986 - CG U CGACCAAG G CACCG CAU CC 22 17517
HSV-UL54-1987 - CCG U CGACCAAG GCACCGCAU CC 23 17518
HSV-UL54-1988 - CCCGUCGACCAAGGCACCGCAUCC 24 17519
HSV-UL54-1989 - CCCGAG UCCGACAGCAGC 18 17520
HSV-UL54-1990 - CCCCGAGUCCGACAGCAGC 19 17521
HSV-UL54-111 - ACCCCGAGUCCGACAGCAGC 20 6534
HSV-UL54-1991 - GACCCCGAGUCCGACAGCAGC 21 17522
HSV-UL54-1992 - CGACCCCGAGUCCGACAGCAGC 22 17523
HSV-UL54-1993 - ACG ACCCCG AG U CCG ACAGCAG C 23 17524
HSV-UL54-1994 - GACGACCCCGAGUCCGACAGCAGC 24 17525
HSV-UL54-1995 - ACCUGUCCGACAGCGAGC 18 17526
HSV-UL54-1996 - GACCUGUCCGACAGCGAGC 19 17527
HSV-UL54-678 - GGACCUG U CCG ACAG CG AG C 20 7093
HSV-UL54-1997 - UGGACCUGUCCGACAGCGAGC 21 17528
HSV-UL54-1998 - UUGGACCUGUCCGACAGCGAGC 22 17529
HSV-UL54-1999 - AU UGGACCUGUCCGACAGCGAGC 23 17530
HSV-UL54-2000 - GAUUGGACCUGUCCGACAGCGAGC 24 17531
HSV-UL54-2001 - CUUCCCCCCGGGAACCGC 18 17532
HSV-UL54-2002 - GCUUCCCCCCGGGAACCGC 19 17533
HSV-UL54-720 - GGCUUCCCCCCGGGAACCGC 20 7119 HSV-UL54-2003 - CGGCUUCCCCCCGGGAACCGC 21 17534
HSV-UL54-2004 - UCGGCUUCCCCCCGGGAACCGC 22 17535
HSV-UL54-2005 - GUCGGCUUCCCCCCGGGAACCGC 23 17536
HSV-UL54-2006 - GGUCGGCUUCCCCCCGGGAACCGC 24 17537
HSV-UL54-2007 - GGGCGGCGAGGUCGCCGC 18 17538
HSV-UL54-2008 - CGGGCGGCGAGGUCGCCGC 19 17539
HSV-UL54-140 - GCGGGCGGCGAGGUCGCCGC 20 6563
HSV-UL54-2009 - GGCGGGCGGCGAGGUCGCCGC 21 17540
HSV-UL54-2010 - AGGCGGGCGGCGAGGUCGCCGC 22 17541
HSV-UL54-2011 - GAGGCGGGCGGCGAGGUCGCCGC 23 17542
HSV-UL54-2012 - CGAGGCGGGCGGCGAGGUCGCCGC 24 17543
HSV-UL54-2013 - CUCGCCCGGCAGCGCGGC 18 17544
HSV-UL54-2014 - CCUCGCCCGGCAGCGCGGC 19 17545
HSV-UL54-126 - GCCUCGCCCGGCAGCGCGGC 20 6549
HSV-UL54-2015 - CGCCUCGCCCGGCAGCGCGGC 21 17546
HSV-UL54-2016 - ACGCCUCGCCCGGCAGCGCGGC 22 17547
HSV-UL54-2017 - GACGCCUCGCCCGGCAGCGCGGC 23 17548
HSV-UL54-2018 - CGACGCCUCGCCCGGCAGCGCGGC 24 17549
HSV-UL54-2019 - CUGUCCGACAGCGAGCUC 18 17550
HSV-UL54-2020 - CCUGUCCGACAGCGAGCUC 19 17551
HSV-UL54-679 - ACCUGUCCGACAGCGAGCUC 20 7094
HSV-UL54-2021 - GACCUGUCCGACAGCGAGCUC 21 17552
HSV-UL54-2022 - GGACCUGUCCGACAGCGAGCUC 22 17553
HSV-UL54-2023 - UGGACCUGUCCGACAGCGAGCUC 23 17554
HSV-UL54-2024 - UUGGACCUGUCCGACAGCGAGCUC 24 17555
HSV-UL54-2025 - AGCUCGAGGAGGACGCUC 18 17556
HSV-UL54-2026 - GAGCUCGAGGAGGACGCUC 19 17557
HSV-UL54-5 - CGAGCUCGAGGAGGACGCUC 20 6428
HSV-UL54-2027 - GCGAGCUCGAGGAGGACGCUC 21 17558
HSV-UL54-2028 - AGCG AGCUCGAGGAGGACGCUC 22 17559
HSV-UL54-2029 - CAGCGAGCUCGAGGAGGACGCUC 23 17560
HSV-UL54-2030 - ACAGCGAGCUCGAGGAGGACGCUC 24 17561
HSV-UL54-2031 - ACCCCGCCGGCGCGUCUC 18 17562
HSV-UL54-2032 - AACCCCGCCGGCGCGUCUC 19 17563
HSV-UL54-2033 - AAACCCCGCCGGCGCGUCUC 20 17564
HSV-UL54-2034 - AAAACCCCGCCGGCGCGUCUC 21 17565
HSV-UL54-2035 - CAAAACCCCGCCGGCGCGUCUC 22 17566
HSV-UL54-2036 - CCAAAACCCCGCCGGCGCGUCUC 23 17567
HSV-UL54-2037 - ACCAAA ACCCCG CCG G CG CG U CU C 24 17568
HSV-UL54-2038 - CCCCGAGUCCGACAGCAG 18 17569
HSV-UL54-2039 - ACCCCG AGUCCGACAGCAG 19 17570
HSV-UL54-110 - GACCCCGAGUCCGACAGCAG 20 6533
HSV-UL54-2040 - CGACCCCGAGUCCGACAGCAG 21 17571
HSV-UL54-2041 - ACGACCCCGAG UCCGACAGCAG 22 17572
HSV-UL54-2042 - GACGACCCCGAGUCCGACAGCAG 23 17573
HSV-UL54-2043 - CGACGACCCCG AGUCCGACAGCAG 24 17574 HSV-UL54-2044 - GCUCUGGAGCGGGACGAG 18 17575
HSV-UL54-2045 - CGCUCUGGAGCGGGACGAG 19 17576
HSV-UL54-692 - ACGCUCUGGAGCGGGACGAG 20 7104
HSV-UL54-2046 - GACGCUCUGGAGCGGGACGAG 21 17577
HSV-UL54-2047 - GGACGCUCUGGAGCGGGACGAG 22 17578
HSV-UL54-2048 - AGGACGCUCUGGAGCGGGACGAG 23 17579
HSV-UL54-2049 - GAGGACGCUCUGGAGCGGGACGAG 24 17580
HSV-UL54-2050 - AGGCACCGCAUCCCCGAG 18 17581
HSV-UL54-2051 - AAGGCACCGCAUCCCCGAG 19 17582
HSV-UL54-727 - CAAGGCACCGCAUCCCCGAG 20 7121
HSV-UL54-2052 - CCAAGGCACCGCAUCCCCGAG 21 17583
HSV-UL54-2053 - ACCAAGGCACCGCAUCCCCGAG 22 17584
HSV-UL54-2054 - GACCAAG G CACCG CAU CCCCG AG 23 17585
HSV-UL54-2055 - CGACCAAGGCACCGCAUCCCCGAG 24 17586
HSV-UL54-2056 - UCCGACAGCGAGCUCGAG 18 17587
HSV-UL54-2057 - GUCCGACAGCGAGCUCGAG 19 17588
HSV-UL54-687 - UGUCCGACAGCGAGCUCGAG 20 7100
HSV-UL54-2058 - CUGUCCGACAGCGAGCUCGAG 21 17589
HSV-UL54-2059 - CCUGUCCGACAGCGAGCUCGAG 22 17590
HSV-UL54-2060 - ACCUGUCCGACAGCGAGCUCGAG 23 17591
HSV-UL54-2061 - GACCUGUCCGACAGCGAGCUCGAG 24 17592
HSV-UL54-2062 - UGGAAGACCCCUGCGGAG 18 17593
HSV-UL54-2063 - AUGGAAGACCCCUGCGGAG 19 17594
HSV-UL54-682 - CAUGGAAGACCCCUGCGGAG 20 7096
HSV-UL54-2064 - ACAUGGAAGACCCCUGCGGAG 21 17595
HSV-UL54-2065 - GACAUGGAAGACCCCUGCGGAG 22 17596
HSV-UL54-2066 - GGACAUGGAAGACCCCUGCGGAG 23 17597
HSV-UL54-2067 - AGGACAUGGAAGACCCCUGCGGAG 24 17598
HSV-UL54-2068 - GAGGAGGACGCUCUGGAG 18 17599
HSV-UL54-2069 - CGAGGAGGACGCUCUGGAG 19 17600
HSV-UL54-105 - UCGAGGAGGACGCUCUGGAG 20 6528
HSV-UL54-2070 - CUCGAGGAGGACGCUCUGGAG 21 17601
HSV-UL54-2071 - GCUCGAGGAGGACGCUCUGGAG 22 17602
HSV-UL54-2072 - AGCUCGAGGAGGACGCUCUGGAG 23 17603
HSV-UL54-2073 - GAGCUCGAGGAGGACGCUCUGGAG 24 17604
HSV-UL54-2074 - CCCCCCGGGAACCGCACG 18 17605
HSV-UL54-2075 - UCCCCCCGGGAACCGCACG 19 17606
HSV-UL54-17 - UUCCCCCCGGGAACCGCACG 20 6440
HSV-UL54-2076 - CUUCCCCCCGGGAACCGCACG 21 17607
HSV-UL54-2077 - GCUUCCCCCCGGGAACCGCACG 22 17608
HSV-UL54-2078 - GGCUUCCCCCCGGGAACCGCACG 23 17609
HSV-UL54-2079 - CGGCUUCCCCCCGGGAACCGCACG 24 17610
HSV-UL54-2080 - AAGACCCCUGCGGAGACG 18 17611
HSV-UL54-2081 - GAAGACCCCUGCGGAGACG 19 17612
HSV-UL54-704 - GGAAGACCCCUGCGGAGACG 20 7111
HSV-UL54-2082 - UGGAAGACCCCUGCGGAGACG 21 17613 HSV-UL54-2083 - AUGGAAGACCCCUGCGGAGACG 22 17614
HSV-UL54-2084 - CAUGGAAGACCCCUGCGGAGACG 23 17615
HSV-UL54-2085 - ACAUGGAAGACCCCUGCGGAGACG 24 17616
HSV-UL54-2086 - ACGCUCUGGAGCGGGACG 18 17617
HSV-UL54-2087 - GACGCUCUGGAGCGGGACG 19 17618
HSV-UL54-107 - GGACGCUCUGGAGCGGGACG 20 6530
HSV-UL54-2088 - AGGACGCUCUGGAGCGGGACG 21 17619
HSV-UL54-2089 - GAGG ACGCUCUGGAGCGGGACG 22 17620
HSV-UL54-2090 - GG AGGACGCUCUGGAGCGGGACG 23 17621
HSV-UL54-2091 - AGGAGGACGCUCUGGAGCGGGACG 24 17622
HSV-UL54-2092 - CGGGCGGCGAGGUCGCCG 18 17623
HSV-UL54-2093 - GCGGGCGGCGAGGUCGCCG 19 17624
HSV-UL54-729 - GGCGGGCGGCGAGGUCGCCG 20 7123
HSV-UL54-2094 - AGGCGGGCGGCGAGGUCGCCG 21 17625
HSV-UL54-2095 - GAGGCGGGCGGCGAGGUCGCCG 22 17626
HSV-UL54-2096 - CG AGGCGGGCGGCGAGGUCGCCG 23 17627
HSV-UL54-2097 - CCGAGGCGGGCGGCGAGGUCGCCG 24 17628
HSV-UL54-2098 - GCCUCGCCCGGCAGCGCG 18 17629
HSV-UL54-2099 - CGCCUCGCCCGGCAGCGCG 19 17630
HSV-UL54-711 - ACGCCUCGCCCGGCAGCGCG 20 7116
HSV-UL54-2100 - GACGCCUCGCCCGGCAGCGCG 21 17631
HSV-UL54-2101 - CGACGCCUCGCCCGGCAGCGCG 22 17632
HSV-UL54-2102 - UCGACGCCUCGCCCGGCAGCGCG 23 17633
HSV-UL54-2103 - CUCGACGCCUCGCCCGGCAGCGCG 24 17634
HSV-UL54-2104 - UCGCCCGGCAGCGCGGCG 18 17635
HSV-UL54-2105 - CUCGCCCGGCAGCGCGGCG 19 17636
HSV-UL54-127 - CCUCGCCCGGCAGCGCGGCG 20 6550
HSV-UL54-2106 - GCCUCGCCCGGCAGCGCGGCG 21 17637
HSV-UL54-2107 - CGCCUCGCCCGGCAGCGCGGCG 22 17638
HSV-UL54-2108 - ACGCCUCGCCCGGCAGCGCGGCG 23 17639
HSV-UL54-2109 - GACGCCUCGCCCGGCAGCGCGGCG 24 17640
HSV-UL54-2110 - GCAUCCCCGAGGCGGGCG 18 17641
HSV-UL54-2111 - CGCAUCCCCGAGGCGGGCG 19 17642
HSV-UL54-728 - CCGCAUCCCCGAGGCGGGCG 20 7122
HSV-UL54-2112 - ACCGCAUCCCCGAGGCGGGCG 21 17643
HSV-UL54-2113 - CACCGCAUCCCCGAGGCGGGCG 22 17644
HSV-UL54-2114 - GCACCGCAUCCCCGAGGCGGGCG 23 17645
HSV-UL54-2115 - GGCACCGCAUCCCCGAGGCGGGCG 24 17646
HSV-UL54-2116 - AGCGGGGAGUGUUCCUCG 18 17647
HSV-UL54-2117 - CAGCGGGGAGUGUUCCUCG 19 17648
HSV-UL54-697 - GCAGCGGGGAGUGUUCCUCG 20 7107
HSV-UL54-2118 - AGCAGCGGGGAGUGUUCCUCG 21 17649
HSV-UL54-2119 - CAGCAGCGGGGAGUGUUCCUCG 22 17650
HSV-UL54-2120 - ACAGCAGCGGGGAGUGUUCCUCG 23 17651
HSV-UL54-2121 - GACAGCAGCGGGGAGUGUUCCUCG 24 17652
HSV-UL54-2122 - UGUCCGACAGCGAGCUCG 18 17653 HSV-UL54-2123 - CUGUCCGACAGCGAGCUCG 19 17654
HSV-UL54-3 - CCUGUCCGACAGCGAGCUCG 20 6426
HSV-UL54-2124 - ACCUGUCCGACAGCGAGCUCG 21 17655
HSV-UL54-2125 - GACCUGUCCGACAGCGAGCUCG 22 17656
HSV-UL54-2126 - GG ACCUGUCCGACAGCGAGCUCG 23 17657
HSV-UL54-2127 - UGGACCUGUCCGACAGCGAGCUCG 24 17658
HSV-UL54-2128 - CCCCCGGGAACCGCACGG 18 17659
HSV-UL54-2129 - CCCCCCGGGAACCGCACGG 19 17660
HSV-UL54-18 - UCCCCCCGGGAACCGCACGG 20 6441
HSV-UL54-2130 - UUCCCCCCGGGAACCGCACGG 21 17661
HSV-UL54-2131 - CUUCCCCCCGGGAACCGCACGG 22 17662
HSV-UL54-2132 - GCUUCCCCCCGGGAACCGCACGG 23 17663
HSV-UL54-2133 - GGCUUCCCCCCGGGAACCGCACGG 24 17664
HSV-UL54-2134 - AGACCCCUGCGGAGACGG 18 17665
HSV-UL54-2135 - AAGACCCCUGCGGAGACGG 19 17666
HSV-UL54-117 - GAAGACCCCUGCGGAGACGG 20 6540
HSV-UL54-2136 - GGAAGACCCCUGCGGAGACGG 21 17667
HSV-UL54-2137 - UGGAAGACCCCUGCGGAGACGG 22 17668
HSV-UL54-2138 - AUGG AAGACCCCUGCGGAGACGG 23 17669
HSV-UL54-2139 - CAUGGAAGACCCCUGCGGAGACGG 24 17670
HSV-UL54-2140 - CCUCGCCCGGCAGCGCGG 18 17671
HSV-UL54-2141 - GCCUCGCCCGGCAGCGCGG 19 17672
HSV-UL54-125 - CGCCUCGCCCGGCAGCGCGG 20 6548
HSV-UL54-2142 - ACGCCUCGCCCGGCAGCGCGG 21 17673
HSV-UL54-2143 - GACGCCUCGCCCGGCAGCGCGG 22 17674
HSV-UL54-2144 - CGACGCCUCGCCCGGCAGCGCGG 23 17675
HSV-UL54-2145 - UCGACGCCUCGCCCGGCAGCGCGG 24 17676
HSV-UL54-2146 - GGGAGUGUUCCUCGUCGG 18 17677
HSV-UL54-2147 - GGGGAGUGUUCCUCGUCGG 19 17678
HSV-UL54-698 - CGGGGAGUGUUCCUCGUCGG 20 7108
HSV-UL54-2148 - GCGGGGAGUGUUCCUCGUCGG 21 17679
HSV-UL54-2149 - AGCGGGGAGUGUUCCUCGUCGG 22 17680
HSV-UL54-2150 - CAGCGGGGAGUGUUCCUCGUCGG 23 17681
HSV-UL54-2151 - GCAGCGGGGAGUGUUCCUCGUCGG 24 17682
HSV-UL54-2152 - CCCUGCGGAGACGGAGGG 18 17683
HSV-UL54-2153 - CCCCUGCGGAGACGGAGGG 19 17684
HSV-UL54-706 - ACCCCUGCGGAGACGGAGGG 20 7112
HSV-UL54-2154 - GACCCCUGCGGAGACGGAGGG 21 17685
HSV-UL54-2155 - AG ACCCCUGCGGAGACGGAGGG 22 17686
HSV-UL54-2156 - AAGACCCCUGCGGAGACGGAGGG 23 17687
HSV-UL54-2157 - GAAGACCCCUGCGGAGACGGAGGG 24 17688
HSV-UL54-2158 - CCCCGGGAACCGCACGGG 18 17689
HSV-UL54-2159 - CCCCCGGGAACCGCACGGG 19 17690
HSV-UL54-19 - CCCCCCGGGAACCGCACGGG 20 6442
HSV-UL54-2160 - UCCCCCCGGGAACCGCACGGG 21 17691
HSV-UL54-2161 - UUCCCCCCGGGAACCGCACGGG 22 17692 HSV-UL54-2162 - CUUCCCCCCGGGAACCGCACGGG 23 17693
HSV-UL54-2163 - GCUUCCCCCCGGGAACCGCACGGG 24 17694
HSV-UL54-2164 - AGGACGCUCUGGAGCGGG 18 17695
HSV-UL54-2165 - GAGGACGCUCUGGAGCGGG 19 17696
HSV-UL54-691 - GGAGGACGCUCUGGAGCGGG 20 7103
HSV-UL54-2166 - AGGAGGACGCUCUGGAGCGGG 21 17697
HSV-UL54-2167 - GAGG AGGACGCUCUGGAGCGGG 22 17698
HSV-UL54-2168 - CGAGGAGGACGCUCUGGAGCGGG 23 17699
HSV-UL54-2169 - UCGAGGAGGACGCUCUGGAGCGGG 24 17700
HSV-UL54-2170 - CCUGCGGAGACGGAGGGG 18 17701
HSV-UL54-2171 - CCCUGCGGAGACGGAGGGG 19 17702
HSV-UL54-119 - CCCCUGCGGAGACGGAGGGG 20 6542
HSV-UL54-2172 - ACCCCUGCGGAGACGGAGGGG 21 17703
HSV-UL54-2173 - GACCCCUGCGGAGACGGAGGGG 22 17704
HSV-UL54-2174 - AGACCCCUGCGGAGACGGAGGGG 23 17705
HSV-UL54-2175 - AAGACCCCUGCGGAGACGGAGGGG 24 17706
HSV-UL54-2176 - GCGAGGUCGCCGCCGGGG 18 17707
HSV-UL54-2177 - GGCGAGGUCGCCGCCGGGG 19 17708
HSV-UL54-731 - CGGCGAGGUCGCCGCCGGGG 20 7124
HSV-UL54-2178 - GCGGCGAGGUCGCCGCCGGGG 21 17709
HSV-UL54-2179 - GGCGGCGAGGUCGCCGCCGGGG 22 17710
HSV-UL54-2180 - GGGCGGCGAGGUCGCCGCCGGGG 23 17711
HSV-UL54-2181 - CGGGCGGCGAGGUCGCCGCCGGGG 24 17712
HSV-UL54-2182 - GGACAUGGAAGACCCCUG 18 17713
HSV-UL54-2183 - AGGACAUGGAAGACCCCUG 19 17714
HSV-UL54-115 - GAGGACAUGGAAGACCCCUG 20 6538
HSV-UL54-2184 - CGAGGACAUGGAAGACCCCUG 21 17715
HSV-UL54-2185 - ACGAGGACAUGGAAGACCCCUG 22 17716
HSV-UL54-2186 - GACGAGGACAUGGAAGACCCCUG 23 17717
HSV-UL54-2187 - GGACGAGGACAUGGAAGACCCCUG 24 17718
HSV-UL54-2188 - AGGACAUGGAAGACCCCU 18 17719
HSV-UL54-2189 - GAGGACAUGGAAGACCCCU 19 17720
HSV-UL54-681 - CG AGGACAUGGAAGACCCCU 20 7095
HSV-UL54-2190 - ACGAGGACAUGGAAGACCCCU 21 17721
HSV-UL54-2191 - GACGAGGACAUGGAAGACCCCU 22 17722
HSV-UL54-2192 - GGACG AGGACAUGGAAGACCCCU 23 17723
HSV-UL54-2193 - CGGACGAGGACAUGGAAGACCCCU 24 17724
HSV-UL54-2194 - CGGCGUGUGGUCGCGCCU 18 17725
HSV-UL54-2195 - CCGGCGUGUGGUCGCGCCU 19 17726
HSV-UL54-128 - ACCGGCGUGUGGUCGCGCCU 20 6551
HSV-UL54-2196 - CACCGGCGUGUGGUCGCGCCU 21 17727
HSV-UL54-2197 - CCACCGGCGUGUGGUCGCGCCU 22 17728
HSV-UL54-2198 - ACCACCGGCGUGUGGUCGCGCCU 23 17729
HSV-UL54-2199 - GACCACCGGCGUGUGGUCGCGCCU 24 17730
HSV-UL54-2200 - GAGCUCGAGGAGGACGCU 18 17731
HSV-UL54-2201 - CGAGCUCGAGGAGGACGCU 19 17732 HSV-UL54-688 - GCGAGCUCGAGGAGGACGCU 20 7101
HSV-UL54-2202 - AGCGAGCUCGAGGAGGACGCU 21 17733
HSV-UL54-2203 - CAGCGAGCUCGAGGAGGACGCU 22 17734
HSV-UL54-2204 - ACAGCGAGCUCGAGGAGGACGCU 23 17735
HSV-UL54-2205 - GACAGCGAGCUCGAGGAGGACGCU 24 17736
Table 15E provides exemplary targeting domains for knocking out the UL54 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene), and start with a 5'G. The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 15E
Figure imgf000678_0001
HSV-UL54-2227 + GACGCGGUUGGCGAGGCGGGC 21 17758
HSV-UL54-1412 + GCCGUCCGUCCGCGCCGACG 20 16943
HSV-UL54-2228 + GGCCGUCCGUCCGCGCCGACG 21 17759
HSV-UL54-2229 + GGGCCGUCCGUCCGCGCCGACG 22 17760
HSV-UL54-2230 + GGGGCCGUCCGUCCGCGCCGACG 23 17761
HSV-UL54-2231 + GGUU UCCCAGGAAACCCG 18 17762
HSV-UL54-2232 + GGGUU UCCCAGGAAACCCG 19 17763
HSV-UL54-2233 + G ACCAGGG U U UCCCAGGAAACCCG 24 17764
HSV-UL54-2234 + GCAGAACCGCCCGAACGG 18 17765
HSV-UL54-2235 + GAUCGCAGAACCGCCCGAACGG 22 17766
HSV-UL54-2236 + GGAUCGCAGAACCGCCCGAACGG 23 17767
HSV-UL54-1480 + GUUUCUGGAGACGCGCCGG 19 17011
HSV-UL54-1481 + GCGUUUCUGGAGACGCGCCGG 21 17012
HSV-UL54-1482 + GGCGUUUCUGGAGACGCGCCGG 22 17013
HSV-UL54-1483 + GGGCGUU UCUGGAGACGCGCCGG 23 17014
HSV-UL54-2237 + GCGGCCGUCCGCGUGCGG 18 17768
HSV-UL54-1436 + GCGCGGCCGUCCGCGUGCGG 20 16967
HSV-UL54-2238 + GGCGCGGCCGUCCGCGUGCGG 21 17769
HSV-UL54-2239 + GGGCGCGGCCGUCCGCGUGCGG 22 17770
HSV-UL54-2240 + GGGGCGCGGCCGUCCGCGUGCGG 23 17771
HSV-UL54-2241 + GCGGAGCGGCAGAUUGUG 18 17772
HSV-UL54-2242 + GGCGGAGCGGCAGAUUGUG 19 17773
HSV-UL54-2243 + GGGCGGAGCGGCAGAUUGUG 20 17774
HSV-UL54-2244 + GGGGCGGAGCGGCAGAUUGUG 21 17775
HSV-UL54-2245 + GGGGGCGGAGCGGCAGAUUGUG 22 17776
HSV-UL54-2246 + GACCGCCGCGCGCUCGGAU 19 17777
HSV-UL54-2247 + GCUCGACCGCCGCGCGCUCGGAU 23 17778
HSV-UL54-2248 + GCGGCCCGCGGGUUGGCU 18 17779
HSV-UL54-2249 + GACGCGGCCCGCGGGUUGGCU 21 17780
HSV-UL54-2250 + GUCGACGCGGCCCGCGGGUUGGCU 24 17781
HSV-UL54-1490 - G U CUCCAG AAACG CCCACAACCAA 24 17021
HSV-UL54-2251 - GAAAUACUGGACACGCACCGCC 22 17782
HSV-UL54-2252 - GCAACUCCCUAU UUUAGGC 19 17783
HSV-UL54-2253 - G U U U G ACGCCG AG ACCCG 18 17784
HSV-UL54-2254 - GGUUUGACGCCGAGACCCG 19 17785
HSV-UL54-939 - GGGUUUGACGCCGAG ACCCG 20 7282
HSV-UL54-2255 - GGGGUUUGACGCCGAGACCCG 21 17786
HSV-UL54-2256 - GGGGGUUUGACGCCGAG ACCCG 22 17787
HSV-UL54-2257 - GGGGGGUUUGACGCCGAGACCCG 23 17788
HSV-UL54-2258 - GGGGGGGUUUGACGCCGAGACCCG 24 17789
HSV-UL54-2259 - GUGCUGGCCACCCAAGCGG 19 17790
HSV-UL54-306 - GUCAUGCAAGACCCCUUUGG 20 6729
HSV-UL54-2260 - GGUCAUGCAAGACCCCUUUGG 21 17791
HSV-UL54-2261 - GAUCGACUACACGACCGU 18 17792
HSV-UL54-350 - GAGAUCGACUACACGACCGU 20 6773
HSV-UL54-2262 - GGAGAUCGACUACACGACCGU 21 17793 HSV-UL54-2263 - GUCGGAGAUCGACUACACGACCGU 24 17794
HSV-UL54-2264 - GCGACGCCUGUCGGACAUU 19 17795
HSV-UL54-960 - GGCGACGCCUGUCGGACAUU 20 7297
HSV-UL54-2265 - GCGGCGACGCCUGUCGGACAUU 22 17796
Table 15F provides exemplary targeting domains for knocking out the UL54 gene selected according to the six tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). The PAM is NNGRRT. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 15F
Figure imgf000680_0001
HSV-UL54-2289 + UGGCCUUGGCUGUCGACGCGGCCC 24 17820
HSV-UL54-2290 + UCCGCGCCGCGCCUCGCC 18 17821
HSV-UL54-2291 + CUCCGCGCCGCGCCUCGCC 19 17822
HSV-UL54-2292 + CCUCCGCGCCGCGCCUCGCC 20 17823
HSV-UL54-2293 + CCCUCCGCGCCGCGCCUCGCC 21 17824
HSV-UL54-2294 + CCCCUCCGCGCCGCGCCUCGCC 22 17825
HSV-UL54-2295 + UCCCCUCCGCGCCGCGCCUCGCC 23 17826
HSV-UL54-2296 + CUCCCCUCCGCGCCGCGCCUCGCC 24 17827
HSV-UL54-2297 + CGGCGUCAAACCCCCCCGC 19 17828
HSV-UL54-2298 + UCGGCGUCAAACCCCCCCGC 20 17829
HSV-UL54-2299 + CUCGGCGUCAAACCCCCCCGC 21 17830
HSV-UL54-2300 + UCUCGGCGUCAAACCCCCCCGC 22 17831
HSV-UL54-2301 + CGCUCGACCGCCGCGCGC 18 17832
HSV-UL54-2302 + UGCGCUCGACCGCCGCGCGC 20 17833
HSV-UL54-2303 + AUGCGCUCGACCGCCGCGCGC 21 17834
HSV-UL54-2304 + UGAUGCGCUCGACCGCCGCGCGC 23 17835
HSV-UL54-2305 + CUGAUGCGCUCGACCGCCGCGCGC 24 17836
HSV-UL54-2306 + CGCGGUUGGCGAGGCGGGC 19 17837
HSV-UL54-2307 + ACGCGGUUGGCGAGGCGGGC 20 17838
HSV-UL54-2308 + CGACGCGGUUGGCGAGGCGGGC 22 17839
HSV-UL54-2309 + UCGACGCGGUUGGCGAGGCGGGC 23 17840
HSV-UL54-2310 + CUCGACGCGGUUGGCGAGGCGGGC 24 17841
HSV-UL54-2311 + CGUCCGUCCGCGCCGACG 18 17842
HSV-UL54-2312 + CCGUCCGUCCGCGCCGACG 19 17843
HSV-UL54-2313 + CGGGGCCGUCCGUCCGCGCCGACG 24 17844
HSV-UL54-2314 + AGGGU U UCCCAGGAAACCCG 20 17845
HSV-UL54-2315 + CAGGGUUUCCCAGGAAACCCG 21 17846
HSV-UL54-2316 + CCAGGG U U U CCCAG G AAACCCG 22 17847
HSV-UL54-2317 + ACCAGGGUUU CCCAG G AAACCCG 23 17848
HSV-UL54-2318 + CG CAG AACCGCCCG AACG G 19 17849
HSV-UL54-1432 + UCG CAG AACCG CCCG AACG G 20 16963
HSV-UL54-2319 + AUCGCAG AACCGCCCG AACGG 21 17850
HSV-UL54-2320 + UGGAUCGCAGAACCGCCCGAACGG 24 17851
HSV-UL54-1516 + UUUCUGGAGACGCGCCGG 18 17047
HSV-UL54-1220 + CGUUUCUGGAGACGCGCCGG 20 16751
HSV-UL54-1517 + UGGGCGUUUCUGGAGACGCGCCGG 24 17048
HSV-UL54-2321 + CGCGGCCGUCCGCGUGCGG 19 17852
HSV-UL54-2322 + CGGGGCGCGGCCGUCCGCGUGCGG 24 17853
HSV-UL54-2323 + UGGGGGCGGAGCGGCAGAUUGUG 23 17854
HSV-UL54-2324 + CUGGGGGCGGAGCGGCAGAUUGUG 24
17855
HSV-UL54-2325 + ACCGCCGCGCGCUCGGAU 18 17856
HSV-UL54-2326 + CGACCGCCGCGCGCUCGGAU 20 17857
HSV-UL54-2327 + UCGACCGCCGCGCGCUCGGAU 21 17858
HSV-UL54-2328 + CUCGACCGCCGCGCGCUCGGAU 22 17859
HSV-UL54-2329 + CGCUCGACCGCCGCGCGCUCGGAU 24 17860 HSV-UL54-2330 + CGCGGCCCGCGGGUUGGCU 19 17861
HSV-UL54-2331 + ACGCGGCCCGCGGGUUGGCU 20 17862
HSV-UL54-2332 + CGACGCGGCCCGCGGGUUGGCU 22 17863
HSV-UL54-2333 + UCGACGCGGCCCGCGGGUUGGCU 23 17864
HSV-UL54-1561 - AGAAACGCCCACAACCAA 18 17092
HSV-UL54-1562 - CAGAAACGCCCACAACCAA 19 17093
HSV-UL54-1234 - CCAGAAACGCCCACAACCAA 20 16765
HSV-UL54-1539 - UCCAGAAACGCCCACAACCAA 21 17070
HSV-UL54-1540 - CU CCAG AAACG CCCACAACCAA 22 17071
HSV-UL54-1541 - U CU CCAGAAACGCCCACAACCAA 23 17072
HSV-UL54-2334 - UACUGGACACGCACCGCC 18 17865
HSV-UL54-2335 - AUACUGGACACGCACCGCC 19 17866
HSV-UL54-365 - AAUACUGGACACGCACCGCC 20 6788
HSV-UL54-2336 - AAAUACUGGACACGCACCGCC 21 17867
HSV-UL54-2337 - UGAAAUACUGGACACGCACCGCC 23 17868
HSV-UL54-2338 - UUGAAAUACUGGACACGCACCGCC 24 17869
HSV-UL54-2339 - AUCGAGGCCCUGGCGUCC 18 17870
HSV-UL54-2340 - CAUCGAGGCCCUGGCGUCC 19 17871
HSV-UL54-948 - UCAUCGAGGCCCUGGCGUCC 20 7288
HSV-UL54-2341 - CUCAUCGAGGCCCUGGCGUCC 21 17872
HSV-UL54-2342 - UCUCAUCGAGGCCCUGGCGUCC 22 17873
HSV-UL54-2343 - AUCUCAUCGAGGCCCUGGCGUCC 23 17874
HSV-UL54-2344 - AAUCUCAUCGAGGCCCUGGCGUCC 24 17875
HSV-UL54-2345 - CAACUCCCUAUUUUAGGC 18 17876
HSV-UL54-2346 - UGCAACUCCCUAUUUUAGGC 20 17877
HSV-UL54-2347 - CUGCAACUCCCUAUUUUAGGC 21 17878
HSV-UL54-2348 - ACUGCAACUCCCUAUUUUAGGC 22 17879
HSV-UL54-2349 - UACUGCAACUCCCUAUUUUAGGC 23 17880
HSV-UL54-2350 - CUACUGCAACUCCCUAUUUUAGGC 24 17881
HSV-UL54-2351 - UGCUGGCCACCCAAGCGG 18 17882
HSV-UL54-314 - CGUGCUGGCCACCCAAGCGG 20 6737
HSV-UL54-2352 - CCGUGCUGGCCACCCAAGCGG 21 17883
HSV-UL54-2353 - CCCGUGCUGGCCACCCAAGCGG 22 17884
HSV-UL54-2354 - UCCCGUGCUGGCCACCCAAGCGG 23 17885
HSV-UL54-2355 - CUCCCGUGCUGGCCACCCAAGCGG 24 17886
HSV-UL54-2356 - CAUGCAAGACCCCU UUGG 18 17887
HSV-UL54-2357 - UCAUGCAAGACCCCUUUGG 19 17888
HSV-UL54-2358 - UGGUCAUGCAAGACCCCUUUGG 22 17889
HSV-UL54-2359 - CUGGUCAUGCAAGACCCCUUUGG 23 17890
HSV-UL54-2360 - CCU GG U CAU G CAAG ACCCCU U UG G 24 17891
HSV-UL54-2361 - AUCCCGGGGGCCUGCAUG 18 17892
HSV-UL54-2362 - CAUCCCGGGGGCCUGCAUG 19 17893
HSV-UL54-973 - ACAUCCCGGGGGCCUGCAUG 20 7304
HSV-UL54-2363 - UACAUCCCGGGGGCCUGCAUG 21 17894
HSV-UL54-2364 - UUACAUCCCGGGGGCCUGCAUG 22 17895
HSV-UL54-2365 - UUUACAUCCCGGGGGCCUGCAUG 23 17896 HSV-UL54-2366 - UUUUACAUCCCGGGGGCCUGCAUG 24 17897
HSV-UL54-2367 - AGAUCGACUACACGACCGU 19 17898
HSV-UL54-2368 - CGGAGAUCGACUACACGACCGU 22 17899
HSV-UL54-2369 - UCGG AGAUCGACUACACGACCGU 23 17900
HSV-UL54-2370 - CGACGCCUGUCGGACAUU 18 17901
HSV-UL54-2371 - CGGCGACGCCUGUCGGACAUU 21 17902
HSV-UL54-2372 - CGCGGCGACGCCUGUCGGACAUU 23 17903
HSV-UL54-2373 - UCGCGGCGACGCCUGUCGGACAUU 24 17904
Table 15G provides exemplary targeting domains for knocking out the UL54 gene selected according to the seven tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). The PAM is NNGRRV. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a S. aureus Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single-stranded break (Cas9 nickase).
Table 15G
Figure imgf000683_0001
HSV-UL54-2392 + GGGCCUUCAGGUAGCACUGCAGAA 24 17923
HSV-UL54-2393 + UUUGCCGUGCACAUAUAA 18 17924
HSV-UL54-2394 + AUUUGCCGUGCACAUAUAA 19 17925
HSV-UL54-1361 + UAU UUGCCGUGCACAUAUAA 20 16892
HSV-UL54-2395 + GUAUUUGCCGUGCACAUAUAA 21 17926
HSV-UL54-2396 + AGUAUUUGCCGUGCACAUAUAA 22 17927
HSV-UL54-2397 + AAG UAUUUGCCGUGCACAUAUAA 23 17928
HSV-UL54-2398 + GAAGUAUUUGCCGUGCACAUAUAA 24 17929
HSV-UL54-2399 + GCCAGGAUGACCAACACA 18 17930
HSV-UL54-2400 + GGCCAGGAUGACCAACACA 19 17931
HSV-UL54-2401 + GGGCCAGGAUGACCAACACA 20 17932
HSV-UL54-2402 + CG G G CCAG G AU G ACCAACACA 21 17933
HSV-UL54-2403 + GCGGGCCAGGAUGACCAACACA 22 17934
HSV-UL54-2404 + GGCGGGCCAGGAUGACCAACACA 23 17935
HSV-UL54-2405 + AGGCGGGCCAGGAUGACCAACACA 24 17936
HSV-UL54-2406 + GGAAACGGCAUCCCGCCA 18 17937
HSV-UL54-2407 + GGGAAACGGCAUCCCGCCA 19 17938
HSV-UL54-2408 + CG G G AAACG G CAU CCCG CCA 20 17939
HSV-UL54-2409 + GCGGGAAACGGCAUCCCGCCA 21 17940
HSV-UL54-2410 + GGCGGGAAACGGCAUCCCGCCA 22 17941
HSV-UL54-2411 + CGGCGGGAAACGGCAUCCCGCCA 23 17942
HSV-UL54-2412 + GCGGCGGGAAACGGCAUCCCGCCA 24 17943
HSV-UL54-2413 + CCGCUUGGGUGGCCAGCA 18 17944
HSV-UL54-2414 + CCCGCUUGGGUGGCCAGCA 19 17945
HSV-UL54-419 + CCCCGCUUGGGUGGCCAGCA 20 6842
HSV-UL54-2415 + CCCCCGCUUGGGUGGCCAGCA 21 17946
HSV-UL54-2416 + CCCCCCGCUUGGGUGGCCAGCA 22 17947
HSV-UL54-2417 + CCCCCCCGCUUGGGUGGCCAGCA 23 17948
HSV-UL54-2418 + ACCCCCCCGCUUGGGUGGCCAGCA 24 17949
HSV-UL54-2419 + GGGUCGAUGGUGUCGGCA 18 17950
HSV-UL54-2420 + GGGGUCGAUGGUGUCGGCA 19 17951
HSV-UL54-2421 + CGGGGUCGAUGGUGUCGGCA 20 17952
HSV-UL54-2422 + GCGGGGUCGAUGGUGUCGGCA 21 17953
HSV-UL54-2423 + GGCGGGGUCGAUGGUGUCGGCA 22 17954
HSV-UL54-2424 + CGGCGGGGUCGAUGGUGUCGGCA 23 17955
HSV-UL54-2425 + ACGGCGGGGUCGAUGGUGUCGGCA 24 17956
HSV-UL54-2426 + UCAGGGACAGCGCCAUCA 18 17957
HSV-UL54-2427 + GUCAGGGACAGCGCCAUCA 19 17958
HSV-UL54-2428 + GG UCAGGGACAGCGCCAUCA 20 17959
HSV-UL54-2429 + GGGUCAGGGACAGCGCCAUCA 21 17960
HSV-UL54-2430 + GGGGUCAGGGACAGCGCCAUCA 22 17961
HSV-UL54-2431 + GGGGG UCAGGGACAGCGCCAUCA 23 17962
HSV-UL54-2432 + GGGGGGUCAGGGACAGCGCCAUCA 24 17963
HSV-UL54-2433 + UGCGUGUCCAGUAUUUCA 18 17964
HSV-UL54-2434 + GUGCGUGUCCAGUAUUUCA 19 17965
HSV-UL54-2435 + GGUGCGUGUCCAGUAUUUCA 20 17966 HSV-UL54-2436 + CGGUGCGUGUCCAGUAUUUCA 21 17967
HSV-UL54-2437 + GCGGUGCGUGUCCAGUAUUUCA 22 17968
HSV-UL54-2438 + GGCGGUGCGUGUCCAGUAUUUCA 23 17969
HSV-UL54-2439 + UGGCGGUGCGUGUCCAGUAUUUCA 24 17970
HSV-UL54-2440 + UUCAGGUAGCACUGCAGA 18 17971
HSV-UL54-2441 + CUUCAGGUAGCACUGCAGA 19 17972
HSV-UL54-2442 + CCUUCAGGUAGCACUGCAGA 20 17973
HSV-UL54-2443 + GCCUUCAGGUAGCACUGCAGA 21 17974
HSV-UL54-2444 + GGCCUUCAGGUAGCACUGCAGA 22 17975
HSV-UL54-2445 + GGGCCUUCAGGUAGCACUGCAGA 23 17976
HSV-UL54-2446 + CGGGCCUUCAGGUAGCACUGCAGA 24 17977
HSV-UL54-2447 + GUCAGCUCGCACACGCGA 18 17978
HSV-UL54-2448 + CGUCAGCUCGCACACGCGA 19 17979
HSV-UL54-2449 + CCGUCAGCUCGCACACGCGA 20 17980
HSV-UL54-2450 + GCCGUCAGCUCGCACACGCGA 21 17981
HSV-UL54-2451 + GGCCGUCAGCUCGCACACGCGA 22 17982
HSV-UL54-2452 + UGGCCGUCAGCUCGCACACGCGA 23 17983
HSV-UL54-2453 + CUGGCCGUCAGCUCGCACACGCGA 24 17984
HSV-UL54-2454 + GACAGCGCCAUCAGCGGA 18 17985
HSV-UL54-2455 + GGACAGCGCCAUCAGCGGA 19 17986
HSV-UL54-1371 + GGGACAGCGCCAUCAGCGGA 20 16902
HSV-UL54-2456 + AGGGACAGCGCCAUCAGCGGA 21 17987
HSV-UL54-2457 + CAGGGACAGCGCCAUCAGCGGA 22 17988
HSV-UL54-2458 + UCAGGGACAGCGCCAUCAGCGGA 23 17989
HSV-UL54-2459 + GUCAGGGACAGCGCCAUCAGCGGA 24 17990
HSV-UL54-2460 + GCGCCUUUCGCUCCGGGA 18 17991
HSV-UL54-2461 + GGCGCCUUUCGCUCCGGGA 19 17992
HSV-UL54-2462 + GGGCGCCUUUCGCUCCGGGA 20 17993
HSV-UL54-2463 + AGGGCGCCUUUCGCUCCGGGA 21 17994
HSV-UL54-2464 + GAGGGCGCCUU UCGCUCCGGGA 22 17995
HSV-UL54-2465 + AGAGGGCGCCU UUCGCUCCGGGA 23 17996
HSV-UL54-2466 + CAGAGGGCGCCUU UCGCUCCGGGA 24 17997
HSV-UL54-2467 + AUUUGCCGUGCACAUAUA 18 17998
HSV-UL54-2468 + UAUUUGCCGUGCACAUAUA 19 17999
HSV-UL54-1375 + GUAUUUGCCGUGCACAUAUA 20 16906
HSV-UL54-2469 + AGUAUUUGCCGUGCACAUAUA 21 18000
HSV-UL54-2470 + AAGUAUUUGCCGUGCACAUAUA 22 18001
HSV-UL54-2471 + GAAG UAUUUGCCGUGCACAUAUA 23 18002
HSV-UL54-2472 + AGAAGUAUUUGCCGUGCACAUAUA 24 18003
HSV-UL54-2473 + CGCUUGGGUGGCCAGCAC 18 18004
HSV-UL54-2474 + CCGCUUGGGUGGCCAGCAC 19 18005
HSV-UL54-420 + CCCGCUUGGGUGGCCAGCAC 20 6843
HSV-UL54-2475 + CCCCGCUUGGGUGGCCAGCAC 21 18006
HSV-UL54-2476 + CCCCCGCUUGGGUGGCCAGCAC 22 18007
HSV-UL54-2477 + CCCCCCGCUUGGGUGGCCAGCAC 23 18008
HSV-UL54-2478 + CCCCCCCGCUUGGGUGGCCAGCAC 24 18009 HSV-UL54-2479 + CCGUCCGUCCGCGCCGAC 18 18010
HSV-UL54-2480 + GCCGUCCGUCCGCGCCGAC 19 18011
HSV-UL54-2481 + GGCCGUCCGUCCGCGCCGAC 20 18012
HSV-UL54-2482 + GGGCCGUCCGUCCGCGCCGAC 21 18013
HSV-UL54-2483 + GGGGCCGUCCGUCCGCGCCGAC 22 18014
HSV-UL54-2484 + CGGGGCCGUCCGUCCGCGCCGAC 23 18015
HSV-UL54-2485 + CCGGGGCCGUCCGUCCGCGCCGAC 24 18016
HSV-UL54-2486 + UCAGCUCGCACACGCGAC 18 18017
HSV-UL54-2487 + G U CAGCU CG CACACG CG AC 19 18018
HSV-UL54-1379 + CGUCAGCUCGCACACGCGAC 20 16910
HSV-UL54-2488 + CCGUCAGCUCGCACACGCGAC 21 18019
HSV-UL54-2489 + GCCGUCAGCUCGCACACGCGAC 22 18020
HSV-UL54-2490 + GGCCGUCAGCUCGCACACGCGAC 23 18021
HSV-UL54-2491 + UGGCCGUCAGCUCGCACACGCGAC 24 18022
HSV-UL54-2492 + CGCCUUUCGCUCCGGGAC 18 18023
HSV-UL54-2493 + GCGCCUUUCGCUCCGGGAC 19 18024
HSV-UL54-1380 + GGCGCCUUUCGCUCCGGGAC 20 16911
HSV-UL54-2494 + GGGCGCCUUUCGCUCCGGGAC 21 18025
HSV-UL54-2495 + AGGGCGCCUUUCGCUCCGGGAC 22 18026
HSV-UL54-2496 + GAGGGCGCCUUUCGCUCCGGGAC 23 18027
HSV-UL54-2497 + AGAGGGCGCCUUUCGCUCCGGGAC 24 18028
HSV-UL54-2498 + AAAGGGGUCUUGCAUGAC 18 18029
HSV-UL54-2499 + CAAAGGGGUCUUGCAUGAC 19 18030
HSV-UL54-429 + CCAAAGGGGUCUUGCAUGAC 20 6852
HSV-UL54-2500 + GCCAAAGGGGUCUUGCAUGAC 21 18031
HSV-UL54-2501 + CGCCAAAGGGGUCUUGCAUGAC 22 18032
HSV-UL54-2502 + CCGCCAAAGGGGUCUUGCAUGAC 23 18033
HSV-UL54-2503 + CCCGCCAAAGGGGUCU UGCAUGAC 24 18034
HSV-UL54-2504 + CUCGUGGCCGCGGGCCCC 18 18035
HSV-UL54-2505 + CCUCGUGGCCGCGGGCCCC 19 18036
HSV-UL54-1386 + GCCUCGUGGCCGCGGGCCCC 20 16917
HSV-UL54-2506 + UGCCUCGUGGCCGCGGGCCCC 21 18037
HSV-UL54-2507 + GUGCCUCGUGGCCGCGGGCCCC 22 18038
HSV-UL54-2508 + CGUGCCUCGUGGCCGCGGGCCCC 23 18039
HSV-UL54-2509 + GCGUGCCUCGUGGCCGCGGGCCCC 24 18040
HSV-UL54-2510 + UGGCCAGCACGGGAGCCC 18 18041
HSV-UL54-2511 + GUGGCCAGCACGGGAGCCC 19 18042
HSV-UL54-1387 + G G U G G CCAG CACG G G AG CCC 20 16918
HSV-UL54-2512 + GGGUGGCCAGCACGGGAGCCC 21 18043
HSV-UL54-2513 + UGGGUGGCCAGCACGGGAGCCC 22 18044
HSV-UL54-2514 + UUGGG UGGCCAGCACGGGAGCCC 23 18045
HSV-UL54-2515 + CUUGGGUGGCCAGCACGGGAGCCC 24 18046
HSV-UL54-2516 + GACCCGCCAUGCAGGCCC 18 18047
HSV-UL54-2517 + AGACCCGCCAUGCAGGCCC 19 18048
HSV-UL54-2518 + G AG ACCCG CCAUGCAG G CCC 20 18049
HSV-UL54-2519 + UGAGACCCGCCAUGCAGGCCC 21 18050 HSV-UL54-2520 + AUGAGACCCGCCAUGCAGGCCC 22 18051
HSV-UL54-2521 + AAUGAGACCCGCCAUGCAGGCCC 23 18052
HSV-UL54-2522 + CAAUGAGACCCGCCAUGCAGGCCC 24 18053
HSV-UL54-2523 + CCUCGUGGCCGCGGGCCC 18 18054
HSV-UL54-2524 + GCCUCGUGGCCGCGGGCCC 19 18055
HSV-UL54-2525 + UGCCUCGUGGCCGCGGGCCC 20 18056
HSV-UL54-2526 + GUGCCUCGUGGCCGCGGGCCC 21 18057
HSV-UL54-2527 + CGUGCCUCGUGGCCGCGGGCCC 22 18058
HSV-UL54-2528 + GCGUGCCUCGUGGCCGCGGGCCC 23 18059
HSV-UL54-2529 + CGCGUGCCUCGUGGCCGCGGGCCC 24 18060
HSV-UL54-2530 + GAGCGACCAGGGUUUCCC 18 18061
HSV-UL54-2531 + UGAGCGACCAGGGUUUCCC 19 18062
HSV-UL54-1388 + GUGAGCGACCAGGGUUUCCC 20 16919
HSV-UL54-2532 + CGUGAGCGACCAGGGUUUCCC 21 18063
HSV-UL54-2533 + CCGUGAGCGACCAGGGUUUCCC 22 18064
HSV-UL54-2534 + GCCGUGAGCGACCAGGGUUUCCC 23 18065
HSV-UL54-2535 + GGCCGUGAGCGACCAGGGUUUCCC 24 18066
HSV-UL54-2536 + GUGGCCAGCACGGGAGCC 18 18067
HSV-UL54-2537 + GGUGGCCAGCACGGGAGCC 19 18068
HSV-UL54-2538 + GGGUGGCCAGCACGGGAGCC 20 18069
HSV-UL54-2539 + UGGGUGGCCAGCACGGGAGCC 21 18070
HSV-UL54-2540 + UUGGGUGGCCAGCACGGGAGCC 22 18071
HSV-UL54-2541 + CU UGGGUGGCCAGCACGGGAGCC 23 18072
HSV-UL54-2542 + GCUUGGGUGGCCAGCACGGGAGCC 24 18073
HSV-UL54-2543 + UGUCCGACAGGCGUCGCC 18 18074
HSV-UL54-2544 + AUGUCCGACAGGCGUCGCC 19 18075
HSV-UL54-997 + AAUGUCCGACAGGCGUCGCC 20 7320
HSV-UL54-2545 + UAAUGUCCGACAGGCGUCGCC 21 18076
HSV-UL54-2546 + UUAAUGUCCGACAGGCGUCGCC 22 18077
HSV-UL54-2547 + CUUAAUGUCCGACAGGCGUCGCC 23 18078
HSV-UL54-2548 + CCUUAAUGUCCGACAGGCGUCGCC 24 18079
HSV-UL54-2549 + GUCCAGCCCGCACAGGCC 18 18080
HSV-UL54-2550 + CGUCCAGCCCGCACAGGCC 19 18081
HSV-UL54-2551 + UCGUCCAGCCCGCACAGGCC 20 18082
HSV-UL54-2552 + GUCGUCCAGCCCGCACAGGCC 21 18083
HSV-UL54-2553 + GGUCGUCCAGCCCGCACAGGCC 22 18084
HSV-UL54-2554 + AGGUCGUCCAGCCCGCACAGGCC 23 18085
HSV-UL54-2555 + CAGGUCGUCCAGCCCGCACAGGCC 24 18086
HSV-UL54-2556 + GCGGUAGAGGCUCGGGCC 18 18087
HSV-UL54-2557 + UGCGGUAGAGGCUCGGGCC 19 18088
HSV-UL54-2558 + GUGCGGUAGAGGCUCGGGCC 20 18089
HSV-UL54-2559 + UGU GCGGUAGAGGCUCGGGCC 21 18090
HSV-UL54-2560 + AUG UGCGGUAGAGGCUCGGGCC 22 18091
HSV-UL54-2561 + AAUGUGCGGUAGAGGCUCGGGCC 23 18092
HSV-UL54-2562 + GAAUGUGCGGUAGAGGCUCGGGCC 24 18093
HSV-UL54-2563 + GGCGCGUGCCUCGUGGCC 18 18094 HSV-UL54-2564 + UGGCGCGUGCCUCGUGGCC 19 18095
HSV-UL54-2565 + CUGGCGCGUGCCUCGUGGCC 20 18096
HSV-UL54-2566 + CCUGGCGCGUGCCUCGUGGCC 21 18097
HSV-UL54-2567 + GCCUGGCGCGUGCCUCGUGGCC 22 18098
HSV-UL54-2568 + GGCCUGGCGCGUGCCUCGUGGCC 23 18099
HSV-UL54-2569 + GGGCCUGGCGCGUGCCUCGUGGCC 24 18100
HSV-UL54-2570 + CACGCCAGCGUCUCAUCC 18 18101
HSV-UL54-2571 + CCACGCCAGCGUCUCAUCC 19 18102
HSV-UL54-2572 + ACCACGCCAGCGUCUCAUCC 20 18103
HSV-UL54-2573 + CACCACGCCAGCGUCUCAUCC 21 18104
HSV-UL54-2574 + GCACCACGCCAGCGUCUCAUCC 22 18105
HSV-UL54-2575 + UGCACCACGCCAGCGUCUCAUCC 23 18106
HSV-UL54-2576 + U U G CACCACG CCAGCG U CU CAUCC 24 18107
HSV-UL54-2577 + GUUCCGAUGAUAGGGUCC 18 18108
HSV-UL54-2578 + CGUUCCGAUGAUAGGGUCC 19 18109
HSV-UL54-400 + CCGUUCCGAUGAUAGGGUCC 20 6823
HSV-UL54-2579 + GCCGUUCCGAUGAUAGGGUCC 21 18110
HSV-UL54-2580 + CGCCGUUCCGAUGAUAGGGUCC 22 18111
HSV-UL54-2581 + CCGCCGUUCCGAUGAUAGGGUCC 23 18112
HSV-UL54-2582 + GCCGCCGUUCCGAUGAUAGGGUCC 24 18113
HSV-UL54-2583 + UGAGCGACCAGGGUUUCC 18 18114
HSV-UL54-2584 + GUGAGCGACCAGGGUUUCC 19 18115
HSV-UL54-2585 + CGUGAGCGACCAGGGUUUCC 20 18116
HSV-UL54-2586 + CCGUGAGCGACCAGGGUUUCC 21 18117
HSV-UL54-2587 + GCCGUGAGCGACCAGGGUUUCC 22 18118
HSV-UL54-2588 + GGCCG UGAGCGACCAGGGUUUCC 23 18119
HSV-UL54-2589 + GGGCCGUGAGCGACCAGGGUUUCC 24 18120
HSV-UL54-2590 + CCCGCUUGGGUGGCCAGC 18 18121
HSV-UL54-2591 + CCCCGCUUGGGUGGCCAGC 19 18122
HSV-UL54-2592 + CCCCCGCUUGGGUGGCCAGC 20 18123
HSV-UL54-2593 + CCCCCCGCUUGGGUGGCCAGC 21 18124
HSV-UL54-2594 + CCCCCCCGCUUGGGUGGCCAGC 22 18125
HSV-UL54-2595 + ACCCCCCCGCUUGGGUGGCCAGC 23 18126
HSV-UL54-2596 + AACCCCCCCGCUUGGGUGGCCAGC 24 18127
HSV-UL54-2597 + CGUCUCAUCCGCGGACGC 18 18128
HSV-UL54-2598 + GCGUCUCAUCCGCGGACGC 19 18129
HSV-UL54-2599 + AGCGUCUCAUCCGCGGACGC 20 18130
HSV-UL54-2600 + CAGCGUCUCAUCCGCGGACGC 21 18131
HSV-UL54-2601 + CCAGCGUCUCAUCCGCGGACGC 22 18132
HSV-UL54-2602 + GCCAGCGUCUCAUCCGCGGACGC 23 18133
HSV-UL54-2603 + CGCCAGCGUCUCAUCCGCGGACGC 24 18134
HSV-UL54-2604 + UAUGGAUCGCAGAACCGC 18 18135
HSV-UL54-2605 + AUAUGGAUCGCAGAACCGC 19 18136
HSV-UL54-2606 + GAUAUGGAUCGCAGAACCGC 20 18137
HSV-UL54-2607 + GGAUAUGGAUCGCAGAACCGC 21 18138
HSV-UL54-2608 + CGG AUAUGGAUCGCAGAACCGC 22 18139 HSV-UL54-2609 + UCGGAUAUGGAUCGCAGAACCGC 23 18140
HSV-UL54-2610 + CUCGGAUAUGGAUCGCAGAACCGC 24 18141
HSV-UL54-2611 + CCUCGCCGUGGGUGGCGC 18 18142
HSV-UL54-2612 + GCCUCGCCGUGGGUGGCGC 19 18143
HSV-UL54-455 + CGCCUCGCCGUGGGUGGCGC 20 6878
HSV-UL54-2613 + GCGCCUCGCCGUGGGUGGCGC 21 18144
HSV-UL54-2614 + CGCGCCUCGCCGUGGGUGGCGC 22 18145
HSV-UL54-2615 + CCGCGCCUCGCCGUGGGUGGCGC 23 18146
HSV-UL54-2616 + GCCGCGCCUCGCCGUGGGUGGCGC 24 18147
HSV-UL54-2617 + CGAAUGUGCGGUAGAGGC 18 18148
HSV-UL54-2618 + GCGAAUGUGCGGUAGAGGC 19 18149
HSV-UL54-2619 + UGCGAAUGUGCGGUAGAGGC 20 18150
HSV-UL54-2620 + CUGCGAAUGUGCGGUAGAGGC 21 18151
HSV-UL54-2621 + GCUGCGAAUGUGCGGUAGAGGC 22 18152
HSV-UL54-2622 + GGCUGCGAAUGUGCGGUAGAGGC 23 18153
HSV-UL54-2623 + UGGCUGCGAAUGUGCGGUAGAGGC 24
18154
HSV-UL54-2624 + CCAGGGGCUGUUCGCGGC 18 18155
HSV-UL54-2625 + CCCAGGGGCUGUUCGCGGC 19 18156
HSV-UL54-1397 + GCCCAGGGGCUGUUCGCGGC 20 16928
HSV-UL54-2626 + AGCCCAGGGGCUGUUCGCGGC 21 18157
HSV-UL54-2627 + GAGCCCAGGGGCUGUUCGCGGC 22 18158
HSV-UL54-2628 + GGAGCCCAGGGGCUGUUCGCGGC 23 18159
HSV-UL54-2629 + GGGAGCCCAGGGGCUGUUCGCGGC 24 18160
HSV-UL54-2630 + GCGCGGCCGUCCGCGUGC 18 18161
HSV-UL54-2631 + GGCGCGGCCGUCCGCGUGC 19 18162
HSV-UL54-440 + GGGCGCGGCCGUCCGCGUGC 20 6863
HSV-UL54-2632 + GGGGCGCGGCCGUCCGCGUGC 21 18163
HSV-UL54-2633 + CGGGGCGCGGCCGUCCGCGUGC 22 18164
HSV-UL54-2634 + CCGGGGCGCGGCCGUCCGCGUGC 23 18165
HSV-UL54-2635 + ACCGGGGCGCGGCCGUCCGCGUGC 24 18166
HSV-UL54-2636 + AGAGGGCGCCUUUCGCUC 18 18167
HSV-UL54-2637 + CAGAGGGCGCCUUUCGCUC 19 18168
HSV-UL54-1400 + GCAGAGGGCGCCUUUCGCUC 20 16931
HSV-UL54-2638 + GGCAGAGGGCGCCU UUCGCUC 21 18169
HSV-UL54-2639 + CGGCAGAGGGCGCCUUUCGCUC 22 18170
HSV-UL54-2640 + UCGGCAGAGGGCGCCU UUCGCUC 23 18171
HSV-UL54-2641 + GUCGGCAGAGGGCGCCUUUCGCUC 24 18172
HSV-UL54-2642 + CGUUCCGAUGAUAGGGUC 18 18173
HSV-UL54-2643 + CCGUUCCGAUGAUAGGGUC 19 18174
HSV-UL54-2644 + GCCGUUCCGAUGAUAGGGUC 20 18175
HSV-UL54-2645 + CGCCGUUCCGAUGAUAGGGUC 21 18176
HSV-UL54-2646 + CCGCCGUUCCGAUGAUAGGGUC 22 18177
HSV-UL54-2647 + GCCGCCGUUCCGAUGAUAGGGUC 23 18178
HSV-UL54-2648 + GGCCGCCGUUCCGAUGAUAGGGUC 24 18179
HSV-UL54-2649 + UCCGCGUGCGGGGGGGUC 18 18180 HSV-UL54-2650 + GUCCGCGUGCGGGGGGGUC 19 18181
HSV-UL54-1402 + CGUCCGCGUGCGGGGGGGUC 20 16933
HSV-UL54-2651 + CCGUCCGCGUGCGGGGGGGUC 21 18182
HSV-UL54-2652 + GCCGUCCGCGUGCGGGGGGGUC 22 18183
HSV-UL54-2653 + GGCCGUCCGCGUGCGGGGGGGUC 23 18184
HSV-UL54-2654 + CGGCCGUCCGCGUGCGGGGGGGUC 24 18185
HSV-UL54-1663 + CUUGGU UGUGGGCGUUUC 18 17194
HSV-UL54-1664 + CCUUGGUUGUGGGCGUUUC 19 17195
HSV-UL54-1237 + CCCUUGGUUGUGGGCGUUUC 20 16768
HSV-UL54-1665 + CCCCUUGGUUGUGGGCGUUUC 21 17196
HSV-UL54-1666 + CCCCCUUGGUUGUGGGCGUUUC 22 17197
HSV-UL54-1667 + ACCCCCUUGGUUGUGGGCGUUUC 23 17198
HSV-UL54-1668 + GACCCCCUUGGUUGUGGGCGUUUC 24 17199
HSV-UL54-2655 + UAAAAUAGGGAGUUGCAG 18 18186
HSV-UL54-2656 + CUAAAAUAGGGAGUUGCAG 19 18187
HSV-UL54-2657 + CCUAAAAUAGGGAGUUGCAG 20 18188
HSV-UL54-2658 + GCCUAAAAUAGGGAGUUGCAG 21 18189
HSV-UL54-2659 + UGCCUAAAAUAGGGAGUUGCAG 22 18190
HSV-UL54-2660 + UUGCCUAAAAUAGGGAGUUGCAG 23 18191
HSV-UL54-2661 + CUUGCCUAAAAUAGGGAGUUGCAG 24 18192
HSV-UL54-2662 + CAGGGACAGCGCCAUCAG 18 18193
HSV-UL54-2663 + UCAGGGACAGCGCCAUCAG 19 18194
HSV-UL54-1408 + GUCAGGGACAGCG CCAU CAG 20 16939
HSV-UL54-2664 + GGUCAGGGACAGCGCCAUCAG 21 18195
HSV-UL54-2665 + GGG UCAGGGACAGCGCCAUCAG 22 18196
HSV-UL54-2666 + GGGGU CAGGGACAGCGCCAUCAG 23 18197
HSV-UL54-2667 + GGGGGUCAGGGACAGCGCCAUCAG 24 18198
HSV-UL54-2668 + CUCGACGCGGUUGGCGAG 18 18199
HSV-UL54-2669 + GCUCGACGCGGUUGGCGAG 19 18200
HSV-UL54-388 + CGCUCGACGCGGUUGGCGAG 20 6811
HSV-UL54-2670 + GCGCUCGACGCGGUUGGCGAG 21 18201
HSV-UL54-2671 + CGCGCUCGACGCGGUUGGCGAG 22 18202
HSV-UL54-2672 + CCGCGCUCGACGCGGUUGGCGAG 23 18203
HSV-UL54-2673 + GCCGCGCUCGACGCGGUUGGCGAG 24 18204
HSV-UL54-2674 + ACAGCGCCAUCAGCGGAG 18 18205
HSV-UL54-2675 + GACAGCGCCAUCAGCGGAG 19 18206
HSV-UL54-1409 + GGACAGCGCCAUCAGCGGAG 20 16940
HSV-UL54-2676 + G G G ACAG CG CCAU CAG CG G AG 21 18207
HSV-UL54-2677 + AGGGACAGCGCCAUCAGCGGAG 22 18208
HSV-UL54-2678 + CAG G G ACAG CG CCAU CAG CG GAG 23 18209
HSV-UL54-2679 + UCAGGGACAGCGCCAUCAGCGGAG 24 18210
HSV-UL54-2680 + CGCAGAACCGCCCGAACG 18 18211
HSV-UL54-2681 + U CG CAG AACCG CCCGAACG 19 18212
HSV-UL54-2682 + AUCGCAGAACCGCCCGAACG 20 18213
HSV-UL54-2683 + GAU CGCAGAACCGCCCGAACG 21 18214
HSV-UL54-2684 + GGAUCGCAGAACCGCCCGAACG 22 18215 HSV-UL54-2685 + UGGAUCGCAGAACCGCCCGAACG 23 18216
HSV-UL54-2686 + AUGGAUCGCAGAACCGCCCGAACG 24 18217
HSV-UL54-2687 + CGCGGGCCCCCGGAGACG 18 18218
HSV-UL54-2688 + CCGCGGGCCCCCGGAGACG 19 18219
HSV-UL54-2689 + GCCGCGGGCCCCCGGAGACG 20 18220
HSV-UL54-2690 + GGCCGCGGGCCCCCGGAGACG 21 18221
HSV-UL54-2691 + UGGCCGCGGGCCCCCGGAGACG 22 18222
HSV-UL54-2692 + GUGGCCGCGGGCCCCCGGAGACG 23 18223
HSV-UL54-2693 + CGUGGCCGCGGGCCCCCGGAGACG 24 18224
HSV-UL54-1681 + GUU UCUGGAGACGCGCCG 18 17212
HSV-UL54-1682 + CGUUUCUGGAGACGCGCCG 19 17213
HSV-UL54-1683 + GCGUUUCUGGAGACGCGCCG 20 17214
HSV-UL54-1684 + GGCGUU UCUGGAGACGCGCCG 21 17215
HSV-UL54-1685 + GGGCGUUUCUGGAGACGCGCCG 22 17216
HSV-UL54-1686 + UGGGCGU UUCUGGAGACGCGCCG 23 17217
HSV-UL54-1687 + GUGGGCGUUUCUGGAGACGCGCCG 24 17218
HSV-UL54-2694 + GGGACAGCGCCAUCAGCG 18 18225
HSV-UL54-2695 + AGGGACAGCGCCAUCAGCG 19 18226
HSV-UL54-2696 + CAGGGACAGCGCCAUCAGCG 20 18227
HSV-UL54-2697 + UCAGGGACAGCGCCAUCAGCG 21 18228
HSV-UL54-2698 + GUCAGGGACAGCGCCAUCAGCG 22 18229
HSV-UL54-2699 + GGUCAGGGACAGCGCCAUCAGCG 23 18230
HSV-UL54-2700 + GGGUCAGGGACAGCGCCAUCAGCG 24 18231
HSV-UL54-2701 + GCCCAGGGGCUGUUCGCG 18 18232
HSV-UL54-2702 + AGCCCAGGGGCUGUUCGCG 19 18233
HSV-UL54-2703 + GAGCCCAGGGGCUGUUCGCG 20 18234
HSV-UL54-2704 + GGAGCCCAGGGGCUGUUCGCG 21 18235
HSV-UL54-2705 + GGGAGCCCAGGGGCUGUUCGCG 22 18236
HSV-UL54-2706 + CGGG AGCCCAGGGGCUGUUCGCG 23 18237
HSV-UL54-2707 + ACGGGAGCCCAGGGGCUGUUCGCG 24 18238
HSV-UL54-2708 + GCCUCGCCGUGGGUGGCG 18 18239
HSV-UL54-2709 + CGCCUCGCCGUGGGUGGCG 19 18240
HSV-UL54-2710 + GCGCCUCGCCGUGGGUGGCG 20 18241
HSV-UL54-2711 + CGCGCCUCGCCGUGGGUGGCG 21 18242
HSV-UL54-2712 + CCGCGCCUCGCCGUGGGUGGCG 22 18243
HSV-UL54-2713 + GCCGCGCCUCGCCGUGGGUGGCG 23 18244
HSV-UL54-2714 + CGCCGCGCCUCGCCGUGGGUGGCG 24 18245
HSV-UL54-2715 + CGCGGCCGUCCGCGUGCG 18 18246
HSV-UL54-2716 + GCGCGGCCGUCCGCGUGCG 19 18247
HSV-UL54-1425 + GGCGCGGCCGUCCGCGUGCG 20 16956
HSV-UL54-2717 + GGGCGCGGCCGUCCGCGUGCG 21 18248
HSV-UL54-2718 + GGGGCGCGGCCGUCCGCGUGCG 22 18249
HSV-UL54-2719 + CGGGGCGCGGCCGUCCGCGUGCG 23 18250
HSV-UL54-2720 + CCGGGGCGCGGCCGUCCGCGUGCG 24 18251
HSV-UL54-2721 + GCGCUCGGAUAUGGAUCG 18 18252
HSV-UL54-2722 + CGCGCUCGGAUAUGGAUCG 19 18253 HSV-UL54-2723 + GCGCGCUCGGAUAUGGAUCG 20 18254
HSV-UL54-2724 + CGCGCGCUCGGAUAUGGAUCG 21 18255
HSV-UL54-2725 + CCGCGCGCUCGGAUAUGGAUCG 22 18256
HSV-UL54-2726 + GCCGCGCGCUCGGAUAUGGAUCG 23 18257
HSV-UL54-2727 + CGCCGCGCGCUCGGAUAUGGAUCG 24 18258
HSV-UL54-2728 + GCGGACGCCAGGGCCUCG 18 18259
HSV-UL54-2729 + CGCGGACGCCAGGGCCUCG 19 18260
HSV-UL54-1008 + CCGCGGACGCCAGGGCCUCG 20 7329
HSV-UL54-2730 + UCCGCGGACGCCAGGGCCUCG 21 18261
HSV-UL54-2731 + AUCCGCGGACGCCAGGGCCUCG 22 18262
HSV-UL54-2732 + CAUCCGCGGACGCCAGGGCCUCG 23 18263
HSV-UL54-2733 + UCAUCCGCGGACGCCAGGGCCUCG 24 18264
HSV-UL54-2734 + CAGCGCCAUCAGCGGAGG 18 18265
HSV-UL54-2735 + ACAGCGCCAUCAGCGGAGG 19 18266
HSV-UL54-1431 + GACAGCGCCAUCAGCGGAGG 20 16962
HSV-UL54-2736 + GGACAGCGCCAUCAGCGGAGG 21 18267
HSV-UL54-2737 + GGGACAGCGCCAUCAGCGGAGG 22 18268
HSV-UL54-2738 + AGGGACAGCGCCAUCAGCGGAGG 23 18269
HSV-UL54-2739 + CAGGGACAGCGCCAUCAGCGGAGG 24 18270
HSV-UL54-2740 + GGACAGCGCCAUCAGCGG 18 18271
HSV-UL54-2741 + GGGACAGCGCCAUCAGCGG 19 18272
HSV-UL54-1434 + AGGGACAGCGCCAUCAGCGG 20 16965
HSV-UL54-2742 + CAGGGACAGCG CCAU CAG CG G 21 18273
HSV-UL54-2743 + UCAGGGACAGCGCCAUCAGCGG 22 18274
HSV-UL54-2744 + GUCAGGGACAGCGCCAUCAGCGG 23 18275
HSV-UL54-2745 + GGUCAGGGACAGCGCCAUCAGCGG 24 18276
HSV-UL54-2746 + CCCAGGGGCUGUUCGCGG 18 18277
HSV-UL54-2747 + GCCCAGGGGCUGU UCGCGG 19 18278
HSV-UL54-1435 + AGCCCAGGGGCUGUUCGCGG 20 16966
HSV-UL54-2748 + GAGCCCAGGGGCUGUUCGCGG 21 18279
HSV-UL54-2749 + GGAGCCCAGGGGCUGUUCGCGG 22 18280
HSV-UL54-2750 + GGG AGCCCAGGGGCUGUUCGCGG 23 18281
HSV-UL54-2751 + CGGGAGCCCAGGGGCUGUUCGCGG 24 18282
HSV-UL54-2752 + UUGGCUGCGAAUGUGCGG 18 18283
HSV-UL54-2753 + GUUGGCUGCGAAUGUGCGG 19 18284
HSV-UL54-2754 + GGUUGGCUGCGAAUGUGCGG 20 18285
HSV-UL54-2755 + GGGUUGGCUGCGAAUGUGCGG 21 18286
HSV-UL54-2756 + CGGG UUGGCUGCGAAUGUGCGG 22 18287
HSV-UL54-2757 + GCGGGUUGGCUGCGAAUGUGCGG 23 18288
HSV-UL54-2758 + CGCGGGUUGGCUGCGAAUGUGCGG 24
18289
HSV-UL54-2759 + CGGGGUCGAUGGUGUCGG 18 18290
HSV-UL54-2760 + GCGGGGUCGAUGGUGUCGG 19 18291
HSV-UL54-2761 + GGCGGGGUCGAUGGUGUCGG 20 18292
HSV-UL54-2762 + CGGCGGGGUCGAUGGUGUCGG 21 18293
HSV-UL54-2763 + ACGGCGGGGUCGAUGGUGUCGG 22 18294 HSV-UL54-2764 + AACGGCGGGGUCGAUGGUGUCGG 23 18295
HSV-UL54-2765 + GAACGGCGGGGUCGAUGGUGUCGG 24
18296
HSV-UL54-2766 + AUGAUAGGGUCCUGGGGG 18 18297
HSV-UL54-2767 + GAUGAUAGGGUCCUGGGGG 19 18298
HSV-UL54-1442 + CGAUGAUAGGGUCCUGGGGG 20 16973
HSV-UL54-2768 + CCGAUGAUAGGGUCCUGGGGG 21 18299
HSV-UL54-2769 + UCCGAUGAUAGGGUCCUGGGGG 22 18300
HSV-UL54-2770 + UUCCGAUGAUAGGGUCCUGGGGG 23 18301
HSV-UL54-2771 + GUUCCGAUGAUAGGGUCCUGGGGG 24
18302
HSV-UL54-2772 + GAUGAUAGGGUCCUGGGG 18 18303
HSV-UL54-2773 + CGAUGAUAGGGUCCUGGGG 19 18304
HSV-UL54-2774 + CCGAUGAUAGGGUCCUGGGG 20 18305
HSV-UL54-2775 + UCCGAUGAUAGGGUCCUGGGG 21 18306
HSV-UL54-2776 + UUCCGAUGAUAGGGUCCUGGGG 22 18307
HSV-UL54-2777 + GU UCCGAUGAUAGGGUCCUGGGG 23 18308
HSV-UL54-2778 + CGUUCCGAUGAUAGGGUCCUGGGG 24 18309
HSV-UL54-2779 + GGCCUUCAGGUAGCACUG 18 18310
HSV-UL54-2780 + GGGCCUUCAGGUAGCACUG 19 18311
HSV-UL54-397 + CGGGCCUUCAGGUAGCACUG 20 6820
HSV-UL54-2781 + UCGGGCCUUCAGGUAGCACUG 21 18312
HSV-UL54-2782 + CUCGGGCCUUCAGGUAGCACUG 22 18313
HSV-UL54-2783 + CCUCGGGCCUUCAGGUAGCACUG 23 18314
HSV-UL54-2784 + GCCUCGGGCCUUCAGGUAGCACUG 24 18315
HSV-UL54-2785 + GGCGCGGCCGUCCGCGUG 18 18316
HSV-UL54-2786 + GGGCGCGGCCGUCCGCGUG 19 18317
HSV-UL54-1447 + GGGGCGCGGCCGUCCGCGUG 20 16978
HSV-UL54-2787 + CGGGGCGCGGCCGUCCGCGUG 21 18318
HSV-UL54-2788 + CCGGGGCGCGGCCGUCCGCGUG 22 18319
HSV-UL54-2789 + ACCGGGGCGCGGCCGUCCGCGUG 23 18320
HSV-UL54-2790 + GACCGGGGCGCGGCCGUCCGCGUG 24 18321
HSV-UL54-2791 + AAGGGGCGCAGGCGCGUG 18 18322
HSV-UL54-2792 + AAAGGGGCGCAGGCGCGUG 19 18323
HSV-UL54-2793 + GAAAGGGGCGCAGGCGCGUG 20 18324
HSV-UL54-2794 + AGAAAGGGGCGCAGGCGCGUG 21 18325
HSV-UL54-2795 + CAG AAAGGGGCGCAGGCGCGUG 22 18326
HSV-UL54-2796 + GCAGAAAGGGGCGCAGGCGCGUG 23 18327
HSV-UL54-2797 + UGCAGAAAGGGGCGCAGGCGCGUG 24 18328
HSV-UL54-1485 + GCCGGCGGGGUU UUGGUG 18 17016
HSV-UL54-1528 + CGCCGGCGGGGUUUUGGUG 19 17059
HSV-UL54-23 + GCGCCGGCGGGGUUUUGGUG 20 6446
HSV-UL54-1529 + CGCGCCGGCGGGGUUUUGGUG 21 17060
HSV-UL54-1530 + ACGCGCCGGCGGGGUUUUGGUG 22 17061
HSV-UL54-1486 + GACGCGCCGGCGGGGUUUUGGUG 23 17017 HSV-UL54-1531 + AGACGCGCCGGCGGGGUUUUGGUG 24
17062
HSV-UL54-2798 + CCGCGCUCGACGCGGUUG 18 18329
HSV-UL54-2799 + GCCGCGCUCGACGCGGUUG 19 18330
HSV-UL54-2800 + CGCCGCGCUCGACGCGGUUG 20 18331
HSV-UL54-2801 + ACGCCGCGCUCGACGCGGUUG 21 18332
HSV-UL54-2802 + CACGCCGCGCUCGACGCGGUUG 22 18333
HSV-UL54-2803 + ACACGCCGCGCUCGACGCGGUUG 23 18334
HSV-UL54-2804 + GACACGCCGCGCUCGACGCGGUUG 24 18335
HSV-UL54-2805 + UUUAUUCUUGCCUAAAAU 18 18336
HSV-UL54-2806 + GUUUAUUCUUGCCUAAAAU 19 18337
HSV-UL54-1449 + UGUUUAUUCUUGCCUAAAAU 20 16980
HSV-UL54-2807 + AUGUUUAUUCUUGCCUAAAAU 21 18338
HSV-UL54-2808 + UAUGUUUAUUCUUGCCUAAAAU 22 18339
HSV-UL54-2809 + AUAUGUUUAUUCUUGCCUAAAAU 23 18340
HSV-UL54-2810 + AAUAUGUUUAUUCUUGCCUAAAAU 24 18341
HSV-UL54-2811 + UAU UUGCCGUGCACAUAU 18 18342
HSV-UL54-2812 + GUAUUUGCCGUGCACAUAU 19 18343
HSV-UL54-2813 + AGUAUUUGCCGUGCACAUAU 20 18344
HSV-UL54-2814 + AAGUAUUUGCCGUGCACAUAU 21 18345
HSV-UL54-2815 + GAAGUAUUUGCCGUGCACAUAU 22 18346
HSV-UL54-2816 + AGAAGUAUUUGCCGUGCACAUAU 23 18347
HSV-UL54-2817 + UAGAAGUAUUUGCCGUGCACAUAU 24 18348
HSV-UL54-2818 + UUCCGAUGAUAGGGUCCU 18 18349
HSV-UL54-2819 + GUUCCGAUGAUAGGGUCCU 19 18350
HSV-UL54-1453 + CGUUCCGAUGAUAGGGUCCU 20 16984
HSV-UL54-2820 + CCGUUCCGAUGAUAGGGUCCU 21 18351
HSV-UL54-2821 + GCCGUUCCGAUGAUAGGGUCCU 22 18352
HSV-UL54-2822 + CGCCGUUCCGAUGAUAGGGUCCU 23 18353
HSV-UL54-2823 + CCGCCGUUCCGAUGAUAGGGUCCU 24 18354
HSV-UL54-2824 + CAGAGGGCGCCUUUCGCU 18 18355
HSV-UL54-2825 + GCAGAGGGCGCCU UUCGCU 19 18356
HSV-UL54-2826 + GGCAGAGGGCGCCUUUCGCU 20 18357
HSV-UL54-2827 + CGGCAGAGGGCGCCUUUCGCU 21 18358
HSV-UL54-2828 + UCGGCAGAGGGCGCCUUUCGCU 22 18359
HSV-UL54-2829 + GUCGGCAGAGGGCGCCUUUCGCU 23 18360
HSV-UL54-2830 + UGUCGGCAGAGGGCGCCUUUCGCU 24 18361
HSV-UL54-2831 + GGGCGCGGCCGUCCGCGU 18 18362
HSV-UL54-2832 + GGGGCGCGGCCGUCCGCGU 19 18363
HSV-UL54-2833 + CGGGGCGCGGCCGUCCGCGU 20 18364
HSV-UL54-2834 + CCGGGGCGCGGCCGUCCGCGU 21 18365
HSV-UL54-2835 + ACCGGGGCGCGGCCGUCCGCGU 22 18366
HSV-UL54-2836 + GACCGGGGCGCGGCCGUCCGCGU 23 18367
HSV-UL54-2837 + GGACCGGGGCGCGGCCGUCCGCGU 24 18368
HSV-UL54-2838 + GUCCGCGUGCGGGGGGGU 18 18369
HSV-UL54-2839 + CGUCCGCGUGCGGGGGGGU 19 18370 HSV-UL54-2840 + CCGUCCGCGUGCGGGGGGGU 20 18371
HSV-UL54-2841 + GCCGUCCGCGUGCGGGGGGGU 21 18372
HSV-UL54-2842 + GGCCGUCCGCGUGCGGGGGGGU 22 18373
HSV-UL54-2843 + CGGCCGUCCGCGUGCGGGGGGGU 23 18374
HSV-UL54-2844 + GCGGCCGUCCGCGUGCGGGGGGGU 24 18375
HSV-UL54-1836 + CGCCGGCGGGGUUU UGGU 18 17367
HSV-UL54-1837 + GCGCCGGCGGGGUUUUGGU 19 17368
HSV-UL54-1838 + CGCGCCGGCGGGGUUUUGGU 20 17369
HSV-UL54-1839 + ACGCGCCGGCGGGGUU UUGGU 21 17370
HSV-UL54-1840 + GACGCGCCGGCGGGGUUUUGGU 22 17371
HSV-UL54-1841 + AGACGCGCCGGCGGGGU UUUGGU 23 17372
HSV-UL54-1842 + GAGACGCGCCGGCGGGGUUUUGGU 24
17373
HSV-UL54-2845 + GUGGCGACCCCCUUGGUU 18 18376
HSV-UL54-2846 + GGUGGCGACCCCCUUGGUU 19 18377
HSV-UL54-2847 + GGGUGGCGACCCCCUUGGUU 20 18378
HSV-UL54-2848 + GGGGUGGCGACCCCCUUGGUU 21 18379
HSV-UL54-2849 + CGGGGUGGCGACCCCCUUGGUU 22 18380
HSV-UL54-2850 + GCGGGGUGGCGACCCCCUUGGUU 23 18381
HSV-UL54-2851 + CGCGGGGUGGCGACCCCCUUGGU U 24 18382
HSV-UL54-1855 + CCUUGGU UGUGGGCGUUU 18 17386
HSV-UL54-1856 + CCCUUGGUUGUGGGCGUUU 19 17387
HSV-UL54-1857 + CCCCUUGGUUGUGGGCGUUU 20 17388
HSV-UL54-1858 + CCCCCUUGGUUGUGGGCGUUU 21 17389
HSV-UL54-1859 + ACCCCCUUGGUUGUGGGCGUUU 22 17390
HSV-UL54-1860 + GACCCCCUUGGUUGUGGGCGUUU 23 17391
HSV-UL54-1861 + CGACCCCCUUGGUUGUGGGCGUUU 24 17392
HSV-UL54-2852 - CCCGUGCUGGCCACCCAA 18 18383
HSV-UL54-2853 - UCCCGUGCUGGCCACCCAA 19 18384
HSV-UL54-933 - CUCCCGUGCUGGCCACCCAA 20 7280
HSV-UL54-2854 - GCUCCCGUGCUGGCCACCCAA 21 18385
HSV-UL54-2855 - GGCUCCCGUGCUGGCCACCCAA 22 18386
HSV-UL54-2856 - GGGCUCCCGUGCUGGCCACCCAA 23 18387
HSV-UL54-2857 - UGGGCUCCCGUGCUGGCCACCCAA 24 18388
HSV-UL54-1874 - CAGAAACGCCCACAACCA 18 17405
HSV-UL54-1875 - CCAG AAACG CCCACAACCA 19 17406
HSV-UL54-1216 - UCCAGAAACGCCCACAACCA 20 16747
HSV-UL54-1876 - CUCCAGAAACGCCCACAACCA 21 17407
HSV-UL54-1877 - UCUCCAGAAACGCCCACAACCA 22 17408
HSV-UL54-1878 - GUCUCCAGAAACGCCCACAACCA 23 17409
HSV-UL54-1879 - CG U CU CCAG AAACG CCCACAACCA 24 17410
HSV-UL54-2858 - CGGCGGUCGAGCGCAUCA 18 18389
HSV-UL54-2859 - GCGGCGGUCGAGCGCAUCA 19 18390
HSV-UL54-927 - CGCGGCGGUCGAGCGCAUCA 20 7275
HSV-UL54-2860 - GCGCGGCGGUCGAGCGCAUCA 21 18391
HSV-UL54-2861 - CGCGCGGCGGUCGAGCGCAUCA 22 18392 HSV-UL54-2862 - GCGCGCGGCGGUCGAGCGCAUCA 23 18393
HSV-UL54-2863 - AGCGCGCGGCGGUCGAGCGCAUCA 24 18394
HSV-UL54-2864 - GCCCCCAGGACCCUAUCA 18 18395
HSV-UL54-2865 - CGCCCCCAGGACCCUAUCA 19 18396
HSV-UL54-951 - CCGCCCCCAGGACCCUAUCA 20 7290
HSV-UL54-2866 - UCCGCCCCCAGGACCCUAUCA 21 18397
HSV-UL54-2867 - CUCCGCCCCCAGGACCCUAUCA 22 18398
HSV-UL54-2868 - GCUCCGCCCCCAGGACCCUAUCA 23 18399
HSV-UL54-2869 - CGCUCCGCCCCCAGGACCCUAUCA 24 18400
HSV-UL54-2870 - UGCGCCAGGAAAAUCUCA 18 18401
HSV-UL54-2871 - CUGCGCCAGGAAAAUCUCA 19 18402
HSV-UL54-947 - GCUGCGCCAGGAAAAUCUCA 20 7287
HSV-UL54-2872 - UGCUGCGCCAGGAAAAUCUCA 21 18403
HSV-UL54-2873 - GUGCUGCGCCAGGAAAAUCUCA 22 18404
HSV-UL54-2874 - CGUGCUGCGCCAGG AAAAU CU CA 23 18405
HSV-UL54-2875 - GCGUGCUGCGCCAGGAAAAUCUCA 24 18406
HSV-UL54-2876 - CCUGCAUGGCGGGUCUCA 18 18407
HSV-UL54-2877 - GCCUGCAUGGCGGGUCUCA 19 18408
HSV-UL54-974 - GGCCUGCAUGGCGGGUCUCA 20 7305
HSV-UL54-2878 - GGGCCUGCAUGGCGGGUCUCA 21 18409
HSV-UL54-2879 - GGGGCCUGCAUGGCGGGUCUCA 22 18410
HSV-UL54-2880 - GGGGGCCUGCAUGGCGGGUCUCA 23 18411
HSV-UL54-2881 - CGGGGGCCUGCAUGGCGGGUCUCA 24 18412
HSV-UL54-2882 - CCGCGCCCCGGUCCCGGA 18 18413
HSV-UL54-2883 - GCCGCGCCCCGGUCCCGGA 19 18414
HSV-UL54-923 - GGCCGCGCCCCGGUCCCGGA 20 7271
HSV-UL54-2884 - CGGCCGCGCCCCGGUCCCGGA 21 18415
HSV-UL54-2885 - ACGGCCGCGCCCCGGUCCCGGA 22 18416
HSV-UL54-2886 - GACGGCCGCGCCCCGGUCCCGGA 23 18417
HSV-UL54-2887 - GGACGGCCGCGCCCCGGUCCCGGA 24 18418
HSV-UL54-2888 - GGCGAGGCGCGGCGCGGA 18 18419
HSV-UL54-2889 - CGGCGAGGCGCGGCGCGGA 19 18420
HSV-UL54-283 - ACGGCGAGGCGCGGCGCGGA 20 6706
HSV-UL54-2890 - CACGGCGAGGCGCGGCGCGGA 21 18421
HSV-UL54-2891 - CCACGGCGAGGCGCGGCGCGGA 22 18422
HSV-UL54-2892 - CCCACGGCGAGGCGCGGCGCGGA 23 18423
HSV-UL54-2893 - ACCCACGGCGAGGCGCGGCGCGGA 24 18424
HSV-UL54-2894 - GCGGGUCUCAUUGAAAUA 18 18425
HSV-UL54-2895 - GGCGGGUCUCAUUGAAAUA 19 18426
HSV-UL54-975 - UGGCGGGUCUCAUUGAAAUA 20 7306
HSV-UL54-2896 - AUGGCGGGUCUCAUUGAAAUA 21 18427
HSV-UL54-2897 - CAUGGCGGGUCUCAUUGAAAUA 22 18428
HSV-UL54-2898 - GCAUGGCGGGUCUCAUUGAAAUA 23 18429
HSV-UL54-2899 - UGCAUGGCGGGUCUCAUUGAAAUA 24 18430
HSV-UL54-2900 - UCCCUGACCCCCCCGCAC 18 18431
HSV-UL54-2901 - GUCCCUGACCCCCCCGCAC 19 18432 HSV-UL54-920 - UGUCCCUGACCCCCCCGCAC 20 7269
HSV-UL54-2902 - CUGUCCCUGACCCCCCCGCAC 21 18433
HSV-UL54-2903 - GCUGUCCCUGACCCCCCCGCAC 22 18434
HSV-UL54-2904 - CGCUGUCCCUGACCCCCCCGCAC 23 18435
HSV-UL54-2905 - GCGCUGUCCCUGACCCCCCCGCAC 24 18436
HSV-UL54-2906 - CCCUUUCUGCAGUGCUAC 18 18437
HSV-UL54-2907 - CCCCUUUCUGCAGUGCUAC 19 18438
HSV-UL54-955 - GCCCCUUUCUGCAGUGCUAC 20 7292
HSV-UL54-2908 - CGCCCCUUUCUGCAGUGCUAC 21 18439
HSV-UL54-2909 - GCGCCCCUUUCUGCAGUGCUAC 22 18440
HSV-UL54-2910 - UGCGCCCCUUUCUGCAGUGCUAC 23 18441
HSV-UL54-2911 - CUGCGCCCCUUUCUGCAGUGCUAC 24 18442
HSV-UL54-1934 - CCAGAAACGCCCACAACC 18 17465
HSV-UL54-1935 - UCCAGAAACGCCCACAACC 19 17466
HSV-UL54-1936 - CUCCAGAAACGCCCACAACC 20 17467
HSV-UL54-1937 - U CU CCAGAAACGCCCACAACC 21 17468
HSV-UL54-1938 - G U CUCCAG AAACG CCCACAACC 22 17469
HSV-UL54-1939 - CGUCUCCAGAAACGCCCACAACC 23 17470
HSV-UL54-1940 - GCGUCUCCAG AAACG CCCACAACC 24 17471
HSV-UL54-2912 - GAGAUCGACUACACGACC 18 18443
HSV-UL54-2913 - GGAGAUCGACUACACGACC 19 18444
HSV-UL54-964 - CGGAGAUCGACUACACGACC 20 7300
HSV-UL54-2914 - UCGGAGAUCGACUACACGACC 21 18445
HSV-UL54-2915 - GUCGGAGAUCGACUACACGACC 22 18446
HSV-UL54-2916 - UGUCGGAGAUCGACUACACGACC 23 18447
HSV-UL54-2917 - GUGUCGGAGAUCGACUACACGACC 24 18448
HSV-UL54-2918 - CACAU U CG CAG CCA ACCC 18 18449
HSV-UL54-2919 - G CACAU U CG CAG CCAACCC 19 18450
HSV-UL54-944 - CGCACAUUCGCAGCCAACCC 20 7285
HSV-UL54-2920 - CCG CACAU U CG CAGCCAACCC 21 18451
HSV-UL54-2921 - ACCGCACAUUCGCAGCCAACCC 22 18452
HSV-UL54-2922 - UACCGCACAUUCGCAGCCAACCC 23 18453
HSV-UL54-2923 - CUACCGCACAUUCGCAGCCAACCC 24 18454
HSV-UL54-2924 - AAUCUGCCGCUCCGCCCC 18 18455
HSV-UL54-2925 - CAAUCUGCCGCUCCGCCCC 19 18456
HSV-UL54-950 - ACAAUCUGCCGCUCCGCCCC 20 7289
HSV-UL54-2926 - CACAAUCUGCCGCUCCGCCCC 21 18457
HSV-UL54-2927 - CCACAAUCUGCCGCUCCGCCCC 22 18458
HSV-UL54-2928 - ACCACAAUCUGCCGCUCCGCCCC 23 18459
HSV-UL54-2929 - CACCACAAUCUGCCGCUCCGCCCC 24 18460
HSV-UL54-2930 - UCCCGCCGCGAACAGCCC 18 18461
HSV-UL54-2931 - UUCCCGCCGCGAACAGCCC 19 18462
HSV-UL54-932 - UUUCCCGCCGCGAACAGCCC 20 7279
HSV-UL54-2932 - G U U U CCCG CCG CG AACAG CCC 21 18463
HSV-UL54-2933 - CGUUUCCCGCCGCGAACAGCCC 22 18464
HSV-UL54-2934 - CCGUUUCCCGCCGCGAACAGCCC 23 18465 HSV-UL54-2935 - GCCGUUUCCCGCCGCGAACAGCCC 24 18466
HSV-UL54-2936 - GAUGCACUUUUACAUCCC 18 18467
HSV-UL54-2937 - CGAUGCACUUUUACAUCCC 19 18468
HSV-UL54-358 - ACGAUGCACUUUUACAUCCC 20 6781
HSV-UL54-2938 - GACGAUGCACUUUUACAUCCC 21 18469
HSV-UL54-2939 - AGACGAUGCACUUUUACAUCCC 22 18470
HSV-UL54-2940 - GAGACGAUGCACUUUUACAUCCC 23 18471
HSV-UL54-2941 - CGAGACGAUGCACUUUUACAUCCC 24 18472
HSV-UL54-2942 - GGGAUGCCGUUUCCCGCC 18 18473
HSV-UL54-2943 - CGGGAUGCCGUUUCCCGCC 19 18474
HSV-UL54-931 - GCGGGAUGCCGUUUCCCGCC 20 7278
HSV-UL54-2944 - GGCGGGAUGCCGUUUCCCGCC 21 18475
HSV-UL54-2945 - UGGCGGGAUGCCGUUUCCCGCC 22 18476
HSV-UL54-2946 - UUGGCGGGAUGCCGUUUCCCGCC 23 18477
HSV-UL54-2947 - UUUGGCGGGAUGCCGUUUCCCGCC 24 18478
HSV-UL54-2948 - GCGACUGCGUGCUGCGCC 18 18479
HSV-UL54-2949 - CGCGACUGCGUGCUGCGCC 19 18480
HSV-UL54-326 - GCGCGACUGCGUGCUGCGCC 20 6749
HSV-UL54-2950 - UGCGCGACUGCGUGCUGCGCC 21 18481
HSV-UL54-2951 - AUGCGCGACUGCGUGCUGCGCC 22 18482
HSV-UL54-2952 - CAUGCGCGACUGCGUGCUGCGCC 23 18483
HSV-UL54-2953 - CCAUGCGCGACUGCGUGCUGCGCC 24 18484
HSV-UL54-2954 - CUCCGGGGGCCCGCGGCC 18 18485
HSV-UL54-2955 - UCUCCGGGGGCCCGCGGCC 19 18486
HSV-UL54-910 - GUCUCCGGGGGCCCGCGGCC 20 7264
HSV-UL54-2956 - CGUCUCCGGGGGCCCGCGGCC 21 18487
HSV-UL54-2957 - ACGUCUCCGGGGGCCCGCGGCC 22 18488
HSV-UL54-2958 - GACGUCUCCGGGGGCCCGCGGCC 23 18489
HSV-UL54-2959 - CGACGUCUCCGGGGGCCCGCGGCC 24 18490
HSV-UL54-2960 - CGAUGCACUUUUACAUCC 18 18491
HSV-UL54-2961 - ACGAUGCACUUUUACAUCC 19 18492
HSV-UL54-357 - GACGAUGCACUUUUACAUCC 20 6780
HSV-UL54-2962 - AGACGAUGCACUUUUACAUCC 21 18493
HSV-UL54-2963 - GAGACGAUGCACUUUUACAUCC 22 18494
HSV-UL54-2964 - CGAGACGAUGCACUUUUACAUCC 23 18495
HSV-UL54-2965 - GCGAGACGAUGCACUUUUACAUCC 24 18496
HSV-UL54-2966 - GAGCAGCUCGACGUCUCC 18 18497
HSV-UL54-2967 - GGAGCAGCUCGACGUCUCC 19 18498
HSV-UL54-286 - GGGAGCAGCUCGACGUCUCC 20 6709
HSV-UL54-2968 - GGGGAGCAGCUCGACGUCUCC 21 18499
HSV-UL54-2969 - AGGGGAGCAGCUCGACGUCUCC 22 18500
HSV-UL54-2970 - GAGGGGAGCAGCUCGACGUCUCC 23 18501
HSV-UL54-2971 - GGAGGGGAGCAGCUCGACGUCUCC 24 18502
HSV-UL54-2972 - ACGGCCGCGCCCCGGUCC 18 18503
HSV-UL54-2973 - GACGGCCGCGCCCCGGUCC 19 18504
HSV-UL54-296 - GGACGGCCGCGCCCCGGUCC 20 6719 HSV-UL54-2974 - CGGACGGCCGCGCCCCGGUCC 21 18505
HSV-UL54-2975 - GCGGACGGCCGCGCCCCGGUCC 22 18506
HSV-UL54-2976 - CGCGGACGGCCGCGCCCCGGUCC 23 18507
HSV-UL54-2977 - ACGCGGACGGCCGCGCCCCGGUCC 24 18508
HSV-UL54-2978 - GAGACCCGUCGGGUUUCC 18 18509
HSV-UL54-2979 - CGAGACCCGUCGGGUUUCC 19 18510
HSV-UL54-319 - CCGAGACCCGUCGGGUUUCC 20 6742
HSV-UL54-2980 - GCCGAGACCCGUCGGGUUUCC 21 18511
HSV-UL54-2981 - CGCCGAGACCCGUCGGGUUUCC 22 18512
HSV-UL54-2982 - ACGCCGAGACCCGUCGGGUUUCC 23 18513
HSV-UL54-2983 - GACGCCGAGACCCGUCGGGUUUCC 24 18514
HSV-UL54-2984 - CGUGCUGGCCACCCAAGC 18 18515
HSV-UL54-2985 - CCGUGCUGGCCACCCAAGC 19 18516
HSV-UL54-312 - CCCGUGCUGGCCACCCAAGC 20 6735
HSV-UL54-2986 - UCCCGUGCUGGCCACCCAAGC 21 18517
HSV-UL54-2987 - CUCCCGUGCUGGCCACCCAAGC 22 18518
HSV-UL54-2988 - GCUCCCGUGCUGGCCACCCAAGC 23 18519
HSV-UL54-2989 - GGCUCCCGUGCUGGCCACCCAAGC 24 18520
HSV-UL54-2990 - AUACUGGACACGCACCGC 18 18521
HSV-UL54-2991 - AAUACUGGACACGCACCGC 19 18522
HSV-UL54-976 - AAAUACUGGACACGCACCGC 20 7307
HSV-UL54-2992 - GAAAUACUGGACACGCACCGC 21 18523
HSV-UL54-2993 - UGAAAUACUGGACACGCACCGC 22 18524
HSV-UL54-2994 - UUG AAAUACUGGACACGCACCGC 23 18525
HSV-UL54-2995 - AUU GAAAUACUGGACACGCACCGC 24 18526
HSV-UL54-2996 - CGCGACUGCGUGCUGCGC 18 18527
HSV-UL54-2997 - GCGCGACUGCGUGCUGCGC 19 18528
HSV-UL54-945 - UGCGCGACUGCGUGCUGCGC 20 7286
HSV-UL54-2998 - AUGCGCGACUGCGUGCUGCGC 21 18529
HSV-UL54-2999 - CAUGCGCGACUGCGUGCUGCGC 22 18530
HSV-UL54-3000 - CCAUGCGCGACUGCGUGCUGCGC 23 18531
HSV-UL54-3001 - GCCAUGCGCGACUGCGUGCUGCGC 24 18532
HSV-UL54-3002 - GCAGUGCUACCUGAAGGC 18 18533
HSV-UL54-3003 - UGCAGUGCUACCUGAAGGC 19 18534
HSV-UL54-956 - CUGCAGUGCUACCUGAAGGC 20 7293
HSV-UL54-3004 - UCUGCAGUGCUACCUGAAGGC 21 18535
HSV-UL54-3005 - UUCUGCAGUGCUACCUGAAGGC 22 18536
HSV-UL54-3006 - UUUCUGCAGUGCUACCUGAAGGC 23 18537
HSV-UL54-3007 - CUUUCUGCAGUGCUACCUGAAGGC 24 18538
HSV-UL54-3008 - ACCCUGGUCGCUCACGGC 18 18539
HSV-UL54-3009 - AACCCUGGUCGCUCACGGC 19 18540
HSV-UL54-943 - AAACCCUGGUCGCUCACGGC 20 7284
HSV-UL54-3010 - GAAACCCUGGUCGCUCACGGC 21 18541
HSV-UL54-3011 - GG AAACCCU G G U CG CU CACG GC 22 18542
HSV-UL54-3012 - GGGAAACCCUGGUCGCUCACGGC 23 18543
HSV-UL54-3013 - UGGGAAACCCUGGUCGCUCACGGC 24 18544 HSV-UL54-3014 - CCCACGGCGAGGCGCGGC 18 18545
HSV-UL54-3015 - ACCCACGGCGAGGCGCGGC 19 18546
HSV-UL54-908 - CACCCACGGCGAGGCGCGGC 20 7263
HSV-UL54-3016 - CCACCCACGGCGAGGCGCGGC 21 18547
HSV-UL54-3017 - GCCACCCACGGCGAGGCGCGGC 22 18548
HSV-UL54-3018 - CGCCACCCACGGCGAGGCGCGGC 23 18549
HSV-UL54-3019 - GCGCCACCCACGGCGAGGCGCGGC 24 18550
HSV-UL54-3020 - UCGCCACCCCGCGUCGGC 18 18551
HSV-UL54-3021 - GUCGCCACCCCGCGUCGGC 19 18552
HSV-UL54-911 - GGUCGCCACCCCGCGUCGGC 20 7265
HSV-UL54-3022 - GGGUCGCCACCCCGCGUCGGC 21 18553
HSV-UL54-3023 - GGGGUCGCCACCCCGCGUCGGC 22 18554
HSV-UL54-3024 - GGGGGUCGCCACCCCGCGUCGGC 23 18555
HSV-UL54-3025 - AGGGGGUCGCCACCCCGCGUCGGC 24 18556
HSV-UL54-3026 - GAACGGCGGCCGCCGUGC 18 18557
HSV-UL54-3027 - GGAACGGCGGCCGCCGUGC 19 18558
HSV-UL54-336 - CGGAACGGCGGCCGCCGUGC 20 6759
HSV-UL54-3028 - UCGGAACGGCGGCCGCCGUGC 21 18559
HSV-UL54-3029 - AUCGGAACGGCGGCCGCCGUGC 22 18560
HSV-UL54-3030 - CAUCGGAACGGCGGCCGCCGUGC 23 18561
HSV-UL54-3031 - UCAUCGGAACGGCGGCCGCCGUGC 24 18562
HSV-UL54-3032 - ACGAUGCACUUUUACAUC 18 18563
HSV-UL54-3033 - GACGAUGCACUUUUACAUC 19 18564
HSV-UL54-970 - AGACGAUGCACUUUUACAUC 20 7303
HSV-UL54-3034 - GAGACGAUGCACUUUUACAUC 21 18565
HSV-UL54-3035 - CGAGACGAUGCACUUUUACAUC 22 18566
HSV-UL54-3036 - GCGAGACGAUGCACUUUUACAUC 23 18567
HSV-UL54-3037 - GGCGAGACGAUGCACUUUUACAUC 24 18568
HSV-UL54-3038 - GGAGCAGCUCGACGUCUC 18 18569
HSV-UL54-3039 - GGGAGCAGCUCGACGUCUC 19 18570
HSV-UL54-285 - GGGGAGCAGCUCGACGUCUC 20 6708
HSV-UL54-3040 - AGGGGAGCAGCUCGACGUCUC 21 18571
HSV-UL54-3041 - GAGGGGAGCAGCUCGACGUCUC 22 18572
HSV-UL54-3042 - GG AGGGGAGCAGCUCGACGUCUC 23 18573
HSV-UL54-3043 - CGGAGGGGAGCAGCUCGACGUCUC 24 18574
HSV-UL54-2031 - ACCCCGCCGGCGCGUCUC 18 17562
HSV-UL54-2032 - AACCCCGCCGGCGCGUCUC 19 17563
HSV-UL54-2033 - AAACCCCGCCGGCGCGUCUC 20 17564
HSV-UL54-2034 - AAAACCCCGCCGGCGCGUCUC 21 17565
HSV-UL54-2035 - CAAAACCCCGCCGGCGCGUCUC 22 17566
HSV-UL54-2036 - CCAAAACCCCGCCGGCGCGUCUC 23 17567
HSV-UL54-2037 - ACCAAAACCCCGCCGGCGCGUCUC 24 17568
HSV-UL54-3044 - GACGGCCGCGCCCCGGUC 18 18575
HSV-UL54-3045 - GGACGGCCGCGCCCCGGUC 19 18576
HSV-UL54-921 - CGGACGGCCGCGCCCCGGUC 20 7270
HSV-UL54-3046 - GCGGACGGCCGCGCCCCGGUC 21 18577 HSV-UL54-3047 - CGCGGACGGCCGCGCCCCGGUC 22 18578
HSV-UL54-3048 - ACGCGGACGGCCGCGCCCCGGUC 23 18579
HSV-UL54-3049 - CACGCGGACGGCCGCGCCCCGGUC 24 18580
HSV-UL54-3050 - CGAGACCCGUCGGGUUUC 18 18581
HSV-UL54-3051 - CCGAGACCCGUCGGGUUUC 19 18582
HSV-UL54-940 - GCCGAGACCCGUCGGGUUUC 20 7283
HSV-UL54-3052 - CGCCGAGACCCGUCGGGUUUC 21 18583
HSV-UL54-3053 - ACGCCGAGACCCGUCGGGUUUC 22 18584
HSV-UL54-3054 - GACGCCGAGACCCGUCGGGUUUC 23 18585
HSV-UL54-3055 - UGACGCCGAGACCCGUCGGGUUUC 24 18586
HSV-UL54-3056 - CCGUGCUGGCCACCCAAG 18 18587
HSV-UL54-3057 - CCCGUGCUGGCCACCCAAG 19 18588
HSV-UL54-311 - UCCCGUGCUGGCCACCCAAG 20 6734
HSV-UL54-3058 - CUCCCGUGCUGGCCACCCAAG 21 18589
HSV-UL54-3059 - GCUCCCGUGCUGGCCACCCAAG 22 18590
HSV-UL54-3060 - GGCUCCCGUGCUGGCCACCCAAG 23 18591
HSV-UL54-3061 - GGGCUCCCGUGCUGGCCACCCAAG 24 18592
HSV-UL54-3062 - GCGAGGCGCGGCGCGGAG 18 18593
HSV-UL54-3063 - GGCGAGGCGCGGCGCGGAG 19 18594
HSV-UL54-284 - CGGCGAGGCGCGGCGCGGAG 20 6707
HSV-UL54-3064 - ACGGCGAGGCGCGGCGCGGAG 21 18595
HSV-UL54-3065 - CACGGCGAGGCGCGGCGCGGAG 22 18596
HSV-UL54-3066 - CCACGGCGAGGCGCGGCGCGGAG 23 18597
HSV-UL54-3067 - CCCACGGCGAGGCGCGGCGCGGAG 24 18598
HSV-UL54-3068 - GCCCCGGCGCCACCCACG 18 18599
HSV-UL54-3069 - GGCCCCGGCGCCACCCACG 19 18600
HSV-UL54-913 - CGGCCCCGGCGCCACCCACG 20 7267
HSV-UL54-3070 - ACGGCCCCGGCGCCACCCACG 21 18601
HSV-UL54-3071 - GACGGCCCCGGCGCCACCCACG 22 18602
HSV-UL54-3072 - GGACGGCCCCGGCGCCACCCACG 23 18603
HSV-UL54-3073 - CGGACGGCCCCGGCGCCACCCACG 24 18604
HSV-UL54-3074 - AAGCGGGGGGGUUUGACG 18 18605
HSV-UL54-3075 - CAAGCGGGGGGGUUUGACG 19 18606
HSV-UL54-938 - CCAAGCGGGGGGGUUUGACG 20 7281
HSV-UL54-3076 - CCCAAGCGGGGGGGUUUGACG 21 18607
HSV-UL54-3077 - ACCCAAGCGGGGGGGUUUGACG 22 18608
HSV-UL54-3078 - CACCCAAGCGGGGGGGU UUGACG 23 18609
HSV-UL54-3079 - CCACCCAAGCGGGGGGGUUUGACG 24 18610
HSV-UL54-3080 - AG AU CGACU ACACGACCG 18 18611
HSV-UL54-3081 - GAGAUCGACUACACGACCG 19 18612
HSV-UL54-349 - GGAGAUCGACU ACACGACCG 20 6772
HSV-UL54-3082 - CGGAGAUCGACU ACACGACCG 21 18613
HSV-UL54-3083 - UCGGAGAUCGACU ACACGACCG 22 18614
HSV-UL54-3084 - GUCGGAGAUCGACUACACGACCG 23 18615
HSV-UL54-3085 - UGUCGGAGAUCGACUACACGACCG 24 18616
HSV-UL54-3086 - CCGUGGGGGUUGGGGCCG 18 18617 HSV-UL54-3087 - ACCGUGGGGGUUGGGGCCG 19 18618
HSV-UL54-969 - GACCGUGGGGGUUGGGGCCG 20 7302
HSV-UL54-3088 - CGACCGUGGGGGU UGGGGCCG 21 18619
HSV-UL54-3089 - ACGACCGUGGGGGUUGGGGCCG 22 18620
HSV-UL54-3090 - CACGACCGUGGGGGUUGGGGCCG 23 18621
HSV-UL54-3091 - ACACGACCGUGGGGGUUGGGGCCG 24 18622
HSV-UL54-3092 - GUGCUGGCCACCCAAGCG 18 18623
HSV-UL54-3093 - CGUGCUGGCCACCCAAGCG 19 18624
HSV-UL54-313 - CCGUGCUGGCCACCCAAGCG 20 6736
HSV-UL54-3094 - CCCGUGCUGGCCACCCAAGCG 21 18625
HSV-UL54-3095 - UCCCGUGCUGGCCACCCAAGCG 22 18626
HSV-UL54-3096 - CUCCCGUGCUGG CCACCCAAG CG 23 18627
HSV-UL54-3097 - GCUCCCGUGCUGGCCACCCAAGCG 24 18628
HSV-UL54-3098 - CCCGCCUCGCCAACCGCG 18 18629
HSV-UL54-3099 - GCCCGCCUCGCCAACCGCG 19 18630
HSV-UL54-961 - GGCCCGCCUCGCCAACCGCG 20 7298
HSV-UL54-3100 - UGGCCCGCCUCGCCAACCGCG 21 18631
HSV-UL54-3101 - CUGGCCCGCCUCGCCAACCGCG 22 18632
HSV-UL54-3102 - CCUGGCCCGCCUCGCCAACCGCG 23 18633
HSV-UL54-3103 - UCCUGGCCCGCCUCGCCAACCGCG 24 18634
HSV-UL54-3104 - ACGGCGAGGCGCGGCGCG 18 18635
HSV-UL54-3105 - CACGGCGAGGCGCGGCGCG 19 18636
HSV-UL54-907 - CCACGGCGAGGCGCGGCGCG 20 7262
HSV-UL54-3106 - CCCACGGCGAGGCGCGGCGCG 21 18637
HSV-UL54-3107 - ACCCACGGCGAGGCGCGGCGCG 22 18638
HSV-UL54-3108 - CACCCACGGCGAGGCGCGGCGCG 23 18639
HSV-UL54-3109 - CCACCCACGGCGAGGCGCGGCGCG 24 18640
HSV-UL54-3110 - CCACGGCGAGGCGCGGCG 18 18641
HSV-UL54-3111 - CCCACGGCGAGGCGCGGCG 19 18642
HSV-UL54-281 - ACCCACGGCGAGGCGCGGCG 20 6704
HSV-UL54-3112 - CACCCACGGCGAGGCGCGGCG 21 18643
HSV-UL54-3113 - CCACCCACGGCGAGGCGCGGCG 22 18644
HSV-UL54-3114 - GCCACCCACGGCGAGGCGCGGCG 23 18645
HSV-UL54-3115 - CGCCACCCACGGCGAGGCGCGGCG 24 18646
HSV-UL54-3116 - AGGCCCUGGCGUCCGCGG 18 18647
HSV-UL54-3117 - GAGGCCCUGGCGUCCGCGG 19 18648
HSV-UL54-671 - CGAGGCCCUGGCGUCCGCGG 20 7089
HSV-UL54-3118 - UCGAGGCCCUGGCGUCCGCGG 21 18649
HSV-UL54-3119 - AUCGAGGCCCUGGCGUCCGCGG 22 18650
HSV-UL54-3120 - CAUCGAGGCCCUGGCGUCCGCGG 23 18651
HSV-UL54-3121 - UCAUCGAGGCCCUGGCGUCCGCGG 24 18652
HSV-UL54-3122 - CGGCGAGGCGCGGCGCGG 18 18653
HSV-UL54-3123 - ACGGCGAGGCGCGGCGCGG 19 18654
HSV-UL54-282 - CACGGCGAGGCGCGGCGCGG 20 6705
HSV-UL54-3124 - CCACGGCGAGGCGCGGCGCGG 21 18655
HSV-UL54-3125 - CCCACGGCGAGGCGCGGCGCGG 22 18656 HSV-UL54-3126 - ACCCACGGCGAGGCGCGGCGCGG 23 18657
HSV-UL54-3127 - CACCCACGGCGAGGCGCGGCGCGG 24 18658
HSV-UL54-3128 - CACCCCGCGUCGGCGCGG 18 18659
HSV-UL54-3129 - CCACCCCGCGUCGGCGCGG 19 18660
HSV-UL54-912 - GCCACCCCGCGUCGGCGCGG 20 7266
HSV-UL54-3130 - CGCCACCCCGCGUCGGCGCGG 21 18661
HSV-UL54-3131 - UCGCCACCCCGCGUCGGCGCGG 22 18662
HSV-UL54-3132 - GUCGCCACCCCGCGUCGGCGCGG 23 18663
HSV-UL54-3133 - GGUCGCCACCCCGCGUCGGCGCGG 24 18664
HSV-UL54-3134 - UAUCCGAGCGCGCGGCGG 18 18665
HSV-UL54-3135 - AUAUCCGAGCGCGCGGCGG 19 18666
HSV-UL54-926 - CAUAUCCGAGCGCGCGGCGG 20 7274
HSV-UL54-3136 - CCAUAUCCGAGCGCGCGGCGG 21 18667
HSV-UL54-3137 - UCCAUAUCCGAGCGCGCGGCGG 22 18668
HSV-UL54-3138 - AUCCAUAUCCGAGCGCGCGGCGG 23 18669
HSV-UL54-3139 - GAUCCAUAUCCGAGCGCGCGGCGG 24 18670
HSV-UL54-3140 - GCCCGAGGCCUGUGCGGG 18 18671
HSV-UL54-3141 - GGCCCGAGGCCUGUGCGGG 19 18672
HSV-UL54-958 - AGGCCCGAGGCCUGUGCGGG 20 7295
HSV-UL54-3142 - AAGGCCCGAGGCCUGUGCGGG 21 18673
HSV-UL54-3143 - GAAGGCCCGAGGCCUGUGCGGG 22 18674
HSV-UL54-3144 - UG AAGGCCCGAGGCCUGUGCGGG 23 18675
HSV-UL54-3145 - CUGAAGGCCCGAGGCCUGUGCGGG 24 18676
HSV-UL54-3146 - ACUACACGACCGUGGGGG 18 18677
HSV-UL54-3147 - GACUACACGACCGUGGGGG 19 18678
HSV-UL54-967 - CGACUACACGACCGUGGGGG 20 7301
HSV-UL54-3148 - UCG ACUACACGACCGUGGGGG 21 18679
HSV-UL54-3149 - AUCGACUACACGACCGUGGGGG 22 18680
HSV-UL54-3150 - GAUCGACUACACGACCGUGGGGG 23 18681
HSV-UL54-3151 - AGAUCGACUACACGACCGUGGGGG 24 18682
HSV-UL54-3152 - UGCUCGCGGCGACGCCUG 18 18683
HSV-UL54-3153 - GUGCUCGCGGCGACGCCUG 19 18684
HSV-UL54-959 - UGUGCUCGCGGCGACGCCUG 20 7296
HSV-UL54-3154 - CUGUGCUCGCGGCGACGCCUG 21 18685
HSV-UL54-3155 - CCUGUGCUCGCGGCGACGCCUG 22 18686
HSV-UL54-3156 - ACCUGUGCUCGCGGCGACGCCUG 23 18687
HSV-UL54-3157 - GACCUGUGCUCGCGGCGACGCCUG 24 18688
HSV-UL54-3158 - GGAACGGCGGCCGCCGUG 18 18689
HSV-UL54-3159 - CGGAACGGCGGCCGCCGUG 19 18690
HSV-UL54-953 - UCGGAACGGCGGCCGCCGUG 20 7291
HSV-UL54-3160 - AUCGGAACGGCGGCCGCCGUG 21 18691
HSV-UL54-3161 - CAUCGGAACGGCGGCCGCCGUG 22 18692
HSV-UL54-3162 - UCAUCGGAACGGCGGCCGCCGUG 23 18693
HSV-UL54-3163 - AUCAUCGGAACGGCGGCCGCCGUG 24 18694
HSV-UL54-3164 - CGCGUCGAGCGCGGCGUG 18 18695
HSV-UL54-3165 - CCGCGUCGAGCGCGGCGUG 19 18696 HSV-UL54-962 - ACCGCGUCGAGCGCGGCGUG 20 7299
HSV-UL54-3166 - AACCGCGUCGAGCGCGGCGUG 21 18697
HSV-UL54-3167 - CAACCGCGUCGAGCGCGGCGUG 22 18698
HSV-UL54-3168 - CCAACCGCGUCGAGCGCGGCGUG 23 18699
HSV-UL54-3169 - GCCAACCGCGUCGAGCGCGGCGUG 24 18700
HSV-UL54-3170 - U CAU G CAAG ACCCCU U U G 18 18701
HSV-UL54-3171 - GUCAUGCAAGACCCCUUUG 19 18702
HSV-UL54-929 - GGUCAUGCAAGACCCCUUUG 20 7277
HSV-UL54-3172 - UGGUCAUGCAAGACCCCUUUG 21 18703
HSV-UL54-3173 - CUGGUCAUGCAAGACCCCUUUG 22 18704
HSV-UL54-3174 - CCUGGUCAUGCAAGACCCCUUUG 23 18705
HSV-UL54-3175 - CCCUGG UCAUGCAAGACCCCU U UG 24 18706
HSV-UL54-3176 - CCCCCAGGACCCUAUCAU 18 18707
HSV-UL54-3177 - GCCCCCAGGACCCUAUCAU 19 18708
HSV-UL54-333 - CGCCCCCAGGACCCUAUCAU 20 6756
HSV-UL54-3178 - CCGCCCCCAGGACCCUAUCAU 21 18709
HSV-UL54-3179 - UCCGCCCCCAGGACCCUAUCAU 22 18710
HSV-UL54-3180 - CUCCGCCCCCAGGACCCUAUCAU 23 18711
HSV-UL54-3181 - GCUCCGCCCCCAGGACCCUAUCAU 24 18712
HSV-UL54-3182 - CGGUUCUGCGAUCCAUAU 18 18713
HSV-UL54-3183 - GCGGUUCUGCGAUCCAUAU 19 18714
HSV-UL54-925 - GGCGGUUCUGCGAUCCAUAU 20 7273
HSV-UL54-3184 - GGGCGGUUCUGCGAUCCAUAU 21 18715
HSV-UL54-3185 - CGGGCGGUUCUGCGAUCCAUAU 22 18716
HSV-UL54-3186 - UCGGGCGGUUCUGCGAUCCAUAU 23 18717
HSV-UL54-3187 - UUCGGGCGGUUCUGCGAUCCAUAU 24 18718
HSV-UL54-3188 - AGACCCGUCGGGUUUCCU 18 18719
HSV-UL54-3189 - GAGACCCGUCGGGUUUCCU 19 18720
HSV-UL54-320 - CGAGACCCGUCGGGUU UCCU 20 6743
HSV-UL54-3190 - CCGAGACCCG UCGGGU U UCCU 21 18721
HSV-UL54-3191 - GCCGAGACCCGUCGGGUUUCCU 22 18722
HSV-UL54-3192 - CGCCGAGACCCGUCGGGUUUCCU 23 18723
HSV-UL54-3193 - ACGCCGAGACCCGUCGGGUUUCCU 24 18724
HSV-UL54-3194 - AGCGCAUCAGCGAAAGCU 18 18725
HSV-UL54-3195 - GAGCGCAUCAGCGAAAGCU 19 18726
HSV-UL54-928 - CG AGCGCAUCAGCGAAAGCU 20 7276
HSV-UL54-3196 - UCGAGCGCAUCAGCGAAAGCU 21 18727
HSV-UL54-3197 - GUCGAGCGCAUCAGCGAAAGCU 22 18728
HSV-UL54-3198 - GG UCGAGCGCAUCAGCGAAAGCU 23 18729
HSV-UL54-3199 - CGGUCGAGCGCAUCAGCGAAAGCU 24 18730
HSV-UL54-3200 - GGGAGCAGCUCGACGUCU 18 18731
HSV-UL54-3201 - GGGGAGCAGCUCGACGUCU 19 18732
HSV-UL54-917 - AGGGGAGCAGCUCGACGUCU 20 7268
HSV-UL54-3202 - GAGGGGAGCAGCUCGACGUCU 21 18733
HSV-UL54-3203 - GGAGGGGAGCAGCUCGACGUCU 22 18734
HSV-UL54-3204 - CGG AGGGGAGCAGCUCGACGUCU 23 18735 HSV-UL54-3205 - GCGGAGGGGAGCAGCUCGACGUCU 24 18736
HSV-UL54-3206 - CACCAUCGACCCCGCCGU 18 18737
HSV-UL54-3207 - ACACCAUCGACCCCGCCGU 19 18738
HSV-UL54-924 - GACACCAUCGACCCCGCCGU 20 7272
HSV-UL54-3208 - CGACACCAUCGACCCCGCCGU 21 18739
HSV-UL54-3209 - CCGACACCAUCGACCCCGCCGU 22 18740
HSV-UL54-3210 - GCCGACACCAUCGACCCCGCCGU 23 18741
HSV-UL54-3211 - U GCCG ACACCAU CG ACCCCG CCG U 24 18742
HSV-UL54-3212 - CUACACGACCGUGGGGGU 18 18743
HSV-UL54-3213 - ACUACACGACCGUGGGGGU 19 18744
HSV-UL54-353 - GACUACACGACCGUGGGGGU 20 6776
HSV-UL54-3214 - CG ACUACACGACCGUGGGGGU 21 18745
HSV-UL54-3215 - UCGACUACACGACCGUGGGGGU 22 18746
HSV-UL54-3216 - AUCGACUACACGACCGUGGGGGU 23 18747
HSV-UL54-3217 - GAUCGACUACACGACCGUGGGGGU 24 18748
HSV-UL54-3218 - UGAAGGCCCGAGGCCUGU 18 18749
HSV-UL54-3219 - CUGAAGGCCCGAGGCCUGU 19 18750
HSV-UL54-957 - CCUGAAGGCCCGAGGCCUGU 20 7294
HSV-UL54-3220 - ACCUGAAGGCCCGAGGCCUGU 21 18751
HSV-UL54-3221 - UACCUGAAGGCCCGAGGCCUGU 22 18752
HSV-UL54-3222 - CUACCUGAAGGCCCGAGGCCUGU 23 18753
HSV-UL54-3223 - GCUACCUGAAGGCCCGAGGCCUGU 24 18754
HSV-UL54-3224 - AGUGUUCCAGUCGCGUGU 18 18755
HSV-UL54-3225 - GAGUGUUCCAGUCGCGUGU 19 18756
HSV-UL54-978 - GGAGUGUUCCAGUCGCGUGU 20 7308
HSV-UL54-3226 - AGGAGUGUUCCAGUCGCGUGU 21 18757
HSV-UL54-3227 - CAGGAGUGUUCCAGUCGCGUGU 22 18758
HSV-UL54-3228 - CCAGGAGUGUUCCAGUCGCGUGU 23 18759
HSV-UL54-3229 - GCCAGGAGUGUUCCAGUCGCGUGU 24 18760
HSV-UL54-3230 - GCGUCGAGCGCGGCGUGU 18 18761
HSV-UL54-3231 - CGCGUCGAGCGCGGCGUGU 19 18762
HSV-UL54-348 - CCGCGUCGAGCGCGGCGUGU 20 6771
HSV-UL54-3232 - ACCGCGUCGAGCGCGGCGUGU 21 18763
HSV-UL54-3233 - AACCGCGUCGAGCGCGGCGUGU 22 18764
HSV-UL54-3234 - CAACCGCGUCGAGCGCGGCGUGU 23 18765
HSV-UL54-3235 - CCAACCGCGUCGAGCGCGGCGUGU 24 18766
Table 16A provides exemplary targeting domains for knocking out the UL54 gene selected according to the first tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon), have a high level of orthogonality and start with a 5'G. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase).
Table 16A
Figure imgf000706_0001
Table 16B provides exemplary targeting domains for knocking out the UL54 gene selected according to the second tier parameters. The targeting domains bind within the first 500 bp of the coding sequence (e.g., within 500 bp downstream from the start codon) and have a high level of orthogonality. It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase). Table 16B
Figure imgf000706_0002
Table 16C provides exemplary targeting domains for knocking out the UL54 gene selected according to the fifth tier parameters. The targeting domains fall in the coding sequence of the gene, downstream of the first 500bp of coding sequence (e.g., anywhere from +500 (relative to the start codon) to the stop codon of the gene). It is contemplated herein that in an embodiment the targeting domain hybridizes to the target domain through
complementary base pairing. Any of the targeting domains in the table can be used with a N. meningitidis Cas9 molecule that generates a double stranded break (Cas9 nuclease) or a single- stranded break (Cas9 nickase). Table 16C
Figure imgf000707_0001
III. Cas9 Molecules
Cas9 molecules of a variety of species can be used in the methods and compositions described herein. While the S. pyogenes, S. aureus and S. thermophilus Cas9 molecules are the subject of much of the disclosure herein, Cas9 molecules of, derived from, or based on the Cas9 proteins of other species listed herein can be used as well. In other words, while the much of the description herein uses S. pyogenes and S. thermophilus Cas9 molecules, Cas9 molecules from the other species can replace them, e.g., Staphylococcus aureus and Neisseria meningitidis Cas9 molecules. Additional Cas9 species include: Acidovorax avenae, Actinobacillus pleuropneumoniae, Actinobacillus succinogenes, Actinobacillus suis, Actinomyces sp., cycliphilus denitrificans, Aminomonas paucivorans, Bacillus cereus, Bacillus smithii, Bacillus thuringiensis, Bacteroides sp., Blastopirellula marina,
Bradyrhizobium sp., Brevibacillus laterosporus, Campylobacter coli, Campylobacter jejuni, Campylobacter lari, Candidatus Puniceispirillum, Clostridium cellulolyticum, Clostridium perfringens, Corynebacterium accolens, Corynebacterium diphtheria, Corynebacterium matruchotii, Dinoroseobacter shibae, Eubacterium dolichum, gamma proteobacterium, Gluconacetobacter diazotrophicus, Haemophilus parainfluenzae, Haemophilus sputorum, Helicobacter canadensis, Helicobacter cinaedi, Helicobacter mustelae, Ilyobacter polytropus, Kingella kingae, Lactobacillus crispatus, Listeria ivanovii, Listeria
monocytogenes, Listeriaceae bacterium, Methylocystis sp., Methylosinus trichosporium, Mobiluncus mulieris, Neisseria bacilliformis, Neisseria cinerea, Neisseria flavescens, Neisseria lactamica, Neisseria meningitidis, Neisseria sp., Neisseria wadsworthii,
Nitrosomonas sp., Parvibaculum lavamentivorans, Pasteurella multocida, Phascolarctobacterium succinatutens, Ralstonia syzygii, Rhodopseudomonas palustris, Rhodovulum sp., Simonsiella muelleri, Sphingomonas sp., Sporolactobacillus vineae, Staphylococcus lugdunensis, Streptococcus sp., Subdoligranulum sp., Tistrella mobilis, Treponema sp., or Verminephrobacter eiseniae.
A Cas9 molecule, or Cas9 polypeptide, as that term is used herein, refers to a molecule or polypeptide that can interact with a guide RNA (gRNA) molecule and, in concert with the gRNA molecule, home or localizes to a site which comprises a target domain and PAM sequence. Cas9 molecule and Cas9 polypeptide, as those terms are used herein, refer to naturally occurring Cas9 molecules and to engineered, altered, or modified Cas9 molecules or Cas9 polypeptides that differ, e.g., by at least one amino acid residue, from a reference sequence, e.g., the most similar naturally occurring Cas9 molecule or a sequence of Table 17 or 18.
Cas9 Domains
Crystal structures have been determined for two different naturally occurring bacterial
Cas9 molecules (Jinek et al., Science, 343(6176): 1247997, 2014) and for 5". pyogenes Cas9 with a guide RNA (e.g., a synthetic fusion of crRNA and tracrRNA) (Nishimasu et al., Cell, 156:935-949, 2014; and Anders et al., Nature, 2014, doi: 10.1038/naturel3579).
A naturally occurring Cas9 molecule comprises two lobes: a recognition (REC) lobe and a nuclease (NUC) lobe; each of which further comprises domains described herein. Figs. 9A-9B provide a schematic of the organization of important Cas9 domains in the primary structure. The domain nomenclature and the numbering of the amino acid residues encompassed by each domain used throughout this disclosure is as described in Nishimasu et al. The numbering of the amino acid residues is with reference to Cas9 from S. pyogenes.
The REC lobe comprises the arginine-rich bridge helix (BH), the REC1 domain, and the REC2 domain. The REC lobe does not share structural similarity with other known proteins, indicating that it is a Cas9-specific functional domain. The BH domain is a long a helix and arginine rich region and comprises amino acids 60-93 of the sequence of S.
pyogenes Cas9. The REC1 domain is important for recognition of the repeat: anti-repeat duplex, e.g., of a gRNA or a tracrRNA, and is therefore critical for Cas9 activity by recognizing the target sequence. The REC1 domain comprises two REC1 motifs at amino acids 94 to 179 and 308 to 717 of the sequence of S. pyogenes Cas9. These two REC1 domains, though separated by the REC2 domain in the linear primary structure, assemble in the tertiary structure to form the REC1 domain. The REC2 domain, or parts thereof, may also play a role in the recognition of the repeat: anti-repeat duplex. The REC2 domain comprises amino acids 180-307 of the sequence of S. pyogenes Cas9.
The NUC lobe comprises the RuvC domain (also referred to herein as RuvC-like domain), the HNH domain (also referred to herein as HNH-like domain), and the PAM- interacting (PI) domain. The RuvC domain shares structural similarity to retroviral integrase superfamily members and cleaves a single strand, e.g., the non-complementary strand of the target nucleic acid molecule. The RuvC domain is assembled from the three split RuvC motifs (RuvC I, RuvCII, and RuvCIII, which are often commonly referred to in the art as RuvCI domain, or N-terminal RuvC domain, RuvCII domain, and RuvCIII domain) at amino acids 1-59, 718-769, and 909-1098, respectively, of the sequence of S. pyogenes Cas9.
Similar to the REC1 domain, the three RuvC motifs are linearly separated by other domains in the primary structure, however in the tertiary structure, the three RuvC motifs assemble and form the RuvC domain. The HNH domain shares structural similarity with HNH endonucleases, and cleaves a single strand, e.g., the complementary strand of the target nucleic acid molecule. The HNH domain lies between the RuvC II-III motifs and comprises amino acids 775-908 of the sequence of S. pyogenes Cas9. The PI domain interacts with the PAM of the target nucleic acid molecule, and comprises amino acids 1099-1368 of the sequence of S. pyogenes Cas9.
A RuvC-like domain and an HNH-like domain
In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises an HNH-like domain and a RuvC-like domain. In an embodiment, cleavage activity is dependent on a RuvC-like domain and an HNH-like domain. A Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, can comprise one or more of the following domains: a RuvC-like domain and an HNH-like domain. In an embodiment, a Cas9 molecule or Cas9 polypeptide is an eaCas9 molecule or eaCas9 polypeptide and the eaCas9 molecule or eaCas9 polypeptide comprises a RuvC-like domain, e.g., a RuvC-like domain described below, and/or an HNH-like domain, e.g., an HNH-like domain described below.
RuvC-like domains
In an embodiment, a RuvC-like domain cleaves, a single strand, e.g., the non- complementary strand of the target nucleic acid molecule. The Cas9 molecule or Cas9 polypeptide can include more than one RuvC-like domain (e.g., one, two, three or more RuvC-like domains). In an embodiment, a RuvC-like domain is at least 5, 6, 7, 8 amino acids in length but not more than 20, 19, 18, 17, 16 or 15 amino acids in length. In an embodiment, the Cas9 molecule or Cas9 polypeptide comprises an N-terminal RuvC-like domain of about 10 to 20 amino acids, e.g., about 15 amino acids in length.
N-terminal RuvC-like domains
Some naturally occurring Cas9 molecules comprise more than one RuvC-like domain with cleavage being dependent on the N-terminal RuvC-like domain. Accordingly, Cas9 molecules or Cas9 polypeptide can comprise an N-terminal RuvC-like domain. Exemplary N-terminal RuvC-like domains are described below.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an N- terminal RuvC-like domain comprising an amino acid sequence of formula I:
D-X1-G-X2-X3-X4-X5-G-X6-X7-X8-X9 (SEQ ID NO: 8),
wherein,
XI is selected from I, V, M, L and T (e.g., selected from I, V, and L);
X2 is selected from T, I, V, S, N, Y, E and L (e.g., selected from T, V, and I);
X3 is selected from N, S, G, A, D, T, R, M and F (e.g., A or N);
X4 is selected from S, Y, N and F (e.g., S);
X5 is selected from V, I, L, C, T and F (e.g., selected from V, I and L);
X6 is selected from W, F, V, Y, S and L (e.g., W);
X7 is selected from A, S, C, V and G (e.g., selected from A and S);
X8 is selected from V, I, L, A, M and H (e.g., selected from V, I, M and L); and
X9 is selected from any amino acid or is absent (e.g., selected from T, V, I, L, Δ, F, S, A, Y, M and R, or, e.g., selected from T, V, I, L and Δ).
In an embodiment, the N-terminal RuvC-like domain differs from a sequence of SEQ
ID NO:8, by as many as 1 but no more than 2, 3, 4, or 5 residues.
In embodiment, the N-terminal RuvC-like domain is cleavage competent.
In embodiment, the N-terminal RuvC-like domain is cleavage incompetent.
In an embodiment, a eaCas9 molecule or eaCas9 polypeptide comprises an N-terminal RuvC-like domain comprising an amino acid sequence of formula II:
D-X1-G-X2-X3-S-X5-G-X6-X7-X8-X9, (SEQ ID NO: 9),
wherein
XI is selected from I, V, M, L and T (e.g., selected from I, V, and L);
X2 is selected from T, I, V, S, N, Y, E and L (e.g., selected from T, V, and I); X3 is selected from N, S, G, A, D, T, R, M and F (e.g., A or N);
X5 is selected from V, I, L, C, T and F (e.g., selected from V, I and L);
X6 is selected from W, F, V, Y, S and L (e.g., W);
X7 is selected from A, S, C, V and G (e.g., selected from A and S);
X8 is selected from V, I, L, A, M and H (e.g., selected from V, I, M and L); and
X9 is selected from any amino acid or is absent (e.g., selected from T, V, I, L, Δ, F, S, A, Y, M and R or selected from e.g., T, V, I, L and Δ).
In an embodiment, the N-terminal RuvC-like domain differs from a sequence of SEQ ID NO: 9 by as many as 1 but no more than 2, 3, 4, or 5 residues.
In an embodiment, the N-terminal RuvC-like domain comprises an amino acid sequence of formula III:
D-I-G-X2-X3-S-V-G-W-A-X8-X9 (SEQ ID NO: 10),
wherein
X2 is selected from T, I, V, S, N, Y, E and L (e.g., selected from T, V, and I);
X3 is selected from N, S, G, A, D, T, R, M and F (e.g., A or N);
X8 is selected from V, I, L, A, M and H (e.g., selected from V, I, M and L); and
X9 is selected from any amino acid or is absent (e.g., selected from T, V, I, L, Δ, F, S, A, Y, M and R or selected from e.g., T, V, I, L and Δ).
In an embodiment, the N-terminal RuvC-like domain differs from a sequence of SEQ ID NO: 10 by as many as 1 but no more than, 2, 3, 4, or 5 residues.
In an embodiment, the N-terminal RuvC-like domain comprises an amino acid sequence of formula III:
D-I-G-T-N-S-V-G-W-A-V-X (SEQ ID NO: 11),
wherein
X is a non-polar alkyl amino acid or a hydroxyl amino acid, e.g., X is selected from
V, I, L and T (e.g., the eaCas9 molecule can comprise an N-terminal RuvC-like domain shown in Figs. 2A-2G (is depicted as Y)).
In an embodiment, the N-terminal RuvC-like domain differs from a sequence of SEQ ID NO: 11 by as many as 1 but no more than, 2, 3, 4, or 5 residues.
In an embodiment, the N-terminal RuvC-like domain differs from a sequence of an N- terminal RuvC like domain disclosed herein, e.g., in Figs. 3A-3B or Figs. 7A-7B, as many as 1 but no more than 2, 3, 4, or 5 residues. In an embodiment, 1, 2, 3 or all of the highly conserved residues identified in Figs. 3A-3B or Figs. 7A-7B are present. In an embodiment, the N-terminal RuvC-like domain differs from a sequence of an N- terminal RuvC-like domain disclosed herein, e.g., in Figs. 4A-4B or Figs. 7A-7B, as many as 1 but no more than 2, 3, 4, or 5 residues. In an embodiment, 1, 2, or all of the highly conserved residues identified in Figs. 4A-4B or Figs. 7A-7B are present.
Additional RuvC-like domains
In addition to the N-terminal RuvC-like domain, the Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, can comprise one or more additional RuvC-like domains. In an embodiment, the Cas9 molecule or Cas9 polypeptide can comprise two additional RuvC-like domains. Preferably, the additional RuvC-like domain is at least 5 amino acids in length and, e.g., less than 15 amino acids in length, e.g., 5 to 10 amino acids in length, e.g., 8 amino acids in length.
An additional RuvC-like domain can comprise an amino acid sequence:
I-X1-X2-E-X3-A-R-E (SEQ ID NO: 12), wherein
XI is V or H,
X2 is I, L or V (e.g., I or V); and
X3 is M or T.
In an embodiment, the additional RuvC-like domain comprises the amino acid sequence:
I-V-X2-E-M-A-R-E (SEQ ID NO: 13), wherein
X2 is I, L or V (e.g., I or V) (e.g., the eaCas9 molecule or eaCas9 polypeptide can comprise an additional RuvC-like domain shown in Fig. 2A-2G or Figs. 7A-7B (depicted as B)).
An additional RuvC-like domain can comprise an amino acid sequence:
H-H-A-X1-D-A-X2-X3 (SEQ ID NO: 14), wherein
XI is H or L;
X2 is R or V; and
X3 is E or V.
In an embodiment, the additional RuvC-like domain comprises the amino acid sequence : H-H- A-H-D- A- Y-L (SEQ ID NO : 15) .
In an embodiment, the additional RuvC-like domain differs from a sequence of SEQ ID NO: 12, 13, 14 or 15 by as many as 1 but no more than 2, 3, 4, or 5 residues.
In some embodiments, the sequence flanking the N-terminal RuvC-like domain is a sequences of formula V: K-X1'-Y-X2'-X3'-X4'-Z-T-D-X9'-Y, (SEQ ID NO: 16).
wherein
XI ' is selected from K and P,
X2' is selected from V, L, I, and F (e.g., V, I and L);
X3' is selected from G, A and S (e.g., G),
X4' is selected from L, I, V and F (e.g., L);
X9' is selected from D, E, N and Q; and
Z is an N-terminal RuvC-like domain, e.g., as described above.
HNH-like domains
In an embodiment, an HNH-like domain cleaves a single stranded complementary domain, e.g., a complementary strand of a double stranded nucleic acid molecule. In an embodiment, an HNH-like domain is at least 15, 20, 25 amino acids in length but not more than 40, 35 or 30 amino acids in length, e.g., 20 to 35 amino acids in length, e.g., 25 to 30 amino acids in length. Exemplary HNH-like domains are described below.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an HNH- like domain having an amino acid sequence of formula VI:
X1-X2-X3-H-X4-X5-P-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-N-X16-X17- X18-X19-X20-X21-X22-X23-N (SEQ ID NO: 17), wherein
XI is selected from D, E, Q and N (e.g., D and E);
X2 is selected from L, I, R, Q, V, M and K;
X3 is selected from D and E;
X4 is selected from I, V, T, A and L (e.g., A, I and V);
X5 is selected from V, Y, I, L, F and W (e.g., V, I and L);
X6 is selected from Q, H, R, K, Y, I, L, F and W;
X7 is selected from S, A, D, T and K (e.g., S and A);
X8 is selected from F, L, V, K, Y, M, I, R, A, E, D and Q (e.g., F);
X9 is selected from L, R, T, I, V, S, C, Y, K, F and G;
X10 is selected from K, Q, Y, T, F, L, W, M, A, E, G, and S;
XI I is selected from D, S, N, R, L and T (e.g., D);
X12 is selected from D, N and S;
X13 is selected from S, A, T, G and R (e.g., S);
X14 is selected from I, L, F, S, R, Y, Q, W, D, K and H (e.g., I, L and F);
X15 is selected from D, S, I, N, E, A, H, F, L, Q, M, G, Y and V; X16 is selected from K, L, R, M, T and F (e.g., L, R and K);
X17 is selected from V, L, I, A and T;
X18 is selected from L, I, V and A (e.g., L and I);
X19 is selected from T, V, C, E, S and A (e.g., T and V);
X20 is selected from R, F, T, W, E, L, N, C, K, V, S, Q, I, Y, H and A;
X21 is selected from S, P, R, K, N, A, H, Q, G and L;
X22 is selected from D, G, T, N, S, K, A, I, E, L, Q, R and Y; and
X23 is selected from K, V, A, E, Y, I, C, L, S, T, G, K, M, D and F.
In an embodiment, a HNH-like domain differs from a sequence of SEQ ID NO: 17 by at least one but no more than, 2, 3, 4, or 5 residues.
In an embodiment, the HNH-like domain is cleavage competent.
In an embodiment, the HNH-like domain is cleavage incompetent.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an HNH- like domain comprising an amino acid sequence of formula VII:
X1-X2-X3-H-X4-X5-P-X6-S-X8-X9-X10-D-D-S-X14-X15-N-K-V-L-X19-X20- X21-X22-X23-N (SEQ ID NO: 18),
wherein
XI is selected from D and E;
X2 is selected from L, I, R, Q, V, M and K;
X3 is selected from D and E;
X4 is selected from I, V, T, A and L (e.g., A, I and V);
X5 is selected from V, Y, I, L, F and W (e.g., V, I and L);
X6 is selected from Q, H, R, K, Y, I, L, F and W;
X8 is selected from F, L, V, K, Y, M, I, R, A, E, D and Q (e.g., F);
X9 is selected from L, R, T, I, V, S, C, Y, K, F and G;
X10 is selected from K, Q, Y, T, F, L, W, M, A, E, G, and S;
X14 is selected from I, L, F, S, R, Y, Q, W, D, K and H (e.g., I, L and F);
X15 is selected from D, S, I, N, E, A, H, F, L, Q, M, G, Y and V;
X19 is selected from T, V, C, E, S and A (e.g., T and V);
X20 is selected from R, F, T, W, E, L, N, C, K, V, S, Q, I, Y, H and A;
X21 is selected from S, P, R, K, N, A, H, Q, G and L;
X22 is selected from D, G, T, N, S, K, A, I, E, L, Q, R and Y; and
X23 is selected from K, V, A, E, Y, I, C, L, S, T, G, K, M, D and F. In an embodiment, the HNH-like domain differs from a sequence of SEQ ID NO: 18 by 1, 2, 3, 4, or 5 residues.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an HNH- like domain comprising an amino acid sequence of formula VII:
X1-V-X3-H-I-V-P-X6-S-X8-X9-X10-D-D-S-X14-X15-N-K-V-L-T-X20-X21-X22- X23-N (SEQ ID NO: 19),
wherein
XI is selected from D and E;
X3 is selected from D and E;
X6 is selected from Q, H, R, K, Y, I, L and W;
X8 is selected from F, L, V, K, Y, M, I, R, A, E, D and Q (e.g., F);
X9 is selected from L, R, T, I, V, S, C, Y, K, F and G;
X10 is selected from K, Q, Y, T, F, L, W, M, A, E, G, and S;
X14 is selected from I, L, F, S, R, Y, Q, W, D, K and H (e.g., I, L and F);
X15 is selected from D, S, I, N, E, A, H, F, L, Q, M, G, Y and V;
X20 is selected from R, F, T, W, E, L, N, C, K, V, S, Q, I, Y, H and A;
X21 is selected from S, P, R, K, N, A, H, Q, G and L;
X22 is selected from D, G, T, N, S, K, A, I, E, L, Q, R and Y; and
X23 is selected from K, V, A, E, Y, I, C, L, S, T, G, K, M, D and F.
In an embodiment, the HNH-like domain differs from a sequence of SEQ ID NO: 19 by 1, 2, 3, 4, or 5 residues.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an HNH- like domain having an amino acid sequence of formula VIII:
D-X2-D-H-I-X5-P-Q-X7-F-X9-X10-D-X12-S-I-D-N-X16-V-L-X19-X20-S-X22- X23-N (SEQ ID NO:20),
wherein
X2 is selected from I and V;
X5 is selected from I and V;
X7 is selected from A and S;
X9 is selected from I and L;
X10 is selected from K and T;
X12 is selected from D and N;
X16 is selected from R, K and L; X19 is selected from T and V;
X20 is selected from S and R; X22 is selected from K, D and A; and
X23 is selected from E, K, G and N (e.g., the eaCas9 molecule or eaCas9 polypeptide can comprise an HNH-like domain as described herein).
In an embodiment, the HNH-like domain differs from a sequence of SEQ ID NO: 20 by as many as 1 but no more than 2, 3, 4, or 5 residues.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises the amino acid sequence of formula IX:
L-Y- Y-L-Q-N-G-Xl ' -D-M-Y-X2' -X3 ' -X4' -X5 ' -L-D-I— X6' -XT -L-S-X8 ' -Y-Z-N- R-X9'-K-X10'-D-X11'-V-P (SEQ ID NO: 21),
wherein
XI ' is selected from K and R;
X2' is selected from V and T;
X3' is selected from G and D;
X4' is selected from E, Q and D;
X5' is selected from E and D;
X6' is selected from D, N and H;
X7' is selected from Y, R and N;
X8' is selected from Q, D and N; X9' is selected from G and E;
X10' is selected from S and G;
XI 1 ' is selected from D and N; and
Z is an HNH-like domain, e.g., as described above.
In an embodiment, the eaCas9 molecule or eaCas9 polypeptide comprises an amino acid sequence that differs from a sequence of SEQ ID NO:21 by as many as 1 but no more than 2, 3, 4, or 5 residues.
In an embodiment, the HNH-like domain differs from a sequence of an HNH-like domain disclosed herein, e.g., in Figs. 5A-5C or Figs. 7A-7B, as many as 1 but no more than
2, 3, 4, or 5 residues. In an embodiment, 1 or both of the highly conserved residues identified in Figs. 5A-5C or Figs. 7A-7B are present.
In an embodiment, the HNH -like domain differs from a sequence of an HNH-like domain disclosed herein, e.g., in Figs. 6A-6B or Figs. 7A-7B, as many as 1 but no more than
2, 3, 4, or 5 residues. In an embodiment, 1, 2, all 3 of the highly conserved residues identified in Figs. 6A-6B or Figs. 7A-7B are present. Cas9 Activities
Nuclease and Helicase Activities
In an embodiment, the Cas9 molecule or Cas9 polypeptide is capable of cleaving a target nucleic acid molecule. Typically wild type Cas9 molecules cleave both strands of a target nucleic acid molecule. Cas9 molecules and Cas9 polypeptides can be engineered to alter nuclease cleavage (or other properties), e.g., to provide a Cas9 molecule or Cas9 peolypeptide which is a nickase, or which lacks the ability to cleave target nucleic acid. A Cas9 molecule or Cas9 polypeptide that is capable of cleaving a target nucleic acid molecule is referred to herein as an eaCas9 (an enzymatically active Cas9) molecule or eaCas9 polypeptide. In an embodiment, an eaCas9 molecule, comprises one or more of the following activities:
a nickase activity, i.e., the ability to cleave a single strand, e.g., the non- complementary strand or the complementary strand, of a nucleic acid molecule;
a double stranded nuclease activity, i.e., the ability to cleave both strands of a double stranded nucleic acid and create a double stranded break, which in an embodiment is the presence of two nickase activities;
an endonuclease activity;
an exonuclease activity; and
a helicase activity, i.e., the ability to unwind the helical structure of a double stranded nucleic acid.
In an embodiment, an enzymatically active Cas9 or an eaCas9 molecule or an eaCas9 polypeptide cleaves both DNA strands and results in a double stranded break. In an embodiment, an eaCas9 molecule or eaCas9 polypeptide cleaves only one strand, e.g., the strand to which the gRNA hybridizes to, or the strand complementary to the strand the gRNA hybridizes with. In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises cleavage activity associated with an HNH-like domain. In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises cleavage activity associated with an N-terminal RuvC-like domain. In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises cleavage activity associated with an HNH-like domain and cleavage activity associated with an N-terminal RuvC-like domain. In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an active, or cleavage competent, HNH-like domain and an inactive, or cleavage incompetent, N-terminal RuvC-like domain. In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an inactive, or cleavage incompetent, HNH-like domain and an active, or cleavage competent, N-terminal RuvC-like domain. Some Cas9 molecules or Cas9 polypeptides have the ability to interact with a gRNA molecule, and in conjunction with the gRNA molecule localize to a core target domain, but are incapable of cleaving the target nucleic acid, or incapable of cleaving at efficient rates. Cas9 molecules having no, or no substantial, cleavage activity are referred to herein as an eiCas9 molecule or eiCas9 polypeptide. For example, an eiCas9 molecule or eiCas9 polypeptide can lack cleavage activity or have substantially less, e.g., less than 20, 10, 5, 1 or 0.1 % of the cleavage activity of a reference Cas9 molecule or eiCas9 polypeptide, as measured by an assay described herein. Targeting and PAMs
A Cas9 molecule or Cas9 polypeptide, is a polypeptide that can interact with a guide RNA (gRNA) molecule and, in concert with the gRNA molecule, localizes to a site which comprises a target domain and PAM sequence.
In an embodiment, the ability of an eaCas9 molecule or eaCas9 polypeptide to interact with and cleave a target nucleic acid is PAM sequence dependent. A PAM sequence is a sequence in the target nucleic acid. In an embodiment, cleavage of the target nucleic acid occurs upstream from the PAM sequence. EaCas9 molecules from different bacterial species can recognize different sequence motifs (e.g., PAM sequences). In an embodiment, an eaCas9 molecule of S. pyogenes recognizes the sequence motif NGG and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from that sequence. See, e.g., Mali et al. , SCIENCE 2013; 339(6121): 823-826. In an embodiment, an eaCas9 molecule of S. thermophilus recognizes the sequence motif NGGNG and NNAGAAW (W \ or T) and directs cleavage of a core target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from these sequences. See, e.g., Horvath et al., SCIENCE 2010;
327(5962): 167-170, and Deveau et al., J BACTERIOL 2008; 190(4): 1390-1400. In an embodiment, an eaCas9 molecule of S. mutans recognizes the sequence motif NGG and/or NAAR (R = A or G) and directs cleavage of a core target nucleic acid sequence 1 to 10, e.g., 3 to 5 base pairs, upstream from this sequence. See, e.g., Deveau et al., J BACTERIOL 2008; 190(4): 1390-1400. In an embodiment, an eaCas9 molecule of S. aureus recognizes the sequence motif NNGRR (R = A or G) and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from that sequence. In an embodiment, an eaCas9 molecule of S. aureus recognizes the sequence motif NNGRRN (R = A or G) and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from that sequence. In an embodiment, an eaCas9 molecule of S. aureus recognizes the sequence motif NNGRRT (R = A or G) and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from that sequence. In an embodiment, an eaCas9 molecule of S. aureus recognizes the sequence motif NNGRRV (R = A or G, V = A, G or C) and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from that sequence. In an embodiment, an eaCas9 molecule of Neisseria meningitidis recognizes the sequence motif NNNNGATT or NNNGCTT and directs cleavage of a target nucleic acid sequence 1 to 10, e.g., 3 to 5, base pairs upstream from that sequence. See, e.g., Hou et al., PNAS Early Edition 2013, 1-6. The ability of a Cas9 molecule to recognize a PAM sequence can be determined, e.g., using a transformation assay described in Jinek et al., SCIENCE 2012 337:816. In the aforementioned embodiments, N can be any nucleotide residue, e.g., any of A, G, C or T.
As is discussed herein, Cas9 molecules can be engineered to alter the PAM specificity of the Cas9 molecule.
Exemplary naturally occurring Cas9 molecules are described in Chylinski et al., RNA BIOLOGY 2013 10:5, 727-737. Such Cas9 molecules include Cas9 molecules of a cluster 1 bacterial family, cluster 2 bacterial family, cluster 3 bacterial family, cluster 4 bacterial family, cluster 5 bacterial family, cluster 6 bacterial family, a cluster 7 bacterial family, a cluster 8 bacterial family, a cluster 9 bacterial family, a cluster 10 bacterial family, a cluster 11 bacterial family, a cluster 12 bacterial family, a cluster 13 bacterial family, a cluster 14 bacterial fami iy. a cluster 15 bacterial fami iy. a cluster 16 bacterial fami iy. a cluster 17 bacterial fami iy. a cluster 18 bacterial fami iy. a cluster 19 bacterial fami iy. a cluster 20 bacterial fami iy. a cluster 21 bacterial fami iy. a cluster 22 bacterial fami iy. a cluster 23 bacterial fami iy. a cluster 24 bacterial fami iy. a cluster 25 bacterial fami iy. a cluster 26 bacterial fami iy. a cluster 27 bacterial fami iy. a cluster 28 bacterial fami iy. a cluster 29 bacterial fami iy. a cluster 30 bacterial fami iy. a cluster 31 bacterial fami iy. a cluster 32 bacterial fami iy. a cluster 33 bacterial fami iy. a cluster 34 bacterial fami iy. a cluster 35 bacterial fami iy. a cluster 36 bacterial fami iy. a cluster 37 bacterial fami iy. a cluster 38 bacterial fami iy. a cluster 39 bacterial fami iy. a cluster 40 bacterial fami iy. a cluster 41 bacterial fami iy. a cluster 42 bacterial fami iy. a cluster 43 bacterial fami iy. a cluster 44 bacterial fami iy. a cluster 45 bacterial fami iy. a cluster 46 bacterial fami iy. a cluster 47 bacterial fami iy. a cluster 48 bacterial fami iy. a cluster 49 bacterial fami iy. a cluster 50 bacterial fami iy. a cluster 51 bacterial fami iy. a cluster 52 bacterial fami iy. a cluster 53 bacterial fami iy. a cluster 54 bacterial fami iy. a cluster 55 bacterial fami iy. a cluster 56 bacterial fami iy. a cluster 57 bacterial fami iy. a cluster 58 bacterial fami iy. a cluster 59 bacterial family, a cluster 60 bacterial family, a cluster 61 bacterial family, a cluster 62 bacterial family, a cluster 63 bacterial family, a cluster 64 bacterial family, a cluster 65 bacterial family, a cluster 66 bacterial family, a cluster 67 bacterial family, a cluster 68 bacterial family, a cluster 69 bacterial family, a cluster 70 bacterial family, a cluster 71 bacterial family, a cluster 72 bacterial family, a cluster 73 bacterial family, a cluster 74 bacterial family, a cluster 75 bacterial family, a cluster 76 bacterial family, a cluster 77 bacterial family, or a cluster 78 bacterial family.
Exemplary naturally occurring Cas9 molecules include a Cas9 molecule of a cluster 1 bacterial family. Examples include a Cas9 molecule of: S. pyogenes (e.g., strain SF370, MGAS10270, MGAS10750, MGAS2096, MGAS315, MGAS5005, MGAS6180,
MGAS9429, NZ131 and SSI-1), 5". thermophilus (e.g., strain LMD-9), 5". pseudoporcinus (e.g., strain SPIN 20026), S. mutans (e.g., strain UA159, NN2025), S. macacae (e.g., strain NCTC11558), S. gallolyticus (e.g., strain UCN34, ATCC BAA-2069), S. equines (e.g., strain ATCC 9812, MGCS 124), S. dysdalactiae (e.g., strain GGS 124), S. bovis (e.g., strain ATCC 700338), S. anginosus (e.g., strain F0211), S. agalactiae (e.g., strain NEM316, A909), Listeria monocytogenes (e.g., strain F6854), Listeria innocua (L. innocua, e.g., strain Clipl l262), Enterococcus italicus (e.g., strain DSM 15952), or Enterococcus faecium (e.g., strain 1,231,408). Additional exemplary Cas9 molecules are a Cas9 molecule of Neisseria meningitidis (Hou et al., PNAS Early Edition 2013, 1-6 and a S. aureus cas9 molecule.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence:
having 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology with;
differs at no more than, 2, 5, 10, 15, 20, 30, or 40% of the amino acid residues when compared with;
differs by at least 1, 2, 5, 10 or 20 amino acids, but by no more than 100, 80, 70, 60, 50, 40 or 30 amino acids from; or
is identical to any Cas9 molecule sequence described herein, or a naturally occurring Cas9 molecule sequence, e.g., a Cas9 molecule from a species listed herein or described in Chylinski et al, RNA BIOLOGY 2013 10:5, 727-737; Hou et al , PNAS Early Edition 2013, 1- 6; SEQ ID NO: 1-4. In an embodiment, the Cas9 molecule or Cas9 polypeptide comprises one or more of the following activities: a nickase activity; a double stranded cleavage activity (e.g., an endonuclease and/or exonuclease activity); a helicase activity; or the ability, together with a gRNA molecule, to localize to a target nucleic acid. In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises any of the amino acid sequence of the consensus sequence of Figs. 2A-2G, wherein "*" indicates any amino acid found in the corresponding position in the amino acid sequence of a Cas9 molecule or Cas9 polypeptide of S. pyogenes, S. thermophilus, S. mutans and L. innocua, and "-" indicates any amino acid. In an embodiment, a Cas9 molecule differs from the sequence of the consensus sequence of Figs. 2A-2G by at least 1, but no more than 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues. In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises the amino acid sequence of SEQ ID NO:7 of Figs. 7A-7B, wherein "*" indicates any amino acid found in the corresponding position in the amino acid sequence of a Cas9 molecule of S. pyogenes, or N. meningitidis, "-" indicates any amino acid, and "-" indicates any amino acid or absent. In an embodiment, a Cas9 molecule or Cas9 polypeptide differs from the sequence of SEQ ID NO:6 or 7 disclosed in Figs. 7A-7B by at least 1, but no more than 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues.
A comparison of the sequence of a number of Cas9 molecules or Cas9 polypeptide indicate that certain regions are conserved. These are identified below as:
region 1 ( residuesl to 180, or in the case of region 1 'residues 120 to 180) region 2 ( residues360 to 480);
region 3 ( residues 660 to 720);
region 4 ( residues 817 to 900); and
region 5 ( residues 900 to 960);
In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises regions 1-5, together with sufficient additional Cas9 molecule sequence to provide a biologically active molecule, e.g., a Cas9 molecule having at least one activity described herein. In an embodiment, each of regions 1-5, independently, have 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology with the corresponding residues of a Cas9 molecule or Cas9 polypeptide described herein, e.g., a sequence from Figs. 2A-2G or from Figs. 7A- 7B.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence referred to as region 1:
having 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology with amino acids 1-180 (the numbering is according to the motif sequence in Figs. 2A-2G; 52% of residues in the four Cas9 sequences in Figs. 2A-2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes;
differs by at least 1, 2, 5, 10 or 20 amino acids but by no more than 90, 80, 70, 60, 50, 40 or 30 amino acids from amino acids 1-180 of the amino acid sequence of Cas9 of S.
pyogenes, S. thermophilus, S. mutans or Listeria innocua; or
is identical to 1-180 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or /.. innocua.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence referred to as region :
having 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology with amino acids 120-180 (55% of residues in the four Cas9 sequences in Figs. 2A-2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, .V. mutans or L. innocua;
differs by at least 1, 2, or 5 amino acids but by no more than 35, 30, 25, 20 or 10 amino acids from amino acids 120-180 of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or /.. innocua ; or
is identical to 120-180 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or /.. innocua.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence referred to as region 2:
having 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology with amino acids 360-480 (52% of residues in the four Cas9 sequences in Figs. 2A-2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or /.. innocua;
differs by at least 1, 2, or 5 amino acids but by no more than 35, 30, 25, 20 or 10 amino acids from amino acids 360-480 of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or /.. innocua; or
is identical to 360-480 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or /.. innocua.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence referred to as region 3:
having 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology with amino acids 660-720 (56% of residues in the four Cas9 sequences in Figs. 2A-2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or L. innocua;
differs by at least 1, 2, or 5 amino acids but by no more than 35, 30, 25, 20 or 10 amino acids from amino acids 660-720 of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or /.. innocua; or
is identical to 660-720 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or /.. innocua.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or easCas9 polypeptide, comprises an amino acid sequence referred to as region 4:
having 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology with amino acids 817-900 (55% of residues in the four Cas9 sequences in Figs. 2A-2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or /.. innocua;
differs by at least 1, 2, or 5 amino acids but by no more than 35, 30, 25, 20 or 10 amino acids from amino acids 817-900 of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or /.. innocua; or
is identical to 817-900 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or /.. innocua.
In an embodiment, a Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, comprises an amino acid sequence referred to as region 5:
having 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology with amino acids 900-960 (60% of residues in the four Cas9 sequences in Figs. 2A-2G are conserved) of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or /.. innocua;
differs by at least 1, 2, or 5 amino acids but by no more than 35, 30, 25, 20 or 10 amino acids from amino acids 900-960 of the amino acid sequence of Cas9 of S. pyogenes, S. thermophilus, S. mutans or /.. innocua; or
is identical to 900-960 of the amino acid sequence of Cas9 of S. pyogenes, S.
thermophilus, S. mutans or /.. innocua.
Engineered or Altered Cas9 Molecules and Cas9 Polypeptides
Cas9 molecules and Cas9 polypeptides described herein, e.g., naturally occurring Cas9 molecules can possess any of a number of properties, including: nickase activity, nuclease activity (e.g., endonuclease and/or exonuc lease activity); helicase activity; the ability to associate functionally with a gRNA molecule; and the ability to target (or localize to) a site on a nucleic acid (e.g., PAM recognition and specificity). In an embodiment, a Cas9 molecule or Cas9 polypeptide can include all or a subset of these properties. In typical embodiments, a Cas9 molecule or Cas9 polypeptide have the ability to interact with a gRNA molecule and, in concert with the gRNA molecule, localize to a site in a nucleic acid. Other activities, e.g., PAM specificity, cleavage activity, or helicase activity can vary more widely in Cas9 molecules and Cas9 polypeptides.
Cas9 molecules include engineered Cas9 molecules and engineered Cas9
polypeptides (engineered, as used in this context, means merely that the Cas9 molecule or Cas9 polypeptide differs from a reference sequences, and implies no process or origin limitation). An engineered Cas9 molecule or Cas9 polypeptide can comprise altered enzymatic properties, e.g., altered nuclease activity, (as compared with a naturally occurring or other reference Cas9 molecule) or altered helicase activity. As discussed herein, an engineered Cas9 molecule or Cas9 polypeptide can have nickase activity (as opposed to double strand nuclease activity). In an embodiment an engineered Cas9 molecule or Cas9 polypeptide can have an alteration that alters its size, e.g., a deletion of amino acid sequence that reduces its size, e.g., without significant effect on one or more, or any Cas9 activity. In an embodiment, an engineered Cas9 molecule or Cas9 polypeptide can comprise an alteration that affects PAM recognition. E.g., an engineered Cas9 molecule can be altered to recognize a PAM sequence other than that recognized by the endogenous wild- type PI domain. In an embodiment, a Cas9 molecule or Cas9 polypeptide can differ in sequence from a naturally occurring Cas9 molecule but not have significant alteration in one or more Cas9 activities.
Cas9 molecules or Cas9 polypeptides with desired properties can be made in a number of ways, e.g., by alteration of a parental, e.g., naturally occurring Cas9 molecules or Cas9 polypeptides to provide an altered Cas9 molecule or Cas9 polypeptides having a desired property. For example, one or more mutations or differences relative to a parental Cas9 molecule can be introduced. Such mutations and differences comprise: substitutions (e.g., conservative substitutions or substitutions of non-essential amino acids); insertions; or deletions. In an embodiment, a Cas9 molecule or Cas9 polypeptide can comprises one or more mutations or differences, e.g., at least 1, 2, 3, 4, 5, 10, 15, 20, 30, 40 or 50 mutations, but less than 200, 100, or 80 mutations relative to a reference, e.g., a parental, Cas9 molecule.
In an embodiment, a mutation or mutations do not have a substantial effect on a Cas9 activity, e.g. a Cas9 activity described herein. In an embodiment, a mutation or mutations have a substantial effect on a Cas9 activity, e.g. a Cas9 activity described herein.
Non-Cleaving and Modified-Cleavage Cas9 Molecules and Cas9 Polypeptides
In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises a cleavage property that differs from naturally occurring Cas9 molecules, e.g., that differs from the naturally occurring Cas9 molecule having the closest homology. For example, a Cas9 molecule or Cas9 polypeptide can differ from naturally occurring Cas9 molecules, e.g., a Cas9 molecule of S. pyogenes, as follows: its ability to modulate, e.g., decreased or increased, cleavage of a double stranded nucleic acid (endonuc lease and/or exonuclease activity), e.g., as compared to a naturally occurring Cas9 molecule (e.g., a Cas9 molecule of S. pyogenes); its ability to modulate, e.g., decreased or increased, cleavage of a single strand of a nucleic acid, e.g., a non-complementary strand of a nucleic acid molecule or a complementary strand of a nucleic acid molecule (nickase activity) , e.g., as compared to a naturally occurring Cas9 molecule (e.g., a Cas9 molecule of S. pyogenes); or the ability to cleave a nucleic acid molecule, e.g., a double stranded or single stranded nucleic acid molecule, can be eliminated.
Modified Cleavage eaCas9 Molecules and eaCas9 Polypeptides
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises one or more of the following activities: cleavage activity associated with an N-terminal RuvC-like domain; cleavage activity associated with an HNH-like domain; cleavage activity associated with an HNH-like domain and cleavage activity associated with an N-terminal RuvC-like domain.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an active, or cleavage competent, HNH-like domain (e.g., an HNH-like domain described herein, e.g., SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21) and an inactive, or cleavage incompetent, N-terminal RuvC-like domain. An exemplary inactive, or cleavage incompetent N-terminal RuvC-like domain can have a mutation of an aspartic acid in an N-terminal RuvC-like domain, e.g., an aspartic acid at position 9 of the consensus sequence disclosed in Figs. 2A-2G or an aspartic acid at position 10 of SEQ ID NO: 7, e.g., can be substituted with an alanine. In an embodiment, the eaCas9 molecule or eaCas9 polypeptide differs from wild type in the N-terminal RuvC-like domain and does not cleave the target nucleic acid, or cleaves with significantly less efficiency, e.g., less than 20, 10, 5, 1 or .1 % of the cleavage activity of a reference Cas9 molecule, e.g., as measured by an assay described herein. The reference Cas9 molecule can by a naturally occurring unmodified Cas9 molecule, e.g., a naturally occurring Cas9 molecule such as a Cas9 molecule of S.
pyogenes, or S. thermophilus. In an embodiment, the reference Cas9 molecule is the naturally occurring Cas9 molecule having the closest sequence identity or homology.
In an embodiment, an eaCas9 molecule or eaCas9 polypeptide comprises an inactive, or cleavage incompetent, HNH domain and an active, or cleavage competent, N-terminal RuvC-like domain (e.g., a RuvC-like domain described herein, e.g., SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16). Exemplary inactive, or cleavage incompetent HNH- like domains can have a mutation at one or more of: a histidine in an HNH-like domain, e.g., a histidine shown at position 856 of the consensus sequence disclosed in Figs. 2A-2G, e.g., can be substituted with an alanine; and one or more asparagines in an HNH-like domain, e.g., an asparagine shown at position 870 of the consensus sequence disclosed in Figs. 2A-2G and/or at position 879 of the consensus sequence disclosed in Figs. 2A-2G, e.g., can be substituted with an alanine. In an embodiment, the eaCas9 differs from wild type in the HNH-like domain and does not cleave the target nucleic acid, or cleaves with significantly less efficiency, e.g., less than 20, 10, 5, 1 or 0.1% of the cleavage activity of a reference Cas9 molecule, e.g., as measured by an assay described herein. The reference Cas9 molecule can by a naturally occurring unmodified Cas9 molecule, e.g., a naturally occurring Cas9 molecule such as a Cas9 molecule of S. pyogenes, or S. thermophilus. In an embodiment, the reference Cas9 molecule is the naturally occurring Cas9 molecule having the closest sequence identity or homology.
Alterations in the Ability to Cleave One or Both Strands of a Target Nucleic Acid In an embodiment, exemplary Cas9 activities comprise one or more of PAM specificity, cleavage activity, and helicase activity. A mutation(s) can be present, e.g., in one or more RuvC-like domain, e.g., an N-terminal RuvC-like domain; an HNH-like domain; a region outside the RuvC-like domains and the HNH-like domain. In some embodiments, a mutation(s) is present in a RuvC-like domain, e.g., an N-terminal RuvC-like domain. In some embodiments, a mutation(s) is present in an HNH-like domain. In some embodiments, mutations are present in both a RuvC-like domain, e.g., an N-terminal RuvC-like domain and an HNH-like domain.
Exemplary mutations that may be made in the RuvC domain or HNH domain with reference to the S. pyogenes sequence include: D10A, E762A, H840A, N854A, N863A and/or D986A.
In an embodiment, a Cas9 molecule or Cas9 polypeptide is an eiCas9 molecule or eiCas9 polypeptide comprising one or more differences in a RuvC domain and/or in an HNH domain as compared to a reference Cas9 molecule, and the eiCas9 molecule or eiCas9 polypeptide does not cleave a nucleic acid, or cleaves with significantly less efficiency than does wildype, e.g., when compared with wild type in a cleavage assay, e.g., as described herein, cuts with less than 50, 25, 10, or 1% of a reference Cas9 molecule, as measured by an assay described herein.
Whether or not a particular sequence, e.g., a substitution, may affect one or more activity, such as targeting activity, cleavage activity, etc., can be evaluated or predicted, e.g., by evaluating whether the mutation is conservative or by the method described in Section IV. In an embodiment, a "non-essential" amino acid residue, as used in the context of a Cas9 molecule, is a residue that can be altered from the wild-type sequence of a Cas9 molecule, e.g., a naturally occurring Cas9 molecule, e.g., an eaCas9 molecule, without abolishing or more preferably, without substantially altering a Cas9 activity (e.g., cleavage activity), whereas changing an "essential" amino acid residue results in a substantial loss of activity (e.g., cleavage activity).
In an embodiment, a Cas9 molecule or Cas9 polypeptide comprises a cleavage property that differs from naturally occurring Cas9 molecules, e.g., that differs from the naturally occurring Cas9 molecule having the closest homology. For example, a Cas9 molecule or Cas9 polypeptide can differ from naturally occurring Cas9 molecules, e.g., a Cas9 molecule of S aureus, S. pyogenes, or C. jejuni as follows: its ability to modulate, e.g., decreased or increased, cleavage of a double stranded break (endonuclease and/or exonuclease activity), e.g., as compared to a naturally occurring Cas9 molecule (e.g., a Cas9 molecule of S aureus, S. pyogenes, or C. jejuni); its ability to modulate, e.g., decreased or increased, cleavage of a single strand of a nucleic acid, e.g., a non-complimentary strand of a nucleic acid molecule or a complementary strand of a nucleic acid molecule (nickase activity), e.g., as compared to a naturally occurring Cas9 molecule (e.g., a Cas9 molecule of S aureus, S. pyogenes, or C. jejuni); or the ability to cleave a nucleic acid molecule, e.g., a double stranded or single stranded nucleic acid molecule, can be eliminated.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide is an eaCas9 molecule or eaCas9 polypeptide comprising one or more of the following activities: cleavage activity associated with a RuvC domain; cleavage activity associated with an HNH domain; cleavage activity associated with an HNH domain and cleavage activity associated with a RuvC domain.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide is an eiCas9 molecule or eiCas9 polypeptide which does not cleave a nucleic acid molecule (either double stranded or single stranded nucleic acid molecules) or cleaves a nucleic acid molecule with significantly less efficiency, e.g., less than 20, 10, 5, 1 or 0.1% of the cleavage activity of a reference Cas9 molecule, e.g., as measured by an assay described herein. The reference Cas9 molecule can be a naturally occurring unmodified Cas9 molecule, e.g., a naturally occurring Cas9 molecule such as a Cas9 molecule of S. pyogenes, S. thermophilus, S. aureus, C. jejuni or N. meningitidis. In an embodiment, the reference Cas9 molecule is the naturally occurring Cas9 molecule having the closest sequence identity or homology. In an embodiment, the eiCas9 molecule or eiCas9 polypeptide lacks substantial cleavage activity associated with a RuvC domain and cleavage activity associated with an ΗΝΗ domain.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide is an eaCas9 molecule or eaCas9 polypeptides comprising the fixed amino acid residues of S. pyogenes shown in the consensus sequence disclosed in Figs. 2A-2G, and has one or more amino acids that differ from the amino acid sequence of S. pyogenes (e.g., has a substitution) at one or more residue (e.g., 2, 3, 5, 10, 15, 20, 30, 50, 70, 80, 90, 100, 200 amino acid residues) represented by an "-" in the consensus sequence disclosed in Figs. 2A-2G or SEQ ID NO:7.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptides comprises a sequence in which:
the sequence corresponding to the fixed sequence of the consensus sequence disclosed in Figs. 2A-2Gdiffers at no more than 1, 2, 3, 4, 5, 10, 15, or 20% of the fixed residues in the consensus sequence disclosed in Figs. 2A-2G;
the sequence corresponding to the residues identified by "*" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, or 40% of the "*" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. pyogenes Cas9 molecule; and,
the sequence corresponding to the residues identified by "-" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 55, or 60% of the "-" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. pyogenes Cas9 molecule.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptides is an eaCas9 molecule or eaCas9 polypeptidecomprising the fixed amino acid residues of S. thermophilus shown in the consensus sequence disclosed in Figs. 2A-2G, and has one or more amino acids that differ from the amino acid sequence of S. thermophilus (e.g., has a substitution) at one or more residue (e.g., 2, 3, 5, 10, 15, 20, 30, 50, 70, 80, 90, 100, 200 amino acid residues) represented by an "-" in the consensus sequence disclosed in Figs. 2A-2G. In an
embodiment
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide comprises a sequence in which: the sequence corresponding to the fixed sequence of the consensus sequence disclosed in Figs. 2A-2G differs at no more than 1, 2, 3, 4, 5, 10, 15, or 20% of the fixed residues in the consensus sequence disclosed in Figs. 2A-2G;
the sequence corresponding to the residues identified by "*" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, or 40% of the "*" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. thermophilus Cas9 molecule; and,
the sequence corresponding to the residues identified by "-" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 55, or 60% of the "-" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. thermophilus Cas9 molecule.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide is an eaCas9 molecule or ea Cas9 polypeptide comprising the fixed amino acid residues of S. mutans shown in the consensus sequence disclosed in Figs. 2A-2G, and has one or more amino acids that differ from the amino acid sequence of S. mutans (e.g., has a substitution) at one or more residue (e.g., 2, 3, 5, 10, 15, 20, 30, 50, 70, 80, 90, 100, 200 amino acid residues) represented by an "-" in the consensus sequence disclosed in Figs. 2A-2G.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide comprises a sequence in which:
the sequence corresponding to the fixed sequence of the consensus sequence disclosed in Figs. 2A-2G differs at no more than 1, 2, 3, 4, 5, 10, 15, or 20% of the fixed residues in the consensus sequence disclosed in Figs. 2A-2G;
the sequence corresponding to the residues identified by "*" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, or 40% of the "*" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. mutans Cas9 molecule; and,
the sequence corresponding to the residues identified by "-" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 55, or 60% of the "-" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an S. mutans Cas9 molecule.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide is an eaCas9 molecule or eaCas9 polypeptide comprising the fixed amino acid residues of L. innocula shown in the consensus sequence disclosed in Figs. 2A-2G, and has one or more amino acids that differ from the amino acid sequence of L. innocula (e.g., has a substitution) at one or more residue (e.g., 2, 3, 5, 10, 15, 20, 30, 50, 70, 80, 90, 100, 200 amino acid residues) represented by an "-"in the consensus sequence disclosed in Figs. 2A-2G.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide comprises a sequence in which:
the sequence corresponding to the fixed sequence of the consensus sequence disclosed in Figs. 2A-2G differs at no more than 1, 2, 3, 4, 5, 10, 15, or 20% of the fixed residues in the consensus sequence disclosed in Figs. 2A-2G;
the sequence corresponding to the residues identified by "*" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, or 40% of the "*" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an L. innocula Cas9 molecule; and,
the sequence corresponding to the residues identified by "-" in the consensus sequence disclosed in Figs. 2A-2G differ at no more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 55, or 60% of the "-" residues from the corresponding sequence of naturally occurring Cas9 molecule, e.g., an L. innocula Cas9 molecule.
In an embodiment, the altered Cas9 molecule or Cas9 polypeptide, e.g., an eaCas9 molecule or eaCas9 polypeptide, can be a fusion, e.g., of two of more different Cas9 molecules, e.g., of two or more naturally occurring Cas9 molecules of different species. For example, a fragment of a naturally occurring Cas9 molecule of one species can be fused to a fragment of a Cas9 molecule of a second species. As an example, a fragment of a Cas9 molecule of S. pyoge es comprising an N-terminal RuvC-like domain can be fused to a fragment of a Cas9 molecule of a species other than S. pyogenes (e.g., S. thermophilus) comprising an HNH-like domain. Cas9 Molecules and Cas9 polypeptides with Altered PAM Recognition or no PAM
Recognition
Naturally occurring Cas9 molecules can recognize specific PAM sequences, for example, the PAM recognition sequences described above for S. pyogenes, S. thermophiles, S. mutans, S. aureus and N. meningitidis.
In an embodiment, a Cas9 molecule or Cas9 polypeptide has the same PAM specificities as a naturally occurring Cas9 molecule. In other embodiments, a Cas9 molecule or Cas9 polypeptide has a PAM specificity not associated with a naturally occurring Cas9 molecule, or a PAM specificity not associated with the naturally occurring Cas9 molecule to which it has the closest sequence homology. For example, a naturally occurring Cas9 molecule or Cas9 polypeptide can be altered, e.g., to alter PAM recognition, e.g., to alter the PAM sequence that the Cas9 molecule recognizes to decrease off target sites and/or improve specificity; or eliminate a PAM recognition requirement. In an embodiment, a Cas9 molecule or Cas9 polypeptide can be altered, e.g., to increase length of PAM recognition sequence and/or improve Cas9 specificity to high level of identity (e.g., 98%, 99% or 100% match between gRNA and a PAM sequence), e.g., to decrease off target sites and increase specificity. In an embodiment, the length of the PAM recognition sequence is at least 4, 5, 6, 7, 8, 9, 10 or 15 amino acids in length. In an embodiment, the Cas9 specificity requires at least 90%, 95%, 96%, 97%, 98%, 99% or more homology between the gRNA and the PAM sequence. Cas9 molecules or Cas9 polypeptide that recognize different PAM sequences and/or have reduced off-target activity can be generated using directed evolution. Exemplary methods and systems that can be used for directed evolution of Cas9 molecules are described, e.g., in Esvelt et al. NATURE 2011, 472(7344): 499-503. Candidate Cas9 molecules can be evaluated, e.g., by methods described in Section IV.
Alterations of the PI domain, which mediates PAM recognition, are discussed below.
Synthetic Cas9 Molecules and Cas9 Polypeptides with Altered PI Domains
Current genome-editing methods are limited in the diversity of target sequences that can be targeted by the PAM sequence that is recognized by the Cas9 molecule utilized. A synthetic Cas9 molecule (or Syn-Cas9 molecule), or synthetic Cas9 polypeptide (or Syn-Cas9 polypeptide), as that term is used herein, refers to a Cas9 molecule or Cas9 polypeptide that comprises a Cas9 core domain from one bacterial species and a functional altered PI domain, i.e., a PI domain other than that naturally associated with the Cas9 core domain, e.g., from a different bacterial species.
In an embodiment, the altered PI domain recognizes a PAM sequence that is different from the PAM sequence recognized by the naturally-occurring Cas9 from which the Cas9 core domain is derived. In an embodiment, the altered PI domain recognizes the same PAM sequence recognized by the naturally-occurring Cas9 from which the Cas9 core domain is derived, but with different affinity or specificity. A Syn-Cas9 molecule or Syn-Cas9 polypetide can be, respectively, a Syn-eaCas9 molecule or Syn-eaCas9 polypeptide or a Syn- eiCas9 molecule Syn-eiCas9 polypeptide.
An exemplary Syn-Cas9 molecule or Syn-Cas9 polypetide comprises:
a) a Cas9 core domain, e.g., a Cas9 core domain from Table 17 or 18, e.g., a S.
aureus, S. pyogenes, or C. jejuni Cas9 core domain; and b) an altered PI domain from a species X Cas9 sequence selected from Tables 20 and
21.
In an embodiment, the RKR motif (the PAM binding motif) of said altered PI domain comprises: differences at 1, 2, or 3 amino acid residues; a difference in amino acid sequence at the first, second, or third position; differences in amino acid sequence at the first and second positions, the first and third positions, or the second and third positions; as compared with the sequence of the RKR motif of the native or endogenous PI domain associated with the Cas9 core domain.
In an embodiment, the Cas9 core domain comprises the Cas9 core domain from a species X Cas9 from Table 17 and said altered PI domain comprises a PI domain from a species Y Cas9 from Table 17.
In an embodiment, the RKR motif of the species X Cas9 is other than the RKR motif of the species Y Cas9.
In an embodiment, the RKR motif of the altered PI domain is selected from XXY, XNG, and XNQ.
In an embodiment, the altered PI domain has at least 60, 70, 80, 90, 95, or 100% homology with the amino acid sequence of a naturally occurring PI domain of said species Y from Table 17.
In an embodiment, the altered PI domain differs by no more than 50, 40, 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1 amino acid residue from the amino acid sequence of a naturally occurring PI domain of said second species from Table 17.
In an embodiment, the Cas9 core domain comprises a S. aureus core domain and altered PI domain comprises: an A. denitrificans PI domain; a C. jejuni PI domain; a H. mustelae PI domain; or an altered PI domain of species X PI domain, wherein species X is selected from Table 21.
In an embodiment, the Cas9 core domain comprises a S. pyogenes core domain and the altered PI domain comprises: an A. denitrificans PI domain; a C. jejuni PI domain; a H. mustelae PI domain; or an altered PI domain of species X PI domain, wherein species X is selected from Table 21.
In an embodiment, the Cas9 core domain comprises a C. jejuni core domain and the altered PI domain comprises: an A. denitrificans PI domain; a H. mustelae PI domain; or an altered PI domain of species X PI domain, wherein species X is selected from Table 21.
In an embodiment, the Cas9 molecule or Cas9 polypeptide further comprises a linker disposed between said Cas9 core domain and said altered PI domain. In an embodiment, the linker comprises: a linker described elsewhere herein disposed between the Cas9 core domain and the heterologous PI domain. Suitable linkers are further described in Section V.
Exemplary altered PI domains for use in Syn-Cas9 molecules are described in Tables 20 and 21. The sequences for the 83 Cas9 orthologs referenced in Tables 20 and 21 are provided in Table 17. Table 19 provides the Cas9 orthologs with known PAM sequences and the corresponding RKR motif.
In an embodiment, a Syn-Cas9 molecule or Syn-Cas9 polypeptide may also be size- optimized, e.g., the Syn-Cas9 molecule or Syn-Cas9 polypeptide comprises one or more deletions, and optionally one or more linkers disposed between the amino acid residues flanking the deletions. In an embodiment, a Syn-Cas9 molecule or Syn-Cas9 polypeptide comprises a REC deletion.
Size- Optimized Cas9 Molecules and Cas9 Polypeptides
Engineered Cas9 molecules and engineered Cas9 polypeptides described herein include a Cas9 molecule or Cas9 polypeptide comprising a deletion that reduces the size of the molecule while still retaining desired Cas9 properties, e.g., essentially native
conformation, Cas9 nuclease activity, and/or target nucleic acid molecule recognition.
Provided herein are Cas9 molecules or Cas9 polypeptides comprising one or more deletions and optionally one or more linkers, wherein a linker is disposed between the amino acid residues that flank the deletion. Methods for identifying suitable deletions in a reference Cas9 molecule, methods for generating Cas9 molecules with a deletion and a linker, and methods for using such Cas9 molecules will be apparent to one of ordinary skill in the art upon review of this document.
A Cas9 molecule, e.g., a S. aureus, S. pyogenes, or C. jejuni, Cas9 molecule, having a deletion is smaller, e.g., has reduced number of amino acids, than the corresponding naturally-occurring Cas9 molecule. The smaller size of the Cas9 molecules allows increased flexibility for delivery methods, and thereby increases utility for genome-editing. A Cas9 molecule or Cas9 polypeptide can comprise one or more deletions that do not substantially affect or decrease the activity of the resultant Cas9 molecules or Cas9 polypeptides described herein. Activities that are retained in the Cas9 molecules or Cas9 polypeptides comprising a deletion as described herein include one or more of the following:
a nickase activity, i.e., the ability to cleave a single strand, e.g., the non- complementary strand or the complementary strand, of a nucleic acid molecule; a double stranded nuclease activity, i.e., the ability to cleave both strands of a double stranded nucleic acid and create a double stranded break, which in an embodiment is the presence of two nickase activities;
an endonuclease activity;
an exonuclease activity;
a helicase activity, i.e., the ability to unwind the helical structure of a double stranded nucleic acid;
and recognition activity of a nucleic acid molecule, e.g., a target nucleic acid or a gRNA.
Activity of the Cas9 molecules or Cas9 polypeptides described herein can be assessed using the activity assays described herein or in the art.
Identifying regions suitable for deletion
Suitable regions of Cas9 molecules for deletion can be identified by a variety of methods. Naturally-occurring orthologous Cas9 molecules from various bacterial species, e.g., any one of those listed in Table 17, can be modeled onto the crystal structure of S. pyogenes Cas9 (Nishimasu et al., Cell, 156:935-949, 2014) to examine the level of conservation across the selected Cas9 orthologs with respect to the three-dimensional conformation of the protein. Less conserved or unconserved regions that are spatially located distant from regions involved in Cas9 activity, e.g., interface with the target nucleic acid molecule and/or gRNA, represent regions or domains are candidates for deletion without substantially affecting or decreasing Cas9 activity.
REC-Optimized Cas9 Molecules and Cas9 Polypeptides
A REC-optimized Cas9 molecule, or a REC-optimized Cas9 polypeptide, as that term is used herein, refers to a Cas9 molecule or Cas9 polypeptide that comprises a deletion in one or both of the REC2 domain and the REICT domain (collectively a REC deletion), wherein the deletion comprises at least 10% of the amino acid residues in the cognate domain. A REC-optimized Cas9 molecule or Cas9 polypeptide can be an eaCas9 molecule or eaCas9 polypetide, or an eiCas9 molecule or eiCas9 polypeptide. An exemplary REC-optimized Cas9 molecule or REC-optimized Cas9 polypeptide comprises:
a) a deletion selected from:
i) a REC2 deletion;
ii) a RECICT deletion; or iii) a REC 1 SUB deletion.
Optionally, a linker is disposed between the amino acid residues that flank the deletion. In an embodiment, a Cas9 molecule or Cas9 polypeptide includes only one deletion, or only two deletions. A Cas9 molecule or Cas9 polypeptide can comprise a REC2 deletion and a REClcr deletion. A Cas9 molecule or Cas9 polypeptide can comprise a REC2 deletion and a REC 1 SUB deletion.
Generally, the deletion will contain at least 10% of the amino acids in the cognate domain, e.g., a REC2 deletion will include at least 10% of the amino acids in the REC2 domain. A deletion can comprise: at least 10, 20, 30, 40, 50, 60, 70, 80, or 90% of the amino acid residues of its cognate domain; all of the amino acid residues of its cognate domain; an amino acid residue outside its cognate domain; a plurality of amino acid residues outside its cognate domain; the amino acid residue immediately N terminal to its cognate domain; the amino acid residue immediately C terminal to its cognate domain; the amino acid residue immediately N terminal to its cognate and the amino acid residue immediately C terminal to its cognate domain; a plurality of, e.g., up to 5, 10, 15, or 20, amino acid residues N terminal to its cognate domain; a plurality of, e.g., up to 5, 10, 15, or 20, amino acid residues C terminal to its cognate domain; a plurality of, e.g., up to 5, 10, 15, or 20, amino acid residues N terminal to to its cognate domain and a plurality of e.g., up to 5, 10, 15, or 20, amino acid residues C terminal to its cognate domain.
In an embodiment, a deletion does not extend beyond: its cognate domain; the N terminal amino acid residue of its cognate domain; the C terminal amino acid residue of its cognate domain.
A REC-optimized Cas9 molecule or REC-optimized Cas9 polypeptide can include a linker disposed between the amino acid residues that flank the deletion. Any linkers known in the art that maintain the conformation or native fold of the Cas9 molecule (thereby retaining Cas9 activity) can be used between the amino acid resides that flank a REC deletion in a REC-optimized Cas9 molecule or REC-optimized Cas9 polypeptide. Linkers for use in generating recombinant proteins, e.g., multi-domain proteins, are known in the art (Chen et al., Adv Drug Delivery Rev, 65: 1357-69, 2013).
In an embodiment, a REC-optimized Cas9 molecule or REC-optimized Cas9 polypeptide comprises an amino acid sequence that, other than any REC deletion and associated linker, has at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, or 100% homology with the amino acid sequence of a naturally occurring Cas 9, e.g., a Cas9 molecule described in Table 17, e.g., a S. aureus Cas9 molecule, a S. pyogenes Cas9 molecule, or a C. jejuni Cas9 molecule.
In an embodiment, a a REC-optimized Cas9 molecule or REC-optimized Cas9 polypeptide comprises an amino acid sequence that, other than any REC deletion and associated linker, differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25, amino acid residues from the amino acid sequence of a naturally occurring Cas 9, e.g., a Cas9 molecule described in Table 17, e.g., a S. aureus Cas9 molecule, a S. pyogenes Cas9 molecule, or a C. jejuni Cas9 molecule.
In an embodiment, a REC-optimized Cas9 molecule or REC-optimized Cas9 polypeptide comprises an amino acid sequence that, other than any REC deletion and associate linker, differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25% of the, amino acid residues from the amino acid sequence of a naturally occurring Cas 9, e.g., a Cas9 molecule described in Table 17, e.g., a S. aureus Cas9 molecule, a S. pyogenes Cas9 molecule, or a C. jejuni Cas9 molecule.
For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman, (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics
Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Brent et al., (2003) Current Protocols in Molecular Biology).
Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402; and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller, (1988) Comput. Appl. Biosci. 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (1970) J. Mol. Biol. 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
Sequence information for exemplary REC deletions are provided for 83 naturally- occurring Cas9 orthologs in Table 17.
The amino acid sequences of exemplary Cas9 molecules from different bacterial species are shown below.
Table 17. Amino Acid Sequence of Cas9 Orthologs
Figure imgf000737_0001
17330 312
gil366983953lgblEHN59352.11
Fructobacillus fructosus KCTC SEQ ID NO: 168 314 147 488 571 76 488 571 76
3544 313
gil339625081lreflZP_08660870.
1
Catenibacterium mitsuokai SEQ ID NO: 173 318 146 511 594 78 511 594 78 DSM 15897 314
gil224543312lreflZP_03683851.
1
Finegoldia magna ATCC 29328 SEQ ID NO: 168 313 146 452 534 77 452 534 77 gill69823755lreflYP_00169136 315
6.1
CoriobacteriumglomeransPW2 SEQ ID NO: 175 318 144 511 592 82 511 592 82 gil328956315lreflYP_00437364 316
8.1
Eubacterium yurii ATCC 43715 SEQ ID NO: 169 310 142 552 633 76 552 633 76 gil306821691 lreflZP_07455288. 317
1
Peptoniphilus duerdenii ATCC SEQ ID NO: 171 311 141 535 615 76 535 615 76
BAA- 1640 318
gil304438954lreflZP_07398877.
1
Acidaminococcus sp. D21 SEQ ID NO: 167 306 140 511 591 75 511 591 75 gil227824983lreflZP_03989815. 319
1
Lactobacillus farciminis KCTC SEQ ID NO: 171 310 140 542 621 85 542 621 85
3681 320
gil336394882lreflZP_08576281.
1
Streptococcus sanguinis SK49 SEQ ID NO: 185 324 140 411 490 85 411 490 85 gil422884106lreflZP_16930555. 321
1
Coprococcus catus GD-7 SEQ ID NO: 172 310 139 556 634 76 556 634 76 gil291520705lemblCBK78998.1 322
1
Streptococcus mutans UA159 SEQ ID NO: 176 314 139 392 470 84 392 470 84 gil24379809lreflNP_721764.1l 323
Streptococcus pyogenes Ml SEQ ID NO: 176 314 139 523 600 82 523 600 82 GAS 324
gill3622193lgblAAK33936.1l
Streptococcus thermophilus SEQ ID NO: 176 314 139 481 558 81 481 558 81 LMD-9 325
gil 116628213 Irefl YP_820832.11
Fusobacteriumnucleatum SEQ ID NO: 171 308 138 537 614 76 537 614 76 ATCC49256 326
gil34762592lreflZP_00143587.1
1
Planococcus antarcticus DSM SEQ ID NO: 162 299 138 538 614 94 538 614 94
14505 327
gil389815359lreflZP_10206685.
1
Treponema denticola ATCC SEQ ID NO: 169 305 137 524 600 81 524 600 81 35405 328
gil42525843lref INP_970941.11
Solobacterium moorei F0204 SEQ ID NO: 179 314 136 544 619 77 544 619 77
329 gil320528778lreflZP_08029929.
1
Staphylococcus SEQ ID NO: 164 299 136 531 606 92 531 606 92 pseudintermedius ED99 330
gil323463801lgblADX75954.1l
Flavobacterium branchiophilum SEQ ID NO: 162 286 125 538 613 63 538 613 63
FL-15 331
gil347536497lreflYP_00484392
2.1
Ignavibacterium album JCM SEQ ID NO: 223 329 107 357 432 90 357 432 90 16511 332
gil385811609lrellYP_00584800
5.1
Bergeyella zoohelcum ATCC SEQ ID NO: 165 261 97 529 604 56 529 604 56
43767 333
gil423317190lreflZP_17295095.
1
Nitrobacter hamburgensis X14 SEQ ID NO: 169 253 85 536 611 48 536 611 48 gil92109262lreflYP_571550.1l 334
Odoribacter laneus YIT 12061 SEQ ID NO: 164 242 79 535 610 63 535 610 63 gil374384763lreflZP_09642280. 335
1
Legionella pneumophila str. SEQ ID NO: 164 239 76 402 476 67 402 476 67
Paris 336
gil54296138lreflYP_122507.1l
Bacteroides sp. 20 3 SEQ ID NO: 198 269 72 530 604 83 530 604 83 gil301311869lrellZP_07217791. 337
1
Akkermansia muciniphila SEQ ID NO: 136 202 67 348 418 62 348 418 62 ATCC BAA-835 338
gill87736489lreflYP_00187860
1.
Prevotella sp. C561 SEQ ID NO: 184 250 67 357 425 78 357 425 78 gil345885718lrellZP_08837074. 339
1
Wolinella succinogenes DSM SEQ ID NO: 157 218 36 401 468 60 401 468 60
1740 340
gil34557932lreflNP_907747.1l
Alicyclobacillus hesperidum SEQ ID NO: 142 196 55 416 482 61 416 482 61 U H17-3-68 341
gil403744858lreflZP_10953934.
1
Caenispirillum salinarum AK4 SEQ ID NO: 161 214 54 330 393 68 330 393 68 gil427429481 lreflZP_l 8919511. 342
1
Eubacterium rectale ATCC SEQ ID NO: 133 185 53 322 384 60 322 384 60 33656 343
gil238924075lrellYP_00293759
1.1
Mycoplasma synoviae 53 SEQ ID NO: 187 239 53 319 381 80 319 381 80 gil71894592lref 1 YP_278700.11 344
Porphyromonas sp. oral taxon SEQ ID NO: 150 202 53 309 371 60 309 371 60
279 str. F0450 345
gil402847315lrellZP_10895610.
1
Streptococcus thermophilus SEQ ID NO: 127 178 139 424 486 81 424 486 81 LMD-9 346
gil 116627542lrell YP_820161.11 oseburia inulinivorans DSM SEQ ID NO: 154 204 51 318 380 69 318 380 69 16841 347
gil225377804lreflZP_03755025.
1
Methylosinus trichosporium SEQ ID NO: 144 193 50 426 488 64 426 488 64 OB 3b 348
gil296446027lreflZP_06887976.
1
Ruminococcus albus 8 SEQ ID NO: 139 187 49 351 412 55 351 412 55 gil325677756lreflZP_08157403. 349
1
Bifidobacterium longum SEQ ID NO: 183 230 48 370 431 44 370 431 44 DJO10A 350
gill89440764lreflYP_00195584
5.
Enterococcus faecalis TX0012 SEQ ID NO: 123 170 48 327 387 60 327 387 60 gil315149830lgblEFT93846.11 351
Mycoplasma mobile 163K SEQ ID NO: 179 226 48 314 374 79 314 374 79 gil47458868lreflYP_015730.1l 352
Actinomyces coleocanis DSM SEQ ID NO: 147 193 47 358 418 40 358 418 40
15436 353
gil227494853lreflZP_03925169.
1
Dinoroseobacter shibae DFL 12 SEQ ID NO: 138 184 47 338 398 48 338 398 48 gil 159042956lrefl YP_00153175 354
0.1
Actinomyces sp. oral taxon 180 SEQ ID NO: 183 228 46 349 409 40 349 409 40 str. F0310 355
gil315605738lreflZP_07880770.
1
Alcanivorax sp. Wl l-5 SEQ ID NO: 139 183 45 344 404 61 344 404 61 gil407803669lreflZP_l 1150502. 356
1
Aminomonas paucivorans DSM SEQ ID NO: 134 178 45 341 401 63 341 401 63
12260 357
gil312879015lreflZP_07738815.
1
Mycoplasma canis PG 14 SEQ ID NO: 139 183 45 319 379 76 319 379 76 gil384393286lgblEIE39736.11 358
Lactobacillus coryniformis SEQ ID NO: 141 184 44 328 387 61 328 387 61 KCTC 3535 359
gil336393381lreflZP_08574780.
1
Elusimicrobium minutum SEQ ID NO: 177 219 43 322 381 47 322 381 47 Peil91 360
gill87250660lreflYP_00187514
2.1
Neisseria meningitidis Z2491 SEQ ID NO: 147 189 43 360 419 61 360 419 61 gil218767588lreflYP_00234210 361
0.1
Pasteurella multocida str. Pm70 SEQ ID NO: 139 181 43 319 378 61 319 378 61 gil 15602992lref INP_246064.11 362
Rhodovulum sp. PH10 SEQ ID NO: 141 183 43 319 378 48 319 378 48 gil402849997lreflZP_10898214. 363
1
Eubacterium dolichum DSM SEQ ID NO: 131 172 42 303 361 59 303 361 59
3991 364 gil 160915782lreflZP_02077990.
1
Nitratifractor salsuginis DSM SEQ ID NO: 143 184 42 347 404 61 347 404 61
16511 365
gil319957206lreflYP_00416846
9.1
Rhodospirillum rubrum ATCC SEQ ID NO: 139 180 42 314 371 55 314 371 55
11170 366
gil83591793lref 1 YP_425545.11
Clostridium cellulolyticum H10 SEQ ID NO: 137 176 40 320 376 61 320 376 61 gil220930482lreflYP_00250739 367
1.1
Helicobacter mustelae 12198 SEQ ID NO: 148 187 40 298 354 48 298 354 48 gil291276265lrellYP_00351603 368
7.1
Ilyobacter polytropus DSM SEQ ID NO: 134 173 40 462 517 63 462 517 63 2926 369
gil310780384lrellYP_00396871
6.1
Sphaerochaeta globus str. SEQ ID NO: 163 202 40 335 389 45 335 389 45 Buddy 370
gil325972003lrellYP_00424819
4.1
Staphylococcus lugdunensis SEQ ID NO: 128 167 40 337 391 57 337 391 57 M23590 371
gil315659848lrellZP_07912707.
1
Treponema sp. JC4 SEQ ID NO: 144 183 40 328 382 63 328 382 63 gil384109266lrellZP_10010146. 372
1
uncultured delta SEQ ID NO: 154 193 40 313 365 55 313 365 55 proteobacterium HF0070 373
07E19
gil297182908lgblADI19058.1 l
Alicycliphilus denitrificans SEQ ID NO: 140 178 39 317 366 48 317 366 48 K601 374
gil330822845lreflYP_00438614
8.1
Azospirillum sp. B510 SEQ ID NO: 205 243 39 342 389 46 342 389 46 gil288957741lreflYP_00344808 375
2.1
Bradyrhizobium sp. BTAil SEQ ID NO: 143 181 39 323 370 48 323 370 48 gill48255343lreflYP_00123992 376
8.1
Parvibaculum lavamentivorans SEQ ID NO: 138 176 39 327 374 58 327 374 58
DS-1 377
gill54250555lreflYP_00141137
9.1
Prevotella timonensis CRIS 5C- SEQ ID NO: 170 208 39 328 375 61 328 375 61
B l 378
gil282880052lreflZP_06288774.
1
Bacillus smithii 7 3 47FAA SEQ ID NO: 134 171 38 401 448 63 401 448 63 gil365156657lrellZP_09352959. 379
1
Cand. Puniceispirillum SEQ ID NO: 135 172 38 344 391 53 344 391 53 marinum IMCC1322 380
gil294086111lreflYP_00355287
1.1 Barnesiella intestinihominis SEQ ID NO: 140 176 37 371 417 60 371 417 60 YIT 11860 381
gil404487228lreflZP_l 1022414.
1
alstonia syzygii R24 SEQ ID NO: 140 176 37 395 440 50 395 440 50 gil344171927lemblCCA84553.1 382
1
Wolinella succinogenes DSM SEQ ID NO: 145 180 36 348 392 60 348 392 60
1740 383
gil34557790lref INP_907605.11
Mycoplasma gallisepticum str. SEQ ID NO: 144 177 34 373 416 71 373 416 71
F 384
gil284931710lgblADC31648.1l
Acidothermus cellulolyticus SEQ ID NO: 150 182 33 341 380 58 341 380 58
11B 385
gil 117929158lreflYP_873709.11
Mycoplasma ovipneumoniae SEQ ID NO: 156 184 29 381 420 62 381 420 62
SCOl 386
gil363542550lreflZP_09312133.
1
Table 18. Amino Acid Sequence of Cas9 Core Domains
Figure imgf000742_0001
Table 19. Identified PAM sequences and corresponding RKR motifs.
Figure imgf000742_0002
PI domains are provided in Tables 20 and 21. Table 20. Altered PI Domains
Figure imgf000743_0001
Table 21. Other Altered PI Domains
Figure imgf000743_0002
Actinomyces sp. oral taxon 180 str. F0310 895 1181 287 KEK
Treponema sp. JC4 832 1062 231 KIS
Fusobacteriumnucleatum ATCC49256 1073 1374 302 KKV
Lactobacillus farciminis KCTC 3681 1101 1356 256 KKV
Nitratifractor salsuginis DSM 16511 840 1132 293 KMR
Lactobacillus coryniformis KCTC 3535 850 1119 270 KNK
Mycoplasma mobile 163K 916 1236 321 KNY
Flavobacterium branchiophilum FL-15 1182 1473 292 KQK
Prevotella timonensis CRIS 5C-B1 957 1218 262 KQQ
Methylosinus trichosporium OB 3b 830 1082 253 KRP
Prevotella sp. C561 1099 1424 326 KRY
Mycoplasma gallisepticum str. F 911 1269 359 KTA
Lactobacillus rhamnosus GG 1077 1363 287 KYG
Wolinella succinogenes DSM 1740 811 1059 249 LPN
Streptococcus thermophilus LMD-9 1099 1388 290 MLA
Treponema denticola ATCC 35405 1092 1395 304 NDS
Bergeyella zoohelcum ATCC 43767 1098 1415 318 NEK
Veillonella atypica ACS-134-V-Col7a 1107 1398 292 NGF
Neisseria meningitidis Z2491 835 1082 248 NHN
Ignavibacterium album JCM 16511 1296 1688 393 NKK
Ruminococcus albus 8 853 1156 304 NNF
Streptococcus thermophilus LMD-9 811 1121 311 NNK
Barnesiella intestinihominis YIT 11860 871 1153 283 NPV
Azospirillum sp. B510 911 1168 258 PFH
Rhodospirillum rubrum ATCC 11170 863 1173 311 PRG
Planococcus antarcticus DSM 14505 1087 1333 247 PYY
Staphylococcus pseudintermedius ED99 1073 1334 262 QIV
Alcanivorax sp. Wll-5 843 1113 271 RIE
Bradyrhizobium sp. BTAil 811 1064 254 RIY
Streptococcus pyogenes M 1 GAS 1099 1368 270 RKR
Streptococcus mutans UA159 1078 1345 268 RKR
Streptococcus Pyogenes 1099 1368 270 RKR
Bacteroides sp. 20 3 1147 1517 371 RNI
S. aureus 772 1053 282 RNK
Solobacterium moorei F0204 1062 1327 266 RSG
Finegoldia magna ATCC 29328 1081 1348 268 RTE uncultured delta proteobacterium HF0070 07E19 770 1011 242 SGG
Acidaminococcus sp. D21 1064 1358 295 SIG
Eubacterium rectale ATCC 33656 824 1114 291 SKK
Caenispirillum salinarum AK4 1048 1442 395 SLV
Acidothermus cellulolyticus 1 IB 830 1138 309 SPS
Catenibacterium mitsuokai DSM 15897 1068 1329 262 SPT Parvibaculum lavamentivorans DS-1 827 1037 211 TGN
Staphylococcus lugdunensis M23590 772 1054 283 TKK
Streptococcus sanguinis SK49 1123 1421 299 TRM
Elusimicrobium minutum Peil91 910 1195 286 TTG
Nitrobacter hamburgensis X14 914 1166 253 VAY
Mycoplasma synoviae 53 991 1314 324 VGF
Sphaerochaeta globus str. Buddy 877 1179 303 VKG
Ilyobacter polytropus DSM 2926 837 1092 256 VNG
Rhodovulum sp. PH10 821 1059 239 VPY
Bifidobacterium longum DJO10A 904 1187 284 VRK
Amino acid sequences described in Table 17:
SEQ ID NO: 304
MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRH RIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEV EEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKV QKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVK YAYNADLYNALNDLNNLVITRDENEKLEYYEKFQI IENVFKQKKKPTLKQIAKEILVNEEDI KGYRVTSTGKPEFTNLKVYHDIKDITARKEI IENAELLDQIAKILTIYQSSEDIQEELTNLN SELTQEEIEQISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQK EIPTTLVDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQK RNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHI IPRSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKISYETFKKHILNLAKGKGRISK TKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKSINGGFTS FLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEI ETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLN GLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKY SKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKWKLSLKPYRFDVYLDNGVYKFVTVKN LDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRI EVNMIDITYREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG
SEQ ID NO: 305
MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEAT RLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFI QLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGL TPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNT EITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEF YKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLK DNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRK VTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIV LTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDF LKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKW DELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSD NVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKH VAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLAN GEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNS DKLIARKKDWDPKKYGGFDSPTVAYSVLWAKVEKGKSKKLKSVKELLGITIMERSSFEKNP IDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI REQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQ LGGD
SEQ ID NO: 306
MARILAFDIGI SSIGWAFSENDELKDCGVRIFTKVENPKTGESLALPRRLARSARKRLARRK ARLNHLKHLIANEFKLNYEDYQSFDESLAKAYKGSLISPYELRFRALNELLSKQDFARVILH IAKRRGYDDIKNSDDKEKGAILKAIKQNEEKLANYQSVGEYLYKEYFQKFKENSKEFTNVRN KKESYERCIAQSFLKDELKLIFKKQREFGFSFSKKFEEEVLSVAFYKRALKDFSHLVGNCSF FTDEKRAPKNSPLAFMFVALTRI INLLNNLKNTEGILYTKDDLNALLNEVLKNGTLTYKQTK KLLGLSDDYEFKGEKGTYFIEFKKYKEFIKALGEHNLSQDDLNEIAKDITLIKDEIKLKKAL AKYDLNQNQIDSLSKLEFKDHLNISFKALKLVTPLMLEGKKYDEACNELNLKVAINEDKKDF LPAFNETYYKDEVTNPWLRAIKEYRKVLNALLKKYGKVHKINIELAREVGKNHSQRAKIEK EQNENYKAKKDAELECEKLGLKINSKNILKLRLFKEQKEFCAYSGEKIKISDLQDEKMLEID HIYPYSRSFDDSYMNKVLVFTKQNQEKLNQTPFEAFGNDSAKWQKIEVLAKNLPTKKQKRIL DKNYKDKEQKNFKDRNLNDTRYIARLVLNYTKDYLDFLPLSDDENTKLNDTQKGSKVHVEAK SGMLTSALRHTWGFSAKDRNNHLHHAIDAVI IAYANNSIVKAFSDFKKEQESNSAELYAKKI SELDYKNKRKFFEPFSGFRQKVLDKIDEIFVSKPERKKPSGALHEETFRKEEEFYQSYGGKE GVLKALELGKIRKVNGKIVKNGDMFRVDIFKHKKTNKFYAVPIYTMDFALKVLPNKAVARSK KGEIKDWILMDENYEFCFSLYKDSLILIQTKDMQEPEFVYYNAFTSSTVSLIVSKHDNKFET LSKNQKILFKNANEKEVIAKSIGIQNLKVFEKYIVSALGEVTKAEFRQREDFKK
SEQ ID NO: 307
MKRILGLDLGTNSIGWALVNEAENKDERSSIVKLGVRVNPLTVDELTNFEKGKSITTNADRT LKRGMRRNLQRYKLRRETLTEVLKEHKLITEDTILSENGNRTTFETYRLRAKAVTEEISLEE FARVLLMINKKRGYKSSRKAKGVEEGTLIDGMDIARELYNNNLTPGELCLQLLDAGKKFLPD FYRSDLQNELDRIWEKQKEYYPEILTDVLKEELRGKKRDAVWAICAKYFVWKENYTEWNKEK GKTEQQEREHKLEGIYSKRKRDEAKRENLQWRVNGLKEKLSLEQLVIVFQEMNTQINNSSGY LGAISDRSKELYFNKQTVGQYQMEMLDKNPNASLRNMVFYRQDYLDEFNMLWEKQAVYHKEL TEELKKEIRDI IIFYQRRLKSQKGLIGFCEFESRQIEVDIDGKKKIKTVGNRVISRSSPLFQ EFKIWQILNNIEVTVVGKKRKRRKLKENYSALFEELNDAEQLELNGSRRLCQEEKELLAQEL FIRDKMTKSEVLKLLFDNPQELDLNFKTIDGNKTGYALFQAYSKMIEMSGHEPVDFKKPVEK WEYIKAVFDLLNWNTDILGFNSNEELDNQPYYKLWHLLYSFEGDNTPTGNGRLIQKMTELY GFEKEYATILANVSFQDDYGSLSAKAIHKILPHLKEGNRYDVACVYAGYRHSESSLTREEIA NKVLKDRLMLLPKNSLHNPWEKILNQMVNVINVI IDIYGKPDEIRVELARELKKNAKEREE LTKSIAQTTKAHEEYKTLLQTEFGLTNVSRTDILRYKLYKELESCGYKTLYSNTYISREKLF SKEFDIEHIIPQARLFDDSFSNKTLEARSVNIEKGNKTAYDFVKEKFGESGADNSLEHYLNN IEDLFKSGKISKTKYNKLKMAEQDIPDGFIERDLRNTQYIAKKALSMLNEISHRVVATSGSV TDKLREDWQLIDVMKELNWEKYKALGLVEYFEDRDGRQIGRIKDWTKRNDHRHHAMDALTVA FTKDVFIQYFNNKNASLDPNANEHAIKNKYFQNGRAIAPMPLREFRAEAKKHLENTLISIKA KNKVITGNINKTRKKGGVNKNMQQTPRGQLHLETIYGSGKQYLTKEEKVNASFDMRKIGTVS KSAYRDALLKRLYENDNDPKKAFAGKNSLDKQPIWLDKEQMRKVPEKVKIVTLEAIYTIRKE ISPDLKVDKVIDVGVRKILIDRLNEYGNDAKKAFSNLDKNPIWLNKEKGISIKRVTISGISN AQSLHVKKDKDGKPILDENGRNIPVDFVNTGNNHHVAVYYRPVIDKRGQLVVDEAGNPKYEL EEVWSFFEAVTRANLGLPIIDKDYKTTEGWQFLFSMKQNEYFVFPNEKTGFNPKEIDLLDV ENYGLISPNLFRVQKFSLKNYVFRHHLETTIKDTSSILRGITWIDFRSSKGLDTIVKVRVNH IGQIVSVGEY SEQ ID NO: 308
MSRKNYVDDYAISLDIGNASVGWSAFTPNYRLVRAKGHELIGVRLFDPADTAESRRMARTTR RRYSRRRWRLRLLDALFDQALSEIDPSFLARRKYSWVHPDDENNADCWYGSVLFDSNEQDKR FYEKYPTIYHLRKALMEDDSQHDIREIYLAIHHMVKYRGNFLVEGTLESSNAFKEDELLKLL GRITRYEMSEGEQNSDIEQDDENKLVAPANGQLADALCATRGSRSMRVDNALEALSAVNDLS REQRAIVKAIFAGLEGNKLDLAKIFVSKEFSSENKKILGIYFNKSDYEEKCVQIVDSGLLDD EEREFLDRMQGQYNAIALKQLLGRSTSVSDSKCASYDAHRANWNLIKLQLRTKENEKDINEN YGILVGWKIDSGQRKSVRGESAYENMRKKANVFFKKMIETSDLSETDKNRLIHDIEEDKLFP IQRDSDNGVIPHQLHQNELKQIIKKQGKYYPFLLDAFEKDGKQINKIEGLLTFRVPYFVGPL WPEDLQKSDNSENHWMVRKKKGEITPWNFDEMVDKDASGRKFIERLVGTDSYLLGEPTLPK NSLLYQEYEVLNELNNVRLSVRTGNHWNDKRRMRLGREEKTLLCQRLFMKGQTVTKRTAENL LRKEYGRTYELSGLSDESKFTSSLSTYGKMCRIFGEKYVNEHRDLMEKIVELQTVFEDKETL LHQLRQLEGISEADCALLVNTHYTGWGRLSRKLLTTKAGECKISDDFAPRKHSIIEIMRAED RNLMEIITDKQLGFSDWIEQENLGAENGSSLMEWDDLRVSPKVKRGIIQSIRLIDDISKAV GKRPSRIFLELADDIQPSGRTISRKSRLQDLYRNANLGKEFKGIADELNACSDKDLQDDRLF LYYTQLGKDMYTGEELDLDRLSSAYDIDHIIPQAVTQNDSIDNRVLVARAENARKTDSFTYM PQIADRMRNFWQILLDNGLISRVKFERLTRQNEFSEREKERFVQRSLVETRQIMKNVATLMR QRYGNSAAVIGLNAELTKEMHRYLGFSHKNRDINDYHHAQDALCVGIAGQFAANRGFFADGE VSDGAQNSYNQYLRDYLRGYREKLSAEDRKQGRAFGFIVGSMRSQDEQKRVNPRTGEWWSE EDKDYLRKVMNYRKMLVTQKVGDDFGALYDETRYAATDPKGIKGIPFDGAKQDTSLYGGFSS AKPAYAVLIESKGKTRLVNVTMQEYSLLGDRPSDDELRKVLAKKKSEYAKANILLRHVPKMQ LIRYGGGLMVIKSAGELNNAQQLWLPYEEYCYFDDLSQGKGSLEKDDLKKLLDSILGSVQCL YPWHRFTEEELADLHVAFDKLPEDEKKNVITGIVSALHADAKTANLSIVGMTGSWRRMNNKS GYTFSDEDEFIFQSPSGLFEKRVTVGELKRKAKKEVNSKYRTNEKRLPTLSGASQP
SEQ ID NO: 309
METQTSNQLITSHLKDYPKQDYFVGLDIGTNSVGWAVTNTSYELLKFHSHKMWGSRLFEEGE SAVTRRGFRSMRRRLERRKLRLKLLEELFADAMAQVDSTFFIRLHESKYHYEDKTTGHSSKH ILFIDEDYTDQDYFTEYPTIYHLRKDLMENGTDDIRKLFLAVHHILKYRGNFLYEGATFNSN AFTFEDVLKQALVNITFNCFDTNSAISSISNILMESGKTKSDKAKAIERLVDTYTVFDEVNT PDKPQKEQVKEDKKTLKAFANLVLGLSANLIDLFGSVEDIDDDLKKLQIVGDTYDEKRDELA KVWGDEIHIIDDCKSVYDAIILMSIKEPGLTISQSKVKAFDKHKEDLVILKSLLKLDRNVYN EMFKSDKKGLHNYVHYIKQGRTEETSCSREDFYKYTKKIVEGLADSKDKEYILNEIELQTLL PLQRIKDNGVIPYQLHLEELKVILDKCGPKFPFLHTVSDGFSVTEKLIKMLEFRIPYYVGPL NTHHNIDNGGFSWAVRKQAGRVTPWNFEEKIDREKSAAAFIKNLTNKCTYLFGEDVLPKSSL LYSEFMLLNELNNVRIDGKALAQGVKQHLIDSIFKQDHKKMTKNRIELFLKDNNYITKKHKP EITGLDGEIKNDLTSYRDMVRILGNNFDVSMAEDI ITDITIFGESKKMLRQTLRNKFGSQLN DETIKKLSKLRYRDWGRLSKKLLKGIDGCDKAGNGAPKTIIELMRNDSYNLMEILGDKFSFM ECIEEENAKLAQGQVVNPHDIIDELALSPAVKRAVWQALRIVDEVAHIKKALPSRIFVEVAR TNKSEKKKKDSRQKRLSDLYSAIKKDDVLQSGLQDKEFGALKSGLANYDDAALRSKKLYLYY TQMGRCAYTGNIIDLNQLNTDNYDIDHIYPRSLTKDDSFDNLVLCERTANAKKSDIYPIDNR IQTKQKPFWAFLKHQGLISERKYERLTRIAPLTADDLSGFIARQLVETNQSVKATTTLLRRL YPDIDWFVKAENVSDFRHNNNFIKVRSLNHHHHAKDAYLNIVVGNVYHEKFTRNFRLFFKK NGANRTYNLAKMFNYDVICTNAQDGKAWDVKTSMNTVKKMMASNDVRVTRRLLEQSGALADA TIYKASVAAKAKDGAYIGMKTKYSVFADVTKYGGMTKIKNAYSIIVQYTGKKGEEIKEIVPL PIYLINRNATDIELIDYVKSVIPKAKDISIKYRKLCINQLVKVNGFYYYLGGKTNDKIYIDN AIELWPHDIATYIKLLDKYDLLRKENKTLKASSITTSIYNINTSTVVSLNKVGIDVFDYFM SKLRTPLYMKMKGNKVDELSSTGRSKFIKMTLEEQSIYLLEVLNLLTNSKTTFDVKPLGITG SRSTIGVKIHNLDEFKIINESITGLYSNEVTIV SEQ ID NO: 310
MTKLNQPYGIGLDIGSNSIGFAVVDANSHLLRLKGETAIGARLFREGQSAADRRGSRTTRRR LSRTRWRLSFLRDFFAPHITKIDPDFFLRQKYSEISPKDKDRFKYEKRLFNDRTDAEFYEDY PSMYHLRLHLMTHTHKADPREIFLAIHHILKSRGHFLTPGAAKDFNTDKVDLEDIFPALTEA YAQVYPDLELTFDLAKADDFKAKLLDEQATPSDTQKALVNLLLSSDGEKEIVKKRKQVLTEF AKAITGLKTKFNLALGTEVDEADASNWQFSMGQLDDKWSNIETSMTDQGTEIFEQIQELYRA RLLNGIVPAGMSLSQAKVADYGQHKEDLELFKTYLKKLNDHELAKTIRGLYDRYINGDDAKP FLREDFVKALTKEVTAHPNEVSEQLLNRMGQANFMLKQRTKANGAIPIQLQQRELDQIIANQ SKYYDWLAAPNPVEAHRWKMPYQLDELLNFHIPYYVGPLITPKQQAESGENVFAWMVRKDPS GNITPYNFDEKVDREASANTFIQRMKTTDTYLIGEDVLPKQSLLYQKYEVLNELNNVRINNE CLGTDQKQRLIREVFERHSSVTIKQVADNLVAHGDFARRPEIRGLADEKRFLSSLSTYHQLK EILHEAIDDPTKLLDIENI ITWSTVFEDHTIFETKLAEIEWLDPKKINELSGIRYRGWGQFS RKLLDGLKLGNGHTVIQELMLSNHNLMQILADETLKETMTELNQDKLKTDDIEDVINDAYTS PSNKKALRQVLRWEDIKHAANGQDPSWLFIETADGTGTAGKRTQSRQKQIQTVYANAAQEL IDSAVRGELEDKIADKASFTDRLVLYFMQGGRDIYTGAPLNIDQLSHYDIDHILPQSLIKDD SLDNRVLVNATINREKNNVFASTLFAGKMKATWRKWHEAGLISGRKLRNLMLRPDEIDKFAK GFVARQLVETRQIIKLTEQIAAAQYPNTKIIAVKAGLSHQLREELDFPKNRDVNHYHHAFDA FLAARIGTYLLKRYPKLAPFFTYGEFAKVDVKKFREFNFIGALTHAKKNIIAKDTGEIVWDK ERDIRELDRIYNFKRMLITHEVYFETADLFKQTIYAAKDSKERGGSKQLIPKKQGYPTQVYG GYTQESGSYNALVRVAEADTTAYQVIKISAQNASKIASANLKSREKGKQLLNEIVVKQLAKR RKNWKPSANSFKIVIPRFGMGTLFQNAKYGLFMVNSDTYYRNYQELWLSRENQKLLKKLFSI KYEKTQMNHDALQVYKAIIDQVEKFFKLYDINQFRAKLSDAIERFEKLPINTDGNKIGKTET LRQILIGLQANGTRSNVKNLGIKTDLGLLQVGSGIKLDKDTQIVYQSPSGLFKRRIPLADL SEQ ID NO: 311
MTKEYYLGLDVGTNSVGWAVTDSQYNLCKFKKKDMWGIRLFESANTAKDRRLQRGNRRRLER KKQRIDLLQEIFSPEICKIDPTFFIRLNESRLHLEDKSNDFKYPLFIEKDYSDIEYYKEFPT IFHLRKHLIESEEKQDIRLIYLALHNI IKTRGHFLIDGDLQSAKQLRPILDTFLLSLQEEQN LSVSLSENQKDEYEEILKNRSIAKSEKVKKLKNLFEISDELEKEEKKAQSAVIENFCKFIVG NKGDVCKFLRVSKEELEIDSFSFSEGKYEDDIVKNLEEKVPEKVYLFEQMKAMYDWNILVDI LETEEYISFAKVKQYEKHKTNLRLLRDIILKYCTKDEYNRMFNDEKEAGSYTAYVGKLKKNN KKYWIEKKRNPEEFYKSLGKLLDKIEPLKEDLEVLTMMIEECKNHTLLPIQKNKDNGVIPHQ VHEVELKKILENAKKYYSFLTETDKDGYSWQKIESIFRFRIPYYVGPLSTRHQEKGSNVWM VRKPGREDRIYPWNMEEIIDFEKSNENFITRMTNKCTYLIGEDVLPKHSLLYSKYMVLNELN NVKVRGKKLPTSLKQKVFEDLFENKSKVTGKNLLEYLQIQDKDIQIDDLSGFDKDFKTSLKS YLDFKKQIFGEEIEKESIQNMIEDIIKWITIYGNDKEMLKRVIRANYSNQLTEEQMKKITGF QYSGWGNFSKMFLKGISGSDVSTGETFDIITAMWETDNNLMQILSKKFTFMDNVEDFNSGKV GKIDKITYDSTVKEMFLSPENKRAVWQTIQVAEEIKKVMGCEPKKIFIEMARGGEKVKKRTK SRKAQLLELYAACEEDCRELIKEIEDRDERDFNSMKLFLYYTQFGKCMYSGDDIDINELIRG NSKWDRDHIYPQSKIKDDSIDNLVLVNKTYNAKKSNELLSEDIQKKMHSFWLSLLNKKLITK SKYDRLTRKGDFTDEELSGFIARQLVETRQSTKAIADIFKQIYSSEVVYVKSSLVSDFRKKP LNYLKSRRVNDYHHAKDAYLNIVVGNVYNKKFTSNPIQWMKKNRDTNYSLNKVFEHDWING EVIWEKCTYHEDTNTYDGGTLDRIRKIVERDNILYTEYAYCEKGELFNATIQNKNGNSTVSL KKGLDVKKYGGYFSANTSYFSLIEFEDKKGDRARHIIGVPIYIANMLEHSPSAFLEYCEQKG YQNVRILVEKIKKNSLLIINGYPLRIRGENEVDTSFKRAIQLKLDQKNYELVRNIEKFLEKY VEKKGNYPIDENRDHITHEKMNQLYEVLLSKMKKFNKKGMADPSDRIEKSKPKFIKLEDLID KINVINKMLNLLRCDNDTKADLSLIELPKNAGSFVVKKNTIGKSKIILVNQSVTGLYENRRE L SEQ ID NO: 312 MARDYSVGLDIGTSSVGWAAIDNKYHLIRAKSKNLIGVRLFDSAVTAEKRRGYRTTRRRLSR RHWRLRLLNDIFAGPLTDFGDENFLARLKYSWVHPQDQSNQAHFAAGLLFDSKEQDKDFYRK YPTIYHLRLALMNDDQKHDLREVYLAIHHLVKYRGHFLIEGDVKADSAFDVHTFADAIQRYA ESNNSDENLLGKIDEKKLSAALTDKHGSKSQRAETAETAFDILDLQSKKQIQAILKSWGNQ ANLMAIFGLDSSAISKDEQKNYKFSFDDADIDEKIADSEALLSDTEFEFLCDLKAAFDGLTL KMLLGDDKTVSAAMVRRFNEHQKDWEYIKSHIRNAKNAGNGLYEKSKKFDGINAAYLALQSD NEDDRKKAKKIFQDEISSADIPDDVKADFLKKIDDDQFLPIQRTKNNGTIPHQLHRNELEQI IEKQGIYYPFLKDTYQENSHELNKITALINFRVPYYVGPLVEEEQKIADDGKNIPDPTNHWM VRKSNDTITPWNLSQWDLDKSGRRFIERLTGTDTYLIGEPTLPKNSLLYQKFDVLQELNNI RVSGRRLDIRAKQDAFEHLFKVQKTVSATNLKDFLVQAGYISEDTQIEGLADVNGKNFNNAL TTYNYLVSVLGREFVENPSNEELLEEITELQTVFEDKKVLRRQLDQLDGLSDHNREKLSRKH YTGWGRISKKLLTTKIVQNADKIDNQTFDVPRMNQSIIDTLYNTKMNLMEI INNAEDDFGVR AWIDKQNTTDGDEQDVYSLIDELAGPKEIKRGIVQSFRILDDITKAVGYAPKRVYLEFARKT QESHLTNSRKNQLSTLLKNAGLSELVTQVSQYDAAALQNDRLYLYFLQQGKDMYSGEKLNLD NLSNYDIDHIIPQAYTKDNSLDNRVLVSNITNRRKSDSSNYLPALIDKMRPFWSVLSKQGLL SKHKFANLTRTRDFDDMEKERFIARSLVETRQIIKNVASLIDSHFGGETKAVAIRSSLTADM RRYVDIPKNRDINDYHHAFDALLFSTVGQYTENSGLMKKGQLSDSAGNQYNRYIKEWIHAAR LNAQSQRVNPFGFWGSMRNAAPGKLNPETGEITPEENADWSIADLDYLHKVMNFRKITVTR RLKDQKGQLYDESRYPSVLHDAKSKASINFDKHKPVDLYGGFSSAKPAYAALIKFKNKFRLV NVLRQWTYSDKNSEDYILEQIRGKYPKAEMVLSHIPYGQLVKKDGALVTISSATELHNFEQL WLPLADYKLINTLLKTKEDNLVDILHNRLDLPEMTIESAFYKAFDSILSFAFNRYALHQNAL VKLQAHRDDFNALNYEDKQQTLERILDALHASPASSDLKKINLSSGFGRLFSPSHFTLADTD EFIFQSVTGLFSTQKTVAQLYQETK SEQ ID NO: 313
MVYDVGLDIGTGSVGWVALDENGKLARAKGKNLVGVRLFDTAQTAADRRGFRTTRRRLSRRK WRLRLLDELFSAEINEIDSSFFQRLKYSYVHPKDEENKAHYYGGYLFPTEEETKKFHRSYPT IYHLRQELMAQPNKRFDIREIYLAIHHLVKYRGHFLSSQEKITIGSTYNPEDLANAIEVYAD EKGLSWELNNPEQLTEIISGEAGYGLNKSMKADEALKLFEFDNNQDKVAIKTLLAGLTGNQI DFAKLFGKDISDKDEAKLWKLKLDDEALEEKSQTILSQLTDEEIELFHAWQAYDGFVLIGL LNGADSVSAAMVQLYDQHREDRKLLKSLAQKAGLKHKRFSEIYEQLALATDEATIKNGISTA RELVEESNLSKEVKEDTLRRLDENEFLPKQRTKANSVIPHQLHLAELQKILQNQGQYYPFLL DTFEKEDGQDNKIEELLRFRIPYYVGPLVTKKDVEHAGGDADNHWVERNEGFEKSRVTPWNF DKVFNRDKAARDFIERLTGNDTYLIGEKTLPQNSLRYQLFTVLNELNNVRVNGKKFDSKTKA DLINDLFKARKTVSLSALKDYLKAQGKGDVTITGLADESKFNSSLSSYNDLKKTFDAEYLEN EDNQETLEKIIEIQTVFEDSKIASRELSKLPLDDDQVKKLSQTHYTGWGRLSEKLLDSKIID ERGQKVSILDKLKSTSQNFMSIINNDKYGVQAWITEQNTGSSKLTFDEKVNELTTSPANKRG IKQSFAVLNDIKKAMKEEPRRVYLEFAREDQTSVRSVPRYNQLKEKYQSKSLSEEAKVLKKT LDGNKNKMSDDRYFLYFQQQGKDMYTGRPINFERLSQDYDIDHIIPQAFTKDDSLDNRVLVS RPENARKSDSFAYTDEVQKQDGSLWTSLLKSGFINRKKYERLTKAGKYLDGQKTGFIARQLV ETRQ11KNVASLIEGEYENSKAVAIRSEITADMRLLVGIKKHREINSFHHAFDALLITAAGQ YMQNRYPDRDSTNVYNEFDRYTNDYLKNLRQLSSRDEVRRLKSFGFVVGTMRKGNEDWSEEN TSYLRKVMMFKNILTTKKTEKDRGPLNKETIFSPKSGKKLIPLNSKRSDTALYGGYSNVYSA YMTLVRANGKNLLIKIPISIANQIEVGNLKINDYIVNNPAIKKFEKILISKLPLGQLVNEDG NLIYLASNEYRHNAKQLWLSTTDADKIASISENSSDEELLEAYDILTSENVKNRFPFFKKDI DKLSQVRDEFLDSDKRIAVIQTILRGLQIDAAYQAPVKI ISKKVSDWHKLQQSGGIKLSDNS EMIYQSATGIFETRVKISDLL
SEQ ID NO: 314
IVDYCIGLDLGTGSVGWAVVDMNHRLMKRNGKHLWGSRLFSNAETAANRRASRSIRRRYNKR RERIRLLRAILQDMVLEKDPTFFIRLEHTSFLDEEDKAKYLGTDYKDNYNLFIDEDFNDYTY YHKYPTIYHLRKALCESTEKADPRLIYLALHHIVKYRGNFLYEGQKFNMDASNIEDKLSDIF TQFTSFNNIPYEDDEKKNLEILEILKKPLSKKAKVDEVMTLIAPEKDYKSAFKELVTGIAGN KMNVTKMILCEPIKQGDSEIKLKFSDSNYDDQFSEVEKDLGEYVEFVDALHNVYSWVELQTI MGATHTDNASISEAMVSRYNKHHDDLKLLKDCIKNNVPNKYFDMFRNDSEKSKGYYNYINRP SKAPVDEFYKYVKKCIEKVDTPEAKQILNDIELENFLLKQNSRTNGSVPYQMQLDEMIKIID NQAEYYPILKEKREQLLSILTFRIPYYFGPLNETSEHAWIKRLEGKENQRILPWNYQDIVDV DATAEGFIKRMRSYCTYFPDEEVLPKNSLIVSKYEVYNELNKIRVDDKLLEVDVKNDIYNEL FMKNKTVTEKKLKNWLVNNQCCSKDAEIKGFQKENQFSTSLTPWIDFTNIFGKIDQSNFDLI E I IYDLTVFEDKKIMKRRLKKKYALPDDKVKQILKLKYKDWSRLSKKLLDGIVADNRFGSS VTVLDVLEMSRLNLMEIINDKDLGYAQMIEEATSCPEDGKFTYEEVERLAGSPALKRGIWQS LQIVEEITKVMKCRPKYIYIEFERSEEAKERTESKIKKLENVYKDLDEQTKKEYKSVLEELK GFDNTKKISSDSLFLYFTQLGKCMYSGKKLDIDSLDKYQIDHIVPQSLVKDDSFDNRVLWP SENQRKLDDLVVPFDIRDKMYRFWKLLFDHELISPKKFYSLIKTEYTERDEERFINRQLVET RQITKNVTQIIEDHYSTTKVAAIRANLSHEFRVKNHIYKNRDINDYHHAHDAYIVALIGGFM RDRYPNMHDSKAVYSEYMKMFRKNKNDQKRWKDGFVINSMNYPYEVDGKLIWNPDLINEIKK CFYYKDCYCTTKLDQKSGQLFNLTVLSNDAHADKGVTKAWPVNKNRSDVHKYGGFSGLQYT IVAIEGQKKKGKKTELVKKISGVPLHLKAASINEKINYIEEKEGLSDVRIIKDNIPVNQMIE MDGGEYLLTSPTEYVNARQLVLNEKQCALIADIYNAIYKQDYDNLDDILMIQLYIELTNKMK VLYPAYRGIAEKFESMNENYWISKEEKA I IKQMLIVMHRGPQNG IVYDDFKISDRIGRL KTKNHNLNNIVFISQSPTGIYTKKYKL
SEQ ID NO: 315
MKSEKKYYIGLDVGTNSVGWAVTDEFYNILRAKGKDLWGVRLFEKADTAANTRIFRSGRRRN DRKGMRLQILREIFEDEIKKVDKDFYDRLDESKFWAEDKKVSGKYSLFNDKNFSDKQYFEKF PTIFHLRKYLMEEHGKVDIRYYFLAINQMMKRRGHFLIDGQISHVTDDKPLKEQLILLINDL LKIELEEELMDSIFEILADVNEKRTDKKNNLKELIKGQDFNKQEGNILNSIFESIVTGKAKI KNI ISDEDILEKIKEDNKEDFVLTGDSYEENLQYFEEVLQENITLFNTLKSTYDFLILQSIL KGKSTLSDAQVERYDEHKKDLEILKKVIKKYDEDGKLFKQVFKEDNGNGYVSYIGYYLNKNK KITAKKKISNIEFTKYVKGILEKQCDCEDEDVKYLLGKIEQENFLLKQISSINSVIPHQIHL FELDKILENLAKNYPSFNNKKEEFTKIEKIRKTFTFRIPYYVGPLNDYHKNNGGNAWIFRNK GEKIRPWNFEKIVDLHKSEEEFIKRMLNQCTYLPEETVLPKSSILYSEYMVLNELNNLRING KPLDTDVKLKLIEELFKKKTKVTLKSIRDYMVRNNFADKEDFDNSEKNLEIASNMKSYIDFN NILEDKFDVEMVEDLIEKITIHTGNKKLLKKYIEETYPDLSSSQIQKIINLKYKDWGRLSRK LLDGIKGTKKETEKTDTVINFLRNSSDNLMQIIGSQNYSFNEYIDKLRKKYIPQEISYEWE NLYVSPSVKKMIWQVIRVTEEITKVMGYDPDKIFIEMAKSEEEKKTTISRKNKLLDLYKAIK KDERDSQYEKLLTGLNKLDDSDLRSRKLYLYYTQMGRDMYTGEKIDLDKLFDSTHYDKDHII PQSMKKDDSIINNLVLVNKNANQTTKGNIYPVPSSIRNNPKIYNYWKYLMEKEFISKEKYNR LIRNTPLTNEELGGFINRQLVETRQSTKAIKELFEKFYQKSKI IPVKASLASDLRKDMNTLK SREVNDLHHAHDAFLNIVAGDVWNREFTSNPINYVKENREGDKVKYSLSKDFTRPRKSKGKV IWTPEKGRKLIVDTLNKPSVLISNESHVKKGELFNATIAGKKDYKKGKIYLPLKKDDRLQDV SKYGGYKAINGAFFFLVEHTKSKKRIRSIELFPLHLLSKFYEDKNTVLDYAINVLQLQDPKI IIDKINYRTEI IIDNFSYLISTKSNDGSITVKPNEQMYWRVDEISNLKKIENKYKKDAILTE EDRKIMESYIDKIYQQFKAGKYKNRRTTDTI IEKYEIIDLDTLDNKQLYQLLVAFISLSYKT SNNAVDFTVIGLGTECGKPRITNLPDNTYLVYKSITGIYEKRIRIK
SEQ ID NO: 316
MKLRGIEDDYSIGLDMGTSSVGWAVTDERGTLAHFKRKPTWGSRLFREAQTAAVARMPRGQR RRYVRRRWRLDLLQKLFEQQMEQADPDFFIRLRQSRLLRDDRAEEHADYRWPLFNDCKFTER DYYQRFPTIYHVRSWLMETDEQADIRLIYLALHNIVKHRGNFLREGQSLSAKSARPDEALNH LRETLRVWSSERGFECSIADNGSILAMLTHPDLSPSDRRKKIAPLFDVKSDDAAADKKLGIA LAGAVIGLKTEFKNIFGDFPCEDSSIYLSNDEAVDAVRSACPDDCAELFDRLCEVYSAYVLQ GLLSYAPGQTISANMVEKYRRYGEDLALLKKLVKIYAPDQYRMFFSGATYPGTGIYDAAQAR GYTKYNLGPKKSEYKPSESMQYDDFRKAVEKLFAKTDARADERYRMMMDRFDKQQFLRRLKT SDNGSIYHQLHLEELKAIVENQGRFYPFLKRDADKLVSLVSFRIPYYVGPLSTRNARTDQHG ENRFAWSERKPGMQDEPIFPWNWESIIDRSKSAEKFILRMTGMCTYLQQEPVLPKSSLLYEE FCVLNELNGAHWSIDGDDEHRFDAADREGIIEELFRRKRTVSYGDVAGWMERERNQIGAHVC GGQGEKGFESKLGSYIFFCKDVFKVERLEQSDYPMIERI ILWNTLFEDRKILSQRLKEEYGS RLSAEQIKTICKKRFTGWGRLSEKFLTGITVQVDEDSVSIMDVLREGCPVSGKRGRAMVMME ILRDEELGFQKKVDDFNRAFFAENAQALGVNELPGSPAVRRSLNQSIRIVDEIASIAGKAPA NIFIEVTRDEDPKKKGRRTKRRYNDLKDALEAFKKEDPELWRELCETAPNDMDERLSLYFMQ RGKCLYSGRAIDIHQLSNAGIYEVDHI IPRTYVKDDSLENKALVYREENQRKTDMLLIDPEI RRRMSGYWRMLHEAKLIGDKKFRNLLRSRIDDKALKGFIARQLVETGQMVKLVRSLLEARYP ETNIISVKASISHDLRTAAELVKCREANDFHHAHDAFLACRVGLFIQKRHPCVYENPIGLSQ WRNYVRQQADIFKRCRTIPGSSGFIVNSFMTSGFDKETGEIFKDDWDAEAEVEGIRRSLNF RQCFISRMPFEDHGVFWDATIYSPRAKKTAALPLKQGLNPSRYGSFSREQFAYFFIYKARNP RKEQTLFEFAQVPVRLSAQIRQDENALERYARELAKDQGLEFIRIERSKILKNQLIEIDGDR LCITGKEEVRNACELAFAQDEMRVIRMLVSEKPVSRECVISLFNRILLHGDQASRRLSKQLK LALLSEAFSEASDNVQRNVVLGLIAIFNGSTNMVNLSDIGGSKFAGNVRIKYKKELASPKVN VHLIDQSVTGMFERRTKIGL SEQ ID NO: 317
MENKQYYIGLDVGTNSVGWAVTDTSYNLLRAKGKDMWGARLFEKANTAAERRTKRTSRRRSE REKARKAMLKELFADEINRVDPSFFIRLEESKFFLDDRSENNRQRYTLFNDATFTDKDYYEK YKTIFHLRSALINSDEKFDVRLVFLAILNLFSHRGHFLNASLKGDGDIQGMDVFYNDLVESC EYFEIELPRITNIDNFEKILSQKGKSRTKILEELSEELSISKKDKSKYNLIKLISGLEASW ELYNIEDIQDENKKIKIGFRESDYEESSLKVKEIIGDEYFDLVERAKSVHDMGLLSNIIGNS KYLCEARVEAYENHHKDLLKIKELLKKYDKKAYNDMFRKMTDKNYSAYVGSVNSNIAKERRS VDKRKIEDLYKYIEDTALKNIPDDNKDKIEILEKIKLGEFLKKQLTASNGVIPNQLQSRELR AILKKAENYLPFLKEKGEKNLTVSEMI IQLFEFQIPYYVGPLDKNPKKDNKANSWAKIKQGG RILPWNFEDKVDVKGSRKEFIEKMVRKCTYISDEHTLPKQSLLYEKFMVLNEINNIKIDGEK ISVEAKQKIYNDLFVKGKKVSQKDIKKELISLNIMDKDSVLSGTDTVCNAYLSSIGKFTGVF KEEINKQSIVDMIEDIIFLKTVYGDEKRFVKEEIVEKYGDEIDKDKIKRILGFKFSNWGNLS KSFLELEGADVGTGEVRSI IQSLWETNFNLMELLSSRFTYMDELEKRVKKLEKPLSEWTIED LDDMYLSSPVKRMIWQSMKIVDEIQTVIGYAPKRIFVEMTRSEGEKVRTKSRKDRLKELYNG IKEDSKQWVKELDSKDESYFRSKKMYLYYLQKGRCMYSGEVIELDKLMDDNLYDIDHIYPRS FVKDDSLDNLVLVKKEINNRKQNDPITPQIQASCQGFWKILHDQGFMSNEKYSRLTRKTQEF SDEEKLSFINRQIVETGQATKCMAQILQKSMGEDVDWFSKARLVSEFRHKFELFKSRLIND FHHANDAYLNIWGNSYFVKFTRNPANFIKDARKNPDNPVYKYHMDRFFERDVKSKSEVAWI GQSEGNSGTIVIVKKTMAKNSPLITKKVEEGHGSITKETIVGVKEIKFGRNKVEKADKTPKK PNLQAYRPIKTSDERLCNILRYGGRTSISISGYCLVEYVKKRKTIRSLEAIPVYLGRKDSLS EEKLLNYFRYNLNDGGKDSVSDIRLCLPFISTNSLVKIDGYLYYLGGKNDDRIQLYNAYQLK MKKEEVEYIRKIEKAVSMSKFDEIDREKNPVLTEEKNIELYNKIQDKFENTVFSKRMSLVKY NKKDLSFGDFLKNKKSKFEEIDLEKQCKVLYNIIFNLSNLKEVDLSDIGGSKSTGKCRCKKN ITNYKEFKLIQQSITGLYSCEKDLMTI SEQ ID NO: 318
MKNLKEYYIGLDIGTASVGWAVTDESYNIPKFNGKKMWGVRLFDDAKTAEERRTQRGSRRRL NRRKERINLLQDLFATEISKVDPNFFLRLDNSDLYREDKDEKLKSKYTLFNDKDFKDRDYHK KYPTIHHLIMDLIEDEGKKDIRLLYLACHYLLKNRGHFIFEGQKFDTKNSFDKSINDLKIHL RDEYNIDLEFNNEDLIEIITDTTLNKTNKKKELKNIVGDTKFLKAISAIMIGSSQKLVDLFE DGEFEETTVKSVDFSTTAFDDKYSEYEEALGDTISLLNILKSIYDSSILENLLKDADKSKDG NKYISKAFVKKFNKHGKDLKTLKRIIKKYLPSEYANIFRNKSINDNYVAYTKSNITSNKRTK ASKFTKQEDFYKFIKKHLDTIKETKLNSSENEDLKLIDEMLTDIEFKTFIPKLKSSDNGVIP YQLKLMELKKILDNQSKYYDFLNESDEYGTVKDKVESIMEFRIPYYVGPLNPDSKYAWIKRE NTKITPWNFKDIVDLDSSREEFIDRLIGRCTYLKEEKVLPKASLIYNEFMVLNELNNLKLNE FLITEEMKKAIFEELFKTKKKVTLKAVSNLLKKEFNLTGDILLSGTDGDFKQGLNSYIDFKN IIGDKVDRDDYRIKIEEIIKLIVLYEDDKTYLKKKIKSAYKNDFTDDEIKKIAALNYKDWGR LSKRFLTGIEGVDKTTGEKGSIIYFMREYNLNLMELMSGHYTFTEEVEKLNPVENRELCYEM VDELYLSPSVKRMLWQSLRWDEIKRI IGKDPKKIFIEMARAKEAKNSRKESRKNKLLEFYK FGKKAFINEIGEERYNYLLNEINSEEESKFRWDNLYLYYTQLGRCMYSLEPIDLADLKSNNI YDQDHIYPKSKIYDDSLENRVLVKKNLNHEKGNQYPIPEKVLNKNAYGFWKILFDKGLIGQK KYTRLTRRTPFEERELAEFIERQIVETRQATKETANLLKNICQDSEIVYSKAENASRFRQEF DIIKCRTVNDLHHMHDAYLNIWGNVYNTKFTKNPLNFIKDKDNVRSYNLENMFKYDWRGS YTAWIADDSEGNVKAATIKKVKRELEGKNYRFTRMSYIGTGGLYDQNLMRKGKGQIPQKENT NKSNIEKYGGYNKASSAYFALIESDGKAGRERTLETIPIMVYNQEKYGNTEAVDKYLKDNLE LQDPKILKDKIKINSLIKLDGFLYNIKGKTGDSLSIAGSVQLIVNKEEQKLIKKMDKFLVKK KDNKDIKVTSFDNIKEEELIKLYKTLSDKLNNGIYSNKRNNQAKNISEALDKFKEISIEEKI DVLNQIILLFQSYNNGCNLKSIGLSAKTGWFIPKKLNYKECKLINQSITGLFENEVDLLNL
SEQ ID NO: 319
MGKMYYLGLDIGTNSVGYAVTDPSYHLLKFKGEPMWGAHVFAAGNQSAERRSFRTSRRRLDR RQQRVKLVQEIFAPVISPIDPRFFIRLHESALWRDDVAETDKHIFFNDPTYTDKEYYSDYPT IHHLIVDLMESSEKHDPRLVYLAVAWLVAHRGHFLNEVDKDNIGDVLSFDAFYPEFLAFLSD NGVSPWVCESKALQATLLSRNSVNDKYKALKSLIFGSQKPEDNFDANISEDGLIQLLAGKKV KVNKLFPQESNDASFTLNDKEDAIEEILGTLTPDECEWIAHIRRLFDWAIMKHALKDGRTIS ESKVKLYEQHHHDLTQLKYFVKTYLAKEYDDIFRNVDSETTKNYVAYSYHVKEVKGTLPKNK ATQEEFCKYVLGKVKNIECSEADKVDFDEMIQRLTDNSFMPKQVSGENRVIPYQLYYYELKT ILNKAASYLPFLTQCGKDAISNQDKLLSIMTFRIPYFVGPLRKDNSEHAWLERKAGKIYPWN FNDKVDLDKSEEAFIRRMTNTCTYYPGEDVLPLDSLIYEKFMILNEINNIRIDGYPISVDVK QQVFGLFEKKRRVTVKDIQNLLLSLGALDKHGKLTGIDTTIHSNYNTYHHFKSLMERGVLTR DDVERIVERMTYSDDTKRVRLWLNNNYGTLTADDVKHISRLRKHDFGRLSKMFLTGLKGVHK ETGERASILDFMWNTNDNLMQLLSECYTFSDEITKLQEAYYAKAQLSLNDFLDSMYISNAVK RPIYRTLAWNDIRKACGTAPKRIFIEMARDGESKKKRSVTRREQIKNLYRSIRKDFQQEVD FLEKILENKSDGQLQSDALYLYFAQLGRDMYTGDPIKLEHIKDQSFYNIDHIYPQSMVKDDS LDNKVLVQSEINGEKSSRYPLDAAIRNKMKPLWDAYYNHGLISLKKYQRLTRSTPFTDDEKW DFINRQLVETRQSTKALAILLKRKFPDTEIVYSKAGLSSDFRHEFGLVKSRNINDLHHAKDA FLAIVTGNVYHERFNRRWFMVNQPYSVKTKTLFTHSIKNGNFVAWNGEEDLGRIVKMLKQNK NTIHFTRFSFDRKEGLFDIQPLKASTGLVPRKAGLDWKYGGYDKSTAAYYLLVRFTLEDKK TQHKLMMIPVEGLYKARIDHDKEFLTDYAQTTISEILQKDKQKVINIMFPMGTRHIKLNSMI SIDGFYLSIGGKSSKGKSVLCHAMVPLIVPHKIECYIKAMESFARKFKENNKLRIVEKFDKI TVEDNLNLYELFLQKLQHNPYNKFFSTQFDVLTNGRSTFTKLSPEEQVQTLLNILSIFKTCR SSGCDLKSINGSAQAARIMISADLTGLSKKYSDIRLVEQSASGLFVSKSQNLLEYL
SEQ ID NO: 320
MTKKEQPYNIGLDIGTSSVGWAVTNDNYDLLNIKKKNLWGVRLFEEAQTAKETRLNRSTRRR YRRRKNRINWLNEIFSEELAKTDPSFLIRLQNSWVSKKDPDRKRDKYNLFIDGPYTDKEYYR EFPTIFHLRKELILNKDKADIRLIYLALHNILKYRGNFTYEHQKFNISNLNNNLSKELIELN QQLIKYDISFPDDCDWNHISDILIGRGNATQKSSNILKDFTLDKETKKLLKEVINLILGNVA HLNTIFKTSLTKDEEKLNFSGKDIESKLDDLDSILDDDQFTVLDAANRIYSTITLNEILNGE SYFSMAKVNQYENHAIDLCKLRDMWHTTKNEEAVEQSRQAYDDYINKPKYGTKELYTSLKKF LKVALPTNLAKEAEEKISKGTYLVKPRNSENGWPYQLNKIEMEKIIDNQSQYYPFLKENKE KLLSILSFRIPYYVGPLQSAEKNPFAWMERKSNGHARPWNFDEIVDREKSSNKFIRRMTVTD SYLVGEPVLPKNSLIYQRYEVLNELNNIRITENLKTNPIGSRLTVETKQRIYNELFKKYKKV TVKKLTKWLIAQGYYKNPILIGLSQKDEFNSTLTTYLDMKKIFGSSFMEDNKNYDQIEELIE WLTIFEDKQILNEKLHSSKYSYTPDQIKKISNMRYKGWGRLSKKILMDITTETNTPQLLQLS NYSILDLMWATNNNFISIMSNDKYDFKNYIENHNLNKNEDQNISDLVNDIHVSPALKRGITQ SIKIVQEIVKFMGHAPKHIFIEVTRETKKSEITTSREKRIKRLQSKLLNKANDFKPQLREYL VPNKKIQEELKKHKNDLSSERIMLYFLQNGKSLYSEESLNINKLSDYQVDHILPRTYIPDDS LENKALVLAKENQRKADDLLLNSNVIDRNLERWTYMLNNNMIGLKKFKNLTRRVITDKDKLG FIHRQLVQTSQMVKGVANILDNMYKNQGTTCIQARANLSTAFRKALSGQDDTYHFKHPELVK NRNVNDFHHAQDAYLASFLGTYRLRRFPTNEMLLMNGEYNKFYGQVKELYSKKKKLPDSRKN GFI ISPLVNGTTQYDRNTGEIIWNVGFRDKILKIFNYHQCNVTRKTEIKTGQFYDQTIYSPK NPKYKKLIAQKKDMDPNIYGGFSGDNKSSITIVKIDNNKIKPVAIPIRLINDLKDKKTLQNW LEENVKHKKSIQIIKNNVPIGQI IYSKKVGLLSLNSDREVANRQQLILPPEHSALLRLLQIP DEDLDQILAFYDKNILVEILQELITKMKKFYPFYKGEREFLIANIENFNQATTSEKVNSLEE LITLLHANSTSAHLIFNNIEKKAFGRKTHGLTLNNTDFIYQSVTGLYETRIHIE SEQ ID NO: 321
MTKFNKNYSIGLDIGVSSVGYAVVTEDYRVPAFKFKVLGNTEKEKIKKNLIGSTTFVSAQPA KGTRVFRVNRRRIDRRNHRITYLRDIFQKEIEKVDKNFYRRLDESFRVLGDKSEDLQIKQPF FGDKELETAYHKKYPTIYHLRKHLADADKNSPVADIREVYMAISHILKYRGHFLTLDKINPN NINMQNSWIDFIESCQEVFDLEISDESKNIADIFKSSENRQEKVKKILPYFQQELLKKDKSI FKQLLQLLFGLKTKFKDCFELEEEPDLNFSKENYDENLENFLGSLEEDFSDVFAKLKVLRDT ILLSGMLTYTGATHARFSATMVERYEEHRKDLQRFKFFIKQNLSEQDYLDIFGRKTQNGFDV DKETKGYVGYITNKMVLTNPQKQKTIQQNFYDYISGKITGIEGAEYFLNKISDGTFLRKLRT SDNGAIPNQIHAYELEKIIERQGKDYPFLLENKDKLLSILTFKIPYYVGPLAKGSNSRFAWI KRATSSDILDDNDEDTRNGKIRPWNYQKLINMDETRDAFITNLIGNDIILLNEKVLPKRSLI YEEVMLQNELTRVKYKDKYGKAHFFDSELRQNIINGLFKNNSKRVNAKSLIKYLSDNHKDLN AIEIVSGVEKGKSFNSTLKTYNDLKTIFSEELLDSEIYQKELEEIIKVITVFDDKKSIKNYL TKFFGHLEILDEEKINQLSKLRYSGWGRYSAKLLLDIRDEDTGFNLLQFLRNDEENRNLTKL ISDNTLSFEPKIKDIQSKSTIEDDIFDEIKKLAGSPAIKRGILNSIKIVDELVQI IGYPPHN IVIEMARENMTTEEGQKKAKTRKTKLESALKNIENSLLENGKVPHSDEQLQSEKLYLYYLQN GKDMYTLDKTGSPAPLYLDQLDQYEVDHIIPYSFLPIDSIDNKVLTHRENNQQKLNNIPDKE TVANMKPFWEKLYNAKLISQTKYQRLTTSERTPDGVLTESMKAGFIERQLVETRQIIKHVAR ILDNRFSDTKI ITLKSQLITNFRNTFHIAKIRELNDYHHAHDAYLAVWGQTLLKVYPKLAP ELIYGHHAHFNRHEENKATLRKHLYSNIMRFFNNPDSKVSKDIWDCNRDLPIIKDVIYNSQI NFVKRTMIKKGAFYNQNPVGKFNKQLAANNRYPLKTKALCLDTSIYGGYGPMNSALSII IIA ERFNEKKGKIETVKEFHDIFIIDYEKFNNNPFQFLNDTSENGFLKKNNINRVLGFYRIPKYS LMQKIDGTRMLFESKSNLHKATQFKLTKTQNELFFHMKRLLTKSNLMDLKSKSAIKESQNFI LKHKEEFDNISNQLSAFSQKMLGNTTSLKNLIKGYNERKIKEIDIRDETIKYFYDNFIKMFS FVKSGAPKDINDFFDNKCTVARMRPKPDKKLLNATLIHQSITGLYETRIDLSKLGED SEQ ID NO: 322
MKQEYFLGLDMGTGSLGWAVTDSTYQVMRKHGKALWGTRLFESASTAEERRMFRTARRRLDR RNWRIQVLQEIFSEEISKVDPGFFLRMKESKYYPEDKRDAEGNCPELPYALFVDDNYTDKNY HKDYPTIYHLRKMLMETTEIPDIRLVYLVLHHMMKHRGHFLLSGDISQIKEFKSTFEQLIQN IQDEELEWHISLDDAAIQFVEHVLKDRNLTRSTKKSRLIKQLNAKSACEKAILNLLSGGTVK LSDIFNNKELDESERPKVSFADSGYDDYIGIVEAELAEQYYIIASAKAVYDWSVLVEILGNS VSISEAKIKVYQKHQADLKTLKKIVRQYMTKEDYKRVFVDTEEKLNNYSAYIGMTKKNGKKV DLKSKQCTQADFYDFLKKNVIKVIDHKEITQEIESEIEKENFLPKQVTKDNGVIPYQVHDYE LKKILDNLGTRMPFIKENAEKIQQLFEFRIPYYVGPLNRVDDGKDGKFTWSVRKSDARIYPW NFTEVIDVEASAEKFIRRMTNKCTYLVGEDVLPKDSLVYSKFMVLNELNNLRLNGEKISVEL KQRIYEELFCKYRKVTRKKLERYLVIEGIAKKGVEITGIDGDFKASLTAYHDFKERLTDVQL SQRAKEAIVLNWLFGDDKKLLKQRLSKMYPNLTTGQLKGICSLSYQGWGRLSKTFLEEITV PAPGTGEVWNIMTALWQTNDNLMQLLSRNYGFTNEVEEFNTLKKETDLSYKTVDELYVSPAV KRQIWQTLKWKEIQKVMGNAPKRVFVEMAREKQEGKRSDSRKKQLVELYRACKNEERDWIT ELNAQSDQQLRSDKLFLYYIQKGRCMYSGETIQLDELWDNTKYDIDHIYPQSKTMDDSLNNR VLVKKNYNAIKSDTYPLSLDIQKKMMSFWKMLQQQGFITKEKYVRLVRSDELSADELAGFIE RQIVETRQSTKAVATILKEALPDTEIVYVKAGNVSNFRQTYELLKVREMNDLHHAKDAYLNI WGNAYFVKFTKNAAWFIRNNPGRSYNLKRMFEFDIERSGEIAWKAGNKGSIVTVKKVMQKN NILVTRKAYEVKGGLFDQQIMKKGKGQVPIKGNDERLADIEKYGGYNKAAGTYFMLVKSLDK KGKEIRTIEFVPLYLKNQIEINHESAIQYLAQERGLNSPEILLSKIKIDTLFKVDGFKMWLS GRTGNQLIFKGANQLILSHQEAAILKGWKYVNRKNENKDAKLSERDGMTEEKLLQLYDTFL DKLSNTVYSIRLSAQIKTLTEKRAKFIGLSNEDQCIVLNEILHMFQCQSGSANLKLIGGPGS AGILVMNNNITACKQISVINQSPTGIYEKEIDLIKL
SEQ ID NO: 323
MKKPYSIGLDIGTNSVGWAWTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTAEDR RLKRTARRRYTRRRNRILYLQEIFSEEMGKVDDSFFHRLEDSFLVTEDKRGERHPIFGNLEE EVKYHENFPTIYHLRQYLADNPEKVDLRLVYLALAHIIKFRGHFLIEGKFDTRNNDVQRLFQ EFLAVYDNTFENSSLQEQNVQVEEILTDKISKSAKKDRVLKLFPNEKSNGRFAEFLKLIVGN QADFKKHFELEEKAPLQFSKDTYEEELEVLLAQIGDNYAELFLSAKKLYDSILLSGILTVTD VGTKAPLSASMIQRYNEHQMDLAQLKQFIRQKLSDKYNEVFSDVSKDGYAGYIDGKTNQEAF YKYLKGLLNKIEGSGYFLDKIEREDFLRKQRTFDNGSIPHQIHLQEMRAIIRRQAEFYPFLA DNQDRIEKLLTFRIPYYVGPLARGKSDFAWLSRKSADKITPWNFDEIVDKESSAEAFINRMT NYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKTEQGKTAFFDANMKQEIFDGVFKVYRKV TKDKLMDFLEKEFDEFRIVDLTGLDKENKVFNASYGTYHDLCKILDKDFLDNSKNEKILEDI VLTLTLFEDREMIRKRLENYSDLLTKEQVKKLERRHYTGWGRLSAELIHGIRNKESRKTILD YLIDDGNSNRNFMQLINDDALSFKEEIAKAQVIGETDNLNQWSDIAGSPAIKKGILQSLKI VDELVKIMGHQPENIWEMARENQFTNQGRRNSQQRLKGLTDSIKEFGSQILKEHPVENSQL QNDRLFLYYLQNGRDMYTGEELDIDYLSQYDIDHI IPQAFIKDNSIDNRVLTSSKENRGKSD DVPSKDVVRKMKSYWSKLLSAKLITQRKFDNLTKAERGGLTDDDKAGFIKRQLVETRQITKH VARILDERFNTETDENNKKIRQVKIVTLKSNLVSNFRKEFELYKVREINDYHHAHDAYLNAV IGKALLGVYPQLEPEFVYGDYPHFHGHKENKATAKKFFYSNIMNFFKKDDVRTDKNGEI IWK KDEHISNIKKVLSYPQVNIVKKVEEQTGGFSKESILPKGNSDKLIPRKTKKFYWDTKKYGGF DSPIVAYSILVIADIEKGKSKKLKTVKALVGVTIMEKMTFERDPVAFLERKGYRNVQEE il KLPKYSLFKLENGRKRLLASARELQKGNEIVLPNHLGTLLYHAKNIHKVDEPKHLDYVDKHK DEFKELLDWSNFSKKYTLAEGNLEKIKELYAQNNGEDLKELASSFINLLTFTAIGAPATFK FFDKNIDRKRYTSTTEILNATLIHQSITGLYETRIDLNKLGGD
SEQ ID NO: 324
MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEAT RLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFI QLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGL TPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNT EITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEF YKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLK DNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRK VTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIV LTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDF LKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKW DELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSD NVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKH VAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLAN GEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNS DKLIARKKDWDPKKYGGFDSPTVAYSVLWAKVEKGKSKKLKSVKELLGITIMERSSFEKNP IDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI REQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQ LGGD
SEQ ID NO: 325
MTKPYSIGLDIGTNSVGWAVTTDNYKVPSKKMKVLGNTSKKYIKKNLLGVLLFDSGITAEGR RLKRTARRRYTRRRNRILYLQEIFSTEMATLDDAFFQRLDDSFLVPDDKRDSKYPIFGNLVE EKAYHDEFPTIYHLRKYLADSTKKADLRLVYLALAHMIKYRGHFLIEGEFNSKNNDIQKNFQ DFLDTYNAIFESDLSLENSKQLEEIVKDKISKLEKKDRILKLFPGEKNSGIFSEFLKLIVGN QADFRKCFNLDEKASLHFSKESYDEDLETLLGYIGDDYSDVFLKAKKLYDAILLSGFLTVTD NETEAPLSSAMIKRYNEHKEDLALLKEYIRNISLKTYNEVFKDDTKNGYAGYIDGKTNQEDF YVYLKKLLAEFEGADYFLEKIDREDFLRKQRTFDNGSIPYQIHLQEMRAILDKQAKFYPFLA KNKERIEKILTFRIPYYVGPLARGNSDFAWSIRKRNEKITPWNFEDVIDKESSAEAFINRMT SFDLYLPEEKVLPKHSLLYETFNVYNELTKVRFIAESMRDYQFLDSKQKKDIVRLYFKDKRK VTDKDIIEYLHAIYGYDGIELKGIEKQFNSSLSTYHDLLNIINDKEFLDDSSNEAIIEEIIH TLTIFEDREMIKQRLSKFENIFDKSVLKKLSRRHYTGWGKLSAKLINGIRDEKSGNTILDYL IDDGISNRNFMQLIHDDALSFKKKIQKAQIIGDEDKGNIKEWKSLPGSPAIKKGILQSIKI VDELVKVMGGRKPESIWEMARENQYTNQGKSNSQQRLKRLEKSLKELGSKILKENIPAKLS KIDNNALQNDRLYLYYLQNGKDMYTGDDLDIDRLSNYDIDHIIPQAFLKDNSIDNKVLVSSA SNRGKSDDVPSLEWKKRKTFWYQLLKSKLISQRKFDNLTKAERGGLSPEDKAGFIQRQLVE TRQITKHVARLLDEKFNNKKDENNRAVRTVKIITLKSTLVSQFRKDFELYKVREINDFHHAH DAYLNAVVASALLKKYPKLEPEFVYGDYPKYNSFRERKSATEKVYFYSNIMNIFKKSISLAD GRVIERPLIEVNEETGESVWNKESDLATVRRVLSYPQVNWKKVEEQNHGLDRGKPKGLFNA NLSSKPKPNSNENLVGAKEYLDPKKYGGYAGISNSFTVLVKGTIEKGAKKKITNVLEFQGIS ILDRINYRKDKLNFLLEKGYKDIELIIELPKYSLFELSDGSRRMLASILSTNNKRGEIHKGN QIFLSQKFVKLLYHAKRISNTINENHRKYVENHKKEFEELFYYILEFNENYVGAKKNGKLLN SAFQSWQNHSIDELCSSFIGPTGSERKGLFELTSRGSAADFEFLGVKIPRYRDYTPSSLLKD ATLIHQSVTGLYETRIDLAKLGEG
SEQ ID NO: 326
MKKQKFSDYYLGFDIGTNSVGWCVTDLDYNVLRFNKKDMWGSRLFDEAKTAAERRVQRNSRR RLKRRKWRLNLLEEIFSDEIMKIDSNFFRRLKESSLWLEDKNSKEKFTLFNDDNYKDYDFYK QYPTIFHLRDELIKNPEKKDIRLIYLALHSIFKSRGHFLFEGQNLKEIKNFETLYNNLISFL EDNGINKSIDKDNIEKLEKIICDSGKGLKDKEKEFKGIFNSDKQLVAIFKLSVGSSVSLNDL FDTDEYKKEEVEKEKISFREQIYEDDKPIYYSILGEKIELLDIAKSFYDFMVLNNILSDSNY ISEAKVKLYEEHKKDLKNLKYIIRKYNKENYDKLFKDKNENNYPAYIGLNKEKDKKEWEKS RLKIDDLIKVIKGYLPKPERIEEKDKTIFNEILNKIELKTILPKQRISDNGTLPYQIHEVEL EKILENQSKYYDFLNYEENGVSTKDKLLKTFKFRIPYYVGPLNSYHKDKGGNSWIVRKEEGK ILPWNFEQKVDIEKSAEEFIKRMTNKCTYLNGEDVIPKDSFLYSEYI ILNELNKVQVNDEFL NEENKRKIIDELFKENKKVSEKKFKEYLLVNQIANRTVELKGIKDSFNSNYVSYIKFKDIFG EKLNLDIYKEISEKSILWKCLYGDDKKIFEKKIKNEYGDILNKDEIKKINSFKFNTWGRLSE KLLTGIEFINLETGECYSSVMEALRRTNYNLMELLSSKFTLQESIDNENKEMNEVSYRDLIE ESYVSPSLKRAILQTLKIYEEIKKITGRVPKKVFIEMARGGDESMKNKKIPARQEQLKKLYD SCGNDIANFSIDIKEMKNSLSSYDNNSLRQKKLYLYYLQFGKCMYTGREIDLDRLLQNNDTY DIDHIYPRSKVIKDDSFDNLVLVLKNENAEKSNEYPVKKEIQEKMKSFWRFLKEKNFISDEK YKRLTGKDDFELRGFMARQLVNVRQTTKEVGKILQQIEPEIKIVYSKAEIASSFREMFDFIK VRELNDTHHAKDAYLNIVAGNVYNTKFTEKPYRYLQEIKENYDVKKIYNYDIKNAWDKENSL EIVKKNMEKNTVNITRFIKEEKGELFNLNPIKKGETSNEIISIKPKLYDGKDNKLNEKYGYY TSLKAAYFIYVEHEKKNKKVKTFERITRIDSTLIKNEKNLIKYLVSQKKLLNPKI IKKIYKE QTLIIDSYPYTFTGVDSNKKVELKNKKQLYLEKKYEQILKNALKFVEDNQGETEENYKFIYL KKRNNNEKNETIDAVKERYNIEFNEMYDKFLEKLSSKDYKNYINNKLYTNFLNSKEKFKKLK LWEKSLILREFLKIFNKNTYGKYEIKDSQTKEKLFSFPEDTGRIRLGQSSLGNNKELLEESV TGLFVKKIKL SEQ ID NO: 327
MKNYTIGLDIGVASVGWVCIDE YKILNYNNRHAFGVHEFESAESAAGRRLKRGMRRRYNRR KKRLQLLQSLFDSYITDSGFFSKTDSQHFWKNNNEFENRSLTEVLSSLRISSRKYPTIYHLR SDLIESNKKMDLRLVYLALHNLVKYRGHFLQEGNWSEAASAEGMDDQLLELVTRYAELENLS PLDLSESQWKAAETLLLNRNLTKTDQSKELTAMFGKEYEPFCKLVAGLGVSLHQLFPSSEQA LAYKETKTKVQLSNENVEEVMELLLEEESALLEAVQPFYQQWLYELLKGETYVAKAKVSAF KQYQKDMASLKNLLDKTFGEKVYRSYFISDKNSQREYQKSHKVEVLCKLDQFNKEAKFAETF YKDLKKLLEDKSKTSIGTTEKDEMLRI IKAIDSNQFLQKQKGIQNAAIPHQNSLYEAEKILR NQQAHYPFITTEWIEKVKQILAFRIPYYIGPLVKDTTQSPFSWVERKGDAPITPWNFDEQID KAASAEAFISRMRKTCTYLKGQEVLPKSSLTYERFEVLNELNGIQLRTTGAESDFRHRLSYE MKCWIIDNVFKQYKTVSTKRLLQELKKSPYADELYDEHTGEIKEVFGTQKENAFATSLSGYI SMKSILGAWDDNPAMTEELIYWIAVFEDREILHLKIQEKYPSITDVQRQKLALVKLPGWGR FSRLLIDGLPLDEQGQSVLDHMEQYSSVFMEVLKNKGFGLEKKIQKMNQHQVDGTKKIRYED IEELAGSPALKRGIWRSVKIVEELVSIFGEPANIVLEVAREDGEKKRTKSRKDQWEELTKTT LKNDPDLKSFIGEIKSQGDQRFNEQRFWLYVTQQGKCLYTGKALDIQNLSMYEVDHILPQNF VKDDSLDNLALVMPEANQRKNQVGQNKMPLEIIEANQQYAMRTLWERLHELKLISSGKLGRL KKPSFDEVDKDKFIARQLVETRQIIKHVRDLLDERFSKSDIHLVKAGIVSKFRRFSEIPKIR DYNNKHHAMDALFAAALIQSILGKYGKNFLAFDLSKKDRQKQWRSVKGSNKEFFLFKNFGNL RLQSPVTGEEVSGVEYMKHVYFELPWQTTKMTQTGDGMFYKESIFSPKVKQAKYVSPKTEKF VHDEVKNHSICLVEFTFMKKEKEVQETKFIDLKVIEHHQFLKEPESQLAKFLAEKETNSPII HARIIRTIPKYQKIWIEHFPYYFISTRELHNARQFEISYELMEKVKQLSERSSVEELKIVFG LLIDQMNDNYPIYTKSSIQDRVQKFVDTQLYDFKSFEIGFEELKKAVAANAQRSDTFGSRIS KKPKPEEVAIGYESITGLKYRKPRSWGTKR
SEQ ID NO: 328
MKKEIKDYFLGLDVGTGSVGWAVTDTDYKLLKANRKDLWGMRCFETAETAEVRRLHRGARRR IERRKKRIKLLQELFSQEIAKTDEGFFQRMKESPFYAEDKTILQENTLFNDKDFADKTYHKA YPTINHLIKAWIENKVKPDPRLLYLACHNIIKKRGHFLFEGDFDSENQFDTSIQALFEYLRE DMEVDIDADSQKVKEILKDSSLKNSEKQSRLNKILGLKPSDKQKKAITNLISGNKINFADLY DNPDLKDAEKNSISFSKDDFDALSDDLASILGDSFELLLKAKAVYNCSVLSKVIGDEQYLSF AKVKIYEKHKTDLTKLKNVIKKHFPKDYKKVFGYNKNEKNNNNYSGYVGVCKTKSKKLI INN SVNQEDFYKFLKTILSAKSEIKEVNDILTEIETGTFLPKQISKSNAEIPYQLRKMELEKILS NAEKHFSFLKQKDEKGLSHSEKI IMLLTFKIPYYIGPINDNHKKFFPDRCWWKKEKSPSGK TTPWNFFDHIDKEKTAEAFITSRTNFCTYLVGESVLPKSSLLYSEYTVLNEINNLQIIIDGK NICDIKLKQKIYEDLFKKYKKITQKQISTFIKHEGICNKTDEVIILGIDKECTSSLKSYIEL KNIFGKQVDEISTKNMLEEIIRWATIYDEGEGKTILKTKIKAEYGKYCSDEQIKKILNLKFS GWGRLSRKFLETVTSEMPGFSEPVNIITAMRETQNNLMELLSSEFTFTENIKKINSGFEDAE KQFSYDGLVKPLFLSPSVKKMLWQTLKLVKEISHITQAPPKKIFIEMAKGAELEPARTKTRL KILQDLYNNCKNDADAFSSEIKDLSGKIENEDNLRLRSDKLYLYYTQLGKCMYCGKPIEIGH VFDTSNYDIDHIYPQSKIKDDSISNRVLVCSSCNKNKEDKYPLKSEIQSKQRGFWNFLQRNN FISLEKLNRLTRATPISDDETAKFIARQLVETRQATKVAAKVLEKMFPETKIVYSKAETVSM FRNKFDIVKCREINDFHHAHDAYLNIVVGNVYNTKFTNNPWNFIKEKRDNPKIADTYNYYKV FDYDVKRN ITAWEKGKTI ITVKDMLKRNTPIYTRQAACKKGELFNQTIMKKGLGQHPLKKE GPFSNISKYGGYNKVSAAYYTLIEYEEKGNKIRSLETIPLYLVKDIQKDQDVLKSYLTDLLG KKEFKILVPKIKINSLLKINGFPCHITGKTNDSFLLRPAVQFCCSNNEVLYFKKI IRFSEIR SQREKIGKTISPYEDLSFRSYIKENLWKKTKNDEIGEKEFYDLLQKKNLEIYDMLLTKHKDT IYKKRPNSATIDILVKGKEKFKSLIIENQFEVILEILKLFSATRNVSDLQHIGGSKYSGVAK IGNKISSLDNCILIYQSITGIFEKRIDLLKV
SEQ ID NO: 329
MEGQMKNNGNNLQQGNYYLGLDVGTSSVGWAVTDTDYNVLKFRGKSMWGARLFDEASTAEER RTHRGNRRRLARRKYRLLLLEQLFEKEIRKIDDNFFVRLHESNLWADDKSKPSKFLLFNDTN FTDKDYLKKYPTIYHLRSDLIHNSTEHDIRLVFLALHHLIKYRGHFIYDNSANGDVKTLDEA VSDFEEYLNENDIEFNIENKKEFINVLSDKHLTKKEKKISLKKLYGDITDSENINISVLIEM LSGSSISLSNLFKDIEFDGKQNLSLDSDIEETLNDWDILGDNIDLLIHAKEVYDIAVLTSS LGKHKYLCDAKVELFEKNKKDLMILKKYIKKNHPEDYKKIFSSPTEKKNYAAYSQTNSKNVC SQEEFCLFIKPYIRDMVKSENEDEVRIAKEVEDKSFLTKLKGTNNSVVPYQIHERELNQILK NIVAYLPFMNDEQEDISWDKIKLIFKFKIPYYVGPLNTKSTRSWVYRSDEKIYPWNFSNVI DLDKTAHEFMNRLIGRCTYTNDPVLPMDSLLYSKYNVLNEINPIKVNGKAIPVEVKQAIYTD LFENSKKKVTRKSIYIYLLKNGYIEKEDIVSGIDIEIKSKLKSHHDFTQIVQENKCTPEEIE RIIKGILVYSDDKSMLRRWLKNNIKGLSENDVKYLAKLNYKEWGRLSKTLLTDIYTINPEDG EACSILDIMWNTNATLMEILSNEKYQFKQNIENYKAENYDEKQNLHEELDDMYISPAARRSI WQALRIVDEIVDIKKSAPKKIFIEMAREKKSAMKKKRTESRKDTLLELYKSCKSQADGFYDE ELFEKLSNESNSRLRRDQLYLYYTQMGRSMYTGKRIDFDKLINDKNTYDIDHIYPRSKIKDD SITNRVLVEKDINGEKTDIYPISEDIRQKMQPFWKILKEKGLINEEKYKRLTRNYELTDEEL SSFVARQLVETQQSTKALATLLKKEYPSAKIVYSKAGNVSEFRNRKDKELPKFREINDLHHA KDAYLNIWGNVYDTKFTEKFFNNIRNENYSLKRVFDFSVPGAWDAKGSTFNTIKKYMAKNN PIIAFAPYEVKGELFDQQIVPKGKGQFPIKQGKDIEKYGGYNKLSSAFLFAVEYKGKKARER SLETVYIKDVELYLQDPIKYCESVLGLKEPQIIKPKILMGSLFSINNKKLVVTGRSGKQYVC HHIYQLSINDEDSQYLKNIAKYLQEEPDGNIERQNILNITSVNNIKLFDVLCTKFNSNTYEI ILNSLKNDVNEGREKFSELDILEQCNILLQLLKAFKCNRESSNLEKLNNKKQAGVIVIPHLF TKCSVFKVIHQSITGLFEKEMDLLK
SEQ ID NO: 330
MGRKPYILSLDIGTGSVGYACMDKGFNVLKYHDKDALGVYLFDGALTAQERRQFRTSRRRKN RRIKRLGLLQELLAPLVQNPNFYQFQRQFAWKNDNMDFKNKSLSEVLSFLGYESKKYPTIYH LQEALLLKDEKFDPELIYMALYHLVKYRGHFLFDHLKIENLTNNDNMHDFVELIETYENLNN IKLNLDYEKTKVIYEILKDNEMTKNDRAKRVKNMEKKLEQFSIMLLGLKFNEGKLFNHADNA EELKGANQSHTFADNYEENLTPFLTVEQSEFIERANKIYLSLTLQDILKGKKSMAMSKVAAY DKFRNELKQVKDIVYKADSTRTQFKKIFVSSKKSLKQYDATPNDQTFSSLCLFDQYLIRPKK QYSLLIKELKKIIPQDSELYFEAENDTLLKVLNTTDNASIPMQINLYEAETILRNQQKYHAE ITDEMIEKVLSLIQFRIPYYVGPLVNDHTASKFGWMERKSNESIKPWNFDEWDRSKSATQF IRRMTNKCSYLINEDVLPKNSLLYQEMEVLNELNATQIRLQTDPKNRKYRMMPQIKLFAVEH IFKKYKTVSHSKFLEIMLNSNHRENFMNHGEKLSIFGTQDDKKFASKLSSYQDMTKIFGDIE GKRAQIEEIIQWITIFEDKKILVQKLKECYPELTSKQINQLKKLNYSGWGRLSEKLLTHAYQ GHSIIELLRHSDENFMEILTNDVYGFQNFIKEENQVQSNKIQHQDIANLTTSPALKKGIWST IKLVRELTSIFGEPEKIIMEFATEDQQKGKKQKSRKQLWDDNIKKNKLKSVDEYKYIIDVAN KLNNEQLQQEKLWLYLSQNGKCMYSGQSIDLDALLSPNATKHYEVDHIFPRSFIKDDSIDNK VLVIKKMNQTKGDQVPLQFIQQPYERIAYWKSLNKAGLISDSKLHKLMKPEFTAMDKEGFIQ RQLVETRQISVHVRDFLKEEYPNTKVIPMKAKMVSEFRKKFDIPKIRQMNDAHHAIDAYLNG WYHGAQLAYPNVDLFDFNFKWEKVREKWKALGEFNTKQKSRELFFFKKLEKMEVSQGERLI SKIKLDMNHFKINYSRKLANIPQQFYNQTAVSPKTAELKYESNKSNEWYKGLTPYQTYWA IKSVNKKGKEKMEYQMIDHYVFDFYKFQNGNEKELALYLAQRENKDEVLDAQIVYSLNKGDL LYINNHPCYFVSRKEVINAKQFELTVEQQLSLYNVMNNKETNVEKLLIEYDFIAEKVINEYH HYLNSKLKEKRVRTFFSESNQTHEDFIKALDELFKWTASATRSDKIGSRKNSMTHRAFLGK GKDVKIAYTSISGLKTTKPKSLFKLAESRNEL SEQ ID NO: 331
MAKILGLDLGTNSIGWAWERENIDFSLIDKGVRIFSEGVKSEKGIESSRAAERTGYRSARK IKYRRKLRKYETLKVLSLNRMCPLSIEEVEEWKKSGFKDYPLNPEFLKWLSTDEESNVNPYF FRDRASKHKVSLFELGRAFYHIAQRRGFLSNRLDQSAEGILEEHCPKIEAIVEDLISIDEIS TNITDYFFETGILDSNEKNGYAKDLDEGDKKLVSLYKSLLAILKKNESDFENCKSEIIERLN KKDVLGKVKGKIKDISQAMLDGNYKTLGQYFYSLYSKEKIRNQYTSREEHYLSEFITICKVQ GIDQINEEEKINEKKFDGLAKDLYKAIFFQRPLKSQKGLIGKCSFEKSKSRCAISHPDFEEY RMWTYLNTIKIGTQSDKKLRFLTQDEKLKLVPKFYRKNDFNFDVLAKELIEKGSSFGFYKSS KKNDFFYWFNYKPTDTVAACQVAASLKNAIGEDWKTKSFKYQTINSNKEQVSRTVDYKDLWH LLTVATSDVYLYEFAIDKLGLDEKNAKAFSKTKLKKDFASLSLSAINKILPYLKEGLLYSHA VFVA IE IVDE IWKDEKQRDYIKTQISEI IENYTLEKSRFEIINGLLKEYKSENEDGKRV YYSKEAEQSFENDLKKKLVLFYKSNEIENKEQQETIFNELLPIFIQQLKDYEFIKIQRLDQK VLIFLKGKNETGQIFCTEEKGTAEEKEKKIKNRLKKLYHPSDIEKFKKKIIKDEFGNEKIVL GSPLTPSIKNPMAMRALHQLRKVLNALILEGQIDEKTIIHIEMARELNDANKRKGIQDYQND NKKFREDAIKEIKKLYFEDCKKEVEPTEDDILRYQLWMEQNRSEIYEEGKNISICDIIGSNP AYDIEHTIPRSRSQDNSQMNKTLCSQRFNREVKKQSMPIELNNHLEILPRIAHWKEEADNLT REIEIISRSIKAAATKEIKDKKIRRRHYLTLKRDYLQGKYDRFIWEEPKVGFKNSQIPDTGI ITKYAQAYLKSYFKKVESVKGGMVAEFRKIWGIQESFIDENGMKHYKVKDRSKHTHHTIDAI TIACMTKEKYDVLAHAWTLEDQQNKKEARSI IEASKPWKTFKEDLLKIEEEILVSHYTPDNV KKQAKKIVRVRGKKQFVAEVERDVNGKAVPKKAASGKTIYKLDGEGKKLPRLQQGDTIRGSL HQDSIYGAIKNPLNTDEIKYVIRKDLESIKGSDVESIVDEWKEKIKEAIANKVLLLSSNAQ QKNKLVGTVWMNEEKRIAINKVRIYANSVKNPLHIKEHSLLSKSKHVHKQKVYGQNDENYAM AIYELDGKRDFELINIFNLAKLIKQGQGFYPLHKKKEIKGKIVFVPIEKRNKRDVVLKRGQQ WFYDKEVENPKDISEIVDFKGRIYIIEGLSIQRIVRPSGKVDEYGVIMLRYFKEARKADDI KQDNFKPDGVFKLGENKPTRKMNHQFTAFVEGIDFKVLPSGKFEKI
SEQ ID NO: 332
MEFKKVLGLDIGTNSIGCALLSLPKSIQDYGKGGRLEWLTSRVIPLDADYMKAFIDGKNGLP QVITPAGKRRQKRGSRRLKHRYKLRRSRLIRVFKTLNWLPEDFPLDNPKRIKETISTEGKFS FRISDYVPISDESYREFYREFGYPENEIEQVIEEINFRRKTKGKNKNPMIKLLPEDWWYYL RKKALIKPTTKEELIRIIYLFNQRRGFKSSRKDLTETAILDYDEFAKRLAEKEKYSAENYET KFVSITKVKEVVELKTDGRKGKKRFKVILEDSRIEPYEIERKEKPDWEGKEYTFLVTQKLEK GKFKQNKPDLPKEEDWALCTTALDNRMGSKHPGEFFFDELLKAFKEKRGYKIRQYPVNRWRY KKELEFIWTKQCQLNPELNNLNINKEILRKLATVLYPSQSKFFGPKIKEFENSDVLHIISED IIYYQRDLKSQKSLISECRYEKRKGIDGEIYGLKCIPKSSPLYQEFRIWQDIHNIKVIRKES EVNGKKKINIDETQLYINENIKEKLFELFNSKDSLSEKDILELISLNIINSGIKISKKEEET THRINLFANRKELKGNETKSRYRKVFKKLGFDGEYILNHPSKLNRLWHSDYSNDYADKEKTE KSILSSLGWKNRNGKWEKSKNYDVFNLPLEVAKAIANLPPLKKEYGSYSALAIRKMLWMRD GKYWQHPDQIAKDQENTSLMLFDKNLIQLTNNQRKVLNKYLLTLAEVQKRSTLIKQKLNEIE HNPYKLELVSDQDLEKQVLKSFLEKKNESDYLKGLKTYQAGYLIYGKHSEKDVPIVNSPDEL GEYIRKKLPNNSLRNPIVEQVIRETIFIVRDVWKSFGIIDEIHIELGRELKNNSEERKKTSE SQEKNFQEKERARKLLKELLNSSNFEHYDENGNKIFSSFTVNPNPDSPLDIEKFRIWKNQSG LTDEELNKKLKDEKIPTEIEVKKYILWLTQKCRSPYTGKIIPLSKLFDSNVYEIEHIIPRSK MKNDSTNNLVICELGVNKAKGDRLAANFISESNGKCKFGEVEYTLLKYGDYLQYCKDTFKYQ KAKYKNLLATEPPEDFIERQINDTRYIGRKLAELLTPWKDSKNIIFTIGSITSELKITWGL NGVWKDILRPRFKRLESIINKKLIFQDEDDPNKYHFDLSINPQLDKEGLKRLDHRHHALDAT IIAATTREHVRYLNSLNAADNDEEKREYFLSLCNHKIRDFKLPWENFTSEVKSKLLSCVVSY KESKPILSDPFNKYLKWEYKNGKWQKVFAIQIKNDRWKAVRRSMFKEPIGTVWIKKIKEVSL KEAIKIQAIWEEVKNDPVRKKKEKYIYDDYAQKVIAKIVQELGLSSSMRKQDDEKLNKFINE AKVSAGVNKNLNTTNKTIYNLEGRFYEKIKVAEYVLYKAKRMPLNKKEYIEKLSLQKMFNDL PNFILEKSILDNYPEILKELESDNKYI IEPHKKNNPVNRLLLEHILEYHNNPKEAFSTEGLE KLNKKAINKIGKPIKYITRLDGDINEEEIFRGAVFETDKGSNVYFVMYENNQTKDREFLKPN PSISVLKAIEHKNKIDFFAPNRLGFSRIILSPGDLVYVPTNDQYVLIKDNSSNETIINWDDN EFISNRIYQVKKFTGNSCYFLKNDIASLILSYSASNGVGEFGSQNISEYSVDDPPIRIKDVC IKIRVDRLGNVRPL SEQ ID NO: 333
MKHILGLDLGTNSIGWALIERNIEEKYGKIIGMGSRIVPMGAELSKFEQGQAQTKNADRRTN RGARRLNKRYKQRRNKLIYILQKLDMLPSQIKLKEDFSDPNKIDKITILPISKKQEQLTAFD LVSLRVKALTEKVGLEDLGKIIYKYNQLRGYAGGSLEPEKEDIFDEEQSKDKKNKSFIAFSK IVFLGEPQEEIFKNKKLNRRAIIVETEEGNFEGSTFLENIKVGDSLELLINISASKSGDTIT IKLPNKTNWRKKMENIENQLKEKSKEMGREFYISEFLLELLKENRWAKIRNNTILRARYESE FEAIWNEQVKHYPFLENLDKKTLIEIVSFIFPGEKESQKKYRELGLEKGLKYIIKNQWFYQ RELKDQSHLISDCRYEPNEKAIAKSHPVFQEYKVWEQINKLIVNTKIEAGTNRKGEKKYKYI DRPIPTALKEWIFEELQNKKEITFSAIFKKLKAEFDLREGIDFLNGMSPKDKLKGNETKLQL QKSLGELWDVLGLDSINRQIELWNILYNEKGNEYDLTSDRTSKVLEFINKYGNNIVDDNAEE TAIRISKIKFARAYSSLSLKAVERILPLVRAGKYFNNDFSQQLQSKILKLLNENVEDPFAKA AQTYLDNNQSVLSEGGVGNSIATILVYDKHTAKEYSHDELYKSYKEINLLKQGDLRNPLVEQ IINEALVLIRDIWKNYGIKPNEIRVELARDLKNSAKERATIHKRNKDNQTINNKIKETLVKN KKELSLANIEKVKLWEAQRHLSPYTGQPIPLSDLFDKEKYDVDHIIPISRYFDDSFTNKVIS EKSVNQEKANRTAMEYFEVGSLKYSIFTKEQFIAHVNEYFSGVKRKNLLATSIPEDPVQRQI KDTQYIAIRVKEELNKIVGNENVKTTTGSITDYLRNHWGLTDKFKLLLKERYEALLESEKFL EAEYDNYKKDFDSRKKEYEEKEVLFEEQELTREEFIKEYKENYIRYKKNKLIIKGWSKRIDH RHHAIDALIVACTEPAHIKRLNDLNKVLQDWLVEHKSEFMPNFEGSNSELLEEILSLPENER TEIFTQIEKFRAIEMPWKGFPEQVEQKLKEI IISHKPKDKLLLQYNKAGDRQIKLRGQLHEG TLYGISQGKEAYRIPLTKFGGSKFATEKNIQKIVSPFLSGFIANHLKEYNNKKEEAFSAEGI MDLNNKLAQYRNEKGELKPHTPISTVKIYYKDPSKNKKKKDEEDLSLQKLDREKAFNEKLYV KTGDNYLFAVLEGEIKTKKTSQIKRLYDIISFFDATNFLKEEFRNAPDKKTFDKDLLFRQYF EERNKAKLLFTLKQGDFVYLPNENEEVILDKESPLYNQYWGDLKERGKNIYWQKFSKKQIY FIKHTIADIIKKDVEFGSQNCYETVEGRSIKENCFKLEIDRLGNIVKVIKR SEQ ID NO: 334
MHVEIDFPHFSRGDSHLAMNKNEILRGSSVLYRLGLDLGSNSLGWFVTHLEKRGDRHEPVAL GPGGVRIFPDGRDPQSGTSNAVDRRMARGARKRRDRFVERRKELIAALIKYNLLPDDARERR ALEVLDPYALRKTALTDTLPAHHVGRALFHLNQRRGFQSNRKTDSKQSEDGAIKQAASRLAT DKGNETLGVFFADMHLRKSYEDRQTAIRAELVRLGKDHLTGNARKKIWAKVRKRLFGDEVLP RADAPHGVRARATITGTKASYDYYPTRDMLRDEFNAIWAGQSAHHATITDEARTEIEHI IFY QRPLKPAIVGKCTLDPATRPFKEDPEGYRAPWSHPLAQRFRILSEARNLEIRDTGKGSRRLT KEQSDLVVAALLANREVKFDKLRTLLKLPAEARFNLESDRRAALDGDQTAARLSDKKGFNKA WRGFPPERQIAIVARLEETEDENELIAWLEKECALDGAAAARVANTTLPDGHCRLGLRAIKK IVPIMQDGLDEDGVAGAGYHIAAKRAGYDHAKLPTGEQLGRLPYYGQWLQDAWGSGDARDQ KEKQYGQFPNPTVHIGLGQLRRVVNDLIDKYGPPTEISIEFTRALKLSEQQKAERQREQRRN QDKNKARAEELAKFGRPANPRNLLKMRLWEELAHDPLDRKCVYTGEQISIERLLSDEVDIDH ILPVAMTLDDSPANKIICMRYANRHKRKQTPSEAFGSSPTLQGHRYNWDDIAARATGLPRNK RWRFDANAREEFDKRGGFLARQLNETGWLARLAKQYLGAVTDPNQIWWPGRLTSMLRGKWG LNGLLPSDNYAGVQDKAEEFLASTDDMEFSGVKNRADHRHHAIDGLVTALTDRSLLWKMANA YDEEHEKFVIEPPWPTMRDDLKAALEKMWSHKPDHGIEGKLHEDSAYGFVKPLDATGLKEE EAGNLVYRKAIESLNENEVDRIRDIQLRTIVRDHVNVEKTKGVALADALRQLQAPSDDYPQF KHGLRHVRILKKEKGDYLVPIANRASGVAYKAYSAGENFCVEVFETAGGKWDGEAVRRFDAN KKNAGPKIAHAPQWRDANEGAKLVMRIHKGDLIRLDHEGRARIMWHRLDAAAGRFKLADHN ETGNLDKRHATNNDIDPFRWLMASYNTLKKLAAVPVRVDELGRVWRVMPN SEQ ID NO: 335
METTLGIDLGTNSIGLALVDQEEHQILYSGVRIFPEGINKDTIGLGEKEESRNATRRAKRQM RRQYFRKKLRKAKLLELLIAYDMCPLKPEDVRRWKNWDKQQKSTVRQFPDTPAFREWLKQNP YELRKQAVTEDVTRPELGRILYQMIQRRGFLSSRKGKEEGKIFTGKDRMVGIDETRKNLQKQ TLGAYLYDIAPKNGEKYRFRTERVRARYTLRDMYIREFEIIWQRQAGHLGLAHEQATRKKNI FLEGSATNVRNSKLITHLQAKYGRGHVLIEDTRITVTFQLPLKEVLGGKIEIEEEQLKFKSN ESVLFWQRPLRSQKSLLSKCVFEGRNFYDPVHQKWIIAGPTPAPLSHPEFEEFRAYQFINNI IYGKNEHLTAIQREAVFELMCTESKDFNFEKIPKHLKLFEKFNFDDTTKVPACTTISQLRKL FPHPVWEEKREEIWHCFYFYDDNTLLFEKLQKDYALQTNDLEKIKKIRLSESYGNVSLKAIR RINPYLKKGYAYSTAVLLGGIRNSFGKRFEYFKEYEPEIEKAVCRILKEKNAEGEVIRKIKD YLVHNRFGFAKNDRAFQKLYHHSQAITTQAQKERLPETGNLRNPIVQQGLNELRRTVNKLLA TCREKYGPSFKFDHIHVEMGRELRSSKTEREKQSRQIRENEKKNEAAKVKLAEYGLKAYRDN IQKYLLYKEIEEKGGTVCCPYTGKTL ISHTLGSDNSVQIEHI IPYSISLDDSLANKTLCDA TFNREKGELTPYDFYQKDPSPEKWGASSWEEIEDRAFRLLPYAKAQRFIRRKPQESNEFISR QLNDTRYISKKAVEYLSAICSDVKAFPGQLTAELRHLWGLNNILQSAPDITFPLPVSATENH REYYVITNEQNEVIRLFPKQGETPRTEKGELLLTGEVERKVFRCKGMQEFQTDVSDGKYWRR IKLSSSVTWSPLFAPKPISADGQIVLKGRIEKGVFVCNQLKQKLKTGLPDGSYWISLPVISQ TFKEGESVNNSKLTSQQVQLFGRVREGIFRCHNYQCPASGADGNFWCTLDTDTAQPAFTPIK NAPPGVGGGQI ILTGDVDDKGIFHADDDLHYELPASLPKGKYYGIFTVESCDPTLIPIELSA PKTSKGENLIEGNIWVDEHTGEVRFDPKKNREDQRHHAIDAIVIALSSQSLFQRLSTYNARR ENKKRGLDSTEHFPSPWPGFAQDVRQSWPLLVSYKQNPKTLCKISKTLYKDGKKIHSCGNA VRGQLHKETVYGQRTAPGATEKSYHIRKDIRELKTSKHIGKWDITIRQMLLKHLQENYHID ITQEFNIPSNAFFKEGVYRIFLPNKHGEPVPIKKIRMKEELGNAERLKDNINQYVNPRNNHH VMIYQDADGNLKEEIVSFWSVIERQNQGQPIYQLPREGRNIVSILQINDTFLIGLKEEEPEV YRNDLSTLSKHLYRVQKLSGMYYTFRHHLASTLNNEREEFRIQSLEAWKRANPVKVQIDEIG RITFLNGPLC
SEQ ID NO: 336
MESSQILSPIGIDLGGKFTGVCLSHLEAFAELPNHANTKYSVILIDHNNFQLSQAQRRATRH RVRNKKRNQFVKRVALQLFQHILSRDLNAKEETALCHYLNNRGYTYVDTDLDEYIKDETTIN LLKELLPSESEHNFIDWFLQKMQSSEFRKILVSKVEEKKDDKELKNAVKNIKNFITGFEKNS VEGHRHRKVYFENIKSDITKDNQLDSIKKKIPSVCLSNLLGHLSNLQWKNLHRYLAKNPKQF DEQTFGNEFLRMLKNFRHLKGSQESLAVRNLIQQLEQSQDYISILEKTPPEITIPPYEARTN TGMEKDQSLLLNPEKLNNLYPNWRNLIPGIIDAHPFLEKDLEHTKLRDRKRIISPSKQDEKR DSYILQRYLDLNKKIDKFKIKKQLSFLGQGKQLPANLIETQKEMETHFNSSLVSVLIQIASA YNKEREDAAQGIWFDNAFSLCELSNINPPRKQKILPLLVGAILSEDFINNKDKWAKFKIFWN THKIGRTSLKSKCKEIEEARKNSGNAFKIDYEEALNHPEHSNNKALIKIIQTIPDIIQAIQS HLGHNDSQALIYHNPFSLSQLYTILETKRDGFHKNCVAVTCENYWRSQKTEIDPEISYASRL PADSVRPFDGVLARMMQRLAYEIAMAKWEQIKHIPDNSSLLIPIYLEQNRFEFEESFKKIKG SSSDKTLEQAIEKQNIQWEEKFQRIINASMNICPYKGASIGGQGEIDHIYPRSLSKKHFGVI FNSEVNLIYCSSQGNREKKEEHYLLEHLSPLYLKHQFGTDNVSDIKNFISQNVANIKKYISF HLLTPEQQKAARHALFLDYDDEAFKTITKFLMSQQKARVNGTQKFLGKQIMEFLSTLADSKQ LQLEFSIKQITAEEVHDHRELLSKQEPKLVKSRQQSFPSHAIDATLTMSIGLKEFPQFSQEL DNSWFINHLMPDEVHLNPVRSKEKYNKPNISSTPLFKDSLYAERFIPVWVKGETFAIGFSEK DLFEIKPSNKEKLFTLLKTYSTKNPGESLQELQAKSKAKWLYFPINKTLALEFLHHYFHKEI VTPDDTTVCHFINSLRYYTKKESITVKILKEPMPVLSVKFESSKKNVLGSFKHTIALPATKD WERLFNHPNFLALKANPAPNPKEFNEFIRKYFLSDNNPNSDIPNNGHNIKPQKHKAVRKVFS LPVIPGNAGTMMRIRRKDNKGQPLYQLQTIDDTPSMGIQINEDRLVKQEVLMDAYKTRNLST IDGINNSEGQAYATFDNWLTLPVSTFKPEIIKLEMKPHSKTRRYIRITQSLADFIKTIDEAL MIKPSDSIDDPLNMPNEIVCKNKLFGNELKPRDGKMKIVSTGKIVTYEFESDSTPQWIQTLY VTQLKKQP
SEQ ID NO: 337
MKKIVGLDLGTNSIGWALINAYINKEHLYGIEACGSRIIPMDAAILGNFDKGNSISQTADRT SYRGIRRLRERHLLRRERLHRILDLLGFLPKHYSDSLNRYGKFLNDIECKLPWVKDETGSYK FIFQESFKEMLANFTEHHPILIANNKKVPYDWTIYYLRKKALTQKISKEELAWILLNFNQKR GYYQLRGEEEETPNKLVEYYSLKVEKVEDSGERKGKDTWYNVHLENGMIYRRTSNIPLDWEG KTKEFIVTTDLEADGSPKKDKEGNIKRSFRAPKDDDWTLIKKKTEADIDKIKMTVGAYIYDT LLQKPDQKIRGKLVRTIERKYYKNELYQILKTQSEFHEELRDKQLYIACLNELYPNNEPRRN SISTRDFCHLFIEDI IFYQRPLKSKKSLIDNCPYEENRYIDKESGEIKHASIKCIAKSHPLY QEFRLWQFIVNLRIYRKETDVDVTQELLPTEADYVTLFEWLNEKKEIDQKAFFKYPPFGFKK TTSNYRWNYVEDKPYPCNETHAQIIARLGKAHIPKAFLSKEKEETLWHILYSIEDKQEIEKA LHSFANKNNLSEEFIEQFKNFPPFKKEYGSYSAKAIKKLLPLMRMGKYWSIENIDNGTRIRI NKI IDGEYDE IRERVRQKAINLTDITHFRALPLWLACYLVYDRHSEVKDIVKWKTPKDIDL YLKSFKQHSLRNPIVEQVITETLRTVRDIWQQVGHIDEIHIELGREMKNPADKRARMSQQMI KNENTNLRIKALLTEFLNPEFGIENVRPYSPSQQDLLRIYEEGVLNSILELPEDIGIILGKF NQTDTLKRPTRSEILRYKLWLEQKYRSPYTGEMIPLSKLFTPAYEIEHIIPQSRYFDDSLSN KVICESEINKLKDRSLGYEFIKNHHGEKVELAFDKPVEVLSVEAYEKLVHESYSHNRSKMKK LLMEDIPDQFIERQLNDSRYISKWKSLLSNIVREENEQEAISKNVIPCTGGITDRLKKDWG INDVWNKIVLPRFIRLNELTESTRFTSINTNNTMIPSMPLELQKGFNKKRIDHRHHAMDAII IACANRNIVNYLNNVSASKNTKITRRDLQTLLCHKDKTDNNGNYKWVIDKPWETFTQDTLTA LQKITVSFKQNLRVINKTTNHYQHYENGKKIVSNQSKGDSWAIRKSMHKETVHGEVNLRMIK TVSFNEALKKPQAIVEMDLKKKILAMLELGYDTKRIKNYFEENKDTWQDINPSKIKVYYFTK ETKDRYFAVRKPIDTSFDKKKIKESITDTGIQQIMLRHLETKDNDPTLAFSPDGIDEMNRNI LILNKGKKHQPIYKVRVYEKAEKFTVGQKGNKRTKFVEAAKGTNLFFAIYETEEIDKDTKKV IRKRSYSTIPLNWIERQKQGLSSAPEDENGNLPKYILSPNDLVYVPTQEEINKGEWMPID RDRIYKMVDSSGITANFIPASTANLIFALPKATAEIYCNGENCIQNEYGIGSPQSKNQKAIT GEMVKEICFPIKVDRLGNI IQVGSCILTN
SEQ ID NO: 338
MSRSLTFSFDIGYASIGWAVIASASHDDADPSVCGCGTVLFPKDDCQAFKRREYRRLRRNIR SRRVRIERIGRLLVQAQIITPEMKETSGHPAPFYLASEALKGHRTLAPIELWHVLRWYAHNR GYDNNASWSNSLSEDGGNGEDTERVKHAQDLMDKHGTATMAETICRELKLEEGKADAPMEVS TPAYKNLNTAFPRLIVEKEVRRILELSAPLIPGLTAEIIELIAQHHPLTTEQRGVLLQHGIK LARRYRGSLLFGQLIPRFDNRIISRCPVTWAQVYEAELKKGNSEQSARERAEKLSKVPTANC PEFYEYRMARILCNIRADGEPLSAEIRRELMNQARQEGKLTKASLEKAISSRLGKETETNVS NYFTLHPDSEEALYLNPAVEVLQRSGIGQILSPSVYRIAANRLRRGKSVTPNYLLNLLKSRG ESGEALEKKIEKESKKKEADYADTPLKPKYATGRAPYARTVLKKWEEILDGEDPTRPARGE AHPDGELKAHDGCLYCLLDTDSSVNQHQKERRLDTMTNNHLVRHRMLILDRLLKDLIQDFAD GQKDRISRVCVEVGKELTTFSAMDSKKIQRELTLRQKSHTDAVNRLKRKLPGKALSANLIRK CRIAMDMNWTCPFTGATYGDHELENLELEHIVPHSFRQSNALSSLVLTWPGVNRMKGQRTGY DFVEQEQENPVPDKPNLHICSLNNYRELVEKLDDKKGHEDDRRRKKKRKALLMVRGLSHKHQ SQNHEAMKEIGMTEGMMTQSSHLMKLACKSIKTSLPDAHIDMIPGAVTAEVRKAWDVFGVFK ELCPEAADPDSGKILKENLRSLTHLHHALDACVLGLIPYIIPAHHNGLLRRVLAMRRIPEKL IPQVRPVANQRHYVLNDDGRMMLRDLSASLKENIREQLMEQRVIQHVPADMGGALLKETMQR VLSVDGSGEDAMVSLSKKKDGKKEKNQVKASKLVGVFPEGPSKLKALKAAIEIDGNYGVALD PKPWIRHIKVFKRIMALKEQNGGKPVRILKKGMLIHLTSSKDPKHAGVWRIESIQDSKGGV KLDLQRAHCAVPKNKTHECNWREVDLISLLKKYQMKRYPTSYTGTPR SEQ ID NO: 339
MTQKVLGLDLGTNSIGSAVRNLDLSDDLQWQLEFFSSDIFRSSVNKESNGREYSLAAQRSAH RRSRGLNEVRRRRLWATLNLLIKHGFCPMSSESLMRWCTYDKRKGLFREYPIDDKDFNAWIL LDFNGDGRPDYSSPYQLRRELVTRQFDFEQPIERYKLGRALYHIAQHRGFKSSKGETLSQQE TNSKPSSTDEIPDVAGAMKASEEKLSKGLSTYMKEHNLLTVGAAFAQLEDEGVRVRNNNDYR AIRSQFQHEIETIFKFQQGLSVESELYERLISEKKNVGTIFYKRPLRSQRGNVGKCTLERSK PRCAIGHPLFEKFRAWTLINNIKVRMSVDTLDEQLPMKLRLDLYNECFLAFVRTEFKFEDIR KYLEKRLGIHFSYNDKTINYKDSTSVAGCPITARFRKMLGEEWESFRVEGQKERQAHSKN I SFHRVSYSIEDIWHFCYDAEEPEAVLAFAQETLRLERKKAEELVRIWSAMPQGYAMLSQKAI RNINKILMLGLKYSDAVILAKVPELVDVSDEELLSIAKDYYLVEAQVNYDKRINSIVNGLIA KYKSVSEEYRFADHNYEYLLDESDEKDIIRQIENSLGARRWSLMDANEQTDILQKVRDRYQD FFRSHERKFVESPKLGESFENYLTKKFPMVEREQWKKLYHPSQITIYRPVSVGKDRSVLRLG NPDIGAIKNPTVLRVLNTLRRRVNQLLDDGVISPDETRVWETARELNDANRKWALDTYNRI RHDENEKIKKILEEFYPKRDGISTDDIDKARYVIDQREVDYFTGSKTYNKDIKKYKFWLEQG GQCMYTGRTINLSNLFDPNAFDIEHTIPESLSFDSSDMNLTLCDAHYNRFIKKNHIPTDMPN YDKAITIDGKEYPAITSQLQRWVERVERLNRNVEYWKGQARRAQNKDRKDQCMREMHLWKME LEYWKKKLERFTVTEVTDGFKNSQLVDTRVITRHAVLYLKSIFPHVDVQRGDVTAKFRKILG IQSVDEKKDRSLHSHHAIDATTLTIIPVSAKRDRMLELFAKIEEINKMLSFSGSEDRTGLIQ ELEGLKNKLQMEVKVCRIGHNVSEIGTFINDNIIVNHHIKNQALTPVRRRLRKKGYIVGGVD NPRWQTGDALRGEIHKASYYGAITQFAKDDEGKVLMKEGRPQVNPTIKFVIRRELKYKKSAA DSGFASWDDLGKAIVDKELFALMKGQFPAETSFKDACEQGIYMIKKGKNGMPDIKLHHIRHV RCEAPQSGLKIKEQTYKSEKEYKRYFYAAVGDLYAMCCYTNGKIREFRIYSLYDVSCHRKSD IEDIPEFITDKKGNRLMLDYKLRTGDMILLYKDNPAELYDLDNVNLSRRLYKINRFESQSNL VLMTHHLSTSKERGRSLGKTVDYQNLPESIRSSVKSLNFLIMGENRDFVIKNGKI IFNHR
SEQ ID NO: 340
MLVSPISVDLGGKNTGFFSFTDSLDNSQSGTVIYDESFVLSQVGRRSKRHSKRNNLRNKLVK RLFLLILQEHHGLSIDVLPDEIRGLFNKRGYTYAGFELDEKKKDALESDTLKEFLSEKLQSI DRDSDVEDFLNQIASNAESFKDYKKGFEAVFASATHSPNKKLELKDELKSEYGENAKELLAG LRVTKEILDEFDKQENQGNLPRAKYFEELGEYIATNEKVKSFFDSNSLKLTDMTKLIGNISN YQLKELRRYFNDKEMEKGDIWIPNKLHKITERFVRSWHPKNDADRQRRAELMKDLKSKEIME LLTTTEPVMTIPPYDDMNNRGAVKCQTLRLNEEYLDKHLPNWRDIAKRLNHGKFNDDLADST VKGYSEDSTLLHRLLDTSKEIDIYELRGKKPNELLVKTLGQSDANRLYGFAQNYYELIRQKV RAGIWVPVKNKDDSLNLEDNSNMLKRCNHNPPHKKNQIHNLVAGILGVKLDEAKFAEFEKEL WSAKVGNKKLSAYCKNIEELRKTHGNTFKIDIEELRKKDPAELSKEEKAKLRLTDDVILNEW SQKIANFFDIDDKHRQRFNNLFSMAQLHTVIDTPRSGFSSTCKRCTAENRFRSETAFYNDET GEFHKKATATCQRLPADTQRPFSGKIERYIDKLGYELAKIKAKELEGMEAKEIKVPIILEQN AFEYEESLRKSKTGSNDRVINSKKDRDGKKLAKAKENAEDRLKDKDKRIKAFSSGICPYCGD TIGDDGEIDHILPRSHTLKIYGTVFNPEGNLIYVHQKCNQAKADSIYKLSDIKAGVSAQWIE EQVANIKGYKTFSVLSAEQQKAFRYALFLQNDNEAYKKVVDWLRTDQSARVNGTQKYLAKKI QEKLTKMLPNKHLSFEFILADATEVSELRRQYARQNPLLAKAEKQAPSSHAIDAVMAFVARY QKVFKDGTPPNADEVAKLAMLDSWNPASNEPLTKGLSTNQKIEKMIKSGDYGQKNMREVFGK SIFGENAIGERYKPIWQEGGYYIGYPATVKKGYELKNCKWTSKNDIAKLEKIIKNQDLIS LKENQYIKIFSINKQTISELSNRYFNMNYKNLVERDKEIVGLLEFIVENCRYYTKKVDVKFA PKYIHETKYPFYDDWRRFDEAWRYLQENQNKTSSKDRFVIDKSSLNEYYQPDKNEYKLDVDT QPIWDDFCRWYFLDRYKTANDKKSIRIKARKTFSLLAESGVQGKVFRAKRKIPTGYAYQALP MDNNVIAGDYANILLEANSKTLSLVPKSGISIEKQLDKKLDVIKKTDVRGLAIDNNSFFNAD FDTHGIRLIVENTSVKVGNFPISAIDKSAKRMIFRALFEKEKGKRKKKTTISFKESGPVQDY LKVFLKKIVKIQLRTDGSISNIVVRKNAADFTLSFRSEHIQKLLK SEQ ID NO: 341
MAYRLGLDIGITSVGWAWALEKDESGLKPVRIQDLGVRIFDKAEDSKTGASLALPRREARS ARRRTRRRRHRLWRVKRLLEQHGILSMEQIEALYAQRTSSPDVYALRVAGLDRCLIAEEIAR VLIHIAHRRGFQSNRKSEIKDSDAGKLLKAVQENENLMQSKGYRTVAEMLVSEATKTDAEGK LVHGKKHGYVSNVRNKAGEYRHTVSRQAIVDEVRKIFAAQRALGNDVMSEELEDSYLKILCS QRNFDDGPGGDSPYGHGSVSPDGVRQSIYERMVGSCTFETGEKRAPRSSYSFERFQLLTKW NLRIYRQQEDGGRYPCELTQTERARVIDCAYEQTKITYGKLRKLLDMKDTESFAGLTYGLNR SRNKTEDTVFVEMKFYHEVRKALQRAGVFIQDLSIETLDQIGWILSVWKSDDNRRKKLSTLG LSDNVIEELLPLNGSKFGHLSLKAIRKILPFLEDGYSYDVACELAGYQFQGKTEYVKQRLLP PLGEGEVTNPVVRRALSQAIKWNAVIRKHGSPESIHIELARELSKNLDERRKIEKAQKENQ KNNEQIKDEIREILGSAHVTGRDIVKYKLFKQQQEFCMYSGEKLDVTRLFEPGYAEVDHIIP YGISFDDSYDNKVLVKTEQNRQKGNRTPLEYLRDKPEQKAKFIALVESIPLSQKKKNHLLMD KRAIDLEQEGFRERNLSDTRYITRALMNHIQAWLLFDETASTRSKRVVCVNGAVTAYMRARW GLTKDRDAGDKHHAADAWVACIGDSLIQRVTKYDKFKRNALADRNRYVQQVSKSEGITQYV DKETGEVFTWESFDERKFLPNEPLEPWPFFRDELLARLSDDPSKNIRAIGLLTYSETEQIDP IFVSRMPTRKVTGAAHKETIRSPRIVKVDDNKGTEIQWVSKVALTELKLTKDGEIKDYFRP EDDPRLYNTLRERLVQFGGDAKAAFKEPVYKISKDGSVRTPVRKVKIQEKLTLGVPVHGGRG IAENGGMVRIDVFAKGGKYYFVPIYVADVLKRELPNRLATAHKPYSEWRWDDSYQFKFSLY PNDAVMIKPSREVDITYKDRKEPVGCRIMYFVSANIASASISLRTHDNSGELEGLGIQGLEV FEKYWGPLGDTHPVYKERRMPFRVERKMN
SEQ ID NO: 342
MPVLSPLSPNAAQGRRRWSLALDIGEGSIGWAVAEVDAEGRVLQLTGTGVTLFPSAWSNENG TYVAHGAADRAVRGQQQRHDSRRRRLAGLARLCAPVLERSPEDLKDLTRTPPKADPRAIFFL RADAARRPLDGPELFRVLHHMAAHRGIRLAELQEVDPPPESDADDAAPAATEDEDGTRRAAA DERAFRRLMAEHMHRHGTQPTCGEIMAGRLRETPAGAQPVTRARDGLRVGGGVAVPTRALIE QEFDAIRAIQAPRHPDLPWDSLRRLVLDQAPIAVPPATPCLFLEELRRRGETFQGRTITREA IDRGLTVDPLIQALRIRETVGNLRLHERITEPDGRQRYVPRAMPELGLSHGELTAPERDTLV RALMHDPDGLAAKDGRIPYTRLRKLIGYDNSPVCFAQERDTSGGGITVNPTDPLMARWIDGW VDLPLKARSLYVRDVVARGADSAALARLLAEGAHGVPPVAAAAVPAATAAILESDIMQPGRY SVCPWAAEAILDAWANAPTEGFYDVTRGLFGFAPGEIVLEDLRRARGALLAHLPRTMAAART PNRAAQQRGPLPAYESVIPSQLITSLRRAHKGRAADWSAADPEERNPFLRTWTGNAATDHIL NQVRKTANEVITKYGNRRGWDPLPSRITVELAREAKHGVIRRNEIAKENRENEGRRKKESAA LDTFCQDNTVSWQAGGLPKERAALRLRLAQRQEFFCPYCAERPKLRATDLFSPAETEIDHVI ERRMGGDGPDNLVLAHKDCNNAKGKKTPHEHAGDLLDSPALAALWQGWRKENADRLKGKGHK ARTPREDKDFMDRVGWRFEEDARAKAEENQERRGRRMLHDTARATRLARLYLAAAVMPEDPA EIGAPPVETPPSPEDPTGYTAIYRTISRVQPVNGSVTHMLRQRLLQRDKNRDYQTHHAEDAC LLLLAGPAWQAFNTEAAQHGADAPDDRPVDLMPTSDAYHQQRRARALGRVPLATVDAALAD IVMPESDRQDPETGRVHWRLTRAGRGLKRRIDDLTRNCVILSRPRRPSETGTPGALHNATHY GRREITVDGRTDTWTQRMNARDLVALLDNAKIVPAARLDAAAPGDTILKEICTEIADRHDR WDPEGTHARRWISARLAALVPAHAEAVARDIAELADLDALADADRTPEQEARRSALRQSPY LGRAISAKKADGRARAREQEILTRALLDPHWGPRGLRHLIMREARAPSLVRIRANKTDAFGR PVPDAAVWVKTDGNAVSQLWRLTSWTDDGRRIPLPKPIEKRIEISNLEYARLNGLDEGAGV TGNNAPPRPLRQDIDRLTPLWRDHGTAPGGYLGTAVGELEDKARSALRGKAMRQTLTDAGIT AEAGWRLDSEGAVCDLEVAKGDTVKKDGKTYKVGVITQGIFGMPVDAAGSAPRTPEDCEKFE EQYGIKPWKAKGIPLA
SEQ ID NO: 343
MNYTEKEKLFMKYILALDIGIASVGWAILDKESETVIEAGSNIFPEASAADNQLRRDMRGAK RNNRRLKTRINDFIKLWENNNLSIPQFKSTEIVGLKVRAITEEITLDELYLILYSYLKHRGI SYLEDALDDTVSGSSAYANGLKLNAKELETHYPCEIQQERLNTIGKYRGQSQIINENGEVLD LSNVFTIGAYRKEIQRVFEIQKKYHPELTDEFCDGYMLIFNRKRKYYEGPGNEKSRTDYGRF TTKLDANGNYITEDNIFEKLIGKCSVYPDELRAAAASYTAQEYNVLNDLNNLTINGRKLEEN EKHEIVERIKSSNTINMRKIISDCMGENIDDFAGARIDKSGKEIFHKFEVYNKMRKALLEIG IDISNYSREELDEIGYIMTINTDKEAMMEAFQKSWIDLSDDVKQCLINMRKTNGALFNKWQS FSLKIMNELIPEMYAQPKEQMTLLTEMGVTKGTQEEFAGLKYIPVDVVSEDIFNPWRRSVR ISFKILNAVLKKYKALDTIVIEMPRDRNSEEQKKRINDSQKLNEKEMEYIEKKLAVTYGIKL SPSDFSSQKQLSLKLKLWNEQDGICLYSGKTIDPNDIINNPQLFEIDHIIPRSISFDDARSN KVLVYRSENQKKGNQTPYYYLTHSHSEWSFEQYKATVMNLSKKKEYAISRKKIQNLLYSEDI TKMDVLKGFINRNINDTSYASRLVLNTIQNFFMANEADTKVKVIKGSYTHQMRCNLKLDKNR DESYSHHAVDAMLIGYSELGYEAYHKLQGEFIDFETGEILRKDMWDENMSDEVYADYLYGKK WANIRNEWKAEKNVKYWHYVMRKSNRGLCNQTIRGTREYDGKQYKINKLDIRTKEGIKVFA KLAFSKKDSDRERLLVYLNDRRTFDDLCKIYEDYSDAANPFVQYEKETGDI IRKYSKKHNGP RIDKLKYKDGEVGACIDISHKYGFEKGSKKVILESLVPYRMDVYYKEENHSYYLVGVKQSDI KFEKGRNVIDEEAYARILVNEKMIQPGQSRADLENLGFKFKLSFYKNDIIEYEKDGKIYTER LVSRTMPKQRNYIETKPIDKAKFEKQNLVGLGKTKFIKKYRYDILGNKYSCSEEKFTSFC
SEQ ID NO: 344
MLRLYCANNLVLNNVQNLWKYLLLLIFDKKI IFLFKIKVILIRRYMENNNKEKIVIGFDLGV ASVGWSIVNAETKEVIDLGVRLFSEPEKADYRRAKRTTRRLLRRKKFKREKFHKLILKNAEI FGLQSRNEILNVYKDQSSKYRNILKLKINALKEEIKPSELVWILRDYLQNRGYFYKNEKLTD EFVSNSFPSKKLHEHYEKYGFFRGSVKLDNKLDNKKDKAKEKDEEEESDAKKESEELIFSNK QWINEIVKVFENQSYLTESFKEEYLKLFNYVRPFNKGPGSKNSRTAYGVFSTDIDPETNKFK DYSNIWDKTIGKCSLFEEEIRAPKNLPSALIFNLQNEICTIKNEFTEFKNWWLNAEQKSEIL KFVFTELFNWKDKKYSDKKFNKNLQDKIKKYLLNFALENFNLNEEILKNRDLENDTVLGLKG VKYYEKSNATADAALEFSSLKPLYVFIKFLKEKKLDLNYLLGLENTEILYFLDSIYLAISYS SDLKERNEWFKKLLKELYPKIKNNNLEIIENVEDIFEITDQEKFESFSKTHSLSREAFNHII PLLLSNNEGKNYESLKHSNEELKKRTEKAELKAQQNQKYLKDNFLKEALVPLSVKTSVLQAI KIFNQIIKNFGKKYEISQVVIEMARELTKPNLEKLLNNATNSNIKILKEKLDQTEKFDDFTK KKFIDKIENSVVFRNKLFLWFEQDRKDPYTQLDIKINEIEDETEIDHVIPYSKSADDSWFNK LLVKKSTNQLKKNKTVWEYYQNESDPEAKWNKFVAWAKRIYLVQKSDKESKDNSEKNSIFKN KKPNLKFKNITKKLFDPYKDLGFLARNLNDTRYATKVFRDQLNNYSKHHSKDDENKLFKWC MNGSITSFLRKSMWRKNEEQVYRFNFWKKDRDQFFHHAVDASI IAIFSLLTKTLYNKLRVYE SYDVQRREDGVYLINKETGEVKKADKDYWKDQHNFLKIRENAIEIKNVLNNVDFQNQVRYSR KANTKLNTQLFNETLYGVKEFENNFYKLEKVNLFSRKDLRKFILEDLNEESEKNKKNENGSR KRILTEKYIVDEILQILENEEFKDSKSDINALNKYMDSLPSKFSEFFSQDFINKCKKENSLI LTFDAIKHNDPKKVIKIKNLKFFREDATLKNKQAVHKDSKNQIKSFYESYKCVGFIWLKNKN DLEESIFVPINSRVIHFGDKDKDIFDFDSYNKEKLLNEINLKRPENKKFNSINEIEFVKFVK PGALLLNFENQQIYYISTLESSSLRAKIKLLNKMDKGKAVSMKKITNPDEYKIIEHVNPLGI NLNWTKKLENNN
SEQ ID NO: 345
MLMSKHVLGLDLGVGSIGWCLIALDAQGDPAEILGMGSRWPLNNATKAIEAFNAGAAFTAS QERTARRTMRRGFARYQLRRYRLRRELEKVGMLPDAALIQLPLLELWELRERAATAGRRLTL PELGRVLCHINQKRGYRHVKSDAAAIVGDEGEKKKDSNSAYLAGIRANDEKLQAEHKTVGQY FAEQLRQNQSESPTGGISYRIKDQIFSRQCYIDEYDQIMAVQRVHYPDILTDEFIRMLRDEV IFMQRPLKSCKHLVSLCEFEKQERVMRVQQDDGKGGWQLVERRVKFGPKVAPKSSPLFQLCC IYEAVNNIRLTRPNGSPCDITPEERAKIVAHLQSSASLSFAALKKLLKEKALIADQLTSKSG LKGNSTRVALASALQPYPQYHHLLDMELETRMMTVQLTDEETGEVTEREVAWTDSYVRKPL YRLWHILYSIEEREAMRRALITQLGMKEEDLDGGLLDQLYRLDFVKPGYGNKSAKFICKLLP QLQQGLGYSEACAAVGYRHSNSPTSEEITERTLLEKIPLLQRNELRQPLVEKILNQMINLVN ALKAEYGIDEVRVELARELKMSREERERMARNNKDREERNKGVAAKIRECGLYPTKPRIQKY MLWKEAGRQCLYCGRSIEEEQCLREGGMEVEHIIPKSVLYDDSYGNKTCACRRCNKEKGNRT ALEYIRAKGREAEYMKRINDLLKEKKISYSKHQRLRWLKEDIPSDFLERQLRLTQYISRQAM AILQQGIRRVSASEGGVTARLRSLWGYGKILHTLNLDRYDSMGETERVSREGEATEELHITN WSKRMDHRHHAIDALWACTRQSYIQRLNRLSSEFGREDKKKEDQEAQEQQATETGRLSNLE RWLTQRPHFSVRTVSDKVAEILISYRPGQRVVTRGR IYRKKMADGREVSCVQRGVLVPRGE LMEASFYGKILSQGRVRIVKRYPLHDLKGEVVDPHLRELITTYNQELKSREKGAPIPPLCLD KDKKQEVRSVRCYAKTLSLDKAIPMCFDEKGEPTAFVKSASNHHLALYRTPKGKLVESIVTF WDAVDRARYGIPLVITHPREVMEQVLQRGDIPEQVLSLLPPSDWVFVDSLQQDEMWIGLSD EELQRALEAQNYRKISEHLYRVQKMSSSYYVFRYHLETSVADDKNTSGRIPKFHRVQSLKAY EERNIRKVRVDLLGRISLL
SEQ ID NO: 346
MSDLVLGLDIGIGSVGVGILNKVTGEI IHK SRIFPAAQAENNLVRRTNRQGRRLARRKKHR RVRLNRLFEESGLITDFTKISINLNPYQLRVKGLTDELSNEELFIALKNMVKHRGISYLDDA SDDGNSSVGDYAQIVKENSKQLETKTPGQIQLERYQTYGQLRGDFTVEKDGKKHRLINVFPT SAYRSEALRILQTQQEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGRYRTSGETL DNIFGILIGKCTFYPDEFRAAKASYTAQEFNLLNDLNNLTVPTETKKLSKEQKNQIINYVKN EKAMGPAKLFKYIAKLLSCDVADIKGYRIDKSGKAEIHTFEAYRKMKTLETLDIEQMDRETL DKLAYVLTLNTEREGIQEALEHEFADGSFSQKQVDELVQFRKANSSIFGKGWHNFSVKLMME LIPELYETSEEQMTILTRLGKQKTTSSSNKTKYIDEKLLTEEIYNPVVAKSVRQAIKIVNAA IKEYGDFDNIVIEMARETNEDDEKKAIQKIQKANKDEKDAAMLKAANQYNGKAELPHSVFHG HKQLATKIRLWHQQGERCLYTGKTISIHDLINNSNQFEVDHILPLSITFDDSLANKVLVYAT ANQEKGQRTPYQALDSMDDAWSFRELKAFVRESKTLSNKKKEYLLTEEDISKFDVRKKFIER NLVDTRYASRVVLNALQEHFRAHKIDTKVSVVRGQFTSQLRRHWGIEKTRDTYHHHAVDALI IAASSQLNLWKKQKNTLVSYSEDQLLDIETGELISDDEYKESVFKAPYQHFVDTLKSKEFED SILFSYQVDSKFNRKISDATIYATRQAKVGKDKADETYVLGKIKDIYTQDGYDAFMKIYKKD KSKFLMYRHDPQTFEKVIEPILENYPNKQINEKGKEVPCNPFLKYKEEHGYIRKYSKKGNGP EIKSLKYYDSKLGNHIDITPKDSNNKVVLQSVSPWRADVYFNKTTGKYEILGLKYADLQFEK GTGTYKISQEKYNDIKKKEGVDSDSEFKFTLYKNDLLLVKDTETKEQQLFRFLSRTMPKQKH YVELKPYDKQKFEGGEALIKVLGNVANSGQCKKGLGKSNISIYKVRTDVLGNQHI IKNEGDK PKLDF
SEQ ID NO: 347
MNAEHGKEGLLIMEENFQYRIGLDIGITSVGWAVLQNNSQDEPVRITDLGVRIFDVAENPKN GDALAAPRRDARTTRRRLRRRRHRLERIKFLLQENGLIEMDSFMERYYKGNLPDVYQLRYEG LDRKLKDEELAQVLIHIAKHRGFRSTRKAETKEKEGGAVLKATTENQKIMQEKGYRTVGEML YLDEAFHTECLWNEKGYVLTPRNRPDDYKHTILRSMLVEEVHAIFAAQRAHGNQKATEGLEE AYVEIMTSQRSFDMGPGLQPDGKPSPYAMEGFGDRVGKCTFEKDEYRAPKATYTAELFVALQ KINHTKLIDEFGTGRFFSEEERKTIIGLLLSSKELKYGTIRKKLNIDPSLKFNSLNYSAKKE GETEEERVLDTEKAKFASMFWTYEYSKCLKDRTEEMPVGEKADLFDRIGEILTAYKNDDSRS SRLKELGLSGEEIDGLLDLSPAKYQRVSLKAMRKMQPYLEDGLIYDKACEAAGYDFRALNDG NKKHLLKGEEINAIVNDITNPWKRSVSQTIKVINAIIQKYGSPQAVNIELAREMSKNFQDR TNLEKEMKKRQQENERAKQQIIELGKQNPTGQDILKYRLWNDQGGYCLYSGKKIPLEELFDG GYDIDHILPYSITFDDSYRNKVLVTAQENRQKGNRTPYEYFGADEKRWEDYEASVRLLVRDY KKQQKLLKKNFTEEERKEFKERNLNDTKYITRWYNMIRQNLELEPFNHPEKKKQVWAVNGA VTSYLRKRWGLMQKDRSTDRHHAMDAVVIACCTDGMIHKISRYMQGRELAYSRNFKFPDEET GEILNRDNFTREQWDEKFGVKVPLPWNSFRDELDIRLLNEDPKNFLLTHADVQRELDYPGWM YGEEESPIEEGRYINYIRPLFVSRMPNHKVTGSAHDATIRSARDYETRGWITKVPLTDLKL NKDNEIEGYYDKDSDRLLYQALVRQLLLHGNDGKKAFAEDFHKPKADGTEGPWRKVKIEKK QTSGVMVRGGTGIAANGEMVRIDVFRENGKYYFVPVYTADWRKVLPNRAATHTKPYSEWRV MDDANFVFSLYSRDLIHVKSKKDIKTNLVNGGLLLQKEIFAYYTGADIATASIAGFANDSNF KFRGLGIQSLEIFEKCQVDILGNISWRHENRQEFH
SEQ ID NO: 348
MRVLGLDAGIASLGWALIEIEESNRGELSQGTIIGAGTWMFDAPEEKTQAGAKLKSEQRRTF RGQRRWRRRRQRMNEVRRILHSHGLLPSSDRDALKQPGLDPWRIRAEALDRLLGPVELAVA LGHIARHRGFKSNSKGAKTNDPADDTSKMKRAVNETREKLARFGSAAKMLVEDESFVLRQTP TKNGASEIVRRFRNREGDYSRSLLRDDLAAEMRALFTAQARFQSAIATADLQTAFTKAAFFQ RPLQDSEKLVGPCPFEVDEKRAPKRGYSFELFRFLSRLNHVTLRDGKQERTLTRDELALAAA DFGAAAKVSFTALRKKLKLPETTVFVGVKADEESKLDWARSGKAAEGTARLRSVIVDALGE LAWGALLCSPEKLDKIAEVISFRSDIGRISEGLAQAGCNAPLVDALTAAASDGRFDPFTGAG HISSKAARNILSGLRQGMTYDKACCAADYDHTASRERGAFDVGGHGREALKRILQEERISRE LVGSPTARKALIESIKQVKAIVERYGVPDRIHVELARDVGKSIEEREEITRGIEKRNRQKDK LRGLFEKEVGRPPQDGARGKEELLRFELWSEQMGRCLYTDDYISPSQLVATDDAVQVDHILP WSRFADDSYANKTLCMAKANQDKKGRTPYEWFKAEKTDTEWDAFIVRVEALADMKGFKKRNY KLRNAEEAAAKFRNRNLNDTRWACRLLAEALKQLYPKGEKDKDGKERRRVFSRPGALTDRLR RAWGLQWMKKSTKGDRIPDDRHHALDAIVIAATTESLLQRATREVQEIEDKGLHYDLVKNVT PPWPGFREQAVEAVEKVFVARAERRRARGKAHDATIRHIAVREGEQRVYERRKVAELKLADL DRVKDAERNARLIEKLRNWIEAGSPKDDPPLSPKGDPIFKVRLVTKSKVNIALDTGNPKRPG TVDRGEMARVDVFRKASKKGKYEYYLVPIYPHDIATMKTPPIRAVQAYKPEDEWPEMDSSYE FCWSLVPMTYLQVISSKGEIFEGYYRGMNRSVGAIQLSAHSNSSDWQGIGARTLTEFKKFN VDRFGRKHEVERELRTWRGETWRGKAYI
SEQ ID NO: 349
MGNYYLGLDVGIGSIGWAVINIEKKRIEDFNVRIFKSGEIQEKNRNSRASQQCRRSRGLRRL YRRKSHRKLRLKNYLSIIGLTTSEKIDYYYETADNNVIQLRNKGLSEKLTPEEIAACLIHIC NNRGYKDFYEVNVEDIEDPDERNEYKEEHDSIVLISNLMNEGGYCTPAEMICNCREFDEPNS VYRKFHNSAASKNHYLITRHMLVKEVDLILENQSKYYGILDDKTIAKIKDI IFAQRDFEIGP GKNERFRRFTGYLDSIGKCQFFKDQERGSRFTVIADIYAFVNVLSQYTYTNNRGESVFDTSF ANDLINSALKNGSMDKRELKAIAKSYHIDISDKNSDTSLTKCFKYIKWKPLFEKYGYDWDK LIENYTDTDNNVLNRIGIVLSQAQTPKRRREKLKALNIGLDDGLINELTKLKLSGTANVSYK YMQGSIEAFCEGDLYGKYQAKFNKEIPDIDENAKPQKLPPFKNEDDCEFFKNPWFRSINET RKLINAI IDKYGYPAAVNIETADELNKTFEDRAIDTKRNNDNQKENDRIVKEIIECIKCDEV HARHLIEKYKLWEAQEGKCLYSGETITKEDMLRDKDKLFEVDHIVPYSLILDNTINNKALVY AEENQKKGQRTPLMYMNEAQAADYRVRVNTMFKSKKCSKKKYQYLMLPDLNDQELLGGWRSR NLNDTRYICKYLVNYLRKNLRFDRSYESSDEDDLKIRDHYRVFPVKSRFTSMFRRWWLNEKT WGRYDKAELKKLTYLDHAADAII IANCRPEYWLAGEKLKLNKMYHQAGKRITPEYEQSKKA CIDNLYKLFRMDRRTAEKLLSGHGRLTPIIPNLSEEVDKRLWDKNIYEQFWKDDKDKKSCEE LYRENVASLYKGDPKFASSLSMPVISLKPDHKYRGTITGEEAIRVKEIDGKLIKLKRKSISE ITAESINSIYTDDKILIDSLKTIFEQADYKDVGDYLKKTNQHFFTTSSGKRVNKVTVIEKVP SRWLRKEIDDNNFSLLNDSSYYCIELYKDSKGDNNLQGIAMSDIVHDRKTKKLYLKPDFNYP DDYYTHVMYIFPGDYLRIKSTSKKSGEQLKFEGYFISVKNVNENSFRFISDNKPCAKDKRVS ITKKDIVIKLAVDLMGKVQGENNGKGISCGEPLSLLKEKN SEQ ID NO: 350
MLSRQLLGASHLARPVSYSYNVQDNDVHCSYGERCFMRGKRYRIGIDVGLNSVGLAAVEVSD ENSPVRLLNAQSVIHDGGVDPQKNKEAITRKNMSGVARRTRRMRRRKRERLHKLDMLLGKFG YPVIEPESLDKPFEEWHVRAELATRYIEDDELRRESISIALRHMARHRGWRNPYRQVDSLIS DNPYSKQYGELKEKAKAYNDDATAAEEESTPAQLVVAMLDAGYAEAPRLRWRTGSKKPDAEG YLPVRLMQEDNANELKQIFRVQRVPADEWKPLFRSVFYAVSPKGSAEQRVGQDPLAPEQARA LKASLAFQEYRIANVITNLRIKDASAELRKLTVDEKQSIYDQLVSPSSEDITWSDLCDFLGF KRSQLKGVGSLTEDGEERISSRPPRLTSVQRIYESDNKIRKPLVAWWKSASDNEHEAMIRLL SNTVDIDKVREDVAYASAIEFIDGLDDDALTKLDSVDLPSGRAAYSVETLQKLTRQMLTTDD DLHEARKTLFNVTDSWRPPADPIGEPLGNPSVDRVLKNVNRYLMNCQQRWGNPVSVNIEHVR SSFSSVAFARKDKREYEKNNEKRSIFRSSLSEQLRADEQMEKVRESDLRRLEAIQRQNGQCL YCGRTITFRTCEMDHIVPRKGVGSTNTRTNFAAVCAECNRMKSNTPFAIWARSEDAQTRGVS LAEAKKRVTMFTFNPKSYAPREVKAFKQAVIARLQQTEDDAAIDNRSIESVAWMADELHRRI DWYFNAKQYVNSASIDDAEAETMKTTVSVFQGRVTASARRAAGIEGKIHFIGQQSKTRLDRR HHAVDASVIAMMNTAAAQTLMERESLRESQRLIGLMPGERSWKEYPYEGTSRYESFHLWLDN MDVLLELLNDALDNDRIAVMQSQRYVLGNSIAHDATIHPLEKVPLGSAMSADLIRRASTPAL WCALTRLPDYDEKEGLPEDSHREIRVHDTRYSADDEMGFFASQAAQIAVQEGSADIGSAIHH ARVYRCWKTNAKGVRKYFYGMIRVFQTDLLRACHDDLFTVPLPPQSISMRYGEPRWQALQS GNAQYLGSLWGDEIEMDFSSLDVDGQIGEYLQFFSQFSGGNLAWKHWWDGFFNQTQLRIR PRYLAAEGLAKAFSDDWPDGVQKIVTKQGWLPPVNTASKTAVRIVRRNAFGEPRLSSAHHM PCSWQWRHE
SEQ ID NO: 351
MYSIGLDLGISSVGWSVIDERTGNVIDLGVRLFSAKNSEKNLERRTNRGGRRLIRRKTNRLK DAKKILAAVGFYEDKSLKNSCPYQLRVKGLTEPLSRGEIYKVTLHILKKRGISYLDEVDTEA AKESQDYKEQVRKNAQLLTKYTPGQIQLQRLKENNRVKTGINAQGNYQLNVFKVSAYANELA TILKTQQAFYPNELTDDWIALFVQPGIAEEAGLIYRKRPYYHGPGNEANNSPYGRWSDFQKT GEPATNIFDKLIGKDFQGELRASGLSLSAQQYNLLNDLTNLKIDGEVPLSSEQKEYILTELM TKEFTRFGVNDWKLLGVKKERLSGWRLDKKGKPEIHTLKGYRNWRKIFAEAGIDLATLPTE TIDCLAKVLTLNTEREGIENTLAFELPELSESVKLLVLDRYKELSQSISTQSWHRFSLKTLH LLIPELMNATSEQNTLLEQFQLKSDVRKRYSEYKKLPTKDVLAEIYNPTVNKTVSQAFKVID ALLVKYGKEQIRYITIEMPRDDNEEDEKKRIKELHAKNSQRKNDSQSYFMQKSGWSQEKFQT TIQKNRRFLAKLLYYYEQDGICAYTGLPISPELLVSDSTEIDHIIPISISLDDSINNKVLVL SKANQVKGQQTPYDAWMDGSFKKINGKFSNWDDYQKWVESRHFSHKKENNLLETRNIFDSEQ VEKFLARNLNDTRYASRLVLNTLQSFFTNQETKVRWNGSFTHTLRKKWGADLDKTRETHHH HAVDATLCAVTSFVKVSRYHYAVKEETGEKVMREIDFETGEIVNEMSYWEFKKSKKYERKTY QVKWPNFREQLKPVNLHPRIKFSHQVDRKANRKLSDATIYSVREKTEVKTLKSGKQKITTDE YTIGKIKDIYTLDGWEAFKKKQDKLLMKDLDEKTYERLLSIAETTPDFQEVEEKNGKVKRVK RSPFAVYCEENDIPAIQKYAKKNNGPLIRSLKYYDGKLNKHINITKDSQGRPVEKTKNGRKV TLQSLKPYRYDIYQDLETKAYYTVQLYYSDLRFVEGKYGITEKEYMKKVAEQTKGQWRFCF SLQKNDGLEIEWKDSQRYDVRFYNFQSANSINFKGLEQEMMPAENQFKQKPYNNGAINLNIA KYGKEGKKLRKFNTDILGKKHYLFYEKEPKNIIK
SEQ ID NO: 352
MYFYKNKENKLNKKVVLGLDLGIASVGWCLTDISQKEDNKFPI ILHGVRLFETVDDSDDKLL NETRRKKRGQRRRNRRLFTRKRDFIKYLIDNNIIELEFDKNPKILVRNFIEKYINPFSKNLE LKYKSVTNLPIGFHNLRKAAINEKYKLDKSELIVLLYFYLSLRGAFFDNPEDTKSKEMNKNE IEIFDKNESIKNAEFPIDKIIEFYKISGKIRSTINLKFGHQDYLKEIKQVFEKQNIDFMNYE KFAMEEKSFFSRIRNYSEGPGNEKSFSKYGLYANENGNPELIINEKGQKIYTKIFKTLWESK IGKCSYDKKLYRAPKNSFSAKVFDITNKLTDWKHKNEYISERLKRKILLSRFLNKDSKSAVE KILKEENIKFENLSEIAYNKDDNKINLPIINAYHSLTTIFKKHLINFENYLISNENDLSKLM SFYKQQSEKLFVPNEKGSYEINQNNNVLHIFDAISNILNKFSTIQDRIRILEGYFEFSNLKK DVKSSEIYSEIAKLREFSGTSSLSFGAYYKFIPNLISEGSKNYSTISYEEKALQNQKNNFSH SNLFEKTWVEDLIASPTVKRSLRQTMNLLKEIFKYSEKNNLEIEKIVVEVTRSSNNKHERKK IEGINKYRKEKYEELKKVYDLPNENTTLLKKLWLLRQQQGYDAYSLRKIEANDVINKPWNYD IDHIVPRSISFDDSFSNLVIVNKLDNAKKSNDLSAKQFIEKIYGIEKLKEAKENWGNWYLRN ANGKAFNDKGKFIKLYTIDNLDEFDNSDFINRNLSDTSYITNALVNHLTFSNSKYKYSVVSV NGKQTSNLRNQIAFVGIKNNKETEREWKRPEGFKSINSNDFLIREEGKNDVKDDVLIKDRSF NGHHAEDAYFITIISQYFRSFKRIERLNVNYRKETRELDDLEKNNIKFKEKASFDNFLLINA LDELNEKLNQMRFSRMVITKKNTQLFNETLYSGKYDKGKNTIKKVEKLNLLDNRTDKIKKIE EFFDEDKLKENELTKLHIFNHDKNLYETLKI IWNEVKIEIKNKNLNEKNYFKYFVNKKLQEG KISFNEWVPILDNDFKIIRKIRYIKFSSEEKETDEIIFSQSNFLKIDQRQNFSFHNTLYWVQ IWVYKNQKDQYCFISIDARNSKFEKDEIKINYEKLKTQKEKLQIINEEPILKINKGDLFENE EKELFYIVGRDEKPQKLEIKYILGKKIKDQKQIQKPVKKYFPNWKKVNLTYMGEIFKK
SEQ ID NO: 353
MDNKNYRIGIDVGLNSIGFCAVEVDQHDTPLGFLNLSVYRHDAGIDPNGKKTNTTRLAMSGV ARRTRRLFRKRKRRLAALDRFIEAQGWTLPDHADYKDPYTPWLVRAELAQTPIRDENDLHEK LAIAVRHIARHRGWRSPWVPVRSLHVEQPPSDQYLALKERVEAKTLLQMPEGATPAEMVVAL DLSVDVNLRPKNREKTDTRPENKKPGFLGGKLMQSDNANELRKIAKIQGLDDALLRELIELV FAADSPKGASGELVGYDVLPGQHGKRRAEKAHPAFQRYRIASIVSNLRIRHLGSGADERLDV ETQKRVFEYLLNAKPTADITWSDVAEEIGVERNLLMGTATQTADGERASAKPPVDVTNVAFA TCKIKPLKEWWLNADYEARCVMVSALSHAEKLTEGTAAEVEVAEFLQNLSDEDNEKLDSFSL PIGRAAYSVDSLERLTKRMIENGEDLFEARVNEFGVSEDWRPPAEPIGARVGNPAVDRVLKA VNRYLMAAEAEWGAPLSVNIEHVREGFISKRQAVEIDRENQKRYQRNQAVRSQIADHINATS GVRGSDVTRYLAIQRQNGECLYCGTAITFVNSEMDHIVPRAGLGSTNTRDNLVATCERCNKS KSNKPFAVWAAECGIPGVSVAEALKRVDFWIADGFASSKEHRELQKGVKDRLKRKVSDPEID NRSMESVAWMARELAHRVQYYFDEKHTGTKVRVFRGSLTSAARKASGFESRVNFIGGNGKTR LDRRHHAMDAATVAMLRNSVAKTLVLRGNIRASERAIGAAETWKSFRGENVADRQIFESWSE NMRVLVEKFNLALYNDEVSIFSSLRLQLGNGKAHDDTITKLQMHKVGDAWSLTEIDRASTPA LWCALTRQPDFTWKDGLPANEDRTIIVNGTHYGPLDKVGIFGKAAASLLVRGGSVDIGSAIH HARIYRIAGKKPTYGMVRVFAPDLLRYRNEDLFNVELPPQSVSMRYAEPKVREAIREGKAEY LGWLWGDELLLDLSSETSGQIAELQQDFPGTTHWTVAGFFSPSRLRLRPVYLAQEGLGEDV SEGSKSI IAGQGWRPAVNKVFGSAMPEVIRRDGLGRKRRFSYSGLPVSWQG
SEQ ID NO: 354
MRLGLDIGTSSIGWWLYETDGAGSDARITGVVDGGVRIFSDGRDPKSGASLAVDRRAARAMR RRRDRYLRRRATLMKVLAETGLMPADPAEAKALEALDPFALRAAGLDEPLPLPHLGRALFHL NQRRGFKSNRKTDRGDNESGKIKDATARLDMEMMANGARTYGEFLHKRRQKATDPRHVPSVR TRLSIANRGGPDGKEEAGYDFYPDRRHLEEEFHKLWAAQGAHHPELTETLRDLLFEKIFFQR PLKEPEVGLCLFSGHHGVPPKDPRLPKAHPLTQRRVLYETVNQLRVTADGREARPLTREERD QVIHALDNKKPTKSLSSMVLKLPALAKVLKLRDGERFTLETGVRDAIACDPLRASPAHPDRF GPRWSILDADAQWEVISRIRRVQSDAEHAALVDWLTEAHGLDRAHAEATAHAPLPDGYGRLG LTATTRILYQLTADVVTYADAVKACGWHHSDGRTGECFDRLPYYGEVLERHVIPGSYHPDDD DITRFGRITNPTVHIGLNQLRRLVNRI IETHGKPHQIWELARDLKKSEEQKRADIKRIRDT TEAAKKRSEKLEELEIEDNGRNRMLLRLWEDLNPDDAMRRFCPYTGTRISAAMIFDGSCDVD HILPYSRTLDDSFPNRTLCLREANRQKRNQTPWQAWGDTPHWHAIAANLKNLPENKRWRFAP DAMTRFEGENGFLDRALKDTQYLARISRSYLDTLFTKGGHVWVVPGRFTEMLRRHWGLNSLL SDAGRGAVKAKNRTDHRHHAIDAAVIAATDPGLLNRISRAAGQGEAAGQSAELIARDTPPPW EGFRDDLRVRLDRIIVSHRADHGRIDHAARKQGRDSTAGQLHQETAYSIVDDIHVASRTDLL SLKPAQLLDEPGRSGQVRDPQLRKALRVATGGKTGKDFENALRYFASKPGPYQAIRRVRIIK PLQAQARVPVPAQDPIKAYQGGSNHLFEIWRLPDGEIEAQVITSFEAHTLEGEKRPHPAAKR LLRVHKGDMVALERDGRRVVGHVQKMDIANGLFIVPHNEANADTRNNDKSDPFKWIQIGARP AIASGIRRVSVDEIGRLRDGGTRPI
SEQ ID NO: 355
MLHCIAVIRVPPSEEPGFFETHADSCALCHHGCMTYAANDKAIRYRVGIDVGLRSIGFCAVE VDDEDHPIRILNSWHVHDAGTGGPGETESLRKRSGVAARARRRGRAEKQRLKKLDVLLEEL GWGVSSNELLDSHAPWHIRKRLVSEYIEDETERRQCLSVAMAHIARHRGWRNSFSKVDTLLL EQAPSDRMQGLKERVEDRTGLQFSEEVTQGELVATLLEHDGDVTIRGFVRKGGKATKVHGVL EGKYMQSDLVAELRQICRTQRVSETTFEKLVLSIFHSKEPAPSAARQRERVGLDELQLALDP AAKQPRAERAHPAFQKFKVVATLANMRIREQSAGERSLTSEELNRVARYLLNHTESESPTWD DVARKLEVPRHRLRGSSRASLETGGGLTYPPVDDTTVRVMSAEVDWLADWWDCANDESRGHM IDAISNGCGSEPDDVEDEEVNELISSATAEDMLKLELLAKKLPSGRVAYSLKTLREVTAAIL ETGDDLSQAITRLYGVDPGWVPTPAPIEAPVGNPSVDRVLKQVARWLKFASKRWGVPQTVNI EHTREGLKSASLLEEERERWERFEARREIRQKEMYKRLGISGPFRRSDQVRYEILDLQDCAC LYCGNEINFQTFEVDHIIPRVDASSDSRRTNLAAVCHSCNSAKGGLAFGQWVKRGDCPSGVS LENAIKRVRSWSKDRLGLTEKAMGKRKSEVISRLKTEMPYEEFDGRSMESVAWMAIELKKRI EGYFNSDRPEGCAAVQVNAYSGRLTACARRAAHVDKRVRLIRLKGDDGHHKNRFDRRNHAMD ALVIALMTPAIARTIAVREDRREAQQLTRAFESWKNFLGSEERMQDRWESWIGDVEYACDRL NELIDADKIPVTENLRLRNSGKLHADQPESLKKARRGSKRPRPQRYVLGDALPADVINRVTD PGLWTALVRAPGFDSQLGLPADLNRGLKLRGKRISADFPIDYFPTDSPALAVQGGYVGLEFH HARLYRI IGPKEKVKYALLRVCAIDLCGIDCDDLFEVELKPSSISMRTADAKLKEAMGNGSA KQIGWLVLGDEIQIDPTKFPKQSIGKFLKECGPVSSWRVSALDTPSKITLKPRLLSNEPLLK TSRVGGHESDLWAECVEKIMKKTGWVVEINALCQSGLIRVIRRNALGEVRTSPKSGLPISL NLR
SEQ ID NO: 356
MRYRVGLDLGTASVGAAVFSMDEQGNPMELIWHYERLFSEPLVPDMGQLKPKKAARRLARQQ RRQIDRRASRLRRIAIVSRRLGIAPGRNDSGVHGNDVPTLRAMAVNERIELGQLRAVLLRMG KKRGYGGTFKAVRKVGEAGEVASGASRLEEEMVALASVQNKDSVTVGEYLAARVEHGLPSKL KVAANNEYYAPEYALFRQYLGLPAIKGRPDCLPNMYALRHQIEHEFERIWATQSQFHDVMKD HGVKEEIRNAIFFQRPLKSPADKVGRCSLQTNLPRAPRAQIAAQNFRIEKQMADLRWGMGRR AEMLNDHQKAVIRELLNQQKELSFRKIYKELERAGCPGPEGKGLNMDRAALGGRDDLSGNTT LAAWRKLGLEDRWQELDEVTQIQVINFLADLGSPEQLDTDDWSCRFMGKNGRPRNFSDEFVA FMNELRMTDGFDRLSKMGFEGGRSSYSIKALKALTEWMIAPHWRETPETHRVDEEAAIRECY PESLATPAQGGRQSKLEPPPLTGNEWDVALRQVRHTINMMIDDLGSVPAQIWEMAREMKG GVTRRNDIEKQNKRFASERKKAAQSIEENGKTPTPARILRYQLWIEQGHQCPYCESNISLEQ ALSGAYTNFEHILPRTLTQIGRKRSELVLAHRECNDEKGNRTPYQAFGHDDRRWRIVEQRAN ALPKKSSRKTRLLLLKDFEGEALTDESIDEFADRQLHESSWLAKVTTQWLSSLGSDVYVSRG SLTAELRRRWGLDTVIPQVRFESGMPVVDEEGAEITPEEFEKFRLQWEGHRVTREMRTDRRP DKRIDHRHHLVDAIVTALTSRSLYQQYAKAWKVADEKQRHGRVDVKVELPMPILTIRDIALE AVRSVRISHKPDRYPDGRFFEATAYGIAQRLDERSGEKVDWLVSRKSLTDLAPEKKSIDVDK VRANISRIVGEAIRLHISNIFEKRVSKGMTPQQALREPIEFQGNILRKVRCFYSKADDCVRI EHSSRRGHHYKMLLNDGFAYMEVPCKEGILYGVPNLVRPSEAVGIKRAPESGDFIRFYKGDT VKNIKTGRVYTIKQILGDGGGKLILTPVTETKPADLLSAKWGRLKVGGRNIHLLRLCAE
SEQ ID NO: 357
MIGEHVRGGCLFDDHWTPNWGAFRLPNTVRTFTKAENPKDGSSLAEPRRQARGLRRRLRRKT QRLEDLRRLLAKEGVLSLSDLETLFRETPAKDPYQLRAEGLDRPLSFPEWVRVLYHITKHRG FQSNRRNPVEDGQERSRQEEEGKLLSGVGENERLLREGGYRTAGEMLARDPKFQDHRRNRAG DYSHTLSRSLLLEEARRLFQSQRTLGNPHASSNLEEAFLHLVAFQNPFASGEDIRNKAGHCS LEPDQIRAPRRSASAETFMLLQKTGNLRLIHRRTGEERPLTDKEREQIHLLAWKQEKVTHKT LRRHLEIPEEWLFTGLPYHRSGDKAEEKLFVHLAGIHEIRKALDKGPDPAVWDTLRSRRDLL DSIADTLTFYKNEDEILPRLESLGLSPENARALAPLSFSGTAHLSLSALGKLLPHLEEGKSY TQARADAGYAAPPPDRHPKLPPLEEADWRNPWFRALTQTRKVVNALVRRYGPPWCIHLETA RELSQPAKVRRRIETEQQANEKKKQQAEREFLDIVGTAPGPGDLLKMRLWREQGGFCPYCEE YLNPTRLAEPGYAEMDHILPYSRSLDNGWHNRVLVHGKDNRDKGNRTPFEAFGGDTARWDRL VAWVQASHLSAPKKRNLLREDFGEEAERELKDRNLTDTRFITKTAATLLRDRLTFHPEAPKD PVMTLNGRLTAFLRKQWGLHKNRKNGDLHHALDAAVLAVASRSFVYRLSSHNAAWGELPRGR EAENGFSLPYPAFRSEVLARLCPTREEILLRLDQGGVGYDEAFRNGLRPVFVSRAPSRRLRG KAHMETLRSPKWKDHPEGPRTASRIPLKDLNLEKLERMVGKDRDRKLYEALRERLAAFGGNG KKAFVAPFRKPCRSGEGPLVRSLRIFDSGYSGVELRDGGEVYAVADHESMVRVDVYAKKNRF YLVPVYVADVARGIVKNRAIVAHKSEEEWDLVDGSFDFRFSLFPGDLVEIEKKDGAYLGYYK SCHRGDGRLLLDRHDRMPRESDCGTFYVSTRKDVLSMSKYQVDPLGEIRLVGSEKPPFVL
SEQ ID NO: 358
MEKKRKVTLGFDLGIASVGWAIVDSETNQVYKLGSRLFDAPDTNLERRTQRGTRRLLRRRKY RNQKFYNLVKRTEVFGLSSREAIENRFRELSIKYPNIIELKTKALSQEVCPDEIAWILHDYL KNRGYFYDEKETKEDFDQQTVESMPSYKLNEFYKKYGYFKGALSQPTESEMKDNKDLKEAFF FDFSNKEWLKEINYFFNVQKNILSETFIEEFKKIFSFTRDISKGPGSDNMPSPYGIFGEFGD NGQGGRYEHIWDKNIGKCSIFTNEQRAPKYLPSALIFNFLNELANIRLYSTDKKNIQPLWKL SSVDKLNILLNLFNLPISEKKKKLTSTNINDIVKKESIKSIMISVEDIDMIKDEWAGKEPNV YGVGLSGLNIEESAKENKFKFQDLKILNVLINLLDNVGIKFEFKDRNDIIKNLELLDNLYLF LIYQKESNNKDSSIDLFIAKNESLNIENLKLKLKEFLLGAGNEFENHNSKTHSLSKKAIDEI LPKLLDNNEGWNLEAIKNYDEEIKSQIEDNSSLMAKQDKKYLNDNFLKDAILPPNVKVTFQQ AILIFNKIIQKFSKDFEIDKWIELAREMTQDQENDALKGIAKAQKSKKSLVEERLEANNID KSVFNDKYEKLIYKIFLWISQDFKDPYTGAQISVNEIVNNKVEIDHI IPYSLCFDDSSANKV LVHKQSNQEKSNSLPYEYIKQGHSGWNWDEFTKYVKRVFVNNVDSILSKKERLKKSENLLTA SYDGYDKLGFLARNLNDTRYATILFRDQLNNYAEHHLIDNKKMFKVIAMNGAVTSFIRKNMS YDNKLRLKDRSDFSHHAYDAAIIALFSNKTKTLYNLIDPSLNGIISKRSEGYWVIEDRYTGE IKELKKEDWTSIKNNVQARKIAKEIEEYLIDLDDEVFFSRKTKRKTNRQLYNETIYGIATKT DEDGITNYYKKEKFSILDDKDIYLRLLREREKFVINQSNPEVIDQIIEIIESYGKENNIPSR DEAINIKYTKNKINYNLYLKQYMRSLTKSLDQFSEEFINQMIANKTFVLYNPTKNTTRKIKF LRLVNDVKINDIRKNQVINKFNGKNNEPKAFYE I SLGAIVFKNSANNFKTLSI TQIAIF GDKNWDIEDFKTYNMEKIEKYKEIYGIDKTYNFHSFIFPGTILLDKQNKEFYYISSIQTVRD IIEIKFLNKIEFKDENKNQDTSKTPKRLMFGIKSIMNNYEQVDISPFGINKKIFE
SEQ ID NO: 359
MGYRIGLDVGITSTGYAVLKTDKNGLPYKILTLDSVIYPRAENPQTGASLAEPRRIKRGLRR RTRRTKFRKQRTQQLFIHSGLLSKPEIEQILATPQAKYSVYELRVAGLDRRLTNSELFRVLY FFIGHRGFKSNRKAELNPENEADKKQMGQLLNSIEEIRKAIAEKGYRTVGELYLKDPKYNDH KRNKGYIDGYLSTPNRQMLVDEIKQILDKQRELGNEKLTDEFYATYLLGDENRAGIFQAQRD FDEGPGAGPYAGDQIKKMVGKDIFEPTEDRAAKATYTFQYFNLLQKMTSLNYQNTTGDTWHT LNGLDRQAIIDAVFAKAEKPTKTYKPTDFGELRKLLKLPDDARFNLVNYGSLQTQKEIETVE KKTRFVDFKAYHDLVKVLPEEMWQSRQLLDHIGTALTLYSSDKRRRRYFAEELNLPAELIEK LLPLNFSKFGHLSIKSMQNIIPYLEMGQVYSEATTNTGYDFRKKQISKDTIREEITNPVVRR AVTKTIKIVEQIIRRYGKPDGINIELARELGRNFKERGDIQKRQDKNRQTNDKIAAELTELG IPVNGQNIIRYKLHKEQNGVDPYTGDQIPFERAFSEGYEVDHI IPYSISWDDSYTNKVLTSA KCNREKGNRIPMVYLANNEQRLNALTNIADNIIRNSRKRQKLLKQKLSDEELKDWKQRNIND TRFITRVLYNYFRQAIEFNPELEKKQRVLPLNGEVTSKIRSRWGFLKVREDGDLHHAIDATV IAAITPKFIQQVTKYSQHQEVKNNQALWHDAEIKDAEYAAEAQRMDADLFNKIFNGFPLPWP EFLDELLARISDNPVEMMKSRSWNTYTPIEIAKLKPVFVVRLANHKISGPAHLDTIRSAKLF DEKGIVLSRVSITKLKINKKGQVATGDGIYDPENSNNGDKWYSAIRQALEAHNGSGELAFP DGYLEYVDHGTKKLVRKVRVAKKVSLPVRLKNKAAADNGSMVRIDVFNTGKKFVFVPIYIKD TVEQVLPNKAIARGKSLWYQITESDQFCFSLYPGDMVHIESKTGIKPKYSNKENNTSWPIK NFYGYFDGADIATASILVRAHDSSYTARSIGIAGLLKFEKYQVDYFGRYHKVHEKKRQLFVK RDE SEQ ID NO: 360 MQKNINTKQNHIYIKQAQKIKEKLGDKPYRIGLDLGVGSIGFAIVSMEENDGNVLLPKEIIM VGSRIFKASAGAADRKLSRGQRNNHRHTRERMRYLWKVLAEQKLALPVPADLDRKENSSEGE TSAKRFLGDVLQKDIYELRVKSLDERLSLQELGYVLYHIAGHRGSSAIRTFENDSEEAQKEN TENKKIAGNIKRLMAKKNYRTYGEYLYKEFFENKEKHKREKISNAANNHKFSPTRDLVIKEA EAILKKQAGKDGFHKELTEEYIEKLTKAIGYESEKLIPESGFCPYLKDEKRLPASHKLNEER RLWETLNNARYSDPIVDIVTGEITGYYEKQFTKEQKQKLFDYLLTGSELTPAQTKKLLGLKN TNFEDIILQGRDKKAQKIKGYKLIKLESMPFWARLSEAQQDSFLYDWNSCPDEKLLTEKLSN EYHLTEEEIDNAFNEIVLSSSYAPLGKSAMLIILEKIKNDLSYTEAVEEALKEGKLTKEKQA IKDRLPYYGAVLQESTQKI IAKGFSPQFKDKGYKTPHTNKYELEYGRIANPWHQTLNELRK LVNEIIDILGKKPCEIGLETARELKKSAEDRSKLSREQNDNESNRNRIYEIYIRPQQQVIIT RRENPRNYILKFELLEEQKSQCPFCGGQISPNDIINNQADIEHLFPIAESEDNGRNNLVISH SACNADKAKRSPWAAFASAAKDSKYDYNRILSNVKENIPHKAWRFNQGAFEKFIENKPMAAR FKTDNSYISKVAHKYLACLFEKPNIICVKGSLTAQLRMAWGLQGLMIPFAKQLITEKESESF NKDVNSNKKIRLDNRHHALDAIVIAYASRGYGNLLNKMAGKDYKINYSERNWLSKILLPPNN IVWENIDADLESFESSVKTALKNAFISVKHDHSDNGELVKGTMYKIFYSERGYTLTTYKKLS ALKLTDPQKKKTPKDFLETALLKFKGRESEMKNEKIKSAIENNKRLFDVIQDNLEKAKKLLE EENEKSKAEGKKEKNINDASIYQKAISLSGDKYVQLSKKEPGKFFAISKPTPTTTGYGYDTG DSLCVDLYYDNKGKLCGEI IRKIDAQQKNPLKYKEQGFTLFERIYGGDILEVDFDIHSDKNS FRNNTGSAPENRVFIKVGTFTEITNN IQIWFGNI IKSTGGQDDSFTINSMQQYNPRKLILS SCGFIKYRSPILKNKEG
SEQ ID NO: 361
MAAFKPNPINYILGLDIGIASVGWAMVEIDEDENPICLIDLGVRVFERAEVPKTGDSLAMAR RLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTP LEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVADNAHALQTGDFRTPAELALNKFE KESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSG DAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPY RKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPL NLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPL MEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPWLRALSQARKVINGWRRYG SPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRL YEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPY EYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVA DRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAWVACSTVAMQQKITRF VRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKL RTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLK LKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQK TGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAWQGKDEEDWQLID DSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKT ALSFQKYQIDELGKEIRPCRLKKRPPVR
SEQ ID NO: 362
MQTTNLSYILGLDLGIASVGWAVVEINENEDPIGLIDVGVRIFERAEVPKTGESLALSRRLA RSTRRLIRRRAHRLLLAKRFLKREGILSTIDLEKGLPNQAWELRVAGLERRLSAIEWGAVLL HLIKHRGYLSKRKNESQTNNKELGALLSGVAQNHQLLQSDDYRTPAELALKKFAKEEGHIRN QRGAYTHTFNRLDLLAELNLLFAQQHQFGNPHCKEHIQQYMTELLMWQKPALSGEAILKMLG KCTHEKNEFKAAKHTYSAERFVWLTKLNNLRILEDGAERALNEEERQLLINHPYEKSKLTYA QVRKLLGLSEQAIFKHLRYSKENAESATFMELKAWHAIRKALENQGLKDTWQDLAKKPDLLD EIGTAFSLYKTDEDIQQYLTNKVPNSVINALLVSLNFDKFIELSLKSLRKILPLMEQGKRYD QACREIYGHHYGEANQKTSQLLPAIPAQEIRNPWLRTLSQARKVINAIIRQYGSPARVHIE TGRELGKSFKERREIQKQQEDNRTKRESAVQKFKELFSDFSSEPKSKDILKFRLYEQQHGKC LYSGKEINIHRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLASENQNKGNQTPYEWLQGKIN SERWKNFVALVLGSQCSAAKKQRLLTQVIDDNKFIDRNLNDTRYIARFLSNYIQENLLLVGK NKKNVFTPNGQITALLRSRWGLIKARENNNRHHALDAIVVACATPSMQQKITRFIRFKEVHP YKIENRYEMVDQESGEIISPHFPEPWAYFRQEVNIRVFDNHPDTVLKEMLPDRPQANHQFVQ PLFVSRAPTRKMSGQGHMETIKSAKRLAEGISVLRIPLTQLKPNLLENMVNKEREPALYAGL KARLAEFNQDPAKAFATPFYKQGGQQVKAIRVEQVQKSGVLVRENNGVADNASIVRTDVFIK NNKFFLVPIYTWQVAKGILPNKAIVAHKNEDEWEEMDEGAKFKFSLFPNDLVELKTKKEYFF GYYIGLDRATGNISLKEHDGEISKGKDGVYRVGVKLALSFEKYQVDELGKNRQICRPQQRQP VR
SEQ ID NO: 363
MGIRFAFDLGTNSIGWAVWRTGPGVFGEDTAASLDGSGVLIFKDGRNPKDGQSLATMRRVPR QSRKRRDRFVLRRRDLLAALRKAGLFPVDVEEGRRLAATDPYHLRAKALDESLTPHEMGRVI FHLNQRRGFRSNRKADRQDREKGKIAEGSKRLAETLAATNCRTLGEFLWSRHRGTPRTRSPT RIRMEGEGAKALYAFYPTREMVRAEFERLWTAQSRFAPDLLTPERHEEIAGILFRQRDLAPP KIGCCTFEPSERRLPRALPSVEARGIYERLAHLRITTGPVSDRGLTRPERDVLASALLAGKS LTFKAVRKTLKILPHALVNFEEAGEKGLDGALTAKLLSKPDHYGAAWHGLSFAEKDTFVGKL LDEADEERLIRRLVTENRLSEDAARRCASIPLADGYGRLGRTANTEILAALVEETDETGTW TYAEAVRRAGERTGRNWHHSDERDGVILDRLPYYGEILQRHWPGSGEPEEKNEAARWGRLA NPTVHIGLNQLRKWNRLIAAHGRPDQIWELARELKLNREQKERLDRENRKNREENERRTA ILAEHGQRDTAENKIRLRLFEEQARANAGIALCPYTGRAIGIAELFTSEVEIDHILPVSLTL DDSLANRVLCRREA REKRRQTPFQAFGATPAWNDIVARAAKLPPNKRWRFDPAALERFERE GGFLGRQLNETKYLSRLAKIYLGKICDPDRVYVTPGTLTGLLRARWGLNSILSDSNFKNRSD HRHHAVDAWIGVLTRGMIQRIAHDAARAEDQDLDRVFRDVPVPFEDFRDHVRERVSTITVA VKPEHGKGGALHEDTSYGLVPDTDPNAALGNLWRKPIRSLTAGEVDRVRDRALRARLGALA APFRDESGRVRDAKGLAQALEAFGAENGIRRVRILKPDASWTIADRRTGVPYRAVAPGENH HVDIVQMRDGSWRGFAASVFEVNRPGWRPEWEVKKLGGKLVMRLHKGDMVELSDKDGQRRVK WQQIEISANRVRLSPHNDGGKLQDRHADADDPFRWDLATIPLLKDRGCVAVRVDPIGVVTL RRSNV
SEQ ID NO: 364
MMEVFMGRLVLGLDIGITSVGFGIIDLDESEIVDYGVRLFKEGTAAENETRRTKRGGRRLKR RRVTRREDMLHLLKQAGIISTSFHPLNNPYDVRVKGLNERLNGEELATALLHLCKHRGSSVE TIEDDEAKAKEAGETKKVLSMNDQLLKSGKYVCEIQKERLRTNGHIRGHENNFKTRAYVDEA FQILSHQDLSNELKSAIITIISRKRMYYDGPGGPLSPTPYGRYTYFGQKEPIDLIEKMRGKC SLFPNEPRAPKLAYSAELFNLLNDLNNLSIEGEKLTSEQKAMILKIVHEKGKITPKQLAKEV GVSLEQIRGFRIDTKGSPLLSELTGYKMIREVLEKSNDEHLEDHVFYDEIAEILTKTKDIEG RKKQISELSSDLNEESVHQLAGLTKFTAYHSLSFKALRLINEEMLKTELNQMQSITLFGLKQ NNELSVKGMKNIQADDTAILSPVAKRAQRETFKWNRLREIYGEFDSIWEMAREKNSEEQR KAIRERQKFFEMRNKQVADIIGDDRKINAKLREKLVLYQEQDGKTAYSLEPIDLKLLIDDPN AYEVDHI IPISISLDDSITNKVLVTHRENQEKGNLTPISAFVKGRFTKGSLAQYKAYCLKLK EKNIKTNKGYRKKVEQYLLNENDIYKYDIQKEFINRNLVDTSYASRVVLNTLTTYFKQNEIP TKVFTVKGSLTNAFRRKINLKKDRDEDYGHHAIDALIIASMPKMRLLSTIFSRYKIEDIYDE STGEVFSSGDDSMYYDDRYFAFIASLKAIKVRKFSHKIDTKPNRSVADETIYSTRVIDGKEK WKKYKDIYDPKFTALAEDILNNAYQEKYLMALHDPQTFDQIVKWNYYFEEMSKSEKYFTK DKKGRIKISGMNPLSLYRDEHGMLKKYSKKGDGPAITQMKYFDGVLGNHIDISAHYQVRDKK WLQQISPYRTDFYYSKENGYKFVTIRYKDVRWSEKKKKYVIDQQDYAMKKAEKKIDDTYEF QFSMHRDELIGITKAEGEALIYPDETWHNFNFFFHAGETPEILKFTATNNDKSNKIEVKPIH CYCKMRLMPTISKKIVRIDKYATDWGNLYKVKKNTLKFEFD
SEQ ID NO: 365 MKKILGVDLGITSFGYAILQETGKDLYRCLDNSWMRNNPYDEKSGESSQSIRSTQKSMRRL IEKRKKRIRCVAQTMERYGILDYSETMKINDPKNNPIKNRWQLRAVDAWKRPLSPQELFAIF AHMAKHRGYKSIATEDLIYELELELGLNDPEKESEKKADERRQVYNALRHLEELRKKYGGET IAQTIHRAVEAGDLRSYRNHDDYEKMIRREDIEEEIEKVLLRQAELGALGLPEEQVSELIDE LKACITDQEMPTIDESLFGKCTFYKDELAAPAYSYLYDLYRLYKKLADLNIDGYEVTQEDRE KVIEWVEKKIAQGKNLKKITHKDLRKILGLAPEQKIFGVEDERIVKGKKEPRTFVPFFFLAD IAKFKELFASIQKHPDALQIFRELAEILQRSKTPQEALDRLRALMAGKGIDTDDRELLELFK NKRSGTRELSHRYILEALPLFLEGYDEKEVQRILGFDDREDYSRYPKSLRHLHLREGNLFEK EENPINNHAVKSLASWALGLIADLSWRYGPFDEIILETTRDALPEKIRKEIDKAMREREKAL DKI IGKYKKEFPSIDKRLARKIQLWERQKGLDLYSGKVINLSQLLDGSADIEHIVPQSLGGL STDYNTIVTLKSVNAAKGNRLPGDWLAGNPDYRERIGMLSEKGLIDWKKRKNLLAQSLDEIY TENTHSKGIRATSYLEALVAQVLKRYYPFPDPELRKNGIGVRMIPGKVTSKTRSLLGIKSKS RETNFHHAEDALILSTLTRGWQNRLHRMLRDNYGKSEAELKELWKKYMPHIEGLTLADYIDE AFRRFMSKGEESLFYRDMFDTIRSISYWVDKKPLSASSHKETVYSSRHEVPTLRKNILEAFD SLNVIKDRHKLTTEEFMKRYDKEIRQKLWLHRIGNTNDESYRAVEERATQIAQILTRYQLMD AQNDKEIDEKFQQALKELITSPIEVTGKLLRKMRFVYDKLNAMQIDRGLVETDKNMLGIHIS KGPNEKLIFRRMDVNNAHELQKERSGILCYLNEMLFIFNKKGLIHYGCLRSYLEKGQGSKYI ALFNPRFPANPKAQPSKFTSDSKIKQVGIGSATGI IKAHLDLDGHVRSYEVFGTLPEGSIEW FKEESGYGRVEDDPHH
SEQ ID NO: 366
MRPIEPWILGLDIGTDSLGWAVFSCEEKGPPTAKELLGGGVRLFDSGRDAKDHTSRQAERGA FRRARRQTRTWPWRRDRLIALFQAAGLTPPAAETRQIALALRREAVSRPLAPDALWAALLHL AHHRGFRSNRIDKRERAAAKALAKAKPAKATAKATAPAKEADDEAGFWEGAEAALRQRMAAS GAPTVGALLADDLDRGQPVRMRYNQSDRDGVVAPTRALIAEELAEIVARQSSAYPGLDWPAV TRLVLDQRPLRSKGAGPCAFLPGEDRALRALPTVQDFIIRQTLANLRLPSTSADEPRPLTDE EHAKALALLSTARFVEWPALRRALGLKRGVKFTAETERNGAKQAARGTAGNLTEAILAPLIP GWSGWDLDRKDRVFSDLWAARQDRSALLALIGDPRGPTRVTEDETAEAVADAIQIVLPTGRA SLSAKAARAIAQAMAPGIGYDEAVTLALGLHHSHRPRQERLARLPYYAAALPDVGLDGDPVG PPPAEDDGAAAEAYYGRIGNISVHIALNETRKIVNALLHRHGPILRLVMVETTRELKAGADE RKRMIAEQAERERE AEIDVELRKSDRWMA ARERRQRVRLARRQNNLCPYTSTPIGHADLL GDAYDIDHVIPLARGGRDSLDNMVLCQSDANKTKGDKTPWEAFHDKPGWIAQRDDFLARLDP QTAKALAWRFADDAGERVARKSAEDEDQGFLPRQLTDTGYIARVALRYLSLVTNEPNAVVAT NGRLTGLLRLAWDITPGPAPRDLLPTPRDALRDDTAARRFLDGLTPPPLAKAVEGAVQARLA ALGRSRVADAGLADALGLTLASLGGGGKNRADHRHHFIDAAMIAVTTRGLINQINQASGAGR ILDLRKWPRTNFEPPYPTFRAEVMKQWDHIHPSIRPAHRDGGSLHAATVFGVRNRPDARVLV QRKPVEKLFLDANAKPLPADKIAEIIDGFASPRMAKRFKALLARYQAAHPEVPPALAALAVA RDPAFGPRGMTANTVIAGRSDGDGEDAGLITPFRANPKAAVRTMGNAVYEVWEIQVKGRPRW THRVLTRFDRTQPAPPPPPENARLVMRLRRGDLVYWPLESGDRLFLVKKMAVDGRLALWPAR LATGKATALYAQLSCPNINLNGDQGYCVQSAEGIRKEKIRTTSCTALGRLRLSKKAT
SEQ ID NO: 367
MKYTLGLDVGIASVGWAVIDKDNNKIIDLGVRCFDKAEESKTGESLATARRIARGMRRRISR RSQRLRLVKKLFVQYEIIKDSSEFNRIFDTSRDGWKDPWELRYNALSRILKPYELVQVLTHI TKRRGFKSNRKEDLSTTKEGWITSIKNNSEMLRTKNYRTIGEMIFMETPENSNKRNKVDEY IHTIAREDLLNEIKYIFSIQRKLGSPFVTEKLEHDFLNIWEFQRPFASGDSILSKVGKCTLL KEELRAPTSCYTSEYFGLLQSINNLVLVEDNNTLTLNNDQRAKIIEYAHFKNEIKYSEIRKL LDIEPEILFKAHNLTHKNPSGNNESKKFYEMKSYHKLKSTLPTDIWGKLHSNKESLDNLFYC LTVYKNDNEIKDYLQANNLDYLIEYIAKLPTFNKFKHLSLVAMKRIIPFMEKGYKYSDACNM AELDFTGSSKLEKCNKLTVEPIIENVTNPWIRALTQARKVINAIIQKYGLPYMVNIELARE AGMTRQDRDNLKKEHENNRKAREKISDLIRQNGRVASGLDILKWRLWEDQGGRCAYSGKPIP VCDLLNDSLTQIDHIYPYSRSMDDSYMNKVLVLTDENQNKRSYTPYEVWGSTEKWEDFEARI YSMHLPQSKEKRLLNRNFITKDLDSFISRNLNDTRYISRFLKNYIESYLQFSNDSPKSCWC VNGQCTAQLRSRWGLNKNREESDLHHALDAAVIACADRKIIKEITNYYNERENHNYKVKYPL PWHSFRQDLMETLAGVFISRAPRRKITGPAHDETIRSPKHFNKGLTSVKIPLTTVTLEKLET MVKNTKGGISDKAVYNVLKNRLIEHNNKPLKAFAEKIYKPLKNGTNGAIIRSIRVETPSYTG VFRNEGKGISDNSLMVRVDVFKKKDKYYLVPIYVAHMIKKELPSKAIVPLKPESQWELIDST HEFLFSLYQNDYLVIKTKKGITEGYYRSCHRGTGSLSLMPHFANNKNVKIDIGVRTAISIEK YNVDILGNKSIVKGEPRRGMEKYNSFKSN SEQ ID NO: 368
MIRTLGIDIGIASIGWAVIEGEYTDKGLENKEIVASGVRVFTKAENPKNKESLALPRTLARS ARRRNARKKGRIQQVKHYLSKALGLDLECFVQGEKLATLFQTSKDFLSPWELRERALYRVLD KEELARVILHIAKRRGYDDITYGVEDNDSGKIKKAIAENSKRIKEEQCKTIGEMMYKLYFQK SLNVRNKKESYNRCVGRSELREELKTIFQIQQELKSPWVNEELIYKLLGNPDAQSKQEREGL IFYQRPLKGFGDKIGKCSHIKKGENSPYRACKHAPSAEEFVALTKSINFLKNLTNRHGLCFS QEDMCVYLGKILQEAQKNEKGLTYSKLKLLLDLPSDFEFLGLDYSGKNPEKAVFLSLPSTFK LNKITQDRKTQDKIANILGANKDWEAILKELESLQLSKEQIQTIKDAKLNFSKHINLSLEAL YHLLPLMREGKRYDEGVEILQERGIFSKPQPKNRQLLPPLSELAKEESYFDIPNPVLRRALS EFRKWNALLEKYGGFHYFHIELTRDVCKAKSARMQLEKINKKNKSENDAASQLLEVLGLPN TYNNRLKCKLWKQQEEYCLYSGEKITIDHLKDQRALQIDHAFPLSRSLDDSQSNKVLCLTSS NQEKSNKTPYEWLGSDEKKWDMYVGRVYSSNFSPSKKRKLTQKNFKERNEEDFLARNLVDTG YIGRVTKEYIKHSLSFLPLPDGKKEHIRIISGSMTSTMRSFWGVQEKNRDHHLHHAQDAIII ACIEPSMIQKYTTYLKDKETHRLKSHQKAQILREGDHKLSLRWPMSNFKDKIQESIQ I IPS HHVSHKVTGELHQETVRTKEFYYQAFGGEEGVKKALKFGKIREINQGIVDNGAMVRVDIFKS KDKGKFYAVPIYTYDFAIGKLPNKAIVQGKKNGIIKDWLEMDENYEFCFSLFKNDCIKIQTK EMQEAVLAIYKSTNSAKATIELEHLSKYALKNEDEEKMFTDTDKEKNKTMTRESCGIQGLKV FQKVKLSVLGEVLEHKPRNRQNIALKTTPKHV
SEQ ID NO: 369
MKYSIGLDIGIASVGWSVINKDKERIEDMGVRIFQKAENPKDGSSLASSRREKRGSRRRNRR KKHRLDRIKNILCESGLVKKNEIEKIYKNAYLKSPWELRAKSLEAKISNKEIAQILLHIAKR RGFKSFRKTDRNADDTGKLLSGIQENKKIMEEKGYLTIGDMVAKDPKFNTHVRNKAGSYLFS FSRKLLEDEVRKIQAKQKELGNTHFTDDVLEKYIEVFNSQRNFDEGPSKPSPYYSEIGQIAK MIGNCTFESSEKRTAKNTWSGERFVFLQKLNNFRIVGLSGKRPLTEEERDIVEKEVYLKKEV RYEKLRKILYLKEEERFGDLNYSKDEKQDKKTEKTKFISLIGNYTIKKLNLSEKLKSEIEED KSKLDKI IEILTFNKSDKTIESNLKKLELSREDIEILLSEEFSGTLNLSLKAIKKILPYLEK GLSYNEACEKADYDYKNNGIKFKRGELLPWDKDLIANPWLRAISQTRKVVNAI IRKYGTP HTIHVEVARDLAKSYDDRQTIIKENKKRELENEKTKKFISEEFGIKNVKGKLLLKYRLYQEQ EGRCAYSRKELSLSEVILDESMTDIDHIIPYSRSMDDSYSNKVLVLSGENRKKSNLLPKEYF DRQGRDWDTFVLNVKAMKIHPRKKSNLLKEKFTREDNKDWKSRALNDTRYISRFVANYLENA LEYRDDSPKKRVFMIPGQLTAQLRARWRLNKVRENGDLHHALDAAWAVTDQKAINNISNIS RYKELKNCKDVIPSIEYHADEETGEVYFEEVKDTRFPMPWSGFDLELQKRLESENPREEFYN LLSDKRYLGWFNYEEGFIEKLRPVFVSRMPNRGVKGQAHQETIRSSKKISNQIAVSKKPLNS IKLKDLEKMQGRDTDRKLYEALKNRLEEYDDKPEKAFAEPFYKPTNSGKRGPLVRGIKVEEK QNVGVYVNGGQASNGSMVRIDVFRKNGKFYTVPIYVHQTLLKELPNRAINGKPYKDWDLIDG SFEFLYSFYPNDLIEIEFGKSKSIKNDNKLTKTEIPEVNLSEVLGYYRGMDTSTGAATIDTQ DGKIQMRIGIKTVKNIKKYQVDVLGNVYKVKREKRQTF
SEQ ID NO: 370
MSKKVSRRYEEQAQEICQRLGSRPYSIGLDLGVGSIGVAVAAYDPIKKQPSDLVFVSSRIFI PSTGAAERRQKRGQRNSLRHRANRLKFLWKLLAERNLMLSYSEQDVPDPARLRFEDAWRAN PYELRLKGLNEQLTLSELGYALYHIANHRGSSSVRTFLDEEKSSDDKKLEEQQAMTEQLAKE KGISTFIEVLTAFNTNGLIGYRNSESVKSKGVPVPTRDI ISNEIDVLLQTQKQFYQEILSDE YCDRIVSAILFENEKIVPEAGCCPYFPDEKKLPRCHFLNEERRLWEAINNARIKMPMQEGAA KRYQSASFSDEQRHILFHIARSGTDITPKLVQKEFPALKTSIIVLQGKEKAIQKIAGFRFRR LEEKSFWKRLSEEQKDDFFSAWTNTPDDKRLSKYLMKHLLLTENEWDALKTVSLIGDYGPI GKTATQLLMKHLEDGLTYTEALERGMETGEFQELSVWEQQSLLPYYGQILTGSTQALMGKYW HSAFKEKRDSEGFFKPNTNSDEEKYGRIANPWHQTLNELRKLMNELITILGAKPQEITVEL ARELKVGAEKREDIIKQQTKQEKEAVLAYSKYCEPNNLDKRYIERFRLLEDQAFVCPYCLEH ISVADIAAGRADVDHIFPRDDTADNSYGNKVVAHRQCNDIKGKRTPYAAFSNTSAWGPIMHY LDETPGMWRKRRKFETNEEEYAKYLQSKGFVSRFESDNSYIAKAAKEYLRCLFNPNNVTAVG SLKGMETSILRKAWNLQGIDDLLGSRHWSKDADTSPTMRKNRDDNRHHGLDAIVALYCSRSL VQMINTMSEQGKRAVEIEAMIPIPGYASEPNLSFEAQRELFRKKILEFMDLHAFVSMKTDND ANGALLKDTVYSILGADTQGEDLVFWKKKIKDIGVKIGDYEEVASAIRGRITDKQPKWYPM EMKDKIEQLQSKNEAALQKYKESLVQAAAVLEESNRKLIESGKKPIQLSEKTISKKALELVG GYYYLISNNKRTKTFWKEPSNEVKGFAFDTGSNLCLDFYHDAQGKLCGEI IRKIQAMNPSY KPAYMKQGYSLYVRLYQGDVCELRASDLTEAESNLAKTTHVRLPNAKPGRTFVII ITFTEMG SGYQIYFSNLAKSKKGQDTSFTLTTIKNYDVRKVQLSSAGLVRYVSPLLVDKIEKDEVALCG E SEQ ID NO: 371
MNQKFILGLDIGITSVGYGLIDYETKNIIDAGVRLFPEANVENNEGRRSKRGSRRLKRRRIH RLERVKKLLEDYNLLDQSQIPQSTNPYAIRVKGLSEALSKDELVIALLHIAKRRGIHKIDVI DSNDDVGNELSTKEQLNKNSKLLKDKFVCQIQLERMNEGQVRGEKNRFKTADIIKEIIQLLN VQKNFHQLDENFINKYIELVEMRREYFEGPGKGSPYGWEGDPKAWYETLMGHCTYFPDELRS VKYAYSADLFNALNDLNNLVIQRDGLSKLEYHEKYHIIENVFKQKKKPTLKQIANEINVNPE DIKGYRITKSGKPQFTEFKLYHDLKSVLFDQSILENEDVLDQIAEILTIYQDKDSIKSKLTE LDILLNEEDKENIAQLTGYTGTHRLSLKCIRLVLEEQWYSSRNQMEIFTHLNIKPKKINLTA ANKIPKAMIDEFILSPWKRTFGQAINLINKIIEKYGVPEDII IELARENNSKDKQKFINEM QKKNENTRKRINEIIGKYGNQNAKRLVEKIRLHDEQEGKCLYSLESIPLEDLLNNPNHYEVD HIIPRSVSFDNSYHNKVLVKQSENSKKSNLTPYQYFNSGKSKLSYNQFKQHILNLSKSQDRI SKKKKEYLLEERDINKFEVQKEFINRNLVDTRYATRELTNYLKAYFSANNMNVKVKTINGSF TDYLRKVWKFKKERNHGYKHHAEDALI IANADFLFKENKKLKAVNSVLEKPEIESKQLDIQV DSEDNYSEMFI IPKQVQDIKDFRNFKYSHRVDKKPNRQLINDTLYSTRKKDNSTYIVQTIKD IYAKDNTTLKKQFDKSPEKFLMYQHDPRTFEKLEVIMKQYANEKNPLAKYHEETGEYLTKYS KKNNGPIVKSLKYIGNKLGSHLDVTHQFKSSTKKLVKLSIKPYRFDVYLTDKGYKFITISYL DVLKKDNYYYIPEQKYDKLKLGKAIDKNAKFIASFYKNDLIKLDGEIYKIIGVNSDTRNMIE LDLPDIRYKEYCELNNIKGEPRIKKTIGKKVNSIEKLTTDVLGNVFTNTQYTKPQLLFKRGN
SEQ ID NO: 372
MIMKLEKWRLGLDLGTNSIGWSVFSLDKDNSVQDLIDMGVRIFSDGRDPKTKEPLAVARRTA RSQRKLIYRRKLRRKQVFKFLQEQGLFPKTKEECMTLKSLNPYELRIKALDEKLEPYELGRA LFNLAVRRGFKSNRKDGSREEVSEKKSPDEIKTQADMQTHLEKAIKENGCRTITEFLYKNQG ENGGIRFAPGRMTYYPTRKMYEEEFNLIRSKQEKYYPQVDWDDIYKAIFYQRPLKPQQRGYC IYENDKERTFKAMPCSQKLRILQDIGNLAYYEGGSKKRVELNDNQDKVLYELLNSKDKVTFD QMRKALCLADSNSFNLEENRDFLIGNPTAVKMRSKNRFGKLWDEIPLEEQDLIIETIITADE DDAVYEVIKKYDLTQEQRDFIVKNTILQSGTSMLCKEVSEKLVKRLEEIADLKYHEAVESLG YKFADQTVEKYDLLPYYGKVLPGSTMEIDLSAPETNPEKHYGKISNPTVHVALNQTRWVNA LIKEYGKPSQIAIELSRDLKNNVEKKAEIARKQNQRAKENIAINDTISALYHTAFPGKSFYP NRNDRMKYRLWSELGLGNKCIYCGKGISGAELFTKEIEIEHILPFSRTLLDAESNLTVAHSS CNAFKAERSPFEAFGTNPSGYSWQEIIQRANQLKNTSKKNKFSPNAMDSFEKDSSFIARQLS DNQYIAKAALRYLKCLVENPSDVWTTNGSMTKLLRDKWEMDSILCRKFTEKEVALLGLKPEQ IGNYKKNRFDHRHHAIDAVVIGLTDRSMVQKLATKNSHKGNRIEIPEFPILRSDLIEKVKNI WSFKPDHGAEGKLSKETLLGKIKLHGKETFVCRENIVSLSEKNLDDIVDEIKSKVKDYVAK HKGQKIEAVLSDFSKENGIKKVRCVNRVQTPIEITSGKISRYLSPEDYFAAVIWEIPGEKKT FKAQYIRRNEVEKNSKGLNWKPAVLENGKPHPAAKQVCLLHKDDYLEFSDKGKMYFCRIAG YAATNNKLDIRPVYAVSYCADWINSTNETMLTGYWKPTPTQNWVSVNVLFDKQKARLVTVSP IGRVFRK
SEQ ID NO: 373
MSSKAIDSLEQLDLFKPQEYTLGLDLGIKSIGWAILSGERIANAGVYLFETAEELNSTGNKL ISKAAERGRKRRIRRMLDRKARRGRHIRYLLEREGLPTDELEEWVHQSNRTLWDVRAEAVE RKLTKQELAAVLFHLVRHRGYFPNTKKLPPDDESDSADEEQGKINRATSRLREELKASDCKT IGQFLAQNRDRQRNREGDYSNLMARKLVFEEALQILAFQRKQGHELSKDFEKTYLDVLMGQR SGRSPKLGNCSLIPSELRAPSSAPSTEWFKFLQNLGNLQISNAYREEWSIDAPRRAQIIDAC SQRSTSSYWQIRRDFQIPDEYRFNLVNYERRDPDVDLQEYLQQQERKTLANFRNWKQLEKII GTGHPIQTLDEAARLITLIKDDEKLSDQLADLLPEASDKAITQLCELDFTTAAKISLEAMYR ILPHMNQGMGFFDACQQESLPEIGVPPAGDRVPPFDEMYNPWNRVLSQSRKLINAVIDEYG MPAKIRVELARDLGKGRELRERIKLDQLDKSKQNDQRAEDFRAEFQQAPRGDQSLRYRLWKE QNCTCPYSGRMIPVNSVLSEDTQIDHILPISQSFDNSLSNKVLCFTEENAQKSNRTPFEYLD AADFQRLEAISGNWPEAKRNKLLHKSFGKVAEEWKSRALNDTRYLTSALADHLRHHLPDSKI QTVNGRITGYLRKQWGLEKDRDKHTHHAVDAIWACTTPAIVQQVTLYHQDIRRYKKLGEKR PTPWPETFRQDVLDVEEEIFITRQPKKVSGGIQTKDTLRKHRSKPDRQRVALTKVKLADLER LVEKDASNRNLYEHLKQCLEESGDQPTKAFKAPFYMPSGPEAKQRPILSKVTLLREKPEPPK QLTELSGGRRYDSMAQGRLDIYRYKPGGKRKDEYRWLQRMIDLMRGEENVHVFQKGVPYDQ GPEIEQNYTFLFSLYFDDLVEFQRSADSEVIRGYYRTFNIANGQLKISTYLEGRQDFDFFGA NRLAHFAKVQVNLLGKVIK
SEQ ID NO: 374
MRSLRYRLALDLGSTSLGWALFRLDACNRPTAVIKAGVRIFSDGRNPKDGSSLAVTRRAARA MRRRRDRLLKRKTRMQAKLVEHGFFPADAGKRKALEQLNPYALRAKGLQEALLPGEFARALF HINQRRGFKSNRKTDKKDNDSGVLKKAIGQLRQQMAEQGSRTVGEYLWTRLQQGQGVRARYR EKPYTTEEGKKRIDKSYDLYIDRAMIEQEFDALWAAQAAFNPTLFHEAARADLKDTLLHQRP LRPVKPGRCTLLPEEERAPLALPSTQRFRIHQEVNHLRLLDENLREVALTLAQRDAWTALE TKAKLSFEQIRKLLKLSGSVQFNLEDAKRTELKGNATSAALARKELFGAAWSGFDEALQDEI VWQLVTEEGEGALIAWLQTHTGVDEARAQAIVDVSLPEGYGNLSRKALARIVPALRAAVITY DKAVQAAGFDHHSQLGFEYDASEVEDLVHPETGEIRSVFKQLPYYGKALQRHVAFGSGKPED PDEKRYGKIANPTVHIGLNQVRMWNALIRRYGRPTEWIELARDLKQSREQKVEAQRRQAD NQRRNARIRRSIAEVLGIGEERVRGSDIQKWICWEELSFDAADRRCPYSGVQISAAMLLSDE VEVEHILPFSKTLDDSLNNRTVAMRQANRIKRNRTPWDARAEFEAQGWSYEDILQRAERMPL RKRYRFAPDGYERWLGDDKDFLARALNDTRYLSRVAAEYLRLVCPGTRVIPGQLTALLRGKF GLNDVLGLDGEKNRNDHRHHAVDACVIGVTDQGLMQRFATASAQARGDGLTRLVDGMPMPWP TYRDHVERAVRHIWVSHRPDHGFEGAMMEETSYGIRKDGSIKQRRKADGSAGREISNLIRIH EATQPLRHGVSADGQPLAYKGYVGGSNYCIEITVNDKGKWEGEVISTFRAYGWRAGGMGRL RNPHEGQNGRKLIMRLVIGDSVRLEVDGAERTMRIVKISGSNGQIFMAPIHEANVDARNTDK QDAFTYTSKYAGSLQKAKTRRVTISPIGEVRDPGFKG
SEQ ID NO: 375
MARPAFRAPRREHVNGWTPDPHRISKPFFILVSWHLLSRWIDSSSGCFPGTSRDHTDKFAE WECAVQPYRLSFDLGTNSIGWGLLNLDRQGKPREIRALGSRIFSDGRDPQDKASLAVARRLA RQMRRRRDRYLTRRTRLMGALVRFGLMPADPAARKRLEVAVDPYLARERATRERLEPFEIGR ALFHLNQRRGYKPVRTATKPDEEAGKVKEAVERLEAAIAAAGAPTLGAWFAWRKTRGETLRA RLAGKGKEAAYPFYPARRMLEAEFDTLWAEQARHHPDLLTAEAREILRHRIFHQRPLKPPPV GRCTLYPDDGRAPRALPSAQRLRLFQELASLRVIHLDLSERPLTPAERDRIVAFVQGRPPKA GRKPGKVQKSVPFEKLRGLLELPPGTGFSLESDKRPELLGDETGARIAPAFGPGWTALPLEE QDALVELLLTEAEPERAIAALTARWALDEATAAKLAGATLPDFHGRYGRRAVAELLPVLERE TRGDPDGRVRPIRLDEAVKLLRGGKDHSDFSREGALLDALPYYGAVLERHVAFGTGNPADPE EKRVGRVANPTVHIALNQLRHLVNAILARHGRPEEIVIELARDLKRSAEDRRREDKRQADNQ KRNEERKRLILSLGERPTPRNLLKLRLWEEQGPVENRRCPYSGETISMRMLLSEQVDIDHIL PFSVSLDDSAANKWCLREANRIKRNRSPWEAFGHDSERWAGILARAEALPKNKRWRFAPDA LEKLEGEGGLRARHLNDTRHLSRLAVEYLRCVCPKVRVSPGRLTALLRRRWGIDAILAEADG PPPEVPAETLDPSPAEKNRADHRHHALDAWIGCIDRSMVQRVQLAAASAEREAAARED IR RVLEGFKEEPWDGFRAELERRARTIWSHRPEHGIGGALHKETAYGPVDPPEEGFNLWRKP IDGLSKDEINSVRDPRLRRALIDRLAIRRRDANDPATALAKAAEDLAAQPASRGIRRVRVLK KESNPIRVEHGGNPSGPRSGGPFHKLLLAGEVHHVDVALRADGRRWVGHWVTLFEAHGGRGA DGAAAPPRLGDGERFLMRLHKGDCLKLEHKGRVRVMQWKLEPSSNSWWEPHQVKTDRSK HVKISCDQLRARGARRVTVDPLGRVRVHAPGARVGIGGDAGRTAMEPAEDIS
SEQ ID NO: 376
MKRTSLRAYRLGVDLGANSLGWFWWLDDHGQPEGLGPGGVRIFPDGRNPQSKQSNAAGRRL ARSARRRRDRYLQRRGKLMGLLVKHGLMPADEPARKRLECLDPYGLRAKALDEVLPLHHVGR ALFHLNQRRGLFANRAIEQGDKDASAIKAAAGRLQTSMQACGARTLGEFLNRRHQLRATVRA RSPVGGDVQARYEFYPTRAMVDAEFEAIWAAQAPHHPTMTAEAHDTIREAIFSQRAMKRPSI GKCSLDPATSQDDVDGFRCAWSHPLAQRFRIWQDVRNLAWETGPTSSRLGKEDQDKVARAL LQTDQLSFDEIRGLLGLPSDARFNLESDRRDHLKGDATGAILSARRHFGPAWHDRSLDRQID IVALLESALDEAAIIASLGTTHSLDEAAAQRALSALLPDGYCRLGLRAIKRVLPLMEAGRTY AEAASAAGYDHALLPGGKLSPTGYLPYYGQWLQNDWGSDDERDTNERRWGRLPNPTVHIGI GQLRRWNELIRWHGPPAEITVELTRDLKLSPRRLAELEREQAENQRKNDKRTSLLRKLGLP ASTHNLLKLRLWDEQGDVASECPYTGEAIGLERLVSDDVDIDHLIPFSISWDDSAANKVVCM RYANREKGNRTPFEAFGHRQGRPYDWADIAERAARLPRGKRWRFGPGARAQFEELGDFQARL LNETSWLARVAKQYLAAVTHPHRIHVLPGRLTALLRATWELNDLLPGSDDRAAKSRKDHRHH AIDALVAALTDQALLRRMANAHDDTRRKIEVLLPWPTFRIDLETRLKAMLVSHKPDHGLQAR LHEDTAYGTVEHPETEDGANLVYRKTFVDISEKEIDRIRDRRLRDLVRAHVAGERQQGKTLK AAVLSFAQRRDIAGHPNGIRHVRLTKSIKPDYLVPIRDKAGRIYKSYNAGENAFVDILQAES GRWIARATTVFQANQANESHDAPAAQPIMRVFKGDMLRIDHAGAEKFVKIVRLSPSNNLLYL VEHHQAGVFQTRHDDPEDSFRWLFASFDKLREWNAELVRIDTLGQPWRRKRGLETGSEDATR IGWTRPKKWP
SEQ ID NO: 377
MERIFGFDIGTTSIGFSVIDYSSTQSAGNIQRLGVRIFPEARDPDGTPLNQQRRQKRMMRRQ LRRRRIRRKALNETLHEAGFLPAYGSADWPVVMADEPYELRRRGLEEGLSAYEFGRAIYHLA QHRHFKGRELEESDTPDPDVDDEKEAANERAATLKALKNEQTTLGAWLARRPPSDRKRGIHA HRNWAEEFERLWEVQSKFHPALKSEEMRARISDTIFAQRPVFWRKNTLGECRFMPGEPLCP KGSWLSQQRRMLEKLNNLAIAGGNARPLDAEERDAILSKLQQQASMSWPGVRSALKALYKQR GEPGAEKSLKFNLELGGESKLLGNALEAKLADMFGPDWPAHPRKQEIRHAVHERLWAADYGE TPDKKRVIILSEKDRKAHREAAANSFVADFGITGEQAAQLQALKLPTGWEPYSIPALNLFLA ELEKGERFGALVNGPDWEGWRRTNFPHRNQPTGEILDKLPSPASKEERERISQLRNPTVVRT QNELRKVVNNLIGLYGKPDRIRIEVGRDVGKSKREREEIQSGIRRNEKQRKKATEDLIKNGI ANPSRDDVEKWILWKEGQERCPYTGDQIGFNALFREGRYEVEHIWPRSRSFDNSPRNKTLCR KDVNIEKGNRMPFEAFGHDEDRWSAIQIRLQGMVSAKGGTGMSPGKVKRFLAKTMPEDFAAR QLNDTRYAAKQILAQLKRLWPDMGPEAPVKVEAVTGQVTAQLRKLWTLNNILADDGEKTRAD HRHHAIDALTVACTHPGMTNKLSRYWQLRDDPRAEKPALTPPWDTIRADAEKAVSEIWSHR VRKKVSGPLHKETTYGDTGTDIKTKSGTYRQFVTRKKIESLSKGELDEIRDPRIKEIVAAHV AGRGGDPKKAFPPYPCVSPGGPEIRKVRLTSKQQLNLMAQTGNGYADLGSNHHIAIYRLPDG KADFEIVSLFDASRRLAQRNPIVQRTRADGASFVMSLAAGEAIMIPEGSKKGIWIVQGVWAS GQVVLERDTDADHSTTTRPMPNPILKDDAKKVSIDPIGRVRPSND
SEQ ID NO: 378
MNKRILGLDTGTNSLGWAVVDWDEHAQSYELIKYGDVIFQEGVKIEKGIESSKAAERSGYKA IRKQYFRRRLRKIQVLKVLVKYHLCPYLSDDDLRQWHLQKQYPKSDELMLWQRTSDEEGKNP YYDRHRCLHEKLDLTVEADRYTLGRALYHLTQRRGFLSNRLDTSADNKEDGWKSGISQLST EMEEAGCEYLGDYFYKLYDAQGNKVRIRQRYTDRNKHYQHEFDAICEKQELSSELIEDLQRA IFFQLPLKSQRHGVGRCTFERGKPRCADSHPDYEEFRMLCFVNNIQVKGPHDLELRPLTYEE REKIEPLFFRKSKPNFDFEDIAKALAGKKNYAWIHDKEERAYKFNYRMTQGVPGCPTIAQLK SIFGDDWKTGIAETYTLIQKKNGSKSLQEMVDDVWNVLYSFSSVEKLKEFAHHKLQLDEESA EKFAKIKLSHSFAALSLKAIRKFLPFLRKGMYYTHASFFANIPTIVGKEIWNKEQNRKYIME NVGELVFNYQPKHREVQGTIEMLIKDFLANNFELPAGATDKLYHPSMIETYPNAQRNEFGIL QLGSPRTNAIRNPMAMRSLHILRRWNQLLKESIIDENTEVHVEYARELNDANKRRAIADRQ KEQDKQHKKYGDEIRKLYKEETGKDIEPTQTDVLKFQLWEEQNHHCLYTGEQIGITDFIGSN PKFDIEHTIPQSVGGDSTQMNLTLCDNRFNREVKKAKLPTELANHEEILTRIEPWKNKYEQL VKERDKQRTFAGMDKAVKDIRIQKRHKLQMEIDYWRGKYERFTMTEVPEGFSRRQGTGIGLI SRYAGLYLKSLFHQADSRNKSNVYWKGVATAEFRKMWGLQSEYEKKCRDNHSHHCMDAITI ACIGKREYDLMAEYYRMEETFKQGRGSKPKFSKPWATFTEDVLNIYKNLLVVHDTPNNMPKH TKKYVQTSIGKVLAQGDTARGSLHLDTYYGAIERDGEIRYWRRPLSSFTKPEELENIVDET VKRTIKEAIADKNFKQAIAEPIYMNEEKGILIKKVRCFAKSVKQPINIRQHRDLSKKEYKQQ YHVMNENNYLLAIYEGLVKNKWREFEIVSYIEAAKYYKRSQDRNIFSSIVPTHSTKYGLPL KTKLLMGQLVLMFEENPDEIQVDNTKDLVKRLYKVVGIEKDGRIKFKYHQEARKEGLPIFST PYKNNDDYAPIFRQSINNINILVDGIDFTIDILGKVTLKE
SEQ ID NO: 379
MNYKMGLDIGIASVGWAVINLDLKRIEDLGVRIFDKAEHPQNGESLALPRRIARSARRRLRR RKHRLERIRRLLVSENVLTKEEMNLLFKQKKQIDVWQLRVDALERKLNNDELARVLLHLAKR RGFKSNRKSERNSKESSEFLKNIEENQSILAQYRSVGEMIVKDSKFAYHKRNKLDSYSNMIA RDDLEREIKLIFEKQREFNNPVCTERLEEKYLNIWSSQRPFASKEDIEKKVGFCTFEPKEKR APKATYTFQSFIVWEHINKLRLVSPDETRALTEIERNLLYKQAFSKNKMTYYDIRKLLNLSD DIHFKGLLYDPKSSLKQIENIRFLELDSYHKIRKCIENVYGKDGIRMFNETDIDTFGYALTI FKDDEDIVAYLQNEYITKNGKRVSNLANKVYDKSLIDELLNLSFSKFAHLSMKAIRNILPYM EQGEIYSKACELAGYNFTGPKKKEKALLLPVIPNIANPVVMRALTQSRKWNAIIKKYGSPV SIHIELARDLSHSFDERKKIQKDQTENRKKNETAIKQLIEYELTKNPTGLDIVKFKLWSEQQ GRCMYSLKPIELERLLEPGYVEVDHILPYSRSLDDSYANKVLVLTKENREKGNHTPVEYLGL GSERWKKFEKFVLANKQFSKKKKQNLLRLRYEETEEKEFKERNLNDTRYISKFFANFIKEHL KFADGDGGQKVYTINGKITAHLRSRWDFNKNREESDLHHAVDAVIVACATQGMIKKITEFYK AREQNKESAKKKEPIFPQPWPHFADELKARLSKFPQESIEAFALGNYDRKKLESLRPVFVSR MPKRSVTGAAHQETLRRCVGIDEQSGKIQTAVKTKLSDIKLDKDGHFPMYQKESDPRTYEAI RQRLLEHNNDPKKAFQEPLYKPKKNGEPGPVIRTVKIIDTKNKWHLDGSKTVAYNSNIVRT DVFEKDGKYYCVPVYTMDIMKGTLPNKAIEANKPYSEWKEMTEEYTFQFSLFPNDLVRIVLP REKTIKTSTNEEIIIKDIFAYYKTIDSATGGLELISHDRNFSLRGVGSKTLKRFEKYQVDVL GNIHKVKGEKRVGLAAPTNQKKGKTVDSLQSVSD
SEQ ID NO: 380
MRRLGLDLGTNSIGWCLLDLGDDGEPVSIFRTGARIFSDGRDPKSLGSLKATRREARLTRRR RDRFIQRQKNLINALVKYGLMPADEIQRQALAYKDPYPIRKKALDEAIDPYEMGRAIFHINQ RRGFKSNRKSADNEAGWKQSIADLEMKLGEAGARTIGEFLADRQATNDTVRARRLSGTNAL YEFYPDRYMLEQEFDTLWAKQAAFNPSLYIEAARERLKEIVFFQRKLKPQEVGRCIFLSDED RISKALPSFQRFRIYQELSNLAWIDHDGVAHRITASLALRDHLFDELEHKKKLTFKAMRAIL RKQGWDYPVGFNLESDNRDHLIGNLTSCIMRDAKKMIGSAWDRLDEEEQDSFILMLQDDQK GDDEVRSILTQQYGLSDDVAEDCLDVRLPDGHGSLSKKAIDRILPVLRDQGLIYYDAVKEAG LGEANLYDPYAALSDKLDYYGKALAGHVMGASGKFEDSDEKRYGTISNPTVHIALNQVRAW NELIRLHGKPDEWIEIGRDLPMGADGKRELERFQKEGRAKNERARDELKKLGHIDSRESRQ KFQLWEQLAKEPVDRCCPFTGKMMSISDLFSDKVEIEHLLPFSLTLDDSMANKTVCFRQANR DKGNRAPFDAFGNSPAGYDWQEILGRSQNLPYAKRWRFLPDAMKRFEADGGFLERQLNDTRY ISRYTTEYISTIIPKNKIWWTGRLTSLLRGFWGLNSILRGHNTDDGTPAKKSRDDHRHHAI DAIWGMTSRGLLQKVSKAARRSEDLDLTRLFEGRIDPWDGFRDEVKKHIDAIIVSHRPRKK SQGALHNDTAYGIVEHAENGASTWHRVPITSLGKQSDIEKVRDPLIKSALLNETAGLSGKS FENAVQKWCADNSIKSLRIVETVSIIPITDKEGVAYKGYKGDGNAYMDIYQDPTSSKWKGEI VSRFDANQKGFIPSWQSQFPTARLIMRLRINDLLKLQDGEIEEIYRVQRLSGSKILMAPHTE ANVDARDRDKNDTFKLTSKSPGKLQSASARKVHISPTGLIREG
SEQ ID NO: 381
MKNILGLDLGLSSIGWSVIRENSEEQELVAMGSRVVSLTAAELSSFTQGNGVSINSQRTQKR TQRKGYDRYQLRRTLLRNKLDTLGMLPDDSLSYLPKLQLWGLRAKAVTQRIELNELGRVLLH LNQKRGYKSIKSDFSGDKKITDYVKTVKTRYDELKEMRLTIGELFFRRLTENAFFRCKEQVY PRQAYVEEFDCIMNCQRKFYPDILTDETIRCIRDEIIYYQRPLKSCKYLVSRCEFEKRFYLN AAGKKTEAGPKVSPRTSPLFQVCRLWESINNIWKDRRNEIVFISAEQRAALFDFLNTHEKL KGSDLLKLLGLSKTYGYRLGEQFKTGIQGNKTRVEIERALGNYPDKKRLLQFNLQEESSSMV NTETGEI IPMISLSFEQEPLYRLWHVLYSIDDREQLQSVLRQKFGIDDDEVLERLSAIDLVK AGFGNKSSKAIRRILPFLQLGMNYAEACEAAGYNHSNNYTKAENEARALLDRLPAIKKNELR QPVVEKILNQMVNWNALMEKYGRFDEIRVELARELKQSKEERSNTYKSINKNQRENEQIAK RIVEYGVPTRSRIQKYKMWEESKHCCIYCGQPVDVGDFLRGFDVEVEHIIPKSLYFDDSFAN KVCSCRSCNKEKNNRTAYDYMKSKGEKALSDYVERVNTMYTNNQISKTKWQNLLTPVDKISI DFIDRQLRESQYIARKAKEILTSICYNVTATSGSVTSFLRHVWGWDTVLHDLNFDRYKKVGL TEVIEVNHRGSVIRREQIKDWSKRFDHRHHAIDALTIACTKQAYIQRLNNLRAEEGPDFNKM SLERYIQSQPHFSVAQVREAVDRILVSFRAGKRAVTPGKRYIRKNRKRISVQSVLIPRGALS EESVYGVIHVWEKDEQGHVIQKQRAVMKYPITSINREMLDKEKWDKRIHRILSGRLAQYND NPKEAFAKPVYIDKECRIPIRTVRCFAKPAINTLVPLKKDDKGNPVAWVNPGNNHHVAIYRD EDGKYKERTVTFWEAVDRCRVGIPAIVTQPDTIWDNILQRNDISENVLESLPDVKWQFVLSL QQNEMFILGMNEEDYRYAMDQQDYALLNKYLYRVQKLSKSDYSFRYHTETSVEDKYDGKPNL KLSMQMGKLKRVSIKSLLGLNPHKVHISVLGEIKEIS SEQ ID NO: 382
MAEKQHRWGLDIGTNSIGWAVIALIEGRPAGLVATGSRIFSDGRNPKDGSSLAVERRGPRQM RRRRDRYLRRRDRFMQALINVGLMPGDAAARKALVTENPYVLRQRGLDQALTLPEFGRALFH LNQRRGFQSNRKTDRATAKESGKVKNAIAAFRAGMGNARTVGEALARRLEDGRPVRARMVGQ GKDEHYELYIAREWIAQEFDALWASQQRFHAEVLADAARDRLRAILLFQRKLLPVPVGKCFL EPNQPRVAAALPSAQRFRLMQELNHLRVMTLADKRERPLSFQERNDLLAQLVARPKCGFDML RKIVFGANKEAYRFTIESERRKELKGCDTAAKLAKVNALGTRWQALSLDEQDRLVCLLLDGE NDAVLADALREHYGLTDAQIDTLLGLSFEDGHMRLGRSALLRVLDALESGRDEQGLPLSYDK AWAAGYPAHTADLENGERDALPYYGELLWRYTQDAPTAKNDAERKFGKIANPTVHIGLNQL RKLVNALIQRYGKPAQIWELARNLKAGLEEKERIKKQQTANLERNERIRQKLQDAGVPDNR ENRLRMRLFEELGQGNGLGTPCIYSGRQISLQRLFSNDVQVDHILPFSKTLDDSFANKVLAQ HDANRYKGNRGPFEAFGANRDGYAWDDIRARAAVLPRNKRNRFAETAMQDWLHNETDFLARQ LTDTAYLSRVARQYLTAICSKDDVYVSPGRLTAMLRAKWGLNRVLDGVMEEQGRPAVKNRDD HRHHAIDAWIGATDRAMLQQVATLAARAREQDAERLIGDMPTPWPNFLEDVRAAVARCWS HKPDHGPEGGLHNDTAYGIVAGPFEDGRYRVRHRVSLFDLKPGDLSNVRCDAPLQAELEPIF EQDDARAREVALTALAERYRQRKVWLEELMSVLPIRPRGEDGKTLPDSAPYKAYKGDSNYCY ELFINERGRWDGELISTFRANQAAYRRFRNDPARFRRYTAGGRPLLMRLCINDYIAVGTAAE RTIFRWKMSENKITLAEHFEGGTLKQRDADKDDPFKYLTKSPGALRDLGARRIFVDLIGRV LDPGIKGD
SEQ ID NO: 383
MIERILGVDLGISSLGWAIVEYDKDDEAANRIIDCGVRLFTAAETPKKKESPNKARREARGI RRVLNRRRVRMNMIKKLFLRAGLIQDVDLDGEGGMFYSKANRADVWELRHDGLYRLLKGDEL ARVLIHIAKHRGYKFIGDDEADEESGKVKKAGWLRQNFEAAGCRTVGEWLWRERGANGKKR NKHGDYEISIHRDLLVEEVEAIFVAQQEMRSTIATDALKAAYREIAFFVRPMQRIEKMVGHC TYFPEERRAPKSAPTAEKFIAISKFFSTVIIDNEGWEQKIIERKTLEELLDFAVSREKVEFR HLRKFLDLSDNEIFKGLHYKGKPKTAKKREATLFDPNEPTELEFDKVEAEKKAWISLRGAAK LREALGNEFYGRFVALGKHADEATKILTYYKDEGQKRRELTKLPLEAEMVERLVKIGFSDFL KLSLKAIRDILPAMESGARYDEAVLMLGVPHKEKSAILPPLNKTDIDILNPTVIRAFAQFRK VANALVRKYGAFDRVHFELAREINTKGEIEDIKESQRKNEKERKEAADWIAETSFQVPLTRK NILKKRLYIQQDGRCAYTGDVIELERLFDEGYCEIDHILPRSRSADDSFANKVLCLARANQQ KTDRTPYEWFGHDAARWNAFETRTSAPSNRVRTGKGKIDRLLKKNFDENSEMAFKDRNLNDT RYMARAIKTYCEQYWVFKNSHTKAPVQVRSGKLTSVLRYQWGLESKDRESHTHHAVDAI IIA FSTQGMVQKLSEYYRFKETHREKERPKLAVPLANFRDAVEEATRIENTETVKEGVEVKRLLI SRPPRARVTGQAHEQTAKPYPRIKQVKNKKKWRLAPIDEEKFESFKADRVASANQKNFYETS TIPRVDVYHKKGKFHLVPIYLHEMVLNELPNLSLGTNPEAMDENFFKFSIFKDDLISIQTQG TPKKPAKIIMGYFKNMHGANMVLSSINNSPCEGFTCTPVSMDKKHKDKCKLCPEENRIAGRC LQGFLDYWSQEGLRPPRKEFECDQGVKFALDVKKYQIDPLGYYYEVKQEKRLGTIPQMRSAK KLVKK
SEQ ID NO: 384
MNNSIKSKPEVTIGLDLGVGSVGWAIVDNETNIIHHLGSRLFSQAKTAEDRRSFRGVRRLIR RRKYKLKRFVNLIWKYNSYFGFKNKEDILNNYQEQQKLHNTVLNLKSEALNAKIDPKALSWI LHDYLKNRGHFYEDNRDFNVYPTKELAKYFDKYGYYKGI IDSKEDNDNKLEEELTKYKFSNK HWLEEVKKVLSNQTGLPEKFKEEYESLFSYVRNYSEGPGSINSVSPYGIYHLDEKEGKVVQK YNNIWDKTIGKCNIFPDEYRAPKNSPIAMIFNEINELSTIRSYSIYLTGWFINQEFKKAYLN KLLDLLIKTNGEKPIDARQFKKLREETIAESIGKETLKDVENEEKLEKEDHKWKLKGLKLNT NGKIQYNDLSSLAKFVHKLKQHLKLDFLLEDQYATLDKINFLQSLFVYLGKHLRYSNRVDSA NLKEFSDSNKLFERILQKQKDGLFKLFEQTDKDDEKILAQTHSLSTKAMLLAITRMTNLDND EDNQKNNDKGWNFEAIKNFDQKFIDITKKNNNLSLKQNKRYLDDRFINDAILSPGVKRILRE ATKVFNAILKQFSEEYDVTKWIELARELSEEKELENTKNYKKLIKKNGDKISEGLKALGIS EDEIKDILKSPTKSYKFLLWLQQDHIDPYSLKEIAFDDIFTKTEKFEIDHI IPYSISFDDSS SNKLLVLAESNQAKSNQTPYEFISSGNAGIKWEDYEAYCRKFKDGDSSLLDSTQRSKKFAKM MKTDTSSKYDIGFLARNLNDTRYATIVFRDALEDYANNHLVEDKPMFKWCINGSVTSFLRK NFDDSSYAKKDRDKNIHHAVDASIISIFSNETKTLFNQLTQFADYKLFKNTDGSWKKIDPKT GWTEVTDENWKQIRVRNQVSEIAKVIEKYIQDSNIERKARYSRKIENKTNISLFNDTVYSA KKVGYEDQIKRKNLKTLDIHESAKENKNSKVKRQFVYRKLVNVSLLNNDKLADLFAEKEDIL MYRANPWVINLAEQIFNEYTENKKIKSQNVFEKYMLDLTKEFPEKFSEFLVKSMLRNKTAII YDDKKNIVHRIKRLKMLSSELKENKLSNVIIRSKNQSGTKLSYQDTINSLALMIMRSIDPTA KKQYIRVPLNTLNLHLGDHDFDLHNMDAYLKKPKFVKYLKANEIGDEYKPWRVLTSGTLLIH KKDKKLMYISSFQNLNDVIEIKNLIETEYKENDDSDSKKKKKANRFLMTLSTILNDYILLDA KDNFDILGLSKNRIDEILNSKLGLDKIVK
SEQ ID NO: 385
MGGSEVGTVPVTWRLGVDVGERSIGLAAVSYEEDKPKEILAAVSWIHDGGVGDERSGASRLA LRGMARRARRLRRFRRARLRDLDMLLSELGWTPLPDKNVSPVDAWLARKRLAEEYWDETER RRLLGYAVSHMARHRGWRNPWTTIKDLKNLPQPSDSWERTRESLEARYSVSLEPGTVGQWAG YLLQRAPGIRLNPTQQSAGRRAELSNATAFETRLRQEDVLWELRCIADVQGLPEDWSNVID AVFCQKRPSVPAERIGRDPLDPSQLRASRACLEFQEYRIVAAVANLRIRDGSGSRPLSLEER NAVIEALLAQTERSLTWSDIALEILKLPNESDLTSVPEEDGPSSLAYSQFAPFDETSARIAE FIAKNRRKIPTFAQWWQEQDRTSRSDLVAALADNSIAGEEEQELLVHLPDAELEALEGLALP SGRVAYSRLTLSGLTRVMRDDGVDVHNARKTCFGVDDNWRPPLPALHEATGHPWDRNLAIL RKFLSSATMRWGPPQSIWELARGASESRERQAEEEAARRAHRKANDRIRAELRASGLSDPS PADLVRARLLELYDCHCMYCGAPISWENSELDHIVPRTDGGSNRHENLAITCGACNKEKGRR PFASWAETSNRVQLRDVIDRVQKLKYSGNMYWTRDEFSRYKKSWARLKRRTSDPEVIQSIE STGYAAVALRDRLLSYGEKNGVAQVAVFRGGVTAEARRWLDISIERLFSRVAIFAQSTSTKR LDRRHHAVDAVVLTTLTPGVAKTLADARSRRVSAEFWRRPSDVNRHSTEEPQSPAYRQWKES CSGLGDLLISTAARDSIAVAAPLRLRPTGALHEETLRAFSEHTVGAAWKGAELRRIVEPEVY AAFLALTDPGGRFLKVSPSEDVLPADENRHIVLSDRVLGPRDRVKLFPDDRGSIRVRGGAAY IASFHHARVFRWGSSHSPSFALLRVSLADLAVAGLLRDGVDVFTAELPPWTPAWRYASIALV KAVESGDAKQVGWLVPGDELDFGPEGVTTAAGDLSMFLKYFPERHWVVTGFEDDKRINLKPA FLSAEQAEVLRTERSDRPDTLTEAGEILAQFFPRCWRATVAKVLCHPGLTVIRRTALGQPRW RRGHLPYSWRPWSADPWSGGTP
SEQ ID NO: 386
MHNKKNITIGFDLGIASIGWAIIDSTTSKILDWGTRTFEERKTANERRAFRSTRRNIRRKAY RNQRFINLILKYKDLFELKNISDIQRANKKDTENYEKIISFFTEIYKKCAAKHSNILEVKVK ALDSKIEKLDLIWILHDYLENRGFFYDLEEENVADKYEGIEHPSILLYDFFKKNGFFKSNSS IPKDLGGYSFSNLQWVNEIKKLFEVQEINPEFSEKFLNLFTSVRDYAKGPGSEHSASEYGIF QKDEKGKVFKKYDNIWDKTIGKCSFFVEENRSPVNYPSYEIFNLLNQLINLSTDLKTTNKKI WQLSSNDRNELLDELLKVKEKAKIISISLKKNEIKKIILKDFGFEKSDIDDQDTIEGRKIIK EEPTTKLEVTKHLLATIYSHSSDSNWININNILEFLPYLDAICIILDREKSRGQDEVLKKLT EKNIFEVLKIDREKQLDFVKSIFSNTKFNFKKIGNFSLKAIREFLPKMFEQNKNSEYLKWKD EEIRRKWEEQKSKLGKTDKKTKYLNPRIFQDEIISPGTKNTFEQAVLVLNQIIKKYSKENII DAI IIESPREKNDKKTIEEIKKRNKKGKGKTLEKLFQILNLENKGYKLSDLETKPAKLLDRL RFYHQQDGIDLYTLDKINIDQLINGSQKYEIEHIIPYSMSYDNSQANKILTEKAENLKKGKL IASEYIKRNGDEFYNKYYEKAKELFINKYKKNKKLDSYVDLDEDSAKNRFRFLTLQDYDEFQ VEFLARNLNDTRYSTKLFYHALVEHFENNEFFTYIDENSSKHKVKISTIKGHVTKYFRAKPV QKNNGPNENLNNNKPEKIEKNRENNEHHAVDAAIVAIIGNKNPQIANLLTLADNKTDKKFLL HDENYKENIETGELVKIPKFEVDKLAKVEDLKKIIQEKYEEAKKHTAIKFSRKTRTILNGGL SDETLYGFKYDEKEDKYFKIIKKKLVTSKNEELKKYFENPFGKKADGKSEYTVLMAQSHLSE FNKLKEIFEKYNGFSNKTGNAFVEYMNDLALKEPTLKAEIESAKSVEKLLYYNFKPSDQFTY HDNINNKSFKRFYKNIRIIEYKSIPIKFKILSKHDGGKSFKDTLFSLYSLVYKVYENGKESY KSIPVTSQMRNFGIDEFDFLDENLYNKEKLDIYKSDFAKPIPVNCKPVFVLKKGSILKKKSL DIDDFKETKETEEGNYYFISTISKRFNRDTAYGLKPLKLSWKPVAEPSTNPIFKEYIPIHL DELGNEYPVKIKEHTDDEKLMCTIK Nucleic Acids Encoding Cas9 Molecules
Nucleic acids encoding the Cas9 molecules or Cas9 polypeptides, e.g., an eaCas9 molecule or eaCas9 poypeptides are provided herein.
Exemplary nucleic acids encoding Cas9 molecules or Cas9 polypeptides are described in Cong etal, ScffiNCE 2013, 399(6121):819-823; Wang et al, CELL 2013, 153(4):910-918; Mali et al, ScffiNCE 2013, 399(6121):823-826; Jinek et al, SCIENCE 2012, 337(6096):816- 821. Another exemplary nucleic acid encoding a Cas9 molecule or Cas9 polypeptides is shown in Fig. 8. In an embodiment, a nucleic acid encoding a Cas9 molecule or Cas9 polypeptides can be a synthetic nucleic acid sequence. For example, the synthetic nucleic acid molecule can be chemically modified, e.g., as described in Section VIII. In an embodiment, the Cas9 mRNA has one or more (e.g., all of the following properties: it is capped, polyadenylated, substituted with 5-methylcytidine and/or pseudouridine.
In addition, or alternatively, the synthetic nucleic acid sequence can be codon optimized, e.g., at least one non-common codon or less-common codon has been replaced by a common codon. For example, the synthetic nucleic acid can direct the synthesis of an optimized messenger mRNA, e.g., optimized for expression in a mammalian expression system, e.g., described herein.
In addition, or alternatively, a nucleic acid encoding a Cas9 molecule or Cas9 polypeptides may comprise a nuclear localization sequence (NLS). Nuclear localization sequences are known in the art.
Provided below is an exemplary codon optimized nucleic acid sequence encoding a Cas9 molecule of S. pyogenes.
ATGGATAAAA AGTACAGCAT CGGGCTGGAC ATCGGTACAA ACTCAGTGGG GTGGGCCGTG ATTACGGACG AGTACAAGGT ACCCTCCAAA AAATTTAAAG TGCTGGGTAA CACGGACAGA CACTCTATAA AGAAAAATCT TATTGGAGCC TTGCTGTTCG ACTCAGGCGA GACAGCCGAA GCCACAAGGT TGAAGCGGAC CGCCAGGAGG CGGTATACCA GGAGAAAGAA CCGCATATGC TACCTGCAAG AAATCTTCAG TAACGAGATG GCAAAGGTTG ACGATAGCTT TTTCCATCGC CTGGAAGAAT CCTTTCTTGT TGAGGAAGAC AAGAAGCACG AACGGCACCC CATCTTTGGC AATATTGTCG ACGAAGTGGC ATATCACGAA AAGTACCCGA CTATCTACCA CCTCAGGAAG AAGCTGGTGG ACTCTACCGA TAAGGCGGAC CTCAGACTTA TTTATTTGGC ACTCGCCCAC AT GAT T AAA T TTAGAGGACA TTTCTTGATC GAGGGCGACC TGAACCCGGA CAACAGTGAC GTCGATAAGC TGTTCATCCA ACTTGTGCAG ACCTACAATC AACTGTTCGA AGAAAACCCT ATAAATGCTT CAGGAGTCGA CGCTAAAGCA ATCCTGTCCG CGCGCCTCTC AAAATCTAGA AGACTTGAGA ATCTGATTGC TCAGTTGCCC GGGGAAAAGA AAAATGGATT GTTTGGCAAC CTGATCGCCC TCAGTCTCGG ACTGACCCCA AATTTCAAAA GTAACTTCGA CCTGGCCGAA GACGCTAAGC TCCAGCTGTC CAAGGACACA TACGATGACG ACCTCGACAA TCTGCTGGCC CAGATTGGGG ATCAGTACGC CGATCTCTTT TTGGCAGCAA AGAACCTGTC CGACGCCATC CTGTTGAGCG ATATCTTGAG AGTGAACACC GAAATTACTA AAGCACCCCT TAGCGCATCT ATGATCAAGC GGTACGACGA GCATCATCAG GATCTGACCC TGCTGAAGGC TCTTGTGAGG CAACAGCTCC CCGAAAAATA CAAGGAAATC TTCTTTGACC AG AG C AAAAA CGGCTACGCT GGCTATATAG ATGGTGGGGC CAGTCAGGAG GAATTCTATA AATTCATCAA GCCCATTCTC GAGAAAATGG ACGGCACAGA GGAGTTGCTG GTCAAACTTA ACAGGGAGGA CCTGCTGCGG AAGCAGCGGA CCTTTGACAA CGGGTCTATC CCCCACCAGA TTCATCTGGG CGAACTGCAC GCAATCCTGA GGAGGCAGGA GGATTTTTAT CCTTTTCTTA AAGATAACCG CGAGAAAATA GAAAAGATTC TTACATTCAG GATCCCGTAC TACGTGGGAC CTCTCGCCCG GGGCAATTCA CGGTTTGCCT GGATGACAAG GAAGTCAGAG GAGACTATTA CACCTTGGAA CTTCGAAGAA GTGGTGGACA AGGGTGCATC TGCCCAGTCT TTCATCGAGC GGATGACAAA TTTTGACAAG AACCTCCCTA ATGAGAAGGT GCTGCCCAAA CATTCTCTGC TCTACGAGTA CTTTACCGTC TACAATGAAC TGACTAAAGT CAAGTACGTC ACCGAGGGAA TGAGGAAGCC GGCATTCCTT AGTGGAGAAC AGAAGAAGGC GATTGTAGAC CTGTTGTTCA AGACCAACAG GAAGGTGACT GTGAAGCAAC TTAAAGAAGA CTACTTTAAG AAGATCGAAT GTTTTGACAG TGTGGAAATT TCAGGGGTTG AAGACCGCTT CAATGCGTCA TTGGGGACTT AC CAT GAT CT TCTCAAGATC ATAAAGGACA AAGACTTCCT GGACAACGAA GAAAATGAGG ATATTCTCGA AGACATCGTC CTCACCCTGA CCCTGTTCGA AGACAGGGAA ATGATAGAAG AGCGCTTGAA AACCTATGCC CACCTCTTCG ACGATAAAGT TAT GAAG C AG CTGAAGCGCA GGAGATACAC AGGATGGGGA AGATTGTCAA GGAAGCTGAT CAATGGAATT AGGGATAAAC AGAGTGGCAA GACCATACTG GATTTCCTCA AATCTGATGG CTTCGCCAAT AGGAACTTCA TGCAACTGAT TCACGATGAC TCTCTTACCT TCAAGGAGGA CATTCAAAAG GCTCAGGTGA GCGGGCAGGG AGACTCCCTT CATGAACACA TCGCGAATTT GGCAGGTTCC CCCGCTATTA AAAAGGGCAT CCTTCAAACT GTCAAGGTGG TGGATGAATT GGTCAAGGTA ATGGGCAGAC ATAAGCCAGA AAATATTGTG ATCGAGATGG CCCGCGAAAA CCAGACCACA CAGAAGGGCC AGAAAAATAG TAGAGAGCGG ATGAAGAGGA TCGAGGAGGG CATCAAAGAG CTGGGATCTC AGATTCTCAA AGAACACCCC GTAGAAAACA CACAGCTGCA GAACGAAAAA TTGTACTTGT ACTATCTGCA GAACGGCAGA GACATGTACG TCGACCAAGA AC TT GAT ATT AATAGACTGT CCGACTATGA CGTAGACCAT ATCGTGCCCC AGTCCTTCCT GAAGGACGAC TCCATTGATA ACAAAGTCTT GACAAGAAGC GACAAGAACA GGGGTAAAAG TGATAATGTG CCTAGCGAGG AGGTGGTGAA AAAAAT GAAG AACTACTGGC GACAGCTGCT TAATGCAAAG CTCATTACAC AACGGAAGTT CGATAATCTG ACGAAAGCAG AGAGAGGTGG CTTGTCTGAG TTGGACAAGG CAGGGTTTAT TAAGCGGCAG CTGGTGGAAA CTAGGCAGAT CACAAAGCAC GTGGCGCAGA TTTTGGACAG CCGGATGAAC ACAAAATACG ACGAAAATGA TAAACTGATA CGAGAGGTCA AAGTTATCAC GCTGAAAAGC AAGCTGGTGT CCGATTTTCG GAAAGACTTC CAGTTCTACA AAGTTCGCGA GATTAATAAC TACCATCATG CTCACGATGC GTACCTGAAC GCTGTTGTCG GGACCGCCTT GATAAAGAAG TACCCAAAGC TGGAATCCGA GTTCGTATAC GGGGATTACA AAGTGTACGA TGTGAGGAAA ATGATAGCCA AGTCCGAGCA GGAGATTGGA AAGGCCACAG CTAAGTACTT CTTTTATTCT AACATCATGA ATTTTTTTAA GACGGAAATT ACCCTGGCCA ACGGAGAGAT CAGAAAGCGG CCCCTTATAG AGACAAATGG TGAAACAGGT GAAATCGTCT GGGATAAGGG CAGGGATTTC GCTACTGTGA GGAAGGTGCT GAGTATGCCA CAGGTAAATA TCGTGAAAAA AACCGAAGTA CAGACCGGAG GATTTTCCAA GGAAAGCATT TTGCCTAAAA GAAACTCAGA CAAGCTCATC GCCCGCAAGA AAGATTGGGA CCCTAAGAAA TACGGGGGAT TTGACTCACC CACCGTAGCC TATTCTGTGC TGGTGGTAGC TAAGGTGGAA AAAGGAAAGT CTAAGAAGCT GAAGTCCGTG AAGGAACTCT TGGGAATCAC TATCATGGAA AG AT CATC CT TTGAAAAGAA CCCTATCGAT TTCCTGGAGG CTAAGGGTTA CAAGGAGGTC AAGAAAGACC TCATCATTAA ACTGCCAAAA TACTCTCTCT TCGAGCTGGA AAATGGCAGG AAGAGAATGT TGGCCAGCGC CGGAGAGCTG CAAAAGGGAA ACGAGCTTGC TCTGCCCTCC AAATATGTTA ATTTTCTCTA TCTCGCTTCC CACTATGAAA AGCTGAAAGG GTCTCCCGAA GATAACGAGC AGAAGCAGCT GTTCGTCGAA CAGCACAAGC ACTATCTGGA TGAAATAATC GAACAAATAA GCGAGTTCAG CAAAAGGGTT ATCCTGGCGG ATGCTAATTT GGACAAAGTA CTGTCTGCTT ATAACAAGCA CCGGGATAAG CCTATTAGGG AACAAGCCGA GAATATAATT CACCTCTTTA CACTCACGAA TCTCGGAGCC CCCGCCGCCT TCAAATACTT TGATACGACT ATCGACCGGA
AACGGTATAC CAGTACCAAA GAGGTCCTCG ATGCCACCCT CATCCACCAG TCAATTACTG GCCTGTACGA AACACGGATC GACCTCTCTC AACTGGGCGG CGACTAG
(SEQ ID NO: 22)
Provided below is the corresponding amino acid sequence of a S. pyogenes Cas9 molecule.
MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEAT RLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFI QLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGL TPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNT EITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEF YKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLK DNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRK VTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIV LTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDF LKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKW DELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSD NVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKH VAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLAN GEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNS DKLIARKKDWDPKKYGGFDSPTVAYSVLWAKVEKGKSKKLKSVKELLGITIMERSSFEKNP IDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI REQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQ LGGD*
(SEQ ID NO: 23)
Provided below is an exemplary codon optimized nucleic acid sequence encoding a Cas9 molecule of N. meningitidis.
ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCAG CGTGGGCTGGGCCATGGTGGAGATCGACGAGGACGAGAACCCCATCTGCCTGATCGACCTGG GTGTGCGCGTGTTCGAGCGCGCTGAGGTGCCCAAGACTGGTGACAGTCTGGCTATGGCTCGC CGGCTTGCTCGCTCTGTTCGGCGCCTTACTCGCCGGCGCGCTCACCGCCTTCTGCGCGCTCG CCGCCTGCTGAAGCGCGAGGGTGTGCTGCAGGCTGCCGACTTCGACGAGAACGGCCTGATCA AGAGCCTGCCCAACACTCCTTGGCAGCTGCGCGCTGCCGCTCTGGACCGCAAGCTGACTCCT CTGGAGTGGAGCGCCGTGCTGCTGCACCTGATCAAGCACCGCGGCTACCTGAGCCAGCGCAA GAACGAGGGCGAGACCGCCGACAAGGAGCTGGGTGCTCTGCTGAAGGGCGTGGCCGACAACG CCCACGCCCTGCAGACTGGTGACTTCCGCACTCCTGCTGAGCTGGCCCTGAACAAGTTCGAG AAGGAGAGCGGCCACATCCGCAACCAGCGCGGCGACTACAGCCACACCTTCAGCCGCAAGGA CCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGA GCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGCCCCGCCCTGAGCGGC GACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCAGCCGAGCCCAAGGCCGCCAA GAACACCTACACCGCCGAGCGCTTCATCTGGCTGACCAAGCTGAACAACCTGCGCATCCTGG AGCAGGGCAGCGAGCGCCCCCTGACCGACACCGAGCGCGCCACCCTGATGGACGAGCCCTAC CGCAAGAGCAAGCTGACCTACGCCCAGGCCCGCAAGCTGCTGGGTCTGGAGGACACCGCCTT CTTCAAGGGCCTGCGCTACGGCAAGGACAACGCCGAGGCCAGCACCCTGATGGAGATGAAGG CCTACCACGCCATCAGCCGCGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGAGTCCTCTG AACCTGAGCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCAGCCTGTTCAAGACCGACGA GGACATCACCGGCCGCCTGAAGGACCGCATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGC ACATCAGCTTCGACAAGTTCGTGCAGATCAGCCTGAAGGCCCTGCGCCGCATCGTGCCCCTG ATGGAGCAGGGCAAGCGCTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAA GAAGAACACCGAGGAGAAGATCTACCTGCCTCCTATCCCCGCCGACGAGATCCGCAACCCCG TGGTGCTGCGCGCCCTGAGCCAGGCCCGCAAGGTGATCAACGGCGTGGTGCGCCGCTACGGC AGCCCCGCCCGCATCCACATCGAGACCGCCCGCGAGGTGGGCAAGAGCTTCAAGGACCGCAA GGAGATCGAGAAGCGCCAGGAGGAGAACCGCAAGGACCGCGAGAAGGCCGCCGCCAAGTTCC GCGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGAGCAAGGACATCCTGAAGCTGCGCCTG TACGAGCAGCAGCACGGCAAGTGCCTGTACAGCGGCAAGGAGATCAACCTGGGCCGCCTGAA CGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCAGCCGCACCTGGGACGACAGCT TCAACAACAAGGTGCTGGTGCTGGGCAGCGAGAACCAGAACAAGGGCAACCAGACCCCCTAC GAGTACTTCAACGGCAAGGACAACAGCCGCGAGTGGCAGGAGTTCAAGGCCCGCGTGGAGAC CAGCCGCTTCCCCCGCAGCAAGAAGCAGCGCATCCTGCTGCAGAAGTTCGACGAGGACGGCT TCAAGGAGCGCAACCTGAACGACACCCGCTACGTGAACCGCTTCCTGTGCCAGTTCGTGGCC GACCGCATGCGCCTGACCGGCAAGGGCAAGAAGCGCGTGTTCGCCAGCAACGGCCAGATCAC CAACCTGCTGCGCGGCTTCTGGGGCCTGCGCAAGGTGCGCGCCGAGAACGACCGCCACCACG CCCTGGACGCCGTGGTGGTGGCCTGCAGCACCGTGGCCATGCAGCAGAAGATCACCCGCTTC GTGCGCTACAAGGAGATGAACGCCTTCGACGGTAAAACCATCGACAAGGAGACCGGCGAGGT GCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCC GCGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTG CGCACCCTGCTGGCCGAGAAGCTGAGCAGCCGCCCTGAGGCCGTGCACGAGTACGTGACTCC TCTGTTCGTGAGCCGCGCCCCCAACCGCAAGATGAGCGGTCAGGGTCACATGGAGACCGTGA AGAGCGCCAAGCGCCTGGACGAGGGCGTGAGCGTGCTGCGCGTGCCCCTGACCCAGCTGAAG CTGAAGGACCTGGAGAAGATGGTGAACCGCGAGCGCGAGCCCAAGCTGTACGAGGCCCTGAA GGCCCGCCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGT ACGACAAGGCCGGCAACCGCACCCAGCAGGTGAAGGCCGTGCGCGTGGAGCAGGTGCAGAAG ACCGGCGTGTGGGTGCGCAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGCGTGGA CGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACAGCTGGCAGGTGGCCAAGG GCATCCTGCCCGACCGCGCCGTGGTGCAGGGCAAGGACGAGGAGGACTGGCAGCTGATCGAC GACAGCTTCAACTTCAAGTTCAGCCTGCACCCCAACGACCTGGTGGAGGTGATCACCAAGAA GGCCCGCATGTTCGGCTACTTCGCCAGCTGCCACCGCGGCACCGGCAACATCAACATCCGCA TCCACGACCTGGACCACAAGATCGGCAAGAACGGCATCCTGGAGGGCATCGGCGTGAAGACC GCCCTGAGCTTCCAGAAGTACCAGATCGACGAGCTGGGCAAGGAGATCCGCCCCTGCCGCCT GAAGAAGCGCCCTCCTGTGCGCTAA
(SEQ ID NO: 24)
Provided below is the corresponding amino acid sequence of a N. meningitidisCas9 molecule.
MAAFKPNPINYILGLDIGIASVGWAMVEIDEDENPICLIDLGVRVFERAEVPKTGDSLAMAR RLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTP LEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVADNAHALQTGDFRTPAELALNKFE KESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSG DAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPY RKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPL NLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPL MEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPWLRALSQARKVINGWRRYG SPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRL YEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPY EYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVA DRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAWVACSTVAMQQKITRF VRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKL RTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLK LKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQK TGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAWQGKDEEDWQLID DSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKT ALSFQKYQIDELGKEIRPCRLKKRPPVR*
(SEQ ID NO: 25)
Provided below is an amino acid sequence of a S. aureus Cas9 molecule.
MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRH RIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEV EEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKV QKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVK YAYNADLYNALNDLNNLVITRDENEKLEYYEKFQI IENVFKQKKKPTLKQIAKEILVNEEDI KGYRVTSTGKPEFTNLKVYHDIKDITARKEI IENAELLDQIAKILTIYQSSEDIQEELTNLN SELTQEEIEQISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQK EIPTTLVDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQK RNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHI IPRSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKISYETFKKHILNLAKGKGRISK TKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKSINGGFTS FLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEI ETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLN GLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKY SKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKWKLSLKPYRFDVYLDNGVYKFVTVKN LDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRI EVNMIDITYREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG* (SEQ ID NO: 26)
Provided below is an exemplary codon optimized nucleic acid sequence encoding a
Cas9 molecule of S. aureus Cas9.
ATGAAAAGGAACTACATTCTGGGGCTGGACATCGGGATTACAAGCGTGGGGTATGGGATTAT TGACTATGAAACAAGGGACGTGATCGACGCAGGCGTCAGACTGTTCAAGGAGGCCAACGTGG AAAACAATGAGGGACGGAGAAGCAAGAGGGGAGCCAGGCGCCTGAAACGACGGAGAAGGCAC AGAATCCAGAGGGTGAAGAAACTGCTGTTCGATTACAACCTGCTGACCGACCATTCTGAGCT GAGTGGAATTAATCCTTATGAAGCCAGGGTGAAAGGCCTGAGTCAGAAGCTGTCAGAGGAAG AGTTTTCCGCAGCTCTGCTGCACCTGGCTAAGCGCCGAGGAGTGCATAACGTCAATGAGGTG GAAGAGGACACCGGCAACGAGCTGTCTACAAAGGAACAGATCTCACGCAATAGCAAAGCTCT GGAAGAGAAGTATGTCGCAGAGCTGCAGCTGGAACGGCTGAAGAAAGATGGCGAGGTGAGAG GGTCAATTAATAGGTTCAAGACAAGCGACTACGTCAAAGAAGCCAAGCAGCTGCTGAAAGTG CAGAAGGCTTACCACCAGCTGGATCAGAGCTTCATCGATACTTATATCGACCTGCTGGAGAC TCGGAGAACCTACTATGAGGGACCAGGAGAAGGGAGCCCCTTCGGATGGAAAGACATCAAGG AATGGTACGAGATGCTGATGGGACATTGCACCTATTTTCCAGAAGAGCTGAGAAGCGTCAAG TACGCTTATAACGCAGATCTGTACAACGCCCTGAATGACCTGAACAACCTGGTCATCACCAG GGATGAAAACGAGAAACTGGAATACTATGAGAAGTTCCAGATCATCGAAAACGTGTTTAAGC AGAAGAAAAAGCCTACACTGAAACAGATTGCTAAGGAGATCCTGGTCAACGAAGAGGACATC AAGGGCTACCGGGTGACAAGCACTGGAAAACCAGAGTTCACCAATCTGAAAGTGTATCACGA TATTAAGGACATCACAGCACGGAAAGAAATCATTGAGAACGCCGAACTGCTGGATCAGATTG CTAAGATCCTGACTATCTACCAGAGCTCCGAGGACATCCAGGAAGAGCTGACTAACCTGAAC AGCGAGCTGACCCAGGAAGAGATCGAACAGATTAGTAATCTGAAGGGGTACACCGGAACACA CAACCTGTCCCTGAAAGCTATCAATCTGATTCTGGATGAGCTGTGGCATACAAACGACAATC AGATTGCAATCTTTAACCGGCTGAAGCTGGTCCCAAAAAAGGTGGACCTGAGTCAGCAGAAA GAGATCCCAACCACACTGGTGGACGATTTCATTCTGTCACCCGTGGTCAAGCGGAGCTTCAT CCAGAGCATCAAAGTGATCAACGCCATCATCAAGAAGTACGGCCTGCCCAATGATATCATTA TCGAGCTGGCTAGGGAGAAGAACAGCAAGGACGCACAGAAGATGATCAATGAGATGCAGAAA CGAAACCGGCAGACCAATGAACGCATTGAAGAGATTATCCGAACTACCGGGAAAGAGAACGC AAAGTACCTGATTGAAAAAATCAAGCTGCACGATATGCAGGAGGGAAAGTGTCTGTATTCTC TGGAGGCCATCCCCCTGGAGGACCTGCTGAACAATCCATTCAACTACGAGGTCGATCATATT ATCCCCAGAAGCGTGTCCTTCGACAATTCCTTTAACAACAAGGTGCTGGTCAAGCAGGAAGA GAACTCTAAAAAGGGCAATAGGACTCCTTTCCAGTACCTGTCTAGTTCAGATTCCAAGATCT CTTACGAAACCTTTAAAAAGCACATTCTGAATCTGGCCAAAGGAAAGGGCCGCATCAGCAAG ACCAAAAAGGAGTACCTGCTGGAAGAGCGGGACATCAACAGATTCTCCGTCCAGAAGGATTT TATTAACCGGAATCTGGTGGACACAAGATACGCTACTCGCGGCCTGATGAATCTGCTGCGAT CCTATTTCCGGGTGAACAATCTGGATGTGAAAGTCAAGTCCATCAACGGCGGGTTCACATCT TTTCTGAGGCGCAAATGGAAGTTTAAAAAGGAGCGCAACAAAGGGTACAAGCACCATGCCGA AGATGCTCTGATTATCGCAAATGCCGACTTCATCTTTAAGGAGTGGAAAAAGCTGGACAAAG CCAAGAAAGTGATGGAGAACCAGATGTTCGAAGAGAAGCAGGCCGAATCTATGCCCGAAATC GAGACAGAACAGGAGTACAAGGAGATTTTCATCACTCCTCACCAGATCAAGCATATCAAGGA TTTCAAGGACTACAAGTACTCTCACCGGGTGGATAAAAAGCCCAACAGAGAGCTGATCAATG ACACCCTGTATAGTACAAGAAAAGACGATAAGGGGAATACCCTGATTGTGAACAATCTGAAC GGACTGTACGACAAAGATAATGACAAGCTGAAAAAGCTGATCAACAAAAGTCCCGAGAAGCT GCTGATGTACCACCATGATCCTCAGACATATCAGAAACTGAAGCTGATTATGGAGCAGTACG GCGACGAGAAGAACCCACTGTATAAGTACTATGAAGAGACTGGGAACTACCTGACCAAGTAT AGCAAAAAGGATAATGGCCCCGTGATCAAGAAGATCAAGTACTATGGGAACAAGCTGAATGC CCATCTGGACATCACAGACGATTACCCTAACAGTCGCAACAAGGTGGTCAAGCTGTCACTGA AGCCATACAGATTCGATGTCTATCTGGACAACGGCGTGTATAAATTTGTGACTGTCAAGAAT CTGGATGTCATCAAAAAGGAGAACTACTATGAAGTGAATAGCAAGTGCTACGAAGAGGCTAA AAAGCTGAAAAAGATTAGCAACCAGGCAGAGTTCATCGCCTCCTTTTACAACAACGACCTGA TTAAGATCAATGGCGAACTGTATAGGGTCATCGGGGTGAACAATGATCTGCTGAACCGCATT GAAGTGAATATGATTGACATCACTTACCGAGAGTATCTGGAAAACATGAATGATAAGCGCCC CCCTCGAATTATCAAAACAATTGCCTCTAAGACTCAGAGTATCAAAAAGTACTCAACCGACA TTCTGGGAAACCTGTATGAGGTGAAGAGCAAAAAGCACCCTCAGATTATCAAAAAGGGC
(SEQ ID NO: 39)
If any of the above Cas9 sequences are fused with a peptide or polypeptide at the C- terminus, it is understood that the stop codon will be removed.
Other Cas Molecules and Cas9 polypeptides
Various types of Cas molecules or Cas9 polypeptides can be used to practice the inventions disclosed herein. In some embodiments, Cas molecules of Type II Cas systems are used. In other embodiments, Cas molecules of other Cas systems are used. For example Type I or Type III Cas molecules may be used. Exemplary Cas molecules (and Cas systems) are described, e.g., in Haft et al, PLoS COMPUTATIONAL BIOLOGY 2005, 1(6): e60 and Makarova et al, NATURE REVIEW MICROBIOLOGY 2011, 9:467-477, the contents of both references are incorporated herein by reference in their entirety. Exemplary Cas molecules (and Cas systems) are also shown in Table 22.
Figure imgf000788_0001
Table 22: Cas Systems
Gene System type Name from Structure of Families (and Representatives name* or subtype Haft et al.% encoded superfamily) of
protein (PDB encoded
accessions)*" protein***
cas8b • Subtype I- cshl and NA BH0338-like MTH1090 and
B** TM1802 TM1802 cas8c • Subtype I- csdl and csp2 NA BH0338-like BH0338
C**
cas9 • Type II** csnl and csxl2 NA COG3513 FTN_0757 and
SPyl046 cas 10 • Type III** cmr2, csml NA COG1353 MTH326, Rv2823c§§ and csxll and TM1794§§ cas 10 d • Subtype I- csc3 NA COG1353 slr7011
D**
csyl • Subtype I- csyl NA yl724-like yl724
F**
csy2 • Subtype I-F csy2 NA (RAMP) yl725
csy3 • Subtype I-F csy3 NA (RAMP) yl726
csel • Subtype I- csel NA YgcL-like ygcL
E**
cse2 • Subtype I-E cse2 2ZCA YgcK-like ygcK
cscl • Subtype I-D cscl NA air 1563 -like alrl563
(RAMP)
csc2 • Subtype I-D cscl and csc2 NA COG1337 slr7012
(RAMP)
csa5 • Subtype I-A csa5 NA AF1870 AF1870, MJ0380,
PF0643 and SS01398 csn2 • Subtype II- csn2 NA SPyl049-like SPyl049
A
csm2 • Subtype III- csm2 NA COG1421 MTH1081 and
A** SERP2460 csm3 • Subtype III- csc2 and csm3 NA COG1337 MTH1080 and A (RAMP) SERP2459 csm4 • Subtype III- csm4 NA COG1567 MTH1079 and A (RAMP) SERP2458 csm5 • Subtype III- csm5 NA COG1332 MTH1078 and A (RAMP) SERP2457 csm6 • Subtype III- APE2256 and 2WTE COG1517 APE2256 and
A csm6 SS01445 cmrl • Subtype III- cmrl NA COG1367 PF1130
B (RAMP)
cmr3 • Subtype Hi- cmr3 NA COG1769 PF1128
fi (RAMP)
cmr4 • Subtype III- cmr4 NA COG1336 PF1126
B (RAMP)
cmr5 • Subtype Ill- cmr5 2ZOP and COG3337 MTH324 and PF1125 Table 22: Cas Systems
Gene System type Name from Structure of Families (and Representatives name* or subtype Haft et al.% encoded superfamily) of
protein (PDB encoded
accessions)*" protein***
B** 20EB
cmr6 • Subtype III- cmr6 NA COG1604 PF1124
B (RAMP)
csbl • Subtype I-U GSU0053 NA (RAMP) Balac_1306 and
GSU0053 csbl • Subtype I- NA NA (RAMP) Balac_1305 and
GSU0054 csb3 • Subtype I-U NA NA (RAMP) Balac_1303§§ csxl7 • Subtype I-U NA NA NA Btus_2683 csxl4 • Subtype I-U NA NA NA GSU0052 csxlO • Subtype I-U csxlO NA (RAMP) Caur_2274 csxl6 • Subtype III- VVA1548 NA NA VVA1548
U
csaX • Subtype III- csaX NA NA SS01438
U
csx3 • Subtype III- csx3 NA NA AF1864
U
csxl • Subtype III- csa3, csxl, 1XMX and 2171 COG1517 and MJ1666, NE0113, U csx2, DXTHG, COG4006 PF1127 and TM1812
NE0113 and
TIG 02710
csxl5 • Unknown NA NA TTE2665 TTE2665 csfl • Type U csfl NA NA AFE_1038 csfl • Type U csfl NA (RAMP) AFE_1039 csfl • Type U csfl NA (RAMP) AFE_1040 csfl • Type U csfl NA NA AFE_1037
IV. Functional Analysis of Candidate Molecules
Candidate Cas9 molecules, candidate gRNA molecules, candidate Cas9
molecule/gRNA molecule complexes, can be evaluated by art-known methods or as described herein. For example, exemplary methods for evaluating the endonuclease activity of Cas9 molecule are described, e.g., in Jinek et ah, SCIENCE 2012, 337(6096):816-821.
Binding and Cleavage Assay: Testing the endonuclease activity of Cas9 molecule The ability of a Cas9 molecule/gRNA molecule complex to bind to and cleave a target nucleic acid can be evaluated in a plasmid cleavage assay. In this assay, synthetic or in vitro- transcribed gRNA molecule is pre-annealed prior to the reaction by heating to 95 °C and slowly cooling down to room temperature. Native or restriction digest- linearized plasmid DNA (300 ng (~8 nM)) is incubated for 60 min at 37°C with purified Cas9 protein molecule (50-500 nM) and gRNA (50-500 nM, 1:1) in a Cas9 plasmid cleavage buffer (20 mM HEPES pH 7.5, 150 mM KCl, 0.5 mM DTT, 0.1 mM EDTA) with or without 10 mM MgCl2. The reactions are stopped with 5X DNA loading buffer (30% glycerol, 1.2% SDS, 250 mM EDTA), resolved by a 0.8 or 1% agarose gel electrophoresis and visualized by ethidium bromide staining. The resulting cleavage products indicate whether the Cas9 molecule cleaves both DNA strands, or only one of the two strands. For example, linear DNA products indicate the cleavage of both DNA strands. Nicked open circular products indicate that only one of the two strands is cleaved.
Alternatively, the ability of a Cas9 molecule/gRNA molecule complex to bind to and cleave a target nucleic acid can be evaluated in an oligonucleotide DNA cleavage assay. In this assay, DNA oligonucleotides (10 pmol) are radiolabeled by incubating with 5 units T4 polynucleotide kinase and -3-6 pmol (-20^40 mCi) [γ-32Ρ]-ΑΤΡ in IX T4 polynucleotide kinase reaction buffer at 37°C for 30 min, in a 50 μΕ reaction. After heat inactivation (65°C for 20 min), reactions are purified through a column to remove unincorporated label. Duplex substrates (100 nM) are generated by annealing labeled oligonucleotides with equimolar amounts of unlabeled complementary oligonucleotide at 95°C for 3 min, followed by slow cooling to room temperature. For cleavage assays, gRNA molecules are annealed by heating to 95 °C for 30 s, followed by slow cooling to room temperature. Cas9 (500 nM final concentration) is pre-incubated with the annealed gRNA molecules (500 nM) in cleavage assay buffer (20 mM HEPES pH 7.5, 100 mM KCl, 5 mM MgC12, 1 mM DTT, 5% glycerol) in a total volume of 9 μΐ. Reactions are initiated by the addition of 1 μΐ target DNA (10 nM) and incubated for 1 h at 37 °C. Reactions are quenched by the addition of 20 μΐ of loading dye (5 mM EDTA, 0.025% SDS, 5% glycerol in formamide) and heated to 95°C for 5 min. Cleavage products are resolved on 12% denaturing polyacrylamide gels containing 7 M urea and visualized by phosphorimaging. The resulting cleavage products indicate that whether the complementary strand, the non-complementary strand, or both, are cleaved.
One or both of these assays can be used to evaluate the suitability of a candidate gRNA molecule or candidate Cas9 molecule.
Binding Assay: Testing the binding of Cas9 molecule to target DNA
Exemplary methods for evaluating the binding of Cas9 molecule to target DNA are described, e.g., in Jinek et al, SCIENCE 2012; 337(6096):816-821. For example, in an electrophoretic mobility shift assay, target DNA duplexes are formed by mixing of each strand (10 nmol) in deionized water, heating to 95 °C for 3 min and slow cooling to room temperature. All DNAs are purified on 8% native gels containing IX TBE. DNA bands are visualized by UV shadowing, excised, and eluted by soaking gel pieces in DEPC-treated H20. Eluted DNA is ethanol precipitated and dissolved in DEPC- treated H20. DNA samples are 5' end labeled with [γ-32Ρ]-ΑΤΡ using T4 polynucleotide kinase for 30 min at 37°C. Polynucleotide kinase is heat denatured at 65°C for 20 min, and unincorporated radiolabel is removed using a column. Binding assays are performed in buffer containing 20 mM HEPES pH 7.5, 100 mM KC1, 5 mM MgCl2, 1 mM DTT and 10% glycerol in a total volume of 10 μΐ. Cas9 protein molecule is programmed with equimolar amounts of pre-annealed gRNA molecule and titrated from 100 pM to 1 μΜ. Radiolabeled DNA is added to a final concentration of 20 pM. Samples are incubated for 1 h at 37°C and resolved at 4°C on an 8% native polyacrylamide gel containing IX TBE and 5 mM MgCl2. Gels are dried and DNA visualized by phosphorimaging.
Differential Scanning Flourimetry (DSF)
The thermostability of Cas9-gRNA ribonucleoprotein (RNP) complexes can be measured via DSF. This technique measures the thermostability of a protein, which can increase under favorable conditions such as the addition of a binding RNA molecule, e.g., a gRNA.
The assay is performed using two different protocols, one to test the best
stoichiometric ratio of gRNA:Cas9 protein and another to determine the best solution conditions for RNP formation.
To determine the best solution to form RNP complexes, a 2uM solution of Cas9 in water+lOx SYPRO Orange® (Life Techonologies cat#S-6650) and dispensed into a 384 well plate. An equimolar amount of gRNA diluted in solutions with varied pH and salt is then added. After incubating at room temperature for 10' and brief centrifugation to remove any bubbles,a Bio-Rad CFX384™ Real-Time System CIOOO Touch™ Thermal Cycler with the Bio-Rad CFX Manager software is used to run a gradient from 20°C to 90°C with a 1° increase in temperature every lOseconds.
The second assay consists of mixing various concentrations of gRNA with 2uM Cas9 in optimal buffer from assay 1 above and incubating at RT for 10' in a 384 well plate. An equal volume of optimal buffer + lOx SYPRO Orange® (Life Techonologies cat#S-6650) is added and the plate sealed with Microseal® B adhesive (MSB- 1001). Following brief centrifugation to remove any bubbles, a Bio-Rad CFX384™ Real-Time System CIOOO Touch™ Thermal Cycler with the Bio-Rad CFX Manager software is used to run a gradient from 20°C to 90°C with a 1° increase in temperature every lOseconds. V. Genome Editing Approaches
Described herein are methods for targeted knockout of one or more copies (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more copies) of the UL19, UL30, UL48 and/or UL54 gene, e.g., using one or more of the approaches or pathways described herein, e.g., using NHEJ.
V.l NHEJ Approaches for Gene Targeting
As described herein, nuclease-induced non-homologous end-joining (NHEJ) can be used to target gene-specific knockouts. Nuclease-induced NHEJ can also be used to remove (e.g., delete) sequence (e.g., coding sequence, non-coding sequence, or sequence insertions) in a gene of interest.
While not wishing to be bound by theory, it is believed that, in an embodiment, the genomic alterations associated with the methods described herein rely on nuclease-induced NHEJ and the error-prone nature of the NHEJ repair pathway. NHEJ repairs a double-strand break in the DNA by joining together the two ends; however, generally, the original sequence is restored only if two compatible ends, exactly as they were formed by the double- strand break, are perfectly ligated. The DNA ends of the double-strand break are frequently the subject of enzymatic processing, resulting in the addition or removal of nucleotides, at one or both strands, prior to rejoining of the ends. This results in the presence of insertion and/or deletion (indel) mutations in the DNA sequence at the site of the NHEJ repair. Two-thirds of these mutations typically alter the reading frame and, therefore, produce a non-functional protein. Additionally, mutations that maintain the reading frame, but which insert or delete a significant amount of sequence, can destroy functionality of the protein. This is locus dependent as mutations in critical functional domains are likely less tolerable than mutations in non-critical regions of the protein.
The indel mutations generated by NHEJ are unpredictable in nature; however, at a given break site certain indel sequences are favored and are over represented in the population, likely due to small regions of microhomology. The lengths of deletions can vary widely; most commonly in the 1-50 bp range, but they can easily reach greater than 100-200 bp. Insertions tend to be shorter and often include short duplications of the sequence immediately surrounding the break site. However, it is possible to obtain large insertions, and in these cases, the inserted sequence has often been traced to other regions of the genome or to plasmid DNA present in the cells.
Because NHEJ is a mutagenic process, it can also be used to delete small sequence motifs as long as the generation of a specific final sequence is not required. If a double- strand break is targeted near to a short target sequence, the deletion mutations caused by the NHEJ repair often span, and therefore remove, the unwanted nucleotides. For the deletion of larger DNA segments, introducing two double-strand breaks, one on each side of the sequence, can result in NHEJ between the ends with removal of the entire intervening sequence. Both of these approaches can be used to delete specific DNA sequences; however, the error-prone nature of NHEJ may still produce indel mutations at the site of repair.
Both double strand cleaving eaCas9 molecules and single strand, or nickase, eaCas9 molecules can be used in the methods and compositions described herein to generate NHEJ- mediated indels. NHEJ-mediated indels targeted to the the gene, e.g., a coding region, e.g., an early coding region of a gene, of interest can be used to knockout (i.e., eliminate expression of) a gene of interest. For example, early coding region of a gene of interest includes sequence immediately following a transcription start site, within a first exon of the coding sequence, or within 500 bp of the transcription start site (e.g., less than 500, 450, 400, 350, 300, 250, 200, 150, 100 or 50 bp).
In some embodiments, NHEJ-mediated indels are introduced into more than one HSV-2 target gene. In an embodiment, in which Cas9 double- stranded nuclease or Cas9 single- stranded nickase is used to introduce mutations into two HSV-2 genes, e.g., UL19 and UL30, UL19 and UL48, UL19 and UL54, UL30 and UL48, UL30 and UL54, or UL48 and UL54, individual gRNAs or gRNA pairs targeting both genes are provided together with Cas9 double- stranded nuclease or single- stranded nickase. In an embodiment, in which Cas9 double- stranded nuclease or Cas9 single-stranded nickase is used to introduce mutations into three HSV-2 genes, e.g., UL19 and UL30 and UL48, or UL19 and UL30 and UL54, UL19 and UL48 and UL54, or UL30 and UL48 and UL54, individual gRNAs or gRNA pairs targeting all three genes are provided together with Cas9 double- stranded nuclease or single- stranded nickase. In an embodiment, in which Cas9 double-stranded nuclease or Cas9 single- stranded nickase is used to introduce mutations into four HSV-2 genes, e.g., UL19 and UL30 and UL48 and UL54, individual gRNAs or gRNA pairs targeting all four genes are provided together with Cas9 double-stranded nuclease or single-stranded nickase.
Placement of double strand or single strand breaks relative to the target position In an embodiment, in which a gRNA and Cas9 nuclease generate a double strand break for the purpose of inducing NHEJ-mediated indels, a gRNA, e.g., a unimolecular (or chimeric) or modular gRNA molecule, is configured to position one double-strand break in close proximity to a nucleotide of the target position, e.g., a HSV-2 target UL19 position, a HSV-2 target UL30 position, a HSV-2 target UL48 position or a HSV-2 target UL54 position. In an embodiment, the cleavage site is between 0-30 bp away from the target position (e.g., less than 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 bp from the target position).
In an embodiment, in which two gRNAs complexing with Cas9 nickases induce two single strand breaks for the purpose of inducing NHEJ-mediated indels, two gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to position two single-strand breaks to provide for NHEJ repair a nucleotide of the target position. In an embodiment, the gRNAs are configured to position cuts at the same position, or within a few nucleotides of one another, on different strands, essentially mimicking a double strand break. In an embodiment, the closer nick is between 0-30 bp away from the target position (e.g., less than 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 bp from the target position), and the two nicks are within 25-55 bp of each other (e.g., between 25 to 50, 25 to 45, 25 to 40, 25 to 35, 25 to 30, 50 to 55, 45 to 55, 40 to 55, 35 to 55, 30 to 55, 30 to 50, 35 to 50, 40 to 50 , 45 to 50, 35 to 45, or 40 to 45 bp) and no more than 100 bp away from each other (e.g., no more than 90, 80, 70, 60, 50, 40, 30, 20 or 10 bp). In an embodiment, the gRNAs are configured to place a single strand break on either side of a nucleotide of the target position.
Both double strand cleaving eaCas9 molecules and single strand, or nickase, eaCas9 molecules can be used in the methods and compositions described herein to generate breaks both sides of a target position. Double strand or paired single strand breaks may be generated on both sides of a target position to remove the nucleic acid sequence between the two cuts (e.g., the region between the two breaks in deleted). In one embodiment, two gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to position a double-strand break on both sides of a target position. In an alternate embodiment, three gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to position a double strand break (i.e., one gRNA complexes with a cas9 nuclease) and two single strand breaks or paired single stranded breaks (i.e., two gRNAs complex with Cas9 nickases) on either side of the target position. In another embodiment, four gRNAs, e.g., independently, unimolecular (or chimeric) or modular gRNA, are configured to generate two pairs of single stranded breaks (i.e., two pairs of two gRNAs complex with Cas9 nickases) on either side of the target position. The double strand break(s) or the closer of the two single strand nicks in a pair will ideally be within 0-500 bp of the target position (e.g., no more than 450, 400, 350, 300, 250, 200, 150, 100, 50 or 25 bp from the target position). When nickases are used, the two nicks in a pair are within 25-55 bp of each other (e.g., between 25 to 50, 25 to 45, 25 to 40, 25 to 35, 25 to 30, 50 to 55, 45 to 55, 40 to 55, 35 to 55, 30 to 55, 30 to 50, 35 to 50, 40 to 50 , 45 to 50, 35 to 45, or 40 to 45 bp) and no more than 100 bp away from each other (e.g., no more than 90, 80, 70, 60, 50, 40, 30, 20 or 10 bp).
V.2 Single-Strand Annealing
Single strand annealing (SSA) is another DNA repair process that repairs a double- strand break between two repeat sequences present in a target nucleic acid. Repeat sequences utilized by the SSA pathway are generally greater than 30 nucleotides in length. Resection at the break ends occurs to reveal repeat sequences on both strands of the target nucleic acid. After resection, single strand overhangs containing the repeat sequences are coated with RPA protein to prevent the repeats sequences from inappropriate annealing, e.g., to themselves. RAD52 binds to and each of the repeat sequences on the overhangs and aligns the sequences to enable the annealing of the complementary repeat sequences. After annealing, the single- strand flaps of the overhangs are cleaved. New DNA synthesis fills in any gaps, and ligation restores the DNA duplex. As a result of the processing, the DNA sequence between the two repeats is deleted. The length of the deletion can depend on many factors including the location of the two repeats utilized, and the pathway or processivity of the resection.
In contrast to HDR pathways, SSA does not require a template nucleic acid to alter or correct a target nucleic acid sequence. Instead, the complementary repeat sequence is utilized. V. 3 Other DNA Repair Pathways
SSBR (single strand break repair)
Single- stranded breaks (SSB) in the genome are repaired by the SSBR pathway, which is a distinct mechanism from the DSB repair mechanisms discussed above. The SSBR pathway has four major stages: SSB detection, DNA end processing, DNA gap filling, and DNA ligation. A more detailed explanation is given in Caldecott, Nature Reviews Genetics 9, 619-631 (August 2008), and a summary is given here.
In the first stage, when a SSB forms, PARP1 and/or PARP2 recognize the break and recruit repair machinery. The binding and activity of PARP1 at DNA breaks is transient and it seems to accelerate SSBr by promoting the focal accumulation or stability of SSBr protein complexes at the lesion. Arguably the most important of these SSBr proteins is XRCC1, which functions as a molecular scaffold that interacts with, stabilizes, and stimulates multiple enzymatic components of the SSBr process including the protein responsible for cleaning the DNA 3' and 5' ends. For instance, XRCC1 interacts with several proteins (DNA polymerase beta, PNK, and three nucleases, APE1, APTX, and APLF) that promote end processing. APE1 has endonuc lease activity. APLF exhibits endonuclease and 3' to 5' exonuclease activities. APTX has endonuclease and 3' to 5' exonuclease activity.
This end processing is an important stage of SSBR since the 3' - and/or 5 '-termini of most, if not all, SSBs are 'damaged'. End processing generally involves restoring a damaged 3 '-end to a hydroxylated state and and/or a damaged 5' end to a phosphate moiety, so that the ends become ligation-competent. Enzymes that can process damaged 3 ' termini include PNKP, APE1, and TDP1. Enzymes that can process damaged 5' termini include PNKP, DNA polymerase beta, and APTX. LIG3 (DNA ligase III) can also participate in end processing. Once the ends are cleaned, gap filling can occur.
At the DNA gap filling stage, the proteins typically present are PARP1, DNA polymerase beta, XRCC1, FEN1 (flap endonculease 1), DNA polymerase delta/epsilon, PCNA, and LIG1. There are two ways of gap filling, the short patch repair and the long patch repair. Short patch repair involves the insertion of a single nucleotide that is missing. At some SSBs, "gap filling" might continue displacing two or more nucleotides
(displacement of up to 12 bases have been reported). FENl is an endonuclease that removes the displaced 5 '-residues. Multiple DNA polymerases, including Pol β , are involved in the repair of SSBs, with the choice of DNA polymerase influenced by the source and type of SSB.
In the fourth stage, a DNA ligase such as LIG1 (Ligase I) or LIG3 (Ligase III) catalyzes joining of the ends. Short patch repair uses Ligase III and long patch repair uses Ligase I.
Sometimes, SSBR is replication-coupled. This pathway can involve one or more of CtIP, MRN, ERCC1, and FENl. Additional factors that may promote SSBR include:
aPARP, PARP1, PARP2, PARG, XRCC1, DNA polymerase b, DNA polymerase d, DNA polymerase e, PCNA, LIG1, PNK, PNKP, APE1, APTX, APLF, TDP1, LIG3, FENl, CtIP, MRN, and ERCC1.
MMR (mismatch repair) Cells contain three excision repair pathways: MMR, BER, and NER. The excision repair pathways hace a common feature in that they typically recognize a lesion on one strand of the DNA, then exo/endonucleaseases remove the lesion and leave a 1-30 nucleotide gap that is sub- sequentially filled in by DNA polymerase and finally sealed with ligase. A more complete picture is given in Li, Cell Research (2008) 18:85-98, and a summary is provided here.
Mismatch repair (MMR) operates on mispaired DNA bases.
The MSH2/6 or MSH2/3 complexes both have ATPases activity that plays an important role in mismatch recognition and the initiation of repair. MSH2/6 preferentially recognizes base-base mismatches and identifies mispairs of 1 or 2 nucleotides, while MSH2/3 preferentially recognizes larger ID mispairs.
hMLHl heterodimerizes with hPMS2 to form hMutL which possesses an ATPase activity and is important for multiple steps of MMR. It possesses a PCNA/replication factor C (RFC)-dependent endonuclease activity which plays an important role in 3' nick-directed MMR involving EXOl. (EXOl is a participant in both HR and MMR.) It regulates termination of mismatch-provoked excision. Ligase I is the relevant ligase for this pathway. Additional factors that may promote MMR include: EXOl, MSH2, MSH3, MSH6, MLH1, PMS2, MLH3, DNA Pol d, RPA, HMGB1, RFC, and DNA ligase I. Base excision repair (BER)
The base excision repair (BER) pathway is active throughout the cell cycle; it is responsible primarily for removing small, non-helix-distorting base lesions from the genome. In contrast, the related Nucleotide Excision Repair pathway (discussed in the next section) repairs bulky helix-distorting lesions. A more detailed explanation is given in Caldecott, Nature Reviews Genetics 9, 619-631 (August 2008), and a summary is given here.
Upon DNA base damage, base excision repair (BER) is initiated and the process can be simplified into five major steps: (a) removal of the damaged DNA base; (b) incision of the subsequent a basic site; (c) clean-up of the DNA ends; (d) insertion of the correct nucleotide into the repair gap; and (e) ligation of the remaining nick in the DNA backbone. These last steps are similar to the SSBR.
In the first step, a damage-specific DNA glycosylase excises the damaged base through cleavage of the N-glycosidic bond linking the base to the sugar phosphate backbone. Then AP endonuclease- 1 (APE1) or bifunctional DNA glycosylases with an associated lyase activity incised the phosphodiester backbone to create a DNA single strand break (SSB). The third step of BER involves cleaning-up of the DNA ends. The fourth step in BER is conducted by Pol β that adds a new complementary nucleotide into the repair gap and in the final step XRCCl/Ligase III seals the remaining nick in the DNA backbone. This completes the short-patch BER pathway in which the majority (-80%) of damaged DNA bases are repaired. However, if the 5' -ends in step 3 are resistant to end processing activity, following one nucleotide insertion by Pol β there is then a polymerase switch to the replicative DNA polymerases, Pol δ/ε, which then add -2-8 more nucleotides into the DNA repair gap. This creates a 5' -flap structure, which is recognized and excised by flap endonuclease-1 (FEN-1) in association with the processivity factor proliferating cell nuclear antigen (PCNA). DNA ligase I then seals the remaining nick in the DNA backbone and completes long-patch BER. Additional factors that may promote the BER pathway include: DNA glycosylase, APE1, Polb, Pold, Pole, XRCC1, Ligase III, FEN-1, PCNA, RECQL4, WRN, MYH, PNKP, and APTX.
Nucleotide excision repair (NER)
Nucleotide excision repair (NER) is an important excision mechanism that removes bulky helix-distorting lesions from DNA. Additional details about NER are given in Marteijn et al., Nature Reviews Molecular Cell Biology 15, 465-481 (2014), and a summary is given here. NER a broad pathway encompassing two smaller pathways: global genomic NER (GG- NER) and transcription coupled repair NER (TC-NER). GG-NER and TC-NER use different factors for recognizing DNA damage. However, they utilize the same machinery for lesion incision, repair, and ligation.
Once damage is recognized, the cell removes a short single- stranded DNA segment that contains the lesion. Endonuc leases XPF/ERCC1 and XPG (encoded by ERCC5) remove the lesion by cutting the damaged strand on either side of the lesion, resulting in a single- strand gap of 22-30 nucleotides. Next, the cell performs DNA gap filling synthesis and ligation. Involved in this process are: PCNA, RFC, DNA Pol δ, DNA Pol ε or DNA Pol κ, and DNA ligase I or XRCCl/Ligase III. Replicating cells tend to use DNA pol ε and DNA ligase I, while non-replicating cells tend to use DNA Pol δ, DNA Pol κ, and the XRCC1/ Ligase III complex to perform the ligation step.
NER can involve the following factors: XPA-G, POLH, XPF, ERCC1, XPA-G, and LIG1. Transcription-coupled NER (TC-NER) can involve the following factors: CSA, CSB, XPB, XPD, XPG, ERCCl, and TTDA. Additional factors that may promote the NER repair pathway include XPA-G, POLH, XPF, ERCCl, XPA-G, LIG1, CSA, CSB, XPA, XPB, XPC, XPD, XPF, XPG, TTDA, UVSSA, USP7, CETN2, RAD23B, UV-DDB, CAK subcomplex, RPA, and PCNA.
Interstrand Crosslink (ICL)
A dedicated pathway called the ICL repair pathway repairs interstrand crosslinks. Interstrand crosslinks, or covalent crosslinks between bases in different DNA strand, can occur during replication or transcription. ICL repair involves the coordination of multiple repair processes, in particular, nucleolytic activity, translesion synthesis (TLS), and HDR. Nucleases are recruited to excise the ICL on either side of the crosslinked bases, while TLS and HDR are coordinated to repair the cut strands. ICL repair can involve the following factors: endonucleases, e.g., XPF and RAD51C, endonucleases such as RAD51, translesion polymerases, e.g., DNA polymerase zeta and Revl), and the Fanconi anemia (FA) proteins, e.g., FancJ.
Other pathways
Several other DNA repair pathways exist in mammals.
Translesion synthesis (TLS) is a pathway for repairing a single stranded break left after a defective replication event and involves translesion polymerases, e.g., DNA pol and Revl..
Error-free postreplication repair (PRR) is another pathway for repairing a single stranded break left after a defective replication event. V.4 Examples of gRNAs in Genome Editing Methods
gRNA molecules as described herein can be used with Cas9 molecules that generate a double strand break or a single strand break to alter the sequence of a target nucleic acid, e.g., a target position or target genetic signature. gRNA molecules useful in these methods are described below.
In an embodiment, the gRNA, e.g., a chimeric gRNA, is configured such that it comprises one or more of the following properties;
a) it can position, e.g., when targeting a Cas9 molecule that makes double strand breaks, a double strand break (i) within 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 nucleotides of a target position, or (ii) sufficiently close that the target position is within the region of end resection;
b) it has a targeting domain of at least 16 nucleotides, e.g., a targeting domain of (i) 16, (ii), 17, (iii) 18, (iv) 19, (v) 20, (vi) 21, (vii) 22, (viii) 23, (ix) 24, (x) 25, or (xi) 26 nucleotides; and
c)
(i) the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail and proximal domain, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom;
(ii) there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S.
thermophilus, S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom;
(iii) there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain, e.g., at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than l, 2, 3, 4, 5; 6, 7, 8, 9 or l0 nucleotides therefrom;
(iv) the tail domain is at least 10, 15, 20, 25, 30, 35 or 40 nucleotides in length, e.g., it comprises at least 10, 15, 20, 25, 30, 35 or 40 nucleotides from a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom; or
(v) the tail domain comprises 15, 20, 25, 30, 35, 40 nucleotides or all of the corresponding portions of a naturally occurring tail domain, e.g., a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain.
In an embodiment, the gRNA is configured such that it comprises properties: a and In an embodiment, the gRNA is configured such that it comprises properties: a and b(ii).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(iii).
In an embodiment, the gRNA is configured such that it comprises properties b(iv).
In an embodiment, the gRNA is configured such that it comprises properties b(v).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(vi).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(vii).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(viii).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(ix).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(x).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(xi).
In an embodiment, the gRNA is configured such that it comprises properties: a and c.
In an embodiment, the gRNA is configured such that in comprises properties: a, b, and c.
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(i), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(i), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(ii), and c(i). In an embodiment, the gRNA is configured such that in comprises properties: a(i b(ii), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(iii), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(iii), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(iv), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(iv), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(v), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(v), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(vi), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(vi), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(vii), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(vii), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(viii), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(viii), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(ix), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(ix), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(x), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(x), and c(ii). In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(xi), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(xi), and c(ii).
In an embodiment, the gRNA, e.g., a chimeric gRNA, is configured such that it comprises one or more of the following properties;
a) one or both of the gRNAs can position, e.g., when targeting a Cas9 molecule that makes single strand breaks, a single strand break within (i) 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 nucleotides of a target position, or (ii) sufficiently close that the target position is within the region of end resection;
b) one or both have a targeting domain of at least 16 nucleotides, e.g., a targeting domain of (i) 16, (ii), 17, (iii) 18, (iv) 19, (v) 20, (vi) 21, (vii) 22, (viii) 23, (ix) 24, (x) 25, or (xi) 26 nucleotides; and
c)
(i) the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail and proximal domain, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom;
(ii) there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S.
thermophilus, S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom;
(iii) there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain, e.g., at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than l, 2, 3, 4, 5; 6, 7, 8, 9 or l0 nucleotides therefrom; (iv) the tail domain is at least 10, 15, 20, 25, 30, 35 or 40 nucleotides in length, e.g., it comprises at least 10, 15, 20, 25, 30, 35 or 40 nucleotides from a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom; or
(v) the tail domain comprises 15, 20, 25, 30, 35, 40 nucleotides or all of the corresponding portions of a naturally occurring tail domain, e.g., a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain.
In an embodiment, the gRNA is configured such that it comprises properties: a and b(i).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(ii).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(iii).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(iv).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(v).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(vi).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(vii).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(viii).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(ix).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(x).
In an embodiment, the gRNA is configured such that it comprises properties: a and b(xi).
In an embodiment, the gRNA is configured such that it comprises properties: a and c. In an embodiment, the gRNA is configured such that in comprises properties: a, b, and c. In an embodiment, the gRNA is configured such that in comprises properties: a(i b(i), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(i), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(ii), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(ii), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(iii), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(iii), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(iv), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(iv), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(v), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(v), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(vi), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(vi), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(vii), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(vii), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(viii), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(viii), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i b(ix), and c(i). In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(ix), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(x), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(x), and c(ii).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(xi), and c(i).
In an embodiment, the gRNA is configured such that in comprises properties: a(i), b(xi), and c(ii).
In an embodiment, the gRNA is used with a Cas9 nickase molecule having HNH activity, e.g., a Cas9 molecule having the RuvC activity inactivated, e.g., a Cas9 molecule having a mutation at D10, e.g., the D10A mutation.
In an embodiment, the gRNA is used with a Cas9 nickase molecule having RuvC activity, e.g., a Cas9 molecule having the HNH activity inactivated, e.g., a Cas9 molecule having a mutation at 840, e.g., the H840A.
In an embodiment, the gRNAs are used with a Cas9 nickase molecule having RuvC activity, e.g., a Cas9 molecule having the HNH activity inactivated, e.g., a Cas9 molecule having a mutation at N863, e.g., the N863A mutation.
In an embodiment, a pair of gRNAs, e.g., a pair of chimeric gRNAs, comprising a first and a second gRNA, is configured such that they comprises one or more of the following properties;
a) one or both of the gRNAs can position, e.g., when targeting a Cas9 molecule that makes single strand breaks, a single strand break within (i) 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 nucleotides of a target position, or (ii) sufficiently close that the target position is within the region of end resection;
b) one or both have a targeting domain of at least 16 nucleotides, e.g., a targeting domain of (i) 16, (ii), 17, (iii) 18, (iv) 19, (v) 20, (vi) 21, (vii) 22, (viii) 23, (ix) 24, (x) 25, or (xi) 26 nucleotides;
c) for one or both:
(i) the proximal and tail domain, when taken together, comprise at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail and proximal domain, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom;
(ii) there are at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides 3' to the last nucleotide of the second complementarity domain, e.g., at least 15, 18, 20, 25, 30, 31, 35, 40, 45, 49, 50, or 53 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S.
thermophilus, S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom;
(iii) there are at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides 3' to the last nucleotide of the second complementarity domain that is complementary to its corresponding nucleotide of the first complementarity domain, e.g., at least 16, 19, 21, 26, 31, 32, 36, 41, 46, 50, 51, or 54 nucleotides from the corresponding sequence of a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis gRNA, or a sequence that differs by no more than l, 2, 3, 4, 5; 6, 7, 8, 9 or l0 nucleotides therefrom;
(iv) the tail domain is at least 10, 15, 20, 25, 30, 35 or 40 nucleotides in length, e.g., it comprises at least 10, 15, 20, 25, 30, 35 or 40 nucleotides from a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain; or, or a sequence that differs by no more than 1, 2, 3, 4, 5; 6, 7, 8, 9 or 10 nucleotides therefrom; or
(v) the tail domain comprises 15, 20, 25, 30, 35, 40 nucleotides or all of the corresponding portions of a naturally occurring tail domain, e.g., a naturally occurring S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis tail domain;
d) the gRNAs are configured such that, when hybridized to target nucleic acid, they are separated by 0-50, 0-100, 0-200, at least 10, at least 20, at least 30 or at least 50 nucleotides;
e) the breaks made by the first gRNA and second gRNA are on different strands; and f) the PAMs are facing outwards.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(ii). In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(iii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(iv).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(v).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(vi).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(vii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(viii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(ix).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(x).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a and b(xi).
In an embodiment, one or both of the gRNAs configured such that it comprises properties: a and c.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a, b, and c.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(i), and c(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(i), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(i), c, and d.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(i), c, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(i), c, d, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(ii), and c(i). In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(ii), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(ii), c, and d.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(ii), c, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(ii), c, d, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(iii), and c(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(iii), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(iii), c, and d.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(iii), c, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(iii), c, d, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(iv), and c(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(iv), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(iv), c, and d.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(iv), c, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(iv), c, d, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(v), and c(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(v), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(v), c, and d. In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(v), c, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(v), c, d, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(vi), and c(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(vi), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(vi), c, and d.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(vi), c, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(vi), c, d, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(vii), and c(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(vii), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(vii), c, and d.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(vii), c, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(vii), c, d, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(viii), and c(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(viii), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(viii), c, and d.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(viii), c, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(viii), c, d, and e. In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(ix), and c(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(ix), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(ix), c, and d.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(ix), c, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(ix), c, d, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(x), and c(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(x), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(x), c, and d.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(x), c, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(x), c, d, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(xi), and c(i).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(xi), and c(ii).
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(xi), c, and d.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(xi), c, and e.
In an embodiment, one or both of the gRNAs is configured such that it comprises properties: a(i), b(xi), c, d, and e.
In an embodiment, the gRNAs are used with a Cas9 nickase molecule having HNH activity, e.g., a Cas9 molecule having the RuvC activity inactivated, e.g., a Cas9 molecule having a mutation at D10, e.g., the D10A mutation. In an embodiment, the gRNAs are used with a Cas9 nickase molecule having RuvC activity, e.g., a Cas9 molecule having the HNH activity inactivated, e.g., a Cas9 molecule having a mutation at H840, e.g., the H840A mutation.
In an embodiment, the gRNAs are used with a Cas9 nickase molecule having RuvC activity, e.g., a Cas9 molecule having the HNH activity inactivated, e.g., a Cas9 molecule having a mutation at N863, e.g., the N863A mutation.
VI. Target Cells
Cas9 molecules and gRNA molecules, e.g., a Cas9 molecule/gRNA molecule complex, can be used to manipulate a cell, e.g., to edit a target nucleic acid, in a wide variety of cells.
In an embodiment, a cell is manipulated by editing (e.g., introducing a mutation in) one or more target genes, e.g., HSV-2 target genes, e.g., target genes as described herein, e.g., one or more of the UL19, UL30, UL48 or UL54 genes. In an embodiment, the expression of one or more target genes (e.g., one or more target genes described herein, e.g., one or more of the UL19, UL30, UL48 or UL54 genes) is modulated, e.g., in vivo.
The Cas9 and gRNA molecules described herein can be delivered to a target cell. In an embodiment, the target cell is an epithelial cell, e.g., an epithelial cell of the oropharynx (including, e.g., an epithelial cell of the nose, gums, lips, tongue or pharynx), an epithelial cell of the finger or fingernail bed, or an epithelial cell of the ano-genital area (including, e.g., an epithelial cell of the penis, scrotum, vulva, vagina, cervix, anus or thighs). In an embodiment, the target cell is a neuronal cell, e.g., a cranial ganglion neuron (e.g. a trigeminal ganglion neuron, e.g., an oculomotor nerve ganglion neuron, e.g., an abducens nerve ganglion neuron, e.g., a trochlear nerve ganglion neuron), e.g. a cervical ganglion neuron, e.g., a sacral ganglion neuron, a sensory ganglion neuron, a cortical neuron, a cerebellar neuron or a hippocampal neuron. In an embodiment, the target cell is an optic cell, e.g. an epithelial cell of the eye, e.g. an epithelial cell of the eyelid, e.g., a conjunctival cell, e.g., a conjunctival epithelial cell, e.g., a corneal keratocyte, e.g., a limbus cell, e.g., a corneal epithelial cell, e.g., a corneal stromal cell, e.g., a ciliary body cell, e.g., a scleral cell, e.g., a lens cell, e.g., a choroidal cell, e.g., a retinal cell, e.g., a rod photoreceptor cell, e.g., a cone photoreceptor cell, e.g., a retinal pigment epithelium cell, e.g., a horizontal cell, e.g., an amacrine cell, e.g., a ganglion cell. VII. Delivery, Formulations and Routes of Administration
The components, e.g., a Cas9 molecule and gRNA molecule can be delivered or formulated in a variety of forms, see, e.g., Tables 23-24. In an embodiment, one Cas9 molecule and two or more (e.g., 2, 3, 4, or more) different gRNA molecules are delivered, e.g., by an AAV vector. In an embodiment, the sequence encoding the Cas9 molecule and the sequence(s) encoding the two or more (e.g., 2, 3, 4, or more) different gRNA molecules are present on the same nucleic acid molecule, e.g., an AAV vector. When a Cas9 or gRNA component is encoded as DNA for delivery, the DNA will typically but not necessarily include a control region, e.g., comprising a promoter, to effect expression. Useful promoters for Cas9 molecule sequences include CMV, EFS, EF-la, MSCV, PGK, CAG control promoters. In an embodiment, the promoter is a constitutive promoter. In another embodiment, the promoter is a tissue specific promoter. Useful promoters for gRNAs include HI, 7SK, tRNA, and U6 promoters. Promoters with similar or dissimilar strengths can be selected to tune the expression of components. Sequences encoding a Cas9 molecule can comprise a nuclear localization signal (NLS), e.g., an SV40 NLS. In an embodiment, the sequence encoding a Cas9 molecule comprises at least two nuclear localization signals. In an embodiment a promoter for a Cas9 molecule or a gRNA molecule can be, independently, inducible, tissue specific, or cell specific.
Table 23 provides examples of how the components can be formulated, delivered, or administered.
Table 23
Figure imgf000814_0001
in vitro transcribed or synthesized RNA. mRNA DNA In this embodiment, a Cas9 molecule, typically
an eaCas9 molecule, is translated from in vitro transcribed mRNA, and a gRNA is transcribed from DNA.
Protein DNA In this embodiment, a Cas9 molecule, typically
an eaCas9 molecule, is provided as a protein,
and a gRNA is transcribed from DNA.
Protein RNA In this embodiment, an eaCas9 molecule is
provided as a protein, and a gRNA is provided
as transcribed or synthesized RNA.
Table 24 summarizes various delivery methods for the components of a Cas system, e.g., the Cas9 molecule component and the gRNA molecule component, as described herein. Table 24
Figure imgf000815_0001
Mammalian YES Transient NO Nucleic Acids
Virus-like
Particles
Biological YES Transient NO Nucleic Acids liposomes:
Erythrocyte
Ghosts and
Exosomes
DNA-based Delivery of a Cas9 molecule and/or one or more gRNA molecule
Nucleic acids encoding Cas9 molecules (e.g., eaCas9 molecules) and/or gRNA molecules, can be administered to subjects or delivered into cells by art-known methods or as described herein. For example, Cas9-encoding and/or gRNA-encoding DNA can be delivered, e.g., by vectors (e.g., viral or non-viral vectors), non- vector based methods (e.g., using naked DNA or DNA complexes), or a combination thereof.
DNA encoding Cas9 molecules (e.g., eaCas9 molecules) and/or gRNA molecules can be conjugated to molecules promoting uptake by the target cells (e.g., the target cells described herein).
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a vector (e.g., viral vector/virus or plasmid).
A vector can comprise a sequence that encodes a Cas9 molecule and/or a gRNA molecule. A vector can also comprise a sequence encoding a signal peptide (e.g., for nuclear localization, nucleolar localization, mitochondrial localization), fused, e.g., to a Cas9 molecule sequence. For example, ae vector can comprise a nuclear localization sequence (e.g., from SV40) fused to the sequence encoding the Cas9 molecule.
One or more regulatory/control elements, e.g., a promoter, an enhancer, an intron, a polyadenylation signal, a Kozak consensus sequence, internal ribosome entry sites (IRES), a 2A sequence, and splice acceptor or donor can be included in the vectors. In some embodiments, the promoter is recognized by RNA polymerase II (e.g., a CMV promoter). In other embodiments, the promoter is recognized by RNA polymerase III (e.g., a U6 promoter). In some embodiments, the promoter is a regulated promoter (e.g., inducible promoter). In other embodiments, the promoter is a constitutive promoter. In some embodiments, the promoter is a tissue specific promoter. In some embodiments, the promoter is a viral promoter. In other embodiments, the promoter is a non- viral promoter.
In some embodiments, the vector or delivery vehicle is a viral vector (e.g., for generation of recombinant viruses). In some embodiments, the virus is a DNA virus (e.g., dsDNA or ssDNA virus). In other embodiments, the virus is an RNA virus (e.g., an ssRNA virus). Exemplary viral vectors/viruses include, e.g., retroviruses, lentiviruses, adenovirus, adeno-associated virus (AAV), vaccinia viruses, poxviruses, and herpes simplex viruses.
In some embodiments, the virus infects dividing cells. In other embodiments, the virus infects non-dividing cells. In some embodiments, the virus infects both dividing and non-dividing cells. In some embodiments, the virus can integrate into the host genome. In some embodiments, the virus is engineered to have reduced immunity, e.g., in human. In some embodiments, the virus is replication-competent. In other embodiments, the virus is replication-defective, e.g., having one or more coding regions for the genes necessary for additional rounds of virion replication and/or packaging replaced with other genes or deleted. In some embodiments, the virus causes transient expression of the Cas9 molecule and/or the gRNA molecule. In other embodiments, the virus causes long-lasting, e.g., at least 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 9 months, 1 year, 2 years, or permanent expression, of the Cas9 molecule and/or the gRNA molecule. The packaging capacity of the viruses may vary, e.g., from at least about 4 kb to at least about 30 kb, e.g., at least about 5 kb, 10 kb, 15 kb, 20 kb, 25 kb, 30 kb, 35 kb, 40 kb, 45 kb, or 50 kb.
In an embodiment, the viral vector recognizes a specific cell type or tissue. For example, the viral vector can be pseudotyped with a different/alternative viral envelope glycoprotein; engineered with a cell type-specific receptor (e.g., genetic modification(s) of one or more viral envelope glycoproteins to incorporate a targeting ligand such as a peptide ligand, a single chain antibody, or a growth factor); and/or engineered to have a molecular bridge with dual specificities with one end recognizing a viral glycoprotein and the other end recognizing a moiety of the target cell surface (e.g., a ligand-receptor, monoclonal antibody, avidin-biotin and chemical conjugation).
Exemplary viral vectors/viruses include, e.g., retroviruses, lentiviruses, adenovirus, adeno-associated virus (AAV), vaccinia viruses, poxviruses, and herpes simplex viruses.
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a recombinant retrovirus. In some embodiments, the retrovirus (e.g., Moloney murine leukemia virus) comprises a reverse transcriptase, e.g., that allows integration into the host genome. In some embodiments, the retrovirus is replication-competent. In other embodiments, the retrovirus is replication-defective, e.g., having one of more coding regions for the genes necessary for additional rounds of virion replication and packaging replaced with other genes, or deleted. In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a recombinant lentivirus. For example, the lentivirus is replication-defective, e.g., does not comprise one or more genes required for viral replication.
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a recombinant adenovirus. In some embodiments, the adenovirus is engineered to have reduced immunity in human.
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a recombinant AAV. In some embodiments, the AAV does not incorporate its genome into that of a host cell, e.g., a target cell as describe herein. In some embodiments, the AAV can incorporate at least part of its genome into that of a host cell, e.g., a target cell as described herein. In some embodiments, the AAV is a self-complementary adeno-associated virus (scAAV), e.g., a scAAV that packages both strands which anneal together to form double stranded DNA. AAV serotypes that may be used in the disclosed methods, include AAV1, AAV2, modified AAV2 (e.g., modifications at Y444F, Y500F, Y730F and/or S662V), AAV3, modified AAV3 (e.g., modifications at Y705F, Y731F and/or T492V), AAV4,
AAV5, AAV6, modified AAV6 (e.g., modifications at S663V and/or T492V), AAV8, AAV 8.2, AAV9, AAV rh 10, and pseudotyped AAV, such as AAV2/8, AAV2/5 and AAV2/6 can also be used in the disclosed methods. In an embodiment, an AAV capsid that can be used in the methods described herein is a capsid sequence from serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV.rh8, AAV.rhlO, AAV.rh32/33, AAV.rh43, AAV.rh64Rl, or AAV7m8.
In an embodiment, the Cas9- and/or gRNA-encoding DNA is delivered in a re- engineered AAV capsid, e.g., with 50% or greater, e.g., 60% or greater, 70% or greater, 80% or greater, 90% or greater, or 95% or greater, sequence homology with a capsid sequence from serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV.rh8, AAV.rhlO, AAV.rh32/33, AAV.rh43, or AAV.rh64Rl.
In an embodiment, the Cas9- and/or gRNA-encoding DNA is delivered by a chimeric AAV capsid. Exemplary chimeric AAV capsids include, but are not limited to, AAV9il, AAV2i8, AAV-DJ, AAV2G9, AAV2i8G9, or AAV8G9.
In an embodiment, the AAV is a self-complementary adeno-associated virus
(scAAV), e.g., a scAAV that packages both strands which anneal together to form double stranded DNA.
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a hybrid virus, e.g., a hybrid of one or more of the viruses described herein. In an embodiment, the hybrid virus is hybrid of an AAV (e.g., of any AAV serotype), with a Bocavirus, B 19 virus, porcine AAV, goose AAV, feline AAV, canine AAV, or MVM.
A Packaging cell is used to form a virus particle that is capable of infecting a target cell. Such a cell includes a 293 cell, which can package adenovirus, and a ψ2 cell or a PA317 cell, which can package retrovirus. A viral vector used in gene therapy is usually generated by a producer cell line that packages a nucleic acid vector into a viral particle. The vector typically contains the minimal viral sequences required for packaging and subsequent integration into a host or target cell (if applicable), with other viral sequences being replaced by an expression cassette encoding the protein to be expressed, eg. Cas9. For example, an AAV vector used in gene therapy typically only possesses inverted terminal repeat (ITR) sequences from the AAV genome which are required for packaging and gene expression in the host or target cell. The missing viral functions can be supplied in trans by the packaging cell line and/or plasmid containing E2A, E4, and VA genes from adenovirus, and plasmid encoding Rep and Cap genes from AAV, as described in "Triple Transfection Protocol." Henceforth, the viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. In embodiment, the viral DNA is packaged in a producer cell line, which contains E1A and/or E1B genes from adenovirus. The cell line is also infected with adenovirus as a helper. The helper virus (e.g., adenovirus or HSV) or helper plasmid promotes replication of the AAV vector and expression of AAV genes from the helper plasmid with ITRs. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV.
In an embodiment, the viral vector has the ability of cell type and/or tissue type recognition. For example, the viral vector can be pseudotyped with a different/alternative viral envelope glycoprotein; engineered with a cell type-specific receptor (e.g.,
geneticmodification of the viral envelope glycoproteins to incorporate targeting ligands such as a peptide ligand, a single chain antibodie, a growth factor); and/or engineered to have a molecular bridge with dual specificities with one end recognizing a viral glycoprotein and the other end recognizing a moiety of the target cell surface (e.g., ligand-receptor, monoclonal antibody, avidin-biotin and chemical conjugation).
In an embodiment, the viral vector achieves cell type specific expression. For example, a tissue-specific promoter can be constructed to restrict expression of the transgene (Cas 9 and gRNA) in only the target cell. The specificity of the vector can also be mediated by microRNA-dependent control of transgene expression. In an embodiment, the viral vector has increased efficiency of fusion of the viral vector and a target cell membrane. For example, a fusion protein such as fusion-competent hemagglutin (HA) can be incorporated to increase viral uptake into cells. In an embodiment, the viral vector has the ability of nuclear localization. For example, aviruse that requires the breakdown of the nuclear envelope (during cell division) and therefore will not infect a non-diving cell can be altered to incorporate a nuclear localization peptide in the matrix protein of the virus thereby enabling the transduction of non-proliferating cells.
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a non- vector based method (e.g., using naked DNA or DNA complexes). For example, the DNA can be delivered, e.g., by organically modified silica or silicate (Ormosil), electroporation, gene gun, sonoporation, magnetofection, lipid- mediated transfection, dendrimers, inorganic nanoparticles, calcium phosphates, or a combination thereof.
In some embodiments, the Cas9- and/or gRNA-encoding DNA is delivered by a combination of a vector and a non- vector based method. For example, a virosome comprises a liposome combined with an inactivated virus (e.g., HIV or influenza virus), which can result in more efficient gene transfer, e.g., in a respiratory epithelial cell than either a viral or a liposomal method alone.
In an embodiment, the delivery vehicle is a non- viral vector. In an embodiment, the non- viral vector is an inorganic nanoparticle. Exemplary inorganic nanoparticles include, e.g., magnetic nanoparticles (e.g., Fe3Mn02) or silica. The outer surface of the nanoparticle can be conjugated with a positively charged polymer (e.g., polyethylenimine, polylysine, polyserine) which allows for attachment (e.g., conjugation or entrapment) of payload.. In an embodiment, the non- viral vector is an organic nanoparticle (e.g., entrapment of the payload inside the nanoparticle). Exemplary organic nanoparticles include, e.g., SNALP liposomes that contain cationic lipids together with neutral helper lipids which are coated with polyethylene glycol (PEG) and protamine and nucleic acid complex coated with lipid coating.
Exemplary lipids for gene transfer are shown below in Table 25.
Table 25: Lipids Used for Gene Transfer
Lipid Abbreviation Feature l,2-Dioleoyl-sn-glycero-3-phosphatidylcholine DOPC Helper l,2-Dioleoyl-sn-glycero-3-phosphatidylethanolamine DOPE Helper
Cholesterol Helper
A-[l-(2,3-Dioleyloxy)prophyl]AWA -trimethylammonium chloride DOTMA Cationic l,2-Dioleoyloxy-3-trimethylammonium-propane DOTAP Cationic
Dioctadecylamidoglycylspermine DOGS Cationic
Figure imgf000821_0001
noey- met y- - met yamno utyrate n- - atonc
Exemplary polymers for gene transfer are shown below in Table 26.
Table 26: Polymers Used for Gene Transfer
Figure imgf000821_0002
Figure imgf000822_0001
extran-sperm ne -
In an embodiment, the vehicle has targeting modifications to increase target cell update of nanoparticles and liposomes, e.g., cell specific antigens, monoclonal antibodies, single chain antibodies, aptamers, polymers, sugars, and cell penetrating peptides. In an embodiment, the vehicle uses fusogenic and endosome-destabilizing peptides/polymers. In an embodiment, the vehicle undergoes acid-triggered conformational changes (e.g., to accelerate endosomal escape of the cargo). In an embodiment, a stimuli-cleavable polymer is used, e.g., for release in a cellular compartment. For example, disulfide-based cationic polymers that are cleaved in the reducing cellular environment can be used.
In an embodiment, the delivery vehicle is a biological non- viral delivery vehicle. In an embodiment, the vehicle is an attenuated bacterium (e.g., naturally or artificially engineered to be invasive but attenuated to prevent pathogenesis and expressing the transgene (e.g., Listeria monocytogenes, certain Salmonella strains, Bifidobacterium longum, and modified Escherichia coli), bacteria having nutritional and tissue-specific tropism to target specific tissues, bacteria having modified surface proteins to alter target tissue specificity). In an embodiment, the vehicle is a genetically modified bacteriophage (e.g., engineered phages having large packaging capacity, less immunogenic, containing mammalian plasmid maintenance sequences and having incorporated targeting ligands). In an embodiment, the vehicle is a mammalian virus-like particle. For example, modified viral particles can be generated (e.g., by purification of the "empty" particles followed by ex vivo assembly of the virus with the desired cargo). The vehicle can also be engineered to incorporate targeting ligands to alter target tissue specificity. In an embodiment, the vehicle is a biological liposome. For example, the biological liposome is a phospholipid-based particle derived from human cells (e.g., erythrocyte ghosts, which are red blood cells broken down into spherical structures derived from the subject (e.g., tissue targeting can be achieved by attachment of various tissue or cell-specific ligands), or secretory exosomes -subject (i.e., patient) derived membrane-bound nanovescicle (30 -100 nm) of endocytic origin (e.g., can be produced from various cell types and can therefore be taken up by cells without the need of for targeting ligands).
In an embodiment, one or more nucleic acid molecules (e.g., DNA molecules) other than the components of a Cas system, e.g., the Cas9 molecule component and/or the gRNA molecule component described herein, are delivered. In an embodiment, the nucleic acid molecule is delivered at the same time as one or more of the components of the Cas system are delivered. In an embodiment, the nucleic acid molecule is delivered before or after (e.g., less than about 30 minutes, 1 hour, 2 hours, 3 hours, 6 hours, 9 hours, 12 hours, 1 day, 2 days, 3 days, 1 week, 2 weeks, or 4 weeks) one or more of the components of the Cas system are delivered. In an embodiment, the nucleic acid molecule is delivered by a different means than one or more of the components of the Cas system, e.g., the Cas9 molecule component and/or the gRNA molecule component, are delivered. The nucleic acid molecule can be delivered by any of the delivery methods described herein. For example, the nucleic acid molecule can be delivered by a viral vector, e.g., an integration-deficient lentivirus, and the Cas9 molecule component and/or the gRNA molecule component can be delivered by electroporation, e.g., such that the toxicity caused by nucleic acids (e.g., DNAs) can be reduced. In an embodiment, the nucleic acid molecule encodes a therapeutic protein, e.g., a protein described herein. In an embodiment, the nucleic acid molecule encodes an RNA molecule, e.g., an RNA molecule described herein.
Delivery of RNA encoding a Cas 9 molecule
RNA encoding Cas9 molecules (e.g., eaCas9 molecules or eiCas9 molecules) and/or gRNA molecules, can be delivered into cells, e.g., target cells described herein, by art-known methods or as described herein. For example, Cas9-encoding and/or gRNA-encoding RNA can be delivered, e.g., by microinjection, electroporation, lipid-mediated transfection, peptide-mediated delivery, or a combination thereof. Cas9-encoding and/or gRNA-encoding RNA can be conjugated to molecules promoting uptake by the target cells (e.g., target cells described herein). Delivery Cas9 molecule protein
Cas9 molecules (e.g., eaCas9 molecules or eiCas9 molecules) can be delivered into cells by art-known methods or as described herein. For example, Cas9 protein molecules can be delivered, e.g., by microinjection, electroporation, lipid-mediated transfection, peptide- mediated delivery, or a combination thereof. Delivery can be accompanied by DNA encoding a gRNA or by a gRNA. Cas9 protein can be conjugated to molecules promoting uptake by the target cells (e.g., target cells described herein).
Multiplex Delivery of gRNAs
In some embodiments, the Cas9 molecule, e.g., double-stranded nuclease or single- stranded nickase, is delivered together with gRNAs or gRNA pairs targeting more than one HSV-2 target position. The gRNAs can be provided in different forms, e.g., the forms described in Table 23. The gRNAs can be delivered by different methods, e.g., the methods described in Table 24. It is contemplated herein that the Cas9 molecule, and gRNAs or gRNA pairs targeting more than one HSV-2 target position could be contained within a single or multiple delivery vector or formulation including, e.g., those described above.
Route of Administration
Systemic modes of administration include oral and parenteral routes. Parenteral routes include, by way of example, intravenous, intrarterial, intraosseous, intramuscular, intradermal, subcutaneous, intranasal and intraperitoneal routes. Components administered systemically may be modified or formulated to target the components to epithelial or neuronal cells.
Local modes of administration include, by way of example, topical, intrathecal, intraspinal, intra-cerebroventricular, intraparenchymal (e.g., into the parenchyma of the brain or spinal cord), and intraocular, including intra vitreal, intracorneal, and intraretinal routes. In an embodiment, local modes of administration include intraocular, e.g., intrascleral, e.g., intracorneal, e.g., intravitreal, e.g., intraretinal, e.g. submacular, e.g., intra-lens. In an embodiment, components described herein are delivered subretinally, e.g., by subretinal injection. In an embodiment, components described herein are delivered by intravitreal injection.
In an embodiment, local modes of administration include topical, e.g., topical optic delivery, e.g., topical dermal delivery. In an embodiment, local modes of administration include intra-parenchymal into the dorsal root ganglion at the level of the trigeminal nerve. In an embodiment, local modes of administration include intra-parenchymal into the dorsal root ganglion at the level of the sacral ganglia. In an embodiment, local modes of administration include intra-parenchymal into the dorsal root ganglion at the level of the lumbar ganglia. In an embodiment, local modes of administration include intra-parenchymal into the dorsal root ganglion at the level of the thoracic ganglia. In an embodiment, local modes of administration include intra- parenchymal into the dorsal root ganglion at the level of the cervical ganglia, e.g., superior cervical ganglion, e.g., middle cervical ganglion, e.g., inferior cervical ganglion.
In an embodiment, significantly smaller amounts of the components (compared with systemic approaches) may exert an effect when administered locally (for example, topically; for example intracorneally) compared to when administered systemically (for example, intravenously). Local modes of administration can reduce or eliminate the incidence of potentially toxic side effects that may occur when therapeutically effective amounts of a component are administered systemically.
In an embodiment, components described herein are delivered by topical
administration to epithelial cells, e.g., epithelial cells of the oropharynx (including, e.g., epithelial cells of the nose, gums, lips, tongue or pharynx), epithelial cells of the finger or fingernail bed, or epithelial cells of the ano-genital area (including, e.g., epithelial cells of the penis, vulva, vagina or anus). In an embodiment, components described herein are delivered by topical administration to the eye (including, e.g., corneal epithelium, e.g., corneal stroma, e.g., epithelium of upper and lower eyelid, e.g., lens).
In an embodiment, nanoparticle or viral, e.g., AAV vector, delivery is via topical administration.
Administration may be provided as a periodic bolus or as continuous infusion from an internal reservoir or from an external reservoir (for example, from an intravenous bag). Components may be administered locally, for example, by continuous release from a sustained release drug delivery device.
Administration may be provided as continuous infusion from an internal reservoir (for example, from an implant disposed at an intra- or extra-ocular location (see, U.S. Pat. Nos. 5,443,505 and 5,766,242)) or from an external reservoir (for example, from an intravenous bag). Components may be administered locally, for example, by continuous release from a sustained release drug delivery device immobilized to an inner wall of the eye or via targeted transscleral controlled release into the choroid (see, for example, PCT/USOO/00207, PCT/US02/14279, Ambati et al. (2000) Invest. Ophthalmol. Vis. Sci. 41: 1181-1185, and Ambati et al. (2000) Invest. Ophthalmol. Vis. Sci. 41:1186-1191). A variety of devices suitable for administering components locally to the inside of the eye are known in the art. See, for example, U.S. Pat. Nos. 6,251,090, 6,299,895, 6,416,777, 6,413,540, and
PCT/USOO/28187.
In addition, components may be formulated to permit release over a prolonged period of time. A release system can include a matrix of a biodegradable material or a material which releases the incorporated components by diffusion. The components can be homogeneously or heterogeneously distributed within the release system. A variety of release systems may be useful, however, the choice of the appropriate system will depend upon rate of release required by a particular application. Both non-degradable and degradable release systems can be used. Suitable release systems include polymers and polymeric matrices, non-polymeric matrices, or inorganic and organic excipients and diluents such as, but not limited to, calcium carbonate and sugar (for example, trehalose). Release systems may be natural or synthetic. However, synthetic release systems are preferred because generally they are more reliable, more reproducible and produce more defined release profiles. The release system material can be selected so that components having different molecular weights are released by diffusion through or degradation of the material.
Representative synthetic, biodegradable polymers include, for example: polyamides such as poly(amino acids) and poly(peptides); polyesters such as poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), and poly(caprolactone); poly(anhydrides); polyorthoesters; polycarbonates; and chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof. Representative synthetic, non-degradable polymers include, for example: polyethers such as poly(ethylene oxide), poly(ethylene glycol), and poly(tetramethylene oxide); vinyl polymers- polyacrylates and polymethacrylates such as methyl, ethyl, other alkyl, hydroxyethyl methacrylate, acrylic and methacrylic acids, and others such as poly(vinyl alcohol), poly(vinyl pyrolidone), and poly(vinyl acetate); poly(urethanes); cellulose and its derivatives such as alkyl, hydroxyalkyl, ethers, esters, nitrocellulose, and various cellulose acetates; polysiloxanes; and any chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof.
Poly(lactide-co-glycolide) microsphere can also be used for injection. Typically the microspheres are composed of a polymer of lactic acid and glycolic acid, which are structured to form hollow spheres. The spheres can be approximately 15-30 microns in diameter and can be loaded with components described herein. Bi-Modal or Differential Delivery of Components
Separate delivery of the components of a Cas system, e.g., the Cas9 molecule component and the gRNA molecule component, and more particularly, delivery of the components by differing modes, can enhance performance, e.g., by improving tissue specificity and safety.
In an embodiment, the Cas 9 molecule and the gRNA molecule are delivered by different modes, or as sometimes referred to herein as differential modes. Different or differential modes, as used herein, refer modes of delivery that confer different
pharmacodynamic or pharmacokinetic properties on the subject component molecule, e.g., a Cas9 molecule, or gRNA molecule,. For example, the modes of delivery can result in different tissue distribution, different half-life, or different temporal distribution, e.g., in a selected compartment, tissue, or organ.
Some modes of delivery, e.g., delivery by a nucleic acid vector that persists in a cell, or in progeny of a cell, e.g., by autonomous replication or insertion into cellular nucleic acid, result in more persistent expression of and presence of a component. Examples include viral, e.g., adeno- associated virus or lentivirus, delivery.
By way of example, the components, e.g., a Cas9 molecule and a gRNA molecule, can be delivered by modes that differ in terms of resulting half-life or persistent of the delivered component the body, or in a particular compartment, tissue or organ. In an embodiment, a gRNA molecule can be delivered by such modes. The Cas9 molecule component can be delivered by a mode which results in less persistence or less exposure to the body or a particular compartment or tissue or organ.
More generally, in an embodiment, a first mode of delivery is used to deliver a first component and a second mode of delivery is used to deliver a second component. The first mode of delivery confers a first pharmacodynamic or pharmacokinetic property. The first pharmacodynamic property can be, e.g., distribution, persistence, or exposure, of the component, or of a nucleic acid that encodes the component, in the body, a compartment, tissue or organ. The second mode of delivery confers a second pharmacodynamic or pharmacokinetic property. The second pharmacodynamic property can be, e.g., distribution, persistence, or exposure, of the component, or of a nucleic acid that encodes the component, in the body, a compartment, tissue or organ.
In an embodiment, the first pharmacodynamic or pharmacokinetic property, e.g., distribution, persistence or exposure, is more limited than the second pharmacodynamic or pharmacokinetic property.
In an embodiment, the first mode of delivery is selected to optimize, e.g., minimize, a pharmacodynamic or pharmacokinetic property, e.g., distribution, persistence or exposure.
In an embodiment, the second mode of delivery is selected to optimize, e.g., maximize, a pharmacodynamic or pharmcokinetic property, e.g., distribution, persistence or exposure.
In an embodiment, the first mode of delivery comprises the use of a relatively persistent element, e.g., a nucleic acid, e.g., a plasmid or viral vector, e.g., an AAV or lentivirus. As such vectors are relatively persistent product transcribed from them would be relatively persistent.
In an embodiment, the second mode of delivery comprises a relatively transient element, e.g., an RNA or protein.
In an embodiment, the first component comprises gRNA, and the delivery mode is relatively persistent, e.g., the gRNA is transcribed from a plasmid or viral vector, e.g., an
AAV or lentivirus. Transcription of these genes would be of little physiological consequence because the genes do not encode for a protein product, and the gRNAs are incapable of acting in isolation. The second component, a Cas9 molecule, is delivered in a transient manner, for example as mRNA or as protein, ensuring that the full Cas9 molecule/gRNA molecule complex is only present and active for a short period of time.
Furthermore, the components can be delivered in different molecular form or with different delivery vectors that complement one another to enhance safety and tissue specificity.
Use of differential delivery modes can enhance performance, safety and efficacy. E.g., the likelihood of an eventual off-target modification can be reduced. Delivery of immunogenic components, e.g., Cas9 molecules, by less persistent modes can reduce immunogenicity, as peptides from the bacterially-derived Cas enzyme are displayed on the surface of the cell by MHC molecules. A two-part delivery system can alleviate these drawbacks.
Differential delivery modes can be used to deliver components to different, but overlapping target regions. The formation active complex is minimized outside the overlap of the target regions. Thus, in an embodiment, a first component, e.g., a gRNA molecule is delivered by a first delivery mode that results in a first spatial, e.g., tissue, distribution. A second component, e.g., a Cas9 molecule is delivered by a second delivery mode that results in a second spatial, e.g., tissue, distribution. In an embodiment, the first mode comprises a first element selected from a liposome, nanoparticle, e.g., polymeric nanoparticle, and a nucleic acid, e.g., viral vector. The second mode comprises a second element selected from the group. In an embodiment, the first mode of delivery comprises a first targeting element, e.g., a cell specific receptor or an antibody, and the second mode of delivery does not include that element. In embodiment, the second mode of delivery comprises a second targeting element, e.g., a second cell specific receptor or second antibody.
When the Cas9 molecule is delivered in a virus delivery vector, a liposome, or polymeric nanoparticle, there is the potential for delivery to and therapeutic activity in multiple tissues, when it may be desirable to only target a single tissue. A two-part delivery system can resolve this challenge and enhance tissue specificity. If the gRNA molecule and the Cas9 molecule are packaged in separated delivery vehicles with distinct but overlapping tissue tropism, the fully functional complex is only be formed in the tissue that is targeted by both vectors.
Ex vivo delivery
In some embodiments, components described in Table 23 are introduced into cells which are then introduced into the subject, e.g., cells are removed from a subject, manipulated ex vivo and then introduced into the subject. Methods of introducing the components can include, e.g., any of the delivery methods described in Table 24. VIII. Modified Nucleosides, Nucleotides, and Nucleic Acids
Modified nucleosides and modified nucleotides can be present in nucleic acids, e.g., particularly gRNA, but also other forms of RNA, e.g., mRNA, RNAi, or siRNA. As described herein, "nucleoside" is defined as a compound containing a five-carbon sugar molecule (a pentose or ribose) or derivative thereof, and an organic base, purine or pyrimidine, or a derivative thereof. As described herein, "nucleotide" is defined as a nucleoside further comprising a phosphate group.
Modified nucleosides and nucleotides can include one or more of: (i) alteration, e.g., replacement, of one or both of the non-linking phosphate oxygens and/or of one or more of the linking phosphate oxygens in the phosphodiester backbone linkage;
(ii) alteration, e.g., replacement, of a constituent of the ribose sugar, e.g., of the 2' hydroxyl on the ribose sugar;
(iii) wholesale replacement of the phosphate moiety with "dephospho" linkers;
(iv) modification or replacement of a naturally occurring nucleobase;
(v) replacement or modification of the ribose-phosphate backbone;
(vi) modification of the 3' end or 5' end of the oligonucleotide, e.g., removal, modification or replacement of a terminal phosphate group or conjugation of a moiety; and
(vii) modification of the sugar.
The modifications listed above can be combined to provide modified nucleosides and nucleotides that can have two, three, four, or more modifications. For example, a modified nucleoside or nucleotide can have a modified sugar and a modified nucleobase. In an embodiment, every base of a gRNA is modified, e.g., all bases have a modified phosphate group, e.g., all are phosphorothioate groups. In an embodiment, all, or substantially all, of the phosphate groups of a unimolecular or modular gRNA molecule are replaced with phosphorothioate groups.
In an embodiment, modified nucleotides, e.g., nucleotides having modifications as described herein, can be incorporated into a nucleic acid, e.g., a "modified nucleic acid." In some embodiments, the modified nucleic acids comprise one, two, three or more modified nucleotides. In some embodiments, at least 5% (e.g., at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%) of the positions in a modified nucleic acid are a modified nucleotides.
Unmodified nucleic acids can be prone to degradation by, e.g., cellular nucleases. For example, nucleases can hydrolyze nucleic acid phosphodiester bonds. Accordingly, in one aspect the modified nucleic acids described herein can contain one or more modified nucleosides or nucleotides, e.g., to introduce stability toward nucleases.
In some embodiments, the modified nucleosides, modified nucleotides, and modified nucleic acids described herein can exhibit a reduced innate immune response when introduced into a population of cells, both in vivo and ex vivo. The term "innate immune response" includes a cellular response to exogenous nucleic acids, including single stranded nucleic acids, generally of viral or bacterial origin, which involves the induction of cytokine expression and release, particularly the interferons, and cell death. In some embodiments, the modified nucleosides, modified nucleotides, and modified nucleic acids described herein can disrupt binding of a major groove interacting partner with the nucleic acid. In some embodiments, the modified nucleosides, modified nucleotides, and modified nucleic acids described herein can exhibit a reduced innate immune response when introduced into a population of cells, both in vivo and ex vivo, and also disrupt binding of a major groove interacting partner with the nucleic acid.
Definitions of Chemical Groups
As used herein, "alkyl" is meant to refer to a saturated hydrocarbon group which is straight-chained or branched. Example alkyl groups include methyl (Me), ethyl (Et), propyl (e.g. , n-propyl and isopropyl), butyl (e.g. , n-butyl, isobutyl, t-butyl), pentyl (e.g. , n-pentyl, isopentyl, neopentyl), and the like. An alkyl group can contain from 1 to about 20, from 2 to about 20, from 1 to about 12, from 1 to about 8, from 1 to about 6, from 1 to about 4, or from 1 to about 3 carbon atoms.
As used herein, "aryl" refers to monocyclic or polycyclic (e.g. , having 2, 3 or 4 fused rings) aromatic hydrocarbons such as, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, aryl groups have from 6 to about 20 carbon atoms.
As used herein, "alkenyl" refers to an aliphatic group containing at least one double bond.
As used herein, "alkynyl" refers to a straight or branched hydrocarbon chain containing 2-12 carbon atoms and characterized in having one or more triple bonds.
Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl, and 3- hexynyl.
As used herein, "arylalkyl" or "aralkyl" refers to an alkyl moiety in which an alkyl hydrogen atom is replaced by an aryl group. Aralkyl includes groups in which more than one hydrogen atom has been replaced by an aryl group. Examples of "arylalkyl" or "aralkyl" include benzyl, 2-phenylethyl, 3-phenylpropyl, 9-fluorenyl, benzhydryl, and trityl groups.
As used herein, "cycloalkyl" refers to a cyclic, bicyclic, tricyclic, or polycyclic non- aromatic hydrocarbon groups having 3 to 12 carbons. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. As used herein, "heterocyclyl" refers to a monovalent radical of a heterocyclic ring system. Representative heterocyclyls include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, and morpholinyl.
As used herein, "heteroaryl" refers to a monovalent radical of a heteroaromatic ring system. Examples of heteroaryl moieties include, but are not limited to, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrrolyl, furanyl, indolyl, thiophenyl pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, indolizinyl, purinyl, naphthyridinyl, quinolyl, and pteridinyl. Phosphate Backbone Modifications
The Phosphate Group
In some embodiments, the phosphate group of a modified nucleotide can be modified by replacing one or more of the oxygens with a different substituent. Further, the modified nucleotide, e.g., modified nucleotide present in a modified nucleic acid, can include the wholesale replacement of an unmodified phosphate moiety with a modified phosphate as described herein. In some embodiments, the modification of the phosphate backbone can include alterations that result in either an uncharged linker or a charged linker with unsymmetrical charge distribution.
Examples of modified phosphate groups include, phosphorothioate,
phosphoroselenates, borano phosphates, borano phosphate esters, hydrogen phosphonates, phosphoroamidates, alkyl or aryl phosphonates and phosphotriesters. In some embodiments, one of the non-bridging phosphate oxygen atoms in the phosphate backbone moiety can be replaced by any of the following groups: sulfur (S), selenium (Se), BR3 (wherein R can be, e.g., hydrogen, alkyl, or aryl), C (e.g., an alkyl group, an aryl group, and the like), H, NR2 (wherein R can be, e.g., hydrogen, alkyl, or aryl), or OR (wherein R can be, e.g., alkyl or aryl). The phosphorous atom in an unmodified phosphate group is achiral. However, replacement of one of the non-bridging oxygens with one of the above atoms or groups of atoms can render the phosphorous atom chiral; that is to say that a phosphorous atom in a phosphate group modified in this way is a stereogenic center. The stereogenic phosphorous atom can possess either the "R" configuration (herein Rp) or the "S" configuration (herein Sp).
Phosphorodithioates have both non-bridging oxygens replaced by sulfur. The phosphorus center in the phosphorodithioates is achiral which precludes the formation of oligoribonucleotide diastereomers. In some embodiments, modifications to one or both non- bridging oxygens can also include the replacement of the non-bridging oxygens with a group independently selected from S, Se, B, C, H, N, and OR (R can be, e.g., alkyl or aryl).
The phosphate linker can also be modified by replacement of a bridging oxygen, (i.e., the oxygen that links the phosphate to the nucleoside), with nitrogen (bridged
phosphoroamidates), sulfur (bridged phosphorothioates) and carbon (bridged
methylenephosphonates). The replacement can occur at either linking oxygen or at both of the linking oxygens.
Replacement of the Phosphate Group
The phosphate group can be replaced by non-phosphorus containing connectors. In some embodiments, the charge phosphate group can be replaced by a neutral moiety.
Examples of moieties which can replace the phosphate group can include, without limitation, e.g., methyl phosphonate, hydroxylamino, siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo,
methylenedimethylhydrazo and methyleneoxymethylimino.
Replacement of the Ribophosphate Backbone
Scaffolds that can mimic nucleic acids can also be constructed wherein the phosphate linker and ribose sugar are replaced by nuclease resistant nucleoside or nucleotide surrogates. In some embodiments, the nucleobases can be tethered by a surrogate backbone. Examples can include, without limitation, the morpholino, cyclobutyl, pyrrolidine and peptide nucleic acid (PNA) nucleoside surrogates.
Sugar Modifications
The modified nucleosides and modified nucleotides can include one or more modifications to the sugar group. For example, the 2' hydroxyl group (OH) can be modified or replaced with a number of different "oxy" or "deoxy" substituents. In some embodiments, modifications to the 2' hydroxyl group can enhance the stability of the nucleic acid since the hydroxyl can no longer be deprotonated to form a 2'-alkoxide ion. The 2'-alkoxide can catalyze degradation by intramolecular nucleophilic attack on the linker phosphorus atom.
Examples of "oxy"-2' hydroxyl group modifications can include alkoxy or aryloxy
(OR, wherein "R" can be, e.g., alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or a sugar);
polyethyleneglycols (PEG), 0(CH2CH20)nCH2CH2OR wherein R can be, e.g., H or optionally substituted alkyl, and n can be an integer from 0 to 20 (e.g., from 0 to 4, from 0 to 8, from 0 to 10, from 0 to 16, from 1 to 4, from 1 to 8, from 1 to 10, from 1 to 16, from 1 to 20, from 2 to 4, from 2 to 8, from 2 to 10, from 2 to 16, from 2 to 20, from 4 to 8, from 4 to 10, from 4 to 16, and from 4 to 20). In some embodiments, the "oxy"-2' hydroxyl group modification can include "locked" nucleic acids (LNA) in which the 2' hydroxyl can be connected, e.g., by a Ci_6 alkylene or Ci_6 heteroalkylene bridge, to the 4' carbon of the same ribose sugar, where exemplary bridges can include methylene, propylene, ether, or amino bridges; O-amino (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine, or polyamino) and aminoalkoxy, 0(CH2)n-amino, (wherein amino can be, e.g., NH2;
alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine, or polyamino). In some embodiments, the "oxy"-2' hydroxyl group modification can include the methoxyethyl group (MOE), (OCH2CH2OCH3, e.g., a PEG derivative).
"Deoxy" modifications can include hydrogen (i.e. deoxyribose sugars, e.g., at the overhang portions of partially ds RNA); halo (e.g., bromo, chloro, fluoro, or iodo); amino (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, or amino acid);
NH(CH2CH2NH)nCH2CH2-amino (wherein amino can be, e.g., as described herein), - NHC(0)R (wherein R can be, e.g., alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar), cyano; mercapto; alkyl-thio-alkyl; thioalkoxy; and alkyl, cycloalkyl, aryl, alkenyl and alkynyl, which may be optionally substituted with e.g., an amino as described herein.
The sugar group can also contain one or more carbons that possess the opposite stereochemical configuration than that of the corresponding carbon in ribose. Thus, a modified nucleic acid can include nucleotides containing e.g., arabinose, as the sugar. The nucleotide "monomer" can have an alpha linkage at the position on the sugar, e.g., alpha- nucleosides. The modified nucleic acids can also include "abasic" sugars, which lack a nucleobase at C- 1 ' . These abasic sugars can also be further modified at one or more of the constituent sugar atoms. The modified nucleic acids can also include one or more sugars that are in the L form, e.g. L- nucleosides.
Generally, RNA includes the sugar group ribose, which is a 5-membered ring having an oxygen. Exemplary modified nucleosides and modified nucleotides can include, without limitation, replacement of the oxygen in ribose (e.g., with sulfur (S), selenium (Se), or alkylene, such as, e.g., methylene or ethylene); addition of a double bond (e.g., to replace ribose with cyclopentenyl or cyclohexenyl); ring contraction of ribose (e.g., to form a 4- membered ring of cyclobutane or oxetane); ring expansion of ribose (e.g., to form a 6- or 7- membered ring having an additional carbon or heteroatom, such as for example,
anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino that also has a phosphoramidate backbone). In some embodiments, the modified nucleotides can include multicyclic forms (e.g., tricyclo; and "unlocked" forms, such as glycol nucleic acid (GNA) (e.g., R-GNA or S-GNA, where ribose is replaced by glycol units attached to phosphodiester bonds), threose nucleic acid (TNA, where ribose is replaced with a-L-threofuranosyl- (3'→2')).
Modifications on the Nucleobase
The modified nucleosides and modified nucleotides described herein, which can be incorporated into a modified nucleic acid, can include a modified nucleobase. Examples of nucleobases include, but are not limited to, adenine (A), guanine (G), cytosine (C), and uracil (U). These nucleobases can be modified or wholly replaced to provide modified nucleosides and modified nucleotides that can be incorporated into modified nucleic acids. The nucleobase of the nucleotide can be independently selected from a purine, a pyrimidine, a purine or pyrimidine analog. In some embodiments, the nucleobase can include, for example, naturally-occurring and synthetic derivatives of a base.
Uracil
In some embodiments, the modified nucleobase is a modified uracil. Exemplary nucleobases and nucleosides having a modified uracil include without limitation
pseudouridine (ψ), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza- uridine, 2-thio-uridine (s2U), 4-thio-uridine (s4U), 4-thio-pseudouridine, 2-thio- pseudouridine, 5 -hydroxy-uridine (ho5U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo- uridine or 5-bromo-uridine), 3-methyl-uridine (m3U), 5-methoxy-uridine (mo5U), uridine 5- oxyacetic acid (cmo5U), uridine 5-oxyacetic acid methyl ester (mcmo5U), 5-carboxymethyl- uridine (cm5U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm5U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm5U), 5-methoxycarbonylmethyl-uridine (mcm5U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm5s2U), 5-aminomethyl-2-thio- uridine (nm5s2U), 5-methylaminomethyl-uridine (mnm5U), 5-methylaminomethyl-2-thio- uridine (mnm5s2U), 5-methylaminomethyl-2-seleno-uridine (mnm5se2U), 5- carbamoylmethyl-uridine (ncm5U), 5-carboxymethylaminomethyl-uridine (cmnm5U), 5- carboxymethylaminomethyl-2-thio-uridine (cmnm 5s2U), 5 -propynyl -uridine, 1-propynyl- pseudouridine, 5-taurinomethyl-uridine (tcm5U), 1-taurinomethyl-pseudouridine, 5- taurinomethyl-2-thio-uridine(Tm5s2U), l-taurinomethyl-4-thio-pseudouridine, 5-methyl- uridine (m5U, i.e., having the nucleobase deoxy thy mine), 1 -methyl -pseudouridine (ηι ψ), 5- methyl-2-thio-uridine (m5s2U), l-methyl-4-thio-pseudouridine (m vi/), 4-thio-l-methyl- pseudouridine, 3-methyl-pseudouridine (ιη3ψ), 2-thio- 1-methyl-pseudouridine, 1-methyl-l- deaza-pseudouridine, 2-thio-l-methyl-l-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m5D), 2-thio- dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N 1-methyl-pseudouridine, 3-(3- amino-3-carboxypropyl)uridine (acp3U), l-methyl-3-(3-amino-3- carboxypropyl)pseudouridine
Figure imgf000836_0001
5-(isopentenylaminomethyl)uridine (inm5U), 5- (isopentenylaminomethyl)-2-thio-uridine (inm5s2U), a-thio-uridine, 2'-0-methyl-uridine (Um), 5,2'-0-dimethyl-uridine (m5Um), 2'-0-methyl-pseudouridine (ψηι), 2-thio-2'-0- methyl-uridine (s2Um), 5-methoxycarbonylmethyl-2'-0-methyl-uridine (mcm 5Um), 5- carbamoylmethyl-2'-0-methyl-uridine (ncm 5Um), 5-carboxymethylaminomethyl-2'-0- methyl-uridine (cmnm 5Um), 3,2'-0-dimethyl-uridine (m3Um), 5-(isopentenylaminomethyl)- 2'-0-methyl-uridine (inm 5Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F- uridine, 2'-OH-ara-uridine, 5-(2-carbomethoxyvinyl) uridine, 5-[3-(l-E- propenylamino)uridine, pyrazolo[3,4-d]pyrimidines, xanthine, and hypoxanthine.
Cytosine
In some embodiments, the modified nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having a modified cytosine include without limitation 5-aza- cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine (m3C), N4-acetyl-cytidine (act), 5-formyl-cytidine (f5C), N4-methyl-cytidine (m4C), 5-methyl-cytidine (m5C), 5-halo- cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C), 1-methyl- pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine (s2C), 2-thio- 5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-l-methyl-pseudoisocytidine, 4-thio-l- methyl-l-deaza-pseudoisocytidine, 1 -methyl- 1-deaza-pseudoisocytidine, zebularine, 5-aza- zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy- cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-l -methyl - pseudoisocytidine, lysidine (k2C), a-thio-cytidine, 2'-0-methyl-cytidine (Cm), 5,2'-0- dimethyl-cytidine (m5Cm), N4-acetyl-2'-0-methyl-cytidine (ac4Cm), N4,2'-0-dimethyl- cytidine (m4Cm), 5-formyl-2'-0-methyl-cytidine (f 5Cm), N4,N4,2'-0-trimethyl-cytidine (m4 2Cm), 1-thio-cytidine, 2'-F-ara-cytidine, 2'-F-cytidine, and 2'-OH-ara-cytidine.
Adenine In some embodiments, the modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having a modified adenine include without limitation 2-amino- purine, 2,6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo- purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza- adenosine, 7-deaza-8-aza-adenosine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine (m]A), 2- methyl-adenosine (m2A), N6-methyl-adenosine (m6A), 2-methylthio-N6-methyl-adenosine (ms2m6A), N6-isopentenyl-adenosine (i6A), 2-methylthio-N6-isopentenyl-adenosine
(ms2i6A), N6-(cis-hydroxyisopentenyl)adenosine (io6A), 2-methylthio-N6-(cis- hydroxyisopentenyl)adenosine (ms2io6A), N6-glycinylcarbamoyl-adenosine (g6A), N6- threonylcarbamoyl-adenosine (t6A), N6-methyl-N6-threonylcarbamoyl-adenosine (m6t6A), 2- methylthio-N6-threonylcarbamoyl-adenosine (ms2g6A), N6,N6-dimethyl-adenosine (m6 2A), N6-hydroxynorvalylcarbamoyl-adenosine (hn6A), 2-methylthio-N6- hydroxynorvalylcarbamoyl-adenosine (ms2hn6A), N6-acetyl-adenosine (ac6A), 7-methyl- adenosine, 2-methylthio-adenosine, 2-methoxy-adenosine, a-thio-adenosine, 2'-0-methyl- adenosine (Am), N6,2'-0-dimethyl-adenosine (m6Am), N6-Methyl-2'-deoxyadenosine, N6,N6,2'-0-trimethyl-adenosine (m6 2Am), l,2'-0-dimethyl-adenosine (tt^Am), 2'-0- ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl -purine, 1-thio-adenosine, 8-azido- adenosine, 2'-F-ara-adenosine, 2'-F-adenosine, 2'-OH-ara-adenosine, and N6-(19-amino- pentaoxanonadecyl)-adenosine.
Guanine
In some embodiments, the modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having a modified guanine include without limitation inosine (I), 1-methyl-inosine (m]I), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG- 14), isowyosine (imG2), wybutosine (yW), peroxywybutosine (o2yW),
hydroxywybutosine (OHyW), undermodified hydroxywybutosine (OHyW*), 7-deaza- guanosine, queuosine (Q), epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl- queuosine (manQ), 7-cyano-7-deaza-guanosine (preQo), 7-aminomethyl-7-deaza-guanosine (preQi), archaeosine (G+), 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza- guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine (m7G), 6-thio-7-methyl- guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methyl-guanosine (m'G), N2-methyl- guanosine (m2G), N2,N2-dimethyl-guanosine (m2 2G), N2,7-dimethyl-guanosine (m2,7G), N2, N2,7-dimethyl-guanosine (m2,2,7G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1- methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2-dimethyl-6-thio-guanosine, a- thio-guanosine, 2'-0-methyl-guanosine (Gm), N2-methyl-2'-0-methyl-guanosine (m2Gm), N2,N2-dimethyl-2'-0-methyl-guanosine (m2 2Gm), l-methyl-2'-0-methyl-guanosine (m'Gm), N2,7-dimethyl-2'-0-methyl-guanosine (m2,7Gm), 2'-0-methyl -inosine (Im), l,2'-0-dimethyl- inosine (m'lm), 06-phenyl-2'-deoxyinosine, 2'-0-ribosylguanosine (phosphate) (Gr(p)), 1- thio-guanosine, 06-methyl-guanosine, 06-Methyl-2'-deoxy guanosine, 2'-F-ara-guanosine, and 2'-F-guanosine.
Exemplary Modified gRNAs
In some embodiments, the modified nucleic acids can be modified gRNAs. It is to be understood that any of the gRNAs described herein can be modified in accordance with this section, including any gRNA that comprises a targeting domain from any of Tables 1A-1G, 2A-2F, 3A-3F, 4A-4G, 5A-5E, 6A-6G, 7A-7D, 8A-8E, 9A-9G, 10A-10D, 11A-11E, 12A- 12G, 13A-13B, 14A-14E, 15A-15G, or 16A-16C.
As discussed above, transiently expressed or delivered nucleic acids can be prone to degradation by, e.g., cellular nucleases. Accordingly, in one aspect the modified gRNAs described herein can contain one or more modified nucleosides or nucleotides which introduce stability toward nucleases. While not wishing to be bound by theory it is also believed that certain modified gRNAs described herein can exhibit a reduced innate immune response when introduced into a population of cells, particularly the cells of the present invention. As noted above, the term "innate immune response" includes a cellular response to exogenous nucleic acids, including single stranded nucleic acids, generally of viral or bacterial origin, which involves the induction of cytokine expression and release, particularly the interferons, and cell death.
While some of the exemplary modification discussed in this section may be included at any position within the gRNA sequence, in some embodiments, a gRNA comprises a modification at or near its 5' end (e.g., within 1-10, 1-5, or 1-2 nucleotides of its 5' end). In some embodiments, a gRNA comprises a modification at or near its 3' end (e.g., within 1-10, 1-5, or 1-2 nucleotides of its 3' end). In some embodiments, a gRNA comprises both a modification at or near its 5' end and a modification at or near its 3' end.
In an embodiment, the 5 ' end of a gRNA is modified by the inclusion of a eukaryotic mRNA cap structure or cap analog (e.g., a G(5')ppp(5')G cap analog, a m7G(5')ppp(5')G cap analog, or a 3'-0-Me-m7G(5')ppp(5')G anti reverse cap analog (ARCA)). The cap or cap analog can be included during either chemical synthesis or in vitro transcription of the gRNA. In an embodiment, an in vitro transcribed gRNA is modified by treatment with a phosphatase (e.g., calf intestinal alkaline phosphatase) to remove the 5' triphosphate group.
In an embodiment, the 3 ' end of a gRNA is modified by the addition of one or more (e.g., 25-200) adenine (A) residues. The polyA tract can be contained in the nucleic acid (e.g., plasmid, PCR product, viral genome) encoding the gRNA, or can be added to the gRNA during chemical synthesis, or following in vitro transcription using a polyadenosine polymerase (e.g., E. coli Poly(A)Polymerase).
In an embodiment, in vitro transcribed gRNA contains both a 5 ' cap structure or cap analog and a 3' polyA tract. In an embodiment, an in vitro transcribed gRNA is modified by treatment with a phosphatase (e.g., calf intestinal alkaline phosphatase) to remove the 5' triphosphate group and comprises a 3' polyA tract.
In some embodiments, gRNAs can be modified at a 3' terminal U ribose. For example, the two terminal hydroxyl groups of the U ribose can be oxidized to aldehyde groups and a concomitant opening of the ribose ring to afford a modified nucleoside as shown below:
Figure imgf000839_0001
wherein "U" can be an unmodified or modified uridine.
In another embodiment, the 3' terminal U can be modified with a 2' 3' cyclic phosphate as shown below:
Figure imgf000839_0002
wherein "U" can be an unmodified or modified uridine.
In some embodiments, the gRNA molecules may contain 3' nucleotides which can be stabilized against degradation, e.g., by incorporating one or more of the modified nucleotides described herein. In this embodiment, e.g., uridines can be replaced with modified uridines, e.g., 5-(2-amino)propyl uridine, and 5-bromo uridine, or with any of the modified uridines described herein; adenosines and guanosines can be replaced with modified adenosines and guanosines, e.g., with modifications at the 8-position, e.g., 8-bromo guanosine, or with any of the modified adenosines or guanosines described herein.
In some embodiments, sugar-modified ribonucleotides can be incorporated into the gRNA, e.g., wherein the 2' OH-group is replaced by a group selected from H, -OR, -R (wherein R can be, e.g., alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar), halo, -SH, -SR (wherein R can be, e.g., alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar), amino (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, or amino acid); or cyano (-CN). In some embodiments, the phosphate backbone can be modified as described herein, e.g., with a phosphothioate group. In some embodiments, one or more of the nucleotides of the gRNA can each independently be a modified or unmodified nucleotide including, but not limited to 2 '-sugar modified, such as, 2'-0-methyl, 2'-0-methoxyethyl, or 2'-Fluoro modified including, e.g., 2'-F or 2'-0-methyl, adenosine (A), 2'-F or 2'-0-methyl, cytidine (C), 2'-F or 2'-0-methyl, uridine (U), 2'-F or 2'-0-methyl, thymidine (T), 2'-F or 2'-0-methyl, guanosine (G), 2'-0- methoxyethyl-5-methyluridine (Teo), 2'-0-methoxyethyladenosine (Aeo), 2'-0- methoxyethyl-5-methylcytidine (m5Ceo), and any combinations thereof.
In some embodiments, a gRNA can include "locked" nucleic acids (LNA) in which the 2' OH-group can be connected, e.g., by a Cl-6 alkylene or Cl-6 heteroalkylene bridge, to the 4' carbon of the same ribose sugar, where exemplary bridges can include methylene, propylene, ether, or amino bridges; O-amino (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine, or polyamino) and aminoalkoxy or 0(CH2)n-amino (wherein amino can be, e.g., NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine, or polyamino).
In some embodiments, a gRNA can include a modified nucleotide which is multicyclic (e.g., tricyclo; and "unlocked" forms, such as glycol nucleic acid (GNA) (e.g., R- GNA or S-GNA, where ribose is replaced by glycol units attached to phosphodiester bonds), or threose nucleic acid (TNA, where ribose is replaced with a-L-threofuranosyl-(3'→2')).
Generally, gRNA molecules include the sugar group ribose, which is a 5-membered ring having an oxygen. Exemplary modified gRNAs can include, without limitation, replacement of the oxygen in ribose (e.g., with sulfur (S), selenium (Se), or alkylene, such as, e.g., methylene or ethylene); addition of a double bond (e.g., to replace ribose with cyclopentenyl or cyclohexenyl); ring contraction of ribose (e.g., to form a 4-membered ring of cyclobutane or oxetane); ring expansion of ribose (e.g., to form a 6- or 7-membered ring having an additional carbon or heteroatom, such as for example, anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino that also has a phosphoramidate backbone). Although the majority of sugar analog alterations are localized to the 2' position, other sites are amenable to modification, including the 4' position. In an embodiment, a gRNA comprises a 4'-S, 4'-Se or a 4'-C-aminomethyl-2'-0-Me modification.
In some embodiments, deaza nucleotides, e.g., 7-deaza-adenosine, can be
incorporated into the gRNA. In some embodiments, O- and N-alkylated nucleotides, e.g., N6-methyl adenosine, can be incorporated into the gRNA. In some embodiments, one or more or all of the nucleotides in a gRNA molecule are deoxynucleotides. miRNA binding sites
microrNAs (or miRNAs) are naturally occurring cellular 19-25 nucleotide long noncoding RNAs. They bind to nucleic acid molecules having an appropriate miRNA binding site, e.g., in the 3' UTR of an mRNA, and down-regulate gene expression. While not wishing to be bound by theory it is believed that the down regulation is either by reducing nucleic acid molecule stability or by inhibiting translation. An RNA species disclosed herein, e.g., an mRNA encoding Cas9 can comprise an miRNA binding site, e.g., in its 3'UTR. The miRNA binding site can be selected to promote down regulation of expression is a selected cell type. By way of example, the incorporation of a binding site for miR-122, a microrNA abundant in liver, can inhibit the expression of the gene of interest in the liver.
EXAMPLES
The following Examples are merely illustrative and are not intended to limit the scope or content of the invention in any way.
Example 1 : Evaluation of candidate guide RNAs (gRNAs)
The suitability of candidate gRNAs can be evaluated as described in this example. Although described for a chimeric gRNA, the approach can also be used to evaluate modular gRNAs.
Cloning gRNAs into Vectors
For each gRNA, a pair of overlapping oligonucleotides is designed and obtained. Oligonucleotides are annealed and ligated into a digested vector backbone containing an upstream U6 promoter and the remaining sequence of a long chimeric gRNA. Plasmid is sequence-verified and prepped to generate sufficient amounts of transfection-quality DNA. Alternate promoters maybe used to drive in vivo transcription (e.g. HI promoter) or for in vitro transcription (e.g., a T7 promoter).
Cloning gRNAs in linear dsDNA molecule (STITCHR)
For each gRNA, a single oligonucleotide is designed and obtained. The U6 promoter and the gRNA scaffold (e.g. including everything except the targeting domain, e.g., including sequences derived from the crRNA and tracrRNA, e.g., including a first complementarity domain; a linking domain; a second complementarity domain; a proximal domain; and a tail domain) are separately PCR amplified and purified as dsDNA molecules. The gRNA- specific oligonucleotide is used in a PCR reaction to stitch together the U6 and the gRNA scaffold, linked by the targeting domain specified in the oligonucleotide. Resulting dsDNA molecule (STITCHR product) is purified for transfection. Alternate promoters may be used to drive in vivo transcription (e.g., HI promoter) or for in vitro transcription (e.g., T7 promoter). Any gRNA scaffold may be used to create gRNAs compatible with Cas9s from any bacterial species.
Initial gRNA Screen
Each gRNA to be tested is transfected, along with a plasmid expressing Cas9 and a small amount of a GFP-expressing plasmid into human cells. In preliminary experiments, these cells can be immortalized human cell lines such as 293T, K562 or U20S.
Alternatively, primary human cells may be used. In this case, cells may be relevant to the eventual therapeutic cell target (for example, an erythroid cell). The use of primary cells similar to the potential therapeutic target cell population may provide important information on gene targeting rates in the context of endogenous chromatin and gene expression.
Transfection may be performed using lipid transfection (such as Lipofectamine or Fugene) or by electroporation (such as Lonza Nucleofection). Following transfection, GFP expression can be determined either by fluorescence microscopy or by flow cytometry to confirm consistent and high levels of transfection. These preliminary transfections can comprise different gRNAs and different targeting approaches (17-mers, 20-mers, nuclease, dual-nickase, etc.) to determine which gRNAs/combinations of gRNAs give the greatest activity.
Efficiency of cleavage with each gRNA may be assessed by measuring NHEJ- induced indel formation at the target locus by a T7El-type assay or by sequencing.
Alternatively, other mismatch-sensitive enzymes, such as Cell/Surveyor nuclease, may also be used. For the T7E1 assay, PCR amplicons are approximately 500-700bp with the intended cut site placed asymmetrically in the amplicon. Following amplification, purification and size- verification of PCR products, DNA is denatured and re-hybridized by heating to 95 °C and then slowly cooling. Hybridized PCR products are then digested with T7 Endonuclease I (or other mismatch-sensitive enzyme) which recognizes and cleaves non-perfectly matched DNA. If indels are present in the original template DNA, when the amplicons are denatured and re-annealed, this results in the hybridization of DNA strands harboring different indels and therefore lead to double-stranded DNA that is not perfectly matched. Digestion products may be visualized by gel electrophoresis or by capillary electrophoresis. The fraction of DNA that is cleaved (density of cleavage products divided by the density of cleaved and uncleaved) may be used to estimate a percent NHEJ using the following equation: NHEJ = (1-(1 -fraction cleaved)'72). The T7E1 assay is sensitive down to about 2-5% NHEJ.
Sequencing may be used instead of, or in addition to, the T7E1 assay. For Sanger sequencing, purified PCR amplicons are cloned into a plasmid backbone, transformed, miniprepped and sequenced with a single primer. Sanger sequencing may be used for determining the exact nature of indels after determining the NHEJ rate by T7E1.
Sequencing may also be performed using next generation sequencing techniques. When using next generation sequencing, amplicons may be 300-500bp with the intended cut site placed asymmetrically. Following PCR, next generation sequencing adapters and barcodes (for example Illumina multiplex adapters and indexes) may be added to the ends of the amplicon, e.g., for use in high throughput sequencing (for example on an Illumina MiSeq). This method allows for detection of very low NHEJ rates.
Example 2: Assessment of Gene Targeting by NHEJ
The gRNAs that induce the greatest levels of NHEJ in initial tests can be selected for further evaluation of gene targeting efficiency. In this case, cells are derived from disease subjects and, therefore, harbor the relevant mutation.
Following transfection (usually 2-3 days post-transfection,) genomic DNA may be isolated from a bulk population of transfected cells and PCR may be used to amplify the target region. Following PCR, gene targeting efficiency to generate the desired mutations (either knockout of a target gene or removal of a target sequence motif) may be determined by sequencing. For Sanger sequencing, PCR amplicons may be 500-700bp long. For next generation sequencing, PCR amplicons may be 300-500bp long. If the goal is to knockout gene function, sequencing may be used to assess what percent of viral copies have undergone NHEJ-induced indels that result in a frameshift or large deletion or insertion that would be expected to destroy gene function. If the goal is to remove a specific sequence motif, sequencing may be used to assess what percent of viral copies have undergone NHEJ- induced deletions that span this sequence.
Incorporation by Reference
All publications, patents, and patent applications mentioned herein are hereby incorporated by reference in their entirety as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

CLAIMS What is claimed is:
1. A gRNA molecule comprising a targeting domain which is complementary with a target domain from the UL19, UL30, UL48 or UL54 gene.
2. The gRNA molecule of claim 1 , wherein said targeting domain is configured to
provide a cleavage event selected from a double strand break and a single strand break, within 500, 400, 300, 200, 100, 50, 25, or 10 nucleotides of a HSV-2 target position.
3. The gRNA molecule of claim 1 or 2, wherein said targeting domain is complementary with a target domain from the UL19 gene.
4. The gRNA molecule of claim 1 or 2, wherein said targeting domain is complementary with a target domain from the UL30 gene.
5. The gRNA molecule of claim 1 or 2, wherein said targeting domain is complementary with a target domain from the UL48 gene.
6. The gRNA molecule of claim 1 or 2, wherein said targeting domain is complementary with a target domain from the UL54 gene.
7. The gRNA molecule of any of claims 1-6, wherein said targeting domain is
configured to target the coding region, optionally an early coding region, of the UL19, UL30, UL48 or UL54 gene.
8. The gRNA molecule of any of claims 1-7, wherein said targeting domain comprises a sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence from any of Tables 1A-1G, 2A-2F, 3A-3F, 4A-4G, 5A- 5E, 6A-6G, 7A-7D, 8A-8E, 9A-9G, 10A-10D, 11A-11E, 12A-12G, 13A-13B, 14A- 14E, 15A-15G, or 16A-16C.
9. The gRNA molecule of any of claims 1-7, wherein said targeting domain comprises a sequence that is the same as a targeting domain sequence from any of Tables 1A-1G, 2A-2F, 3A-3F, 4A-4G, 5A-5E, 6A-6G, 7A-7D, 8A-8E, 9A-9G, 10A-10D, 11A-11E, 12A-12G, 13A-13B, 14A-14E, 15A-15G, or 16A-16C.
10. The gRNA molecule of any of claims 1-9, wherein said gRNA is a modular gRNA molecule.
11. The gRNA molecule of any of claims 1-9, wherein said gRNA is a chimeric gRNA molecule.
12. The gRNA molecule of any of claims 1-11, wherein said targeting domain is 16
nucleotides or more in length.
13. The gRNA molecule of any of claims 1-12, wherein said targeting domain is 17 or 18 nucleotides or morein length.
14. The gRNA molecule of any of claims 1-13, wherein said targeting domain is 19 nucleotides or more in length.
15. The gRNA molecule of any of claims 1-14, wherein said targeting domain is 20 nucleotides or more in length.
16. The gRNA molecule of any of claims 1-15, wherein said targeting domain is 21 nucleotides or more in length.
17. The gRNA molecule of any of claims 1-16, wherein said targeting domain is 22 nucleotides or more in length.
18. The gRNA molecule of any of claims 1-17, wherein said targeting domain is 23 nucleotides or more in length.
19. The gRNA molecule of any of claims 1-18, wherein said targeting domain is 24 nucleotides or more in length.
20. The gRNA molecule of any of claims 1-19, wherein said targeting domain is 25 nucleotides or more in length.
21. The gRNA molecule of any of claims 1-20, wherein said targeting domain is 26 nucleotides or more in length.
22. The gRNA molecule of any of claims 1-21, comprising from 5' to 3' :
a targeting domain;
a first complementarity domain;
a linking domain;
a second complementarity domain;
a proximal domain; and
a tail domain.
23. The gRNA molecule of any of claims 1-21, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and
a targeting domain of 17 or 18 nucleotides in length.
24. The gRNA molecule of any of claims 1-23, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 25 nucleotides in length; and a targeting domain of 17 or 18 nucleotides in length.
25. The gRNA molecule of any of claims 1-24, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and
a targeting domain of 17 nucleotides in length.
26. The gRNA molecule of any of claims 1-25, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and
a targeting domain of 17 nucleotides in length.
27. A nucleic acid that comprises: (a) sequence that encodes a gRNA molecule
comprising a targeting domain that is complementary with a HSV-2 target domain in a UL19, UL30, UL48 or UL54 gene.
28. The nucleic acid of claim 27, wherein said gRNA molecule is a gRNA molecule of any of claims 1-26.
29. The nucleic acid of claim 27 or 28, wherein said targeting domain is configured to provide a cleavage event selected from a double strand break and a single strand break, within 500, 400, 300, 200, 100, 50, 25, or 10 nucleotides of the HSV-2 target position.
30. The nucleic acid of any of claims 27-29, wherein said targeting domain is configured to target the coding region, optionally an early coding region, of the UL19, UL30, UL48 or UL54 gene.
31. The nucleic acid of any of claims 27-30, wherein said targeting domain comprises a sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence from any of Tables 1A-1G, 2A-2F, 3A-3F, 4A-4G, 5A- 5E, 6A-6G, 7A-7D, 8A-8E, 9A-9G, 10A-10D, 11A-11E, 12A-12G, 13A-13B, 14A- 14E, 15A-15G, or 16A-16C.
32. The nucleic acid of any of claims 27-30, wherein said targeting domain comprises a sequence that is the same as a targeting domain sequence from any of Tables 1A-1G, 2A-2F, 3A-3F, 4A-4G, 5A-5E, 6A-6G, 7A-7D, 8A-8E, 9A-9G, 10A-10D, 11A-11E, 12A-12G, 13A-13B, 14A-14E, 15A-15G, or 16A-16C.
33. The nucleic acid of any of claims 27-32, wherein said gRNA is a modular gRN molecule.
34. The nucleic acid of any of claims 27-32, wherein said gRNA is a chimeric gRN molecule.
35. The nucleic acid of any of claims 27-34, wherein said targeting domain is 16 nucleotides or more in length.
36. The nucleic acid of any of claims 32-35, wherein said targeting domain is 17 or nucleotides or more in length.
37. The nucleic acid of any of claims 32-36, wherein said targeting domain is 19 nucleotides or more in length.
38. The nucleic acid of any of claims 32-37, wherein said targeting domain is 20 nucleotides or more in length.
39. The nucleic acid of any of claims 32-38, wherein said targeting domain is 21 nucleotides or more in length.
40. The nucleic acid of any of claims 32-39, wherein said targeting domain is 22 nucleotides or more in length.
41. The nucleic acid of any of claims 32-40, wherein said targeting domain is 23 nucleotides or more in length.
42. The nucleic acid of any of claims 32-41, wherein said targeting domain is 24 nucleotides or more in length.
43. The nucleic acid of any of claims 32-42, wherein said targeting domain is 25 nucleotides or more in length.
44. The nucleic acid of any of claims 32-43, wherein said targeting domain is 26 nucleotides or more in length.
45. The nucleic acid of any of claims 27-44, comprising from 5' to 3':
a targeting domain;
a first complementarity domain;
a linking domain;
a second complementarity domain;
a proximal domain; and
a tail domain.
46. The nucleic acid of any of claims 27-45, comprising:
a linking domain of no more than 25 nucleotides in length; a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and
a targeting domain of 17 or 18 nucleotides in length.
47. The nucleic acid of any of claims 27-46, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 25 nucleotides in length; and
a targeting domain of 17 or 18 nucleotides in length.
48. The nucleic acid of any of claims 27-47, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and
a targeting domain of 17 nucleotides in length.
49. The nucleic acid of any of claims 27-48, comprising:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and
a targeting domain of 17 nucleotides in length.
50. The nucleic acid of any of claims 27-49, further comprising: (b) sequence that
encodes a Cas9 molecule.
51. The nucleic acid of claim 50, wherein said Cas9 molecule is an eaCas9 molecule.
52. The nucleic acid of claim 51 , wherein said eaCas9 molecule comprises a nickase molecule.
53. The nucleic acid of claim 51, wherein said eaCas9 molecule forms a double strand break in a target nucleic acid.
54. The nucleic acid of any of claims 51, or 52, wherein said eaCas9 molecule forms a single strand break in a target nucleic acid.
55. The nucleic acid of any of claims 51, 52 or 54, wherein said single strand break is formed in the strand of the target nucleic acid to which the targeting domain of said gRNA molecule is complementary.
56. The nucleic acid of any of claims 51, 52 or 54, wherein said single strand break is formed in the strand of the target nucleic acid other than the strand to which to which the targeting domain of said gRNA is complementary.
57. The nucleic acid of any of claims 51, 52 or 54, wherein said eaCas9 molecule comprises HNH-like domain cleavage activity but has no, or no significant, N- terminal RuvC-like domain cleavage activity.
58. The nucleic acid of any of claims 51, 52, 54, or 57, wherein said eaCas9 molecule is an HNH-like domain nickase.
59. The nucleic acid of any of claims 51, 52, 54, 57, or 58, wherein said eaCas9 molecule comprises a mutation at D10.
60. The nucleic acid of any of claims 51, 52 or 54, wherein said eaCas9 molecule
comprises N-terminal RuvC-like domain cleavage activity but has no, or no significant, HNH-like domain cleavage activity.
61. The nucleic acid of any of claims 51, 52, 54, or 60, wherein said eaCas9 molecule is an N-terminal RuvC-like domain nickase.
62. The nucleic acid of any of claims 51, 52, 54, 60, or 61, wherein said eaCas9 molecule comprises a mutation at H840 or N863.
63. The nucleic acid of any of claims 27-62, further comprising: (c) sequence that
encodes a second gRNA molecule described herein having a targeting domain that is complementary to a second target domain of the UL19, UL30, UL48 or UL54 gene.
64. The nucleic acid of claim 63, wherein said second gRNA molecule is a gRNA
molecule of any of claims 1-26.
65. The nucleic acid of claim 63 or 64, wherein said targeting domain of said second gRNA is configured to provide a cleavage event selected from a double strand break and a single strand break, within 500, 400, 300, 200, 100, 50, 25, or 10 nucleotides of the HSV-2 target position.
66. The nucleic acid of any of claims 63-65, wherein said targeting domain of said second gRNA is configured to target the coding region, optionally an early coding region, of the UL19, UL30, UL48 or UL54 gene.
67. The nucleic acid of any of claims 63-66, wherein said targeting domain of said second gRNA comprises a sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence from any of Tables 1A-1G, 2A-2F, 3A-3F, 4A-4G, 5A-5E, 6A-6G, 7A-7D, 8A-8E, 9A-9G, 10A-10D, 11A-11E, 12A- 12G, 13A-13B, 14A-14E, 15A-15G, or 16A-16C.
68. The nucleic acid of any of claims 63-66, wherein said targeting domain of said second gRNA comprises a sequence that is the same as a targeting domain sequence from any of Tables 1A-1G, 2A-2F, 3A-3F, 4A-4G, 5A-5E, 6A-6G, 7A-7D, 8A-8E, 9A-9G, 10A-10D, 11A-11E, 12A-12G, 13A-13B, 14A-14E, 15A-15G, or 16A-16C.
69. The nucleic acid of any of claims 63-68, wherein said second gRNA molecule is a modular gRNA molecule.
70. The nucleic acid of any of claims 63-68, wherein said second gRNA molecule is a chimeric gRNA molecule.
71. The nucleic acid of any of claims 63-70, wherein said targeting domain of the second gRNA molecule is 16 nucleotides or more in length.
72. The nucleic acid of any of claims 63-71, wherein said targeting domain of the second gRNA molecule is 17 or 18 nucleotides or more in length.
73. The nucleic acid of any of claims 63-72, wherein said targeting domain of the second gRNA molecule is 19 nucleotidesor more in length.
74. The nucleic acid of any of claims 63-73, wherein said targeting domain of the second gRNA molecule is 20 nucleotides or more in length.
75. The nucleic acid of any of claims 63-74, wherein said targeting domain of the second gRNA molecule is 21 nucleotides or more in length.
76. The nucleic acid of any of claims 63-75, wherein said targeting domain of the second gRNA molecule is 22 nucleotides or more in length.
77. The nucleic acid of any of claims 63-76, wherein said targeting domain of the second gRNA molecule is 23 nucleotides or more in length.
78. The nucleic acid of any of claims 63-77, wherein said targeting domain of the second gRNA molecule is 24 nucleotides or more in length.
79. The nucleic acid of any of claims 63-78, wherein said targeting domain of the second gRNA molecule is 25 nucleotides or more in length.
80. The nucleic acid of any of claims 63-79, wherein said targeting domain of the second gRNA molecule is 26 nucleotides or more in length.
81. The nucleic acid of any of claims 63-80, wherein said second gRNA molecule
comprises from 5' to 3' :
a targeting domain;
a first complementarity domain;
a linking domain;
a second complementarity domain;
a proximal domain; and
a tail domain.
82. The nucleic acid of any of claims 63-81, wherein said second gRNA molecule comprises:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 20 nucleotides in length; and
a targeting domain of 17 or 18 nucleotides in length.
83. The nucleic acid of any of claims 63-82, wherein said second molecule gRNA
molecule comprises:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 25 nucleotides in length; and
a targeting domain of 17 or 18 nucleotides in length.
84. The nucleic acid of any of claims 63-83, wherein said second gRNA molecule
comprises:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 30 nucleotides in length; and
a targeting domain of 17 nucleotides in length.
85. The nucleic acid of any of claims 63-84, wherein said second gRNA molecule
comprises:
a linking domain of no more than 25 nucleotides in length;
a proximal and tail domain, that taken together, are at least 40 nucleotides in length; and
a targeting domain of 17 nucleotides in length.
86. The nucleic acid of any of claims 63-85, further comprising a third gRNA molecule.
87. The nucleic acid of claim 86, further comprising a fourth gRNA molecule.
88. The nucleic acid of any of claims 27-62, wherein said nucleic acid does not comprise (c) a sequence that encodes a second gRNA molecule.
89. The nucleic acid of any of claims 50-88, wherein each of (a) and (b) is present on the same nucleic acid molecule.
90. The nucleic acid of claim 89, wherein said nucleic acid molecule is an AAV vector.
91. The nucleic acid of any of claims 50-88, wherein: (a) is present on a first nucleic acid molecule; and (b) is present on a second nucleic acid molecule.
92. The nucleic acid of claim 91, wherein said first and second nucleic acid molecules are AAV vectors.
93. The nucleic acid of any of claims 63-87 or 89-92, wherein each of (a) and (c) is present on the same nucleic acid molecule.
94. The nucleic acid of claim 93, wherein said nucleic acid molecule is an AAV vector.
95. The nucleic acid of any of claims 63-87 or 89-92, wherein: (a) is present on a first nucleic acid molecule; and (c) is present on a second nucleic acid molecule.
96. The nucleic acid of claim 95, wherein said first and second nucleic acid molecules are AAV vectors.
97. The nucleic acid of any of claims 72-87, 89, 90, 93, or 94, wherein each of (a), (b), and (c) are present on the same nucleic acid molecule.
98. The nucleic acid of claim 97, wherein said nucleic acid molecule is an AAV vector.
99. The nucleic acid of any of claims 27-87 or 89-96, wherein:
one of (a), (b), and (c) is encoded on a first nucleic acid molecule; and
a second and third of (a), (b), and (c) is encoded on a second nucleic acid molecule.
100. The nucleic acid of claim 99, wherein said first and second nucleic acid
molecules are AAV vectors.
101. The nucleic acid of any of claims 27-87, 91, 92, 95, 96, 99, or 100, wherein:
(a) is present on a first nucleic acid molecule; and (b) and (c) are present on a second nucleic acid molecule.
102. The nucleic acid of claim 101, wherein said first and second nucleic acid molecules are AAV vectors.
103. The nucleic acid of any of claims 27-87, 91-94, 99, or 100, wherein: (b) is present on a first nucleic acid molecule; and (a) and (c) are present on a second nucleic acid molecule.
104. The nucleic acid of claim 103, wherein said first and second nucleic acid molecules are AAV vectors.
105. The nucleic acid of any of claims 27-87, 89, 90, 95, 96, 99, or 100, wherein:
(c) is present on a first nucleic acid molecule; and (b) and (a) are present on a second nucleic acid molecule.
106. The nucleic acid of claim 105, wherein said first and second nucleic acid molecules are AAV vectors.
107. The nucleic acid of any of claims 91, 95, 99, 101, 103, or 105, wherein said first nucleic acid molecule is other than an AAV vector and said second nucleic acid molecule is an AAV vector.
108. The nucleic acid of any of claims 27-107, wherein said nucleic acid comprises a promoter operably linked to the sequence that encodes said gRNA molecule of (a).
109. The nucleic acid of any of claims 63-87 or 89-108, wherein said nucleic acid comprises a second promoter operably linked to the sequence that encodes the second gRNA molecule of (c).
110. The nucleic acid of claims 109, wherein the promoter and second promoter differ from one another.
111. The nucleic acid of claims 109, wherein the promoter and second promoter are the same.
112. The nucleic acid of any of claims 63-111, wherein said nucleic acid comprises a promoter operably linked to the sequence that encodes the Cas9 molecule of (b).
113. A composition comprising the (a) gRNA molecule of any of claims 1-26.
114. The composition of claim 113, further comprising (b) a Cas9 molecule of any of claims 50-62.
115. The composition of any of claims 113-114, further comprising (c) a second gRNA molecule of any of claims 63-85.
116. The composition of any of claims 113-115, further comprising a third gRNA molecule.
117. The composition of claim 116, further comprising a fourth gRNA molecule.
118. A method of altering a cell comprising contacting said cell with:
(a) a gRNA of any of claims 1-26;
(b) a Cas9 molecule of any of claims 50-62; and
optionally, (c) a second gRNA molecule of any of claims 63-85.
119. The method of claim 118, further comprising a third gRNA molecule.
120. The method of claim 119, further comprising a fourth gRNA molecule.
121. The method of claim 118, comprising contacting said cell with (a), (b), and
(c) .
122. The method of any of claims 118-121, wherein said cell is from a subject suffering from HSV-2.
123. The method of any of claims 118-122, wherein said cell is an epithelial cell.
124. The method of any of claims 118-122, wherein said cell is a neuronal cell.
125. The method of claim 118-124, wherein said contacting step is performed in vivo.
126. The method of any of claims 118-125, comprising acquiring knowledge of the sequence of the HSV-2 target position in said cell.
127. The method of claim 126, comprising acquiring knowledge of the sequence of the HSV-2 target position in said cell by sequencing a portion of the UL19, UL30, UL48 or UL54 gene.
128. The method of any of claims 118-127, comprising inducing a HSV-2 target position mutation.
129. The method of any of claims 118-128, wherein the contacting step comprises contacting said cell with a nucleic acid that encodes at least one of (a), (b), and (c).
130. The method of any of claims 118-129, wherein the contacting step comprises contacting the cell with a nucleic acid of any of claims 27-112.
131. The method of any of claims 118-130, wherein the contacting step comprises delivering to said cell said Cas9 molecule of (b) and a nucleic acid which encodes (a) and optionally (c).
132. The method of any of claims 118-131, wherein the contacting step comprises delivering to said cell said Cas9 molecule of (b), said gRNA molecule of (a) and optionally said second gRNA molecule of (c).
133. The method of any of claims 118-132, wherein the contacting step comprises delivering to said cell said gRNA molecule of (a), optionally said second gRNA molecule of (c) and a nucleic acid that encodes the Cas9 molecule of (b).
134. A method of treating a subject, comprising contacting a subject or a cell from said subject with:
(a) a gRNA of any of claims 1-26;
(b) a Cas9 molecule of any of claims 50-62; and
optionally, (c) a second gRNA of any of claims 63-85.
135. The method of claim 134, further comprising contacting the subject or a cell from the subject with a third gRNA molecule.
136. The method of claim 135, further comprising contacting the subject or a cell from the subject with a fourth gRNA molecule.
137. The method of any of claims 134-136, further comprising contacting said subject or a cell from said subject with (a), (b), and (c).
138. The method of any one of claims 134-137, wherein said subject is suffering from HSV-2.
139. The method of any of claims 134-138, wherein said subject would benefit from a mutation at the HSV-2 target position of the UL19, UL30, UL48 or UL54 gene.
140. The method of any of claims 134-138, wherein said subject would benefit from a mutation in one or more of the UL19, UL30, UL48 and UL54 genes.
141. The method of any of claims 134-138, wherein said subject would benefit from a mutation in two or more of the UL19, UL30, UL48 and UL54 genes.
142. The method of any of claims 134-138, wherein said subject would benefit from a mutation in three or more of the UL19, UL30, UL48 and UL54 genes.
143. The method of any of claims 134-138, wherein said subject would benefit from a mutation in each of the UL19, UL30, UL48 and UL54 genes.
144. The method of any of claims 135-143, comprising acquiring knowledge of the sequence of the HSV-2 target position in said subject.
145. The method of claim 144, comprising acquiring knowledge of the sequence of the HSV-2 target position in said subject by sequencing a portion of the UL19, UL30, UL48 or UL54 gene.
146. The method of any of claims 134-145, comprising inducing a HSV-2 target position mutation in the UL19, UL30, UL48 or UL54 gene.
147. The method of any of claims 134-146, wherein said contacting step is
performed in vivo.
148. The method of claim 147, wherein said contacting step comprises intravenous injection.
149. The method of any of claims 134-148, wherein the contacting step comprises contacting said subject or a cell from the subject with a nucleic acid that encodes at least one of (a), (b), and (c).
150. The method of any of claims 134-149, wherein the contacting step comprises contacting said subject or a cell from the subject with a nucleic acid of any of any of claims 27-112.
151. The method of any of claims 134-150, wherein the contacting step comprises delivering to said subject said Cas9 molecule of (b) and a nucleic acid which encodes and (a) and optionally (c).
152. The method of any of claims 134-150, wherein the contacting step comprises delivering to said subject said Cas9 molecule of (b), and said gRNA of (a) and optionally said second gRNA of (c).
153. The method of any of claims 134-150, wherein the contacting step comprises delivering to said subject said gRNA of (a), optionally said second gRNA of (c) and a nucleic acid that encodes the Cas9 molecule of (b).
154. A reaction mixture comprising a gRNA, a nucleic acid, or a composition described herein, and a cell from a subject having HSV-2, or a subject which would benefit from a mutation at a HSV-2 target position of the UL19, UL30, UL48 or UL54 gene.
155. A kit comprising, (a) gRNA molecule of any of claims 1-26, or nucleic acid that encodes said gRNA, and one or more of the following:
(b) a Cas9 molecule of any of claims 50-62;
(c) a second gRNA molecule of any of claims 63-85; and
(d) nucleic acid that encodes one or more of (b) and (c).
156. The kit of claim 155, comprising nucleic acid that encodes one or more of (a), (b) and (c).
157. The kit of claim 155 or 156, further comprising a third gRNA molecule
targeting a UL19, UL30, UL48 or UL54 target position.
158. The kit of claim 157, further comprising a fourth gRNA molecule targeting a
UL19, UL30, UL48 or UL54 target position.
159. A gRNA molecule of any of claims 1-26 for use in treating HSV-2 in a
subject.
160. The gRNA molecule of claim 159, wherein the gRNA molecule is used in combination with (b) a Cas9 molecule of any of claims 50-62.
161. The gRNA molecule of claims 159 or 160, wherein the gRNA molecule is used in combination with (c) a second gRNA molecule of any of claims 63-85.
162. Use of a gRNA molecule of any of claims 1-26 in the manufacture of a
medicament for treating HSV-2 in a subject.
163. The use of claim 162, wherein the medicament further comprises (b) a Cas9 molecule of any of claims 50-62.
164. The use of any of claims 162 or 163, wherein the medicament further
comprises (c) a second gRNA molecule of any of claims 63-85.
. A composition of any of claims 113-117 for use in treating HSV-2 in a subject.
PCT/US2015/023921 2014-04-01 2015-04-01 Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2) WO2015153791A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973792P 2014-04-01 2014-04-01
US61/973,792 2014-04-01

Publications (1)

Publication Number Publication Date
WO2015153791A1 true WO2015153791A1 (en) 2015-10-08

Family

ID=52829478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/023921 WO2015153791A1 (en) 2014-04-01 2015-04-01 Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)

Country Status (1)

Country Link
WO (1) WO2015153791A1 (en)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
WO2017062855A1 (en) 2015-10-09 2017-04-13 Monsanto Technology Llc Novel rna-guided nucleases and uses thereof
WO2017075475A1 (en) * 2015-10-30 2017-05-04 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US20180000970A1 (en) * 2015-01-14 2018-01-04 Temple University - of Commonwealth System of Higher Eduction Rna guided eradication of herpes simplex type i and other related herpesviruses
WO2018081504A1 (en) * 2016-10-28 2018-05-03 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
WO2018106268A1 (en) * 2016-01-25 2018-06-14 Excision Biotherapeutics Rna guided eradication of human jc virus and other polyomaviruses
WO2018118586A1 (en) * 2016-12-22 2018-06-28 Agenovir Corporation Antiviral/endogenous combination therapy
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10136649B2 (en) 2015-05-29 2018-11-27 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acids
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US20190062734A1 (en) * 2016-04-13 2019-02-28 Editas Medicine, Inc. Grna fusion molecules, gene editing systems, and methods of use thereof
US10227581B2 (en) 2013-08-22 2019-03-12 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2019178427A1 (en) 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
US10711267B2 (en) 2018-10-01 2020-07-14 North Carolina State University Recombinant type I CRISPR-Cas system
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
WO2021067788A1 (en) 2019-10-03 2021-04-08 Artisan Development Labs, Inc. Crispr systems with engineered dual guide nucleic acids
IT202000008014A1 (en) * 2020-04-15 2021-10-15 Fond Telethon Guide RNA and their uses
US11155823B2 (en) 2015-06-15 2021-10-26 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials
US11180751B2 (en) 2015-06-18 2021-11-23 The Broad Institute, Inc. CRISPR enzymes and systems
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11286480B2 (en) 2015-09-28 2022-03-29 North Carolina State University Methods and compositions for sequence specific antimicrobials
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11439712B2 (en) 2014-04-08 2022-09-13 North Carolina State University Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11466271B2 (en) 2017-02-06 2022-10-11 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133099A2 (en) * 2005-06-03 2006-12-14 The Cbr Institute For Biomedical Research, Inc. Sirna microbicides for preventing and treating viral diseases
US20100256219A1 (en) * 2009-04-01 2010-10-07 University Of Zuerich Small interfering DNA (siDNA) oligonucleotides as an antiviral agent against Herpes virus infections
WO2013176772A1 (en) * 2012-05-25 2013-11-28 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133099A2 (en) * 2005-06-03 2006-12-14 The Cbr Institute For Biomedical Research, Inc. Sirna microbicides for preventing and treating viral diseases
US20100256219A1 (en) * 2009-04-01 2010-10-07 University Of Zuerich Small interfering DNA (siDNA) oligonucleotides as an antiviral agent against Herpes virus infections
WO2013176772A1 (en) * 2012-05-25 2013-11-28 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

Non-Patent Citations (44)

* Cited by examiner, † Cited by third party
Title
ANN RAN F ET AL: "Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity", CELL, CELL PRESS, US, vol. 154, no. 6, 12 September 2013 (2013-09-12), pages 1380 - 1389, XP002718603, ISSN: 0092-8674, [retrieved on 20130829], DOI: 10.1016/J.CELL.2013.08.021 *
BAE ET AL., B PUBMED PMID: 24463181, 2014
BAE S; PARK J; KIM JS, BIOINFORMATICS, 17 February 2014 (2014-02-17)
BAE S; PARK J; KIM JS., BIOINFORMATICS, 17 February 2014 (2014-02-17)
BANERJEE; ROUSE: "Human Herpesviruses", 2007, CAMBRIDGE UNIVERSITY PRESS
BELSHE ET AL., NEW ENGLAND JOURNAL OF MEDICINE, vol. 366, no. 1, 2012, pages 34 - 43
BROWN ZA ET AL., JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 289, no. 2, 2003, pages 203 - 209
CHYLINSKI ET AL., RNA BIOL., vol. 10, no. 5, 2013, pages 726 - 737
DAWSON, SUVEY OF OPHTHALMOLOGY, vol. 21, no. 2, 1976, pages 121 - 135
DINH T-H ET AL., SEXUALLY TRANSMITTED DISEASE, vol. 35, no. 1, 2008, pages 19 - 21
F. ZHANG ET AL: "CRISPR/Cas9 for genome editing: progress, implications and challenges", HUMAN MOLECULAR GENETICS, vol. 23, no. R1, 20 March 2014 (2014-03-20), gb, pages R40 - R46, XP055196378, ISSN: 0964-6906, DOI: 10.1093/hmg/ddu125 *
FAROOQ; SHUKLA, SURVEY OF OPHTHALMOLOGY, vol. 57, no. 5, 2012, pages 448 - 462
FLEMING ET AL., NEW ENGLAND JOURNAL OF MEDICINE, vol. 337, 1997, pages 1105 - 11
FU ET AL., NAT BIOTECHNOL, 2014
FU ET AL.: "Improving CRISPR-Cas nuclease specificity using truncated guide RNA", NAT BIOTECHNOL., 26 January 2014 (2014-01-26)
FU ET AL.: "Improving CRISPR-Cas nuclease specificity using truncated guide RNAs", NAT BIOTECHNOL., 26 January 2014 (2014-01-26)
HEIGWER ET AL., N METHODS, vol. 11, no. 2, 2014, pages 122 - 3
HOMA ET AL., REVIEWS OF MEDICAL VIROLOGY, vol. 7, no. 2, 1997, pages 107 - 122
HSU ET AL., N BIOTECHNOL, vol. 31, no. 9, pages 827 - 32
JEFFRY D SANDER ET AL: "CRISPR-Cas systems for editing, regulating and targeting genomes", NATURE BIOTECHNOLOGY, vol. 32, no. 4, 2 March 2014 (2014-03-02), pages 347 - 355, XP055172520, ISSN: 1087-0156, DOI: 10.1038/nbt.2842 *
JIN ET AL., PLOS ONE, vol. 9, no. 5, 2014, pages E96623
KIMBERLIN ET AL., PEDIATRICS., vol. 108, 2001, pages 230 - 238
KRAWCZYK, PUBLIC LIBRARY OF SCIENCE ONE, vol. 10, no. 1, 2015, pages EOL 16800
L. CONG ET AL: "Multiplex Genome Engineering Using CRISPR/Cas Systems", SCIENCE, vol. 339, no. 6121, 15 February 2013 (2013-02-15), pages 819 - 823, XP055181426, ISSN: 0036-8075, DOI: 10.1126/science.1231143 *
LABETOULLE, OPHTHALMOLOGY, vol. 112, no. 5, 2005, pages 888 - 895
MALI ET AL., SCIENCE, vol. 339, no. 6121, 2013, pages 823 - 826
MARTINE AUBERT ET AL: "In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing Endonuclease", MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 3, no. 2, 4 February 2014 (2014-02-04), pages e146, XP055198360, DOI: 10.1038/mtna.2013.75 *
MISAKI WAYENGERA: "Identity of zinc finger nucleases with specificity to herpes simplex virus type II genomic DNA: novel HSV-2 vaccine/therapy precursors", THEORETICAL BIOLOGY AND MEDICAL MODELLING, BIOMED CENTRAL LTD., LONDON, GB, vol. 8, no. 1, 24 June 2011 (2011-06-24), pages 23, XP021103892, ISSN: 1742-4682, DOI: 10.1186/1742-4682-8-23 *
MOSSMAN ET AL., JOURNAL OF VIROLOGY, vol. 74, no. 14, 2000, pages 6287 - 6289
PALLISER DEBORAH ET AL: "An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 439, no. 7072, 5 January 2006 (2006-01-05), pages 89 - 94, XP002550734, ISSN: 0028-0836, [retrieved on 20051123], DOI: 10.1038/NATURE04263 *
PEPOSE ET AL.: "Ocular Infection and Immunity", 1996, MOSBY, pages: 1155 - 1168
PRASHANT MALI ET AL: "Cas9 as a versatile tool for engineering biology", NATURE METHODS, NATURE PUBLISHING GROUP, GB, vol. 10, no. 10, 1 October 2013 (2013-10-01), pages 957 - 963, XP002718606, ISSN: 1548-7105, [retrieved on 20130927], DOI: 10.1038/NMETH.2649 *
ROY ET AL., OCULAR IMMUNOLOGY AND INFLAMMATION, vol. 22, no. 3, 2014, pages 170 - 174
SABA ET AL., BRITISH MEDICAL JOURNAL, vol. 344, 2012, pages E3166
SANDER ET AL., NAR, vol. 35, 2007, pages W599 - 605
SANDER ET AL., NAR, vol. 38, 2010
SANDER ET AL., NAR, vol. 38, 2010, pages W462 - 8
SANDRI-GOLDI, FRONTIERS IN BIOSCIENCE, vol. 13, 2008, pages 5241 - 5256
SVOBODOVA ET AL., JOURNAL OF VIROLOGY, vol. 86, no. 1, 2012, pages 473 - 483
WILHELMUS, ARCHIVES OF OPHTHALMOLOGY, vol. 99, no. 9, 1981, pages 1578 - 82
XIAO A ET AL., B, 2014
XU ET AL., ABSTRACT 739 IN 42ND ANNUAL MEETING OF THE INFECTIOUS DISEASES SOCIETY OF AMERICA, 30 September 2004 (2004-09-30)
YUXUAN WU ET AL: "Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9", CELL STEM CELL, vol. 13, no. 6, 1 December 2013 (2013-12-01), pages 659 - 662, XP055196555, ISSN: 1934-5909, DOI: 10.1016/j.stem.2013.10.016 *
ZHOU ET AL., JOURNAL OF VIROLOGY, vol. 88, no. 19, 2014, pages 11121 - 11129

Cited By (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US11920181B2 (en) 2013-08-09 2024-03-05 President And Fellows Of Harvard College Nuclease profiling system
US10954548B2 (en) 2013-08-09 2021-03-23 President And Fellows Of Harvard College Nuclease profiling system
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US10227581B2 (en) 2013-08-22 2019-03-12 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US11299755B2 (en) 2013-09-06 2022-04-12 President And Fellows Of Harvard College Switchable CAS9 nucleases and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US10912833B2 (en) 2013-09-06 2021-02-09 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
US11499169B2 (en) 2013-10-30 2022-11-15 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US10640788B2 (en) 2013-11-07 2020-05-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAs
US11390887B2 (en) 2013-11-07 2022-07-19 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US10190137B2 (en) 2013-11-07 2019-01-29 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US11124782B2 (en) 2013-12-12 2021-09-21 President And Fellows Of Harvard College Cas variants for gene editing
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
US11439712B2 (en) 2014-04-08 2022-09-13 North Carolina State University Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11578343B2 (en) 2014-07-30 2023-02-14 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
US11753651B2 (en) 2014-08-28 2023-09-12 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
EP3985115A1 (en) 2014-12-12 2022-04-20 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
EP3702456A1 (en) 2014-12-24 2020-09-02 The Broad Institute, Inc. Crispr having or associated with destabilization domains
AU2016206692B2 (en) * 2015-01-14 2022-03-17 Temple University-Of The Commonwealth System Of Higher Education RNA guided eradication of herpes simplex type I and other related herpesviruses
JP7305301B2 (en) 2015-01-14 2023-07-10 テンプル・ユニバーシティ-オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション RNA-guided elimination of herpes simplex type 1 and other related herpes viruses
EP3244932A4 (en) * 2015-01-14 2018-07-18 Temple University Of The Commonwealth System Of Higher Education Rna guided eradication of herpes simplex type i and other related herpesviruses
US20180000970A1 (en) * 2015-01-14 2018-01-04 Temple University - of Commonwealth System of Higher Eduction Rna guided eradication of herpes simplex type i and other related herpesviruses
JP2018507183A (en) * 2015-01-14 2018-03-15 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションTemple University−Of The Commonwealth System Of Higher Education RNA-guided removal of herpes simplex type 1 and other related herpesviruses
JP2022023099A (en) * 2015-01-14 2022-02-07 テンプル・ユニバーシティ-オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション Rna guided eradication of herpes simplex type i and other related herpesviruses
US11261451B2 (en) 2015-05-29 2022-03-01 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acids
US10136649B2 (en) 2015-05-29 2018-11-27 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acids
US11155823B2 (en) 2015-06-15 2021-10-26 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials
US11180751B2 (en) 2015-06-18 2021-11-23 The Broad Institute, Inc. CRISPR enzymes and systems
US11286480B2 (en) 2015-09-28 2022-03-29 North Carolina State University Methods and compositions for sequence specific antimicrobials
EP3359644A4 (en) * 2015-10-09 2019-08-14 Monsanto Technology LLC Novel rna-guided nucleases and uses thereof
AU2016334225B2 (en) * 2015-10-09 2022-11-10 Monsanto Technology Llc Novel RNA-guided nucleases and uses thereof
US11692182B2 (en) 2015-10-09 2023-07-04 Monsanto Technology Llc RNA-guided DNA nucleases and uses thereof
WO2017062855A1 (en) 2015-10-09 2017-04-13 Monsanto Technology Llc Novel rna-guided nucleases and uses thereof
CN108513579A (en) * 2015-10-09 2018-09-07 孟山都技术公司 Novel RNA guidance quality nuclease and application thereof
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
CN109312338A (en) * 2015-10-30 2019-02-05 爱迪塔斯医药公司 The CRISPR/CAS correlation technique and composition for treating herpes simplex virus
US11001844B2 (en) 2015-10-30 2021-05-11 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for treating herpes simplex virus
WO2017075475A1 (en) * 2015-10-30 2017-05-04 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
AU2016343991B2 (en) * 2015-10-30 2022-12-01 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating herpes simplex virus
US11834649B2 (en) 2015-10-30 2023-12-05 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating herpes simplex virus
CN109312338B (en) * 2015-10-30 2022-09-27 爱迪塔斯医药公司 CRISPR/CAS related methods and compositions for treating herpes simplex virus
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
WO2018106268A1 (en) * 2016-01-25 2018-06-14 Excision Biotherapeutics Rna guided eradication of human jc virus and other polyomaviruses
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
WO2017158153A1 (en) 2016-03-17 2017-09-21 Imba - Institut Für Molekulare Biotechnologie Gmbh Conditional crispr sgrna expression
US20190062734A1 (en) * 2016-04-13 2019-02-28 Editas Medicine, Inc. Grna fusion molecules, gene editing systems, and methods of use thereof
US11702651B2 (en) 2016-08-03 2023-07-18 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10947530B2 (en) 2016-08-03 2021-03-16 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11390861B2 (en) 2016-10-28 2022-07-19 Editas Medicine, Inc. CRISPR/cas-related methods and compositions for treating herpes simplex virus
WO2018081504A1 (en) * 2016-10-28 2018-05-03 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
WO2018118586A1 (en) * 2016-12-22 2018-06-28 Agenovir Corporation Antiviral/endogenous combination therapy
US11820969B2 (en) 2016-12-23 2023-11-21 President And Fellows Of Harvard College Editing of CCR2 receptor gene to protect against HIV infection
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11466271B2 (en) 2017-02-06 2022-10-11 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11932884B2 (en) 2017-08-30 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2019178427A1 (en) 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
EP4257696A2 (en) 2018-03-14 2023-10-11 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
US10711267B2 (en) 2018-10-01 2020-07-14 North Carolina State University Recombinant type I CRISPR-Cas system
US11680259B2 (en) 2018-10-01 2023-06-20 North Carolina State University Recombinant type I CRISPR-CAS system
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11795452B2 (en) 2019-03-19 2023-10-24 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11643652B2 (en) 2019-03-19 2023-05-09 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
WO2021067788A1 (en) 2019-10-03 2021-04-08 Artisan Development Labs, Inc. Crispr systems with engineered dual guide nucleic acids
IT202000008014A1 (en) * 2020-04-15 2021-10-15 Fond Telethon Guide RNA and their uses
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion

Similar Documents

Publication Publication Date Title
US11834649B2 (en) CRISPR/CAS-related methods and compositions for treating herpes simplex virus
EP3126497B1 (en) Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
WO2015153791A1 (en) Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
US20220135970A1 (en) Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
EP3126495A1 (en) Crispr/cas-related methods and compositions for treating primary open angle glaucoma
WO2015148860A1 (en) Crispr/cas-related methods and compositions for treating beta-thalassemia
CA2985615A1 (en) Crispr/cas-related methods and compositions for treating hiv infection and aids
EP3116997A1 (en) Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
EP3129485A2 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
AU2015236128A1 (en) CRISPR/CAS-related methods and compositions for treating HIV infection and AIDS
US20220273818A1 (en) Compositions and methods for treating cep290-associated disease
US20230295725A1 (en) Compositions and methods for treating cep290-associated disease
US20230038993A1 (en) Compositions and methods for treating cep290-associated disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15716368

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase
122 Ep: pct application non-entry in european phase

Ref document number: 15716368

Country of ref document: EP

Kind code of ref document: A1